data_1ax3_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1ax3 _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.532 0.258 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.0 89.92 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 172.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t -13.36 116.17 0.04 OUTLIER Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 126.965 2.106 . . . . 0.0 115.377 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -71.38 -34.88 9.07 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.995 2.463 . . . . 0.0 117.37 -174.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -143.3 162.73 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.819 1.191 . . . . 0.0 111.371 -175.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -101.52 135.65 42.68 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 174.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 161.96 -136.33 4.32 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -127.79 124.63 38.12 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 124.941 1.297 . . . . 0.0 110.34 -178.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 45.9 mt -80.19 145.43 9.17 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -143.95 141.67 18.94 Favored Pre-proline 0 N--CA 1.452 -0.347 0 C-N-CA 125.08 1.352 . . . . 0.0 107.903 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -54.94 145.33 63.26 Favored 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 122.163 1.908 . . . . 0.0 111.183 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.67 -39.19 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.853 1.261 . . . . 0.0 112.316 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 p -53.48 -31.61 46.57 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.362 1.465 . . . . 0.0 112.442 179.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -69.78 -14.32 62.71 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.898 0.879 . . . . 0.0 112.852 -178.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -69.87 130.26 90.26 Favored Pre-proline 0 CA--C 1.539 0.53 0 O-C-N 121.373 -0.829 . . . . 0.0 111.057 -175.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -76.38 62.6 6.99 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.416 2.744 . . . . 0.0 111.374 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.21 132.01 2.88 Favored 'General case' 0 C--O 1.226 -0.138 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 22.0 mp0 -54.9 -53.05 60.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.521 1.128 . . . . 0.0 112.675 -176.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.0 t -51.68 -57.0 3.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 123.299 0.639 . . . . 0.0 110.317 -177.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -64.95 -53.54 44.73 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.264 0.226 . . . . 0.0 110.535 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.9 t -51.99 -43.05 63.44 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -90.91 13.36 66.25 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-O 117.994 -1.448 . . . . 0.0 111.814 -177.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp 69.44 -34.68 0.29 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 119.421 1.611 . . . . 0.0 114.52 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.419 ' H ' ' C ' ' A' ' 36' ' ' GLY . 15.7 tpt 26.16 -76.31 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 130.056 3.343 . . . . 0.0 116.426 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.1 ttm -79.49 -15.98 56.82 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 114.142 1.164 . . . . 0.0 114.142 -174.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.51 -135.75 2.73 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 120.037 1.29 . . . . 0.0 113.076 -178.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -129.1 163.1 26.2 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 175.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 167.27 -157.5 29.96 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.877 -1.154 . . . . 0.0 112.586 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -162.35 171.07 17.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.053 0.541 . . . . 0.0 109.839 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.35 149.18 31.51 Favored 'General case' 0 CA--C 1.502 -0.867 0 O-C-N 124.119 0.887 . . . . 0.0 109.429 176.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.0 mp -124.21 133.56 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 102.482 -3.155 . . . . 0.0 102.482 170.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.2 tt -99.38 108.44 50.33 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.789 -4.523 . . . . 0.0 98.789 170.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -82.8 161.04 16.29 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.347 2.698 . . . . 0.0 113.932 -168.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.3 p -124.59 -55.56 1.63 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.699 1.2 . . . . 0.0 108.723 175.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -68.15 124.15 22.66 Favored 'General case' 0 N--CA 1.457 -0.11 0 C-N-CA 122.303 0.241 . . . . 0.0 110.857 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.33 37.11 2.0 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 70.7 mt -138.43 120.63 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.24 109.35 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -174.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.7 m -89.25 -178.26 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.941 -1.504 . . . . 0.0 106.941 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.59 146.19 33.5 Favored Pre-proline 0 N--CA 1.465 0.306 0 CA-C-O 117.561 -1.209 . . . . 0.0 111.464 -174.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -63.3 -44.6 14.37 Favored 'Trans proline' 0 C--N 1.348 0.53 0 N-CA-C 107.453 -1.787 . . . . 0.0 107.453 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.4 p -146.2 145.59 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 102.433 -3.173 . . . . 0.0 102.433 171.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 28.6 mtm180 -97.27 -75.21 0.55 Allowed 'General case' 0 N--CA 1.45 -0.447 1 N-CA-C 98.979 -4.452 . . . . 0.0 98.979 169.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.23 -78.19 1.46 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 107.141 -2.383 . . . . 0.0 107.141 171.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.75 118.73 5.84 Favored 'General case' 0 N--CA 1.438 -1.067 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 28.3 mm -65.98 124.85 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 175.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.42 -42.47 12.81 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 124.069 0.948 . . . . 0.0 109.206 -177.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -156.88 152.66 27.05 Favored 'General case' 0 N--CA 1.463 0.204 0 O-C-N 121.94 -0.475 . . . . 0.0 111.722 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -82.89 170.55 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.845 1.658 . . . . 0.0 112.323 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -76.54 135.85 68.32 Favored Pre-proline 0 N--CA 1.437 -1.118 0 CA-C-N 112.681 -2.054 . . . . 0.0 109.778 173.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -74.37 -43.28 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.374 1.383 . . . . 0.0 108.61 172.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.4 p -131.39 46.24 2.69 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 126.192 1.797 . . . . 0.0 109.917 -177.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 16.5 ttmt 57.16 -17.41 0.02 OUTLIER 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 128.225 2.61 . . . . 0.0 116.609 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -75.98 -5.9 48.46 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 116.769 2.137 . . . . 0.0 116.769 -174.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.35 160.53 43.66 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 120.456 1.48 . . . . 0.0 110.348 -173.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.0 tt -157.23 157.15 3.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -117.31 128.58 7.92 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 107.646 -2.181 . . . . 0.0 107.646 178.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.9 mt -124.74 171.75 9.85 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 124.724 1.209 . . . . 0.0 110.359 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.47 139.33 20.88 Favored 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 126.631 1.972 . . . . 0.0 105.697 174.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 89.4 p . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 176.235 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 38.2 ttp180 . . . . . 0 CA--C 1.53 0.203 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -106.48 130.64 54.24 Favored 'General case' 0 N--CA 1.445 -0.678 0 C-N-CA 129.374 3.069 . . . . 0.0 104.386 177.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.4 mt -120.22 145.16 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 C-N-CA 124.339 1.056 . . . . 0.0 110.649 -172.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 46.7 tp -124.38 131.45 53.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 173.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 79.4 mt -121.93 146.8 26.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 123.789 0.836 . . . . 0.0 109.317 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.34 136.23 41.36 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 169.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -106.96 108.4 19.89 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 125.224 1.41 . . . . 0.0 109.037 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.53 -178.0 7.17 Favored Glycine 0 CA--C 1.534 1.22 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -176.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.7 mm -118.87 143.54 29.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 t70 65.69 11.58 7.64 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.38 1.072 . . . . 0.0 113.143 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 p -74.83 -32.51 61.96 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 125.583 1.553 . . . . 0.0 108.587 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.5 p -54.57 -49.85 63.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 113.202 -1.817 . . . . 0.0 107.143 170.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -62.69 -42.42 99.62 Favored 'General case' 0 C--O 1.227 -0.119 0 C-N-CA 124.668 1.187 . . . . 0.0 109.641 177.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 24.5 tp -66.21 -2.55 4.41 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.463 1.505 . . . . 0.0 111.539 176.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.5 mtmm 51.94 34.1 13.0 Favored 'General case' 0 C--N 1.344 0.329 0 C-N-CA 125.18 1.392 . . . . 0.0 111.325 -179.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.95 30.91 60.77 Favored Glycine 0 CA--C 1.537 1.45 0 CA-C-O 120.015 -0.325 . . . . 0.0 112.802 -178.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -67.21 93.38 0.3 Allowed 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.759 1.279 . . . . 0.0 109.477 178.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.54 7.98 4.57 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 126.682 2.087 . . . . 0.0 112.122 -178.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -101.35 153.04 20.01 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.696 1.198 . . . . 0.0 110.732 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 59.3 m -145.41 121.81 10.97 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.3 -2.111 . . . . 0.0 105.3 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 35.1 p -96.04 128.22 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.539 0.736 . . . . 0.0 110.371 -173.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -92.05 -49.12 6.38 Favored 'General case' 0 N--CA 1.448 -0.57 0 O-C-N 124.336 1.023 . . . . 0.0 109.431 -178.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.9 m -75.22 124.7 33.63 Favored 'Isoleucine or valine' 0 C--N 1.34 0.193 0 C-N-CA 117.21 -1.796 . . . . 0.0 107.749 173.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.7 m -100.8 55.71 0.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 103.578 -2.749 . . . . 0.0 103.578 170.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.5 0.0 OUTLIER 5.39 64.15 0.0 OUTLIER 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 130.767 3.627 . . . . 0.0 117.915 -168.517 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -81.28 61.24 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 173.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.391 3.3 p30 6.01 -94.56 0.0 OUTLIER 'General case' 0 N--CA 1.439 -0.987 0 C-N-CA 128.506 2.722 . . . . 0.0 116.939 -174.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.4 mmm180 -55.69 106.09 0.23 Allowed 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 126.472 1.909 . . . . 0.0 112.262 -175.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.6 159.19 8.53 Favored 'Isoleucine or valine' 0 C--N 1.342 0.239 0 C-N-CA 124.841 1.257 . . . . 0.0 111.704 179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -85.88 155.34 58.5 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 118.473 -0.775 . . . . 0.0 109.636 177.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo -48.82 168.61 0.1 Allowed 'Trans proline' 0 CA--C 1.534 0.514 1 C-N-CA 126.824 5.016 . . . . 0.0 120.381 -173.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 69.69 -97.37 0.55 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 125.956 1.741 . . . . 0.0 112.754 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 26.3 tt0 1.97 92.97 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 131.03 3.732 . . . . 0.0 114.102 -176.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 21.1 ttmt 4.21 114.82 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 130.321 3.449 . . . . 0.0 117.193 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 91.1 mt -81.87 -50.97 8.58 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.922 0.889 . . . . 0.0 108.988 173.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 96.1 mt -138.06 155.25 48.99 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.769 1.628 . . . . 0.0 110.512 -176.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.42 132.53 53.98 Favored 'General case' 0 CA--C 1.516 -0.328 1 N-CA-C 100.106 -4.035 . . . . 0.0 100.106 167.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.66 122.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.01 -165.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -71.63 69.07 0.62 Allowed 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.409 1.083 . . . . 0.0 111.025 -179.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 56.5 mt -49.11 -42.81 40.39 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.69 0.796 . . . . 0.0 111.166 178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -50.03 -48.43 52.73 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.628 0.771 . . . . 0.0 112.131 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.48 -31.34 22.85 Favored 'General case' 0 CA--C 1.527 0.078 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.8 t -64.02 -51.76 65.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.64 -0.662 . . . . 0.0 109.945 179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.407 0.0 OUTLIER -41.11 -57.95 3.11 Favored Pre-proline 0 CA--C 1.542 0.647 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -177.303 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -59.27 -19.34 49.74 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.256 1.971 . . . . 0.0 113.227 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -98.43 11.42 38.21 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.826 0.85 . . . . 0.0 112.283 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.83 151.31 73.82 Favored Pre-proline 0 CA--C 1.532 0.284 0 CA-C-N 119.837 1.199 . . . . 0.0 110.86 178.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -72.97 -24.06 17.87 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 122.744 2.296 . . . . 0.0 110.658 177.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 14.6 t -158.75 147.91 18.89 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.389 0.614 . . . . 0.0 109.864 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.0 tp -97.54 2.25 49.89 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.862 1.665 . . . . 0.0 110.51 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 19.3 mmt -52.01 119.19 4.05 Favored 'General case' 0 C--N 1.344 0.36 0 CA-C-N 118.208 0.458 . . . . 0.0 109.794 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 32.2 m -111.37 89.48 10.45 Favored Pre-proline 0 N--CA 1.447 -0.609 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -81.08 146.56 16.06 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.331 2.021 . . . . 0.0 111.364 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.4 mt -127.37 126.47 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 175.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.41 147.83 26.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 N-CA-C 106.819 -1.549 . . . . 0.0 106.819 178.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -122.55 125.71 46.27 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 101.945 -3.354 . . . . 0.0 101.945 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.7 p -89.15 -82.77 0.24 Allowed 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.4 0.546 . . . . 0.0 111.422 -171.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 20.6 p30 -47.37 -49.01 25.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.111 1.765 . . . . 0.0 111.884 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 23.0 mt 42.8 49.03 5.02 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 125.111 1.365 . . . . 0.0 110.864 178.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 34.82 40.96 0.05 Allowed 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.325 1.85 . . . . 0.0 111.966 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 36.88 55.18 1.2 Allowed 'General case' 0 N--CA 1.446 -0.631 0 C-N-CA 128.319 2.648 . . . . 0.0 114.349 -176.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 163.09 -3.48 0.07 OUTLIER Glycine 0 CA--C 1.524 0.625 0 CA-C-O 118.885 -0.953 . . . . 0.0 114.482 175.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 63.7 mm-40 -76.61 109.86 10.71 Favored 'General case' 0 C--O 1.228 -0.074 0 CA-C-N 119.219 1.51 . . . . 0.0 110.483 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.4 p -78.8 138.68 38.31 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 171.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -85.55 84.79 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.5 m -78.27 93.76 4.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 O-C-N 120.6 -1.312 . . . . 0.0 110.844 -175.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 14.2 mt -64.91 130.91 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 C-N-CA 123.939 0.896 . . . . 0.0 108.608 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -107.44 -55.36 2.36 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.711 1.204 . . . . 0.0 108.026 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.84 70.22 1.91 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.357 0.599 . . . . 0.0 110.511 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 24.7 m -79.0 63.92 3.79 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 178.35 -140.91 4.8 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.368 -1.893 . . . . 0.0 108.368 -176.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.6 t -66.43 151.84 46.34 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 117.039 0.419 . . . . 0.0 110.989 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -133.97 154.07 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.538 1.535 . . . . 0.0 107.996 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -132.95 150.92 52.12 Favored 'General case' 0 C--O 1.233 0.22 0 C-N-CA 124.965 1.306 . . . . 0.0 108.634 178.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -57.48 150.33 18.98 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.149 0.979 . . . . 0.0 112.12 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 58.51 3.52 0.29 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 127.148 2.179 . . . . 0.0 115.263 174.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 55.5 mm-40 -72.29 164.25 26.6 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 119.056 0.844 . . . . 0.0 111.075 179.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -114.04 168.23 9.99 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.715 2.406 . . . . 0.0 108.22 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 25.9 t0 51.73 40.53 27.73 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.099 1.36 . . . . 0.0 112.811 176.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -99.78 -43.64 11.24 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.414 1.086 . . . . 0.0 109.636 178.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.1 p -142.69 143.97 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 105.782 -1.933 . . . . 0.0 105.782 173.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -123.65 116.11 22.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.232 0.613 . . . . 0.0 109.547 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.4 mp -79.23 104.06 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 103.54 -2.763 . . . . 0.0 103.54 173.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -142.83 158.11 43.95 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 123.175 0.59 . . . . 0.0 109.865 -174.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.8 mptt . . . . . 0 CA--C 1.53 0.195 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.188 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.452 -0.329 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -103.61 90.92 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 C-N-CA 122.714 0.406 . . . . 0.0 111.686 -177.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 89.9 p -22.94 124.03 0.14 Allowed Pre-proline 0 CA--C 1.555 1.141 0 C-N-CA 126.037 1.735 . . . . 0.0 114.298 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -73.97 -36.74 3.25 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.023 2.482 . . . . 0.0 118.201 -171.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.44 148.33 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 119.905 1.229 . . . . 0.0 111.524 -175.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.6 m -80.48 140.6 35.83 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 173.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 163.58 -142.93 8.19 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -116.8 126.78 53.58 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 124.818 1.247 . . . . 0.0 108.457 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 tt -85.11 154.88 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -145.09 144.31 23.27 Favored Pre-proline 0 N--CA 1.451 -0.419 0 C-N-CA 124.989 1.316 . . . . 0.0 107.619 177.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -62.88 31.19 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 124.832 3.688 . . . . 0.0 116.838 177.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER 72.34 -39.69 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.071 1.349 . . . . 0.0 113.077 179.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -44.85 -41.38 7.03 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 125.298 1.439 . . . . 0.0 112.177 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.23 -14.1 62.73 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.646 1.579 . . . . 0.0 113.089 -175.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.6 t -71.3 127.91 90.8 Favored Pre-proline 0 CA--C 1.536 0.411 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 58.02 6.78 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.567 2.178 . . . . 0.0 112.043 -176.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -166.96 107.57 0.63 Allowed 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.686 -0.634 . . . . 0.0 110.203 177.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -28.6 -53.39 0.1 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 129.233 3.013 . . . . 0.0 115.967 -179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 60.5 t -53.76 -45.61 61.74 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 CA-C-O 121.406 0.622 . . . . 0.0 109.703 -178.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -76.69 -54.47 6.6 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.9 m -45.37 -43.9 11.39 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 124.609 1.164 . . . . 0.0 114.119 -178.438 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.417 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -98.6 12.76 62.94 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 117.926 -1.486 . . . . 0.0 112.61 -176.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 56.8 mttp 70.97 -34.11 0.29 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 119.723 1.761 . . . . 0.0 113.994 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.417 ' H ' ' C ' ' A' ' 36' ' ' GLY . 26.3 ttt 28.57 -71.57 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 130.895 3.678 . . . . 0.0 117.191 178.276 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ttt -79.03 -17.08 55.91 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.971 0.908 . . . . 0.0 112.732 -175.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -168.15 -137.03 2.15 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . 0.409 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.3 t0 -133.65 158.03 44.28 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 171.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -176.98 -162.79 28.06 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 119.361 -1.399 . . . . 0.0 113.46 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -151.4 165.14 35.02 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.991 1.316 . . . . 0.0 107.516 177.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -119.11 141.59 48.65 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -115.88 132.59 64.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 170.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.42 107.03 42.97 Favored Pre-proline 0 N--CA 1.445 -0.69 1 N-CA-C 98.298 -4.705 . . . . 0.0 98.298 169.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -82.9 167.01 14.67 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.732 2.954 . . . . 0.0 114.417 -168.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.8 p -127.73 -67.74 0.81 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.312 1.445 . . . . 0.0 108.499 176.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -53.24 124.81 15.59 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.802 0.841 . . . . 0.0 111.973 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.01 39.31 2.03 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 173.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.3 mt -140.01 117.14 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 104.181 -2.526 . . . . 0.0 104.181 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.9 t -116.71 114.01 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 123.904 0.881 . . . . 0.0 109.024 -175.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.3 m -90.64 178.03 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 172.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -97.85 145.73 30.25 Favored Pre-proline 0 C--O 1.223 -0.318 0 CA-C-O 117.147 -1.406 . . . . 0.0 110.064 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -62.43 -39.18 47.69 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 N-CA-C 106.92 -1.992 . . . . 0.0 106.92 172.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 p -157.54 139.57 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 101.495 -3.52 . . . . 0.0 101.495 169.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.29 -67.71 0.84 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 178.282 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 62.86 -74.4 0.03 OUTLIER Glycine 0 C--N 1.34 0.768 0 C-N-CA 126.155 1.835 . . . . 0.0 112.334 172.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.97 114.16 3.37 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 39.0 mm -61.74 128.33 23.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.138 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 8.4 tt -78.89 -52.55 8.14 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 177.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -179.19 161.81 1.15 Allowed 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 28.9 m -136.94 123.17 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 125.506 1.522 . . . . 0.0 107.503 175.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 153.84 0.6 Allowed Pre-proline 0 CA--C 1.537 0.454 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 176.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -50.42 -34.44 41.52 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 123.068 2.512 . . . . 0.0 112.671 175.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 25.0 p -79.62 4.14 16.91 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.972 0.909 . . . . 0.0 112.458 -179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 11.4 tppt? 66.36 -33.79 0.2 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 128.351 2.66 . . . . 0.0 115.803 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -54.44 -32.71 58.08 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 114.8 1.407 . . . . 0.0 114.8 -174.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.07 178.89 6.7 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 114.663 1.356 . . . . 0.0 114.663 -173.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.789 23.1 mm 117.86 -131.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.331 1 C-N-CA 132.719 4.408 . . . . 0.0 109.607 -179.312 . . . . . . . . 3 2 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.28 171.44 41.97 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 119.448 2.539 . . . . 0.0 119.448 -176.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.9 mt -118.97 179.68 4.08 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.81 2.444 . . . . 0.0 109.591 -177.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -149.63 152.3 35.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 127.016 2.126 . . . . 0.0 105.425 177.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 53.9 p . . . . . 0 CA--C 1.535 0.366 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 176.589 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 42.6 mtt85 . . . . . 0 N--CA 1.458 -0.056 0 CA-C-O 121.652 0.739 . . . . 0.0 109.988 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . 0.421 ' H ' ' ND2' ' A' ' 135' ' ' ASN . 8.4 tm-20 -76.87 134.19 39.08 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 176.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.3 mt -120.7 111.54 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.218 0.607 . . . . 0.0 110.995 -172.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.7 tt -83.04 138.28 33.79 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 68.3 mt -134.17 148.37 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 125.122 1.369 . . . . 0.0 108.887 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.42 78.92 1.64 Allowed 'General case' 0 C--N 1.34 0.192 0 C-N-CA 124.77 1.228 . . . . 0.0 109.743 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -51.52 107.02 0.16 Allowed 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 123.102 0.561 . . . . 0.0 111.558 -178.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.53 -173.29 2.51 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.647 0.641 . . . . 0.0 113.086 -178.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mm -121.67 146.0 27.43 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.3 t70 65.12 7.86 4.39 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.855 0.862 . . . . 0.0 113.07 -178.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -71.61 -35.21 70.39 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 125.738 1.615 . . . . 0.0 107.996 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 13.1 p -55.14 -45.79 77.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 CA-C-N 113.122 -1.854 . . . . 0.0 108.048 171.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.23 -38.66 92.05 Favored 'General case' 0 C--N 1.339 0.137 0 C-N-CA 124.354 1.061 . . . . 0.0 109.743 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.65 2.06 7.2 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 126.199 1.8 . . . . 0.0 110.615 175.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.4 mttp 45.88 30.23 0.84 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 128.016 2.526 . . . . 0.0 114.372 176.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.97 24.94 55.66 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.876 -0.402 . . . . 0.0 112.156 -178.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -56.66 -35.14 68.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 119.145 1.473 . . . . 0.0 112.79 -178.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -89.43 10.32 73.78 Favored Glycine 0 CA--C 1.533 1.192 0 CA-C-N 112.765 -2.016 . . . . 0.0 113.032 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -108.55 108.14 18.92 Favored 'General case' 0 C--N 1.343 0.325 0 CA-C-N 119.234 1.517 . . . . 0.0 111.996 -174.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.0 m -91.17 100.14 13.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.8 p -80.21 130.44 35.22 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 121.276 -0.89 . . . . 0.0 111.117 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -90.78 -46.96 7.91 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.705 1.202 . . . . 0.0 109.109 178.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.5 m -66.59 133.85 30.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 C-N-CA 118.105 -1.438 . . . . 0.0 108.421 174.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 59.5 m -110.88 53.29 0.71 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 170.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.292 3.4 pm0 -7.07 75.71 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.552 1 C-N-CA 131.815 4.046 . . . . 0.0 116.797 -171.603 . . . . . . . . 3 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.04 45.32 3.01 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 113.187 -1.824 . . . . 0.0 109.596 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 4.2 p30 5.23 41.57 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.226 2 C-N-CA 133.016 4.526 . . . . 0.0 122.206 -176.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.38 123.89 1.95 Allowed 'General case' 0 N--CA 1.436 -1.154 1 C-N-CA 133.163 4.585 . . . . 0.0 105.298 176.408 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -163.58 150.74 3.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 119.524 1.056 . . . . 0.0 110.482 -171.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -85.85 149.81 51.68 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 118.17 -0.919 . . . . 0.0 110.631 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_exo -46.71 150.84 2.29 Favored 'Trans proline' 0 CA--C 1.532 0.402 1 C-N-CA 126.222 4.615 . . . . 0.0 117.668 -176.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 66.44 -79.57 0.12 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.071 1.32 . . . . 0.0 112.504 176.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 1.44 76.12 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 131.581 3.953 . . . . 0.0 113.698 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? 17.49 109.94 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 129.723 3.209 . . . . 0.0 117.29 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 88.3 mt -78.75 -50.02 12.07 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 12.5 mt -144.56 156.8 44.32 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.971 0.909 . . . . 0.0 111.836 -173.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -119.06 131.39 55.95 Favored 'General case' 0 CA--C 1.516 -0.346 1 N-CA-C 98.694 -4.558 . . . . 0.0 98.694 165.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -140.91 129.89 24.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -166.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -76.24 63.2 1.86 Allowed 'General case' 0 C--O 1.234 0.25 0 CA-C-O 121.509 0.671 . . . . 0.0 110.068 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 78.6 mt -55.26 -34.56 64.15 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 123.221 0.609 . . . . 0.0 110.654 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.44 -40.23 71.29 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.047 0.539 . . . . 0.0 111.915 177.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.33 -35.3 17.27 Favored 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 122.788 0.435 . . . . 0.0 111.197 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.63 -51.19 75.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.554 -0.716 . . . . 0.0 109.518 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 20.8 pttm -40.66 -57.64 3.02 Favored Pre-proline 0 CA--C 1.541 0.616 0 N-CA-C 116.957 2.206 . . . . 0.0 116.957 -177.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -60.79 -25.64 81.52 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.696 2.264 . . . . 0.0 113.151 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -83.78 -43.03 15.85 Favored 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.62 0.646 . . . . 0.0 111.148 -178.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 35.7 m -78.91 150.57 75.37 Favored Pre-proline 0 CA--C 1.534 0.363 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -73.01 -25.19 16.52 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.515 2.143 . . . . 0.0 110.12 176.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.9 t -159.06 145.06 16.55 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 123.397 0.679 . . . . 0.0 109.539 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.9 tp -101.95 4.92 40.5 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.331 1.452 . . . . 0.0 110.287 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.8 mmt -51.97 111.4 0.6 Allowed 'General case' 0 C--N 1.342 0.263 0 C-N-CA 123.764 0.826 . . . . 0.0 110.104 179.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.7 m -107.3 114.57 60.86 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -90.55 145.75 4.0 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.976 2.45 . . . . 0.0 108.937 179.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.2 mp -124.84 116.57 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 101.787 -3.412 . . . . 0.0 101.787 172.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -124.58 117.21 49.79 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 C-N-CA 124.607 1.163 . . . . 0.0 108.719 -176.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -91.05 121.86 33.21 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.163 -2.532 . . . . 0.0 104.163 178.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -86.63 -73.17 0.47 Allowed 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.638 0.654 . . . . 0.0 110.757 -174.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . 0.421 ' ND2' ' H ' ' A' ' 79' ' ' GLU . 6.5 p30 -75.09 63.5 1.28 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 122.164 0.983 . . . . 0.0 112.507 -178.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . 0.409 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 29.8 mt -77.02 65.12 2.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.864 1.666 . . . . 0.0 108.34 177.152 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.48 46.97 0.08 Allowed 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 127.432 2.293 . . . . 0.0 111.179 -175.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 31.9 58.61 0.34 Allowed 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.852 2.861 . . . . 0.0 115.374 -175.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 156.56 -4.82 0.19 Allowed Glycine 0 CA--C 1.525 0.664 0 CA-C-O 118.972 -0.905 . . . . 0.0 114.32 174.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -74.87 111.81 10.44 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 119.18 1.49 . . . . 0.0 110.031 -179.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 59.9 p -78.42 133.37 37.51 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 176.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.26 0.4 OUTLIER -84.37 82.72 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 CA-C-O 122.875 1.321 . . . . 0.0 107.964 -176.646 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 41.9 m -79.08 94.65 5.36 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 120.986 -1.071 . . . . 0.0 110.363 -176.504 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 10.5 mt -57.91 128.32 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.4 mmpt? -98.5 -52.63 3.57 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 125.188 1.395 . . . . 0.0 108.931 177.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -79.0 61.51 3.19 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 120.819 0.342 . . . . 0.0 110.133 -178.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 60.2 p -77.84 72.77 4.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.843 0.857 . . . . 0.0 110.472 -176.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.37 -143.74 5.54 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 26.5 t -72.2 146.45 47.34 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 19.2 m -137.1 156.51 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.617 0.767 . . . . 0.0 109.33 -178.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -114.05 158.38 21.29 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 174.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.21 164.8 26.17 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.12 0.486 . . . . 0.0 110.249 175.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 60.7 32.91 20.31 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.339 1.055 . . . . 0.0 112.953 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -105.79 145.79 30.71 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 175.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -115.79 161.9 18.08 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.133 0.973 . . . . 0.0 110.585 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 19.3 t70 56.99 18.46 3.97 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 126.436 1.894 . . . . 0.0 113.566 -177.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -61.64 -21.2 24.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 125.464 1.506 . . . . 0.0 112.006 177.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 13.4 p -138.83 150.44 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 126.554 1.941 . . . . 0.0 107.048 178.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -120.77 109.07 14.72 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.184 0.994 . . . . 0.0 109.765 177.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.2 mp -77.65 92.47 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 N-CA-C 104.345 -2.465 . . . . 0.0 104.345 178.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 58.5 mt-10 -119.25 122.7 42.52 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.233 1.013 . . . . 0.0 111.055 -174.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--N 1.332 -0.179 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 177.332 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.529 0.171 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 . . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -131.27 96.99 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 122.231 2.287 . . . . 0.0 110.272 176.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 t -32.57 120.94 0.41 Allowed Pre-proline 0 CA--C 1.548 0.887 0 C-N-CA 125.574 1.55 . . . . 0.0 112.808 -178.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -74.06 -38.14 2.35 Favored 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 123.29 2.66 . . . . 0.0 117.571 -171.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.92 152.02 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 120.113 1.324 . . . . 0.0 109.84 -176.049 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.6 m -79.09 134.17 36.75 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 172.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.86 -177.09 45.54 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -92.0 122.08 34.17 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.4 tt -86.61 138.65 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 123.12 0.568 . . . . 0.0 110.141 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 78.8 m-70 -137.66 145.63 49.64 Favored Pre-proline 0 C--O 1.234 0.278 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 176.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.47 145.69 67.18 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.115 1.877 . . . . 0.0 110.218 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.4 tp -50.8 -33.84 12.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 p -56.02 -27.71 54.25 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 123.78 0.832 . . . . 0.0 112.388 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -76.22 -11.89 60.0 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.923 0.889 . . . . 0.0 112.714 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.3 t -66.85 129.45 94.05 Favored Pre-proline 0 CA--C 1.538 0.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.445 -178.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -77.17 59.48 6.59 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.696 2.931 . . . . 0.0 111.024 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -167.58 105.19 0.52 Allowed 'General case' 0 N--CA 1.463 0.209 0 O-C-N 121.356 -0.84 . . . . 0.0 109.344 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -24.56 -58.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 128.162 2.585 . . . . 0.0 114.164 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.9 t -48.57 -50.44 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 123.954 0.902 . . . . 0.0 110.464 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -76.31 -47.81 22.29 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.2 m -49.31 -41.29 38.0 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 113.793 1.035 . . . . 0.0 113.793 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -104.6 20.27 39.81 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-O 118.081 -1.4 . . . . 0.0 110.897 -177.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.0 mttt 72.03 -46.52 0.65 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.401 1.48 . . . . 0.0 113.248 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 45.0 tpp 45.16 -72.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.731 2.812 . . . . 0.0 115.352 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.7 ttp -101.8 -14.69 17.19 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.314 1.446 . . . . 0.0 113.018 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.06 -169.21 38.0 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 119.531 1.06 . . . . 0.0 111.965 -178.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -128.79 157.54 41.17 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.99 -126.71 1.35 Allowed Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 108.533 -1.827 . . . . 0.0 108.533 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -166.44 167.1 16.01 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 118.125 0.963 . . . . 0.0 111.542 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.35 126.19 45.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.475 1.11 . . . . 0.0 108.5 177.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.0 mm -107.31 121.12 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 104.193 -2.521 . . . . 0.0 104.193 170.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 7.0 tt -89.03 109.5 31.12 Favored Pre-proline 0 C--O 1.233 0.233 1 N-CA-C 100.073 -4.047 . . . . 0.0 100.073 170.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -81.52 162.61 19.34 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 123.594 2.863 . . . . 0.0 115.037 -167.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.2 p -132.04 -63.52 0.81 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.639 1.576 . . . . 0.0 108.947 177.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.43 123.93 17.83 Favored 'General case' 0 C--N 1.338 0.096 0 C-N-CA 122.56 0.344 . . . . 0.0 110.166 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.08 45.34 2.98 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 173.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.2 mt -145.84 115.96 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 105.17 -2.159 . . . . 0.0 105.17 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.1 t -114.01 121.51 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 125.084 1.354 . . . . 0.0 108.252 -177.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.9 m -103.66 156.93 5.34 Favored 'Isoleucine or valine' 0 C--N 1.339 0.11 0 C-N-CA 123.642 0.777 . . . . 0.0 110.071 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 m -69.12 127.17 93.13 Favored Pre-proline 0 CA--C 1.537 0.471 0 CA-C-O 117.598 -1.191 . . . . 0.0 109.92 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -60.41 -33.2 94.39 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.763 2.976 . . . . 0.0 111.302 177.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.1 m -150.6 144.16 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 102.139 -3.282 . . . . 0.0 102.139 172.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 -98.72 -97.41 0.22 Allowed 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 101.754 -3.424 . . . . 0.0 101.754 169.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.95 -66.43 3.59 Favored Glycine 0 CA--C 1.535 1.303 0 N-CA-C 106.575 -2.61 . . . . 0.0 106.575 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.21 132.36 2.49 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 166.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.0 mm -65.04 131.78 30.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 103.55 -2.759 . . . . 0.0 103.55 169.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 29.3 tp -79.01 -46.36 18.33 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 175.0 156.05 0.15 Allowed 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 125.669 1.588 . . . . 0.0 107.787 176.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.3 t -131.12 121.06 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -47.44 153.01 1.05 Allowed Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 112.579 0.585 . . . . 0.0 112.579 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -59.67 -14.97 28.92 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 124.192 3.262 . . . . 0.0 113.652 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 40.5 p -76.26 -21.29 56.49 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.078 0.951 . . . . 0.0 109.697 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 70.98 9.52 6.78 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 128.14 2.576 . . . . 0.0 111.03 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -83.91 -31.21 25.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 118.611 -0.709 . . . . 0.0 112.864 -176.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.82 -175.38 5.33 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.679 1.127 . . . . 0.0 112.348 -174.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.965 16.6 mm 130.89 -141.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.334 -0.085 1 C-N-CA 132.018 4.127 . . . . 0.0 111.824 176.4 . . . . . . . . 3 2 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -152.14 176.2 30.53 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 118.511 2.164 . . . . 0.0 118.511 -171.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.2 mp -132.51 158.46 42.05 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 128.012 2.525 . . . . 0.0 109.817 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.7 mm-40 -133.03 123.85 26.57 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 177.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.3 p . . . . . 0 C--N 1.322 -0.629 0 C-N-CA 124.689 1.196 . . . . 0.0 108.778 177.82 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 . . . . . 0 N--CA 1.46 0.036 0 CA-C-O 121.821 0.82 . . . . 0.0 111.824 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -76.34 141.15 41.64 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 174.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.2 mt -126.66 144.36 37.08 Favored 'Isoleucine or valine' 0 C--N 1.338 0.08 0 N-CA-C 112.789 0.662 . . . . 0.0 112.789 -172.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -119.82 136.63 54.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 128.891 2.876 . . . . 0.0 105.732 175.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.0 mt -131.48 140.15 49.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 C-N-CA 125.075 1.35 . . . . 0.0 107.764 177.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -132.89 114.81 14.49 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -76.05 116.52 16.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 118.766 0.712 . . . . 0.0 110.402 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.63 -170.57 4.82 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.694 -0.562 . . . . 0.0 111.694 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 22.5 mm -116.59 141.36 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.7 t0 50.2 41.98 24.76 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.412 1.085 . . . . 0.0 112.892 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.423 ' O ' ' N ' ' A' ' 90' ' ' SER . 7.7 p -83.83 -89.12 0.1 Allowed 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 103.273 -2.862 . . . . 0.0 103.273 172.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.3 p 33.03 -67.31 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 C-N-CA 128.313 2.645 . . . . 0.0 116.946 172.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.423 ' N ' ' O ' ' A' ' 88' ' ' THR . 12.9 m -63.43 -40.44 97.18 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 126.27 1.828 . . . . 0.0 109.758 176.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -58.35 -43.53 88.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 126.862 2.065 . . . . 0.0 108.8 178.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? 77.02 169.59 0.24 Allowed 'General case' 0 N--CA 1.442 -0.871 0 C-N-CA 126.823 2.049 . . . . 0.0 106.837 -174.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.03 54.96 0.56 Allowed Glycine 0 CA--C 1.538 1.493 0 C-N-CA 124.898 1.237 . . . . 0.0 112.718 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -75.41 79.88 2.47 Favored 'General case' 0 CA--C 1.519 -0.236 0 O-C-N 121.158 -1.201 . . . . 0.0 108.781 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.78 11.72 2.31 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 112.919 -1.946 . . . . 0.0 111.594 -176.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -96.94 96.93 8.86 Favored 'General case' 0 C--N 1.342 0.267 0 C-N-CA 124.753 1.221 . . . . 0.0 110.731 -175.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.4 m -79.72 94.67 5.78 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 35.9 p -79.51 122.93 27.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 121.569 -0.707 . . . . 0.0 110.653 -176.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -83.57 -53.18 5.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 27.9 m -84.82 131.02 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 171.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 69.6 m -96.06 57.63 1.79 Allowed 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 170.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.378 0.0 OUTLIER 37.97 49.6 1.2 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 111.458 -2.61 . . . . 0.0 110.6 -167.265 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -72.44 59.46 1.57 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 129.639 3.495 . . . . 0.0 111.152 -178.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.401 16.4 p30 2.04 -103.22 0.0 OUTLIER 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 119.583 3.179 . . . . 0.0 119.583 -178.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.322 0.1 OUTLIER -40.6 131.29 2.33 Favored 'General case' 0 N--CA 1.432 -1.367 1 N-CA-C 125.478 5.362 . . . . 0.0 125.478 -165.667 . . . . . . . . 4 3 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.489 9.7 p 32.63 -38.27 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.247 2 N-CA-C 130.203 7.112 . . . . 0.0 130.203 168.148 . . . . . . . . 3 2 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . 0.287 0.0 OUTLIER -70.33 115.16 31.88 Favored Pre-proline 0 C--N 1.308 -1.197 0 C-N-CA 115.422 -2.511 . . . . 0.0 114.333 -166.865 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo -62.45 162.82 22.71 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 124.875 3.717 . . . . 0.0 113.576 -170.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 54.04 15.91 5.63 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 124.423 1.011 . . . . 0.0 115.314 174.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -59.88 136.89 58.15 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 117.987 0.893 . . . . 0.0 108.752 178.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -64.23 119.42 10.22 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 174.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.6 mt -81.07 -52.33 7.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 17.1 mt -145.56 149.31 34.35 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.29 1.036 . . . . 0.0 110.995 -173.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -114.39 128.19 56.22 Favored 'General case' 0 CA--C 1.515 -0.402 1 N-CA-C 98.762 -4.532 . . . . 0.0 98.762 165.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.65 127.0 44.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.744 -165.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -74.26 68.29 1.47 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.664 0.786 . . . . 0.0 110.108 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.0 mt -54.2 -38.36 65.56 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.929 0.491 . . . . 0.0 111.102 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -53.68 -44.75 69.97 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.99 0.516 . . . . 0.0 112.162 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.89 -32.52 20.16 Favored 'General case' 0 CA--C 1.527 0.079 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -67.13 -50.59 62.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 O-C-N 121.759 -0.588 . . . . 0.0 110.326 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.345 22.1 pttm -37.0 -54.15 1.84 Allowed Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 118.283 2.698 . . . . 0.0 118.283 -176.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -52.63 -22.15 16.33 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.66 2.24 . . . . 0.0 114.095 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 -84.19 -14.36 50.31 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 118.13 -0.938 . . . . 0.0 113.096 -177.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 29.3 m -108.77 149.05 38.99 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 119.731 1.15 . . . . 0.0 112.44 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.32 -26.29 20.85 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.586 2.19 . . . . 0.0 110.372 175.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 10.0 m -157.85 137.41 12.03 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.564 1.146 . . . . 0.0 108.287 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 13.2 tp -90.29 6.78 41.5 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.876 0.87 . . . . 0.0 111.396 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.1 mmt -50.57 114.26 1.09 Allowed 'General case' 0 C--N 1.342 0.244 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 45.6 m -107.73 88.36 4.3 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -72.49 139.92 32.27 Favored 'Trans proline' 0 N--CA 1.445 -1.352 0 C-N-CA 121.923 1.749 . . . . 0.0 111.976 -178.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 16.6 mm -115.51 128.48 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 102.404 -3.184 . . . . 0.0 102.404 173.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.5 t -137.43 122.36 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -175.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -84.72 123.05 29.95 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.035 -2.58 . . . . 0.0 104.035 174.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 40.2 p -80.74 -72.78 0.4 Allowed 'General case' 0 C--O 1.227 -0.129 0 CA-C-N 118.841 0.746 . . . . 0.0 110.796 -175.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 22.2 p30 -65.14 -30.06 70.96 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -177.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 mt 46.27 44.54 12.5 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.156 0.982 . . . . 0.0 110.347 -176.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 42.53 37.39 0.97 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 126.351 1.86 . . . . 0.0 112.662 -175.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 75.5 mm-40 48.25 75.32 0.14 Allowed 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 126.706 2.002 . . . . 0.0 113.874 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.03 -14.21 5.19 Favored Glycine 0 C--N 1.335 0.484 0 CA-C-O 118.702 -1.055 . . . . 0.0 113.339 174.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -72.65 139.21 47.19 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.206 1.503 . . . . 0.0 109.776 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 77.2 p -111.87 130.81 55.7 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 124.97 1.308 . . . . 0.0 109.128 176.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -60.42 112.6 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 123.973 0.909 . . . . 0.0 110.387 -175.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 87.28 2.61 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 126.407 1.883 . . . . 0.0 106.518 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 34.7 mt -66.77 131.82 32.35 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -96.58 -44.2 7.25 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -47.23 83.1 0.0 OUTLIER 'General case' 0 C--N 1.34 0.158 0 C-N-CA 126.348 1.859 . . . . 0.0 114.206 -178.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 37.7 m -82.71 54.59 2.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 123.996 0.918 . . . . 0.0 108.787 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 157.47 -171.65 34.73 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.211 -0.755 . . . . 0.0 111.211 -177.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 29.6 t -58.47 138.05 56.93 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 122.794 0.438 . . . . 0.0 110.101 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.7 m -92.86 -173.01 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 123.7 0.8 . . . . 0.0 109.928 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.85 166.7 29.76 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.62 155.03 24.64 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.986 0.812 . . . . 0.0 110.336 176.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 62.56 5.12 1.55 Allowed 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.762 1.625 . . . . 0.0 114.301 178.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -67.95 118.22 10.85 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 62.7 tt0 -67.51 138.03 56.23 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . 0.417 ' C ' ' H ' ' A' ' 158' ' ' VAL . 29.2 t70 84.92 -113.87 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 128.327 2.651 . . . . 0.0 109.043 -179.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.366 1.7 mp 73.31 -28.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 129.565 3.146 . . . . 0.0 111.509 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.417 ' H ' ' C ' ' A' ' 156' ' ' ASP . 11.0 p -134.9 148.09 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 127.519 2.328 . . . . 0.0 106.978 169.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -134.67 144.93 48.1 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 104.009 -2.589 . . . . 0.0 104.009 173.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -112.0 112.55 40.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.156 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.1 134.02 44.74 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 123.66 0.784 . . . . 0.0 111.247 -174.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp . . . . . 0 CA--C 1.528 0.117 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 176.73 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.528 0.119 0 N-CA-C 114.387 1.254 . . . . 0.0 114.387 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -142.55 103.88 1.05 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 C-N-CA 126.68 1.992 . . . . 0.0 106.267 172.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 t -29.14 118.53 0.28 Allowed Pre-proline 0 CA--C 1.552 1.033 0 C-N-CA 124.728 1.211 . . . . 0.0 113.43 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -75.31 -37.47 1.87 Allowed 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 122.693 2.262 . . . . 0.0 117.324 -173.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.27 148.06 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 120.397 1.453 . . . . 0.0 109.3 -176.727 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.4 m -78.64 137.04 37.64 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 175.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.19 -147.14 14.54 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -107.72 144.1 35.3 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.1 tt -105.62 95.17 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 C-N-CA 124.304 1.041 . . . . 0.0 108.398 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -85.63 151.58 55.86 Favored Pre-proline 0 C--O 1.237 0.404 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.26 145.32 88.5 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 N-CA-C 107.888 -1.62 . . . . 0.0 107.888 174.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.3 tp -50.67 -32.64 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.672 0.789 . . . . 0.0 111.134 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.9 -29.87 63.41 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.829 1.252 . . . . 0.0 113.057 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -82.24 3.65 26.64 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.2 t -82.06 128.04 69.56 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-O 117.508 -1.234 . . . . 0.0 111.755 -176.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_exo -58.74 40.75 0.05 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 1 C-N-CA 126.354 4.702 . . . . 0.0 117.451 175.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -164.48 109.59 0.97 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 120.98 1.718 . . . . 0.0 109.033 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 18.8 mp0 -34.13 -48.52 0.32 Allowed 'General case' 0 C--O 1.231 0.117 0 C-N-CA 128.956 2.902 . . . . 0.0 114.401 -176.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.5 p -53.44 -38.95 34.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 CA-C-N 118.158 0.435 . . . . 0.0 110.878 -178.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -84.48 -48.83 9.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 177.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -51.03 -39.23 55.38 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -178.131 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.38 17.15 57.24 Favored Glycine 0 N--CA 1.445 -0.716 0 CA-C-O 118.219 -1.323 . . . . 0.0 111.06 -177.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.7 mttp 71.18 -40.71 0.48 Allowed 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.463 1.505 . . . . 0.0 114.07 178.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 29.97 -73.96 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 130.005 3.322 . . . . 0.0 116.753 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.19 -21.3 46.56 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.476 1.11 . . . . 0.0 113.263 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 172.43 -144.21 7.83 Favored Glycine 0 C--O 1.223 -0.564 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -141.57 160.05 40.95 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.55 -126.13 1.23 Allowed Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.05 163.73 15.86 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 118.636 1.218 . . . . 0.0 112.261 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.94 96.88 7.84 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 124.575 1.15 . . . . 0.0 110.466 -178.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 32.1 mm -80.44 126.11 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.4 tt -101.03 105.5 39.03 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 100.529 -3.878 . . . . 0.0 100.529 171.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -84.37 168.18 11.68 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.891 3.061 . . . . 0.0 114.255 -168.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.9 p -130.8 -71.7 0.57 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.347 1.459 . . . . 0.0 108.199 176.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -48.89 127.25 13.72 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 124.609 1.164 . . . . 0.0 112.088 178.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.21 42.26 2.34 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 173.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 35.9 mt -143.74 120.87 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 104.381 -2.452 . . . . 0.0 104.381 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.1 t -119.97 131.09 73.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 124.911 1.284 . . . . 0.0 107.549 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.4 m -110.72 159.39 10.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 C-N-CA 124.08 0.952 . . . . 0.0 110.947 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.84 132.7 94.83 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-O 118.41 -0.805 . . . . 0.0 110.21 -179.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -68.58 -15.95 42.02 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.638 2.892 . . . . 0.0 115.926 -177.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -143.99 162.02 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.046 0 CA-C-N 119.523 1.056 . . . . 0.0 110.409 -178.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 9.0 ptp85 -76.73 117.14 18.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 168.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 172.96 -179.62 44.28 Favored Glycine 0 N--CA 1.433 -1.529 0 C-N-CA 115.277 -3.344 . . . . 0.0 114.954 -167.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.63 127.91 42.05 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 124.558 1.143 . . . . 0.0 109.815 -176.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 9.6 mm -73.94 113.32 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 N-CA-C 102.633 -3.099 . . . . 0.0 102.633 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 61.0 tp -76.44 -47.93 21.37 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -174.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -174.77 157.4 2.47 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 13.5 t -138.91 119.24 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 175.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -42.04 151.53 0.34 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.572 0.624 . . . . 0.0 112.201 177.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.19 -26.36 15.03 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 123.89 3.06 . . . . 0.0 114.303 175.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 19.2 p -75.73 -15.2 60.31 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 123.871 0.869 . . . . 0.0 110.925 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 71.87 10.11 6.2 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.545 1.538 . . . . 0.0 113.536 178.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.469 ' CG ' ' HA ' ' A' ' 89' ' ' VAL . 22.6 p-80 -90.51 -31.62 16.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 119.428 1.013 . . . . 0.0 113.403 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.97 -178.82 7.16 Favored 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -171.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.663 23.0 mm 124.01 -132.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 1 C-N-CA 135.155 5.382 . . . . 0.0 105.216 -176.709 . . . . . . . . 3 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -169.86 -179.1 41.33 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 119.165 2.426 . . . . 0.0 119.165 -177.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.6 mp -124.56 172.33 9.3 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.747 2.419 . . . . 0.0 110.279 -178.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -134.42 142.01 47.0 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 169.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 40.8 p . . . . . 0 C--N 1.324 -0.516 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.041 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -103.53 136.35 43.43 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 173.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 22.3 mt -125.01 122.95 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -173.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 28.2 tp -89.65 136.83 32.8 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 127.193 2.197 . . . . 0.0 106.914 173.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.4 mt -120.14 155.63 23.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.652 1.181 . . . . 0.0 109.522 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.57 96.64 1.79 Allowed 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 126.223 1.809 . . . . 0.0 107.021 174.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -73.68 76.69 1.53 Allowed 'General case' 0 N--CA 1.454 -0.238 0 O-C-N 121.519 -0.738 . . . . 0.0 110.565 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.11 170.84 39.89 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.634 1.588 . . . . 0.0 111.775 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 2.0 tp -107.41 125.86 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.845 1.658 . . . . 0.0 106.935 178.03 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t0 58.88 38.6 24.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 125.323 1.449 . . . . 0.0 111.206 -176.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -95.88 -70.85 0.7 Allowed 'General case' 0 CA--C 1.496 -1.126 0 N-CA-C 101.366 -3.568 . . . . 0.0 101.366 171.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.469 ' HA ' ' CG ' ' A' ' 68' ' ' HIS 0.335 1.3 p 45.44 49.22 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 104.492 -2.41 . . . . 0.0 104.492 -172.758 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 21.4 m 12.97 48.38 0.0 OUTLIER 'General case' 0 C--N 1.35 0.592 1 C-N-CA 133.111 4.565 . . . . 0.0 112.83 -165.219 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.9 mt 33.66 50.52 0.31 Allowed 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 131.053 3.741 . . . . 0.0 109.001 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 90.5 mttt 76.66 50.26 0.05 Allowed 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 128.148 2.579 . . . . 0.0 111.595 -176.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 47.43 37.28 12.24 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 126.472 1.987 . . . . 0.0 114.059 -178.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -92.5 161.66 14.53 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 170.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 63.56 -4.14 1.11 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.137 1.351 . . . . 0.0 114.822 178.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -106.64 105.57 15.67 Favored 'General case' 0 C--N 1.342 0.262 0 CA-C-N 119.077 1.438 . . . . 0.0 111.327 -175.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 18.9 m -93.11 104.36 16.57 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 174.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.6 t -80.15 148.83 30.77 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 119.203 0.91 . . . . 0.0 110.775 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.408 ' CE1' ' HG3' ' A' ' 114' ' ' GLU . 39.3 m-85 -115.9 3.85 13.77 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 126.323 1.849 . . . . 0.0 110.785 179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.6 m -134.02 145.96 32.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 176.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.6 m -82.6 -16.87 46.83 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.973 1.309 . . . . 0.0 112.211 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.472 1.3 pp20? 73.29 140.86 0.06 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.203 3.001 . . . . 0.0 109.574 -172.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 97.5 -16.48 60.5 Favored Glycine 0 CA--C 1.54 1.642 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -169.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -57.87 115.66 2.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.632 1.973 . . . . 0.0 108.901 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.25 123.01 29.67 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 128.912 2.885 . . . . 0.0 114.254 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.345 27.3 m 52.23 70.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.301 0 C-N-CA 126.992 2.117 . . . . 0.0 116.032 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 138.44 26.55 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 170.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -93.63 -135.49 0.01 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.004 0 C-N-CA 124.978 3.785 . . . . 0.0 108.522 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -64.21 30.09 0.09 OUTLIER Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.334 1.921 . . . . 0.0 115.678 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.8 tt0 -64.58 149.8 48.12 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 169.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -64.32 122.11 15.91 Favored 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.739 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.7 mt -80.44 -49.43 11.44 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 175.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.1 mt -144.04 152.43 41.0 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.007 0.923 . . . . 0.0 110.708 -173.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.408 ' HG3' ' CE1' ' A' ' 99' ' ' PHE . 93.2 mt-10 -114.49 128.83 56.54 Favored 'General case' 0 CA--C 1.517 -0.298 1 N-CA-C 98.95 -4.463 . . . . 0.0 98.95 165.802 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.44 128.47 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.469 -165.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -76.82 63.57 2.23 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.623 0.725 . . . . 0.0 109.856 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 80.0 mt -54.34 -37.68 65.16 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 123.248 0.619 . . . . 0.0 110.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -53.76 -43.37 69.13 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.761 0.824 . . . . 0.0 112.247 178.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.92 -34.54 20.9 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.059 0.391 . . . . 0.0 111.411 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 75.4 t -62.01 -55.43 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.355 18.8 pttp -38.96 -58.33 1.76 Allowed Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 117.596 2.443 . . . . 0.0 117.596 -176.098 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.49 -20.28 48.43 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.774 2.316 . . . . 0.0 113.717 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -100.13 9.2 43.18 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 118.551 -0.738 . . . . 0.0 112.726 -176.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 22.8 m -136.23 158.48 73.53 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 119.573 1.079 . . . . 0.0 109.36 -178.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -75.7 -30.0 6.63 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.017 1.811 . . . . 0.0 112.783 -177.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -163.88 133.96 4.2 Favored 'General case' 0 N--CA 1.454 -0.241 0 O-C-N 121.395 -0.816 . . . . 0.0 111.287 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -93.42 9.07 38.02 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.961 0.904 . . . . 0.0 111.564 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -50.89 110.04 0.38 Allowed 'General case' 0 C--N 1.342 0.242 0 C-N-CA 124.301 1.041 . . . . 0.0 108.327 177.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.8 m -95.83 102.49 10.52 Favored Pre-proline 0 N--CA 1.447 -0.607 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -92.39 99.66 0.18 Allowed 'Trans proline' 0 N--CA 1.444 -1.422 0 C-N-CA 123.414 2.743 . . . . 0.0 107.679 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.08 126.5 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 103.503 -2.777 . . . . 0.0 103.503 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.05 120.43 51.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 CA-C-O 121.928 0.871 . . . . 0.0 109.303 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.485 ' N ' ' CD1' ' A' ' 133' ' ' PHE . 0.5 OUTLIER -83.0 114.14 21.06 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 101.732 -3.432 . . . . 0.0 101.732 177.592 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -77.16 -79.69 0.11 Allowed 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 121.007 0.432 . . . . 0.0 111.216 -170.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.23 68.12 0.72 Allowed 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.988 0.899 . . . . 0.0 111.298 -178.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.1 mt -76.76 65.28 2.47 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.128 -0.982 . . . . 0.0 108.364 177.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 10.18 63.03 0.0 OUTLIER 'General case' 0 C--N 1.347 0.458 0 C-N-CA 130.582 3.553 . . . . 0.0 112.815 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 25.97 58.02 0.06 Allowed 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 128.52 2.728 . . . . 0.0 114.514 -176.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 148.71 6.2 0.23 Allowed Glycine 0 CA--C 1.524 0.617 0 CA-C-O 118.577 -1.124 . . . . 0.0 114.033 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . 0.621 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 22.4 mt-10 -77.76 92.76 4.21 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 119.439 1.62 . . . . 0.0 107.894 177.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 70.1 p -76.69 135.06 39.08 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -177.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.2 t -87.32 90.74 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 124.0 0.92 . . . . 0.0 109.26 -176.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 42.1 m -85.68 95.6 9.42 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 33.0 mt -64.58 131.84 30.36 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -100.94 -45.9 5.28 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 124.665 1.186 . . . . 0.0 109.055 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.67 74.81 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.234 0 C-N-CA 126.113 1.765 . . . . 0.0 112.02 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.1 m -79.71 54.47 1.82 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.443 1.097 . . . . 0.0 110.025 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 160.7 179.66 35.6 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 40.5 t -57.16 144.83 33.46 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.172 0.589 . . . . 0.0 111.616 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 4.9 m -145.04 166.96 10.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -102.36 166.86 10.33 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 124.849 1.26 . . . . 0.0 111.48 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.29 163.41 23.02 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 63.96 -9.42 0.15 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.727 2.011 . . . . 0.0 114.552 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 34.2 mm-40 -64.32 148.96 49.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.456 1.025 . . . . 0.0 111.581 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -99.33 159.38 15.05 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.527 2.331 . . . . 0.0 111.099 -176.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 24.9 t70 57.55 21.83 7.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 126.137 1.775 . . . . 0.0 114.621 174.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -70.35 -28.64 36.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 C-N-CA 123.61 0.764 . . . . 0.0 111.812 178.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.44 145.14 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 C-N-CA 125.5 1.52 . . . . 0.0 107.866 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -120.57 111.86 18.2 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 174.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . 0.621 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.03 110.53 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 103.84 -2.652 . . . . 0.0 103.84 172.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -109.11 125.04 51.73 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.956 1.303 . . . . 0.0 109.883 -178.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 56.2 tptt . . . . . 0 C--N 1.333 -0.14 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.109 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.461 0.117 0 CA-C-O 118.311 -0.852 . . . . 0.0 111.467 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.2 m -90.51 101.5 12.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 CA-C-N 118.882 0.765 . . . . 0.0 110.568 177.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.3 p -35.44 115.56 0.56 Allowed Pre-proline 0 CA--C 1.556 1.211 0 C-N-CA 125.831 1.652 . . . . 0.0 110.891 177.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -75.72 -30.45 6.16 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.832 2.354 . . . . 0.0 117.685 -171.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.49 148.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 120.513 1.506 . . . . 0.0 110.806 -176.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.8 m -79.27 138.81 37.91 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 171.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.62 -151.69 20.51 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -117.05 116.33 27.14 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.218 1.407 . . . . 0.0 108.435 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 7.5 mt -78.84 138.17 20.58 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 CA-C-N 118.666 0.666 . . . . 0.0 109.617 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -137.03 144.75 47.56 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 174.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -54.9 142.73 74.67 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 C-N-CA 121.967 1.778 . . . . 0.0 110.109 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.22 -36.44 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 124.646 1.178 . . . . 0.0 113.187 -177.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.2 p -51.38 -32.68 26.91 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.911 1.285 . . . . 0.0 112.559 178.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -75.94 -9.61 58.75 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 124.224 1.009 . . . . 0.0 112.505 -175.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 52.9 t -75.16 119.73 78.33 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-O 117.662 -1.161 . . . . 0.0 111.529 -176.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -59.34 53.94 0.07 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 1 C-N-CA 126.067 4.511 . . . . 0.0 117.071 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -167.69 112.03 0.67 Allowed 'General case' 0 N--CA 1.463 0.186 0 O-C-N 120.464 -1.398 . . . . 0.0 108.684 177.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -30.67 -51.46 0.15 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 127.609 2.363 . . . . 0.0 114.589 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.3 t -52.97 -47.33 53.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 CA-C-O 121.508 0.67 . . . . 0.0 110.05 -178.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -78.08 -46.95 19.41 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -50.38 -43.01 54.3 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.412 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -97.62 11.94 64.69 Favored Glycine 0 C--N 1.338 0.657 0 CA-C-O 118.909 -0.94 . . . . 0.0 111.499 -178.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? 70.13 -34.8 0.3 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.809 1.644 . . . . 0.0 114.032 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.412 ' H ' ' C ' ' A' ' 36' ' ' GLY . 1.6 tmt? 32.18 -69.27 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 131.286 3.834 . . . . 0.0 116.576 178.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 7.8 tpt -78.58 -19.99 51.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.185 0.994 . . . . 0.0 111.981 -175.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.15 -133.13 1.82 Allowed Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -136.45 158.56 44.14 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 172.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 176.19 -154.45 16.93 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.383 -0.913 . . . . 0.0 111.706 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -158.25 164.48 36.43 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 122.533 0.333 . . . . 0.0 110.2 178.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.45 146.3 28.3 Favored 'General case' 0 CA--C 1.508 -0.665 0 C-N-CA 123.742 0.817 . . . . 0.0 109.369 178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.93 128.19 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 102.635 -3.098 . . . . 0.0 102.635 169.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.3 tt -91.33 106.78 17.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 172.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -61.32 170.34 5.35 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 124.111 3.207 . . . . 0.0 116.166 -171.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.5 p -152.29 -65.01 0.17 Allowed 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 125.089 1.356 . . . . 0.0 107.876 176.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -61.85 127.61 32.25 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.47 0.708 . . . . 0.0 110.188 176.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.83 43.95 2.9 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 172.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -145.36 124.35 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 127.381 2.273 . . . . 0.0 105.138 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 89.9 t -123.53 126.49 73.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.03 155.04 9.0 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 C-N-CA 123.716 0.807 . . . . 0.0 110.268 178.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.79 139.31 95.5 Favored Pre-proline 0 N--CA 1.449 -0.519 0 C-N-CA 123.585 0.754 . . . . 0.0 110.192 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -78.28 -21.91 10.08 Favored 'Trans proline' 0 N--CA 1.453 -0.885 0 C-N-CA 123.51 2.807 . . . . 0.0 114.221 -177.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.7 m -138.92 166.61 22.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.163 0 C-N-CA 124.325 1.05 . . . . 0.0 111.007 -177.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -78.81 115.96 18.83 Favored 'General case' 0 C--O 1.234 0.253 1 N-CA-C 99.376 -4.305 . . . . 0.0 99.376 168.338 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.32 176.6 47.89 Favored Glycine 0 N--CA 1.441 -1.015 0 C-N-CA 115.606 -3.188 . . . . 0.0 117.015 -168.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 123.72 30.54 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.769 1.628 . . . . 0.0 108.505 178.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 16.7 mm -75.45 95.77 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 172.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 49.9 tp -72.41 -51.27 21.13 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -171.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -171.19 137.06 1.1 Allowed 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 118.472 0.578 . . . . 0.0 111.423 177.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -128.15 123.9 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 103.761 -2.681 . . . . 0.0 103.761 172.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.33 156.61 0.48 Allowed Pre-proline 0 CA--C 1.54 0.578 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -178.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -50.05 -29.71 22.63 Favored 'Trans proline' 0 C--N 1.348 0.517 0 C-N-CA 123.924 3.083 . . . . 0.0 114.562 178.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.6 p -77.56 -9.04 58.7 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.511 1.124 . . . . 0.0 111.64 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.22 8.43 3.36 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 127.835 2.454 . . . . 0.0 113.202 -178.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -80.88 -27.76 36.22 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -160.68 -176.35 5.5 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 119.204 0.911 . . . . 0.0 111.677 -174.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.898 18.3 mm 129.0 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.184 1 C-N-CA 131.846 4.058 . . . . 0.0 111.355 176.485 . . . . . . . . 3 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -147.36 168.23 28.44 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 116.6 1.4 . . . . 0.0 116.6 -173.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -132.49 169.15 16.98 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 126.349 1.86 . . . . 0.0 108.619 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.11 144.71 38.82 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 175.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 89.2 p . . . . . 0 C--N 1.32 -0.685 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 176.446 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 . . . . . 0 C--O 1.238 0.464 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -111.55 148.3 33.53 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.283 2.233 . . . . 0.0 107.107 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.38 144.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 124.269 1.028 . . . . 0.0 109.66 -176.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -125.62 132.58 52.46 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 128.159 2.583 . . . . 0.0 105.439 176.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 39.0 mt -131.98 141.9 44.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 C-N-CA 124.798 1.239 . . . . 0.0 109.715 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -132.55 104.96 6.94 Favored 'General case' 0 C--O 1.226 -0.178 0 C-N-CA 124.335 1.054 . . . . 0.0 108.475 174.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.7 t80 -68.35 109.65 3.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 121.109 -0.995 . . . . 0.0 109.092 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.67 -165.82 7.79 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -176.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 31.4 mt -122.29 136.5 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.7 t0 55.48 42.61 29.69 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.555 1.142 . . . . 0.0 112.645 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.435 ' O ' ' N ' ' A' ' 90' ' ' SER . 1.8 p -80.19 -85.22 0.09 Allowed 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 103.093 -2.929 . . . . 0.0 103.093 172.215 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.1 p 26.43 -64.82 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 C-N-CA 128.883 2.873 . . . . 0.0 117.293 173.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 88' ' ' THR . 11.8 m -60.44 -36.83 79.13 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 126.624 1.97 . . . . 0.0 109.675 178.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -50.9 -36.71 39.65 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 128.216 2.606 . . . . 0.0 109.617 176.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp 70.49 151.75 0.1 Allowed 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 126.303 1.841 . . . . 0.0 109.673 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -65.91 25.99 0.15 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 115.153 0.821 . . . . 0.0 115.153 -178.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 20.5 mm-40 -59.21 -35.16 73.13 Favored 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.689 1.744 . . . . 0.0 112.085 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -98.02 15.26 61.81 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.764 178.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -123.31 96.57 5.04 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 118.884 1.342 . . . . 0.0 109.545 -176.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.7 m -81.52 111.77 18.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 173.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.8 p -86.11 138.53 31.85 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.563 -0.711 . . . . 0.0 111.279 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . 0.41 ' CE1' ' HG3' ' A' ' 114' ' ' GLU . 35.8 m-85 -107.51 7.16 28.68 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 125.57 1.548 . . . . 0.0 113.389 -177.21 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 20.5 m -140.42 144.37 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 175.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.7 m -79.51 -15.77 57.16 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.175 0.99 . . . . 0.0 112.772 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.442 16.1 pm0 69.03 147.46 0.06 Allowed 'General case' 0 N--CA 1.446 -0.671 0 C-N-CA 130.065 3.346 . . . . 0.0 111.209 -173.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 95.22 -21.78 42.25 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 124.709 1.147 . . . . 0.0 110.466 -172.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -60.63 124.57 20.78 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.919 1.688 . . . . 0.0 108.914 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.33 123.64 31.8 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 129.162 2.985 . . . . 0.0 113.308 -174.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.373 28.5 m 52.23 69.89 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.142 0 N-CA-C 117.018 2.229 . . . . 0.0 117.018 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.35 139.85 27.36 Favored Pre-proline 0 N--CA 1.45 -0.455 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 168.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -88.19 -151.25 0.04 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 123.686 2.924 . . . . 0.0 108.544 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -69.68 54.36 0.71 Allowed Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.908 1.242 . . . . 0.0 113.924 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -54.22 -55.07 31.57 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 124.97 1.308 . . . . 0.0 110.037 177.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt 144.87 125.67 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.621 1 C-N-CA 132.615 4.366 . . . . 0.0 106.098 -175.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 69.9 mt -91.83 -45.51 8.35 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 123.652 0.781 . . . . 0.0 109.385 178.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.2 mt -147.52 151.87 37.07 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 122.798 0.439 . . . . 0.0 111.101 -174.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . 0.41 ' HG3' ' CE1' ' A' ' 99' ' ' PHE . 99.1 mt-10 -116.31 127.21 54.49 Favored 'General case' 0 CA--C 1.517 -0.291 1 N-CA-C 98.557 -4.608 . . . . 0.0 98.557 165.796 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.23 126.34 45.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.721 -166.357 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -74.75 61.03 0.96 Allowed 'General case' 0 C--O 1.233 0.224 0 C-N-CA 125.259 1.423 . . . . 0.0 111.239 -176.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.5 mt -45.94 -41.82 12.08 Favored 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 124.326 1.05 . . . . 0.0 111.94 -178.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -49.15 -41.4 36.17 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.622 0.769 . . . . 0.0 112.501 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -92.57 -33.77 14.3 Favored 'General case' 0 CA--C 1.527 0.066 0 C-N-CA 123.467 0.707 . . . . 0.0 111.353 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.26 -51.95 64.77 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.617 -0.677 . . . . 0.0 109.468 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.368 46.1 pttt -41.87 -58.07 3.58 Favored Pre-proline 0 CA--C 1.541 0.599 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -177.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -57.18 -19.8 35.56 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.435 2.09 . . . . 0.0 113.327 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -95.49 7.98 44.63 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 118.097 -0.954 . . . . 0.0 112.488 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 23.9 m -132.91 150.51 75.87 Favored Pre-proline 0 N--CA 1.466 0.333 0 CA-C-N 120.086 1.312 . . . . 0.0 111.506 179.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -73.78 -27.41 12.52 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 C-N-CA 122.867 2.378 . . . . 0.0 111.635 179.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -157.42 132.01 8.56 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.598 -0.689 . . . . 0.0 109.926 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -90.35 -2.06 57.96 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.712 1.205 . . . . 0.0 111.769 -179.019 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.6 mmt -49.65 111.26 0.48 Allowed 'General case' 0 C--N 1.34 0.194 0 C-N-CA 124.399 1.08 . . . . 0.0 109.353 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 49.9 m -102.73 110.14 62.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 -178.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -91.33 137.62 2.1 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 122.843 2.362 . . . . 0.0 110.538 -179.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 15.3 mm -114.46 121.17 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 102.893 -3.003 . . . . 0.0 102.893 173.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.1 t -126.43 149.11 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -177.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -123.1 124.99 44.34 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 36.1 p -83.58 -67.76 0.76 Allowed 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.771 0.796 . . . . 0.0 110.638 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.8 p30 -72.0 51.7 0.23 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.99 1.716 . . . . 0.0 113.587 -177.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 78.2 mt -80.49 54.31 2.03 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.393 1.077 . . . . 0.0 108.961 175.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 16.33 55.67 0.01 OUTLIER 'General case' 0 C--N 1.346 0.438 0 C-N-CA 129.59 3.156 . . . . 0.0 113.403 -177.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 27.56 56.47 0.08 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 127.715 2.406 . . . . 0.0 113.829 -175.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 165.68 -10.83 0.07 OUTLIER Glycine 0 CA--C 1.526 0.758 0 CA-C-O 119.321 -0.71 . . . . 0.0 113.638 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . 0.52 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 16.2 mt-10 -78.73 82.07 4.98 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.752 1.276 . . . . 0.0 107.932 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.7 p -74.3 138.49 43.59 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.404 -0.81 . . . . 0.0 109.93 -175.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -83.65 122.29 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 123.66 0.784 . . . . 0.0 109.234 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.6 m -112.75 97.82 6.81 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.867 1.267 . . . . 0.0 109.178 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.2 pt -71.08 108.37 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 176.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -77.08 -55.47 5.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -82.88 66.08 8.32 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 49.2 m -77.6 69.72 3.88 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.81 -150.16 7.62 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 107.105 -2.398 . . . . 0.0 107.105 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 10.4 t -75.64 146.08 40.56 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 118.297 1.048 . . . . 0.0 110.556 178.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -143.71 167.3 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 124.555 1.142 . . . . 0.0 109.777 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 35.2 m-80 -113.69 163.75 14.59 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 125.236 1.414 . . . . 0.0 107.647 174.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.94 165.35 25.4 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 170.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 56.88 48.42 15.99 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.565 1.146 . . . . 0.0 111.862 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -121.96 159.18 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 173.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -126.46 153.66 44.77 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 119.228 0.922 . . . . 0.0 111.188 -176.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.7 t70 62.95 13.65 6.83 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 126.702 2.001 . . . . 0.0 113.191 -176.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.54 -37.85 78.79 Favored 'Isoleucine or valine' 0 C--O 1.233 0.207 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.7 p -117.88 129.29 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 N-CA-C 103.486 -2.783 . . . . 0.0 103.486 168.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -122.81 123.73 41.7 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . 0.52 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.26 130.61 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 174.584 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -130.97 139.25 50.0 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.221 1.408 . . . . 0.0 107.269 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.3 tptm . . . . . 0 C--N 1.331 -0.215 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 -177.795 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.226 -0.168 0 N-CA-C 105.6 -2.0 . . . . 0.0 105.6 . . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.32 91.3 2.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.269 0 CA-C-N 118.991 0.814 . . . . 0.0 112.352 -176.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.6 t -21.95 111.34 0.14 Allowed Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 126.373 1.869 . . . . 0.0 112.282 176.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -74.11 -28.58 10.74 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.181 2.587 . . . . 0.0 118.338 -169.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.64 153.31 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 120.339 1.427 . . . . 0.0 110.496 -176.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 92.1 m -88.32 125.38 34.65 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 172.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 179.72 -170.43 41.74 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -176.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -98.63 133.93 42.27 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 11.2 tt -81.94 146.22 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 123.111 0.564 . . . . 0.0 111.148 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -144.8 137.35 13.49 Favored Pre-proline 0 C--O 1.237 0.397 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -59.58 146.18 95.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.094 1.863 . . . . 0.0 111.452 178.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.9 tp -50.04 -36.93 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 C-N-CA 125.176 1.39 . . . . 0.0 112.062 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 p -70.27 -12.08 61.34 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.034 1.734 . . . . 0.0 114.195 -179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -112.79 29.12 8.22 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.897 0.772 . . . . 0.0 111.636 -173.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.3 t -94.08 135.11 24.95 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 124.327 1.051 . . . . 0.0 109.564 178.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -65.5 50.82 0.24 Allowed 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 124.216 3.277 . . . . 0.0 115.054 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -166.77 133.89 2.49 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 120.489 -1.382 . . . . 0.0 109.815 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -59.8 -47.51 85.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.873 1.269 . . . . 0.0 113.109 -177.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 55.0 t -55.07 -54.97 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 118.596 0.634 . . . . 0.0 109.389 -178.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -61.38 -58.68 7.25 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.973 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 59.0 m -69.47 -16.0 63.38 Favored 'General case' 0 N--CA 1.461 0.082 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -177.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -88.91 -0.1 81.62 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 108.44 -1.864 . . . . 0.0 108.44 173.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 57.5 mttp 74.16 -39.88 0.44 Allowed 'General case' 0 C--N 1.346 0.438 0 C-N-CA 126.498 1.919 . . . . 0.0 111.56 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.433 ' H ' ' C ' ' A' ' 36' ' ' GLY . 14.9 tpt 28.9 -76.74 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 130.436 3.494 . . . . 0.0 116.461 178.263 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 11.0 ttt -79.24 -17.57 54.52 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.741 0.816 . . . . 0.0 113.059 -175.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.44 -135.28 2.83 Favored Glycine 0 C--N 1.338 0.643 0 CA-C-N 119.128 0.877 . . . . 0.0 112.382 -176.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -137.23 157.84 45.75 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.53 -157.77 19.15 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.764 -175.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -158.74 158.81 34.36 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.773 1.229 . . . . 0.0 108.203 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.23 132.96 52.49 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-N 118.836 0.744 . . . . 0.0 110.418 177.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 22.6 mm -117.35 107.25 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 173.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 11.9 tp -74.79 119.06 74.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 N-CA-C 102.329 -3.212 . . . . 0.0 102.329 172.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.04 153.38 22.04 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 123.095 2.53 . . . . 0.0 113.721 -168.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 79.2 p -126.18 -45.78 1.68 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.651 0.78 . . . . 0.0 112.242 178.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -64.43 -42.27 96.11 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.58 25.34 70.32 Favored Glycine 0 CA--C 1.533 1.188 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -173.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 54.0 mt -136.5 123.59 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 102.496 -3.149 . . . . 0.0 102.496 177.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 79.1 t -124.49 124.66 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 C-N-CA 124.397 1.079 . . . . 0.0 109.945 -171.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -107.12 155.8 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.126 0 C-N-CA 123.715 0.806 . . . . 0.0 109.493 176.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -61.82 139.63 95.52 Favored Pre-proline 0 N--CA 1.448 -0.551 0 C-N-CA 123.624 0.77 . . . . 0.0 110.544 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -75.31 -13.01 20.9 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 124.307 3.338 . . . . 0.0 115.03 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -148.11 161.65 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.056 0 CA-C-N 119.443 1.02 . . . . 0.0 110.213 -176.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 116.99 19.6 Favored 'General case' 0 C--O 1.237 0.402 1 N-CA-C 100.103 -4.036 . . . . 0.0 100.103 167.653 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 173.27 -177.34 45.73 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 115.544 -3.217 . . . . 0.0 116.428 -168.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.15 122.04 28.78 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.161 0.984 . . . . 0.0 112.512 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.4 mm -66.2 125.59 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 N-CA-C 103.058 -2.942 . . . . 0.0 103.058 168.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 40.7 tp -78.39 -40.75 35.23 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 119.643 1.111 . . . . 0.0 109.213 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -175.43 -163.75 0.13 Allowed 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . 0.412 ' HA ' ' CG2' ' A' ' 70' ' ' ILE . 7.3 p -160.51 125.42 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 172.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.3 m-85 -68.0 145.1 97.61 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 119.291 0.951 . . . . 0.0 110.361 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -50.6 -29.27 24.59 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 123.484 2.789 . . . . 0.0 113.532 176.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.1 p -77.3 -7.91 56.76 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.756 0.822 . . . . 0.0 111.956 -178.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.8 ttmt 64.06 -11.18 0.12 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.828 1.651 . . . . 0.0 114.914 177.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 9.3 p-80 -74.72 -29.4 61.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 121.665 -0.647 . . . . 0.0 112.688 -175.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.46 176.8 11.62 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-N 118.893 0.77 . . . . 0.0 110.368 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . 0.541 ' CG1' ' H ' ' A' ' 71' ' ' GLY . 0.1 OUTLIER 157.31 -148.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.355 0 C-N-CA 130.492 3.517 . . . . 0.0 106.056 176.318 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . 0.541 ' H ' ' CG1' ' A' ' 70' ' ' ILE . . . -152.51 174.21 31.44 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 123.477 0.561 . . . . 0.0 111.804 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -141.19 176.78 8.56 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 126.486 1.914 . . . . 0.0 108.045 -178.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 30.5 mt-30 -143.08 156.02 44.73 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 103.634 -2.728 . . . . 0.0 103.634 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 69.6 p . . . . . 0 C--N 1.326 -0.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.608 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 69.0 mtm180 . . . . . 0 CA--C 1.525 0.012 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -73.45 119.77 18.14 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.7 mp -98.38 149.97 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 125.432 1.493 . . . . 0.0 108.574 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.6 tp -128.88 136.05 49.91 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 127.745 2.418 . . . . 0.0 104.849 176.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 46.0 mt -129.93 136.2 59.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -129.74 84.71 2.23 Favored 'General case' 0 N--CA 1.466 0.335 0 C-N-CA 123.481 0.712 . . . . 0.0 110.619 176.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -56.67 98.94 0.03 OUTLIER 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.528 0.731 . . . . 0.0 111.303 -179.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.75 -177.16 5.17 Favored Glycine 0 CA--C 1.531 1.059 0 C-N-CA 124.092 0.853 . . . . 0.0 112.463 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.1 mt -121.73 140.23 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 69.82 9.4 7.13 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.384 1.474 . . . . 0.0 112.313 -177.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -75.6 -34.41 60.62 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 126.358 1.863 . . . . 0.0 108.156 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.5 p -54.32 -46.79 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 CA-C-N 113.468 -1.696 . . . . 0.0 108.028 171.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -62.05 -39.21 91.57 Favored 'General case' 0 N--CA 1.455 -0.198 0 C-N-CA 124.491 1.116 . . . . 0.0 109.425 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.99 3.17 5.67 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.934 1.694 . . . . 0.0 111.322 177.14 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 48.13 32.48 3.02 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 126.068 1.747 . . . . 0.0 112.993 178.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.74 28.29 60.07 Favored Glycine 0 CA--C 1.535 1.323 0 O-C-N 122.009 -0.432 . . . . 0.0 112.828 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 51.9 mt-10 -72.4 91.04 1.33 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.963 1.381 . . . . 0.0 108.843 178.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 6.12 4.24 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 126.745 2.117 . . . . 0.0 111.391 -176.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.416 ' CD1' HG11 ' A' ' 115' ' ' VAL . 14.6 m-30 -103.27 131.12 50.57 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.187 1.395 . . . . 0.0 108.477 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 14.3 m -119.98 122.79 41.95 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 126.245 1.818 . . . . 0.0 107.159 -179.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.1 p -99.32 124.63 44.57 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.612 0.765 . . . . 0.0 109.957 -176.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -90.59 -48.81 6.85 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.566 1.546 . . . . 0.0 111.294 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.418 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.4 m -73.43 130.76 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 C-N-CA 117.149 -1.82 . . . . 0.0 107.283 175.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 71.1 m -94.51 55.1 1.9 Allowed 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 102.743 -3.058 . . . . 0.0 102.743 168.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.418 ' H ' ' C ' ' A' ' 100' ' ' VAL 0.588 0.4 OUTLIER 43.58 -77.63 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.774 0 C-N-CA 130.627 3.571 . . . . 0.0 113.465 -167.57 . . . . . . . . 4 4 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.4 35.6 36.2 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 125.108 1.337 . . . . 0.0 110.45 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.373 4.1 p30 4.38 -106.6 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 130.049 3.34 . . . . 0.0 119.313 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -33.62 111.94 0.12 Allowed 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 130.993 3.717 . . . . 0.0 119.047 -169.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.363 27.4 m 48.61 68.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 129.08 2.952 . . . . 0.0 118.036 173.487 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 139.22 27.48 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 167.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -90.37 -145.04 0.03 OUTLIER 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.56 2.84 . . . . 0.0 108.302 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -70.81 52.05 0.92 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 124.875 1.226 . . . . 0.0 113.885 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.7 tp60 -61.83 -22.25 65.34 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 125.858 1.663 . . . . 0.0 113.707 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt 108.1 111.84 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 130.103 3.361 . . . . 0.0 107.971 -176.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 73.5 mt -80.25 -53.2 6.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 23.0 mt -143.04 163.94 31.44 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 123.743 0.817 . . . . 0.0 111.721 -174.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -128.19 135.33 49.58 Favored 'General case' 0 CA--C 1.515 -0.4 1 N-CA-C 99.81 -4.145 . . . . 0.0 99.81 166.707 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . 0.416 HG11 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -144.92 121.28 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -166.303 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -70.53 64.98 0.29 Allowed 'General case' 0 C--O 1.234 0.246 0 C-N-CA 125.569 1.548 . . . . 0.0 113.019 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 88.5 mt -40.81 -54.27 2.7 Favored 'General case' 0 C--O 1.226 -0.165 0 C-N-CA 124.91 1.284 . . . . 0.0 111.909 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -49.81 -41.36 44.57 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.485 1.114 . . . . 0.0 113.879 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.43 -35.01 15.4 Favored 'General case' 0 C--O 1.23 0.056 0 C-N-CA 122.454 0.302 . . . . 0.0 111.496 -177.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.9 t -67.21 -50.61 61.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 O-C-N 121.764 -0.585 . . . . 0.0 109.529 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.347 48.5 pttt -40.11 -57.78 2.61 Favored Pre-proline 0 CA--C 1.539 0.55 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.91 -21.85 43.06 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 122.509 2.139 . . . . 0.0 113.132 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -97.43 6.89 47.51 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 118.387 -0.816 . . . . 0.0 112.655 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 30.2 m -136.49 151.14 72.39 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-N 119.898 1.226 . . . . 0.0 110.262 178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.79 -25.16 12.59 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.535 2.157 . . . . 0.0 112.206 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.9 m -158.24 128.09 5.95 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 119.038 0.835 . . . . 0.0 111.27 -177.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.32 -0.23 57.31 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.823 1.249 . . . . 0.0 110.72 176.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 82.6 mmm -50.37 103.0 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 126.221 1.808 . . . . 0.0 109.754 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 68.6 m -99.09 117.39 64.27 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 123.814 0.845 . . . . 0.0 109.091 -177.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.56 139.49 1.87 Allowed 'Trans proline' 0 N--CA 1.442 -1.556 0 C-N-CA 123.211 2.607 . . . . 0.0 108.914 178.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mp -113.08 117.82 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 N-CA-C 100.523 -3.88 . . . . 0.0 100.523 171.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -126.01 158.13 35.55 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -134.1 137.49 44.62 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 103.751 -2.685 . . . . 0.0 103.751 -176.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -92.46 -73.41 0.55 Allowed 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 119.223 0.92 . . . . 0.0 109.216 -179.195 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -75.96 68.79 2.5 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -78.6 66.0 4.01 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 171.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 31.46 47.45 0.06 Allowed 'General case' 0 C--N 1.343 0.299 0 C-N-CA 127.831 2.452 . . . . 0.0 111.717 -173.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 29.61 61.22 0.16 Allowed 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 128.243 2.617 . . . . 0.0 114.343 -177.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.38 -14.78 0.22 Allowed Glycine 0 CA--C 1.525 0.668 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.968 177.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . 0.524 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 44.2 mm-40 -80.4 123.66 28.22 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.201 1.001 . . . . 0.0 109.638 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.2 p -89.78 143.28 26.93 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.925 0.89 . . . . 0.0 109.257 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -89.94 113.23 25.8 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 C-N-CA 123.664 0.786 . . . . 0.0 109.874 -178.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 36.2 m -106.74 98.85 8.47 Favored 'General case' 0 C--N 1.34 0.178 0 C-N-CA 124.333 1.053 . . . . 0.0 110.576 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 3.2 pt -64.07 128.74 26.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 175.325 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -98.09 -34.71 10.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.064 0.946 . . . . 0.0 112.223 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -70.98 100.72 2.03 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 119.773 1.169 . . . . 0.0 109.915 178.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 1.2 m -79.49 51.26 1.22 Allowed 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 176.2 -145.76 7.7 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -175.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 47.1 t -73.92 132.49 42.52 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 122.203 -0.586 . . . . 0.0 111.216 -178.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 18.4 m -89.7 157.15 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 174.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.78 152.44 49.27 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.5 mtp180 -58.29 150.07 22.82 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 122.685 0.394 . . . . 0.0 111.603 177.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 63.03 1.73 0.91 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 126.412 1.885 . . . . 0.0 115.339 172.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 58.9 mm-40 -70.13 119.32 14.15 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 119.569 1.077 . . . . 0.0 108.635 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -81.99 125.86 31.28 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 121.369 0.604 . . . . 0.0 112.242 -176.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.9 t0 70.08 27.9 4.19 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 128.472 2.709 . . . . 0.0 115.459 175.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.26 1.7 mp -71.27 -8.89 12.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 CA-C-O 121.306 0.575 . . . . 0.0 110.264 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.7 p -122.39 120.15 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 102.75 -3.056 . . . . 0.0 102.75 168.385 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 5.5 mtpm? -108.13 128.42 54.68 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . 0.524 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.45 133.14 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -145.08 -174.87 4.48 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 125.078 1.351 . . . . 0.0 108.716 -177.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 49.3 mtmt . . . . . 0 C--O 1.233 0.201 0 C-N-CA 125.307 1.443 . . . . 0.0 107.31 174.981 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.529 0.163 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.9 m -125.44 84.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-N 118.61 0.641 . . . . 0.0 112.65 -176.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 21.9 t -19.86 122.01 0.09 OUTLIER Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 129.373 3.069 . . . . 0.0 112.553 177.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -71.48 -37.35 5.65 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 117.632 2.128 . . . . 0.0 117.632 -171.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.3 151.64 18.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 119.717 1.144 . . . . 0.0 111.387 -175.109 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.1 m -88.46 146.38 25.24 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.42 -128.6 2.17 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -127.57 138.64 52.94 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.007 1.323 . . . . 0.0 108.141 178.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.8 tt -106.51 139.71 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 16.6 m-70 -136.94 155.55 76.27 Favored Pre-proline 0 N--CA 1.453 -0.315 0 C-N-CA 125.628 1.571 . . . . 0.0 108.329 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 146.08 84.25 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 N-CA-C 107.916 -1.609 . . . . 0.0 107.916 172.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -56.79 -21.31 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.534 -1.666 . . . . 0.0 113.119 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.0 p -53.42 -32.51 50.03 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.562 0.745 . . . . 0.0 111.124 175.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -77.11 -6.1 51.55 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.903 0.881 . . . . 0.0 113.075 -175.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.3 t -77.84 132.6 67.53 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 119.228 0.922 . . . . 0.0 110.171 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -77.32 58.12 6.14 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 123.692 2.928 . . . . 0.0 111.176 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -168.83 110.25 0.51 Allowed 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 20.0 mp0 -37.42 -44.8 0.66 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 127.486 2.314 . . . . 0.0 113.553 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 95.4 t -50.26 -43.82 22.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 123.414 0.686 . . . . 0.0 110.16 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -87.3 -48.99 7.55 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.757 0.823 . . . . 0.0 109.52 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.12 -40.99 34.52 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.03 13.93 60.22 Favored Glycine 0 C--N 1.338 0.676 0 CA-C-O 118.938 -0.923 . . . . 0.0 111.853 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 37.1 mttp 70.31 -34.05 0.28 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.757 1.623 . . . . 0.0 114.584 179.106 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.5 ttm 24.38 -61.6 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 1 C-N-CA 132.029 4.131 . . . . 0.0 118.203 178.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.11 -22.72 48.47 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.944 0.898 . . . . 0.0 111.59 -177.276 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.02 -128.89 1.3 Allowed Glycine 0 C--N 1.336 0.535 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -131.4 159.25 38.53 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 171.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.4 -166.18 34.25 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.016 -1.088 . . . . 0.0 113.461 -176.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 p90 -144.38 160.92 40.23 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 124.534 1.134 . . . . 0.0 109.714 178.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -105.95 118.46 36.67 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.525 1.53 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.6 mm -98.46 130.3 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 172.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 tt -101.11 108.01 52.69 Favored Pre-proline 0 N--CA 1.448 -0.541 1 N-CA-C 99.604 -4.221 . . . . 0.0 99.604 170.105 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -85.91 148.49 9.5 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 122.617 2.211 . . . . 0.0 114.958 -168.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.5 p -113.51 -51.24 2.81 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.974 1.31 . . . . 0.0 108.685 174.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -73.56 122.4 22.17 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.515 0.326 . . . . 0.0 111.328 179.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.22 41.07 2.6 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 173.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 81.0 mt -136.22 113.78 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 103.413 -2.81 . . . . 0.0 103.413 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.2 t -119.54 119.62 61.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 C-N-CA 123.769 0.828 . . . . 0.0 109.87 -172.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.3 m -99.87 164.7 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 CA-C-O 121.159 0.504 . . . . 0.0 109.935 176.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.5 m -76.46 131.93 73.66 Favored Pre-proline 0 N--CA 1.45 -0.444 0 CA-C-O 117.576 -1.202 . . . . 0.0 108.423 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -60.96 -31.79 91.79 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.002 2.468 . . . . 0.0 110.783 177.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.8 m -151.11 150.09 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 102.925 -2.991 . . . . 0.0 102.925 173.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.0 tpt180 -101.25 -93.74 0.29 Allowed 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 101.176 -3.638 . . . . 0.0 101.176 169.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.75 2.5 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 107.405 -2.278 . . . . 0.0 107.405 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 125.23 1.91 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 167.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.5 mm -62.92 128.62 25.16 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 169.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.05 -49.04 11.38 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 178.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -175.88 151.15 1.08 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.434 0.294 . . . . 0.0 111.361 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.5 m -113.17 126.23 70.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 169.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -65.73 156.63 82.51 Favored Pre-proline 0 CA--C 1.534 0.333 0 O-C-N 121.426 -0.796 . . . . 0.0 110.03 -176.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -48.44 -43.4 32.84 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.114 2.543 . . . . 0.0 112.952 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.0 p -79.57 3.87 17.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.842 1.257 . . . . 0.0 112.761 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.18 -21.9 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 128.525 2.73 . . . . 0.0 116.84 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.409 ' HE2' ' CD2' ' A' ' 83' ' ' HIS . 0.0 OUTLIER -63.87 -31.54 72.75 Favored 'General case' 0 C--O 1.227 -0.103 0 CA-C-N 119.483 1.038 . . . . 0.0 111.884 -174.8 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . 0.401 ' HB3' ' CE1' ' A' ' 83' ' ' HIS . . . -103.6 135.67 44.74 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.091 0.956 . . . . 0.0 110.081 -179.365 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.9 mt -140.06 146.54 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -125.32 136.74 9.95 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 125.862 1.696 . . . . 0.0 109.076 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.8 mp -137.86 163.82 30.5 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 124.959 1.304 . . . . 0.0 110.409 -177.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 70.8 mt-30 -145.38 125.23 13.46 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 57.2 p . . . . . 0 CA--C 1.538 0.519 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 175.443 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.261 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -93.09 126.8 38.36 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 125.589 1.556 . . . . 0.0 106.932 177.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 5.8 mt -125.03 143.45 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.1 0.96 . . . . 0.0 111.205 -172.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -122.89 130.74 53.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.219 2.208 . . . . 0.0 105.413 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.5 mt -123.49 146.73 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 C-N-CA 124.767 1.227 . . . . 0.0 108.019 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . 0.409 ' CD2' ' HE2' ' A' ' 68' ' ' HIS . 0.2 OUTLIER -134.33 131.8 38.77 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 105.283 -2.117 . . . . 0.0 105.283 171.324 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -103.05 106.21 16.68 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 124.774 1.229 . . . . 0.0 107.879 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.1 -169.82 34.94 Favored Glycine 0 CA--C 1.534 1.229 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 29.3 mm -109.78 -84.42 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.05 0 CA-C-O 123.224 1.488 . . . . 0.0 110.469 -178.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.41 4.82 0.48 Allowed 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 126.432 1.893 . . . . 0.0 113.033 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.22 -30.24 71.11 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.438 1.895 . . . . 0.0 107.573 175.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.55 -46.98 89.75 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 CA-C-N 114.374 -1.285 . . . . 0.0 108.348 174.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.68 -41.02 98.21 Favored 'General case' 0 C--O 1.227 -0.112 0 C-N-CA 125.036 1.334 . . . . 0.0 109.017 177.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -65.05 -8.41 16.19 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 125.69 1.596 . . . . 0.0 110.943 176.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? 52.54 34.14 14.91 Favored 'General case' 0 C--N 1.343 0.315 0 C-N-CA 125.301 1.441 . . . . 0.0 111.823 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.18 21.07 61.33 Favored Glycine 0 CA--C 1.536 1.37 0 CA-C-O 119.67 -0.517 . . . . 0.0 112.875 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.84 90.18 1.1 Allowed 'General case' 0 C--N 1.341 0.227 0 CA-C-N 119.388 1.594 . . . . 0.0 108.625 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 141.83 -2.41 1.9 Allowed Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.484 1.992 . . . . 0.0 111.591 -175.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -97.86 103.53 15.47 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 125.57 1.548 . . . . 0.0 111.063 -176.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 50.0 m -84.36 98.15 9.87 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.636 -2.727 . . . . 0.0 103.636 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 43.0 p -79.59 121.37 25.18 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 121.793 -0.567 . . . . 0.0 109.983 -177.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -79.94 -52.82 7.38 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.524 1.13 . . . . 0.0 109.361 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 24.3 m -82.17 129.0 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.121 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.43 175.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 67.5 m -98.21 56.69 1.2 Allowed 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 102.397 -3.186 . . . . 0.0 102.397 169.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.312 7.8 pt-20 36.16 61.08 0.8 Allowed 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 111.09 -2.777 . . . . 0.0 110.734 -167.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.42 55.08 2.41 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 111.108 -2.769 . . . . 0.0 109.834 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.35 3.3 p30 1.81 -110.63 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 130.997 3.719 . . . . 0.0 118.566 -178.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 45.0 mmm-85 -44.94 142.46 1.81 Allowed 'General case' 0 N--CA 1.425 -1.698 1 N-CA-C 122.56 4.281 . . . . 0.0 122.56 -167.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.722 4.7 m 36.95 -55.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.428 2 N-CA-C 130.351 7.167 . . . . 0.0 130.351 173.971 . . . . . . . . 3 2 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.52 121.98 86.29 Favored Pre-proline 0 C--N 1.317 -0.831 0 C-N-CA 116.472 -2.091 . . . . 0.0 113.172 -165.083 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -69.84 172.31 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 125.021 3.814 . . . . 0.0 113.081 -169.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 55.81 19.51 21.67 Favored Glycine 0 CA--C 1.528 0.895 0 C-N-CA 124.582 1.087 . . . . 0.0 115.21 176.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -61.6 143.22 56.4 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 118.488 1.144 . . . . 0.0 109.328 177.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -69.96 119.61 14.43 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.2 mt -80.85 -51.43 8.61 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -143.28 155.17 44.41 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 -174.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -122.39 125.76 46.57 Favored 'General case' 0 CA--C 1.514 -0.425 1 N-CA-C 98.305 -4.702 . . . . 0.0 98.305 166.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.36 129.33 56.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 114.691 -1.141 . . . . 0.0 112.165 -165.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -73.22 67.95 0.98 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.798 0.839 . . . . 0.0 110.397 -179.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.8 mt -52.59 -41.56 63.73 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-O 119.301 -0.38 . . . . 0.0 110.583 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -49.45 -44.46 45.63 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 123.507 0.723 . . . . 0.0 112.272 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.59 -35.33 19.51 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 117.933 0.333 . . . . 0.0 111.841 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 53.9 t -64.59 -49.69 79.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 121.537 -0.727 . . . . 0.0 110.567 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.357 0.0 OUTLIER -47.48 -53.84 26.7 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 116.943 2.201 . . . . 0.0 116.943 -177.557 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -60.9 -25.64 81.71 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.231 1.954 . . . . 0.0 112.323 177.151 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -79.92 -50.15 10.87 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 118.651 0.66 . . . . 0.0 110.617 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 18.7 m -79.72 142.83 57.51 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.721 -177.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.33 -15.81 22.34 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.48 2.12 . . . . 0.0 111.717 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 16.6 m -156.76 128.41 7.13 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.07 0.948 . . . . 0.0 108.907 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.2 tp -94.73 9.91 37.1 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.403 1.481 . . . . 0.0 111.54 -178.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 74.1 mmm -53.42 118.75 4.09 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 34.0 m -113.94 86.96 11.89 Favored Pre-proline 0 N--CA 1.445 -0.678 0 C-N-CA 126.168 1.787 . . . . 0.0 107.752 -177.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -83.25 149.72 13.41 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.814 1.676 . . . . 0.0 112.403 -178.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mp -122.13 130.3 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 103.494 -2.78 . . . . 0.0 103.494 174.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -126.56 143.55 39.67 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 C-N-CA 125.751 1.62 . . . . 0.0 106.93 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -117.15 123.56 47.02 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 64.7 p -83.96 -72.22 0.47 Allowed 'General case' 0 C--N 1.335 -0.06 0 CA-C-O 121.504 0.669 . . . . 0.0 111.046 -171.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p30 -71.7 52.63 0.22 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 126.091 1.756 . . . . 0.0 113.113 -178.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 38.8 mt -74.35 63.68 1.06 Allowed 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.324 1.45 . . . . 0.0 109.38 177.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 17.4 57.69 0.01 OUTLIER 'General case' 0 C--N 1.348 0.503 0 C-N-CA 129.509 3.124 . . . . 0.0 112.209 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 23.88 57.43 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.108 2.963 . . . . 0.0 114.371 -174.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.26 -5.51 0.12 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-O 119.006 -0.886 . . . . 0.0 113.891 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . 0.587 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 29.7 mt-10 -75.49 93.14 2.94 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 119.254 1.527 . . . . 0.0 108.796 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 34.1 p -76.65 130.46 37.83 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.836 0.827 . . . . 0.0 109.421 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -83.6 100.35 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 14.8 m -98.71 102.28 13.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.971 1.308 . . . . 0.0 110.578 -175.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 8.4 pt -66.95 146.3 13.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 O-C-N 121.909 -0.494 . . . . 0.0 110.363 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -119.13 -45.5 2.55 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.976 1.71 . . . . 0.0 110.359 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -66.87 79.94 0.11 Allowed 'General case' 0 C--O 1.224 -0.244 0 CA-C-O 121.45 0.643 . . . . 0.0 109.929 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.3 m -77.82 65.82 3.36 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.805 0.842 . . . . 0.0 109.848 -176.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 162.48 -128.69 1.92 Allowed Glycine 0 C--N 1.336 0.554 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -177.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.2 t -66.7 157.92 31.46 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.188 178.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 2.9 p -138.96 153.25 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 C-N-CA 125.604 1.561 . . . . 0.0 107.684 178.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -125.93 150.39 48.01 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 125.222 1.409 . . . . 0.0 108.379 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 35.8 ptt85 -74.37 162.07 29.23 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 176.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 61.69 55.0 2.81 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 126.262 1.825 . . . . 0.0 111.881 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 33.2 mm-40 -146.64 155.78 42.7 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.91 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . 0.447 ' C ' ' H ' ' A' ' 157' ' ' ILE . 23.5 tt0 -103.79 -70.16 0.78 Allowed 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 119.862 1.21 . . . . 0.0 111.188 176.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -50.12 5.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 130.4 3.48 . . . . 0.0 118.047 -172.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.447 ' H ' ' C ' ' A' ' 155' ' ' GLU . 1.7 mp -76.86 -32.04 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 129.785 3.234 . . . . 0.0 106.262 173.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.58 145.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 127.128 2.171 . . . . 0.0 106.59 175.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 4.6 mmpt? -132.42 125.92 31.88 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 178.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . 0.587 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -78.88 125.93 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 172.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -138.44 163.64 31.41 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.45 1.1 . . . . 0.0 109.502 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 65.6 mttm . . . . . 0 C--O 1.231 0.129 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 175.357 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.465 0.305 0 N-CA-C 114.32 1.23 . . . . 0.0 114.32 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.7 m -83.05 98.15 4.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 C-N-CA 123.95 0.9 . . . . 0.0 111.128 175.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 34.7 t -36.07 121.18 0.71 Allowed Pre-proline 0 CA--C 1.547 0.84 0 C-N-CA 126.686 1.994 . . . . 0.0 111.163 174.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -76.2 -38.95 0.95 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.803 2.335 . . . . 0.0 117.773 -173.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.13 146.57 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 CA-C-N 120.245 1.384 . . . . 0.0 110.395 -175.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.8 m -78.83 135.44 37.05 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 173.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.18 -167.97 41.01 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 -178.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -96.17 135.09 38.45 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.9 tt -97.19 143.07 13.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 123.01 0.524 . . . . 0.0 109.994 -179.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -145.29 156.25 53.97 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 178.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -62.54 155.33 58.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 N-CA-C 107.097 -1.924 . . . . 0.0 107.097 171.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 tt -62.65 -34.36 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.468 -178.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 m -71.03 74.05 0.63 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.685 1.194 . . . . 0.0 109.01 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -179.64 -34.58 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 127.994 2.518 . . . . 0.0 108.992 -174.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 91.0 t -58.47 127.66 81.84 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 117.63 -1.176 . . . . 0.0 111.025 -178.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_exo -57.57 59.68 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.191 1 C-N-CA 126.381 4.72 . . . . 0.0 115.778 176.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -171.43 119.65 0.47 Allowed 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 125.953 1.701 . . . . 0.0 107.707 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 6.8 pm0 -54.48 -44.8 72.94 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.429 1.092 . . . . 0.0 113.817 -177.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 40.7 t -56.49 -56.84 11.57 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -178.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -62.64 -52.85 61.72 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.3 t -50.83 -42.36 58.45 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.951 0.9 . . . . 0.0 113.394 -177.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.427 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -89.42 11.59 69.39 Favored Glycine 0 N--CA 1.446 -0.634 0 CA-C-O 118.198 -1.334 . . . . 0.0 112.022 -178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 58.5 mttm 72.35 -36.33 0.35 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.564 1.682 . . . . 0.0 113.242 -179.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.427 ' H ' ' C ' ' A' ' 36' ' ' GLY . 1.0 OUTLIER 28.68 -78.77 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 130.398 3.479 . . . . 0.0 116.226 179.589 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.5 ttp -83.17 -7.3 59.64 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -174.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.63 -138.19 2.75 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 38.9 t0 -140.11 158.7 43.63 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 172.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.77 -168.75 37.83 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 119.937 -1.125 . . . . 0.0 113.334 -176.213 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -141.68 156.83 45.61 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.635 1.174 . . . . 0.0 109.448 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.82 127.09 52.51 Favored 'General case' 0 CA--C 1.51 -0.587 0 C-N-CA 124.282 1.033 . . . . 0.0 109.876 179.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 28.4 mm -107.84 128.53 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 104.611 -2.366 . . . . 0.0 104.611 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.7 tt -96.97 102.97 13.31 Favored Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 172.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -63.37 157.16 51.88 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.951 3.101 . . . . 0.0 116.585 -169.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.4 p -138.84 -51.13 0.55 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.856 1.263 . . . . 0.0 109.528 173.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -80.14 130.67 35.41 Favored 'General case' 0 C--N 1.342 0.263 0 O-C-N 121.926 -0.484 . . . . 0.0 110.455 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -66.42 -24.35 72.24 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.824 -0.911 . . . . 0.0 110.824 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -78.2 108.52 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 C-N-CA 124.585 1.154 . . . . 0.0 107.923 -179.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.22 116.65 52.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 125.212 1.405 . . . . 0.0 108.14 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.5 m -93.41 155.68 3.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.147 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 47.1 m -73.17 139.94 79.6 Favored Pre-proline 0 N--CA 1.448 -0.574 0 CA-C-O 118.6 -0.714 . . . . 0.0 111.144 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -64.17 -35.9 50.01 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 N-CA-C 107.609 -1.727 . . . . 0.0 107.609 171.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.6 p -175.98 150.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 129.798 3.239 . . . . 0.0 103.68 175.346 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 43.1 mtm180 -112.14 -75.93 0.6 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.19 -68.38 2.35 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.49 128.32 8.03 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 104.228 -2.508 . . . . 0.0 104.228 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.1 mm -61.13 130.47 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 7.3 tt -77.45 -51.96 9.91 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 104.601 -2.37 . . . . 0.0 104.601 178.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 50.9 t30 179.62 165.5 1.1 Allowed 'General case' 0 CA--C 1.527 0.081 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 m -152.35 129.09 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 C-N-CA 126.239 1.816 . . . . 0.0 106.168 174.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -47.49 146.47 3.46 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-O 118.744 -0.646 . . . . 0.0 111.092 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -50.0 -33.74 35.44 Favored 'Trans proline' 0 CA--C 1.534 0.525 0 C-N-CA 123.534 2.823 . . . . 0.0 113.796 176.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 37.0 p -77.67 -7.98 57.24 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 124.574 1.15 . . . . 0.0 111.993 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 68.38 13.4 9.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.205 1.802 . . . . 0.0 113.641 178.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.445 ' ND1' ' N ' ' A' ' 89' ' ' VAL . 0.0 OUTLIER -77.91 -23.62 48.61 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 119.358 0.981 . . . . 0.0 111.626 -179.333 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -167.12 -173.22 2.25 Favored 'General case' 0 C--O 1.225 -0.22 0 CA-C-N 120.12 1.327 . . . . 0.0 110.777 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 1.06 1.9 mt 130.97 -139.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.192 1 C-N-CA 136.95 6.1 . . . . 0.0 110.372 176.382 . . . . . . . . 3 2 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -157.04 170.13 34.28 Favored Glycine 0 CA--C 1.531 1.061 0 N-CA-C 118.229 2.052 . . . . 0.0 118.229 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 18.1 mt -124.03 174.35 7.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 128.199 2.6 . . . . 0.0 109.085 -177.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -126.28 -165.42 1.44 Allowed 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 60.3 p . . . . . 0 N--CA 1.44 -0.957 0 C-N-CA 125.611 1.564 . . . . 0.0 107.39 176.776 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 . . . . . 0 CA--C 1.533 0.301 0 CA-C-O 120.991 0.424 . . . . 0.0 110.563 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -92.85 131.58 37.76 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 127.642 2.377 . . . . 0.0 105.605 -179.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 34.1 mt -123.04 119.62 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 O-C-N 123.436 0.46 . . . . 0.0 112.056 -173.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 6.0 tp -89.09 139.63 30.27 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 171.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 72.8 mt -130.33 132.49 64.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -123.75 84.47 2.28 Favored 'General case' 0 C--O 1.223 -0.298 0 O-C-N 123.526 0.517 . . . . 0.0 111.77 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.52 104.75 0.24 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.236 0.614 . . . . 0.0 111.932 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.76 -177.93 7.64 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 122.092 0.829 . . . . 0.0 112.323 179.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.9 mm -123.92 146.54 29.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 174.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 37.2 t70 50.77 32.29 6.94 Favored 'General case' 0 CA--C 1.543 0.702 0 CA-C-O 121.91 0.862 . . . . 0.0 111.295 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.8 m -97.85 -25.07 15.16 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.803 2.041 . . . . 0.0 107.289 -177.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.445 ' N ' ' ND1' ' A' ' 68' ' ' HIS . 4.0 p -53.6 -43.71 55.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 C-N-CA 126.258 1.823 . . . . 0.0 107.634 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -58.73 -26.2 63.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.801 2.04 . . . . 0.0 111.898 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.14 -11.21 60.45 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.892 1.677 . . . . 0.0 109.608 177.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp 51.55 29.66 5.69 Favored 'General case' 0 C--N 1.342 0.244 0 C-N-CA 126.325 1.85 . . . . 0.0 112.38 178.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.22 26.71 50.82 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-O 118.702 -1.054 . . . . 0.0 112.53 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.266 0.2 OUTLIER -59.15 -18.25 34.38 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.851 1.826 . . . . 0.0 115.478 -176.776 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -122.3 21.17 7.8 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 126.11 1.814 . . . . 0.0 110.849 177.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -106.05 85.2 2.17 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 118.089 0.944 . . . . 0.0 111.046 -177.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.66 101.11 5.61 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.326 -2.472 . . . . 0.0 104.326 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.8 t -87.01 157.82 19.37 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-O 121.183 0.516 . . . . 0.0 110.605 -179.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -115.59 5.23 14.31 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.038 1.735 . . . . 0.0 112.224 -175.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.5 m -129.42 137.06 57.9 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.147 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 68.6 m -107.03 49.31 0.81 Allowed 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 169.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.299 1.3 pm0 -2.68 70.98 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 132.184 4.194 . . . . 0.0 116.644 -172.661 . . . . . . . . 3 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -85.99 46.44 3.62 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 112.845 -1.979 . . . . 0.0 109.882 176.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 3.36 52.08 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.21 0 C-N-CA 131.356 3.863 . . . . 0.0 120.897 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -168.74 121.78 0.82 Allowed 'General case' 0 C--N 1.312 -1.022 1 C-N-CA 133.475 4.71 . . . . 0.0 107.051 176.553 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -167.52 136.72 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 118.784 0.72 . . . . 0.0 111.073 -172.332 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -78.74 149.99 75.11 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 118.146 -0.93 . . . . 0.0 109.853 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -55.67 175.55 0.2 Allowed 'Trans proline' 0 CA--C 1.542 0.896 1 C-N-CA 125.696 4.264 . . . . 0.0 117.837 -174.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 51.85 -7.65 0.01 OUTLIER Glycine 0 C--N 1.344 0.985 0 C-N-CA 129.28 3.324 . . . . 0.0 119.238 175.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 25.0 tt0 -61.63 160.59 11.2 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 120.31 2.055 . . . . 0.0 110.128 178.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -67.04 140.64 57.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 122.94 0.496 . . . . 0.0 109.76 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 94.5 mt -108.63 -37.39 5.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 124.246 1.018 . . . . 0.0 110.088 176.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 22.2 mt -143.23 146.99 34.14 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.61 0.764 . . . . 0.0 110.208 -176.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -132.94 68.49 1.5 Allowed 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -79.45 127.03 39.38 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 CA-C-N 109.053 -3.703 . . . . 0.0 110.621 -171.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -76.19 67.64 2.5 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.008 0.923 . . . . 0.0 109.179 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -48.61 -39.37 23.69 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.651 0.78 . . . . 0.0 111.727 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -54.04 -42.18 68.89 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.113 0.565 . . . . 0.0 112.201 178.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.07 -33.29 18.35 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.744 0.417 . . . . 0.0 111.39 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 79.5 t -63.31 -53.91 39.66 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.372 17.8 pttp -40.45 -58.23 2.56 Favored Pre-proline 0 CA--C 1.541 0.611 0 N-CA-C 116.97 2.211 . . . . 0.0 116.97 -176.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -58.53 -20.1 47.85 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.436 2.091 . . . . 0.0 113.36 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -100.03 8.26 44.11 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 118.301 -0.857 . . . . 0.0 112.674 -177.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 33.3 m -133.9 147.67 65.12 Favored Pre-proline 0 CA--C 1.535 0.382 0 CA-C-N 119.986 1.266 . . . . 0.0 109.856 178.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -71.04 -36.55 7.29 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.98 2.453 . . . . 0.0 111.622 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 62.3 p -151.45 121.85 7.33 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -177.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.0 tp -79.88 -2.95 45.88 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.136 1.374 . . . . 0.0 111.904 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -44.88 117.92 1.47 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 124.842 1.257 . . . . 0.0 110.465 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.6 m -117.7 107.47 44.46 Favored Pre-proline 0 N--CA 1.447 -0.581 0 C-N-CA 124.034 0.933 . . . . 0.0 108.692 -178.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -91.53 143.59 3.01 Favored 'Trans proline' 0 N--CA 1.441 -1.617 0 C-N-CA 123.039 2.492 . . . . 0.0 110.249 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 17.2 mm -113.9 116.82 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.5 t -121.48 123.61 69.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 C-N-CA 125.006 1.323 . . . . 0.0 108.632 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -95.9 117.66 31.04 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 178.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 52.6 p -84.1 -73.91 0.4 Allowed 'General case' 0 C--O 1.23 0.045 0 CA-C-O 121.467 0.651 . . . . 0.0 111.563 -171.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p-10 -73.08 57.61 0.47 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.824 1.65 . . . . 0.0 111.38 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 20.5 mt -72.01 66.72 0.6 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.918 1.687 . . . . 0.0 109.007 177.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.91 47.68 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 129.179 2.992 . . . . 0.0 112.488 -176.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 29.34 55.48 0.12 Allowed 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 127.81 2.444 . . . . 0.0 113.34 -174.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.43 -5.29 0.05 OUTLIER Glycine 0 CA--C 1.526 0.738 0 CA-C-O 118.896 -0.946 . . . . 0.0 114.332 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . 0.579 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 21.0 mt-10 -83.83 139.87 32.39 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.185 1.492 . . . . 0.0 109.83 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 45.4 p -110.91 136.58 49.72 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -91.28 101.93 12.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -178.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 20.3 m -100.01 105.83 17.54 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 123.96 0.904 . . . . 0.0 110.493 -176.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 20.1 pt -67.05 139.71 20.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.799 -0.563 . . . . 0.0 110.252 177.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.6 mmpt? -101.83 -41.42 6.52 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 125.155 1.382 . . . . 0.0 108.864 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.39 86.9 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.208 1.003 . . . . 0.0 112.783 -176.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.5 m -80.73 54.68 2.18 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 177.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.49 -178.65 37.31 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -177.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 35.4 t -52.07 146.8 8.22 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.567 0.747 . . . . 0.0 112.416 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.9 m -115.47 159.55 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 125.207 1.403 . . . . 0.0 109.827 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.8 157.3 30.05 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.75 1.22 . . . . 0.0 108.321 175.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.47 158.86 28.45 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.473 0.654 . . . . 0.0 110.738 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 64.58 -10.11 0.16 Allowed 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 126.137 1.775 . . . . 0.0 114.868 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.67 149.81 38.4 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.933 1.242 . . . . 0.0 109.571 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -120.54 158.14 27.94 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 29.9 t0 63.89 26.56 14.29 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 128.074 2.549 . . . . 0.0 112.009 -174.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -82.87 -22.75 8.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 C-N-CA 123.825 0.85 . . . . 0.0 108.825 176.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.3 p -142.36 149.66 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 127.897 2.479 . . . . 0.0 106.477 175.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -131.81 127.47 36.7 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 174.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . 0.579 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.54 122.0 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 170.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -105.52 176.11 5.27 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 106.544 -1.651 . . . . 0.0 106.544 174.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.0 tppt? . . . . . 0 CA--C 1.532 0.254 0 O-C-N 121.292 -0.88 . . . . 0.0 110.956 -179.358 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.529 0.138 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 m -90.75 84.81 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 122.598 0.359 . . . . 0.0 110.894 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -19.1 115.52 0.09 OUTLIER Pre-proline 0 CA--C 1.546 0.789 0 C-N-CA 127.016 2.127 . . . . 0.0 113.667 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -75.02 -26.01 11.28 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 122.718 2.278 . . . . 0.0 117.535 -170.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -138.25 158.08 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 119.886 1.221 . . . . 0.0 109.445 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.9 m -94.61 128.6 41.36 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 174.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.67 -161.68 33.16 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.585 -0.341 . . . . 0.0 112.654 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -95.24 118.46 32.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.846 1.258 . . . . 0.0 108.551 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.94 136.04 25.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 C-N-CA 123.455 0.702 . . . . 0.0 109.427 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -135.13 142.9 43.61 Favored Pre-proline 0 C--O 1.236 0.345 0 C-N-CA 126.486 1.914 . . . . 0.0 107.048 177.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -64.61 160.06 41.88 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 121.446 1.431 . . . . 0.0 108.476 176.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 tp -61.55 -39.88 84.57 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 57.1 m -76.48 74.1 3.22 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.124 0.97 . . . . 0.0 109.344 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -178.54 -37.34 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 127.601 2.36 . . . . 0.0 108.986 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 97.0 t -52.0 115.45 6.71 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-O 117.507 -1.235 . . . . 0.0 111.905 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_exo -58.06 64.37 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.212 1 C-N-CA 125.515 4.144 . . . . 0.0 115.551 177.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -133.58 -42.63 0.84 Allowed 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 -177.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 105.73 -65.08 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 129.695 3.198 . . . . 0.0 110.606 -178.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 92.3 t -52.67 -62.13 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 C-N-CA 124.004 0.922 . . . . 0.0 108.722 179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -59.99 -42.79 94.98 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.909 0.385 . . . . 0.0 110.123 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -51.57 -45.51 63.12 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 124.012 0.925 . . . . 0.0 112.81 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -92.99 17.57 57.91 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-O 118.274 -1.292 . . . . 0.0 110.5 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 60.5 mttp 73.79 -47.77 0.66 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.079 1.752 . . . . 0.0 111.359 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 19.6 ttt 35.49 -67.17 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 130.602 3.561 . . . . 0.0 117.077 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 33.2 ttm -87.52 -23.6 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.385 1.074 . . . . 0.0 112.435 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.67 -148.1 9.53 Favored Glycine 0 C--O 1.224 -0.505 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -177.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -142.47 159.75 41.61 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-N 118.349 1.074 . . . . 0.0 108.582 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.3 -127.29 1.45 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 106.773 -2.531 . . . . 0.0 106.773 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -177.01 -179.28 0.9 Allowed 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 119.055 1.427 . . . . 0.0 110.763 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -127.67 135.86 50.79 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 123.734 0.814 . . . . 0.0 109.447 176.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -109.49 98.55 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 103.316 -2.846 . . . . 0.0 103.316 172.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.5 tt -58.81 113.6 7.11 Favored Pre-proline 0 CA--C 1.532 0.258 0 N-CA-C 103.08 -2.933 . . . . 0.0 103.08 175.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -78.07 149.01 25.12 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 122.916 2.411 . . . . 0.0 115.005 -167.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 p -115.74 -47.88 2.78 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 125.217 1.407 . . . . 0.0 107.594 173.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -76.76 122.39 24.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.11 44.21 2.79 Favored Glycine 0 CA--C 1.531 1.082 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 173.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.1 mt -144.33 126.37 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 104.446 -2.427 . . . . 0.0 104.446 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 66.3 t -126.66 126.71 69.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 C-N-CA 125.019 1.328 . . . . 0.0 109.033 -173.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.7 m -109.78 157.59 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.833 1.253 . . . . 0.0 110.792 178.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.6 m -62.87 133.02 95.07 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.873 -0.517 . . . . 0.0 111.077 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.04 -13.89 23.67 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.278 3.319 . . . . 0.0 116.531 -174.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -151.31 165.54 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 CA-C-N 119.441 1.018 . . . . 0.0 109.713 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -76.12 125.54 29.34 Favored 'General case' 0 C--O 1.236 0.394 1 N-CA-C 99.122 -4.399 . . . . 0.0 99.122 166.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 179.82 171.95 43.31 Favored Glycine 0 N--CA 1.435 -1.425 0 C-N-CA 116.658 -2.687 . . . . 0.0 113.198 -168.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.64 126.24 34.84 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.58 116.9 8.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 102.644 -3.095 . . . . 0.0 102.644 168.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 85.1 mt -78.53 -50.04 12.27 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 32.6 t30 178.16 164.1 0.7 Allowed 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 124.14 0.976 . . . . 0.0 108.372 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.4 m -137.74 116.73 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 126.732 2.013 . . . . 0.0 106.079 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.73 154.03 0.73 Allowed Pre-proline 0 N--CA 1.469 0.524 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -52.05 -33.29 52.44 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 123.483 2.788 . . . . 0.0 113.212 176.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.8 p -78.09 -2.84 39.29 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.996 0.919 . . . . 0.0 111.631 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.76 21.48 1.94 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 127.244 2.218 . . . . 0.0 114.301 179.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 25.9 p-80 -89.31 -25.02 21.86 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 118.46 -0.781 . . . . 0.0 111.18 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -162.5 -172.62 3.22 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.566 0.621 . . . . 0.0 112.531 -172.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.716 27.6 mm 125.89 -127.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.478 1 C-N-CA 134.583 5.153 . . . . 0.0 107.177 -179.815 . . . . . . . . 3 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 177.71 -172.83 45.54 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 118.354 2.101 . . . . 0.0 118.354 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.0 mp -133.7 169.58 16.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 126.856 2.062 . . . . 0.0 109.42 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.76 126.94 37.7 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 171.018 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 54.2 p . . . . . 0 N--CA 1.427 -1.579 0 CA-C-O 123.774 1.749 . . . . 0.0 108.136 175.988 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.1 tpp85 . . . . . 0 C--O 1.23 0.071 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.61 101.39 8.29 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 125.457 1.503 . . . . 0.0 108.434 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.0 mt -96.81 103.85 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 126.479 1.912 . . . . 0.0 109.92 -176.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.0 tt -79.18 135.59 36.85 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 105.055 -2.202 . . . . 0.0 105.055 171.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.3 mt -113.97 153.22 15.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 125.179 1.392 . . . . 0.0 108.613 179.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.34 144.75 29.99 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 171.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.98 91.36 3.26 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.377 1.471 . . . . 0.0 110.504 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.27 154.63 5.43 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -178.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mt -98.33 135.28 33.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.267 -1.753 . . . . 0.0 106.267 178.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.0 t70 70.25 18.11 6.94 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.626 1.17 . . . . 0.0 112.818 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 p -81.9 -32.03 31.15 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 124.872 1.269 . . . . 0.0 108.501 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 8.1 p -55.06 -44.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.784 1.233 . . . . 0.0 108.143 172.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -61.34 -35.43 77.41 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.777 1.231 . . . . 0.0 109.813 176.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.99 9.43 5.44 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 126.851 2.061 . . . . 0.0 110.915 176.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.6 mttp 47.27 35.2 3.6 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 127.067 2.147 . . . . 0.0 114.787 173.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.05 19.12 63.29 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.63 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -71.26 90.47 0.92 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.064 1.432 . . . . 0.0 109.908 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.21 -1.06 6.61 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 126.068 1.794 . . . . 0.0 111.928 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.446 ' CD1' HG13 ' A' ' 115' ' ' VAL . 16.4 m-30 -100.42 111.57 23.84 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.723 1.209 . . . . 0.0 109.662 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 9.6 m -104.28 113.49 27.08 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 124.779 1.232 . . . . 0.0 108.132 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.7 p -81.43 144.94 31.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 118.92 0.782 . . . . 0.0 111.292 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -114.95 -41.98 3.28 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.186 1.394 . . . . 0.0 111.959 -178.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.417 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.4 m -70.94 130.19 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 174.438 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 61.0 m -92.28 53.71 2.18 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 104.934 -2.247 . . . . 0.0 104.934 172.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.417 ' H ' ' C ' ' A' ' 100' ' ' VAL 0.365 1.2 pm0 16.35 62.89 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.466 3.507 . . . . 0.0 113.01 -169.509 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -79.09 48.99 3.44 Favored Glycine 0 CA--C 1.524 0.629 0 CA-C-N 111.729 -2.487 . . . . 0.0 109.818 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.403 4.3 p30 2.66 -111.25 0.0 OUTLIER 'General case' 0 N--CA 1.435 -1.22 0 C-N-CA 129.627 3.171 . . . . 0.0 117.366 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.254 0.2 OUTLIER -35.92 118.29 0.5 Allowed 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 121.599 3.926 . . . . 0.0 121.599 -169.726 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.268 27.6 m 36.89 70.39 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 128.421 2.688 . . . . 0.0 117.241 170.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.39 127.93 25.41 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 170.018 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -97.01 154.75 1.1 Allowed 'Trans proline' 0 N--CA 1.449 -1.141 0 C-N-CA 124.594 3.529 . . . . 0.0 110.401 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 49.07 2.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.303 0 N-CA-C 118.362 2.105 . . . . 0.0 118.362 172.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -60.69 136.49 58.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 119.948 1.874 . . . . 0.0 107.935 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -59.12 117.02 4.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.0 mt -79.91 -47.53 14.92 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.8 mp -149.97 166.0 30.97 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -177.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -126.33 132.1 51.68 Favored 'General case' 0 CA--C 1.518 -0.262 1 N-CA-C 98.458 -4.645 . . . . 0.0 98.458 166.243 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . 0.446 HG13 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -141.25 123.19 14.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.846 -166.176 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 63.1 t0 -72.55 70.54 0.92 Allowed 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 124.497 1.119 . . . . 0.0 110.772 -178.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -50.37 -45.1 54.98 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.347 0.659 . . . . 0.0 110.432 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -50.71 -50.11 55.96 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.362 1.065 . . . . 0.0 112.709 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.87 -33.34 24.83 Favored 'General case' 0 CA--C 1.527 0.087 0 N-CA-C 111.771 0.285 . . . . 0.0 111.771 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -65.28 -52.86 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.776 -0.578 . . . . 0.0 109.993 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.344 19.4 pttp -40.25 -57.31 2.94 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 117.413 2.375 . . . . 0.0 117.413 -177.066 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -57.09 -22.04 45.46 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.526 2.15 . . . . 0.0 113.146 179.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -94.11 4.97 53.14 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 118.08 -0.962 . . . . 0.0 112.683 -178.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 21.3 m -136.1 150.19 70.45 Favored Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 120.182 1.355 . . . . 0.0 111.992 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -71.17 -28.9 18.2 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 122.891 2.394 . . . . 0.0 111.974 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 3.2 m -158.79 131.59 7.05 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.54 0.609 . . . . 0.0 110.024 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -90.4 21.44 3.88 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.114 1.366 . . . . 0.0 112.055 -177.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 24.3 mmt -59.64 146.85 39.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 121.348 -0.845 . . . . 0.0 110.933 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 18.2 p -112.41 68.69 0.96 Allowed Pre-proline 0 CA--C 1.536 0.418 0 C-N-CA 124.558 1.143 . . . . 0.0 108.296 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.45 92.83 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.236 1.957 . . . . 0.0 112.825 -175.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 3.2 mt -86.15 129.97 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 105.315 -2.105 . . . . 0.0 105.315 175.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.6 t -133.59 121.67 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-O 121.798 0.809 . . . . 0.0 109.192 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -82.15 108.83 15.92 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 101.653 -3.462 . . . . 0.0 101.653 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.8 p -75.5 -63.55 1.26 Allowed 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.712 0.768 . . . . 0.0 109.75 -173.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -72.16 52.14 0.25 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.682 1.193 . . . . 0.0 113.951 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 56.9 mt -78.96 49.11 0.89 Allowed 'General case' 0 CA--C 1.539 0.547 0 O-C-N 121.083 -1.011 . . . . 0.0 109.042 173.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 23.99 40.42 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 130.0 3.32 . . . . 0.0 115.042 -179.21 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 38.85 45.31 0.93 Allowed 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.209 1.804 . . . . 0.0 112.604 -175.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -175.69 -8.86 0.02 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 119.062 -0.855 . . . . 0.0 113.997 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . 0.606 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 9.8 mm-40 -86.87 92.33 8.96 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 118.945 1.373 . . . . 0.0 108.299 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -77.37 132.44 38.55 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 123.248 0.619 . . . . 0.0 110.164 -177.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 1.9 t -86.15 91.4 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 125.293 1.437 . . . . 0.0 109.782 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.0 m -88.54 96.26 10.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 27.1 mt -65.76 131.8 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -102.47 -42.2 6.04 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 125.774 1.629 . . . . 0.0 110.801 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -54.72 83.75 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.186 0 C-N-CA 124.907 1.283 . . . . 0.0 112.799 -176.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 22.4 m -80.93 55.9 2.59 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.778 0.831 . . . . 0.0 109.418 179.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.68 -167.47 36.47 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 41.6 t -60.16 152.72 23.78 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 123.12 0.568 . . . . 0.0 110.831 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 55.2 t -123.49 148.81 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 C-N-CA 124.944 1.298 . . . . 0.0 107.739 178.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.1 m-80 -119.48 153.43 35.32 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.789 1.636 . . . . 0.0 110.111 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -47.53 135.45 11.15 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.838 0.855 . . . . 0.0 110.628 177.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 67.23 8.57 6.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.509 1.924 . . . . 0.0 114.933 178.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -64.5 150.88 45.8 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 120.062 1.301 . . . . 0.0 108.859 174.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -122.84 161.53 23.88 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 125.215 1.406 . . . . 0.0 108.487 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 21.1 t0 66.69 14.1 9.63 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 125.735 1.614 . . . . 0.0 113.713 -178.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.408 ' CD1' ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -65.65 -26.76 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 C-N-CA 124.371 1.068 . . . . 0.0 111.104 176.736 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.5 p -138.75 147.2 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 C-N-CA 125.626 1.57 . . . . 0.0 107.935 179.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.18 109.76 15.37 Favored 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . 0.606 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -77.57 98.85 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 174.724 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -87.93 147.94 24.82 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.038 0.935 . . . . 0.0 108.87 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.1 tptm . . . . . 0 C--N 1.329 -0.297 0 CA-C-O 121.927 0.87 . . . . 0.0 109.026 -178.437 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 t80 . . . . . 0 CA--C 1.534 0.365 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.1 m -78.73 80.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.178 0 O-C-N 120.481 -1.387 . . . . 0.0 111.435 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -21.68 105.04 0.09 OUTLIER Pre-proline 0 CA--C 1.551 1.015 0 C-N-CA 129.229 3.012 . . . . 0.0 109.605 175.183 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.06 -20.56 21.63 Favored 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 123.535 2.823 . . . . 0.0 119.177 -167.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.35 147.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.34 0.164 0 CA-C-N 119.699 1.136 . . . . 0.0 110.547 -177.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.2 m -85.79 135.31 33.78 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 173.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 166.59 -140.38 6.29 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 -178.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.1 tp10 -125.81 122.68 36.87 Favored 'General case' 0 CA--C 1.528 0.122 0 C-N-CA 124.933 1.293 . . . . 0.0 110.089 -178.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.55 146.01 9.11 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -142.52 140.23 18.5 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 125.155 1.382 . . . . 0.0 107.656 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -57.13 145.55 85.79 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.116 1.877 . . . . 0.0 110.161 176.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -49.37 -37.63 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 124.304 1.041 . . . . 0.0 112.596 -178.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.6 p -55.96 -28.66 58.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.105 1.362 . . . . 0.0 112.606 178.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -77.23 -8.81 58.2 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 123.678 0.791 . . . . 0.0 112.745 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.7 t -74.26 131.01 81.32 Favored Pre-proline 0 CA--C 1.535 0.402 0 O-C-N 121.162 -0.961 . . . . 0.0 109.994 -178.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -77.17 55.93 5.24 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.515 2.81 . . . . 0.0 111.954 -177.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -167.72 108.68 0.59 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.47 -0.768 . . . . 0.0 109.19 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -35.47 -48.17 0.48 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 127.521 2.329 . . . . 0.0 115.375 -176.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.0 p -50.57 -38.1 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 122.932 0.493 . . . . 0.0 110.938 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -89.38 -49.7 6.55 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 124.115 0.966 . . . . 0.0 108.828 177.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -48.07 -40.96 24.74 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.765 1.024 . . . . 0.0 113.765 -177.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.404 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -100.48 15.01 59.1 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.201 -1.333 . . . . 0.0 111.956 -177.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 53.1 mttp 71.87 -39.22 0.44 Allowed 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 119.285 1.542 . . . . 0.0 113.813 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.404 ' H ' ' C ' ' A' ' 36' ' ' GLY . 9.4 ttp 27.97 -69.18 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 131.341 3.856 . . . . 0.0 117.118 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.9 ttp -79.54 -25.53 41.65 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 126.047 1.739 . . . . 0.0 113.541 -175.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.71 -141.1 4.21 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 119.605 1.093 . . . . 0.0 110.658 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -121.96 154.4 37.24 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 174.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 179.51 -165.2 33.73 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.236 -175.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -159.37 168.91 25.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.37 151.28 29.97 Favored 'General case' 0 CA--C 1.501 -0.942 0 CA-C-O 121.346 0.593 . . . . 0.0 109.475 175.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 4.4 mp -125.08 132.31 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 102.18 -3.267 . . . . 0.0 102.18 170.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.0 tt -96.15 108.74 43.24 Favored Pre-proline 0 N--CA 1.442 -0.837 1 N-CA-C 98.589 -4.597 . . . . 0.0 98.589 169.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -82.17 156.1 17.19 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 123.664 2.909 . . . . 0.0 114.405 -168.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.2 p -124.98 -45.83 1.86 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.895 1.278 . . . . 0.0 108.794 174.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 120.34 14.59 Favored 'General case' 0 C--N 1.339 0.11 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 177.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.69 37.59 2.09 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 175.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.7 mt -142.33 119.39 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 127.007 2.123 . . . . 0.0 105.85 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.08 113.86 45.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.157 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.1 m -100.53 152.26 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 C-N-CA 123.094 0.558 . . . . 0.0 109.988 179.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 70.6 m -58.24 130.0 83.56 Favored Pre-proline 0 CA--C 1.537 0.463 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.106 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.2 -22.94 13.96 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 124.938 3.759 . . . . 0.0 115.774 -175.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.6 m -137.79 161.68 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 123.914 0.885 . . . . 0.0 109.769 -173.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.1 ttt180 -76.71 126.31 30.76 Favored 'General case' 0 CA--C 1.518 -0.271 1 N-CA-C 99.562 -4.236 . . . . 0.0 99.562 167.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.31 175.07 47.23 Favored Glycine 0 N--CA 1.436 -1.343 0 C-N-CA 116.709 -2.663 . . . . 0.0 114.33 -167.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 36.2 mtmt -100.62 135.16 42.49 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.231 1.812 . . . . 0.0 108.371 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 26.9 mm -76.47 107.93 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 173.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 64.3 tp -77.3 -50.6 12.48 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 123.358 0.663 . . . . 0.0 109.998 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.6 t30 179.53 107.68 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.3 m -117.82 147.4 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 123.587 0.755 . . . . 0.0 112.392 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER 42.53 123.72 0.0 OUTLIER Pre-proline 0 CA--C 1.536 0.441 1 C-N-CA 132.901 4.48 . . . . 0.0 120.801 171.706 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -80.94 -50.16 0.05 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.216 0 N-CA-C 106.676 -2.086 . . . . 0.0 106.676 168.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 8.9 p -113.99 43.08 1.91 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 127.281 2.232 . . . . 0.0 111.14 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 ttmm 56.91 25.62 10.74 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 115.762 1.764 . . . . 0.0 115.762 171.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -135.09 9.32 3.51 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 115.262 1.578 . . . . 0.0 115.262 -175.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -168.25 -159.29 0.27 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 122.053 2.206 . . . . 0.0 113.988 -173.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 1.014 0.2 OUTLIER 93.18 -161.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 131.632 3.973 . . . . 0.0 117.697 172.683 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -115.14 154.1 17.2 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 120.06 2.784 . . . . 0.0 120.06 -167.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.8 mp -133.23 165.83 23.89 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 128.558 2.743 . . . . 0.0 108.519 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.7 mm-40 -136.86 139.58 41.78 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 175.153 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.8 m . . . . . 0 C--N 1.322 -0.618 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.356 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 41.6 mtm180 . . . . . 0 CA--C 1.533 0.299 0 N-CA-C 111.569 0.211 . . . . 0.0 111.569 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -90.0 130.12 36.23 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.0 mt -119.05 150.49 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 C-N-CA 124.89 1.276 . . . . 0.0 110.744 -176.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.75 132.84 44.17 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 128.373 2.669 . . . . 0.0 105.94 177.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.4 mt -124.87 143.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 124.841 1.256 . . . . 0.0 108.853 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -134.82 124.73 25.56 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -87.78 122.52 31.53 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 118.675 -0.679 . . . . 0.0 109.558 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.05 -157.4 5.9 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 118.358 0.526 . . . . 0.0 112.491 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 17.6 mm -132.77 142.92 41.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 106.36 -1.719 . . . . 0.0 106.36 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.6 t70 58.96 29.06 18.46 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.058 0.943 . . . . 0.0 112.555 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 p -86.41 -37.3 18.5 Favored 'General case' 0 CA--C 1.517 -0.296 0 C-N-CA 126.162 1.785 . . . . 0.0 108.067 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 3.7 p -51.46 -46.75 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.235 171.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -61.6 -31.33 71.4 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.332 1.453 . . . . 0.0 111.147 178.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.89 -2.99 29.37 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.344 2.258 . . . . 0.0 110.379 178.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm 51.61 33.44 10.72 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 125.176 1.39 . . . . 0.0 112.629 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.49 18.15 63.05 Favored Glycine 0 CA--C 1.537 1.426 0 O-C-N 121.919 -0.488 . . . . 0.0 113.357 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -73.01 85.27 1.29 Allowed 'General case' 0 C--N 1.34 0.152 0 CA-C-N 118.88 1.34 . . . . 0.0 109.745 179.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 17.48 1.7 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.714 2.102 . . . . 0.0 111.575 -177.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -117.26 150.15 39.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.8 1.24 . . . . 0.0 109.907 -178.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 30.7 m -145.15 102.45 3.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.8 p -81.33 127.49 32.8 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.964 0.906 . . . . 0.0 108.959 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -91.13 -45.03 8.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.859 1.264 . . . . 0.0 112.612 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 6.7 m -73.36 129.19 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 118.383 -1.327 . . . . 0.0 111.67 -177.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -87.97 64.56 7.88 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 172.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.3 0.0 OUTLIER -14.11 84.47 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 130.039 3.336 . . . . 0.0 116.485 -173.213 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.14 -2.12 0.03 OUTLIER Glycine 0 CA--C 1.534 1.257 0 CA-C-N 113.528 -1.669 . . . . 0.0 113.194 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 121.57 14.71 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 127.266 2.226 . . . . 0.0 107.073 177.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.94 121.02 41.66 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 127.808 2.443 . . . . 0.0 111.061 -179.427 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.337 33.7 m 43.23 66.62 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 C-N-CA 126.682 1.993 . . . . 0.0 115.615 178.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -132.7 141.58 41.65 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 171.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -103.37 171.29 0.21 Allowed 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.935 3.09 . . . . 0.0 110.529 -179.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 60.04 -23.01 0.04 OUTLIER Glycine 0 CA--C 1.534 1.234 0 N-CA-C 118.856 2.303 . . . . 0.0 118.856 170.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -50.24 137.49 18.06 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 120.457 2.128 . . . . 0.0 110.529 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -60.59 123.7 18.18 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.5 mt -85.79 -48.2 9.01 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.5 mp -143.12 155.8 44.66 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.724 0.81 . . . . 0.0 110.666 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -122.11 135.36 54.79 Favored 'General case' 0 C--O 1.236 0.356 1 N-CA-C 99.023 -4.436 . . . . 0.0 99.023 167.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.71 126.47 12.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.592 -165.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 38.7 m-20 -76.83 61.61 1.93 Allowed 'General case' 0 C--O 1.235 0.294 0 C-N-CA 124.904 1.282 . . . . 0.0 110.544 -178.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.0 mt -45.12 -45.5 11.28 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 123.886 0.875 . . . . 0.0 112.192 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -44.95 -42.01 7.78 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.488 1.115 . . . . 0.0 112.611 178.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.56 -33.67 15.81 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.113 0.565 . . . . 0.0 111.364 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 96.6 t -62.62 -52.78 55.46 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 O-C-N 121.756 -0.59 . . . . 0.0 110.004 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.391 8.8 ptmt -42.79 -57.22 5.11 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 116.895 2.183 . . . . 0.0 116.895 -177.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -61.59 -21.37 71.84 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 122.187 1.925 . . . . 0.0 113.184 178.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 -87.88 -42.29 12.62 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 119.064 0.847 . . . . 0.0 111.317 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.9 m -78.69 149.19 74.15 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.95 -0.469 . . . . 0.0 111.807 -177.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -70.53 -24.5 26.07 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.506 2.137 . . . . 0.0 110.228 175.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.2 t -158.05 145.06 17.93 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.2 tp -98.18 6.5 47.42 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.56 1.144 . . . . 0.0 110.31 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 21.3 mmt -53.36 115.16 1.77 Allowed 'General case' 0 C--N 1.344 0.343 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 47.3 m -106.33 88.6 3.34 Favored Pre-proline 0 N--CA 1.447 -0.579 0 C-N-CA 124.706 1.203 . . . . 0.0 108.241 -178.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -72.93 144.0 37.64 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 122.668 2.246 . . . . 0.0 111.948 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.9 mt -125.01 126.29 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 103.788 -2.671 . . . . 0.0 103.788 173.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -123.53 153.41 29.16 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 C-N-CA 126.008 1.723 . . . . 0.0 106.651 178.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -129.92 121.58 26.9 Favored 'General case' 0 N--CA 1.428 -1.541 0 N-CA-C 102.914 -2.995 . . . . 0.0 102.914 -176.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 23.9 p -89.18 -86.17 0.19 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 -177.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -77.49 54.82 1.21 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 122.922 0.489 . . . . 0.0 111.696 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -78.26 80.07 4.69 Favored 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 174.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.12 51.51 0.21 Allowed 'General case' 0 C--N 1.343 0.289 0 C-N-CA 127.819 2.448 . . . . 0.0 111.641 -175.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 21.55 69.57 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 129.261 3.024 . . . . 0.0 113.964 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 146.42 -3.25 1.01 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-O 118.591 -1.116 . . . . 0.0 113.455 176.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -70.99 115.57 10.27 Favored 'General case' 0 C--N 1.339 0.116 0 CA-C-N 119.686 1.743 . . . . 0.0 109.933 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 81.5 p -78.78 128.99 34.13 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.266 0.4 OUTLIER -81.05 78.73 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 CA-C-O 123.498 1.618 . . . . 0.0 106.8 -177.538 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 38.5 m -78.8 91.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 120.962 -1.086 . . . . 0.0 111.249 -174.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.3 pt -63.19 104.58 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 C-N-CA 123.004 0.522 . . . . 0.0 109.597 176.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.23 -56.01 4.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -84.14 69.97 10.47 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 46.4 m -77.7 68.66 3.82 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 176.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.17 -142.06 3.83 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 106.433 -2.667 . . . . 0.0 106.433 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.4 t -67.0 145.99 54.83 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 117.975 0.888 . . . . 0.0 110.645 177.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 3.8 p -123.57 153.59 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 C-N-CA 125.881 1.673 . . . . 0.0 107.351 177.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.68 158.1 40.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 -65.46 147.99 52.48 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 43.44 48.69 6.12 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 128.109 2.564 . . . . 0.0 114.057 172.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -89.29 10.21 23.09 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 177.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 53.62 8.86 0.15 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 128.752 2.821 . . . . 0.0 115.566 177.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -156.97 -126.13 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 125.146 1.378 . . . . 0.0 107.405 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.312 1.5 mp 80.63 -36.89 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 128.559 2.744 . . . . 0.0 108.615 178.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -119.85 129.11 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 168.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 9.2 mmmt -111.3 111.51 22.61 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 124.168 0.987 . . . . 0.0 109.077 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.3 mp -77.24 91.51 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 103.409 -2.812 . . . . 0.0 103.409 175.049 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -103.46 116.1 31.77 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.587 1.555 . . . . 0.0 110.282 -173.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 28.6 tptp . . . . . 0 CA--C 1.528 0.129 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 178.987 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 29.3 t80 . . . . . 0 N--CA 1.451 -0.406 0 N-CA-C 104.402 -2.444 . . . . 0.0 104.402 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.76 77.05 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.4 t -15.91 124.06 0.04 OUTLIER Pre-proline 0 CA--C 1.552 1.043 0 C-N-CA 129.063 2.945 . . . . 0.0 114.449 179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -74.8 -42.72 0.51 Allowed 'Trans proline' 0 CA--C 1.538 0.684 0 N-CA-C 120.825 3.356 . . . . 0.0 120.825 -170.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.16 145.49 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 121.014 1.734 . . . . 0.0 111.665 -172.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 m -79.88 131.88 35.96 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 171.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 178.41 -160.49 26.55 Favored Glycine 0 CA--C 1.518 0.249 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.7 tp10 -108.04 131.74 54.28 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.1 tt -75.85 151.71 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-N 118.679 0.672 . . . . 0.0 110.535 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.5 m-70 -140.14 129.75 13.59 Favored Pre-proline 0 N--CA 1.446 -0.628 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 172.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -57.41 143.0 95.22 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 122.512 2.141 . . . . 0.0 107.578 174.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.8 tp -43.46 -49.45 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 123.764 0.826 . . . . 0.0 112.269 -177.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 p -53.9 -24.58 16.59 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.14 1.376 . . . . 0.0 114.321 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -78.81 -8.06 58.43 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 118.756 0.707 . . . . 0.0 112.61 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 93.0 t -70.1 134.67 87.35 Favored Pre-proline 0 CA--C 1.543 0.696 0 O-C-N 121.106 -0.996 . . . . 0.0 110.922 -177.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.85 64.6 5.92 Favored 'Trans proline' 0 CA--C 1.537 0.673 0 C-N-CA 124.674 3.582 . . . . 0.0 110.556 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.09 178.69 6.84 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.37 1.468 . . . . 0.0 107.177 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.46 -63.83 1.2 Allowed 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 124.383 1.073 . . . . 0.0 110.565 178.314 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.9 p -47.26 -56.6 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 C-N-CA 124.22 1.008 . . . . 0.0 112.775 -177.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -61.06 -57.32 13.05 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-O 121.703 0.763 . . . . 0.0 108.959 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.3 m -53.67 -36.97 62.71 Favored 'General case' 0 N--CA 1.446 -0.648 0 C-N-CA 126.18 1.792 . . . . 0.0 115.592 -174.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -87.35 7.04 82.27 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 26.1 mtmt 74.99 -39.94 0.42 Allowed 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.974 1.71 . . . . 0.0 111.44 -177.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.438 ' H ' ' C ' ' A' ' 36' ' ' GLY . 26.6 ttt 28.01 -70.05 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 131.305 3.842 . . . . 0.0 116.909 177.687 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 9.6 tpt -79.13 -16.98 55.9 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.383 1.073 . . . . 0.0 112.654 -176.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.37 -135.29 2.18 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -178.556 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -131.24 154.94 47.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 105.833 -1.914 . . . . 0.0 105.833 173.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.94 -159.48 22.79 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.249 -0.977 . . . . 0.0 114.177 -174.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 25.5 p90 -163.63 171.15 16.13 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.01 0.924 . . . . 0.0 109.521 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -120.34 137.3 54.35 Favored 'General case' 0 CA--C 1.508 -0.669 0 C-N-CA 122.936 0.494 . . . . 0.0 109.705 174.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 20.3 mm -112.09 129.6 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.903 0 N-CA-C 103.38 -2.822 . . . . 0.0 103.38 171.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 15.6 tp -94.85 110.63 50.7 Favored Pre-proline 0 N--CA 1.446 -0.651 0 N-CA-C 102.019 -3.326 . . . . 0.0 102.019 172.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -64.55 155.27 67.46 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 123.639 2.893 . . . . 0.0 116.916 -169.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.3 p -127.55 -50.94 1.38 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.124 1.37 . . . . 0.0 107.725 171.132 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -79.0 122.5 26.26 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 123.276 0.63 . . . . 0.0 110.37 177.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 40.31 2.26 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 174.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 72.7 mt -136.89 117.82 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.767 -2.679 . . . . 0.0 103.767 -179.237 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.3 t -120.59 109.4 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 122.962 0.505 . . . . 0.0 110.128 -173.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.5 m -91.15 -173.2 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 172.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.6 m -116.3 147.57 39.78 Favored Pre-proline 0 N--CA 1.469 0.49 0 CA-C-O 117.199 -1.381 . . . . 0.0 112.723 -175.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -61.54 -38.92 58.98 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 121.883 1.722 . . . . 0.0 108.305 174.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.46 142.0 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 102.921 -2.992 . . . . 0.0 102.921 171.151 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 29.1 mtm180 -95.12 -79.91 0.42 Allowed 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 102.094 -3.299 . . . . 0.0 102.094 171.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.88 -73.76 0.99 Allowed Glycine 0 C--N 1.338 0.64 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 176.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.21 123.1 8.72 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 24.1 mm -70.12 128.4 33.39 Favored 'Isoleucine or valine' 0 C--N 1.344 0.369 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.7 tt -78.43 -52.54 8.41 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.049 -2.204 . . . . 0.0 105.049 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 174.18 161.17 0.18 Allowed 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 124.614 1.166 . . . . 0.0 108.56 178.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.7 p -135.54 121.5 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 172.04 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -38.53 146.46 0.3 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.791 0.723 . . . . 0.0 112.947 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -58.63 -43.01 48.42 Favored 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.931 2.421 . . . . 0.0 109.723 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 15.9 p -78.23 74.27 4.77 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 173.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -34.4 93.24 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 129.261 3.024 . . . . 0.0 113.471 -173.671 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -158.56 -19.2 0.07 Allowed 'General case' 0 C--O 1.225 -0.229 0 N-CA-C 113.409 0.892 . . . . 0.0 113.409 175.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -164.77 -177.84 4.96 Favored 'General case' 0 C--O 1.222 -0.363 0 CA-C-N 120.238 1.381 . . . . 0.0 110.839 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.875 14.3 mm 135.57 -128.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 1 C-N-CA 133.254 4.622 . . . . 0.0 109.141 177.274 . . . . . . . . 3 2 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.4 175.29 42.49 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 118.769 2.268 . . . . 0.0 118.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 39.0 mt -128.72 172.94 10.76 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 127.478 2.311 . . . . 0.0 109.576 -178.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 -148.61 140.91 24.14 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.828 1.651 . . . . 0.0 106.835 176.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 59.6 p . . . . . 0 CA--C 1.536 0.417 0 CA-C-O 121.049 0.452 . . . . 0.0 110.363 178.33 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.4 ttp180 . . . . . 0 CA--C 1.529 0.137 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -79.28 134.32 36.64 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.3 mp -116.85 114.67 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 C-N-CA 123.268 0.627 . . . . 0.0 109.905 -177.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -81.2 125.84 30.78 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 104.196 -2.52 . . . . 0.0 104.196 170.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 62.7 mt -123.06 132.01 72.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -128.29 132.77 48.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 106.309 -1.737 . . . . 0.0 106.309 174.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -116.44 104.42 11.43 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 126.16 1.784 . . . . 0.0 109.489 -177.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.77 163.06 10.02 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 -178.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 10.7 mm -109.02 119.85 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 -179.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.4 t70 77.09 4.61 3.28 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.391 1.477 . . . . 0.0 113.779 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -61.78 -24.87 67.12 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 120.761 -1.212 . . . . 0.0 110.757 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -59.86 -47.88 89.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 C-N-CA 125.92 1.688 . . . . 0.0 108.127 173.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 4.5 m -63.47 -35.59 80.94 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.125 0.97 . . . . 0.0 108.766 177.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.58 19.75 0.78 Allowed 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 125.426 1.49 . . . . 0.0 110.873 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 4.8 mptt 37.77 37.59 0.13 Allowed 'General case' 0 C--N 1.346 0.42 0 C-N-CA 128.658 2.783 . . . . 0.0 114.595 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 52.58 34.42 43.07 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -67.41 92.64 0.3 Allowed 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 121.401 -1.058 . . . . 0.0 110.164 -178.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.47 1.67 5.12 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 126.043 1.782 . . . . 0.0 112.214 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -96.58 103.35 15.26 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.801 1.241 . . . . 0.0 111.263 -176.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.5 m -89.7 105.78 18.03 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.081 -2.192 . . . . 0.0 105.081 172.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.7 p -81.6 123.85 29.03 Favored 'General case' 0 N--CA 1.451 -0.406 0 O-C-N 121.613 -0.68 . . . . 0.0 110.402 -178.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -81.41 -52.3 7.41 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.915 1.286 . . . . 0.0 108.911 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.9 m -78.32 130.46 36.16 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 C-N-CA 117.999 -1.48 . . . . 0.0 107.224 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.5 m -94.37 57.06 2.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 169.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.341 9.8 pt-20 29.32 65.96 0.11 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 128.737 2.815 . . . . 0.0 111.681 -168.33 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -73.3 58.44 1.94 Allowed Glycine 0 CA--C 1.525 0.662 0 CA-C-N 111.574 -2.557 . . . . 0.0 111.253 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -10.59 -17.87 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.533 2 C-N-CA 136.188 5.795 . . . . 0.0 124.342 -179.317 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -142.88 110.7 5.9 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 128.062 2.545 . . . . 0.0 106.612 178.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.0 155.76 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 123.908 0.883 . . . . 0.0 112.833 -171.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -80.88 151.61 70.89 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-O 117.948 -1.025 . . . . 0.0 108.662 175.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -47.88 164.62 0.16 Allowed 'Trans proline' 0 CA--C 1.533 0.428 1 C-N-CA 127.018 5.145 . . . . 0.0 120.304 -174.158 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 68.45 -92.5 0.27 Allowed Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.84 1.686 . . . . 0.0 113.678 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 35.5 tp60 1.18 101.9 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.793 1 C-N-CA 132.258 4.223 . . . . 0.0 114.735 -176.548 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -4.14 112.95 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 130.168 3.387 . . . . 0.0 116.172 178.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.6 mt -83.18 -45.25 14.12 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 173.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.0 mt -140.38 151.23 44.8 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.723 1.209 . . . . 0.0 111.282 -174.285 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -119.84 128.58 53.82 Favored 'General case' 0 CA--C 1.514 -0.407 1 N-CA-C 99.12 -4.4 . . . . 0.0 99.12 167.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.93 124.41 27.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-N 115.1 -0.954 . . . . 0.0 112.756 -165.223 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -73.87 69.13 1.37 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.938 0.895 . . . . 0.0 110.037 178.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.1 mt -47.2 -52.49 15.62 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.793 0.837 . . . . 0.0 110.583 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -43.46 -49.65 7.16 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 125.392 1.477 . . . . 0.0 112.343 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -82.81 -31.36 28.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 123.175 0.297 . . . . 0.0 111.774 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 42.2 t -63.1 -56.48 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 118.901 -0.571 . . . . 0.0 110.839 179.007 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.324 3.8 pttm -42.78 -56.29 6.22 Favored Pre-proline 0 N--CA 1.47 0.535 0 N-CA-C 116.391 1.997 . . . . 0.0 116.391 -176.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -60.86 -14.63 33.41 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.699 1.6 . . . . 0.0 113.22 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 -98.98 5.08 47.36 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.056 -0.973 . . . . 0.0 112.303 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 20.1 m -142.07 155.11 65.44 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 120.332 1.424 . . . . 0.0 112.166 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.31 -39.78 89.16 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.086 2.524 . . . . 0.0 113.927 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -159.97 141.37 12.62 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.156 0.582 . . . . 0.0 110.012 -177.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -92.46 14.58 16.27 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.539 1.135 . . . . 0.0 112.068 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.4 mmt -53.04 134.01 38.33 Favored 'General case' 0 N--CA 1.457 -0.111 0 O-C-N 121.415 -0.803 . . . . 0.0 110.369 -178.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -110.28 78.78 1.46 Allowed Pre-proline 0 N--CA 1.451 -0.378 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 176.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.2 136.59 27.1 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 C-N-CA 122.449 2.1 . . . . 0.0 110.269 178.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -128.98 134.66 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 178.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 t -136.53 126.15 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 125.165 1.386 . . . . 0.0 108.55 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 -92.93 124.13 36.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 103.525 -2.769 . . . . 0.0 103.525 176.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 77.7 p -86.49 -82.28 0.2 Allowed 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.071 0.85 . . . . 0.0 109.319 -176.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -77.01 52.34 0.87 Allowed 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -78.78 72.26 5.29 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.249 -0.907 . . . . 0.0 108.666 174.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 41.87 47.86 3.74 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 126.603 1.961 . . . . 0.0 111.256 -178.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 18.9 68.42 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 129.394 3.077 . . . . 0.0 113.245 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 154.75 -9.65 0.39 Allowed Glycine 0 CA--C 1.523 0.574 0 CA-C-O 118.508 -1.162 . . . . 0.0 113.021 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 59.1 mm-40 -69.09 116.93 10.1 Favored 'General case' 0 C--N 1.342 0.281 0 CA-C-N 119.626 1.713 . . . . 0.0 110.069 178.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.2 p -77.73 136.07 38.11 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.828 -1.915 . . . . 0.0 105.828 173.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -86.69 86.74 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 -176.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.2 m -77.42 83.31 3.85 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.82 -1.175 . . . . 0.0 110.99 -175.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 2.1 pt -56.59 111.15 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 173.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -88.73 -38.57 14.62 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 123.892 0.877 . . . . 0.0 109.636 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -81.12 75.77 8.08 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.463 -175.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 50.6 p -77.39 69.44 3.65 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 169.38 -137.43 4.52 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -176.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.7 t -75.43 149.07 38.64 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.7 m -119.98 158.93 21.59 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 C-N-CA 125.374 1.469 . . . . 0.0 109.048 178.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -131.79 166.98 20.34 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 125.688 1.595 . . . . 0.0 112.22 176.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 73.5 mtm-85 -85.65 154.25 21.81 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -175.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 57.52 55.11 5.9 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 126.448 1.899 . . . . 0.0 113.591 176.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 4.3 mm-40 -143.05 161.12 38.99 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.964 0.906 . . . . 0.0 109.76 176.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . 0.471 ' C ' ' H ' ' A' ' 157' ' ' ILE . 62.9 tt0 -105.52 -61.1 1.53 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 122.817 1.294 . . . . 0.0 112.314 -177.412 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.68 27.34 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 127.705 2.402 . . . . 0.0 114.682 -174.326 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.471 ' H ' ' C ' ' A' ' 155' ' ' GLU . 1.7 mp -103.17 -34.7 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 130.225 3.41 . . . . 0.0 104.976 177.451 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 59.4 t -149.05 109.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 106.062 -1.829 . . . . 0.0 106.062 173.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -101.77 124.31 47.2 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 118.049 0.386 . . . . 0.0 111.78 -176.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.4 mp -78.15 108.8 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 174.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -128.9 150.62 50.28 Favored 'General case' 0 C--O 1.226 -0.157 0 C-N-CA 124.383 1.073 . . . . 0.0 109.261 -175.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 50.9 tptt . . . . . 0 C--N 1.333 -0.136 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -179.815 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.225 -0.215 0 N-CA-C 104.269 -2.493 . . . . 0.0 104.269 . . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.4 m -123.77 85.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 CA-C-N 118.846 0.748 . . . . 0.0 110.958 -176.375 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.4 p -19.45 110.25 0.09 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 129.569 3.147 . . . . 0.0 110.512 177.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -68.64 -25.13 34.6 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.776 2.317 . . . . 0.0 117.931 -168.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.95 146.1 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.611 1.096 . . . . 0.0 109.598 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.1 m -79.34 137.45 37.33 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 170.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 173.82 -158.25 27.09 Favored Glycine 0 C--O 1.227 -0.312 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -108.4 120.61 42.89 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 tt -85.51 134.92 26.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 118.569 0.622 . . . . 0.0 109.718 178.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -137.59 149.42 64.97 Favored Pre-proline 0 N--CA 1.451 -0.389 0 C-N-CA 125.79 1.636 . . . . 0.0 107.753 176.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.65 143.37 96.57 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 121.366 1.378 . . . . 0.0 108.566 173.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -55.05 -24.82 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -173.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.3 p -52.42 -31.02 32.28 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 124.279 1.032 . . . . 0.0 111.134 174.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -75.16 -9.72 58.8 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.5 1.12 . . . . 0.0 112.65 -176.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.9 t -76.63 131.74 73.53 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 119.13 0.877 . . . . 0.0 109.861 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -77.8 60.1 7.1 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 123.17 2.58 . . . . 0.0 110.847 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -165.55 102.6 0.71 Allowed 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.487 -0.758 . . . . 0.0 110.01 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -24.41 -59.0 0.05 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.476 2.71 . . . . 0.0 115.055 -178.45 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -52.03 -41.85 33.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 123.178 0.591 . . . . 0.0 111.583 -177.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -80.67 -48.56 12.43 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.7 m -48.71 -41.54 32.16 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -179.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -99.61 11.2 61.2 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-O 118.629 -1.095 . . . . 0.0 111.515 -178.411 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm 73.37 -39.5 0.44 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.573 1.549 . . . . 0.0 112.773 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.415 ' H ' ' C ' ' A' ' 36' ' ' GLY . 13.7 tpt 21.7 -62.24 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 1 C-N-CA 132.264 4.226 . . . . 0.0 117.996 178.455 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -77.71 -21.63 51.67 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.991 0.916 . . . . 0.0 111.898 -176.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.32 -136.29 2.78 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -130.27 157.55 42.21 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 172.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.71 -167.74 36.87 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.943 -176.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -146.81 154.72 41.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 124.283 1.033 . . . . 0.0 109.718 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.76 119.09 38.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.009 0.923 . . . . 0.0 109.917 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.3 mm -100.8 129.53 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 171.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.3 tt -98.14 105.83 30.98 Favored Pre-proline 0 N--CA 1.45 -0.426 0 N-CA-C 101.326 -3.583 . . . . 0.0 101.326 172.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -60.5 167.31 8.26 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 123.434 2.756 . . . . 0.0 117.124 -169.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.1 p -146.98 -58.92 0.28 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.72 1.608 . . . . 0.0 106.942 173.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -69.81 119.0 13.37 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 175.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.75 44.85 3.03 Favored Glycine 0 CA--C 1.53 1.005 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 22.0 mt -144.06 114.64 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 N-CA-C 105.253 -2.129 . . . . 0.0 105.253 -177.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.65 126.14 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 124.479 1.111 . . . . 0.0 109.131 -175.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.8 m -109.29 156.91 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 C-N-CA 123.387 0.675 . . . . 0.0 110.363 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 m -65.67 127.2 92.86 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-O 118.982 -0.532 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.49 -7.96 22.5 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 124.468 3.445 . . . . 0.0 116.765 -174.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.4 m -147.99 169.51 3.58 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 CA-C-N 119.754 1.161 . . . . 0.0 109.388 -177.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.06 116.18 17.49 Favored 'General case' 0 C--O 1.235 0.336 1 N-CA-C 97.978 -4.823 . . . . 0.0 97.978 166.893 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.69 170.26 42.11 Favored Glycine 0 N--CA 1.438 -1.215 0 C-N-CA 116.026 -2.988 . . . . 0.0 116.557 -167.08 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 10.0 mtpp -97.2 132.84 42.57 Favored 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 127.989 2.515 . . . . 0.0 109.003 -175.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.7 mm -72.8 123.96 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 104.618 -2.364 . . . . 0.0 104.618 173.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 42.0 tp -78.63 -48.88 14.2 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 179.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -177.46 171.79 1.91 Allowed 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 123.531 0.732 . . . . 0.0 109.444 173.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 51.5 t -144.16 115.08 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 176.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -45.5 147.33 1.47 Allowed Pre-proline 0 CA--C 1.542 0.65 0 CA-C-N 118.689 0.677 . . . . 0.0 111.454 177.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.45 -24.22 11.84 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 124.102 3.202 . . . . 0.0 114.881 176.247 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.8 p -76.34 -15.17 60.03 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.636 1.174 . . . . 0.0 111.165 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.6 tppt? 70.94 4.8 5.22 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 127.852 2.461 . . . . 0.0 113.344 -178.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.2 p-80 -78.97 -25.93 43.48 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 113.41 0.893 . . . . 0.0 113.41 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.96 -173.94 2.53 Favored 'General case' 0 C--O 1.222 -0.348 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -172.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.62 25.9 mm 132.03 -124.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.345 1 C-N-CA 136.505 5.922 . . . . 0.0 105.75 178.863 . . . . . . . . 3 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -179.96 -176.68 47.55 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 116.976 1.55 . . . . 0.0 116.976 -179.106 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.3 mp -126.29 171.92 10.54 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 127.519 2.327 . . . . 0.0 110.126 -178.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -140.36 136.37 33.09 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 62.9 p . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.925 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 24.8 mtp180 . . . . . 0 C--O 1.235 0.338 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 13.2 tm-20 -93.3 150.72 20.27 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 126.866 2.066 . . . . 0.0 109.318 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.65 103.39 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 C-N-CA 124.376 1.071 . . . . 0.0 109.052 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.4 tt -85.64 136.64 33.29 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.498 -1.668 . . . . 0.0 106.498 174.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 20.0 mt -122.77 148.72 26.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 123.444 0.698 . . . . 0.0 109.938 -178.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.37 126.48 21.17 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 170.551 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -102.41 106.22 16.94 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.705 1.202 . . . . 0.0 108.773 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 64.29 176.63 4.73 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 118.184 0.447 . . . . 0.0 113.09 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.6 mm -113.29 141.17 29.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.9 t70 63.27 13.32 6.88 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.423 1.089 . . . . 0.0 112.486 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 p -74.15 -39.74 63.06 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 126.265 1.826 . . . . 0.0 107.231 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 p -47.11 -47.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 124.923 1.289 . . . . 0.0 109.287 171.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -63.98 -54.58 32.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 125.347 1.459 . . . . 0.0 111.304 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.23 -36.89 78.74 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 123.991 0.916 . . . . 0.0 112.008 -178.257 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 81.5 mttt 79.57 145.6 0.09 Allowed 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 128.854 2.862 . . . . 0.0 108.706 -176.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.45 48.71 0.29 Allowed Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.609 1.1 . . . . 0.0 115.537 -176.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 25.7 pt-20 -63.75 -17.31 62.9 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 119.168 1.484 . . . . 0.0 113.67 177.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -109.84 15.43 31.43 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 126.544 2.021 . . . . 0.0 111.13 177.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -107.95 99.42 8.88 Favored 'General case' 0 C--N 1.343 0.283 0 CA-C-N 118.156 0.978 . . . . 0.0 110.665 -176.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -79.44 93.99 5.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 174.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 p -79.11 127.4 31.96 Favored 'General case' 0 N--CA 1.453 -0.31 0 O-C-N 120.983 -1.073 . . . . 0.0 110.505 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -89.17 -49.11 6.94 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 123.836 0.854 . . . . 0.0 110.375 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -78.1 133.29 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.032 0 C-N-CA 119.019 -1.072 . . . . 0.0 110.559 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 m -87.73 61.5 6.5 Favored 'General case' 0 C--N 1.333 -0.128 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 172.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.271 1.6 pm0 3.22 79.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 130.451 3.501 . . . . 0.0 115.211 -174.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 174.65 6.54 0.02 OUTLIER Glycine 0 CA--C 1.533 1.202 0 CA-C-N 113.32 -1.763 . . . . 0.0 114.812 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.24 121.52 14.46 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 119.493 1.646 . . . . 0.0 107.396 176.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 37.8 mmt-85 -100.07 100.53 11.41 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 129.796 3.238 . . . . 0.0 111.817 -175.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.551 7.3 p 60.47 78.23 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 N-CA-C 116.813 2.153 . . . . 0.0 116.813 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -135.99 150.14 70.5 Favored Pre-proline 0 N--CA 1.446 -0.632 0 CA-C-N 111.933 -2.394 . . . . 0.0 105.141 169.15 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -105.42 142.59 0.1 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.969 3.112 . . . . 0.0 111.803 -177.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 56.93 15.26 12.46 Favored Glycine 0 CA--C 1.531 1.046 0 O-C-N 121.417 -0.802 . . . . 0.0 114.289 175.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.3 130.28 45.41 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 25.7 ttpt -59.39 117.64 5.07 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.112 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.4 mt -80.41 -54.2 5.92 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 25.0 mt -144.82 151.13 38.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.215 1.006 . . . . 0.0 110.871 -173.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 6.1 tm-20 -116.45 128.44 55.48 Favored 'General case' 0 CA--C 1.515 -0.398 1 N-CA-C 97.922 -4.844 . . . . 0.0 97.922 166.098 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.52 121.69 22.78 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.834 -166.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -71.91 69.96 0.73 Allowed 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.844 1.258 . . . . 0.0 111.112 -177.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.3 mt -47.95 -44.85 30.53 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.057 0.943 . . . . 0.0 110.718 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -52.83 -43.78 66.24 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.473 0.709 . . . . 0.0 112.794 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -84.71 -33.36 23.16 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.114 0.416 . . . . 0.0 111.305 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 40.3 t -63.87 -56.25 17.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 O-C-N 121.865 -0.522 . . . . 0.0 109.852 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.359 0.1 OUTLIER -40.74 -55.52 4.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 117.891 2.552 . . . . 0.0 117.891 -177.125 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -57.91 -21.65 50.38 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.515 2.143 . . . . 0.0 112.87 178.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -93.68 9.57 36.42 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.457 -0.782 . . . . 0.0 112.216 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 15.9 m -138.96 152.02 69.36 Favored Pre-proline 0 C--N 1.344 0.36 0 CA-C-N 119.923 1.238 . . . . 0.0 111.695 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.03 -26.8 12.62 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.044 2.496 . . . . 0.0 111.594 179.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 15.6 t -153.1 142.81 21.97 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.09 6.99 47.56 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.226 1.01 . . . . 0.0 110.595 178.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 16.5 mmt -51.01 119.61 4.12 Favored 'General case' 0 C--N 1.344 0.347 0 CA-C-N 118.5 0.591 . . . . 0.0 109.955 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 29.9 m -117.2 87.52 24.05 Favored Pre-proline 0 N--CA 1.446 -0.66 0 C-N-CA 125.588 1.555 . . . . 0.0 107.645 -177.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -84.89 151.61 11.2 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 C-N-CA 121.411 1.407 . . . . 0.0 112.011 -178.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.3 mp -118.55 130.14 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 N-CA-C 102.792 -3.04 . . . . 0.0 102.792 173.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.0 t -128.6 153.4 38.05 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.58 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -127.02 109.82 12.31 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 103.418 -2.808 . . . . 0.0 103.418 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.0 p -75.2 -78.05 0.11 Allowed 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -175.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -74.03 65.86 1.15 Allowed 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.587 0.708 . . . . 0.0 112.096 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 16.4 mt -72.81 70.41 0.98 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.144 1.378 . . . . 0.0 108.273 176.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 27.74 48.99 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 128.508 2.723 . . . . 0.0 111.921 -176.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 28.5 53.52 0.08 Allowed 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 128.74 2.816 . . . . 0.0 114.44 -175.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 167.09 -4.71 0.05 OUTLIER Glycine 0 CA--C 1.528 0.848 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.227 178.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . 0.507 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 3.7 mm-40 -87.35 148.01 25.23 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.838 1.319 . . . . 0.0 110.178 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 51.0 p -123.89 140.42 53.0 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.943 1.297 . . . . 0.0 108.102 179.035 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -86.08 95.35 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-O 122.064 0.935 . . . . 0.0 108.952 -177.563 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 62.1 m -84.74 87.36 7.3 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.301 -0.875 . . . . 0.0 109.836 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.8 pt -66.07 128.78 29.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 174.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -103.2 -46.9 4.48 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.557 1.143 . . . . 0.0 109.708 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -76.14 156.69 33.53 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.433 0.635 . . . . 0.0 111.629 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 27.9 p -150.62 113.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 104.774 -2.306 . . . . 0.0 104.774 178.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 115.8 -151.57 18.33 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.9 t -59.12 139.93 56.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.347 1.074 . . . . 0.0 112.379 -177.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.5 m -143.52 146.32 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 C-N-CA 126.23 1.812 . . . . 0.0 108.64 177.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -101.59 160.18 14.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.491 1.116 . . . . 0.0 110.768 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.2 ttp180 -75.77 154.99 35.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.524 1.53 . . . . 0.0 110.887 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 57.98 52.96 7.23 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.903 1.681 . . . . 0.0 113.222 178.219 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -135.93 168.01 20.14 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.635 1.574 . . . . 0.0 108.509 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . 0.42 ' C ' ' H ' ' A' ' 157' ' ' ILE . 0.5 OUTLIER -119.69 -77.53 0.58 Allowed 'General case' 0 C--N 1.344 0.327 0 CA-C-N 120.027 1.285 . . . . 0.0 114.238 179.403 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -37.08 -7.62 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.065 1 C-N-CA 132.073 4.149 . . . . 0.0 120.194 -174.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . 0.42 ' H ' ' C ' ' A' ' 155' ' ' GLU . 4.9 mp -68.39 -33.44 60.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 130.874 3.67 . . . . 0.0 106.889 174.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -137.29 133.62 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 C-N-CA 127.281 2.233 . . . . 0.0 106.599 173.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -127.08 133.03 50.52 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . 0.507 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.06 116.2 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 175.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -98.26 170.83 8.6 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 175.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp . . . . . 0 CA--C 1.532 0.259 0 O-C-N 121.457 -0.777 . . . . 0.0 110.811 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.469 0.5 0 CA-C-O 118.386 -0.816 . . . . 0.0 110.637 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.3 m -117.35 108.36 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 119.244 0.929 . . . . 0.0 109.04 172.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.3 t -38.87 115.96 0.95 Allowed Pre-proline 0 CA--C 1.553 1.066 0 C-N-CA 124.759 1.224 . . . . 0.0 111.761 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -76.82 -23.38 10.95 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 123.507 2.805 . . . . 0.0 118.293 -172.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.89 154.41 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 120.698 1.59 . . . . 0.0 109.989 -178.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.5 m -89.74 137.73 32.08 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 175.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 160.71 -130.71 2.44 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -131.32 139.01 49.47 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 124.653 1.181 . . . . 0.0 109.087 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.9 tt -101.39 131.6 48.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 CA-C-N 118.673 0.669 . . . . 0.0 110.01 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.64 145.49 49.6 Favored Pre-proline 0 N--CA 1.452 -0.358 0 C-N-CA 126.069 1.748 . . . . 0.0 108.036 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -62.82 141.97 86.93 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 121.749 1.633 . . . . 0.0 108.598 174.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.6 tt -53.61 -27.29 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 114.334 1.235 . . . . 0.0 114.334 -174.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.7 p -55.02 -29.0 56.41 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.879 0.871 . . . . 0.0 111.553 176.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -78.98 -1.45 35.47 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.81 0.844 . . . . 0.0 112.937 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.4 t -81.68 134.58 50.42 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.068 -1.02 . . . . 0.0 110.181 -178.292 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -77.83 54.1 4.68 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.741 2.961 . . . . 0.0 111.934 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -167.98 109.28 0.58 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.308 0.958 . . . . 0.0 110.651 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -29.43 -54.48 0.14 Allowed 'General case' 0 C--O 1.234 0.249 0 C-N-CA 128.35 2.66 . . . . 0.0 115.186 -177.716 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -51.56 -40.49 25.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.973 0.416 . . . . 0.0 110.565 -176.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . 0.44 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 24.5 m-85 -83.15 -52.87 6.23 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 177.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -46.66 -39.94 12.27 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 114.349 1.241 . . . . 0.0 114.349 -177.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -109.11 22.77 24.62 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-O 118.339 -1.256 . . . . 0.0 111.39 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.8 mppt? 70.69 -45.02 0.6 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.028 1.731 . . . . 0.0 114.384 178.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.8 tpp 32.76 -68.92 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 130.2 3.4 . . . . 0.0 116.703 -178.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.32 -26.01 42.28 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.974 1.31 . . . . 0.0 112.771 -176.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.12 -154.55 16.09 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -178.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -108.39 153.34 23.43 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 174.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -174.25 -167.46 33.77 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.42 -176.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.4 p90 -150.02 165.13 33.64 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.894 1.278 . . . . 0.0 109.044 -178.461 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -117.85 117.19 28.61 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 123.706 0.802 . . . . 0.0 111.289 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -87.83 134.34 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 103.994 -2.595 . . . . 0.0 103.994 170.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.2 tt -100.89 106.62 45.22 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.054 -4.795 . . . . 0.0 98.054 169.287 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_endo -83.92 161.38 13.9 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 123.439 2.76 . . . . 0.0 114.191 -168.051 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.7 p -130.18 -53.39 1.11 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.867 1.267 . . . . 0.0 109.639 176.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -67.11 128.03 34.85 Favored 'General case' 0 CA--C 1.519 -0.214 0 O-C-N 122.18 -0.325 . . . . 0.0 111.493 179.432 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.45 39.55 1.93 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 174.089 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 5.0 mp -143.62 120.53 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 104.676 -2.342 . . . . 0.0 104.676 178.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 69.8 t -119.41 120.08 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 C-N-CA 125.695 1.598 . . . . 0.0 107.415 -176.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 22.0 m -106.77 157.29 7.06 Favored 'Isoleucine or valine' 0 C--N 1.338 0.099 0 N-CA-C 114.42 1.266 . . . . 0.0 114.42 -175.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 48.2 m -61.62 125.76 85.32 Favored Pre-proline 0 CA--C 1.537 0.48 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.488 179.017 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -77.52 -4.12 14.31 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 124.945 3.763 . . . . 0.0 116.012 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.5 m -155.21 172.88 0.57 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 125.297 1.439 . . . . 0.0 108.055 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . 0.432 ' NE ' ' H ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -76.26 87.89 3.09 Favored 'General case' 0 C--N 1.34 0.16 1 N-CA-C 98.374 -4.676 . . . . 0.0 98.374 168.028 . . . . . . . . 4 4 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.07 176.26 30.43 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 118.543 2.177 . . . . 0.0 118.543 -164.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.01 110.54 5.31 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 172.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.2 mm -61.82 125.14 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 37.1 mt -78.95 -48.75 13.94 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 105.779 -1.934 . . . . 0.0 105.779 173.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -173.25 159.33 3.8 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.4 t -135.4 119.81 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 102.879 -3.008 . . . . 0.0 102.879 173.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -45.55 147.39 1.49 Allowed Pre-proline 0 CA--C 1.535 0.384 0 O-C-N 123.43 0.456 . . . . 0.0 111.55 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -56.51 -25.96 61.26 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.642 2.228 . . . . 0.0 111.214 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 55.2 p -79.97 13.49 2.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 117.03 -1.462 . . . . 0.0 112.596 177.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . 0.275 0.1 OUTLIER 66.28 -39.6 0.33 Allowed 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 117.857 2.539 . . . . 0.0 117.857 178.477 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.9 p-80 -57.63 -26.6 61.82 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 116.269 1.951 . . . . 0.0 116.269 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.93 -175.99 5.67 Favored 'General case' 0 C--O 1.221 -0.396 0 N-CA-C 114.292 1.219 . . . . 0.0 114.292 -172.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.847 26.9 mm 127.0 -135.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.52 -0.192 1 C-N-CA 133.25 4.62 . . . . 0.0 110.289 178.51 . . . . . . . . 3 2 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -166.89 173.47 42.2 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 118.43 2.132 . . . . 0.0 118.43 -176.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.7 mp -127.64 175.16 8.49 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 128.208 2.603 . . . . 0.0 109.854 -177.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -137.07 160.74 38.07 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 103.258 -2.867 . . . . 0.0 103.258 168.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 83.6 p . . . . . 0 CA--C 1.535 0.388 0 O-C-N 124.055 0.847 . . . . 0.0 109.448 177.861 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 74.4 mtp180 . . . . . 0 CA--C 1.524 -0.041 0 CA-C-O 121.655 0.74 . . . . 0.0 109.84 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -79.63 109.96 14.51 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 125.327 1.451 . . . . 0.0 107.389 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.4 mp -95.96 116.56 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 C-N-CA 125.381 1.472 . . . . 0.0 109.763 -176.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 9.2 tp -93.58 122.29 35.87 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 105.316 -2.105 . . . . 0.0 105.316 172.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.0 mt -113.82 134.53 56.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 124.938 1.295 . . . . 0.0 108.741 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -131.24 109.76 10.63 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 171.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -78.51 119.6 22.02 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 118.708 -0.663 . . . . 0.0 109.443 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.1 -161.26 2.97 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-O 121.71 0.617 . . . . 0.0 113.341 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.9 mm -131.17 145.5 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.4 t70 62.67 15.34 7.96 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.5 1.12 . . . . 0.0 113.426 179.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.9 p -78.52 -37.7 42.42 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 126.251 1.821 . . . . 0.0 107.468 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 9.1 p -50.71 -45.26 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 CA-C-N 113.77 -1.559 . . . . 0.0 108.787 172.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -63.31 -37.86 88.92 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 125.531 1.532 . . . . 0.0 111.329 178.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.65 -39.44 94.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 127.145 2.178 . . . . 0.0 109.898 -179.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mttp 59.62 88.01 0.08 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.782 1.633 . . . . 0.0 114.223 175.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.4 -55.63 2.85 Favored Glycine 0 CA--C 1.539 1.582 0 O-C-N 121.375 -0.828 . . . . 0.0 112.856 175.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -28.17 108.3 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 128.911 2.884 . . . . 0.0 114.034 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 92.24 -2.14 74.39 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-N 113.976 -1.466 . . . . 0.0 114.764 175.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.432 ' CG ' HG13 ' A' ' 115' ' ' VAL . 2.4 m-85 -108.86 109.51 20.63 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 117.857 0.828 . . . . 0.0 109.823 -176.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.7 m -79.9 81.18 6.2 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 102.741 -3.059 . . . . 0.0 102.741 169.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.8 p -76.99 114.09 15.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 -178.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -77.64 -46.17 22.86 Favored 'General case' 0 CA--C 1.511 -0.551 0 C-N-CA 123.459 0.703 . . . . 0.0 111.297 -173.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.56 125.98 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 C-N-CA 117.122 -1.831 . . . . 0.0 109.96 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.7 m -92.48 58.39 3.16 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 102.375 -3.195 . . . . 0.0 102.375 168.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.449 0.0 OUTLIER 30.47 54.35 0.16 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 129.307 3.043 . . . . 0.0 112.907 -168.43 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.03 62.92 2.08 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 110.265 -3.152 . . . . 0.0 110.712 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 33.0 t70 3.92 -106.46 0.0 OUTLIER 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 130.098 3.359 . . . . 0.0 116.312 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -55.14 106.99 0.26 Allowed 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.084 1.754 . . . . 0.0 111.617 -173.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 2.5 m -124.14 157.1 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 126.811 2.044 . . . . 0.0 111.692 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.4 mm-40 -86.83 164.17 37.97 Favored Pre-proline 0 CA--C 1.535 0.379 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 172.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -70.25 154.21 65.98 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 N-CA-C 106.58 -2.123 . . . . 0.0 106.58 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.9 -15.15 8.62 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 119.586 -1.292 . . . . 0.0 114.072 178.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.29 125.96 25.66 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 106.606 -1.628 . . . . 0.0 106.606 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . 0.311 0.0 OUTLIER -66.74 119.95 12.68 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.102 0.865 . . . . 0.0 111.428 -177.268 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 77.4 mt -79.67 -41.5 26.74 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.3 mp -147.82 146.26 29.06 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.126 0.97 . . . . 0.0 111.059 -178.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -114.55 130.6 56.77 Favored 'General case' 0 N--CA 1.463 0.196 1 N-CA-C 99.203 -4.369 . . . . 0.0 99.203 166.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . 0.432 HG13 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -138.74 127.81 30.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.633 -164.307 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -75.71 65.41 1.87 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-O 121.137 0.494 . . . . 0.0 110.247 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.5 mt -50.42 -38.1 41.37 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 123.617 0.767 . . . . 0.0 111.796 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -54.21 -40.19 67.38 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 122.899 0.48 . . . . 0.0 112.162 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -91.06 -32.77 15.76 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 122.829 0.452 . . . . 0.0 111.34 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.27 -48.58 84.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 O-C-N 121.622 -0.673 . . . . 0.0 109.699 178.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.376 40.6 pttt -41.73 -58.38 3.23 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 116.498 2.036 . . . . 0.0 116.498 -177.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -59.42 -20.0 54.22 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.258 1.972 . . . . 0.0 113.137 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -95.61 9.11 41.37 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.773 0.829 . . . . 0.0 112.351 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 31.4 m -133.44 149.46 72.38 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 119.747 1.158 . . . . 0.0 109.9 177.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -72.24 -27.71 16.22 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.576 2.184 . . . . 0.0 111.187 179.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 5.4 m -160.2 138.31 10.03 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.0 tp -91.54 7.11 42.94 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.344 1.058 . . . . 0.0 111.524 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 20.3 mmt -50.3 116.13 1.74 Allowed 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.71 0.804 . . . . 0.0 109.226 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 50.1 m -108.59 84.38 2.42 Favored Pre-proline 0 N--CA 1.444 -0.744 0 C-N-CA 124.276 1.03 . . . . 0.0 108.317 -179.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . 0.44 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 72.5 Cg_endo -72.41 142.29 36.72 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.44 2.094 . . . . 0.0 110.765 179.039 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 29.6 mt -131.15 128.52 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 104.459 -2.422 . . . . 0.0 104.459 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -125.59 152.55 32.56 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 C-N-CA 125.314 1.446 . . . . 0.0 107.863 -177.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -120.69 117.8 28.43 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 102.867 -3.012 . . . . 0.0 102.867 177.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.4 p -81.38 -67.89 0.74 Allowed 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.478 0.656 . . . . 0.0 110.353 -173.003 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.6 p30 -70.82 51.88 0.14 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 126.442 1.897 . . . . 0.0 113.034 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.7 mt -75.72 63.84 1.66 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.809 1.244 . . . . 0.0 108.874 177.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 24.32 49.96 0.01 OUTLIER 'General case' 0 C--N 1.346 0.445 0 C-N-CA 128.969 2.908 . . . . 0.0 112.051 -176.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 28.03 54.21 0.07 Allowed 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 128.649 2.78 . . . . 0.0 114.135 -174.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.9 0.05 OUTLIER Glycine 0 CA--C 1.528 0.873 0 CA-C-O 118.853 -0.97 . . . . 0.0 114.3 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . 0.48 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 26.8 mt-10 -80.96 138.34 36.09 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.152 1.476 . . . . 0.0 109.701 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 7.7 p -111.08 139.39 46.48 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.223 1.409 . . . . 0.0 109.273 179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.64 120.79 35.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.3 m -114.75 95.71 5.37 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.665 1.186 . . . . 0.0 111.308 -174.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 2.3 pt -63.32 124.75 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 176.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -96.08 -53.82 3.52 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.655 1.182 . . . . 0.0 108.376 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -86.22 74.0 10.11 Favored 'General case' 0 N--CA 1.456 -0.136 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 47.1 p -77.04 72.76 3.61 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 -179.364 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 179.87 -136.51 2.77 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -177.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.0 t -69.0 148.78 49.6 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.38 163.02 38.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 C-N-CA 125.222 1.409 . . . . 0.0 108.097 177.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -133.44 162.59 31.46 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.687 1.195 . . . . 0.0 109.039 -178.313 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 68.6 mtp180 -65.23 147.6 53.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.869 0.468 . . . . 0.0 110.509 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 25.8 tp10 57.65 12.97 1.76 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 126.847 2.059 . . . . 0.0 114.749 173.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -71.55 117.87 13.66 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -65.97 137.47 57.15 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . 0.465 ' C ' ' H ' ' A' ' 158' ' ' VAL . 27.9 t0 74.18 -111.81 0.04 OUTLIER 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 128.027 2.531 . . . . 0.0 108.448 -175.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.271 1.6 mp 70.86 -29.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 129.456 3.103 . . . . 0.0 110.866 -176.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . 0.465 ' H ' ' C ' ' A' ' 156' ' ' ASP . 6.2 p -143.35 119.4 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 130.197 3.399 . . . . 0.0 105.003 173.148 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 28.0 tttm -111.9 139.3 47.5 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.767 0.427 . . . . 0.0 110.077 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . 0.48 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.14 132.06 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 172.152 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -141.26 167.96 20.91 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 106.627 -1.619 . . . . 0.0 106.627 177.482 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 24.1 tptp . . . . . 0 C--N 1.33 -0.239 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.865 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.45 -0.462 0 CA-C-O 121.146 0.498 . . . . 0.0 109.691 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.7 m -77.9 84.16 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 O-C-N 121.857 -0.527 . . . . 0.0 111.747 -176.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.7 t -10.66 112.97 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 128.64 2.776 . . . . 0.0 113.796 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.42 -32.3 3.02 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 122.601 2.201 . . . . 0.0 115.781 -174.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.65 139.62 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 120.4 1.455 . . . . 0.0 109.933 -177.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 56.4 m -78.18 140.84 38.97 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 168.28 -159.82 33.15 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 -103.02 126.44 50.2 Favored 'General case' 0 N--CA 1.458 -0.072 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 176.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.2 tt -97.26 141.27 16.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 CA-C-N 118.57 0.623 . . . . 0.0 109.695 -179.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 25.5 m-70 -136.78 148.31 62.81 Favored Pre-proline 0 C--O 1.235 0.316 0 C-N-CA 124.701 1.2 . . . . 0.0 108.019 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.89 146.11 69.61 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.025 1.817 . . . . 0.0 110.176 176.151 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.7 tp -49.53 -34.88 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 C-N-CA 123.766 0.826 . . . . 0.0 113.117 -177.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 p -55.83 -26.78 48.25 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.863 0.865 . . . . 0.0 112.581 178.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -74.99 -13.05 60.47 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.829 0.852 . . . . 0.0 112.594 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.3 t -67.85 129.18 93.36 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.306 -0.871 . . . . 0.0 110.057 -177.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -76.52 59.48 6.2 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 124.197 3.265 . . . . 0.0 111.849 -178.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -169.08 108.66 0.45 Allowed 'General case' 0 N--CA 1.465 0.296 0 O-C-N 121.351 -0.843 . . . . 0.0 110.104 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -24.25 -58.86 0.05 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.153 2.581 . . . . 0.0 114.98 -179.018 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 52.7 t -52.9 -50.24 44.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.613 0.765 . . . . 0.0 110.082 -178.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -71.49 -48.36 49.53 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.3 m -49.44 -43.11 44.59 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.968 0.907 . . . . 0.0 113.068 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -94.94 11.88 69.1 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-O 118.907 -0.94 . . . . 0.0 111.456 -178.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt 71.55 -37.18 0.38 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.749 1.62 . . . . 0.0 113.358 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.419 ' H ' ' C ' ' A' ' 36' ' ' GLY . 1.1 tmt? 30.8 -71.78 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 131.063 3.745 . . . . 0.0 116.538 178.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 37.8 tpp -78.4 -16.82 57.23 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.013 0.925 . . . . 0.0 112.145 -175.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.99 -133.93 2.11 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -146.26 163.31 35.89 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 173.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 164.87 -134.9 3.49 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -168.07 169.89 10.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 117.967 0.884 . . . . 0.0 111.546 -177.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.22 132.46 48.13 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 124.061 0.945 . . . . 0.0 109.25 179.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -109.39 135.62 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 103.102 -2.925 . . . . 0.0 103.102 168.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.1 tt -101.25 104.74 35.14 Favored Pre-proline 0 N--CA 1.447 -0.619 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 171.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.16 169.81 1.36 Allowed 'Trans proline' 0 C--N 1.348 0.543 1 C-N-CA 125.375 4.05 . . . . 0.0 116.278 -171.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 65.7 p -155.38 -54.94 0.09 Allowed 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 124.14 0.976 . . . . 0.0 111.279 176.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -57.84 -43.86 86.11 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -176.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.29 25.81 69.83 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -174.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -139.04 130.9 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 176.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.7 t -125.11 126.07 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 -175.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.1 m -105.71 162.84 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 C-N-CA 124.013 0.925 . . . . 0.0 111.075 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 15.9 m -67.46 126.39 92.49 Favored Pre-proline 0 CA--C 1.536 0.419 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -75.66 -16.72 18.63 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 124.125 3.216 . . . . 0.0 115.577 -174.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.18 163.97 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.067 0 CA-C-N 118.861 0.755 . . . . 0.0 109.183 -174.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 18.1 ttt85 -75.67 119.29 19.5 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 100.31 -3.959 . . . . 0.0 100.31 169.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.1 177.1 48.32 Favored Glycine 0 N--CA 1.436 -1.31 0 C-N-CA 116.562 -2.732 . . . . 0.0 115.089 -168.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.01 133.85 34.96 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.621 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 10.0 mm -79.22 100.03 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 172.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 46.7 tp -73.66 -56.5 4.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 -174.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.83 163.86 5.07 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 115.936 1.828 . . . . 0.0 115.936 174.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.5 m -144.18 118.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 176.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -40.12 153.8 0.2 Allowed Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 119.086 0.857 . . . . 0.0 111.8 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.02 -22.01 44.67 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.262 2.641 . . . . 0.0 113.545 178.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 17.8 p -77.1 -7.73 56.26 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.947 1.299 . . . . 0.0 110.939 177.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.09 25.17 10.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 127.106 2.162 . . . . 0.0 110.692 -174.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -93.94 -28.03 16.03 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.87 -178.23 4.18 Favored 'General case' 0 C--O 1.222 -0.365 0 CA-C-N 120.146 1.339 . . . . 0.0 109.768 -178.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.752 24.2 mm 137.73 -125.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.409 1 C-N-CA 132.95 4.5 . . . . 0.0 109.676 177.162 . . . . . . . . 3 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -177.04 174.69 47.26 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 117.172 1.629 . . . . 0.0 117.172 -177.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.3 mp -128.51 169.78 13.95 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 127.612 2.365 . . . . 0.0 110.137 -176.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 84.5 mt-30 -143.1 126.47 16.68 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 123.313 0.645 . . . . 0.0 111.049 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 m . . . . . 0 CA--C 1.533 0.296 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 174.791 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? . . . . . 0 CA--C 1.531 0.219 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -95.71 132.42 40.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.247 1.419 . . . . 0.0 107.803 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.75 113.59 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 C-N-CA 124.128 0.971 . . . . 0.0 111.538 -174.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.6 tt -85.56 137.41 32.89 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 106.006 -1.85 . . . . 0.0 106.006 171.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.1 mt -133.19 137.18 53.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.188 0.995 . . . . 0.0 109.574 179.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -126.16 120.51 30.28 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 171.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -68.92 122.18 18.12 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 175.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.37 -147.1 0.97 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-N 119.245 0.929 . . . . 0.0 113.119 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.7 mm -128.06 143.57 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.4 t0 49.31 44.13 23.37 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.418 1.087 . . . . 0.0 113.044 178.438 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.5 p -90.79 -19.05 23.9 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.655 1.582 . . . . 0.0 108.427 177.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.4 p -52.39 -46.22 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 174.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.8 m -61.63 -23.17 65.86 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.62 1.568 . . . . 0.0 112.736 176.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.54 -18.5 59.76 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.312 1.445 . . . . 0.0 108.836 177.312 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 59.9 mttm 47.95 33.89 3.7 Favored 'General case' 0 C--N 1.344 0.336 0 C-N-CA 125.831 1.652 . . . . 0.0 112.379 178.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.1 17.03 54.71 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.321 -1.266 . . . . 0.0 114.446 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.71 1.88 1.6 Allowed 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 120.232 2.016 . . . . 0.0 115.116 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -136.43 18.03 3.71 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 126.668 2.08 . . . . 0.0 110.193 175.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 22.4 m-30 -118.75 155.94 30.23 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.702 1.251 . . . . 0.0 110.638 -177.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.7 m -148.95 131.0 15.34 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.0 p -101.48 146.32 27.8 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 123.658 0.783 . . . . 0.0 112.173 -176.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -127.34 20.42 6.78 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.698 1.599 . . . . 0.0 113.753 -174.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.5 m -150.62 154.21 9.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.208 0 C-N-CA 123.861 0.864 . . . . 0.0 109.27 175.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.9 m -87.71 125.32 34.34 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 170.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.84 78.72 2.11 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 123.189 1.471 . . . . 0.0 109.851 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 179.06 -18.4 0.03 OUTLIER Glycine 0 CA--C 1.532 1.15 0 C-N-CA 128.447 2.927 . . . . 0.0 110.601 -176.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -53.41 120.09 5.64 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.168 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.14 115.4 28.96 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 127.709 2.404 . . . . 0.0 113.167 -170.161 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.372 20.8 m 52.03 74.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 117.154 2.279 . . . . 0.0 117.154 175.054 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -140.71 144.72 37.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 168.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -102.82 171.74 0.22 Allowed 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 123.733 2.955 . . . . 0.0 109.68 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 52.71 -8.82 0.01 OUTLIER Glycine 0 CA--C 1.536 1.399 0 N-CA-C 120.039 2.775 . . . . 0.0 120.039 170.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.2 tp60 -59.22 142.01 52.86 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 120.957 2.378 . . . . 0.0 109.264 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 16.6 ptpt -61.07 114.26 3.01 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 175.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 78.2 mt -79.53 -52.26 8.25 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 20.5 mt -141.41 159.34 42.43 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.979 0.511 . . . . 0.0 111.625 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -122.46 134.69 54.58 Favored 'General case' 0 CA--C 1.516 -0.363 1 N-CA-C 99.965 -4.087 . . . . 0.0 99.965 166.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -147.37 117.92 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -166.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -71.12 72.59 0.61 Allowed 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.799 1.639 . . . . 0.0 111.978 -175.352 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.6 mt -47.71 -42.18 24.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.493 178.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -54.21 -39.89 67.11 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.72 -33.52 19.98 Favored 'General case' 0 CA--C 1.529 0.141 0 CA-C-O 120.815 0.341 . . . . 0.0 111.125 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.98 -50.36 65.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 O-C-N 121.705 -0.622 . . . . 0.0 110.237 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.388 3.2 pptp? -42.59 -54.93 7.65 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -178.485 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.16 -24.2 76.13 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.422 2.082 . . . . 0.0 112.862 177.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -84.15 -42.77 15.66 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.806 0.73 . . . . 0.0 111.108 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.2 m -78.69 147.91 71.96 Favored Pre-proline 0 CA--C 1.535 0.398 0 O-C-N 122.025 -0.422 . . . . 0.0 111.769 -177.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -70.48 -27.28 23.24 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.617 2.211 . . . . 0.0 110.462 176.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.8 m -158.04 137.81 12.16 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.659 1.184 . . . . 0.0 108.218 179.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -87.1 2.96 48.1 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 124.313 1.045 . . . . 0.0 111.788 -178.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.3 mmt -55.04 103.92 0.1 Allowed 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.029 0.932 . . . . 0.0 110.346 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 53.3 m -90.05 105.32 10.89 Favored Pre-proline 0 N--CA 1.445 -0.69 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -84.26 136.8 6.86 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.723 2.282 . . . . 0.0 108.521 -177.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.1 mt -118.88 120.22 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.817 0 N-CA-C 102.721 -3.066 . . . . 0.0 102.721 175.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.3 t -130.05 114.73 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.598 0 CA-C-O 122.368 1.08 . . . . 0.0 108.242 -177.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -81.89 116.8 21.71 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 103.914 -2.624 . . . . 0.0 103.914 176.564 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 82.1 p -83.03 -83.47 0.14 Allowed 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.94 0.4 . . . . 0.0 110.319 -173.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -75.61 64.27 1.65 Allowed 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.542 0.737 . . . . 0.0 110.806 179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 17.0 mt -65.33 -29.76 70.54 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 124.288 1.035 . . . . 0.0 112.968 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 127.76 -132.7 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 1 C-N-CA 132.631 4.372 . . . . 0.0 105.587 -176.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -136.1 146.6 47.17 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 127.228 2.211 . . . . 0.0 108.471 177.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 59.33 37.53 92.06 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 -177.053 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -97.35 82.42 3.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 C-N-CA 126.127 1.771 . . . . 0.0 107.569 -177.421 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 71.1 p -79.48 115.22 18.98 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.071 178.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -72.93 78.83 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -178.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -82.72 92.32 7.18 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.842 -176.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 39.9 mt -65.44 129.83 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 9.8 mmpt? -98.21 -51.03 4.14 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.508 1.523 . . . . 0.0 108.853 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -75.65 69.55 2.37 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.57 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 54.2 p -77.48 73.4 4.05 Favored 'General case' 0 CA--C 1.533 0.304 0 O-C-N 121.368 -0.832 . . . . 0.0 108.851 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 175.12 -124.61 1.02 Allowed Glycine 0 CA--C 1.52 0.401 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -177.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.2 t -94.15 151.0 19.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 2.6 m -131.72 148.85 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 125.031 1.332 . . . . 0.0 107.586 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -114.89 155.32 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 177.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.8 mtm105 -57.74 157.64 7.13 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 120.913 0.387 . . . . 0.0 110.483 177.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 70.25 -12.59 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.568 1.547 . . . . 0.0 115.055 175.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -63.17 131.51 48.71 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-N 119.989 1.268 . . . . 0.0 107.745 176.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -97.32 -36.37 10.42 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 115.51 1.671 . . . . 0.0 115.51 -173.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -87.62 21.4 2.58 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 127.658 2.383 . . . . 0.0 113.938 -176.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -71.29 -26.57 27.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.6 p -142.39 152.59 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 125.567 1.547 . . . . 0.0 108.643 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -128.24 116.51 19.98 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 173.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.7 mp -78.89 87.0 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 102.554 -3.128 . . . . 0.0 102.554 172.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -85.88 148.33 25.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.461 1.104 . . . . 0.0 111.004 -173.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.8 mmtt . . . . . 0 N--CA 1.455 -0.19 0 C-N-CA 124.057 0.943 . . . . 0.0 109.604 178.07 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.41 ' CZ ' ' CE1' ' A' ' 133' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.455 -0.206 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 . . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 m -115.99 96.28 4.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.388 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 177.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 90.6 p -35.23 119.11 0.6 Allowed Pre-proline 0 CA--C 1.556 1.206 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -77.64 -28.39 5.37 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.677 2.251 . . . . 0.0 116.738 -171.428 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.29 146.07 28.52 Favored 'Isoleucine or valine' 0 C--N 1.341 0.239 0 CA-C-N 119.42 1.009 . . . . 0.0 110.96 -176.035 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.4 m -79.04 137.75 37.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 172.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 167.41 -150.35 16.76 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.193 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -118.18 129.18 55.36 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.152 0.981 . . . . 0.0 109.153 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 2.7 mt -79.95 137.27 21.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 176.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -131.16 144.58 54.09 Favored Pre-proline 0 N--CA 1.45 -0.429 0 C-N-CA 126.003 1.721 . . . . 0.0 106.732 175.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -58.22 143.55 96.84 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.407 2.071 . . . . 0.0 110.001 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.1 tp -52.38 -39.75 29.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.207 0.527 . . . . 0.0 111.24 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 p -56.0 -28.1 55.77 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.565 1.546 . . . . 0.0 112.902 177.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -79.68 -8.24 59.1 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.414 0.686 . . . . 0.0 112.826 -178.382 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.402 ' CG2' ' HB1' ' A' ' 44' ' ' ALA . 58.8 t -69.71 123.43 88.56 Favored Pre-proline 0 CA--C 1.539 0.539 0 CA-C-O 117.82 -1.086 . . . . 0.0 111.693 -177.132 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -61.43 61.55 0.11 Allowed 'Trans proline' 0 CA--C 1.549 1.233 0 C-N-CA 124.971 3.781 . . . . 0.0 115.137 177.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -168.59 131.72 1.44 Allowed 'General case' 0 CA--C 1.528 0.12 0 O-C-N 120.565 -1.334 . . . . 0.0 108.447 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -53.89 -51.09 64.8 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 113.884 1.068 . . . . 0.0 113.884 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.8 t -54.71 -55.96 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 123.22 0.608 . . . . 0.0 109.603 -178.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -64.06 -54.09 39.55 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.819 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 79.3 p -58.05 -34.14 69.77 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 113.517 0.932 . . . . 0.0 113.517 -178.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . 0.412 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -89.64 10.73 72.52 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-O 118.173 -1.348 . . . . 0.0 110.854 -179.423 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 72.18 -40.77 0.48 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 125.873 1.669 . . . . 0.0 112.793 -177.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' MET . . . . . 0.412 ' H ' ' C ' ' A' ' 36' ' ' GLY . 14.9 tpt 25.43 -68.87 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 130.907 3.683 . . . . 0.0 117.144 -179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.7 tpp -78.96 -20.95 47.95 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.505 1.122 . . . . 0.0 113.53 -175.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 171.45 -145.36 8.77 Favored Glycine 0 C--N 1.337 0.617 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 -178.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -136.18 160.77 37.67 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.219 1.01 . . . . 0.0 108.559 174.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 165.28 -130.31 2.14 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -178.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -166.39 173.62 9.79 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 117.822 0.811 . . . . 0.0 110.485 -175.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . 0.402 ' HB1' ' CG2' ' A' ' 29' ' ' VAL . . . -113.25 140.71 47.74 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 178.193 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -111.47 136.23 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.603 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 169.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.6 105.63 34.98 Favored Pre-proline 0 N--CA 1.444 -0.759 0 N-CA-C 100.64 -3.837 . . . . 0.0 100.64 170.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -59.56 172.79 1.85 Allowed 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 124.548 3.499 . . . . 0.0 115.482 -173.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 67.3 p -154.34 -64.37 0.13 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 123.895 0.878 . . . . 0.0 110.504 177.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -51.4 -46.87 63.02 Favored 'General case' 0 C--N 1.335 -0.06 0 C-N-CA 125.859 1.664 . . . . 0.0 114.913 -176.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.31 28.93 60.96 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.811 -1.315 . . . . 0.0 109.811 -173.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.7 mt -139.58 120.65 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 102.664 -3.087 . . . . 0.0 102.664 177.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 45.0 t -126.12 123.74 64.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 C-N-CA 124.26 1.024 . . . . 0.0 109.764 -171.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.5 m -109.6 169.66 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.187 0.995 . . . . 0.0 109.036 176.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.1 p -63.7 148.66 94.04 Favored Pre-proline 0 CA--C 1.537 0.48 0 O-C-N 121.331 -0.856 . . . . 0.0 111.071 -177.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -87.64 -16.14 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 124.29 3.327 . . . . 0.0 112.707 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.1 m -145.32 166.83 10.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 123.891 0.876 . . . . 0.0 110.052 -176.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.1 mtt-85 -78.46 119.54 21.92 Favored 'General case' 0 N--CA 1.454 -0.253 1 N-CA-C 98.887 -4.486 . . . . 0.0 98.887 168.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 171.37 -177.4 44.27 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 115.078 -3.439 . . . . 0.0 115.587 -167.547 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.73 135.51 41.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 126.011 1.724 . . . . 0.0 110.451 -177.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.4 mm -79.07 114.9 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 103.537 -2.764 . . . . 0.0 103.537 170.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 34.3 tp -77.8 -53.41 7.53 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -176.29 155.79 1.52 Allowed 'General case' 0 C--O 1.228 -0.033 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.5 m -135.32 120.73 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.417 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -43.77 149.75 0.61 Allowed Pre-proline 0 CA--C 1.539 0.538 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -49.65 -28.16 16.46 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 124.077 3.184 . . . . 0.0 113.861 177.08 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 24.7 p -78.02 1.22 21.6 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.457 0.703 . . . . 0.0 111.969 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 46.84 62.35 2.4 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 127.323 2.249 . . . . 0.0 113.125 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . 0.422 ' CG ' ' HA ' ' A' ' 89' ' ' VAL . 15.4 p-80 -146.93 -38.82 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 122.307 -0.246 . . . . 0.0 111.619 176.147 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -128.19 177.32 7.0 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.694 24.5 mm 116.0 -134.38 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.306 0 C-N-CA 131.654 3.982 . . . . 0.0 108.342 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -171.88 179.71 43.38 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 118.637 2.215 . . . . 0.0 118.637 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.7 mp -126.53 173.07 9.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 127.771 2.428 . . . . 0.0 109.073 -177.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -145.09 137.84 26.24 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 176.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 84.1 p . . . . . 0 CA--C 1.535 0.396 0 CA-C-O 121.154 0.502 . . . . 0.0 109.812 178.86 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.2 mtp-105 . . . . . 0 N--CA 1.457 -0.106 0 CA-C-O 121.456 0.646 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -77.95 125.57 29.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.06 108.37 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 C-N-CA 124.722 1.209 . . . . 0.0 109.597 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -85.01 134.48 34.22 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 126.083 1.753 . . . . 0.0 106.732 174.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.0 mt -128.01 153.79 37.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 C-N-CA 125.339 1.455 . . . . 0.0 110.106 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -151.25 76.46 1.22 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 125.788 1.635 . . . . 0.0 109.191 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -50.86 104.07 0.07 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.186 0.594 . . . . 0.0 112.592 -176.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.62 173.27 5.39 Favored Glycine 0 CA--C 1.533 1.189 0 C-N-CA 124.685 1.136 . . . . 0.0 112.745 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.1 mm -108.72 130.93 60.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 124.484 1.114 . . . . 0.0 108.932 -178.301 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 48.89 43.1 21.34 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.965 1.306 . . . . 0.0 110.917 -178.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.6 -72.6 0.61 Allowed 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 102.16 -3.274 . . . . 0.0 102.16 174.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . 0.422 ' HA ' ' CG ' ' A' ' 68' ' ' HIS 0.33 3.3 p 44.89 49.64 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 104.065 -2.568 . . . . 0.0 104.065 -173.507 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' SER . . . . . 0.411 ' HB3' ' CD1' ' A' ' 96' ' ' PHE . 19.3 m 12.1 45.83 0.0 OUTLIER 'General case' 0 C--N 1.349 0.565 1 C-N-CA 134.077 4.951 . . . . 0.0 114.178 -164.679 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.0 mt 37.48 50.16 1.07 Allowed 'General case' 0 N--CA 1.434 -1.235 0 C-N-CA 130.492 3.517 . . . . 0.0 107.139 178.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 76.43 53.52 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 128.798 2.839 . . . . 0.0 111.36 -176.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.04 -64.12 1.61 Allowed Glycine 0 CA--C 1.535 1.296 0 C-N-CA 124.387 0.994 . . . . 0.0 111.713 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 22.62 -98.22 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 127.694 2.397 . . . . 0.0 115.873 178.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -59.89 -1.68 1.53 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 127.302 2.382 . . . . 0.0 115.859 -176.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . 0.411 ' CD1' ' HB3' ' A' ' 90' ' ' SER . 4.6 m-85 -103.75 97.54 7.54 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 119.001 1.4 . . . . 0.0 113.145 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.9 m -80.05 99.99 7.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 105.785 -1.931 . . . . 0.0 105.785 173.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 29.0 p -83.45 135.37 34.7 Favored 'General case' 0 N--CA 1.451 -0.414 0 O-C-N 121.556 -0.715 . . . . 0.0 110.945 -178.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -103.79 -42.12 5.71 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.058 1.343 . . . . 0.0 111.927 -177.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.28 136.0 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.736 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 58.7 m -87.83 66.43 8.76 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 170.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.258 1.6 pm0 -24.72 96.69 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 129.074 2.95 . . . . 0.0 112.999 -173.162 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 154.06 -17.96 0.63 Allowed Glycine 0 CA--C 1.537 1.466 0 C-N-CA 128.157 2.789 . . . . 0.0 109.744 -175.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -42.87 107.74 0.09 Allowed 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 129.612 3.165 . . . . 0.0 107.821 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.0 119.3 30.24 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 127.496 2.318 . . . . 0.0 114.077 -172.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.336 34.4 m 48.02 66.82 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 126.653 1.981 . . . . 0.0 115.395 177.461 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.97 133.79 25.19 Favored Pre-proline 0 N--CA 1.454 -0.275 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 171.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -98.4 147.15 0.65 Allowed 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 123.346 2.697 . . . . 0.0 110.472 -177.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 58.02 18.37 33.54 Favored Glycine 0 CA--C 1.528 0.894 0 O-C-N 121.724 -0.61 . . . . 0.0 113.551 177.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -61.96 139.51 58.39 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -66.06 116.88 7.64 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 49.6 mt -81.04 -54.19 5.77 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.7 mt -149.08 157.45 43.41 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.34 0.656 . . . . 0.0 111.856 -172.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -124.75 129.42 50.44 Favored 'General case' 0 CA--C 1.519 -0.234 1 N-CA-C 98.738 -4.541 . . . . 0.0 98.738 165.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . 0.406 HG13 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -139.22 127.91 28.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -164.101 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -75.01 67.41 1.71 Allowed 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.045 0.938 . . . . 0.0 110.48 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 93.1 mt -52.05 -45.85 64.85 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.194 179.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -48.98 -45.3 41.94 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 124.231 1.012 . . . . 0.0 112.611 -178.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.84 -33.91 24.77 Favored 'General case' 0 CA--C 1.527 0.092 0 CA-C-N 118.184 0.447 . . . . 0.0 111.6 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.08 -58.49 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 O-C-N 121.937 -0.477 . . . . 0.0 109.806 178.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 2.5 pptp? -38.16 -57.0 1.87 Allowed Pre-proline 0 CA--C 1.542 0.658 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 -176.664 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -60.88 -18.25 55.74 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.427 2.085 . . . . 0.0 113.572 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -104.55 10.66 34.95 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 118.386 -0.816 . . . . 0.0 112.797 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 26.9 m -137.57 151.97 71.97 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 119.884 1.22 . . . . 0.0 110.595 -178.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -64.45 -36.22 45.21 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.086 2.524 . . . . 0.0 113.202 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.6 t -156.58 153.0 27.95 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 119.059 0.845 . . . . 0.0 110.556 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.4 tp -100.62 -1.77 34.5 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.549 1.54 . . . . 0.0 110.565 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -53.22 116.97 2.68 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 118.311 0.505 . . . . 0.0 109.643 179.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 52.7 m -107.99 118.81 51.85 Favored Pre-proline 0 N--CA 1.446 -0.646 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -87.05 150.43 8.23 Favored 'Trans proline' 0 N--CA 1.442 -1.525 0 C-N-CA 122.056 1.838 . . . . 0.0 107.75 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.8 mt -132.59 113.93 21.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 101.586 -3.487 . . . . 0.0 101.586 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.94 122.07 51.18 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.012 -173.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . 0.41 ' CE1' ' CZ ' ' A' ' 15' ' ' PHE . 4.7 m-85 -86.29 112.3 21.27 Favored 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 177.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.0 p -74.41 -76.06 0.15 Allowed 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 121.853 0.835 . . . . 0.0 109.401 -175.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -76.78 69.4 3.13 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.707 0.803 . . . . 0.0 110.771 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.3 mt -68.86 169.21 11.94 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 171.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.72 -139.07 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.482 -0.761 . . . . 0.0 111.128 -178.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -67.06 81.12 0.12 Allowed 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.683 0.793 . . . . 0.0 112.417 -176.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 47.51 38.02 13.6 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.76 1.171 . . . . 0.0 111.068 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -55.23 119.25 5.24 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 111.517 0.192 . . . . 0.0 111.517 -176.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -78.02 132.09 37.64 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 172.504 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.266 1.0 OUTLIER -84.99 88.61 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 -176.51 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.8 t -78.4 83.99 4.59 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -173.183 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.8 mt -62.26 118.92 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 124.595 1.158 . . . . 0.0 108.116 179.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -97.77 -55.25 2.86 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.974 1.31 . . . . 0.0 108.938 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.71 66.34 1.45 Allowed 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.319 0.648 . . . . 0.0 111.587 -177.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 35.1 m -78.61 65.44 3.88 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.556 0.742 . . . . 0.0 109.011 178.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.38 -145.78 6.44 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -177.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 12.3 t -76.2 150.74 37.04 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 117.325 0.563 . . . . 0.0 110.646 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.68 156.02 28.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.087 1.355 . . . . 0.0 108.463 178.168 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -109.45 -171.43 1.84 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.424 1.49 . . . . 0.0 108.489 175.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 52.5 mtm-85 -85.65 157.69 20.27 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.971 0.805 . . . . 0.0 110.354 177.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 45.63 38.91 4.42 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.621 1.969 . . . . 0.0 114.432 177.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -76.09 134.07 40.13 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 104.8 -2.296 . . . . 0.0 104.8 172.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -108.99 35.86 3.09 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.733 0.813 . . . . 0.0 111.759 -177.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -172.6 94.61 0.13 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.198 1.799 . . . . 0.0 108.448 177.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -150.97 -37.73 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -175.524 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 57.8 t -151.5 104.29 0.28 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.058 0 CA-C-N 119.397 0.999 . . . . 0.0 108.594 -177.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.2 mttm -90.13 124.49 34.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -176.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.5 mp -78.86 107.77 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 104.378 -2.453 . . . . 0.0 104.378 174.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 24.9 pt-20 -153.73 -175.35 5.33 Favored 'General case' 0 C--O 1.227 -0.127 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -175.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 C--N 1.332 -0.185 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.261 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.451 -0.398 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -78.89 85.15 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.114 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.3 t -10.59 109.39 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.814 0 C-N-CA 127.839 2.456 . . . . 0.0 113.211 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -68.81 -28.15 30.46 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.595 2.197 . . . . 0.0 116.449 -173.318 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -149.0 145.93 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.918 1.235 . . . . 0.0 110.232 -177.322 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.9 m -79.07 136.68 37.23 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.0 -150.11 14.2 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tp10 -117.13 123.21 46.19 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.785 1.634 . . . . 0.0 108.71 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 10.1 mt -85.07 125.66 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -117.92 142.8 31.44 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 173.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -55.15 152.65 29.8 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 121.814 1.676 . . . . 0.0 109.515 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.3 tp -57.06 -49.01 80.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.1 m -67.86 85.41 0.22 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.732 1.613 . . . . 0.0 108.604 176.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.5 t70 172.95 -35.66 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 127.373 2.269 . . . . 0.0 108.81 -176.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 96.5 t -52.86 138.29 44.15 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 124.643 1.177 . . . . 0.0 110.558 -179.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -72.95 59.26 3.54 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 124.127 3.218 . . . . 0.0 111.542 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -171.74 130.81 0.68 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 124.923 1.289 . . . . 0.0 108.592 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -62.03 -48.42 80.37 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 124.322 1.049 . . . . 0.0 113.061 -177.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.6 t -50.24 -55.23 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -65.06 -58.79 5.15 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.397 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -58.08 -27.99 64.17 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 115.244 1.572 . . . . 0.0 115.244 -177.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -95.36 10.12 69.38 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-O 117.899 -1.501 . . . . 0.0 110.646 -178.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 61.3 mttm 74.42 -46.25 0.61 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.574 1.55 . . . . 0.0 111.928 -178.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 36.9 ttm 39.29 -64.92 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 130.533 3.533 . . . . 0.0 117.272 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 29.9 ttp -109.34 -10.28 14.93 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.712 1.205 . . . . 0.0 113.452 -176.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -171.83 -165.55 29.18 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-N 119.464 1.029 . . . . 0.0 110.796 -179.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -131.72 156.58 45.67 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 176.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 168.45 -137.07 4.38 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.28 166.13 14.86 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 118.048 0.924 . . . . 0.0 111.214 -175.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.31 113.29 26.66 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 123.043 0.537 . . . . 0.0 111.485 -179.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -88.65 129.21 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 103.887 -2.634 . . . . 0.0 103.887 169.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.0 tt -96.03 109.2 45.6 Favored Pre-proline 0 N--CA 1.448 -0.542 1 N-CA-C 98.34 -4.689 . . . . 0.0 98.34 168.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.6 161.54 24.92 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.501 2.801 . . . . 0.0 115.336 -167.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.4 p -136.9 -41.54 0.59 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.588 1.155 . . . . 0.0 111.981 177.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.99 -44.36 91.62 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.37 23.8 77.19 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 -174.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.5 mt -139.99 111.97 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 177.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 47.0 t -100.39 122.71 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.883 1.273 . . . . 0.0 108.673 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.39 156.04 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 123.389 0.676 . . . . 0.0 110.349 177.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 17.4 m -63.88 122.11 75.06 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.81 -21.52 12.52 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 124.923 3.749 . . . . 0.0 114.662 -176.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -136.48 173.09 14.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 124.94 1.296 . . . . 0.0 108.842 -175.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.29 90.59 3.76 Favored 'General case' 0 CA--C 1.518 -0.275 1 N-CA-C 98.228 -4.73 . . . . 0.0 98.228 168.858 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -90.26 174.52 40.29 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 117.381 1.712 . . . . 0.0 117.381 -166.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.88 134.09 21.68 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 101.475 -3.528 . . . . 0.0 101.475 170.471 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -88.79 127.3 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -169.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.402 ' O ' ' CB ' ' A' ' 62' ' ' ASN . 78.5 mt -79.74 -29.66 40.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 169.161 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 59.1 t30 125.79 -176.53 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 129.587 3.155 . . . . 0.0 109.514 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.98 122.24 51.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 C-N-CA 127.452 2.301 . . . . 0.0 106.353 172.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -44.77 157.92 0.3 Allowed Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 124.315 1.046 . . . . 0.0 111.316 175.361 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -51.4 -29.47 31.05 Favored 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.381 2.721 . . . . 0.0 113.414 174.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.6 p -76.94 -5.98 50.69 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.429 1.092 . . . . 0.0 111.646 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? 60.53 16.4 6.44 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.334 1.854 . . . . 0.0 115.007 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 16.1 p-80 -98.03 -33.77 11.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.562 0.345 . . . . 0.0 111.654 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -149.17 -177.58 5.9 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-N 118.186 0.448 . . . . 0.0 111.929 -173.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.541 24.4 mm 131.82 -123.39 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.453 1 C-N-CA 136.273 5.829 . . . . 0.0 102.359 -177.199 . . . . . . . . 3 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -178.4 -173.23 43.6 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 116.751 -2.643 . . . . 0.0 119.382 177.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.4 mp -137.32 170.83 15.42 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 127.208 2.203 . . . . 0.0 108.488 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -147.83 157.26 43.44 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 172.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 81.3 p . . . . . 0 C--O 1.225 -0.235 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 174.27 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.6 mmt85 . . . . . 0 N--CA 1.456 -0.144 0 CA-C-O 121.353 0.597 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -80.37 110.29 15.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 177.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.94 127.28 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 124.063 0.945 . . . . 0.0 111.464 -174.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 33.5 tp -103.23 135.07 45.57 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 104.375 -2.454 . . . . 0.0 104.375 170.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.4 mt -120.43 155.37 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 C-N-CA 124.965 1.306 . . . . 0.0 107.589 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -149.37 81.95 1.41 Allowed 'General case' 0 C--O 1.224 -0.281 0 N-CA-C 104.96 -2.237 . . . . 0.0 104.96 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -63.12 97.33 0.11 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -176.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 69.27 168.33 5.79 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.226 0.917 . . . . 0.0 111.586 -175.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 15.8 mm -100.26 135.89 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 124.623 1.169 . . . . 0.0 109.094 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 57.24 23.98 9.36 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.943 1.297 . . . . 0.0 112.732 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 p -76.93 -32.97 57.74 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.657 1.583 . . . . 0.0 107.567 175.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.8 p -56.71 -46.16 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-N 113.76 -1.563 . . . . 0.0 107.546 170.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.73 -42.28 98.75 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 124.187 0.995 . . . . 0.0 108.546 176.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -73.61 12.27 0.67 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 125.525 1.53 . . . . 0.0 111.682 175.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 48.3 tttp 45.68 35.06 1.97 Allowed 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.869 2.067 . . . . 0.0 113.258 177.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 55.39 28.44 50.57 Favored Glycine 0 CA--C 1.535 1.289 0 O-C-N 121.751 -0.593 . . . . 0.0 112.751 -179.116 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -70.97 91.56 0.88 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 118.744 1.272 . . . . 0.0 109.769 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 132.61 -1.05 4.72 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 126.435 1.969 . . . . 0.0 111.707 -178.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 16.5 m-30 -96.52 131.91 42.64 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 124.507 1.123 . . . . 0.0 109.675 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 10.9 m -120.55 113.96 21.05 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 126.597 1.959 . . . . 0.0 107.316 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 44.9 p -93.38 126.49 38.54 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 121.056 -1.028 . . . . 0.0 111.213 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -90.26 -26.73 19.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 123.932 0.893 . . . . 0.0 108.998 176.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' VAL . . . . . 0.555 ' HB ' ' CG ' ' A' ' 102' ' ' GLU . 3.1 m -52.63 126.83 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-O 121.192 0.52 . . . . 0.0 110.995 179.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 24.9 m -115.51 -52.34 2.65 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 127.456 2.302 . . . . 0.0 105.255 175.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' GLU . . . . . 0.555 ' CG ' ' HB ' ' A' ' 100' ' ' VAL . 0.1 OUTLIER 50.77 107.98 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 120.969 3.692 . . . . 0.0 120.969 166.26 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.23 55.35 2.12 Favored Glycine 0 CA--C 1.53 1.0 1 N-CA-C 100.996 -4.842 . . . . 0.0 100.996 164.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.253 7.4 p-10 6.77 70.36 0.0 OUTLIER 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 118.569 2.803 . . . . 0.0 118.569 -169.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -169.58 137.04 1.72 Allowed 'General case' 0 N--CA 1.43 -1.464 1 C-N-CA 132.916 4.486 . . . . 0.0 105.655 173.309 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -157.27 158.19 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 125.681 1.592 . . . . 0.0 108.692 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -89.04 163.42 34.61 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 106.425 -1.695 . . . . 0.0 106.425 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -70.71 169.54 19.87 Favored 'Trans proline' 0 N--CA 1.451 -0.978 0 N-CA-C 108.259 -1.477 . . . . 0.0 108.259 178.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 73.45 -27.77 0.86 Allowed Glycine 0 CA--C 1.534 1.227 0 O-C-N 121.02 -1.05 . . . . 0.0 115.38 175.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.4 tp-100 -58.07 139.88 53.75 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 119.527 1.664 . . . . 0.0 109.8 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -70.16 128.3 35.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.875 0.47 . . . . 0.0 111.544 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 72.1 mt -105.04 -41.49 5.57 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.937 0.895 . . . . 0.0 111.807 -178.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 48.5 mt -143.99 146.52 32.96 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 123.588 0.755 . . . . 0.0 109.371 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -118.06 133.24 56.09 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 100.683 -3.821 . . . . 0.0 100.683 167.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.15 117.47 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -166.731 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 62.9 t0 -67.69 74.11 0.17 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.408 1.483 . . . . 0.0 112.395 -175.273 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 75.8 mt -50.43 -47.49 56.64 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.687 178.242 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -49.4 -49.07 46.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.588 1.155 . . . . 0.0 112.684 -177.323 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.25 -34.36 25.85 Favored 'General case' 0 C--N 1.333 -0.121 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 49.4 t -65.16 -53.65 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 O-C-N 121.697 -0.627 . . . . 0.0 110.541 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.328 19.1 pttp -42.92 -54.64 8.54 Favored Pre-proline 0 CA--C 1.54 0.595 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -61.12 -24.07 78.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.49 2.127 . . . . 0.0 112.716 178.248 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 57.3 m-80 -90.18 -48.24 7.29 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 118.46 0.573 . . . . 0.0 111.885 -177.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.77 147.93 56.37 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -174.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_exo -51.61 -41.51 60.76 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 124.064 3.176 . . . . 0.0 114.804 179.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.2 m -158.81 142.7 15.31 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.825 -0.547 . . . . 0.0 110.235 -176.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.2 tp -88.09 -4.6 58.75 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 124.878 1.271 . . . . 0.0 112.293 -178.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.1 mmt -46.93 118.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.028 0.931 . . . . 0.0 109.802 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.4 m -112.1 94.23 24.88 Favored Pre-proline 0 N--CA 1.448 -0.534 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -76.5 111.06 3.18 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 123.594 2.863 . . . . 0.0 108.74 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mt -94.28 119.06 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 N-CA-C 102.718 -3.068 . . . . 0.0 102.718 174.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.2 t -126.56 129.06 71.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -97.39 114.61 26.46 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 104.343 -2.465 . . . . 0.0 104.343 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 44.8 p -80.28 -75.39 0.27 Allowed 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . 0.259 0.4 OUTLIER -74.06 69.68 1.5 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-O 122.204 1.002 . . . . 0.0 111.207 179.156 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 13.2 mt -78.21 62.2 2.87 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 126.174 1.79 . . . . 0.0 107.537 175.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.53 -109.63 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.578 2.351 . . . . 0.0 112.545 -177.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -80.33 58.64 3.16 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 125.146 1.379 . . . . 0.0 112.446 -178.265 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 46.19 35.67 6.82 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 124.259 0.933 . . . . 0.0 110.959 -178.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -49.01 126.91 13.32 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.349 0.659 . . . . 0.0 112.014 -175.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 31.8 p -86.54 133.35 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.256 0.3 OUTLIER -85.58 87.48 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 CA-C-O 122.407 1.099 . . . . 0.0 109.936 -176.009 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.5 m -79.33 84.48 5.25 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 120.646 -1.284 . . . . 0.0 110.85 -177.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 6.5 mt -60.66 130.67 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 124.287 1.035 . . . . 0.0 108.656 178.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.33 -52.78 2.75 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.769 0.828 . . . . 0.0 108.767 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -78.95 64.64 3.94 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 122.892 0.477 . . . . 0.0 109.933 179.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 45.0 m -78.98 66.05 4.32 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -171.45 -148.79 6.23 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 107.809 -2.116 . . . . 0.0 107.809 -177.375 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 15.8 t -78.14 148.11 34.28 Favored 'General case' 0 N--CA 1.456 -0.136 0 CA-C-N 117.658 0.729 . . . . 0.0 110.735 178.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.63 160.59 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 124.864 1.266 . . . . 0.0 108.663 178.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -114.78 157.79 22.75 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.719 1.208 . . . . 0.0 108.592 176.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 2.2 ptm180 -66.43 154.11 41.05 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 53.15 59.98 4.06 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.537 1.535 . . . . 0.0 112.06 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 16.9 mm-40 -131.07 151.02 51.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 126.821 2.048 . . . . 0.0 105.751 175.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.47 166.0 14.19 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.2 1.4 . . . . 0.0 111.05 -177.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 16.9 t70 70.63 -7.48 1.04 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 117.051 2.241 . . . . 0.0 117.051 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -53.06 -31.87 17.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 C-N-CA 127.213 2.205 . . . . 0.0 112.501 177.116 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -145.47 133.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -108.75 120.53 42.75 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.414 0.686 . . . . 0.0 109.828 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.3 mp -79.1 97.22 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.204 -2.146 . . . . 0.0 105.204 173.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -108.7 -155.26 0.55 Allowed 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 125.369 1.467 . . . . 0.0 107.963 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 35.5 mtmm . . . . . 0 C--N 1.333 -0.131 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 176.977 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 16.3 tpt . . . . . 0 N--CA 1.453 -0.277 0 CA-C-O 121.221 0.534 . . . . 0.0 109.728 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 27.3 mm -75.4 73.7 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.1 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -65.56 79.94 0.06 Allowed 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.523 1.129 . . . . 0.0 111.662 -178.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 14.3 mp0 -49.02 -44.8 73.31 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 124.238 1.015 . . . . 0.0 113.652 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -66.4 40.4 0.15 Allowed 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 123.886 3.057 . . . . 0.0 116.306 -177.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.1 tt -79.22 63.55 3.89 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 120.44 -1.413 . . . . 0.0 107.26 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 40.6 mt-30 -78.3 -50.68 11.37 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 125.135 1.374 . . . . 0.0 112.035 -175.608 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 56.5 t30 72.18 154.12 0.14 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 125.584 1.554 . . . . 0.0 110.582 -176.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -70.45 -62.84 1.24 Allowed 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 177.736 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.9 tp -79.95 52.13 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-O 121.705 0.764 . . . . 0.0 109.392 178.089 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -78.48 50.5 3.52 Favored Glycine 0 CA--C 1.529 0.917 0 O-C-N 120.928 -1.108 . . . . 0.0 111.794 -179.278 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -118.5 82.38 1.84 Allowed 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 18.5 mp0 -76.53 66.81 2.6 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 177.445 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.8 t 46.85 44.84 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.765 2.026 . . . . 0.0 108.86 -179.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -132.63 83.29 2.06 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 114.561 -1.199 . . . . 0.0 112.705 -175.925 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.0 89.92 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 172.165 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t -13.36 116.17 0.04 OUTLIER Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 126.965 2.106 . . . . 0.0 115.377 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -71.38 -34.88 9.07 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.995 2.463 . . . . 0.0 117.37 -174.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -143.3 162.73 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.819 1.191 . . . . 0.0 111.371 -175.228 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -101.52 135.65 42.68 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 174.785 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 161.96 -136.33 4.32 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -127.79 124.63 38.12 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 124.941 1.297 . . . . 0.0 110.34 -178.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 45.9 mt -80.19 145.43 9.17 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.016 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -143.95 141.67 18.94 Favored Pre-proline 0 N--CA 1.452 -0.347 0 C-N-CA 125.08 1.352 . . . . 0.0 107.903 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -54.94 145.33 63.26 Favored 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 122.163 1.908 . . . . 0.0 111.183 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.67 -39.19 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.853 1.261 . . . . 0.0 112.316 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 p -53.48 -31.61 46.57 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.362 1.465 . . . . 0.0 112.442 179.143 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -69.78 -14.32 62.71 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.898 0.879 . . . . 0.0 112.852 -178.593 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -69.87 130.26 90.26 Favored Pre-proline 0 CA--C 1.539 0.53 0 O-C-N 121.373 -0.829 . . . . 0.0 111.057 -175.151 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -76.38 62.6 6.99 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.416 2.744 . . . . 0.0 111.374 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.21 132.01 2.88 Favored 'General case' 0 C--O 1.226 -0.138 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 22.0 mp0 -54.9 -53.05 60.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.521 1.128 . . . . 0.0 112.675 -176.451 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.0 t -51.68 -57.0 3.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 123.299 0.639 . . . . 0.0 110.317 -177.675 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -64.95 -53.54 44.73 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.264 0.226 . . . . 0.0 110.535 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.9 t -51.99 -43.05 63.44 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -90.91 13.36 66.25 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-O 117.994 -1.448 . . . . 0.0 111.814 -177.841 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp 69.44 -34.68 0.29 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 119.421 1.611 . . . . 0.0 114.52 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.419 ' H ' ' C ' ' A' ' 36' ' ' GLY . 15.7 tpt 26.16 -76.31 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 130.056 3.343 . . . . 0.0 116.426 -179.576 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.1 ttm -79.49 -15.98 56.82 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 114.142 1.164 . . . . 0.0 114.142 -174.263 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.51 -135.75 2.73 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 120.037 1.29 . . . . 0.0 113.076 -178.111 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -129.1 163.1 26.2 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 175.717 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 167.27 -157.5 29.96 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.877 -1.154 . . . . 0.0 112.586 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -162.35 171.07 17.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.053 0.541 . . . . 0.0 109.839 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.35 149.18 31.51 Favored 'General case' 0 CA--C 1.502 -0.867 0 O-C-N 124.119 0.887 . . . . 0.0 109.429 176.729 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.0 mp -124.21 133.56 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 102.482 -3.155 . . . . 0.0 102.482 170.314 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.2 tt -99.38 108.44 50.33 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.789 -4.523 . . . . 0.0 98.789 170.626 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -82.8 161.04 16.29 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.347 2.698 . . . . 0.0 113.932 -168.463 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.3 p -124.59 -55.56 1.63 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.699 1.2 . . . . 0.0 108.723 175.551 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -68.15 124.15 22.66 Favored 'General case' 0 N--CA 1.457 -0.11 0 C-N-CA 122.303 0.241 . . . . 0.0 110.857 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.33 37.11 2.0 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 70.7 mt -138.43 120.63 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.24 109.35 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -174.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.7 m -89.25 -178.26 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.941 -1.504 . . . . 0.0 106.941 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.59 146.19 33.5 Favored Pre-proline 0 N--CA 1.465 0.306 0 CA-C-O 117.561 -1.209 . . . . 0.0 111.464 -174.683 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -63.3 -44.6 14.37 Favored 'Trans proline' 0 C--N 1.348 0.53 0 N-CA-C 107.453 -1.787 . . . . 0.0 107.453 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 3.4 p -146.2 145.59 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 102.433 -3.173 . . . . 0.0 102.433 171.506 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 28.6 mtm180 -97.27 -75.21 0.55 Allowed 'General case' 0 N--CA 1.45 -0.447 1 N-CA-C 98.979 -4.452 . . . . 0.0 98.979 169.659 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.23 -78.19 1.46 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 107.141 -2.383 . . . . 0.0 107.141 171.474 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.75 118.73 5.84 Favored 'General case' 0 N--CA 1.438 -1.067 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.893 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 28.3 mm -65.98 124.85 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 175.725 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.42 -42.47 12.81 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 124.069 0.948 . . . . 0.0 109.206 -177.44 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -156.88 152.66 27.05 Favored 'General case' 0 N--CA 1.463 0.204 0 O-C-N 121.94 -0.475 . . . . 0.0 111.722 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -82.89 170.55 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.845 1.658 . . . . 0.0 112.323 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -76.54 135.85 68.32 Favored Pre-proline 0 N--CA 1.437 -1.118 0 CA-C-N 112.681 -2.054 . . . . 0.0 109.778 173.589 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -74.37 -43.28 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.374 1.383 . . . . 0.0 108.61 172.901 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.4 p -131.39 46.24 2.69 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 126.192 1.797 . . . . 0.0 109.917 -177.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 16.5 ttmt 57.16 -17.41 0.02 OUTLIER 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 128.225 2.61 . . . . 0.0 116.609 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -75.98 -5.9 48.46 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 116.769 2.137 . . . . 0.0 116.769 -174.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.35 160.53 43.66 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 120.456 1.48 . . . . 0.0 110.348 -173.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.0 tt -157.23 157.15 3.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -117.31 128.58 7.92 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 107.646 -2.181 . . . . 0.0 107.646 178.186 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.9 mt -124.74 171.75 9.85 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 124.724 1.209 . . . . 0.0 110.359 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.47 139.33 20.88 Favored 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 126.631 1.972 . . . . 0.0 105.697 174.201 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 89.4 p -71.93 -83.05 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 176.235 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -121.84 -70.04 0.8 Allowed 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.206 1.402 . . . . 0.0 107.684 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -168.62 85.07 0.09 OUTLIER Glycine 0 CA--C 1.521 0.437 0 N-CA-C 106.097 -2.801 . . . . 0.0 106.097 178.276 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 169.15 -41.35 0.21 Allowed Glycine 0 C--N 1.337 0.584 0 CA-C-O 119.36 -0.689 . . . . 0.0 111.639 -176.606 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 38.2 ttp180 -122.56 109.07 13.86 Favored 'General case' 0 C--N 1.341 0.208 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 177.742 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -106.48 130.64 54.24 Favored 'General case' 0 N--CA 1.445 -0.678 0 C-N-CA 129.374 3.069 . . . . 0.0 104.386 177.712 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.4 mt -120.22 145.16 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 C-N-CA 124.339 1.056 . . . . 0.0 110.649 -172.12 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 46.7 tp -124.38 131.45 53.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 173.634 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 79.4 mt -121.93 146.8 26.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 123.789 0.836 . . . . 0.0 109.317 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.34 136.23 41.36 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 169.9 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -106.96 108.4 19.89 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 125.224 1.41 . . . . 0.0 109.037 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.53 -178.0 7.17 Favored Glycine 0 CA--C 1.534 1.22 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -176.372 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.7 mm -118.87 143.54 29.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 t70 65.69 11.58 7.64 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.38 1.072 . . . . 0.0 113.143 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 p -74.83 -32.51 61.96 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 125.583 1.553 . . . . 0.0 108.587 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.5 p -54.57 -49.85 63.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 113.202 -1.817 . . . . 0.0 107.143 170.512 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -62.69 -42.42 99.62 Favored 'General case' 0 C--O 1.227 -0.119 0 C-N-CA 124.668 1.187 . . . . 0.0 109.641 177.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 24.5 tp -66.21 -2.55 4.41 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.463 1.505 . . . . 0.0 111.539 176.706 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.5 mtmm 51.94 34.1 13.0 Favored 'General case' 0 C--N 1.344 0.329 0 C-N-CA 125.18 1.392 . . . . 0.0 111.325 -179.157 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.95 30.91 60.77 Favored Glycine 0 CA--C 1.537 1.45 0 CA-C-O 120.015 -0.325 . . . . 0.0 112.802 -178.583 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -67.21 93.38 0.3 Allowed 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.759 1.279 . . . . 0.0 109.477 178.464 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.54 7.98 4.57 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 126.682 2.087 . . . . 0.0 112.122 -178.493 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -101.35 153.04 20.01 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.696 1.198 . . . . 0.0 110.732 -177.441 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 59.3 m -145.41 121.81 10.97 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.3 -2.111 . . . . 0.0 105.3 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 35.1 p -96.04 128.22 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.539 0.736 . . . . 0.0 110.371 -173.255 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -92.05 -49.12 6.38 Favored 'General case' 0 N--CA 1.448 -0.57 0 O-C-N 124.336 1.023 . . . . 0.0 109.431 -178.289 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.9 m -75.22 124.7 33.63 Favored 'Isoleucine or valine' 0 C--N 1.34 0.193 0 C-N-CA 117.21 -1.796 . . . . 0.0 107.749 173.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.7 m -100.8 55.71 0.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 103.578 -2.749 . . . . 0.0 103.578 170.852 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.5 0.0 OUTLIER 5.39 64.15 0.0 OUTLIER 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 130.767 3.627 . . . . 0.0 117.915 -168.517 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -81.28 61.24 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 173.239 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.391 3.3 p30 6.01 -94.56 0.0 OUTLIER 'General case' 0 N--CA 1.439 -0.987 0 C-N-CA 128.506 2.722 . . . . 0.0 116.939 -174.283 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.4 mmm180 -55.69 106.09 0.23 Allowed 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 126.472 1.909 . . . . 0.0 112.262 -175.269 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.6 159.19 8.53 Favored 'Isoleucine or valine' 0 C--N 1.342 0.239 0 C-N-CA 124.841 1.257 . . . . 0.0 111.704 179.051 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -85.88 155.34 58.5 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 118.473 -0.775 . . . . 0.0 109.636 177.218 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo -48.82 168.61 0.1 Allowed 'Trans proline' 0 CA--C 1.534 0.514 1 C-N-CA 126.824 5.016 . . . . 0.0 120.381 -173.081 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 69.69 -97.37 0.55 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 125.956 1.741 . . . . 0.0 112.754 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 26.3 tt0 1.97 92.97 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 131.03 3.732 . . . . 0.0 114.102 -176.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 21.1 ttmt 4.21 114.82 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 130.321 3.449 . . . . 0.0 117.193 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 91.1 mt -81.87 -50.97 8.58 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.922 0.889 . . . . 0.0 108.988 173.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 96.1 mt -138.06 155.25 48.99 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.769 1.628 . . . . 0.0 110.512 -176.494 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.42 132.53 53.98 Favored 'General case' 0 CA--C 1.516 -0.328 1 N-CA-C 100.106 -4.035 . . . . 0.0 100.106 167.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -147.66 122.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.01 -165.603 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -71.63 69.07 0.62 Allowed 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.409 1.083 . . . . 0.0 111.025 -179.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 56.5 mt -49.11 -42.81 40.39 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.69 0.796 . . . . 0.0 111.166 178.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -50.03 -48.43 52.73 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.628 0.771 . . . . 0.0 112.131 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.48 -31.34 22.85 Favored 'General case' 0 CA--C 1.527 0.078 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.8 t -64.02 -51.76 65.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.64 -0.662 . . . . 0.0 109.945 179.402 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.407 0.0 OUTLIER -41.11 -57.95 3.11 Favored Pre-proline 0 CA--C 1.542 0.647 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -177.303 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -59.27 -19.34 49.74 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.256 1.971 . . . . 0.0 113.227 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -98.43 11.42 38.21 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.826 0.85 . . . . 0.0 112.283 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.83 151.31 73.82 Favored Pre-proline 0 CA--C 1.532 0.284 0 CA-C-N 119.837 1.199 . . . . 0.0 110.86 178.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -72.97 -24.06 17.87 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 122.744 2.296 . . . . 0.0 110.658 177.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 14.6 t -158.75 147.91 18.89 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.389 0.614 . . . . 0.0 109.864 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.0 tp -97.54 2.25 49.89 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.862 1.665 . . . . 0.0 110.51 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 19.3 mmt -52.01 119.19 4.05 Favored 'General case' 0 C--N 1.344 0.36 0 CA-C-N 118.208 0.458 . . . . 0.0 109.794 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 32.2 m -111.37 89.48 10.45 Favored Pre-proline 0 N--CA 1.447 -0.609 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -81.08 146.56 16.06 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.331 2.021 . . . . 0.0 111.364 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.4 mt -127.37 126.47 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 175.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.41 147.83 26.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 N-CA-C 106.819 -1.549 . . . . 0.0 106.819 178.926 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -122.55 125.71 46.27 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 101.945 -3.354 . . . . 0.0 101.945 178.649 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.7 p -89.15 -82.77 0.24 Allowed 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.4 0.546 . . . . 0.0 111.422 -171.838 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 20.6 p30 -47.37 -49.01 25.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.111 1.765 . . . . 0.0 111.884 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 23.0 mt 42.8 49.03 5.02 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 125.111 1.365 . . . . 0.0 110.864 178.584 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 34.82 40.96 0.05 Allowed 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.325 1.85 . . . . 0.0 111.966 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 36.88 55.18 1.2 Allowed 'General case' 0 N--CA 1.446 -0.631 0 C-N-CA 128.319 2.648 . . . . 0.0 114.349 -176.277 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 163.09 -3.48 0.07 OUTLIER Glycine 0 CA--C 1.524 0.625 0 CA-C-O 118.885 -0.953 . . . . 0.0 114.482 175.211 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 63.7 mm-40 -76.61 109.86 10.71 Favored 'General case' 0 C--O 1.228 -0.074 0 CA-C-N 119.219 1.51 . . . . 0.0 110.483 -179.943 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.4 p -78.8 138.68 38.31 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 171.817 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -85.55 84.79 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.5 m -78.27 93.76 4.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 O-C-N 120.6 -1.312 . . . . 0.0 110.844 -175.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 14.2 mt -64.91 130.91 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 C-N-CA 123.939 0.896 . . . . 0.0 108.608 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -107.44 -55.36 2.36 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.711 1.204 . . . . 0.0 108.026 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.84 70.22 1.91 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.357 0.599 . . . . 0.0 110.511 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 24.7 m -79.0 63.92 3.79 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 178.35 -140.91 4.8 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.368 -1.893 . . . . 0.0 108.368 -176.485 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.6 t -66.43 151.84 46.34 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 117.039 0.419 . . . . 0.0 110.989 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -133.97 154.07 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.538 1.535 . . . . 0.0 107.996 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -132.95 150.92 52.12 Favored 'General case' 0 C--O 1.233 0.22 0 C-N-CA 124.965 1.306 . . . . 0.0 108.634 178.009 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -57.48 150.33 18.98 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.149 0.979 . . . . 0.0 112.12 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 58.51 3.52 0.29 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 127.148 2.179 . . . . 0.0 115.263 174.379 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 55.5 mm-40 -72.29 164.25 26.6 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 119.056 0.844 . . . . 0.0 111.075 179.008 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -114.04 168.23 9.99 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.715 2.406 . . . . 0.0 108.22 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 25.9 t0 51.73 40.53 27.73 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.099 1.36 . . . . 0.0 112.811 176.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.9 OUTLIER -99.78 -43.64 11.24 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.414 1.086 . . . . 0.0 109.636 178.674 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.1 p -142.69 143.97 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 105.782 -1.933 . . . . 0.0 105.782 173.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -123.65 116.11 22.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.232 0.613 . . . . 0.0 109.547 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.4 mp -79.23 104.06 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 103.54 -2.763 . . . . 0.0 103.54 173.371 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -142.83 158.11 43.95 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 123.175 0.59 . . . . 0.0 109.865 -174.231 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.8 mptt . . . . . 0 CA--C 1.53 0.195 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.188 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.3 mmt . . . . . 0 N--CA 1.454 -0.239 0 CA-C-O 120.867 0.365 . . . . 0.0 110.017 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 26.3 mt -76.26 68.08 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.39 5.62 18.25 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.888 1.275 . . . . 0.0 112.003 -178.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.5 pm0 -67.99 155.2 92.43 Favored Pre-proline 0 CA--C 1.538 0.481 0 CA-C-O 118.918 -0.563 . . . . 0.0 109.985 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_exo -53.69 125.76 19.66 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.419 2.079 . . . . 0.0 110.283 177.231 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 71.9 mt -75.89 67.58 2.29 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 121.267 0.556 . . . . 0.0 109.868 -179.179 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -168.86 -172.06 1.51 Allowed 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 126.846 2.058 . . . . 0.0 106.841 -178.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -64.94 138.55 58.43 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 172.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -67.52 -5.64 16.1 Favored 'General case' 0 CA--C 1.536 0.424 0 N-CA-C 114.785 1.402 . . . . 0.0 114.785 -176.243 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 32.0 pt 37.06 45.96 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 126.981 2.112 . . . . 0.0 113.44 178.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 148.47 -66.51 0.39 Allowed Glycine 0 C--N 1.336 0.562 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -178.526 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -79.45 55.09 1.86 Allowed 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 122.067 0.936 . . . . 0.0 110.44 -178.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -84.03 54.23 2.86 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.986 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.9 p 45.23 36.72 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.174 0 C-N-CA 125.738 1.615 . . . . 0.0 110.583 -171.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.16 99.92 8.01 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 112.719 -2.037 . . . . 0.0 106.583 -176.916 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -103.61 90.92 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 C-N-CA 122.714 0.406 . . . . 0.0 111.686 -177.739 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 89.9 p -22.94 124.03 0.14 Allowed Pre-proline 0 CA--C 1.555 1.141 0 C-N-CA 126.037 1.735 . . . . 0.0 114.298 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -73.97 -36.74 3.25 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.023 2.482 . . . . 0.0 118.201 -171.654 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.44 148.33 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 119.905 1.229 . . . . 0.0 111.524 -175.422 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.6 m -80.48 140.6 35.83 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 173.957 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 163.58 -142.93 8.19 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -116.8 126.78 53.58 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 124.818 1.247 . . . . 0.0 108.457 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 tt -85.11 154.88 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -145.09 144.31 23.27 Favored Pre-proline 0 N--CA 1.451 -0.419 0 C-N-CA 124.989 1.316 . . . . 0.0 107.619 177.745 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -62.88 31.19 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 124.832 3.688 . . . . 0.0 116.838 177.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER 72.34 -39.69 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.071 1.349 . . . . 0.0 113.077 179.28 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -44.85 -41.38 7.03 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 125.298 1.439 . . . . 0.0 112.177 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.23 -14.1 62.73 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.646 1.579 . . . . 0.0 113.089 -175.978 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.6 t -71.3 127.91 90.8 Favored Pre-proline 0 CA--C 1.536 0.411 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 58.02 6.78 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.567 2.178 . . . . 0.0 112.043 -176.953 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -166.96 107.57 0.63 Allowed 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.686 -0.634 . . . . 0.0 110.203 177.348 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -28.6 -53.39 0.1 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 129.233 3.013 . . . . 0.0 115.967 -179.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 60.5 t -53.76 -45.61 61.74 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 CA-C-O 121.406 0.622 . . . . 0.0 109.703 -178.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -76.69 -54.47 6.6 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.9 m -45.37 -43.9 11.39 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 124.609 1.164 . . . . 0.0 114.119 -178.438 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.417 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -98.6 12.76 62.94 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 117.926 -1.486 . . . . 0.0 112.61 -176.406 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 56.8 mttp 70.97 -34.11 0.29 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 119.723 1.761 . . . . 0.0 113.994 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.417 ' H ' ' C ' ' A' ' 36' ' ' GLY . 26.3 ttt 28.57 -71.57 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 130.895 3.678 . . . . 0.0 117.191 178.276 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ttt -79.03 -17.08 55.91 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.971 0.908 . . . . 0.0 112.732 -175.599 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -168.15 -137.03 2.15 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . 0.409 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.3 t0 -133.65 158.03 44.28 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 171.848 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -176.98 -162.79 28.06 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 119.361 -1.399 . . . . 0.0 113.46 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -151.4 165.14 35.02 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.991 1.316 . . . . 0.0 107.516 177.406 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -119.11 141.59 48.65 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -115.88 132.59 64.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 170.576 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.42 107.03 42.97 Favored Pre-proline 0 N--CA 1.445 -0.69 1 N-CA-C 98.298 -4.705 . . . . 0.0 98.298 169.249 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -82.9 167.01 14.67 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.732 2.954 . . . . 0.0 114.417 -168.214 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.8 p -127.73 -67.74 0.81 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.312 1.445 . . . . 0.0 108.499 176.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -53.24 124.81 15.59 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.802 0.841 . . . . 0.0 111.973 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.01 39.31 2.03 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 173.826 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.3 mt -140.01 117.14 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 104.181 -2.526 . . . . 0.0 104.181 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.9 t -116.71 114.01 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 123.904 0.881 . . . . 0.0 109.024 -175.408 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.3 m -90.64 178.03 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 172.744 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -97.85 145.73 30.25 Favored Pre-proline 0 C--O 1.223 -0.318 0 CA-C-O 117.147 -1.406 . . . . 0.0 110.064 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -62.43 -39.18 47.69 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 N-CA-C 106.92 -1.992 . . . . 0.0 106.92 172.256 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 p -157.54 139.57 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 101.495 -3.52 . . . . 0.0 101.495 169.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -91.29 -67.71 0.84 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 178.282 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 62.86 -74.4 0.03 OUTLIER Glycine 0 C--N 1.34 0.768 0 C-N-CA 126.155 1.835 . . . . 0.0 112.334 172.569 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.97 114.16 3.37 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.217 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 39.0 mm -61.74 128.33 23.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.138 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 8.4 tt -78.89 -52.55 8.14 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 177.236 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -179.19 161.81 1.15 Allowed 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 28.9 m -136.94 123.17 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 125.506 1.522 . . . . 0.0 107.503 175.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 153.84 0.6 Allowed Pre-proline 0 CA--C 1.537 0.454 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 176.353 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -50.42 -34.44 41.52 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 123.068 2.512 . . . . 0.0 112.671 175.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 25.0 p -79.62 4.14 16.91 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.972 0.909 . . . . 0.0 112.458 -179.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 11.4 tppt? 66.36 -33.79 0.2 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 128.351 2.66 . . . . 0.0 115.803 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -54.44 -32.71 58.08 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 114.8 1.407 . . . . 0.0 114.8 -174.315 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.07 178.89 6.7 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 114.663 1.356 . . . . 0.0 114.663 -173.542 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.789 23.1 mm 117.86 -131.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.331 1 C-N-CA 132.719 4.408 . . . . 0.0 109.607 -179.312 . . . . . . . . 3 2 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.28 171.44 41.97 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 119.448 2.539 . . . . 0.0 119.448 -176.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.9 mt -118.97 179.68 4.08 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.81 2.444 . . . . 0.0 109.591 -177.655 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -149.63 152.3 35.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 127.016 2.126 . . . . 0.0 105.425 177.088 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 53.9 p -92.09 -123.19 0.08 Allowed 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 176.589 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -120.95 -60.74 1.62 Allowed 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 127.357 2.263 . . . . 0.0 105.827 175.711 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -78.41 61.64 3.87 Favored Glycine 0 CA--C 1.528 0.856 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 175.096 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 60.95 -116.48 9.39 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 42.6 mtt85 48.65 72.56 0.27 Allowed 'General case' 0 C--N 1.338 0.101 0 C-N-CA 125.276 1.431 . . . . 0.0 109.988 -178.303 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . 0.421 ' H ' ' ND2' ' A' ' 135' ' ' ASN . 8.4 tm-20 -76.87 134.19 39.08 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 176.744 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.3 mt -120.7 111.54 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.218 0.607 . . . . 0.0 110.995 -172.658 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.7 tt -83.04 138.28 33.79 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.517 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 68.3 mt -134.17 148.37 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 125.122 1.369 . . . . 0.0 108.887 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.42 78.92 1.64 Allowed 'General case' 0 C--N 1.34 0.192 0 C-N-CA 124.77 1.228 . . . . 0.0 109.743 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.3 t80 -51.52 107.02 0.16 Allowed 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 123.102 0.561 . . . . 0.0 111.558 -178.378 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.53 -173.29 2.51 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.647 0.641 . . . . 0.0 113.086 -178.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mm -121.67 146.0 27.43 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.3 t70 65.12 7.86 4.39 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.855 0.862 . . . . 0.0 113.07 -178.963 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -71.61 -35.21 70.39 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 125.738 1.615 . . . . 0.0 107.996 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 13.1 p -55.14 -45.79 77.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 CA-C-N 113.122 -1.854 . . . . 0.0 108.048 171.881 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.23 -38.66 92.05 Favored 'General case' 0 C--N 1.339 0.137 0 C-N-CA 124.354 1.061 . . . . 0.0 109.743 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.65 2.06 7.2 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 126.199 1.8 . . . . 0.0 110.615 175.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.4 mttp 45.88 30.23 0.84 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 128.016 2.526 . . . . 0.0 114.372 176.522 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.97 24.94 55.66 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.876 -0.402 . . . . 0.0 112.156 -178.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -56.66 -35.14 68.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 119.145 1.473 . . . . 0.0 112.79 -178.49 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -89.43 10.32 73.78 Favored Glycine 0 CA--C 1.533 1.192 0 CA-C-N 112.765 -2.016 . . . . 0.0 113.032 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -108.55 108.14 18.92 Favored 'General case' 0 C--N 1.343 0.325 0 CA-C-N 119.234 1.517 . . . . 0.0 111.996 -174.514 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.0 m -91.17 100.14 13.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.921 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.8 p -80.21 130.44 35.22 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 121.276 -0.89 . . . . 0.0 111.117 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -90.78 -46.96 7.91 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.705 1.202 . . . . 0.0 109.109 178.442 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.5 m -66.59 133.85 30.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 C-N-CA 118.105 -1.438 . . . . 0.0 108.421 174.491 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 59.5 m -110.88 53.29 0.71 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 170.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.292 3.4 pm0 -7.07 75.71 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.552 1 C-N-CA 131.815 4.046 . . . . 0.0 116.797 -171.603 . . . . . . . . 3 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.04 45.32 3.01 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 113.187 -1.824 . . . . 0.0 109.596 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 4.2 p30 5.23 41.57 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.226 2 C-N-CA 133.016 4.526 . . . . 0.0 122.206 -176.814 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.38 123.89 1.95 Allowed 'General case' 0 N--CA 1.436 -1.154 1 C-N-CA 133.163 4.585 . . . . 0.0 105.298 176.408 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -163.58 150.74 3.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 119.524 1.056 . . . . 0.0 110.482 -171.511 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -85.85 149.81 51.68 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 118.17 -0.919 . . . . 0.0 110.631 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_exo -46.71 150.84 2.29 Favored 'Trans proline' 0 CA--C 1.532 0.402 1 C-N-CA 126.222 4.615 . . . . 0.0 117.668 -176.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 66.44 -79.57 0.12 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.071 1.32 . . . . 0.0 112.504 176.873 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 1.44 76.12 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 131.581 3.953 . . . . 0.0 113.698 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? 17.49 109.94 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 129.723 3.209 . . . . 0.0 117.29 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 88.3 mt -78.75 -50.02 12.07 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.68 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 12.5 mt -144.56 156.8 44.32 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.971 0.909 . . . . 0.0 111.836 -173.061 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -119.06 131.39 55.95 Favored 'General case' 0 CA--C 1.516 -0.346 1 N-CA-C 98.694 -4.558 . . . . 0.0 98.694 165.586 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -140.91 129.89 24.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -166.497 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -76.24 63.2 1.86 Allowed 'General case' 0 C--O 1.234 0.25 0 CA-C-O 121.509 0.671 . . . . 0.0 110.068 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 78.6 mt -55.26 -34.56 64.15 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 123.221 0.609 . . . . 0.0 110.654 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.44 -40.23 71.29 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.047 0.539 . . . . 0.0 111.915 177.57 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.33 -35.3 17.27 Favored 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 122.788 0.435 . . . . 0.0 111.197 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.63 -51.19 75.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.554 -0.716 . . . . 0.0 109.518 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 20.8 pttm -40.66 -57.64 3.02 Favored Pre-proline 0 CA--C 1.541 0.616 0 N-CA-C 116.957 2.206 . . . . 0.0 116.957 -177.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -60.79 -25.64 81.52 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.696 2.264 . . . . 0.0 113.151 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -83.78 -43.03 15.85 Favored 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.62 0.646 . . . . 0.0 111.148 -178.148 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 35.7 m -78.91 150.57 75.37 Favored Pre-proline 0 CA--C 1.534 0.363 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.162 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -73.01 -25.19 16.52 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.515 2.143 . . . . 0.0 110.12 176.465 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.9 t -159.06 145.06 16.55 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 123.397 0.679 . . . . 0.0 109.539 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.9 tp -101.95 4.92 40.5 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.331 1.452 . . . . 0.0 110.287 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.8 mmt -51.97 111.4 0.6 Allowed 'General case' 0 C--N 1.342 0.263 0 C-N-CA 123.764 0.826 . . . . 0.0 110.104 179.031 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 85.7 m -107.3 114.57 60.86 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -179.672 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -90.55 145.75 4.0 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.976 2.45 . . . . 0.0 108.937 179.634 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.2 mp -124.84 116.57 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 101.787 -3.412 . . . . 0.0 101.787 172.918 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -124.58 117.21 49.79 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 C-N-CA 124.607 1.163 . . . . 0.0 108.719 -176.914 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -91.05 121.86 33.21 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.163 -2.532 . . . . 0.0 104.163 178.349 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -86.63 -73.17 0.47 Allowed 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.638 0.654 . . . . 0.0 110.757 -174.346 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . 0.421 ' ND2' ' H ' ' A' ' 79' ' ' GLU . 6.5 p30 -75.09 63.5 1.28 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 122.164 0.983 . . . . 0.0 112.507 -178.808 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . 0.409 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 29.8 mt -77.02 65.12 2.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.864 1.666 . . . . 0.0 108.34 177.152 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.48 46.97 0.08 Allowed 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 127.432 2.293 . . . . 0.0 111.179 -175.929 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 31.9 58.61 0.34 Allowed 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.852 2.861 . . . . 0.0 115.374 -175.972 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 156.56 -4.82 0.19 Allowed Glycine 0 CA--C 1.525 0.664 0 CA-C-O 118.972 -0.905 . . . . 0.0 114.32 174.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 43.7 mt-10 -74.87 111.81 10.44 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 119.18 1.49 . . . . 0.0 110.031 -179.008 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 59.9 p -78.42 133.37 37.51 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 176.885 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.26 0.4 OUTLIER -84.37 82.72 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 CA-C-O 122.875 1.321 . . . . 0.0 107.964 -176.646 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 41.9 m -79.08 94.65 5.36 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 120.986 -1.071 . . . . 0.0 110.363 -176.504 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 10.5 mt -57.91 128.32 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.4 mmpt? -98.5 -52.63 3.57 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 125.188 1.395 . . . . 0.0 108.931 177.827 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -79.0 61.51 3.19 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 120.819 0.342 . . . . 0.0 110.133 -178.482 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 60.2 p -77.84 72.77 4.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.843 0.857 . . . . 0.0 110.472 -176.861 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.37 -143.74 5.54 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 26.5 t -72.2 146.45 47.34 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 19.2 m -137.1 156.51 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.617 0.767 . . . . 0.0 109.33 -178.543 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -114.05 158.38 21.29 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 174.415 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.21 164.8 26.17 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.12 0.486 . . . . 0.0 110.249 175.091 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 60.7 32.91 20.31 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.339 1.055 . . . . 0.0 112.953 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -105.79 145.79 30.71 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 175.044 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -115.79 161.9 18.08 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.133 0.973 . . . . 0.0 110.585 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 19.3 t70 56.99 18.46 3.97 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 126.436 1.894 . . . . 0.0 113.566 -177.489 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -61.64 -21.2 24.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 125.464 1.506 . . . . 0.0 112.006 177.728 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 13.4 p -138.83 150.44 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 126.554 1.941 . . . . 0.0 107.048 178.804 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -120.77 109.07 14.72 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.184 0.994 . . . . 0.0 109.765 177.136 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.2 mp -77.65 92.47 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 N-CA-C 104.345 -2.465 . . . . 0.0 104.345 178.178 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 58.5 mt-10 -119.25 122.7 42.52 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.233 1.013 . . . . 0.0 111.055 -174.158 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--N 1.332 -0.179 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 177.332 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.8 mtm . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.991 0.424 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.1 mm -120.43 146.4 25.34 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 C-N-CA 125.409 1.483 . . . . 0.0 107.485 177.416 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -67.94 79.01 0.22 Allowed 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.703 0.801 . . . . 0.0 112.453 -179.299 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 58.89 71.46 0.97 Allowed Pre-proline 0 CA--C 1.536 0.416 0 C-N-CA 125.588 1.555 . . . . 0.0 112.614 176.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -72.2 77.31 2.04 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.052 2.501 . . . . 0.0 108.736 177.513 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 45.62 36.76 2.77 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 127.428 2.291 . . . . 0.0 112.055 -175.94 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -150.11 166.57 29.37 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 127.165 2.186 . . . . 0.0 106.606 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 t30 63.9 89.42 0.09 Allowed 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 125.082 1.353 . . . . 0.0 112.842 177.235 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 68.88 -60.33 0.45 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 126.975 2.11 . . . . 0.0 112.969 176.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.8 mt 57.54 38.65 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 124.356 1.063 . . . . 0.0 110.016 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.12 66.23 2.9 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.244 -1.543 . . . . 0.0 109.244 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 29.7 tt0 -63.53 72.16 0.02 OUTLIER 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 125.927 1.691 . . . . 0.0 113.69 -174.04 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -75.8 161.12 29.29 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.262 1.425 . . . . 0.0 110.383 176.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.5 p -71.92 102.34 1.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 CA-C-O 122.464 1.126 . . . . 0.0 113.587 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -163.33 151.46 13.55 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 129.998 3.319 . . . . 0.0 102.831 173.475 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -131.27 96.99 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 122.231 2.287 . . . . 0.0 110.272 176.676 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 t -32.57 120.94 0.41 Allowed Pre-proline 0 CA--C 1.548 0.887 0 C-N-CA 125.574 1.55 . . . . 0.0 112.808 -178.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -74.06 -38.14 2.35 Favored 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 123.29 2.66 . . . . 0.0 117.571 -171.917 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.92 152.02 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 120.113 1.324 . . . . 0.0 109.84 -176.049 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.6 m -79.09 134.17 36.75 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 172.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.86 -177.09 45.54 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -92.0 122.08 34.17 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.4 tt -86.61 138.65 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 123.12 0.568 . . . . 0.0 110.141 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 78.8 m-70 -137.66 145.63 49.64 Favored Pre-proline 0 C--O 1.234 0.278 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 176.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.47 145.69 67.18 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.115 1.877 . . . . 0.0 110.218 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.4 tp -50.8 -33.84 12.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.729 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 p -56.02 -27.71 54.25 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 123.78 0.832 . . . . 0.0 112.388 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -76.22 -11.89 60.0 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.923 0.889 . . . . 0.0 112.714 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 42.3 t -66.85 129.45 94.05 Favored Pre-proline 0 CA--C 1.538 0.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.445 -178.292 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -77.17 59.48 6.59 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.696 2.931 . . . . 0.0 111.024 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -167.58 105.19 0.52 Allowed 'General case' 0 N--CA 1.463 0.209 0 O-C-N 121.356 -0.84 . . . . 0.0 109.344 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -24.56 -58.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 128.162 2.585 . . . . 0.0 114.164 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.9 t -48.57 -50.44 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 123.954 0.902 . . . . 0.0 110.464 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -76.31 -47.81 22.29 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.2 m -49.31 -41.29 38.0 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 113.793 1.035 . . . . 0.0 113.793 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -104.6 20.27 39.81 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-O 118.081 -1.4 . . . . 0.0 110.897 -177.068 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.0 mttt 72.03 -46.52 0.65 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.401 1.48 . . . . 0.0 113.248 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 45.0 tpp 45.16 -72.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.731 2.812 . . . . 0.0 115.352 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.7 ttp -101.8 -14.69 17.19 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.314 1.446 . . . . 0.0 113.018 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.06 -169.21 38.0 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 119.531 1.06 . . . . 0.0 111.965 -178.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -128.79 157.54 41.17 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.99 -126.71 1.35 Allowed Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 108.533 -1.827 . . . . 0.0 108.533 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -166.44 167.1 16.01 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 118.125 0.963 . . . . 0.0 111.542 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.35 126.19 45.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.475 1.11 . . . . 0.0 108.5 177.418 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.0 mm -107.31 121.12 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 104.193 -2.521 . . . . 0.0 104.193 170.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 7.0 tt -89.03 109.5 31.12 Favored Pre-proline 0 C--O 1.233 0.233 1 N-CA-C 100.073 -4.047 . . . . 0.0 100.073 170.498 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -81.52 162.61 19.34 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 123.594 2.863 . . . . 0.0 115.037 -167.649 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.2 p -132.04 -63.52 0.81 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.639 1.576 . . . . 0.0 108.947 177.095 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.43 123.93 17.83 Favored 'General case' 0 C--N 1.338 0.096 0 C-N-CA 122.56 0.344 . . . . 0.0 110.166 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.08 45.34 2.98 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 173.304 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.2 mt -145.84 115.96 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 105.17 -2.159 . . . . 0.0 105.17 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.1 t -114.01 121.51 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 125.084 1.354 . . . . 0.0 108.252 -177.283 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.9 m -103.66 156.93 5.34 Favored 'Isoleucine or valine' 0 C--N 1.339 0.11 0 C-N-CA 123.642 0.777 . . . . 0.0 110.071 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 m -69.12 127.17 93.13 Favored Pre-proline 0 CA--C 1.537 0.471 0 CA-C-O 117.598 -1.191 . . . . 0.0 109.92 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -60.41 -33.2 94.39 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.763 2.976 . . . . 0.0 111.302 177.521 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.1 m -150.6 144.16 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 102.139 -3.282 . . . . 0.0 102.139 172.704 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 -98.72 -97.41 0.22 Allowed 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 101.754 -3.424 . . . . 0.0 101.754 169.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.95 -66.43 3.59 Favored Glycine 0 CA--C 1.535 1.303 0 N-CA-C 106.575 -2.61 . . . . 0.0 106.575 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.21 132.36 2.49 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 166.617 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.0 mm -65.04 131.78 30.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 103.55 -2.759 . . . . 0.0 103.55 169.069 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 29.3 tp -79.01 -46.36 18.33 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 175.0 156.05 0.15 Allowed 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 125.669 1.588 . . . . 0.0 107.787 176.034 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.3 t -131.12 121.06 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -47.44 153.01 1.05 Allowed Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 112.579 0.585 . . . . 0.0 112.579 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -59.67 -14.97 28.92 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 124.192 3.262 . . . . 0.0 113.652 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 40.5 p -76.26 -21.29 56.49 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.078 0.951 . . . . 0.0 109.697 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 70.98 9.52 6.78 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 128.14 2.576 . . . . 0.0 111.03 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -83.91 -31.21 25.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 118.611 -0.709 . . . . 0.0 112.864 -176.927 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.82 -175.38 5.33 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.679 1.127 . . . . 0.0 112.348 -174.314 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.965 16.6 mm 130.89 -141.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.334 -0.085 1 C-N-CA 132.018 4.127 . . . . 0.0 111.824 176.4 . . . . . . . . 3 2 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -152.14 176.2 30.53 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 118.511 2.164 . . . . 0.0 118.511 -171.804 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.2 mp -132.51 158.46 42.05 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 128.012 2.525 . . . . 0.0 109.817 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.7 mm-40 -133.03 123.85 26.57 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 177.379 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.3 p -73.79 -83.57 0.05 OUTLIER 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 124.689 1.196 . . . . 0.0 108.778 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -149.28 52.04 0.95 Allowed 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 127.138 2.175 . . . . 0.0 107.608 -179.194 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 80.25 -70.45 2.95 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 107.916 -2.073 . . . . 0.0 107.916 -174.512 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.29 112.2 4.37 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 125.313 1.435 . . . . 0.0 111.25 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 93.1 62.01 0.0 OUTLIER 'General case' 0 C--N 1.335 -0.058 0 C-N-CA 129.494 3.117 . . . . 0.0 111.824 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -76.34 141.15 41.64 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 174.43 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.2 mt -126.66 144.36 37.08 Favored 'Isoleucine or valine' 0 C--N 1.338 0.08 0 N-CA-C 112.789 0.662 . . . . 0.0 112.789 -172.795 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -119.82 136.63 54.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 128.891 2.876 . . . . 0.0 105.732 175.789 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.0 mt -131.48 140.15 49.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 C-N-CA 125.075 1.35 . . . . 0.0 107.764 177.529 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -132.89 114.81 14.49 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -76.05 116.52 16.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 118.766 0.712 . . . . 0.0 110.402 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.63 -170.57 4.82 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.694 -0.562 . . . . 0.0 111.694 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 22.5 mm -116.59 141.36 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.159 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.7 t0 50.2 41.98 24.76 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.412 1.085 . . . . 0.0 112.892 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.423 ' O ' ' N ' ' A' ' 90' ' ' SER . 7.7 p -83.83 -89.12 0.1 Allowed 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 103.273 -2.862 . . . . 0.0 103.273 172.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.3 p 33.03 -67.31 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 C-N-CA 128.313 2.645 . . . . 0.0 116.946 172.354 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.423 ' N ' ' O ' ' A' ' 88' ' ' THR . 12.9 m -63.43 -40.44 97.18 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 126.27 1.828 . . . . 0.0 109.758 176.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -58.35 -43.53 88.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 126.862 2.065 . . . . 0.0 108.8 178.415 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? 77.02 169.59 0.24 Allowed 'General case' 0 N--CA 1.442 -0.871 0 C-N-CA 126.823 2.049 . . . . 0.0 106.837 -174.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.03 54.96 0.56 Allowed Glycine 0 CA--C 1.538 1.493 0 C-N-CA 124.898 1.237 . . . . 0.0 112.718 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -75.41 79.88 2.47 Favored 'General case' 0 CA--C 1.519 -0.236 0 O-C-N 121.158 -1.201 . . . . 0.0 108.781 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.78 11.72 2.31 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 112.919 -1.946 . . . . 0.0 111.594 -176.93 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -96.94 96.93 8.86 Favored 'General case' 0 C--N 1.342 0.267 0 C-N-CA 124.753 1.221 . . . . 0.0 110.731 -175.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.4 m -79.72 94.67 5.78 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 35.9 p -79.51 122.93 27.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 121.569 -0.707 . . . . 0.0 110.653 -176.446 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -83.57 -53.18 5.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 27.9 m -84.82 131.02 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 171.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 69.6 m -96.06 57.63 1.79 Allowed 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 170.351 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.378 0.0 OUTLIER 37.97 49.6 1.2 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 111.458 -2.61 . . . . 0.0 110.6 -167.265 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -72.44 59.46 1.57 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 129.639 3.495 . . . . 0.0 111.152 -178.066 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.401 16.4 p30 2.04 -103.22 0.0 OUTLIER 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 119.583 3.179 . . . . 0.0 119.583 -178.942 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.322 0.1 OUTLIER -40.6 131.29 2.33 Favored 'General case' 0 N--CA 1.432 -1.367 1 N-CA-C 125.478 5.362 . . . . 0.0 125.478 -165.667 . . . . . . . . 4 3 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.489 9.7 p 32.63 -38.27 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.247 2 N-CA-C 130.203 7.112 . . . . 0.0 130.203 168.148 . . . . . . . . 3 2 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . 0.287 0.0 OUTLIER -70.33 115.16 31.88 Favored Pre-proline 0 C--N 1.308 -1.197 0 C-N-CA 115.422 -2.511 . . . . 0.0 114.333 -166.865 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 47.7 Cg_exo -62.45 162.82 22.71 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 124.875 3.717 . . . . 0.0 113.576 -170.141 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 54.04 15.91 5.63 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 124.423 1.011 . . . . 0.0 115.314 174.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -59.88 136.89 58.15 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 117.987 0.893 . . . . 0.0 108.752 178.929 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -64.23 119.42 10.22 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 174.381 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.6 mt -81.07 -52.33 7.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 17.1 mt -145.56 149.31 34.35 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.29 1.036 . . . . 0.0 110.995 -173.387 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -114.39 128.19 56.22 Favored 'General case' 0 CA--C 1.515 -0.402 1 N-CA-C 98.762 -4.532 . . . . 0.0 98.762 165.609 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.65 127.0 44.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.744 -165.469 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -74.26 68.29 1.47 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.664 0.786 . . . . 0.0 110.108 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.0 mt -54.2 -38.36 65.56 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.929 0.491 . . . . 0.0 111.102 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -53.68 -44.75 69.97 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.99 0.516 . . . . 0.0 112.162 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.89 -32.52 20.16 Favored 'General case' 0 CA--C 1.527 0.079 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -67.13 -50.59 62.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 O-C-N 121.759 -0.588 . . . . 0.0 110.326 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.345 22.1 pttm -37.0 -54.15 1.84 Allowed Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 118.283 2.698 . . . . 0.0 118.283 -176.796 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -52.63 -22.15 16.33 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.66 2.24 . . . . 0.0 114.095 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 -84.19 -14.36 50.31 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 118.13 -0.938 . . . . 0.0 113.096 -177.767 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 29.3 m -108.77 149.05 38.99 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 119.731 1.15 . . . . 0.0 112.44 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.32 -26.29 20.85 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.586 2.19 . . . . 0.0 110.372 175.674 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 10.0 m -157.85 137.41 12.03 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.564 1.146 . . . . 0.0 108.287 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 13.2 tp -90.29 6.78 41.5 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.876 0.87 . . . . 0.0 111.396 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.1 mmt -50.57 114.26 1.09 Allowed 'General case' 0 C--N 1.342 0.244 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 45.6 m -107.73 88.36 4.3 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -72.49 139.92 32.27 Favored 'Trans proline' 0 N--CA 1.445 -1.352 0 C-N-CA 121.923 1.749 . . . . 0.0 111.976 -178.718 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 16.6 mm -115.51 128.48 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 102.404 -3.184 . . . . 0.0 102.404 173.555 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.5 t -137.43 122.36 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -175.989 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -84.72 123.05 29.95 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.035 -2.58 . . . . 0.0 104.035 174.673 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 40.2 p -80.74 -72.78 0.4 Allowed 'General case' 0 C--O 1.227 -0.129 0 CA-C-N 118.841 0.746 . . . . 0.0 110.796 -175.683 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 22.2 p30 -65.14 -30.06 70.96 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -177.37 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 mt 46.27 44.54 12.5 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.156 0.982 . . . . 0.0 110.347 -176.973 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 42.53 37.39 0.97 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 126.351 1.86 . . . . 0.0 112.662 -175.645 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 75.5 mm-40 48.25 75.32 0.14 Allowed 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 126.706 2.002 . . . . 0.0 113.874 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.03 -14.21 5.19 Favored Glycine 0 C--N 1.335 0.484 0 CA-C-O 118.702 -1.055 . . . . 0.0 113.339 174.723 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -72.65 139.21 47.19 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.206 1.503 . . . . 0.0 109.776 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 77.2 p -111.87 130.81 55.7 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 124.97 1.308 . . . . 0.0 109.128 176.022 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -60.42 112.6 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 123.973 0.909 . . . . 0.0 110.387 -175.363 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 87.28 2.61 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 126.407 1.883 . . . . 0.0 106.518 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 34.7 mt -66.77 131.82 32.35 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -96.58 -44.2 7.25 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -47.23 83.1 0.0 OUTLIER 'General case' 0 C--N 1.34 0.158 0 C-N-CA 126.348 1.859 . . . . 0.0 114.206 -178.753 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 37.7 m -82.71 54.59 2.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 123.996 0.918 . . . . 0.0 108.787 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 157.47 -171.65 34.73 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.211 -0.755 . . . . 0.0 111.211 -177.548 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 29.6 t -58.47 138.05 56.93 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 122.794 0.438 . . . . 0.0 110.101 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.7 m -92.86 -173.01 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 123.7 0.8 . . . . 0.0 109.928 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.85 166.7 29.76 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.62 155.03 24.64 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.986 0.812 . . . . 0.0 110.336 176.034 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 62.56 5.12 1.55 Allowed 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.762 1.625 . . . . 0.0 114.301 178.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -67.95 118.22 10.85 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 62.7 tt0 -67.51 138.03 56.23 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . 0.417 ' C ' ' H ' ' A' ' 158' ' ' VAL . 29.2 t70 84.92 -113.87 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 128.327 2.651 . . . . 0.0 109.043 -179.318 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.366 1.7 mp 73.31 -28.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 129.565 3.146 . . . . 0.0 111.509 179.687 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.417 ' H ' ' C ' ' A' ' 156' ' ' ASP . 11.0 p -134.9 148.09 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 127.519 2.328 . . . . 0.0 106.978 169.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 26.3 mtpp -134.67 144.93 48.1 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 104.009 -2.589 . . . . 0.0 104.009 173.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 0.3 OUTLIER -112.0 112.55 40.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.156 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.1 134.02 44.74 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 123.66 0.784 . . . . 0.0 111.247 -174.908 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp . . . . . 0 CA--C 1.528 0.117 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 176.73 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.8 ttt . . . . . 0 N--CA 1.455 -0.212 0 CA-C-O 120.995 0.426 . . . . 0.0 109.866 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 37.1 mm -74.09 79.26 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.239 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -62.93 67.68 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 126.548 1.939 . . . . 0.0 113.9 -175.767 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -119.05 -72.67 0.02 OUTLIER Pre-proline 0 CA--C 1.537 0.47 0 C-N-CA 126.238 1.815 . . . . 0.0 108.273 176.494 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.41 157.49 60.86 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 CA-C-N 121.258 1.485 . . . . 0.0 109.495 176.181 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.25 64.62 0.38 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.853 1.261 . . . . 0.0 112.245 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -71.69 59.82 0.34 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.123 1.769 . . . . 0.0 112.055 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 25.4 t30 -66.16 149.33 50.47 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.854 -0.529 . . . . 0.0 110.223 178.875 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 54.0 mt-10 -76.06 73.14 2.92 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 176.132 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.7 pt -66.51 69.93 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 124.797 1.239 . . . . 0.0 112.486 -178.113 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.72 67.67 1.62 Allowed Glycine 0 CA--C 1.526 0.729 0 C-N-CA 124.332 0.968 . . . . 0.0 110.776 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -74.07 79.25 1.72 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 40.2 mm-40 -73.36 64.65 0.83 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 122.949 0.5 . . . . 0.0 110.486 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER 69.14 -3.51 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 C-N-CA 128.352 2.661 . . . . 0.0 115.116 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.83 147.35 26.86 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 125.443 1.497 . . . . 0.0 114.387 -176.239 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -142.55 103.88 1.05 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 C-N-CA 126.68 1.992 . . . . 0.0 106.267 172.995 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 t -29.14 118.53 0.28 Allowed Pre-proline 0 CA--C 1.552 1.033 0 C-N-CA 124.728 1.211 . . . . 0.0 113.43 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -75.31 -37.47 1.87 Allowed 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 122.693 2.262 . . . . 0.0 117.324 -173.115 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.27 148.06 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 120.397 1.453 . . . . 0.0 109.3 -176.727 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.4 m -78.64 137.04 37.64 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 175.301 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.19 -147.14 14.54 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -107.72 144.1 35.3 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.858 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.1 tt -105.62 95.17 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 C-N-CA 124.304 1.041 . . . . 0.0 108.398 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -85.63 151.58 55.86 Favored Pre-proline 0 C--O 1.237 0.404 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.047 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.26 145.32 88.5 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 N-CA-C 107.888 -1.62 . . . . 0.0 107.888 174.887 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.3 tp -50.67 -32.64 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.672 0.789 . . . . 0.0 111.134 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.9 -29.87 63.41 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.829 1.252 . . . . 0.0 113.057 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -82.24 3.65 26.64 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.524 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.2 t -82.06 128.04 69.56 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-O 117.508 -1.234 . . . . 0.0 111.755 -176.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_exo -58.74 40.75 0.05 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 1 C-N-CA 126.354 4.702 . . . . 0.0 117.451 175.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -164.48 109.59 0.97 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 120.98 1.718 . . . . 0.0 109.033 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 18.8 mp0 -34.13 -48.52 0.32 Allowed 'General case' 0 C--O 1.231 0.117 0 C-N-CA 128.956 2.902 . . . . 0.0 114.401 -176.805 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.5 p -53.44 -38.95 34.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 CA-C-N 118.158 0.435 . . . . 0.0 110.878 -178.606 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -84.48 -48.83 9.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 177.419 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -51.03 -39.23 55.38 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -178.131 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.38 17.15 57.24 Favored Glycine 0 N--CA 1.445 -0.716 0 CA-C-O 118.219 -1.323 . . . . 0.0 111.06 -177.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.7 mttp 71.18 -40.71 0.48 Allowed 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.463 1.505 . . . . 0.0 114.07 178.88 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 29.97 -73.96 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 130.005 3.322 . . . . 0.0 116.753 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.19 -21.3 46.56 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.476 1.11 . . . . 0.0 113.263 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 172.43 -144.21 7.83 Favored Glycine 0 C--O 1.223 -0.564 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -141.57 160.05 40.95 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.482 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.55 -126.13 1.23 Allowed Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.05 163.73 15.86 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 118.636 1.218 . . . . 0.0 112.261 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -99.94 96.88 7.84 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 124.575 1.15 . . . . 0.0 110.466 -178.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 32.1 mm -80.44 126.11 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.4 tt -101.03 105.5 39.03 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 100.529 -3.878 . . . . 0.0 100.529 171.381 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -84.37 168.18 11.68 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.891 3.061 . . . . 0.0 114.255 -168.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.9 p -130.8 -71.7 0.57 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.347 1.459 . . . . 0.0 108.199 176.081 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -48.89 127.25 13.72 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 124.609 1.164 . . . . 0.0 112.088 178.748 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.21 42.26 2.34 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 173.899 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 35.9 mt -143.74 120.87 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 104.381 -2.452 . . . . 0.0 104.381 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 53.1 t -119.97 131.09 73.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 124.911 1.284 . . . . 0.0 107.549 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.4 m -110.72 159.39 10.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 C-N-CA 124.08 0.952 . . . . 0.0 110.947 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.84 132.7 94.83 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-O 118.41 -0.805 . . . . 0.0 110.21 -179.584 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -68.58 -15.95 42.02 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.638 2.892 . . . . 0.0 115.926 -177.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -143.99 162.02 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.046 0 CA-C-N 119.523 1.056 . . . . 0.0 110.409 -178.66 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 9.0 ptp85 -76.73 117.14 18.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 168.716 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 172.96 -179.62 44.28 Favored Glycine 0 N--CA 1.433 -1.529 0 C-N-CA 115.277 -3.344 . . . . 0.0 114.954 -167.246 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.63 127.91 42.05 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 124.558 1.143 . . . . 0.0 109.815 -176.233 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 9.6 mm -73.94 113.32 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 N-CA-C 102.633 -3.099 . . . . 0.0 102.633 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 61.0 tp -76.44 -47.93 21.37 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -174.571 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -174.77 157.4 2.47 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 13.5 t -138.91 119.24 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 175.791 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -42.04 151.53 0.34 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.572 0.624 . . . . 0.0 112.201 177.91 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.19 -26.36 15.03 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 123.89 3.06 . . . . 0.0 114.303 175.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 19.2 p -75.73 -15.2 60.31 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 123.871 0.869 . . . . 0.0 110.925 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 71.87 10.11 6.2 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.545 1.538 . . . . 0.0 113.536 178.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.469 ' CG ' ' HA ' ' A' ' 89' ' ' VAL . 22.6 p-80 -90.51 -31.62 16.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 119.428 1.013 . . . . 0.0 113.403 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.97 -178.82 7.16 Favored 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -171.007 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.663 23.0 mm 124.01 -132.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 1 C-N-CA 135.155 5.382 . . . . 0.0 105.216 -176.709 . . . . . . . . 3 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -169.86 -179.1 41.33 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 119.165 2.426 . . . . 0.0 119.165 -177.829 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.6 mp -124.56 172.33 9.3 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.747 2.419 . . . . 0.0 110.279 -178.208 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -134.42 142.01 47.0 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 169.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 40.8 p -73.91 -127.37 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.041 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -70.53 -48.44 55.47 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 120.653 -1.279 . . . . 0.0 108.36 176.719 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 170.42 64.78 0.04 OUTLIER Glycine 0 CA--C 1.521 0.406 0 N-CA-C 106.545 -2.622 . . . . 0.0 106.545 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -165.58 -93.81 0.09 OUTLIER Glycine 0 C--N 1.334 0.425 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 -177.808 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -60.38 123.27 16.79 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 117.795 0.798 . . . . 0.0 109.424 178.041 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -103.53 136.35 43.43 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 173.676 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 22.3 mt -125.01 122.95 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -173.782 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 28.2 tp -89.65 136.83 32.8 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 127.193 2.197 . . . . 0.0 106.914 173.367 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.4 mt -120.14 155.63 23.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.652 1.181 . . . . 0.0 109.522 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.57 96.64 1.79 Allowed 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 126.223 1.809 . . . . 0.0 107.021 174.977 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.0 OUTLIER -73.68 76.69 1.53 Allowed 'General case' 0 N--CA 1.454 -0.238 0 O-C-N 121.519 -0.738 . . . . 0.0 110.565 -178.071 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.11 170.84 39.89 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.634 1.588 . . . . 0.0 111.775 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 2.0 tp -107.41 125.86 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.845 1.658 . . . . 0.0 106.935 178.03 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t0 58.88 38.6 24.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 125.323 1.449 . . . . 0.0 111.206 -176.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -95.88 -70.85 0.7 Allowed 'General case' 0 CA--C 1.496 -1.126 0 N-CA-C 101.366 -3.568 . . . . 0.0 101.366 171.541 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.469 ' HA ' ' CG ' ' A' ' 68' ' ' HIS 0.335 1.3 p 45.44 49.22 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 104.492 -2.41 . . . . 0.0 104.492 -172.758 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 21.4 m 12.97 48.38 0.0 OUTLIER 'General case' 0 C--N 1.35 0.592 1 C-N-CA 133.111 4.565 . . . . 0.0 112.83 -165.219 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.9 mt 33.66 50.52 0.31 Allowed 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 131.053 3.741 . . . . 0.0 109.001 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 90.5 mttt 76.66 50.26 0.05 Allowed 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 128.148 2.579 . . . . 0.0 111.595 -176.966 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 47.43 37.28 12.24 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 126.472 1.987 . . . . 0.0 114.059 -178.35 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -92.5 161.66 14.53 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 170.366 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 63.56 -4.14 1.11 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.137 1.351 . . . . 0.0 114.822 178.695 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -106.64 105.57 15.67 Favored 'General case' 0 C--N 1.342 0.262 0 CA-C-N 119.077 1.438 . . . . 0.0 111.327 -175.72 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 18.9 m -93.11 104.36 16.57 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 174.341 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.6 t -80.15 148.83 30.77 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 119.203 0.91 . . . . 0.0 110.775 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.408 ' CE1' ' HG3' ' A' ' 114' ' ' GLU . 39.3 m-85 -115.9 3.85 13.77 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 126.323 1.849 . . . . 0.0 110.785 179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.6 m -134.02 145.96 32.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 176.611 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.6 m -82.6 -16.87 46.83 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.973 1.309 . . . . 0.0 112.211 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.472 1.3 pp20? 73.29 140.86 0.06 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.203 3.001 . . . . 0.0 109.574 -172.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 97.5 -16.48 60.5 Favored Glycine 0 CA--C 1.54 1.642 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -169.23 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -57.87 115.66 2.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.632 1.973 . . . . 0.0 108.901 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.25 123.01 29.67 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 128.912 2.885 . . . . 0.0 114.254 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.345 27.3 m 52.23 70.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.301 0 C-N-CA 126.992 2.117 . . . . 0.0 116.032 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 138.44 26.55 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 170.161 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -93.63 -135.49 0.01 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.004 0 C-N-CA 124.978 3.785 . . . . 0.0 108.522 -179.229 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -64.21 30.09 0.09 OUTLIER Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.334 1.921 . . . . 0.0 115.678 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.8 tt0 -64.58 149.8 48.12 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 169.262 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -64.32 122.11 15.91 Favored 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.739 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.7 mt -80.44 -49.43 11.44 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 175.468 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.1 mt -144.04 152.43 41.0 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.007 0.923 . . . . 0.0 110.708 -173.873 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.408 ' HG3' ' CE1' ' A' ' 99' ' ' PHE . 93.2 mt-10 -114.49 128.83 56.54 Favored 'General case' 0 CA--C 1.517 -0.298 1 N-CA-C 98.95 -4.463 . . . . 0.0 98.95 165.802 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.44 128.47 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.469 -165.603 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -76.82 63.57 2.23 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.623 0.725 . . . . 0.0 109.856 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 80.0 mt -54.34 -37.68 65.16 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 123.248 0.619 . . . . 0.0 110.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -53.76 -43.37 69.13 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.761 0.824 . . . . 0.0 112.247 178.342 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.92 -34.54 20.9 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.059 0.391 . . . . 0.0 111.411 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 75.4 t -62.01 -55.43 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.722 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.355 18.8 pttp -38.96 -58.33 1.76 Allowed Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 117.596 2.443 . . . . 0.0 117.596 -176.098 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.49 -20.28 48.43 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.774 2.316 . . . . 0.0 113.717 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -100.13 9.2 43.18 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 118.551 -0.738 . . . . 0.0 112.726 -176.795 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 22.8 m -136.23 158.48 73.53 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 119.573 1.079 . . . . 0.0 109.36 -178.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -75.7 -30.0 6.63 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.017 1.811 . . . . 0.0 112.783 -177.47 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -163.88 133.96 4.2 Favored 'General case' 0 N--CA 1.454 -0.241 0 O-C-N 121.395 -0.816 . . . . 0.0 111.287 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -93.42 9.07 38.02 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.961 0.904 . . . . 0.0 111.564 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -50.89 110.04 0.38 Allowed 'General case' 0 C--N 1.342 0.242 0 C-N-CA 124.301 1.041 . . . . 0.0 108.327 177.87 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.8 m -95.83 102.49 10.52 Favored Pre-proline 0 N--CA 1.447 -0.607 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -92.39 99.66 0.18 Allowed 'Trans proline' 0 N--CA 1.444 -1.422 0 C-N-CA 123.414 2.743 . . . . 0.0 107.679 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.08 126.5 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 103.503 -2.777 . . . . 0.0 103.503 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.05 120.43 51.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 CA-C-O 121.928 0.871 . . . . 0.0 109.303 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.485 ' N ' ' CD1' ' A' ' 133' ' ' PHE . 0.5 OUTLIER -83.0 114.14 21.06 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 101.732 -3.432 . . . . 0.0 101.732 177.592 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -77.16 -79.69 0.11 Allowed 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 121.007 0.432 . . . . 0.0 111.216 -170.824 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.23 68.12 0.72 Allowed 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.988 0.899 . . . . 0.0 111.298 -178.696 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.1 mt -76.76 65.28 2.47 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.128 -0.982 . . . . 0.0 108.364 177.119 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 10.18 63.03 0.0 OUTLIER 'General case' 0 C--N 1.347 0.458 0 C-N-CA 130.582 3.553 . . . . 0.0 112.815 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 25.97 58.02 0.06 Allowed 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 128.52 2.728 . . . . 0.0 114.514 -176.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 148.71 6.2 0.23 Allowed Glycine 0 CA--C 1.524 0.617 0 CA-C-O 118.577 -1.124 . . . . 0.0 114.033 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . 0.621 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 22.4 mt-10 -77.76 92.76 4.21 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 119.439 1.62 . . . . 0.0 107.894 177.251 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 70.1 p -76.69 135.06 39.08 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -177.359 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.2 t -87.32 90.74 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 124.0 0.92 . . . . 0.0 109.26 -176.768 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 42.1 m -85.68 95.6 9.42 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 33.0 mt -64.58 131.84 30.36 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.394 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -100.94 -45.9 5.28 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 124.665 1.186 . . . . 0.0 109.055 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.67 74.81 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.234 0 C-N-CA 126.113 1.765 . . . . 0.0 112.02 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.1 m -79.71 54.47 1.82 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.443 1.097 . . . . 0.0 110.025 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 160.7 179.66 35.6 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 40.5 t -57.16 144.83 33.46 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.172 0.589 . . . . 0.0 111.616 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 4.9 m -145.04 166.96 10.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -102.36 166.86 10.33 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 124.849 1.26 . . . . 0.0 111.48 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.29 163.41 23.02 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 63.96 -9.42 0.15 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.727 2.011 . . . . 0.0 114.552 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 34.2 mm-40 -64.32 148.96 49.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.456 1.025 . . . . 0.0 111.581 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -99.33 159.38 15.05 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.527 2.331 . . . . 0.0 111.099 -176.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 24.9 t70 57.55 21.83 7.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 126.137 1.775 . . . . 0.0 114.621 174.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -70.35 -28.64 36.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 C-N-CA 123.61 0.764 . . . . 0.0 111.812 178.951 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.44 145.14 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 C-N-CA 125.5 1.52 . . . . 0.0 107.866 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -120.57 111.86 18.2 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 174.054 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . 0.621 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.03 110.53 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 103.84 -2.652 . . . . 0.0 103.84 172.871 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -109.11 125.04 51.73 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.956 1.303 . . . . 0.0 109.883 -178.188 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 56.2 tptt . . . . . 0 C--N 1.333 -0.14 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.109 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 38.7 mtt . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 9.4 tp -49.62 -31.67 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 123.324 0.65 . . . . 0.0 112.239 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.59 38.28 4.15 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.802 0.841 . . . . 0.0 111.126 178.205 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -156.02 122.15 2.59 Favored Pre-proline 0 CA--C 1.537 0.476 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -72.09 63.44 3.37 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 123.174 2.583 . . . . 0.0 113.918 -177.02 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 17.9 tp 38.7 58.73 1.66 Allowed 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.58 2.352 . . . . 0.0 113.604 176.775 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 10.5 pt20 -163.76 -143.92 0.08 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 125.101 1.36 . . . . 0.0 107.661 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 29.0 t30 -128.84 148.77 50.92 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 175.332 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 24.4 mp0 -70.62 70.58 0.46 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.537 1.135 . . . . 0.0 111.478 -178.197 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.9 pt -137.48 119.46 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 C-N-CA 125.851 1.66 . . . . 0.0 106.863 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 77.11 -72.58 2.08 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 107.04 -2.424 . . . . 0.0 107.04 -175.143 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -79.69 70.62 6.23 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 104.697 -2.335 . . . . 0.0 104.697 171.151 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -122.08 -166.95 1.47 Allowed 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.024 1.729 . . . . 0.0 111.829 -178.017 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.486 8.1 p 64.64 -114.0 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 116.687 2.106 . . . . 0.0 116.687 176.339 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.66 130.76 39.25 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 127.552 2.341 . . . . 0.0 111.467 -168.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.2 m -90.51 101.5 12.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 CA-C-N 118.882 0.765 . . . . 0.0 110.568 177.072 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.3 p -35.44 115.56 0.56 Allowed Pre-proline 0 CA--C 1.556 1.211 0 C-N-CA 125.831 1.652 . . . . 0.0 110.891 177.317 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -75.72 -30.45 6.16 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.832 2.354 . . . . 0.0 117.685 -171.01 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.49 148.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 120.513 1.506 . . . . 0.0 110.806 -176.764 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.8 m -79.27 138.81 37.91 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 171.539 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.62 -151.69 20.51 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -117.05 116.33 27.14 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.218 1.407 . . . . 0.0 108.435 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 7.5 mt -78.84 138.17 20.58 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 CA-C-N 118.666 0.666 . . . . 0.0 109.617 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -137.03 144.75 47.56 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 174.458 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -54.9 142.73 74.67 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 C-N-CA 121.967 1.778 . . . . 0.0 110.109 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.22 -36.44 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 124.646 1.178 . . . . 0.0 113.187 -177.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.2 p -51.38 -32.68 26.91 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.911 1.285 . . . . 0.0 112.559 178.185 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -75.94 -9.61 58.75 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 124.224 1.009 . . . . 0.0 112.505 -175.288 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 52.9 t -75.16 119.73 78.33 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-O 117.662 -1.161 . . . . 0.0 111.529 -176.374 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -59.34 53.94 0.07 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 1 C-N-CA 126.067 4.511 . . . . 0.0 117.071 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -167.69 112.03 0.67 Allowed 'General case' 0 N--CA 1.463 0.186 0 O-C-N 120.464 -1.398 . . . . 0.0 108.684 177.083 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -30.67 -51.46 0.15 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 127.609 2.363 . . . . 0.0 114.589 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.3 t -52.97 -47.33 53.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 CA-C-O 121.508 0.67 . . . . 0.0 110.05 -178.627 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -78.08 -46.95 19.41 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -50.38 -43.01 54.3 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.412 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -97.62 11.94 64.69 Favored Glycine 0 C--N 1.338 0.657 0 CA-C-O 118.909 -0.94 . . . . 0.0 111.499 -178.779 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? 70.13 -34.8 0.3 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.809 1.644 . . . . 0.0 114.032 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.412 ' H ' ' C ' ' A' ' 36' ' ' GLY . 1.6 tmt? 32.18 -69.27 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 131.286 3.834 . . . . 0.0 116.576 178.312 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 7.8 tpt -78.58 -19.99 51.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.185 0.994 . . . . 0.0 111.981 -175.918 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.15 -133.13 1.82 Allowed Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 44.9 t0 -136.45 158.56 44.14 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 172.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 176.19 -154.45 16.93 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.383 -0.913 . . . . 0.0 111.706 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 38.7 p90 -158.25 164.48 36.43 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 122.533 0.333 . . . . 0.0 110.2 178.72 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.45 146.3 28.3 Favored 'General case' 0 CA--C 1.508 -0.665 0 C-N-CA 123.742 0.817 . . . . 0.0 109.369 178.267 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 4.4 mp -124.93 128.19 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 102.635 -3.098 . . . . 0.0 102.635 169.131 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.3 tt -91.33 106.78 17.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 172.865 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -61.32 170.34 5.35 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 124.111 3.207 . . . . 0.0 116.166 -171.074 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.5 p -152.29 -65.01 0.17 Allowed 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 125.089 1.356 . . . . 0.0 107.876 176.361 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -61.85 127.61 32.25 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.47 0.708 . . . . 0.0 110.188 176.812 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.83 43.95 2.9 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 172.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -145.36 124.35 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 127.381 2.273 . . . . 0.0 105.138 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 89.9 t -123.53 126.49 73.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.03 155.04 9.0 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 C-N-CA 123.716 0.807 . . . . 0.0 110.268 178.7 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.79 139.31 95.5 Favored Pre-proline 0 N--CA 1.449 -0.519 0 C-N-CA 123.585 0.754 . . . . 0.0 110.192 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -78.28 -21.91 10.08 Favored 'Trans proline' 0 N--CA 1.453 -0.885 0 C-N-CA 123.51 2.807 . . . . 0.0 114.221 -177.299 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.7 m -138.92 166.61 22.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.163 0 C-N-CA 124.325 1.05 . . . . 0.0 111.007 -177.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -78.81 115.96 18.83 Favored 'General case' 0 C--O 1.234 0.253 1 N-CA-C 99.376 -4.305 . . . . 0.0 99.376 168.338 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.32 176.6 47.89 Favored Glycine 0 N--CA 1.441 -1.015 0 C-N-CA 115.606 -3.188 . . . . 0.0 117.015 -168.839 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 123.72 30.54 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.769 1.628 . . . . 0.0 108.505 178.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 16.7 mm -75.45 95.77 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 172.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 49.9 tp -72.41 -51.27 21.13 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -171.05 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -171.19 137.06 1.1 Allowed 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 118.472 0.578 . . . . 0.0 111.423 177.323 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -128.15 123.9 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 103.761 -2.681 . . . . 0.0 103.761 172.433 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.33 156.61 0.48 Allowed Pre-proline 0 CA--C 1.54 0.578 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -178.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -50.05 -29.71 22.63 Favored 'Trans proline' 0 C--N 1.348 0.517 0 C-N-CA 123.924 3.083 . . . . 0.0 114.562 178.265 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.6 p -77.56 -9.04 58.7 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.511 1.124 . . . . 0.0 111.64 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.22 8.43 3.36 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 127.835 2.454 . . . . 0.0 113.202 -178.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -80.88 -27.76 36.22 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -160.68 -176.35 5.5 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 119.204 0.911 . . . . 0.0 111.677 -174.111 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.898 18.3 mm 129.0 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.184 1 C-N-CA 131.846 4.058 . . . . 0.0 111.355 176.485 . . . . . . . . 3 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -147.36 168.23 28.44 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 116.6 1.4 . . . . 0.0 116.6 -173.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -132.49 169.15 16.98 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 126.349 1.86 . . . . 0.0 108.619 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.11 144.71 38.82 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 175.847 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 89.2 p -81.5 -112.67 0.02 OUTLIER 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 176.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -148.72 -55.94 0.2 Allowed 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 128.248 2.619 . . . . 0.0 106.689 177.024 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -75.52 62.31 2.73 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 124.113 0.863 . . . . 0.0 111.5 177.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 72.34 -54.05 1.51 Allowed Glycine 0 CA--C 1.532 1.126 0 N-CA-C 115.585 0.994 . . . . 0.0 115.585 175.739 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 -39.53 121.52 1.22 Allowed 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.696 1.199 . . . . 0.0 113.656 -174.595 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -111.55 148.3 33.53 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.283 2.233 . . . . 0.0 107.107 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.38 144.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 124.269 1.028 . . . . 0.0 109.66 -176.585 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -125.62 132.58 52.46 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 128.159 2.583 . . . . 0.0 105.439 176.693 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 39.0 mt -131.98 141.9 44.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 C-N-CA 124.798 1.239 . . . . 0.0 109.715 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -132.55 104.96 6.94 Favored 'General case' 0 C--O 1.226 -0.178 0 C-N-CA 124.335 1.054 . . . . 0.0 108.475 174.648 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.7 t80 -68.35 109.65 3.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 121.109 -0.995 . . . . 0.0 109.092 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.67 -165.82 7.79 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -176.785 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 31.4 mt -122.29 136.5 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.7 t0 55.48 42.61 29.69 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.555 1.142 . . . . 0.0 112.645 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.435 ' O ' ' N ' ' A' ' 90' ' ' SER . 1.8 p -80.19 -85.22 0.09 Allowed 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 103.093 -2.929 . . . . 0.0 103.093 172.215 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 12.1 p 26.43 -64.82 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 C-N-CA 128.883 2.873 . . . . 0.0 117.293 173.441 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 88' ' ' THR . 11.8 m -60.44 -36.83 79.13 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 126.624 1.97 . . . . 0.0 109.675 178.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -50.9 -36.71 39.65 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 128.216 2.606 . . . . 0.0 109.617 176.343 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp 70.49 151.75 0.1 Allowed 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 126.303 1.841 . . . . 0.0 109.673 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -65.91 25.99 0.15 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 115.153 0.821 . . . . 0.0 115.153 -178.315 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 20.5 mm-40 -59.21 -35.16 73.13 Favored 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.689 1.744 . . . . 0.0 112.085 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -98.02 15.26 61.81 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.764 178.23 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -123.31 96.57 5.04 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 118.884 1.342 . . . . 0.0 109.545 -176.716 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.7 m -81.52 111.77 18.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 173.251 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.8 p -86.11 138.53 31.85 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.563 -0.711 . . . . 0.0 111.279 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . 0.41 ' CE1' ' HG3' ' A' ' 114' ' ' GLU . 35.8 m-85 -107.51 7.16 28.68 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 125.57 1.548 . . . . 0.0 113.389 -177.21 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 20.5 m -140.42 144.37 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 175.808 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.7 m -79.51 -15.77 57.16 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.175 0.99 . . . . 0.0 112.772 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.442 16.1 pm0 69.03 147.46 0.06 Allowed 'General case' 0 N--CA 1.446 -0.671 0 C-N-CA 130.065 3.346 . . . . 0.0 111.209 -173.214 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 95.22 -21.78 42.25 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 124.709 1.147 . . . . 0.0 110.466 -172.84 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -60.63 124.57 20.78 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.919 1.688 . . . . 0.0 108.914 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.33 123.64 31.8 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 129.162 2.985 . . . . 0.0 113.308 -174.571 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.373 28.5 m 52.23 69.89 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.142 0 N-CA-C 117.018 2.229 . . . . 0.0 117.018 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.35 139.85 27.36 Favored Pre-proline 0 N--CA 1.45 -0.455 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 168.767 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -88.19 -151.25 0.04 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 123.686 2.924 . . . . 0.0 108.544 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -69.68 54.36 0.71 Allowed Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.908 1.242 . . . . 0.0 113.924 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -54.22 -55.07 31.57 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 124.97 1.308 . . . . 0.0 110.037 177.314 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt 144.87 125.67 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.621 1 C-N-CA 132.615 4.366 . . . . 0.0 106.098 -175.591 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 69.9 mt -91.83 -45.51 8.35 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 123.652 0.781 . . . . 0.0 109.385 178.182 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.2 mt -147.52 151.87 37.07 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 122.798 0.439 . . . . 0.0 111.101 -174.881 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . 0.41 ' HG3' ' CE1' ' A' ' 99' ' ' PHE . 99.1 mt-10 -116.31 127.21 54.49 Favored 'General case' 0 CA--C 1.517 -0.291 1 N-CA-C 98.557 -4.608 . . . . 0.0 98.557 165.796 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.23 126.34 45.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.721 -166.357 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -74.75 61.03 0.96 Allowed 'General case' 0 C--O 1.233 0.224 0 C-N-CA 125.259 1.423 . . . . 0.0 111.239 -176.765 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.5 mt -45.94 -41.82 12.08 Favored 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 124.326 1.05 . . . . 0.0 111.94 -178.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -49.15 -41.4 36.17 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.622 0.769 . . . . 0.0 112.501 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -92.57 -33.77 14.3 Favored 'General case' 0 CA--C 1.527 0.066 0 C-N-CA 123.467 0.707 . . . . 0.0 111.353 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.26 -51.95 64.77 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.617 -0.677 . . . . 0.0 109.468 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.368 46.1 pttt -41.87 -58.07 3.58 Favored Pre-proline 0 CA--C 1.541 0.599 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -177.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -57.18 -19.8 35.56 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.435 2.09 . . . . 0.0 113.327 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -95.49 7.98 44.63 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 118.097 -0.954 . . . . 0.0 112.488 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 23.9 m -132.91 150.51 75.87 Favored Pre-proline 0 N--CA 1.466 0.333 0 CA-C-N 120.086 1.312 . . . . 0.0 111.506 179.643 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -73.78 -27.41 12.52 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 C-N-CA 122.867 2.378 . . . . 0.0 111.635 179.243 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -157.42 132.01 8.56 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.598 -0.689 . . . . 0.0 109.926 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -90.35 -2.06 57.96 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.712 1.205 . . . . 0.0 111.769 -179.019 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.6 mmt -49.65 111.26 0.48 Allowed 'General case' 0 C--N 1.34 0.194 0 C-N-CA 124.399 1.08 . . . . 0.0 109.353 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 49.9 m -102.73 110.14 62.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 -178.432 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -91.33 137.62 2.1 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 122.843 2.362 . . . . 0.0 110.538 -179.201 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 15.3 mm -114.46 121.17 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 102.893 -3.003 . . . . 0.0 102.893 173.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.1 t -126.43 149.11 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -177.393 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -123.1 124.99 44.34 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 36.1 p -83.58 -67.76 0.76 Allowed 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.771 0.796 . . . . 0.0 110.638 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.8 p30 -72.0 51.7 0.23 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.99 1.716 . . . . 0.0 113.587 -177.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 78.2 mt -80.49 54.31 2.03 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.393 1.077 . . . . 0.0 108.961 175.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 16.33 55.67 0.01 OUTLIER 'General case' 0 C--N 1.346 0.438 0 C-N-CA 129.59 3.156 . . . . 0.0 113.403 -177.938 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 27.56 56.47 0.08 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 127.715 2.406 . . . . 0.0 113.829 -175.465 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 165.68 -10.83 0.07 OUTLIER Glycine 0 CA--C 1.526 0.758 0 CA-C-O 119.321 -0.71 . . . . 0.0 113.638 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . 0.52 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 16.2 mt-10 -78.73 82.07 4.98 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.752 1.276 . . . . 0.0 107.932 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.7 p -74.3 138.49 43.59 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.404 -0.81 . . . . 0.0 109.93 -175.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -83.65 122.29 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 123.66 0.784 . . . . 0.0 109.234 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.6 m -112.75 97.82 6.81 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.867 1.267 . . . . 0.0 109.178 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.2 pt -71.08 108.37 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 176.503 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -77.08 -55.47 5.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -82.88 66.08 8.32 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 49.2 m -77.6 69.72 3.88 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.81 -150.16 7.62 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 107.105 -2.398 . . . . 0.0 107.105 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 10.4 t -75.64 146.08 40.56 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 118.297 1.048 . . . . 0.0 110.556 178.316 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -143.71 167.3 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 124.555 1.142 . . . . 0.0 109.777 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 35.2 m-80 -113.69 163.75 14.59 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 125.236 1.414 . . . . 0.0 107.647 174.557 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.94 165.35 25.4 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 170.637 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 56.88 48.42 15.99 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.565 1.146 . . . . 0.0 111.862 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -121.96 159.18 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 173.83 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -126.46 153.66 44.77 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 119.228 0.922 . . . . 0.0 111.188 -176.687 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.7 t70 62.95 13.65 6.83 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 126.702 2.001 . . . . 0.0 113.191 -176.554 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.54 -37.85 78.79 Favored 'Isoleucine or valine' 0 C--O 1.233 0.207 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.7 p -117.88 129.29 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 N-CA-C 103.486 -2.783 . . . . 0.0 103.486 168.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -122.81 123.73 41.7 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . 0.52 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.26 130.61 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 174.584 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -130.97 139.25 50.0 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.221 1.408 . . . . 0.0 107.269 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.3 tptm . . . . . 0 C--N 1.331 -0.215 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 -177.795 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.2 mtt . . . . . 0 N--CA 1.453 -0.303 0 CA-C-O 120.652 0.263 . . . . 0.0 110.675 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 23.2 mt -78.17 65.31 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.68 -35.19 18.12 Favored 'General case' 0 C--O 1.223 -0.332 0 C-N-CA 124.974 1.31 . . . . 0.0 111.92 -177.431 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 51.58 72.29 1.25 Allowed Pre-proline 0 CA--C 1.543 0.69 0 C-N-CA 124.507 1.123 . . . . 0.0 112.331 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -55.19 127.37 26.02 Favored 'Trans proline' 0 N--CA 1.455 -0.771 0 C-N-CA 123.288 2.659 . . . . 0.0 111.609 179.567 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 21.9 tp -69.49 70.96 0.29 Allowed 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.434 1.494 . . . . 0.0 111.088 -178.045 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 57.51 15.94 3.04 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.762 2.025 . . . . 0.0 114.058 178.383 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.2 t-20 -165.72 156.32 13.29 Favored 'General case' 0 N--CA 1.454 -0.263 0 O-C-N 121.374 -0.829 . . . . 0.0 108.935 177.669 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -160.84 -43.23 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 128.107 2.563 . . . . 0.0 107.142 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 79.0 mt -50.74 102.53 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 126.918 2.087 . . . . 0.0 106.724 175.406 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 171.09 -52.43 0.19 Allowed Glycine 0 CA--C 1.524 0.631 0 N-CA-C 106.104 -2.798 . . . . 0.0 106.104 -176.342 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 41.17 46.95 2.75 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 126.105 1.762 . . . . 0.0 113.408 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -68.97 153.42 43.82 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.819 1.647 . . . . 0.0 110.673 176.924 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.4 m -63.99 66.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.133 0 N-CA-C 117.776 2.51 . . . . 0.0 117.776 -175.058 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -135.43 105.82 6.4 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 105.6 -2.0 . . . . 0.0 105.6 171.482 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.32 91.3 2.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.269 0 CA-C-N 118.991 0.814 . . . . 0.0 112.352 -176.901 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.6 t -21.95 111.34 0.14 Allowed Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 126.373 1.869 . . . . 0.0 112.282 176.602 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -74.11 -28.58 10.74 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.181 2.587 . . . . 0.0 118.338 -169.716 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.64 153.31 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 120.339 1.427 . . . . 0.0 110.496 -176.722 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 92.1 m -88.32 125.38 34.65 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 172.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 179.72 -170.43 41.74 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -176.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -98.63 133.93 42.27 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 11.2 tt -81.94 146.22 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 123.111 0.564 . . . . 0.0 111.148 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -144.8 137.35 13.49 Favored Pre-proline 0 C--O 1.237 0.397 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -59.58 146.18 95.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.094 1.863 . . . . 0.0 111.452 178.509 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.9 tp -50.04 -36.93 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 C-N-CA 125.176 1.39 . . . . 0.0 112.062 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 p -70.27 -12.08 61.34 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.034 1.734 . . . . 0.0 114.195 -179.436 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -112.79 29.12 8.22 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.897 0.772 . . . . 0.0 111.636 -173.537 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.3 t -94.08 135.11 24.95 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 124.327 1.051 . . . . 0.0 109.564 178.605 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -65.5 50.82 0.24 Allowed 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 124.216 3.277 . . . . 0.0 115.054 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -166.77 133.89 2.49 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 120.489 -1.382 . . . . 0.0 109.815 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -59.8 -47.51 85.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.873 1.269 . . . . 0.0 113.109 -177.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 55.0 t -55.07 -54.97 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 118.596 0.634 . . . . 0.0 109.389 -178.61 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -61.38 -58.68 7.25 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.973 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 59.0 m -69.47 -16.0 63.38 Favored 'General case' 0 N--CA 1.461 0.082 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -177.292 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.433 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -88.91 -0.1 81.62 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 108.44 -1.864 . . . . 0.0 108.44 173.975 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 57.5 mttp 74.16 -39.88 0.44 Allowed 'General case' 0 C--N 1.346 0.438 0 C-N-CA 126.498 1.919 . . . . 0.0 111.56 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.433 ' H ' ' C ' ' A' ' 36' ' ' GLY . 14.9 tpt 28.9 -76.74 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 130.436 3.494 . . . . 0.0 116.461 178.263 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 11.0 ttt -79.24 -17.57 54.52 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.741 0.816 . . . . 0.0 113.059 -175.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.44 -135.28 2.83 Favored Glycine 0 C--N 1.338 0.643 0 CA-C-N 119.128 0.877 . . . . 0.0 112.382 -176.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -137.23 157.84 45.75 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.53 -157.77 19.15 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.764 -175.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -158.74 158.81 34.36 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.773 1.229 . . . . 0.0 108.203 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.23 132.96 52.49 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-N 118.836 0.744 . . . . 0.0 110.418 177.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 22.6 mm -117.35 107.25 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 173.896 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 11.9 tp -74.79 119.06 74.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 N-CA-C 102.329 -3.212 . . . . 0.0 102.329 172.067 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.04 153.38 22.04 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 123.095 2.53 . . . . 0.0 113.721 -168.98 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 79.2 p -126.18 -45.78 1.68 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.651 0.78 . . . . 0.0 112.242 178.929 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -64.43 -42.27 96.11 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.833 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.58 25.34 70.32 Favored Glycine 0 CA--C 1.533 1.188 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -173.012 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 54.0 mt -136.5 123.59 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 102.496 -3.149 . . . . 0.0 102.496 177.042 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 79.1 t -124.49 124.66 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 C-N-CA 124.397 1.079 . . . . 0.0 109.945 -171.752 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -107.12 155.8 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.126 0 C-N-CA 123.715 0.806 . . . . 0.0 109.493 176.743 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -61.82 139.63 95.52 Favored Pre-proline 0 N--CA 1.448 -0.551 0 C-N-CA 123.624 0.77 . . . . 0.0 110.544 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -75.31 -13.01 20.9 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 124.307 3.338 . . . . 0.0 115.03 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -148.11 161.65 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.056 0 CA-C-N 119.443 1.02 . . . . 0.0 110.213 -176.651 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 116.99 19.6 Favored 'General case' 0 C--O 1.237 0.402 1 N-CA-C 100.103 -4.036 . . . . 0.0 100.103 167.653 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 173.27 -177.34 45.73 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 115.544 -3.217 . . . . 0.0 116.428 -168.451 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.15 122.04 28.78 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.161 0.984 . . . . 0.0 112.512 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.4 mm -66.2 125.59 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 N-CA-C 103.058 -2.942 . . . . 0.0 103.058 168.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 40.7 tp -78.39 -40.75 35.23 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 119.643 1.111 . . . . 0.0 109.213 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -175.43 -163.75 0.13 Allowed 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.412 ' HA ' ' CG2' ' A' ' 70' ' ' ILE . 7.3 p -160.51 125.42 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 172.446 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.3 m-85 -68.0 145.1 97.61 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 119.291 0.951 . . . . 0.0 110.361 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -50.6 -29.27 24.59 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 123.484 2.789 . . . . 0.0 113.532 176.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.1 p -77.3 -7.91 56.76 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.756 0.822 . . . . 0.0 111.956 -178.92 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.8 ttmt 64.06 -11.18 0.12 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.828 1.651 . . . . 0.0 114.914 177.618 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 9.3 p-80 -74.72 -29.4 61.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 121.665 -0.647 . . . . 0.0 112.688 -175.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.46 176.8 11.62 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-N 118.893 0.77 . . . . 0.0 110.368 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . 0.541 ' CG1' ' H ' ' A' ' 71' ' ' GLY . 0.1 OUTLIER 157.31 -148.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.355 0 C-N-CA 130.492 3.517 . . . . 0.0 106.056 176.318 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . 0.541 ' H ' ' CG1' ' A' ' 70' ' ' ILE . . . -152.51 174.21 31.44 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 123.477 0.561 . . . . 0.0 111.804 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -141.19 176.78 8.56 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 126.486 1.914 . . . . 0.0 108.045 -178.128 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 30.5 mt-30 -143.08 156.02 44.73 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 103.634 -2.728 . . . . 0.0 103.634 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 69.6 p -78.26 -117.46 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -71.1 -51.04 27.36 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.366 -0.834 . . . . 0.0 108.79 177.107 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -171.73 46.27 0.18 Allowed Glycine 0 CA--C 1.528 0.874 0 N-CA-C 109.006 -1.637 . . . . 0.0 109.006 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 179.93 179.12 48.79 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 107.031 -2.428 . . . . 0.0 107.031 -178.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 69.0 mtm180 55.94 65.91 1.33 Allowed 'General case' 0 C--N 1.337 0.031 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -175.65 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -73.45 119.77 18.14 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.7 mp -98.38 149.97 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 125.432 1.493 . . . . 0.0 108.574 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.6 tp -128.88 136.05 49.91 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 127.745 2.418 . . . . 0.0 104.849 176.087 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 46.0 mt -129.93 136.2 59.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -129.74 84.71 2.23 Favored 'General case' 0 N--CA 1.466 0.335 0 C-N-CA 123.481 0.712 . . . . 0.0 110.619 176.993 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -56.67 98.94 0.03 OUTLIER 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.528 0.731 . . . . 0.0 111.303 -179.241 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.75 -177.16 5.17 Favored Glycine 0 CA--C 1.531 1.059 0 C-N-CA 124.092 0.853 . . . . 0.0 112.463 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.1 mt -121.73 140.23 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 69.82 9.4 7.13 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.384 1.474 . . . . 0.0 112.313 -177.428 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -75.6 -34.41 60.62 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 126.358 1.863 . . . . 0.0 108.156 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.5 p -54.32 -46.79 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 CA-C-N 113.468 -1.696 . . . . 0.0 108.028 171.653 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -62.05 -39.21 91.57 Favored 'General case' 0 N--CA 1.455 -0.198 0 C-N-CA 124.491 1.116 . . . . 0.0 109.425 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.99 3.17 5.67 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.934 1.694 . . . . 0.0 111.322 177.14 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 48.13 32.48 3.02 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 126.068 1.747 . . . . 0.0 112.993 178.141 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.74 28.29 60.07 Favored Glycine 0 CA--C 1.535 1.323 0 O-C-N 122.009 -0.432 . . . . 0.0 112.828 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 51.9 mt-10 -72.4 91.04 1.33 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.963 1.381 . . . . 0.0 108.843 178.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 6.12 4.24 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 126.745 2.117 . . . . 0.0 111.391 -176.877 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.416 ' CD1' HG11 ' A' ' 115' ' ' VAL . 14.6 m-30 -103.27 131.12 50.57 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.187 1.395 . . . . 0.0 108.477 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 14.3 m -119.98 122.79 41.95 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 126.245 1.818 . . . . 0.0 107.159 -179.315 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.1 p -99.32 124.63 44.57 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.612 0.765 . . . . 0.0 109.957 -176.372 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -90.59 -48.81 6.85 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.566 1.546 . . . . 0.0 111.294 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.418 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.4 m -73.43 130.76 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 C-N-CA 117.149 -1.82 . . . . 0.0 107.283 175.666 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 71.1 m -94.51 55.1 1.9 Allowed 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 102.743 -3.058 . . . . 0.0 102.743 168.693 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.418 ' H ' ' C ' ' A' ' 100' ' ' VAL 0.588 0.4 OUTLIER 43.58 -77.63 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.774 0 C-N-CA 130.627 3.571 . . . . 0.0 113.465 -167.57 . . . . . . . . 4 4 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.4 35.6 36.2 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 125.108 1.337 . . . . 0.0 110.45 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.373 4.1 p30 4.38 -106.6 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 130.049 3.34 . . . . 0.0 119.313 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -33.62 111.94 0.12 Allowed 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 130.993 3.717 . . . . 0.0 119.047 -169.234 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.363 27.4 m 48.61 68.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 129.08 2.952 . . . . 0.0 118.036 173.487 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 139.22 27.48 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 167.797 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -90.37 -145.04 0.03 OUTLIER 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.56 2.84 . . . . 0.0 108.302 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -70.81 52.05 0.92 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 124.875 1.226 . . . . 0.0 113.885 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.7 tp60 -61.83 -22.25 65.34 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 125.858 1.663 . . . . 0.0 113.707 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt 108.1 111.84 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 130.103 3.361 . . . . 0.0 107.971 -176.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 73.5 mt -80.25 -53.2 6.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 23.0 mt -143.04 163.94 31.44 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 123.743 0.817 . . . . 0.0 111.721 -174.728 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -128.19 135.33 49.58 Favored 'General case' 0 CA--C 1.515 -0.4 1 N-CA-C 99.81 -4.145 . . . . 0.0 99.81 166.707 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.416 HG11 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -144.92 121.28 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -166.303 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -70.53 64.98 0.29 Allowed 'General case' 0 C--O 1.234 0.246 0 C-N-CA 125.569 1.548 . . . . 0.0 113.019 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 88.5 mt -40.81 -54.27 2.7 Favored 'General case' 0 C--O 1.226 -0.165 0 C-N-CA 124.91 1.284 . . . . 0.0 111.909 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -49.81 -41.36 44.57 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.485 1.114 . . . . 0.0 113.879 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.43 -35.01 15.4 Favored 'General case' 0 C--O 1.23 0.056 0 C-N-CA 122.454 0.302 . . . . 0.0 111.496 -177.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.9 t -67.21 -50.61 61.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 O-C-N 121.764 -0.585 . . . . 0.0 109.529 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.347 48.5 pttt -40.11 -57.78 2.61 Favored Pre-proline 0 CA--C 1.539 0.55 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.91 -21.85 43.06 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 122.509 2.139 . . . . 0.0 113.132 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -97.43 6.89 47.51 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 118.387 -0.816 . . . . 0.0 112.655 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 30.2 m -136.49 151.14 72.39 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-N 119.898 1.226 . . . . 0.0 110.262 178.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.79 -25.16 12.59 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.535 2.157 . . . . 0.0 112.206 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.9 m -158.24 128.09 5.95 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 119.038 0.835 . . . . 0.0 111.27 -177.764 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.32 -0.23 57.31 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.823 1.249 . . . . 0.0 110.72 176.708 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 82.6 mmm -50.37 103.0 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 126.221 1.808 . . . . 0.0 109.754 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 68.6 m -99.09 117.39 64.27 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 123.814 0.845 . . . . 0.0 109.091 -177.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.56 139.49 1.87 Allowed 'Trans proline' 0 N--CA 1.442 -1.556 0 C-N-CA 123.211 2.607 . . . . 0.0 108.914 178.749 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mp -113.08 117.82 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 N-CA-C 100.523 -3.88 . . . . 0.0 100.523 171.469 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -126.01 158.13 35.55 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 32.5 m-85 -134.1 137.49 44.62 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 103.751 -2.685 . . . . 0.0 103.751 -176.534 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -92.46 -73.41 0.55 Allowed 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 119.223 0.92 . . . . 0.0 109.216 -179.195 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -75.96 68.79 2.5 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 2.9 mm? -78.6 66.0 4.01 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 171.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 31.46 47.45 0.06 Allowed 'General case' 0 C--N 1.343 0.299 0 C-N-CA 127.831 2.452 . . . . 0.0 111.717 -173.813 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 29.61 61.22 0.16 Allowed 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 128.243 2.617 . . . . 0.0 114.343 -177.464 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.38 -14.78 0.22 Allowed Glycine 0 CA--C 1.525 0.668 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.968 177.773 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . 0.524 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 44.2 mm-40 -80.4 123.66 28.22 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.201 1.001 . . . . 0.0 109.638 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.2 p -89.78 143.28 26.93 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.925 0.89 . . . . 0.0 109.257 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -89.94 113.23 25.8 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 C-N-CA 123.664 0.786 . . . . 0.0 109.874 -178.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 36.2 m -106.74 98.85 8.47 Favored 'General case' 0 C--N 1.34 0.178 0 C-N-CA 124.333 1.053 . . . . 0.0 110.576 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 3.2 pt -64.07 128.74 26.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 175.325 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -98.09 -34.71 10.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.064 0.946 . . . . 0.0 112.223 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -70.98 100.72 2.03 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 119.773 1.169 . . . . 0.0 109.915 178.257 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 1.2 m -79.49 51.26 1.22 Allowed 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.174 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 176.2 -145.76 7.7 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -175.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 47.1 t -73.92 132.49 42.52 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 122.203 -0.586 . . . . 0.0 111.216 -178.792 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 18.4 m -89.7 157.15 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 174.493 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.78 152.44 49.27 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 179.345 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.5 mtp180 -58.29 150.07 22.82 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 122.685 0.394 . . . . 0.0 111.603 177.634 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 63.03 1.73 0.91 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 126.412 1.885 . . . . 0.0 115.339 172.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 58.9 mm-40 -70.13 119.32 14.15 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 119.569 1.077 . . . . 0.0 108.635 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -81.99 125.86 31.28 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 121.369 0.604 . . . . 0.0 112.242 -176.355 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.9 t0 70.08 27.9 4.19 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 128.472 2.709 . . . . 0.0 115.459 175.188 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.26 1.7 mp -71.27 -8.89 12.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 CA-C-O 121.306 0.575 . . . . 0.0 110.264 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.7 p -122.39 120.15 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 102.75 -3.056 . . . . 0.0 102.75 168.385 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 5.5 mtpm? -108.13 128.42 54.68 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . 0.524 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.45 133.14 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.729 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -145.08 -174.87 4.48 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 125.078 1.351 . . . . 0.0 108.716 -177.912 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 49.3 mtmt . . . . . 0 C--O 1.233 0.201 0 C-N-CA 125.307 1.443 . . . . 0.0 107.31 174.981 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.482 ' H1 ' ' HB2' ' A' ' 107' ' ' GLU . 42.3 ttp . . . . . 0 N--CA 1.455 -0.202 0 N-CA-C 111.366 0.136 . . . . 0.0 111.366 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 24.8 mt -76.55 66.12 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 C-N-CA 123.751 0.82 . . . . 0.0 108.901 -179.022 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.37 60.45 2.02 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 123.691 0.797 . . . . 0.0 109.583 178.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 57.8 tt0 -151.97 130.75 6.42 Favored Pre-proline 0 CA--C 1.533 0.3 0 C-N-CA 124.126 0.97 . . . . 0.0 108.514 -178.738 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -74.43 81.92 1.97 Allowed 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 122.532 2.155 . . . . 0.0 109.359 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 57.1 mt -66.65 69.85 0.07 Allowed 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.565 1.146 . . . . 0.0 112.389 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -76.59 62.18 1.89 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.613 1.565 . . . . 0.0 108.988 176.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -77.17 168.4 20.12 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.576 1.55 . . . . 0.0 110.252 -178.375 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -76.36 -52.41 9.96 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 124.093 0.957 . . . . 0.0 110.932 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.5 tt -166.4 147.76 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 -178.658 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 119.43 -100.71 0.81 Allowed Glycine 0 CA--C 1.522 0.493 0 N-CA-C 108.071 -2.011 . . . . 0.0 108.071 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -88.0 133.3 33.98 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 175.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -145.54 -140.79 0.11 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.408 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.0 t -55.51 -52.77 43.4 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.105 0 C-N-CA 124.849 1.259 . . . . 0.0 113.724 -177.576 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -79.25 128.96 33.97 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.9 m -125.44 84.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-N 118.61 0.641 . . . . 0.0 112.65 -176.159 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 21.9 t -19.86 122.01 0.09 OUTLIER Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 129.373 3.069 . . . . 0.0 112.553 177.524 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -71.48 -37.35 5.65 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 117.632 2.128 . . . . 0.0 117.632 -171.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.3 151.64 18.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 119.717 1.144 . . . . 0.0 111.387 -175.109 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.1 m -88.46 146.38 25.24 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.42 -128.6 2.17 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -127.57 138.64 52.94 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.007 1.323 . . . . 0.0 108.141 178.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.8 tt -106.51 139.71 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 16.6 m-70 -136.94 155.55 76.27 Favored Pre-proline 0 N--CA 1.453 -0.315 0 C-N-CA 125.628 1.571 . . . . 0.0 108.329 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 146.08 84.25 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 N-CA-C 107.916 -1.609 . . . . 0.0 107.916 172.534 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -56.79 -21.31 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.534 -1.666 . . . . 0.0 113.119 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.0 p -53.42 -32.51 50.03 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.562 0.745 . . . . 0.0 111.124 175.074 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -77.11 -6.1 51.55 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.903 0.881 . . . . 0.0 113.075 -175.083 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.3 t -77.84 132.6 67.53 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 119.228 0.922 . . . . 0.0 110.171 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -77.32 58.12 6.14 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 123.692 2.928 . . . . 0.0 111.176 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -168.83 110.25 0.51 Allowed 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 20.0 mp0 -37.42 -44.8 0.66 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 127.486 2.314 . . . . 0.0 113.553 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 95.4 t -50.26 -43.82 22.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 123.414 0.686 . . . . 0.0 110.16 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -87.3 -48.99 7.55 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.757 0.823 . . . . 0.0 109.52 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.12 -40.99 34.52 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.03 13.93 60.22 Favored Glycine 0 C--N 1.338 0.676 0 CA-C-O 118.938 -0.923 . . . . 0.0 111.853 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 37.1 mttp 70.31 -34.05 0.28 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.757 1.623 . . . . 0.0 114.584 179.106 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.5 ttm 24.38 -61.6 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 1 C-N-CA 132.029 4.131 . . . . 0.0 118.203 178.319 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.11 -22.72 48.47 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.944 0.898 . . . . 0.0 111.59 -177.276 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.02 -128.89 1.3 Allowed Glycine 0 C--N 1.336 0.535 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 40.0 t0 -131.4 159.25 38.53 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 171.321 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.4 -166.18 34.25 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.016 -1.088 . . . . 0.0 113.461 -176.872 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 p90 -144.38 160.92 40.23 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 124.534 1.134 . . . . 0.0 109.714 178.553 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -105.95 118.46 36.67 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.525 1.53 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.6 mm -98.46 130.3 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 172.675 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 tt -101.11 108.01 52.69 Favored Pre-proline 0 N--CA 1.448 -0.541 1 N-CA-C 99.604 -4.221 . . . . 0.0 99.604 170.105 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -85.91 148.49 9.5 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 122.617 2.211 . . . . 0.0 114.958 -168.118 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.5 p -113.51 -51.24 2.81 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.974 1.31 . . . . 0.0 108.685 174.498 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -73.56 122.4 22.17 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.515 0.326 . . . . 0.0 111.328 179.215 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.22 41.07 2.6 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 173.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 81.0 mt -136.22 113.78 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 103.413 -2.81 . . . . 0.0 103.413 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.2 t -119.54 119.62 61.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 C-N-CA 123.769 0.828 . . . . 0.0 109.87 -172.657 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.3 m -99.87 164.7 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 CA-C-O 121.159 0.504 . . . . 0.0 109.935 176.802 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.5 m -76.46 131.93 73.66 Favored Pre-proline 0 N--CA 1.45 -0.444 0 CA-C-O 117.576 -1.202 . . . . 0.0 108.423 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -60.96 -31.79 91.79 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.002 2.468 . . . . 0.0 110.783 177.469 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 10.8 m -151.11 150.09 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 102.925 -2.991 . . . . 0.0 102.925 173.389 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.0 tpt180 -101.25 -93.74 0.29 Allowed 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 101.176 -3.638 . . . . 0.0 101.176 169.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.75 2.5 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 107.405 -2.278 . . . . 0.0 107.405 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 125.23 1.91 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 167.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.5 mm -62.92 128.62 25.16 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 169.909 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.05 -49.04 11.38 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 178.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -175.88 151.15 1.08 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.434 0.294 . . . . 0.0 111.361 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.5 m -113.17 126.23 70.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 169.53 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 5.7 m-85 -65.73 156.63 82.51 Favored Pre-proline 0 CA--C 1.534 0.333 0 O-C-N 121.426 -0.796 . . . . 0.0 110.03 -176.621 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -48.44 -43.4 32.84 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.114 2.543 . . . . 0.0 112.952 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.0 p -79.57 3.87 17.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.842 1.257 . . . . 0.0 112.761 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.18 -21.9 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 128.525 2.73 . . . . 0.0 116.84 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.409 ' HE2' ' CD2' ' A' ' 83' ' ' HIS . 0.0 OUTLIER -63.87 -31.54 72.75 Favored 'General case' 0 C--O 1.227 -0.103 0 CA-C-N 119.483 1.038 . . . . 0.0 111.884 -174.8 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . 0.401 ' HB3' ' CE1' ' A' ' 83' ' ' HIS . . . -103.6 135.67 44.74 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.091 0.956 . . . . 0.0 110.081 -179.365 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.9 mt -140.06 146.54 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -125.32 136.74 9.95 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 125.862 1.696 . . . . 0.0 109.076 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.8 mp -137.86 163.82 30.5 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 124.959 1.304 . . . . 0.0 110.409 -177.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 70.8 mt-30 -145.38 125.23 13.46 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 57.2 p -73.01 72.76 1.15 Allowed 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 175.443 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.4 t0 44.42 60.26 2.92 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.374 2.27 . . . . 0.0 110.183 -177.597 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 81.07 -11.67 41.39 Favored Glycine 0 CA--C 1.531 1.083 0 CA-C-N 114.722 -1.127 . . . . 0.0 114.024 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -78.36 -102.84 0.2 Allowed Glycine 0 CA--C 1.53 0.998 0 CA-C-N 119.076 1.438 . . . . 0.0 112.802 -177.756 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.25 116.96 19.06 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 -178.307 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -93.09 126.8 38.36 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 125.589 1.556 . . . . 0.0 106.932 177.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 5.8 mt -125.03 143.45 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.1 0.96 . . . . 0.0 111.205 -172.003 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -122.89 130.74 53.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.219 2.208 . . . . 0.0 105.413 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.5 mt -123.49 146.73 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 C-N-CA 124.767 1.227 . . . . 0.0 108.019 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . 0.409 ' CD2' ' HE2' ' A' ' 68' ' ' HIS . 0.2 OUTLIER -134.33 131.8 38.77 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 105.283 -2.117 . . . . 0.0 105.283 171.324 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -103.05 106.21 16.68 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 124.774 1.229 . . . . 0.0 107.879 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.1 -169.82 34.94 Favored Glycine 0 CA--C 1.534 1.229 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 29.3 mm -109.78 -84.42 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.05 0 CA-C-O 123.224 1.488 . . . . 0.0 110.469 -178.104 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.41 4.82 0.48 Allowed 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 126.432 1.893 . . . . 0.0 113.033 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.22 -30.24 71.11 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.438 1.895 . . . . 0.0 107.573 175.195 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.55 -46.98 89.75 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 CA-C-N 114.374 -1.285 . . . . 0.0 108.348 174.362 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.68 -41.02 98.21 Favored 'General case' 0 C--O 1.227 -0.112 0 C-N-CA 125.036 1.334 . . . . 0.0 109.017 177.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -65.05 -8.41 16.19 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 125.69 1.596 . . . . 0.0 110.943 176.727 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? 52.54 34.14 14.91 Favored 'General case' 0 C--N 1.343 0.315 0 C-N-CA 125.301 1.441 . . . . 0.0 111.823 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.18 21.07 61.33 Favored Glycine 0 CA--C 1.536 1.37 0 CA-C-O 119.67 -0.517 . . . . 0.0 112.875 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.84 90.18 1.1 Allowed 'General case' 0 C--N 1.341 0.227 0 CA-C-N 119.388 1.594 . . . . 0.0 108.625 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 141.83 -2.41 1.9 Allowed Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.484 1.992 . . . . 0.0 111.591 -175.144 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -97.86 103.53 15.47 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 125.57 1.548 . . . . 0.0 111.063 -176.758 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 50.0 m -84.36 98.15 9.87 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.636 -2.727 . . . . 0.0 103.636 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 43.0 p -79.59 121.37 25.18 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 121.793 -0.567 . . . . 0.0 109.983 -177.205 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -79.94 -52.82 7.38 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.524 1.13 . . . . 0.0 109.361 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 24.3 m -82.17 129.0 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.121 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.43 175.142 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 67.5 m -98.21 56.69 1.2 Allowed 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 102.397 -3.186 . . . . 0.0 102.397 169.105 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.312 7.8 pt-20 36.16 61.08 0.8 Allowed 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 111.09 -2.777 . . . . 0.0 110.734 -167.498 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.42 55.08 2.41 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 111.108 -2.769 . . . . 0.0 109.834 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.35 3.3 p30 1.81 -110.63 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 130.997 3.719 . . . . 0.0 118.566 -178.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 45.0 mmm-85 -44.94 142.46 1.81 Allowed 'General case' 0 N--CA 1.425 -1.698 1 N-CA-C 122.56 4.281 . . . . 0.0 122.56 -167.03 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.722 4.7 m 36.95 -55.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.428 2 N-CA-C 130.351 7.167 . . . . 0.0 130.351 173.971 . . . . . . . . 3 2 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . 0.482 ' HB2' ' H1 ' ' A' ' 1' ' ' MET . 0.8 OUTLIER -72.52 121.98 86.29 Favored Pre-proline 0 C--N 1.317 -0.831 0 C-N-CA 116.472 -2.091 . . . . 0.0 113.172 -165.083 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -69.84 172.31 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 125.021 3.814 . . . . 0.0 113.081 -169.12 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 55.81 19.51 21.67 Favored Glycine 0 CA--C 1.528 0.895 0 C-N-CA 124.582 1.087 . . . . 0.0 115.21 176.282 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -61.6 143.22 56.4 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 118.488 1.144 . . . . 0.0 109.328 177.775 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -69.96 119.61 14.43 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.2 mt -80.85 -51.43 8.61 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -143.28 155.17 44.41 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 -174.008 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -122.39 125.76 46.57 Favored 'General case' 0 CA--C 1.514 -0.425 1 N-CA-C 98.305 -4.702 . . . . 0.0 98.305 166.296 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.36 129.33 56.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 114.691 -1.141 . . . . 0.0 112.165 -165.711 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -73.22 67.95 0.98 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.798 0.839 . . . . 0.0 110.397 -179.209 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.8 mt -52.59 -41.56 63.73 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-O 119.301 -0.38 . . . . 0.0 110.583 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -49.45 -44.46 45.63 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 123.507 0.723 . . . . 0.0 112.272 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.59 -35.33 19.51 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 117.933 0.333 . . . . 0.0 111.841 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 53.9 t -64.59 -49.69 79.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 121.537 -0.727 . . . . 0.0 110.567 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.357 0.0 OUTLIER -47.48 -53.84 26.7 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 116.943 2.201 . . . . 0.0 116.943 -177.557 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -60.9 -25.64 81.71 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.231 1.954 . . . . 0.0 112.323 177.151 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -79.92 -50.15 10.87 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 118.651 0.66 . . . . 0.0 110.617 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 18.7 m -79.72 142.83 57.51 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.721 -177.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.33 -15.81 22.34 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.48 2.12 . . . . 0.0 111.717 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 16.6 m -156.76 128.41 7.13 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.07 0.948 . . . . 0.0 108.907 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.2 tp -94.73 9.91 37.1 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.403 1.481 . . . . 0.0 111.54 -178.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 74.1 mmm -53.42 118.75 4.09 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 34.0 m -113.94 86.96 11.89 Favored Pre-proline 0 N--CA 1.445 -0.678 0 C-N-CA 126.168 1.787 . . . . 0.0 107.752 -177.247 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 60.9 Cg_endo -83.25 149.72 13.41 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.814 1.676 . . . . 0.0 112.403 -178.435 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mp -122.13 130.3 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 103.494 -2.78 . . . . 0.0 103.494 174.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -126.56 143.55 39.67 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 C-N-CA 125.751 1.62 . . . . 0.0 106.93 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -117.15 123.56 47.02 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 64.7 p -83.96 -72.22 0.47 Allowed 'General case' 0 C--N 1.335 -0.06 0 CA-C-O 121.504 0.669 . . . . 0.0 111.046 -171.677 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p30 -71.7 52.63 0.22 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 126.091 1.756 . . . . 0.0 113.113 -178.325 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 38.8 mt -74.35 63.68 1.06 Allowed 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.324 1.45 . . . . 0.0 109.38 177.176 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 17.4 57.69 0.01 OUTLIER 'General case' 0 C--N 1.348 0.503 0 C-N-CA 129.509 3.124 . . . . 0.0 112.209 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 23.88 57.43 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.108 2.963 . . . . 0.0 114.371 -174.801 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.26 -5.51 0.12 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-O 119.006 -0.886 . . . . 0.0 113.891 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . 0.587 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 29.7 mt-10 -75.49 93.14 2.94 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 119.254 1.527 . . . . 0.0 108.796 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 34.1 p -76.65 130.46 37.83 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.836 0.827 . . . . 0.0 109.421 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -83.6 100.35 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 14.8 m -98.71 102.28 13.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.971 1.308 . . . . 0.0 110.578 -175.778 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 8.4 pt -66.95 146.3 13.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 O-C-N 121.909 -0.494 . . . . 0.0 110.363 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -119.13 -45.5 2.55 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.976 1.71 . . . . 0.0 110.359 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -66.87 79.94 0.11 Allowed 'General case' 0 C--O 1.224 -0.244 0 CA-C-O 121.45 0.643 . . . . 0.0 109.929 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.3 m -77.82 65.82 3.36 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.805 0.842 . . . . 0.0 109.848 -176.234 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 162.48 -128.69 1.92 Allowed Glycine 0 C--N 1.336 0.554 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -177.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.2 t -66.7 157.92 31.46 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.188 178.279 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 2.9 p -138.96 153.25 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 C-N-CA 125.604 1.561 . . . . 0.0 107.684 178.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -125.93 150.39 48.01 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 125.222 1.409 . . . . 0.0 108.379 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 35.8 ptt85 -74.37 162.07 29.23 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 176.268 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 61.69 55.0 2.81 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 126.262 1.825 . . . . 0.0 111.881 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 33.2 mm-40 -146.64 155.78 42.7 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.91 179.671 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . 0.447 ' C ' ' H ' ' A' ' 157' ' ' ILE . 23.5 tt0 -103.79 -70.16 0.78 Allowed 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 119.862 1.21 . . . . 0.0 111.188 176.345 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -50.12 5.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 130.4 3.48 . . . . 0.0 118.047 -172.048 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.447 ' H ' ' C ' ' A' ' 155' ' ' GLU . 1.7 mp -76.86 -32.04 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 129.785 3.234 . . . . 0.0 106.262 173.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.58 145.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 127.128 2.171 . . . . 0.0 106.59 175.449 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 4.6 mmpt? -132.42 125.92 31.88 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 178.164 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . 0.587 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -78.88 125.93 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 172.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -138.44 163.64 31.41 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.45 1.1 . . . . 0.0 109.502 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 65.6 mttm . . . . . 0 C--O 1.231 0.129 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 175.357 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.5 mtm . . . . . 0 N--CA 1.452 -0.333 0 CA-C-O 120.556 0.217 . . . . 0.0 110.778 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 10.6 tp -74.57 72.94 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 CA-C-O 121.474 0.654 . . . . 0.0 110.388 -178.448 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -70.68 66.72 0.35 Allowed 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.669 1.187 . . . . 0.0 111.322 -179.334 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -146.84 171.08 6.78 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 128.047 2.539 . . . . 0.0 105.748 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -52.06 117.74 3.87 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.251 1.967 . . . . 0.0 110.239 178.33 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 82.3 mt -77.67 63.93 2.86 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.633 0.773 . . . . 0.0 110.634 -175.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 35.9 mt-30 66.86 -63.14 0.28 Allowed 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 126.651 1.98 . . . . 0.0 110.965 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -143.87 127.39 16.96 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 125.436 1.494 . . . . 0.0 107.093 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -76.15 68.91 2.64 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.905 0.482 . . . . 0.0 110.025 -179.656 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -72.1 72.49 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 C-N-CA 124.795 1.238 . . . . 0.0 108.66 178.506 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 78.27 -58.01 4.04 Favored Glycine 0 CA--C 1.527 0.838 0 O-C-N 121.024 -1.047 . . . . 0.0 111.047 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 57.41 83.09 0.11 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.01 1.724 . . . . 0.0 112.241 177.427 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -150.78 170.19 19.85 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.787 2.035 . . . . 0.0 109.067 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.442 14.9 p 57.2 -125.07 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 N-CA-C 116.692 2.108 . . . . 0.0 116.692 173.874 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -77.97 135.33 37.79 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.28 1.432 . . . . 0.0 114.32 -168.275 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.7 m -83.05 98.15 4.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 C-N-CA 123.95 0.9 . . . . 0.0 111.128 175.533 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 34.7 t -36.07 121.18 0.71 Allowed Pre-proline 0 CA--C 1.547 0.84 0 C-N-CA 126.686 1.994 . . . . 0.0 111.163 174.918 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -76.2 -38.95 0.95 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.803 2.335 . . . . 0.0 117.773 -173.021 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.13 146.57 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 CA-C-N 120.245 1.384 . . . . 0.0 110.395 -175.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.8 m -78.83 135.44 37.05 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 173.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.18 -167.97 41.01 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 -178.645 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -96.17 135.09 38.45 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.9 tt -97.19 143.07 13.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 123.01 0.524 . . . . 0.0 109.994 -179.256 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -145.29 156.25 53.97 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 178.875 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -62.54 155.33 58.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 N-CA-C 107.097 -1.924 . . . . 0.0 107.097 171.311 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 tt -62.65 -34.36 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.468 -178.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 m -71.03 74.05 0.63 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.685 1.194 . . . . 0.0 109.01 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -179.64 -34.58 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 127.994 2.518 . . . . 0.0 108.992 -174.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 91.0 t -58.47 127.66 81.84 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 117.63 -1.176 . . . . 0.0 111.025 -178.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_exo -57.57 59.68 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.191 1 C-N-CA 126.381 4.72 . . . . 0.0 115.778 176.407 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -171.43 119.65 0.47 Allowed 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 125.953 1.701 . . . . 0.0 107.707 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 6.8 pm0 -54.48 -44.8 72.94 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.429 1.092 . . . . 0.0 113.817 -177.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 40.7 t -56.49 -56.84 11.57 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -178.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -62.64 -52.85 61.72 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.3 t -50.83 -42.36 58.45 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.951 0.9 . . . . 0.0 113.394 -177.773 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.427 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -89.42 11.59 69.39 Favored Glycine 0 N--CA 1.446 -0.634 0 CA-C-O 118.198 -1.334 . . . . 0.0 112.022 -178.528 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 58.5 mttm 72.35 -36.33 0.35 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.564 1.682 . . . . 0.0 113.242 -179.047 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.427 ' H ' ' C ' ' A' ' 36' ' ' GLY . 1.0 OUTLIER 28.68 -78.77 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 130.398 3.479 . . . . 0.0 116.226 179.589 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.5 ttp -83.17 -7.3 59.64 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -174.498 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.63 -138.19 2.75 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 38.9 t0 -140.11 158.7 43.63 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 172.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.77 -168.75 37.83 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 119.937 -1.125 . . . . 0.0 113.334 -176.213 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -141.68 156.83 45.61 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.635 1.174 . . . . 0.0 109.448 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.82 127.09 52.51 Favored 'General case' 0 CA--C 1.51 -0.587 0 C-N-CA 124.282 1.033 . . . . 0.0 109.876 179.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 28.4 mm -107.84 128.53 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 104.611 -2.366 . . . . 0.0 104.611 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.7 tt -96.97 102.97 13.31 Favored Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 172.751 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -63.37 157.16 51.88 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.951 3.101 . . . . 0.0 116.585 -169.377 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.4 p -138.84 -51.13 0.55 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.856 1.263 . . . . 0.0 109.528 173.502 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -80.14 130.67 35.41 Favored 'General case' 0 C--N 1.342 0.263 0 O-C-N 121.926 -0.484 . . . . 0.0 110.455 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -66.42 -24.35 72.24 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.824 -0.911 . . . . 0.0 110.824 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 2.5 mp -78.2 108.52 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 C-N-CA 124.585 1.154 . . . . 0.0 107.923 -179.246 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.22 116.65 52.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 125.212 1.405 . . . . 0.0 108.14 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.5 m -93.41 155.68 3.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.147 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 47.1 m -73.17 139.94 79.6 Favored Pre-proline 0 N--CA 1.448 -0.574 0 CA-C-O 118.6 -0.714 . . . . 0.0 111.144 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -64.17 -35.9 50.01 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 N-CA-C 107.609 -1.727 . . . . 0.0 107.609 171.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.6 p -175.98 150.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 129.798 3.239 . . . . 0.0 103.68 175.346 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 43.1 mtm180 -112.14 -75.93 0.6 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.791 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.19 -68.38 2.35 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.438 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.49 128.32 8.03 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 104.228 -2.508 . . . . 0.0 104.228 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.1 mm -61.13 130.47 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 7.3 tt -77.45 -51.96 9.91 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 104.601 -2.37 . . . . 0.0 104.601 178.361 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 50.9 t30 179.62 165.5 1.1 Allowed 'General case' 0 CA--C 1.527 0.081 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.237 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 2.7 m -152.35 129.09 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 C-N-CA 126.239 1.816 . . . . 0.0 106.168 174.512 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -47.49 146.47 3.46 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-O 118.744 -0.646 . . . . 0.0 111.092 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -50.0 -33.74 35.44 Favored 'Trans proline' 0 CA--C 1.534 0.525 0 C-N-CA 123.534 2.823 . . . . 0.0 113.796 176.6 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 37.0 p -77.67 -7.98 57.24 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 124.574 1.15 . . . . 0.0 111.993 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 68.38 13.4 9.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.205 1.802 . . . . 0.0 113.641 178.366 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.445 ' ND1' ' N ' ' A' ' 89' ' ' VAL . 0.0 OUTLIER -77.91 -23.62 48.61 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 119.358 0.981 . . . . 0.0 111.626 -179.333 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -167.12 -173.22 2.25 Favored 'General case' 0 C--O 1.225 -0.22 0 CA-C-N 120.12 1.327 . . . . 0.0 110.777 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 1.06 1.9 mt 130.97 -139.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.192 1 C-N-CA 136.95 6.1 . . . . 0.0 110.372 176.382 . . . . . . . . 3 2 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -157.04 170.13 34.28 Favored Glycine 0 CA--C 1.531 1.061 0 N-CA-C 118.229 2.052 . . . . 0.0 118.229 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 18.1 mt -124.03 174.35 7.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 128.199 2.6 . . . . 0.0 109.085 -177.663 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -126.28 -165.42 1.44 Allowed 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.098 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 60.3 p -166.11 154.52 10.87 Favored 'General case' 0 N--CA 1.44 -0.957 0 C-N-CA 125.611 1.564 . . . . 0.0 107.39 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -59.35 -34.79 72.81 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 124.918 1.287 . . . . 0.0 108.717 175.921 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -74.45 10.4 8.47 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 123.716 0.674 . . . . 0.0 112.279 176.174 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 82.43 -41.18 2.79 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 119.538 1.669 . . . . 0.0 112.813 177.396 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -42.34 103.98 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 125.341 1.457 . . . . 0.0 110.563 179.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -92.85 131.58 37.76 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 127.642 2.377 . . . . 0.0 105.605 -179.477 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 34.1 mt -123.04 119.62 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 O-C-N 123.436 0.46 . . . . 0.0 112.056 -173.315 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 6.0 tp -89.09 139.63 30.27 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 171.529 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 72.8 mt -130.33 132.49 64.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -123.75 84.47 2.28 Favored 'General case' 0 C--O 1.223 -0.298 0 O-C-N 123.526 0.517 . . . . 0.0 111.77 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.52 104.75 0.24 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.236 0.614 . . . . 0.0 111.932 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.76 -177.93 7.64 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 122.092 0.829 . . . . 0.0 112.323 179.282 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.9 mm -123.92 146.54 29.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 174.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 37.2 t70 50.77 32.29 6.94 Favored 'General case' 0 CA--C 1.543 0.702 0 CA-C-O 121.91 0.862 . . . . 0.0 111.295 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.8 m -97.85 -25.07 15.16 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.803 2.041 . . . . 0.0 107.289 -177.846 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.445 ' N ' ' ND1' ' A' ' 68' ' ' HIS . 4.0 p -53.6 -43.71 55.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 C-N-CA 126.258 1.823 . . . . 0.0 107.634 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -58.73 -26.2 63.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.801 2.04 . . . . 0.0 111.898 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.14 -11.21 60.45 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.892 1.677 . . . . 0.0 109.608 177.149 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp 51.55 29.66 5.69 Favored 'General case' 0 C--N 1.342 0.244 0 C-N-CA 126.325 1.85 . . . . 0.0 112.38 178.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.22 26.71 50.82 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-O 118.702 -1.054 . . . . 0.0 112.53 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.266 0.2 OUTLIER -59.15 -18.25 34.38 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.851 1.826 . . . . 0.0 115.478 -176.776 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -122.3 21.17 7.8 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 126.11 1.814 . . . . 0.0 110.849 177.482 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.5 m-85 -106.05 85.2 2.17 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 118.089 0.944 . . . . 0.0 111.046 -177.378 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.66 101.11 5.61 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.326 -2.472 . . . . 0.0 104.326 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.8 t -87.01 157.82 19.37 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-O 121.183 0.516 . . . . 0.0 110.605 -179.22 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -115.59 5.23 14.31 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.038 1.735 . . . . 0.0 112.224 -175.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.5 m -129.42 137.06 57.9 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.147 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 68.6 m -107.03 49.31 0.81 Allowed 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 169.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.299 1.3 pm0 -2.68 70.98 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 132.184 4.194 . . . . 0.0 116.644 -172.661 . . . . . . . . 3 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -85.99 46.44 3.62 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 112.845 -1.979 . . . . 0.0 109.882 176.571 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 3.36 52.08 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.21 0 C-N-CA 131.356 3.863 . . . . 0.0 120.897 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -168.74 121.78 0.82 Allowed 'General case' 0 C--N 1.312 -1.022 1 C-N-CA 133.475 4.71 . . . . 0.0 107.051 176.553 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -167.52 136.72 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 118.784 0.72 . . . . 0.0 111.073 -172.332 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -78.74 149.99 75.11 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 118.146 -0.93 . . . . 0.0 109.853 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -55.67 175.55 0.2 Allowed 'Trans proline' 0 CA--C 1.542 0.896 1 C-N-CA 125.696 4.264 . . . . 0.0 117.837 -174.396 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 51.85 -7.65 0.01 OUTLIER Glycine 0 C--N 1.344 0.985 0 C-N-CA 129.28 3.324 . . . . 0.0 119.238 175.316 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 25.0 tt0 -61.63 160.59 11.2 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 120.31 2.055 . . . . 0.0 110.128 178.981 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -67.04 140.64 57.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 122.94 0.496 . . . . 0.0 109.76 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 94.5 mt -108.63 -37.39 5.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 124.246 1.018 . . . . 0.0 110.088 176.547 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 22.2 mt -143.23 146.99 34.14 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.61 0.764 . . . . 0.0 110.208 -176.38 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -132.94 68.49 1.5 Allowed 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -79.45 127.03 39.38 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 CA-C-N 109.053 -3.703 . . . . 0.0 110.621 -171.755 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -76.19 67.64 2.5 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.008 0.923 . . . . 0.0 109.179 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -48.61 -39.37 23.69 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.651 0.78 . . . . 0.0 111.727 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -54.04 -42.18 68.89 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.113 0.565 . . . . 0.0 112.201 178.548 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.07 -33.29 18.35 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.744 0.417 . . . . 0.0 111.39 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 79.5 t -63.31 -53.91 39.66 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.372 17.8 pttp -40.45 -58.23 2.56 Favored Pre-proline 0 CA--C 1.541 0.611 0 N-CA-C 116.97 2.211 . . . . 0.0 116.97 -176.464 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -58.53 -20.1 47.85 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.436 2.091 . . . . 0.0 113.36 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -100.03 8.26 44.11 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 118.301 -0.857 . . . . 0.0 112.674 -177.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 33.3 m -133.9 147.67 65.12 Favored Pre-proline 0 CA--C 1.535 0.382 0 CA-C-N 119.986 1.266 . . . . 0.0 109.856 178.711 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -71.04 -36.55 7.29 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.98 2.453 . . . . 0.0 111.622 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 62.3 p -151.45 121.85 7.33 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -177.532 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.0 tp -79.88 -2.95 45.88 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.136 1.374 . . . . 0.0 111.904 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -44.88 117.92 1.47 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 124.842 1.257 . . . . 0.0 110.465 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.6 m -117.7 107.47 44.46 Favored Pre-proline 0 N--CA 1.447 -0.581 0 C-N-CA 124.034 0.933 . . . . 0.0 108.692 -178.425 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -91.53 143.59 3.01 Favored 'Trans proline' 0 N--CA 1.441 -1.617 0 C-N-CA 123.039 2.492 . . . . 0.0 110.249 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 17.2 mm -113.9 116.82 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.034 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.5 t -121.48 123.61 69.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 C-N-CA 125.006 1.323 . . . . 0.0 108.632 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -95.9 117.66 31.04 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 178.37 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 52.6 p -84.1 -73.91 0.4 Allowed 'General case' 0 C--O 1.23 0.045 0 CA-C-O 121.467 0.651 . . . . 0.0 111.563 -171.233 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p-10 -73.08 57.61 0.47 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.824 1.65 . . . . 0.0 111.38 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 20.5 mt -72.01 66.72 0.6 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.918 1.687 . . . . 0.0 109.007 177.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.91 47.68 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 129.179 2.992 . . . . 0.0 112.488 -176.722 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 29.34 55.48 0.12 Allowed 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 127.81 2.444 . . . . 0.0 113.34 -174.809 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.43 -5.29 0.05 OUTLIER Glycine 0 CA--C 1.526 0.738 0 CA-C-O 118.896 -0.946 . . . . 0.0 114.332 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . 0.579 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 21.0 mt-10 -83.83 139.87 32.39 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.185 1.492 . . . . 0.0 109.83 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 45.4 p -110.91 136.58 49.72 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.898 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -91.28 101.93 12.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -178.402 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 20.3 m -100.01 105.83 17.54 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 123.96 0.904 . . . . 0.0 110.493 -176.828 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 20.1 pt -67.05 139.71 20.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.799 -0.563 . . . . 0.0 110.252 177.044 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.6 mmpt? -101.83 -41.42 6.52 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 125.155 1.382 . . . . 0.0 108.864 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.39 86.9 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.208 1.003 . . . . 0.0 112.783 -176.863 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.5 m -80.73 54.68 2.18 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 177.779 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.49 -178.65 37.31 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -177.074 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 35.4 t -52.07 146.8 8.22 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.567 0.747 . . . . 0.0 112.416 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.9 m -115.47 159.55 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 125.207 1.403 . . . . 0.0 109.827 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.8 157.3 30.05 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.75 1.22 . . . . 0.0 108.321 175.635 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.47 158.86 28.45 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.473 0.654 . . . . 0.0 110.738 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 64.58 -10.11 0.16 Allowed 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 126.137 1.775 . . . . 0.0 114.868 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.67 149.81 38.4 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.933 1.242 . . . . 0.0 109.571 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -120.54 158.14 27.94 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.214 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 29.9 t0 63.89 26.56 14.29 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 128.074 2.549 . . . . 0.0 112.009 -174.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -82.87 -22.75 8.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 C-N-CA 123.825 0.85 . . . . 0.0 108.825 176.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.3 p -142.36 149.66 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 127.897 2.479 . . . . 0.0 106.477 175.662 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -131.81 127.47 36.7 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 174.741 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . 0.579 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.54 122.0 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 170.797 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -105.52 176.11 5.27 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 106.544 -1.651 . . . . 0.0 106.544 174.553 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.0 tppt? . . . . . 0 CA--C 1.532 0.254 0 O-C-N 121.292 -0.88 . . . . 0.0 110.956 -179.358 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.3 mtp . . . . . 0 N--CA 1.45 -0.426 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 16.3 pt -64.68 145.23 14.06 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.247 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.19 67.82 1.4 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 123.339 0.655 . . . . 0.0 111.458 -178.081 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -52.62 113.1 4.05 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 124.255 1.022 . . . . 0.0 111.062 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -79.75 169.52 18.07 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 122.528 2.152 . . . . 0.0 109.547 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -75.78 67.66 2.24 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 123.499 0.72 . . . . 0.0 109.306 179.097 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 24.1 mt-30 -131.61 161.09 33.51 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.438 1.495 . . . . 0.0 107.862 177.829 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -145.72 -158.22 0.88 Allowed 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.4 mm-40 -76.47 63.25 1.99 Allowed 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 120.057 1.299 . . . . 0.0 109.785 177.35 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.0 pp -140.46 -143.67 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 126.886 2.074 . . . . 0.0 106.5 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 155.62 -131.39 3.05 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 106.374 -2.691 . . . . 0.0 106.374 178.475 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 49.37 60.93 3.42 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.313 1.045 . . . . 0.0 110.347 178.496 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -81.89 -158.96 0.26 Allowed 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 173.878 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.7 t -80.77 47.19 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 O-C-N 120.29 -1.506 . . . . 0.0 109.763 178.399 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.32 85.06 7.28 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 m -90.75 84.81 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 122.598 0.359 . . . . 0.0 110.894 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -19.1 115.52 0.09 OUTLIER Pre-proline 0 CA--C 1.546 0.789 0 C-N-CA 127.016 2.127 . . . . 0.0 113.667 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -75.02 -26.01 11.28 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 122.718 2.278 . . . . 0.0 117.535 -170.755 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -138.25 158.08 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 119.886 1.221 . . . . 0.0 109.445 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.9 m -94.61 128.6 41.36 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 174.439 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.67 -161.68 33.16 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.585 -0.341 . . . . 0.0 112.654 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -95.24 118.46 32.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.846 1.258 . . . . 0.0 108.551 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.94 136.04 25.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 C-N-CA 123.455 0.702 . . . . 0.0 109.427 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -135.13 142.9 43.61 Favored Pre-proline 0 C--O 1.236 0.345 0 C-N-CA 126.486 1.914 . . . . 0.0 107.048 177.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -64.61 160.06 41.88 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 121.446 1.431 . . . . 0.0 108.476 176.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 tp -61.55 -39.88 84.57 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.268 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 57.1 m -76.48 74.1 3.22 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.124 0.97 . . . . 0.0 109.344 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -178.54 -37.34 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 127.601 2.36 . . . . 0.0 108.986 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 97.0 t -52.0 115.45 6.71 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-O 117.507 -1.235 . . . . 0.0 111.905 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_exo -58.06 64.37 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.212 1 C-N-CA 125.515 4.144 . . . . 0.0 115.551 177.046 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -133.58 -42.63 0.84 Allowed 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 -177.467 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 105.73 -65.08 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 129.695 3.198 . . . . 0.0 110.606 -178.48 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 92.3 t -52.67 -62.13 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 C-N-CA 124.004 0.922 . . . . 0.0 108.722 179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -59.99 -42.79 94.98 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.909 0.385 . . . . 0.0 110.123 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -51.57 -45.51 63.12 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 124.012 0.925 . . . . 0.0 112.81 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -92.99 17.57 57.91 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-O 118.274 -1.292 . . . . 0.0 110.5 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 60.5 mttp 73.79 -47.77 0.66 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.079 1.752 . . . . 0.0 111.359 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 19.6 ttt 35.49 -67.17 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 130.602 3.561 . . . . 0.0 117.077 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 33.2 ttm -87.52 -23.6 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.385 1.074 . . . . 0.0 112.435 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.67 -148.1 9.53 Favored Glycine 0 C--O 1.224 -0.505 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -177.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -142.47 159.75 41.61 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-N 118.349 1.074 . . . . 0.0 108.582 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.3 -127.29 1.45 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 106.773 -2.531 . . . . 0.0 106.773 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -177.01 -179.28 0.9 Allowed 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 119.055 1.427 . . . . 0.0 110.763 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -127.67 135.86 50.79 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 123.734 0.814 . . . . 0.0 109.447 176.201 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -109.49 98.55 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 103.316 -2.846 . . . . 0.0 103.316 172.812 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.5 tt -58.81 113.6 7.11 Favored Pre-proline 0 CA--C 1.532 0.258 0 N-CA-C 103.08 -2.933 . . . . 0.0 103.08 175.708 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -78.07 149.01 25.12 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 122.916 2.411 . . . . 0.0 115.005 -167.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 p -115.74 -47.88 2.78 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 125.217 1.407 . . . . 0.0 107.594 173.98 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -76.76 122.39 24.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.11 44.21 2.79 Favored Glycine 0 CA--C 1.531 1.082 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 173.239 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.1 mt -144.33 126.37 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 104.446 -2.427 . . . . 0.0 104.446 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 66.3 t -126.66 126.71 69.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 C-N-CA 125.019 1.328 . . . . 0.0 109.033 -173.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.7 m -109.78 157.59 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.833 1.253 . . . . 0.0 110.792 178.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.6 m -62.87 133.02 95.07 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.873 -0.517 . . . . 0.0 111.077 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.04 -13.89 23.67 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.278 3.319 . . . . 0.0 116.531 -174.92 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -151.31 165.54 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 CA-C-N 119.441 1.018 . . . . 0.0 109.713 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -76.12 125.54 29.34 Favored 'General case' 0 C--O 1.236 0.394 1 N-CA-C 99.122 -4.399 . . . . 0.0 99.122 166.768 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 179.82 171.95 43.31 Favored Glycine 0 N--CA 1.435 -1.425 0 C-N-CA 116.658 -2.687 . . . . 0.0 113.198 -168.235 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.64 126.24 34.84 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.58 116.9 8.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 102.644 -3.095 . . . . 0.0 102.644 168.775 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 85.1 mt -78.53 -50.04 12.27 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 32.6 t30 178.16 164.1 0.7 Allowed 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 124.14 0.976 . . . . 0.0 108.372 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.4 m -137.74 116.73 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 126.732 2.013 . . . . 0.0 106.079 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.73 154.03 0.73 Allowed Pre-proline 0 N--CA 1.469 0.524 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -52.05 -33.29 52.44 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 123.483 2.788 . . . . 0.0 113.212 176.492 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.8 p -78.09 -2.84 39.29 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.996 0.919 . . . . 0.0 111.631 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.76 21.48 1.94 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 127.244 2.218 . . . . 0.0 114.301 179.397 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 25.9 p-80 -89.31 -25.02 21.86 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 118.46 -0.781 . . . . 0.0 111.18 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -162.5 -172.62 3.22 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.566 0.621 . . . . 0.0 112.531 -172.919 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.716 27.6 mm 125.89 -127.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.478 1 C-N-CA 134.583 5.153 . . . . 0.0 107.177 -179.815 . . . . . . . . 3 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 177.71 -172.83 45.54 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 118.354 2.101 . . . . 0.0 118.354 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.0 mp -133.7 169.58 16.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 126.856 2.062 . . . . 0.0 109.42 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.76 126.94 37.7 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 171.018 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 54.2 p -68.18 172.78 5.34 Favored 'General case' 0 N--CA 1.427 -1.579 0 CA-C-O 123.774 1.749 . . . . 0.0 108.136 175.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -55.2 -37.75 67.51 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 112.143 -2.299 . . . . 0.0 108.999 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -87.49 13.01 61.36 Favored Glycine 0 CA--C 1.534 1.239 0 C-N-CA 124.334 0.968 . . . . 0.0 112.589 177.441 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 75.55 14.73 81.76 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-N 118.287 1.044 . . . . 0.0 114.503 178.037 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.1 tpp85 -70.77 107.49 4.0 Favored 'General case' 0 C--N 1.339 0.152 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 177.73 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.61 101.39 8.29 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 125.457 1.503 . . . . 0.0 108.434 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.0 mt -96.81 103.85 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 126.479 1.912 . . . . 0.0 109.92 -176.296 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.0 tt -79.18 135.59 36.85 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 105.055 -2.202 . . . . 0.0 105.055 171.116 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.3 mt -113.97 153.22 15.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 125.179 1.392 . . . . 0.0 108.613 179.065 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.34 144.75 29.99 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 171.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.98 91.36 3.26 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.377 1.471 . . . . 0.0 110.504 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.27 154.63 5.43 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -178.494 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mt -98.33 135.28 33.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.267 -1.753 . . . . 0.0 106.267 178.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.0 t70 70.25 18.11 6.94 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.626 1.17 . . . . 0.0 112.818 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 p -81.9 -32.03 31.15 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 124.872 1.269 . . . . 0.0 108.501 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 8.1 p -55.06 -44.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.784 1.233 . . . . 0.0 108.143 172.575 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -61.34 -35.43 77.41 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.777 1.231 . . . . 0.0 109.813 176.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.99 9.43 5.44 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 126.851 2.061 . . . . 0.0 110.915 176.734 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.6 mttp 47.27 35.2 3.6 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 127.067 2.147 . . . . 0.0 114.787 173.809 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.05 19.12 63.29 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.63 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -71.26 90.47 0.92 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.064 1.432 . . . . 0.0 109.908 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.21 -1.06 6.61 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 126.068 1.794 . . . . 0.0 111.928 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.446 ' CD1' HG13 ' A' ' 115' ' ' VAL . 16.4 m-30 -100.42 111.57 23.84 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.723 1.209 . . . . 0.0 109.662 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 9.6 m -104.28 113.49 27.08 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 124.779 1.232 . . . . 0.0 108.132 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.7 p -81.43 144.94 31.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 118.92 0.782 . . . . 0.0 111.292 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -114.95 -41.98 3.28 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.186 1.394 . . . . 0.0 111.959 -178.369 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.417 ' C ' ' H ' ' A' ' 102' ' ' GLU . 16.4 m -70.94 130.19 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 174.438 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 61.0 m -92.28 53.71 2.18 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 104.934 -2.247 . . . . 0.0 104.934 172.001 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.417 ' H ' ' C ' ' A' ' 100' ' ' VAL 0.365 1.2 pm0 16.35 62.89 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.466 3.507 . . . . 0.0 113.01 -169.509 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -79.09 48.99 3.44 Favored Glycine 0 CA--C 1.524 0.629 0 CA-C-N 111.729 -2.487 . . . . 0.0 109.818 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.403 4.3 p30 2.66 -111.25 0.0 OUTLIER 'General case' 0 N--CA 1.435 -1.22 0 C-N-CA 129.627 3.171 . . . . 0.0 117.366 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.254 0.2 OUTLIER -35.92 118.29 0.5 Allowed 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 121.599 3.926 . . . . 0.0 121.599 -169.726 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.268 27.6 m 36.89 70.39 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 128.421 2.688 . . . . 0.0 117.241 170.99 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.39 127.93 25.41 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 170.018 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -97.01 154.75 1.1 Allowed 'Trans proline' 0 N--CA 1.449 -1.141 0 C-N-CA 124.594 3.529 . . . . 0.0 110.401 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 49.07 2.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.303 0 N-CA-C 118.362 2.105 . . . . 0.0 118.362 172.449 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -60.69 136.49 58.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 119.948 1.874 . . . . 0.0 107.935 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -59.12 117.02 4.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.0 mt -79.91 -47.53 14.92 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.45 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.8 mp -149.97 166.0 30.97 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -177.623 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -126.33 132.1 51.68 Favored 'General case' 0 CA--C 1.518 -0.262 1 N-CA-C 98.458 -4.645 . . . . 0.0 98.458 166.243 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.446 HG13 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -141.25 123.19 14.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.846 -166.176 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 63.1 t0 -72.55 70.54 0.92 Allowed 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 124.497 1.119 . . . . 0.0 110.772 -178.279 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -50.37 -45.1 54.98 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.347 0.659 . . . . 0.0 110.432 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -50.71 -50.11 55.96 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.362 1.065 . . . . 0.0 112.709 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.87 -33.34 24.83 Favored 'General case' 0 CA--C 1.527 0.087 0 N-CA-C 111.771 0.285 . . . . 0.0 111.771 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -65.28 -52.86 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.776 -0.578 . . . . 0.0 109.993 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.344 19.4 pttp -40.25 -57.31 2.94 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 117.413 2.375 . . . . 0.0 117.413 -177.066 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -57.09 -22.04 45.46 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.526 2.15 . . . . 0.0 113.146 179.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -94.11 4.97 53.14 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 118.08 -0.962 . . . . 0.0 112.683 -178.132 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 21.3 m -136.1 150.19 70.45 Favored Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 120.182 1.355 . . . . 0.0 111.992 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -71.17 -28.9 18.2 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 122.891 2.394 . . . . 0.0 111.974 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 3.2 m -158.79 131.59 7.05 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.54 0.609 . . . . 0.0 110.024 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -90.4 21.44 3.88 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.114 1.366 . . . . 0.0 112.055 -177.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 24.3 mmt -59.64 146.85 39.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 121.348 -0.845 . . . . 0.0 110.933 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 18.2 p -112.41 68.69 0.96 Allowed Pre-proline 0 CA--C 1.536 0.418 0 C-N-CA 124.558 1.143 . . . . 0.0 108.296 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.45 92.83 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.236 1.957 . . . . 0.0 112.825 -175.083 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 3.2 mt -86.15 129.97 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 105.315 -2.105 . . . . 0.0 105.315 175.498 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.6 t -133.59 121.67 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-O 121.798 0.809 . . . . 0.0 109.192 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -82.15 108.83 15.92 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 101.653 -3.462 . . . . 0.0 101.653 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.8 p -75.5 -63.55 1.26 Allowed 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.712 0.768 . . . . 0.0 109.75 -173.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -72.16 52.14 0.25 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.682 1.193 . . . . 0.0 113.951 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 56.9 mt -78.96 49.11 0.89 Allowed 'General case' 0 CA--C 1.539 0.547 0 O-C-N 121.083 -1.011 . . . . 0.0 109.042 173.697 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 23.99 40.42 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 130.0 3.32 . . . . 0.0 115.042 -179.21 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 38.85 45.31 0.93 Allowed 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.209 1.804 . . . . 0.0 112.604 -175.232 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -175.69 -8.86 0.02 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 119.062 -0.855 . . . . 0.0 113.997 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . 0.606 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 9.8 mm-40 -86.87 92.33 8.96 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 118.945 1.373 . . . . 0.0 108.299 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -77.37 132.44 38.55 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 123.248 0.619 . . . . 0.0 110.164 -177.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 1.9 t -86.15 91.4 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 125.293 1.437 . . . . 0.0 109.782 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.0 m -88.54 96.26 10.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 27.1 mt -65.76 131.8 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -102.47 -42.2 6.04 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 125.774 1.629 . . . . 0.0 110.801 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -54.72 83.75 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.186 0 C-N-CA 124.907 1.283 . . . . 0.0 112.799 -176.71 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 22.4 m -80.93 55.9 2.59 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.778 0.831 . . . . 0.0 109.418 179.563 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.68 -167.47 36.47 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.051 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 41.6 t -60.16 152.72 23.78 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 123.12 0.568 . . . . 0.0 110.831 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 55.2 t -123.49 148.81 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 C-N-CA 124.944 1.298 . . . . 0.0 107.739 178.238 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.1 m-80 -119.48 153.43 35.32 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.789 1.636 . . . . 0.0 110.111 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -47.53 135.45 11.15 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.838 0.855 . . . . 0.0 110.628 177.696 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 67.23 8.57 6.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.509 1.924 . . . . 0.0 114.933 178.224 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -64.5 150.88 45.8 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 120.062 1.301 . . . . 0.0 108.859 174.283 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -122.84 161.53 23.88 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 125.215 1.406 . . . . 0.0 108.487 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 21.1 t0 66.69 14.1 9.63 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 125.735 1.614 . . . . 0.0 113.713 -178.932 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.408 ' CD1' ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -65.65 -26.76 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 C-N-CA 124.371 1.068 . . . . 0.0 111.104 176.736 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.5 p -138.75 147.2 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 C-N-CA 125.626 1.57 . . . . 0.0 107.935 179.36 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.18 109.76 15.37 Favored 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.394 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . 0.606 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -77.57 98.85 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 174.724 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -87.93 147.94 24.82 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.038 0.935 . . . . 0.0 108.87 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.1 tptm . . . . . 0 C--N 1.329 -0.297 0 CA-C-O 121.927 0.87 . . . . 0.0 109.026 -178.437 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.0 ppp? . . . . . 0 CA--C 1.537 0.455 0 N-CA-C 112.948 0.722 . . . . 0.0 112.948 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 15.7 pt -74.21 61.12 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 124.508 1.123 . . . . 0.0 111.802 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.93 79.97 1.65 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.692 0.797 . . . . 0.0 108.987 177.707 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 72.0 mt-10 -46.89 126.9 8.62 Favored Pre-proline 0 CA--C 1.541 0.597 0 C-N-CA 123.745 0.818 . . . . 0.0 110.563 -179.139 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -74.39 69.53 5.01 Favored 'Trans proline' 0 N--CA 1.456 -0.711 0 C-N-CA 123.187 2.591 . . . . 0.0 111.469 -177.072 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -160.67 170.2 21.3 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 124.665 1.186 . . . . 0.0 108.729 178.12 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -101.72 146.73 27.35 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -163.75 149.92 11.5 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -161.14 30.68 0.14 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.15 1.38 . . . . 0.0 109.572 176.166 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.5 pp -132.83 -34.49 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.255 0 C-N-CA 123.674 0.79 . . . . 0.0 111.731 -178.567 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -155.87 -125.46 0.91 Allowed Glycine 0 C--N 1.335 0.492 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.02 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 51.82 -160.8 0.09 Allowed 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 125.138 1.375 . . . . 0.0 110.032 179.197 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 22.87 52.76 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 129.147 2.979 . . . . 0.0 118.438 174.287 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 74.4 t -145.31 -39.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -160.3 113.97 2.15 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 123.411 0.684 . . . . 0.0 112.119 -173.347 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.1 m -78.73 80.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.178 0 O-C-N 120.481 -1.387 . . . . 0.0 111.435 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -21.68 105.04 0.09 OUTLIER Pre-proline 0 CA--C 1.551 1.015 0 C-N-CA 129.229 3.012 . . . . 0.0 109.605 175.183 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.06 -20.56 21.63 Favored 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 123.535 2.823 . . . . 0.0 119.177 -167.42 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.35 147.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.34 0.164 0 CA-C-N 119.699 1.136 . . . . 0.0 110.547 -177.05 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.2 m -85.79 135.31 33.78 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 173.947 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 166.59 -140.38 6.29 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 -178.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.1 tp10 -125.81 122.68 36.87 Favored 'General case' 0 CA--C 1.528 0.122 0 C-N-CA 124.933 1.293 . . . . 0.0 110.089 -178.532 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.55 146.01 9.11 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.006 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -142.52 140.23 18.5 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 125.155 1.382 . . . . 0.0 107.656 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -57.13 145.55 85.79 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.116 1.877 . . . . 0.0 110.161 176.351 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -49.37 -37.63 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 124.304 1.041 . . . . 0.0 112.596 -178.449 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.6 p -55.96 -28.66 58.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.105 1.362 . . . . 0.0 112.606 178.353 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -77.23 -8.81 58.2 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 123.678 0.791 . . . . 0.0 112.745 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.7 t -74.26 131.01 81.32 Favored Pre-proline 0 CA--C 1.535 0.402 0 O-C-N 121.162 -0.961 . . . . 0.0 109.994 -178.07 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -77.17 55.93 5.24 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.515 2.81 . . . . 0.0 111.954 -177.979 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -167.72 108.68 0.59 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.47 -0.768 . . . . 0.0 109.19 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -35.47 -48.17 0.48 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 127.521 2.329 . . . . 0.0 115.375 -176.56 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.0 p -50.57 -38.1 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 122.932 0.493 . . . . 0.0 110.938 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 23.2 m-85 -89.38 -49.7 6.55 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 124.115 0.966 . . . . 0.0 108.828 177.155 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -48.07 -40.96 24.74 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.765 1.024 . . . . 0.0 113.765 -177.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.404 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -100.48 15.01 59.1 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.201 -1.333 . . . . 0.0 111.956 -177.015 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 53.1 mttp 71.87 -39.22 0.44 Allowed 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 119.285 1.542 . . . . 0.0 113.813 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.404 ' H ' ' C ' ' A' ' 36' ' ' GLY . 9.4 ttp 27.97 -69.18 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 131.341 3.856 . . . . 0.0 117.118 -179.497 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.9 ttp -79.54 -25.53 41.65 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 126.047 1.739 . . . . 0.0 113.541 -175.33 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.71 -141.1 4.21 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 119.605 1.093 . . . . 0.0 110.658 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -121.96 154.4 37.24 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 174.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 179.51 -165.2 33.73 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.236 -175.806 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 37.4 p90 -159.37 168.91 25.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.955 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -112.37 151.28 29.97 Favored 'General case' 0 CA--C 1.501 -0.942 0 CA-C-O 121.346 0.593 . . . . 0.0 109.475 175.919 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 4.4 mp -125.08 132.31 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 102.18 -3.267 . . . . 0.0 102.18 170.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.0 tt -96.15 108.74 43.24 Favored Pre-proline 0 N--CA 1.442 -0.837 1 N-CA-C 98.589 -4.597 . . . . 0.0 98.589 169.976 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -82.17 156.1 17.19 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 123.664 2.909 . . . . 0.0 114.405 -168.201 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.2 p -124.98 -45.83 1.86 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.895 1.278 . . . . 0.0 108.794 174.711 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 120.34 14.59 Favored 'General case' 0 C--N 1.339 0.11 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 177.492 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.69 37.59 2.09 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 175.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.7 mt -142.33 119.39 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 127.007 2.123 . . . . 0.0 105.85 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.08 113.86 45.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.157 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.1 m -100.53 152.26 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 C-N-CA 123.094 0.558 . . . . 0.0 109.988 179.081 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 70.6 m -58.24 130.0 83.56 Favored Pre-proline 0 CA--C 1.537 0.463 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.106 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.2 -22.94 13.96 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 124.938 3.759 . . . . 0.0 115.774 -175.464 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.6 m -137.79 161.68 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 123.914 0.885 . . . . 0.0 109.769 -173.54 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.1 ttt180 -76.71 126.31 30.76 Favored 'General case' 0 CA--C 1.518 -0.271 1 N-CA-C 99.562 -4.236 . . . . 0.0 99.562 167.957 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.31 175.07 47.23 Favored Glycine 0 N--CA 1.436 -1.343 0 C-N-CA 116.709 -2.663 . . . . 0.0 114.33 -167.853 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 36.2 mtmt -100.62 135.16 42.49 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.231 1.812 . . . . 0.0 108.371 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 26.9 mm -76.47 107.93 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 173.333 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 64.3 tp -77.3 -50.6 12.48 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 123.358 0.663 . . . . 0.0 109.998 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.6 t30 179.53 107.68 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 10.3 m -117.82 147.4 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 123.587 0.755 . . . . 0.0 112.392 -178.285 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER 42.53 123.72 0.0 OUTLIER Pre-proline 0 CA--C 1.536 0.441 1 C-N-CA 132.901 4.48 . . . . 0.0 120.801 171.706 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -80.94 -50.16 0.05 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.216 0 N-CA-C 106.676 -2.086 . . . . 0.0 106.676 168.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 8.9 p -113.99 43.08 1.91 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 127.281 2.232 . . . . 0.0 111.14 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 ttmm 56.91 25.62 10.74 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 115.762 1.764 . . . . 0.0 115.762 171.748 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -135.09 9.32 3.51 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 115.262 1.578 . . . . 0.0 115.262 -175.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -168.25 -159.29 0.27 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 122.053 2.206 . . . . 0.0 113.988 -173.06 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 1.014 0.2 OUTLIER 93.18 -161.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 131.632 3.973 . . . . 0.0 117.697 172.683 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -115.14 154.1 17.2 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 120.06 2.784 . . . . 0.0 120.06 -167.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.8 mp -133.23 165.83 23.89 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 128.558 2.743 . . . . 0.0 108.519 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.7 mm-40 -136.86 139.58 41.78 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 175.153 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.8 m -82.33 -131.72 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.356 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -88.74 49.9 1.87 Allowed 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 107.356 -1.349 . . . . 0.0 107.356 174.916 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.57 -49.25 3.03 Favored Glycine 0 CA--C 1.53 1.027 0 C-N-CA 124.323 0.963 . . . . 0.0 112.905 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -56.81 -16.58 17.9 Favored Glycine 0 CA--C 1.534 1.264 0 N-CA-C 116.118 1.207 . . . . 0.0 116.118 -177.015 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 41.6 mtm180 -142.04 104.54 4.5 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 119.226 1.513 . . . . 0.0 111.569 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -90.0 130.12 36.23 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.0 mt -119.05 150.49 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 C-N-CA 124.89 1.276 . . . . 0.0 110.744 -176.329 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.75 132.84 44.17 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 128.373 2.669 . . . . 0.0 105.94 177.15 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.4 mt -124.87 143.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 124.841 1.256 . . . . 0.0 108.853 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -134.82 124.73 25.56 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.136 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -87.78 122.52 31.53 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 118.675 -0.679 . . . . 0.0 109.558 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.05 -157.4 5.9 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 118.358 0.526 . . . . 0.0 112.491 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 17.6 mm -132.77 142.92 41.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 106.36 -1.719 . . . . 0.0 106.36 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.6 t70 58.96 29.06 18.46 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.058 0.943 . . . . 0.0 112.555 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 p -86.41 -37.3 18.5 Favored 'General case' 0 CA--C 1.517 -0.296 0 C-N-CA 126.162 1.785 . . . . 0.0 108.067 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 3.7 p -51.46 -46.75 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.235 171.154 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -61.6 -31.33 71.4 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.332 1.453 . . . . 0.0 111.147 178.312 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.89 -2.99 29.37 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.344 2.258 . . . . 0.0 110.379 178.3 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm 51.61 33.44 10.72 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 125.176 1.39 . . . . 0.0 112.629 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.49 18.15 63.05 Favored Glycine 0 CA--C 1.537 1.426 0 O-C-N 121.919 -0.488 . . . . 0.0 113.357 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -73.01 85.27 1.29 Allowed 'General case' 0 C--N 1.34 0.152 0 CA-C-N 118.88 1.34 . . . . 0.0 109.745 179.609 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 17.48 1.7 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.714 2.102 . . . . 0.0 111.575 -177.809 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 37.1 m-85 -117.26 150.15 39.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.8 1.24 . . . . 0.0 109.907 -178.381 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 30.7 m -145.15 102.45 3.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.8 p -81.33 127.49 32.8 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.964 0.906 . . . . 0.0 108.959 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -91.13 -45.03 8.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.859 1.264 . . . . 0.0 112.612 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 6.7 m -73.36 129.19 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 118.383 -1.327 . . . . 0.0 111.67 -177.992 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -87.97 64.56 7.88 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 172.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.3 0.0 OUTLIER -14.11 84.47 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 130.039 3.336 . . . . 0.0 116.485 -173.213 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.14 -2.12 0.03 OUTLIER Glycine 0 CA--C 1.534 1.257 0 CA-C-N 113.528 -1.669 . . . . 0.0 113.194 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 121.57 14.71 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 127.266 2.226 . . . . 0.0 107.073 177.045 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.94 121.02 41.66 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 127.808 2.443 . . . . 0.0 111.061 -179.427 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.337 33.7 m 43.23 66.62 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 C-N-CA 126.682 1.993 . . . . 0.0 115.615 178.781 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -132.7 141.58 41.65 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 171.949 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -103.37 171.29 0.21 Allowed 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.935 3.09 . . . . 0.0 110.529 -179.048 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 60.04 -23.01 0.04 OUTLIER Glycine 0 CA--C 1.534 1.234 0 N-CA-C 118.856 2.303 . . . . 0.0 118.856 170.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -50.24 137.49 18.06 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 120.457 2.128 . . . . 0.0 110.529 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -60.59 123.7 18.18 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.5 mt -85.79 -48.2 9.01 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.108 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.5 mp -143.12 155.8 44.66 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.724 0.81 . . . . 0.0 110.666 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -122.11 135.36 54.79 Favored 'General case' 0 C--O 1.236 0.356 1 N-CA-C 99.023 -4.436 . . . . 0.0 99.023 167.075 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.71 126.47 12.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.592 -165.754 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 38.7 m-20 -76.83 61.61 1.93 Allowed 'General case' 0 C--O 1.235 0.294 0 C-N-CA 124.904 1.282 . . . . 0.0 110.544 -178.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.0 mt -45.12 -45.5 11.28 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 123.886 0.875 . . . . 0.0 112.192 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -44.95 -42.01 7.78 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.488 1.115 . . . . 0.0 112.611 178.063 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.56 -33.67 15.81 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.113 0.565 . . . . 0.0 111.364 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 96.6 t -62.62 -52.78 55.46 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 O-C-N 121.756 -0.59 . . . . 0.0 110.004 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.391 8.8 ptmt -42.79 -57.22 5.11 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 116.895 2.183 . . . . 0.0 116.895 -177.79 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -61.59 -21.37 71.84 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 122.187 1.925 . . . . 0.0 113.184 178.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 -87.88 -42.29 12.62 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 119.064 0.847 . . . . 0.0 111.317 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.9 m -78.69 149.19 74.15 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.95 -0.469 . . . . 0.0 111.807 -177.183 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -70.53 -24.5 26.07 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.506 2.137 . . . . 0.0 110.228 175.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.2 t -158.05 145.06 17.93 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.725 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.2 tp -98.18 6.5 47.42 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.56 1.144 . . . . 0.0 110.31 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 21.3 mmt -53.36 115.16 1.77 Allowed 'General case' 0 C--N 1.344 0.343 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 47.3 m -106.33 88.6 3.34 Favored Pre-proline 0 N--CA 1.447 -0.579 0 C-N-CA 124.706 1.203 . . . . 0.0 108.241 -178.622 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 83.8 Cg_endo -72.93 144.0 37.64 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 122.668 2.246 . . . . 0.0 111.948 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.9 mt -125.01 126.29 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 103.788 -2.671 . . . . 0.0 103.788 173.102 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -123.53 153.41 29.16 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 C-N-CA 126.008 1.723 . . . . 0.0 106.651 178.669 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -129.92 121.58 26.9 Favored 'General case' 0 N--CA 1.428 -1.541 0 N-CA-C 102.914 -2.995 . . . . 0.0 102.914 -176.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 23.9 p -89.18 -86.17 0.19 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 -177.041 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -77.49 54.82 1.21 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 122.922 0.489 . . . . 0.0 111.696 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -78.26 80.07 4.69 Favored 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 174.692 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.12 51.51 0.21 Allowed 'General case' 0 C--N 1.343 0.289 0 C-N-CA 127.819 2.448 . . . . 0.0 111.641 -175.747 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 21.55 69.57 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 129.261 3.024 . . . . 0.0 113.964 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 146.42 -3.25 1.01 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-O 118.591 -1.116 . . . . 0.0 113.455 176.981 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 56.0 mt-10 -70.99 115.57 10.27 Favored 'General case' 0 C--N 1.339 0.116 0 CA-C-N 119.686 1.743 . . . . 0.0 109.933 179.886 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 81.5 p -78.78 128.99 34.13 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.12 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.266 0.4 OUTLIER -81.05 78.73 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 CA-C-O 123.498 1.618 . . . . 0.0 106.8 -177.538 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 38.5 m -78.8 91.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 120.962 -1.086 . . . . 0.0 111.249 -174.44 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.3 pt -63.19 104.58 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 C-N-CA 123.004 0.522 . . . . 0.0 109.597 176.649 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.23 -56.01 4.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -84.14 69.97 10.47 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 46.4 m -77.7 68.66 3.82 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 176.666 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.17 -142.06 3.83 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 106.433 -2.667 . . . . 0.0 106.433 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.4 t -67.0 145.99 54.83 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 117.975 0.888 . . . . 0.0 110.645 177.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 3.8 p -123.57 153.59 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 C-N-CA 125.881 1.673 . . . . 0.0 107.351 177.317 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.68 158.1 40.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 -65.46 147.99 52.48 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 43.44 48.69 6.12 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 128.109 2.564 . . . . 0.0 114.057 172.816 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -89.29 10.21 23.09 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 177.528 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 53.62 8.86 0.15 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 128.752 2.821 . . . . 0.0 115.566 177.801 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -156.97 -126.13 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 125.146 1.378 . . . . 0.0 107.405 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.312 1.5 mp 80.63 -36.89 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 128.559 2.744 . . . . 0.0 108.615 178.552 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -119.85 129.11 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 168.372 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 9.2 mmmt -111.3 111.51 22.61 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 124.168 0.987 . . . . 0.0 109.077 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.3 mp -77.24 91.51 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 103.409 -2.812 . . . . 0.0 103.409 175.049 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -103.46 116.1 31.77 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.587 1.555 . . . . 0.0 110.282 -173.009 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 28.6 tptp . . . . . 0 CA--C 1.528 0.129 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 178.987 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.3 mtm . . . . . 0 CA--C 1.531 0.214 0 CA-C-O 120.77 0.319 . . . . 0.0 110.82 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 33.4 pt -74.47 -172.5 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 123.809 0.844 . . . . 0.0 110.343 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.71 63.19 0.84 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 123.764 0.826 . . . . 0.0 111.028 179.055 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -66.02 -46.9 63.99 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 124.466 1.106 . . . . 0.0 113.745 -179.472 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -78.13 70.39 7.14 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 121.418 1.412 . . . . 0.0 111.535 -175.473 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 93.8 mt -70.47 67.96 0.36 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.813 1.645 . . . . 0.0 110.496 178.829 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 18.4 mt-30 -71.66 72.52 0.76 Allowed 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 125.541 1.536 . . . . 0.0 110.948 -178.614 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -60.13 97.46 0.05 OUTLIER 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.575 0.75 . . . . 0.0 110.338 178.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 72.07 -62.6 0.46 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 126.763 2.025 . . . . 0.0 111.226 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.298 15.5 tt 52.73 -58.68 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 C-N-CA 129.562 3.145 . . . . 0.0 116.378 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.92 57.25 0.54 Allowed Glycine 0 CA--C 1.524 0.595 0 N-CA-C 109.266 -1.533 . . . . 0.0 109.266 -178.354 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -134.46 -1.06 2.87 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.72 1.608 . . . . 0.0 113.751 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.401 ' C ' ' H ' ' A' ' 15' ' ' PHE . 1.8 pm0 -86.94 166.77 14.85 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.847 1.259 . . . . 0.0 111.545 179.568 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.311 6.5 t 59.2 -17.76 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 N-CA-C 119.156 3.021 . . . . 0.0 119.156 176.105 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.401 ' H ' ' C ' ' A' ' 13' ' ' GLU . 29.3 t80 -152.11 127.94 10.25 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 127.877 2.471 . . . . 0.0 104.402 175.98 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.76 77.05 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.4 t -15.91 124.06 0.04 OUTLIER Pre-proline 0 CA--C 1.552 1.043 0 C-N-CA 129.063 2.945 . . . . 0.0 114.449 179.576 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_endo -74.8 -42.72 0.51 Allowed 'Trans proline' 0 CA--C 1.538 0.684 0 N-CA-C 120.825 3.356 . . . . 0.0 120.825 -170.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -138.16 145.49 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 121.014 1.734 . . . . 0.0 111.665 -172.646 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 m -79.88 131.88 35.96 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 171.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 178.41 -160.49 26.55 Favored Glycine 0 CA--C 1.518 0.249 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.7 tp10 -108.04 131.74 54.28 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.1 tt -75.85 151.71 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-N 118.679 0.672 . . . . 0.0 110.535 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.5 m-70 -140.14 129.75 13.59 Favored Pre-proline 0 N--CA 1.446 -0.628 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 172.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -57.41 143.0 95.22 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 122.512 2.141 . . . . 0.0 107.578 174.751 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.8 tp -43.46 -49.45 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 123.764 0.826 . . . . 0.0 112.269 -177.666 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 p -53.9 -24.58 16.59 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.14 1.376 . . . . 0.0 114.321 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -78.81 -8.06 58.43 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 118.756 0.707 . . . . 0.0 112.61 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 93.0 t -70.1 134.67 87.35 Favored Pre-proline 0 CA--C 1.543 0.696 0 O-C-N 121.106 -0.996 . . . . 0.0 110.922 -177.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.85 64.6 5.92 Favored 'Trans proline' 0 CA--C 1.537 0.673 0 C-N-CA 124.674 3.582 . . . . 0.0 110.556 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.09 178.69 6.84 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.37 1.468 . . . . 0.0 107.177 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.46 -63.83 1.2 Allowed 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 124.383 1.073 . . . . 0.0 110.565 178.314 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.9 p -47.26 -56.6 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 C-N-CA 124.22 1.008 . . . . 0.0 112.775 -177.411 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -61.06 -57.32 13.05 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-O 121.703 0.763 . . . . 0.0 108.959 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.3 m -53.67 -36.97 62.71 Favored 'General case' 0 N--CA 1.446 -0.648 0 C-N-CA 126.18 1.792 . . . . 0.0 115.592 -174.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.438 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -87.35 7.04 82.27 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.498 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 26.1 mtmt 74.99 -39.94 0.42 Allowed 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.974 1.71 . . . . 0.0 111.44 -177.368 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.438 ' H ' ' C ' ' A' ' 36' ' ' GLY . 26.6 ttt 28.01 -70.05 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 131.305 3.842 . . . . 0.0 116.909 177.687 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 9.6 tpt -79.13 -16.98 55.9 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.383 1.073 . . . . 0.0 112.654 -176.279 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.37 -135.29 2.18 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -178.556 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -131.24 154.94 47.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 105.833 -1.914 . . . . 0.0 105.833 173.467 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.94 -159.48 22.79 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.249 -0.977 . . . . 0.0 114.177 -174.953 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 25.5 p90 -163.63 171.15 16.13 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.01 0.924 . . . . 0.0 109.521 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -120.34 137.3 54.35 Favored 'General case' 0 CA--C 1.508 -0.669 0 C-N-CA 122.936 0.494 . . . . 0.0 109.705 174.045 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 20.3 mm -112.09 129.6 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.903 0 N-CA-C 103.38 -2.822 . . . . 0.0 103.38 171.189 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 15.6 tp -94.85 110.63 50.7 Favored Pre-proline 0 N--CA 1.446 -0.651 0 N-CA-C 102.019 -3.326 . . . . 0.0 102.019 172.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -64.55 155.27 67.46 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 123.639 2.893 . . . . 0.0 116.916 -169.487 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.3 p -127.55 -50.94 1.38 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.124 1.37 . . . . 0.0 107.725 171.132 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -79.0 122.5 26.26 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 123.276 0.63 . . . . 0.0 110.37 177.553 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 40.31 2.26 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 174.491 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 72.7 mt -136.89 117.82 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.767 -2.679 . . . . 0.0 103.767 -179.237 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.3 t -120.59 109.4 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 122.962 0.505 . . . . 0.0 110.128 -173.891 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.5 m -91.15 -173.2 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 172.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.6 m -116.3 147.57 39.78 Favored Pre-proline 0 N--CA 1.469 0.49 0 CA-C-O 117.199 -1.381 . . . . 0.0 112.723 -175.108 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -61.54 -38.92 58.98 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 121.883 1.722 . . . . 0.0 108.305 174.65 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.46 142.0 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 102.921 -2.992 . . . . 0.0 102.921 171.151 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 29.1 mtm180 -95.12 -79.91 0.42 Allowed 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 102.094 -3.299 . . . . 0.0 102.094 171.902 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.88 -73.76 0.99 Allowed Glycine 0 C--N 1.338 0.64 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 176.166 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.21 123.1 8.72 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.765 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 24.1 mm -70.12 128.4 33.39 Favored 'Isoleucine or valine' 0 C--N 1.344 0.369 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.7 tt -78.43 -52.54 8.41 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.049 -2.204 . . . . 0.0 105.049 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 174.18 161.17 0.18 Allowed 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 124.614 1.166 . . . . 0.0 108.56 178.539 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.7 p -135.54 121.5 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 172.04 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -38.53 146.46 0.3 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.791 0.723 . . . . 0.0 112.947 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -58.63 -43.01 48.42 Favored 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.931 2.421 . . . . 0.0 109.723 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 15.9 p -78.23 74.27 4.77 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 173.591 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -34.4 93.24 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 129.261 3.024 . . . . 0.0 113.471 -173.671 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -158.56 -19.2 0.07 Allowed 'General case' 0 C--O 1.225 -0.229 0 N-CA-C 113.409 0.892 . . . . 0.0 113.409 175.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -164.77 -177.84 4.96 Favored 'General case' 0 C--O 1.222 -0.363 0 CA-C-N 120.238 1.381 . . . . 0.0 110.839 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.875 14.3 mm 135.57 -128.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 1 C-N-CA 133.254 4.622 . . . . 0.0 109.141 177.274 . . . . . . . . 3 2 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.4 175.29 42.49 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 118.769 2.268 . . . . 0.0 118.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 39.0 mt -128.72 172.94 10.76 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 127.478 2.311 . . . . 0.0 109.576 -178.255 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 -148.61 140.91 24.14 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.828 1.651 . . . . 0.0 106.835 176.339 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 59.6 p -77.45 -106.95 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.417 0 CA-C-O 121.049 0.452 . . . . 0.0 110.363 178.33 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -90.41 53.24 2.41 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 175.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 79.86 -56.11 4.53 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -174.933 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.54 173.97 28.79 Favored Glycine 0 CA--C 1.533 1.202 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 176.766 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.4 ttp180 54.13 69.73 0.69 Allowed 'General case' 0 CA--C 1.529 0.137 0 C-N-CA 124.446 1.099 . . . . 0.0 108.84 -177.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -79.28 134.32 36.64 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.3 mp -116.85 114.67 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 C-N-CA 123.268 0.627 . . . . 0.0 109.905 -177.521 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -81.2 125.84 30.78 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 104.196 -2.52 . . . . 0.0 104.196 170.706 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 62.7 mt -123.06 132.01 72.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -128.29 132.77 48.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 106.309 -1.737 . . . . 0.0 106.309 174.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -116.44 104.42 11.43 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 126.16 1.784 . . . . 0.0 109.489 -177.608 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.77 163.06 10.02 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 -178.261 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 10.7 mm -109.02 119.85 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 -179.05 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.4 t70 77.09 4.61 3.28 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.391 1.477 . . . . 0.0 113.779 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -61.78 -24.87 67.12 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 120.761 -1.212 . . . . 0.0 110.757 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -59.86 -47.88 89.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 C-N-CA 125.92 1.688 . . . . 0.0 108.127 173.594 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 4.5 m -63.47 -35.59 80.94 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.125 0.97 . . . . 0.0 108.766 177.43 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.58 19.75 0.78 Allowed 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 125.426 1.49 . . . . 0.0 110.873 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 4.8 mptt 37.77 37.59 0.13 Allowed 'General case' 0 C--N 1.346 0.42 0 C-N-CA 128.658 2.783 . . . . 0.0 114.595 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 52.58 34.42 43.07 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.486 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -67.41 92.64 0.3 Allowed 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 121.401 -1.058 . . . . 0.0 110.164 -178.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.47 1.67 5.12 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 126.043 1.782 . . . . 0.0 112.214 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -96.58 103.35 15.26 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.801 1.241 . . . . 0.0 111.263 -176.552 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.5 m -89.7 105.78 18.03 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.081 -2.192 . . . . 0.0 105.081 172.931 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.7 p -81.6 123.85 29.03 Favored 'General case' 0 N--CA 1.451 -0.406 0 O-C-N 121.613 -0.68 . . . . 0.0 110.402 -178.329 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -81.41 -52.3 7.41 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.915 1.286 . . . . 0.0 108.911 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.9 m -78.32 130.46 36.16 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 C-N-CA 117.999 -1.48 . . . . 0.0 107.224 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.5 m -94.37 57.06 2.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 169.37 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.341 9.8 pt-20 29.32 65.96 0.11 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 128.737 2.815 . . . . 0.0 111.681 -168.33 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -73.3 58.44 1.94 Allowed Glycine 0 CA--C 1.525 0.662 0 CA-C-N 111.574 -2.557 . . . . 0.0 111.253 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -10.59 -17.87 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.533 2 C-N-CA 136.188 5.795 . . . . 0.0 124.342 -179.317 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -142.88 110.7 5.9 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 128.062 2.545 . . . . 0.0 106.612 178.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.0 155.76 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 123.908 0.883 . . . . 0.0 112.833 -171.847 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -80.88 151.61 70.89 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-O 117.948 -1.025 . . . . 0.0 108.662 175.162 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -47.88 164.62 0.16 Allowed 'Trans proline' 0 CA--C 1.533 0.428 1 C-N-CA 127.018 5.145 . . . . 0.0 120.304 -174.158 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 68.45 -92.5 0.27 Allowed Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.84 1.686 . . . . 0.0 113.678 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 35.5 tp60 1.18 101.9 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.793 1 C-N-CA 132.258 4.223 . . . . 0.0 114.735 -176.548 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -4.14 112.95 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 130.168 3.387 . . . . 0.0 116.172 178.344 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.6 mt -83.18 -45.25 14.12 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 173.563 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.0 mt -140.38 151.23 44.8 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.723 1.209 . . . . 0.0 111.282 -174.285 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -119.84 128.58 53.82 Favored 'General case' 0 CA--C 1.514 -0.407 1 N-CA-C 99.12 -4.4 . . . . 0.0 99.12 167.363 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.93 124.41 27.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-N 115.1 -0.954 . . . . 0.0 112.756 -165.223 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -73.87 69.13 1.37 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.938 0.895 . . . . 0.0 110.037 178.984 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.1 mt -47.2 -52.49 15.62 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.793 0.837 . . . . 0.0 110.583 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -43.46 -49.65 7.16 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 125.392 1.477 . . . . 0.0 112.343 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -82.81 -31.36 28.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 123.175 0.297 . . . . 0.0 111.774 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 42.2 t -63.1 -56.48 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 118.901 -0.571 . . . . 0.0 110.839 179.007 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.324 3.8 pttm -42.78 -56.29 6.22 Favored Pre-proline 0 N--CA 1.47 0.535 0 N-CA-C 116.391 1.997 . . . . 0.0 116.391 -176.93 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -60.86 -14.63 33.41 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.699 1.6 . . . . 0.0 113.22 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 -98.98 5.08 47.36 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.056 -0.973 . . . . 0.0 112.303 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 20.1 m -142.07 155.11 65.44 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 120.332 1.424 . . . . 0.0 112.166 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.31 -39.78 89.16 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.086 2.524 . . . . 0.0 113.927 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -159.97 141.37 12.62 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.156 0.582 . . . . 0.0 110.012 -177.511 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -92.46 14.58 16.27 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.539 1.135 . . . . 0.0 112.068 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.4 mmt -53.04 134.01 38.33 Favored 'General case' 0 N--CA 1.457 -0.111 0 O-C-N 121.415 -0.803 . . . . 0.0 110.369 -178.377 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -110.28 78.78 1.46 Allowed Pre-proline 0 N--CA 1.451 -0.378 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 176.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.2 136.59 27.1 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 C-N-CA 122.449 2.1 . . . . 0.0 110.269 178.381 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -128.98 134.66 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 178.395 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 t -136.53 126.15 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 125.165 1.386 . . . . 0.0 108.55 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.9 m-85 -92.93 124.13 36.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 103.525 -2.769 . . . . 0.0 103.525 176.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 77.7 p -86.49 -82.28 0.2 Allowed 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.071 0.85 . . . . 0.0 109.319 -176.117 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -77.01 52.34 0.87 Allowed 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -78.78 72.26 5.29 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.249 -0.907 . . . . 0.0 108.666 174.509 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 41.87 47.86 3.74 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 126.603 1.961 . . . . 0.0 111.256 -178.259 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 18.9 68.42 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 129.394 3.077 . . . . 0.0 113.245 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 154.75 -9.65 0.39 Allowed Glycine 0 CA--C 1.523 0.574 0 CA-C-O 118.508 -1.162 . . . . 0.0 113.021 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 59.1 mm-40 -69.09 116.93 10.1 Favored 'General case' 0 C--N 1.342 0.281 0 CA-C-N 119.626 1.713 . . . . 0.0 110.069 178.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.2 p -77.73 136.07 38.11 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.828 -1.915 . . . . 0.0 105.828 173.006 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -86.69 86.74 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 -176.768 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.2 m -77.42 83.31 3.85 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.82 -1.175 . . . . 0.0 110.99 -175.034 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 2.1 pt -56.59 111.15 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 173.636 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -88.73 -38.57 14.62 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 123.892 0.877 . . . . 0.0 109.636 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -81.12 75.77 8.08 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.463 -175.782 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 50.6 p -77.39 69.44 3.65 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 169.38 -137.43 4.52 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -176.7 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.7 t -75.43 149.07 38.64 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.7 m -119.98 158.93 21.59 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 C-N-CA 125.374 1.469 . . . . 0.0 109.048 178.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -131.79 166.98 20.34 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 125.688 1.595 . . . . 0.0 112.22 176.416 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 73.5 mtm-85 -85.65 154.25 21.81 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -175.347 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 57.52 55.11 5.9 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 126.448 1.899 . . . . 0.0 113.591 176.324 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 4.3 mm-40 -143.05 161.12 38.99 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.964 0.906 . . . . 0.0 109.76 176.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . 0.471 ' C ' ' H ' ' A' ' 157' ' ' ILE . 62.9 tt0 -105.52 -61.1 1.53 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 122.817 1.294 . . . . 0.0 112.314 -177.412 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 0.9 OUTLIER -65.68 27.34 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 127.705 2.402 . . . . 0.0 114.682 -174.326 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.471 ' H ' ' C ' ' A' ' 155' ' ' GLU . 1.7 mp -103.17 -34.7 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 130.225 3.41 . . . . 0.0 104.976 177.451 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 59.4 t -149.05 109.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 106.062 -1.829 . . . . 0.0 106.062 173.147 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -101.77 124.31 47.2 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 118.049 0.386 . . . . 0.0 111.78 -176.772 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.4 mp -78.15 108.8 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 174.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -128.9 150.62 50.28 Favored 'General case' 0 C--O 1.226 -0.157 0 C-N-CA 124.383 1.073 . . . . 0.0 109.261 -175.783 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 50.9 tptt . . . . . 0 C--N 1.333 -0.136 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -179.815 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.8 ttt . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.0 mm -77.07 62.77 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 124.463 1.105 . . . . 0.0 108.562 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.39 55.09 0.96 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 124.519 1.128 . . . . 0.0 111.93 -177.523 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -61.28 -42.97 88.24 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-O 118.005 -0.998 . . . . 0.0 112.463 177.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -67.4 66.14 0.73 Allowed 'Trans proline' 0 CA--C 1.544 1.007 0 C-N-CA 123.568 2.845 . . . . 0.0 113.219 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 94.7 mt -73.31 65.29 0.85 Allowed 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.295 1.438 . . . . 0.0 110.696 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -73.53 56.64 0.52 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.998 1.719 . . . . 0.0 111.393 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -77.37 73.65 3.94 Favored 'General case' 0 C--O 1.231 0.1 0 O-C-N 121.508 -0.745 . . . . 0.0 109.288 179.631 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 46.61 54.32 8.94 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 124.892 1.277 . . . . 0.0 111.467 177.274 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 45.2 pt -92.12 18.32 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 C-N-CA 123.89 0.876 . . . . 0.0 113.232 -176.906 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 177.07 -147.06 8.12 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 107.487 -2.245 . . . . 0.0 107.487 179.068 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -79.81 68.35 5.86 Favored 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 177.513 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -105.2 -139.25 0.36 Allowed 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 116.464 2.024 . . . . 0.0 116.464 -172.743 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -71.64 52.05 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 116.96 2.207 . . . . 0.0 116.96 -169.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -160.53 128.45 4.53 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 104.269 -2.493 . . . . 0.0 104.269 171.255 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.4 m -123.77 85.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 CA-C-N 118.846 0.748 . . . . 0.0 110.958 -176.375 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.4 p -19.45 110.25 0.09 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 129.569 3.147 . . . . 0.0 110.512 177.806 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -68.64 -25.13 34.6 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.776 2.317 . . . . 0.0 117.931 -168.498 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.95 146.1 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.611 1.096 . . . . 0.0 109.598 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.1 m -79.34 137.45 37.33 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 170.615 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 173.82 -158.25 27.09 Favored Glycine 0 C--O 1.227 -0.312 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -108.4 120.61 42.89 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.17 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 tt -85.51 134.92 26.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 118.569 0.622 . . . . 0.0 109.718 178.635 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -137.59 149.42 64.97 Favored Pre-proline 0 N--CA 1.451 -0.389 0 C-N-CA 125.79 1.636 . . . . 0.0 107.753 176.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.65 143.37 96.57 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 121.366 1.378 . . . . 0.0 108.566 173.935 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -55.05 -24.82 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -173.774 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.3 p -52.42 -31.02 32.28 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 124.279 1.032 . . . . 0.0 111.134 174.696 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -75.16 -9.72 58.8 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.5 1.12 . . . . 0.0 112.65 -176.448 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.9 t -76.63 131.74 73.53 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 119.13 0.877 . . . . 0.0 109.861 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -77.8 60.1 7.1 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 123.17 2.58 . . . . 0.0 110.847 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -165.55 102.6 0.71 Allowed 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.487 -0.758 . . . . 0.0 110.01 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -24.41 -59.0 0.05 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.476 2.71 . . . . 0.0 115.055 -178.45 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -52.03 -41.85 33.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 123.178 0.591 . . . . 0.0 111.583 -177.723 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -80.67 -48.56 12.43 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.7 m -48.71 -41.54 32.16 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -179.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.415 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -99.61 11.2 61.2 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-O 118.629 -1.095 . . . . 0.0 111.515 -178.411 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm 73.37 -39.5 0.44 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.573 1.549 . . . . 0.0 112.773 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.415 ' H ' ' C ' ' A' ' 36' ' ' GLY . 13.7 tpt 21.7 -62.24 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 1 C-N-CA 132.264 4.226 . . . . 0.0 117.996 178.455 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -77.71 -21.63 51.67 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.991 0.916 . . . . 0.0 111.898 -176.465 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.32 -136.29 2.78 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -130.27 157.55 42.21 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 172.915 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.71 -167.74 36.87 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.943 -176.103 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -146.81 154.72 41.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 124.283 1.033 . . . . 0.0 109.718 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.76 119.09 38.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.009 0.923 . . . . 0.0 109.917 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.3 mm -100.8 129.53 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 171.334 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.3 tt -98.14 105.83 30.98 Favored Pre-proline 0 N--CA 1.45 -0.426 0 N-CA-C 101.326 -3.583 . . . . 0.0 101.326 172.561 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -60.5 167.31 8.26 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 123.434 2.756 . . . . 0.0 117.124 -169.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.1 p -146.98 -58.92 0.28 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.72 1.608 . . . . 0.0 106.942 173.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -69.81 119.0 13.37 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 175.724 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.75 44.85 3.03 Favored Glycine 0 CA--C 1.53 1.005 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 22.0 mt -144.06 114.64 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 N-CA-C 105.253 -2.129 . . . . 0.0 105.253 -177.045 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.65 126.14 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 124.479 1.111 . . . . 0.0 109.131 -175.373 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.8 m -109.29 156.91 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 C-N-CA 123.387 0.675 . . . . 0.0 110.363 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 m -65.67 127.2 92.86 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-O 118.982 -0.532 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.49 -7.96 22.5 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 124.468 3.445 . . . . 0.0 116.765 -174.573 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.4 m -147.99 169.51 3.58 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 CA-C-N 119.754 1.161 . . . . 0.0 109.388 -177.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.06 116.18 17.49 Favored 'General case' 0 C--O 1.235 0.336 1 N-CA-C 97.978 -4.823 . . . . 0.0 97.978 166.893 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.69 170.26 42.11 Favored Glycine 0 N--CA 1.438 -1.215 0 C-N-CA 116.026 -2.988 . . . . 0.0 116.557 -167.08 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 10.0 mtpp -97.2 132.84 42.57 Favored 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 127.989 2.515 . . . . 0.0 109.003 -175.015 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.7 mm -72.8 123.96 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 104.618 -2.364 . . . . 0.0 104.618 173.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 42.0 tp -78.63 -48.88 14.2 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 179.515 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -177.46 171.79 1.91 Allowed 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 123.531 0.732 . . . . 0.0 109.444 173.872 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 51.5 t -144.16 115.08 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 176.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -45.5 147.33 1.47 Allowed Pre-proline 0 CA--C 1.542 0.65 0 CA-C-N 118.689 0.677 . . . . 0.0 111.454 177.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.45 -24.22 11.84 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 124.102 3.202 . . . . 0.0 114.881 176.247 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.8 p -76.34 -15.17 60.03 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.636 1.174 . . . . 0.0 111.165 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.6 tppt? 70.94 4.8 5.22 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 127.852 2.461 . . . . 0.0 113.344 -178.837 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.2 p-80 -78.97 -25.93 43.48 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 113.41 0.893 . . . . 0.0 113.41 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.96 -173.94 2.53 Favored 'General case' 0 C--O 1.222 -0.348 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -172.296 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.62 25.9 mm 132.03 -124.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.345 1 C-N-CA 136.505 5.922 . . . . 0.0 105.75 178.863 . . . . . . . . 3 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -179.96 -176.68 47.55 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 116.976 1.55 . . . . 0.0 116.976 -179.106 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.3 mp -126.29 171.92 10.54 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 127.519 2.327 . . . . 0.0 110.126 -178.613 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -140.36 136.37 33.09 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.477 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 62.9 p -71.66 -92.12 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.925 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -150.21 -64.04 0.21 Allowed 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.221 1.409 . . . . 0.0 109.504 179.229 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -76.23 60.99 3.12 Favored Glycine 0 CA--C 1.527 0.787 0 C-N-CA 123.627 0.632 . . . . 0.0 111.54 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 75.29 -60.07 2.77 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.054 0.835 . . . . 0.0 112.388 178.79 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 24.8 mtp180 -19.23 96.92 0.01 OUTLIER 'General case' 0 C--O 1.235 0.338 0 C-N-CA 128.449 2.7 . . . . 0.0 112.836 -179.403 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 13.2 tm-20 -93.3 150.72 20.27 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 126.866 2.066 . . . . 0.0 109.318 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.65 103.39 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 C-N-CA 124.376 1.071 . . . . 0.0 109.052 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.4 tt -85.64 136.64 33.29 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.498 -1.668 . . . . 0.0 106.498 174.467 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 20.0 mt -122.77 148.72 26.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 123.444 0.698 . . . . 0.0 109.938 -178.738 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.37 126.48 21.17 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 170.551 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -102.41 106.22 16.94 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.705 1.202 . . . . 0.0 108.773 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 64.29 176.63 4.73 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 118.184 0.447 . . . . 0.0 113.09 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.6 mm -113.29 141.17 29.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.9 t70 63.27 13.32 6.88 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.423 1.089 . . . . 0.0 112.486 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 p -74.15 -39.74 63.06 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 126.265 1.826 . . . . 0.0 107.231 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 p -47.11 -47.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 124.923 1.289 . . . . 0.0 109.287 171.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -63.98 -54.58 32.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 125.347 1.459 . . . . 0.0 111.304 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.23 -36.89 78.74 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 123.991 0.916 . . . . 0.0 112.008 -178.257 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 81.5 mttt 79.57 145.6 0.09 Allowed 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 128.854 2.862 . . . . 0.0 108.706 -176.67 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.45 48.71 0.29 Allowed Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.609 1.1 . . . . 0.0 115.537 -176.25 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 25.7 pt-20 -63.75 -17.31 62.9 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 119.168 1.484 . . . . 0.0 113.67 177.687 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -109.84 15.43 31.43 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 126.544 2.021 . . . . 0.0 111.13 177.033 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -107.95 99.42 8.88 Favored 'General case' 0 C--N 1.343 0.283 0 CA-C-N 118.156 0.978 . . . . 0.0 110.665 -176.809 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -79.44 93.99 5.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 174.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 p -79.11 127.4 31.96 Favored 'General case' 0 N--CA 1.453 -0.31 0 O-C-N 120.983 -1.073 . . . . 0.0 110.505 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -89.17 -49.11 6.94 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 123.836 0.854 . . . . 0.0 110.375 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -78.1 133.29 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.032 0 C-N-CA 119.019 -1.072 . . . . 0.0 110.559 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 m -87.73 61.5 6.5 Favored 'General case' 0 C--N 1.333 -0.128 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 172.793 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.271 1.6 pm0 3.22 79.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 130.451 3.501 . . . . 0.0 115.211 -174.244 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 174.65 6.54 0.02 OUTLIER Glycine 0 CA--C 1.533 1.202 0 CA-C-N 113.32 -1.763 . . . . 0.0 114.812 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.24 121.52 14.46 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 119.493 1.646 . . . . 0.0 107.396 176.115 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 37.8 mmt-85 -100.07 100.53 11.41 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 129.796 3.238 . . . . 0.0 111.817 -175.297 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.551 7.3 p 60.47 78.23 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 N-CA-C 116.813 2.153 . . . . 0.0 116.813 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -135.99 150.14 70.5 Favored Pre-proline 0 N--CA 1.446 -0.632 0 CA-C-N 111.933 -2.394 . . . . 0.0 105.141 169.15 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -105.42 142.59 0.1 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.969 3.112 . . . . 0.0 111.803 -177.123 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 56.93 15.26 12.46 Favored Glycine 0 CA--C 1.531 1.046 0 O-C-N 121.417 -0.802 . . . . 0.0 114.289 175.588 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.3 130.28 45.41 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.393 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 25.7 ttpt -59.39 117.64 5.07 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.112 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.4 mt -80.41 -54.2 5.92 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 25.0 mt -144.82 151.13 38.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.215 1.006 . . . . 0.0 110.871 -173.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 6.1 tm-20 -116.45 128.44 55.48 Favored 'General case' 0 CA--C 1.515 -0.398 1 N-CA-C 97.922 -4.844 . . . . 0.0 97.922 166.098 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.52 121.69 22.78 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.834 -166.719 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -71.91 69.96 0.73 Allowed 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.844 1.258 . . . . 0.0 111.112 -177.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.3 mt -47.95 -44.85 30.53 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.057 0.943 . . . . 0.0 110.718 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -52.83 -43.78 66.24 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.473 0.709 . . . . 0.0 112.794 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -84.71 -33.36 23.16 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.114 0.416 . . . . 0.0 111.305 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 40.3 t -63.87 -56.25 17.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 O-C-N 121.865 -0.522 . . . . 0.0 109.852 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.359 0.1 OUTLIER -40.74 -55.52 4.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 117.891 2.552 . . . . 0.0 117.891 -177.125 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -57.91 -21.65 50.38 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.515 2.143 . . . . 0.0 112.87 178.893 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -93.68 9.57 36.42 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.457 -0.782 . . . . 0.0 112.216 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 15.9 m -138.96 152.02 69.36 Favored Pre-proline 0 C--N 1.344 0.36 0 CA-C-N 119.923 1.238 . . . . 0.0 111.695 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.03 -26.8 12.62 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.044 2.496 . . . . 0.0 111.594 179.291 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 15.6 t -153.1 142.81 21.97 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.09 6.99 47.56 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.226 1.01 . . . . 0.0 110.595 178.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 16.5 mmt -51.01 119.61 4.12 Favored 'General case' 0 C--N 1.344 0.347 0 CA-C-N 118.5 0.591 . . . . 0.0 109.955 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 29.9 m -117.2 87.52 24.05 Favored Pre-proline 0 N--CA 1.446 -0.66 0 C-N-CA 125.588 1.555 . . . . 0.0 107.645 -177.082 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 49.8 Cg_endo -84.89 151.61 11.2 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 C-N-CA 121.411 1.407 . . . . 0.0 112.011 -178.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.3 mp -118.55 130.14 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 N-CA-C 102.792 -3.04 . . . . 0.0 102.792 173.853 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.0 t -128.6 153.4 38.05 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.58 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -127.02 109.82 12.31 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 103.418 -2.808 . . . . 0.0 103.418 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.0 p -75.2 -78.05 0.11 Allowed 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -175.864 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -74.03 65.86 1.15 Allowed 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.587 0.708 . . . . 0.0 112.096 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 16.4 mt -72.81 70.41 0.98 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.144 1.378 . . . . 0.0 108.273 176.315 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 27.74 48.99 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 128.508 2.723 . . . . 0.0 111.921 -176.63 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 28.5 53.52 0.08 Allowed 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 128.74 2.816 . . . . 0.0 114.44 -175.647 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 167.09 -4.71 0.05 OUTLIER Glycine 0 CA--C 1.528 0.848 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.227 178.499 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . 0.507 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 3.7 mm-40 -87.35 148.01 25.23 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.838 1.319 . . . . 0.0 110.178 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 51.0 p -123.89 140.42 53.0 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.943 1.297 . . . . 0.0 108.102 179.035 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -86.08 95.35 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-O 122.064 0.935 . . . . 0.0 108.952 -177.563 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 62.1 m -84.74 87.36 7.3 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.301 -0.875 . . . . 0.0 109.836 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.8 pt -66.07 128.78 29.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 174.733 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -103.2 -46.9 4.48 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.557 1.143 . . . . 0.0 109.708 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -76.14 156.69 33.53 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.433 0.635 . . . . 0.0 111.629 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 27.9 p -150.62 113.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 104.774 -2.306 . . . . 0.0 104.774 178.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 115.8 -151.57 18.33 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.9 t -59.12 139.93 56.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.347 1.074 . . . . 0.0 112.379 -177.701 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.5 m -143.52 146.32 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 C-N-CA 126.23 1.812 . . . . 0.0 108.64 177.363 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -101.59 160.18 14.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.491 1.116 . . . . 0.0 110.768 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.2 ttp180 -75.77 154.99 35.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.524 1.53 . . . . 0.0 110.887 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 57.98 52.96 7.23 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.903 1.681 . . . . 0.0 113.222 178.219 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 17.2 mm-40 -135.93 168.01 20.14 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.635 1.574 . . . . 0.0 108.509 177.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . 0.42 ' C ' ' H ' ' A' ' 157' ' ' ILE . 0.5 OUTLIER -119.69 -77.53 0.58 Allowed 'General case' 0 C--N 1.344 0.327 0 CA-C-N 120.027 1.285 . . . . 0.0 114.238 179.403 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -37.08 -7.62 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.065 1 C-N-CA 132.073 4.149 . . . . 0.0 120.194 -174.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . 0.42 ' H ' ' C ' ' A' ' 155' ' ' GLU . 4.9 mp -68.39 -33.44 60.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 130.874 3.67 . . . . 0.0 106.889 174.565 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -137.29 133.62 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 C-N-CA 127.281 2.233 . . . . 0.0 106.599 173.428 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -127.08 133.03 50.52 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . 0.507 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.06 116.2 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 175.347 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -98.26 170.83 8.6 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 175.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp . . . . . 0 CA--C 1.532 0.259 0 O-C-N 121.457 -0.777 . . . . 0.0 110.811 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.0 ttt . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 33.1 mm -44.02 -41.87 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 126.349 1.86 . . . . 0.0 112.976 -177.377 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.74 71.89 3.33 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.638 0.732 . . . . 0.0 110.243 -179.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -24.8 -57.17 0.16 Allowed Pre-proline 0 CA--C 1.54 0.593 0 C-N-CA 128.062 2.545 . . . . 0.0 116.243 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -67.63 74.01 0.62 Allowed 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.611 2.207 . . . . 0.0 112.2 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 71.1 mt 45.13 41.99 6.29 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 126.23 1.812 . . . . 0.0 111.969 178.43 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 54.3 mm-40 57.1 47.81 16.62 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.921 0.888 . . . . 0.0 110.282 -177.511 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 59.6 46.0 12.52 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 125.259 1.424 . . . . 0.0 108.078 -176.555 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 16.2 mp0 48.91 61.07 3.29 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.493 1.117 . . . . 0.0 108.423 -176.428 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.2 mt 73.13 -40.79 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 126.535 1.934 . . . . 0.0 110.796 -176.029 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 76.35 -71.33 2.05 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -68.54 68.19 0.14 Allowed 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 126.058 1.743 . . . . 0.0 111.735 -178.839 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -150.02 -161.68 1.39 Allowed 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 126.678 1.991 . . . . 0.0 110.93 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.472 12.9 p 65.23 -73.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 119.286 3.069 . . . . 0.0 119.286 175.392 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -115.43 153.26 31.39 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 125.213 1.405 . . . . 0.0 110.637 -170.639 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.3 m -117.35 108.36 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 119.244 0.929 . . . . 0.0 109.04 172.504 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.3 t -38.87 115.96 0.95 Allowed Pre-proline 0 CA--C 1.553 1.066 0 C-N-CA 124.759 1.224 . . . . 0.0 111.761 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -76.82 -23.38 10.95 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 123.507 2.805 . . . . 0.0 118.293 -172.338 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.89 154.41 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 120.698 1.59 . . . . 0.0 109.989 -178.552 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.5 m -89.74 137.73 32.08 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 175.329 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 160.71 -130.71 2.44 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -131.32 139.01 49.47 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 124.653 1.181 . . . . 0.0 109.087 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.9 tt -101.39 131.6 48.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 CA-C-N 118.673 0.669 . . . . 0.0 110.01 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.64 145.49 49.6 Favored Pre-proline 0 N--CA 1.452 -0.358 0 C-N-CA 126.069 1.748 . . . . 0.0 108.036 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -62.82 141.97 86.93 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 121.749 1.633 . . . . 0.0 108.598 174.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.6 tt -53.61 -27.29 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 114.334 1.235 . . . . 0.0 114.334 -174.431 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.7 p -55.02 -29.0 56.41 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.879 0.871 . . . . 0.0 111.553 176.111 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -78.98 -1.45 35.47 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.81 0.844 . . . . 0.0 112.937 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.4 t -81.68 134.58 50.42 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.068 -1.02 . . . . 0.0 110.181 -178.292 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -77.83 54.1 4.68 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.741 2.961 . . . . 0.0 111.934 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -167.98 109.28 0.58 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.308 0.958 . . . . 0.0 110.651 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -29.43 -54.48 0.14 Allowed 'General case' 0 C--O 1.234 0.249 0 C-N-CA 128.35 2.66 . . . . 0.0 115.186 -177.716 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -51.56 -40.49 25.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.973 0.416 . . . . 0.0 110.565 -176.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . 0.44 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 24.5 m-85 -83.15 -52.87 6.23 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 177.666 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -46.66 -39.94 12.27 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 114.349 1.241 . . . . 0.0 114.349 -177.79 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -109.11 22.77 24.62 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-O 118.339 -1.256 . . . . 0.0 111.39 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.8 mppt? 70.69 -45.02 0.6 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.028 1.731 . . . . 0.0 114.384 178.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.8 tpp 32.76 -68.92 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 130.2 3.4 . . . . 0.0 116.703 -178.096 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.32 -26.01 42.28 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.974 1.31 . . . . 0.0 112.771 -176.652 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.12 -154.55 16.09 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -178.957 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -108.39 153.34 23.43 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 174.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -174.25 -167.46 33.77 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.42 -176.325 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 9.4 p90 -150.02 165.13 33.64 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.894 1.278 . . . . 0.0 109.044 -178.461 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -117.85 117.19 28.61 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 123.706 0.802 . . . . 0.0 111.289 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -87.83 134.34 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 103.994 -2.595 . . . . 0.0 103.994 170.023 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.2 tt -100.89 106.62 45.22 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.054 -4.795 . . . . 0.0 98.054 169.287 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_endo -83.92 161.38 13.9 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 123.439 2.76 . . . . 0.0 114.191 -168.051 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.7 p -130.18 -53.39 1.11 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.867 1.267 . . . . 0.0 109.639 176.63 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -67.11 128.03 34.85 Favored 'General case' 0 CA--C 1.519 -0.214 0 O-C-N 122.18 -0.325 . . . . 0.0 111.493 179.432 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.45 39.55 1.93 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 174.089 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 5.0 mp -143.62 120.53 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 104.676 -2.342 . . . . 0.0 104.676 178.187 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 69.8 t -119.41 120.08 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 C-N-CA 125.695 1.598 . . . . 0.0 107.415 -176.055 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 22.0 m -106.77 157.29 7.06 Favored 'Isoleucine or valine' 0 C--N 1.338 0.099 0 N-CA-C 114.42 1.266 . . . . 0.0 114.42 -175.879 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 48.2 m -61.62 125.76 85.32 Favored Pre-proline 0 CA--C 1.537 0.48 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.488 179.017 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -77.52 -4.12 14.31 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 124.945 3.763 . . . . 0.0 116.012 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.5 m -155.21 172.88 0.57 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 125.297 1.439 . . . . 0.0 108.055 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . 0.432 ' NE ' ' H ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -76.26 87.89 3.09 Favored 'General case' 0 C--N 1.34 0.16 1 N-CA-C 98.374 -4.676 . . . . 0.0 98.374 168.028 . . . . . . . . 4 4 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.07 176.26 30.43 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 118.543 2.177 . . . . 0.0 118.543 -164.971 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.01 110.54 5.31 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 172.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.2 mm -61.82 125.14 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 37.1 mt -78.95 -48.75 13.94 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 105.779 -1.934 . . . . 0.0 105.779 173.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -173.25 159.33 3.8 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.4 t -135.4 119.81 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 102.879 -3.008 . . . . 0.0 102.879 173.459 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -45.55 147.39 1.49 Allowed Pre-proline 0 CA--C 1.535 0.384 0 O-C-N 123.43 0.456 . . . . 0.0 111.55 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -56.51 -25.96 61.26 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.642 2.228 . . . . 0.0 111.214 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 55.2 p -79.97 13.49 2.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 117.03 -1.462 . . . . 0.0 112.596 177.294 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . 0.275 0.1 OUTLIER 66.28 -39.6 0.33 Allowed 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 117.857 2.539 . . . . 0.0 117.857 178.477 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.9 p-80 -57.63 -26.6 61.82 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 116.269 1.951 . . . . 0.0 116.269 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.93 -175.99 5.67 Favored 'General case' 0 C--O 1.221 -0.396 0 N-CA-C 114.292 1.219 . . . . 0.0 114.292 -172.237 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.847 26.9 mm 127.0 -135.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.52 -0.192 1 C-N-CA 133.25 4.62 . . . . 0.0 110.289 178.51 . . . . . . . . 3 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -166.89 173.47 42.2 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 118.43 2.132 . . . . 0.0 118.43 -176.044 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.7 mp -127.64 175.16 8.49 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 128.208 2.603 . . . . 0.0 109.854 -177.825 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -137.07 160.74 38.07 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 103.258 -2.867 . . . . 0.0 103.258 168.567 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 83.6 p -79.69 -99.77 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.388 0 O-C-N 124.055 0.847 . . . . 0.0 109.448 177.861 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -98.57 -56.4 2.47 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 124.553 1.141 . . . . 0.0 108.97 177.603 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -158.26 49.05 0.43 Allowed Glycine 0 CA--C 1.524 0.615 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 179.25 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 168.02 -168.95 41.11 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 107.87 -2.092 . . . . 0.0 107.87 -178.079 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 74.4 mtp180 49.37 68.64 0.69 Allowed 'General case' 0 CA--C 1.524 -0.041 0 C-N-CA 124.833 1.253 . . . . 0.0 109.84 -178.72 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -79.63 109.96 14.51 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 125.327 1.451 . . . . 0.0 107.389 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.4 mp -95.96 116.56 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 C-N-CA 125.381 1.472 . . . . 0.0 109.763 -176.467 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 9.2 tp -93.58 122.29 35.87 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 105.316 -2.105 . . . . 0.0 105.316 172.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.0 mt -113.82 134.53 56.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 124.938 1.295 . . . . 0.0 108.741 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -131.24 109.76 10.63 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 171.799 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 6.4 t80 -78.51 119.6 22.02 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 118.708 -0.663 . . . . 0.0 109.443 179.871 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.1 -161.26 2.97 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-O 121.71 0.617 . . . . 0.0 113.341 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.9 mm -131.17 145.5 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.4 t70 62.67 15.34 7.96 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.5 1.12 . . . . 0.0 113.426 179.713 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.9 p -78.52 -37.7 42.42 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 126.251 1.821 . . . . 0.0 107.468 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 9.1 p -50.71 -45.26 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 CA-C-N 113.77 -1.559 . . . . 0.0 108.787 172.386 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -63.31 -37.86 88.92 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 125.531 1.532 . . . . 0.0 111.329 178.455 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.65 -39.44 94.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 127.145 2.178 . . . . 0.0 109.898 -179.804 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mttp 59.62 88.01 0.08 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.782 1.633 . . . . 0.0 114.223 175.853 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.4 -55.63 2.85 Favored Glycine 0 CA--C 1.539 1.582 0 O-C-N 121.375 -0.828 . . . . 0.0 112.856 175.244 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -28.17 108.3 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 128.911 2.884 . . . . 0.0 114.034 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 92.24 -2.14 74.39 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-N 113.976 -1.466 . . . . 0.0 114.764 175.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.432 ' CG ' HG13 ' A' ' 115' ' ' VAL . 2.4 m-85 -108.86 109.51 20.63 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 117.857 0.828 . . . . 0.0 109.823 -176.684 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.7 m -79.9 81.18 6.2 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 102.741 -3.059 . . . . 0.0 102.741 169.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.8 p -76.99 114.09 15.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 -178.492 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -77.64 -46.17 22.86 Favored 'General case' 0 CA--C 1.511 -0.551 0 C-N-CA 123.459 0.703 . . . . 0.0 111.297 -173.265 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.56 125.98 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 C-N-CA 117.122 -1.831 . . . . 0.0 109.96 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.7 m -92.48 58.39 3.16 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 102.375 -3.195 . . . . 0.0 102.375 168.476 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.449 0.0 OUTLIER 30.47 54.35 0.16 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 129.307 3.043 . . . . 0.0 112.907 -168.43 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.03 62.92 2.08 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 110.265 -3.152 . . . . 0.0 110.712 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 33.0 t70 3.92 -106.46 0.0 OUTLIER 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 130.098 3.359 . . . . 0.0 116.312 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -55.14 106.99 0.26 Allowed 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.084 1.754 . . . . 0.0 111.617 -173.018 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 2.5 m -124.14 157.1 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 126.811 2.044 . . . . 0.0 111.692 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.4 mm-40 -86.83 164.17 37.97 Favored Pre-proline 0 CA--C 1.535 0.379 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 172.289 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -70.25 154.21 65.98 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 N-CA-C 106.58 -2.123 . . . . 0.0 106.58 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.9 -15.15 8.62 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 119.586 -1.292 . . . . 0.0 114.072 178.466 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.29 125.96 25.66 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 106.606 -1.628 . . . . 0.0 106.606 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . 0.311 0.0 OUTLIER -66.74 119.95 12.68 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.102 0.865 . . . . 0.0 111.428 -177.268 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 77.4 mt -79.67 -41.5 26.74 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.3 mp -147.82 146.26 29.06 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.126 0.97 . . . . 0.0 111.059 -178.69 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -114.55 130.6 56.77 Favored 'General case' 0 N--CA 1.463 0.196 1 N-CA-C 99.203 -4.369 . . . . 0.0 99.203 166.539 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.432 HG13 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -138.74 127.81 30.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.633 -164.307 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -75.71 65.41 1.87 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-O 121.137 0.494 . . . . 0.0 110.247 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.5 mt -50.42 -38.1 41.37 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 123.617 0.767 . . . . 0.0 111.796 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -54.21 -40.19 67.38 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 122.899 0.48 . . . . 0.0 112.162 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -91.06 -32.77 15.76 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 122.829 0.452 . . . . 0.0 111.34 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.27 -48.58 84.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 O-C-N 121.622 -0.673 . . . . 0.0 109.699 178.955 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.376 40.6 pttt -41.73 -58.38 3.23 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 116.498 2.036 . . . . 0.0 116.498 -177.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -59.42 -20.0 54.22 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.258 1.972 . . . . 0.0 113.137 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -95.61 9.11 41.37 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.773 0.829 . . . . 0.0 112.351 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 31.4 m -133.44 149.46 72.38 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 119.747 1.158 . . . . 0.0 109.9 177.559 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -72.24 -27.71 16.22 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.576 2.184 . . . . 0.0 111.187 179.433 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 5.4 m -160.2 138.31 10.03 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.282 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.0 tp -91.54 7.11 42.94 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.344 1.058 . . . . 0.0 111.524 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 20.3 mmt -50.3 116.13 1.74 Allowed 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.71 0.804 . . . . 0.0 109.226 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 50.1 m -108.59 84.38 2.42 Favored Pre-proline 0 N--CA 1.444 -0.744 0 C-N-CA 124.276 1.03 . . . . 0.0 108.317 -179.372 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . 0.44 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 72.5 Cg_endo -72.41 142.29 36.72 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.44 2.094 . . . . 0.0 110.765 179.039 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 29.6 mt -131.15 128.52 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 104.459 -2.422 . . . . 0.0 104.459 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -125.59 152.55 32.56 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 C-N-CA 125.314 1.446 . . . . 0.0 107.863 -177.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -120.69 117.8 28.43 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 102.867 -3.012 . . . . 0.0 102.867 177.935 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.4 p -81.38 -67.89 0.74 Allowed 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.478 0.656 . . . . 0.0 110.353 -173.003 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.6 p30 -70.82 51.88 0.14 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 126.442 1.897 . . . . 0.0 113.034 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.7 mt -75.72 63.84 1.66 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.809 1.244 . . . . 0.0 108.874 177.392 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 24.32 49.96 0.01 OUTLIER 'General case' 0 C--N 1.346 0.445 0 C-N-CA 128.969 2.908 . . . . 0.0 112.051 -176.439 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 28.03 54.21 0.07 Allowed 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 128.649 2.78 . . . . 0.0 114.135 -174.894 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.9 0.05 OUTLIER Glycine 0 CA--C 1.528 0.873 0 CA-C-O 118.853 -0.97 . . . . 0.0 114.3 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . 0.48 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 26.8 mt-10 -80.96 138.34 36.09 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.152 1.476 . . . . 0.0 109.701 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 7.7 p -111.08 139.39 46.48 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.223 1.409 . . . . 0.0 109.273 179.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.64 120.79 35.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.3 m -114.75 95.71 5.37 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.665 1.186 . . . . 0.0 111.308 -174.899 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 2.3 pt -63.32 124.75 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 176.655 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -96.08 -53.82 3.52 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.655 1.182 . . . . 0.0 108.376 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -86.22 74.0 10.11 Favored 'General case' 0 N--CA 1.456 -0.136 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 47.1 p -77.04 72.76 3.61 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 -179.364 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 179.87 -136.51 2.77 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -177.391 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.0 t -69.0 148.78 49.6 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.38 163.02 38.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 C-N-CA 125.222 1.409 . . . . 0.0 108.097 177.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -133.44 162.59 31.46 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.687 1.195 . . . . 0.0 109.039 -178.313 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 68.6 mtp180 -65.23 147.6 53.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.869 0.468 . . . . 0.0 110.509 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 25.8 tp10 57.65 12.97 1.76 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 126.847 2.059 . . . . 0.0 114.749 173.855 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -71.55 117.87 13.66 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -65.97 137.47 57.15 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . 0.465 ' C ' ' H ' ' A' ' 158' ' ' VAL . 27.9 t0 74.18 -111.81 0.04 OUTLIER 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 128.027 2.531 . . . . 0.0 108.448 -175.672 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.271 1.6 mp 70.86 -29.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 129.456 3.103 . . . . 0.0 110.866 -176.703 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . 0.465 ' H ' ' C ' ' A' ' 156' ' ' ASP . 6.2 p -143.35 119.4 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 130.197 3.399 . . . . 0.0 105.003 173.148 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 28.0 tttm -111.9 139.3 47.5 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.767 0.427 . . . . 0.0 110.077 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . 0.48 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.14 132.06 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 172.152 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -141.26 167.96 20.91 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 106.627 -1.619 . . . . 0.0 106.627 177.482 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 24.1 tptp . . . . . 0 C--N 1.33 -0.239 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.865 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.7 ttt . . . . . 0 CA--C 1.532 0.276 0 CA-C-O 120.702 0.287 . . . . 0.0 110.406 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 23.2 mm -76.83 67.72 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -71.44 68.1 0.53 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.128 1.371 . . . . 0.0 112.888 -175.298 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -63.79 -47.33 81.61 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-O 118.465 -0.778 . . . . 0.0 110.617 175.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.34 143.86 89.92 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 121.695 1.597 . . . . 0.0 108.117 176.405 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -72.1 61.7 0.45 Allowed 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -175.092 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 28.8 mm100 -81.74 63.22 5.91 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 124.628 1.171 . . . . 0.0 108.079 177.033 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -142.06 43.02 1.68 Allowed 'General case' 0 C--N 1.333 -0.133 0 C-N-CA 123.842 0.857 . . . . 0.0 110.967 -175.96 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 16.6 pm0 -69.08 75.23 0.33 Allowed 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 125.441 1.496 . . . . 0.0 112.062 -178.634 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.6 tp -136.82 -35.8 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 123.928 0.891 . . . . 0.0 112.577 179.513 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 172.13 140.58 3.14 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 179.58 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 52.19 65.95 1.35 Allowed 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.116 0.966 . . . . 0.0 110.597 178.493 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -75.67 52.68 0.67 Allowed 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 124.693 1.197 . . . . 0.0 110.495 -178.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.6 t 46.21 32.01 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 125.589 1.556 . . . . 0.0 109.487 -177.199 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -79.43 75.1 6.04 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.691 -174.069 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.7 m -77.9 84.16 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 O-C-N 121.857 -0.527 . . . . 0.0 111.747 -176.859 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.7 t -10.66 112.97 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 128.64 2.776 . . . . 0.0 113.796 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.42 -32.3 3.02 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 122.601 2.201 . . . . 0.0 115.781 -174.484 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.65 139.62 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 120.4 1.455 . . . . 0.0 109.933 -177.659 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 56.4 m -78.18 140.84 38.97 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 168.28 -159.82 33.15 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 -103.02 126.44 50.2 Favored 'General case' 0 N--CA 1.458 -0.072 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 176.262 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.2 tt -97.26 141.27 16.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 CA-C-N 118.57 0.623 . . . . 0.0 109.695 -179.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 25.5 m-70 -136.78 148.31 62.81 Favored Pre-proline 0 C--O 1.235 0.316 0 C-N-CA 124.701 1.2 . . . . 0.0 108.019 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.89 146.11 69.61 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.025 1.817 . . . . 0.0 110.176 176.151 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.7 tp -49.53 -34.88 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 C-N-CA 123.766 0.826 . . . . 0.0 113.117 -177.144 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 p -55.83 -26.78 48.25 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.863 0.865 . . . . 0.0 112.581 178.301 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -74.99 -13.05 60.47 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.829 0.852 . . . . 0.0 112.594 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.3 t -67.85 129.18 93.36 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.306 -0.871 . . . . 0.0 110.057 -177.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -76.52 59.48 6.2 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 124.197 3.265 . . . . 0.0 111.849 -178.863 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -169.08 108.66 0.45 Allowed 'General case' 0 N--CA 1.465 0.296 0 O-C-N 121.351 -0.843 . . . . 0.0 110.104 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -24.25 -58.86 0.05 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.153 2.581 . . . . 0.0 114.98 -179.018 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 52.7 t -52.9 -50.24 44.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.613 0.765 . . . . 0.0 110.082 -178.06 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -71.49 -48.36 49.53 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.3 m -49.44 -43.11 44.59 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.968 0.907 . . . . 0.0 113.068 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.419 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -94.94 11.88 69.1 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-O 118.907 -0.94 . . . . 0.0 111.456 -178.113 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt 71.55 -37.18 0.38 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.749 1.62 . . . . 0.0 113.358 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.419 ' H ' ' C ' ' A' ' 36' ' ' GLY . 1.1 tmt? 30.8 -71.78 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 131.063 3.745 . . . . 0.0 116.538 178.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 37.8 tpp -78.4 -16.82 57.23 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.013 0.925 . . . . 0.0 112.145 -175.615 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.99 -133.93 2.11 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -146.26 163.31 35.89 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 173.832 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 164.87 -134.9 3.49 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -168.07 169.89 10.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 117.967 0.884 . . . . 0.0 111.546 -177.375 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -102.22 132.46 48.13 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 124.061 0.945 . . . . 0.0 109.25 179.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -109.39 135.62 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 103.102 -2.925 . . . . 0.0 103.102 168.474 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.1 tt -101.25 104.74 35.14 Favored Pre-proline 0 N--CA 1.447 -0.619 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 171.559 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.16 169.81 1.36 Allowed 'Trans proline' 0 C--N 1.348 0.543 1 C-N-CA 125.375 4.05 . . . . 0.0 116.278 -171.952 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 65.7 p -155.38 -54.94 0.09 Allowed 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 124.14 0.976 . . . . 0.0 111.279 176.542 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -57.84 -43.86 86.11 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -176.775 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.29 25.81 69.83 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -174.17 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -139.04 130.9 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 176.12 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.7 t -125.11 126.07 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 -175.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.1 m -105.71 162.84 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 C-N-CA 124.013 0.925 . . . . 0.0 111.075 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 15.9 m -67.46 126.39 92.49 Favored Pre-proline 0 CA--C 1.536 0.419 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.094 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -75.66 -16.72 18.63 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 124.125 3.216 . . . . 0.0 115.577 -174.724 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.18 163.97 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.067 0 CA-C-N 118.861 0.755 . . . . 0.0 109.183 -174.842 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 18.1 ttt85 -75.67 119.29 19.5 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 100.31 -3.959 . . . . 0.0 100.31 169.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.1 177.1 48.32 Favored Glycine 0 N--CA 1.436 -1.31 0 C-N-CA 116.562 -2.732 . . . . 0.0 115.089 -168.066 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.01 133.85 34.96 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.621 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 10.0 mm -79.22 100.03 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 172.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 46.7 tp -73.66 -56.5 4.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 -174.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.83 163.86 5.07 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 115.936 1.828 . . . . 0.0 115.936 174.912 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.5 m -144.18 118.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 176.672 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -40.12 153.8 0.2 Allowed Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 119.086 0.857 . . . . 0.0 111.8 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.02 -22.01 44.67 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.262 2.641 . . . . 0.0 113.545 178.851 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 17.8 p -77.1 -7.73 56.26 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.947 1.299 . . . . 0.0 110.939 177.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.09 25.17 10.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 127.106 2.162 . . . . 0.0 110.692 -174.44 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -93.94 -28.03 16.03 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.87 -178.23 4.18 Favored 'General case' 0 C--O 1.222 -0.365 0 CA-C-N 120.146 1.339 . . . . 0.0 109.768 -178.192 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.752 24.2 mm 137.73 -125.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.409 1 C-N-CA 132.95 4.5 . . . . 0.0 109.676 177.162 . . . . . . . . 3 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -177.04 174.69 47.26 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 117.172 1.629 . . . . 0.0 117.172 -177.773 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.3 mp -128.51 169.78 13.95 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 127.612 2.365 . . . . 0.0 110.137 -176.784 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 84.5 mt-30 -143.1 126.47 16.68 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 123.313 0.645 . . . . 0.0 111.049 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 m -73.6 77.3 1.49 Allowed 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 174.791 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 16.6 t70 46.63 57.83 5.17 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 127.896 2.479 . . . . 0.0 110.357 -178.52 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 73.44 -8.48 9.68 Favored Glycine 0 CA--C 1.533 1.214 0 CA-C-O 119.149 -0.806 . . . . 0.0 113.655 -179.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -87.42 -124.72 1.97 Allowed Glycine 0 C--N 1.339 0.727 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 178.954 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -48.66 110.35 0.34 Allowed 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.988 0.915 . . . . 0.0 110.083 -177.683 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -95.71 132.42 40.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.247 1.419 . . . . 0.0 107.803 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.75 113.59 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 C-N-CA 124.128 0.971 . . . . 0.0 111.538 -174.838 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.6 tt -85.56 137.41 32.89 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 106.006 -1.85 . . . . 0.0 106.006 171.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.1 mt -133.19 137.18 53.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.188 0.995 . . . . 0.0 109.574 179.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 45.4 t-80 -126.16 120.51 30.28 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 171.469 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -68.92 122.18 18.12 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 175.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.37 -147.1 0.97 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-N 119.245 0.929 . . . . 0.0 113.119 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.7 mm -128.06 143.57 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.4 t0 49.31 44.13 23.37 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.418 1.087 . . . . 0.0 113.044 178.438 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.5 p -90.79 -19.05 23.9 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.655 1.582 . . . . 0.0 108.427 177.402 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.4 p -52.39 -46.22 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 174.84 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.8 m -61.63 -23.17 65.86 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.62 1.568 . . . . 0.0 112.736 176.427 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.54 -18.5 59.76 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.312 1.445 . . . . 0.0 108.836 177.312 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 59.9 mttm 47.95 33.89 3.7 Favored 'General case' 0 C--N 1.344 0.336 0 C-N-CA 125.831 1.652 . . . . 0.0 112.379 178.112 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.1 17.03 54.71 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.321 -1.266 . . . . 0.0 114.446 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.71 1.88 1.6 Allowed 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 120.232 2.016 . . . . 0.0 115.116 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -136.43 18.03 3.71 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 126.668 2.08 . . . . 0.0 110.193 175.996 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 22.4 m-30 -118.75 155.94 30.23 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.702 1.251 . . . . 0.0 110.638 -177.809 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.7 m -148.95 131.0 15.34 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.0 p -101.48 146.32 27.8 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 123.658 0.783 . . . . 0.0 112.173 -176.47 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -127.34 20.42 6.78 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.698 1.599 . . . . 0.0 113.753 -174.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.5 m -150.62 154.21 9.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.208 0 C-N-CA 123.861 0.864 . . . . 0.0 109.27 175.354 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.9 m -87.71 125.32 34.34 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 170.39 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.84 78.72 2.11 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 123.189 1.471 . . . . 0.0 109.851 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 179.06 -18.4 0.03 OUTLIER Glycine 0 CA--C 1.532 1.15 0 C-N-CA 128.447 2.927 . . . . 0.0 110.601 -176.768 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -53.41 120.09 5.64 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.168 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.14 115.4 28.96 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 127.709 2.404 . . . . 0.0 113.167 -170.161 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.372 20.8 m 52.03 74.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 117.154 2.279 . . . . 0.0 117.154 175.054 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -140.71 144.72 37.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 168.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -102.82 171.74 0.22 Allowed 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 123.733 2.955 . . . . 0.0 109.68 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 52.71 -8.82 0.01 OUTLIER Glycine 0 CA--C 1.536 1.399 0 N-CA-C 120.039 2.775 . . . . 0.0 120.039 170.109 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.2 tp60 -59.22 142.01 52.86 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 120.957 2.378 . . . . 0.0 109.264 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 16.6 ptpt -61.07 114.26 3.01 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 175.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 78.2 mt -79.53 -52.26 8.25 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 20.5 mt -141.41 159.34 42.43 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.979 0.511 . . . . 0.0 111.625 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -122.46 134.69 54.58 Favored 'General case' 0 CA--C 1.516 -0.363 1 N-CA-C 99.965 -4.087 . . . . 0.0 99.965 166.8 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -147.37 117.92 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -166.826 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -71.12 72.59 0.61 Allowed 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.799 1.639 . . . . 0.0 111.978 -175.352 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.6 mt -47.71 -42.18 24.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.493 178.618 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -54.21 -39.89 67.11 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.72 -33.52 19.98 Favored 'General case' 0 CA--C 1.529 0.141 0 CA-C-O 120.815 0.341 . . . . 0.0 111.125 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.98 -50.36 65.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 O-C-N 121.705 -0.622 . . . . 0.0 110.237 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.388 3.2 pptp? -42.59 -54.93 7.65 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -178.485 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.16 -24.2 76.13 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.422 2.082 . . . . 0.0 112.862 177.399 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -84.15 -42.77 15.66 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.806 0.73 . . . . 0.0 111.108 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.2 m -78.69 147.91 71.96 Favored Pre-proline 0 CA--C 1.535 0.398 0 O-C-N 122.025 -0.422 . . . . 0.0 111.769 -177.327 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -70.48 -27.28 23.24 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.617 2.211 . . . . 0.0 110.462 176.154 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.8 m -158.04 137.81 12.16 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.659 1.184 . . . . 0.0 108.218 179.08 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -87.1 2.96 48.1 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 124.313 1.045 . . . . 0.0 111.788 -178.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.3 mmt -55.04 103.92 0.1 Allowed 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.029 0.932 . . . . 0.0 110.346 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 53.3 m -90.05 105.32 10.89 Favored Pre-proline 0 N--CA 1.445 -0.69 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -84.26 136.8 6.86 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.723 2.282 . . . . 0.0 108.521 -177.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.1 mt -118.88 120.22 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.817 0 N-CA-C 102.721 -3.066 . . . . 0.0 102.721 175.284 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.3 t -130.05 114.73 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.598 0 CA-C-O 122.368 1.08 . . . . 0.0 108.242 -177.389 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -81.89 116.8 21.71 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 103.914 -2.624 . . . . 0.0 103.914 176.564 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 82.1 p -83.03 -83.47 0.14 Allowed 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.94 0.4 . . . . 0.0 110.319 -173.658 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -75.61 64.27 1.65 Allowed 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.542 0.737 . . . . 0.0 110.806 179.331 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 17.0 mt -65.33 -29.76 70.54 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 124.288 1.035 . . . . 0.0 112.968 178.715 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 127.76 -132.7 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 1 C-N-CA 132.631 4.372 . . . . 0.0 105.587 -176.858 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -136.1 146.6 47.17 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 127.228 2.211 . . . . 0.0 108.471 177.569 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 59.33 37.53 92.06 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 -177.053 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -97.35 82.42 3.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 C-N-CA 126.127 1.771 . . . . 0.0 107.569 -177.421 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 71.1 p -79.48 115.22 18.98 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.071 178.496 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -72.93 78.83 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -178.799 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -82.72 92.32 7.18 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.842 -176.448 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 39.9 mt -65.44 129.83 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.272 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 9.8 mmpt? -98.21 -51.03 4.14 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.508 1.523 . . . . 0.0 108.853 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -75.65 69.55 2.37 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.57 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 54.2 p -77.48 73.4 4.05 Favored 'General case' 0 CA--C 1.533 0.304 0 O-C-N 121.368 -0.832 . . . . 0.0 108.851 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 175.12 -124.61 1.02 Allowed Glycine 0 CA--C 1.52 0.401 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -177.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.2 t -94.15 151.0 19.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.377 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 2.6 m -131.72 148.85 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 125.031 1.332 . . . . 0.0 107.586 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -114.89 155.32 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 177.261 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.8 mtm105 -57.74 157.64 7.13 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 120.913 0.387 . . . . 0.0 110.483 177.823 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 70.25 -12.59 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.568 1.547 . . . . 0.0 115.055 175.485 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -63.17 131.51 48.71 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-N 119.989 1.268 . . . . 0.0 107.745 176.815 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -97.32 -36.37 10.42 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 115.51 1.671 . . . . 0.0 115.51 -173.616 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -87.62 21.4 2.58 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 127.658 2.383 . . . . 0.0 113.938 -176.321 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -71.29 -26.57 27.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.6 p -142.39 152.59 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 125.567 1.547 . . . . 0.0 108.643 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -128.24 116.51 19.98 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 173.747 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.7 mp -78.89 87.0 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 102.554 -3.128 . . . . 0.0 102.554 172.966 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -85.88 148.33 25.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.461 1.104 . . . . 0.0 111.004 -173.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.8 mmtt . . . . . 0 N--CA 1.455 -0.19 0 C-N-CA 124.057 0.943 . . . . 0.0 109.604 178.07 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.429 ' H3 ' HD11 ' A' ' 51' ' ' ILE . 64.1 mtt . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 25.2 mm -91.28 -50.16 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 177.583 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 65.6 -67.52 0.13 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 126.644 1.977 . . . . 0.0 112.578 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 43.91 61.34 10.75 Favored Pre-proline 0 CA--C 1.537 0.468 0 C-N-CA 126.504 1.921 . . . . 0.0 110.528 -178.375 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -68.03 82.29 0.47 Allowed 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.753 2.302 . . . . 0.0 113.321 -175.011 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 35.5 mt -78.31 59.3 2.29 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.512 0.672 . . . . 0.0 109.31 176.232 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.38 68.16 5.32 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.1 t30 -58.68 152.46 18.66 Favored 'General case' 0 C--O 1.234 0.244 0 O-C-N 122.288 -0.257 . . . . 0.0 110.923 -179.306 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -72.07 75.16 0.94 Allowed 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.8 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 53.6 mt 78.95 142.95 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.271 0 C-N-CA 127.231 2.212 . . . . 0.0 109.032 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 176.25 -61.98 0.1 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 107.205 -2.358 . . . . 0.0 107.205 -179.597 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -77.59 157.39 30.3 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 124.011 0.924 . . . . 0.0 108.754 176.953 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 44.3 mm-40 -76.18 66.36 2.3 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 173.256 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.31 7.5 p 40.24 74.34 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 C-N-CA 127.608 2.363 . . . . 0.0 113.929 -177.411 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.41 ' CZ ' ' CE1' ' A' ' 133' ' ' PHE . 0.1 OUTLIER -144.97 126.46 15.0 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 174.966 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 m -115.99 96.28 4.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.388 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 177.675 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 90.6 p -35.23 119.11 0.6 Allowed Pre-proline 0 CA--C 1.556 1.206 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -77.64 -28.39 5.37 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.677 2.251 . . . . 0.0 116.738 -171.428 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.29 146.07 28.52 Favored 'Isoleucine or valine' 0 C--N 1.341 0.239 0 CA-C-N 119.42 1.009 . . . . 0.0 110.96 -176.035 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.4 m -79.04 137.75 37.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 172.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 167.41 -150.35 16.76 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.193 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -118.18 129.18 55.36 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.152 0.981 . . . . 0.0 109.153 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 2.7 mt -79.95 137.27 21.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 176.262 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -131.16 144.58 54.09 Favored Pre-proline 0 N--CA 1.45 -0.429 0 C-N-CA 126.003 1.721 . . . . 0.0 106.732 175.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -58.22 143.55 96.84 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.407 2.071 . . . . 0.0 110.001 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.1 tp -52.38 -39.75 29.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.207 0.527 . . . . 0.0 111.24 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 p -56.0 -28.1 55.77 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.565 1.546 . . . . 0.0 112.902 177.834 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -79.68 -8.24 59.1 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.414 0.686 . . . . 0.0 112.826 -178.382 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.402 ' CG2' ' HB1' ' A' ' 44' ' ' ALA . 58.8 t -69.71 123.43 88.56 Favored Pre-proline 0 CA--C 1.539 0.539 0 CA-C-O 117.82 -1.086 . . . . 0.0 111.693 -177.132 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_exo -61.43 61.55 0.11 Allowed 'Trans proline' 0 CA--C 1.549 1.233 0 C-N-CA 124.971 3.781 . . . . 0.0 115.137 177.359 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -168.59 131.72 1.44 Allowed 'General case' 0 CA--C 1.528 0.12 0 O-C-N 120.565 -1.334 . . . . 0.0 108.447 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -53.89 -51.09 64.8 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 113.884 1.068 . . . . 0.0 113.884 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.8 t -54.71 -55.96 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 123.22 0.608 . . . . 0.0 109.603 -178.119 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -64.06 -54.09 39.55 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.819 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 79.3 p -58.05 -34.14 69.77 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 113.517 0.932 . . . . 0.0 113.517 -178.333 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . 0.412 ' C ' ' H ' ' A' ' 38' ' ' MET . . . -89.64 10.73 72.52 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-O 118.173 -1.348 . . . . 0.0 110.854 -179.423 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 72.18 -40.77 0.48 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 125.873 1.669 . . . . 0.0 112.793 -177.401 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' MET . . . . . 0.412 ' H ' ' C ' ' A' ' 36' ' ' GLY . 14.9 tpt 25.43 -68.87 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 130.907 3.683 . . . . 0.0 117.144 -179.422 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.7 tpp -78.96 -20.95 47.95 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.505 1.122 . . . . 0.0 113.53 -175.214 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 171.45 -145.36 8.77 Favored Glycine 0 C--N 1.337 0.617 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 -178.293 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -136.18 160.77 37.67 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.219 1.01 . . . . 0.0 108.559 174.569 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 165.28 -130.31 2.14 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -178.42 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 8.5 p90 -166.39 173.62 9.79 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 117.822 0.811 . . . . 0.0 110.485 -175.805 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . 0.402 ' HB1' ' CG2' ' A' ' 29' ' ' VAL . . . -113.25 140.71 47.74 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 178.193 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -111.47 136.23 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.603 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 169.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.6 105.63 34.98 Favored Pre-proline 0 N--CA 1.444 -0.759 0 N-CA-C 100.64 -3.837 . . . . 0.0 100.64 170.304 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -59.56 172.79 1.85 Allowed 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 124.548 3.499 . . . . 0.0 115.482 -173.095 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 67.3 p -154.34 -64.37 0.13 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 123.895 0.878 . . . . 0.0 110.504 177.563 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -51.4 -46.87 63.02 Favored 'General case' 0 C--N 1.335 -0.06 0 C-N-CA 125.859 1.664 . . . . 0.0 114.913 -176.666 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.31 28.93 60.96 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.811 -1.315 . . . . 0.0 109.811 -173.617 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.429 HD11 ' H3 ' ' A' ' 1' ' ' MET . 30.7 mt -139.58 120.65 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 102.664 -3.087 . . . . 0.0 102.664 177.357 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 45.0 t -126.12 123.74 64.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 C-N-CA 124.26 1.024 . . . . 0.0 109.764 -171.637 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.5 m -109.6 169.66 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.187 0.995 . . . . 0.0 109.036 176.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.1 p -63.7 148.66 94.04 Favored Pre-proline 0 CA--C 1.537 0.48 0 O-C-N 121.331 -0.856 . . . . 0.0 111.071 -177.755 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -87.64 -16.14 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 124.29 3.327 . . . . 0.0 112.707 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.1 m -145.32 166.83 10.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 123.891 0.876 . . . . 0.0 110.052 -176.818 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.1 mtt-85 -78.46 119.54 21.92 Favored 'General case' 0 N--CA 1.454 -0.253 1 N-CA-C 98.887 -4.486 . . . . 0.0 98.887 168.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 171.37 -177.4 44.27 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 115.078 -3.439 . . . . 0.0 115.587 -167.547 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.73 135.51 41.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 126.011 1.724 . . . . 0.0 110.451 -177.888 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.4 mm -79.07 114.9 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 103.537 -2.764 . . . . 0.0 103.537 170.037 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 34.3 tp -77.8 -53.41 7.53 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -176.29 155.79 1.52 Allowed 'General case' 0 C--O 1.228 -0.033 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.5 m -135.32 120.73 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.417 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -43.77 149.75 0.61 Allowed Pre-proline 0 CA--C 1.539 0.538 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -49.65 -28.16 16.46 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 124.077 3.184 . . . . 0.0 113.861 177.08 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 24.7 p -78.02 1.22 21.6 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.457 0.703 . . . . 0.0 111.969 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 46.84 62.35 2.4 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 127.323 2.249 . . . . 0.0 113.125 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . 0.422 ' CG ' ' HA ' ' A' ' 89' ' ' VAL . 15.4 p-80 -146.93 -38.82 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 122.307 -0.246 . . . . 0.0 111.619 176.147 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -128.19 177.32 7.0 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.694 24.5 mm 116.0 -134.38 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.306 0 C-N-CA 131.654 3.982 . . . . 0.0 108.342 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -171.88 179.71 43.38 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 118.637 2.215 . . . . 0.0 118.637 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.7 mp -126.53 173.07 9.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 127.771 2.428 . . . . 0.0 109.073 -177.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -145.09 137.84 26.24 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 176.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 84.1 p -77.68 -108.84 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 121.154 0.502 . . . . 0.0 109.812 178.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -87.42 52.68 2.56 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 175.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 78.77 -60.47 4.11 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 108.949 -1.661 . . . . 0.0 108.949 -175.604 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.31 169.99 31.42 Favored Glycine 0 CA--C 1.531 1.083 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 176.612 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.2 mtp-105 58.5 71.81 0.56 Allowed 'General case' 0 N--CA 1.457 -0.106 0 C-N-CA 124.503 1.121 . . . . 0.0 109.489 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -77.95 125.57 29.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.06 108.37 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 C-N-CA 124.722 1.209 . . . . 0.0 109.597 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -85.01 134.48 34.22 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 126.083 1.753 . . . . 0.0 106.732 174.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.0 mt -128.01 153.79 37.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 C-N-CA 125.339 1.455 . . . . 0.0 110.106 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -151.25 76.46 1.22 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 125.788 1.635 . . . . 0.0 109.191 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.7 t80 -50.86 104.07 0.07 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.186 0.594 . . . . 0.0 112.592 -176.591 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.62 173.27 5.39 Favored Glycine 0 CA--C 1.533 1.189 0 C-N-CA 124.685 1.136 . . . . 0.0 112.745 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.1 mm -108.72 130.93 60.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 124.484 1.114 . . . . 0.0 108.932 -178.301 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 48.89 43.1 21.34 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.965 1.306 . . . . 0.0 110.917 -178.62 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.6 -72.6 0.61 Allowed 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 102.16 -3.274 . . . . 0.0 102.16 174.638 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . 0.422 ' HA ' ' CG ' ' A' ' 68' ' ' HIS 0.33 3.3 p 44.89 49.64 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 104.065 -2.568 . . . . 0.0 104.065 -173.507 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' SER . . . . . 0.411 ' HB3' ' CD1' ' A' ' 96' ' ' PHE . 19.3 m 12.1 45.83 0.0 OUTLIER 'General case' 0 C--N 1.349 0.565 1 C-N-CA 134.077 4.951 . . . . 0.0 114.178 -164.679 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 2.0 mt 37.48 50.16 1.07 Allowed 'General case' 0 N--CA 1.434 -1.235 0 C-N-CA 130.492 3.517 . . . . 0.0 107.139 178.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 76.43 53.52 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 128.798 2.839 . . . . 0.0 111.36 -176.029 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.04 -64.12 1.61 Allowed Glycine 0 CA--C 1.535 1.296 0 C-N-CA 124.387 0.994 . . . . 0.0 111.713 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 22.62 -98.22 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 127.694 2.397 . . . . 0.0 115.873 178.471 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -59.89 -1.68 1.53 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 127.302 2.382 . . . . 0.0 115.859 -176.59 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . 0.411 ' CD1' ' HB3' ' A' ' 90' ' ' SER . 4.6 m-85 -103.75 97.54 7.54 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 119.001 1.4 . . . . 0.0 113.145 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.9 m -80.05 99.99 7.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 105.785 -1.931 . . . . 0.0 105.785 173.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 29.0 p -83.45 135.37 34.7 Favored 'General case' 0 N--CA 1.451 -0.414 0 O-C-N 121.556 -0.715 . . . . 0.0 110.945 -178.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -103.79 -42.12 5.71 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.058 1.343 . . . . 0.0 111.927 -177.756 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.28 136.0 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.736 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 58.7 m -87.83 66.43 8.76 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 170.646 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.258 1.6 pm0 -24.72 96.69 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 129.074 2.95 . . . . 0.0 112.999 -173.162 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 154.06 -17.96 0.63 Allowed Glycine 0 CA--C 1.537 1.466 0 C-N-CA 128.157 2.789 . . . . 0.0 109.744 -175.287 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -42.87 107.74 0.09 Allowed 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 129.612 3.165 . . . . 0.0 107.821 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.0 119.3 30.24 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 127.496 2.318 . . . . 0.0 114.077 -172.954 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.336 34.4 m 48.02 66.82 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 126.653 1.981 . . . . 0.0 115.395 177.461 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.97 133.79 25.19 Favored Pre-proline 0 N--CA 1.454 -0.275 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 171.731 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -98.4 147.15 0.65 Allowed 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 123.346 2.697 . . . . 0.0 110.472 -177.189 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 58.02 18.37 33.54 Favored Glycine 0 CA--C 1.528 0.894 0 O-C-N 121.724 -0.61 . . . . 0.0 113.551 177.02 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -61.96 139.51 58.39 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.709 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -66.06 116.88 7.64 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.916 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 49.6 mt -81.04 -54.19 5.77 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.7 mt -149.08 157.45 43.41 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.34 0.656 . . . . 0.0 111.856 -172.437 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -124.75 129.42 50.44 Favored 'General case' 0 CA--C 1.519 -0.234 1 N-CA-C 98.738 -4.541 . . . . 0.0 98.738 165.858 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . 0.406 HG13 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -139.22 127.91 28.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -164.101 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -75.01 67.41 1.71 Allowed 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.045 0.938 . . . . 0.0 110.48 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 93.1 mt -52.05 -45.85 64.85 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.194 179.175 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -48.98 -45.3 41.94 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 124.231 1.012 . . . . 0.0 112.611 -178.581 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.84 -33.91 24.77 Favored 'General case' 0 CA--C 1.527 0.092 0 CA-C-N 118.184 0.447 . . . . 0.0 111.6 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.08 -58.49 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 O-C-N 121.937 -0.477 . . . . 0.0 109.806 178.903 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 2.5 pptp? -38.16 -57.0 1.87 Allowed Pre-proline 0 CA--C 1.542 0.658 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 -176.664 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -60.88 -18.25 55.74 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.427 2.085 . . . . 0.0 113.572 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -104.55 10.66 34.95 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 118.386 -0.816 . . . . 0.0 112.797 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 26.9 m -137.57 151.97 71.97 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 119.884 1.22 . . . . 0.0 110.595 -178.887 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -64.45 -36.22 45.21 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.086 2.524 . . . . 0.0 113.202 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.6 t -156.58 153.0 27.95 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 119.059 0.845 . . . . 0.0 110.556 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.4 tp -100.62 -1.77 34.5 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.549 1.54 . . . . 0.0 110.565 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -53.22 116.97 2.68 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 118.311 0.505 . . . . 0.0 109.643 179.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 52.7 m -107.99 118.81 51.85 Favored Pre-proline 0 N--CA 1.446 -0.646 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.391 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -87.05 150.43 8.23 Favored 'Trans proline' 0 N--CA 1.442 -1.525 0 C-N-CA 122.056 1.838 . . . . 0.0 107.75 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.8 mt -132.59 113.93 21.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 101.586 -3.487 . . . . 0.0 101.586 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.94 122.07 51.18 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.012 -173.334 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . 0.41 ' CE1' ' CZ ' ' A' ' 15' ' ' PHE . 4.7 m-85 -86.29 112.3 21.27 Favored 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 177.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.0 p -74.41 -76.06 0.15 Allowed 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 121.853 0.835 . . . . 0.0 109.401 -175.729 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -76.78 69.4 3.13 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.707 0.803 . . . . 0.0 110.771 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.3 mt -68.86 169.21 11.94 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 171.076 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.72 -139.07 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.482 -0.761 . . . . 0.0 111.128 -178.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -67.06 81.12 0.12 Allowed 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.683 0.793 . . . . 0.0 112.417 -176.493 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 47.51 38.02 13.6 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.76 1.171 . . . . 0.0 111.068 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 70.0 mm-40 -55.23 119.25 5.24 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 111.517 0.192 . . . . 0.0 111.517 -176.907 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -78.02 132.09 37.64 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 172.504 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.266 1.0 OUTLIER -84.99 88.61 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 -176.51 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.8 t -78.4 83.99 4.59 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -173.183 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.8 mt -62.26 118.92 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 124.595 1.158 . . . . 0.0 108.116 179.362 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -97.77 -55.25 2.86 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.974 1.31 . . . . 0.0 108.938 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.71 66.34 1.45 Allowed 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.319 0.648 . . . . 0.0 111.587 -177.396 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 35.1 m -78.61 65.44 3.88 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.556 0.742 . . . . 0.0 109.011 178.814 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.38 -145.78 6.44 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -177.99 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 12.3 t -76.2 150.74 37.04 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 117.325 0.563 . . . . 0.0 110.646 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.68 156.02 28.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.087 1.355 . . . . 0.0 108.463 178.168 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -109.45 -171.43 1.84 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.424 1.49 . . . . 0.0 108.489 175.988 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 52.5 mtm-85 -85.65 157.69 20.27 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.971 0.805 . . . . 0.0 110.354 177.558 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 45.63 38.91 4.42 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.621 1.969 . . . . 0.0 114.432 177.662 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -76.09 134.07 40.13 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 104.8 -2.296 . . . . 0.0 104.8 172.488 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -108.99 35.86 3.09 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.733 0.813 . . . . 0.0 111.759 -177.809 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -172.6 94.61 0.13 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.198 1.799 . . . . 0.0 108.448 177.423 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -150.97 -37.73 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -175.524 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 57.8 t -151.5 104.29 0.28 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.058 0 CA-C-N 119.397 0.999 . . . . 0.0 108.594 -177.419 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.2 mttm -90.13 124.49 34.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -176.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.5 mp -78.86 107.77 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 104.378 -2.453 . . . . 0.0 104.378 174.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 24.9 pt-20 -153.73 -175.35 5.33 Favored 'General case' 0 C--O 1.227 -0.127 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -175.787 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 C--N 1.332 -0.185 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.261 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.7 mtm . . . . . 0 N--CA 1.454 -0.255 0 N-CA-C 111.704 0.261 . . . . 0.0 111.704 . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mp 77.03 -54.83 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 C-N-CA 126.605 1.962 . . . . 0.0 107.258 -173.804 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.8 64.08 1.23 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.349 1.06 . . . . 0.0 109.811 176.189 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.6 mm-40 -68.81 -42.39 24.17 Favored Pre-proline 0 CA--C 1.538 0.508 0 CA-C-O 118.259 -0.876 . . . . 0.0 112.402 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -56.26 154.72 27.61 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.282 1.988 . . . . 0.0 112.465 -178.795 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 71.8 mt -73.54 67.9 1.12 Allowed 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.664 0.786 . . . . 0.0 110.749 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -70.8 176.16 4.46 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.692 0.797 . . . . 0.0 109.947 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -54.49 105.59 0.16 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 123.891 0.876 . . . . 0.0 110.294 178.424 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -48.66 -61.09 2.21 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.723 1.609 . . . . 0.0 112.933 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 35.2 mt -77.78 72.8 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -178.007 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.18 -51.83 4.53 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 -179.622 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . 0.355 0.0 OUTLIER 72.69 -49.91 0.7 Allowed 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 127.092 2.157 . . . . 0.0 115.945 178.354 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 72.2 mt-10 27.84 63.88 0.1 Allowed 'General case' 0 C--N 1.321 -0.654 0 C-N-CA 130.629 3.572 . . . . 0.0 113.207 177.759 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.3 p 23.53 92.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.461 0.111 0 C-N-CA 128.023 2.529 . . . . 0.0 115.557 178.376 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -161.3 82.15 0.62 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 113.77 -1.559 . . . . 0.0 107.803 176.314 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -78.89 85.15 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.114 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.202 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.3 t -10.59 109.39 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.814 0 C-N-CA 127.839 2.456 . . . . 0.0 113.211 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -68.81 -28.15 30.46 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.595 2.197 . . . . 0.0 116.449 -173.318 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -149.0 145.93 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.918 1.235 . . . . 0.0 110.232 -177.322 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.9 m -79.07 136.68 37.23 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.217 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.0 -150.11 14.2 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tp10 -117.13 123.21 46.19 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.785 1.634 . . . . 0.0 108.71 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 10.1 mt -85.07 125.66 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -117.92 142.8 31.44 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 173.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -55.15 152.65 29.8 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 121.814 1.676 . . . . 0.0 109.515 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.3 tp -57.06 -49.01 80.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.1 m -67.86 85.41 0.22 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.732 1.613 . . . . 0.0 108.604 176.478 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.5 t70 172.95 -35.66 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 127.373 2.269 . . . . 0.0 108.81 -176.046 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 96.5 t -52.86 138.29 44.15 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 124.643 1.177 . . . . 0.0 110.558 -179.333 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -72.95 59.26 3.54 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 124.127 3.218 . . . . 0.0 111.542 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -171.74 130.81 0.68 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 124.923 1.289 . . . . 0.0 108.592 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -62.03 -48.42 80.37 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 124.322 1.049 . . . . 0.0 113.061 -177.261 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.6 t -50.24 -55.23 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.2 m-85 -65.06 -58.79 5.15 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.397 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -58.08 -27.99 64.17 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 115.244 1.572 . . . . 0.0 115.244 -177.301 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -95.36 10.12 69.38 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-O 117.899 -1.501 . . . . 0.0 110.646 -178.981 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 61.3 mttm 74.42 -46.25 0.61 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.574 1.55 . . . . 0.0 111.928 -178.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 36.9 ttm 39.29 -64.92 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 130.533 3.533 . . . . 0.0 117.272 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 29.9 ttp -109.34 -10.28 14.93 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.712 1.205 . . . . 0.0 113.452 -176.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -171.83 -165.55 29.18 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-N 119.464 1.029 . . . . 0.0 110.796 -179.023 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -131.72 156.58 45.67 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 176.6 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 168.45 -137.07 4.38 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.28 166.13 14.86 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 118.048 0.924 . . . . 0.0 111.214 -175.94 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -103.31 113.29 26.66 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 123.043 0.537 . . . . 0.0 111.485 -179.239 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -88.65 129.21 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 103.887 -2.634 . . . . 0.0 103.887 169.765 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.0 tt -96.03 109.2 45.6 Favored Pre-proline 0 N--CA 1.448 -0.542 1 N-CA-C 98.34 -4.689 . . . . 0.0 98.34 168.526 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.6 161.54 24.92 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.501 2.801 . . . . 0.0 115.336 -167.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.4 p -136.9 -41.54 0.59 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.588 1.155 . . . . 0.0 111.981 177.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.99 -44.36 91.62 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.37 23.8 77.19 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 -174.643 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.5 mt -139.99 111.97 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 177.681 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 47.0 t -100.39 122.71 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.883 1.273 . . . . 0.0 108.673 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.39 156.04 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 123.389 0.676 . . . . 0.0 110.349 177.912 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 17.4 m -63.88 122.11 75.06 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.81 -21.52 12.52 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 124.923 3.749 . . . . 0.0 114.662 -176.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -136.48 173.09 14.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 124.94 1.296 . . . . 0.0 108.842 -175.672 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.29 90.59 3.76 Favored 'General case' 0 CA--C 1.518 -0.275 1 N-CA-C 98.228 -4.73 . . . . 0.0 98.228 168.858 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -90.26 174.52 40.29 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 117.381 1.712 . . . . 0.0 117.381 -166.632 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.88 134.09 21.68 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 101.475 -3.528 . . . . 0.0 101.475 170.471 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -88.79 127.3 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -169.791 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.402 ' O ' ' CB ' ' A' ' 62' ' ' ASN . 78.5 mt -79.74 -29.66 40.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 169.161 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 59.1 t30 125.79 -176.53 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 129.587 3.155 . . . . 0.0 109.514 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.98 122.24 51.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 C-N-CA 127.452 2.301 . . . . 0.0 106.353 172.849 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -44.77 157.92 0.3 Allowed Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 124.315 1.046 . . . . 0.0 111.316 175.361 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -51.4 -29.47 31.05 Favored 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.381 2.721 . . . . 0.0 113.414 174.186 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.6 p -76.94 -5.98 50.69 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.429 1.092 . . . . 0.0 111.646 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? 60.53 16.4 6.44 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.334 1.854 . . . . 0.0 115.007 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 16.1 p-80 -98.03 -33.77 11.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.562 0.345 . . . . 0.0 111.654 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -149.17 -177.58 5.9 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-N 118.186 0.448 . . . . 0.0 111.929 -173.575 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.541 24.4 mm 131.82 -123.39 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.453 1 C-N-CA 136.273 5.829 . . . . 0.0 102.359 -177.199 . . . . . . . . 3 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -178.4 -173.23 43.6 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 116.751 -2.643 . . . . 0.0 119.382 177.05 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.4 mp -137.32 170.83 15.42 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 127.208 2.203 . . . . 0.0 108.488 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -147.83 157.26 43.44 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 172.366 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 81.3 p -90.31 -76.41 0.43 Allowed 'General case' 0 C--O 1.225 -0.235 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 174.27 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -131.36 59.66 1.68 Allowed 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 127.0 2.12 . . . . 0.0 105.928 175.777 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 79.86 -60.73 4.38 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 108.046 -2.022 . . . . 0.0 108.046 -173.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -57.35 163.33 7.36 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 174.802 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.6 mmt85 51.91 59.98 4.16 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.574 0.75 . . . . 0.0 109.779 -177.449 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -80.37 110.29 15.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 177.728 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.94 127.28 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 124.063 0.945 . . . . 0.0 111.464 -174.001 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 33.5 tp -103.23 135.07 45.57 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 104.375 -2.454 . . . . 0.0 104.375 170.585 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.4 mt -120.43 155.37 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 C-N-CA 124.965 1.306 . . . . 0.0 107.589 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -149.37 81.95 1.41 Allowed 'General case' 0 C--O 1.224 -0.281 0 N-CA-C 104.96 -2.237 . . . . 0.0 104.96 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -63.12 97.33 0.11 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -176.638 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 69.27 168.33 5.79 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.226 0.917 . . . . 0.0 111.586 -175.816 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 15.8 mm -100.26 135.89 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 124.623 1.169 . . . . 0.0 109.094 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 57.24 23.98 9.36 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.943 1.297 . . . . 0.0 112.732 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 p -76.93 -32.97 57.74 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.657 1.583 . . . . 0.0 107.567 175.397 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.8 p -56.71 -46.16 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-N 113.76 -1.563 . . . . 0.0 107.546 170.702 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.73 -42.28 98.75 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 124.187 0.995 . . . . 0.0 108.546 176.934 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -73.61 12.27 0.67 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 125.525 1.53 . . . . 0.0 111.682 175.593 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 48.3 tttp 45.68 35.06 1.97 Allowed 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.869 2.067 . . . . 0.0 113.258 177.764 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 55.39 28.44 50.57 Favored Glycine 0 CA--C 1.535 1.289 0 O-C-N 121.751 -0.593 . . . . 0.0 112.751 -179.116 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -70.97 91.56 0.88 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 118.744 1.272 . . . . 0.0 109.769 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 132.61 -1.05 4.72 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 126.435 1.969 . . . . 0.0 111.707 -178.056 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 16.5 m-30 -96.52 131.91 42.64 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 124.507 1.123 . . . . 0.0 109.675 -179.267 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 10.9 m -120.55 113.96 21.05 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 126.597 1.959 . . . . 0.0 107.316 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 44.9 p -93.38 126.49 38.54 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 121.056 -1.028 . . . . 0.0 111.213 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -90.26 -26.73 19.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 123.932 0.893 . . . . 0.0 108.998 176.502 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' VAL . . . . . 0.555 ' HB ' ' CG ' ' A' ' 102' ' ' GLU . 3.1 m -52.63 126.83 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-O 121.192 0.52 . . . . 0.0 110.995 179.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 24.9 m -115.51 -52.34 2.65 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 127.456 2.302 . . . . 0.0 105.255 175.763 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' GLU . . . . . 0.555 ' CG ' ' HB ' ' A' ' 100' ' ' VAL . 0.1 OUTLIER 50.77 107.98 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 120.969 3.692 . . . . 0.0 120.969 166.26 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.23 55.35 2.12 Favored Glycine 0 CA--C 1.53 1.0 1 N-CA-C 100.996 -4.842 . . . . 0.0 100.996 164.808 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.253 7.4 p-10 6.77 70.36 0.0 OUTLIER 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 118.569 2.803 . . . . 0.0 118.569 -169.255 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -169.58 137.04 1.72 Allowed 'General case' 0 N--CA 1.43 -1.464 1 C-N-CA 132.916 4.486 . . . . 0.0 105.655 173.309 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -157.27 158.19 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 125.681 1.592 . . . . 0.0 108.692 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -89.04 163.42 34.61 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 106.425 -1.695 . . . . 0.0 106.425 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -70.71 169.54 19.87 Favored 'Trans proline' 0 N--CA 1.451 -0.978 0 N-CA-C 108.259 -1.477 . . . . 0.0 108.259 178.329 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 73.45 -27.77 0.86 Allowed Glycine 0 CA--C 1.534 1.227 0 O-C-N 121.02 -1.05 . . . . 0.0 115.38 175.438 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.4 tp-100 -58.07 139.88 53.75 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 119.527 1.664 . . . . 0.0 109.8 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -70.16 128.3 35.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.875 0.47 . . . . 0.0 111.544 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 72.1 mt -105.04 -41.49 5.57 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.937 0.895 . . . . 0.0 111.807 -178.317 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 48.5 mt -143.99 146.52 32.96 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 123.588 0.755 . . . . 0.0 109.371 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -118.06 133.24 56.09 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 100.683 -3.821 . . . . 0.0 100.683 167.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -143.15 117.47 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -166.731 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 62.9 t0 -67.69 74.11 0.17 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.408 1.483 . . . . 0.0 112.395 -175.273 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 75.8 mt -50.43 -47.49 56.64 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.687 178.242 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -49.4 -49.07 46.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.588 1.155 . . . . 0.0 112.684 -177.323 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.25 -34.36 25.85 Favored 'General case' 0 C--N 1.333 -0.121 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 49.4 t -65.16 -53.65 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 O-C-N 121.697 -0.627 . . . . 0.0 110.541 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.328 19.1 pttp -42.92 -54.64 8.54 Favored Pre-proline 0 CA--C 1.54 0.595 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -61.12 -24.07 78.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.49 2.127 . . . . 0.0 112.716 178.248 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 57.3 m-80 -90.18 -48.24 7.29 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 118.46 0.573 . . . . 0.0 111.885 -177.268 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.77 147.93 56.37 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -174.256 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_exo -51.61 -41.51 60.76 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 124.064 3.176 . . . . 0.0 114.804 179.169 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.2 m -158.81 142.7 15.31 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.825 -0.547 . . . . 0.0 110.235 -176.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.2 tp -88.09 -4.6 58.75 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 124.878 1.271 . . . . 0.0 112.293 -178.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.1 mmt -46.93 118.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.028 0.931 . . . . 0.0 109.802 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.4 m -112.1 94.23 24.88 Favored Pre-proline 0 N--CA 1.448 -0.534 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 74.1 Cg_endo -76.5 111.06 3.18 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 123.594 2.863 . . . . 0.0 108.74 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mt -94.28 119.06 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 N-CA-C 102.718 -3.068 . . . . 0.0 102.718 174.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.2 t -126.56 129.06 71.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -97.39 114.61 26.46 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 104.343 -2.465 . . . . 0.0 104.343 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 44.8 p -80.28 -75.39 0.27 Allowed 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . 0.259 0.4 OUTLIER -74.06 69.68 1.5 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-O 122.204 1.002 . . . . 0.0 111.207 179.156 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 13.2 mt -78.21 62.2 2.87 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 126.174 1.79 . . . . 0.0 107.537 175.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.53 -109.63 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.578 2.351 . . . . 0.0 112.545 -177.852 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -80.33 58.64 3.16 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 125.146 1.379 . . . . 0.0 112.446 -178.265 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 46.19 35.67 6.82 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 124.259 0.933 . . . . 0.0 110.959 -178.882 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 38.9 mt-10 -49.01 126.91 13.32 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.349 0.659 . . . . 0.0 112.014 -175.731 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 31.8 p -86.54 133.35 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.256 0.3 OUTLIER -85.58 87.48 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 CA-C-O 122.407 1.099 . . . . 0.0 109.936 -176.009 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.5 m -79.33 84.48 5.25 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 120.646 -1.284 . . . . 0.0 110.85 -177.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 6.5 mt -60.66 130.67 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 124.287 1.035 . . . . 0.0 108.656 178.418 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.33 -52.78 2.75 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.769 0.828 . . . . 0.0 108.767 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -78.95 64.64 3.94 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 122.892 0.477 . . . . 0.0 109.933 179.324 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 45.0 m -78.98 66.05 4.32 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -171.45 -148.79 6.23 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 107.809 -2.116 . . . . 0.0 107.809 -177.375 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 15.8 t -78.14 148.11 34.28 Favored 'General case' 0 N--CA 1.456 -0.136 0 CA-C-N 117.658 0.729 . . . . 0.0 110.735 178.195 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.63 160.59 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 124.864 1.266 . . . . 0.0 108.663 178.113 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -114.78 157.79 22.75 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.719 1.208 . . . . 0.0 108.592 176.66 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 2.2 ptm180 -66.43 154.11 41.05 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 53.15 59.98 4.06 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.537 1.535 . . . . 0.0 112.06 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 16.9 mm-40 -131.07 151.02 51.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 126.821 2.048 . . . . 0.0 105.751 175.712 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.47 166.0 14.19 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.2 1.4 . . . . 0.0 111.05 -177.338 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 16.9 t70 70.63 -7.48 1.04 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 117.051 2.241 . . . . 0.0 117.051 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -53.06 -31.87 17.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 C-N-CA 127.213 2.205 . . . . 0.0 112.501 177.116 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 62.9 t -145.47 133.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.208 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -108.75 120.53 42.75 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.414 0.686 . . . . 0.0 109.828 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 160' ' ' ILE . . . . . . . . . . . . . 1.3 mp -79.1 97.22 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.204 -2.146 . . . . 0.0 105.204 173.404 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -108.7 -155.26 0.55 Allowed 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 125.369 1.467 . . . . 0.0 107.963 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 35.5 mtmm . . . . . 0 C--N 1.333 -0.131 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 176.977 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.532 0.258 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.0 89.92 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 172.165 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t -13.36 116.17 0.04 OUTLIER Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 126.965 2.106 . . . . 0.0 115.377 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -71.38 -34.88 9.07 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.995 2.463 . . . . 0.0 117.37 -174.371 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -143.3 162.73 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.819 1.191 . . . . 0.0 111.371 -175.228 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -101.52 135.65 42.68 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 174.785 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 161.96 -136.33 4.32 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -127.79 124.63 38.12 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 124.941 1.297 . . . . 0.0 110.34 -178.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 45.9 mt -80.19 145.43 9.17 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.016 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -143.95 141.67 18.94 Favored Pre-proline 0 N--CA 1.452 -0.347 0 C-N-CA 125.08 1.352 . . . . 0.0 107.903 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -54.94 145.33 63.26 Favored 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 122.163 1.908 . . . . 0.0 111.183 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.67 -39.19 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.853 1.261 . . . . 0.0 112.316 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 p -53.48 -31.61 46.57 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.362 1.465 . . . . 0.0 112.442 179.143 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -69.78 -14.32 62.71 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.898 0.879 . . . . 0.0 112.852 -178.593 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -69.87 130.26 90.26 Favored Pre-proline 0 CA--C 1.539 0.53 0 O-C-N 121.373 -0.829 . . . . 0.0 111.057 -175.151 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -76.38 62.6 6.99 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.416 2.744 . . . . 0.0 111.374 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.21 132.01 2.88 Favored 'General case' 0 C--O 1.226 -0.138 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 22.0 mp0 -54.9 -53.05 60.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.521 1.128 . . . . 0.0 112.675 -176.451 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.0 t -51.68 -57.0 3.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 123.299 0.639 . . . . 0.0 110.317 -177.675 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -64.95 -53.54 44.73 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.264 0.226 . . . . 0.0 110.535 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.9 t -51.99 -43.05 63.44 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -90.91 13.36 66.25 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-O 117.994 -1.448 . . . . 0.0 111.814 -177.841 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp 69.44 -34.68 0.29 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 119.421 1.611 . . . . 0.0 114.52 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 15.7 tpt 26.16 -76.31 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 130.056 3.343 . . . . 0.0 116.426 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.1 ttm -79.49 -15.98 56.82 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 114.142 1.164 . . . . 0.0 114.142 -174.263 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.51 -135.75 2.73 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 120.037 1.29 . . . . 0.0 113.076 -178.111 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -129.1 163.1 26.2 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 175.717 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 167.27 -157.5 29.96 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.877 -1.154 . . . . 0.0 112.586 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -162.35 171.07 17.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.053 0.541 . . . . 0.0 109.839 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.35 149.18 31.51 Favored 'General case' 0 CA--C 1.502 -0.867 0 O-C-N 124.119 0.887 . . . . 0.0 109.429 176.729 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.0 mp -124.21 133.56 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 102.482 -3.155 . . . . 0.0 102.482 170.314 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.2 tt -99.38 108.44 50.33 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.789 -4.523 . . . . 0.0 98.789 170.626 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -82.8 161.04 16.29 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.347 2.698 . . . . 0.0 113.932 -168.463 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.3 p -124.59 -55.56 1.63 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.699 1.2 . . . . 0.0 108.723 175.551 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -68.15 124.15 22.66 Favored 'General case' 0 N--CA 1.457 -0.11 0 C-N-CA 122.303 0.241 . . . . 0.0 110.857 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.33 37.11 2.0 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 70.7 mt -138.43 120.63 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.24 109.35 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -174.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.7 m -89.25 -178.26 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.941 -1.504 . . . . 0.0 106.941 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.59 146.19 33.5 Favored Pre-proline 0 N--CA 1.465 0.306 0 CA-C-O 117.561 -1.209 . . . . 0.0 111.464 -174.683 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -63.3 -44.6 14.37 Favored 'Trans proline' 0 C--N 1.348 0.53 0 N-CA-C 107.453 -1.787 . . . . 0.0 107.453 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.48 HG21 ' HA ' ' A' ' 74' ' ' SER . 3.4 p -146.2 145.59 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 102.433 -3.173 . . . . 0.0 102.433 171.506 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.539 ' HB3' HG23 ' A' ' 106' ' ' VAL . 28.6 mtm180 -97.27 -75.21 0.55 Allowed 'General case' 0 N--CA 1.45 -0.447 1 N-CA-C 98.979 -4.452 . . . . 0.0 98.979 169.659 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.23 -78.19 1.46 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 107.141 -2.383 . . . . 0.0 107.141 171.474 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.75 118.73 5.84 Favored 'General case' 0 N--CA 1.438 -1.067 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.893 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.458 HG21 ' CB ' ' A' ' 102' ' ' GLU . 28.3 mm -65.98 124.85 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 175.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.42 -42.47 12.81 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 124.069 0.948 . . . . 0.0 109.206 -177.44 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -156.88 152.66 27.05 Favored 'General case' 0 N--CA 1.463 0.204 0 O-C-N 121.94 -0.475 . . . . 0.0 111.722 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -82.89 170.55 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.845 1.658 . . . . 0.0 112.323 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.545 ' CE2' HD21 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -76.54 135.85 68.32 Favored Pre-proline 0 N--CA 1.437 -1.118 0 CA-C-N 112.681 -2.054 . . . . 0.0 109.778 173.589 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -74.37 -43.28 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.374 1.383 . . . . 0.0 108.61 172.901 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.4 p -131.39 46.24 2.69 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 126.192 1.797 . . . . 0.0 109.917 -177.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.447 ' HA ' ' CB ' ' A' ' 64' ' ' PHE . 16.5 ttmt 57.16 -17.41 0.02 OUTLIER 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 128.225 2.61 . . . . 0.0 116.609 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -75.98 -5.9 48.46 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 116.769 2.137 . . . . 0.0 116.769 -174.399 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.35 160.53 43.66 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 120.456 1.48 . . . . 0.0 110.348 -173.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.0 tt -157.23 157.15 3.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -117.31 128.58 7.92 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 107.646 -2.181 . . . . 0.0 107.646 178.186 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.9 mt -124.74 171.75 9.85 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 124.724 1.209 . . . . 0.0 110.359 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.47 139.33 20.88 Favored 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 126.631 1.972 . . . . 0.0 105.697 174.201 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.48 ' HA ' HG21 ' A' ' 56' ' ' VAL . 89.4 p . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 176.235 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 38.2 ttp180 . . . . . 0 CA--C 1.53 0.203 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -106.48 130.64 54.24 Favored 'General case' 0 N--CA 1.445 -0.678 0 C-N-CA 129.374 3.069 . . . . 0.0 104.386 177.712 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.4 mt -120.22 145.16 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 C-N-CA 124.339 1.056 . . . . 0.0 110.649 -172.12 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 46.7 tp -124.38 131.45 53.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 173.634 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 79.4 mt -121.93 146.8 26.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 123.789 0.836 . . . . 0.0 109.317 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.34 136.23 41.36 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 169.9 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -106.96 108.4 19.89 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 125.224 1.41 . . . . 0.0 109.037 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.53 -178.0 7.17 Favored Glycine 0 CA--C 1.534 1.22 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -176.372 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.7 mm -118.87 143.54 29.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 t70 65.69 11.58 7.64 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.38 1.072 . . . . 0.0 113.143 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 p -74.83 -32.51 61.96 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 125.583 1.553 . . . . 0.0 108.587 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.5 p -54.57 -49.85 63.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 113.202 -1.817 . . . . 0.0 107.143 170.512 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -62.69 -42.42 99.62 Favored 'General case' 0 C--O 1.227 -0.119 0 C-N-CA 124.668 1.187 . . . . 0.0 109.641 177.875 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 24.5 tp -66.21 -2.55 4.41 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.463 1.505 . . . . 0.0 111.539 176.706 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.5 mtmm 51.94 34.1 13.0 Favored 'General case' 0 C--N 1.344 0.329 0 C-N-CA 125.18 1.392 . . . . 0.0 111.325 -179.157 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.95 30.91 60.77 Favored Glycine 0 CA--C 1.537 1.45 0 CA-C-O 120.015 -0.325 . . . . 0.0 112.802 -178.583 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -67.21 93.38 0.3 Allowed 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.759 1.279 . . . . 0.0 109.477 178.464 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.54 7.98 4.57 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 126.682 2.087 . . . . 0.0 112.122 -178.493 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.407 ' CG ' HG12 ' A' ' 115' ' ' VAL . 3.5 m-85 -101.35 153.04 20.01 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.696 1.198 . . . . 0.0 110.732 -177.441 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 59.3 m -145.41 121.81 10.97 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.3 -2.111 . . . . 0.0 105.3 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.421 ' HA ' HD23 ' A' ' 113' ' ' LEU . 35.1 p -96.04 128.22 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.539 0.736 . . . . 0.0 110.371 -173.255 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -92.05 -49.12 6.38 Favored 'General case' 0 N--CA 1.448 -0.57 0 O-C-N 124.336 1.023 . . . . 0.0 109.431 -178.289 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.9 m -75.22 124.7 33.63 Favored 'Isoleucine or valine' 0 C--N 1.34 0.193 0 C-N-CA 117.21 -1.796 . . . . 0.0 107.749 173.494 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.7 m -100.8 55.71 0.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 103.578 -2.749 . . . . 0.0 103.578 170.852 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.458 ' CB ' HG21 ' A' ' 60' ' ' ILE 0.5 0.0 OUTLIER 5.39 64.15 0.0 OUTLIER 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 130.767 3.627 . . . . 0.0 117.915 -168.517 . . . . . . . . 4 4 . 1 . 001 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -81.28 61.24 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 173.239 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ASP . . . . . 0.6 ' O ' HG22 ' A' ' 106' ' ' VAL 0.391 3.3 p30 6.01 -94.56 0.0 OUTLIER 'General case' 0 N--CA 1.439 -0.987 0 C-N-CA 128.506 2.722 . . . . 0.0 116.939 -174.283 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.4 mmm180 -55.69 106.09 0.23 Allowed 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 126.472 1.909 . . . . 0.0 112.262 -175.269 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 106' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 104' ' ' ASP . 0.0 OUTLIER -147.6 159.19 8.53 Favored 'Isoleucine or valine' 0 C--N 1.342 0.239 0 C-N-CA 124.841 1.257 . . . . 0.0 111.704 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -85.88 155.34 58.5 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 118.473 -0.775 . . . . 0.0 109.636 177.218 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo -48.82 168.61 0.1 Allowed 'Trans proline' 0 CA--C 1.534 0.514 1 C-N-CA 126.824 5.016 . . . . 0.0 120.381 -173.081 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 69.69 -97.37 0.55 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 125.956 1.741 . . . . 0.0 112.754 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 26.3 tt0 1.97 92.97 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 131.03 3.732 . . . . 0.0 114.102 -176.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 21.1 ttmt 4.21 114.82 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 130.321 3.449 . . . . 0.0 117.193 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 91.1 mt -81.87 -50.97 8.58 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.922 0.889 . . . . 0.0 108.988 173.59 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 113' ' ' LEU . . . . . 0.545 HD21 ' CE2' ' A' ' 64' ' ' PHE . 96.1 mt -138.06 155.25 48.99 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.769 1.628 . . . . 0.0 110.512 -176.494 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.42 132.53 53.98 Favored 'General case' 0 CA--C 1.516 -0.328 1 N-CA-C 100.106 -4.035 . . . . 0.0 100.106 167.981 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' VAL . . . . . 0.407 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -147.66 122.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.01 -165.603 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -71.63 69.07 0.62 Allowed 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.409 1.083 . . . . 0.0 111.025 -179.021 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 56.5 mt -49.11 -42.81 40.39 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.69 0.796 . . . . 0.0 111.166 178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -50.03 -48.43 52.73 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.628 0.771 . . . . 0.0 112.131 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.48 -31.34 22.85 Favored 'General case' 0 CA--C 1.527 0.078 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.8 t -64.02 -51.76 65.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.64 -0.662 . . . . 0.0 109.945 179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.407 0.0 OUTLIER -41.11 -57.95 3.11 Favored Pre-proline 0 CA--C 1.542 0.647 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -177.303 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -59.27 -19.34 49.74 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.256 1.971 . . . . 0.0 113.227 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -98.43 11.42 38.21 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.826 0.85 . . . . 0.0 112.283 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.83 151.31 73.82 Favored Pre-proline 0 CA--C 1.532 0.284 0 CA-C-N 119.837 1.199 . . . . 0.0 110.86 178.823 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -72.97 -24.06 17.87 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 122.744 2.296 . . . . 0.0 110.658 177.733 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 14.6 t -158.75 147.91 18.89 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.389 0.614 . . . . 0.0 109.864 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.0 tp -97.54 2.25 49.89 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.862 1.665 . . . . 0.0 110.51 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 19.3 mmt -52.01 119.19 4.05 Favored 'General case' 0 C--N 1.344 0.36 0 CA-C-N 118.208 0.458 . . . . 0.0 109.794 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 32.2 m -111.37 89.48 10.45 Favored Pre-proline 0 N--CA 1.447 -0.609 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -81.08 146.56 16.06 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.331 2.021 . . . . 0.0 111.364 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.4 mt -127.37 126.47 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 175.58 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.41 147.83 26.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 N-CA-C 106.819 -1.549 . . . . 0.0 106.819 178.926 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.401 ' HB2' HD21 ' A' ' 136' ' ' LEU . 13.6 m-85 -122.55 125.71 46.27 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 101.945 -3.354 . . . . 0.0 101.945 178.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.7 p -89.15 -82.77 0.24 Allowed 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.4 0.546 . . . . 0.0 111.422 -171.838 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 20.6 p30 -47.37 -49.01 25.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.111 1.765 . . . . 0.0 111.884 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.401 HD21 ' HB2' ' A' ' 133' ' ' PHE . 23.0 mt 42.8 49.03 5.02 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 125.111 1.365 . . . . 0.0 110.864 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 34.82 40.96 0.05 Allowed 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.325 1.85 . . . . 0.0 111.966 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 36.88 55.18 1.2 Allowed 'General case' 0 N--CA 1.446 -0.631 0 C-N-CA 128.319 2.648 . . . . 0.0 114.349 -176.277 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 163.09 -3.48 0.07 OUTLIER Glycine 0 CA--C 1.524 0.625 0 CA-C-O 118.885 -0.953 . . . . 0.0 114.482 175.211 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.677 ' HB3' HG23 ' A' ' 160' ' ' ILE . 63.7 mm-40 -76.61 109.86 10.71 Favored 'General case' 0 C--O 1.228 -0.074 0 CA-C-N 119.219 1.51 . . . . 0.0 110.483 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.4 p -78.8 138.68 38.31 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 171.817 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -85.55 84.79 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.5 m -78.27 93.76 4.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 O-C-N 120.6 -1.312 . . . . 0.0 110.844 -175.559 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 14.2 mt -64.91 130.91 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 C-N-CA 123.939 0.896 . . . . 0.0 108.608 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -107.44 -55.36 2.36 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.711 1.204 . . . . 0.0 108.026 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.84 70.22 1.91 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.357 0.599 . . . . 0.0 110.511 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 24.7 m -79.0 63.92 3.79 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 178.35 -140.91 4.8 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.368 -1.893 . . . . 0.0 108.368 -176.485 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.6 t -66.43 151.84 46.34 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 117.039 0.419 . . . . 0.0 110.989 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -133.97 154.07 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.538 1.535 . . . . 0.0 107.996 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -132.95 150.92 52.12 Favored 'General case' 0 C--O 1.233 0.22 0 C-N-CA 124.965 1.306 . . . . 0.0 108.634 178.009 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -57.48 150.33 18.98 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.149 0.979 . . . . 0.0 112.12 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 58.51 3.52 0.29 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 127.148 2.179 . . . . 0.0 115.263 174.379 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 55.5 mm-40 -72.29 164.25 26.6 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 119.056 0.844 . . . . 0.0 111.075 179.008 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -114.04 168.23 9.99 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.715 2.406 . . . . 0.0 108.22 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 25.9 t0 51.73 40.53 27.73 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.099 1.36 . . . . 0.0 112.811 176.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.445 HD12 ' H ' ' A' ' 158' ' ' VAL . 0.9 OUTLIER -99.78 -43.64 11.24 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.414 1.086 . . . . 0.0 109.636 178.674 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.445 ' H ' HD12 ' A' ' 157' ' ' ILE . 9.1 p -142.69 143.97 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 105.782 -1.933 . . . . 0.0 105.782 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -123.65 116.11 22.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.232 0.613 . . . . 0.0 109.547 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.677 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.4 mp -79.23 104.06 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 103.54 -2.763 . . . . 0.0 103.54 173.371 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -142.83 158.11 43.95 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 123.175 0.59 . . . . 0.0 109.865 -174.231 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.8 mptt . . . . . 0 CA--C 1.53 0.195 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.188 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.452 -0.329 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -103.61 90.92 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 C-N-CA 122.714 0.406 . . . . 0.0 111.686 -177.739 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 89.9 p -22.94 124.03 0.14 Allowed Pre-proline 0 CA--C 1.555 1.141 0 C-N-CA 126.037 1.735 . . . . 0.0 114.298 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -73.97 -36.74 3.25 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.023 2.482 . . . . 0.0 118.201 -171.654 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.44 148.33 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 119.905 1.229 . . . . 0.0 111.524 -175.422 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.6 m -80.48 140.6 35.83 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 173.957 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 163.58 -142.93 8.19 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -116.8 126.78 53.58 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 124.818 1.247 . . . . 0.0 108.457 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 tt -85.11 154.88 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -145.09 144.31 23.27 Favored Pre-proline 0 N--CA 1.451 -0.419 0 C-N-CA 124.989 1.316 . . . . 0.0 107.619 177.745 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -62.88 31.19 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 124.832 3.688 . . . . 0.0 116.838 177.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER 72.34 -39.69 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.071 1.349 . . . . 0.0 113.077 179.28 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -44.85 -41.38 7.03 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 125.298 1.439 . . . . 0.0 112.177 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.23 -14.1 62.73 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.646 1.579 . . . . 0.0 113.089 -175.978 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.6 t -71.3 127.91 90.8 Favored Pre-proline 0 CA--C 1.536 0.411 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 58.02 6.78 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.567 2.178 . . . . 0.0 112.043 -176.953 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -166.96 107.57 0.63 Allowed 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.686 -0.634 . . . . 0.0 110.203 177.348 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -28.6 -53.39 0.1 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 129.233 3.013 . . . . 0.0 115.967 -179.256 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 60.5 t -53.76 -45.61 61.74 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 CA-C-O 121.406 0.622 . . . . 0.0 109.703 -178.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -76.69 -54.47 6.6 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.9 m -45.37 -43.9 11.39 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 124.609 1.164 . . . . 0.0 114.119 -178.438 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -98.6 12.76 62.94 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 117.926 -1.486 . . . . 0.0 112.61 -176.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 56.8 mttp 70.97 -34.11 0.29 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 119.723 1.761 . . . . 0.0 113.994 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 26.3 ttt 28.57 -71.57 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 130.895 3.678 . . . . 0.0 117.191 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ttt -79.03 -17.08 55.91 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.971 0.908 . . . . 0.0 112.732 -175.599 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -168.15 -137.03 2.15 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.445 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.3 t0 -133.65 158.03 44.28 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 171.848 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -176.98 -162.79 28.06 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 119.361 -1.399 . . . . 0.0 113.46 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -151.4 165.14 35.02 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.991 1.316 . . . . 0.0 107.516 177.406 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -119.11 141.59 48.65 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -115.88 132.59 64.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 170.576 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.42 107.03 42.97 Favored Pre-proline 0 N--CA 1.445 -0.69 1 N-CA-C 98.298 -4.705 . . . . 0.0 98.298 169.249 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -82.9 167.01 14.67 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.732 2.954 . . . . 0.0 114.417 -168.214 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.8 p -127.73 -67.74 0.81 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.312 1.445 . . . . 0.0 108.499 176.912 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -53.24 124.81 15.59 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.802 0.841 . . . . 0.0 111.973 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.01 39.31 2.03 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 173.826 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.3 mt -140.01 117.14 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 104.181 -2.526 . . . . 0.0 104.181 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.9 t -116.71 114.01 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 123.904 0.881 . . . . 0.0 109.024 -175.408 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.3 m -90.64 178.03 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 172.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -97.85 145.73 30.25 Favored Pre-proline 0 C--O 1.223 -0.318 0 CA-C-O 117.147 -1.406 . . . . 0.0 110.064 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -62.43 -39.18 47.69 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 N-CA-C 106.92 -1.992 . . . . 0.0 106.92 172.256 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 p -157.54 139.57 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 101.495 -3.52 . . . . 0.0 101.495 169.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.441 ' HE ' ' CG1' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -91.29 -67.71 0.84 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 178.282 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 62.86 -74.4 0.03 OUTLIER Glycine 0 C--N 1.34 0.768 0 C-N-CA 126.155 1.835 . . . . 0.0 112.334 172.569 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.97 114.16 3.37 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.217 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 39.0 mm -61.74 128.33 23.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.138 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 8.4 tt -78.89 -52.55 8.14 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 177.236 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -179.19 161.81 1.15 Allowed 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 28.9 m -136.94 123.17 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 125.506 1.522 . . . . 0.0 107.503 175.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 153.84 0.6 Allowed Pre-proline 0 CA--C 1.537 0.454 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 176.353 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -50.42 -34.44 41.52 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 123.068 2.512 . . . . 0.0 112.671 175.961 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 25.0 p -79.62 4.14 16.91 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.972 0.909 . . . . 0.0 112.458 -179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 11.4 tppt? 66.36 -33.79 0.2 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 128.351 2.66 . . . . 0.0 115.803 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -54.44 -32.71 58.08 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 114.8 1.407 . . . . 0.0 114.8 -174.315 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.07 178.89 6.7 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 114.663 1.356 . . . . 0.0 114.663 -173.542 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.789 23.1 mm 117.86 -131.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.331 1 C-N-CA 132.719 4.408 . . . . 0.0 109.607 -179.312 . . . . . . . . 3 2 . 1 . 002 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.28 171.44 41.97 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 119.448 2.539 . . . . 0.0 119.448 -176.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.9 mt -118.97 179.68 4.08 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.81 2.444 . . . . 0.0 109.591 -177.655 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -149.63 152.3 35.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 127.016 2.126 . . . . 0.0 105.425 177.088 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 53.9 p . . . . . 0 CA--C 1.535 0.366 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 176.589 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 78' ' ' ARG . . . . . 0.407 ' N ' HD22 ' A' ' 135' ' ' ASN . 42.6 mtt85 . . . . . 0 N--CA 1.458 -0.056 0 CA-C-O 121.652 0.739 . . . . 0.0 109.988 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 8.4 tm-20 -76.87 134.19 39.08 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 176.744 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.3 mt -120.7 111.54 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.218 0.607 . . . . 0.0 110.995 -172.658 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.7 tt -83.04 138.28 33.79 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.517 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 68.3 mt -134.17 148.37 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 125.122 1.369 . . . . 0.0 108.887 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.42 78.92 1.64 Allowed 'General case' 0 C--N 1.34 0.192 0 C-N-CA 124.77 1.228 . . . . 0.0 109.743 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.438 ' HA ' HG23 ' A' ' 129' ' ' THR . 1.3 t80 -51.52 107.02 0.16 Allowed 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 123.102 0.561 . . . . 0.0 111.558 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.53 -173.29 2.51 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.647 0.641 . . . . 0.0 113.086 -178.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mm -121.67 146.0 27.43 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.3 t70 65.12 7.86 4.39 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.855 0.862 . . . . 0.0 113.07 -178.963 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -71.61 -35.21 70.39 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 125.738 1.615 . . . . 0.0 107.996 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 13.1 p -55.14 -45.79 77.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 CA-C-N 113.122 -1.854 . . . . 0.0 108.048 171.881 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.23 -38.66 92.05 Favored 'General case' 0 C--N 1.339 0.137 0 C-N-CA 124.354 1.061 . . . . 0.0 109.743 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.65 2.06 7.2 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 126.199 1.8 . . . . 0.0 110.615 175.67 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.4 mttp 45.88 30.23 0.84 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 128.016 2.526 . . . . 0.0 114.372 176.522 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.97 24.94 55.66 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.876 -0.402 . . . . 0.0 112.156 -178.061 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -56.66 -35.14 68.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 119.145 1.473 . . . . 0.0 112.79 -178.49 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -89.43 10.32 73.78 Favored Glycine 0 CA--C 1.533 1.192 0 CA-C-N 112.765 -2.016 . . . . 0.0 113.032 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -108.55 108.14 18.92 Favored 'General case' 0 C--N 1.343 0.325 0 CA-C-N 119.234 1.517 . . . . 0.0 111.996 -174.514 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.0 m -91.17 100.14 13.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.921 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.8 p -80.21 130.44 35.22 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 121.276 -0.89 . . . . 0.0 111.117 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -90.78 -46.96 7.91 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.705 1.202 . . . . 0.0 109.109 178.442 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.441 ' CG1' ' HE ' ' A' ' 57' ' ' ARG . 2.5 m -66.59 133.85 30.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 C-N-CA 118.105 -1.438 . . . . 0.0 108.421 174.491 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 59.5 m -110.88 53.29 0.71 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 170.998 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.292 3.4 pm0 -7.07 75.71 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.552 1 C-N-CA 131.815 4.046 . . . . 0.0 116.797 -171.603 . . . . . . . . 3 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.04 45.32 3.01 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 113.187 -1.824 . . . . 0.0 109.596 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 4.2 p30 5.23 41.57 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.226 2 C-N-CA 133.016 4.526 . . . . 0.0 122.206 -176.814 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.38 123.89 1.95 Allowed 'General case' 0 N--CA 1.436 -1.154 1 C-N-CA 133.163 4.585 . . . . 0.0 105.298 176.408 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -163.58 150.74 3.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 119.524 1.056 . . . . 0.0 110.482 -171.511 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -85.85 149.81 51.68 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 118.17 -0.919 . . . . 0.0 110.631 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_exo -46.71 150.84 2.29 Favored 'Trans proline' 0 CA--C 1.532 0.402 1 C-N-CA 126.222 4.615 . . . . 0.0 117.668 -176.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 66.44 -79.57 0.12 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.071 1.32 . . . . 0.0 112.504 176.873 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 1.44 76.12 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 131.581 3.953 . . . . 0.0 113.698 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? 17.49 109.94 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 129.723 3.209 . . . . 0.0 117.29 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 88.3 mt -78.75 -50.02 12.07 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.68 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 12.5 mt -144.56 156.8 44.32 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.971 0.909 . . . . 0.0 111.836 -173.061 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -119.06 131.39 55.95 Favored 'General case' 0 CA--C 1.516 -0.346 1 N-CA-C 98.694 -4.558 . . . . 0.0 98.694 165.586 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -140.91 129.89 24.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -166.497 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -76.24 63.2 1.86 Allowed 'General case' 0 C--O 1.234 0.25 0 CA-C-O 121.509 0.671 . . . . 0.0 110.068 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 78.6 mt -55.26 -34.56 64.15 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 123.221 0.609 . . . . 0.0 110.654 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.44 -40.23 71.29 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.047 0.539 . . . . 0.0 111.915 177.57 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.33 -35.3 17.27 Favored 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 122.788 0.435 . . . . 0.0 111.197 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.63 -51.19 75.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.554 -0.716 . . . . 0.0 109.518 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 20.8 pttm -40.66 -57.64 3.02 Favored Pre-proline 0 CA--C 1.541 0.616 0 N-CA-C 116.957 2.206 . . . . 0.0 116.957 -177.119 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -60.79 -25.64 81.52 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.696 2.264 . . . . 0.0 113.151 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -83.78 -43.03 15.85 Favored 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.62 0.646 . . . . 0.0 111.148 -178.148 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 35.7 m -78.91 150.57 75.37 Favored Pre-proline 0 CA--C 1.534 0.363 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.162 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -73.01 -25.19 16.52 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.515 2.143 . . . . 0.0 110.12 176.465 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.9 t -159.06 145.06 16.55 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 123.397 0.679 . . . . 0.0 109.539 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.9 tp -101.95 4.92 40.5 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.331 1.452 . . . . 0.0 110.287 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.8 mmt -51.97 111.4 0.6 Allowed 'General case' 0 C--N 1.342 0.263 0 C-N-CA 123.764 0.826 . . . . 0.0 110.104 179.031 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.438 HG23 ' HA ' ' A' ' 84' ' ' PHE . 85.7 m -107.3 114.57 60.86 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -90.55 145.75 4.0 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.976 2.45 . . . . 0.0 108.937 179.634 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.2 mp -124.84 116.57 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 101.787 -3.412 . . . . 0.0 101.787 172.918 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -124.58 117.21 49.79 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 C-N-CA 124.607 1.163 . . . . 0.0 108.719 -176.914 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -91.05 121.86 33.21 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.163 -2.532 . . . . 0.0 104.163 178.349 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -86.63 -73.17 0.47 Allowed 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.638 0.654 . . . . 0.0 110.757 -174.346 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.407 HD22 ' N ' ' A' ' 78' ' ' ARG . 4.0 p-10 -75.09 63.5 1.28 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 122.164 0.983 . . . . 0.0 112.507 -178.808 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.445 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 29.8 mt -77.02 65.12 2.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.864 1.666 . . . . 0.0 108.34 177.152 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.48 46.97 0.08 Allowed 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 127.432 2.293 . . . . 0.0 111.179 -175.929 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 31.9 58.61 0.34 Allowed 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.852 2.861 . . . . 0.0 115.374 -175.972 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 156.56 -4.82 0.19 Allowed Glycine 0 CA--C 1.525 0.664 0 CA-C-O 118.972 -0.905 . . . . 0.0 114.32 174.804 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.615 ' HB3' HG23 ' A' ' 160' ' ' ILE . 43.7 mt-10 -74.87 111.81 10.44 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 119.18 1.49 . . . . 0.0 110.031 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 59.9 p -78.42 133.37 37.51 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 176.885 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.456 HG23 HG13 ' A' ' 160' ' ' ILE 0.26 0.4 OUTLIER -84.37 82.72 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 CA-C-O 122.875 1.321 . . . . 0.0 107.964 -176.646 . . . . . . . . 4 4 . 1 . 002 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 41.9 m -79.08 94.65 5.36 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 120.986 -1.071 . . . . 0.0 110.363 -176.504 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 10.5 mt -57.91 128.32 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.4 mmpt? -98.5 -52.63 3.57 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 125.188 1.395 . . . . 0.0 108.931 177.827 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -79.0 61.51 3.19 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 120.819 0.342 . . . . 0.0 110.133 -178.482 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 60.2 p -77.84 72.77 4.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.843 0.857 . . . . 0.0 110.472 -176.861 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.37 -143.74 5.54 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 26.5 t -72.2 146.45 47.34 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 19.2 m -137.1 156.51 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.617 0.767 . . . . 0.0 109.33 -178.543 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -114.05 158.38 21.29 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 174.415 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.21 164.8 26.17 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.12 0.486 . . . . 0.0 110.249 175.091 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 60.7 32.91 20.31 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.339 1.055 . . . . 0.0 112.953 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -105.79 145.79 30.71 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 175.044 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -115.79 161.9 18.08 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.133 0.973 . . . . 0.0 110.585 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 19.3 t70 56.99 18.46 3.97 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 126.436 1.894 . . . . 0.0 113.566 -177.489 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.434 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -61.64 -21.2 24.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 125.464 1.506 . . . . 0.0 112.006 177.728 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.424 HG21 HG22 ' A' ' 142' ' ' VAL . 13.4 p -138.83 150.44 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 126.554 1.941 . . . . 0.0 107.048 178.804 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -120.77 109.07 14.72 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.184 0.994 . . . . 0.0 109.765 177.136 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.615 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.2 mp -77.65 92.47 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 N-CA-C 104.345 -2.465 . . . . 0.0 104.345 178.178 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 58.5 mt-10 -119.25 122.7 42.52 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.233 1.013 . . . . 0.0 111.055 -174.158 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--N 1.332 -0.179 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 177.332 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.529 0.171 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -131.27 96.99 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 122.231 2.287 . . . . 0.0 110.272 176.676 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 t -32.57 120.94 0.41 Allowed Pre-proline 0 CA--C 1.548 0.887 0 C-N-CA 125.574 1.55 . . . . 0.0 112.808 -178.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -74.06 -38.14 2.35 Favored 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 123.29 2.66 . . . . 0.0 117.571 -171.917 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.92 152.02 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 120.113 1.324 . . . . 0.0 109.84 -176.049 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.6 m -79.09 134.17 36.75 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 172.371 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.86 -177.09 45.54 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -92.0 122.08 34.17 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.4 tt -86.61 138.65 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 123.12 0.568 . . . . 0.0 110.141 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 78.8 m-70 -137.66 145.63 49.64 Favored Pre-proline 0 C--O 1.234 0.278 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 176.379 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.47 145.69 67.18 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.115 1.877 . . . . 0.0 110.218 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.4 tp -50.8 -33.84 12.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.729 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 p -56.02 -27.71 54.25 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 123.78 0.832 . . . . 0.0 112.388 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -76.22 -11.89 60.0 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.923 0.889 . . . . 0.0 112.714 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.675 HG22 ' HB2' ' A' ' 44' ' ' ALA . 42.3 t -66.85 129.45 94.05 Favored Pre-proline 0 CA--C 1.538 0.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.445 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -77.17 59.48 6.59 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.696 2.931 . . . . 0.0 111.024 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -167.58 105.19 0.52 Allowed 'General case' 0 N--CA 1.463 0.209 0 O-C-N 121.356 -0.84 . . . . 0.0 109.344 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -24.56 -58.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 128.162 2.585 . . . . 0.0 114.164 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.9 t -48.57 -50.44 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 123.954 0.902 . . . . 0.0 110.464 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -76.31 -47.81 22.29 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.2 m -49.31 -41.29 38.0 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 113.793 1.035 . . . . 0.0 113.793 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -104.6 20.27 39.81 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-O 118.081 -1.4 . . . . 0.0 110.897 -177.068 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.0 mttt 72.03 -46.52 0.65 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.401 1.48 . . . . 0.0 113.248 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 45.0 tpp 45.16 -72.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.731 2.812 . . . . 0.0 115.352 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.7 ttp -101.8 -14.69 17.19 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.314 1.446 . . . . 0.0 113.018 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.06 -169.21 38.0 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 119.531 1.06 . . . . 0.0 111.965 -178.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -128.79 157.54 41.17 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.99 -126.71 1.35 Allowed Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 108.533 -1.827 . . . . 0.0 108.533 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -166.44 167.1 16.01 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 118.125 0.963 . . . . 0.0 111.542 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.675 ' HB2' HG22 ' A' ' 29' ' ' VAL . . . -99.35 126.19 45.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.475 1.11 . . . . 0.0 108.5 177.418 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.0 mm -107.31 121.12 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 104.193 -2.521 . . . . 0.0 104.193 170.991 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 7.0 tt -89.03 109.5 31.12 Favored Pre-proline 0 C--O 1.233 0.233 1 N-CA-C 100.073 -4.047 . . . . 0.0 100.073 170.498 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -81.52 162.61 19.34 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 123.594 2.863 . . . . 0.0 115.037 -167.649 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.2 p -132.04 -63.52 0.81 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.639 1.576 . . . . 0.0 108.947 177.095 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.43 123.93 17.83 Favored 'General case' 0 C--N 1.338 0.096 0 C-N-CA 122.56 0.344 . . . . 0.0 110.166 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.08 45.34 2.98 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 173.304 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.2 mt -145.84 115.96 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 105.17 -2.159 . . . . 0.0 105.17 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.1 t -114.01 121.51 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 125.084 1.354 . . . . 0.0 108.252 -177.283 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.9 m -103.66 156.93 5.34 Favored 'Isoleucine or valine' 0 C--N 1.339 0.11 0 C-N-CA 123.642 0.777 . . . . 0.0 110.071 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 m -69.12 127.17 93.13 Favored Pre-proline 0 CA--C 1.537 0.471 0 CA-C-O 117.598 -1.191 . . . . 0.0 109.92 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -60.41 -33.2 94.39 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.763 2.976 . . . . 0.0 111.302 177.521 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.1 m -150.6 144.16 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 102.139 -3.282 . . . . 0.0 102.139 172.704 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 -98.72 -97.41 0.22 Allowed 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 101.754 -3.424 . . . . 0.0 101.754 169.354 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.95 -66.43 3.59 Favored Glycine 0 CA--C 1.535 1.303 0 N-CA-C 106.575 -2.61 . . . . 0.0 106.575 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.21 132.36 2.49 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 166.617 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.0 mm -65.04 131.78 30.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 103.55 -2.759 . . . . 0.0 103.55 169.069 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 29.3 tp -79.01 -46.36 18.33 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 175.0 156.05 0.15 Allowed 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 125.669 1.588 . . . . 0.0 107.787 176.034 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.3 t -131.12 121.06 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -47.44 153.01 1.05 Allowed Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 112.579 0.585 . . . . 0.0 112.579 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -59.67 -14.97 28.92 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 124.192 3.262 . . . . 0.0 113.652 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 40.5 p -76.26 -21.29 56.49 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.078 0.951 . . . . 0.0 109.697 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 70.98 9.52 6.78 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 128.14 2.576 . . . . 0.0 111.03 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -83.91 -31.21 25.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 118.611 -0.709 . . . . 0.0 112.864 -176.927 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.82 -175.38 5.33 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.679 1.127 . . . . 0.0 112.348 -174.314 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.965 16.6 mm 130.89 -141.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.334 -0.085 1 C-N-CA 132.018 4.127 . . . . 0.0 111.824 176.4 . . . . . . . . 3 2 . 1 . 003 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -152.14 176.2 30.53 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 118.511 2.164 . . . . 0.0 118.511 -171.804 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.2 mp -132.51 158.46 42.05 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 128.012 2.525 . . . . 0.0 109.817 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.7 mm-40 -133.03 123.85 26.57 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 177.379 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.3 p . . . . . 0 C--N 1.322 -0.629 0 C-N-CA 124.689 1.196 . . . . 0.0 108.778 177.82 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 . . . . . 0 N--CA 1.46 0.036 0 CA-C-O 121.821 0.82 . . . . 0.0 111.824 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -76.34 141.15 41.64 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 174.43 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.2 mt -126.66 144.36 37.08 Favored 'Isoleucine or valine' 0 C--N 1.338 0.08 0 N-CA-C 112.789 0.662 . . . . 0.0 112.789 -172.795 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -119.82 136.63 54.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 128.891 2.876 . . . . 0.0 105.732 175.789 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.0 mt -131.48 140.15 49.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 C-N-CA 125.075 1.35 . . . . 0.0 107.764 177.529 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -132.89 114.81 14.49 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -76.05 116.52 16.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 118.766 0.712 . . . . 0.0 110.402 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.63 -170.57 4.82 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.694 -0.562 . . . . 0.0 111.694 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 22.5 mm -116.59 141.36 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.159 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.7 t0 50.2 41.98 24.76 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.412 1.085 . . . . 0.0 112.892 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.423 ' O ' ' N ' ' A' ' 90' ' ' SER . 7.7 p -83.83 -89.12 0.1 Allowed 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 103.273 -2.862 . . . . 0.0 103.273 172.609 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.435 HG13 ' H ' ' A' ' 90' ' ' SER . 7.3 p 33.03 -67.31 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 C-N-CA 128.313 2.645 . . . . 0.0 116.946 172.354 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.435 ' H ' HG13 ' A' ' 89' ' ' VAL . 12.9 m -63.43 -40.44 97.18 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 126.27 1.828 . . . . 0.0 109.758 176.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -58.35 -43.53 88.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 126.862 2.065 . . . . 0.0 108.8 178.415 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? 77.02 169.59 0.24 Allowed 'General case' 0 N--CA 1.442 -0.871 0 C-N-CA 126.823 2.049 . . . . 0.0 106.837 -174.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.03 54.96 0.56 Allowed Glycine 0 CA--C 1.538 1.493 0 C-N-CA 124.898 1.237 . . . . 0.0 112.718 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -75.41 79.88 2.47 Favored 'General case' 0 CA--C 1.519 -0.236 0 O-C-N 121.158 -1.201 . . . . 0.0 108.781 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.78 11.72 2.31 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 112.919 -1.946 . . . . 0.0 111.594 -176.93 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -96.94 96.93 8.86 Favored 'General case' 0 C--N 1.342 0.267 0 C-N-CA 124.753 1.221 . . . . 0.0 110.731 -175.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.4 m -79.72 94.67 5.78 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 35.9 p -79.51 122.93 27.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 121.569 -0.707 . . . . 0.0 110.653 -176.446 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -83.57 -53.18 5.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 27.9 m -84.82 131.02 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 171.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 69.6 m -96.06 57.63 1.79 Allowed 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 170.351 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.378 0.0 OUTLIER 37.97 49.6 1.2 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 111.458 -2.61 . . . . 0.0 110.6 -167.265 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -72.44 59.46 1.57 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 129.639 3.495 . . . . 0.0 111.152 -178.066 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.401 16.4 p30 2.04 -103.22 0.0 OUTLIER 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 119.583 3.179 . . . . 0.0 119.583 -178.942 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.322 0.1 OUTLIER -40.6 131.29 2.33 Favored 'General case' 0 N--CA 1.432 -1.367 1 N-CA-C 125.478 5.362 . . . . 0.0 125.478 -165.667 . . . . . . . . 4 3 . 1 . 003 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.489 9.7 p 32.63 -38.27 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.247 2 N-CA-C 130.203 7.112 . . . . 0.0 130.203 168.148 . . . . . . . . 3 2 . 1 . 003 nuclear build core ' A' A ' 107' ' ' GLU . . . . . 0.485 ' HA ' ' HD3' ' A' ' 108' ' ' PRO 0.287 0.0 OUTLIER -70.33 115.16 31.88 Favored Pre-proline 0 C--N 1.308 -1.197 0 C-N-CA 115.422 -2.511 . . . . 0.0 114.333 -166.865 . . . . . . . . 4 4 . 1 . 003 nuclear build core ' A' A ' 108' ' ' PRO . . . . . 0.485 ' HD3' ' HA ' ' A' ' 107' ' ' GLU . 47.7 Cg_exo -62.45 162.82 22.71 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 124.875 3.717 . . . . 0.0 113.576 -170.141 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 54.04 15.91 5.63 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 124.423 1.011 . . . . 0.0 115.314 174.7 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -59.88 136.89 58.15 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 117.987 0.893 . . . . 0.0 108.752 178.929 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -64.23 119.42 10.22 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 174.381 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.6 mt -81.07 -52.33 7.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 17.1 mt -145.56 149.31 34.35 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.29 1.036 . . . . 0.0 110.995 -173.387 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -114.39 128.19 56.22 Favored 'General case' 0 CA--C 1.515 -0.402 1 N-CA-C 98.762 -4.532 . . . . 0.0 98.762 165.609 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.65 127.0 44.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.744 -165.469 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -74.26 68.29 1.47 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.664 0.786 . . . . 0.0 110.108 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.0 mt -54.2 -38.36 65.56 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.929 0.491 . . . . 0.0 111.102 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -53.68 -44.75 69.97 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.99 0.516 . . . . 0.0 112.162 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.89 -32.52 20.16 Favored 'General case' 0 CA--C 1.527 0.079 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -67.13 -50.59 62.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 O-C-N 121.759 -0.588 . . . . 0.0 110.326 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.345 22.1 pttm -37.0 -54.15 1.84 Allowed Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 118.283 2.698 . . . . 0.0 118.283 -176.796 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -52.63 -22.15 16.33 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.66 2.24 . . . . 0.0 114.095 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 -84.19 -14.36 50.31 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 118.13 -0.938 . . . . 0.0 113.096 -177.767 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 29.3 m -108.77 149.05 38.99 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 119.731 1.15 . . . . 0.0 112.44 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.32 -26.29 20.85 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.586 2.19 . . . . 0.0 110.372 175.674 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 10.0 m -157.85 137.41 12.03 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.564 1.146 . . . . 0.0 108.287 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 13.2 tp -90.29 6.78 41.5 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.876 0.87 . . . . 0.0 111.396 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.1 mmt -50.57 114.26 1.09 Allowed 'General case' 0 C--N 1.342 0.244 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 45.6 m -107.73 88.36 4.3 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -72.49 139.92 32.27 Favored 'Trans proline' 0 N--CA 1.445 -1.352 0 C-N-CA 121.923 1.749 . . . . 0.0 111.976 -178.718 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 16.6 mm -115.51 128.48 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 102.404 -3.184 . . . . 0.0 102.404 173.555 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.5 t -137.43 122.36 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -175.989 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -84.72 123.05 29.95 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.035 -2.58 . . . . 0.0 104.035 174.673 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 40.2 p -80.74 -72.78 0.4 Allowed 'General case' 0 C--O 1.227 -0.129 0 CA-C-N 118.841 0.746 . . . . 0.0 110.796 -175.683 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 22.2 p30 -65.14 -30.06 70.96 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -177.37 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 mt 46.27 44.54 12.5 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.156 0.982 . . . . 0.0 110.347 -176.973 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 42.53 37.39 0.97 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 126.351 1.86 . . . . 0.0 112.662 -175.645 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 75.5 mm-40 48.25 75.32 0.14 Allowed 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 126.706 2.002 . . . . 0.0 113.874 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.03 -14.21 5.19 Favored Glycine 0 C--N 1.335 0.484 0 CA-C-O 118.702 -1.055 . . . . 0.0 113.339 174.723 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -72.65 139.21 47.19 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.206 1.503 . . . . 0.0 109.776 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 77.2 p -111.87 130.81 55.7 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 124.97 1.308 . . . . 0.0 109.128 176.022 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -60.42 112.6 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 123.973 0.909 . . . . 0.0 110.387 -175.363 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 87.28 2.61 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 126.407 1.883 . . . . 0.0 106.518 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 34.7 mt -66.77 131.82 32.35 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -96.58 -44.2 7.25 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.457 ' HB2' HG23 ' A' ' 157' ' ' ILE . . . -47.23 83.1 0.0 OUTLIER 'General case' 0 C--N 1.34 0.158 0 C-N-CA 126.348 1.859 . . . . 0.0 114.206 -178.753 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 37.7 m -82.71 54.59 2.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 123.996 0.918 . . . . 0.0 108.787 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 157.47 -171.65 34.73 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.211 -0.755 . . . . 0.0 111.211 -177.548 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 29.6 t -58.47 138.05 56.93 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 122.794 0.438 . . . . 0.0 110.101 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.7 m -92.86 -173.01 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 123.7 0.8 . . . . 0.0 109.928 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.85 166.7 29.76 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.62 155.03 24.64 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.986 0.812 . . . . 0.0 110.336 176.034 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 62.56 5.12 1.55 Allowed 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.762 1.625 . . . . 0.0 114.301 178.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -67.95 118.22 10.85 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 62.7 tt0 -67.51 138.03 56.23 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 29.2 t70 84.92 -113.87 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 128.327 2.651 . . . . 0.0 109.043 -179.318 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.457 HG23 ' HB2' ' A' ' 146' ' ' ALA 0.366 1.7 mp 73.31 -28.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 129.565 3.146 . . . . 0.0 111.509 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.0 p -134.9 148.09 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 127.519 2.328 . . . . 0.0 106.978 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 159' ' ' LYS . . . . . 0.496 ' C ' HD13 ' A' ' 160' ' ' ILE . 26.3 mtpp -134.67 144.93 48.1 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 104.009 -2.589 . . . . 0.0 104.009 173.608 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.496 HD13 ' C ' ' A' ' 159' ' ' LYS . 0.3 OUTLIER -112.0 112.55 40.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.156 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.1 134.02 44.74 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 123.66 0.784 . . . . 0.0 111.247 -174.908 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp . . . . . 0 CA--C 1.528 0.117 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 176.73 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.528 0.119 0 N-CA-C 114.387 1.254 . . . . 0.0 114.387 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -142.55 103.88 1.05 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 C-N-CA 126.68 1.992 . . . . 0.0 106.267 172.995 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 t -29.14 118.53 0.28 Allowed Pre-proline 0 CA--C 1.552 1.033 0 C-N-CA 124.728 1.211 . . . . 0.0 113.43 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -75.31 -37.47 1.87 Allowed 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 122.693 2.262 . . . . 0.0 117.324 -173.115 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.27 148.06 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 120.397 1.453 . . . . 0.0 109.3 -176.727 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.4 m -78.64 137.04 37.64 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 175.301 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.19 -147.14 14.54 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -107.72 144.1 35.3 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.858 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.1 tt -105.62 95.17 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 C-N-CA 124.304 1.041 . . . . 0.0 108.398 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -85.63 151.58 55.86 Favored Pre-proline 0 C--O 1.237 0.404 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.047 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.26 145.32 88.5 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 N-CA-C 107.888 -1.62 . . . . 0.0 107.888 174.887 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.3 tp -50.67 -32.64 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.672 0.789 . . . . 0.0 111.134 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.9 -29.87 63.41 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.829 1.252 . . . . 0.0 113.057 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -82.24 3.65 26.64 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.524 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.403 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 58.2 t -82.06 128.04 69.56 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-O 117.508 -1.234 . . . . 0.0 111.755 -176.641 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_exo -58.74 40.75 0.05 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 1 C-N-CA 126.354 4.702 . . . . 0.0 117.451 175.298 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -164.48 109.59 0.97 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 120.98 1.718 . . . . 0.0 109.033 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 18.8 mp0 -34.13 -48.52 0.32 Allowed 'General case' 0 C--O 1.231 0.117 0 C-N-CA 128.956 2.902 . . . . 0.0 114.401 -176.805 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.5 p -53.44 -38.95 34.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 CA-C-N 118.158 0.435 . . . . 0.0 110.878 -178.606 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -84.48 -48.83 9.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 177.419 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -51.03 -39.23 55.38 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -178.131 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.38 17.15 57.24 Favored Glycine 0 N--CA 1.445 -0.716 0 CA-C-O 118.219 -1.323 . . . . 0.0 111.06 -177.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.7 mttp 71.18 -40.71 0.48 Allowed 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.463 1.505 . . . . 0.0 114.07 178.88 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 29.97 -73.96 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 130.005 3.322 . . . . 0.0 116.753 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.19 -21.3 46.56 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.476 1.11 . . . . 0.0 113.263 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 172.43 -144.21 7.83 Favored Glycine 0 C--O 1.223 -0.564 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -141.57 160.05 40.95 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.482 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.55 -126.13 1.23 Allowed Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.05 163.73 15.86 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 118.636 1.218 . . . . 0.0 112.261 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.403 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -99.94 96.88 7.84 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 124.575 1.15 . . . . 0.0 110.466 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 32.1 mm -80.44 126.11 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.4 tt -101.03 105.5 39.03 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 100.529 -3.878 . . . . 0.0 100.529 171.381 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -84.37 168.18 11.68 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.891 3.061 . . . . 0.0 114.255 -168.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.9 p -130.8 -71.7 0.57 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.347 1.459 . . . . 0.0 108.199 176.081 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -48.89 127.25 13.72 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 124.609 1.164 . . . . 0.0 112.088 178.748 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.21 42.26 2.34 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 173.899 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 35.9 mt -143.74 120.87 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 104.381 -2.452 . . . . 0.0 104.381 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' VAL . . . . . 0.408 HG21 ' CE2' ' A' ' 84' ' ' PHE . 53.1 t -119.97 131.09 73.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 124.911 1.284 . . . . 0.0 107.549 -176.528 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.4 m -110.72 159.39 10.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 C-N-CA 124.08 0.952 . . . . 0.0 110.947 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.84 132.7 94.83 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-O 118.41 -0.805 . . . . 0.0 110.21 -179.584 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -68.58 -15.95 42.02 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.638 2.892 . . . . 0.0 115.926 -177.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -143.99 162.02 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.046 0 CA-C-N 119.523 1.056 . . . . 0.0 110.409 -178.66 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 108' ' ' PRO . 9.0 ptp85 -76.73 117.14 18.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 168.716 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 172.96 -179.62 44.28 Favored Glycine 0 N--CA 1.433 -1.529 0 C-N-CA 115.277 -3.344 . . . . 0.0 114.954 -167.246 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.63 127.91 42.05 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 124.558 1.143 . . . . 0.0 109.815 -176.233 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 9.6 mm -73.94 113.32 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 N-CA-C 102.633 -3.099 . . . . 0.0 102.633 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 61.0 tp -76.44 -47.93 21.37 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -174.571 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -174.77 157.4 2.47 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 13.5 t -138.91 119.24 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 175.791 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -42.04 151.53 0.34 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.572 0.624 . . . . 0.0 112.201 177.91 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.19 -26.36 15.03 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 123.89 3.06 . . . . 0.0 114.303 175.0 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 19.2 p -75.73 -15.2 60.31 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 123.871 0.869 . . . . 0.0 110.925 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 71.87 10.11 6.2 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.545 1.538 . . . . 0.0 113.536 178.795 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.437 ' CG ' ' HA ' ' A' ' 89' ' ' VAL . 22.6 p-80 -90.51 -31.62 16.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 119.428 1.013 . . . . 0.0 113.403 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.97 -178.82 7.16 Favored 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -171.007 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.663 23.0 mm 124.01 -132.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 1 C-N-CA 135.155 5.382 . . . . 0.0 105.216 -176.709 . . . . . . . . 3 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -169.86 -179.1 41.33 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 119.165 2.426 . . . . 0.0 119.165 -177.829 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.6 mp -124.56 172.33 9.3 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.747 2.419 . . . . 0.0 110.279 -178.208 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -134.42 142.01 47.0 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 169.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 40.8 p . . . . . 0 C--N 1.324 -0.516 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.041 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -103.53 136.35 43.43 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 173.676 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 22.3 mt -125.01 122.95 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -173.782 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 28.2 tp -89.65 136.83 32.8 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 127.193 2.197 . . . . 0.0 106.914 173.367 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.4 mt -120.14 155.63 23.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.652 1.181 . . . . 0.0 109.522 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.57 96.64 1.79 Allowed 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 126.223 1.809 . . . . 0.0 107.021 174.977 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.408 ' CE2' HG21 ' A' ' 52' ' ' VAL . 1.0 OUTLIER -73.68 76.69 1.53 Allowed 'General case' 0 N--CA 1.454 -0.238 0 O-C-N 121.519 -0.738 . . . . 0.0 110.565 -178.071 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.11 170.84 39.89 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.634 1.588 . . . . 0.0 111.775 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 2.0 tp -107.41 125.86 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.845 1.658 . . . . 0.0 106.935 178.03 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t0 58.88 38.6 24.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 125.323 1.449 . . . . 0.0 111.206 -176.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -95.88 -70.85 0.7 Allowed 'General case' 0 CA--C 1.496 -1.126 0 N-CA-C 101.366 -3.568 . . . . 0.0 101.366 171.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.437 ' HA ' ' CG ' ' A' ' 68' ' ' HIS 0.335 1.3 p 45.44 49.22 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 104.492 -2.41 . . . . 0.0 104.492 -172.758 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 21.4 m 12.97 48.38 0.0 OUTLIER 'General case' 0 C--N 1.35 0.592 1 C-N-CA 133.111 4.565 . . . . 0.0 112.83 -165.219 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.414 HD23 ' HA ' ' A' ' 91' ' ' LEU . 1.9 mt 33.66 50.52 0.31 Allowed 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 131.053 3.741 . . . . 0.0 109.001 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 90.5 mttt 76.66 50.26 0.05 Allowed 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 128.148 2.579 . . . . 0.0 111.595 -176.966 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 47.43 37.28 12.24 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 126.472 1.987 . . . . 0.0 114.059 -178.35 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -92.5 161.66 14.53 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 170.366 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 63.56 -4.14 1.11 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.137 1.351 . . . . 0.0 114.822 178.695 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -106.64 105.57 15.67 Favored 'General case' 0 C--N 1.342 0.262 0 CA-C-N 119.077 1.438 . . . . 0.0 111.327 -175.72 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 18.9 m -93.11 104.36 16.57 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 174.341 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.6 t -80.15 148.83 30.77 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 119.203 0.91 . . . . 0.0 110.775 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -115.9 3.85 13.77 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 126.323 1.849 . . . . 0.0 110.785 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.6 m -134.02 145.96 32.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 176.611 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.6 m -82.6 -16.87 46.83 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.973 1.309 . . . . 0.0 112.211 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.472 1.3 pp20? 73.29 140.86 0.06 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.203 3.001 . . . . 0.0 109.574 -172.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 97.5 -16.48 60.5 Favored Glycine 0 CA--C 1.54 1.642 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -169.23 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -57.87 115.66 2.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.632 1.973 . . . . 0.0 108.901 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.25 123.01 29.67 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 128.912 2.885 . . . . 0.0 114.254 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.345 27.3 m 52.23 70.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.301 0 C-N-CA 126.992 2.117 . . . . 0.0 116.032 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 138.44 26.55 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 170.161 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' PRO . . . . . 0.404 ' HA ' ' HA ' ' A' ' 57' ' ' ARG . 0.9 OUTLIER -93.63 -135.49 0.01 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.004 0 C-N-CA 124.978 3.785 . . . . 0.0 108.522 -179.229 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -64.21 30.09 0.09 OUTLIER Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.334 1.921 . . . . 0.0 115.678 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.8 tt0 -64.58 149.8 48.12 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 169.262 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -64.32 122.11 15.91 Favored 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.739 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.7 mt -80.44 -49.43 11.44 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 175.468 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.1 mt -144.04 152.43 41.0 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.007 0.923 . . . . 0.0 110.708 -173.873 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -114.49 128.83 56.54 Favored 'General case' 0 CA--C 1.517 -0.298 1 N-CA-C 98.95 -4.463 . . . . 0.0 98.95 165.802 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.44 128.47 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.469 -165.603 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -76.82 63.57 2.23 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.623 0.725 . . . . 0.0 109.856 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 80.0 mt -54.34 -37.68 65.16 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 123.248 0.619 . . . . 0.0 110.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -53.76 -43.37 69.13 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.761 0.824 . . . . 0.0 112.247 178.342 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.92 -34.54 20.9 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.059 0.391 . . . . 0.0 111.411 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 75.4 t -62.01 -55.43 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.722 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.355 18.8 pttp -38.96 -58.33 1.76 Allowed Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 117.596 2.443 . . . . 0.0 117.596 -176.098 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.49 -20.28 48.43 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.774 2.316 . . . . 0.0 113.717 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -100.13 9.2 43.18 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 118.551 -0.738 . . . . 0.0 112.726 -176.795 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 22.8 m -136.23 158.48 73.53 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 119.573 1.079 . . . . 0.0 109.36 -178.761 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -75.7 -30.0 6.63 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.017 1.811 . . . . 0.0 112.783 -177.47 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -163.88 133.96 4.2 Favored 'General case' 0 N--CA 1.454 -0.241 0 O-C-N 121.395 -0.816 . . . . 0.0 111.287 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -93.42 9.07 38.02 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.961 0.904 . . . . 0.0 111.564 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -50.89 110.04 0.38 Allowed 'General case' 0 C--N 1.342 0.242 0 C-N-CA 124.301 1.041 . . . . 0.0 108.327 177.87 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.8 m -95.83 102.49 10.52 Favored Pre-proline 0 N--CA 1.447 -0.607 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -92.39 99.66 0.18 Allowed 'Trans proline' 0 N--CA 1.444 -1.422 0 C-N-CA 123.414 2.743 . . . . 0.0 107.679 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.08 126.5 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 103.503 -2.777 . . . . 0.0 103.503 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.05 120.43 51.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 CA-C-O 121.928 0.871 . . . . 0.0 109.303 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.485 ' N ' ' CD1' ' A' ' 133' ' ' PHE . 0.5 OUTLIER -83.0 114.14 21.06 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 101.732 -3.432 . . . . 0.0 101.732 177.592 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -77.16 -79.69 0.11 Allowed 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 121.007 0.432 . . . . 0.0 111.216 -170.824 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 1.4 p-10 -72.23 68.12 0.72 Allowed 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.988 0.899 . . . . 0.0 111.298 -178.696 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.1 mt -76.76 65.28 2.47 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.128 -0.982 . . . . 0.0 108.364 177.119 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 10.18 63.03 0.0 OUTLIER 'General case' 0 C--N 1.347 0.458 0 C-N-CA 130.582 3.553 . . . . 0.0 112.815 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 25.97 58.02 0.06 Allowed 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 128.52 2.728 . . . . 0.0 114.514 -176.085 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 148.71 6.2 0.23 Allowed Glycine 0 CA--C 1.524 0.617 0 CA-C-O 118.577 -1.124 . . . . 0.0 114.033 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.733 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 22.4 mt-10 -77.76 92.76 4.21 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 119.439 1.62 . . . . 0.0 107.894 177.251 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 70.1 p -76.69 135.06 39.08 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -177.359 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.2 t -87.32 90.74 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 124.0 0.92 . . . . 0.0 109.26 -176.768 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 42.1 m -85.68 95.6 9.42 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 33.0 mt -64.58 131.84 30.36 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.394 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -100.94 -45.9 5.28 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 124.665 1.186 . . . . 0.0 109.055 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.67 74.81 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.234 0 C-N-CA 126.113 1.765 . . . . 0.0 112.02 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.1 m -79.71 54.47 1.82 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.443 1.097 . . . . 0.0 110.025 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 160.7 179.66 35.6 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 40.5 t -57.16 144.83 33.46 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.172 0.589 . . . . 0.0 111.616 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 4.9 m -145.04 166.96 10.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -102.36 166.86 10.33 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 124.849 1.26 . . . . 0.0 111.48 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.29 163.41 23.02 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 63.96 -9.42 0.15 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.727 2.011 . . . . 0.0 114.552 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 34.2 mm-40 -64.32 148.96 49.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.456 1.025 . . . . 0.0 111.581 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -99.33 159.38 15.05 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.527 2.331 . . . . 0.0 111.099 -176.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 24.9 t70 57.55 21.83 7.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 126.137 1.775 . . . . 0.0 114.621 174.98 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.464 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -70.35 -28.64 36.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 C-N-CA 123.61 0.764 . . . . 0.0 111.812 178.951 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.44 145.14 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 C-N-CA 125.5 1.52 . . . . 0.0 107.866 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -120.57 111.86 18.2 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 174.054 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.733 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.03 110.53 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 103.84 -2.652 . . . . 0.0 103.84 172.871 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -109.11 125.04 51.73 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.956 1.303 . . . . 0.0 109.883 -178.188 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 56.2 tptt . . . . . 0 C--N 1.333 -0.14 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.109 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.461 0.117 0 CA-C-O 118.311 -0.852 . . . . 0.0 111.467 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.2 m -90.51 101.5 12.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 CA-C-N 118.882 0.765 . . . . 0.0 110.568 177.072 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.3 p -35.44 115.56 0.56 Allowed Pre-proline 0 CA--C 1.556 1.211 0 C-N-CA 125.831 1.652 . . . . 0.0 110.891 177.317 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -75.72 -30.45 6.16 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.832 2.354 . . . . 0.0 117.685 -171.01 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.49 148.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 120.513 1.506 . . . . 0.0 110.806 -176.764 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.8 m -79.27 138.81 37.91 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 171.539 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.62 -151.69 20.51 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -117.05 116.33 27.14 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.218 1.407 . . . . 0.0 108.435 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 7.5 mt -78.84 138.17 20.58 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 CA-C-N 118.666 0.666 . . . . 0.0 109.617 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -137.03 144.75 47.56 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 174.458 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -54.9 142.73 74.67 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 C-N-CA 121.967 1.778 . . . . 0.0 110.109 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.22 -36.44 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 124.646 1.178 . . . . 0.0 113.187 -177.286 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.2 p -51.38 -32.68 26.91 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.911 1.285 . . . . 0.0 112.559 178.185 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -75.94 -9.61 58.75 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 124.224 1.009 . . . . 0.0 112.505 -175.288 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.551 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 52.9 t -75.16 119.73 78.33 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-O 117.662 -1.161 . . . . 0.0 111.529 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -59.34 53.94 0.07 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 1 C-N-CA 126.067 4.511 . . . . 0.0 117.071 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -167.69 112.03 0.67 Allowed 'General case' 0 N--CA 1.463 0.186 0 O-C-N 120.464 -1.398 . . . . 0.0 108.684 177.083 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -30.67 -51.46 0.15 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 127.609 2.363 . . . . 0.0 114.589 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.3 t -52.97 -47.33 53.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 CA-C-O 121.508 0.67 . . . . 0.0 110.05 -178.627 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -78.08 -46.95 19.41 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -50.38 -43.01 54.3 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -97.62 11.94 64.69 Favored Glycine 0 C--N 1.338 0.657 0 CA-C-O 118.909 -0.94 . . . . 0.0 111.499 -178.779 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? 70.13 -34.8 0.3 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.809 1.644 . . . . 0.0 114.032 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.6 tmt? 32.18 -69.27 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 131.286 3.834 . . . . 0.0 116.576 178.312 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 7.8 tpt -78.58 -19.99 51.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.185 0.994 . . . . 0.0 111.981 -175.918 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.15 -133.13 1.82 Allowed Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 44.9 t0 -136.45 158.56 44.14 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 172.944 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 176.19 -154.45 16.93 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.383 -0.913 . . . . 0.0 111.706 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.556 ' CE2' HD11 ' A' ' 45' ' ' ILE . 38.7 p90 -158.25 164.48 36.43 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 122.533 0.333 . . . . 0.0 110.2 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.551 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -102.45 146.3 28.3 Favored 'General case' 0 CA--C 1.508 -0.665 0 C-N-CA 123.742 0.817 . . . . 0.0 109.369 178.267 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.556 HD11 ' CE2' ' A' ' 43' ' ' PHE . 4.4 mp -124.93 128.19 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 102.635 -3.098 . . . . 0.0 102.635 169.131 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.3 tt -91.33 106.78 17.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 172.865 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -61.32 170.34 5.35 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 124.111 3.207 . . . . 0.0 116.166 -171.074 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.5 p -152.29 -65.01 0.17 Allowed 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 125.089 1.356 . . . . 0.0 107.876 176.361 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -61.85 127.61 32.25 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.47 0.708 . . . . 0.0 110.188 176.812 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.83 43.95 2.9 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 172.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -145.36 124.35 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 127.381 2.273 . . . . 0.0 105.138 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 89.9 t -123.53 126.49 73.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.03 155.04 9.0 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 C-N-CA 123.716 0.807 . . . . 0.0 110.268 178.7 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.79 139.31 95.5 Favored Pre-proline 0 N--CA 1.449 -0.519 0 C-N-CA 123.585 0.754 . . . . 0.0 110.192 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -78.28 -21.91 10.08 Favored 'Trans proline' 0 N--CA 1.453 -0.885 0 C-N-CA 123.51 2.807 . . . . 0.0 114.221 -177.299 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.7 m -138.92 166.61 22.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.163 0 C-N-CA 124.325 1.05 . . . . 0.0 111.007 -177.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -78.81 115.96 18.83 Favored 'General case' 0 C--O 1.234 0.253 1 N-CA-C 99.376 -4.305 . . . . 0.0 99.376 168.338 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.32 176.6 47.89 Favored Glycine 0 N--CA 1.441 -1.015 0 C-N-CA 115.606 -3.188 . . . . 0.0 117.015 -168.839 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 123.72 30.54 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.769 1.628 . . . . 0.0 108.505 178.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 16.7 mm -75.45 95.77 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 172.862 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 49.9 tp -72.41 -51.27 21.13 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -171.05 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -171.19 137.06 1.1 Allowed 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 118.472 0.578 . . . . 0.0 111.423 177.323 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -128.15 123.9 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 103.761 -2.681 . . . . 0.0 103.761 172.433 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.33 156.61 0.48 Allowed Pre-proline 0 CA--C 1.54 0.578 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -178.812 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -50.05 -29.71 22.63 Favored 'Trans proline' 0 C--N 1.348 0.517 0 C-N-CA 123.924 3.083 . . . . 0.0 114.562 178.265 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.6 p -77.56 -9.04 58.7 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.511 1.124 . . . . 0.0 111.64 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.22 8.43 3.36 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 127.835 2.454 . . . . 0.0 113.202 -178.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -80.88 -27.76 36.22 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -160.68 -176.35 5.5 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 119.204 0.911 . . . . 0.0 111.677 -174.111 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.402 HG22 ' H ' ' A' ' 71' ' ' GLY 0.898 18.3 mm 129.0 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.184 1 C-N-CA 131.846 4.058 . . . . 0.0 111.355 176.485 . . . . . . . . 4 3 . 1 . 005 nuclear build core ' A' A ' 71' ' ' GLY . . . . . 0.402 ' H ' HG22 ' A' ' 70' ' ' ILE . . . -147.36 168.23 28.44 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 116.6 1.4 . . . . 0.0 116.6 -173.997 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -132.49 169.15 16.98 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 126.349 1.86 . . . . 0.0 108.619 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.11 144.71 38.82 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 175.847 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 89.2 p . . . . . 0 C--N 1.32 -0.685 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 176.446 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 . . . . . 0 C--O 1.238 0.464 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -111.55 148.3 33.53 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.283 2.233 . . . . 0.0 107.107 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.38 144.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 124.269 1.028 . . . . 0.0 109.66 -176.585 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -125.62 132.58 52.46 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 128.159 2.583 . . . . 0.0 105.439 176.693 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 39.0 mt -131.98 141.9 44.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 C-N-CA 124.798 1.239 . . . . 0.0 109.715 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -132.55 104.96 6.94 Favored 'General case' 0 C--O 1.226 -0.178 0 C-N-CA 124.335 1.054 . . . . 0.0 108.475 174.648 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.7 t80 -68.35 109.65 3.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 121.109 -0.995 . . . . 0.0 109.092 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.67 -165.82 7.79 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -176.785 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 31.4 mt -122.29 136.5 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.7 t0 55.48 42.61 29.69 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.555 1.142 . . . . 0.0 112.645 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.435 ' O ' ' N ' ' A' ' 90' ' ' SER . 1.8 p -80.19 -85.22 0.09 Allowed 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 103.093 -2.929 . . . . 0.0 103.093 172.215 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.418 HG13 ' H ' ' A' ' 90' ' ' SER . 12.1 p 26.43 -64.82 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 C-N-CA 128.883 2.873 . . . . 0.0 117.293 173.441 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 88' ' ' THR . 11.8 m -60.44 -36.83 79.13 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 126.624 1.97 . . . . 0.0 109.675 178.468 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -50.9 -36.71 39.65 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 128.216 2.606 . . . . 0.0 109.617 176.343 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp 70.49 151.75 0.1 Allowed 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 126.303 1.841 . . . . 0.0 109.673 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -65.91 25.99 0.15 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 115.153 0.821 . . . . 0.0 115.153 -178.315 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 20.5 mm-40 -59.21 -35.16 73.13 Favored 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.689 1.744 . . . . 0.0 112.085 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -98.02 15.26 61.81 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.764 178.23 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -123.31 96.57 5.04 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 118.884 1.342 . . . . 0.0 109.545 -176.716 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.7 m -81.52 111.77 18.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 173.251 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.8 p -86.11 138.53 31.85 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.563 -0.711 . . . . 0.0 111.279 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -107.51 7.16 28.68 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 125.57 1.548 . . . . 0.0 113.389 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 20.5 m -140.42 144.37 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 175.808 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.7 m -79.51 -15.77 57.16 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.175 0.99 . . . . 0.0 112.772 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.442 16.1 pm0 69.03 147.46 0.06 Allowed 'General case' 0 N--CA 1.446 -0.671 0 C-N-CA 130.065 3.346 . . . . 0.0 111.209 -173.214 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 95.22 -21.78 42.25 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 124.709 1.147 . . . . 0.0 110.466 -172.84 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -60.63 124.57 20.78 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.919 1.688 . . . . 0.0 108.914 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.33 123.64 31.8 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 129.162 2.985 . . . . 0.0 113.308 -174.571 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.373 28.5 m 52.23 69.89 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.142 0 N-CA-C 117.018 2.229 . . . . 0.0 117.018 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.35 139.85 27.36 Favored Pre-proline 0 N--CA 1.45 -0.455 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 168.767 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -88.19 -151.25 0.04 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 123.686 2.924 . . . . 0.0 108.544 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -69.68 54.36 0.71 Allowed Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.908 1.242 . . . . 0.0 113.924 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -54.22 -55.07 31.57 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 124.97 1.308 . . . . 0.0 110.037 177.314 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt 144.87 125.67 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.621 1 C-N-CA 132.615 4.366 . . . . 0.0 106.098 -175.591 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 69.9 mt -91.83 -45.51 8.35 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 123.652 0.781 . . . . 0.0 109.385 178.182 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.2 mt -147.52 151.87 37.07 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 122.798 0.439 . . . . 0.0 111.101 -174.881 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -116.31 127.21 54.49 Favored 'General case' 0 CA--C 1.517 -0.291 1 N-CA-C 98.557 -4.608 . . . . 0.0 98.557 165.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.23 126.34 45.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.721 -166.357 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -74.75 61.03 0.96 Allowed 'General case' 0 C--O 1.233 0.224 0 C-N-CA 125.259 1.423 . . . . 0.0 111.239 -176.765 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.5 mt -45.94 -41.82 12.08 Favored 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 124.326 1.05 . . . . 0.0 111.94 -178.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -49.15 -41.4 36.17 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.622 0.769 . . . . 0.0 112.501 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -92.57 -33.77 14.3 Favored 'General case' 0 CA--C 1.527 0.066 0 C-N-CA 123.467 0.707 . . . . 0.0 111.353 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.26 -51.95 64.77 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.617 -0.677 . . . . 0.0 109.468 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.368 46.1 pttt -41.87 -58.07 3.58 Favored Pre-proline 0 CA--C 1.541 0.599 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -177.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -57.18 -19.8 35.56 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.435 2.09 . . . . 0.0 113.327 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -95.49 7.98 44.63 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 118.097 -0.954 . . . . 0.0 112.488 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 23.9 m -132.91 150.51 75.87 Favored Pre-proline 0 N--CA 1.466 0.333 0 CA-C-N 120.086 1.312 . . . . 0.0 111.506 179.643 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -73.78 -27.41 12.52 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 C-N-CA 122.867 2.378 . . . . 0.0 111.635 179.243 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -157.42 132.01 8.56 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.598 -0.689 . . . . 0.0 109.926 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -90.35 -2.06 57.96 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.712 1.205 . . . . 0.0 111.769 -179.019 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.6 mmt -49.65 111.26 0.48 Allowed 'General case' 0 C--N 1.34 0.194 0 C-N-CA 124.399 1.08 . . . . 0.0 109.353 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 49.9 m -102.73 110.14 62.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 -178.432 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -91.33 137.62 2.1 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 122.843 2.362 . . . . 0.0 110.538 -179.201 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 15.3 mm -114.46 121.17 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 102.893 -3.003 . . . . 0.0 102.893 173.211 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.1 t -126.43 149.11 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -177.393 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -123.1 124.99 44.34 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 36.1 p -83.58 -67.76 0.76 Allowed 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.771 0.796 . . . . 0.0 110.638 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.8 p30 -72.0 51.7 0.23 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.99 1.716 . . . . 0.0 113.587 -177.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.429 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 78.2 mt -80.49 54.31 2.03 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.393 1.077 . . . . 0.0 108.961 175.615 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 16.33 55.67 0.01 OUTLIER 'General case' 0 C--N 1.346 0.438 0 C-N-CA 129.59 3.156 . . . . 0.0 113.403 -177.938 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 27.56 56.47 0.08 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 127.715 2.406 . . . . 0.0 113.829 -175.465 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 165.68 -10.83 0.07 OUTLIER Glycine 0 CA--C 1.526 0.758 0 CA-C-O 119.321 -0.71 . . . . 0.0 113.638 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.585 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 16.2 mt-10 -78.73 82.07 4.98 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.752 1.276 . . . . 0.0 107.932 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.7 p -74.3 138.49 43.59 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.404 -0.81 . . . . 0.0 109.93 -175.992 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -83.65 122.29 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 123.66 0.784 . . . . 0.0 109.234 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.6 m -112.75 97.82 6.81 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.867 1.267 . . . . 0.0 109.178 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.2 pt -71.08 108.37 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 176.503 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -77.08 -55.47 5.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -82.88 66.08 8.32 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 49.2 m -77.6 69.72 3.88 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.81 -150.16 7.62 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 107.105 -2.398 . . . . 0.0 107.105 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 10.4 t -75.64 146.08 40.56 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 118.297 1.048 . . . . 0.0 110.556 178.316 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -143.71 167.3 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 124.555 1.142 . . . . 0.0 109.777 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 35.2 m-80 -113.69 163.75 14.59 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 125.236 1.414 . . . . 0.0 107.647 174.557 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.94 165.35 25.4 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 170.637 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 56.88 48.42 15.99 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.565 1.146 . . . . 0.0 111.862 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -121.96 159.18 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 173.83 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -126.46 153.66 44.77 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 119.228 0.922 . . . . 0.0 111.188 -176.687 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.7 t70 62.95 13.65 6.83 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 126.702 2.001 . . . . 0.0 113.191 -176.554 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.54 -37.85 78.79 Favored 'Isoleucine or valine' 0 C--O 1.233 0.207 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.7 p -117.88 129.29 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 N-CA-C 103.486 -2.783 . . . . 0.0 103.486 168.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -122.81 123.73 41.7 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.585 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.26 130.61 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 174.584 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -130.97 139.25 50.0 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.221 1.408 . . . . 0.0 107.269 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.3 tptm . . . . . 0 C--N 1.331 -0.215 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 -177.795 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.226 -0.168 0 N-CA-C 105.6 -2.0 . . . . 0.0 105.6 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.32 91.3 2.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.269 0 CA-C-N 118.991 0.814 . . . . 0.0 112.352 -176.901 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.6 t -21.95 111.34 0.14 Allowed Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 126.373 1.869 . . . . 0.0 112.282 176.602 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -74.11 -28.58 10.74 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.181 2.587 . . . . 0.0 118.338 -169.716 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.64 153.31 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 120.339 1.427 . . . . 0.0 110.496 -176.722 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 92.1 m -88.32 125.38 34.65 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 172.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 179.72 -170.43 41.74 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -176.129 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -98.63 133.93 42.27 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 11.2 tt -81.94 146.22 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 123.111 0.564 . . . . 0.0 111.148 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -144.8 137.35 13.49 Favored Pre-proline 0 C--O 1.237 0.397 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -59.58 146.18 95.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.094 1.863 . . . . 0.0 111.452 178.509 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.9 tp -50.04 -36.93 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 C-N-CA 125.176 1.39 . . . . 0.0 112.062 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 p -70.27 -12.08 61.34 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.034 1.734 . . . . 0.0 114.195 -179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -112.79 29.12 8.22 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.897 0.772 . . . . 0.0 111.636 -173.537 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.3 t -94.08 135.11 24.95 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 124.327 1.051 . . . . 0.0 109.564 178.605 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -65.5 50.82 0.24 Allowed 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 124.216 3.277 . . . . 0.0 115.054 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -166.77 133.89 2.49 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 120.489 -1.382 . . . . 0.0 109.815 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -59.8 -47.51 85.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.873 1.269 . . . . 0.0 113.109 -177.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 55.0 t -55.07 -54.97 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 118.596 0.634 . . . . 0.0 109.389 -178.61 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -61.38 -58.68 7.25 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.973 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 59.0 m -69.47 -16.0 63.38 Favored 'General case' 0 N--CA 1.461 0.082 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -177.292 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -88.91 -0.1 81.62 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 108.44 -1.864 . . . . 0.0 108.44 173.975 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 57.5 mttp 74.16 -39.88 0.44 Allowed 'General case' 0 C--N 1.346 0.438 0 C-N-CA 126.498 1.919 . . . . 0.0 111.56 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 14.9 tpt 28.9 -76.74 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 130.436 3.494 . . . . 0.0 116.461 178.263 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 11.0 ttt -79.24 -17.57 54.52 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.741 0.816 . . . . 0.0 113.059 -175.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.44 -135.28 2.83 Favored Glycine 0 C--N 1.338 0.643 0 CA-C-N 119.128 0.877 . . . . 0.0 112.382 -176.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -137.23 157.84 45.75 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.53 -157.77 19.15 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.764 -175.62 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -158.74 158.81 34.36 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.773 1.229 . . . . 0.0 108.203 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.23 132.96 52.49 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-N 118.836 0.744 . . . . 0.0 110.418 177.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.457 HD12 HG21 ' A' ' 150' ' ' VAL . 22.6 mm -117.35 107.25 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 173.896 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 11.9 tp -74.79 119.06 74.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 N-CA-C 102.329 -3.212 . . . . 0.0 102.329 172.067 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.04 153.38 22.04 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 123.095 2.53 . . . . 0.0 113.721 -168.98 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 79.2 p -126.18 -45.78 1.68 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.651 0.78 . . . . 0.0 112.242 178.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -64.43 -42.27 96.11 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.833 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.58 25.34 70.32 Favored Glycine 0 CA--C 1.533 1.188 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -173.012 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 54.0 mt -136.5 123.59 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 102.496 -3.149 . . . . 0.0 102.496 177.042 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 79.1 t -124.49 124.66 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 C-N-CA 124.397 1.079 . . . . 0.0 109.945 -171.752 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -107.12 155.8 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.126 0 C-N-CA 123.715 0.806 . . . . 0.0 109.493 176.743 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -61.82 139.63 95.52 Favored Pre-proline 0 N--CA 1.448 -0.551 0 C-N-CA 123.624 0.77 . . . . 0.0 110.544 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -75.31 -13.01 20.9 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 124.307 3.338 . . . . 0.0 115.03 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -148.11 161.65 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.056 0 CA-C-N 119.443 1.02 . . . . 0.0 110.213 -176.651 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 116.99 19.6 Favored 'General case' 0 C--O 1.237 0.402 1 N-CA-C 100.103 -4.036 . . . . 0.0 100.103 167.653 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 173.27 -177.34 45.73 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 115.544 -3.217 . . . . 0.0 116.428 -168.451 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.15 122.04 28.78 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.161 0.984 . . . . 0.0 112.512 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.4 mm -66.2 125.59 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 N-CA-C 103.058 -2.942 . . . . 0.0 103.058 168.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 40.7 tp -78.39 -40.75 35.23 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 119.643 1.111 . . . . 0.0 109.213 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -175.43 -163.75 0.13 Allowed 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.683 ' HA ' HG21 ' A' ' 70' ' ' ILE . 7.3 p -160.51 125.42 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 172.446 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.3 m-85 -68.0 145.1 97.61 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 119.291 0.951 . . . . 0.0 110.361 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -50.6 -29.27 24.59 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 123.484 2.789 . . . . 0.0 113.532 176.096 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.1 p -77.3 -7.91 56.76 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.756 0.822 . . . . 0.0 111.956 -178.92 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.8 ttmt 64.06 -11.18 0.12 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.828 1.651 . . . . 0.0 114.914 177.618 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 9.3 p-80 -74.72 -29.4 61.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 121.665 -0.647 . . . . 0.0 112.688 -175.853 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.46 176.8 11.62 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-N 118.893 0.77 . . . . 0.0 110.368 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.683 HG21 ' HA ' ' A' ' 63' ' ' VAL . 0.1 OUTLIER 157.31 -148.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.355 0 C-N-CA 130.492 3.517 . . . . 0.0 106.056 176.318 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 71' ' ' GLY . . . . . 0.494 ' H ' ' CG1' ' A' ' 70' ' ' ILE . . . -152.51 174.21 31.44 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 123.477 0.561 . . . . 0.0 111.804 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -141.19 176.78 8.56 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 126.486 1.914 . . . . 0.0 108.045 -178.128 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 30.5 mt-30 -143.08 156.02 44.73 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 103.634 -2.728 . . . . 0.0 103.634 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 69.6 p . . . . . 0 C--N 1.326 -0.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.608 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 78' ' ' ARG . . . . . 0.504 ' N ' HD22 ' A' ' 135' ' ' ASN . 69.0 mtm180 . . . . . 0 CA--C 1.525 0.012 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -73.45 119.77 18.14 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.7 mp -98.38 149.97 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 125.432 1.493 . . . . 0.0 108.574 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.6 tp -128.88 136.05 49.91 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 127.745 2.418 . . . . 0.0 104.849 176.087 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 46.0 mt -129.93 136.2 59.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -129.74 84.71 2.23 Favored 'General case' 0 N--CA 1.466 0.335 0 C-N-CA 123.481 0.712 . . . . 0.0 110.619 176.993 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -56.67 98.94 0.03 OUTLIER 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.528 0.731 . . . . 0.0 111.303 -179.241 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.75 -177.16 5.17 Favored Glycine 0 CA--C 1.531 1.059 0 C-N-CA 124.092 0.853 . . . . 0.0 112.463 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.1 mt -121.73 140.23 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 69.82 9.4 7.13 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.384 1.474 . . . . 0.0 112.313 -177.428 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -75.6 -34.41 60.62 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 126.358 1.863 . . . . 0.0 108.156 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.5 p -54.32 -46.79 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 CA-C-N 113.468 -1.696 . . . . 0.0 108.028 171.653 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -62.05 -39.21 91.57 Favored 'General case' 0 N--CA 1.455 -0.198 0 C-N-CA 124.491 1.116 . . . . 0.0 109.425 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.99 3.17 5.67 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.934 1.694 . . . . 0.0 111.322 177.14 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 48.13 32.48 3.02 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 126.068 1.747 . . . . 0.0 112.993 178.141 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.74 28.29 60.07 Favored Glycine 0 CA--C 1.535 1.323 0 O-C-N 122.009 -0.432 . . . . 0.0 112.828 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 51.9 mt-10 -72.4 91.04 1.33 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.963 1.381 . . . . 0.0 108.843 178.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 6.12 4.24 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 126.745 2.117 . . . . 0.0 111.391 -176.877 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.529 ' CD1' HG12 ' A' ' 115' ' ' VAL . 14.6 m-30 -103.27 131.12 50.57 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.187 1.395 . . . . 0.0 108.477 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 14.3 m -119.98 122.79 41.95 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 126.245 1.818 . . . . 0.0 107.159 -179.315 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.1 p -99.32 124.63 44.57 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.612 0.765 . . . . 0.0 109.957 -176.372 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -90.59 -48.81 6.85 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.566 1.546 . . . . 0.0 111.294 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.43 130.76 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 C-N-CA 117.149 -1.82 . . . . 0.0 107.283 175.666 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 71.1 m -94.51 55.1 1.9 Allowed 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 102.743 -3.058 . . . . 0.0 102.743 168.693 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.588 0.4 OUTLIER 43.58 -77.63 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.774 0 C-N-CA 130.627 3.571 . . . . 0.0 113.465 -167.57 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.4 35.6 36.2 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 125.108 1.337 . . . . 0.0 110.45 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.373 4.1 p30 4.38 -106.6 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 130.049 3.34 . . . . 0.0 119.313 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -33.62 111.94 0.12 Allowed 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 130.993 3.717 . . . . 0.0 119.047 -169.234 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.363 27.4 m 48.61 68.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 129.08 2.952 . . . . 0.0 118.036 173.487 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 139.22 27.48 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 167.797 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -90.37 -145.04 0.03 OUTLIER 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.56 2.84 . . . . 0.0 108.302 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -70.81 52.05 0.92 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 124.875 1.226 . . . . 0.0 113.885 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.7 tp60 -61.83 -22.25 65.34 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 125.858 1.663 . . . . 0.0 113.707 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt 108.1 111.84 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 130.103 3.361 . . . . 0.0 107.971 -176.971 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 73.5 mt -80.25 -53.2 6.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 23.0 mt -143.04 163.94 31.44 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 123.743 0.817 . . . . 0.0 111.721 -174.728 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -128.19 135.33 49.58 Favored 'General case' 0 CA--C 1.515 -0.4 1 N-CA-C 99.81 -4.145 . . . . 0.0 99.81 166.707 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 115' ' ' VAL . . . . . 0.529 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -144.92 121.28 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -166.303 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -70.53 64.98 0.29 Allowed 'General case' 0 C--O 1.234 0.246 0 C-N-CA 125.569 1.548 . . . . 0.0 113.019 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 88.5 mt -40.81 -54.27 2.7 Favored 'General case' 0 C--O 1.226 -0.165 0 C-N-CA 124.91 1.284 . . . . 0.0 111.909 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -49.81 -41.36 44.57 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.485 1.114 . . . . 0.0 113.879 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.43 -35.01 15.4 Favored 'General case' 0 C--O 1.23 0.056 0 C-N-CA 122.454 0.302 . . . . 0.0 111.496 -177.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.9 t -67.21 -50.61 61.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 O-C-N 121.764 -0.585 . . . . 0.0 109.529 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.347 48.5 pttt -40.11 -57.78 2.61 Favored Pre-proline 0 CA--C 1.539 0.55 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.91 -21.85 43.06 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 122.509 2.139 . . . . 0.0 113.132 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -97.43 6.89 47.51 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 118.387 -0.816 . . . . 0.0 112.655 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 30.2 m -136.49 151.14 72.39 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-N 119.898 1.226 . . . . 0.0 110.262 178.958 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.79 -25.16 12.59 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.535 2.157 . . . . 0.0 112.206 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.9 m -158.24 128.09 5.95 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 119.038 0.835 . . . . 0.0 111.27 -177.764 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.32 -0.23 57.31 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.823 1.249 . . . . 0.0 110.72 176.708 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 82.6 mmm -50.37 103.0 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 126.221 1.808 . . . . 0.0 109.754 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 68.6 m -99.09 117.39 64.27 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 123.814 0.845 . . . . 0.0 109.091 -177.638 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.56 139.49 1.87 Allowed 'Trans proline' 0 N--CA 1.442 -1.556 0 C-N-CA 123.211 2.607 . . . . 0.0 108.914 178.749 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.51 HD12 ' N ' ' A' ' 131' ' ' ILE . 1.1 mp -113.08 117.82 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 N-CA-C 100.523 -3.88 . . . . 0.0 100.523 171.469 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -126.01 158.13 35.55 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.714 ' HB2' HD21 ' A' ' 136' ' ' LEU . 32.5 m-85 -134.1 137.49 44.62 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 103.751 -2.685 . . . . 0.0 103.751 -176.534 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -92.46 -73.41 0.55 Allowed 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 119.223 0.92 . . . . 0.0 109.216 -179.195 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' ASN . . . . . 0.504 HD22 ' N ' ' A' ' 78' ' ' ARG . 4.6 p-10 -75.96 68.79 2.5 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -178.779 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.714 HD21 ' HB2' ' A' ' 133' ' ' PHE . 2.9 mm? -78.6 66.0 4.01 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 171.457 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 31.46 47.45 0.06 Allowed 'General case' 0 C--N 1.343 0.299 0 C-N-CA 127.831 2.452 . . . . 0.0 111.717 -173.813 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 29.61 61.22 0.16 Allowed 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 128.243 2.617 . . . . 0.0 114.343 -177.464 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.38 -14.78 0.22 Allowed Glycine 0 CA--C 1.525 0.668 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.968 177.773 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.563 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 44.2 mm-40 -80.4 123.66 28.22 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.201 1.001 . . . . 0.0 109.638 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.2 p -89.78 143.28 26.93 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.925 0.89 . . . . 0.0 109.257 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -89.94 113.23 25.8 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 C-N-CA 123.664 0.786 . . . . 0.0 109.874 -178.47 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 36.2 m -106.74 98.85 8.47 Favored 'General case' 0 C--N 1.34 0.178 0 C-N-CA 124.333 1.053 . . . . 0.0 110.576 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 3.2 pt -64.07 128.74 26.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 175.325 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -98.09 -34.71 10.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.064 0.946 . . . . 0.0 112.223 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.567 ' HB2' HG23 ' A' ' 157' ' ' ILE . . . -70.98 100.72 2.03 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 119.773 1.169 . . . . 0.0 109.915 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 1.2 m -79.49 51.26 1.22 Allowed 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.174 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 176.2 -145.76 7.7 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -175.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 47.1 t -73.92 132.49 42.52 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 122.203 -0.586 . . . . 0.0 111.216 -178.792 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.457 HG21 HD12 ' A' ' 45' ' ' ILE . 18.4 m -89.7 157.15 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 174.493 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.78 152.44 49.27 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.5 mtp180 -58.29 150.07 22.82 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 122.685 0.394 . . . . 0.0 111.603 177.634 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 63.03 1.73 0.91 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 126.412 1.885 . . . . 0.0 115.339 172.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 58.9 mm-40 -70.13 119.32 14.15 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 119.569 1.077 . . . . 0.0 108.635 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -81.99 125.86 31.28 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 121.369 0.604 . . . . 0.0 112.242 -176.355 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.9 t0 70.08 27.9 4.19 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 128.472 2.709 . . . . 0.0 115.459 175.188 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.567 HG23 ' HB2' ' A' ' 146' ' ' ALA 0.26 1.7 mp -71.27 -8.89 12.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 CA-C-O 121.306 0.575 . . . . 0.0 110.264 178.257 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.7 p -122.39 120.15 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 102.75 -3.056 . . . . 0.0 102.75 168.385 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 5.5 mtpm? -108.13 128.42 54.68 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.563 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.45 133.14 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.729 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -145.08 -174.87 4.48 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 125.078 1.351 . . . . 0.0 108.716 -177.912 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 49.3 mtmt . . . . . 0 C--O 1.233 0.201 0 C-N-CA 125.307 1.443 . . . . 0.0 107.31 174.981 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.529 0.163 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.9 m -125.44 84.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-N 118.61 0.641 . . . . 0.0 112.65 -176.159 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 21.9 t -19.86 122.01 0.09 OUTLIER Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 129.373 3.069 . . . . 0.0 112.553 177.524 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -71.48 -37.35 5.65 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 117.632 2.128 . . . . 0.0 117.632 -171.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.3 151.64 18.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 119.717 1.144 . . . . 0.0 111.387 -175.109 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.1 m -88.46 146.38 25.24 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.548 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.42 -128.6 2.17 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -127.57 138.64 52.94 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.007 1.323 . . . . 0.0 108.141 178.048 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.8 tt -106.51 139.71 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 16.6 m-70 -136.94 155.55 76.27 Favored Pre-proline 0 N--CA 1.453 -0.315 0 C-N-CA 125.628 1.571 . . . . 0.0 108.329 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 146.08 84.25 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 N-CA-C 107.916 -1.609 . . . . 0.0 107.916 172.534 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -56.79 -21.31 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.534 -1.666 . . . . 0.0 113.119 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.0 p -53.42 -32.51 50.03 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.562 0.745 . . . . 0.0 111.124 175.074 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -77.11 -6.1 51.55 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.903 0.881 . . . . 0.0 113.075 -175.083 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.3 t -77.84 132.6 67.53 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 119.228 0.922 . . . . 0.0 110.171 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -77.32 58.12 6.14 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 123.692 2.928 . . . . 0.0 111.176 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -168.83 110.25 0.51 Allowed 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 20.0 mp0 -37.42 -44.8 0.66 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 127.486 2.314 . . . . 0.0 113.553 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 95.4 t -50.26 -43.82 22.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 123.414 0.686 . . . . 0.0 110.16 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -87.3 -48.99 7.55 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.757 0.823 . . . . 0.0 109.52 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.12 -40.99 34.52 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.03 13.93 60.22 Favored Glycine 0 C--N 1.338 0.676 0 CA-C-O 118.938 -0.923 . . . . 0.0 111.853 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 37.1 mttp 70.31 -34.05 0.28 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.757 1.623 . . . . 0.0 114.584 179.106 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.5 ttm 24.38 -61.6 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 1 C-N-CA 132.029 4.131 . . . . 0.0 118.203 178.319 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.11 -22.72 48.47 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.944 0.898 . . . . 0.0 111.59 -177.276 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.02 -128.89 1.3 Allowed Glycine 0 C--N 1.336 0.535 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 41' ' ' ASP . . . . . 0.418 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.0 t0 -131.4 159.25 38.53 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 171.321 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.4 -166.18 34.25 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.016 -1.088 . . . . 0.0 113.461 -176.872 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 p90 -144.38 160.92 40.23 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 124.534 1.134 . . . . 0.0 109.714 178.553 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -105.95 118.46 36.67 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.525 1.53 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.6 mm -98.46 130.3 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 172.675 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 tt -101.11 108.01 52.69 Favored Pre-proline 0 N--CA 1.448 -0.541 1 N-CA-C 99.604 -4.221 . . . . 0.0 99.604 170.105 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -85.91 148.49 9.5 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 122.617 2.211 . . . . 0.0 114.958 -168.118 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.5 p -113.51 -51.24 2.81 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.974 1.31 . . . . 0.0 108.685 174.498 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -73.56 122.4 22.17 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.515 0.326 . . . . 0.0 111.328 179.215 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.22 41.07 2.6 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 173.055 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 81.0 mt -136.22 113.78 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 103.413 -2.81 . . . . 0.0 103.413 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.2 t -119.54 119.62 61.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 C-N-CA 123.769 0.828 . . . . 0.0 109.87 -172.657 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.3 m -99.87 164.7 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 CA-C-O 121.159 0.504 . . . . 0.0 109.935 176.802 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.5 m -76.46 131.93 73.66 Favored Pre-proline 0 N--CA 1.45 -0.444 0 CA-C-O 117.576 -1.202 . . . . 0.0 108.423 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -60.96 -31.79 91.79 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.002 2.468 . . . . 0.0 110.783 177.469 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' VAL . . . . . 0.453 HG22 HD12 ' A' ' 80' ' ' ILE . 10.8 m -151.11 150.09 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 102.925 -2.991 . . . . 0.0 102.925 173.389 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.0 tpt180 -101.25 -93.74 0.29 Allowed 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 101.176 -3.638 . . . . 0.0 101.176 169.142 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.75 2.5 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 107.405 -2.278 . . . . 0.0 107.405 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 125.23 1.91 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 167.633 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.5 mm -62.92 128.62 25.16 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 169.909 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.05 -49.04 11.38 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 178.518 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -175.88 151.15 1.08 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.434 0.294 . . . . 0.0 111.361 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.5 m -113.17 126.23 70.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 169.53 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.446 ' CG ' ' HB3' ' A' ' 69' ' ' ALA . 5.7 m-85 -65.73 156.63 82.51 Favored Pre-proline 0 CA--C 1.534 0.333 0 O-C-N 121.426 -0.796 . . . . 0.0 110.03 -176.621 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -48.44 -43.4 32.84 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.114 2.543 . . . . 0.0 112.952 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.0 p -79.57 3.87 17.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.842 1.257 . . . . 0.0 112.761 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.18 -21.9 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 128.525 2.73 . . . . 0.0 116.84 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.87 -31.54 72.75 Favored 'General case' 0 C--O 1.227 -0.103 0 CA-C-N 119.483 1.038 . . . . 0.0 111.884 -174.8 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ALA . . . . . 0.446 ' HB3' ' CG ' ' A' ' 64' ' ' PHE . . . -103.6 135.67 44.74 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.091 0.956 . . . . 0.0 110.081 -179.365 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.9 mt -140.06 146.54 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -125.32 136.74 9.95 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 125.862 1.696 . . . . 0.0 109.076 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.8 mp -137.86 163.82 30.5 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 124.959 1.304 . . . . 0.0 110.409 -177.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 70.8 mt-30 -145.38 125.23 13.46 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.606 ' HG ' ' N ' ' A' ' 78' ' ' ARG . 57.2 p . . . . . 0 CA--C 1.538 0.519 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 175.443 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' ARG . . . . . 0.606 ' N ' ' HG ' ' A' ' 74' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.261 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 . . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -93.09 126.8 38.36 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 125.589 1.556 . . . . 0.0 106.932 177.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' ILE . . . . . 0.453 HD12 HG22 ' A' ' 56' ' ' VAL . 5.8 mt -125.03 143.45 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.1 0.96 . . . . 0.0 111.205 -172.003 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -122.89 130.74 53.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.219 2.208 . . . . 0.0 105.413 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.5 mt -123.49 146.73 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 C-N-CA 124.767 1.227 . . . . 0.0 108.019 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -134.33 131.8 38.77 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 105.283 -2.117 . . . . 0.0 105.283 171.324 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -103.05 106.21 16.68 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 124.774 1.229 . . . . 0.0 107.879 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.1 -169.82 34.94 Favored Glycine 0 CA--C 1.534 1.229 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 29.3 mm -109.78 -84.42 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.05 0 CA-C-O 123.224 1.488 . . . . 0.0 110.469 -178.104 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.41 4.82 0.48 Allowed 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 126.432 1.893 . . . . 0.0 113.033 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.22 -30.24 71.11 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.438 1.895 . . . . 0.0 107.573 175.195 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.55 -46.98 89.75 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 CA-C-N 114.374 -1.285 . . . . 0.0 108.348 174.362 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.68 -41.02 98.21 Favored 'General case' 0 C--O 1.227 -0.112 0 C-N-CA 125.036 1.334 . . . . 0.0 109.017 177.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -65.05 -8.41 16.19 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 125.69 1.596 . . . . 0.0 110.943 176.727 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? 52.54 34.14 14.91 Favored 'General case' 0 C--N 1.343 0.315 0 C-N-CA 125.301 1.441 . . . . 0.0 111.823 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.18 21.07 61.33 Favored Glycine 0 CA--C 1.536 1.37 0 CA-C-O 119.67 -0.517 . . . . 0.0 112.875 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.84 90.18 1.1 Allowed 'General case' 0 C--N 1.341 0.227 0 CA-C-N 119.388 1.594 . . . . 0.0 108.625 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 141.83 -2.41 1.9 Allowed Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.484 1.992 . . . . 0.0 111.591 -175.144 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -97.86 103.53 15.47 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 125.57 1.548 . . . . 0.0 111.063 -176.758 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 50.0 m -84.36 98.15 9.87 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.636 -2.727 . . . . 0.0 103.636 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 43.0 p -79.59 121.37 25.18 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 121.793 -0.567 . . . . 0.0 109.983 -177.205 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -79.94 -52.82 7.38 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.524 1.13 . . . . 0.0 109.361 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 24.3 m -82.17 129.0 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.121 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.43 175.142 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 67.5 m -98.21 56.69 1.2 Allowed 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 102.397 -3.186 . . . . 0.0 102.397 169.105 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.312 7.8 pt-20 36.16 61.08 0.8 Allowed 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 111.09 -2.777 . . . . 0.0 110.734 -167.498 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.42 55.08 2.41 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 111.108 -2.769 . . . . 0.0 109.834 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.35 3.3 p30 1.81 -110.63 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 130.997 3.719 . . . . 0.0 118.566 -178.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 45.0 mmm-85 -44.94 142.46 1.81 Allowed 'General case' 0 N--CA 1.425 -1.698 1 N-CA-C 122.56 4.281 . . . . 0.0 122.56 -167.03 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.722 4.7 m 36.95 -55.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.428 2 N-CA-C 130.351 7.167 . . . . 0.0 130.351 173.971 . . . . . . . . 3 2 . 1 . 007 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.52 121.98 86.29 Favored Pre-proline 0 C--N 1.317 -0.831 0 C-N-CA 116.472 -2.091 . . . . 0.0 113.172 -165.083 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -69.84 172.31 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 125.021 3.814 . . . . 0.0 113.081 -169.12 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 55.81 19.51 21.67 Favored Glycine 0 CA--C 1.528 0.895 0 C-N-CA 124.582 1.087 . . . . 0.0 115.21 176.282 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -61.6 143.22 56.4 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 118.488 1.144 . . . . 0.0 109.328 177.775 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -69.96 119.61 14.43 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.2 mt -80.85 -51.43 8.61 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -143.28 155.17 44.41 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 -174.008 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -122.39 125.76 46.57 Favored 'General case' 0 CA--C 1.514 -0.425 1 N-CA-C 98.305 -4.702 . . . . 0.0 98.305 166.296 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.36 129.33 56.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 114.691 -1.141 . . . . 0.0 112.165 -165.711 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -73.22 67.95 0.98 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.798 0.839 . . . . 0.0 110.397 -179.209 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.8 mt -52.59 -41.56 63.73 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-O 119.301 -0.38 . . . . 0.0 110.583 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -49.45 -44.46 45.63 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 123.507 0.723 . . . . 0.0 112.272 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.59 -35.33 19.51 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 117.933 0.333 . . . . 0.0 111.841 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 53.9 t -64.59 -49.69 79.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 121.537 -0.727 . . . . 0.0 110.567 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.357 0.0 OUTLIER -47.48 -53.84 26.7 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 116.943 2.201 . . . . 0.0 116.943 -177.557 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -60.9 -25.64 81.71 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.231 1.954 . . . . 0.0 112.323 177.151 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -79.92 -50.15 10.87 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 118.651 0.66 . . . . 0.0 110.617 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 18.7 m -79.72 142.83 57.51 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.721 -177.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.33 -15.81 22.34 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.48 2.12 . . . . 0.0 111.717 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 16.6 m -156.76 128.41 7.13 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.07 0.948 . . . . 0.0 108.907 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.2 tp -94.73 9.91 37.1 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.403 1.481 . . . . 0.0 111.54 -178.745 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 74.1 mmm -53.42 118.75 4.09 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 34.0 m -113.94 86.96 11.89 Favored Pre-proline 0 N--CA 1.445 -0.678 0 C-N-CA 126.168 1.787 . . . . 0.0 107.752 -177.247 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.477 ' C ' HD12 ' A' ' 131' ' ' ILE . 60.9 Cg_endo -83.25 149.72 13.41 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.814 1.676 . . . . 0.0 112.403 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.477 HD12 ' C ' ' A' ' 130' ' ' PRO . 1.1 mp -122.13 130.3 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 103.494 -2.78 . . . . 0.0 103.494 174.919 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -126.56 143.55 39.67 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 C-N-CA 125.751 1.62 . . . . 0.0 106.93 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -117.15 123.56 47.02 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 64.7 p -83.96 -72.22 0.47 Allowed 'General case' 0 C--N 1.335 -0.06 0 CA-C-O 121.504 0.669 . . . . 0.0 111.046 -171.677 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p30 -71.7 52.63 0.22 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 126.091 1.756 . . . . 0.0 113.113 -178.325 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.418 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 38.8 mt -74.35 63.68 1.06 Allowed 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.324 1.45 . . . . 0.0 109.38 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 17.4 57.69 0.01 OUTLIER 'General case' 0 C--N 1.348 0.503 0 C-N-CA 129.509 3.124 . . . . 0.0 112.209 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 23.88 57.43 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.108 2.963 . . . . 0.0 114.371 -174.801 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.26 -5.51 0.12 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-O 119.006 -0.886 . . . . 0.0 113.891 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.689 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 29.7 mt-10 -75.49 93.14 2.94 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 119.254 1.527 . . . . 0.0 108.796 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 34.1 p -76.65 130.46 37.83 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.836 0.827 . . . . 0.0 109.421 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -83.6 100.35 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 14.8 m -98.71 102.28 13.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.971 1.308 . . . . 0.0 110.578 -175.778 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 8.4 pt -66.95 146.3 13.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 O-C-N 121.909 -0.494 . . . . 0.0 110.363 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -119.13 -45.5 2.55 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.976 1.71 . . . . 0.0 110.359 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -66.87 79.94 0.11 Allowed 'General case' 0 C--O 1.224 -0.244 0 CA-C-O 121.45 0.643 . . . . 0.0 109.929 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.3 m -77.82 65.82 3.36 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.805 0.842 . . . . 0.0 109.848 -176.234 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 162.48 -128.69 1.92 Allowed Glycine 0 C--N 1.336 0.554 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -177.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.2 t -66.7 157.92 31.46 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.188 178.279 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.58 HG23 HG21 ' A' ' 157' ' ' ILE . 2.9 p -138.96 153.25 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 C-N-CA 125.604 1.561 . . . . 0.0 107.684 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -125.93 150.39 48.01 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 125.222 1.409 . . . . 0.0 108.379 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 35.8 ptt85 -74.37 162.07 29.23 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 176.268 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 61.69 55.0 2.81 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 126.262 1.825 . . . . 0.0 111.881 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 154' ' ' GLN . . . . . 0.461 ' CB ' HD13 ' A' ' 157' ' ' ILE . 33.2 mm-40 -146.64 155.78 42.7 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.91 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -103.79 -70.16 0.78 Allowed 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 119.862 1.21 . . . . 0.0 111.188 176.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -50.12 5.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 130.4 3.48 . . . . 0.0 118.047 -172.048 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.58 HG21 HG23 ' A' ' 150' ' ' VAL . 1.7 mp -76.86 -32.04 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 129.785 3.234 . . . . 0.0 106.262 173.186 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.58 145.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 127.128 2.171 . . . . 0.0 106.59 175.449 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 4.6 mmpt? -132.42 125.92 31.88 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 178.164 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.689 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -78.88 125.93 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 172.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -138.44 163.64 31.41 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.45 1.1 . . . . 0.0 109.502 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 65.6 mttm . . . . . 0 C--O 1.231 0.129 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 175.357 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.465 0.305 0 N-CA-C 114.32 1.23 . . . . 0.0 114.32 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.7 m -83.05 98.15 4.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 C-N-CA 123.95 0.9 . . . . 0.0 111.128 175.533 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 34.7 t -36.07 121.18 0.71 Allowed Pre-proline 0 CA--C 1.547 0.84 0 C-N-CA 126.686 1.994 . . . . 0.0 111.163 174.918 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -76.2 -38.95 0.95 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.803 2.335 . . . . 0.0 117.773 -173.021 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.13 146.57 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 CA-C-N 120.245 1.384 . . . . 0.0 110.395 -175.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.8 m -78.83 135.44 37.05 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 173.224 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.18 -167.97 41.01 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 -178.645 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -96.17 135.09 38.45 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.9 tt -97.19 143.07 13.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 123.01 0.524 . . . . 0.0 109.994 -179.256 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -145.29 156.25 53.97 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 178.875 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -62.54 155.33 58.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 N-CA-C 107.097 -1.924 . . . . 0.0 107.097 171.311 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 tt -62.65 -34.36 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.468 -178.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 m -71.03 74.05 0.63 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.685 1.194 . . . . 0.0 109.01 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -179.64 -34.58 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 127.994 2.518 . . . . 0.0 108.992 -174.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.423 ' HA ' ' HD3' ' A' ' 30' ' ' PRO . 91.0 t -58.47 127.66 81.84 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 117.63 -1.176 . . . . 0.0 111.025 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 29' ' ' VAL . 71.2 Cg_exo -57.57 59.68 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.191 1 C-N-CA 126.381 4.72 . . . . 0.0 115.778 176.407 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -171.43 119.65 0.47 Allowed 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 125.953 1.701 . . . . 0.0 107.707 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 6.8 pm0 -54.48 -44.8 72.94 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.429 1.092 . . . . 0.0 113.817 -177.395 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 40.7 t -56.49 -56.84 11.57 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -178.282 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -62.64 -52.85 61.72 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.3 t -50.83 -42.36 58.45 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.951 0.9 . . . . 0.0 113.394 -177.773 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -89.42 11.59 69.39 Favored Glycine 0 N--CA 1.446 -0.634 0 CA-C-O 118.198 -1.334 . . . . 0.0 112.022 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 58.5 mttm 72.35 -36.33 0.35 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.564 1.682 . . . . 0.0 113.242 -179.047 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER 28.68 -78.77 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 130.398 3.479 . . . . 0.0 116.226 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.5 ttp -83.17 -7.3 59.64 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -174.498 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.63 -138.19 2.75 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 38.9 t0 -140.11 158.7 43.63 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 172.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.77 -168.75 37.83 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 119.937 -1.125 . . . . 0.0 113.334 -176.213 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -141.68 156.83 45.61 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.635 1.174 . . . . 0.0 109.448 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.82 127.09 52.51 Favored 'General case' 0 CA--C 1.51 -0.587 0 C-N-CA 124.282 1.033 . . . . 0.0 109.876 179.024 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 28.4 mm -107.84 128.53 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 104.611 -2.366 . . . . 0.0 104.611 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.7 tt -96.97 102.97 13.31 Favored Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 172.751 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -63.37 157.16 51.88 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.951 3.101 . . . . 0.0 116.585 -169.377 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.4 p -138.84 -51.13 0.55 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.856 1.263 . . . . 0.0 109.528 173.502 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -80.14 130.67 35.41 Favored 'General case' 0 C--N 1.342 0.263 0 O-C-N 121.926 -0.484 . . . . 0.0 110.455 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -66.42 -24.35 72.24 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.824 -0.911 . . . . 0.0 110.824 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ILE . . . . . 0.404 ' N ' HD12 ' A' ' 51' ' ' ILE . 2.5 mp -78.2 108.52 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 C-N-CA 124.585 1.154 . . . . 0.0 107.923 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.22 116.65 52.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 125.212 1.405 . . . . 0.0 108.14 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.5 m -93.41 155.68 3.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.147 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 47.1 m -73.17 139.94 79.6 Favored Pre-proline 0 N--CA 1.448 -0.574 0 CA-C-O 118.6 -0.714 . . . . 0.0 111.144 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -64.17 -35.9 50.01 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 N-CA-C 107.609 -1.727 . . . . 0.0 107.609 171.024 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.6 p -175.98 150.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 129.798 3.239 . . . . 0.0 103.68 175.346 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.446 ' CZ ' ' HB3' ' A' ' 110' ' ' GLN . 43.1 mtm180 -112.14 -75.93 0.6 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.791 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.19 -68.38 2.35 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.438 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.49 128.32 8.03 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 104.228 -2.508 . . . . 0.0 104.228 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.1 mm -61.13 130.47 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 7.3 tt -77.45 -51.96 9.91 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 104.601 -2.37 . . . . 0.0 104.601 178.361 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 50.9 t30 179.62 165.5 1.1 Allowed 'General case' 0 CA--C 1.527 0.081 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.237 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.462 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.7 m -152.35 129.09 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 C-N-CA 126.239 1.816 . . . . 0.0 106.168 174.512 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -47.49 146.47 3.46 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-O 118.744 -0.646 . . . . 0.0 111.092 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -50.0 -33.74 35.44 Favored 'Trans proline' 0 CA--C 1.534 0.525 0 C-N-CA 123.534 2.823 . . . . 0.0 113.796 176.6 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 37.0 p -77.67 -7.98 57.24 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 124.574 1.15 . . . . 0.0 111.993 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 68.38 13.4 9.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.205 1.802 . . . . 0.0 113.641 178.366 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.445 ' ND1' ' N ' ' A' ' 89' ' ' VAL . 0.0 OUTLIER -77.91 -23.62 48.61 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 119.358 0.981 . . . . 0.0 111.626 -179.333 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -167.12 -173.22 2.25 Favored 'General case' 0 C--O 1.225 -0.22 0 CA-C-N 120.12 1.327 . . . . 0.0 110.777 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 63' ' ' VAL 1.06 1.9 mt 130.97 -139.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.192 1 C-N-CA 136.95 6.1 . . . . 0.0 110.372 176.382 . . . . . . . . 4 3 . 1 . 008 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -157.04 170.13 34.28 Favored Glycine 0 CA--C 1.531 1.061 0 N-CA-C 118.229 2.052 . . . . 0.0 118.229 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 18.1 mt -124.03 174.35 7.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 128.199 2.6 . . . . 0.0 109.085 -177.663 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -126.28 -165.42 1.44 Allowed 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.098 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 60.3 p . . . . . 0 N--CA 1.44 -0.957 0 C-N-CA 125.611 1.564 . . . . 0.0 107.39 176.776 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 . . . . . 0 CA--C 1.533 0.301 0 CA-C-O 120.991 0.424 . . . . 0.0 110.563 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -92.85 131.58 37.76 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 127.642 2.377 . . . . 0.0 105.605 -179.477 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 34.1 mt -123.04 119.62 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 O-C-N 123.436 0.46 . . . . 0.0 112.056 -173.315 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 6.0 tp -89.09 139.63 30.27 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 171.529 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 72.8 mt -130.33 132.49 64.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -123.75 84.47 2.28 Favored 'General case' 0 C--O 1.223 -0.298 0 O-C-N 123.526 0.517 . . . . 0.0 111.77 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.52 104.75 0.24 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.236 0.614 . . . . 0.0 111.932 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.76 -177.93 7.64 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 122.092 0.829 . . . . 0.0 112.323 179.282 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.9 mm -123.92 146.54 29.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 174.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 37.2 t70 50.77 32.29 6.94 Favored 'General case' 0 CA--C 1.543 0.702 0 CA-C-O 121.91 0.862 . . . . 0.0 111.295 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.8 m -97.85 -25.07 15.16 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.803 2.041 . . . . 0.0 107.289 -177.846 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.445 ' N ' ' ND1' ' A' ' 68' ' ' HIS . 4.0 p -53.6 -43.71 55.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 C-N-CA 126.258 1.823 . . . . 0.0 107.634 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -58.73 -26.2 63.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.801 2.04 . . . . 0.0 111.898 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.14 -11.21 60.45 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.892 1.677 . . . . 0.0 109.608 177.149 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp 51.55 29.66 5.69 Favored 'General case' 0 C--N 1.342 0.244 0 C-N-CA 126.325 1.85 . . . . 0.0 112.38 178.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.22 26.71 50.82 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-O 118.702 -1.054 . . . . 0.0 112.53 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.266 0.2 OUTLIER -59.15 -18.25 34.38 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.851 1.826 . . . . 0.0 115.478 -176.776 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -122.3 21.17 7.8 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 126.11 1.814 . . . . 0.0 110.849 177.482 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.483 ' HA ' HG12 ' A' ' 115' ' ' VAL . 3.5 m-85 -106.05 85.2 2.17 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 118.089 0.944 . . . . 0.0 111.046 -177.378 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.66 101.11 5.61 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.326 -2.472 . . . . 0.0 104.326 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.8 t -87.01 157.82 19.37 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-O 121.183 0.516 . . . . 0.0 110.605 -179.22 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -115.59 5.23 14.31 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.038 1.735 . . . . 0.0 112.224 -175.636 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.5 m -129.42 137.06 57.9 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.147 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 68.6 m -107.03 49.31 0.81 Allowed 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 169.765 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.299 1.3 pm0 -2.68 70.98 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 132.184 4.194 . . . . 0.0 116.644 -172.661 . . . . . . . . 3 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -85.99 46.44 3.62 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 112.845 -1.979 . . . . 0.0 109.882 176.571 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 3.36 52.08 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.21 0 C-N-CA 131.356 3.863 . . . . 0.0 120.897 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -168.74 121.78 0.82 Allowed 'General case' 0 C--N 1.312 -1.022 1 C-N-CA 133.475 4.71 . . . . 0.0 107.051 176.553 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -167.52 136.72 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 118.784 0.72 . . . . 0.0 111.073 -172.332 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -78.74 149.99 75.11 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 118.146 -0.93 . . . . 0.0 109.853 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -55.67 175.55 0.2 Allowed 'Trans proline' 0 CA--C 1.542 0.896 1 C-N-CA 125.696 4.264 . . . . 0.0 117.837 -174.396 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 51.85 -7.65 0.01 OUTLIER Glycine 0 C--N 1.344 0.985 0 C-N-CA 129.28 3.324 . . . . 0.0 119.238 175.316 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 110' ' ' GLN . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 57' ' ' ARG . 25.0 tt0 -61.63 160.59 11.2 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 120.31 2.055 . . . . 0.0 110.128 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -67.04 140.64 57.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 122.94 0.496 . . . . 0.0 109.76 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 94.5 mt -108.63 -37.39 5.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 124.246 1.018 . . . . 0.0 110.088 176.547 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 113' ' ' LEU . . . . . 0.447 ' HB3' HG13 ' A' ' 115' ' ' VAL . 22.2 mt -143.23 146.99 34.14 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.61 0.764 . . . . 0.0 110.208 -176.38 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -132.94 68.49 1.5 Allowed 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' VAL . . . . . 0.483 HG12 ' HA ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -79.45 127.03 39.38 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 CA-C-N 109.053 -3.703 . . . . 0.0 110.621 -171.755 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -76.19 67.64 2.5 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.008 0.923 . . . . 0.0 109.179 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -48.61 -39.37 23.69 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.651 0.78 . . . . 0.0 111.727 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -54.04 -42.18 68.89 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.113 0.565 . . . . 0.0 112.201 178.548 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.07 -33.29 18.35 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.744 0.417 . . . . 0.0 111.39 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 79.5 t -63.31 -53.91 39.66 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.372 17.8 pttp -40.45 -58.23 2.56 Favored Pre-proline 0 CA--C 1.541 0.611 0 N-CA-C 116.97 2.211 . . . . 0.0 116.97 -176.464 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -58.53 -20.1 47.85 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.436 2.091 . . . . 0.0 113.36 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -100.03 8.26 44.11 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 118.301 -0.857 . . . . 0.0 112.674 -177.67 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 33.3 m -133.9 147.67 65.12 Favored Pre-proline 0 CA--C 1.535 0.382 0 CA-C-N 119.986 1.266 . . . . 0.0 109.856 178.711 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -71.04 -36.55 7.29 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.98 2.453 . . . . 0.0 111.622 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 62.3 p -151.45 121.85 7.33 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -177.532 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.0 tp -79.88 -2.95 45.88 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.136 1.374 . . . . 0.0 111.904 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -44.88 117.92 1.47 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 124.842 1.257 . . . . 0.0 110.465 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.6 m -117.7 107.47 44.46 Favored Pre-proline 0 N--CA 1.447 -0.581 0 C-N-CA 124.034 0.933 . . . . 0.0 108.692 -178.425 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -91.53 143.59 3.01 Favored 'Trans proline' 0 N--CA 1.441 -1.617 0 C-N-CA 123.039 2.492 . . . . 0.0 110.249 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 17.2 mm -113.9 116.82 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.034 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.5 t -121.48 123.61 69.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 C-N-CA 125.006 1.323 . . . . 0.0 108.632 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -95.9 117.66 31.04 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 178.37 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 52.6 p -84.1 -73.91 0.4 Allowed 'General case' 0 C--O 1.23 0.045 0 CA-C-O 121.467 0.651 . . . . 0.0 111.563 -171.233 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p-10 -73.08 57.61 0.47 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.824 1.65 . . . . 0.0 111.38 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 20.5 mt -72.01 66.72 0.6 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.918 1.687 . . . . 0.0 109.007 177.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.91 47.68 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 129.179 2.992 . . . . 0.0 112.488 -176.722 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 29.34 55.48 0.12 Allowed 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 127.81 2.444 . . . . 0.0 113.34 -174.809 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.43 -5.29 0.05 OUTLIER Glycine 0 CA--C 1.526 0.738 0 CA-C-O 118.896 -0.946 . . . . 0.0 114.332 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.654 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 21.0 mt-10 -83.83 139.87 32.39 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.185 1.492 . . . . 0.0 109.83 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 45.4 p -110.91 136.58 49.72 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.898 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -91.28 101.93 12.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -178.402 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 20.3 m -100.01 105.83 17.54 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 123.96 0.904 . . . . 0.0 110.493 -176.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 20.1 pt -67.05 139.71 20.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.799 -0.563 . . . . 0.0 110.252 177.044 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.6 mmpt? -101.83 -41.42 6.52 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 125.155 1.382 . . . . 0.0 108.864 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.39 86.9 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.208 1.003 . . . . 0.0 112.783 -176.863 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.5 m -80.73 54.68 2.18 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 177.779 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.49 -178.65 37.31 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -177.074 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 35.4 t -52.07 146.8 8.22 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.567 0.747 . . . . 0.0 112.416 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.9 m -115.47 159.55 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 125.207 1.403 . . . . 0.0 109.827 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.8 157.3 30.05 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.75 1.22 . . . . 0.0 108.321 175.635 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.47 158.86 28.45 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.473 0.654 . . . . 0.0 110.738 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 64.58 -10.11 0.16 Allowed 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 126.137 1.775 . . . . 0.0 114.868 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.67 149.81 38.4 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.933 1.242 . . . . 0.0 109.571 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -120.54 158.14 27.94 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.214 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 29.9 t0 63.89 26.56 14.29 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 128.074 2.549 . . . . 0.0 112.009 -174.642 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -82.87 -22.75 8.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 C-N-CA 123.825 0.85 . . . . 0.0 108.825 176.961 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.3 p -142.36 149.66 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 127.897 2.479 . . . . 0.0 106.477 175.662 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -131.81 127.47 36.7 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 174.741 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.654 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.54 122.0 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 170.797 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -105.52 176.11 5.27 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 106.544 -1.651 . . . . 0.0 106.544 174.553 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.0 tppt? . . . . . 0 CA--C 1.532 0.254 0 O-C-N 121.292 -0.88 . . . . 0.0 110.956 -179.358 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.529 0.138 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 m -90.75 84.81 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 122.598 0.359 . . . . 0.0 110.894 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -19.1 115.52 0.09 OUTLIER Pre-proline 0 CA--C 1.546 0.789 0 C-N-CA 127.016 2.127 . . . . 0.0 113.667 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -75.02 -26.01 11.28 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 122.718 2.278 . . . . 0.0 117.535 -170.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -138.25 158.08 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 119.886 1.221 . . . . 0.0 109.445 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.9 m -94.61 128.6 41.36 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 174.439 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.67 -161.68 33.16 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.585 -0.341 . . . . 0.0 112.654 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -95.24 118.46 32.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.846 1.258 . . . . 0.0 108.551 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.94 136.04 25.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 C-N-CA 123.455 0.702 . . . . 0.0 109.427 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -135.13 142.9 43.61 Favored Pre-proline 0 C--O 1.236 0.345 0 C-N-CA 126.486 1.914 . . . . 0.0 107.048 177.083 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -64.61 160.06 41.88 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 121.446 1.431 . . . . 0.0 108.476 176.296 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 tp -61.55 -39.88 84.57 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.268 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 57.1 m -76.48 74.1 3.22 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.124 0.97 . . . . 0.0 109.344 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -178.54 -37.34 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 127.601 2.36 . . . . 0.0 108.986 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 97.0 t -52.0 115.45 6.71 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-O 117.507 -1.235 . . . . 0.0 111.905 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_exo -58.06 64.37 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.212 1 C-N-CA 125.515 4.144 . . . . 0.0 115.551 177.046 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -133.58 -42.63 0.84 Allowed 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 -177.467 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 105.73 -65.08 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 129.695 3.198 . . . . 0.0 110.606 -178.48 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 92.3 t -52.67 -62.13 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 C-N-CA 124.004 0.922 . . . . 0.0 108.722 179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -59.99 -42.79 94.98 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.909 0.385 . . . . 0.0 110.123 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -51.57 -45.51 63.12 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 124.012 0.925 . . . . 0.0 112.81 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -92.99 17.57 57.91 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-O 118.274 -1.292 . . . . 0.0 110.5 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 60.5 mttp 73.79 -47.77 0.66 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.079 1.752 . . . . 0.0 111.359 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 19.6 ttt 35.49 -67.17 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 130.602 3.561 . . . . 0.0 117.077 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 33.2 ttm -87.52 -23.6 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.385 1.074 . . . . 0.0 112.435 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.67 -148.1 9.53 Favored Glycine 0 C--O 1.224 -0.505 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -177.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -142.47 159.75 41.61 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-N 118.349 1.074 . . . . 0.0 108.582 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.3 -127.29 1.45 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 106.773 -2.531 . . . . 0.0 106.773 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -177.01 -179.28 0.9 Allowed 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 119.055 1.427 . . . . 0.0 110.763 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -127.67 135.86 50.79 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 123.734 0.814 . . . . 0.0 109.447 176.201 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -109.49 98.55 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 103.316 -2.846 . . . . 0.0 103.316 172.812 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.5 tt -58.81 113.6 7.11 Favored Pre-proline 0 CA--C 1.532 0.258 0 N-CA-C 103.08 -2.933 . . . . 0.0 103.08 175.708 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -78.07 149.01 25.12 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 122.916 2.411 . . . . 0.0 115.005 -167.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 p -115.74 -47.88 2.78 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 125.217 1.407 . . . . 0.0 107.594 173.98 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -76.76 122.39 24.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.11 44.21 2.79 Favored Glycine 0 CA--C 1.531 1.082 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 173.239 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.1 mt -144.33 126.37 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 104.446 -2.427 . . . . 0.0 104.446 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 66.3 t -126.66 126.71 69.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 C-N-CA 125.019 1.328 . . . . 0.0 109.033 -173.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.7 m -109.78 157.59 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.833 1.253 . . . . 0.0 110.792 178.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.6 m -62.87 133.02 95.07 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.873 -0.517 . . . . 0.0 111.077 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.04 -13.89 23.67 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.278 3.319 . . . . 0.0 116.531 -174.92 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -151.31 165.54 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 CA-C-N 119.441 1.018 . . . . 0.0 109.713 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -76.12 125.54 29.34 Favored 'General case' 0 C--O 1.236 0.394 1 N-CA-C 99.122 -4.399 . . . . 0.0 99.122 166.768 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 179.82 171.95 43.31 Favored Glycine 0 N--CA 1.435 -1.425 0 C-N-CA 116.658 -2.687 . . . . 0.0 113.198 -168.235 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.64 126.24 34.84 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.58 116.9 8.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 102.644 -3.095 . . . . 0.0 102.644 168.775 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 85.1 mt -78.53 -50.04 12.27 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 32.6 t30 178.16 164.1 0.7 Allowed 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 124.14 0.976 . . . . 0.0 108.372 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.4 m -137.74 116.73 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 126.732 2.013 . . . . 0.0 106.079 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.73 154.03 0.73 Allowed Pre-proline 0 N--CA 1.469 0.524 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -52.05 -33.29 52.44 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 123.483 2.788 . . . . 0.0 113.212 176.492 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.8 p -78.09 -2.84 39.29 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.996 0.919 . . . . 0.0 111.631 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.76 21.48 1.94 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 127.244 2.218 . . . . 0.0 114.301 179.397 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 25.9 p-80 -89.31 -25.02 21.86 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 118.46 -0.781 . . . . 0.0 111.18 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -162.5 -172.62 3.22 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.566 0.621 . . . . 0.0 112.531 -172.919 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.716 27.6 mm 125.89 -127.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.478 1 C-N-CA 134.583 5.153 . . . . 0.0 107.177 -179.815 . . . . . . . . 3 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 177.71 -172.83 45.54 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 118.354 2.101 . . . . 0.0 118.354 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.0 mp -133.7 169.58 16.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 126.856 2.062 . . . . 0.0 109.42 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.76 126.94 37.7 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 171.018 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' SER . . . . . 0.602 ' HG ' ' N ' ' A' ' 78' ' ' ARG . 54.2 p . . . . . 0 N--CA 1.427 -1.579 0 CA-C-O 123.774 1.749 . . . . 0.0 108.136 175.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' ARG . . . . . 0.602 ' N ' ' HG ' ' A' ' 74' ' ' SER . 16.1 tpp85 . . . . . 0 C--O 1.23 0.071 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.61 101.39 8.29 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 125.457 1.503 . . . . 0.0 108.434 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.0 mt -96.81 103.85 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 126.479 1.912 . . . . 0.0 109.92 -176.296 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.0 tt -79.18 135.59 36.85 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 105.055 -2.202 . . . . 0.0 105.055 171.116 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.3 mt -113.97 153.22 15.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 125.179 1.392 . . . . 0.0 108.613 179.065 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.34 144.75 29.99 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 171.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.98 91.36 3.26 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.377 1.471 . . . . 0.0 110.504 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.27 154.63 5.43 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -178.494 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mt -98.33 135.28 33.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.267 -1.753 . . . . 0.0 106.267 178.705 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.0 t70 70.25 18.11 6.94 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.626 1.17 . . . . 0.0 112.818 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 p -81.9 -32.03 31.15 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 124.872 1.269 . . . . 0.0 108.501 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 8.1 p -55.06 -44.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.784 1.233 . . . . 0.0 108.143 172.575 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -61.34 -35.43 77.41 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.777 1.231 . . . . 0.0 109.813 176.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.99 9.43 5.44 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 126.851 2.061 . . . . 0.0 110.915 176.734 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.6 mttp 47.27 35.2 3.6 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 127.067 2.147 . . . . 0.0 114.787 173.809 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.05 19.12 63.29 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.63 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -71.26 90.47 0.92 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.064 1.432 . . . . 0.0 109.908 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.21 -1.06 6.61 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 126.068 1.794 . . . . 0.0 111.928 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.443 ' CD1' HG12 ' A' ' 115' ' ' VAL . 16.4 m-30 -100.42 111.57 23.84 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.723 1.209 . . . . 0.0 109.662 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 9.6 m -104.28 113.49 27.08 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 124.779 1.232 . . . . 0.0 108.132 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.7 p -81.43 144.94 31.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 118.92 0.782 . . . . 0.0 111.292 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -114.95 -41.98 3.28 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.186 1.394 . . . . 0.0 111.959 -178.369 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -70.94 130.19 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 174.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 61.0 m -92.28 53.71 2.18 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 104.934 -2.247 . . . . 0.0 104.934 172.001 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.365 1.2 pm0 16.35 62.89 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.466 3.507 . . . . 0.0 113.01 -169.509 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -79.09 48.99 3.44 Favored Glycine 0 CA--C 1.524 0.629 0 CA-C-N 111.729 -2.487 . . . . 0.0 109.818 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.403 4.3 p30 2.66 -111.25 0.0 OUTLIER 'General case' 0 N--CA 1.435 -1.22 0 C-N-CA 129.627 3.171 . . . . 0.0 117.366 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.254 0.2 OUTLIER -35.92 118.29 0.5 Allowed 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 121.599 3.926 . . . . 0.0 121.599 -169.726 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.268 27.6 m 36.89 70.39 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 128.421 2.688 . . . . 0.0 117.241 170.99 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.39 127.93 25.41 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 170.018 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -97.01 154.75 1.1 Allowed 'Trans proline' 0 N--CA 1.449 -1.141 0 C-N-CA 124.594 3.529 . . . . 0.0 110.401 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 49.07 2.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.303 0 N-CA-C 118.362 2.105 . . . . 0.0 118.362 172.449 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -60.69 136.49 58.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 119.948 1.874 . . . . 0.0 107.935 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -59.12 117.02 4.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.0 mt -79.91 -47.53 14.92 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.45 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.8 mp -149.97 166.0 30.97 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -177.623 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -126.33 132.1 51.68 Favored 'General case' 0 CA--C 1.518 -0.262 1 N-CA-C 98.458 -4.645 . . . . 0.0 98.458 166.243 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 115' ' ' VAL . . . . . 0.443 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -141.25 123.19 14.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.846 -166.176 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 63.1 t0 -72.55 70.54 0.92 Allowed 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 124.497 1.119 . . . . 0.0 110.772 -178.279 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -50.37 -45.1 54.98 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.347 0.659 . . . . 0.0 110.432 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -50.71 -50.11 55.96 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.362 1.065 . . . . 0.0 112.709 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.87 -33.34 24.83 Favored 'General case' 0 CA--C 1.527 0.087 0 N-CA-C 111.771 0.285 . . . . 0.0 111.771 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -65.28 -52.86 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.776 -0.578 . . . . 0.0 109.993 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.344 19.4 pttp -40.25 -57.31 2.94 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 117.413 2.375 . . . . 0.0 117.413 -177.066 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -57.09 -22.04 45.46 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.526 2.15 . . . . 0.0 113.146 179.063 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -94.11 4.97 53.14 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 118.08 -0.962 . . . . 0.0 112.683 -178.132 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 21.3 m -136.1 150.19 70.45 Favored Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 120.182 1.355 . . . . 0.0 111.992 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -71.17 -28.9 18.2 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 122.891 2.394 . . . . 0.0 111.974 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 3.2 m -158.79 131.59 7.05 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.54 0.609 . . . . 0.0 110.024 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -90.4 21.44 3.88 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.114 1.366 . . . . 0.0 112.055 -177.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 24.3 mmt -59.64 146.85 39.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 121.348 -0.845 . . . . 0.0 110.933 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 18.2 p -112.41 68.69 0.96 Allowed Pre-proline 0 CA--C 1.536 0.418 0 C-N-CA 124.558 1.143 . . . . 0.0 108.296 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.45 92.83 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.236 1.957 . . . . 0.0 112.825 -175.083 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 3.2 mt -86.15 129.97 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 105.315 -2.105 . . . . 0.0 105.315 175.498 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.6 t -133.59 121.67 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-O 121.798 0.809 . . . . 0.0 109.192 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -82.15 108.83 15.92 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 101.653 -3.462 . . . . 0.0 101.653 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.8 p -75.5 -63.55 1.26 Allowed 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.712 0.768 . . . . 0.0 109.75 -173.611 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -72.16 52.14 0.25 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.682 1.193 . . . . 0.0 113.951 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 56.9 mt -78.96 49.11 0.89 Allowed 'General case' 0 CA--C 1.539 0.547 0 O-C-N 121.083 -1.011 . . . . 0.0 109.042 173.697 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 23.99 40.42 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 130.0 3.32 . . . . 0.0 115.042 -179.21 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 38.85 45.31 0.93 Allowed 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.209 1.804 . . . . 0.0 112.604 -175.232 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -175.69 -8.86 0.02 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 119.062 -0.855 . . . . 0.0 113.997 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.687 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 9.8 mm-40 -86.87 92.33 8.96 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 118.945 1.373 . . . . 0.0 108.299 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -77.37 132.44 38.55 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 123.248 0.619 . . . . 0.0 110.164 -177.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 1.9 t -86.15 91.4 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 125.293 1.437 . . . . 0.0 109.782 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.0 m -88.54 96.26 10.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 27.1 mt -65.76 131.8 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -102.47 -42.2 6.04 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 125.774 1.629 . . . . 0.0 110.801 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -54.72 83.75 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.186 0 C-N-CA 124.907 1.283 . . . . 0.0 112.799 -176.71 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 22.4 m -80.93 55.9 2.59 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.778 0.831 . . . . 0.0 109.418 179.563 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.68 -167.47 36.47 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.051 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 41.6 t -60.16 152.72 23.78 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 123.12 0.568 . . . . 0.0 110.831 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 55.2 t -123.49 148.81 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 C-N-CA 124.944 1.298 . . . . 0.0 107.739 178.238 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.1 m-80 -119.48 153.43 35.32 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.789 1.636 . . . . 0.0 110.111 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -47.53 135.45 11.15 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.838 0.855 . . . . 0.0 110.628 177.696 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 67.23 8.57 6.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.509 1.924 . . . . 0.0 114.933 178.224 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -64.5 150.88 45.8 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 120.062 1.301 . . . . 0.0 108.859 174.283 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -122.84 161.53 23.88 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 125.215 1.406 . . . . 0.0 108.487 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 21.1 t0 66.69 14.1 9.63 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 125.735 1.614 . . . . 0.0 113.713 -178.932 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.474 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -65.65 -26.76 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 C-N-CA 124.371 1.068 . . . . 0.0 111.104 176.736 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.5 p -138.75 147.2 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 C-N-CA 125.626 1.57 . . . . 0.0 107.935 179.36 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.18 109.76 15.37 Favored 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.394 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.687 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -77.57 98.85 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 174.724 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -87.93 147.94 24.82 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.038 0.935 . . . . 0.0 108.87 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.1 tptm . . . . . 0 C--N 1.329 -0.297 0 CA-C-O 121.927 0.87 . . . . 0.0 109.026 -178.437 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 t80 . . . . . 0 CA--C 1.534 0.365 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.1 m -78.73 80.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.178 0 O-C-N 120.481 -1.387 . . . . 0.0 111.435 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -21.68 105.04 0.09 OUTLIER Pre-proline 0 CA--C 1.551 1.015 0 C-N-CA 129.229 3.012 . . . . 0.0 109.605 175.183 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.06 -20.56 21.63 Favored 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 123.535 2.823 . . . . 0.0 119.177 -167.42 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.35 147.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.34 0.164 0 CA-C-N 119.699 1.136 . . . . 0.0 110.547 -177.05 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.2 m -85.79 135.31 33.78 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 173.947 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 166.59 -140.38 6.29 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 -178.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.1 tp10 -125.81 122.68 36.87 Favored 'General case' 0 CA--C 1.528 0.122 0 C-N-CA 124.933 1.293 . . . . 0.0 110.089 -178.532 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.55 146.01 9.11 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.006 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -142.52 140.23 18.5 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 125.155 1.382 . . . . 0.0 107.656 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -57.13 145.55 85.79 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.116 1.877 . . . . 0.0 110.161 176.351 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -49.37 -37.63 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 124.304 1.041 . . . . 0.0 112.596 -178.449 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.6 p -55.96 -28.66 58.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.105 1.362 . . . . 0.0 112.606 178.353 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -77.23 -8.81 58.2 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 123.678 0.791 . . . . 0.0 112.745 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.425 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 46.7 t -74.26 131.01 81.32 Favored Pre-proline 0 CA--C 1.535 0.402 0 O-C-N 121.162 -0.961 . . . . 0.0 109.994 -178.07 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -77.17 55.93 5.24 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.515 2.81 . . . . 0.0 111.954 -177.979 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -167.72 108.68 0.59 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.47 -0.768 . . . . 0.0 109.19 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -35.47 -48.17 0.48 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 127.521 2.329 . . . . 0.0 115.375 -176.56 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.0 p -50.57 -38.1 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 122.932 0.493 . . . . 0.0 110.938 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.411 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 23.2 m-85 -89.38 -49.7 6.55 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 124.115 0.966 . . . . 0.0 108.828 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -48.07 -40.96 24.74 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.765 1.024 . . . . 0.0 113.765 -177.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.48 15.01 59.1 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.201 -1.333 . . . . 0.0 111.956 -177.015 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 53.1 mttp 71.87 -39.22 0.44 Allowed 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 119.285 1.542 . . . . 0.0 113.813 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 9.4 ttp 27.97 -69.18 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 131.341 3.856 . . . . 0.0 117.118 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.9 ttp -79.54 -25.53 41.65 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 126.047 1.739 . . . . 0.0 113.541 -175.33 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.71 -141.1 4.21 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 119.605 1.093 . . . . 0.0 110.658 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -121.96 154.4 37.24 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 174.478 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 179.51 -165.2 33.73 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.236 -175.806 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.535 ' CE2' HD11 ' A' ' 45' ' ' ILE . 37.4 p90 -159.37 168.91 25.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.425 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -112.37 151.28 29.97 Favored 'General case' 0 CA--C 1.501 -0.942 0 CA-C-O 121.346 0.593 . . . . 0.0 109.475 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.535 HD11 ' CE2' ' A' ' 43' ' ' PHE . 4.4 mp -125.08 132.31 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 102.18 -3.267 . . . . 0.0 102.18 170.868 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.0 tt -96.15 108.74 43.24 Favored Pre-proline 0 N--CA 1.442 -0.837 1 N-CA-C 98.589 -4.597 . . . . 0.0 98.589 169.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -82.17 156.1 17.19 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 123.664 2.909 . . . . 0.0 114.405 -168.201 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.2 p -124.98 -45.83 1.86 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.895 1.278 . . . . 0.0 108.794 174.711 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 120.34 14.59 Favored 'General case' 0 C--N 1.339 0.11 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 177.492 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.69 37.59 2.09 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 175.943 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.7 mt -142.33 119.39 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 127.007 2.123 . . . . 0.0 105.85 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.08 113.86 45.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.157 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.1 m -100.53 152.26 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 C-N-CA 123.094 0.558 . . . . 0.0 109.988 179.081 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 70.6 m -58.24 130.0 83.56 Favored Pre-proline 0 CA--C 1.537 0.463 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.106 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.2 -22.94 13.96 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 124.938 3.759 . . . . 0.0 115.774 -175.464 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.6 m -137.79 161.68 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 123.914 0.885 . . . . 0.0 109.769 -173.54 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.1 ttt180 -76.71 126.31 30.76 Favored 'General case' 0 CA--C 1.518 -0.271 1 N-CA-C 99.562 -4.236 . . . . 0.0 99.562 167.957 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.31 175.07 47.23 Favored Glycine 0 N--CA 1.436 -1.343 0 C-N-CA 116.709 -2.663 . . . . 0.0 114.33 -167.853 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 36.2 mtmt -100.62 135.16 42.49 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.231 1.812 . . . . 0.0 108.371 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 26.9 mm -76.47 107.93 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 173.333 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 64.3 tp -77.3 -50.6 12.48 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 123.358 0.663 . . . . 0.0 109.998 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.6 t30 179.53 107.68 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' VAL . . . . . 0.463 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 10.3 m -117.82 147.4 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 123.587 0.755 . . . . 0.0 112.392 -178.285 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER 42.53 123.72 0.0 OUTLIER Pre-proline 0 CA--C 1.536 0.441 1 C-N-CA 132.901 4.48 . . . . 0.0 120.801 171.706 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -80.94 -50.16 0.05 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.216 0 N-CA-C 106.676 -2.086 . . . . 0.0 106.676 168.392 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 8.9 p -113.99 43.08 1.91 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 127.281 2.232 . . . . 0.0 111.14 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 ttmm 56.91 25.62 10.74 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 115.762 1.764 . . . . 0.0 115.762 171.748 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -135.09 9.32 3.51 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 115.262 1.578 . . . . 0.0 115.262 -175.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -168.25 -159.29 0.27 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 122.053 2.206 . . . . 0.0 113.988 -173.06 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.463 ' HB ' ' HA ' ' A' ' 63' ' ' VAL 1.014 0.2 OUTLIER 93.18 -161.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 131.632 3.973 . . . . 0.0 117.697 172.683 . . . . . . . . 4 4 . 1 . 010 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -115.14 154.1 17.2 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 120.06 2.784 . . . . 0.0 120.06 -167.428 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.8 mp -133.23 165.83 23.89 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 128.558 2.743 . . . . 0.0 108.519 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.7 mm-40 -136.86 139.58 41.78 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 175.153 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.8 m . . . . . 0 C--N 1.322 -0.618 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.356 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 41.6 mtm180 . . . . . 0 CA--C 1.533 0.299 0 N-CA-C 111.569 0.211 . . . . 0.0 111.569 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -90.0 130.12 36.23 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.196 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.0 mt -119.05 150.49 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 C-N-CA 124.89 1.276 . . . . 0.0 110.744 -176.329 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.75 132.84 44.17 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 128.373 2.669 . . . . 0.0 105.94 177.15 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.4 mt -124.87 143.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 124.841 1.256 . . . . 0.0 108.853 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 38.3 t-80 -134.82 124.73 25.56 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.136 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -87.78 122.52 31.53 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 118.675 -0.679 . . . . 0.0 109.558 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.05 -157.4 5.9 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 118.358 0.526 . . . . 0.0 112.491 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 17.6 mm -132.77 142.92 41.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 106.36 -1.719 . . . . 0.0 106.36 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.6 t70 58.96 29.06 18.46 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.058 0.943 . . . . 0.0 112.555 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 p -86.41 -37.3 18.5 Favored 'General case' 0 CA--C 1.517 -0.296 0 C-N-CA 126.162 1.785 . . . . 0.0 108.067 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 3.7 p -51.46 -46.75 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.235 171.154 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -61.6 -31.33 71.4 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.332 1.453 . . . . 0.0 111.147 178.312 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.89 -2.99 29.37 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.344 2.258 . . . . 0.0 110.379 178.3 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm 51.61 33.44 10.72 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 125.176 1.39 . . . . 0.0 112.629 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.49 18.15 63.05 Favored Glycine 0 CA--C 1.537 1.426 0 O-C-N 121.919 -0.488 . . . . 0.0 113.357 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -73.01 85.27 1.29 Allowed 'General case' 0 C--N 1.34 0.152 0 CA-C-N 118.88 1.34 . . . . 0.0 109.745 179.609 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 17.48 1.7 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.714 2.102 . . . . 0.0 111.575 -177.809 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.454 ' CD2' HG12 ' A' ' 115' ' ' VAL . 37.1 m-85 -117.26 150.15 39.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.8 1.24 . . . . 0.0 109.907 -178.381 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 30.7 m -145.15 102.45 3.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.8 p -81.33 127.49 32.8 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.964 0.906 . . . . 0.0 108.959 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -91.13 -45.03 8.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.859 1.264 . . . . 0.0 112.612 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 6.7 m -73.36 129.19 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 118.383 -1.327 . . . . 0.0 111.67 -177.992 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -87.97 64.56 7.88 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 172.825 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.3 0.0 OUTLIER -14.11 84.47 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 130.039 3.336 . . . . 0.0 116.485 -173.213 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.14 -2.12 0.03 OUTLIER Glycine 0 CA--C 1.534 1.257 0 CA-C-N 113.528 -1.669 . . . . 0.0 113.194 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 121.57 14.71 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 127.266 2.226 . . . . 0.0 107.073 177.045 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.94 121.02 41.66 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 127.808 2.443 . . . . 0.0 111.061 -179.427 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.337 33.7 m 43.23 66.62 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 C-N-CA 126.682 1.993 . . . . 0.0 115.615 178.781 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -132.7 141.58 41.65 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 171.949 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -103.37 171.29 0.21 Allowed 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.935 3.09 . . . . 0.0 110.529 -179.048 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 60.04 -23.01 0.04 OUTLIER Glycine 0 CA--C 1.534 1.234 0 N-CA-C 118.856 2.303 . . . . 0.0 118.856 170.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -50.24 137.49 18.06 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 120.457 2.128 . . . . 0.0 110.529 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -60.59 123.7 18.18 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.5 mt -85.79 -48.2 9.01 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.108 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.5 mp -143.12 155.8 44.66 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.724 0.81 . . . . 0.0 110.666 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -122.11 135.36 54.79 Favored 'General case' 0 C--O 1.236 0.356 1 N-CA-C 99.023 -4.436 . . . . 0.0 99.023 167.075 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 115' ' ' VAL . . . . . 0.454 HG12 ' CD2' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -143.71 126.47 12.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.592 -165.754 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 38.7 m-20 -76.83 61.61 1.93 Allowed 'General case' 0 C--O 1.235 0.294 0 C-N-CA 124.904 1.282 . . . . 0.0 110.544 -178.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.0 mt -45.12 -45.5 11.28 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 123.886 0.875 . . . . 0.0 112.192 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -44.95 -42.01 7.78 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.488 1.115 . . . . 0.0 112.611 178.063 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.56 -33.67 15.81 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.113 0.565 . . . . 0.0 111.364 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 96.6 t -62.62 -52.78 55.46 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 O-C-N 121.756 -0.59 . . . . 0.0 110.004 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.391 8.8 ptmt -42.79 -57.22 5.11 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 116.895 2.183 . . . . 0.0 116.895 -177.79 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -61.59 -21.37 71.84 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 122.187 1.925 . . . . 0.0 113.184 178.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 -87.88 -42.29 12.62 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 119.064 0.847 . . . . 0.0 111.317 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.9 m -78.69 149.19 74.15 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.95 -0.469 . . . . 0.0 111.807 -177.183 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -70.53 -24.5 26.07 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.506 2.137 . . . . 0.0 110.228 175.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.2 t -158.05 145.06 17.93 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.725 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.2 tp -98.18 6.5 47.42 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.56 1.144 . . . . 0.0 110.31 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 21.3 mmt -53.36 115.16 1.77 Allowed 'General case' 0 C--N 1.344 0.343 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 47.3 m -106.33 88.6 3.34 Favored Pre-proline 0 N--CA 1.447 -0.579 0 C-N-CA 124.706 1.203 . . . . 0.0 108.241 -178.622 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 83.8 Cg_endo -72.93 144.0 37.64 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 122.668 2.246 . . . . 0.0 111.948 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.9 mt -125.01 126.29 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 103.788 -2.671 . . . . 0.0 103.788 173.102 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -123.53 153.41 29.16 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 C-N-CA 126.008 1.723 . . . . 0.0 106.651 178.669 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -129.92 121.58 26.9 Favored 'General case' 0 N--CA 1.428 -1.541 0 N-CA-C 102.914 -2.995 . . . . 0.0 102.914 -176.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 23.9 p -89.18 -86.17 0.19 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 -177.041 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 21.9 p30 -77.49 54.82 1.21 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 122.922 0.489 . . . . 0.0 111.696 179.488 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -78.26 80.07 4.69 Favored 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 174.692 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.12 51.51 0.21 Allowed 'General case' 0 C--N 1.343 0.289 0 C-N-CA 127.819 2.448 . . . . 0.0 111.641 -175.747 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 21.55 69.57 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 129.261 3.024 . . . . 0.0 113.964 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 146.42 -3.25 1.01 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-O 118.591 -1.116 . . . . 0.0 113.455 176.981 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.704 ' HB3' HG23 ' A' ' 160' ' ' ILE . 56.0 mt-10 -70.99 115.57 10.27 Favored 'General case' 0 C--N 1.339 0.116 0 CA-C-N 119.686 1.743 . . . . 0.0 109.933 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 81.5 p -78.78 128.99 34.13 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.12 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.266 0.4 OUTLIER -81.05 78.73 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 CA-C-O 123.498 1.618 . . . . 0.0 106.8 -177.538 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 38.5 m -78.8 91.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 120.962 -1.086 . . . . 0.0 111.249 -174.44 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.3 pt -63.19 104.58 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 C-N-CA 123.004 0.522 . . . . 0.0 109.597 176.649 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.23 -56.01 4.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 146' ' ' ALA . . . . . 0.731 ' HB3' HG23 ' A' ' 157' ' ' ILE . . . -84.14 69.97 10.47 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 46.4 m -77.7 68.66 3.82 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 176.666 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.17 -142.06 3.83 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 106.433 -2.667 . . . . 0.0 106.433 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.4 t -67.0 145.99 54.83 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 117.975 0.888 . . . . 0.0 110.645 177.4 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 150' ' ' VAL . . . . . 0.66 HG23 HG21 ' A' ' 157' ' ' ILE . 3.8 p -123.57 153.59 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 C-N-CA 125.881 1.673 . . . . 0.0 107.351 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 8.2 m-20 -129.68 158.1 40.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.268 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 -65.46 147.99 52.48 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 43.44 48.69 6.12 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 128.109 2.564 . . . . 0.0 114.057 172.816 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -89.29 10.21 23.09 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 177.528 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 53.62 8.86 0.15 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 128.752 2.821 . . . . 0.0 115.566 177.801 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -156.97 -126.13 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 125.146 1.378 . . . . 0.0 107.405 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.731 HG23 ' HB3' ' A' ' 146' ' ' ALA 0.312 1.5 mp 80.63 -36.89 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 128.559 2.744 . . . . 0.0 108.615 178.552 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -119.85 129.11 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 168.372 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 9.2 mmmt -111.3 111.51 22.61 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 124.168 0.987 . . . . 0.0 109.077 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.704 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.3 mp -77.24 91.51 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 103.409 -2.812 . . . . 0.0 103.409 175.049 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -103.46 116.1 31.77 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.587 1.555 . . . . 0.0 110.282 -173.009 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 28.6 tptp . . . . . 0 CA--C 1.528 0.129 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 178.987 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 29.3 t80 . . . . . 0 N--CA 1.451 -0.406 0 N-CA-C 104.402 -2.444 . . . . 0.0 104.402 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.76 77.05 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.4 t -15.91 124.06 0.04 OUTLIER Pre-proline 0 CA--C 1.552 1.043 0 C-N-CA 129.063 2.945 . . . . 0.0 114.449 179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' PRO . . . . . 0.429 ' HG2' HD12 ' A' ' 19' ' ' ILE . 50.5 Cg_endo -74.8 -42.72 0.51 Allowed 'Trans proline' 0 CA--C 1.538 0.684 0 N-CA-C 120.825 3.356 . . . . 0.0 120.825 -170.467 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ILE . . . . . 0.429 HD12 ' HG2' ' A' ' 18' ' ' PRO . 0.2 OUTLIER -138.16 145.49 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 121.014 1.734 . . . . 0.0 111.665 -172.646 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 m -79.88 131.88 35.96 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 171.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 178.41 -160.49 26.55 Favored Glycine 0 CA--C 1.518 0.249 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.7 tp10 -108.04 131.74 54.28 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.1 tt -75.85 151.71 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-N 118.679 0.672 . . . . 0.0 110.535 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.5 m-70 -140.14 129.75 13.59 Favored Pre-proline 0 N--CA 1.446 -0.628 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 172.407 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -57.41 143.0 95.22 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 122.512 2.141 . . . . 0.0 107.578 174.751 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ILE . . . . . 0.408 HD13 ' C ' ' A' ' 42' ' ' GLY . 1.8 tp -43.46 -49.45 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 123.764 0.826 . . . . 0.0 112.269 -177.666 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 p -53.9 -24.58 16.59 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.14 1.376 . . . . 0.0 114.321 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -78.81 -8.06 58.43 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 118.756 0.707 . . . . 0.0 112.61 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 93.0 t -70.1 134.67 87.35 Favored Pre-proline 0 CA--C 1.543 0.696 0 O-C-N 121.106 -0.996 . . . . 0.0 110.922 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.85 64.6 5.92 Favored 'Trans proline' 0 CA--C 1.537 0.673 0 C-N-CA 124.674 3.582 . . . . 0.0 110.556 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.09 178.69 6.84 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.37 1.468 . . . . 0.0 107.177 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.46 -63.83 1.2 Allowed 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 124.383 1.073 . . . . 0.0 110.565 178.314 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.9 p -47.26 -56.6 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 C-N-CA 124.22 1.008 . . . . 0.0 112.775 -177.411 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -61.06 -57.32 13.05 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-O 121.703 0.763 . . . . 0.0 108.959 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.3 m -53.67 -36.97 62.71 Favored 'General case' 0 N--CA 1.446 -0.648 0 C-N-CA 126.18 1.792 . . . . 0.0 115.592 -174.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.35 7.04 82.27 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 26.1 mtmt 74.99 -39.94 0.42 Allowed 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.974 1.71 . . . . 0.0 111.44 -177.368 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 26.6 ttt 28.01 -70.05 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 131.305 3.842 . . . . 0.0 116.909 177.687 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 9.6 tpt -79.13 -16.98 55.9 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.383 1.073 . . . . 0.0 112.654 -176.279 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.37 -135.29 2.18 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -178.556 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -131.24 154.94 47.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 105.833 -1.914 . . . . 0.0 105.833 173.467 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.408 ' C ' HD13 ' A' ' 26' ' ' ILE . . . -177.94 -159.48 22.79 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.249 -0.977 . . . . 0.0 114.177 -174.953 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 25.5 p90 -163.63 171.15 16.13 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.01 0.924 . . . . 0.0 109.521 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.431 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -120.34 137.3 54.35 Favored 'General case' 0 CA--C 1.508 -0.669 0 C-N-CA 122.936 0.494 . . . . 0.0 109.705 174.045 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 20.3 mm -112.09 129.6 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.903 0 N-CA-C 103.38 -2.822 . . . . 0.0 103.38 171.189 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 15.6 tp -94.85 110.63 50.7 Favored Pre-proline 0 N--CA 1.446 -0.651 0 N-CA-C 102.019 -3.326 . . . . 0.0 102.019 172.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -64.55 155.27 67.46 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 123.639 2.893 . . . . 0.0 116.916 -169.487 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.3 p -127.55 -50.94 1.38 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.124 1.37 . . . . 0.0 107.725 171.132 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -79.0 122.5 26.26 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 123.276 0.63 . . . . 0.0 110.37 177.553 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 40.31 2.26 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 174.491 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 72.7 mt -136.89 117.82 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.767 -2.679 . . . . 0.0 103.767 -179.237 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.3 t -120.59 109.4 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 122.962 0.505 . . . . 0.0 110.128 -173.891 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.5 m -91.15 -173.2 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 172.705 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.6 m -116.3 147.57 39.78 Favored Pre-proline 0 N--CA 1.469 0.49 0 CA-C-O 117.199 -1.381 . . . . 0.0 112.723 -175.108 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -61.54 -38.92 58.98 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 121.883 1.722 . . . . 0.0 108.305 174.65 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.46 142.0 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 102.921 -2.992 . . . . 0.0 102.921 171.151 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 29.1 mtm180 -95.12 -79.91 0.42 Allowed 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 102.094 -3.299 . . . . 0.0 102.094 171.902 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.88 -73.76 0.99 Allowed Glycine 0 C--N 1.338 0.64 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 176.166 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.21 123.1 8.72 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.765 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 24.1 mm -70.12 128.4 33.39 Favored 'Isoleucine or valine' 0 C--N 1.344 0.369 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.7 tt -78.43 -52.54 8.41 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.049 -2.204 . . . . 0.0 105.049 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 174.18 161.17 0.18 Allowed 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 124.614 1.166 . . . . 0.0 108.56 178.539 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.7 p -135.54 121.5 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 172.04 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -38.53 146.46 0.3 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.791 0.723 . . . . 0.0 112.947 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -58.63 -43.01 48.42 Favored 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.931 2.421 . . . . 0.0 109.723 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 15.9 p -78.23 74.27 4.77 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 173.591 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -34.4 93.24 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 129.261 3.024 . . . . 0.0 113.471 -173.671 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' HIS . . . . . 0.442 ' CD2' HG23 ' A' ' 89' ' ' VAL . 0.0 OUTLIER -158.56 -19.2 0.07 Allowed 'General case' 0 C--O 1.225 -0.229 0 N-CA-C 113.409 0.892 . . . . 0.0 113.409 175.31 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -164.77 -177.84 4.96 Favored 'General case' 0 C--O 1.222 -0.363 0 CA-C-N 120.238 1.381 . . . . 0.0 110.839 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.875 14.3 mm 135.57 -128.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 1 C-N-CA 133.254 4.622 . . . . 0.0 109.141 177.274 . . . . . . . . 3 2 . 1 . 011 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.4 175.29 42.49 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 118.769 2.268 . . . . 0.0 118.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 39.0 mt -128.72 172.94 10.76 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 127.478 2.311 . . . . 0.0 109.576 -178.255 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 -148.61 140.91 24.14 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.828 1.651 . . . . 0.0 106.835 176.339 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 59.6 p . . . . . 0 CA--C 1.536 0.417 0 CA-C-O 121.049 0.452 . . . . 0.0 110.363 178.33 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.4 ttp180 . . . . . 0 CA--C 1.529 0.137 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -79.28 134.32 36.64 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.3 mp -116.85 114.67 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 C-N-CA 123.268 0.627 . . . . 0.0 109.905 -177.521 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -81.2 125.84 30.78 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 104.196 -2.52 . . . . 0.0 104.196 170.706 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 62.7 mt -123.06 132.01 72.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -128.29 132.77 48.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 106.309 -1.737 . . . . 0.0 106.309 174.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -116.44 104.42 11.43 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 126.16 1.784 . . . . 0.0 109.489 -177.608 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.77 163.06 10.02 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 -178.261 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 10.7 mm -109.02 119.85 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 -179.05 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.4 t70 77.09 4.61 3.28 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.391 1.477 . . . . 0.0 113.779 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -61.78 -24.87 67.12 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 120.761 -1.212 . . . . 0.0 110.757 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' VAL . . . . . 0.442 HG23 ' CD2' ' A' ' 68' ' ' HIS . 0.5 OUTLIER -59.86 -47.88 89.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 C-N-CA 125.92 1.688 . . . . 0.0 108.127 173.594 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 4.5 m -63.47 -35.59 80.94 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.125 0.97 . . . . 0.0 108.766 177.43 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.58 19.75 0.78 Allowed 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 125.426 1.49 . . . . 0.0 110.873 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 4.8 mptt 37.77 37.59 0.13 Allowed 'General case' 0 C--N 1.346 0.42 0 C-N-CA 128.658 2.783 . . . . 0.0 114.595 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 52.58 34.42 43.07 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.486 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -67.41 92.64 0.3 Allowed 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 121.401 -1.058 . . . . 0.0 110.164 -178.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.47 1.67 5.12 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 126.043 1.782 . . . . 0.0 112.214 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -96.58 103.35 15.26 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.801 1.241 . . . . 0.0 111.263 -176.552 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.5 m -89.7 105.78 18.03 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.081 -2.192 . . . . 0.0 105.081 172.931 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.7 p -81.6 123.85 29.03 Favored 'General case' 0 N--CA 1.451 -0.406 0 O-C-N 121.613 -0.68 . . . . 0.0 110.402 -178.329 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -81.41 -52.3 7.41 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.915 1.286 . . . . 0.0 108.911 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.9 m -78.32 130.46 36.16 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 C-N-CA 117.999 -1.48 . . . . 0.0 107.224 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.5 m -94.37 57.06 2.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 169.37 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.341 9.8 pt-20 29.32 65.96 0.11 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 128.737 2.815 . . . . 0.0 111.681 -168.33 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -73.3 58.44 1.94 Allowed Glycine 0 CA--C 1.525 0.662 0 CA-C-N 111.574 -2.557 . . . . 0.0 111.253 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -10.59 -17.87 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.533 2 C-N-CA 136.188 5.795 . . . . 0.0 124.342 -179.317 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -142.88 110.7 5.9 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 128.062 2.545 . . . . 0.0 106.612 178.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.0 155.76 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 123.908 0.883 . . . . 0.0 112.833 -171.847 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -80.88 151.61 70.89 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-O 117.948 -1.025 . . . . 0.0 108.662 175.162 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -47.88 164.62 0.16 Allowed 'Trans proline' 0 CA--C 1.533 0.428 1 C-N-CA 127.018 5.145 . . . . 0.0 120.304 -174.158 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 68.45 -92.5 0.27 Allowed Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.84 1.686 . . . . 0.0 113.678 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 35.5 tp60 1.18 101.9 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.793 1 C-N-CA 132.258 4.223 . . . . 0.0 114.735 -176.548 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -4.14 112.95 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 130.168 3.387 . . . . 0.0 116.172 178.344 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.6 mt -83.18 -45.25 14.12 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 173.563 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.0 mt -140.38 151.23 44.8 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.723 1.209 . . . . 0.0 111.282 -174.285 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -119.84 128.58 53.82 Favored 'General case' 0 CA--C 1.514 -0.407 1 N-CA-C 99.12 -4.4 . . . . 0.0 99.12 167.363 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.93 124.41 27.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-N 115.1 -0.954 . . . . 0.0 112.756 -165.223 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -73.87 69.13 1.37 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.938 0.895 . . . . 0.0 110.037 178.984 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.1 mt -47.2 -52.49 15.62 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.793 0.837 . . . . 0.0 110.583 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -43.46 -49.65 7.16 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 125.392 1.477 . . . . 0.0 112.343 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -82.81 -31.36 28.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 123.175 0.297 . . . . 0.0 111.774 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 42.2 t -63.1 -56.48 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 118.901 -0.571 . . . . 0.0 110.839 179.007 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.324 3.8 pttm -42.78 -56.29 6.22 Favored Pre-proline 0 N--CA 1.47 0.535 0 N-CA-C 116.391 1.997 . . . . 0.0 116.391 -176.93 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -60.86 -14.63 33.41 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.699 1.6 . . . . 0.0 113.22 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 -98.98 5.08 47.36 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.056 -0.973 . . . . 0.0 112.303 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 20.1 m -142.07 155.11 65.44 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 120.332 1.424 . . . . 0.0 112.166 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.31 -39.78 89.16 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.086 2.524 . . . . 0.0 113.927 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -159.97 141.37 12.62 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.156 0.582 . . . . 0.0 110.012 -177.511 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -92.46 14.58 16.27 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.539 1.135 . . . . 0.0 112.068 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.4 mmt -53.04 134.01 38.33 Favored 'General case' 0 N--CA 1.457 -0.111 0 O-C-N 121.415 -0.803 . . . . 0.0 110.369 -178.377 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -110.28 78.78 1.46 Allowed Pre-proline 0 N--CA 1.451 -0.378 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 176.759 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.2 136.59 27.1 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 C-N-CA 122.449 2.1 . . . . 0.0 110.269 178.381 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -128.98 134.66 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 178.395 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 t -136.53 126.15 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 125.165 1.386 . . . . 0.0 108.55 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.457 ' HB2' ' CD2' ' A' ' 136' ' ' LEU . 13.9 m-85 -92.93 124.13 36.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 103.525 -2.769 . . . . 0.0 103.525 176.819 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 77.7 p -86.49 -82.28 0.2 Allowed 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.071 0.85 . . . . 0.0 109.319 -176.117 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 4.9 p-10 -77.01 52.34 0.87 Allowed 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.457 ' CD2' ' HB2' ' A' ' 133' ' ' PHE . 0.2 OUTLIER -78.78 72.26 5.29 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.249 -0.907 . . . . 0.0 108.666 174.509 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 41.87 47.86 3.74 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 126.603 1.961 . . . . 0.0 111.256 -178.259 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 18.9 68.42 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 129.394 3.077 . . . . 0.0 113.245 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 154.75 -9.65 0.39 Allowed Glycine 0 CA--C 1.523 0.574 0 CA-C-O 118.508 -1.162 . . . . 0.0 113.021 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.666 ' HB3' HG23 ' A' ' 160' ' ' ILE . 59.1 mm-40 -69.09 116.93 10.1 Favored 'General case' 0 C--N 1.342 0.281 0 CA-C-N 119.626 1.713 . . . . 0.0 110.069 178.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.2 p -77.73 136.07 38.11 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.828 -1.915 . . . . 0.0 105.828 173.006 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -86.69 86.74 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 -176.768 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.2 m -77.42 83.31 3.85 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.82 -1.175 . . . . 0.0 110.99 -175.034 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' ILE . . . . . 0.471 HG22 HG22 ' A' ' 158' ' ' VAL . 2.1 pt -56.59 111.15 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 173.636 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -88.73 -38.57 14.62 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 123.892 0.877 . . . . 0.0 109.636 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -81.12 75.77 8.08 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.463 -175.782 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 50.6 p -77.39 69.44 3.65 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 169.38 -137.43 4.52 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -176.7 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.7 t -75.43 149.07 38.64 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.7 m -119.98 158.93 21.59 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 C-N-CA 125.374 1.469 . . . . 0.0 109.048 178.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -131.79 166.98 20.34 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 125.688 1.595 . . . . 0.0 112.22 176.416 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 73.5 mtm-85 -85.65 154.25 21.81 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -175.347 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 57.52 55.11 5.9 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 126.448 1.899 . . . . 0.0 113.591 176.324 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 154' ' ' GLN . . . . . 0.503 ' CB ' HD13 ' A' ' 157' ' ' ILE . 4.3 mm-40 -143.05 161.12 38.99 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.964 0.906 . . . . 0.0 109.76 176.835 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 155' ' ' GLU . . . . . 0.452 ' C ' ' H ' ' A' ' 157' ' ' ILE . 62.9 tt0 -105.52 -61.1 1.53 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 122.817 1.294 . . . . 0.0 112.314 -177.412 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 156' ' ' ASP . . . . . 0.436 ' C ' HD12 ' A' ' 157' ' ' ILE . 0.9 OUTLIER -65.68 27.34 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 127.705 2.402 . . . . 0.0 114.682 -174.326 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.503 HD13 ' CB ' ' A' ' 154' ' ' GLN . 1.7 mp -103.17 -34.7 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 130.225 3.41 . . . . 0.0 104.976 177.451 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.471 HG22 HG22 ' A' ' 144' ' ' ILE . 59.4 t -149.05 109.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 106.062 -1.829 . . . . 0.0 106.062 173.147 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -101.77 124.31 47.2 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 118.049 0.386 . . . . 0.0 111.78 -176.772 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.666 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.4 mp -78.15 108.8 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 174.685 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -128.9 150.62 50.28 Favored 'General case' 0 C--O 1.226 -0.157 0 C-N-CA 124.383 1.073 . . . . 0.0 109.261 -175.783 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 50.9 tptt . . . . . 0 C--N 1.333 -0.136 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -179.815 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.225 -0.215 0 N-CA-C 104.269 -2.493 . . . . 0.0 104.269 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.4 m -123.77 85.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 CA-C-N 118.846 0.748 . . . . 0.0 110.958 -176.375 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.4 p -19.45 110.25 0.09 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 129.569 3.147 . . . . 0.0 110.512 177.806 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -68.64 -25.13 34.6 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.776 2.317 . . . . 0.0 117.931 -168.498 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.95 146.1 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.611 1.096 . . . . 0.0 109.598 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.1 m -79.34 137.45 37.33 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 170.615 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 173.82 -158.25 27.09 Favored Glycine 0 C--O 1.227 -0.312 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -108.4 120.61 42.89 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.17 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 tt -85.51 134.92 26.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 118.569 0.622 . . . . 0.0 109.718 178.635 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -137.59 149.42 64.97 Favored Pre-proline 0 N--CA 1.451 -0.389 0 C-N-CA 125.79 1.636 . . . . 0.0 107.753 176.783 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.65 143.37 96.57 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 121.366 1.378 . . . . 0.0 108.566 173.935 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -55.05 -24.82 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -173.774 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.3 p -52.42 -31.02 32.28 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 124.279 1.032 . . . . 0.0 111.134 174.696 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -75.16 -9.72 58.8 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.5 1.12 . . . . 0.0 112.65 -176.448 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.9 t -76.63 131.74 73.53 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 119.13 0.877 . . . . 0.0 109.861 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -77.8 60.1 7.1 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 123.17 2.58 . . . . 0.0 110.847 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -165.55 102.6 0.71 Allowed 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.487 -0.758 . . . . 0.0 110.01 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -24.41 -59.0 0.05 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.476 2.71 . . . . 0.0 115.055 -178.45 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -52.03 -41.85 33.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 123.178 0.591 . . . . 0.0 111.583 -177.723 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -80.67 -48.56 12.43 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.7 m -48.71 -41.54 32.16 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -179.103 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.61 11.2 61.2 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-O 118.629 -1.095 . . . . 0.0 111.515 -178.411 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm 73.37 -39.5 0.44 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.573 1.549 . . . . 0.0 112.773 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 13.7 tpt 21.7 -62.24 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 1 C-N-CA 132.264 4.226 . . . . 0.0 117.996 178.455 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -77.71 -21.63 51.67 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.991 0.916 . . . . 0.0 111.898 -176.465 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.32 -136.29 2.78 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -130.27 157.55 42.21 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 172.915 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.71 -167.74 36.87 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.943 -176.103 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -146.81 154.72 41.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 124.283 1.033 . . . . 0.0 109.718 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.76 119.09 38.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.009 0.923 . . . . 0.0 109.917 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.3 mm -100.8 129.53 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 171.334 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.3 tt -98.14 105.83 30.98 Favored Pre-proline 0 N--CA 1.45 -0.426 0 N-CA-C 101.326 -3.583 . . . . 0.0 101.326 172.561 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -60.5 167.31 8.26 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 123.434 2.756 . . . . 0.0 117.124 -169.968 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.1 p -146.98 -58.92 0.28 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.72 1.608 . . . . 0.0 106.942 173.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -69.81 119.0 13.37 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 175.724 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.75 44.85 3.03 Favored Glycine 0 CA--C 1.53 1.005 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 22.0 mt -144.06 114.64 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 N-CA-C 105.253 -2.129 . . . . 0.0 105.253 -177.045 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.65 126.14 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 124.479 1.111 . . . . 0.0 109.131 -175.373 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.8 m -109.29 156.91 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 C-N-CA 123.387 0.675 . . . . 0.0 110.363 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 m -65.67 127.2 92.86 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-O 118.982 -0.532 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.49 -7.96 22.5 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 124.468 3.445 . . . . 0.0 116.765 -174.573 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.4 m -147.99 169.51 3.58 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 CA-C-N 119.754 1.161 . . . . 0.0 109.388 -177.207 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.06 116.18 17.49 Favored 'General case' 0 C--O 1.235 0.336 1 N-CA-C 97.978 -4.823 . . . . 0.0 97.978 166.893 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.69 170.26 42.11 Favored Glycine 0 N--CA 1.438 -1.215 0 C-N-CA 116.026 -2.988 . . . . 0.0 116.557 -167.08 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 10.0 mtpp -97.2 132.84 42.57 Favored 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 127.989 2.515 . . . . 0.0 109.003 -175.015 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.7 mm -72.8 123.96 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 104.618 -2.364 . . . . 0.0 104.618 173.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 42.0 tp -78.63 -48.88 14.2 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 179.515 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -177.46 171.79 1.91 Allowed 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 123.531 0.732 . . . . 0.0 109.444 173.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 51.5 t -144.16 115.08 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 176.477 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -45.5 147.33 1.47 Allowed Pre-proline 0 CA--C 1.542 0.65 0 CA-C-N 118.689 0.677 . . . . 0.0 111.454 177.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.45 -24.22 11.84 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 124.102 3.202 . . . . 0.0 114.881 176.247 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.8 p -76.34 -15.17 60.03 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.636 1.174 . . . . 0.0 111.165 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.6 tppt? 70.94 4.8 5.22 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 127.852 2.461 . . . . 0.0 113.344 -178.837 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.2 p-80 -78.97 -25.93 43.48 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 113.41 0.893 . . . . 0.0 113.41 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.96 -173.94 2.53 Favored 'General case' 0 C--O 1.222 -0.348 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -172.296 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.439 HG22 ' N ' ' A' ' 71' ' ' GLY 0.62 25.9 mm 132.03 -124.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.345 1 C-N-CA 136.505 5.922 . . . . 0.0 105.75 178.863 . . . . . . . . 4 3 . 1 . 012 nuclear build core ' A' A ' 71' ' ' GLY . . . . . 0.439 ' N ' HG22 ' A' ' 70' ' ' ILE . . . -179.96 -176.68 47.55 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 116.976 1.55 . . . . 0.0 116.976 -179.106 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.3 mp -126.29 171.92 10.54 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 127.519 2.327 . . . . 0.0 110.126 -178.613 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -140.36 136.37 33.09 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.477 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 62.9 p . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.925 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 24.8 mtp180 . . . . . 0 C--O 1.235 0.338 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 13.2 tm-20 -93.3 150.72 20.27 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 126.866 2.066 . . . . 0.0 109.318 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.65 103.39 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 C-N-CA 124.376 1.071 . . . . 0.0 109.052 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.4 tt -85.64 136.64 33.29 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.498 -1.668 . . . . 0.0 106.498 174.467 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 20.0 mt -122.77 148.72 26.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 123.444 0.698 . . . . 0.0 109.938 -178.738 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.37 126.48 21.17 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 170.551 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -102.41 106.22 16.94 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.705 1.202 . . . . 0.0 108.773 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 64.29 176.63 4.73 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 118.184 0.447 . . . . 0.0 113.09 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.6 mm -113.29 141.17 29.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.9 t70 63.27 13.32 6.88 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.423 1.089 . . . . 0.0 112.486 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 p -74.15 -39.74 63.06 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 126.265 1.826 . . . . 0.0 107.231 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 p -47.11 -47.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 124.923 1.289 . . . . 0.0 109.287 171.916 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -63.98 -54.58 32.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 125.347 1.459 . . . . 0.0 111.304 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.23 -36.89 78.74 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 123.991 0.916 . . . . 0.0 112.008 -178.257 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 81.5 mttt 79.57 145.6 0.09 Allowed 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 128.854 2.862 . . . . 0.0 108.706 -176.67 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.45 48.71 0.29 Allowed Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.609 1.1 . . . . 0.0 115.537 -176.25 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 25.7 pt-20 -63.75 -17.31 62.9 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 119.168 1.484 . . . . 0.0 113.67 177.687 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -109.84 15.43 31.43 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 126.544 2.021 . . . . 0.0 111.13 177.033 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -107.95 99.42 8.88 Favored 'General case' 0 C--N 1.343 0.283 0 CA-C-N 118.156 0.978 . . . . 0.0 110.665 -176.809 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -79.44 93.99 5.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 174.271 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 p -79.11 127.4 31.96 Favored 'General case' 0 N--CA 1.453 -0.31 0 O-C-N 120.983 -1.073 . . . . 0.0 110.505 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -89.17 -49.11 6.94 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 123.836 0.854 . . . . 0.0 110.375 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -78.1 133.29 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.032 0 C-N-CA 119.019 -1.072 . . . . 0.0 110.559 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 m -87.73 61.5 6.5 Favored 'General case' 0 C--N 1.333 -0.128 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 172.793 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.271 1.6 pm0 3.22 79.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 130.451 3.501 . . . . 0.0 115.211 -174.244 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 174.65 6.54 0.02 OUTLIER Glycine 0 CA--C 1.533 1.202 0 CA-C-N 113.32 -1.763 . . . . 0.0 114.812 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.24 121.52 14.46 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 119.493 1.646 . . . . 0.0 107.396 176.115 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 37.8 mmt-85 -100.07 100.53 11.41 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 129.796 3.238 . . . . 0.0 111.817 -175.297 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.551 7.3 p 60.47 78.23 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 N-CA-C 116.813 2.153 . . . . 0.0 116.813 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -135.99 150.14 70.5 Favored Pre-proline 0 N--CA 1.446 -0.632 0 CA-C-N 111.933 -2.394 . . . . 0.0 105.141 169.15 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -105.42 142.59 0.1 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.969 3.112 . . . . 0.0 111.803 -177.123 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 56.93 15.26 12.46 Favored Glycine 0 CA--C 1.531 1.046 0 O-C-N 121.417 -0.802 . . . . 0.0 114.289 175.588 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.3 130.28 45.41 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.393 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 25.7 ttpt -59.39 117.64 5.07 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.112 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.4 mt -80.41 -54.2 5.92 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 25.0 mt -144.82 151.13 38.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.215 1.006 . . . . 0.0 110.871 -173.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 6.1 tm-20 -116.45 128.44 55.48 Favored 'General case' 0 CA--C 1.515 -0.398 1 N-CA-C 97.922 -4.844 . . . . 0.0 97.922 166.098 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.52 121.69 22.78 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.834 -166.719 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -71.91 69.96 0.73 Allowed 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.844 1.258 . . . . 0.0 111.112 -177.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.3 mt -47.95 -44.85 30.53 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.057 0.943 . . . . 0.0 110.718 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -52.83 -43.78 66.24 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.473 0.709 . . . . 0.0 112.794 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -84.71 -33.36 23.16 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.114 0.416 . . . . 0.0 111.305 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 40.3 t -63.87 -56.25 17.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 O-C-N 121.865 -0.522 . . . . 0.0 109.852 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.359 0.1 OUTLIER -40.74 -55.52 4.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 117.891 2.552 . . . . 0.0 117.891 -177.125 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -57.91 -21.65 50.38 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.515 2.143 . . . . 0.0 112.87 178.893 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -93.68 9.57 36.42 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.457 -0.782 . . . . 0.0 112.216 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 15.9 m -138.96 152.02 69.36 Favored Pre-proline 0 C--N 1.344 0.36 0 CA-C-N 119.923 1.238 . . . . 0.0 111.695 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.03 -26.8 12.62 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.044 2.496 . . . . 0.0 111.594 179.291 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 15.6 t -153.1 142.81 21.97 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.09 6.99 47.56 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.226 1.01 . . . . 0.0 110.595 178.404 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 16.5 mmt -51.01 119.61 4.12 Favored 'General case' 0 C--N 1.344 0.347 0 CA-C-N 118.5 0.591 . . . . 0.0 109.955 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 29.9 m -117.2 87.52 24.05 Favored Pre-proline 0 N--CA 1.446 -0.66 0 C-N-CA 125.588 1.555 . . . . 0.0 107.645 -177.082 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.403 ' C ' HD12 ' A' ' 131' ' ' ILE . 49.8 Cg_endo -84.89 151.61 11.2 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 C-N-CA 121.411 1.407 . . . . 0.0 112.011 -178.686 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ILE . . . . . 0.47 HD12 ' N ' ' A' ' 131' ' ' ILE . 1.3 mp -118.55 130.14 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 N-CA-C 102.792 -3.04 . . . . 0.0 102.792 173.853 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.0 t -128.6 153.4 38.05 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.58 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -127.02 109.82 12.31 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 103.418 -2.808 . . . . 0.0 103.418 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.0 p -75.2 -78.05 0.11 Allowed 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -175.864 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -74.03 65.86 1.15 Allowed 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.587 0.708 . . . . 0.0 112.096 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 16.4 mt -72.81 70.41 0.98 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.144 1.378 . . . . 0.0 108.273 176.315 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 27.74 48.99 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 128.508 2.723 . . . . 0.0 111.921 -176.63 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 28.5 53.52 0.08 Allowed 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 128.74 2.816 . . . . 0.0 114.44 -175.647 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 167.09 -4.71 0.05 OUTLIER Glycine 0 CA--C 1.528 0.848 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.227 178.499 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.571 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 3.7 mm-40 -87.35 148.01 25.23 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.838 1.319 . . . . 0.0 110.178 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 51.0 p -123.89 140.42 53.0 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.943 1.297 . . . . 0.0 108.102 179.035 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -86.08 95.35 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-O 122.064 0.935 . . . . 0.0 108.952 -177.563 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 62.1 m -84.74 87.36 7.3 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.301 -0.875 . . . . 0.0 109.836 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.8 pt -66.07 128.78 29.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 174.733 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -103.2 -46.9 4.48 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.557 1.143 . . . . 0.0 109.708 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -76.14 156.69 33.53 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.433 0.635 . . . . 0.0 111.629 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 27.9 p -150.62 113.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 104.774 -2.306 . . . . 0.0 104.774 178.04 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 115.8 -151.57 18.33 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.9 t -59.12 139.93 56.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.347 1.074 . . . . 0.0 112.379 -177.701 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.5 m -143.52 146.32 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 C-N-CA 126.23 1.812 . . . . 0.0 108.64 177.363 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -101.59 160.18 14.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.491 1.116 . . . . 0.0 110.768 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.2 ttp180 -75.77 154.99 35.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.524 1.53 . . . . 0.0 110.887 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 57.98 52.96 7.23 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.903 1.681 . . . . 0.0 113.222 178.219 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 154' ' ' GLN . . . . . 0.634 ' HB2' HD13 ' A' ' 157' ' ' ILE . 17.2 mm-40 -135.93 168.01 20.14 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.635 1.574 . . . . 0.0 108.509 177.792 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -119.69 -77.53 0.58 Allowed 'General case' 0 C--N 1.344 0.327 0 CA-C-N 120.027 1.285 . . . . 0.0 114.238 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -37.08 -7.62 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.065 1 C-N-CA 132.073 4.149 . . . . 0.0 120.194 -174.586 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.672 ' H ' HD12 ' A' ' 157' ' ' ILE . 4.9 mp -68.39 -33.44 60.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 130.874 3.67 . . . . 0.0 106.889 174.565 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -137.29 133.62 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 C-N-CA 127.281 2.233 . . . . 0.0 106.599 173.428 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -127.08 133.03 50.52 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.571 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.06 116.2 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 175.347 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -98.26 170.83 8.6 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 175.551 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp . . . . . 0 CA--C 1.532 0.259 0 O-C-N 121.457 -0.777 . . . . 0.0 110.811 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.469 0.5 0 CA-C-O 118.386 -0.816 . . . . 0.0 110.637 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.3 m -117.35 108.36 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 119.244 0.929 . . . . 0.0 109.04 172.504 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.3 t -38.87 115.96 0.95 Allowed Pre-proline 0 CA--C 1.553 1.066 0 C-N-CA 124.759 1.224 . . . . 0.0 111.761 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -76.82 -23.38 10.95 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 123.507 2.805 . . . . 0.0 118.293 -172.338 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.89 154.41 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 120.698 1.59 . . . . 0.0 109.989 -178.552 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.5 m -89.74 137.73 32.08 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 175.329 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 160.71 -130.71 2.44 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -131.32 139.01 49.47 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 124.653 1.181 . . . . 0.0 109.087 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.9 tt -101.39 131.6 48.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 CA-C-N 118.673 0.669 . . . . 0.0 110.01 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.64 145.49 49.6 Favored Pre-proline 0 N--CA 1.452 -0.358 0 C-N-CA 126.069 1.748 . . . . 0.0 108.036 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -62.82 141.97 86.93 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 121.749 1.633 . . . . 0.0 108.598 174.023 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.6 tt -53.61 -27.29 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 114.334 1.235 . . . . 0.0 114.334 -174.431 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.7 p -55.02 -29.0 56.41 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.879 0.871 . . . . 0.0 111.553 176.111 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -78.98 -1.45 35.47 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.81 0.844 . . . . 0.0 112.937 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.4 t -81.68 134.58 50.42 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.068 -1.02 . . . . 0.0 110.181 -178.292 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -77.83 54.1 4.68 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.741 2.961 . . . . 0.0 111.934 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -167.98 109.28 0.58 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.308 0.958 . . . . 0.0 110.651 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -29.43 -54.48 0.14 Allowed 'General case' 0 C--O 1.234 0.249 0 C-N-CA 128.35 2.66 . . . . 0.0 115.186 -177.716 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -51.56 -40.49 25.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.973 0.416 . . . . 0.0 110.565 -176.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.469 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 24.5 m-85 -83.15 -52.87 6.23 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 177.666 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -46.66 -39.94 12.27 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 114.349 1.241 . . . . 0.0 114.349 -177.79 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -109.11 22.77 24.62 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-O 118.339 -1.256 . . . . 0.0 111.39 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.8 mppt? 70.69 -45.02 0.6 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.028 1.731 . . . . 0.0 114.384 178.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.8 tpp 32.76 -68.92 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 130.2 3.4 . . . . 0.0 116.703 -178.096 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.32 -26.01 42.28 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.974 1.31 . . . . 0.0 112.771 -176.652 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.12 -154.55 16.09 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -178.957 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -108.39 153.34 23.43 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 174.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -174.25 -167.46 33.77 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.42 -176.325 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.506 ' CE2' HG11 ' A' ' 158' ' ' VAL . 9.4 p90 -150.02 165.13 33.64 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.894 1.278 . . . . 0.0 109.044 -178.461 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -117.85 117.19 28.61 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 123.706 0.802 . . . . 0.0 111.289 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -87.83 134.34 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 103.994 -2.595 . . . . 0.0 103.994 170.023 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.2 tt -100.89 106.62 45.22 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.054 -4.795 . . . . 0.0 98.054 169.287 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_endo -83.92 161.38 13.9 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 123.439 2.76 . . . . 0.0 114.191 -168.051 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.7 p -130.18 -53.39 1.11 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.867 1.267 . . . . 0.0 109.639 176.63 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -67.11 128.03 34.85 Favored 'General case' 0 CA--C 1.519 -0.214 0 O-C-N 122.18 -0.325 . . . . 0.0 111.493 179.432 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.45 39.55 1.93 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 174.089 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 5.0 mp -143.62 120.53 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 104.676 -2.342 . . . . 0.0 104.676 178.187 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 69.8 t -119.41 120.08 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 C-N-CA 125.695 1.598 . . . . 0.0 107.415 -176.055 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 22.0 m -106.77 157.29 7.06 Favored 'Isoleucine or valine' 0 C--N 1.338 0.099 0 N-CA-C 114.42 1.266 . . . . 0.0 114.42 -175.879 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 48.2 m -61.62 125.76 85.32 Favored Pre-proline 0 CA--C 1.537 0.48 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.488 179.017 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -77.52 -4.12 14.31 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 124.945 3.763 . . . . 0.0 116.012 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.5 m -155.21 172.88 0.57 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 125.297 1.439 . . . . 0.0 108.055 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ARG . . . . . 0.421 ' NE ' ' H ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -76.26 87.89 3.09 Favored 'General case' 0 C--N 1.34 0.16 1 N-CA-C 98.374 -4.676 . . . . 0.0 98.374 168.028 . . . . . . . . 4 4 . 1 . 013 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.07 176.26 30.43 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 118.543 2.177 . . . . 0.0 118.543 -164.971 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.01 110.54 5.31 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 172.301 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.2 mm -61.82 125.14 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 37.1 mt -78.95 -48.75 13.94 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 105.779 -1.934 . . . . 0.0 105.779 173.655 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -173.25 159.33 3.8 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.168 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.4 t -135.4 119.81 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 102.879 -3.008 . . . . 0.0 102.879 173.459 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -45.55 147.39 1.49 Allowed Pre-proline 0 CA--C 1.535 0.384 0 O-C-N 123.43 0.456 . . . . 0.0 111.55 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -56.51 -25.96 61.26 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.642 2.228 . . . . 0.0 111.214 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 55.2 p -79.97 13.49 2.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 117.03 -1.462 . . . . 0.0 112.596 177.294 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' A' ' 96' ' ' PHE 0.275 0.1 OUTLIER 66.28 -39.6 0.33 Allowed 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 117.857 2.539 . . . . 0.0 117.857 178.477 . . . . . . . . 4 4 . 1 . 013 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.9 p-80 -57.63 -26.6 61.82 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 116.269 1.951 . . . . 0.0 116.269 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.93 -175.99 5.67 Favored 'General case' 0 C--O 1.221 -0.396 0 N-CA-C 114.292 1.219 . . . . 0.0 114.292 -172.237 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.847 26.9 mm 127.0 -135.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.52 -0.192 1 C-N-CA 133.25 4.62 . . . . 0.0 110.289 178.51 . . . . . . . . 3 2 . 1 . 013 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -166.89 173.47 42.2 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 118.43 2.132 . . . . 0.0 118.43 -176.044 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.7 mp -127.64 175.16 8.49 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 128.208 2.603 . . . . 0.0 109.854 -177.825 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -137.07 160.74 38.07 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 103.258 -2.867 . . . . 0.0 103.258 168.567 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 83.6 p . . . . . 0 CA--C 1.535 0.388 0 O-C-N 124.055 0.847 . . . . 0.0 109.448 177.861 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 74.4 mtp180 . . . . . 0 CA--C 1.524 -0.041 0 CA-C-O 121.655 0.74 . . . . 0.0 109.84 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -79.63 109.96 14.51 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 125.327 1.451 . . . . 0.0 107.389 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.4 mp -95.96 116.56 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 C-N-CA 125.381 1.472 . . . . 0.0 109.763 -176.467 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 9.2 tp -93.58 122.29 35.87 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 105.316 -2.105 . . . . 0.0 105.316 172.663 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.0 mt -113.82 134.53 56.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 124.938 1.295 . . . . 0.0 108.741 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -131.24 109.76 10.63 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 171.799 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.435 ' HA ' HG23 ' A' ' 129' ' ' THR . 6.4 t80 -78.51 119.6 22.02 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 118.708 -0.663 . . . . 0.0 109.443 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.1 -161.26 2.97 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-O 121.71 0.617 . . . . 0.0 113.341 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.9 mm -131.17 145.5 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.4 t70 62.67 15.34 7.96 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.5 1.12 . . . . 0.0 113.426 179.713 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.9 p -78.52 -37.7 42.42 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 126.251 1.821 . . . . 0.0 107.468 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 9.1 p -50.71 -45.26 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 CA-C-N 113.77 -1.559 . . . . 0.0 108.787 172.386 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -63.31 -37.86 88.92 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 125.531 1.532 . . . . 0.0 111.329 178.455 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.65 -39.44 94.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 127.145 2.178 . . . . 0.0 109.898 -179.804 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mttp 59.62 88.01 0.08 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.782 1.633 . . . . 0.0 114.223 175.853 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.4 -55.63 2.85 Favored Glycine 0 CA--C 1.539 1.582 0 O-C-N 121.375 -0.828 . . . . 0.0 112.856 175.244 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -28.17 108.3 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 128.911 2.884 . . . . 0.0 114.034 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 92.24 -2.14 74.39 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-N 113.976 -1.466 . . . . 0.0 114.764 175.281 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.473 ' CG ' HG12 ' A' ' 115' ' ' VAL . 2.4 m-85 -108.86 109.51 20.63 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 117.857 0.828 . . . . 0.0 109.823 -176.684 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.7 m -79.9 81.18 6.2 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 102.741 -3.059 . . . . 0.0 102.741 169.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.8 p -76.99 114.09 15.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 -178.492 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' PHE . . . . . 0.402 ' CE1' ' HG3' ' A' ' 114' ' ' GLU . 22.7 m-85 -77.64 -46.17 22.86 Favored 'General case' 0 CA--C 1.511 -0.551 0 C-N-CA 123.459 0.703 . . . . 0.0 111.297 -173.265 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.56 125.98 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 C-N-CA 117.122 -1.831 . . . . 0.0 109.96 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.7 m -92.48 58.39 3.16 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 102.375 -3.195 . . . . 0.0 102.375 168.476 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.449 0.0 OUTLIER 30.47 54.35 0.16 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 129.307 3.043 . . . . 0.0 112.907 -168.43 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.03 62.92 2.08 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 110.265 -3.152 . . . . 0.0 110.712 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 33.0 t70 3.92 -106.46 0.0 OUTLIER 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 130.098 3.359 . . . . 0.0 116.312 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -55.14 106.99 0.26 Allowed 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.084 1.754 . . . . 0.0 111.617 -173.018 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 2.5 m -124.14 157.1 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 126.811 2.044 . . . . 0.0 111.692 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.4 mm-40 -86.83 164.17 37.97 Favored Pre-proline 0 CA--C 1.535 0.379 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 172.289 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -70.25 154.21 65.98 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 N-CA-C 106.58 -2.123 . . . . 0.0 106.58 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.9 -15.15 8.62 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 119.586 -1.292 . . . . 0.0 114.072 178.466 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.29 125.96 25.66 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 106.606 -1.628 . . . . 0.0 106.606 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . 0.311 0.0 OUTLIER -66.74 119.95 12.68 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.102 0.865 . . . . 0.0 111.428 -177.268 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 77.4 mt -79.67 -41.5 26.74 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.3 mp -147.82 146.26 29.06 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.126 0.97 . . . . 0.0 111.059 -178.69 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG3' ' CE1' ' A' ' 99' ' ' PHE . 93.7 mt-10 -114.55 130.6 56.77 Favored 'General case' 0 N--CA 1.463 0.196 1 N-CA-C 99.203 -4.369 . . . . 0.0 99.203 166.539 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 115' ' ' VAL . . . . . 0.473 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -138.74 127.81 30.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.633 -164.307 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -75.71 65.41 1.87 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-O 121.137 0.494 . . . . 0.0 110.247 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.5 mt -50.42 -38.1 41.37 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 123.617 0.767 . . . . 0.0 111.796 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -54.21 -40.19 67.38 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 122.899 0.48 . . . . 0.0 112.162 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -91.06 -32.77 15.76 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 122.829 0.452 . . . . 0.0 111.34 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.27 -48.58 84.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 O-C-N 121.622 -0.673 . . . . 0.0 109.699 178.955 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.376 40.6 pttt -41.73 -58.38 3.23 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 116.498 2.036 . . . . 0.0 116.498 -177.237 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -59.42 -20.0 54.22 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.258 1.972 . . . . 0.0 113.137 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -95.61 9.11 41.37 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.773 0.829 . . . . 0.0 112.351 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 31.4 m -133.44 149.46 72.38 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 119.747 1.158 . . . . 0.0 109.9 177.559 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -72.24 -27.71 16.22 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.576 2.184 . . . . 0.0 111.187 179.433 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 5.4 m -160.2 138.31 10.03 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.282 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.0 tp -91.54 7.11 42.94 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.344 1.058 . . . . 0.0 111.524 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 20.3 mmt -50.3 116.13 1.74 Allowed 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.71 0.804 . . . . 0.0 109.226 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.435 HG23 ' HA ' ' A' ' 84' ' ' PHE . 50.1 m -108.59 84.38 2.42 Favored Pre-proline 0 N--CA 1.444 -0.744 0 C-N-CA 124.276 1.03 . . . . 0.0 108.317 -179.372 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.469 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 72.5 Cg_endo -72.41 142.29 36.72 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.44 2.094 . . . . 0.0 110.765 179.039 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 29.6 mt -131.15 128.52 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 104.459 -2.422 . . . . 0.0 104.459 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -125.59 152.55 32.56 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 C-N-CA 125.314 1.446 . . . . 0.0 107.863 -177.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -120.69 117.8 28.43 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 102.867 -3.012 . . . . 0.0 102.867 177.935 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.4 p -81.38 -67.89 0.74 Allowed 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.478 0.656 . . . . 0.0 110.353 -173.003 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.6 p30 -70.82 51.88 0.14 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 126.442 1.897 . . . . 0.0 113.034 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.7 mt -75.72 63.84 1.66 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.809 1.244 . . . . 0.0 108.874 177.392 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 24.32 49.96 0.01 OUTLIER 'General case' 0 C--N 1.346 0.445 0 C-N-CA 128.969 2.908 . . . . 0.0 112.051 -176.439 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 28.03 54.21 0.07 Allowed 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 128.649 2.78 . . . . 0.0 114.135 -174.894 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.9 0.05 OUTLIER Glycine 0 CA--C 1.528 0.873 0 CA-C-O 118.853 -0.97 . . . . 0.0 114.3 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 26.8 mt-10 -80.96 138.34 36.09 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.152 1.476 . . . . 0.0 109.701 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 7.7 p -111.08 139.39 46.48 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.223 1.409 . . . . 0.0 109.273 179.227 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.64 120.79 35.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.3 m -114.75 95.71 5.37 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.665 1.186 . . . . 0.0 111.308 -174.899 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 2.3 pt -63.32 124.75 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 176.655 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -96.08 -53.82 3.52 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.655 1.182 . . . . 0.0 108.376 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -86.22 74.0 10.11 Favored 'General case' 0 N--CA 1.456 -0.136 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.437 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 47.1 p -77.04 72.76 3.61 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 -179.364 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 179.87 -136.51 2.77 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -177.391 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.0 t -69.0 148.78 49.6 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.38 163.02 38.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 C-N-CA 125.222 1.409 . . . . 0.0 108.097 177.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -133.44 162.59 31.46 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.687 1.195 . . . . 0.0 109.039 -178.313 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 68.6 mtp180 -65.23 147.6 53.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.869 0.468 . . . . 0.0 110.509 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 25.8 tp10 57.65 12.97 1.76 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 126.847 2.059 . . . . 0.0 114.749 173.855 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -71.55 117.87 13.66 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -65.97 137.47 57.15 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 156' ' ' ASP . . . . . 0.462 ' C ' ' H ' ' A' ' 158' ' ' VAL . 27.9 t0 74.18 -111.81 0.04 OUTLIER 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 128.027 2.531 . . . . 0.0 108.448 -175.672 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.271 1.6 mp 70.86 -29.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 129.456 3.103 . . . . 0.0 110.866 -176.703 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.506 HG11 ' CE2' ' A' ' 43' ' ' PHE . 6.2 p -143.35 119.4 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 130.197 3.399 . . . . 0.0 105.003 173.148 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 28.0 tttm -111.9 139.3 47.5 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.767 0.427 . . . . 0.0 110.077 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.533 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.14 132.06 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 172.152 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -141.26 167.96 20.91 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 106.627 -1.619 . . . . 0.0 106.627 177.482 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 24.1 tptp . . . . . 0 C--N 1.33 -0.239 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.865 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.45 -0.462 0 CA-C-O 121.146 0.498 . . . . 0.0 109.691 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.7 m -77.9 84.16 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 O-C-N 121.857 -0.527 . . . . 0.0 111.747 -176.859 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.7 t -10.66 112.97 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 128.64 2.776 . . . . 0.0 113.796 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.42 -32.3 3.02 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 122.601 2.201 . . . . 0.0 115.781 -174.484 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.65 139.62 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 120.4 1.455 . . . . 0.0 109.933 -177.659 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 56.4 m -78.18 140.84 38.97 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 168.28 -159.82 33.15 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 -103.02 126.44 50.2 Favored 'General case' 0 N--CA 1.458 -0.072 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 176.262 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.2 tt -97.26 141.27 16.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 CA-C-N 118.57 0.623 . . . . 0.0 109.695 -179.569 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 25.5 m-70 -136.78 148.31 62.81 Favored Pre-proline 0 C--O 1.235 0.316 0 C-N-CA 124.701 1.2 . . . . 0.0 108.019 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.89 146.11 69.61 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.025 1.817 . . . . 0.0 110.176 176.151 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.7 tp -49.53 -34.88 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 C-N-CA 123.766 0.826 . . . . 0.0 113.117 -177.144 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 p -55.83 -26.78 48.25 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.863 0.865 . . . . 0.0 112.581 178.301 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -74.99 -13.05 60.47 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.829 0.852 . . . . 0.0 112.594 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.522 HG22 ' HB2' ' A' ' 44' ' ' ALA . 46.3 t -67.85 129.18 93.36 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.306 -0.871 . . . . 0.0 110.057 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -76.52 59.48 6.2 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 124.197 3.265 . . . . 0.0 111.849 -178.863 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -169.08 108.66 0.45 Allowed 'General case' 0 N--CA 1.465 0.296 0 O-C-N 121.351 -0.843 . . . . 0.0 110.104 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -24.25 -58.86 0.05 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.153 2.581 . . . . 0.0 114.98 -179.018 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 52.7 t -52.9 -50.24 44.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.613 0.765 . . . . 0.0 110.082 -178.06 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -71.49 -48.36 49.53 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.3 m -49.44 -43.11 44.59 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.968 0.907 . . . . 0.0 113.068 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.94 11.88 69.1 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-O 118.907 -0.94 . . . . 0.0 111.456 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt 71.55 -37.18 0.38 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.749 1.62 . . . . 0.0 113.358 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 30.8 -71.78 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 131.063 3.745 . . . . 0.0 116.538 178.786 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 37.8 tpp -78.4 -16.82 57.23 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.013 0.925 . . . . 0.0 112.145 -175.615 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.99 -133.93 2.11 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -146.26 163.31 35.89 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 173.832 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 164.87 -134.9 3.49 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.28 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -168.07 169.89 10.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 117.967 0.884 . . . . 0.0 111.546 -177.375 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.522 ' HB2' HG22 ' A' ' 29' ' ' VAL . . . -102.22 132.46 48.13 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 124.061 0.945 . . . . 0.0 109.25 179.12 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -109.39 135.62 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 103.102 -2.925 . . . . 0.0 103.102 168.474 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.1 tt -101.25 104.74 35.14 Favored Pre-proline 0 N--CA 1.447 -0.619 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 171.559 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.16 169.81 1.36 Allowed 'Trans proline' 0 C--N 1.348 0.543 1 C-N-CA 125.375 4.05 . . . . 0.0 116.278 -171.952 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 65.7 p -155.38 -54.94 0.09 Allowed 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 124.14 0.976 . . . . 0.0 111.279 176.542 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -57.84 -43.86 86.11 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -176.775 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.29 25.81 69.83 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -174.17 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -139.04 130.9 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 176.12 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.7 t -125.11 126.07 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 -175.605 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.1 m -105.71 162.84 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 C-N-CA 124.013 0.925 . . . . 0.0 111.075 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 15.9 m -67.46 126.39 92.49 Favored Pre-proline 0 CA--C 1.536 0.419 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.094 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -75.66 -16.72 18.63 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 124.125 3.216 . . . . 0.0 115.577 -174.724 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.18 163.97 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.067 0 CA-C-N 118.861 0.755 . . . . 0.0 109.183 -174.842 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 18.1 ttt85 -75.67 119.29 19.5 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 100.31 -3.959 . . . . 0.0 100.31 169.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.1 177.1 48.32 Favored Glycine 0 N--CA 1.436 -1.31 0 C-N-CA 116.562 -2.732 . . . . 0.0 115.089 -168.066 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.01 133.85 34.96 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.621 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 10.0 mm -79.22 100.03 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 172.272 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 46.7 tp -73.66 -56.5 4.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 -174.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.83 163.86 5.07 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 115.936 1.828 . . . . 0.0 115.936 174.912 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.5 m -144.18 118.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 176.672 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -40.12 153.8 0.2 Allowed Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 119.086 0.857 . . . . 0.0 111.8 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.02 -22.01 44.67 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.262 2.641 . . . . 0.0 113.545 178.851 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 17.8 p -77.1 -7.73 56.26 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.947 1.299 . . . . 0.0 110.939 177.041 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.09 25.17 10.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 127.106 2.162 . . . . 0.0 110.692 -174.44 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -93.94 -28.03 16.03 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.87 -178.23 4.18 Favored 'General case' 0 C--O 1.222 -0.365 0 CA-C-N 120.146 1.339 . . . . 0.0 109.768 -178.192 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.47 HG22 ' N ' ' A' ' 71' ' ' GLY 0.752 24.2 mm 137.73 -125.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.409 1 C-N-CA 132.95 4.5 . . . . 0.0 109.676 177.162 . . . . . . . . 4 3 . 1 . 014 nuclear build core ' A' A ' 71' ' ' GLY . . . . . 0.47 ' N ' HG22 ' A' ' 70' ' ' ILE . . . -177.04 174.69 47.26 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 117.172 1.629 . . . . 0.0 117.172 -177.773 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.3 mp -128.51 169.78 13.95 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 127.612 2.365 . . . . 0.0 110.137 -176.784 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 84.5 mt-30 -143.1 126.47 16.68 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 123.313 0.645 . . . . 0.0 111.049 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 m . . . . . 0 CA--C 1.533 0.296 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 174.791 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? . . . . . 0 CA--C 1.531 0.219 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -95.71 132.42 40.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.247 1.419 . . . . 0.0 107.803 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.75 113.59 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 C-N-CA 124.128 0.971 . . . . 0.0 111.538 -174.838 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.6 tt -85.56 137.41 32.89 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 106.006 -1.85 . . . . 0.0 106.006 171.007 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.1 mt -133.19 137.18 53.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.188 0.995 . . . . 0.0 109.574 179.166 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' HIS . . . . . 0.429 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 45.4 t-80 -126.16 120.51 30.28 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 171.469 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -68.92 122.18 18.12 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 175.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.37 -147.1 0.97 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-N 119.245 0.929 . . . . 0.0 113.119 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.7 mm -128.06 143.57 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.544 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.4 t0 49.31 44.13 23.37 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.418 1.087 . . . . 0.0 113.044 178.438 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.5 p -90.79 -19.05 23.9 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.655 1.582 . . . . 0.0 108.427 177.402 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.4 p -52.39 -46.22 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 174.84 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.8 m -61.63 -23.17 65.86 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.62 1.568 . . . . 0.0 112.736 176.427 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.54 -18.5 59.76 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.312 1.445 . . . . 0.0 108.836 177.312 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 59.9 mttm 47.95 33.89 3.7 Favored 'General case' 0 C--N 1.344 0.336 0 C-N-CA 125.831 1.652 . . . . 0.0 112.379 178.112 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.1 17.03 54.71 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.321 -1.266 . . . . 0.0 114.446 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.71 1.88 1.6 Allowed 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 120.232 2.016 . . . . 0.0 115.116 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -136.43 18.03 3.71 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 126.668 2.08 . . . . 0.0 110.193 175.996 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.61 ' CD1' HG12 ' A' ' 115' ' ' VAL . 22.4 m-30 -118.75 155.94 30.23 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.702 1.251 . . . . 0.0 110.638 -177.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.7 m -148.95 131.0 15.34 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.0 p -101.48 146.32 27.8 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 123.658 0.783 . . . . 0.0 112.173 -176.47 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -127.34 20.42 6.78 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.698 1.599 . . . . 0.0 113.753 -174.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.5 m -150.62 154.21 9.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.208 0 C-N-CA 123.861 0.864 . . . . 0.0 109.27 175.354 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.9 m -87.71 125.32 34.34 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 170.39 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.84 78.72 2.11 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 123.189 1.471 . . . . 0.0 109.851 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 179.06 -18.4 0.03 OUTLIER Glycine 0 CA--C 1.532 1.15 0 C-N-CA 128.447 2.927 . . . . 0.0 110.601 -176.768 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -53.41 120.09 5.64 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.168 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.14 115.4 28.96 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 127.709 2.404 . . . . 0.0 113.167 -170.161 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.372 20.8 m 52.03 74.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 117.154 2.279 . . . . 0.0 117.154 175.054 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -140.71 144.72 37.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 168.28 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -102.82 171.74 0.22 Allowed 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 123.733 2.955 . . . . 0.0 109.68 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 52.71 -8.82 0.01 OUTLIER Glycine 0 CA--C 1.536 1.399 0 N-CA-C 120.039 2.775 . . . . 0.0 120.039 170.109 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.2 tp60 -59.22 142.01 52.86 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 120.957 2.378 . . . . 0.0 109.264 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 16.6 ptpt -61.07 114.26 3.01 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 175.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 78.2 mt -79.53 -52.26 8.25 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 20.5 mt -141.41 159.34 42.43 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.979 0.511 . . . . 0.0 111.625 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -122.46 134.69 54.58 Favored 'General case' 0 CA--C 1.516 -0.363 1 N-CA-C 99.965 -4.087 . . . . 0.0 99.965 166.8 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 115' ' ' VAL . . . . . 0.61 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.1 OUTLIER -147.37 117.92 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -166.826 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -71.12 72.59 0.61 Allowed 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.799 1.639 . . . . 0.0 111.978 -175.352 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.6 mt -47.71 -42.18 24.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.493 178.618 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -54.21 -39.89 67.11 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.72 -33.52 19.98 Favored 'General case' 0 CA--C 1.529 0.141 0 CA-C-O 120.815 0.341 . . . . 0.0 111.125 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.98 -50.36 65.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 O-C-N 121.705 -0.622 . . . . 0.0 110.237 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.388 3.2 pptp? -42.59 -54.93 7.65 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -178.485 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.16 -24.2 76.13 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.422 2.082 . . . . 0.0 112.862 177.399 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -84.15 -42.77 15.66 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.806 0.73 . . . . 0.0 111.108 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.2 m -78.69 147.91 71.96 Favored Pre-proline 0 CA--C 1.535 0.398 0 O-C-N 122.025 -0.422 . . . . 0.0 111.769 -177.327 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -70.48 -27.28 23.24 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.617 2.211 . . . . 0.0 110.462 176.154 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.8 m -158.04 137.81 12.16 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.659 1.184 . . . . 0.0 108.218 179.08 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -87.1 2.96 48.1 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 124.313 1.045 . . . . 0.0 111.788 -178.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.3 mmt -55.04 103.92 0.1 Allowed 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.029 0.932 . . . . 0.0 110.346 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 53.3 m -90.05 105.32 10.89 Favored Pre-proline 0 N--CA 1.445 -0.69 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD2' ' HB3' ' A' ' 83' ' ' HIS . 1.7 Cg_endo -84.26 136.8 6.86 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.723 2.282 . . . . 0.0 108.521 -177.824 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.1 mt -118.88 120.22 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.817 0 N-CA-C 102.721 -3.066 . . . . 0.0 102.721 175.284 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.3 t -130.05 114.73 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.598 0 CA-C-O 122.368 1.08 . . . . 0.0 108.242 -177.389 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.473 ' CB ' HD21 ' A' ' 136' ' ' LEU . 4.0 m-85 -81.89 116.8 21.71 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 103.914 -2.624 . . . . 0.0 103.914 176.564 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 82.1 p -83.03 -83.47 0.14 Allowed 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.94 0.4 . . . . 0.0 110.319 -173.658 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 20.1 p30 -75.61 64.27 1.65 Allowed 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.542 0.737 . . . . 0.0 110.806 179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LEU . . . . . 0.473 HD21 ' CB ' ' A' ' 133' ' ' PHE . 17.0 mt -65.33 -29.76 70.54 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 124.288 1.035 . . . . 0.0 112.968 178.715 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 127.76 -132.7 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 1 C-N-CA 132.631 4.372 . . . . 0.0 105.587 -176.858 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -136.1 146.6 47.17 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 127.228 2.211 . . . . 0.0 108.471 177.569 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 59.33 37.53 92.06 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 -177.053 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.403 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 0.0 OUTLIER -97.35 82.42 3.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 C-N-CA 126.127 1.771 . . . . 0.0 107.569 -177.421 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 71.1 p -79.48 115.22 18.98 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.071 178.496 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -72.93 78.83 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -178.799 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -82.72 92.32 7.18 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.842 -176.448 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 39.9 mt -65.44 129.83 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.272 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 9.8 mmpt? -98.21 -51.03 4.14 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.508 1.523 . . . . 0.0 108.853 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -75.65 69.55 2.37 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.57 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 54.2 p -77.48 73.4 4.05 Favored 'General case' 0 CA--C 1.533 0.304 0 O-C-N 121.368 -0.832 . . . . 0.0 108.851 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 175.12 -124.61 1.02 Allowed Glycine 0 CA--C 1.52 0.401 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -177.449 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.2 t -94.15 151.0 19.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.377 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 2.6 m -131.72 148.85 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 125.031 1.332 . . . . 0.0 107.586 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -114.89 155.32 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 177.261 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.8 mtm105 -57.74 157.64 7.13 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 120.913 0.387 . . . . 0.0 110.483 177.823 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 70.25 -12.59 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.568 1.547 . . . . 0.0 115.055 175.485 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -63.17 131.51 48.71 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-N 119.989 1.268 . . . . 0.0 107.745 176.815 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -97.32 -36.37 10.42 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 115.51 1.671 . . . . 0.0 115.51 -173.616 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -87.62 21.4 2.58 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 127.658 2.383 . . . . 0.0 113.938 -176.321 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -71.29 -26.57 27.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.6 p -142.39 152.59 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 125.567 1.547 . . . . 0.0 108.643 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -128.24 116.51 19.98 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 173.747 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.89 87.0 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 102.554 -3.128 . . . . 0.0 102.554 172.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -85.88 148.33 25.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.461 1.104 . . . . 0.0 111.004 -173.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.8 mmtt . . . . . 0 N--CA 1.455 -0.19 0 C-N-CA 124.057 0.943 . . . . 0.0 109.604 178.07 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.41 ' CZ ' ' CE1' ' A' ' 133' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.455 -0.206 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 . . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 m -115.99 96.28 4.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.388 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 177.675 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 90.6 p -35.23 119.11 0.6 Allowed Pre-proline 0 CA--C 1.556 1.206 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -77.64 -28.39 5.37 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.677 2.251 . . . . 0.0 116.738 -171.428 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.29 146.07 28.52 Favored 'Isoleucine or valine' 0 C--N 1.341 0.239 0 CA-C-N 119.42 1.009 . . . . 0.0 110.96 -176.035 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.4 m -79.04 137.75 37.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 172.42 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 167.41 -150.35 16.76 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.193 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -118.18 129.18 55.36 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.152 0.981 . . . . 0.0 109.153 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 2.7 mt -79.95 137.27 21.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 176.262 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -131.16 144.58 54.09 Favored Pre-proline 0 N--CA 1.45 -0.429 0 C-N-CA 126.003 1.721 . . . . 0.0 106.732 175.992 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -58.22 143.55 96.84 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.407 2.071 . . . . 0.0 110.001 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.1 tp -52.38 -39.75 29.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.207 0.527 . . . . 0.0 111.24 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 p -56.0 -28.1 55.77 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.565 1.546 . . . . 0.0 112.902 177.834 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -79.68 -8.24 59.1 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.414 0.686 . . . . 0.0 112.826 -178.382 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.472 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 58.8 t -69.71 123.43 88.56 Favored Pre-proline 0 CA--C 1.539 0.539 0 CA-C-O 117.82 -1.086 . . . . 0.0 111.693 -177.132 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 29' ' ' VAL . 50.0 Cg_exo -61.43 61.55 0.11 Allowed 'Trans proline' 0 CA--C 1.549 1.233 0 C-N-CA 124.971 3.781 . . . . 0.0 115.137 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -168.59 131.72 1.44 Allowed 'General case' 0 CA--C 1.528 0.12 0 O-C-N 120.565 -1.334 . . . . 0.0 108.447 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -53.89 -51.09 64.8 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 113.884 1.068 . . . . 0.0 113.884 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.8 t -54.71 -55.96 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 123.22 0.608 . . . . 0.0 109.603 -178.119 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -64.06 -54.09 39.55 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.819 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 79.3 p -58.05 -34.14 69.77 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 113.517 0.932 . . . . 0.0 113.517 -178.333 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -89.64 10.73 72.52 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-O 118.173 -1.348 . . . . 0.0 110.854 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 72.18 -40.77 0.48 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 125.873 1.669 . . . . 0.0 112.793 -177.401 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 14.9 tpt 25.43 -68.87 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 130.907 3.683 . . . . 0.0 117.144 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.7 tpp -78.96 -20.95 47.95 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.505 1.122 . . . . 0.0 113.53 -175.214 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 171.45 -145.36 8.77 Favored Glycine 0 C--N 1.337 0.617 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 -178.293 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -136.18 160.77 37.67 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.219 1.01 . . . . 0.0 108.559 174.569 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' GLY . . . . . 0.421 ' HA2' HG21 ' A' ' 142' ' ' VAL . . . 165.28 -130.31 2.14 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -178.42 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' PHE . . . . . 0.493 ' CE2' HG21 ' A' ' 158' ' ' VAL . 8.5 p90 -166.39 173.62 9.79 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 117.822 0.811 . . . . 0.0 110.485 -175.805 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.472 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -113.25 140.71 47.74 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 178.193 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -111.47 136.23 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.603 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 169.574 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.6 105.63 34.98 Favored Pre-proline 0 N--CA 1.444 -0.759 0 N-CA-C 100.64 -3.837 . . . . 0.0 100.64 170.304 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -59.56 172.79 1.85 Allowed 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 124.548 3.499 . . . . 0.0 115.482 -173.095 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 67.3 p -154.34 -64.37 0.13 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 123.895 0.878 . . . . 0.0 110.504 177.563 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -51.4 -46.87 63.02 Favored 'General case' 0 C--N 1.335 -0.06 0 C-N-CA 125.859 1.664 . . . . 0.0 114.913 -176.666 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.31 28.93 60.96 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.811 -1.315 . . . . 0.0 109.811 -173.617 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.7 mt -139.58 120.65 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 102.664 -3.087 . . . . 0.0 102.664 177.357 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 45.0 t -126.12 123.74 64.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 C-N-CA 124.26 1.024 . . . . 0.0 109.764 -171.637 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.5 m -109.6 169.66 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.187 0.995 . . . . 0.0 109.036 176.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.1 p -63.7 148.66 94.04 Favored Pre-proline 0 CA--C 1.537 0.48 0 O-C-N 121.331 -0.856 . . . . 0.0 111.071 -177.755 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -87.64 -16.14 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 124.29 3.327 . . . . 0.0 112.707 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.1 m -145.32 166.83 10.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 123.891 0.876 . . . . 0.0 110.052 -176.818 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.1 mtt-85 -78.46 119.54 21.92 Favored 'General case' 0 N--CA 1.454 -0.253 1 N-CA-C 98.887 -4.486 . . . . 0.0 98.887 168.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 171.37 -177.4 44.27 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 115.078 -3.439 . . . . 0.0 115.587 -167.547 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.73 135.51 41.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 126.011 1.724 . . . . 0.0 110.451 -177.888 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.4 mm -79.07 114.9 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 103.537 -2.764 . . . . 0.0 103.537 170.037 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 34.3 tp -77.8 -53.41 7.53 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -176.29 155.79 1.52 Allowed 'General case' 0 C--O 1.228 -0.033 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.5 m -135.32 120.73 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.417 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -43.77 149.75 0.61 Allowed Pre-proline 0 CA--C 1.539 0.538 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -49.65 -28.16 16.46 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 124.077 3.184 . . . . 0.0 113.861 177.08 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 24.7 p -78.02 1.22 21.6 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.457 0.703 . . . . 0.0 111.969 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 46.84 62.35 2.4 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 127.323 2.249 . . . . 0.0 113.125 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 15.4 p-80 -146.93 -38.82 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 122.307 -0.246 . . . . 0.0 111.619 176.147 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -128.19 177.32 7.0 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.694 24.5 mm 116.0 -134.38 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.306 0 C-N-CA 131.654 3.982 . . . . 0.0 108.342 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -171.88 179.71 43.38 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 118.637 2.215 . . . . 0.0 118.637 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.7 mp -126.53 173.07 9.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 127.771 2.428 . . . . 0.0 109.073 -177.218 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -145.09 137.84 26.24 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 176.961 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 84.1 p . . . . . 0 CA--C 1.535 0.396 0 CA-C-O 121.154 0.502 . . . . 0.0 109.812 178.86 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.2 mtp-105 . . . . . 0 N--CA 1.457 -0.106 0 CA-C-O 121.456 0.646 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -77.95 125.57 29.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.06 108.37 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 C-N-CA 124.722 1.209 . . . . 0.0 109.597 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -85.01 134.48 34.22 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 126.083 1.753 . . . . 0.0 106.732 174.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.0 mt -128.01 153.79 37.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 C-N-CA 125.339 1.455 . . . . 0.0 110.106 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -151.25 76.46 1.22 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 125.788 1.635 . . . . 0.0 109.191 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 84' ' ' PHE . . . . . 0.415 ' HA ' HG23 ' A' ' 129' ' ' THR . 1.7 t80 -50.86 104.07 0.07 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.186 0.594 . . . . 0.0 112.592 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.62 173.27 5.39 Favored Glycine 0 CA--C 1.533 1.189 0 C-N-CA 124.685 1.136 . . . . 0.0 112.745 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.1 mm -108.72 130.93 60.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 124.484 1.114 . . . . 0.0 108.932 -178.301 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 48.89 43.1 21.34 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.965 1.306 . . . . 0.0 110.917 -178.62 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.6 -72.6 0.61 Allowed 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 102.16 -3.274 . . . . 0.0 102.16 174.638 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . 0.33 3.3 p 44.89 49.64 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 104.065 -2.568 . . . . 0.0 104.065 -173.507 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' SER . . . . . 0.441 ' HB3' ' CD1' ' A' ' 96' ' ' PHE . 19.3 m 12.1 45.83 0.0 OUTLIER 'General case' 0 C--N 1.349 0.565 1 C-N-CA 134.077 4.951 . . . . 0.0 114.178 -164.679 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 91' ' ' LEU . 2.0 mt 37.48 50.16 1.07 Allowed 'General case' 0 N--CA 1.434 -1.235 0 C-N-CA 130.492 3.517 . . . . 0.0 107.139 178.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 76.43 53.52 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 128.798 2.839 . . . . 0.0 111.36 -176.029 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.04 -64.12 1.61 Allowed Glycine 0 CA--C 1.535 1.296 0 C-N-CA 124.387 0.994 . . . . 0.0 111.713 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 22.62 -98.22 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 127.694 2.397 . . . . 0.0 115.873 178.471 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -59.89 -1.68 1.53 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 127.302 2.382 . . . . 0.0 115.859 -176.59 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' A' ' 90' ' ' SER . 4.6 m-85 -103.75 97.54 7.54 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 119.001 1.4 . . . . 0.0 113.145 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.9 m -80.05 99.99 7.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 105.785 -1.931 . . . . 0.0 105.785 173.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 29.0 p -83.45 135.37 34.7 Favored 'General case' 0 N--CA 1.451 -0.414 0 O-C-N 121.556 -0.715 . . . . 0.0 110.945 -178.525 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -103.79 -42.12 5.71 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.058 1.343 . . . . 0.0 111.927 -177.756 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.28 136.0 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.736 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 58.7 m -87.83 66.43 8.76 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 170.646 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.258 1.6 pm0 -24.72 96.69 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 129.074 2.95 . . . . 0.0 112.999 -173.162 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 154.06 -17.96 0.63 Allowed Glycine 0 CA--C 1.537 1.466 0 C-N-CA 128.157 2.789 . . . . 0.0 109.744 -175.287 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -42.87 107.74 0.09 Allowed 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 129.612 3.165 . . . . 0.0 107.821 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.0 119.3 30.24 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 127.496 2.318 . . . . 0.0 114.077 -172.954 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.336 34.4 m 48.02 66.82 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 126.653 1.981 . . . . 0.0 115.395 177.461 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.97 133.79 25.19 Favored Pre-proline 0 N--CA 1.454 -0.275 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 171.731 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -98.4 147.15 0.65 Allowed 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 123.346 2.697 . . . . 0.0 110.472 -177.189 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 58.02 18.37 33.54 Favored Glycine 0 CA--C 1.528 0.894 0 O-C-N 121.724 -0.61 . . . . 0.0 113.551 177.02 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -61.96 139.51 58.39 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.709 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -66.06 116.88 7.64 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.916 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 49.6 mt -81.04 -54.19 5.77 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.7 mt -149.08 157.45 43.41 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.34 0.656 . . . . 0.0 111.856 -172.437 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -124.75 129.42 50.44 Favored 'General case' 0 CA--C 1.519 -0.234 1 N-CA-C 98.738 -4.541 . . . . 0.0 98.738 165.858 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 115' ' ' VAL . . . . . 0.408 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -139.22 127.91 28.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -164.101 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -75.01 67.41 1.71 Allowed 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.045 0.938 . . . . 0.0 110.48 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 93.1 mt -52.05 -45.85 64.85 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.194 179.175 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -48.98 -45.3 41.94 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 124.231 1.012 . . . . 0.0 112.611 -178.581 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.84 -33.91 24.77 Favored 'General case' 0 CA--C 1.527 0.092 0 CA-C-N 118.184 0.447 . . . . 0.0 111.6 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.08 -58.49 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 O-C-N 121.937 -0.477 . . . . 0.0 109.806 178.903 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 2.5 pptp? -38.16 -57.0 1.87 Allowed Pre-proline 0 CA--C 1.542 0.658 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 -176.664 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -60.88 -18.25 55.74 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.427 2.085 . . . . 0.0 113.572 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -104.55 10.66 34.95 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 118.386 -0.816 . . . . 0.0 112.797 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 26.9 m -137.57 151.97 71.97 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 119.884 1.22 . . . . 0.0 110.595 -178.887 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -64.45 -36.22 45.21 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.086 2.524 . . . . 0.0 113.202 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.6 t -156.58 153.0 27.95 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 119.059 0.845 . . . . 0.0 110.556 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.4 tp -100.62 -1.77 34.5 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.549 1.54 . . . . 0.0 110.565 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -53.22 116.97 2.68 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 118.311 0.505 . . . . 0.0 109.643 179.133 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 129' ' ' THR . . . . . 0.415 HG23 ' HA ' ' A' ' 84' ' ' PHE . 52.7 m -107.99 118.81 51.85 Favored Pre-proline 0 N--CA 1.446 -0.646 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.391 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -87.05 150.43 8.23 Favored 'Trans proline' 0 N--CA 1.442 -1.525 0 C-N-CA 122.056 1.838 . . . . 0.0 107.75 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.8 mt -132.59 113.93 21.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 101.586 -3.487 . . . . 0.0 101.586 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.94 122.07 51.18 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.012 -173.334 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 133' ' ' PHE . . . . . 0.41 ' CE1' ' CZ ' ' A' ' 15' ' ' PHE . 4.7 m-85 -86.29 112.3 21.27 Favored 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 177.54 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.0 p -74.41 -76.06 0.15 Allowed 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 121.853 0.835 . . . . 0.0 109.401 -175.729 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 6.7 p-10 -76.78 69.4 3.13 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.707 0.803 . . . . 0.0 110.771 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.3 mt -68.86 169.21 11.94 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 171.076 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.72 -139.07 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.482 -0.761 . . . . 0.0 111.128 -178.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -67.06 81.12 0.12 Allowed 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.683 0.793 . . . . 0.0 112.417 -176.493 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 47.51 38.02 13.6 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.76 1.171 . . . . 0.0 111.068 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.572 ' HB3' HG23 ' A' ' 160' ' ' ILE . 70.0 mm-40 -55.23 119.25 5.24 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 111.517 0.192 . . . . 0.0 111.517 -176.907 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -78.02 132.09 37.64 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 172.504 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 142' ' ' VAL . . . . . 0.421 HG21 ' HA2' ' A' ' 42' ' ' GLY 0.266 1.0 OUTLIER -84.99 88.61 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 -176.51 . . . . . . . . 4 4 . 1 . 015 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.8 t -78.4 83.99 4.59 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -173.183 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' ILE . . . . . 0.595 HG23 HG22 ' A' ' 158' ' ' VAL . 1.8 mt -62.26 118.92 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 124.595 1.158 . . . . 0.0 108.116 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -97.77 -55.25 2.86 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.974 1.31 . . . . 0.0 108.938 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.71 66.34 1.45 Allowed 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.319 0.648 . . . . 0.0 111.587 -177.396 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 35.1 m -78.61 65.44 3.88 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.556 0.742 . . . . 0.0 109.011 178.814 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.38 -145.78 6.44 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -177.99 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 12.3 t -76.2 150.74 37.04 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 117.325 0.563 . . . . 0.0 110.646 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.68 156.02 28.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.087 1.355 . . . . 0.0 108.463 178.168 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -109.45 -171.43 1.84 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.424 1.49 . . . . 0.0 108.489 175.988 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 52.5 mtm-85 -85.65 157.69 20.27 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.971 0.805 . . . . 0.0 110.354 177.558 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 45.63 38.91 4.42 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.621 1.969 . . . . 0.0 114.432 177.662 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -76.09 134.07 40.13 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 104.8 -2.296 . . . . 0.0 104.8 172.488 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -108.99 35.86 3.09 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.733 0.813 . . . . 0.0 111.759 -177.809 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -172.6 94.61 0.13 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.198 1.799 . . . . 0.0 108.448 177.423 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.44 ' N ' HD13 ' A' ' 157' ' ' ILE . 0.2 OUTLIER -150.97 -37.73 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -175.524 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.595 HG22 HG23 ' A' ' 144' ' ' ILE . 57.8 t -151.5 104.29 0.28 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.058 0 CA-C-N 119.397 0.999 . . . . 0.0 108.594 -177.419 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.2 mttm -90.13 124.49 34.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -176.574 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.572 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.5 mp -78.86 107.77 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 104.378 -2.453 . . . . 0.0 104.378 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 24.9 pt-20 -153.73 -175.35 5.33 Favored 'General case' 0 C--O 1.227 -0.127 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -175.787 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 C--N 1.332 -0.185 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.261 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.451 -0.398 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -78.89 85.15 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.114 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.202 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.3 t -10.59 109.39 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.814 0 C-N-CA 127.839 2.456 . . . . 0.0 113.211 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -68.81 -28.15 30.46 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.595 2.197 . . . . 0.0 116.449 -173.318 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -149.0 145.93 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.918 1.235 . . . . 0.0 110.232 -177.322 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.9 m -79.07 136.68 37.23 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.217 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.0 -150.11 14.2 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tp10 -117.13 123.21 46.19 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.785 1.634 . . . . 0.0 108.71 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 10.1 mt -85.07 125.66 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -117.92 142.8 31.44 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 173.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -55.15 152.65 29.8 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 121.814 1.676 . . . . 0.0 109.515 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.3 tp -57.06 -49.01 80.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.1 m -67.86 85.41 0.22 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.732 1.613 . . . . 0.0 108.604 176.478 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.5 t70 172.95 -35.66 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 127.373 2.269 . . . . 0.0 108.81 -176.046 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 96.5 t -52.86 138.29 44.15 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 124.643 1.177 . . . . 0.0 110.558 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -72.95 59.26 3.54 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 124.127 3.218 . . . . 0.0 111.542 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -171.74 130.81 0.68 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 124.923 1.289 . . . . 0.0 108.592 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -62.03 -48.42 80.37 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 124.322 1.049 . . . . 0.0 113.061 -177.261 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.6 t -50.24 -55.23 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 34' ' ' PHE . . . . . 0.416 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 8.2 m-85 -65.06 -58.79 5.15 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.397 -179.5 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -58.08 -27.99 64.17 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 115.244 1.572 . . . . 0.0 115.244 -177.301 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -95.36 10.12 69.38 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-O 117.899 -1.501 . . . . 0.0 110.646 -178.981 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 61.3 mttm 74.42 -46.25 0.61 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.574 1.55 . . . . 0.0 111.928 -178.023 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 36.9 ttm 39.29 -64.92 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 130.533 3.533 . . . . 0.0 117.272 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 29.9 ttp -109.34 -10.28 14.93 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.712 1.205 . . . . 0.0 113.452 -176.359 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -171.83 -165.55 29.18 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-N 119.464 1.029 . . . . 0.0 110.796 -179.023 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -131.72 156.58 45.67 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 176.6 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 168.45 -137.07 4.38 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.28 166.13 14.86 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 118.048 0.924 . . . . 0.0 111.214 -175.94 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' ALA . . . . . 0.416 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -103.31 113.29 26.66 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 123.043 0.537 . . . . 0.0 111.485 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -88.65 129.21 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 103.887 -2.634 . . . . 0.0 103.887 169.765 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.0 tt -96.03 109.2 45.6 Favored Pre-proline 0 N--CA 1.448 -0.542 1 N-CA-C 98.34 -4.689 . . . . 0.0 98.34 168.526 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.6 161.54 24.92 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.501 2.801 . . . . 0.0 115.336 -167.837 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.4 p -136.9 -41.54 0.59 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.588 1.155 . . . . 0.0 111.981 177.473 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.99 -44.36 91.62 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.37 23.8 77.19 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 -174.643 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.5 mt -139.99 111.97 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 177.681 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 47.0 t -100.39 122.71 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.883 1.273 . . . . 0.0 108.673 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.39 156.04 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 123.389 0.676 . . . . 0.0 110.349 177.912 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 17.4 m -63.88 122.11 75.06 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.81 -21.52 12.52 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 124.923 3.749 . . . . 0.0 114.662 -176.269 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -136.48 173.09 14.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 124.94 1.296 . . . . 0.0 108.842 -175.672 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.29 90.59 3.76 Favored 'General case' 0 CA--C 1.518 -0.275 1 N-CA-C 98.228 -4.73 . . . . 0.0 98.228 168.858 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -90.26 174.52 40.29 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 117.381 1.712 . . . . 0.0 117.381 -166.632 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.88 134.09 21.68 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 101.475 -3.528 . . . . 0.0 101.475 170.471 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ILE . . . . . 0.433 HG21 ' HG3' ' A' ' 102' ' ' GLU . 0.2 OUTLIER -88.79 127.3 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -169.791 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.402 ' O ' ' CB ' ' A' ' 62' ' ' ASN . 78.5 mt -79.74 -29.66 40.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 169.161 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 59.1 t30 125.79 -176.53 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 129.587 3.155 . . . . 0.0 109.514 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.98 122.24 51.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 C-N-CA 127.452 2.301 . . . . 0.0 106.353 172.849 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -44.77 157.92 0.3 Allowed Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 124.315 1.046 . . . . 0.0 111.316 175.361 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -51.4 -29.47 31.05 Favored 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.381 2.721 . . . . 0.0 113.414 174.186 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.6 p -76.94 -5.98 50.69 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.429 1.092 . . . . 0.0 111.646 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? 60.53 16.4 6.44 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.334 1.854 . . . . 0.0 115.007 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 16.1 p-80 -98.03 -33.77 11.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.562 0.345 . . . . 0.0 111.654 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -149.17 -177.58 5.9 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-N 118.186 0.448 . . . . 0.0 111.929 -173.575 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ILE . . . . . 0.432 HG22 ' H ' ' A' ' 71' ' ' GLY 0.541 24.4 mm 131.82 -123.39 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.453 1 C-N-CA 136.273 5.829 . . . . 0.0 102.359 -177.199 . . . . . . . . 4 3 . 1 . 016 nuclear build core ' A' A ' 71' ' ' GLY . . . . . 0.432 ' H ' HG22 ' A' ' 70' ' ' ILE . . . -178.4 -173.23 43.6 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 116.751 -2.643 . . . . 0.0 119.382 177.05 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.4 mp -137.32 170.83 15.42 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 127.208 2.203 . . . . 0.0 108.488 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -147.83 157.26 43.44 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 172.366 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 81.3 p . . . . . 0 C--O 1.225 -0.235 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 174.27 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.6 mmt85 . . . . . 0 N--CA 1.456 -0.144 0 CA-C-O 121.353 0.597 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -80.37 110.29 15.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 177.728 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.94 127.28 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 124.063 0.945 . . . . 0.0 111.464 -174.001 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 33.5 tp -103.23 135.07 45.57 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 104.375 -2.454 . . . . 0.0 104.375 170.585 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.4 mt -120.43 155.37 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 C-N-CA 124.965 1.306 . . . . 0.0 107.589 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -149.37 81.95 1.41 Allowed 'General case' 0 C--O 1.224 -0.281 0 N-CA-C 104.96 -2.237 . . . . 0.0 104.96 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -63.12 97.33 0.11 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -176.638 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 69.27 168.33 5.79 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.226 0.917 . . . . 0.0 111.586 -175.816 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 15.8 mm -100.26 135.89 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 124.623 1.169 . . . . 0.0 109.094 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 57.24 23.98 9.36 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.943 1.297 . . . . 0.0 112.732 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 p -76.93 -32.97 57.74 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.657 1.583 . . . . 0.0 107.567 175.397 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.8 p -56.71 -46.16 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-N 113.76 -1.563 . . . . 0.0 107.546 170.702 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.73 -42.28 98.75 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 124.187 0.995 . . . . 0.0 108.546 176.934 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -73.61 12.27 0.67 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 125.525 1.53 . . . . 0.0 111.682 175.593 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 48.3 tttp 45.68 35.06 1.97 Allowed 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.869 2.067 . . . . 0.0 113.258 177.764 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 55.39 28.44 50.57 Favored Glycine 0 CA--C 1.535 1.289 0 O-C-N 121.751 -0.593 . . . . 0.0 112.751 -179.116 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -70.97 91.56 0.88 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 118.744 1.272 . . . . 0.0 109.769 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 132.61 -1.05 4.72 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 126.435 1.969 . . . . 0.0 111.707 -178.056 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 96' ' ' PHE . . . . . 0.459 ' CD1' HG12 ' A' ' 115' ' ' VAL . 16.5 m-30 -96.52 131.91 42.64 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 124.507 1.123 . . . . 0.0 109.675 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 10.9 m -120.55 113.96 21.05 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 126.597 1.959 . . . . 0.0 107.316 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 44.9 p -93.38 126.49 38.54 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 121.056 -1.028 . . . . 0.0 111.213 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -90.26 -26.73 19.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 123.932 0.893 . . . . 0.0 108.998 176.502 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' VAL . . . . . 0.624 ' HB ' ' CG ' ' A' ' 102' ' ' GLU . 3.1 m -52.63 126.83 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-O 121.192 0.52 . . . . 0.0 110.995 179.213 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 24.9 m -115.51 -52.34 2.65 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 127.456 2.302 . . . . 0.0 105.255 175.763 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' GLU . . . . . 0.624 ' CG ' ' HB ' ' A' ' 100' ' ' VAL . 0.1 OUTLIER 50.77 107.98 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 120.969 3.692 . . . . 0.0 120.969 166.26 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.23 55.35 2.12 Favored Glycine 0 CA--C 1.53 1.0 1 N-CA-C 100.996 -4.842 . . . . 0.0 100.996 164.808 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.253 7.4 p-10 6.77 70.36 0.0 OUTLIER 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 118.569 2.803 . . . . 0.0 118.569 -169.255 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -169.58 137.04 1.72 Allowed 'General case' 0 N--CA 1.43 -1.464 1 C-N-CA 132.916 4.486 . . . . 0.0 105.655 173.309 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -157.27 158.19 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 125.681 1.592 . . . . 0.0 108.692 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -89.04 163.42 34.61 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 106.425 -1.695 . . . . 0.0 106.425 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -70.71 169.54 19.87 Favored 'Trans proline' 0 N--CA 1.451 -0.978 0 N-CA-C 108.259 -1.477 . . . . 0.0 108.259 178.329 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 73.45 -27.77 0.86 Allowed Glycine 0 CA--C 1.534 1.227 0 O-C-N 121.02 -1.05 . . . . 0.0 115.38 175.438 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.4 tp-100 -58.07 139.88 53.75 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 119.527 1.664 . . . . 0.0 109.8 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -70.16 128.3 35.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.875 0.47 . . . . 0.0 111.544 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 112' ' ' LEU . . . . . 0.505 HD22 HG12 ' A' ' 100' ' ' VAL . 72.1 mt -105.04 -41.49 5.57 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.937 0.895 . . . . 0.0 111.807 -178.317 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 48.5 mt -143.99 146.52 32.96 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 123.588 0.755 . . . . 0.0 109.371 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -118.06 133.24 56.09 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 100.683 -3.821 . . . . 0.0 100.683 167.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' VAL . . . . . 0.459 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -143.15 117.47 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -166.731 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 62.9 t0 -67.69 74.11 0.17 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.408 1.483 . . . . 0.0 112.395 -175.273 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 75.8 mt -50.43 -47.49 56.64 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.687 178.242 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -49.4 -49.07 46.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.588 1.155 . . . . 0.0 112.684 -177.323 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.25 -34.36 25.85 Favored 'General case' 0 C--N 1.333 -0.121 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 49.4 t -65.16 -53.65 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 O-C-N 121.697 -0.627 . . . . 0.0 110.541 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.328 19.1 pttp -42.92 -54.64 8.54 Favored Pre-proline 0 CA--C 1.54 0.595 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -61.12 -24.07 78.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.49 2.127 . . . . 0.0 112.716 178.248 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 57.3 m-80 -90.18 -48.24 7.29 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 118.46 0.573 . . . . 0.0 111.885 -177.268 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.77 147.93 56.37 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -174.256 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_exo -51.61 -41.51 60.76 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 124.064 3.176 . . . . 0.0 114.804 179.169 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.2 m -158.81 142.7 15.31 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.825 -0.547 . . . . 0.0 110.235 -176.9 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.2 tp -88.09 -4.6 58.75 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 124.878 1.271 . . . . 0.0 112.293 -178.392 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.1 mmt -46.93 118.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.028 0.931 . . . . 0.0 109.802 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.4 m -112.1 94.23 24.88 Favored Pre-proline 0 N--CA 1.448 -0.534 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' PRO . . . . . 0.416 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 74.1 Cg_endo -76.5 111.06 3.18 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 123.594 2.863 . . . . 0.0 108.74 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mt -94.28 119.06 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 N-CA-C 102.718 -3.068 . . . . 0.0 102.718 174.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.2 t -126.56 129.06 71.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -97.39 114.61 26.46 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 104.343 -2.465 . . . . 0.0 104.343 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 44.8 p -80.28 -75.39 0.27 Allowed 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . 0.259 24.6 p30 -74.06 69.68 1.5 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-O 122.204 1.002 . . . . 0.0 111.207 179.156 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 13.2 mt -78.21 62.2 2.87 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 126.174 1.79 . . . . 0.0 107.537 175.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.53 -109.63 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.578 2.351 . . . . 0.0 112.545 -177.852 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -80.33 58.64 3.16 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 125.146 1.379 . . . . 0.0 112.446 -178.265 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 46.19 35.67 6.82 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 124.259 0.933 . . . . 0.0 110.959 -178.882 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 140' ' ' GLU . . . . . 0.671 ' HB3' HG23 ' A' ' 160' ' ' ILE . 38.9 mt-10 -49.01 126.91 13.32 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.349 0.659 . . . . 0.0 112.014 -175.731 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 31.8 p -86.54 133.35 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.256 0.3 OUTLIER -85.58 87.48 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 CA-C-O 122.407 1.099 . . . . 0.0 109.936 -176.009 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.5 m -79.33 84.48 5.25 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 120.646 -1.284 . . . . 0.0 110.85 -177.657 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 144' ' ' ILE . . . . . 0.521 HG23 HG22 ' A' ' 158' ' ' VAL . 6.5 mt -60.66 130.67 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 124.287 1.035 . . . . 0.0 108.656 178.418 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.33 -52.78 2.75 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.769 0.828 . . . . 0.0 108.767 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -78.95 64.64 3.94 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 122.892 0.477 . . . . 0.0 109.933 179.324 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 45.0 m -78.98 66.05 4.32 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -171.45 -148.79 6.23 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 107.809 -2.116 . . . . 0.0 107.809 -177.375 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 15.8 t -78.14 148.11 34.28 Favored 'General case' 0 N--CA 1.456 -0.136 0 CA-C-N 117.658 0.729 . . . . 0.0 110.735 178.195 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.63 160.59 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 124.864 1.266 . . . . 0.0 108.663 178.113 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -114.78 157.79 22.75 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.719 1.208 . . . . 0.0 108.592 176.66 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 2.2 ptm180 -66.43 154.11 41.05 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 53.15 59.98 4.06 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.537 1.535 . . . . 0.0 112.06 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 16.9 mm-40 -131.07 151.02 51.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 126.821 2.048 . . . . 0.0 105.751 175.712 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.47 166.0 14.19 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.2 1.4 . . . . 0.0 111.05 -177.338 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 16.9 t70 70.63 -7.48 1.04 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 117.051 2.241 . . . . 0.0 117.051 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 157' ' ' ILE . . . . . 0.443 ' CD1' ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -53.06 -31.87 17.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 C-N-CA 127.213 2.205 . . . . 0.0 112.501 177.116 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 158' ' ' VAL . . . . . 0.521 HG22 HG23 ' A' ' 144' ' ' ILE . 62.9 t -145.47 133.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.208 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -108.75 120.53 42.75 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.414 0.686 . . . . 0.0 109.828 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 160' ' ' ILE . . . . . 0.671 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.3 mp -79.1 97.22 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.204 -2.146 . . . . 0.0 105.204 173.404 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -108.7 -155.26 0.55 Allowed 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 125.369 1.467 . . . . 0.0 107.963 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 35.5 mtmm . . . . . 0 C--N 1.333 -0.131 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 176.977 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 16.3 tpt . . . . . 0 N--CA 1.453 -0.277 0 CA-C-O 121.221 0.534 . . . . 0.0 109.728 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 27.3 mm -75.4 73.7 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.1 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -65.56 79.94 0.06 Allowed 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.523 1.129 . . . . 0.0 111.662 -178.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 14.3 mp0 -49.02 -44.8 73.31 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 124.238 1.015 . . . . 0.0 113.652 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -66.4 40.4 0.15 Allowed 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 123.886 3.057 . . . . 0.0 116.306 -177.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.1 tt -79.22 63.55 3.89 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 120.44 -1.413 . . . . 0.0 107.26 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 40.6 mt-30 -78.3 -50.68 11.37 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 125.135 1.374 . . . . 0.0 112.035 -175.608 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 56.5 t30 72.18 154.12 0.14 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 125.584 1.554 . . . . 0.0 110.582 -176.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -70.45 -62.84 1.24 Allowed 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 177.736 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.9 tp -79.95 52.13 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-O 121.705 0.764 . . . . 0.0 109.392 178.089 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -78.48 50.5 3.52 Favored Glycine 0 CA--C 1.529 0.917 0 O-C-N 120.928 -1.108 . . . . 0.0 111.794 -179.278 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -118.5 82.38 1.84 Allowed 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 18.5 mp0 -76.53 66.81 2.6 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 177.445 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.8 t 46.85 44.84 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.765 2.026 . . . . 0.0 108.86 -179.151 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -132.63 83.29 2.06 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 114.561 -1.199 . . . . 0.0 112.705 -175.925 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.0 89.92 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 172.165 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t -13.36 116.17 0.04 OUTLIER Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 126.965 2.106 . . . . 0.0 115.377 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -71.38 -34.88 9.07 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.995 2.463 . . . . 0.0 117.37 -174.371 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -143.3 162.73 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.819 1.191 . . . . 0.0 111.371 -175.228 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -101.52 135.65 42.68 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 174.785 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 161.96 -136.33 4.32 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -127.79 124.63 38.12 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 124.941 1.297 . . . . 0.0 110.34 -178.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 45.9 mt -80.19 145.43 9.17 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.016 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -143.95 141.67 18.94 Favored Pre-proline 0 N--CA 1.452 -0.347 0 C-N-CA 125.08 1.352 . . . . 0.0 107.903 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -54.94 145.33 63.26 Favored 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 122.163 1.908 . . . . 0.0 111.183 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.67 -39.19 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.853 1.261 . . . . 0.0 112.316 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 p -53.48 -31.61 46.57 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.362 1.465 . . . . 0.0 112.442 179.143 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -69.78 -14.32 62.71 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.898 0.879 . . . . 0.0 112.852 -178.593 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -69.87 130.26 90.26 Favored Pre-proline 0 CA--C 1.539 0.53 0 O-C-N 121.373 -0.829 . . . . 0.0 111.057 -175.151 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -76.38 62.6 6.99 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.416 2.744 . . . . 0.0 111.374 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.21 132.01 2.88 Favored 'General case' 0 C--O 1.226 -0.138 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 22.0 mp0 -54.9 -53.05 60.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.521 1.128 . . . . 0.0 112.675 -176.451 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.0 t -51.68 -57.0 3.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 123.299 0.639 . . . . 0.0 110.317 -177.675 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -64.95 -53.54 44.73 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.264 0.226 . . . . 0.0 110.535 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.9 t -51.99 -43.05 63.44 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -90.91 13.36 66.25 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-O 117.994 -1.448 . . . . 0.0 111.814 -177.841 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp 69.44 -34.68 0.29 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 119.421 1.611 . . . . 0.0 114.52 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 15.7 tpt 26.16 -76.31 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 130.056 3.343 . . . . 0.0 116.426 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.1 ttm -79.49 -15.98 56.82 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 114.142 1.164 . . . . 0.0 114.142 -174.263 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.51 -135.75 2.73 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 120.037 1.29 . . . . 0.0 113.076 -178.111 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -129.1 163.1 26.2 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 175.717 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 167.27 -157.5 29.96 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.877 -1.154 . . . . 0.0 112.586 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -162.35 171.07 17.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.053 0.541 . . . . 0.0 109.839 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.35 149.18 31.51 Favored 'General case' 0 CA--C 1.502 -0.867 0 O-C-N 124.119 0.887 . . . . 0.0 109.429 176.729 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.0 mp -124.21 133.56 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 102.482 -3.155 . . . . 0.0 102.482 170.314 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.2 tt -99.38 108.44 50.33 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.789 -4.523 . . . . 0.0 98.789 170.626 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -82.8 161.04 16.29 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.347 2.698 . . . . 0.0 113.932 -168.463 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.3 p -124.59 -55.56 1.63 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.699 1.2 . . . . 0.0 108.723 175.551 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -68.15 124.15 22.66 Favored 'General case' 0 N--CA 1.457 -0.11 0 C-N-CA 122.303 0.241 . . . . 0.0 110.857 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.33 37.11 2.0 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 70.7 mt -138.43 120.63 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.24 109.35 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -174.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.7 m -89.25 -178.26 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.941 -1.504 . . . . 0.0 106.941 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.59 146.19 33.5 Favored Pre-proline 0 N--CA 1.465 0.306 0 CA-C-O 117.561 -1.209 . . . . 0.0 111.464 -174.683 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -63.3 -44.6 14.37 Favored 'Trans proline' 0 C--N 1.348 0.53 0 N-CA-C 107.453 -1.787 . . . . 0.0 107.453 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.48 HG21 ' HA ' ' A' ' 74' ' ' SER . 3.4 p -146.2 145.59 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 102.433 -3.173 . . . . 0.0 102.433 171.506 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.539 ' HB3' HG23 ' A' ' 106' ' ' VAL . 28.6 mtm180 -97.27 -75.21 0.55 Allowed 'General case' 0 N--CA 1.45 -0.447 1 N-CA-C 98.979 -4.452 . . . . 0.0 98.979 169.659 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.23 -78.19 1.46 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 107.141 -2.383 . . . . 0.0 107.141 171.474 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.75 118.73 5.84 Favored 'General case' 0 N--CA 1.438 -1.067 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.893 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.458 HG21 ' CB ' ' A' ' 102' ' ' GLU . 28.3 mm -65.98 124.85 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 175.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.42 -42.47 12.81 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 124.069 0.948 . . . . 0.0 109.206 -177.44 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -156.88 152.66 27.05 Favored 'General case' 0 N--CA 1.463 0.204 0 O-C-N 121.94 -0.475 . . . . 0.0 111.722 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -82.89 170.55 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.845 1.658 . . . . 0.0 112.323 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.545 ' CE2' HD21 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -76.54 135.85 68.32 Favored Pre-proline 0 N--CA 1.437 -1.118 0 CA-C-N 112.681 -2.054 . . . . 0.0 109.778 173.589 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -74.37 -43.28 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.374 1.383 . . . . 0.0 108.61 172.901 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.4 p -131.39 46.24 2.69 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 126.192 1.797 . . . . 0.0 109.917 -177.904 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.447 ' HA ' ' CB ' ' A' ' 64' ' ' PHE . 16.5 ttmt 57.16 -17.41 0.02 OUTLIER 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 128.225 2.61 . . . . 0.0 116.609 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -75.98 -5.9 48.46 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 116.769 2.137 . . . . 0.0 116.769 -174.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.35 160.53 43.66 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 120.456 1.48 . . . . 0.0 110.348 -173.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.0 tt -157.23 157.15 3.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -117.31 128.58 7.92 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 107.646 -2.181 . . . . 0.0 107.646 178.186 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.9 mt -124.74 171.75 9.85 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 124.724 1.209 . . . . 0.0 110.359 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.47 139.33 20.88 Favored 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 126.631 1.972 . . . . 0.0 105.697 174.201 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' SER . . . . . 0.48 ' HA ' HG21 ' A' ' 56' ' ' VAL . 89.4 p -71.93 -83.05 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 176.235 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -121.84 -70.04 0.8 Allowed 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.206 1.402 . . . . 0.0 107.684 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -168.62 85.07 0.09 OUTLIER Glycine 0 CA--C 1.521 0.437 0 N-CA-C 106.097 -2.801 . . . . 0.0 106.097 178.276 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 169.15 -41.35 0.21 Allowed Glycine 0 C--N 1.337 0.584 0 CA-C-O 119.36 -0.689 . . . . 0.0 111.639 -176.606 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 38.2 ttp180 -122.56 109.07 13.86 Favored 'General case' 0 C--N 1.341 0.208 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 177.742 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -106.48 130.64 54.24 Favored 'General case' 0 N--CA 1.445 -0.678 0 C-N-CA 129.374 3.069 . . . . 0.0 104.386 177.712 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.4 mt -120.22 145.16 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 C-N-CA 124.339 1.056 . . . . 0.0 110.649 -172.12 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 46.7 tp -124.38 131.45 53.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 173.634 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 79.4 mt -121.93 146.8 26.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 123.789 0.836 . . . . 0.0 109.317 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.34 136.23 41.36 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 169.9 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -106.96 108.4 19.89 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 125.224 1.41 . . . . 0.0 109.037 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.53 -178.0 7.17 Favored Glycine 0 CA--C 1.534 1.22 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -176.372 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.7 mm -118.87 143.54 29.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 t70 65.69 11.58 7.64 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.38 1.072 . . . . 0.0 113.143 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 p -74.83 -32.51 61.96 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 125.583 1.553 . . . . 0.0 108.587 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.5 p -54.57 -49.85 63.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 113.202 -1.817 . . . . 0.0 107.143 170.512 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -62.69 -42.42 99.62 Favored 'General case' 0 C--O 1.227 -0.119 0 C-N-CA 124.668 1.187 . . . . 0.0 109.641 177.875 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 24.5 tp -66.21 -2.55 4.41 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.463 1.505 . . . . 0.0 111.539 176.706 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.5 mtmm 51.94 34.1 13.0 Favored 'General case' 0 C--N 1.344 0.329 0 C-N-CA 125.18 1.392 . . . . 0.0 111.325 -179.157 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.95 30.91 60.77 Favored Glycine 0 CA--C 1.537 1.45 0 CA-C-O 120.015 -0.325 . . . . 0.0 112.802 -178.583 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -67.21 93.38 0.3 Allowed 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.759 1.279 . . . . 0.0 109.477 178.464 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.54 7.98 4.57 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 126.682 2.087 . . . . 0.0 112.122 -178.493 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.407 ' CG ' HG12 ' A' ' 115' ' ' VAL . 3.5 m-85 -101.35 153.04 20.01 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.696 1.198 . . . . 0.0 110.732 -177.441 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 59.3 m -145.41 121.81 10.97 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.3 -2.111 . . . . 0.0 105.3 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.421 ' HA ' HD23 ' A' ' 113' ' ' LEU . 35.1 p -96.04 128.22 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.539 0.736 . . . . 0.0 110.371 -173.255 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -92.05 -49.12 6.38 Favored 'General case' 0 N--CA 1.448 -0.57 0 O-C-N 124.336 1.023 . . . . 0.0 109.431 -178.289 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.9 m -75.22 124.7 33.63 Favored 'Isoleucine or valine' 0 C--N 1.34 0.193 0 C-N-CA 117.21 -1.796 . . . . 0.0 107.749 173.494 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.7 m -100.8 55.71 0.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 103.578 -2.749 . . . . 0.0 103.578 170.852 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.458 ' CB ' HG21 ' A' ' 60' ' ' ILE 0.5 0.0 OUTLIER 5.39 64.15 0.0 OUTLIER 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 130.767 3.627 . . . . 0.0 117.915 -168.517 . . . . . . . . 4 4 . 1 . 001 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -81.28 61.24 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 173.239 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ASP . . . . . 0.6 ' O ' HG22 ' A' ' 106' ' ' VAL 0.391 3.3 p30 6.01 -94.56 0.0 OUTLIER 'General case' 0 N--CA 1.439 -0.987 0 C-N-CA 128.506 2.722 . . . . 0.0 116.939 -174.283 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.4 mmm180 -55.69 106.09 0.23 Allowed 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 126.472 1.909 . . . . 0.0 112.262 -175.269 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 106' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 104' ' ' ASP . 0.0 OUTLIER -147.6 159.19 8.53 Favored 'Isoleucine or valine' 0 C--N 1.342 0.239 0 C-N-CA 124.841 1.257 . . . . 0.0 111.704 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -85.88 155.34 58.5 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 118.473 -0.775 . . . . 0.0 109.636 177.218 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo -48.82 168.61 0.1 Allowed 'Trans proline' 0 CA--C 1.534 0.514 1 C-N-CA 126.824 5.016 . . . . 0.0 120.381 -173.081 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 69.69 -97.37 0.55 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 125.956 1.741 . . . . 0.0 112.754 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 26.3 tt0 1.97 92.97 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 131.03 3.732 . . . . 0.0 114.102 -176.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 21.1 ttmt 4.21 114.82 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 130.321 3.449 . . . . 0.0 117.193 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 91.1 mt -81.87 -50.97 8.58 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.922 0.889 . . . . 0.0 108.988 173.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.545 HD21 ' CE2' ' A' ' 64' ' ' PHE . 96.1 mt -138.06 155.25 48.99 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.769 1.628 . . . . 0.0 110.512 -176.494 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.42 132.53 53.98 Favored 'General case' 0 CA--C 1.516 -0.328 1 N-CA-C 100.106 -4.035 . . . . 0.0 100.106 167.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.407 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -147.66 122.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.01 -165.603 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -71.63 69.07 0.62 Allowed 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.409 1.083 . . . . 0.0 111.025 -179.021 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 56.5 mt -49.11 -42.81 40.39 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.69 0.796 . . . . 0.0 111.166 178.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -50.03 -48.43 52.73 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.628 0.771 . . . . 0.0 112.131 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.48 -31.34 22.85 Favored 'General case' 0 CA--C 1.527 0.078 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.8 t -64.02 -51.76 65.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.64 -0.662 . . . . 0.0 109.945 179.402 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.407 0.0 OUTLIER -41.11 -57.95 3.11 Favored Pre-proline 0 CA--C 1.542 0.647 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -177.303 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -59.27 -19.34 49.74 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.256 1.971 . . . . 0.0 113.227 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -98.43 11.42 38.21 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.826 0.85 . . . . 0.0 112.283 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.83 151.31 73.82 Favored Pre-proline 0 CA--C 1.532 0.284 0 CA-C-N 119.837 1.199 . . . . 0.0 110.86 178.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -72.97 -24.06 17.87 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 122.744 2.296 . . . . 0.0 110.658 177.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 14.6 t -158.75 147.91 18.89 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.389 0.614 . . . . 0.0 109.864 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.0 tp -97.54 2.25 49.89 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.862 1.665 . . . . 0.0 110.51 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 19.3 mmt -52.01 119.19 4.05 Favored 'General case' 0 C--N 1.344 0.36 0 CA-C-N 118.208 0.458 . . . . 0.0 109.794 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 32.2 m -111.37 89.48 10.45 Favored Pre-proline 0 N--CA 1.447 -0.609 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -81.08 146.56 16.06 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.331 2.021 . . . . 0.0 111.364 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.4 mt -127.37 126.47 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 175.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.41 147.83 26.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 N-CA-C 106.819 -1.549 . . . . 0.0 106.819 178.926 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.401 ' HB2' HD21 ' A' ' 136' ' ' LEU . 13.6 m-85 -122.55 125.71 46.27 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 101.945 -3.354 . . . . 0.0 101.945 178.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.7 p -89.15 -82.77 0.24 Allowed 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.4 0.546 . . . . 0.0 111.422 -171.838 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 20.6 p30 -47.37 -49.01 25.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.111 1.765 . . . . 0.0 111.884 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.401 HD21 ' HB2' ' A' ' 133' ' ' PHE . 23.0 mt 42.8 49.03 5.02 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 125.111 1.365 . . . . 0.0 110.864 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 34.82 40.96 0.05 Allowed 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.325 1.85 . . . . 0.0 111.966 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 36.88 55.18 1.2 Allowed 'General case' 0 N--CA 1.446 -0.631 0 C-N-CA 128.319 2.648 . . . . 0.0 114.349 -176.277 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 163.09 -3.48 0.07 OUTLIER Glycine 0 CA--C 1.524 0.625 0 CA-C-O 118.885 -0.953 . . . . 0.0 114.482 175.211 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.677 ' HB3' HG23 ' A' ' 160' ' ' ILE . 63.7 mm-40 -76.61 109.86 10.71 Favored 'General case' 0 C--O 1.228 -0.074 0 CA-C-N 119.219 1.51 . . . . 0.0 110.483 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.4 p -78.8 138.68 38.31 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 171.817 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -85.55 84.79 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.5 m -78.27 93.76 4.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 O-C-N 120.6 -1.312 . . . . 0.0 110.844 -175.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 14.2 mt -64.91 130.91 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 C-N-CA 123.939 0.896 . . . . 0.0 108.608 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -107.44 -55.36 2.36 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.711 1.204 . . . . 0.0 108.026 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.84 70.22 1.91 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.357 0.599 . . . . 0.0 110.511 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 24.7 m -79.0 63.92 3.79 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 178.35 -140.91 4.8 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.368 -1.893 . . . . 0.0 108.368 -176.485 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.6 t -66.43 151.84 46.34 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 117.039 0.419 . . . . 0.0 110.989 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -133.97 154.07 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.538 1.535 . . . . 0.0 107.996 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -132.95 150.92 52.12 Favored 'General case' 0 C--O 1.233 0.22 0 C-N-CA 124.965 1.306 . . . . 0.0 108.634 178.009 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -57.48 150.33 18.98 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.149 0.979 . . . . 0.0 112.12 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 58.51 3.52 0.29 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 127.148 2.179 . . . . 0.0 115.263 174.379 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 55.5 mm-40 -72.29 164.25 26.6 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 119.056 0.844 . . . . 0.0 111.075 179.008 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -114.04 168.23 9.99 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.715 2.406 . . . . 0.0 108.22 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 25.9 t0 51.73 40.53 27.73 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.099 1.36 . . . . 0.0 112.811 176.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.445 HD12 ' H ' ' A' ' 158' ' ' VAL . 0.9 OUTLIER -99.78 -43.64 11.24 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.414 1.086 . . . . 0.0 109.636 178.674 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.445 ' H ' HD12 ' A' ' 157' ' ' ILE . 9.1 p -142.69 143.97 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 105.782 -1.933 . . . . 0.0 105.782 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -123.65 116.11 22.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.232 0.613 . . . . 0.0 109.547 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.677 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.4 mp -79.23 104.06 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 103.54 -2.763 . . . . 0.0 103.54 173.371 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -142.83 158.11 43.95 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 123.175 0.59 . . . . 0.0 109.865 -174.231 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.8 mptt . . . . . 0 CA--C 1.53 0.195 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.188 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.3 mmt . . . . . 0 N--CA 1.454 -0.239 0 CA-C-O 120.867 0.365 . . . . 0.0 110.017 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 26.3 mt -76.26 68.08 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.39 5.62 18.25 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.888 1.275 . . . . 0.0 112.003 -178.513 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.5 pm0 -67.99 155.2 92.43 Favored Pre-proline 0 CA--C 1.538 0.481 0 CA-C-O 118.918 -0.563 . . . . 0.0 109.985 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_exo -53.69 125.76 19.66 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.419 2.079 . . . . 0.0 110.283 177.231 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 71.9 mt -75.89 67.58 2.29 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 121.267 0.556 . . . . 0.0 109.868 -179.179 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -168.86 -172.06 1.51 Allowed 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 126.846 2.058 . . . . 0.0 106.841 -178.268 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -64.94 138.55 58.43 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 172.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -67.52 -5.64 16.1 Favored 'General case' 0 CA--C 1.536 0.424 0 N-CA-C 114.785 1.402 . . . . 0.0 114.785 -176.243 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 32.0 pt 37.06 45.96 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 126.981 2.112 . . . . 0.0 113.44 178.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 148.47 -66.51 0.39 Allowed Glycine 0 C--N 1.336 0.562 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -178.526 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -79.45 55.09 1.86 Allowed 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 122.067 0.936 . . . . 0.0 110.44 -178.585 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -84.03 54.23 2.86 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.986 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.9 p 45.23 36.72 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.174 0 C-N-CA 125.738 1.615 . . . . 0.0 110.583 -171.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.16 99.92 8.01 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 112.719 -2.037 . . . . 0.0 106.583 -176.916 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -103.61 90.92 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 C-N-CA 122.714 0.406 . . . . 0.0 111.686 -177.739 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 89.9 p -22.94 124.03 0.14 Allowed Pre-proline 0 CA--C 1.555 1.141 0 C-N-CA 126.037 1.735 . . . . 0.0 114.298 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -73.97 -36.74 3.25 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.023 2.482 . . . . 0.0 118.201 -171.654 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.44 148.33 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 119.905 1.229 . . . . 0.0 111.524 -175.422 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.6 m -80.48 140.6 35.83 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 173.957 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 163.58 -142.93 8.19 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -116.8 126.78 53.58 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 124.818 1.247 . . . . 0.0 108.457 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 tt -85.11 154.88 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -145.09 144.31 23.27 Favored Pre-proline 0 N--CA 1.451 -0.419 0 C-N-CA 124.989 1.316 . . . . 0.0 107.619 177.745 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -62.88 31.19 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 124.832 3.688 . . . . 0.0 116.838 177.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER 72.34 -39.69 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.071 1.349 . . . . 0.0 113.077 179.28 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -44.85 -41.38 7.03 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 125.298 1.439 . . . . 0.0 112.177 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.23 -14.1 62.73 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.646 1.579 . . . . 0.0 113.089 -175.978 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.6 t -71.3 127.91 90.8 Favored Pre-proline 0 CA--C 1.536 0.411 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 58.02 6.78 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.567 2.178 . . . . 0.0 112.043 -176.953 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -166.96 107.57 0.63 Allowed 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.686 -0.634 . . . . 0.0 110.203 177.348 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -28.6 -53.39 0.1 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 129.233 3.013 . . . . 0.0 115.967 -179.256 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 60.5 t -53.76 -45.61 61.74 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 CA-C-O 121.406 0.622 . . . . 0.0 109.703 -178.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -76.69 -54.47 6.6 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.9 m -45.37 -43.9 11.39 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 124.609 1.164 . . . . 0.0 114.119 -178.438 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -98.6 12.76 62.94 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 117.926 -1.486 . . . . 0.0 112.61 -176.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 56.8 mttp 70.97 -34.11 0.29 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 119.723 1.761 . . . . 0.0 113.994 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 26.3 ttt 28.57 -71.57 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 130.895 3.678 . . . . 0.0 117.191 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ttt -79.03 -17.08 55.91 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.971 0.908 . . . . 0.0 112.732 -175.599 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -168.15 -137.03 2.15 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.445 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.3 t0 -133.65 158.03 44.28 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 171.848 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -176.98 -162.79 28.06 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 119.361 -1.399 . . . . 0.0 113.46 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -151.4 165.14 35.02 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.991 1.316 . . . . 0.0 107.516 177.406 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -119.11 141.59 48.65 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -115.88 132.59 64.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 170.576 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.42 107.03 42.97 Favored Pre-proline 0 N--CA 1.445 -0.69 1 N-CA-C 98.298 -4.705 . . . . 0.0 98.298 169.249 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -82.9 167.01 14.67 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.732 2.954 . . . . 0.0 114.417 -168.214 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.8 p -127.73 -67.74 0.81 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.312 1.445 . . . . 0.0 108.499 176.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -53.24 124.81 15.59 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.802 0.841 . . . . 0.0 111.973 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.01 39.31 2.03 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 173.826 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.3 mt -140.01 117.14 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 104.181 -2.526 . . . . 0.0 104.181 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.9 t -116.71 114.01 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 123.904 0.881 . . . . 0.0 109.024 -175.408 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.3 m -90.64 178.03 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 172.744 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -97.85 145.73 30.25 Favored Pre-proline 0 C--O 1.223 -0.318 0 CA-C-O 117.147 -1.406 . . . . 0.0 110.064 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -62.43 -39.18 47.69 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 N-CA-C 106.92 -1.992 . . . . 0.0 106.92 172.256 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 p -157.54 139.57 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 101.495 -3.52 . . . . 0.0 101.495 169.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.441 ' HE ' ' CG1' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -91.29 -67.71 0.84 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 178.282 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 62.86 -74.4 0.03 OUTLIER Glycine 0 C--N 1.34 0.768 0 C-N-CA 126.155 1.835 . . . . 0.0 112.334 172.569 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.97 114.16 3.37 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.217 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 39.0 mm -61.74 128.33 23.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.138 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 8.4 tt -78.89 -52.55 8.14 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 177.236 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -179.19 161.81 1.15 Allowed 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 28.9 m -136.94 123.17 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 125.506 1.522 . . . . 0.0 107.503 175.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 153.84 0.6 Allowed Pre-proline 0 CA--C 1.537 0.454 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 176.353 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -50.42 -34.44 41.52 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 123.068 2.512 . . . . 0.0 112.671 175.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 25.0 p -79.62 4.14 16.91 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.972 0.909 . . . . 0.0 112.458 -179.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 11.4 tppt? 66.36 -33.79 0.2 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 128.351 2.66 . . . . 0.0 115.803 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -54.44 -32.71 58.08 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 114.8 1.407 . . . . 0.0 114.8 -174.315 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.07 178.89 6.7 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 114.663 1.356 . . . . 0.0 114.663 -173.542 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.789 23.1 mm 117.86 -131.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.331 1 C-N-CA 132.719 4.408 . . . . 0.0 109.607 -179.312 . . . . . . . . 3 2 . 1 . 002 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.28 171.44 41.97 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 119.448 2.539 . . . . 0.0 119.448 -176.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.9 mt -118.97 179.68 4.08 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.81 2.444 . . . . 0.0 109.591 -177.655 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -149.63 152.3 35.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 127.016 2.126 . . . . 0.0 105.425 177.088 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 53.9 p -92.09 -123.19 0.08 Allowed 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 176.589 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -120.95 -60.74 1.62 Allowed 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 127.357 2.263 . . . . 0.0 105.827 175.711 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -78.41 61.64 3.87 Favored Glycine 0 CA--C 1.528 0.856 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 175.096 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 60.95 -116.48 9.39 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 42.6 mtt85 48.65 72.56 0.27 Allowed 'General case' 0 C--N 1.338 0.101 0 C-N-CA 125.276 1.431 . . . . 0.0 109.988 -178.303 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLU . . . . . 0.48 ' H ' ' ND2' ' A' ' 135' ' ' ASN . 8.4 tm-20 -76.87 134.19 39.08 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 176.744 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.3 mt -120.7 111.54 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.218 0.607 . . . . 0.0 110.995 -172.658 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.7 tt -83.04 138.28 33.79 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.517 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 68.3 mt -134.17 148.37 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 125.122 1.369 . . . . 0.0 108.887 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.42 78.92 1.64 Allowed 'General case' 0 C--N 1.34 0.192 0 C-N-CA 124.77 1.228 . . . . 0.0 109.743 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.438 ' HA ' HG23 ' A' ' 129' ' ' THR . 1.3 t80 -51.52 107.02 0.16 Allowed 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 123.102 0.561 . . . . 0.0 111.558 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.53 -173.29 2.51 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.647 0.641 . . . . 0.0 113.086 -178.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mm -121.67 146.0 27.43 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.3 t70 65.12 7.86 4.39 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.855 0.862 . . . . 0.0 113.07 -178.963 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -71.61 -35.21 70.39 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 125.738 1.615 . . . . 0.0 107.996 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 13.1 p -55.14 -45.79 77.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 CA-C-N 113.122 -1.854 . . . . 0.0 108.048 171.881 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.23 -38.66 92.05 Favored 'General case' 0 C--N 1.339 0.137 0 C-N-CA 124.354 1.061 . . . . 0.0 109.743 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.65 2.06 7.2 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 126.199 1.8 . . . . 0.0 110.615 175.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.4 mttp 45.88 30.23 0.84 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 128.016 2.526 . . . . 0.0 114.372 176.522 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.97 24.94 55.66 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.876 -0.402 . . . . 0.0 112.156 -178.061 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -56.66 -35.14 68.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 119.145 1.473 . . . . 0.0 112.79 -178.49 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -89.43 10.32 73.78 Favored Glycine 0 CA--C 1.533 1.192 0 CA-C-N 112.765 -2.016 . . . . 0.0 113.032 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -108.55 108.14 18.92 Favored 'General case' 0 C--N 1.343 0.325 0 CA-C-N 119.234 1.517 . . . . 0.0 111.996 -174.514 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.0 m -91.17 100.14 13.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.921 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.8 p -80.21 130.44 35.22 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 121.276 -0.89 . . . . 0.0 111.117 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -90.78 -46.96 7.91 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.705 1.202 . . . . 0.0 109.109 178.442 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.441 ' CG1' ' HE ' ' A' ' 57' ' ' ARG . 2.5 m -66.59 133.85 30.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 C-N-CA 118.105 -1.438 . . . . 0.0 108.421 174.491 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 59.5 m -110.88 53.29 0.71 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 170.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.292 3.4 pm0 -7.07 75.71 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.552 1 C-N-CA 131.815 4.046 . . . . 0.0 116.797 -171.603 . . . . . . . . 3 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.04 45.32 3.01 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 113.187 -1.824 . . . . 0.0 109.596 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 4.2 p30 5.23 41.57 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.226 2 C-N-CA 133.016 4.526 . . . . 0.0 122.206 -176.814 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.38 123.89 1.95 Allowed 'General case' 0 N--CA 1.436 -1.154 1 C-N-CA 133.163 4.585 . . . . 0.0 105.298 176.408 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -163.58 150.74 3.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 119.524 1.056 . . . . 0.0 110.482 -171.511 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -85.85 149.81 51.68 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 118.17 -0.919 . . . . 0.0 110.631 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_exo -46.71 150.84 2.29 Favored 'Trans proline' 0 CA--C 1.532 0.402 1 C-N-CA 126.222 4.615 . . . . 0.0 117.668 -176.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 66.44 -79.57 0.12 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.071 1.32 . . . . 0.0 112.504 176.873 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 1.44 76.12 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 131.581 3.953 . . . . 0.0 113.698 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? 17.49 109.94 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 129.723 3.209 . . . . 0.0 117.29 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 88.3 mt -78.75 -50.02 12.07 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.68 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 12.5 mt -144.56 156.8 44.32 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.971 0.909 . . . . 0.0 111.836 -173.061 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -119.06 131.39 55.95 Favored 'General case' 0 CA--C 1.516 -0.346 1 N-CA-C 98.694 -4.558 . . . . 0.0 98.694 165.586 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -140.91 129.89 24.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -166.497 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -76.24 63.2 1.86 Allowed 'General case' 0 C--O 1.234 0.25 0 CA-C-O 121.509 0.671 . . . . 0.0 110.068 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 78.6 mt -55.26 -34.56 64.15 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 123.221 0.609 . . . . 0.0 110.654 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.44 -40.23 71.29 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.047 0.539 . . . . 0.0 111.915 177.57 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.33 -35.3 17.27 Favored 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 122.788 0.435 . . . . 0.0 111.197 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.63 -51.19 75.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.554 -0.716 . . . . 0.0 109.518 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 20.8 pttm -40.66 -57.64 3.02 Favored Pre-proline 0 CA--C 1.541 0.616 0 N-CA-C 116.957 2.206 . . . . 0.0 116.957 -177.119 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -60.79 -25.64 81.52 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.696 2.264 . . . . 0.0 113.151 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -83.78 -43.03 15.85 Favored 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.62 0.646 . . . . 0.0 111.148 -178.148 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 35.7 m -78.91 150.57 75.37 Favored Pre-proline 0 CA--C 1.534 0.363 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.162 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -73.01 -25.19 16.52 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.515 2.143 . . . . 0.0 110.12 176.465 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.9 t -159.06 145.06 16.55 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 123.397 0.679 . . . . 0.0 109.539 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.9 tp -101.95 4.92 40.5 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.331 1.452 . . . . 0.0 110.287 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.8 mmt -51.97 111.4 0.6 Allowed 'General case' 0 C--N 1.342 0.263 0 C-N-CA 123.764 0.826 . . . . 0.0 110.104 179.031 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.438 HG23 ' HA ' ' A' ' 84' ' ' PHE . 85.7 m -107.3 114.57 60.86 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -90.55 145.75 4.0 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.976 2.45 . . . . 0.0 108.937 179.634 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.2 mp -124.84 116.57 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 101.787 -3.412 . . . . 0.0 101.787 172.918 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -124.58 117.21 49.79 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 C-N-CA 124.607 1.163 . . . . 0.0 108.719 -176.914 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -91.05 121.86 33.21 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.163 -2.532 . . . . 0.0 104.163 178.349 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -86.63 -73.17 0.47 Allowed 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.638 0.654 . . . . 0.0 110.757 -174.346 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' ASN . . . . . 0.48 ' ND2' ' H ' ' A' ' 79' ' ' GLU . 6.5 p30 -75.09 63.5 1.28 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 122.164 0.983 . . . . 0.0 112.507 -178.808 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.445 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 29.8 mt -77.02 65.12 2.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.864 1.666 . . . . 0.0 108.34 177.152 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.48 46.97 0.08 Allowed 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 127.432 2.293 . . . . 0.0 111.179 -175.929 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 31.9 58.61 0.34 Allowed 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.852 2.861 . . . . 0.0 115.374 -175.972 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 156.56 -4.82 0.19 Allowed Glycine 0 CA--C 1.525 0.664 0 CA-C-O 118.972 -0.905 . . . . 0.0 114.32 174.804 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.615 ' HB3' HG23 ' A' ' 160' ' ' ILE . 43.7 mt-10 -74.87 111.81 10.44 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 119.18 1.49 . . . . 0.0 110.031 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 59.9 p -78.42 133.37 37.51 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 176.885 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.456 HG23 HG13 ' A' ' 160' ' ' ILE 0.26 0.4 OUTLIER -84.37 82.72 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 CA-C-O 122.875 1.321 . . . . 0.0 107.964 -176.646 . . . . . . . . 4 4 . 1 . 002 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 41.9 m -79.08 94.65 5.36 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 120.986 -1.071 . . . . 0.0 110.363 -176.504 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 10.5 mt -57.91 128.32 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.4 mmpt? -98.5 -52.63 3.57 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 125.188 1.395 . . . . 0.0 108.931 177.827 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -79.0 61.51 3.19 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 120.819 0.342 . . . . 0.0 110.133 -178.482 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 60.2 p -77.84 72.77 4.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.843 0.857 . . . . 0.0 110.472 -176.861 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.37 -143.74 5.54 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 26.5 t -72.2 146.45 47.34 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 19.2 m -137.1 156.51 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.617 0.767 . . . . 0.0 109.33 -178.543 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -114.05 158.38 21.29 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 174.415 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.21 164.8 26.17 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.12 0.486 . . . . 0.0 110.249 175.091 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 60.7 32.91 20.31 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.339 1.055 . . . . 0.0 112.953 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 78.3 mt-30 -105.79 145.79 30.71 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 175.044 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -115.79 161.9 18.08 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.133 0.973 . . . . 0.0 110.585 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 19.3 t70 56.99 18.46 3.97 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 126.436 1.894 . . . . 0.0 113.566 -177.489 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.434 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -61.64 -21.2 24.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 125.464 1.506 . . . . 0.0 112.006 177.728 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.424 HG21 HG22 ' A' ' 142' ' ' VAL . 13.4 p -138.83 150.44 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 126.554 1.941 . . . . 0.0 107.048 178.804 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -120.77 109.07 14.72 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.184 0.994 . . . . 0.0 109.765 177.136 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.615 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.2 mp -77.65 92.47 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 N-CA-C 104.345 -2.465 . . . . 0.0 104.345 178.178 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 58.5 mt-10 -119.25 122.7 42.52 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.233 1.013 . . . . 0.0 111.055 -174.158 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--N 1.332 -0.179 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 177.332 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.8 mtm . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.991 0.424 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.1 mm -120.43 146.4 25.34 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 C-N-CA 125.409 1.483 . . . . 0.0 107.485 177.416 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -67.94 79.01 0.22 Allowed 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.703 0.801 . . . . 0.0 112.453 -179.299 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 58.89 71.46 0.97 Allowed Pre-proline 0 CA--C 1.536 0.416 0 C-N-CA 125.588 1.555 . . . . 0.0 112.614 176.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -72.2 77.31 2.04 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.052 2.501 . . . . 0.0 108.736 177.513 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 45.62 36.76 2.77 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 127.428 2.291 . . . . 0.0 112.055 -175.94 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -150.11 166.57 29.37 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 127.165 2.186 . . . . 0.0 106.606 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 t30 63.9 89.42 0.09 Allowed 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 125.082 1.353 . . . . 0.0 112.842 177.235 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 68.88 -60.33 0.45 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 126.975 2.11 . . . . 0.0 112.969 176.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.8 mt 57.54 38.65 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 124.356 1.063 . . . . 0.0 110.016 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.12 66.23 2.9 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.244 -1.543 . . . . 0.0 109.244 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLU . . . . . 0.48 ' HA ' ' HB2' ' A' ' 156' ' ' ASP . 29.7 tt0 -63.53 72.16 0.02 OUTLIER 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 125.927 1.691 . . . . 0.0 113.69 -174.04 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -75.8 161.12 29.29 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.262 1.425 . . . . 0.0 110.383 176.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.5 p -71.92 102.34 1.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 CA-C-O 122.464 1.126 . . . . 0.0 113.587 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -163.33 151.46 13.55 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 129.998 3.319 . . . . 0.0 102.831 173.475 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -131.27 96.99 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 122.231 2.287 . . . . 0.0 110.272 176.676 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 t -32.57 120.94 0.41 Allowed Pre-proline 0 CA--C 1.548 0.887 0 C-N-CA 125.574 1.55 . . . . 0.0 112.808 -178.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -74.06 -38.14 2.35 Favored 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 123.29 2.66 . . . . 0.0 117.571 -171.917 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.92 152.02 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 120.113 1.324 . . . . 0.0 109.84 -176.049 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.6 m -79.09 134.17 36.75 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 172.371 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.86 -177.09 45.54 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -92.0 122.08 34.17 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.4 tt -86.61 138.65 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 123.12 0.568 . . . . 0.0 110.141 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 78.8 m-70 -137.66 145.63 49.64 Favored Pre-proline 0 C--O 1.234 0.278 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 176.379 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.47 145.69 67.18 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.115 1.877 . . . . 0.0 110.218 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.4 tp -50.8 -33.84 12.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.729 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 p -56.02 -27.71 54.25 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 123.78 0.832 . . . . 0.0 112.388 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -76.22 -11.89 60.0 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.923 0.889 . . . . 0.0 112.714 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.675 HG22 ' HB2' ' A' ' 44' ' ' ALA . 42.3 t -66.85 129.45 94.05 Favored Pre-proline 0 CA--C 1.538 0.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.445 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -77.17 59.48 6.59 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.696 2.931 . . . . 0.0 111.024 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -167.58 105.19 0.52 Allowed 'General case' 0 N--CA 1.463 0.209 0 O-C-N 121.356 -0.84 . . . . 0.0 109.344 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -24.56 -58.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 128.162 2.585 . . . . 0.0 114.164 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.9 t -48.57 -50.44 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 123.954 0.902 . . . . 0.0 110.464 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -76.31 -47.81 22.29 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.2 m -49.31 -41.29 38.0 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 113.793 1.035 . . . . 0.0 113.793 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -104.6 20.27 39.81 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-O 118.081 -1.4 . . . . 0.0 110.897 -177.068 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.0 mttt 72.03 -46.52 0.65 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.401 1.48 . . . . 0.0 113.248 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 45.0 tpp 45.16 -72.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.731 2.812 . . . . 0.0 115.352 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.7 ttp -101.8 -14.69 17.19 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.314 1.446 . . . . 0.0 113.018 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.06 -169.21 38.0 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 119.531 1.06 . . . . 0.0 111.965 -178.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -128.79 157.54 41.17 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.99 -126.71 1.35 Allowed Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 108.533 -1.827 . . . . 0.0 108.533 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -166.44 167.1 16.01 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 118.125 0.963 . . . . 0.0 111.542 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.675 ' HB2' HG22 ' A' ' 29' ' ' VAL . . . -99.35 126.19 45.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.475 1.11 . . . . 0.0 108.5 177.418 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.0 mm -107.31 121.12 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 104.193 -2.521 . . . . 0.0 104.193 170.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 7.0 tt -89.03 109.5 31.12 Favored Pre-proline 0 C--O 1.233 0.233 1 N-CA-C 100.073 -4.047 . . . . 0.0 100.073 170.498 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -81.52 162.61 19.34 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 123.594 2.863 . . . . 0.0 115.037 -167.649 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.2 p -132.04 -63.52 0.81 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.639 1.576 . . . . 0.0 108.947 177.095 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.43 123.93 17.83 Favored 'General case' 0 C--N 1.338 0.096 0 C-N-CA 122.56 0.344 . . . . 0.0 110.166 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.08 45.34 2.98 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 173.304 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.2 mt -145.84 115.96 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 105.17 -2.159 . . . . 0.0 105.17 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.1 t -114.01 121.51 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 125.084 1.354 . . . . 0.0 108.252 -177.283 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.9 m -103.66 156.93 5.34 Favored 'Isoleucine or valine' 0 C--N 1.339 0.11 0 C-N-CA 123.642 0.777 . . . . 0.0 110.071 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 m -69.12 127.17 93.13 Favored Pre-proline 0 CA--C 1.537 0.471 0 CA-C-O 117.598 -1.191 . . . . 0.0 109.92 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -60.41 -33.2 94.39 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.763 2.976 . . . . 0.0 111.302 177.521 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.1 m -150.6 144.16 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 102.139 -3.282 . . . . 0.0 102.139 172.704 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 -98.72 -97.41 0.22 Allowed 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 101.754 -3.424 . . . . 0.0 101.754 169.354 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.95 -66.43 3.59 Favored Glycine 0 CA--C 1.535 1.303 0 N-CA-C 106.575 -2.61 . . . . 0.0 106.575 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.21 132.36 2.49 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 166.617 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.0 mm -65.04 131.78 30.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 103.55 -2.759 . . . . 0.0 103.55 169.069 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 29.3 tp -79.01 -46.36 18.33 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 175.0 156.05 0.15 Allowed 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 125.669 1.588 . . . . 0.0 107.787 176.034 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.3 t -131.12 121.06 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -47.44 153.01 1.05 Allowed Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 112.579 0.585 . . . . 0.0 112.579 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -59.67 -14.97 28.92 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 124.192 3.262 . . . . 0.0 113.652 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 40.5 p -76.26 -21.29 56.49 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.078 0.951 . . . . 0.0 109.697 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 70.98 9.52 6.78 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 128.14 2.576 . . . . 0.0 111.03 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -83.91 -31.21 25.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 118.611 -0.709 . . . . 0.0 112.864 -176.927 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.82 -175.38 5.33 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.679 1.127 . . . . 0.0 112.348 -174.314 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.965 16.6 mm 130.89 -141.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.334 -0.085 1 C-N-CA 132.018 4.127 . . . . 0.0 111.824 176.4 . . . . . . . . 3 2 . 1 . 003 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -152.14 176.2 30.53 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 118.511 2.164 . . . . 0.0 118.511 -171.804 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.2 mp -132.51 158.46 42.05 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 128.012 2.525 . . . . 0.0 109.817 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.7 mm-40 -133.03 123.85 26.57 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 177.379 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.3 p -73.79 -83.57 0.05 OUTLIER 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 124.689 1.196 . . . . 0.0 108.778 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -149.28 52.04 0.95 Allowed 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 127.138 2.175 . . . . 0.0 107.608 -179.194 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 80.25 -70.45 2.95 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 107.916 -2.073 . . . . 0.0 107.916 -174.512 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.29 112.2 4.37 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 125.313 1.435 . . . . 0.0 111.25 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 93.1 62.01 0.0 OUTLIER 'General case' 0 C--N 1.335 -0.058 0 C-N-CA 129.494 3.117 . . . . 0.0 111.824 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -76.34 141.15 41.64 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 174.43 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.2 mt -126.66 144.36 37.08 Favored 'Isoleucine or valine' 0 C--N 1.338 0.08 0 N-CA-C 112.789 0.662 . . . . 0.0 112.789 -172.795 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -119.82 136.63 54.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 128.891 2.876 . . . . 0.0 105.732 175.789 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.0 mt -131.48 140.15 49.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 C-N-CA 125.075 1.35 . . . . 0.0 107.764 177.529 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -132.89 114.81 14.49 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -76.05 116.52 16.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 118.766 0.712 . . . . 0.0 110.402 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.63 -170.57 4.82 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.694 -0.562 . . . . 0.0 111.694 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 22.5 mm -116.59 141.36 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.159 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.7 t0 50.2 41.98 24.76 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.412 1.085 . . . . 0.0 112.892 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.423 ' O ' ' N ' ' A' ' 90' ' ' SER . 7.7 p -83.83 -89.12 0.1 Allowed 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 103.273 -2.862 . . . . 0.0 103.273 172.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.435 HG13 ' H ' ' A' ' 90' ' ' SER . 7.3 p 33.03 -67.31 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 C-N-CA 128.313 2.645 . . . . 0.0 116.946 172.354 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.435 ' H ' HG13 ' A' ' 89' ' ' VAL . 12.9 m -63.43 -40.44 97.18 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 126.27 1.828 . . . . 0.0 109.758 176.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -58.35 -43.53 88.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 126.862 2.065 . . . . 0.0 108.8 178.415 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? 77.02 169.59 0.24 Allowed 'General case' 0 N--CA 1.442 -0.871 0 C-N-CA 126.823 2.049 . . . . 0.0 106.837 -174.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.03 54.96 0.56 Allowed Glycine 0 CA--C 1.538 1.493 0 C-N-CA 124.898 1.237 . . . . 0.0 112.718 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -75.41 79.88 2.47 Favored 'General case' 0 CA--C 1.519 -0.236 0 O-C-N 121.158 -1.201 . . . . 0.0 108.781 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.78 11.72 2.31 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 112.919 -1.946 . . . . 0.0 111.594 -176.93 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -96.94 96.93 8.86 Favored 'General case' 0 C--N 1.342 0.267 0 C-N-CA 124.753 1.221 . . . . 0.0 110.731 -175.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.4 m -79.72 94.67 5.78 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 35.9 p -79.51 122.93 27.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 121.569 -0.707 . . . . 0.0 110.653 -176.446 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -83.57 -53.18 5.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 27.9 m -84.82 131.02 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 171.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 69.6 m -96.06 57.63 1.79 Allowed 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 170.351 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.378 0.0 OUTLIER 37.97 49.6 1.2 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 111.458 -2.61 . . . . 0.0 110.6 -167.265 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -72.44 59.46 1.57 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 129.639 3.495 . . . . 0.0 111.152 -178.066 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.401 16.4 p30 2.04 -103.22 0.0 OUTLIER 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 119.583 3.179 . . . . 0.0 119.583 -178.942 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.322 0.1 OUTLIER -40.6 131.29 2.33 Favored 'General case' 0 N--CA 1.432 -1.367 1 N-CA-C 125.478 5.362 . . . . 0.0 125.478 -165.667 . . . . . . . . 4 3 . 1 . 003 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.489 9.7 p 32.63 -38.27 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.247 2 N-CA-C 130.203 7.112 . . . . 0.0 130.203 168.148 . . . . . . . . 3 2 . 1 . 003 nuclear build full ' A' A ' 107' ' ' GLU . . . . . 0.485 ' HA ' ' HD3' ' A' ' 108' ' ' PRO 0.287 0.0 OUTLIER -70.33 115.16 31.88 Favored Pre-proline 0 C--N 1.308 -1.197 0 C-N-CA 115.422 -2.511 . . . . 0.0 114.333 -166.865 . . . . . . . . 4 4 . 1 . 003 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.485 ' HD3' ' HA ' ' A' ' 107' ' ' GLU . 47.7 Cg_exo -62.45 162.82 22.71 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 124.875 3.717 . . . . 0.0 113.576 -170.141 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 54.04 15.91 5.63 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 124.423 1.011 . . . . 0.0 115.314 174.7 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -59.88 136.89 58.15 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 117.987 0.893 . . . . 0.0 108.752 178.929 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -64.23 119.42 10.22 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 174.381 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.6 mt -81.07 -52.33 7.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 17.1 mt -145.56 149.31 34.35 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.29 1.036 . . . . 0.0 110.995 -173.387 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -114.39 128.19 56.22 Favored 'General case' 0 CA--C 1.515 -0.402 1 N-CA-C 98.762 -4.532 . . . . 0.0 98.762 165.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.65 127.0 44.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.744 -165.469 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -74.26 68.29 1.47 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.664 0.786 . . . . 0.0 110.108 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.0 mt -54.2 -38.36 65.56 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.929 0.491 . . . . 0.0 111.102 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -53.68 -44.75 69.97 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.99 0.516 . . . . 0.0 112.162 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.89 -32.52 20.16 Favored 'General case' 0 CA--C 1.527 0.079 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -67.13 -50.59 62.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 O-C-N 121.759 -0.588 . . . . 0.0 110.326 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.345 22.1 pttm -37.0 -54.15 1.84 Allowed Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 118.283 2.698 . . . . 0.0 118.283 -176.796 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -52.63 -22.15 16.33 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.66 2.24 . . . . 0.0 114.095 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 -84.19 -14.36 50.31 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 118.13 -0.938 . . . . 0.0 113.096 -177.767 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 29.3 m -108.77 149.05 38.99 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 119.731 1.15 . . . . 0.0 112.44 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.32 -26.29 20.85 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.586 2.19 . . . . 0.0 110.372 175.674 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 10.0 m -157.85 137.41 12.03 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.564 1.146 . . . . 0.0 108.287 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 13.2 tp -90.29 6.78 41.5 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.876 0.87 . . . . 0.0 111.396 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.1 mmt -50.57 114.26 1.09 Allowed 'General case' 0 C--N 1.342 0.244 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 45.6 m -107.73 88.36 4.3 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -72.49 139.92 32.27 Favored 'Trans proline' 0 N--CA 1.445 -1.352 0 C-N-CA 121.923 1.749 . . . . 0.0 111.976 -178.718 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 16.6 mm -115.51 128.48 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 102.404 -3.184 . . . . 0.0 102.404 173.555 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.5 t -137.43 122.36 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -175.989 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -84.72 123.05 29.95 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.035 -2.58 . . . . 0.0 104.035 174.673 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 40.2 p -80.74 -72.78 0.4 Allowed 'General case' 0 C--O 1.227 -0.129 0 CA-C-N 118.841 0.746 . . . . 0.0 110.796 -175.683 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 22.2 p30 -65.14 -30.06 70.96 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -177.37 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 mt 46.27 44.54 12.5 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.156 0.982 . . . . 0.0 110.347 -176.973 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 42.53 37.39 0.97 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 126.351 1.86 . . . . 0.0 112.662 -175.645 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 75.5 mm-40 48.25 75.32 0.14 Allowed 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 126.706 2.002 . . . . 0.0 113.874 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.03 -14.21 5.19 Favored Glycine 0 C--N 1.335 0.484 0 CA-C-O 118.702 -1.055 . . . . 0.0 113.339 174.723 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -72.65 139.21 47.19 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.206 1.503 . . . . 0.0 109.776 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 77.2 p -111.87 130.81 55.7 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 124.97 1.308 . . . . 0.0 109.128 176.022 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -60.42 112.6 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 123.973 0.909 . . . . 0.0 110.387 -175.363 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 87.28 2.61 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 126.407 1.883 . . . . 0.0 106.518 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 34.7 mt -66.77 131.82 32.35 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -96.58 -44.2 7.25 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.457 ' HB2' HG23 ' A' ' 157' ' ' ILE . . . -47.23 83.1 0.0 OUTLIER 'General case' 0 C--N 1.34 0.158 0 C-N-CA 126.348 1.859 . . . . 0.0 114.206 -178.753 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 37.7 m -82.71 54.59 2.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 123.996 0.918 . . . . 0.0 108.787 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 157.47 -171.65 34.73 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.211 -0.755 . . . . 0.0 111.211 -177.548 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 29.6 t -58.47 138.05 56.93 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 122.794 0.438 . . . . 0.0 110.101 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.7 m -92.86 -173.01 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 123.7 0.8 . . . . 0.0 109.928 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.85 166.7 29.76 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.62 155.03 24.64 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.986 0.812 . . . . 0.0 110.336 176.034 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 62.56 5.12 1.55 Allowed 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.762 1.625 . . . . 0.0 114.301 178.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -67.95 118.22 10.85 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 62.7 tt0 -67.51 138.03 56.23 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.48 ' HB2' ' HA ' ' A' ' 12' ' ' GLU . 29.2 t70 84.92 -113.87 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 128.327 2.651 . . . . 0.0 109.043 -179.318 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.457 HG23 ' HB2' ' A' ' 146' ' ' ALA 0.366 1.7 mp 73.31 -28.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 129.565 3.146 . . . . 0.0 111.509 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.0 p -134.9 148.09 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 127.519 2.328 . . . . 0.0 106.978 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 159' ' ' LYS . . . . . 0.496 ' C ' HD13 ' A' ' 160' ' ' ILE . 26.3 mtpp -134.67 144.93 48.1 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 104.009 -2.589 . . . . 0.0 104.009 173.608 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.496 HD13 ' C ' ' A' ' 159' ' ' LYS . 0.3 OUTLIER -112.0 112.55 40.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.156 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.1 134.02 44.74 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 123.66 0.784 . . . . 0.0 111.247 -174.908 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp . . . . . 0 CA--C 1.528 0.117 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 176.73 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.8 ttt . . . . . 0 N--CA 1.455 -0.212 0 CA-C-O 120.995 0.426 . . . . 0.0 109.866 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 37.1 mm -74.09 79.26 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.239 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -62.93 67.68 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 126.548 1.939 . . . . 0.0 113.9 -175.767 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -119.05 -72.67 0.02 OUTLIER Pre-proline 0 CA--C 1.537 0.47 0 C-N-CA 126.238 1.815 . . . . 0.0 108.273 176.494 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.41 157.49 60.86 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 CA-C-N 121.258 1.485 . . . . 0.0 109.495 176.181 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.25 64.62 0.38 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.853 1.261 . . . . 0.0 112.245 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -71.69 59.82 0.34 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.123 1.769 . . . . 0.0 112.055 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 25.4 t30 -66.16 149.33 50.47 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.854 -0.529 . . . . 0.0 110.223 178.875 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 54.0 mt-10 -76.06 73.14 2.92 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 176.132 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.7 pt -66.51 69.93 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 124.797 1.239 . . . . 0.0 112.486 -178.113 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.72 67.67 1.62 Allowed Glycine 0 CA--C 1.526 0.729 0 C-N-CA 124.332 0.968 . . . . 0.0 110.776 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -74.07 79.25 1.72 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 40.2 mm-40 -73.36 64.65 0.83 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 122.949 0.5 . . . . 0.0 110.486 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER 69.14 -3.51 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 C-N-CA 128.352 2.661 . . . . 0.0 115.116 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.83 147.35 26.86 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 125.443 1.497 . . . . 0.0 114.387 -176.239 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -142.55 103.88 1.05 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 C-N-CA 126.68 1.992 . . . . 0.0 106.267 172.995 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 t -29.14 118.53 0.28 Allowed Pre-proline 0 CA--C 1.552 1.033 0 C-N-CA 124.728 1.211 . . . . 0.0 113.43 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -75.31 -37.47 1.87 Allowed 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 122.693 2.262 . . . . 0.0 117.324 -173.115 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.27 148.06 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 120.397 1.453 . . . . 0.0 109.3 -176.727 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.4 m -78.64 137.04 37.64 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 175.301 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.19 -147.14 14.54 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -107.72 144.1 35.3 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.858 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.1 tt -105.62 95.17 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 C-N-CA 124.304 1.041 . . . . 0.0 108.398 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -85.63 151.58 55.86 Favored Pre-proline 0 C--O 1.237 0.404 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.047 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.26 145.32 88.5 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 N-CA-C 107.888 -1.62 . . . . 0.0 107.888 174.887 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.3 tp -50.67 -32.64 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.672 0.789 . . . . 0.0 111.134 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.9 -29.87 63.41 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.829 1.252 . . . . 0.0 113.057 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -82.24 3.65 26.64 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.524 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.403 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 58.2 t -82.06 128.04 69.56 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-O 117.508 -1.234 . . . . 0.0 111.755 -176.641 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_exo -58.74 40.75 0.05 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 1 C-N-CA 126.354 4.702 . . . . 0.0 117.451 175.298 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -164.48 109.59 0.97 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 120.98 1.718 . . . . 0.0 109.033 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 18.8 mp0 -34.13 -48.52 0.32 Allowed 'General case' 0 C--O 1.231 0.117 0 C-N-CA 128.956 2.902 . . . . 0.0 114.401 -176.805 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.5 p -53.44 -38.95 34.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 CA-C-N 118.158 0.435 . . . . 0.0 110.878 -178.606 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -84.48 -48.83 9.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 177.419 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -51.03 -39.23 55.38 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -178.131 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.38 17.15 57.24 Favored Glycine 0 N--CA 1.445 -0.716 0 CA-C-O 118.219 -1.323 . . . . 0.0 111.06 -177.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.7 mttp 71.18 -40.71 0.48 Allowed 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.463 1.505 . . . . 0.0 114.07 178.88 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 29.97 -73.96 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 130.005 3.322 . . . . 0.0 116.753 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.19 -21.3 46.56 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.476 1.11 . . . . 0.0 113.263 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 172.43 -144.21 7.83 Favored Glycine 0 C--O 1.223 -0.564 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -141.57 160.05 40.95 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.482 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.55 -126.13 1.23 Allowed Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.05 163.73 15.86 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 118.636 1.218 . . . . 0.0 112.261 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.403 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -99.94 96.88 7.84 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 124.575 1.15 . . . . 0.0 110.466 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 32.1 mm -80.44 126.11 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.4 tt -101.03 105.5 39.03 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 100.529 -3.878 . . . . 0.0 100.529 171.381 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -84.37 168.18 11.68 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.891 3.061 . . . . 0.0 114.255 -168.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.9 p -130.8 -71.7 0.57 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.347 1.459 . . . . 0.0 108.199 176.081 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -48.89 127.25 13.72 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 124.609 1.164 . . . . 0.0 112.088 178.748 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.21 42.26 2.34 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 173.899 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 35.9 mt -143.74 120.87 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 104.381 -2.452 . . . . 0.0 104.381 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.408 HG21 ' CE2' ' A' ' 84' ' ' PHE . 53.1 t -119.97 131.09 73.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 124.911 1.284 . . . . 0.0 107.549 -176.528 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.4 m -110.72 159.39 10.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 C-N-CA 124.08 0.952 . . . . 0.0 110.947 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.84 132.7 94.83 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-O 118.41 -0.805 . . . . 0.0 110.21 -179.584 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -68.58 -15.95 42.02 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.638 2.892 . . . . 0.0 115.926 -177.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -143.99 162.02 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.046 0 CA-C-N 119.523 1.056 . . . . 0.0 110.409 -178.66 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 108' ' ' PRO . 9.0 ptp85 -76.73 117.14 18.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 168.716 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 172.96 -179.62 44.28 Favored Glycine 0 N--CA 1.433 -1.529 0 C-N-CA 115.277 -3.344 . . . . 0.0 114.954 -167.246 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.63 127.91 42.05 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 124.558 1.143 . . . . 0.0 109.815 -176.233 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 9.6 mm -73.94 113.32 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 N-CA-C 102.633 -3.099 . . . . 0.0 102.633 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 61.0 tp -76.44 -47.93 21.37 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -174.571 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -174.77 157.4 2.47 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 13.5 t -138.91 119.24 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 175.791 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -42.04 151.53 0.34 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.572 0.624 . . . . 0.0 112.201 177.91 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.19 -26.36 15.03 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 123.89 3.06 . . . . 0.0 114.303 175.0 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 19.2 p -75.73 -15.2 60.31 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 123.871 0.869 . . . . 0.0 110.925 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 71.87 10.11 6.2 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.545 1.538 . . . . 0.0 113.536 178.795 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.437 ' CG ' ' HA ' ' A' ' 89' ' ' VAL . 22.6 p-80 -90.51 -31.62 16.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 119.428 1.013 . . . . 0.0 113.403 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.97 -178.82 7.16 Favored 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -171.007 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.663 23.0 mm 124.01 -132.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 1 C-N-CA 135.155 5.382 . . . . 0.0 105.216 -176.709 . . . . . . . . 3 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -169.86 -179.1 41.33 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 119.165 2.426 . . . . 0.0 119.165 -177.829 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.6 mp -124.56 172.33 9.3 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.747 2.419 . . . . 0.0 110.279 -178.208 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -134.42 142.01 47.0 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 169.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 40.8 p -73.91 -127.37 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.041 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -70.53 -48.44 55.47 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 120.653 -1.279 . . . . 0.0 108.36 176.719 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 170.42 64.78 0.04 OUTLIER Glycine 0 CA--C 1.521 0.406 0 N-CA-C 106.545 -2.622 . . . . 0.0 106.545 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -165.58 -93.81 0.09 OUTLIER Glycine 0 C--N 1.334 0.425 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 -177.808 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -60.38 123.27 16.79 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 117.795 0.798 . . . . 0.0 109.424 178.041 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -103.53 136.35 43.43 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 173.676 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 22.3 mt -125.01 122.95 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -173.782 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 28.2 tp -89.65 136.83 32.8 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 127.193 2.197 . . . . 0.0 106.914 173.367 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.4 mt -120.14 155.63 23.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.652 1.181 . . . . 0.0 109.522 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.57 96.64 1.79 Allowed 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 126.223 1.809 . . . . 0.0 107.021 174.977 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.408 ' CE2' HG21 ' A' ' 52' ' ' VAL . 1.0 OUTLIER -73.68 76.69 1.53 Allowed 'General case' 0 N--CA 1.454 -0.238 0 O-C-N 121.519 -0.738 . . . . 0.0 110.565 -178.071 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.11 170.84 39.89 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.634 1.588 . . . . 0.0 111.775 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 2.0 tp -107.41 125.86 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.845 1.658 . . . . 0.0 106.935 178.03 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t0 58.88 38.6 24.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 125.323 1.449 . . . . 0.0 111.206 -176.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -95.88 -70.85 0.7 Allowed 'General case' 0 CA--C 1.496 -1.126 0 N-CA-C 101.366 -3.568 . . . . 0.0 101.366 171.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.437 ' HA ' ' CG ' ' A' ' 68' ' ' HIS 0.335 1.3 p 45.44 49.22 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 104.492 -2.41 . . . . 0.0 104.492 -172.758 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 21.4 m 12.97 48.38 0.0 OUTLIER 'General case' 0 C--N 1.35 0.592 1 C-N-CA 133.111 4.565 . . . . 0.0 112.83 -165.219 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.414 HD23 ' HA ' ' A' ' 91' ' ' LEU . 1.9 mt 33.66 50.52 0.31 Allowed 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 131.053 3.741 . . . . 0.0 109.001 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 90.5 mttt 76.66 50.26 0.05 Allowed 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 128.148 2.579 . . . . 0.0 111.595 -176.966 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 47.43 37.28 12.24 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 126.472 1.987 . . . . 0.0 114.059 -178.35 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -92.5 161.66 14.53 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 170.366 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 63.56 -4.14 1.11 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.137 1.351 . . . . 0.0 114.822 178.695 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -106.64 105.57 15.67 Favored 'General case' 0 C--N 1.342 0.262 0 CA-C-N 119.077 1.438 . . . . 0.0 111.327 -175.72 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 18.9 m -93.11 104.36 16.57 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 174.341 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.6 t -80.15 148.83 30.77 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 119.203 0.91 . . . . 0.0 110.775 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -115.9 3.85 13.77 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 126.323 1.849 . . . . 0.0 110.785 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.6 m -134.02 145.96 32.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 176.611 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.6 m -82.6 -16.87 46.83 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.973 1.309 . . . . 0.0 112.211 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.472 1.3 pp20? 73.29 140.86 0.06 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.203 3.001 . . . . 0.0 109.574 -172.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 97.5 -16.48 60.5 Favored Glycine 0 CA--C 1.54 1.642 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -169.23 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -57.87 115.66 2.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.632 1.973 . . . . 0.0 108.901 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.25 123.01 29.67 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 128.912 2.885 . . . . 0.0 114.254 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.345 27.3 m 52.23 70.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.301 0 C-N-CA 126.992 2.117 . . . . 0.0 116.032 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 138.44 26.55 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 170.161 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' PRO . . . . . 0.404 ' HA ' ' HA ' ' A' ' 57' ' ' ARG . 0.9 OUTLIER -93.63 -135.49 0.01 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.004 0 C-N-CA 124.978 3.785 . . . . 0.0 108.522 -179.229 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -64.21 30.09 0.09 OUTLIER Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.334 1.921 . . . . 0.0 115.678 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.8 tt0 -64.58 149.8 48.12 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 169.262 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -64.32 122.11 15.91 Favored 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.739 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.7 mt -80.44 -49.43 11.44 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 175.468 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.1 mt -144.04 152.43 41.0 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.007 0.923 . . . . 0.0 110.708 -173.873 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -114.49 128.83 56.54 Favored 'General case' 0 CA--C 1.517 -0.298 1 N-CA-C 98.95 -4.463 . . . . 0.0 98.95 165.802 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.44 128.47 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.469 -165.603 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -76.82 63.57 2.23 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.623 0.725 . . . . 0.0 109.856 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 80.0 mt -54.34 -37.68 65.16 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 123.248 0.619 . . . . 0.0 110.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -53.76 -43.37 69.13 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.761 0.824 . . . . 0.0 112.247 178.342 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.92 -34.54 20.9 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.059 0.391 . . . . 0.0 111.411 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 75.4 t -62.01 -55.43 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.722 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.355 18.8 pttp -38.96 -58.33 1.76 Allowed Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 117.596 2.443 . . . . 0.0 117.596 -176.098 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.49 -20.28 48.43 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.774 2.316 . . . . 0.0 113.717 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -100.13 9.2 43.18 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 118.551 -0.738 . . . . 0.0 112.726 -176.795 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 22.8 m -136.23 158.48 73.53 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 119.573 1.079 . . . . 0.0 109.36 -178.761 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -75.7 -30.0 6.63 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.017 1.811 . . . . 0.0 112.783 -177.47 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -163.88 133.96 4.2 Favored 'General case' 0 N--CA 1.454 -0.241 0 O-C-N 121.395 -0.816 . . . . 0.0 111.287 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -93.42 9.07 38.02 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.961 0.904 . . . . 0.0 111.564 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -50.89 110.04 0.38 Allowed 'General case' 0 C--N 1.342 0.242 0 C-N-CA 124.301 1.041 . . . . 0.0 108.327 177.87 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.8 m -95.83 102.49 10.52 Favored Pre-proline 0 N--CA 1.447 -0.607 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -92.39 99.66 0.18 Allowed 'Trans proline' 0 N--CA 1.444 -1.422 0 C-N-CA 123.414 2.743 . . . . 0.0 107.679 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.08 126.5 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 103.503 -2.777 . . . . 0.0 103.503 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.05 120.43 51.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 CA-C-O 121.928 0.871 . . . . 0.0 109.303 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.485 ' N ' ' CD1' ' A' ' 133' ' ' PHE . 0.5 OUTLIER -83.0 114.14 21.06 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 101.732 -3.432 . . . . 0.0 101.732 177.592 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -77.16 -79.69 0.11 Allowed 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 121.007 0.432 . . . . 0.0 111.216 -170.824 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.23 68.12 0.72 Allowed 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.988 0.899 . . . . 0.0 111.298 -178.696 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.1 mt -76.76 65.28 2.47 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.128 -0.982 . . . . 0.0 108.364 177.119 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 10.18 63.03 0.0 OUTLIER 'General case' 0 C--N 1.347 0.458 0 C-N-CA 130.582 3.553 . . . . 0.0 112.815 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 25.97 58.02 0.06 Allowed 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 128.52 2.728 . . . . 0.0 114.514 -176.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 148.71 6.2 0.23 Allowed Glycine 0 CA--C 1.524 0.617 0 CA-C-O 118.577 -1.124 . . . . 0.0 114.033 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.733 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 22.4 mt-10 -77.76 92.76 4.21 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 119.439 1.62 . . . . 0.0 107.894 177.251 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 70.1 p -76.69 135.06 39.08 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -177.359 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.2 t -87.32 90.74 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 124.0 0.92 . . . . 0.0 109.26 -176.768 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 42.1 m -85.68 95.6 9.42 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 33.0 mt -64.58 131.84 30.36 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.394 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -100.94 -45.9 5.28 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 124.665 1.186 . . . . 0.0 109.055 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.67 74.81 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.234 0 C-N-CA 126.113 1.765 . . . . 0.0 112.02 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.1 m -79.71 54.47 1.82 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.443 1.097 . . . . 0.0 110.025 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 160.7 179.66 35.6 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 40.5 t -57.16 144.83 33.46 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.172 0.589 . . . . 0.0 111.616 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 4.9 m -145.04 166.96 10.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -102.36 166.86 10.33 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 124.849 1.26 . . . . 0.0 111.48 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.29 163.41 23.02 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 63.96 -9.42 0.15 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.727 2.011 . . . . 0.0 114.552 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 34.2 mm-40 -64.32 148.96 49.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.456 1.025 . . . . 0.0 111.581 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -99.33 159.38 15.05 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.527 2.331 . . . . 0.0 111.099 -176.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 24.9 t70 57.55 21.83 7.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 126.137 1.775 . . . . 0.0 114.621 174.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.464 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -70.35 -28.64 36.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 C-N-CA 123.61 0.764 . . . . 0.0 111.812 178.951 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.44 145.14 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 C-N-CA 125.5 1.52 . . . . 0.0 107.866 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -120.57 111.86 18.2 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 174.054 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.733 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.03 110.53 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 103.84 -2.652 . . . . 0.0 103.84 172.871 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -109.11 125.04 51.73 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.956 1.303 . . . . 0.0 109.883 -178.188 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 56.2 tptt . . . . . 0 C--N 1.333 -0.14 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.109 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 38.7 mtt . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 9.4 tp -49.62 -31.67 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 123.324 0.65 . . . . 0.0 112.239 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.59 38.28 4.15 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.802 0.841 . . . . 0.0 111.126 178.205 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -156.02 122.15 2.59 Favored Pre-proline 0 CA--C 1.537 0.476 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -72.09 63.44 3.37 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 123.174 2.583 . . . . 0.0 113.918 -177.02 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 17.9 tp 38.7 58.73 1.66 Allowed 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.58 2.352 . . . . 0.0 113.604 176.775 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 10.5 pt20 -163.76 -143.92 0.08 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 125.101 1.36 . . . . 0.0 107.661 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 29.0 t30 -128.84 148.77 50.92 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 175.332 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 24.4 mp0 -70.62 70.58 0.46 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.537 1.135 . . . . 0.0 111.478 -178.197 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.9 pt -137.48 119.46 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 C-N-CA 125.851 1.66 . . . . 0.0 106.863 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 77.11 -72.58 2.08 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 107.04 -2.424 . . . . 0.0 107.04 -175.143 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -79.69 70.62 6.23 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 104.697 -2.335 . . . . 0.0 104.697 171.151 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -122.08 -166.95 1.47 Allowed 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.024 1.729 . . . . 0.0 111.829 -178.017 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.486 8.1 p 64.64 -114.0 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 116.687 2.106 . . . . 0.0 116.687 176.339 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.66 130.76 39.25 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 127.552 2.341 . . . . 0.0 111.467 -168.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.2 m -90.51 101.5 12.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 CA-C-N 118.882 0.765 . . . . 0.0 110.568 177.072 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.3 p -35.44 115.56 0.56 Allowed Pre-proline 0 CA--C 1.556 1.211 0 C-N-CA 125.831 1.652 . . . . 0.0 110.891 177.317 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -75.72 -30.45 6.16 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.832 2.354 . . . . 0.0 117.685 -171.01 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.49 148.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 120.513 1.506 . . . . 0.0 110.806 -176.764 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.8 m -79.27 138.81 37.91 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 171.539 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.62 -151.69 20.51 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -117.05 116.33 27.14 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.218 1.407 . . . . 0.0 108.435 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 7.5 mt -78.84 138.17 20.58 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 CA-C-N 118.666 0.666 . . . . 0.0 109.617 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -137.03 144.75 47.56 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 174.458 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -54.9 142.73 74.67 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 C-N-CA 121.967 1.778 . . . . 0.0 110.109 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.22 -36.44 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 124.646 1.178 . . . . 0.0 113.187 -177.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.2 p -51.38 -32.68 26.91 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.911 1.285 . . . . 0.0 112.559 178.185 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -75.94 -9.61 58.75 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 124.224 1.009 . . . . 0.0 112.505 -175.288 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.551 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 52.9 t -75.16 119.73 78.33 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-O 117.662 -1.161 . . . . 0.0 111.529 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -59.34 53.94 0.07 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 1 C-N-CA 126.067 4.511 . . . . 0.0 117.071 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -167.69 112.03 0.67 Allowed 'General case' 0 N--CA 1.463 0.186 0 O-C-N 120.464 -1.398 . . . . 0.0 108.684 177.083 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -30.67 -51.46 0.15 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 127.609 2.363 . . . . 0.0 114.589 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.3 t -52.97 -47.33 53.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 CA-C-O 121.508 0.67 . . . . 0.0 110.05 -178.627 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -78.08 -46.95 19.41 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -50.38 -43.01 54.3 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -97.62 11.94 64.69 Favored Glycine 0 C--N 1.338 0.657 0 CA-C-O 118.909 -0.94 . . . . 0.0 111.499 -178.779 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? 70.13 -34.8 0.3 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.809 1.644 . . . . 0.0 114.032 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.6 tmt? 32.18 -69.27 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 131.286 3.834 . . . . 0.0 116.576 178.312 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 7.8 tpt -78.58 -19.99 51.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.185 0.994 . . . . 0.0 111.981 -175.918 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.15 -133.13 1.82 Allowed Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 44.9 t0 -136.45 158.56 44.14 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 172.944 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 176.19 -154.45 16.93 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.383 -0.913 . . . . 0.0 111.706 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.556 ' CE2' HD11 ' A' ' 45' ' ' ILE . 38.7 p90 -158.25 164.48 36.43 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 122.533 0.333 . . . . 0.0 110.2 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.551 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -102.45 146.3 28.3 Favored 'General case' 0 CA--C 1.508 -0.665 0 C-N-CA 123.742 0.817 . . . . 0.0 109.369 178.267 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.556 HD11 ' CE2' ' A' ' 43' ' ' PHE . 4.4 mp -124.93 128.19 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 102.635 -3.098 . . . . 0.0 102.635 169.131 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.3 tt -91.33 106.78 17.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 172.865 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -61.32 170.34 5.35 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 124.111 3.207 . . . . 0.0 116.166 -171.074 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.5 p -152.29 -65.01 0.17 Allowed 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 125.089 1.356 . . . . 0.0 107.876 176.361 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -61.85 127.61 32.25 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.47 0.708 . . . . 0.0 110.188 176.812 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.83 43.95 2.9 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 172.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -145.36 124.35 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 127.381 2.273 . . . . 0.0 105.138 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 89.9 t -123.53 126.49 73.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.03 155.04 9.0 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 C-N-CA 123.716 0.807 . . . . 0.0 110.268 178.7 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.79 139.31 95.5 Favored Pre-proline 0 N--CA 1.449 -0.519 0 C-N-CA 123.585 0.754 . . . . 0.0 110.192 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -78.28 -21.91 10.08 Favored 'Trans proline' 0 N--CA 1.453 -0.885 0 C-N-CA 123.51 2.807 . . . . 0.0 114.221 -177.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.7 m -138.92 166.61 22.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.163 0 C-N-CA 124.325 1.05 . . . . 0.0 111.007 -177.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -78.81 115.96 18.83 Favored 'General case' 0 C--O 1.234 0.253 1 N-CA-C 99.376 -4.305 . . . . 0.0 99.376 168.338 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.32 176.6 47.89 Favored Glycine 0 N--CA 1.441 -1.015 0 C-N-CA 115.606 -3.188 . . . . 0.0 117.015 -168.839 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 123.72 30.54 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.769 1.628 . . . . 0.0 108.505 178.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 16.7 mm -75.45 95.77 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 172.862 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 49.9 tp -72.41 -51.27 21.13 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -171.05 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -171.19 137.06 1.1 Allowed 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 118.472 0.578 . . . . 0.0 111.423 177.323 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -128.15 123.9 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 103.761 -2.681 . . . . 0.0 103.761 172.433 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.33 156.61 0.48 Allowed Pre-proline 0 CA--C 1.54 0.578 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -178.812 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -50.05 -29.71 22.63 Favored 'Trans proline' 0 C--N 1.348 0.517 0 C-N-CA 123.924 3.083 . . . . 0.0 114.562 178.265 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.6 p -77.56 -9.04 58.7 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.511 1.124 . . . . 0.0 111.64 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.22 8.43 3.36 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 127.835 2.454 . . . . 0.0 113.202 -178.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -80.88 -27.76 36.22 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -160.68 -176.35 5.5 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 119.204 0.911 . . . . 0.0 111.677 -174.111 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.402 HG22 ' H ' ' A' ' 71' ' ' GLY 0.898 18.3 mm 129.0 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.184 1 C-N-CA 131.846 4.058 . . . . 0.0 111.355 176.485 . . . . . . . . 4 3 . 1 . 005 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.402 ' H ' HG22 ' A' ' 70' ' ' ILE . . . -147.36 168.23 28.44 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 116.6 1.4 . . . . 0.0 116.6 -173.997 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -132.49 169.15 16.98 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 126.349 1.86 . . . . 0.0 108.619 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.11 144.71 38.82 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 175.847 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 89.2 p -81.5 -112.67 0.02 OUTLIER 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 176.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -148.72 -55.94 0.2 Allowed 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 128.248 2.619 . . . . 0.0 106.689 177.024 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -75.52 62.31 2.73 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 124.113 0.863 . . . . 0.0 111.5 177.782 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 72.34 -54.05 1.51 Allowed Glycine 0 CA--C 1.532 1.126 0 N-CA-C 115.585 0.994 . . . . 0.0 115.585 175.739 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 -39.53 121.52 1.22 Allowed 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.696 1.199 . . . . 0.0 113.656 -174.595 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -111.55 148.3 33.53 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.283 2.233 . . . . 0.0 107.107 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.38 144.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 124.269 1.028 . . . . 0.0 109.66 -176.585 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -125.62 132.58 52.46 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 128.159 2.583 . . . . 0.0 105.439 176.693 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 39.0 mt -131.98 141.9 44.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 C-N-CA 124.798 1.239 . . . . 0.0 109.715 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -132.55 104.96 6.94 Favored 'General case' 0 C--O 1.226 -0.178 0 C-N-CA 124.335 1.054 . . . . 0.0 108.475 174.648 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.7 t80 -68.35 109.65 3.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 121.109 -0.995 . . . . 0.0 109.092 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.67 -165.82 7.79 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -176.785 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 31.4 mt -122.29 136.5 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.7 t0 55.48 42.61 29.69 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.555 1.142 . . . . 0.0 112.645 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.435 ' O ' ' N ' ' A' ' 90' ' ' SER . 1.8 p -80.19 -85.22 0.09 Allowed 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 103.093 -2.929 . . . . 0.0 103.093 172.215 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.418 HG13 ' H ' ' A' ' 90' ' ' SER . 12.1 p 26.43 -64.82 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 C-N-CA 128.883 2.873 . . . . 0.0 117.293 173.441 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 88' ' ' THR . 11.8 m -60.44 -36.83 79.13 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 126.624 1.97 . . . . 0.0 109.675 178.468 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -50.9 -36.71 39.65 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 128.216 2.606 . . . . 0.0 109.617 176.343 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp 70.49 151.75 0.1 Allowed 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 126.303 1.841 . . . . 0.0 109.673 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -65.91 25.99 0.15 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 115.153 0.821 . . . . 0.0 115.153 -178.315 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 20.5 mm-40 -59.21 -35.16 73.13 Favored 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.689 1.744 . . . . 0.0 112.085 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -98.02 15.26 61.81 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.764 178.23 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -123.31 96.57 5.04 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 118.884 1.342 . . . . 0.0 109.545 -176.716 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.7 m -81.52 111.77 18.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 173.251 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.8 p -86.11 138.53 31.85 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.563 -0.711 . . . . 0.0 111.279 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -107.51 7.16 28.68 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 125.57 1.548 . . . . 0.0 113.389 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 20.5 m -140.42 144.37 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 175.808 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.7 m -79.51 -15.77 57.16 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.175 0.99 . . . . 0.0 112.772 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.442 16.1 pm0 69.03 147.46 0.06 Allowed 'General case' 0 N--CA 1.446 -0.671 0 C-N-CA 130.065 3.346 . . . . 0.0 111.209 -173.214 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 95.22 -21.78 42.25 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 124.709 1.147 . . . . 0.0 110.466 -172.84 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -60.63 124.57 20.78 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.919 1.688 . . . . 0.0 108.914 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.33 123.64 31.8 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 129.162 2.985 . . . . 0.0 113.308 -174.571 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.373 28.5 m 52.23 69.89 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.142 0 N-CA-C 117.018 2.229 . . . . 0.0 117.018 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.35 139.85 27.36 Favored Pre-proline 0 N--CA 1.45 -0.455 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 168.767 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -88.19 -151.25 0.04 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 123.686 2.924 . . . . 0.0 108.544 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -69.68 54.36 0.71 Allowed Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.908 1.242 . . . . 0.0 113.924 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -54.22 -55.07 31.57 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 124.97 1.308 . . . . 0.0 110.037 177.314 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt 144.87 125.67 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.621 1 C-N-CA 132.615 4.366 . . . . 0.0 106.098 -175.591 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 69.9 mt -91.83 -45.51 8.35 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 123.652 0.781 . . . . 0.0 109.385 178.182 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.2 mt -147.52 151.87 37.07 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 122.798 0.439 . . . . 0.0 111.101 -174.881 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -116.31 127.21 54.49 Favored 'General case' 0 CA--C 1.517 -0.291 1 N-CA-C 98.557 -4.608 . . . . 0.0 98.557 165.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.23 126.34 45.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.721 -166.357 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -74.75 61.03 0.96 Allowed 'General case' 0 C--O 1.233 0.224 0 C-N-CA 125.259 1.423 . . . . 0.0 111.239 -176.765 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.5 mt -45.94 -41.82 12.08 Favored 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 124.326 1.05 . . . . 0.0 111.94 -178.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -49.15 -41.4 36.17 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.622 0.769 . . . . 0.0 112.501 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -92.57 -33.77 14.3 Favored 'General case' 0 CA--C 1.527 0.066 0 C-N-CA 123.467 0.707 . . . . 0.0 111.353 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.26 -51.95 64.77 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.617 -0.677 . . . . 0.0 109.468 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.368 46.1 pttt -41.87 -58.07 3.58 Favored Pre-proline 0 CA--C 1.541 0.599 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -177.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -57.18 -19.8 35.56 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.435 2.09 . . . . 0.0 113.327 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -95.49 7.98 44.63 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 118.097 -0.954 . . . . 0.0 112.488 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 23.9 m -132.91 150.51 75.87 Favored Pre-proline 0 N--CA 1.466 0.333 0 CA-C-N 120.086 1.312 . . . . 0.0 111.506 179.643 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -73.78 -27.41 12.52 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 C-N-CA 122.867 2.378 . . . . 0.0 111.635 179.243 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -157.42 132.01 8.56 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.598 -0.689 . . . . 0.0 109.926 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -90.35 -2.06 57.96 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.712 1.205 . . . . 0.0 111.769 -179.019 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.6 mmt -49.65 111.26 0.48 Allowed 'General case' 0 C--N 1.34 0.194 0 C-N-CA 124.399 1.08 . . . . 0.0 109.353 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 49.9 m -102.73 110.14 62.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 -178.432 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -91.33 137.62 2.1 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 122.843 2.362 . . . . 0.0 110.538 -179.201 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 15.3 mm -114.46 121.17 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 102.893 -3.003 . . . . 0.0 102.893 173.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.1 t -126.43 149.11 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -177.393 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -123.1 124.99 44.34 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 36.1 p -83.58 -67.76 0.76 Allowed 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.771 0.796 . . . . 0.0 110.638 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.8 p30 -72.0 51.7 0.23 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.99 1.716 . . . . 0.0 113.587 -177.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.429 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 78.2 mt -80.49 54.31 2.03 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.393 1.077 . . . . 0.0 108.961 175.615 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 16.33 55.67 0.01 OUTLIER 'General case' 0 C--N 1.346 0.438 0 C-N-CA 129.59 3.156 . . . . 0.0 113.403 -177.938 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 27.56 56.47 0.08 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 127.715 2.406 . . . . 0.0 113.829 -175.465 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 165.68 -10.83 0.07 OUTLIER Glycine 0 CA--C 1.526 0.758 0 CA-C-O 119.321 -0.71 . . . . 0.0 113.638 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.585 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 16.2 mt-10 -78.73 82.07 4.98 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.752 1.276 . . . . 0.0 107.932 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.7 p -74.3 138.49 43.59 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.404 -0.81 . . . . 0.0 109.93 -175.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -83.65 122.29 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 123.66 0.784 . . . . 0.0 109.234 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.6 m -112.75 97.82 6.81 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.867 1.267 . . . . 0.0 109.178 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.2 pt -71.08 108.37 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 176.503 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -77.08 -55.47 5.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -82.88 66.08 8.32 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 49.2 m -77.6 69.72 3.88 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.81 -150.16 7.62 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 107.105 -2.398 . . . . 0.0 107.105 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 10.4 t -75.64 146.08 40.56 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 118.297 1.048 . . . . 0.0 110.556 178.316 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -143.71 167.3 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 124.555 1.142 . . . . 0.0 109.777 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 35.2 m-80 -113.69 163.75 14.59 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 125.236 1.414 . . . . 0.0 107.647 174.557 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.94 165.35 25.4 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 170.637 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 56.88 48.42 15.99 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.565 1.146 . . . . 0.0 111.862 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -121.96 159.18 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 173.83 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -126.46 153.66 44.77 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 119.228 0.922 . . . . 0.0 111.188 -176.687 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.7 t70 62.95 13.65 6.83 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 126.702 2.001 . . . . 0.0 113.191 -176.554 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.54 -37.85 78.79 Favored 'Isoleucine or valine' 0 C--O 1.233 0.207 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.7 p -117.88 129.29 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 N-CA-C 103.486 -2.783 . . . . 0.0 103.486 168.871 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -122.81 123.73 41.7 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.585 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.26 130.61 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 174.584 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -130.97 139.25 50.0 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.221 1.408 . . . . 0.0 107.269 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.3 tptm . . . . . 0 C--N 1.331 -0.215 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 -177.795 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.2 mtt . . . . . 0 N--CA 1.453 -0.303 0 CA-C-O 120.652 0.263 . . . . 0.0 110.675 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 23.2 mt -78.17 65.31 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.68 -35.19 18.12 Favored 'General case' 0 C--O 1.223 -0.332 0 C-N-CA 124.974 1.31 . . . . 0.0 111.92 -177.431 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 51.58 72.29 1.25 Allowed Pre-proline 0 CA--C 1.543 0.69 0 C-N-CA 124.507 1.123 . . . . 0.0 112.331 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -55.19 127.37 26.02 Favored 'Trans proline' 0 N--CA 1.455 -0.771 0 C-N-CA 123.288 2.659 . . . . 0.0 111.609 179.567 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 21.9 tp -69.49 70.96 0.29 Allowed 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.434 1.494 . . . . 0.0 111.088 -178.045 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 57.51 15.94 3.04 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.762 2.025 . . . . 0.0 114.058 178.383 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.2 t-20 -165.72 156.32 13.29 Favored 'General case' 0 N--CA 1.454 -0.263 0 O-C-N 121.374 -0.829 . . . . 0.0 108.935 177.669 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -160.84 -43.23 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 128.107 2.563 . . . . 0.0 107.142 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 79.0 mt -50.74 102.53 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 126.918 2.087 . . . . 0.0 106.724 175.406 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 171.09 -52.43 0.19 Allowed Glycine 0 CA--C 1.524 0.631 0 N-CA-C 106.104 -2.798 . . . . 0.0 106.104 -176.342 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 41.17 46.95 2.75 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 126.105 1.762 . . . . 0.0 113.408 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -68.97 153.42 43.82 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.819 1.647 . . . . 0.0 110.673 176.924 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.4 m -63.99 66.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.133 0 N-CA-C 117.776 2.51 . . . . 0.0 117.776 -175.058 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -135.43 105.82 6.4 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 105.6 -2.0 . . . . 0.0 105.6 171.482 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.32 91.3 2.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.269 0 CA-C-N 118.991 0.814 . . . . 0.0 112.352 -176.901 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.6 t -21.95 111.34 0.14 Allowed Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 126.373 1.869 . . . . 0.0 112.282 176.602 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -74.11 -28.58 10.74 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.181 2.587 . . . . 0.0 118.338 -169.716 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.64 153.31 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 120.339 1.427 . . . . 0.0 110.496 -176.722 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 92.1 m -88.32 125.38 34.65 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 172.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 179.72 -170.43 41.74 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -176.129 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -98.63 133.93 42.27 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 11.2 tt -81.94 146.22 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 123.111 0.564 . . . . 0.0 111.148 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -144.8 137.35 13.49 Favored Pre-proline 0 C--O 1.237 0.397 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -59.58 146.18 95.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.094 1.863 . . . . 0.0 111.452 178.509 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.9 tp -50.04 -36.93 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 C-N-CA 125.176 1.39 . . . . 0.0 112.062 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 p -70.27 -12.08 61.34 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.034 1.734 . . . . 0.0 114.195 -179.436 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -112.79 29.12 8.22 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.897 0.772 . . . . 0.0 111.636 -173.537 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.3 t -94.08 135.11 24.95 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 124.327 1.051 . . . . 0.0 109.564 178.605 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -65.5 50.82 0.24 Allowed 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 124.216 3.277 . . . . 0.0 115.054 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -166.77 133.89 2.49 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 120.489 -1.382 . . . . 0.0 109.815 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -59.8 -47.51 85.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.873 1.269 . . . . 0.0 113.109 -177.919 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 55.0 t -55.07 -54.97 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 118.596 0.634 . . . . 0.0 109.389 -178.61 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -61.38 -58.68 7.25 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.973 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 59.0 m -69.47 -16.0 63.38 Favored 'General case' 0 N--CA 1.461 0.082 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -177.292 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -88.91 -0.1 81.62 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 108.44 -1.864 . . . . 0.0 108.44 173.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 57.5 mttp 74.16 -39.88 0.44 Allowed 'General case' 0 C--N 1.346 0.438 0 C-N-CA 126.498 1.919 . . . . 0.0 111.56 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 14.9 tpt 28.9 -76.74 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 130.436 3.494 . . . . 0.0 116.461 178.263 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 11.0 ttt -79.24 -17.57 54.52 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.741 0.816 . . . . 0.0 113.059 -175.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.44 -135.28 2.83 Favored Glycine 0 C--N 1.338 0.643 0 CA-C-N 119.128 0.877 . . . . 0.0 112.382 -176.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -137.23 157.84 45.75 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.53 -157.77 19.15 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.764 -175.62 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -158.74 158.81 34.36 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.773 1.229 . . . . 0.0 108.203 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.23 132.96 52.49 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-N 118.836 0.744 . . . . 0.0 110.418 177.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.457 HD12 HG21 ' A' ' 150' ' ' VAL . 22.6 mm -117.35 107.25 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 173.896 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 11.9 tp -74.79 119.06 74.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 N-CA-C 102.329 -3.212 . . . . 0.0 102.329 172.067 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.04 153.38 22.04 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 123.095 2.53 . . . . 0.0 113.721 -168.98 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 79.2 p -126.18 -45.78 1.68 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.651 0.78 . . . . 0.0 112.242 178.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -64.43 -42.27 96.11 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.833 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.58 25.34 70.32 Favored Glycine 0 CA--C 1.533 1.188 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -173.012 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 54.0 mt -136.5 123.59 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 102.496 -3.149 . . . . 0.0 102.496 177.042 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 79.1 t -124.49 124.66 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 C-N-CA 124.397 1.079 . . . . 0.0 109.945 -171.752 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -107.12 155.8 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.126 0 C-N-CA 123.715 0.806 . . . . 0.0 109.493 176.743 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -61.82 139.63 95.52 Favored Pre-proline 0 N--CA 1.448 -0.551 0 C-N-CA 123.624 0.77 . . . . 0.0 110.544 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -75.31 -13.01 20.9 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 124.307 3.338 . . . . 0.0 115.03 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -148.11 161.65 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.056 0 CA-C-N 119.443 1.02 . . . . 0.0 110.213 -176.651 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 116.99 19.6 Favored 'General case' 0 C--O 1.237 0.402 1 N-CA-C 100.103 -4.036 . . . . 0.0 100.103 167.653 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 173.27 -177.34 45.73 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 115.544 -3.217 . . . . 0.0 116.428 -168.451 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.15 122.04 28.78 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.161 0.984 . . . . 0.0 112.512 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.4 mm -66.2 125.59 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 N-CA-C 103.058 -2.942 . . . . 0.0 103.058 168.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 40.7 tp -78.39 -40.75 35.23 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 119.643 1.111 . . . . 0.0 109.213 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -175.43 -163.75 0.13 Allowed 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.683 ' HA ' HG21 ' A' ' 70' ' ' ILE . 7.3 p -160.51 125.42 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 172.446 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.3 m-85 -68.0 145.1 97.61 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 119.291 0.951 . . . . 0.0 110.361 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -50.6 -29.27 24.59 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 123.484 2.789 . . . . 0.0 113.532 176.096 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.1 p -77.3 -7.91 56.76 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.756 0.822 . . . . 0.0 111.956 -178.92 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.8 ttmt 64.06 -11.18 0.12 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.828 1.651 . . . . 0.0 114.914 177.618 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 9.3 p-80 -74.72 -29.4 61.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 121.665 -0.647 . . . . 0.0 112.688 -175.853 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.46 176.8 11.62 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-N 118.893 0.77 . . . . 0.0 110.368 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.683 HG21 ' HA ' ' A' ' 63' ' ' VAL . 0.1 OUTLIER 157.31 -148.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.355 0 C-N-CA 130.492 3.517 . . . . 0.0 106.056 176.318 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.494 ' H ' ' CG1' ' A' ' 70' ' ' ILE . . . -152.51 174.21 31.44 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 123.477 0.561 . . . . 0.0 111.804 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -141.19 176.78 8.56 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 126.486 1.914 . . . . 0.0 108.045 -178.128 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 30.5 mt-30 -143.08 156.02 44.73 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 103.634 -2.728 . . . . 0.0 103.634 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 69.6 p -78.26 -117.46 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -71.1 -51.04 27.36 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.366 -0.834 . . . . 0.0 108.79 177.107 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -171.73 46.27 0.18 Allowed Glycine 0 CA--C 1.528 0.874 0 N-CA-C 109.006 -1.637 . . . . 0.0 109.006 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 179.93 179.12 48.79 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 107.031 -2.428 . . . . 0.0 107.031 -178.029 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 69.0 mtm180 55.94 65.91 1.33 Allowed 'General case' 0 C--N 1.337 0.031 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -175.65 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -73.45 119.77 18.14 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.7 mp -98.38 149.97 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 125.432 1.493 . . . . 0.0 108.574 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.6 tp -128.88 136.05 49.91 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 127.745 2.418 . . . . 0.0 104.849 176.087 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 46.0 mt -129.93 136.2 59.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -129.74 84.71 2.23 Favored 'General case' 0 N--CA 1.466 0.335 0 C-N-CA 123.481 0.712 . . . . 0.0 110.619 176.993 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -56.67 98.94 0.03 OUTLIER 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.528 0.731 . . . . 0.0 111.303 -179.241 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.75 -177.16 5.17 Favored Glycine 0 CA--C 1.531 1.059 0 C-N-CA 124.092 0.853 . . . . 0.0 112.463 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.1 mt -121.73 140.23 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 69.82 9.4 7.13 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.384 1.474 . . . . 0.0 112.313 -177.428 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -75.6 -34.41 60.62 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 126.358 1.863 . . . . 0.0 108.156 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.5 p -54.32 -46.79 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 CA-C-N 113.468 -1.696 . . . . 0.0 108.028 171.653 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -62.05 -39.21 91.57 Favored 'General case' 0 N--CA 1.455 -0.198 0 C-N-CA 124.491 1.116 . . . . 0.0 109.425 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.99 3.17 5.67 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.934 1.694 . . . . 0.0 111.322 177.14 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 48.13 32.48 3.02 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 126.068 1.747 . . . . 0.0 112.993 178.141 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.74 28.29 60.07 Favored Glycine 0 CA--C 1.535 1.323 0 O-C-N 122.009 -0.432 . . . . 0.0 112.828 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 51.9 mt-10 -72.4 91.04 1.33 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.963 1.381 . . . . 0.0 108.843 178.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 6.12 4.24 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 126.745 2.117 . . . . 0.0 111.391 -176.877 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.529 ' CD1' HG12 ' A' ' 115' ' ' VAL . 14.6 m-30 -103.27 131.12 50.57 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.187 1.395 . . . . 0.0 108.477 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 14.3 m -119.98 122.79 41.95 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 126.245 1.818 . . . . 0.0 107.159 -179.315 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.1 p -99.32 124.63 44.57 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.612 0.765 . . . . 0.0 109.957 -176.372 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -90.59 -48.81 6.85 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.566 1.546 . . . . 0.0 111.294 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.43 130.76 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 C-N-CA 117.149 -1.82 . . . . 0.0 107.283 175.666 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 71.1 m -94.51 55.1 1.9 Allowed 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 102.743 -3.058 . . . . 0.0 102.743 168.693 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.588 0.4 OUTLIER 43.58 -77.63 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.774 0 C-N-CA 130.627 3.571 . . . . 0.0 113.465 -167.57 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.4 35.6 36.2 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 125.108 1.337 . . . . 0.0 110.45 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.373 4.1 p30 4.38 -106.6 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 130.049 3.34 . . . . 0.0 119.313 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -33.62 111.94 0.12 Allowed 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 130.993 3.717 . . . . 0.0 119.047 -169.234 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.363 27.4 m 48.61 68.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 129.08 2.952 . . . . 0.0 118.036 173.487 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 139.22 27.48 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 167.797 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -90.37 -145.04 0.03 OUTLIER 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.56 2.84 . . . . 0.0 108.302 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -70.81 52.05 0.92 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 124.875 1.226 . . . . 0.0 113.885 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.7 tp60 -61.83 -22.25 65.34 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 125.858 1.663 . . . . 0.0 113.707 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt 108.1 111.84 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 130.103 3.361 . . . . 0.0 107.971 -176.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 73.5 mt -80.25 -53.2 6.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 23.0 mt -143.04 163.94 31.44 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 123.743 0.817 . . . . 0.0 111.721 -174.728 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -128.19 135.33 49.58 Favored 'General case' 0 CA--C 1.515 -0.4 1 N-CA-C 99.81 -4.145 . . . . 0.0 99.81 166.707 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.529 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -144.92 121.28 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -166.303 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -70.53 64.98 0.29 Allowed 'General case' 0 C--O 1.234 0.246 0 C-N-CA 125.569 1.548 . . . . 0.0 113.019 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 88.5 mt -40.81 -54.27 2.7 Favored 'General case' 0 C--O 1.226 -0.165 0 C-N-CA 124.91 1.284 . . . . 0.0 111.909 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -49.81 -41.36 44.57 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.485 1.114 . . . . 0.0 113.879 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.43 -35.01 15.4 Favored 'General case' 0 C--O 1.23 0.056 0 C-N-CA 122.454 0.302 . . . . 0.0 111.496 -177.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.9 t -67.21 -50.61 61.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 O-C-N 121.764 -0.585 . . . . 0.0 109.529 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.347 48.5 pttt -40.11 -57.78 2.61 Favored Pre-proline 0 CA--C 1.539 0.55 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.91 -21.85 43.06 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 122.509 2.139 . . . . 0.0 113.132 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -97.43 6.89 47.51 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 118.387 -0.816 . . . . 0.0 112.655 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 30.2 m -136.49 151.14 72.39 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-N 119.898 1.226 . . . . 0.0 110.262 178.958 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.79 -25.16 12.59 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.535 2.157 . . . . 0.0 112.206 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.9 m -158.24 128.09 5.95 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 119.038 0.835 . . . . 0.0 111.27 -177.764 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.32 -0.23 57.31 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.823 1.249 . . . . 0.0 110.72 176.708 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 82.6 mmm -50.37 103.0 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 126.221 1.808 . . . . 0.0 109.754 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 68.6 m -99.09 117.39 64.27 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 123.814 0.845 . . . . 0.0 109.091 -177.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.56 139.49 1.87 Allowed 'Trans proline' 0 N--CA 1.442 -1.556 0 C-N-CA 123.211 2.607 . . . . 0.0 108.914 178.749 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.51 HD12 ' N ' ' A' ' 131' ' ' ILE . 1.1 mp -113.08 117.82 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 N-CA-C 100.523 -3.88 . . . . 0.0 100.523 171.469 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -126.01 158.13 35.55 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.714 ' HB2' HD21 ' A' ' 136' ' ' LEU . 32.5 m-85 -134.1 137.49 44.62 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 103.751 -2.685 . . . . 0.0 103.751 -176.534 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -92.46 -73.41 0.55 Allowed 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 119.223 0.92 . . . . 0.0 109.216 -179.195 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -75.96 68.79 2.5 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.714 HD21 ' HB2' ' A' ' 133' ' ' PHE . 2.9 mm? -78.6 66.0 4.01 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 171.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 31.46 47.45 0.06 Allowed 'General case' 0 C--N 1.343 0.299 0 C-N-CA 127.831 2.452 . . . . 0.0 111.717 -173.813 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 29.61 61.22 0.16 Allowed 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 128.243 2.617 . . . . 0.0 114.343 -177.464 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.38 -14.78 0.22 Allowed Glycine 0 CA--C 1.525 0.668 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.968 177.773 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.563 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 44.2 mm-40 -80.4 123.66 28.22 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.201 1.001 . . . . 0.0 109.638 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.2 p -89.78 143.28 26.93 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.925 0.89 . . . . 0.0 109.257 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -89.94 113.23 25.8 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 C-N-CA 123.664 0.786 . . . . 0.0 109.874 -178.47 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 36.2 m -106.74 98.85 8.47 Favored 'General case' 0 C--N 1.34 0.178 0 C-N-CA 124.333 1.053 . . . . 0.0 110.576 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 3.2 pt -64.07 128.74 26.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 175.325 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -98.09 -34.71 10.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.064 0.946 . . . . 0.0 112.223 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.567 ' HB2' HG23 ' A' ' 157' ' ' ILE . . . -70.98 100.72 2.03 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 119.773 1.169 . . . . 0.0 109.915 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 1.2 m -79.49 51.26 1.22 Allowed 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.174 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 176.2 -145.76 7.7 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -175.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 47.1 t -73.92 132.49 42.52 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 122.203 -0.586 . . . . 0.0 111.216 -178.792 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.457 HG21 HD12 ' A' ' 45' ' ' ILE . 18.4 m -89.7 157.15 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 174.493 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.78 152.44 49.27 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 179.345 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.5 mtp180 -58.29 150.07 22.82 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 122.685 0.394 . . . . 0.0 111.603 177.634 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 63.03 1.73 0.91 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 126.412 1.885 . . . . 0.0 115.339 172.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 58.9 mm-40 -70.13 119.32 14.15 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 119.569 1.077 . . . . 0.0 108.635 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -81.99 125.86 31.28 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 121.369 0.604 . . . . 0.0 112.242 -176.355 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.9 t0 70.08 27.9 4.19 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 128.472 2.709 . . . . 0.0 115.459 175.188 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.567 HG23 ' HB2' ' A' ' 146' ' ' ALA 0.26 1.7 mp -71.27 -8.89 12.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 CA-C-O 121.306 0.575 . . . . 0.0 110.264 178.257 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.7 p -122.39 120.15 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 102.75 -3.056 . . . . 0.0 102.75 168.385 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 5.5 mtpm? -108.13 128.42 54.68 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.563 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.45 133.14 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.729 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -145.08 -174.87 4.48 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 125.078 1.351 . . . . 0.0 108.716 -177.912 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 49.3 mtmt . . . . . 0 C--O 1.233 0.201 0 C-N-CA 125.307 1.443 . . . . 0.0 107.31 174.981 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 42.3 ttp . . . . . 0 N--CA 1.455 -0.202 0 N-CA-C 111.366 0.136 . . . . 0.0 111.366 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 24.8 mt -76.55 66.12 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 C-N-CA 123.751 0.82 . . . . 0.0 108.901 -179.022 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.37 60.45 2.02 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 123.691 0.797 . . . . 0.0 109.583 178.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 57.8 tt0 -151.97 130.75 6.42 Favored Pre-proline 0 CA--C 1.533 0.3 0 C-N-CA 124.126 0.97 . . . . 0.0 108.514 -178.738 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -74.43 81.92 1.97 Allowed 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 122.532 2.155 . . . . 0.0 109.359 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 57.1 mt -66.65 69.85 0.07 Allowed 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.565 1.146 . . . . 0.0 112.389 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -76.59 62.18 1.89 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.613 1.565 . . . . 0.0 108.988 176.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -77.17 168.4 20.12 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.576 1.55 . . . . 0.0 110.252 -178.375 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -76.36 -52.41 9.96 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 124.093 0.957 . . . . 0.0 110.932 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.5 tt -166.4 147.76 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 -178.658 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 119.43 -100.71 0.81 Allowed Glycine 0 CA--C 1.522 0.493 0 N-CA-C 108.071 -2.011 . . . . 0.0 108.071 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -88.0 133.3 33.98 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 175.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -145.54 -140.79 0.11 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.408 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.0 t -55.51 -52.77 43.4 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.105 0 C-N-CA 124.849 1.259 . . . . 0.0 113.724 -177.576 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -79.25 128.96 33.97 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.9 m -125.44 84.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-N 118.61 0.641 . . . . 0.0 112.65 -176.159 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 21.9 t -19.86 122.01 0.09 OUTLIER Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 129.373 3.069 . . . . 0.0 112.553 177.524 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -71.48 -37.35 5.65 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 117.632 2.128 . . . . 0.0 117.632 -171.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.3 151.64 18.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 119.717 1.144 . . . . 0.0 111.387 -175.109 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.1 m -88.46 146.38 25.24 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.548 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.42 -128.6 2.17 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -127.57 138.64 52.94 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.007 1.323 . . . . 0.0 108.141 178.048 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.8 tt -106.51 139.71 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 16.6 m-70 -136.94 155.55 76.27 Favored Pre-proline 0 N--CA 1.453 -0.315 0 C-N-CA 125.628 1.571 . . . . 0.0 108.329 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 146.08 84.25 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 N-CA-C 107.916 -1.609 . . . . 0.0 107.916 172.534 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -56.79 -21.31 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.534 -1.666 . . . . 0.0 113.119 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.0 p -53.42 -32.51 50.03 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.562 0.745 . . . . 0.0 111.124 175.074 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -77.11 -6.1 51.55 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.903 0.881 . . . . 0.0 113.075 -175.083 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.3 t -77.84 132.6 67.53 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 119.228 0.922 . . . . 0.0 110.171 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -77.32 58.12 6.14 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 123.692 2.928 . . . . 0.0 111.176 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -168.83 110.25 0.51 Allowed 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 20.0 mp0 -37.42 -44.8 0.66 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 127.486 2.314 . . . . 0.0 113.553 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 95.4 t -50.26 -43.82 22.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 123.414 0.686 . . . . 0.0 110.16 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -87.3 -48.99 7.55 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.757 0.823 . . . . 0.0 109.52 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.12 -40.99 34.52 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.03 13.93 60.22 Favored Glycine 0 C--N 1.338 0.676 0 CA-C-O 118.938 -0.923 . . . . 0.0 111.853 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 37.1 mttp 70.31 -34.05 0.28 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.757 1.623 . . . . 0.0 114.584 179.106 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.5 ttm 24.38 -61.6 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 1 C-N-CA 132.029 4.131 . . . . 0.0 118.203 178.319 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.11 -22.72 48.47 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.944 0.898 . . . . 0.0 111.59 -177.276 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.02 -128.89 1.3 Allowed Glycine 0 C--N 1.336 0.535 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 41' ' ' ASP . . . . . 0.418 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.0 t0 -131.4 159.25 38.53 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 171.321 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.4 -166.18 34.25 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.016 -1.088 . . . . 0.0 113.461 -176.872 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 p90 -144.38 160.92 40.23 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 124.534 1.134 . . . . 0.0 109.714 178.553 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -105.95 118.46 36.67 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.525 1.53 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.6 mm -98.46 130.3 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 172.675 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 tt -101.11 108.01 52.69 Favored Pre-proline 0 N--CA 1.448 -0.541 1 N-CA-C 99.604 -4.221 . . . . 0.0 99.604 170.105 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -85.91 148.49 9.5 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 122.617 2.211 . . . . 0.0 114.958 -168.118 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.5 p -113.51 -51.24 2.81 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.974 1.31 . . . . 0.0 108.685 174.498 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -73.56 122.4 22.17 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.515 0.326 . . . . 0.0 111.328 179.215 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.22 41.07 2.6 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 173.055 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 81.0 mt -136.22 113.78 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 103.413 -2.81 . . . . 0.0 103.413 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.2 t -119.54 119.62 61.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 C-N-CA 123.769 0.828 . . . . 0.0 109.87 -172.657 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.3 m -99.87 164.7 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 CA-C-O 121.159 0.504 . . . . 0.0 109.935 176.802 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.5 m -76.46 131.93 73.66 Favored Pre-proline 0 N--CA 1.45 -0.444 0 CA-C-O 117.576 -1.202 . . . . 0.0 108.423 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -60.96 -31.79 91.79 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.002 2.468 . . . . 0.0 110.783 177.469 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' VAL . . . . . 0.453 HG22 HD12 ' A' ' 80' ' ' ILE . 10.8 m -151.11 150.09 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 102.925 -2.991 . . . . 0.0 102.925 173.389 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.0 tpt180 -101.25 -93.74 0.29 Allowed 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 101.176 -3.638 . . . . 0.0 101.176 169.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.75 2.5 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 107.405 -2.278 . . . . 0.0 107.405 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 125.23 1.91 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 167.633 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.5 mm -62.92 128.62 25.16 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 169.909 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.05 -49.04 11.38 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 178.518 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -175.88 151.15 1.08 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.434 0.294 . . . . 0.0 111.361 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.5 m -113.17 126.23 70.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 169.53 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.446 ' CG ' ' HB3' ' A' ' 69' ' ' ALA . 5.7 m-85 -65.73 156.63 82.51 Favored Pre-proline 0 CA--C 1.534 0.333 0 O-C-N 121.426 -0.796 . . . . 0.0 110.03 -176.621 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -48.44 -43.4 32.84 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.114 2.543 . . . . 0.0 112.952 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.0 p -79.57 3.87 17.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.842 1.257 . . . . 0.0 112.761 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.18 -21.9 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 128.525 2.73 . . . . 0.0 116.84 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.87 -31.54 72.75 Favored 'General case' 0 C--O 1.227 -0.103 0 CA-C-N 119.483 1.038 . . . . 0.0 111.884 -174.8 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ALA . . . . . 0.446 ' HB3' ' CG ' ' A' ' 64' ' ' PHE . . . -103.6 135.67 44.74 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.091 0.956 . . . . 0.0 110.081 -179.365 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.9 mt -140.06 146.54 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -125.32 136.74 9.95 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 125.862 1.696 . . . . 0.0 109.076 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.8 mp -137.86 163.82 30.5 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 124.959 1.304 . . . . 0.0 110.409 -177.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 70.8 mt-30 -145.38 125.23 13.46 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 57.2 p -73.01 72.76 1.15 Allowed 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 175.443 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.4 t0 44.42 60.26 2.92 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.374 2.27 . . . . 0.0 110.183 -177.597 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 81.07 -11.67 41.39 Favored Glycine 0 CA--C 1.531 1.083 0 CA-C-N 114.722 -1.127 . . . . 0.0 114.024 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -78.36 -102.84 0.2 Allowed Glycine 0 CA--C 1.53 0.998 0 CA-C-N 119.076 1.438 . . . . 0.0 112.802 -177.756 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.25 116.96 19.06 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 -178.307 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -93.09 126.8 38.36 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 125.589 1.556 . . . . 0.0 106.932 177.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' ILE . . . . . 0.453 HD12 HG22 ' A' ' 56' ' ' VAL . 5.8 mt -125.03 143.45 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.1 0.96 . . . . 0.0 111.205 -172.003 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -122.89 130.74 53.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.219 2.208 . . . . 0.0 105.413 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.5 mt -123.49 146.73 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 C-N-CA 124.767 1.227 . . . . 0.0 108.019 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -134.33 131.8 38.77 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 105.283 -2.117 . . . . 0.0 105.283 171.324 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -103.05 106.21 16.68 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 124.774 1.229 . . . . 0.0 107.879 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.1 -169.82 34.94 Favored Glycine 0 CA--C 1.534 1.229 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 29.3 mm -109.78 -84.42 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.05 0 CA-C-O 123.224 1.488 . . . . 0.0 110.469 -178.104 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.41 4.82 0.48 Allowed 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 126.432 1.893 . . . . 0.0 113.033 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.22 -30.24 71.11 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.438 1.895 . . . . 0.0 107.573 175.195 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.55 -46.98 89.75 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 CA-C-N 114.374 -1.285 . . . . 0.0 108.348 174.362 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.68 -41.02 98.21 Favored 'General case' 0 C--O 1.227 -0.112 0 C-N-CA 125.036 1.334 . . . . 0.0 109.017 177.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -65.05 -8.41 16.19 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 125.69 1.596 . . . . 0.0 110.943 176.727 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? 52.54 34.14 14.91 Favored 'General case' 0 C--N 1.343 0.315 0 C-N-CA 125.301 1.441 . . . . 0.0 111.823 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.18 21.07 61.33 Favored Glycine 0 CA--C 1.536 1.37 0 CA-C-O 119.67 -0.517 . . . . 0.0 112.875 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.84 90.18 1.1 Allowed 'General case' 0 C--N 1.341 0.227 0 CA-C-N 119.388 1.594 . . . . 0.0 108.625 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 141.83 -2.41 1.9 Allowed Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.484 1.992 . . . . 0.0 111.591 -175.144 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -97.86 103.53 15.47 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 125.57 1.548 . . . . 0.0 111.063 -176.758 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 50.0 m -84.36 98.15 9.87 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.636 -2.727 . . . . 0.0 103.636 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 43.0 p -79.59 121.37 25.18 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 121.793 -0.567 . . . . 0.0 109.983 -177.205 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -79.94 -52.82 7.38 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.524 1.13 . . . . 0.0 109.361 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 24.3 m -82.17 129.0 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.121 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.43 175.142 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 67.5 m -98.21 56.69 1.2 Allowed 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 102.397 -3.186 . . . . 0.0 102.397 169.105 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.312 7.8 pt-20 36.16 61.08 0.8 Allowed 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 111.09 -2.777 . . . . 0.0 110.734 -167.498 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.42 55.08 2.41 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 111.108 -2.769 . . . . 0.0 109.834 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.35 3.3 p30 1.81 -110.63 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 130.997 3.719 . . . . 0.0 118.566 -178.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 45.0 mmm-85 -44.94 142.46 1.81 Allowed 'General case' 0 N--CA 1.425 -1.698 1 N-CA-C 122.56 4.281 . . . . 0.0 122.56 -167.03 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.722 4.7 m 36.95 -55.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.428 2 N-CA-C 130.351 7.167 . . . . 0.0 130.351 173.971 . . . . . . . . 3 2 . 1 . 007 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.52 121.98 86.29 Favored Pre-proline 0 C--N 1.317 -0.831 0 C-N-CA 116.472 -2.091 . . . . 0.0 113.172 -165.083 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -69.84 172.31 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 125.021 3.814 . . . . 0.0 113.081 -169.12 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 55.81 19.51 21.67 Favored Glycine 0 CA--C 1.528 0.895 0 C-N-CA 124.582 1.087 . . . . 0.0 115.21 176.282 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -61.6 143.22 56.4 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 118.488 1.144 . . . . 0.0 109.328 177.775 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -69.96 119.61 14.43 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.2 mt -80.85 -51.43 8.61 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -143.28 155.17 44.41 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 -174.008 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -122.39 125.76 46.57 Favored 'General case' 0 CA--C 1.514 -0.425 1 N-CA-C 98.305 -4.702 . . . . 0.0 98.305 166.296 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.36 129.33 56.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 114.691 -1.141 . . . . 0.0 112.165 -165.711 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -73.22 67.95 0.98 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.798 0.839 . . . . 0.0 110.397 -179.209 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.8 mt -52.59 -41.56 63.73 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-O 119.301 -0.38 . . . . 0.0 110.583 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -49.45 -44.46 45.63 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 123.507 0.723 . . . . 0.0 112.272 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.59 -35.33 19.51 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 117.933 0.333 . . . . 0.0 111.841 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 53.9 t -64.59 -49.69 79.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 121.537 -0.727 . . . . 0.0 110.567 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.357 0.0 OUTLIER -47.48 -53.84 26.7 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 116.943 2.201 . . . . 0.0 116.943 -177.557 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -60.9 -25.64 81.71 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.231 1.954 . . . . 0.0 112.323 177.151 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -79.92 -50.15 10.87 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 118.651 0.66 . . . . 0.0 110.617 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 18.7 m -79.72 142.83 57.51 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.721 -177.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.33 -15.81 22.34 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.48 2.12 . . . . 0.0 111.717 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 16.6 m -156.76 128.41 7.13 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.07 0.948 . . . . 0.0 108.907 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.2 tp -94.73 9.91 37.1 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.403 1.481 . . . . 0.0 111.54 -178.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 74.1 mmm -53.42 118.75 4.09 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 34.0 m -113.94 86.96 11.89 Favored Pre-proline 0 N--CA 1.445 -0.678 0 C-N-CA 126.168 1.787 . . . . 0.0 107.752 -177.247 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.477 ' C ' HD12 ' A' ' 131' ' ' ILE . 60.9 Cg_endo -83.25 149.72 13.41 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.814 1.676 . . . . 0.0 112.403 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.477 HD12 ' C ' ' A' ' 130' ' ' PRO . 1.1 mp -122.13 130.3 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 103.494 -2.78 . . . . 0.0 103.494 174.919 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -126.56 143.55 39.67 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 C-N-CA 125.751 1.62 . . . . 0.0 106.93 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -117.15 123.56 47.02 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 64.7 p -83.96 -72.22 0.47 Allowed 'General case' 0 C--N 1.335 -0.06 0 CA-C-O 121.504 0.669 . . . . 0.0 111.046 -171.677 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p30 -71.7 52.63 0.22 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 126.091 1.756 . . . . 0.0 113.113 -178.325 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.418 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 38.8 mt -74.35 63.68 1.06 Allowed 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.324 1.45 . . . . 0.0 109.38 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 17.4 57.69 0.01 OUTLIER 'General case' 0 C--N 1.348 0.503 0 C-N-CA 129.509 3.124 . . . . 0.0 112.209 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 23.88 57.43 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.108 2.963 . . . . 0.0 114.371 -174.801 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.26 -5.51 0.12 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-O 119.006 -0.886 . . . . 0.0 113.891 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.689 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 29.7 mt-10 -75.49 93.14 2.94 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 119.254 1.527 . . . . 0.0 108.796 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 34.1 p -76.65 130.46 37.83 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.836 0.827 . . . . 0.0 109.421 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -83.6 100.35 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 14.8 m -98.71 102.28 13.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.971 1.308 . . . . 0.0 110.578 -175.778 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 8.4 pt -66.95 146.3 13.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 O-C-N 121.909 -0.494 . . . . 0.0 110.363 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -119.13 -45.5 2.55 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.976 1.71 . . . . 0.0 110.359 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -66.87 79.94 0.11 Allowed 'General case' 0 C--O 1.224 -0.244 0 CA-C-O 121.45 0.643 . . . . 0.0 109.929 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.3 m -77.82 65.82 3.36 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.805 0.842 . . . . 0.0 109.848 -176.234 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 162.48 -128.69 1.92 Allowed Glycine 0 C--N 1.336 0.554 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -177.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.2 t -66.7 157.92 31.46 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.188 178.279 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.58 HG23 HG21 ' A' ' 157' ' ' ILE . 2.9 p -138.96 153.25 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 C-N-CA 125.604 1.561 . . . . 0.0 107.684 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -125.93 150.39 48.01 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 125.222 1.409 . . . . 0.0 108.379 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 35.8 ptt85 -74.37 162.07 29.23 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 176.268 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 61.69 55.0 2.81 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 126.262 1.825 . . . . 0.0 111.881 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 154' ' ' GLN . . . . . 0.461 ' CB ' HD13 ' A' ' 157' ' ' ILE . 33.2 mm-40 -146.64 155.78 42.7 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.91 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -103.79 -70.16 0.78 Allowed 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 119.862 1.21 . . . . 0.0 111.188 176.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -50.12 5.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 130.4 3.48 . . . . 0.0 118.047 -172.048 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.58 HG21 HG23 ' A' ' 150' ' ' VAL . 1.7 mp -76.86 -32.04 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 129.785 3.234 . . . . 0.0 106.262 173.186 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.58 145.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 127.128 2.171 . . . . 0.0 106.59 175.449 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 4.6 mmpt? -132.42 125.92 31.88 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 178.164 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.689 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -78.88 125.93 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 172.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -138.44 163.64 31.41 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.45 1.1 . . . . 0.0 109.502 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 65.6 mttm . . . . . 0 C--O 1.231 0.129 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 175.357 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.5 mtm . . . . . 0 N--CA 1.452 -0.333 0 CA-C-O 120.556 0.217 . . . . 0.0 110.778 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' ILE . . . . . 0.447 ' O ' HG23 ' A' ' 2' ' ' ILE . 10.6 tp -74.57 72.94 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 CA-C-O 121.474 0.654 . . . . 0.0 110.388 -178.448 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -70.68 66.72 0.35 Allowed 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.669 1.187 . . . . 0.0 111.322 -179.334 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -146.84 171.08 6.78 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 128.047 2.539 . . . . 0.0 105.748 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -52.06 117.74 3.87 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.251 1.967 . . . . 0.0 110.239 178.33 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 82.3 mt -77.67 63.93 2.86 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.633 0.773 . . . . 0.0 110.634 -175.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 35.9 mt-30 66.86 -63.14 0.28 Allowed 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 126.651 1.98 . . . . 0.0 110.965 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -143.87 127.39 16.96 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 125.436 1.494 . . . . 0.0 107.093 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -76.15 68.91 2.64 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.905 0.482 . . . . 0.0 110.025 -179.656 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -72.1 72.49 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 C-N-CA 124.795 1.238 . . . . 0.0 108.66 178.506 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 78.27 -58.01 4.04 Favored Glycine 0 CA--C 1.527 0.838 0 O-C-N 121.024 -1.047 . . . . 0.0 111.047 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 57.41 83.09 0.11 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.01 1.724 . . . . 0.0 112.241 177.427 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -150.78 170.19 19.85 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.787 2.035 . . . . 0.0 109.067 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.442 14.9 p 57.2 -125.07 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 N-CA-C 116.692 2.108 . . . . 0.0 116.692 173.874 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -77.97 135.33 37.79 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.28 1.432 . . . . 0.0 114.32 -168.275 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.7 m -83.05 98.15 4.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 C-N-CA 123.95 0.9 . . . . 0.0 111.128 175.533 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 34.7 t -36.07 121.18 0.71 Allowed Pre-proline 0 CA--C 1.547 0.84 0 C-N-CA 126.686 1.994 . . . . 0.0 111.163 174.918 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -76.2 -38.95 0.95 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.803 2.335 . . . . 0.0 117.773 -173.021 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.13 146.57 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 CA-C-N 120.245 1.384 . . . . 0.0 110.395 -175.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.8 m -78.83 135.44 37.05 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 173.224 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.18 -167.97 41.01 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 -178.645 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -96.17 135.09 38.45 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.9 tt -97.19 143.07 13.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 123.01 0.524 . . . . 0.0 109.994 -179.256 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -145.29 156.25 53.97 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 178.875 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -62.54 155.33 58.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 N-CA-C 107.097 -1.924 . . . . 0.0 107.097 171.311 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 tt -62.65 -34.36 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.468 -178.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 m -71.03 74.05 0.63 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.685 1.194 . . . . 0.0 109.01 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -179.64 -34.58 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 127.994 2.518 . . . . 0.0 108.992 -174.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.423 ' HA ' ' HD3' ' A' ' 30' ' ' PRO . 91.0 t -58.47 127.66 81.84 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 117.63 -1.176 . . . . 0.0 111.025 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 29' ' ' VAL . 71.2 Cg_exo -57.57 59.68 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.191 1 C-N-CA 126.381 4.72 . . . . 0.0 115.778 176.407 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -171.43 119.65 0.47 Allowed 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 125.953 1.701 . . . . 0.0 107.707 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 6.8 pm0 -54.48 -44.8 72.94 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.429 1.092 . . . . 0.0 113.817 -177.395 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 40.7 t -56.49 -56.84 11.57 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -178.282 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -62.64 -52.85 61.72 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.3 t -50.83 -42.36 58.45 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.951 0.9 . . . . 0.0 113.394 -177.773 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -89.42 11.59 69.39 Favored Glycine 0 N--CA 1.446 -0.634 0 CA-C-O 118.198 -1.334 . . . . 0.0 112.022 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 58.5 mttm 72.35 -36.33 0.35 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.564 1.682 . . . . 0.0 113.242 -179.047 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER 28.68 -78.77 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 130.398 3.479 . . . . 0.0 116.226 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.5 ttp -83.17 -7.3 59.64 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -174.498 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.63 -138.19 2.75 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 38.9 t0 -140.11 158.7 43.63 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 172.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.77 -168.75 37.83 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 119.937 -1.125 . . . . 0.0 113.334 -176.213 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -141.68 156.83 45.61 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.635 1.174 . . . . 0.0 109.448 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.82 127.09 52.51 Favored 'General case' 0 CA--C 1.51 -0.587 0 C-N-CA 124.282 1.033 . . . . 0.0 109.876 179.024 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 28.4 mm -107.84 128.53 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 104.611 -2.366 . . . . 0.0 104.611 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.7 tt -96.97 102.97 13.31 Favored Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 172.751 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -63.37 157.16 51.88 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.951 3.101 . . . . 0.0 116.585 -169.377 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.4 p -138.84 -51.13 0.55 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.856 1.263 . . . . 0.0 109.528 173.502 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -80.14 130.67 35.41 Favored 'General case' 0 C--N 1.342 0.263 0 O-C-N 121.926 -0.484 . . . . 0.0 110.455 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -66.42 -24.35 72.24 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.824 -0.911 . . . . 0.0 110.824 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.404 ' N ' HD12 ' A' ' 51' ' ' ILE . 2.5 mp -78.2 108.52 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 C-N-CA 124.585 1.154 . . . . 0.0 107.923 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.22 116.65 52.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 125.212 1.405 . . . . 0.0 108.14 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.5 m -93.41 155.68 3.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.147 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 47.1 m -73.17 139.94 79.6 Favored Pre-proline 0 N--CA 1.448 -0.574 0 CA-C-O 118.6 -0.714 . . . . 0.0 111.144 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -64.17 -35.9 50.01 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 N-CA-C 107.609 -1.727 . . . . 0.0 107.609 171.024 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.6 p -175.98 150.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 129.798 3.239 . . . . 0.0 103.68 175.346 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.446 ' CZ ' ' HB3' ' A' ' 110' ' ' GLN . 43.1 mtm180 -112.14 -75.93 0.6 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.791 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.19 -68.38 2.35 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.438 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.49 128.32 8.03 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 104.228 -2.508 . . . . 0.0 104.228 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.1 mm -61.13 130.47 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 7.3 tt -77.45 -51.96 9.91 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 104.601 -2.37 . . . . 0.0 104.601 178.361 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 50.9 t30 179.62 165.5 1.1 Allowed 'General case' 0 CA--C 1.527 0.081 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.237 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.462 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.7 m -152.35 129.09 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 C-N-CA 126.239 1.816 . . . . 0.0 106.168 174.512 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -47.49 146.47 3.46 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-O 118.744 -0.646 . . . . 0.0 111.092 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -50.0 -33.74 35.44 Favored 'Trans proline' 0 CA--C 1.534 0.525 0 C-N-CA 123.534 2.823 . . . . 0.0 113.796 176.6 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 37.0 p -77.67 -7.98 57.24 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 124.574 1.15 . . . . 0.0 111.993 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 68.38 13.4 9.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.205 1.802 . . . . 0.0 113.641 178.366 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.445 ' ND1' ' N ' ' A' ' 89' ' ' VAL . 0.0 OUTLIER -77.91 -23.62 48.61 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 119.358 0.981 . . . . 0.0 111.626 -179.333 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -167.12 -173.22 2.25 Favored 'General case' 0 C--O 1.225 -0.22 0 CA-C-N 120.12 1.327 . . . . 0.0 110.777 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 63' ' ' VAL 1.06 1.9 mt 130.97 -139.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.192 1 C-N-CA 136.95 6.1 . . . . 0.0 110.372 176.382 . . . . . . . . 4 3 . 1 . 008 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -157.04 170.13 34.28 Favored Glycine 0 CA--C 1.531 1.061 0 N-CA-C 118.229 2.052 . . . . 0.0 118.229 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 18.1 mt -124.03 174.35 7.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 128.199 2.6 . . . . 0.0 109.085 -177.663 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -126.28 -165.42 1.44 Allowed 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.098 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 60.3 p -166.11 154.52 10.87 Favored 'General case' 0 N--CA 1.44 -0.957 0 C-N-CA 125.611 1.564 . . . . 0.0 107.39 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -59.35 -34.79 72.81 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 124.918 1.287 . . . . 0.0 108.717 175.921 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -74.45 10.4 8.47 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 123.716 0.674 . . . . 0.0 112.279 176.174 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 82.43 -41.18 2.79 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 119.538 1.669 . . . . 0.0 112.813 177.396 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -42.34 103.98 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 125.341 1.457 . . . . 0.0 110.563 179.241 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -92.85 131.58 37.76 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 127.642 2.377 . . . . 0.0 105.605 -179.477 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 34.1 mt -123.04 119.62 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 O-C-N 123.436 0.46 . . . . 0.0 112.056 -173.315 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 6.0 tp -89.09 139.63 30.27 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 171.529 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 72.8 mt -130.33 132.49 64.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -123.75 84.47 2.28 Favored 'General case' 0 C--O 1.223 -0.298 0 O-C-N 123.526 0.517 . . . . 0.0 111.77 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.52 104.75 0.24 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.236 0.614 . . . . 0.0 111.932 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.76 -177.93 7.64 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 122.092 0.829 . . . . 0.0 112.323 179.282 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.9 mm -123.92 146.54 29.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 174.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 37.2 t70 50.77 32.29 6.94 Favored 'General case' 0 CA--C 1.543 0.702 0 CA-C-O 121.91 0.862 . . . . 0.0 111.295 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.8 m -97.85 -25.07 15.16 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.803 2.041 . . . . 0.0 107.289 -177.846 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.445 ' N ' ' ND1' ' A' ' 68' ' ' HIS . 4.0 p -53.6 -43.71 55.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 C-N-CA 126.258 1.823 . . . . 0.0 107.634 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -58.73 -26.2 63.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.801 2.04 . . . . 0.0 111.898 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.14 -11.21 60.45 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.892 1.677 . . . . 0.0 109.608 177.149 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp 51.55 29.66 5.69 Favored 'General case' 0 C--N 1.342 0.244 0 C-N-CA 126.325 1.85 . . . . 0.0 112.38 178.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.22 26.71 50.82 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-O 118.702 -1.054 . . . . 0.0 112.53 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.266 0.2 OUTLIER -59.15 -18.25 34.38 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.851 1.826 . . . . 0.0 115.478 -176.776 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -122.3 21.17 7.8 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 126.11 1.814 . . . . 0.0 110.849 177.482 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.483 ' HA ' HG12 ' A' ' 115' ' ' VAL . 3.5 m-85 -106.05 85.2 2.17 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 118.089 0.944 . . . . 0.0 111.046 -177.378 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.66 101.11 5.61 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.326 -2.472 . . . . 0.0 104.326 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.8 t -87.01 157.82 19.37 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-O 121.183 0.516 . . . . 0.0 110.605 -179.22 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -115.59 5.23 14.31 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.038 1.735 . . . . 0.0 112.224 -175.636 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.5 m -129.42 137.06 57.9 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.147 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 68.6 m -107.03 49.31 0.81 Allowed 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 169.765 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.299 1.3 pm0 -2.68 70.98 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 132.184 4.194 . . . . 0.0 116.644 -172.661 . . . . . . . . 3 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -85.99 46.44 3.62 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 112.845 -1.979 . . . . 0.0 109.882 176.571 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 3.36 52.08 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.21 0 C-N-CA 131.356 3.863 . . . . 0.0 120.897 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -168.74 121.78 0.82 Allowed 'General case' 0 C--N 1.312 -1.022 1 C-N-CA 133.475 4.71 . . . . 0.0 107.051 176.553 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -167.52 136.72 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 118.784 0.72 . . . . 0.0 111.073 -172.332 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -78.74 149.99 75.11 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 118.146 -0.93 . . . . 0.0 109.853 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -55.67 175.55 0.2 Allowed 'Trans proline' 0 CA--C 1.542 0.896 1 C-N-CA 125.696 4.264 . . . . 0.0 117.837 -174.396 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 51.85 -7.65 0.01 OUTLIER Glycine 0 C--N 1.344 0.985 0 C-N-CA 129.28 3.324 . . . . 0.0 119.238 175.316 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 110' ' ' GLN . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 57' ' ' ARG . 25.0 tt0 -61.63 160.59 11.2 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 120.31 2.055 . . . . 0.0 110.128 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -67.04 140.64 57.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 122.94 0.496 . . . . 0.0 109.76 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 94.5 mt -108.63 -37.39 5.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 124.246 1.018 . . . . 0.0 110.088 176.547 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 113' ' ' LEU . . . . . 0.447 ' HB3' HG13 ' A' ' 115' ' ' VAL . 22.2 mt -143.23 146.99 34.14 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.61 0.764 . . . . 0.0 110.208 -176.38 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -132.94 68.49 1.5 Allowed 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.483 HG12 ' HA ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -79.45 127.03 39.38 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 CA-C-N 109.053 -3.703 . . . . 0.0 110.621 -171.755 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -76.19 67.64 2.5 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.008 0.923 . . . . 0.0 109.179 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -48.61 -39.37 23.69 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.651 0.78 . . . . 0.0 111.727 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -54.04 -42.18 68.89 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.113 0.565 . . . . 0.0 112.201 178.548 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.07 -33.29 18.35 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.744 0.417 . . . . 0.0 111.39 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 79.5 t -63.31 -53.91 39.66 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.372 17.8 pttp -40.45 -58.23 2.56 Favored Pre-proline 0 CA--C 1.541 0.611 0 N-CA-C 116.97 2.211 . . . . 0.0 116.97 -176.464 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -58.53 -20.1 47.85 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.436 2.091 . . . . 0.0 113.36 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -100.03 8.26 44.11 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 118.301 -0.857 . . . . 0.0 112.674 -177.67 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 33.3 m -133.9 147.67 65.12 Favored Pre-proline 0 CA--C 1.535 0.382 0 CA-C-N 119.986 1.266 . . . . 0.0 109.856 178.711 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -71.04 -36.55 7.29 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.98 2.453 . . . . 0.0 111.622 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 62.3 p -151.45 121.85 7.33 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -177.532 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.0 tp -79.88 -2.95 45.88 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.136 1.374 . . . . 0.0 111.904 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -44.88 117.92 1.47 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 124.842 1.257 . . . . 0.0 110.465 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.6 m -117.7 107.47 44.46 Favored Pre-proline 0 N--CA 1.447 -0.581 0 C-N-CA 124.034 0.933 . . . . 0.0 108.692 -178.425 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -91.53 143.59 3.01 Favored 'Trans proline' 0 N--CA 1.441 -1.617 0 C-N-CA 123.039 2.492 . . . . 0.0 110.249 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 17.2 mm -113.9 116.82 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.034 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.5 t -121.48 123.61 69.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 C-N-CA 125.006 1.323 . . . . 0.0 108.632 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -95.9 117.66 31.04 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 178.37 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 52.6 p -84.1 -73.91 0.4 Allowed 'General case' 0 C--O 1.23 0.045 0 CA-C-O 121.467 0.651 . . . . 0.0 111.563 -171.233 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p-10 -73.08 57.61 0.47 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.824 1.65 . . . . 0.0 111.38 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 20.5 mt -72.01 66.72 0.6 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.918 1.687 . . . . 0.0 109.007 177.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.91 47.68 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 129.179 2.992 . . . . 0.0 112.488 -176.722 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 29.34 55.48 0.12 Allowed 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 127.81 2.444 . . . . 0.0 113.34 -174.809 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.43 -5.29 0.05 OUTLIER Glycine 0 CA--C 1.526 0.738 0 CA-C-O 118.896 -0.946 . . . . 0.0 114.332 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.654 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 21.0 mt-10 -83.83 139.87 32.39 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.185 1.492 . . . . 0.0 109.83 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 45.4 p -110.91 136.58 49.72 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.898 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -91.28 101.93 12.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -178.402 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 20.3 m -100.01 105.83 17.54 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 123.96 0.904 . . . . 0.0 110.493 -176.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 20.1 pt -67.05 139.71 20.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.799 -0.563 . . . . 0.0 110.252 177.044 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.6 mmpt? -101.83 -41.42 6.52 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 125.155 1.382 . . . . 0.0 108.864 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.39 86.9 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.208 1.003 . . . . 0.0 112.783 -176.863 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.5 m -80.73 54.68 2.18 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 177.779 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.49 -178.65 37.31 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -177.074 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 35.4 t -52.07 146.8 8.22 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.567 0.747 . . . . 0.0 112.416 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.9 m -115.47 159.55 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 125.207 1.403 . . . . 0.0 109.827 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.8 157.3 30.05 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.75 1.22 . . . . 0.0 108.321 175.635 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.47 158.86 28.45 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.473 0.654 . . . . 0.0 110.738 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 64.58 -10.11 0.16 Allowed 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 126.137 1.775 . . . . 0.0 114.868 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.67 149.81 38.4 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.933 1.242 . . . . 0.0 109.571 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -120.54 158.14 27.94 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.214 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 29.9 t0 63.89 26.56 14.29 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 128.074 2.549 . . . . 0.0 112.009 -174.642 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -82.87 -22.75 8.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 C-N-CA 123.825 0.85 . . . . 0.0 108.825 176.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.3 p -142.36 149.66 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 127.897 2.479 . . . . 0.0 106.477 175.662 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -131.81 127.47 36.7 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 174.741 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.654 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.54 122.0 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 170.797 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -105.52 176.11 5.27 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 106.544 -1.651 . . . . 0.0 106.544 174.553 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.0 tppt? . . . . . 0 CA--C 1.532 0.254 0 O-C-N 121.292 -0.88 . . . . 0.0 110.956 -179.358 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.3 mtp . . . . . 0 N--CA 1.45 -0.426 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 16.3 pt -64.68 145.23 14.06 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.247 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.19 67.82 1.4 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 123.339 0.655 . . . . 0.0 111.458 -178.081 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -52.62 113.1 4.05 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 124.255 1.022 . . . . 0.0 111.062 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -79.75 169.52 18.07 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 122.528 2.152 . . . . 0.0 109.547 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -75.78 67.66 2.24 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 123.499 0.72 . . . . 0.0 109.306 179.097 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 24.1 mt-30 -131.61 161.09 33.51 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.438 1.495 . . . . 0.0 107.862 177.829 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -145.72 -158.22 0.88 Allowed 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.4 mm-40 -76.47 63.25 1.99 Allowed 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 120.057 1.299 . . . . 0.0 109.785 177.35 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.0 pp -140.46 -143.67 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 126.886 2.074 . . . . 0.0 106.5 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 155.62 -131.39 3.05 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 106.374 -2.691 . . . . 0.0 106.374 178.475 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 49.37 60.93 3.42 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.313 1.045 . . . . 0.0 110.347 178.496 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -81.89 -158.96 0.26 Allowed 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 173.878 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.7 t -80.77 47.19 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 O-C-N 120.29 -1.506 . . . . 0.0 109.763 178.399 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.32 85.06 7.28 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 m -90.75 84.81 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 122.598 0.359 . . . . 0.0 110.894 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -19.1 115.52 0.09 OUTLIER Pre-proline 0 CA--C 1.546 0.789 0 C-N-CA 127.016 2.127 . . . . 0.0 113.667 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -75.02 -26.01 11.28 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 122.718 2.278 . . . . 0.0 117.535 -170.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -138.25 158.08 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 119.886 1.221 . . . . 0.0 109.445 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.9 m -94.61 128.6 41.36 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 174.439 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.67 -161.68 33.16 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.585 -0.341 . . . . 0.0 112.654 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -95.24 118.46 32.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.846 1.258 . . . . 0.0 108.551 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.94 136.04 25.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 C-N-CA 123.455 0.702 . . . . 0.0 109.427 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -135.13 142.9 43.61 Favored Pre-proline 0 C--O 1.236 0.345 0 C-N-CA 126.486 1.914 . . . . 0.0 107.048 177.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -64.61 160.06 41.88 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 121.446 1.431 . . . . 0.0 108.476 176.296 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 tp -61.55 -39.88 84.57 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.268 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 57.1 m -76.48 74.1 3.22 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.124 0.97 . . . . 0.0 109.344 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -178.54 -37.34 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 127.601 2.36 . . . . 0.0 108.986 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 97.0 t -52.0 115.45 6.71 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-O 117.507 -1.235 . . . . 0.0 111.905 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_exo -58.06 64.37 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.212 1 C-N-CA 125.515 4.144 . . . . 0.0 115.551 177.046 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -133.58 -42.63 0.84 Allowed 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 -177.467 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 105.73 -65.08 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 129.695 3.198 . . . . 0.0 110.606 -178.48 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 92.3 t -52.67 -62.13 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 C-N-CA 124.004 0.922 . . . . 0.0 108.722 179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -59.99 -42.79 94.98 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.909 0.385 . . . . 0.0 110.123 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -51.57 -45.51 63.12 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 124.012 0.925 . . . . 0.0 112.81 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -92.99 17.57 57.91 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-O 118.274 -1.292 . . . . 0.0 110.5 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 60.5 mttp 73.79 -47.77 0.66 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.079 1.752 . . . . 0.0 111.359 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 19.6 ttt 35.49 -67.17 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 130.602 3.561 . . . . 0.0 117.077 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 33.2 ttm -87.52 -23.6 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.385 1.074 . . . . 0.0 112.435 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.67 -148.1 9.53 Favored Glycine 0 C--O 1.224 -0.505 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -177.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -142.47 159.75 41.61 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-N 118.349 1.074 . . . . 0.0 108.582 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.3 -127.29 1.45 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 106.773 -2.531 . . . . 0.0 106.773 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -177.01 -179.28 0.9 Allowed 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 119.055 1.427 . . . . 0.0 110.763 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -127.67 135.86 50.79 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 123.734 0.814 . . . . 0.0 109.447 176.201 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -109.49 98.55 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 103.316 -2.846 . . . . 0.0 103.316 172.812 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.5 tt -58.81 113.6 7.11 Favored Pre-proline 0 CA--C 1.532 0.258 0 N-CA-C 103.08 -2.933 . . . . 0.0 103.08 175.708 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -78.07 149.01 25.12 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 122.916 2.411 . . . . 0.0 115.005 -167.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 p -115.74 -47.88 2.78 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 125.217 1.407 . . . . 0.0 107.594 173.98 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -76.76 122.39 24.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.11 44.21 2.79 Favored Glycine 0 CA--C 1.531 1.082 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 173.239 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.1 mt -144.33 126.37 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 104.446 -2.427 . . . . 0.0 104.446 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 66.3 t -126.66 126.71 69.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 C-N-CA 125.019 1.328 . . . . 0.0 109.033 -173.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.7 m -109.78 157.59 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.833 1.253 . . . . 0.0 110.792 178.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.6 m -62.87 133.02 95.07 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.873 -0.517 . . . . 0.0 111.077 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.04 -13.89 23.67 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.278 3.319 . . . . 0.0 116.531 -174.92 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -151.31 165.54 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 CA-C-N 119.441 1.018 . . . . 0.0 109.713 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -76.12 125.54 29.34 Favored 'General case' 0 C--O 1.236 0.394 1 N-CA-C 99.122 -4.399 . . . . 0.0 99.122 166.768 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 179.82 171.95 43.31 Favored Glycine 0 N--CA 1.435 -1.425 0 C-N-CA 116.658 -2.687 . . . . 0.0 113.198 -168.235 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.64 126.24 34.84 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.58 116.9 8.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 102.644 -3.095 . . . . 0.0 102.644 168.775 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 85.1 mt -78.53 -50.04 12.27 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 32.6 t30 178.16 164.1 0.7 Allowed 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 124.14 0.976 . . . . 0.0 108.372 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.4 m -137.74 116.73 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 126.732 2.013 . . . . 0.0 106.079 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.73 154.03 0.73 Allowed Pre-proline 0 N--CA 1.469 0.524 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -52.05 -33.29 52.44 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 123.483 2.788 . . . . 0.0 113.212 176.492 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.8 p -78.09 -2.84 39.29 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.996 0.919 . . . . 0.0 111.631 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.76 21.48 1.94 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 127.244 2.218 . . . . 0.0 114.301 179.397 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 25.9 p-80 -89.31 -25.02 21.86 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 118.46 -0.781 . . . . 0.0 111.18 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -162.5 -172.62 3.22 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.566 0.621 . . . . 0.0 112.531 -172.919 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.716 27.6 mm 125.89 -127.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.478 1 C-N-CA 134.583 5.153 . . . . 0.0 107.177 -179.815 . . . . . . . . 3 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 177.71 -172.83 45.54 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 118.354 2.101 . . . . 0.0 118.354 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.0 mp -133.7 169.58 16.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 126.856 2.062 . . . . 0.0 109.42 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.76 126.94 37.7 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 171.018 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 54.2 p -68.18 172.78 5.34 Favored 'General case' 0 N--CA 1.427 -1.579 0 CA-C-O 123.774 1.749 . . . . 0.0 108.136 175.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -55.2 -37.75 67.51 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 112.143 -2.299 . . . . 0.0 108.999 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -87.49 13.01 61.36 Favored Glycine 0 CA--C 1.534 1.239 0 C-N-CA 124.334 0.968 . . . . 0.0 112.589 177.441 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 75.55 14.73 81.76 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-N 118.287 1.044 . . . . 0.0 114.503 178.037 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.1 tpp85 -70.77 107.49 4.0 Favored 'General case' 0 C--N 1.339 0.152 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 177.73 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.61 101.39 8.29 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 125.457 1.503 . . . . 0.0 108.434 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.0 mt -96.81 103.85 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 126.479 1.912 . . . . 0.0 109.92 -176.296 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.0 tt -79.18 135.59 36.85 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 105.055 -2.202 . . . . 0.0 105.055 171.116 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.3 mt -113.97 153.22 15.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 125.179 1.392 . . . . 0.0 108.613 179.065 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.34 144.75 29.99 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 171.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.98 91.36 3.26 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.377 1.471 . . . . 0.0 110.504 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.27 154.63 5.43 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -178.494 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mt -98.33 135.28 33.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.267 -1.753 . . . . 0.0 106.267 178.705 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.0 t70 70.25 18.11 6.94 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.626 1.17 . . . . 0.0 112.818 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 p -81.9 -32.03 31.15 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 124.872 1.269 . . . . 0.0 108.501 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 8.1 p -55.06 -44.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.784 1.233 . . . . 0.0 108.143 172.575 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -61.34 -35.43 77.41 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.777 1.231 . . . . 0.0 109.813 176.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.99 9.43 5.44 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 126.851 2.061 . . . . 0.0 110.915 176.734 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.6 mttp 47.27 35.2 3.6 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 127.067 2.147 . . . . 0.0 114.787 173.809 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.05 19.12 63.29 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.63 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -71.26 90.47 0.92 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.064 1.432 . . . . 0.0 109.908 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.21 -1.06 6.61 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 126.068 1.794 . . . . 0.0 111.928 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.443 ' CD1' HG12 ' A' ' 115' ' ' VAL . 16.4 m-30 -100.42 111.57 23.84 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.723 1.209 . . . . 0.0 109.662 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 9.6 m -104.28 113.49 27.08 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 124.779 1.232 . . . . 0.0 108.132 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.7 p -81.43 144.94 31.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 118.92 0.782 . . . . 0.0 111.292 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -114.95 -41.98 3.28 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.186 1.394 . . . . 0.0 111.959 -178.369 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -70.94 130.19 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 174.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 61.0 m -92.28 53.71 2.18 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 104.934 -2.247 . . . . 0.0 104.934 172.001 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.365 1.2 pm0 16.35 62.89 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.466 3.507 . . . . 0.0 113.01 -169.509 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -79.09 48.99 3.44 Favored Glycine 0 CA--C 1.524 0.629 0 CA-C-N 111.729 -2.487 . . . . 0.0 109.818 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.403 4.3 p30 2.66 -111.25 0.0 OUTLIER 'General case' 0 N--CA 1.435 -1.22 0 C-N-CA 129.627 3.171 . . . . 0.0 117.366 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.254 0.2 OUTLIER -35.92 118.29 0.5 Allowed 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 121.599 3.926 . . . . 0.0 121.599 -169.726 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.268 27.6 m 36.89 70.39 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 128.421 2.688 . . . . 0.0 117.241 170.99 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.39 127.93 25.41 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 170.018 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -97.01 154.75 1.1 Allowed 'Trans proline' 0 N--CA 1.449 -1.141 0 C-N-CA 124.594 3.529 . . . . 0.0 110.401 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 49.07 2.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.303 0 N-CA-C 118.362 2.105 . . . . 0.0 118.362 172.449 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -60.69 136.49 58.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 119.948 1.874 . . . . 0.0 107.935 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -59.12 117.02 4.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.0 mt -79.91 -47.53 14.92 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.45 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.8 mp -149.97 166.0 30.97 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -177.623 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -126.33 132.1 51.68 Favored 'General case' 0 CA--C 1.518 -0.262 1 N-CA-C 98.458 -4.645 . . . . 0.0 98.458 166.243 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.443 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -141.25 123.19 14.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.846 -166.176 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 63.1 t0 -72.55 70.54 0.92 Allowed 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 124.497 1.119 . . . . 0.0 110.772 -178.279 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -50.37 -45.1 54.98 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.347 0.659 . . . . 0.0 110.432 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -50.71 -50.11 55.96 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.362 1.065 . . . . 0.0 112.709 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.87 -33.34 24.83 Favored 'General case' 0 CA--C 1.527 0.087 0 N-CA-C 111.771 0.285 . . . . 0.0 111.771 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -65.28 -52.86 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.776 -0.578 . . . . 0.0 109.993 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.344 19.4 pttp -40.25 -57.31 2.94 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 117.413 2.375 . . . . 0.0 117.413 -177.066 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -57.09 -22.04 45.46 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.526 2.15 . . . . 0.0 113.146 179.063 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -94.11 4.97 53.14 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 118.08 -0.962 . . . . 0.0 112.683 -178.132 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 21.3 m -136.1 150.19 70.45 Favored Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 120.182 1.355 . . . . 0.0 111.992 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -71.17 -28.9 18.2 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 122.891 2.394 . . . . 0.0 111.974 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 3.2 m -158.79 131.59 7.05 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.54 0.609 . . . . 0.0 110.024 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -90.4 21.44 3.88 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.114 1.366 . . . . 0.0 112.055 -177.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 24.3 mmt -59.64 146.85 39.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 121.348 -0.845 . . . . 0.0 110.933 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 18.2 p -112.41 68.69 0.96 Allowed Pre-proline 0 CA--C 1.536 0.418 0 C-N-CA 124.558 1.143 . . . . 0.0 108.296 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.45 92.83 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.236 1.957 . . . . 0.0 112.825 -175.083 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 3.2 mt -86.15 129.97 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 105.315 -2.105 . . . . 0.0 105.315 175.498 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.6 t -133.59 121.67 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-O 121.798 0.809 . . . . 0.0 109.192 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -82.15 108.83 15.92 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 101.653 -3.462 . . . . 0.0 101.653 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.8 p -75.5 -63.55 1.26 Allowed 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.712 0.768 . . . . 0.0 109.75 -173.611 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -72.16 52.14 0.25 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.682 1.193 . . . . 0.0 113.951 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 56.9 mt -78.96 49.11 0.89 Allowed 'General case' 0 CA--C 1.539 0.547 0 O-C-N 121.083 -1.011 . . . . 0.0 109.042 173.697 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 23.99 40.42 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 130.0 3.32 . . . . 0.0 115.042 -179.21 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 38.85 45.31 0.93 Allowed 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.209 1.804 . . . . 0.0 112.604 -175.232 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -175.69 -8.86 0.02 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 119.062 -0.855 . . . . 0.0 113.997 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.687 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 9.8 mm-40 -86.87 92.33 8.96 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 118.945 1.373 . . . . 0.0 108.299 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -77.37 132.44 38.55 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 123.248 0.619 . . . . 0.0 110.164 -177.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 1.9 t -86.15 91.4 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 125.293 1.437 . . . . 0.0 109.782 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.0 m -88.54 96.26 10.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 27.1 mt -65.76 131.8 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -102.47 -42.2 6.04 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 125.774 1.629 . . . . 0.0 110.801 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -54.72 83.75 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.186 0 C-N-CA 124.907 1.283 . . . . 0.0 112.799 -176.71 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 22.4 m -80.93 55.9 2.59 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.778 0.831 . . . . 0.0 109.418 179.563 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.68 -167.47 36.47 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.051 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 41.6 t -60.16 152.72 23.78 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 123.12 0.568 . . . . 0.0 110.831 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 55.2 t -123.49 148.81 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 C-N-CA 124.944 1.298 . . . . 0.0 107.739 178.238 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.1 m-80 -119.48 153.43 35.32 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.789 1.636 . . . . 0.0 110.111 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -47.53 135.45 11.15 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.838 0.855 . . . . 0.0 110.628 177.696 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 67.23 8.57 6.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.509 1.924 . . . . 0.0 114.933 178.224 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -64.5 150.88 45.8 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 120.062 1.301 . . . . 0.0 108.859 174.283 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -122.84 161.53 23.88 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 125.215 1.406 . . . . 0.0 108.487 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 21.1 t0 66.69 14.1 9.63 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 125.735 1.614 . . . . 0.0 113.713 -178.932 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.474 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -65.65 -26.76 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 C-N-CA 124.371 1.068 . . . . 0.0 111.104 176.736 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.5 p -138.75 147.2 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 C-N-CA 125.626 1.57 . . . . 0.0 107.935 179.36 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.18 109.76 15.37 Favored 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.394 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.687 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -77.57 98.85 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 174.724 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -87.93 147.94 24.82 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.038 0.935 . . . . 0.0 108.87 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.1 tptm . . . . . 0 C--N 1.329 -0.297 0 CA-C-O 121.927 0.87 . . . . 0.0 109.026 -178.437 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.0 ppp? . . . . . 0 CA--C 1.537 0.455 0 N-CA-C 112.948 0.722 . . . . 0.0 112.948 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 15.7 pt -74.21 61.12 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 124.508 1.123 . . . . 0.0 111.802 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.93 79.97 1.65 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.692 0.797 . . . . 0.0 108.987 177.707 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 72.0 mt-10 -46.89 126.9 8.62 Favored Pre-proline 0 CA--C 1.541 0.597 0 C-N-CA 123.745 0.818 . . . . 0.0 110.563 -179.139 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -74.39 69.53 5.01 Favored 'Trans proline' 0 N--CA 1.456 -0.711 0 C-N-CA 123.187 2.591 . . . . 0.0 111.469 -177.072 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -160.67 170.2 21.3 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 124.665 1.186 . . . . 0.0 108.729 178.12 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -101.72 146.73 27.35 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -163.75 149.92 11.5 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -161.14 30.68 0.14 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.15 1.38 . . . . 0.0 109.572 176.166 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.5 pp -132.83 -34.49 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.255 0 C-N-CA 123.674 0.79 . . . . 0.0 111.731 -178.567 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -155.87 -125.46 0.91 Allowed Glycine 0 C--N 1.335 0.492 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.02 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 51.82 -160.8 0.09 Allowed 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 125.138 1.375 . . . . 0.0 110.032 179.197 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 22.87 52.76 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 129.147 2.979 . . . . 0.0 118.438 174.287 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 74.4 t -145.31 -39.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -160.3 113.97 2.15 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 123.411 0.684 . . . . 0.0 112.119 -173.347 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.1 m -78.73 80.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.178 0 O-C-N 120.481 -1.387 . . . . 0.0 111.435 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -21.68 105.04 0.09 OUTLIER Pre-proline 0 CA--C 1.551 1.015 0 C-N-CA 129.229 3.012 . . . . 0.0 109.605 175.183 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.06 -20.56 21.63 Favored 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 123.535 2.823 . . . . 0.0 119.177 -167.42 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.35 147.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.34 0.164 0 CA-C-N 119.699 1.136 . . . . 0.0 110.547 -177.05 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.2 m -85.79 135.31 33.78 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 173.947 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 166.59 -140.38 6.29 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 -178.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.1 tp10 -125.81 122.68 36.87 Favored 'General case' 0 CA--C 1.528 0.122 0 C-N-CA 124.933 1.293 . . . . 0.0 110.089 -178.532 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.55 146.01 9.11 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.006 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -142.52 140.23 18.5 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 125.155 1.382 . . . . 0.0 107.656 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -57.13 145.55 85.79 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.116 1.877 . . . . 0.0 110.161 176.351 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -49.37 -37.63 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 124.304 1.041 . . . . 0.0 112.596 -178.449 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.6 p -55.96 -28.66 58.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.105 1.362 . . . . 0.0 112.606 178.353 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -77.23 -8.81 58.2 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 123.678 0.791 . . . . 0.0 112.745 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.425 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 46.7 t -74.26 131.01 81.32 Favored Pre-proline 0 CA--C 1.535 0.402 0 O-C-N 121.162 -0.961 . . . . 0.0 109.994 -178.07 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -77.17 55.93 5.24 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.515 2.81 . . . . 0.0 111.954 -177.979 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -167.72 108.68 0.59 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.47 -0.768 . . . . 0.0 109.19 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -35.47 -48.17 0.48 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 127.521 2.329 . . . . 0.0 115.375 -176.56 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.0 p -50.57 -38.1 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 122.932 0.493 . . . . 0.0 110.938 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.411 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 23.2 m-85 -89.38 -49.7 6.55 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 124.115 0.966 . . . . 0.0 108.828 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -48.07 -40.96 24.74 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.765 1.024 . . . . 0.0 113.765 -177.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.48 15.01 59.1 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.201 -1.333 . . . . 0.0 111.956 -177.015 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 53.1 mttp 71.87 -39.22 0.44 Allowed 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 119.285 1.542 . . . . 0.0 113.813 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 9.4 ttp 27.97 -69.18 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 131.341 3.856 . . . . 0.0 117.118 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.9 ttp -79.54 -25.53 41.65 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 126.047 1.739 . . . . 0.0 113.541 -175.33 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.71 -141.1 4.21 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 119.605 1.093 . . . . 0.0 110.658 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -121.96 154.4 37.24 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 174.478 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 179.51 -165.2 33.73 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.236 -175.806 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.535 ' CE2' HD11 ' A' ' 45' ' ' ILE . 37.4 p90 -159.37 168.91 25.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.425 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -112.37 151.28 29.97 Favored 'General case' 0 CA--C 1.501 -0.942 0 CA-C-O 121.346 0.593 . . . . 0.0 109.475 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.535 HD11 ' CE2' ' A' ' 43' ' ' PHE . 4.4 mp -125.08 132.31 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 102.18 -3.267 . . . . 0.0 102.18 170.868 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.0 tt -96.15 108.74 43.24 Favored Pre-proline 0 N--CA 1.442 -0.837 1 N-CA-C 98.589 -4.597 . . . . 0.0 98.589 169.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -82.17 156.1 17.19 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 123.664 2.909 . . . . 0.0 114.405 -168.201 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.2 p -124.98 -45.83 1.86 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.895 1.278 . . . . 0.0 108.794 174.711 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 120.34 14.59 Favored 'General case' 0 C--N 1.339 0.11 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 177.492 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.69 37.59 2.09 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 175.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.7 mt -142.33 119.39 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 127.007 2.123 . . . . 0.0 105.85 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.08 113.86 45.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.157 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.1 m -100.53 152.26 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 C-N-CA 123.094 0.558 . . . . 0.0 109.988 179.081 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 70.6 m -58.24 130.0 83.56 Favored Pre-proline 0 CA--C 1.537 0.463 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.106 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.2 -22.94 13.96 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 124.938 3.759 . . . . 0.0 115.774 -175.464 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.6 m -137.79 161.68 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 123.914 0.885 . . . . 0.0 109.769 -173.54 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.1 ttt180 -76.71 126.31 30.76 Favored 'General case' 0 CA--C 1.518 -0.271 1 N-CA-C 99.562 -4.236 . . . . 0.0 99.562 167.957 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.31 175.07 47.23 Favored Glycine 0 N--CA 1.436 -1.343 0 C-N-CA 116.709 -2.663 . . . . 0.0 114.33 -167.853 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 36.2 mtmt -100.62 135.16 42.49 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.231 1.812 . . . . 0.0 108.371 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 26.9 mm -76.47 107.93 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 173.333 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 64.3 tp -77.3 -50.6 12.48 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 123.358 0.663 . . . . 0.0 109.998 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.6 t30 179.53 107.68 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.463 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 10.3 m -117.82 147.4 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 123.587 0.755 . . . . 0.0 112.392 -178.285 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER 42.53 123.72 0.0 OUTLIER Pre-proline 0 CA--C 1.536 0.441 1 C-N-CA 132.901 4.48 . . . . 0.0 120.801 171.706 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -80.94 -50.16 0.05 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.216 0 N-CA-C 106.676 -2.086 . . . . 0.0 106.676 168.392 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 8.9 p -113.99 43.08 1.91 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 127.281 2.232 . . . . 0.0 111.14 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 ttmm 56.91 25.62 10.74 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 115.762 1.764 . . . . 0.0 115.762 171.748 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -135.09 9.32 3.51 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 115.262 1.578 . . . . 0.0 115.262 -175.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -168.25 -159.29 0.27 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 122.053 2.206 . . . . 0.0 113.988 -173.06 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.463 ' HB ' ' HA ' ' A' ' 63' ' ' VAL 1.014 0.2 OUTLIER 93.18 -161.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 131.632 3.973 . . . . 0.0 117.697 172.683 . . . . . . . . 4 4 . 1 . 010 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -115.14 154.1 17.2 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 120.06 2.784 . . . . 0.0 120.06 -167.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.8 mp -133.23 165.83 23.89 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 128.558 2.743 . . . . 0.0 108.519 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.7 mm-40 -136.86 139.58 41.78 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 175.153 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.8 m -82.33 -131.72 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.356 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -88.74 49.9 1.87 Allowed 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 107.356 -1.349 . . . . 0.0 107.356 174.916 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.57 -49.25 3.03 Favored Glycine 0 CA--C 1.53 1.027 0 C-N-CA 124.323 0.963 . . . . 0.0 112.905 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -56.81 -16.58 17.9 Favored Glycine 0 CA--C 1.534 1.264 0 N-CA-C 116.118 1.207 . . . . 0.0 116.118 -177.015 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 41.6 mtm180 -142.04 104.54 4.5 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 119.226 1.513 . . . . 0.0 111.569 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -90.0 130.12 36.23 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.196 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.0 mt -119.05 150.49 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 C-N-CA 124.89 1.276 . . . . 0.0 110.744 -176.329 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.75 132.84 44.17 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 128.373 2.669 . . . . 0.0 105.94 177.15 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.4 mt -124.87 143.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 124.841 1.256 . . . . 0.0 108.853 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 38.3 t-80 -134.82 124.73 25.56 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.136 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -87.78 122.52 31.53 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 118.675 -0.679 . . . . 0.0 109.558 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.05 -157.4 5.9 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 118.358 0.526 . . . . 0.0 112.491 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 17.6 mm -132.77 142.92 41.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 106.36 -1.719 . . . . 0.0 106.36 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.6 t70 58.96 29.06 18.46 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.058 0.943 . . . . 0.0 112.555 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 p -86.41 -37.3 18.5 Favored 'General case' 0 CA--C 1.517 -0.296 0 C-N-CA 126.162 1.785 . . . . 0.0 108.067 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 3.7 p -51.46 -46.75 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.235 171.154 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -61.6 -31.33 71.4 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.332 1.453 . . . . 0.0 111.147 178.312 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.89 -2.99 29.37 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.344 2.258 . . . . 0.0 110.379 178.3 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm 51.61 33.44 10.72 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 125.176 1.39 . . . . 0.0 112.629 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.49 18.15 63.05 Favored Glycine 0 CA--C 1.537 1.426 0 O-C-N 121.919 -0.488 . . . . 0.0 113.357 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -73.01 85.27 1.29 Allowed 'General case' 0 C--N 1.34 0.152 0 CA-C-N 118.88 1.34 . . . . 0.0 109.745 179.609 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 17.48 1.7 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.714 2.102 . . . . 0.0 111.575 -177.809 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.454 ' CD2' HG12 ' A' ' 115' ' ' VAL . 37.1 m-85 -117.26 150.15 39.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.8 1.24 . . . . 0.0 109.907 -178.381 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 30.7 m -145.15 102.45 3.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.8 p -81.33 127.49 32.8 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.964 0.906 . . . . 0.0 108.959 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -91.13 -45.03 8.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.859 1.264 . . . . 0.0 112.612 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 6.7 m -73.36 129.19 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 118.383 -1.327 . . . . 0.0 111.67 -177.992 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -87.97 64.56 7.88 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 172.825 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.3 0.0 OUTLIER -14.11 84.47 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 130.039 3.336 . . . . 0.0 116.485 -173.213 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.14 -2.12 0.03 OUTLIER Glycine 0 CA--C 1.534 1.257 0 CA-C-N 113.528 -1.669 . . . . 0.0 113.194 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 121.57 14.71 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 127.266 2.226 . . . . 0.0 107.073 177.045 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.94 121.02 41.66 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 127.808 2.443 . . . . 0.0 111.061 -179.427 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.337 33.7 m 43.23 66.62 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 C-N-CA 126.682 1.993 . . . . 0.0 115.615 178.781 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -132.7 141.58 41.65 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 171.949 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -103.37 171.29 0.21 Allowed 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.935 3.09 . . . . 0.0 110.529 -179.048 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 60.04 -23.01 0.04 OUTLIER Glycine 0 CA--C 1.534 1.234 0 N-CA-C 118.856 2.303 . . . . 0.0 118.856 170.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -50.24 137.49 18.06 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 120.457 2.128 . . . . 0.0 110.529 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -60.59 123.7 18.18 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.5 mt -85.79 -48.2 9.01 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.108 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.5 mp -143.12 155.8 44.66 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.724 0.81 . . . . 0.0 110.666 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -122.11 135.36 54.79 Favored 'General case' 0 C--O 1.236 0.356 1 N-CA-C 99.023 -4.436 . . . . 0.0 99.023 167.075 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.454 HG12 ' CD2' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -143.71 126.47 12.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.592 -165.754 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 38.7 m-20 -76.83 61.61 1.93 Allowed 'General case' 0 C--O 1.235 0.294 0 C-N-CA 124.904 1.282 . . . . 0.0 110.544 -178.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.0 mt -45.12 -45.5 11.28 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 123.886 0.875 . . . . 0.0 112.192 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -44.95 -42.01 7.78 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.488 1.115 . . . . 0.0 112.611 178.063 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.56 -33.67 15.81 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.113 0.565 . . . . 0.0 111.364 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 96.6 t -62.62 -52.78 55.46 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 O-C-N 121.756 -0.59 . . . . 0.0 110.004 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.391 8.8 ptmt -42.79 -57.22 5.11 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 116.895 2.183 . . . . 0.0 116.895 -177.79 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -61.59 -21.37 71.84 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 122.187 1.925 . . . . 0.0 113.184 178.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 -87.88 -42.29 12.62 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 119.064 0.847 . . . . 0.0 111.317 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.9 m -78.69 149.19 74.15 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.95 -0.469 . . . . 0.0 111.807 -177.183 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -70.53 -24.5 26.07 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.506 2.137 . . . . 0.0 110.228 175.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.2 t -158.05 145.06 17.93 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.725 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.2 tp -98.18 6.5 47.42 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.56 1.144 . . . . 0.0 110.31 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 21.3 mmt -53.36 115.16 1.77 Allowed 'General case' 0 C--N 1.344 0.343 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 47.3 m -106.33 88.6 3.34 Favored Pre-proline 0 N--CA 1.447 -0.579 0 C-N-CA 124.706 1.203 . . . . 0.0 108.241 -178.622 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 83.8 Cg_endo -72.93 144.0 37.64 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 122.668 2.246 . . . . 0.0 111.948 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.9 mt -125.01 126.29 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 103.788 -2.671 . . . . 0.0 103.788 173.102 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -123.53 153.41 29.16 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 C-N-CA 126.008 1.723 . . . . 0.0 106.651 178.669 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -129.92 121.58 26.9 Favored 'General case' 0 N--CA 1.428 -1.541 0 N-CA-C 102.914 -2.995 . . . . 0.0 102.914 -176.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 23.9 p -89.18 -86.17 0.19 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 -177.041 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 21.9 p30 -77.49 54.82 1.21 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 122.922 0.489 . . . . 0.0 111.696 179.488 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -78.26 80.07 4.69 Favored 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 174.692 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.12 51.51 0.21 Allowed 'General case' 0 C--N 1.343 0.289 0 C-N-CA 127.819 2.448 . . . . 0.0 111.641 -175.747 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 21.55 69.57 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 129.261 3.024 . . . . 0.0 113.964 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 146.42 -3.25 1.01 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-O 118.591 -1.116 . . . . 0.0 113.455 176.981 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.704 ' HB3' HG23 ' A' ' 160' ' ' ILE . 56.0 mt-10 -70.99 115.57 10.27 Favored 'General case' 0 C--N 1.339 0.116 0 CA-C-N 119.686 1.743 . . . . 0.0 109.933 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 81.5 p -78.78 128.99 34.13 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.12 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.266 0.4 OUTLIER -81.05 78.73 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 CA-C-O 123.498 1.618 . . . . 0.0 106.8 -177.538 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 38.5 m -78.8 91.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 120.962 -1.086 . . . . 0.0 111.249 -174.44 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.3 pt -63.19 104.58 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 C-N-CA 123.004 0.522 . . . . 0.0 109.597 176.649 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.23 -56.01 4.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 146' ' ' ALA . . . . . 0.731 ' HB3' HG23 ' A' ' 157' ' ' ILE . . . -84.14 69.97 10.47 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 46.4 m -77.7 68.66 3.82 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 176.666 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.17 -142.06 3.83 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 106.433 -2.667 . . . . 0.0 106.433 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.4 t -67.0 145.99 54.83 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 117.975 0.888 . . . . 0.0 110.645 177.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 150' ' ' VAL . . . . . 0.66 HG23 HG21 ' A' ' 157' ' ' ILE . 3.8 p -123.57 153.59 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 C-N-CA 125.881 1.673 . . . . 0.0 107.351 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 8.2 m-20 -129.68 158.1 40.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.268 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 -65.46 147.99 52.48 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 43.44 48.69 6.12 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 128.109 2.564 . . . . 0.0 114.057 172.816 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -89.29 10.21 23.09 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 177.528 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 53.62 8.86 0.15 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 128.752 2.821 . . . . 0.0 115.566 177.801 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -156.97 -126.13 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 125.146 1.378 . . . . 0.0 107.405 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.731 HG23 ' HB3' ' A' ' 146' ' ' ALA 0.312 1.5 mp 80.63 -36.89 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 128.559 2.744 . . . . 0.0 108.615 178.552 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -119.85 129.11 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 168.372 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 9.2 mmmt -111.3 111.51 22.61 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 124.168 0.987 . . . . 0.0 109.077 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.704 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.3 mp -77.24 91.51 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 103.409 -2.812 . . . . 0.0 103.409 175.049 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -103.46 116.1 31.77 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.587 1.555 . . . . 0.0 110.282 -173.009 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 28.6 tptp . . . . . 0 CA--C 1.528 0.129 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 178.987 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.3 mtm . . . . . 0 CA--C 1.531 0.214 0 CA-C-O 120.77 0.319 . . . . 0.0 110.82 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 33.4 pt -74.47 -172.5 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 123.809 0.844 . . . . 0.0 110.343 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.71 63.19 0.84 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 123.764 0.826 . . . . 0.0 111.028 179.055 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -66.02 -46.9 63.99 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 124.466 1.106 . . . . 0.0 113.745 -179.472 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -78.13 70.39 7.14 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 121.418 1.412 . . . . 0.0 111.535 -175.473 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 93.8 mt -70.47 67.96 0.36 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.813 1.645 . . . . 0.0 110.496 178.829 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 18.4 mt-30 -71.66 72.52 0.76 Allowed 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 125.541 1.536 . . . . 0.0 110.948 -178.614 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -60.13 97.46 0.05 OUTLIER 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.575 0.75 . . . . 0.0 110.338 178.743 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 72.07 -62.6 0.46 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 126.763 2.025 . . . . 0.0 111.226 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.298 15.5 tt 52.73 -58.68 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 C-N-CA 129.562 3.145 . . . . 0.0 116.378 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.92 57.25 0.54 Allowed Glycine 0 CA--C 1.524 0.595 0 N-CA-C 109.266 -1.533 . . . . 0.0 109.266 -178.354 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -134.46 -1.06 2.87 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.72 1.608 . . . . 0.0 113.751 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -86.94 166.77 14.85 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.847 1.259 . . . . 0.0 111.545 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.311 6.5 t 59.2 -17.76 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 N-CA-C 119.156 3.021 . . . . 0.0 119.156 176.105 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -152.11 127.94 10.25 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 127.877 2.471 . . . . 0.0 104.402 175.98 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.76 77.05 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.4 t -15.91 124.06 0.04 OUTLIER Pre-proline 0 CA--C 1.552 1.043 0 C-N-CA 129.063 2.945 . . . . 0.0 114.449 179.576 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' PRO . . . . . 0.429 ' HG2' HD12 ' A' ' 19' ' ' ILE . 50.5 Cg_endo -74.8 -42.72 0.51 Allowed 'Trans proline' 0 CA--C 1.538 0.684 0 N-CA-C 120.825 3.356 . . . . 0.0 120.825 -170.467 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ILE . . . . . 0.429 HD12 ' HG2' ' A' ' 18' ' ' PRO . 0.2 OUTLIER -138.16 145.49 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 121.014 1.734 . . . . 0.0 111.665 -172.646 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 m -79.88 131.88 35.96 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 171.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 178.41 -160.49 26.55 Favored Glycine 0 CA--C 1.518 0.249 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.7 tp10 -108.04 131.74 54.28 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.1 tt -75.85 151.71 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-N 118.679 0.672 . . . . 0.0 110.535 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.5 m-70 -140.14 129.75 13.59 Favored Pre-proline 0 N--CA 1.446 -0.628 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 172.407 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -57.41 143.0 95.22 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 122.512 2.141 . . . . 0.0 107.578 174.751 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ILE . . . . . 0.408 HD13 ' C ' ' A' ' 42' ' ' GLY . 1.8 tp -43.46 -49.45 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 123.764 0.826 . . . . 0.0 112.269 -177.666 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 p -53.9 -24.58 16.59 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.14 1.376 . . . . 0.0 114.321 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -78.81 -8.06 58.43 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 118.756 0.707 . . . . 0.0 112.61 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 93.0 t -70.1 134.67 87.35 Favored Pre-proline 0 CA--C 1.543 0.696 0 O-C-N 121.106 -0.996 . . . . 0.0 110.922 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.85 64.6 5.92 Favored 'Trans proline' 0 CA--C 1.537 0.673 0 C-N-CA 124.674 3.582 . . . . 0.0 110.556 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.09 178.69 6.84 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.37 1.468 . . . . 0.0 107.177 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.46 -63.83 1.2 Allowed 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 124.383 1.073 . . . . 0.0 110.565 178.314 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.9 p -47.26 -56.6 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 C-N-CA 124.22 1.008 . . . . 0.0 112.775 -177.411 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -61.06 -57.32 13.05 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-O 121.703 0.763 . . . . 0.0 108.959 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.3 m -53.67 -36.97 62.71 Favored 'General case' 0 N--CA 1.446 -0.648 0 C-N-CA 126.18 1.792 . . . . 0.0 115.592 -174.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.35 7.04 82.27 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 26.1 mtmt 74.99 -39.94 0.42 Allowed 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.974 1.71 . . . . 0.0 111.44 -177.368 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 26.6 ttt 28.01 -70.05 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 131.305 3.842 . . . . 0.0 116.909 177.687 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 9.6 tpt -79.13 -16.98 55.9 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.383 1.073 . . . . 0.0 112.654 -176.279 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.37 -135.29 2.18 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -178.556 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -131.24 154.94 47.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 105.833 -1.914 . . . . 0.0 105.833 173.467 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.408 ' C ' HD13 ' A' ' 26' ' ' ILE . . . -177.94 -159.48 22.79 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.249 -0.977 . . . . 0.0 114.177 -174.953 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 25.5 p90 -163.63 171.15 16.13 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.01 0.924 . . . . 0.0 109.521 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.431 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -120.34 137.3 54.35 Favored 'General case' 0 CA--C 1.508 -0.669 0 C-N-CA 122.936 0.494 . . . . 0.0 109.705 174.045 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 20.3 mm -112.09 129.6 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.903 0 N-CA-C 103.38 -2.822 . . . . 0.0 103.38 171.189 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 15.6 tp -94.85 110.63 50.7 Favored Pre-proline 0 N--CA 1.446 -0.651 0 N-CA-C 102.019 -3.326 . . . . 0.0 102.019 172.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -64.55 155.27 67.46 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 123.639 2.893 . . . . 0.0 116.916 -169.487 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.3 p -127.55 -50.94 1.38 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.124 1.37 . . . . 0.0 107.725 171.132 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -79.0 122.5 26.26 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 123.276 0.63 . . . . 0.0 110.37 177.553 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 40.31 2.26 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 174.491 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 72.7 mt -136.89 117.82 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.767 -2.679 . . . . 0.0 103.767 -179.237 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.3 t -120.59 109.4 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 122.962 0.505 . . . . 0.0 110.128 -173.891 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.5 m -91.15 -173.2 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 172.705 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.6 m -116.3 147.57 39.78 Favored Pre-proline 0 N--CA 1.469 0.49 0 CA-C-O 117.199 -1.381 . . . . 0.0 112.723 -175.108 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -61.54 -38.92 58.98 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 121.883 1.722 . . . . 0.0 108.305 174.65 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.46 142.0 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 102.921 -2.992 . . . . 0.0 102.921 171.151 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 29.1 mtm180 -95.12 -79.91 0.42 Allowed 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 102.094 -3.299 . . . . 0.0 102.094 171.902 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.88 -73.76 0.99 Allowed Glycine 0 C--N 1.338 0.64 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 176.166 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.21 123.1 8.72 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.765 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 24.1 mm -70.12 128.4 33.39 Favored 'Isoleucine or valine' 0 C--N 1.344 0.369 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.7 tt -78.43 -52.54 8.41 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.049 -2.204 . . . . 0.0 105.049 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 174.18 161.17 0.18 Allowed 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 124.614 1.166 . . . . 0.0 108.56 178.539 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.7 p -135.54 121.5 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 172.04 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -38.53 146.46 0.3 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.791 0.723 . . . . 0.0 112.947 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -58.63 -43.01 48.42 Favored 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.931 2.421 . . . . 0.0 109.723 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 15.9 p -78.23 74.27 4.77 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 173.591 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -34.4 93.24 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 129.261 3.024 . . . . 0.0 113.471 -173.671 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' HIS . . . . . 0.442 ' CD2' HG23 ' A' ' 89' ' ' VAL . 0.0 OUTLIER -158.56 -19.2 0.07 Allowed 'General case' 0 C--O 1.225 -0.229 0 N-CA-C 113.409 0.892 . . . . 0.0 113.409 175.31 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -164.77 -177.84 4.96 Favored 'General case' 0 C--O 1.222 -0.363 0 CA-C-N 120.238 1.381 . . . . 0.0 110.839 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.875 14.3 mm 135.57 -128.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 1 C-N-CA 133.254 4.622 . . . . 0.0 109.141 177.274 . . . . . . . . 3 2 . 1 . 011 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.4 175.29 42.49 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 118.769 2.268 . . . . 0.0 118.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 39.0 mt -128.72 172.94 10.76 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 127.478 2.311 . . . . 0.0 109.576 -178.255 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 -148.61 140.91 24.14 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.828 1.651 . . . . 0.0 106.835 176.339 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 59.6 p -77.45 -106.95 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.417 0 CA-C-O 121.049 0.452 . . . . 0.0 110.363 178.33 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -90.41 53.24 2.41 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 175.199 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 79.86 -56.11 4.53 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -174.933 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.54 173.97 28.79 Favored Glycine 0 CA--C 1.533 1.202 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 176.766 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.4 ttp180 54.13 69.73 0.69 Allowed 'General case' 0 CA--C 1.529 0.137 0 C-N-CA 124.446 1.099 . . . . 0.0 108.84 -177.864 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -79.28 134.32 36.64 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.3 mp -116.85 114.67 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 C-N-CA 123.268 0.627 . . . . 0.0 109.905 -177.521 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -81.2 125.84 30.78 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 104.196 -2.52 . . . . 0.0 104.196 170.706 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 62.7 mt -123.06 132.01 72.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -128.29 132.77 48.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 106.309 -1.737 . . . . 0.0 106.309 174.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -116.44 104.42 11.43 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 126.16 1.784 . . . . 0.0 109.489 -177.608 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.77 163.06 10.02 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 -178.261 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 10.7 mm -109.02 119.85 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 -179.05 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.4 t70 77.09 4.61 3.28 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.391 1.477 . . . . 0.0 113.779 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -61.78 -24.87 67.12 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 120.761 -1.212 . . . . 0.0 110.757 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' VAL . . . . . 0.442 HG23 ' CD2' ' A' ' 68' ' ' HIS . 0.5 OUTLIER -59.86 -47.88 89.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 C-N-CA 125.92 1.688 . . . . 0.0 108.127 173.594 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 4.5 m -63.47 -35.59 80.94 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.125 0.97 . . . . 0.0 108.766 177.43 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.58 19.75 0.78 Allowed 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 125.426 1.49 . . . . 0.0 110.873 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 4.8 mptt 37.77 37.59 0.13 Allowed 'General case' 0 C--N 1.346 0.42 0 C-N-CA 128.658 2.783 . . . . 0.0 114.595 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 52.58 34.42 43.07 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.486 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -67.41 92.64 0.3 Allowed 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 121.401 -1.058 . . . . 0.0 110.164 -178.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.47 1.67 5.12 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 126.043 1.782 . . . . 0.0 112.214 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -96.58 103.35 15.26 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.801 1.241 . . . . 0.0 111.263 -176.552 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.5 m -89.7 105.78 18.03 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.081 -2.192 . . . . 0.0 105.081 172.931 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.7 p -81.6 123.85 29.03 Favored 'General case' 0 N--CA 1.451 -0.406 0 O-C-N 121.613 -0.68 . . . . 0.0 110.402 -178.329 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -81.41 -52.3 7.41 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.915 1.286 . . . . 0.0 108.911 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.9 m -78.32 130.46 36.16 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 C-N-CA 117.999 -1.48 . . . . 0.0 107.224 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.5 m -94.37 57.06 2.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 169.37 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.341 9.8 pt-20 29.32 65.96 0.11 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 128.737 2.815 . . . . 0.0 111.681 -168.33 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -73.3 58.44 1.94 Allowed Glycine 0 CA--C 1.525 0.662 0 CA-C-N 111.574 -2.557 . . . . 0.0 111.253 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -10.59 -17.87 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.533 2 C-N-CA 136.188 5.795 . . . . 0.0 124.342 -179.317 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -142.88 110.7 5.9 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 128.062 2.545 . . . . 0.0 106.612 178.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.0 155.76 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 123.908 0.883 . . . . 0.0 112.833 -171.847 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -80.88 151.61 70.89 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-O 117.948 -1.025 . . . . 0.0 108.662 175.162 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -47.88 164.62 0.16 Allowed 'Trans proline' 0 CA--C 1.533 0.428 1 C-N-CA 127.018 5.145 . . . . 0.0 120.304 -174.158 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 68.45 -92.5 0.27 Allowed Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.84 1.686 . . . . 0.0 113.678 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 35.5 tp60 1.18 101.9 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.793 1 C-N-CA 132.258 4.223 . . . . 0.0 114.735 -176.548 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -4.14 112.95 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 130.168 3.387 . . . . 0.0 116.172 178.344 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.6 mt -83.18 -45.25 14.12 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 173.563 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.0 mt -140.38 151.23 44.8 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.723 1.209 . . . . 0.0 111.282 -174.285 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -119.84 128.58 53.82 Favored 'General case' 0 CA--C 1.514 -0.407 1 N-CA-C 99.12 -4.4 . . . . 0.0 99.12 167.363 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.93 124.41 27.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-N 115.1 -0.954 . . . . 0.0 112.756 -165.223 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -73.87 69.13 1.37 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.938 0.895 . . . . 0.0 110.037 178.984 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.1 mt -47.2 -52.49 15.62 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.793 0.837 . . . . 0.0 110.583 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -43.46 -49.65 7.16 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 125.392 1.477 . . . . 0.0 112.343 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -82.81 -31.36 28.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 123.175 0.297 . . . . 0.0 111.774 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 42.2 t -63.1 -56.48 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 118.901 -0.571 . . . . 0.0 110.839 179.007 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.324 3.8 pttm -42.78 -56.29 6.22 Favored Pre-proline 0 N--CA 1.47 0.535 0 N-CA-C 116.391 1.997 . . . . 0.0 116.391 -176.93 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -60.86 -14.63 33.41 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.699 1.6 . . . . 0.0 113.22 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 -98.98 5.08 47.36 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.056 -0.973 . . . . 0.0 112.303 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 20.1 m -142.07 155.11 65.44 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 120.332 1.424 . . . . 0.0 112.166 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.31 -39.78 89.16 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.086 2.524 . . . . 0.0 113.927 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -159.97 141.37 12.62 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.156 0.582 . . . . 0.0 110.012 -177.511 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -92.46 14.58 16.27 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.539 1.135 . . . . 0.0 112.068 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.4 mmt -53.04 134.01 38.33 Favored 'General case' 0 N--CA 1.457 -0.111 0 O-C-N 121.415 -0.803 . . . . 0.0 110.369 -178.377 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -110.28 78.78 1.46 Allowed Pre-proline 0 N--CA 1.451 -0.378 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 176.759 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.2 136.59 27.1 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 C-N-CA 122.449 2.1 . . . . 0.0 110.269 178.381 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -128.98 134.66 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 178.395 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 t -136.53 126.15 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 125.165 1.386 . . . . 0.0 108.55 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.457 ' HB2' ' CD2' ' A' ' 136' ' ' LEU . 13.9 m-85 -92.93 124.13 36.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 103.525 -2.769 . . . . 0.0 103.525 176.819 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 77.7 p -86.49 -82.28 0.2 Allowed 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.071 0.85 . . . . 0.0 109.319 -176.117 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -77.01 52.34 0.87 Allowed 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.457 ' CD2' ' HB2' ' A' ' 133' ' ' PHE . 0.2 OUTLIER -78.78 72.26 5.29 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.249 -0.907 . . . . 0.0 108.666 174.509 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 41.87 47.86 3.74 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 126.603 1.961 . . . . 0.0 111.256 -178.259 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 18.9 68.42 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 129.394 3.077 . . . . 0.0 113.245 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 154.75 -9.65 0.39 Allowed Glycine 0 CA--C 1.523 0.574 0 CA-C-O 118.508 -1.162 . . . . 0.0 113.021 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.666 ' HB3' HG23 ' A' ' 160' ' ' ILE . 59.1 mm-40 -69.09 116.93 10.1 Favored 'General case' 0 C--N 1.342 0.281 0 CA-C-N 119.626 1.713 . . . . 0.0 110.069 178.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.2 p -77.73 136.07 38.11 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.828 -1.915 . . . . 0.0 105.828 173.006 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -86.69 86.74 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 -176.768 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.2 m -77.42 83.31 3.85 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.82 -1.175 . . . . 0.0 110.99 -175.034 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' ILE . . . . . 0.471 HG22 HG22 ' A' ' 158' ' ' VAL . 2.1 pt -56.59 111.15 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 173.636 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -88.73 -38.57 14.62 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 123.892 0.877 . . . . 0.0 109.636 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -81.12 75.77 8.08 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.463 -175.782 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 50.6 p -77.39 69.44 3.65 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 169.38 -137.43 4.52 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -176.7 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.7 t -75.43 149.07 38.64 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.7 m -119.98 158.93 21.59 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 C-N-CA 125.374 1.469 . . . . 0.0 109.048 178.719 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -131.79 166.98 20.34 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 125.688 1.595 . . . . 0.0 112.22 176.416 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 73.5 mtm-85 -85.65 154.25 21.81 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -175.347 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 57.52 55.11 5.9 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 126.448 1.899 . . . . 0.0 113.591 176.324 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 154' ' ' GLN . . . . . 0.503 ' CB ' HD13 ' A' ' 157' ' ' ILE . 4.3 mm-40 -143.05 161.12 38.99 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.964 0.906 . . . . 0.0 109.76 176.835 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 155' ' ' GLU . . . . . 0.452 ' C ' ' H ' ' A' ' 157' ' ' ILE . 62.9 tt0 -105.52 -61.1 1.53 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 122.817 1.294 . . . . 0.0 112.314 -177.412 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.436 ' C ' HD12 ' A' ' 157' ' ' ILE . 0.9 OUTLIER -65.68 27.34 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 127.705 2.402 . . . . 0.0 114.682 -174.326 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.503 HD13 ' CB ' ' A' ' 154' ' ' GLN . 1.7 mp -103.17 -34.7 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 130.225 3.41 . . . . 0.0 104.976 177.451 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.471 HG22 HG22 ' A' ' 144' ' ' ILE . 59.4 t -149.05 109.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 106.062 -1.829 . . . . 0.0 106.062 173.147 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -101.77 124.31 47.2 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 118.049 0.386 . . . . 0.0 111.78 -176.772 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.666 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.4 mp -78.15 108.8 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 174.685 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -128.9 150.62 50.28 Favored 'General case' 0 C--O 1.226 -0.157 0 C-N-CA 124.383 1.073 . . . . 0.0 109.261 -175.783 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 50.9 tptt . . . . . 0 C--N 1.333 -0.136 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -179.815 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.8 ttt . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.0 mm -77.07 62.77 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 124.463 1.105 . . . . 0.0 108.562 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.39 55.09 0.96 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 124.519 1.128 . . . . 0.0 111.93 -177.523 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -61.28 -42.97 88.24 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-O 118.005 -0.998 . . . . 0.0 112.463 177.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -67.4 66.14 0.73 Allowed 'Trans proline' 0 CA--C 1.544 1.007 0 C-N-CA 123.568 2.845 . . . . 0.0 113.219 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 94.7 mt -73.31 65.29 0.85 Allowed 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.295 1.438 . . . . 0.0 110.696 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -73.53 56.64 0.52 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.998 1.719 . . . . 0.0 111.393 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -77.37 73.65 3.94 Favored 'General case' 0 C--O 1.231 0.1 0 O-C-N 121.508 -0.745 . . . . 0.0 109.288 179.631 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 46.61 54.32 8.94 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 124.892 1.277 . . . . 0.0 111.467 177.274 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 45.2 pt -92.12 18.32 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 C-N-CA 123.89 0.876 . . . . 0.0 113.232 -176.906 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 177.07 -147.06 8.12 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 107.487 -2.245 . . . . 0.0 107.487 179.068 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -79.81 68.35 5.86 Favored 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 177.513 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -105.2 -139.25 0.36 Allowed 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 116.464 2.024 . . . . 0.0 116.464 -172.743 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -71.64 52.05 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 116.96 2.207 . . . . 0.0 116.96 -169.115 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -160.53 128.45 4.53 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 104.269 -2.493 . . . . 0.0 104.269 171.255 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.4 m -123.77 85.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 CA-C-N 118.846 0.748 . . . . 0.0 110.958 -176.375 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.4 p -19.45 110.25 0.09 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 129.569 3.147 . . . . 0.0 110.512 177.806 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -68.64 -25.13 34.6 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.776 2.317 . . . . 0.0 117.931 -168.498 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.95 146.1 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.611 1.096 . . . . 0.0 109.598 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.1 m -79.34 137.45 37.33 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 170.615 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 173.82 -158.25 27.09 Favored Glycine 0 C--O 1.227 -0.312 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -108.4 120.61 42.89 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.17 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 tt -85.51 134.92 26.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 118.569 0.622 . . . . 0.0 109.718 178.635 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -137.59 149.42 64.97 Favored Pre-proline 0 N--CA 1.451 -0.389 0 C-N-CA 125.79 1.636 . . . . 0.0 107.753 176.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.65 143.37 96.57 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 121.366 1.378 . . . . 0.0 108.566 173.935 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -55.05 -24.82 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -173.774 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.3 p -52.42 -31.02 32.28 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 124.279 1.032 . . . . 0.0 111.134 174.696 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -75.16 -9.72 58.8 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.5 1.12 . . . . 0.0 112.65 -176.448 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.9 t -76.63 131.74 73.53 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 119.13 0.877 . . . . 0.0 109.861 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -77.8 60.1 7.1 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 123.17 2.58 . . . . 0.0 110.847 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -165.55 102.6 0.71 Allowed 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.487 -0.758 . . . . 0.0 110.01 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -24.41 -59.0 0.05 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.476 2.71 . . . . 0.0 115.055 -178.45 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -52.03 -41.85 33.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 123.178 0.591 . . . . 0.0 111.583 -177.723 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -80.67 -48.56 12.43 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.7 m -48.71 -41.54 32.16 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -179.103 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.61 11.2 61.2 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-O 118.629 -1.095 . . . . 0.0 111.515 -178.411 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm 73.37 -39.5 0.44 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.573 1.549 . . . . 0.0 112.773 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 13.7 tpt 21.7 -62.24 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 1 C-N-CA 132.264 4.226 . . . . 0.0 117.996 178.455 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -77.71 -21.63 51.67 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.991 0.916 . . . . 0.0 111.898 -176.465 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.32 -136.29 2.78 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -130.27 157.55 42.21 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 172.915 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.71 -167.74 36.87 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.943 -176.103 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -146.81 154.72 41.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 124.283 1.033 . . . . 0.0 109.718 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.76 119.09 38.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.009 0.923 . . . . 0.0 109.917 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.3 mm -100.8 129.53 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 171.334 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.3 tt -98.14 105.83 30.98 Favored Pre-proline 0 N--CA 1.45 -0.426 0 N-CA-C 101.326 -3.583 . . . . 0.0 101.326 172.561 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -60.5 167.31 8.26 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 123.434 2.756 . . . . 0.0 117.124 -169.968 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.1 p -146.98 -58.92 0.28 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.72 1.608 . . . . 0.0 106.942 173.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -69.81 119.0 13.37 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 175.724 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.75 44.85 3.03 Favored Glycine 0 CA--C 1.53 1.005 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 22.0 mt -144.06 114.64 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 N-CA-C 105.253 -2.129 . . . . 0.0 105.253 -177.045 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.65 126.14 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 124.479 1.111 . . . . 0.0 109.131 -175.373 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.8 m -109.29 156.91 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 C-N-CA 123.387 0.675 . . . . 0.0 110.363 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 m -65.67 127.2 92.86 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-O 118.982 -0.532 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.49 -7.96 22.5 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 124.468 3.445 . . . . 0.0 116.765 -174.573 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.4 m -147.99 169.51 3.58 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 CA-C-N 119.754 1.161 . . . . 0.0 109.388 -177.207 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.06 116.18 17.49 Favored 'General case' 0 C--O 1.235 0.336 1 N-CA-C 97.978 -4.823 . . . . 0.0 97.978 166.893 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.69 170.26 42.11 Favored Glycine 0 N--CA 1.438 -1.215 0 C-N-CA 116.026 -2.988 . . . . 0.0 116.557 -167.08 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 10.0 mtpp -97.2 132.84 42.57 Favored 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 127.989 2.515 . . . . 0.0 109.003 -175.015 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.7 mm -72.8 123.96 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 104.618 -2.364 . . . . 0.0 104.618 173.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 42.0 tp -78.63 -48.88 14.2 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 179.515 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -177.46 171.79 1.91 Allowed 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 123.531 0.732 . . . . 0.0 109.444 173.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 51.5 t -144.16 115.08 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 176.477 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -45.5 147.33 1.47 Allowed Pre-proline 0 CA--C 1.542 0.65 0 CA-C-N 118.689 0.677 . . . . 0.0 111.454 177.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.45 -24.22 11.84 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 124.102 3.202 . . . . 0.0 114.881 176.247 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.8 p -76.34 -15.17 60.03 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.636 1.174 . . . . 0.0 111.165 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.6 tppt? 70.94 4.8 5.22 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 127.852 2.461 . . . . 0.0 113.344 -178.837 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.2 p-80 -78.97 -25.93 43.48 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 113.41 0.893 . . . . 0.0 113.41 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.96 -173.94 2.53 Favored 'General case' 0 C--O 1.222 -0.348 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -172.296 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.439 HG22 ' N ' ' A' ' 71' ' ' GLY 0.62 25.9 mm 132.03 -124.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.345 1 C-N-CA 136.505 5.922 . . . . 0.0 105.75 178.863 . . . . . . . . 4 3 . 1 . 012 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.439 ' N ' HG22 ' A' ' 70' ' ' ILE . . . -179.96 -176.68 47.55 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 116.976 1.55 . . . . 0.0 116.976 -179.106 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.3 mp -126.29 171.92 10.54 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 127.519 2.327 . . . . 0.0 110.126 -178.613 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -140.36 136.37 33.09 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.477 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 62.9 p -71.66 -92.12 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.925 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -150.21 -64.04 0.21 Allowed 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.221 1.409 . . . . 0.0 109.504 179.229 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -76.23 60.99 3.12 Favored Glycine 0 CA--C 1.527 0.787 0 C-N-CA 123.627 0.632 . . . . 0.0 111.54 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 75.29 -60.07 2.77 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.054 0.835 . . . . 0.0 112.388 178.79 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 24.8 mtp180 -19.23 96.92 0.01 OUTLIER 'General case' 0 C--O 1.235 0.338 0 C-N-CA 128.449 2.7 . . . . 0.0 112.836 -179.403 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 13.2 tm-20 -93.3 150.72 20.27 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 126.866 2.066 . . . . 0.0 109.318 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.65 103.39 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 C-N-CA 124.376 1.071 . . . . 0.0 109.052 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.4 tt -85.64 136.64 33.29 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.498 -1.668 . . . . 0.0 106.498 174.467 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 20.0 mt -122.77 148.72 26.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 123.444 0.698 . . . . 0.0 109.938 -178.738 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.37 126.48 21.17 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 170.551 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -102.41 106.22 16.94 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.705 1.202 . . . . 0.0 108.773 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 64.29 176.63 4.73 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 118.184 0.447 . . . . 0.0 113.09 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.6 mm -113.29 141.17 29.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.9 t70 63.27 13.32 6.88 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.423 1.089 . . . . 0.0 112.486 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 p -74.15 -39.74 63.06 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 126.265 1.826 . . . . 0.0 107.231 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 p -47.11 -47.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 124.923 1.289 . . . . 0.0 109.287 171.916 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -63.98 -54.58 32.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 125.347 1.459 . . . . 0.0 111.304 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.23 -36.89 78.74 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 123.991 0.916 . . . . 0.0 112.008 -178.257 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 81.5 mttt 79.57 145.6 0.09 Allowed 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 128.854 2.862 . . . . 0.0 108.706 -176.67 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.45 48.71 0.29 Allowed Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.609 1.1 . . . . 0.0 115.537 -176.25 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 25.7 pt-20 -63.75 -17.31 62.9 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 119.168 1.484 . . . . 0.0 113.67 177.687 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -109.84 15.43 31.43 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 126.544 2.021 . . . . 0.0 111.13 177.033 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -107.95 99.42 8.88 Favored 'General case' 0 C--N 1.343 0.283 0 CA-C-N 118.156 0.978 . . . . 0.0 110.665 -176.809 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -79.44 93.99 5.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 174.271 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 p -79.11 127.4 31.96 Favored 'General case' 0 N--CA 1.453 -0.31 0 O-C-N 120.983 -1.073 . . . . 0.0 110.505 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -89.17 -49.11 6.94 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 123.836 0.854 . . . . 0.0 110.375 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -78.1 133.29 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.032 0 C-N-CA 119.019 -1.072 . . . . 0.0 110.559 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 m -87.73 61.5 6.5 Favored 'General case' 0 C--N 1.333 -0.128 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 172.793 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.271 1.6 pm0 3.22 79.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 130.451 3.501 . . . . 0.0 115.211 -174.244 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 174.65 6.54 0.02 OUTLIER Glycine 0 CA--C 1.533 1.202 0 CA-C-N 113.32 -1.763 . . . . 0.0 114.812 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.24 121.52 14.46 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 119.493 1.646 . . . . 0.0 107.396 176.115 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 37.8 mmt-85 -100.07 100.53 11.41 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 129.796 3.238 . . . . 0.0 111.817 -175.297 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.551 7.3 p 60.47 78.23 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 N-CA-C 116.813 2.153 . . . . 0.0 116.813 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -135.99 150.14 70.5 Favored Pre-proline 0 N--CA 1.446 -0.632 0 CA-C-N 111.933 -2.394 . . . . 0.0 105.141 169.15 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -105.42 142.59 0.1 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.969 3.112 . . . . 0.0 111.803 -177.123 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 56.93 15.26 12.46 Favored Glycine 0 CA--C 1.531 1.046 0 O-C-N 121.417 -0.802 . . . . 0.0 114.289 175.588 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.3 130.28 45.41 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.393 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 25.7 ttpt -59.39 117.64 5.07 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.112 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.4 mt -80.41 -54.2 5.92 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 25.0 mt -144.82 151.13 38.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.215 1.006 . . . . 0.0 110.871 -173.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 6.1 tm-20 -116.45 128.44 55.48 Favored 'General case' 0 CA--C 1.515 -0.398 1 N-CA-C 97.922 -4.844 . . . . 0.0 97.922 166.098 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.52 121.69 22.78 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.834 -166.719 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -71.91 69.96 0.73 Allowed 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.844 1.258 . . . . 0.0 111.112 -177.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.3 mt -47.95 -44.85 30.53 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.057 0.943 . . . . 0.0 110.718 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -52.83 -43.78 66.24 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.473 0.709 . . . . 0.0 112.794 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -84.71 -33.36 23.16 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.114 0.416 . . . . 0.0 111.305 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 40.3 t -63.87 -56.25 17.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 O-C-N 121.865 -0.522 . . . . 0.0 109.852 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.359 0.1 OUTLIER -40.74 -55.52 4.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 117.891 2.552 . . . . 0.0 117.891 -177.125 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -57.91 -21.65 50.38 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.515 2.143 . . . . 0.0 112.87 178.893 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -93.68 9.57 36.42 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.457 -0.782 . . . . 0.0 112.216 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 15.9 m -138.96 152.02 69.36 Favored Pre-proline 0 C--N 1.344 0.36 0 CA-C-N 119.923 1.238 . . . . 0.0 111.695 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.03 -26.8 12.62 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.044 2.496 . . . . 0.0 111.594 179.291 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 15.6 t -153.1 142.81 21.97 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.09 6.99 47.56 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.226 1.01 . . . . 0.0 110.595 178.404 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 16.5 mmt -51.01 119.61 4.12 Favored 'General case' 0 C--N 1.344 0.347 0 CA-C-N 118.5 0.591 . . . . 0.0 109.955 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 29.9 m -117.2 87.52 24.05 Favored Pre-proline 0 N--CA 1.446 -0.66 0 C-N-CA 125.588 1.555 . . . . 0.0 107.645 -177.082 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.403 ' C ' HD12 ' A' ' 131' ' ' ILE . 49.8 Cg_endo -84.89 151.61 11.2 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 C-N-CA 121.411 1.407 . . . . 0.0 112.011 -178.686 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ILE . . . . . 0.47 HD12 ' N ' ' A' ' 131' ' ' ILE . 1.3 mp -118.55 130.14 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 N-CA-C 102.792 -3.04 . . . . 0.0 102.792 173.853 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.0 t -128.6 153.4 38.05 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.58 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -127.02 109.82 12.31 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 103.418 -2.808 . . . . 0.0 103.418 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.0 p -75.2 -78.05 0.11 Allowed 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -175.864 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -74.03 65.86 1.15 Allowed 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.587 0.708 . . . . 0.0 112.096 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 16.4 mt -72.81 70.41 0.98 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.144 1.378 . . . . 0.0 108.273 176.315 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 27.74 48.99 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 128.508 2.723 . . . . 0.0 111.921 -176.63 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 28.5 53.52 0.08 Allowed 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 128.74 2.816 . . . . 0.0 114.44 -175.647 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 167.09 -4.71 0.05 OUTLIER Glycine 0 CA--C 1.528 0.848 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.227 178.499 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.571 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 3.7 mm-40 -87.35 148.01 25.23 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.838 1.319 . . . . 0.0 110.178 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 51.0 p -123.89 140.42 53.0 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.943 1.297 . . . . 0.0 108.102 179.035 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -86.08 95.35 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-O 122.064 0.935 . . . . 0.0 108.952 -177.563 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 62.1 m -84.74 87.36 7.3 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.301 -0.875 . . . . 0.0 109.836 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.8 pt -66.07 128.78 29.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 174.733 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -103.2 -46.9 4.48 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.557 1.143 . . . . 0.0 109.708 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -76.14 156.69 33.53 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.433 0.635 . . . . 0.0 111.629 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 27.9 p -150.62 113.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 104.774 -2.306 . . . . 0.0 104.774 178.04 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 115.8 -151.57 18.33 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.9 t -59.12 139.93 56.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.347 1.074 . . . . 0.0 112.379 -177.701 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.5 m -143.52 146.32 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 C-N-CA 126.23 1.812 . . . . 0.0 108.64 177.363 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -101.59 160.18 14.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.491 1.116 . . . . 0.0 110.768 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.2 ttp180 -75.77 154.99 35.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.524 1.53 . . . . 0.0 110.887 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 57.98 52.96 7.23 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.903 1.681 . . . . 0.0 113.222 178.219 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 154' ' ' GLN . . . . . 0.634 ' HB2' HD13 ' A' ' 157' ' ' ILE . 17.2 mm-40 -135.93 168.01 20.14 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.635 1.574 . . . . 0.0 108.509 177.792 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -119.69 -77.53 0.58 Allowed 'General case' 0 C--N 1.344 0.327 0 CA-C-N 120.027 1.285 . . . . 0.0 114.238 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -37.08 -7.62 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.065 1 C-N-CA 132.073 4.149 . . . . 0.0 120.194 -174.586 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.672 ' H ' HD12 ' A' ' 157' ' ' ILE . 4.9 mp -68.39 -33.44 60.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 130.874 3.67 . . . . 0.0 106.889 174.565 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -137.29 133.62 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 C-N-CA 127.281 2.233 . . . . 0.0 106.599 173.428 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -127.08 133.03 50.52 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.571 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.06 116.2 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 175.347 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -98.26 170.83 8.6 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 175.551 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp . . . . . 0 CA--C 1.532 0.259 0 O-C-N 121.457 -0.777 . . . . 0.0 110.811 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.0 ttt . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 33.1 mm -44.02 -41.87 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 126.349 1.86 . . . . 0.0 112.976 -177.377 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' ALA . . . . . 0.425 ' HB3' ' HA ' ' A' ' 7' ' ' GLN . . . -76.74 71.89 3.33 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.638 0.732 . . . . 0.0 110.243 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -24.8 -57.17 0.16 Allowed Pre-proline 0 CA--C 1.54 0.593 0 C-N-CA 128.062 2.545 . . . . 0.0 116.243 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -67.63 74.01 0.62 Allowed 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.611 2.207 . . . . 0.0 112.2 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 71.1 mt 45.13 41.99 6.29 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 126.23 1.812 . . . . 0.0 111.969 178.43 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLN . . . . . 0.425 ' HA ' ' HB3' ' A' ' 3' ' ' ALA . 54.3 mm-40 57.1 47.81 16.62 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.921 0.888 . . . . 0.0 110.282 -177.511 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 59.6 46.0 12.52 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 125.259 1.424 . . . . 0.0 108.078 -176.555 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 16.2 mp0 48.91 61.07 3.29 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.493 1.117 . . . . 0.0 108.423 -176.428 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.2 mt 73.13 -40.79 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 126.535 1.934 . . . . 0.0 110.796 -176.029 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 76.35 -71.33 2.05 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -68.54 68.19 0.14 Allowed 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 126.058 1.743 . . . . 0.0 111.735 -178.839 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -150.02 -161.68 1.39 Allowed 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 126.678 1.991 . . . . 0.0 110.93 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.472 12.9 p 65.23 -73.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 119.286 3.069 . . . . 0.0 119.286 175.392 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -115.43 153.26 31.39 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 125.213 1.405 . . . . 0.0 110.637 -170.639 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.3 m -117.35 108.36 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 119.244 0.929 . . . . 0.0 109.04 172.504 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.3 t -38.87 115.96 0.95 Allowed Pre-proline 0 CA--C 1.553 1.066 0 C-N-CA 124.759 1.224 . . . . 0.0 111.761 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -76.82 -23.38 10.95 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 123.507 2.805 . . . . 0.0 118.293 -172.338 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.89 154.41 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 120.698 1.59 . . . . 0.0 109.989 -178.552 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.5 m -89.74 137.73 32.08 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 175.329 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 160.71 -130.71 2.44 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -131.32 139.01 49.47 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 124.653 1.181 . . . . 0.0 109.087 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.9 tt -101.39 131.6 48.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 CA-C-N 118.673 0.669 . . . . 0.0 110.01 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.64 145.49 49.6 Favored Pre-proline 0 N--CA 1.452 -0.358 0 C-N-CA 126.069 1.748 . . . . 0.0 108.036 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -62.82 141.97 86.93 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 121.749 1.633 . . . . 0.0 108.598 174.023 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.6 tt -53.61 -27.29 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 114.334 1.235 . . . . 0.0 114.334 -174.431 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.7 p -55.02 -29.0 56.41 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.879 0.871 . . . . 0.0 111.553 176.111 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -78.98 -1.45 35.47 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.81 0.844 . . . . 0.0 112.937 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.4 t -81.68 134.58 50.42 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.068 -1.02 . . . . 0.0 110.181 -178.292 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -77.83 54.1 4.68 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.741 2.961 . . . . 0.0 111.934 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -167.98 109.28 0.58 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.308 0.958 . . . . 0.0 110.651 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -29.43 -54.48 0.14 Allowed 'General case' 0 C--O 1.234 0.249 0 C-N-CA 128.35 2.66 . . . . 0.0 115.186 -177.716 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -51.56 -40.49 25.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.973 0.416 . . . . 0.0 110.565 -176.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.469 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 24.5 m-85 -83.15 -52.87 6.23 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 177.666 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -46.66 -39.94 12.27 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 114.349 1.241 . . . . 0.0 114.349 -177.79 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -109.11 22.77 24.62 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-O 118.339 -1.256 . . . . 0.0 111.39 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.8 mppt? 70.69 -45.02 0.6 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.028 1.731 . . . . 0.0 114.384 178.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.8 tpp 32.76 -68.92 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 130.2 3.4 . . . . 0.0 116.703 -178.096 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.32 -26.01 42.28 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.974 1.31 . . . . 0.0 112.771 -176.652 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.12 -154.55 16.09 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -178.957 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -108.39 153.34 23.43 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 174.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -174.25 -167.46 33.77 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.42 -176.325 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.506 ' CE2' HG11 ' A' ' 158' ' ' VAL . 9.4 p90 -150.02 165.13 33.64 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.894 1.278 . . . . 0.0 109.044 -178.461 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -117.85 117.19 28.61 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 123.706 0.802 . . . . 0.0 111.289 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -87.83 134.34 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 103.994 -2.595 . . . . 0.0 103.994 170.023 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.2 tt -100.89 106.62 45.22 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.054 -4.795 . . . . 0.0 98.054 169.287 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_endo -83.92 161.38 13.9 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 123.439 2.76 . . . . 0.0 114.191 -168.051 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.7 p -130.18 -53.39 1.11 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.867 1.267 . . . . 0.0 109.639 176.63 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -67.11 128.03 34.85 Favored 'General case' 0 CA--C 1.519 -0.214 0 O-C-N 122.18 -0.325 . . . . 0.0 111.493 179.432 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.45 39.55 1.93 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 174.089 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 5.0 mp -143.62 120.53 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 104.676 -2.342 . . . . 0.0 104.676 178.187 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 69.8 t -119.41 120.08 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 C-N-CA 125.695 1.598 . . . . 0.0 107.415 -176.055 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 22.0 m -106.77 157.29 7.06 Favored 'Isoleucine or valine' 0 C--N 1.338 0.099 0 N-CA-C 114.42 1.266 . . . . 0.0 114.42 -175.879 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 48.2 m -61.62 125.76 85.32 Favored Pre-proline 0 CA--C 1.537 0.48 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.488 179.017 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -77.52 -4.12 14.31 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 124.945 3.763 . . . . 0.0 116.012 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.5 m -155.21 172.88 0.57 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 125.297 1.439 . . . . 0.0 108.055 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ARG . . . . . 0.421 ' NE ' ' H ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -76.26 87.89 3.09 Favored 'General case' 0 C--N 1.34 0.16 1 N-CA-C 98.374 -4.676 . . . . 0.0 98.374 168.028 . . . . . . . . 4 4 . 1 . 013 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.07 176.26 30.43 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 118.543 2.177 . . . . 0.0 118.543 -164.971 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.01 110.54 5.31 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 172.301 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.2 mm -61.82 125.14 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 37.1 mt -78.95 -48.75 13.94 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 105.779 -1.934 . . . . 0.0 105.779 173.655 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -173.25 159.33 3.8 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.168 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.4 t -135.4 119.81 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 102.879 -3.008 . . . . 0.0 102.879 173.459 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -45.55 147.39 1.49 Allowed Pre-proline 0 CA--C 1.535 0.384 0 O-C-N 123.43 0.456 . . . . 0.0 111.55 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -56.51 -25.96 61.26 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.642 2.228 . . . . 0.0 111.214 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 55.2 p -79.97 13.49 2.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 117.03 -1.462 . . . . 0.0 112.596 177.294 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' A' ' 96' ' ' PHE 0.275 0.1 OUTLIER 66.28 -39.6 0.33 Allowed 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 117.857 2.539 . . . . 0.0 117.857 178.477 . . . . . . . . 4 4 . 1 . 013 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.9 p-80 -57.63 -26.6 61.82 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 116.269 1.951 . . . . 0.0 116.269 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.93 -175.99 5.67 Favored 'General case' 0 C--O 1.221 -0.396 0 N-CA-C 114.292 1.219 . . . . 0.0 114.292 -172.237 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.847 26.9 mm 127.0 -135.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.52 -0.192 1 C-N-CA 133.25 4.62 . . . . 0.0 110.289 178.51 . . . . . . . . 3 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -166.89 173.47 42.2 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 118.43 2.132 . . . . 0.0 118.43 -176.044 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.7 mp -127.64 175.16 8.49 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 128.208 2.603 . . . . 0.0 109.854 -177.825 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -137.07 160.74 38.07 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 103.258 -2.867 . . . . 0.0 103.258 168.567 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 83.6 p -79.69 -99.77 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.388 0 O-C-N 124.055 0.847 . . . . 0.0 109.448 177.861 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -98.57 -56.4 2.47 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 124.553 1.141 . . . . 0.0 108.97 177.603 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -158.26 49.05 0.43 Allowed Glycine 0 CA--C 1.524 0.615 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 179.25 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 168.02 -168.95 41.11 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 107.87 -2.092 . . . . 0.0 107.87 -178.079 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 74.4 mtp180 49.37 68.64 0.69 Allowed 'General case' 0 CA--C 1.524 -0.041 0 C-N-CA 124.833 1.253 . . . . 0.0 109.84 -178.72 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -79.63 109.96 14.51 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 125.327 1.451 . . . . 0.0 107.389 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.4 mp -95.96 116.56 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 C-N-CA 125.381 1.472 . . . . 0.0 109.763 -176.467 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 9.2 tp -93.58 122.29 35.87 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 105.316 -2.105 . . . . 0.0 105.316 172.663 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.0 mt -113.82 134.53 56.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 124.938 1.295 . . . . 0.0 108.741 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -131.24 109.76 10.63 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 171.799 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.435 ' HA ' HG23 ' A' ' 129' ' ' THR . 6.4 t80 -78.51 119.6 22.02 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 118.708 -0.663 . . . . 0.0 109.443 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.1 -161.26 2.97 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-O 121.71 0.617 . . . . 0.0 113.341 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.9 mm -131.17 145.5 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.4 t70 62.67 15.34 7.96 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.5 1.12 . . . . 0.0 113.426 179.713 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.9 p -78.52 -37.7 42.42 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 126.251 1.821 . . . . 0.0 107.468 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 9.1 p -50.71 -45.26 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 CA-C-N 113.77 -1.559 . . . . 0.0 108.787 172.386 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -63.31 -37.86 88.92 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 125.531 1.532 . . . . 0.0 111.329 178.455 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.65 -39.44 94.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 127.145 2.178 . . . . 0.0 109.898 -179.804 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mttp 59.62 88.01 0.08 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.782 1.633 . . . . 0.0 114.223 175.853 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.4 -55.63 2.85 Favored Glycine 0 CA--C 1.539 1.582 0 O-C-N 121.375 -0.828 . . . . 0.0 112.856 175.244 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -28.17 108.3 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 128.911 2.884 . . . . 0.0 114.034 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 92.24 -2.14 74.39 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-N 113.976 -1.466 . . . . 0.0 114.764 175.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.473 ' CG ' HG12 ' A' ' 115' ' ' VAL . 2.4 m-85 -108.86 109.51 20.63 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 117.857 0.828 . . . . 0.0 109.823 -176.684 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.7 m -79.9 81.18 6.2 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 102.741 -3.059 . . . . 0.0 102.741 169.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.8 p -76.99 114.09 15.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 -178.492 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' PHE . . . . . 0.402 ' CE1' ' HG3' ' A' ' 114' ' ' GLU . 22.7 m-85 -77.64 -46.17 22.86 Favored 'General case' 0 CA--C 1.511 -0.551 0 C-N-CA 123.459 0.703 . . . . 0.0 111.297 -173.265 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.56 125.98 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 C-N-CA 117.122 -1.831 . . . . 0.0 109.96 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.7 m -92.48 58.39 3.16 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 102.375 -3.195 . . . . 0.0 102.375 168.476 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.449 0.0 OUTLIER 30.47 54.35 0.16 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 129.307 3.043 . . . . 0.0 112.907 -168.43 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.03 62.92 2.08 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 110.265 -3.152 . . . . 0.0 110.712 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 33.0 t70 3.92 -106.46 0.0 OUTLIER 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 130.098 3.359 . . . . 0.0 116.312 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -55.14 106.99 0.26 Allowed 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.084 1.754 . . . . 0.0 111.617 -173.018 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 2.5 m -124.14 157.1 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 126.811 2.044 . . . . 0.0 111.692 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.4 mm-40 -86.83 164.17 37.97 Favored Pre-proline 0 CA--C 1.535 0.379 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 172.289 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -70.25 154.21 65.98 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 N-CA-C 106.58 -2.123 . . . . 0.0 106.58 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.9 -15.15 8.62 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 119.586 -1.292 . . . . 0.0 114.072 178.466 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.29 125.96 25.66 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 106.606 -1.628 . . . . 0.0 106.606 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . 0.311 0.0 OUTLIER -66.74 119.95 12.68 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.102 0.865 . . . . 0.0 111.428 -177.268 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 77.4 mt -79.67 -41.5 26.74 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.3 mp -147.82 146.26 29.06 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.126 0.97 . . . . 0.0 111.059 -178.69 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG3' ' CE1' ' A' ' 99' ' ' PHE . 93.7 mt-10 -114.55 130.6 56.77 Favored 'General case' 0 N--CA 1.463 0.196 1 N-CA-C 99.203 -4.369 . . . . 0.0 99.203 166.539 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.473 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -138.74 127.81 30.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.633 -164.307 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -75.71 65.41 1.87 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-O 121.137 0.494 . . . . 0.0 110.247 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.5 mt -50.42 -38.1 41.37 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 123.617 0.767 . . . . 0.0 111.796 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -54.21 -40.19 67.38 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 122.899 0.48 . . . . 0.0 112.162 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -91.06 -32.77 15.76 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 122.829 0.452 . . . . 0.0 111.34 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.27 -48.58 84.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 O-C-N 121.622 -0.673 . . . . 0.0 109.699 178.955 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.376 40.6 pttt -41.73 -58.38 3.23 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 116.498 2.036 . . . . 0.0 116.498 -177.237 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -59.42 -20.0 54.22 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.258 1.972 . . . . 0.0 113.137 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -95.61 9.11 41.37 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.773 0.829 . . . . 0.0 112.351 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 31.4 m -133.44 149.46 72.38 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 119.747 1.158 . . . . 0.0 109.9 177.559 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -72.24 -27.71 16.22 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.576 2.184 . . . . 0.0 111.187 179.433 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 5.4 m -160.2 138.31 10.03 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.282 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.0 tp -91.54 7.11 42.94 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.344 1.058 . . . . 0.0 111.524 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 20.3 mmt -50.3 116.13 1.74 Allowed 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.71 0.804 . . . . 0.0 109.226 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.435 HG23 ' HA ' ' A' ' 84' ' ' PHE . 50.1 m -108.59 84.38 2.42 Favored Pre-proline 0 N--CA 1.444 -0.744 0 C-N-CA 124.276 1.03 . . . . 0.0 108.317 -179.372 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.469 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 72.5 Cg_endo -72.41 142.29 36.72 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.44 2.094 . . . . 0.0 110.765 179.039 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 29.6 mt -131.15 128.52 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 104.459 -2.422 . . . . 0.0 104.459 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -125.59 152.55 32.56 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 C-N-CA 125.314 1.446 . . . . 0.0 107.863 -177.24 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -120.69 117.8 28.43 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 102.867 -3.012 . . . . 0.0 102.867 177.935 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.4 p -81.38 -67.89 0.74 Allowed 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.478 0.656 . . . . 0.0 110.353 -173.003 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.6 p30 -70.82 51.88 0.14 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 126.442 1.897 . . . . 0.0 113.034 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.7 mt -75.72 63.84 1.66 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.809 1.244 . . . . 0.0 108.874 177.392 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 24.32 49.96 0.01 OUTLIER 'General case' 0 C--N 1.346 0.445 0 C-N-CA 128.969 2.908 . . . . 0.0 112.051 -176.439 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 28.03 54.21 0.07 Allowed 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 128.649 2.78 . . . . 0.0 114.135 -174.894 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.9 0.05 OUTLIER Glycine 0 CA--C 1.528 0.873 0 CA-C-O 118.853 -0.97 . . . . 0.0 114.3 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 26.8 mt-10 -80.96 138.34 36.09 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.152 1.476 . . . . 0.0 109.701 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 7.7 p -111.08 139.39 46.48 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.223 1.409 . . . . 0.0 109.273 179.227 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.64 120.79 35.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.3 m -114.75 95.71 5.37 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.665 1.186 . . . . 0.0 111.308 -174.899 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 2.3 pt -63.32 124.75 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 176.655 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -96.08 -53.82 3.52 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.655 1.182 . . . . 0.0 108.376 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -86.22 74.0 10.11 Favored 'General case' 0 N--CA 1.456 -0.136 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.437 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 47.1 p -77.04 72.76 3.61 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 -179.364 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 179.87 -136.51 2.77 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -177.391 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.0 t -69.0 148.78 49.6 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.38 163.02 38.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 C-N-CA 125.222 1.409 . . . . 0.0 108.097 177.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -133.44 162.59 31.46 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.687 1.195 . . . . 0.0 109.039 -178.313 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 68.6 mtp180 -65.23 147.6 53.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.869 0.468 . . . . 0.0 110.509 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 25.8 tp10 57.65 12.97 1.76 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 126.847 2.059 . . . . 0.0 114.749 173.855 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -71.55 117.87 13.66 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -65.97 137.47 57.15 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 156' ' ' ASP . . . . . 0.462 ' C ' ' H ' ' A' ' 158' ' ' VAL . 27.9 t0 74.18 -111.81 0.04 OUTLIER 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 128.027 2.531 . . . . 0.0 108.448 -175.672 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.271 1.6 mp 70.86 -29.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 129.456 3.103 . . . . 0.0 110.866 -176.703 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.506 HG11 ' CE2' ' A' ' 43' ' ' PHE . 6.2 p -143.35 119.4 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 130.197 3.399 . . . . 0.0 105.003 173.148 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 28.0 tttm -111.9 139.3 47.5 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.767 0.427 . . . . 0.0 110.077 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.533 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.14 132.06 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 172.152 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -141.26 167.96 20.91 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 106.627 -1.619 . . . . 0.0 106.627 177.482 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 24.1 tptp . . . . . 0 C--N 1.33 -0.239 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.865 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.7 ttt . . . . . 0 CA--C 1.532 0.276 0 CA-C-O 120.702 0.287 . . . . 0.0 110.406 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 23.2 mm -76.83 67.72 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -71.44 68.1 0.53 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.128 1.371 . . . . 0.0 112.888 -175.298 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -63.79 -47.33 81.61 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-O 118.465 -0.778 . . . . 0.0 110.617 175.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.34 143.86 89.92 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 121.695 1.597 . . . . 0.0 108.117 176.405 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -72.1 61.7 0.45 Allowed 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -175.092 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 28.8 mm100 -81.74 63.22 5.91 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 124.628 1.171 . . . . 0.0 108.079 177.033 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -142.06 43.02 1.68 Allowed 'General case' 0 C--N 1.333 -0.133 0 C-N-CA 123.842 0.857 . . . . 0.0 110.967 -175.96 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 16.6 pm0 -69.08 75.23 0.33 Allowed 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 125.441 1.496 . . . . 0.0 112.062 -178.634 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.6 tp -136.82 -35.8 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 123.928 0.891 . . . . 0.0 112.577 179.513 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 172.13 140.58 3.14 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 179.58 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 52.19 65.95 1.35 Allowed 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.116 0.966 . . . . 0.0 110.597 178.493 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -75.67 52.68 0.67 Allowed 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 124.693 1.197 . . . . 0.0 110.495 -178.094 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.6 t 46.21 32.01 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 125.589 1.556 . . . . 0.0 109.487 -177.199 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -79.43 75.1 6.04 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.691 -174.069 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.7 m -77.9 84.16 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 O-C-N 121.857 -0.527 . . . . 0.0 111.747 -176.859 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.7 t -10.66 112.97 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 128.64 2.776 . . . . 0.0 113.796 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.42 -32.3 3.02 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 122.601 2.201 . . . . 0.0 115.781 -174.484 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.65 139.62 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 120.4 1.455 . . . . 0.0 109.933 -177.659 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 56.4 m -78.18 140.84 38.97 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 168.28 -159.82 33.15 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 -103.02 126.44 50.2 Favored 'General case' 0 N--CA 1.458 -0.072 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 176.262 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.2 tt -97.26 141.27 16.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 CA-C-N 118.57 0.623 . . . . 0.0 109.695 -179.569 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 25.5 m-70 -136.78 148.31 62.81 Favored Pre-proline 0 C--O 1.235 0.316 0 C-N-CA 124.701 1.2 . . . . 0.0 108.019 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.89 146.11 69.61 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.025 1.817 . . . . 0.0 110.176 176.151 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.7 tp -49.53 -34.88 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 C-N-CA 123.766 0.826 . . . . 0.0 113.117 -177.144 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 p -55.83 -26.78 48.25 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.863 0.865 . . . . 0.0 112.581 178.301 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -74.99 -13.05 60.47 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.829 0.852 . . . . 0.0 112.594 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.522 HG22 ' HB2' ' A' ' 44' ' ' ALA . 46.3 t -67.85 129.18 93.36 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.306 -0.871 . . . . 0.0 110.057 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -76.52 59.48 6.2 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 124.197 3.265 . . . . 0.0 111.849 -178.863 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -169.08 108.66 0.45 Allowed 'General case' 0 N--CA 1.465 0.296 0 O-C-N 121.351 -0.843 . . . . 0.0 110.104 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -24.25 -58.86 0.05 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.153 2.581 . . . . 0.0 114.98 -179.018 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 52.7 t -52.9 -50.24 44.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.613 0.765 . . . . 0.0 110.082 -178.06 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -71.49 -48.36 49.53 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.3 m -49.44 -43.11 44.59 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.968 0.907 . . . . 0.0 113.068 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.94 11.88 69.1 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-O 118.907 -0.94 . . . . 0.0 111.456 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt 71.55 -37.18 0.38 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.749 1.62 . . . . 0.0 113.358 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 30.8 -71.78 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 131.063 3.745 . . . . 0.0 116.538 178.786 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 37.8 tpp -78.4 -16.82 57.23 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.013 0.925 . . . . 0.0 112.145 -175.615 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.99 -133.93 2.11 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -146.26 163.31 35.89 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 173.832 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 164.87 -134.9 3.49 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.28 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -168.07 169.89 10.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 117.967 0.884 . . . . 0.0 111.546 -177.375 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.522 ' HB2' HG22 ' A' ' 29' ' ' VAL . . . -102.22 132.46 48.13 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 124.061 0.945 . . . . 0.0 109.25 179.12 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -109.39 135.62 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 103.102 -2.925 . . . . 0.0 103.102 168.474 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.1 tt -101.25 104.74 35.14 Favored Pre-proline 0 N--CA 1.447 -0.619 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 171.559 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.16 169.81 1.36 Allowed 'Trans proline' 0 C--N 1.348 0.543 1 C-N-CA 125.375 4.05 . . . . 0.0 116.278 -171.952 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 65.7 p -155.38 -54.94 0.09 Allowed 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 124.14 0.976 . . . . 0.0 111.279 176.542 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -57.84 -43.86 86.11 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -176.775 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.29 25.81 69.83 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -174.17 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -139.04 130.9 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 176.12 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.7 t -125.11 126.07 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 -175.605 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.1 m -105.71 162.84 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 C-N-CA 124.013 0.925 . . . . 0.0 111.075 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 15.9 m -67.46 126.39 92.49 Favored Pre-proline 0 CA--C 1.536 0.419 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.094 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -75.66 -16.72 18.63 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 124.125 3.216 . . . . 0.0 115.577 -174.724 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.18 163.97 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.067 0 CA-C-N 118.861 0.755 . . . . 0.0 109.183 -174.842 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 18.1 ttt85 -75.67 119.29 19.5 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 100.31 -3.959 . . . . 0.0 100.31 169.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.1 177.1 48.32 Favored Glycine 0 N--CA 1.436 -1.31 0 C-N-CA 116.562 -2.732 . . . . 0.0 115.089 -168.066 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.01 133.85 34.96 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.621 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 10.0 mm -79.22 100.03 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 172.272 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 46.7 tp -73.66 -56.5 4.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 -174.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.83 163.86 5.07 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 115.936 1.828 . . . . 0.0 115.936 174.912 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.5 m -144.18 118.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 176.672 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -40.12 153.8 0.2 Allowed Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 119.086 0.857 . . . . 0.0 111.8 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.02 -22.01 44.67 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.262 2.641 . . . . 0.0 113.545 178.851 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 17.8 p -77.1 -7.73 56.26 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.947 1.299 . . . . 0.0 110.939 177.041 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.09 25.17 10.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 127.106 2.162 . . . . 0.0 110.692 -174.44 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -93.94 -28.03 16.03 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.87 -178.23 4.18 Favored 'General case' 0 C--O 1.222 -0.365 0 CA-C-N 120.146 1.339 . . . . 0.0 109.768 -178.192 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.47 HG22 ' N ' ' A' ' 71' ' ' GLY 0.752 24.2 mm 137.73 -125.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.409 1 C-N-CA 132.95 4.5 . . . . 0.0 109.676 177.162 . . . . . . . . 4 3 . 1 . 014 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.47 ' N ' HG22 ' A' ' 70' ' ' ILE . . . -177.04 174.69 47.26 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 117.172 1.629 . . . . 0.0 117.172 -177.773 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.3 mp -128.51 169.78 13.95 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 127.612 2.365 . . . . 0.0 110.137 -176.784 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 84.5 mt-30 -143.1 126.47 16.68 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 123.313 0.645 . . . . 0.0 111.049 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 m -73.6 77.3 1.49 Allowed 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 174.791 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 16.6 t70 46.63 57.83 5.17 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 127.896 2.479 . . . . 0.0 110.357 -178.52 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 73.44 -8.48 9.68 Favored Glycine 0 CA--C 1.533 1.214 0 CA-C-O 119.149 -0.806 . . . . 0.0 113.655 -179.284 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -87.42 -124.72 1.97 Allowed Glycine 0 C--N 1.339 0.727 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 178.954 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -48.66 110.35 0.34 Allowed 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.988 0.915 . . . . 0.0 110.083 -177.683 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -95.71 132.42 40.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.247 1.419 . . . . 0.0 107.803 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.75 113.59 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 C-N-CA 124.128 0.971 . . . . 0.0 111.538 -174.838 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.6 tt -85.56 137.41 32.89 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 106.006 -1.85 . . . . 0.0 106.006 171.007 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.1 mt -133.19 137.18 53.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.188 0.995 . . . . 0.0 109.574 179.166 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' HIS . . . . . 0.429 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 45.4 t-80 -126.16 120.51 30.28 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 171.469 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -68.92 122.18 18.12 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 175.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.37 -147.1 0.97 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-N 119.245 0.929 . . . . 0.0 113.119 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.7 mm -128.06 143.57 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.544 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.4 t0 49.31 44.13 23.37 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.418 1.087 . . . . 0.0 113.044 178.438 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.5 p -90.79 -19.05 23.9 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.655 1.582 . . . . 0.0 108.427 177.402 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.4 p -52.39 -46.22 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 174.84 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.8 m -61.63 -23.17 65.86 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.62 1.568 . . . . 0.0 112.736 176.427 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.54 -18.5 59.76 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.312 1.445 . . . . 0.0 108.836 177.312 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 59.9 mttm 47.95 33.89 3.7 Favored 'General case' 0 C--N 1.344 0.336 0 C-N-CA 125.831 1.652 . . . . 0.0 112.379 178.112 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.1 17.03 54.71 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.321 -1.266 . . . . 0.0 114.446 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.71 1.88 1.6 Allowed 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 120.232 2.016 . . . . 0.0 115.116 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -136.43 18.03 3.71 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 126.668 2.08 . . . . 0.0 110.193 175.996 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.61 ' CD1' HG12 ' A' ' 115' ' ' VAL . 22.4 m-30 -118.75 155.94 30.23 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.702 1.251 . . . . 0.0 110.638 -177.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.7 m -148.95 131.0 15.34 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.0 p -101.48 146.32 27.8 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 123.658 0.783 . . . . 0.0 112.173 -176.47 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -127.34 20.42 6.78 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.698 1.599 . . . . 0.0 113.753 -174.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.5 m -150.62 154.21 9.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.208 0 C-N-CA 123.861 0.864 . . . . 0.0 109.27 175.354 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.9 m -87.71 125.32 34.34 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 170.39 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.84 78.72 2.11 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 123.189 1.471 . . . . 0.0 109.851 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 179.06 -18.4 0.03 OUTLIER Glycine 0 CA--C 1.532 1.15 0 C-N-CA 128.447 2.927 . . . . 0.0 110.601 -176.768 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -53.41 120.09 5.64 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.168 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.14 115.4 28.96 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 127.709 2.404 . . . . 0.0 113.167 -170.161 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.372 20.8 m 52.03 74.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 117.154 2.279 . . . . 0.0 117.154 175.054 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -140.71 144.72 37.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 168.28 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -102.82 171.74 0.22 Allowed 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 123.733 2.955 . . . . 0.0 109.68 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 52.71 -8.82 0.01 OUTLIER Glycine 0 CA--C 1.536 1.399 0 N-CA-C 120.039 2.775 . . . . 0.0 120.039 170.109 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.2 tp60 -59.22 142.01 52.86 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 120.957 2.378 . . . . 0.0 109.264 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 16.6 ptpt -61.07 114.26 3.01 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 175.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 78.2 mt -79.53 -52.26 8.25 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 20.5 mt -141.41 159.34 42.43 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.979 0.511 . . . . 0.0 111.625 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -122.46 134.69 54.58 Favored 'General case' 0 CA--C 1.516 -0.363 1 N-CA-C 99.965 -4.087 . . . . 0.0 99.965 166.8 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.61 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.1 OUTLIER -147.37 117.92 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -166.826 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -71.12 72.59 0.61 Allowed 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.799 1.639 . . . . 0.0 111.978 -175.352 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.6 mt -47.71 -42.18 24.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.493 178.618 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -54.21 -39.89 67.11 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.72 -33.52 19.98 Favored 'General case' 0 CA--C 1.529 0.141 0 CA-C-O 120.815 0.341 . . . . 0.0 111.125 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.98 -50.36 65.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 O-C-N 121.705 -0.622 . . . . 0.0 110.237 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.388 3.2 pptp? -42.59 -54.93 7.65 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -178.485 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.16 -24.2 76.13 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.422 2.082 . . . . 0.0 112.862 177.399 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -84.15 -42.77 15.66 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.806 0.73 . . . . 0.0 111.108 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.2 m -78.69 147.91 71.96 Favored Pre-proline 0 CA--C 1.535 0.398 0 O-C-N 122.025 -0.422 . . . . 0.0 111.769 -177.327 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -70.48 -27.28 23.24 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.617 2.211 . . . . 0.0 110.462 176.154 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.8 m -158.04 137.81 12.16 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.659 1.184 . . . . 0.0 108.218 179.08 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -87.1 2.96 48.1 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 124.313 1.045 . . . . 0.0 111.788 -178.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.3 mmt -55.04 103.92 0.1 Allowed 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.029 0.932 . . . . 0.0 110.346 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 53.3 m -90.05 105.32 10.89 Favored Pre-proline 0 N--CA 1.445 -0.69 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD2' ' HB3' ' A' ' 83' ' ' HIS . 1.7 Cg_endo -84.26 136.8 6.86 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.723 2.282 . . . . 0.0 108.521 -177.824 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.1 mt -118.88 120.22 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.817 0 N-CA-C 102.721 -3.066 . . . . 0.0 102.721 175.284 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.3 t -130.05 114.73 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.598 0 CA-C-O 122.368 1.08 . . . . 0.0 108.242 -177.389 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.473 ' CB ' HD21 ' A' ' 136' ' ' LEU . 4.0 m-85 -81.89 116.8 21.71 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 103.914 -2.624 . . . . 0.0 103.914 176.564 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 82.1 p -83.03 -83.47 0.14 Allowed 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.94 0.4 . . . . 0.0 110.319 -173.658 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 20.1 p30 -75.61 64.27 1.65 Allowed 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.542 0.737 . . . . 0.0 110.806 179.331 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LEU . . . . . 0.473 HD21 ' CB ' ' A' ' 133' ' ' PHE . 17.0 mt -65.33 -29.76 70.54 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 124.288 1.035 . . . . 0.0 112.968 178.715 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 127.76 -132.7 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 1 C-N-CA 132.631 4.372 . . . . 0.0 105.587 -176.858 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -136.1 146.6 47.17 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 127.228 2.211 . . . . 0.0 108.471 177.569 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 59.33 37.53 92.06 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 -177.053 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.403 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 0.0 OUTLIER -97.35 82.42 3.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 C-N-CA 126.127 1.771 . . . . 0.0 107.569 -177.421 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 71.1 p -79.48 115.22 18.98 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.071 178.496 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -72.93 78.83 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -178.799 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -82.72 92.32 7.18 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.842 -176.448 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 39.9 mt -65.44 129.83 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.272 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 9.8 mmpt? -98.21 -51.03 4.14 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.508 1.523 . . . . 0.0 108.853 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -75.65 69.55 2.37 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.57 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 54.2 p -77.48 73.4 4.05 Favored 'General case' 0 CA--C 1.533 0.304 0 O-C-N 121.368 -0.832 . . . . 0.0 108.851 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 175.12 -124.61 1.02 Allowed Glycine 0 CA--C 1.52 0.401 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -177.449 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.2 t -94.15 151.0 19.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.377 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 2.6 m -131.72 148.85 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 125.031 1.332 . . . . 0.0 107.586 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -114.89 155.32 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 177.261 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.8 mtm105 -57.74 157.64 7.13 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 120.913 0.387 . . . . 0.0 110.483 177.823 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 70.25 -12.59 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.568 1.547 . . . . 0.0 115.055 175.485 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -63.17 131.51 48.71 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-N 119.989 1.268 . . . . 0.0 107.745 176.815 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -97.32 -36.37 10.42 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 115.51 1.671 . . . . 0.0 115.51 -173.616 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -87.62 21.4 2.58 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 127.658 2.383 . . . . 0.0 113.938 -176.321 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -71.29 -26.57 27.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.6 p -142.39 152.59 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 125.567 1.547 . . . . 0.0 108.643 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -128.24 116.51 19.98 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 173.747 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.89 87.0 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 102.554 -3.128 . . . . 0.0 102.554 172.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -85.88 148.33 25.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.461 1.104 . . . . 0.0 111.004 -173.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.8 mmtt . . . . . 0 N--CA 1.455 -0.19 0 C-N-CA 124.057 0.943 . . . . 0.0 109.604 178.07 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.1 mtt . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 25.2 mm -91.28 -50.16 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 177.583 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 65.6 -67.52 0.13 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 126.644 1.977 . . . . 0.0 112.578 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 43.91 61.34 10.75 Favored Pre-proline 0 CA--C 1.537 0.468 0 C-N-CA 126.504 1.921 . . . . 0.0 110.528 -178.375 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -68.03 82.29 0.47 Allowed 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.753 2.302 . . . . 0.0 113.321 -175.011 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 35.5 mt -78.31 59.3 2.29 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.512 0.672 . . . . 0.0 109.31 176.232 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.38 68.16 5.32 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.1 t30 -58.68 152.46 18.66 Favored 'General case' 0 C--O 1.234 0.244 0 O-C-N 122.288 -0.257 . . . . 0.0 110.923 -179.306 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -72.07 75.16 0.94 Allowed 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.8 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 53.6 mt 78.95 142.95 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.271 0 C-N-CA 127.231 2.212 . . . . 0.0 109.032 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 176.25 -61.98 0.1 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 107.205 -2.358 . . . . 0.0 107.205 -179.597 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -77.59 157.39 30.3 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 124.011 0.924 . . . . 0.0 108.754 176.953 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 44.3 mm-40 -76.18 66.36 2.3 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 173.256 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.31 7.5 p 40.24 74.34 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 C-N-CA 127.608 2.363 . . . . 0.0 113.929 -177.411 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.41 ' CZ ' ' CE1' ' A' ' 133' ' ' PHE . 0.1 OUTLIER -144.97 126.46 15.0 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 174.966 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 m -115.99 96.28 4.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.388 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 177.675 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 90.6 p -35.23 119.11 0.6 Allowed Pre-proline 0 CA--C 1.556 1.206 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -77.64 -28.39 5.37 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.677 2.251 . . . . 0.0 116.738 -171.428 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.29 146.07 28.52 Favored 'Isoleucine or valine' 0 C--N 1.341 0.239 0 CA-C-N 119.42 1.009 . . . . 0.0 110.96 -176.035 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.4 m -79.04 137.75 37.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 172.42 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 167.41 -150.35 16.76 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.193 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -118.18 129.18 55.36 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.152 0.981 . . . . 0.0 109.153 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 2.7 mt -79.95 137.27 21.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 176.262 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -131.16 144.58 54.09 Favored Pre-proline 0 N--CA 1.45 -0.429 0 C-N-CA 126.003 1.721 . . . . 0.0 106.732 175.992 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -58.22 143.55 96.84 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.407 2.071 . . . . 0.0 110.001 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.1 tp -52.38 -39.75 29.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.207 0.527 . . . . 0.0 111.24 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 p -56.0 -28.1 55.77 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.565 1.546 . . . . 0.0 112.902 177.834 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -79.68 -8.24 59.1 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.414 0.686 . . . . 0.0 112.826 -178.382 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.472 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 58.8 t -69.71 123.43 88.56 Favored Pre-proline 0 CA--C 1.539 0.539 0 CA-C-O 117.82 -1.086 . . . . 0.0 111.693 -177.132 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 29' ' ' VAL . 50.0 Cg_exo -61.43 61.55 0.11 Allowed 'Trans proline' 0 CA--C 1.549 1.233 0 C-N-CA 124.971 3.781 . . . . 0.0 115.137 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -168.59 131.72 1.44 Allowed 'General case' 0 CA--C 1.528 0.12 0 O-C-N 120.565 -1.334 . . . . 0.0 108.447 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -53.89 -51.09 64.8 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 113.884 1.068 . . . . 0.0 113.884 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.8 t -54.71 -55.96 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 123.22 0.608 . . . . 0.0 109.603 -178.119 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -64.06 -54.09 39.55 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.819 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 79.3 p -58.05 -34.14 69.77 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 113.517 0.932 . . . . 0.0 113.517 -178.333 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -89.64 10.73 72.52 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-O 118.173 -1.348 . . . . 0.0 110.854 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 72.18 -40.77 0.48 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 125.873 1.669 . . . . 0.0 112.793 -177.401 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 14.9 tpt 25.43 -68.87 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 130.907 3.683 . . . . 0.0 117.144 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.7 tpp -78.96 -20.95 47.95 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.505 1.122 . . . . 0.0 113.53 -175.214 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 171.45 -145.36 8.77 Favored Glycine 0 C--N 1.337 0.617 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 -178.293 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -136.18 160.77 37.67 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.219 1.01 . . . . 0.0 108.559 174.569 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' GLY . . . . . 0.421 ' HA2' HG21 ' A' ' 142' ' ' VAL . . . 165.28 -130.31 2.14 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -178.42 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' PHE . . . . . 0.493 ' CE2' HG21 ' A' ' 158' ' ' VAL . 8.5 p90 -166.39 173.62 9.79 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 117.822 0.811 . . . . 0.0 110.485 -175.805 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.472 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -113.25 140.71 47.74 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 178.193 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -111.47 136.23 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.603 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 169.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.6 105.63 34.98 Favored Pre-proline 0 N--CA 1.444 -0.759 0 N-CA-C 100.64 -3.837 . . . . 0.0 100.64 170.304 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -59.56 172.79 1.85 Allowed 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 124.548 3.499 . . . . 0.0 115.482 -173.095 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 67.3 p -154.34 -64.37 0.13 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 123.895 0.878 . . . . 0.0 110.504 177.563 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -51.4 -46.87 63.02 Favored 'General case' 0 C--N 1.335 -0.06 0 C-N-CA 125.859 1.664 . . . . 0.0 114.913 -176.666 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.31 28.93 60.96 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.811 -1.315 . . . . 0.0 109.811 -173.617 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.7 mt -139.58 120.65 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 102.664 -3.087 . . . . 0.0 102.664 177.357 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 45.0 t -126.12 123.74 64.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 C-N-CA 124.26 1.024 . . . . 0.0 109.764 -171.637 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.5 m -109.6 169.66 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.187 0.995 . . . . 0.0 109.036 176.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.1 p -63.7 148.66 94.04 Favored Pre-proline 0 CA--C 1.537 0.48 0 O-C-N 121.331 -0.856 . . . . 0.0 111.071 -177.755 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -87.64 -16.14 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 124.29 3.327 . . . . 0.0 112.707 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.1 m -145.32 166.83 10.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 123.891 0.876 . . . . 0.0 110.052 -176.818 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.1 mtt-85 -78.46 119.54 21.92 Favored 'General case' 0 N--CA 1.454 -0.253 1 N-CA-C 98.887 -4.486 . . . . 0.0 98.887 168.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 171.37 -177.4 44.27 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 115.078 -3.439 . . . . 0.0 115.587 -167.547 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.73 135.51 41.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 126.011 1.724 . . . . 0.0 110.451 -177.888 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.4 mm -79.07 114.9 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 103.537 -2.764 . . . . 0.0 103.537 170.037 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 34.3 tp -77.8 -53.41 7.53 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -176.29 155.79 1.52 Allowed 'General case' 0 C--O 1.228 -0.033 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.5 m -135.32 120.73 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.417 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -43.77 149.75 0.61 Allowed Pre-proline 0 CA--C 1.539 0.538 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -49.65 -28.16 16.46 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 124.077 3.184 . . . . 0.0 113.861 177.08 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 24.7 p -78.02 1.22 21.6 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.457 0.703 . . . . 0.0 111.969 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 46.84 62.35 2.4 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 127.323 2.249 . . . . 0.0 113.125 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 15.4 p-80 -146.93 -38.82 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 122.307 -0.246 . . . . 0.0 111.619 176.147 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -128.19 177.32 7.0 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.694 24.5 mm 116.0 -134.38 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.306 0 C-N-CA 131.654 3.982 . . . . 0.0 108.342 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -171.88 179.71 43.38 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 118.637 2.215 . . . . 0.0 118.637 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.7 mp -126.53 173.07 9.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 127.771 2.428 . . . . 0.0 109.073 -177.218 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -145.09 137.84 26.24 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 176.961 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 84.1 p -77.68 -108.84 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 121.154 0.502 . . . . 0.0 109.812 178.86 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -87.42 52.68 2.56 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 175.636 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 78.77 -60.47 4.11 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 108.949 -1.661 . . . . 0.0 108.949 -175.604 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.31 169.99 31.42 Favored Glycine 0 CA--C 1.531 1.083 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 176.612 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.2 mtp-105 58.5 71.81 0.56 Allowed 'General case' 0 N--CA 1.457 -0.106 0 C-N-CA 124.503 1.121 . . . . 0.0 109.489 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -77.95 125.57 29.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.06 108.37 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 C-N-CA 124.722 1.209 . . . . 0.0 109.597 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -85.01 134.48 34.22 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 126.083 1.753 . . . . 0.0 106.732 174.93 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.0 mt -128.01 153.79 37.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 C-N-CA 125.339 1.455 . . . . 0.0 110.106 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -151.25 76.46 1.22 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 125.788 1.635 . . . . 0.0 109.191 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' PHE . . . . . 0.415 ' HA ' HG23 ' A' ' 129' ' ' THR . 1.7 t80 -50.86 104.07 0.07 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.186 0.594 . . . . 0.0 112.592 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.62 173.27 5.39 Favored Glycine 0 CA--C 1.533 1.189 0 C-N-CA 124.685 1.136 . . . . 0.0 112.745 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.1 mm -108.72 130.93 60.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 124.484 1.114 . . . . 0.0 108.932 -178.301 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 48.89 43.1 21.34 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.965 1.306 . . . . 0.0 110.917 -178.62 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.6 -72.6 0.61 Allowed 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 102.16 -3.274 . . . . 0.0 102.16 174.638 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . 0.33 3.3 p 44.89 49.64 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 104.065 -2.568 . . . . 0.0 104.065 -173.507 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' SER . . . . . 0.441 ' HB3' ' CD1' ' A' ' 96' ' ' PHE . 19.3 m 12.1 45.83 0.0 OUTLIER 'General case' 0 C--N 1.349 0.565 1 C-N-CA 134.077 4.951 . . . . 0.0 114.178 -164.679 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 91' ' ' LEU . 2.0 mt 37.48 50.16 1.07 Allowed 'General case' 0 N--CA 1.434 -1.235 0 C-N-CA 130.492 3.517 . . . . 0.0 107.139 178.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 76.43 53.52 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 128.798 2.839 . . . . 0.0 111.36 -176.029 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.04 -64.12 1.61 Allowed Glycine 0 CA--C 1.535 1.296 0 C-N-CA 124.387 0.994 . . . . 0.0 111.713 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 22.62 -98.22 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 127.694 2.397 . . . . 0.0 115.873 178.471 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -59.89 -1.68 1.53 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 127.302 2.382 . . . . 0.0 115.859 -176.59 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' A' ' 90' ' ' SER . 4.6 m-85 -103.75 97.54 7.54 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 119.001 1.4 . . . . 0.0 113.145 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.9 m -80.05 99.99 7.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 105.785 -1.931 . . . . 0.0 105.785 173.853 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 29.0 p -83.45 135.37 34.7 Favored 'General case' 0 N--CA 1.451 -0.414 0 O-C-N 121.556 -0.715 . . . . 0.0 110.945 -178.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -103.79 -42.12 5.71 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.058 1.343 . . . . 0.0 111.927 -177.756 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.28 136.0 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.736 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 58.7 m -87.83 66.43 8.76 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 170.646 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.258 1.6 pm0 -24.72 96.69 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 129.074 2.95 . . . . 0.0 112.999 -173.162 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 154.06 -17.96 0.63 Allowed Glycine 0 CA--C 1.537 1.466 0 C-N-CA 128.157 2.789 . . . . 0.0 109.744 -175.287 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -42.87 107.74 0.09 Allowed 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 129.612 3.165 . . . . 0.0 107.821 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.0 119.3 30.24 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 127.496 2.318 . . . . 0.0 114.077 -172.954 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.336 34.4 m 48.02 66.82 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 126.653 1.981 . . . . 0.0 115.395 177.461 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.97 133.79 25.19 Favored Pre-proline 0 N--CA 1.454 -0.275 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 171.731 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -98.4 147.15 0.65 Allowed 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 123.346 2.697 . . . . 0.0 110.472 -177.189 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 58.02 18.37 33.54 Favored Glycine 0 CA--C 1.528 0.894 0 O-C-N 121.724 -0.61 . . . . 0.0 113.551 177.02 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -61.96 139.51 58.39 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.709 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -66.06 116.88 7.64 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.916 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 49.6 mt -81.04 -54.19 5.77 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.7 mt -149.08 157.45 43.41 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.34 0.656 . . . . 0.0 111.856 -172.437 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -124.75 129.42 50.44 Favored 'General case' 0 CA--C 1.519 -0.234 1 N-CA-C 98.738 -4.541 . . . . 0.0 98.738 165.858 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.408 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -139.22 127.91 28.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -164.101 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -75.01 67.41 1.71 Allowed 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.045 0.938 . . . . 0.0 110.48 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 93.1 mt -52.05 -45.85 64.85 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.194 179.175 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -48.98 -45.3 41.94 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 124.231 1.012 . . . . 0.0 112.611 -178.581 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.84 -33.91 24.77 Favored 'General case' 0 CA--C 1.527 0.092 0 CA-C-N 118.184 0.447 . . . . 0.0 111.6 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.08 -58.49 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 O-C-N 121.937 -0.477 . . . . 0.0 109.806 178.903 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 2.5 pptp? -38.16 -57.0 1.87 Allowed Pre-proline 0 CA--C 1.542 0.658 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 -176.664 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -60.88 -18.25 55.74 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.427 2.085 . . . . 0.0 113.572 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -104.55 10.66 34.95 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 118.386 -0.816 . . . . 0.0 112.797 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 26.9 m -137.57 151.97 71.97 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 119.884 1.22 . . . . 0.0 110.595 -178.887 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -64.45 -36.22 45.21 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.086 2.524 . . . . 0.0 113.202 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.6 t -156.58 153.0 27.95 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 119.059 0.845 . . . . 0.0 110.556 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.4 tp -100.62 -1.77 34.5 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.549 1.54 . . . . 0.0 110.565 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -53.22 116.97 2.68 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 118.311 0.505 . . . . 0.0 109.643 179.133 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 129' ' ' THR . . . . . 0.415 HG23 ' HA ' ' A' ' 84' ' ' PHE . 52.7 m -107.99 118.81 51.85 Favored Pre-proline 0 N--CA 1.446 -0.646 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.391 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -87.05 150.43 8.23 Favored 'Trans proline' 0 N--CA 1.442 -1.525 0 C-N-CA 122.056 1.838 . . . . 0.0 107.75 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.8 mt -132.59 113.93 21.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 101.586 -3.487 . . . . 0.0 101.586 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.94 122.07 51.18 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.012 -173.334 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 133' ' ' PHE . . . . . 0.41 ' CE1' ' CZ ' ' A' ' 15' ' ' PHE . 4.7 m-85 -86.29 112.3 21.27 Favored 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 177.54 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.0 p -74.41 -76.06 0.15 Allowed 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 121.853 0.835 . . . . 0.0 109.401 -175.729 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -76.78 69.4 3.13 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.707 0.803 . . . . 0.0 110.771 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.3 mt -68.86 169.21 11.94 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 171.076 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.72 -139.07 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.482 -0.761 . . . . 0.0 111.128 -178.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -67.06 81.12 0.12 Allowed 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.683 0.793 . . . . 0.0 112.417 -176.493 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 47.51 38.02 13.6 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.76 1.171 . . . . 0.0 111.068 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.572 ' HB3' HG23 ' A' ' 160' ' ' ILE . 70.0 mm-40 -55.23 119.25 5.24 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 111.517 0.192 . . . . 0.0 111.517 -176.907 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -78.02 132.09 37.64 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 172.504 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 142' ' ' VAL . . . . . 0.421 HG21 ' HA2' ' A' ' 42' ' ' GLY 0.266 1.0 OUTLIER -84.99 88.61 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 -176.51 . . . . . . . . 4 4 . 1 . 015 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.8 t -78.4 83.99 4.59 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -173.183 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' ILE . . . . . 0.595 HG23 HG22 ' A' ' 158' ' ' VAL . 1.8 mt -62.26 118.92 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 124.595 1.158 . . . . 0.0 108.116 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -97.77 -55.25 2.86 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.974 1.31 . . . . 0.0 108.938 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.71 66.34 1.45 Allowed 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.319 0.648 . . . . 0.0 111.587 -177.396 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 35.1 m -78.61 65.44 3.88 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.556 0.742 . . . . 0.0 109.011 178.814 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.38 -145.78 6.44 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -177.99 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 12.3 t -76.2 150.74 37.04 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 117.325 0.563 . . . . 0.0 110.646 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.68 156.02 28.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.087 1.355 . . . . 0.0 108.463 178.168 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -109.45 -171.43 1.84 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.424 1.49 . . . . 0.0 108.489 175.988 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 52.5 mtm-85 -85.65 157.69 20.27 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.971 0.805 . . . . 0.0 110.354 177.558 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 45.63 38.91 4.42 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.621 1.969 . . . . 0.0 114.432 177.662 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -76.09 134.07 40.13 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 104.8 -2.296 . . . . 0.0 104.8 172.488 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -108.99 35.86 3.09 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.733 0.813 . . . . 0.0 111.759 -177.809 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -172.6 94.61 0.13 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.198 1.799 . . . . 0.0 108.448 177.423 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.44 ' N ' HD13 ' A' ' 157' ' ' ILE . 0.2 OUTLIER -150.97 -37.73 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -175.524 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.595 HG22 HG23 ' A' ' 144' ' ' ILE . 57.8 t -151.5 104.29 0.28 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.058 0 CA-C-N 119.397 0.999 . . . . 0.0 108.594 -177.419 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.2 mttm -90.13 124.49 34.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -176.574 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.572 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.5 mp -78.86 107.77 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 104.378 -2.453 . . . . 0.0 104.378 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 24.9 pt-20 -153.73 -175.35 5.33 Favored 'General case' 0 C--O 1.227 -0.127 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -175.787 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 C--N 1.332 -0.185 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.261 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.7 mtm . . . . . 0 N--CA 1.454 -0.255 0 N-CA-C 111.704 0.261 . . . . 0.0 111.704 . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mp 77.03 -54.83 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 C-N-CA 126.605 1.962 . . . . 0.0 107.258 -173.804 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.8 64.08 1.23 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.349 1.06 . . . . 0.0 109.811 176.189 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.6 mm-40 -68.81 -42.39 24.17 Favored Pre-proline 0 CA--C 1.538 0.508 0 CA-C-O 118.259 -0.876 . . . . 0.0 112.402 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -56.26 154.72 27.61 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.282 1.988 . . . . 0.0 112.465 -178.795 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 71.8 mt -73.54 67.9 1.12 Allowed 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.664 0.786 . . . . 0.0 110.749 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -70.8 176.16 4.46 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.692 0.797 . . . . 0.0 109.947 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -54.49 105.59 0.16 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 123.891 0.876 . . . . 0.0 110.294 178.424 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -48.66 -61.09 2.21 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.723 1.609 . . . . 0.0 112.933 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 35.2 mt -77.78 72.8 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -178.007 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.18 -51.83 4.53 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 -179.622 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . 0.355 0.0 OUTLIER 72.69 -49.91 0.7 Allowed 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 127.092 2.157 . . . . 0.0 115.945 178.354 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 72.2 mt-10 27.84 63.88 0.1 Allowed 'General case' 0 C--N 1.321 -0.654 0 C-N-CA 130.629 3.572 . . . . 0.0 113.207 177.759 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.3 p 23.53 92.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.461 0.111 0 C-N-CA 128.023 2.529 . . . . 0.0 115.557 178.376 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -161.3 82.15 0.62 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 113.77 -1.559 . . . . 0.0 107.803 176.314 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -78.89 85.15 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.114 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.202 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.3 t -10.59 109.39 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.814 0 C-N-CA 127.839 2.456 . . . . 0.0 113.211 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -68.81 -28.15 30.46 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.595 2.197 . . . . 0.0 116.449 -173.318 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -149.0 145.93 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.918 1.235 . . . . 0.0 110.232 -177.322 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.9 m -79.07 136.68 37.23 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.217 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.0 -150.11 14.2 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tp10 -117.13 123.21 46.19 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.785 1.634 . . . . 0.0 108.71 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 10.1 mt -85.07 125.66 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -117.92 142.8 31.44 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 173.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -55.15 152.65 29.8 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 121.814 1.676 . . . . 0.0 109.515 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.3 tp -57.06 -49.01 80.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.1 m -67.86 85.41 0.22 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.732 1.613 . . . . 0.0 108.604 176.478 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.5 t70 172.95 -35.66 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 127.373 2.269 . . . . 0.0 108.81 -176.046 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 96.5 t -52.86 138.29 44.15 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 124.643 1.177 . . . . 0.0 110.558 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -72.95 59.26 3.54 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 124.127 3.218 . . . . 0.0 111.542 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -171.74 130.81 0.68 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 124.923 1.289 . . . . 0.0 108.592 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -62.03 -48.42 80.37 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 124.322 1.049 . . . . 0.0 113.061 -177.261 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.6 t -50.24 -55.23 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 34' ' ' PHE . . . . . 0.416 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 8.2 m-85 -65.06 -58.79 5.15 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.397 -179.5 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -58.08 -27.99 64.17 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 115.244 1.572 . . . . 0.0 115.244 -177.301 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -95.36 10.12 69.38 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-O 117.899 -1.501 . . . . 0.0 110.646 -178.981 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 61.3 mttm 74.42 -46.25 0.61 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.574 1.55 . . . . 0.0 111.928 -178.023 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 36.9 ttm 39.29 -64.92 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 130.533 3.533 . . . . 0.0 117.272 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 29.9 ttp -109.34 -10.28 14.93 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.712 1.205 . . . . 0.0 113.452 -176.359 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -171.83 -165.55 29.18 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-N 119.464 1.029 . . . . 0.0 110.796 -179.023 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -131.72 156.58 45.67 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 176.6 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 168.45 -137.07 4.38 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.28 166.13 14.86 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 118.048 0.924 . . . . 0.0 111.214 -175.94 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' ALA . . . . . 0.416 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -103.31 113.29 26.66 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 123.043 0.537 . . . . 0.0 111.485 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -88.65 129.21 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 103.887 -2.634 . . . . 0.0 103.887 169.765 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.0 tt -96.03 109.2 45.6 Favored Pre-proline 0 N--CA 1.448 -0.542 1 N-CA-C 98.34 -4.689 . . . . 0.0 98.34 168.526 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.6 161.54 24.92 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.501 2.801 . . . . 0.0 115.336 -167.837 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.4 p -136.9 -41.54 0.59 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.588 1.155 . . . . 0.0 111.981 177.473 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.99 -44.36 91.62 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.37 23.8 77.19 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 -174.643 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.5 mt -139.99 111.97 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 177.681 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 47.0 t -100.39 122.71 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.883 1.273 . . . . 0.0 108.673 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.39 156.04 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 123.389 0.676 . . . . 0.0 110.349 177.912 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 17.4 m -63.88 122.11 75.06 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.81 -21.52 12.52 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 124.923 3.749 . . . . 0.0 114.662 -176.269 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -136.48 173.09 14.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 124.94 1.296 . . . . 0.0 108.842 -175.672 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.29 90.59 3.76 Favored 'General case' 0 CA--C 1.518 -0.275 1 N-CA-C 98.228 -4.73 . . . . 0.0 98.228 168.858 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -90.26 174.52 40.29 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 117.381 1.712 . . . . 0.0 117.381 -166.632 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.88 134.09 21.68 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 101.475 -3.528 . . . . 0.0 101.475 170.471 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ILE . . . . . 0.433 HG21 ' HG3' ' A' ' 102' ' ' GLU . 0.2 OUTLIER -88.79 127.3 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -169.791 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.402 ' O ' ' CB ' ' A' ' 62' ' ' ASN . 78.5 mt -79.74 -29.66 40.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 169.161 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 59.1 t30 125.79 -176.53 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 129.587 3.155 . . . . 0.0 109.514 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.98 122.24 51.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 C-N-CA 127.452 2.301 . . . . 0.0 106.353 172.849 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -44.77 157.92 0.3 Allowed Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 124.315 1.046 . . . . 0.0 111.316 175.361 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -51.4 -29.47 31.05 Favored 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.381 2.721 . . . . 0.0 113.414 174.186 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.6 p -76.94 -5.98 50.69 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.429 1.092 . . . . 0.0 111.646 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? 60.53 16.4 6.44 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.334 1.854 . . . . 0.0 115.007 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 16.1 p-80 -98.03 -33.77 11.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.562 0.345 . . . . 0.0 111.654 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -149.17 -177.58 5.9 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-N 118.186 0.448 . . . . 0.0 111.929 -173.575 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ILE . . . . . 0.432 HG22 ' H ' ' A' ' 71' ' ' GLY 0.541 24.4 mm 131.82 -123.39 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.453 1 C-N-CA 136.273 5.829 . . . . 0.0 102.359 -177.199 . . . . . . . . 4 3 . 1 . 016 nuclear build full ' A' A ' 71' ' ' GLY . . . . . 0.432 ' H ' HG22 ' A' ' 70' ' ' ILE . . . -178.4 -173.23 43.6 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 116.751 -2.643 . . . . 0.0 119.382 177.05 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.4 mp -137.32 170.83 15.42 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 127.208 2.203 . . . . 0.0 108.488 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -147.83 157.26 43.44 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 172.366 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 81.3 p -90.31 -76.41 0.43 Allowed 'General case' 0 C--O 1.225 -0.235 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 174.27 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -131.36 59.66 1.68 Allowed 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 127.0 2.12 . . . . 0.0 105.928 175.777 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 79.86 -60.73 4.38 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 108.046 -2.022 . . . . 0.0 108.046 -173.056 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -57.35 163.33 7.36 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 174.802 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.6 mmt85 51.91 59.98 4.16 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.574 0.75 . . . . 0.0 109.779 -177.449 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -80.37 110.29 15.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 177.728 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.94 127.28 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 124.063 0.945 . . . . 0.0 111.464 -174.001 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 33.5 tp -103.23 135.07 45.57 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 104.375 -2.454 . . . . 0.0 104.375 170.585 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.4 mt -120.43 155.37 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 C-N-CA 124.965 1.306 . . . . 0.0 107.589 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -149.37 81.95 1.41 Allowed 'General case' 0 C--O 1.224 -0.281 0 N-CA-C 104.96 -2.237 . . . . 0.0 104.96 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -63.12 97.33 0.11 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -176.638 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 69.27 168.33 5.79 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.226 0.917 . . . . 0.0 111.586 -175.816 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 15.8 mm -100.26 135.89 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 124.623 1.169 . . . . 0.0 109.094 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 57.24 23.98 9.36 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.943 1.297 . . . . 0.0 112.732 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 p -76.93 -32.97 57.74 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.657 1.583 . . . . 0.0 107.567 175.397 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.8 p -56.71 -46.16 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-N 113.76 -1.563 . . . . 0.0 107.546 170.702 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.73 -42.28 98.75 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 124.187 0.995 . . . . 0.0 108.546 176.934 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -73.61 12.27 0.67 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 125.525 1.53 . . . . 0.0 111.682 175.593 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 48.3 tttp 45.68 35.06 1.97 Allowed 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.869 2.067 . . . . 0.0 113.258 177.764 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 55.39 28.44 50.57 Favored Glycine 0 CA--C 1.535 1.289 0 O-C-N 121.751 -0.593 . . . . 0.0 112.751 -179.116 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -70.97 91.56 0.88 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 118.744 1.272 . . . . 0.0 109.769 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 132.61 -1.05 4.72 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 126.435 1.969 . . . . 0.0 111.707 -178.056 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 96' ' ' PHE . . . . . 0.459 ' CD1' HG12 ' A' ' 115' ' ' VAL . 16.5 m-30 -96.52 131.91 42.64 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 124.507 1.123 . . . . 0.0 109.675 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 10.9 m -120.55 113.96 21.05 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 126.597 1.959 . . . . 0.0 107.316 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 44.9 p -93.38 126.49 38.54 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 121.056 -1.028 . . . . 0.0 111.213 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -90.26 -26.73 19.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 123.932 0.893 . . . . 0.0 108.998 176.502 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' VAL . . . . . 0.624 ' HB ' ' CG ' ' A' ' 102' ' ' GLU . 3.1 m -52.63 126.83 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-O 121.192 0.52 . . . . 0.0 110.995 179.213 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 24.9 m -115.51 -52.34 2.65 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 127.456 2.302 . . . . 0.0 105.255 175.763 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' GLU . . . . . 0.624 ' CG ' ' HB ' ' A' ' 100' ' ' VAL . 0.1 OUTLIER 50.77 107.98 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 120.969 3.692 . . . . 0.0 120.969 166.26 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.23 55.35 2.12 Favored Glycine 0 CA--C 1.53 1.0 1 N-CA-C 100.996 -4.842 . . . . 0.0 100.996 164.808 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.253 7.4 p-10 6.77 70.36 0.0 OUTLIER 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 118.569 2.803 . . . . 0.0 118.569 -169.255 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -169.58 137.04 1.72 Allowed 'General case' 0 N--CA 1.43 -1.464 1 C-N-CA 132.916 4.486 . . . . 0.0 105.655 173.309 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -157.27 158.19 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 125.681 1.592 . . . . 0.0 108.692 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -89.04 163.42 34.61 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 106.425 -1.695 . . . . 0.0 106.425 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -70.71 169.54 19.87 Favored 'Trans proline' 0 N--CA 1.451 -0.978 0 N-CA-C 108.259 -1.477 . . . . 0.0 108.259 178.329 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 73.45 -27.77 0.86 Allowed Glycine 0 CA--C 1.534 1.227 0 O-C-N 121.02 -1.05 . . . . 0.0 115.38 175.438 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.4 tp-100 -58.07 139.88 53.75 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 119.527 1.664 . . . . 0.0 109.8 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -70.16 128.3 35.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.875 0.47 . . . . 0.0 111.544 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 112' ' ' LEU . . . . . 0.505 HD22 HG12 ' A' ' 100' ' ' VAL . 72.1 mt -105.04 -41.49 5.57 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.937 0.895 . . . . 0.0 111.807 -178.317 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 48.5 mt -143.99 146.52 32.96 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 123.588 0.755 . . . . 0.0 109.371 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -118.06 133.24 56.09 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 100.683 -3.821 . . . . 0.0 100.683 167.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' VAL . . . . . 0.459 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -143.15 117.47 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -166.731 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 62.9 t0 -67.69 74.11 0.17 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.408 1.483 . . . . 0.0 112.395 -175.273 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 75.8 mt -50.43 -47.49 56.64 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.687 178.242 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -49.4 -49.07 46.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.588 1.155 . . . . 0.0 112.684 -177.323 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.25 -34.36 25.85 Favored 'General case' 0 C--N 1.333 -0.121 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 49.4 t -65.16 -53.65 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 O-C-N 121.697 -0.627 . . . . 0.0 110.541 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.328 19.1 pttp -42.92 -54.64 8.54 Favored Pre-proline 0 CA--C 1.54 0.595 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -61.12 -24.07 78.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.49 2.127 . . . . 0.0 112.716 178.248 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 57.3 m-80 -90.18 -48.24 7.29 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 118.46 0.573 . . . . 0.0 111.885 -177.268 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.77 147.93 56.37 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -174.256 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_exo -51.61 -41.51 60.76 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 124.064 3.176 . . . . 0.0 114.804 179.169 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.2 m -158.81 142.7 15.31 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.825 -0.547 . . . . 0.0 110.235 -176.9 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.2 tp -88.09 -4.6 58.75 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 124.878 1.271 . . . . 0.0 112.293 -178.392 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.1 mmt -46.93 118.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.028 0.931 . . . . 0.0 109.802 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.4 m -112.1 94.23 24.88 Favored Pre-proline 0 N--CA 1.448 -0.534 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' PRO . . . . . 0.416 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 74.1 Cg_endo -76.5 111.06 3.18 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 123.594 2.863 . . . . 0.0 108.74 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mt -94.28 119.06 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 N-CA-C 102.718 -3.068 . . . . 0.0 102.718 174.927 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.2 t -126.56 129.06 71.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -97.39 114.61 26.46 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 104.343 -2.465 . . . . 0.0 104.343 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 44.8 p -80.28 -75.39 0.27 Allowed 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . 0.259 24.6 p30 -74.06 69.68 1.5 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-O 122.204 1.002 . . . . 0.0 111.207 179.156 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 13.2 mt -78.21 62.2 2.87 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 126.174 1.79 . . . . 0.0 107.537 175.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.53 -109.63 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.578 2.351 . . . . 0.0 112.545 -177.852 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -80.33 58.64 3.16 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 125.146 1.379 . . . . 0.0 112.446 -178.265 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 46.19 35.67 6.82 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 124.259 0.933 . . . . 0.0 110.959 -178.882 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 140' ' ' GLU . . . . . 0.671 ' HB3' HG23 ' A' ' 160' ' ' ILE . 38.9 mt-10 -49.01 126.91 13.32 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.349 0.659 . . . . 0.0 112.014 -175.731 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 31.8 p -86.54 133.35 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.256 0.3 OUTLIER -85.58 87.48 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 CA-C-O 122.407 1.099 . . . . 0.0 109.936 -176.009 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.5 m -79.33 84.48 5.25 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 120.646 -1.284 . . . . 0.0 110.85 -177.657 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 144' ' ' ILE . . . . . 0.521 HG23 HG22 ' A' ' 158' ' ' VAL . 6.5 mt -60.66 130.67 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 124.287 1.035 . . . . 0.0 108.656 178.418 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.33 -52.78 2.75 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.769 0.828 . . . . 0.0 108.767 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -78.95 64.64 3.94 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 122.892 0.477 . . . . 0.0 109.933 179.324 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 45.0 m -78.98 66.05 4.32 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -171.45 -148.79 6.23 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 107.809 -2.116 . . . . 0.0 107.809 -177.375 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 15.8 t -78.14 148.11 34.28 Favored 'General case' 0 N--CA 1.456 -0.136 0 CA-C-N 117.658 0.729 . . . . 0.0 110.735 178.195 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.63 160.59 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 124.864 1.266 . . . . 0.0 108.663 178.113 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -114.78 157.79 22.75 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.719 1.208 . . . . 0.0 108.592 176.66 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 2.2 ptm180 -66.43 154.11 41.05 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 53.15 59.98 4.06 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.537 1.535 . . . . 0.0 112.06 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 16.9 mm-40 -131.07 151.02 51.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 126.821 2.048 . . . . 0.0 105.751 175.712 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.47 166.0 14.19 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.2 1.4 . . . . 0.0 111.05 -177.338 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 16.9 t70 70.63 -7.48 1.04 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 117.051 2.241 . . . . 0.0 117.051 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 157' ' ' ILE . . . . . 0.443 ' CD1' ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -53.06 -31.87 17.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 C-N-CA 127.213 2.205 . . . . 0.0 112.501 177.116 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 158' ' ' VAL . . . . . 0.521 HG22 HG23 ' A' ' 144' ' ' ILE . 62.9 t -145.47 133.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.208 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -108.75 120.53 42.75 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.414 0.686 . . . . 0.0 109.828 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 160' ' ' ILE . . . . . 0.671 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.3 mp -79.1 97.22 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.204 -2.146 . . . . 0.0 105.204 173.404 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -108.7 -155.26 0.55 Allowed 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 125.369 1.467 . . . . 0.0 107.963 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 35.5 mtmm . . . . . 0 C--N 1.333 -0.131 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 176.977 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 CA--C 1.532 0.258 0 N-CA-C 112.705 0.632 . . . . 0.0 112.705 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.0 89.92 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 172.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t -13.36 116.17 0.04 OUTLIER Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 126.965 2.106 . . . . 0.0 115.377 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -71.38 -34.88 9.07 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.995 2.463 . . . . 0.0 117.37 -174.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -143.3 162.73 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.819 1.191 . . . . 0.0 111.371 -175.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -101.52 135.65 42.68 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 174.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 161.96 -136.33 4.32 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -127.79 124.63 38.12 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 124.941 1.297 . . . . 0.0 110.34 -178.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 45.9 mt -80.19 145.43 9.17 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -143.95 141.67 18.94 Favored Pre-proline 0 N--CA 1.452 -0.347 0 C-N-CA 125.08 1.352 . . . . 0.0 107.903 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -54.94 145.33 63.26 Favored 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 122.163 1.908 . . . . 0.0 111.183 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.67 -39.19 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.853 1.261 . . . . 0.0 112.316 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 p -53.48 -31.61 46.57 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.362 1.465 . . . . 0.0 112.442 179.143 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -69.78 -14.32 62.71 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.898 0.879 . . . . 0.0 112.852 -178.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -69.87 130.26 90.26 Favored Pre-proline 0 CA--C 1.539 0.53 0 O-C-N 121.373 -0.829 . . . . 0.0 111.057 -175.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -76.38 62.6 6.99 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.416 2.744 . . . . 0.0 111.374 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.21 132.01 2.88 Favored 'General case' 0 C--O 1.226 -0.138 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 22.0 mp0 -54.9 -53.05 60.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.521 1.128 . . . . 0.0 112.675 -176.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.0 t -51.68 -57.0 3.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 123.299 0.639 . . . . 0.0 110.317 -177.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -64.95 -53.54 44.73 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.264 0.226 . . . . 0.0 110.535 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.9 t -51.99 -43.05 63.44 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -90.91 13.36 66.25 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-O 117.994 -1.448 . . . . 0.0 111.814 -177.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp 69.44 -34.68 0.29 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 119.421 1.611 . . . . 0.0 114.52 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 15.7 tpt 26.16 -76.31 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 130.056 3.343 . . . . 0.0 116.426 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.1 ttm -79.49 -15.98 56.82 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 114.142 1.164 . . . . 0.0 114.142 -174.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.51 -135.75 2.73 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 120.037 1.29 . . . . 0.0 113.076 -178.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -129.1 163.1 26.2 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 175.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 167.27 -157.5 29.96 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.877 -1.154 . . . . 0.0 112.586 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -162.35 171.07 17.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.053 0.541 . . . . 0.0 109.839 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.35 149.18 31.51 Favored 'General case' 0 CA--C 1.502 -0.867 0 O-C-N 124.119 0.887 . . . . 0.0 109.429 176.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.0 mp -124.21 133.56 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 102.482 -3.155 . . . . 0.0 102.482 170.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.2 tt -99.38 108.44 50.33 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.789 -4.523 . . . . 0.0 98.789 170.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -82.8 161.04 16.29 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.347 2.698 . . . . 0.0 113.932 -168.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.3 p -124.59 -55.56 1.63 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.699 1.2 . . . . 0.0 108.723 175.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -68.15 124.15 22.66 Favored 'General case' 0 N--CA 1.457 -0.11 0 C-N-CA 122.303 0.241 . . . . 0.0 110.857 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.33 37.11 2.0 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 70.7 mt -138.43 120.63 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.24 109.35 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -174.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.7 m -89.25 -178.26 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.941 -1.504 . . . . 0.0 106.941 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.59 146.19 33.5 Favored Pre-proline 0 N--CA 1.465 0.306 0 CA-C-O 117.561 -1.209 . . . . 0.0 111.464 -174.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -63.3 -44.6 14.37 Favored 'Trans proline' 0 C--N 1.348 0.53 0 N-CA-C 107.453 -1.787 . . . . 0.0 107.453 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.48 HG21 ' HA ' ' A' ' 74' ' ' SER . 3.4 p -146.2 145.59 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 102.433 -3.173 . . . . 0.0 102.433 171.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.539 ' HB3' HG23 ' A' ' 106' ' ' VAL . 28.6 mtm180 -97.27 -75.21 0.55 Allowed 'General case' 0 N--CA 1.45 -0.447 1 N-CA-C 98.979 -4.452 . . . . 0.0 98.979 169.659 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.23 -78.19 1.46 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 107.141 -2.383 . . . . 0.0 107.141 171.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.75 118.73 5.84 Favored 'General case' 0 N--CA 1.438 -1.067 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.458 HG21 ' CB ' ' A' ' 102' ' ' GLU . 28.3 mm -65.98 124.85 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 175.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.42 -42.47 12.81 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 124.069 0.948 . . . . 0.0 109.206 -177.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -156.88 152.66 27.05 Favored 'General case' 0 N--CA 1.463 0.204 0 O-C-N 121.94 -0.475 . . . . 0.0 111.722 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -82.89 170.55 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.845 1.658 . . . . 0.0 112.323 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.545 ' CE2' HD21 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -76.54 135.85 68.32 Favored Pre-proline 0 N--CA 1.437 -1.118 0 CA-C-N 112.681 -2.054 . . . . 0.0 109.778 173.589 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -74.37 -43.28 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.374 1.383 . . . . 0.0 108.61 172.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.4 p -131.39 46.24 2.69 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 126.192 1.797 . . . . 0.0 109.917 -177.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.447 ' HA ' ' CB ' ' A' ' 64' ' ' PHE . 16.5 ttmt 57.16 -17.41 0.02 OUTLIER 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 128.225 2.61 . . . . 0.0 116.609 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -75.98 -5.9 48.46 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 116.769 2.137 . . . . 0.0 116.769 -174.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.35 160.53 43.66 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 120.456 1.48 . . . . 0.0 110.348 -173.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.0 tt -157.23 157.15 3.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -117.31 128.58 7.92 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 107.646 -2.181 . . . . 0.0 107.646 178.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.9 mt -124.74 171.75 9.85 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 124.724 1.209 . . . . 0.0 110.359 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.47 139.33 20.88 Favored 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 126.631 1.972 . . . . 0.0 105.697 174.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.48 ' HA ' HG21 ' A' ' 56' ' ' VAL . 89.4 p . . . . . 0 N--CA 1.449 -0.487 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 176.235 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 38.2 ttp180 . . . . . 0 CA--C 1.53 0.203 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -106.48 130.64 54.24 Favored 'General case' 0 N--CA 1.445 -0.678 0 C-N-CA 129.374 3.069 . . . . 0.0 104.386 177.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.4 mt -120.22 145.16 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 C-N-CA 124.339 1.056 . . . . 0.0 110.649 -172.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 46.7 tp -124.38 131.45 53.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 173.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 79.4 mt -121.93 146.8 26.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 123.789 0.836 . . . . 0.0 109.317 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.34 136.23 41.36 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 169.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -106.96 108.4 19.89 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 125.224 1.41 . . . . 0.0 109.037 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.53 -178.0 7.17 Favored Glycine 0 CA--C 1.534 1.22 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -176.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.7 mm -118.87 143.54 29.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 t70 65.69 11.58 7.64 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.38 1.072 . . . . 0.0 113.143 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 p -74.83 -32.51 61.96 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 125.583 1.553 . . . . 0.0 108.587 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.5 p -54.57 -49.85 63.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 113.202 -1.817 . . . . 0.0 107.143 170.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -62.69 -42.42 99.62 Favored 'General case' 0 C--O 1.227 -0.119 0 C-N-CA 124.668 1.187 . . . . 0.0 109.641 177.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 24.5 tp -66.21 -2.55 4.41 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.463 1.505 . . . . 0.0 111.539 176.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.5 mtmm 51.94 34.1 13.0 Favored 'General case' 0 C--N 1.344 0.329 0 C-N-CA 125.18 1.392 . . . . 0.0 111.325 -179.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.95 30.91 60.77 Favored Glycine 0 CA--C 1.537 1.45 0 CA-C-O 120.015 -0.325 . . . . 0.0 112.802 -178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -67.21 93.38 0.3 Allowed 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.759 1.279 . . . . 0.0 109.477 178.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.54 7.98 4.57 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 126.682 2.087 . . . . 0.0 112.122 -178.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.407 ' CG ' HG12 ' A' ' 115' ' ' VAL . 3.5 m-85 -101.35 153.04 20.01 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.696 1.198 . . . . 0.0 110.732 -177.441 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 59.3 m -145.41 121.81 10.97 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.3 -2.111 . . . . 0.0 105.3 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.421 ' HA ' HD23 ' A' ' 113' ' ' LEU . 35.1 p -96.04 128.22 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.539 0.736 . . . . 0.0 110.371 -173.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -92.05 -49.12 6.38 Favored 'General case' 0 N--CA 1.448 -0.57 0 O-C-N 124.336 1.023 . . . . 0.0 109.431 -178.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.9 m -75.22 124.7 33.63 Favored 'Isoleucine or valine' 0 C--N 1.34 0.193 0 C-N-CA 117.21 -1.796 . . . . 0.0 107.749 173.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.7 m -100.8 55.71 0.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 103.578 -2.749 . . . . 0.0 103.578 170.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.458 ' CB ' HG21 ' A' ' 60' ' ' ILE 0.5 0.0 OUTLIER 5.39 64.15 0.0 OUTLIER 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 130.767 3.627 . . . . 0.0 117.915 -168.517 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -81.28 61.24 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 173.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . 0.6 ' O ' HG22 ' A' ' 106' ' ' VAL 0.391 3.3 p30 6.01 -94.56 0.0 OUTLIER 'General case' 0 N--CA 1.439 -0.987 0 C-N-CA 128.506 2.722 . . . . 0.0 116.939 -174.283 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.4 mmm180 -55.69 106.09 0.23 Allowed 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 126.472 1.909 . . . . 0.0 112.262 -175.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 104' ' ' ASP . 0.0 OUTLIER -147.6 159.19 8.53 Favored 'Isoleucine or valine' 0 C--N 1.342 0.239 0 C-N-CA 124.841 1.257 . . . . 0.0 111.704 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -85.88 155.34 58.5 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 118.473 -0.775 . . . . 0.0 109.636 177.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo -48.82 168.61 0.1 Allowed 'Trans proline' 0 CA--C 1.534 0.514 1 C-N-CA 126.824 5.016 . . . . 0.0 120.381 -173.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 69.69 -97.37 0.55 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 125.956 1.741 . . . . 0.0 112.754 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 26.3 tt0 1.97 92.97 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 131.03 3.732 . . . . 0.0 114.102 -176.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 21.1 ttmt 4.21 114.82 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 130.321 3.449 . . . . 0.0 117.193 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 91.1 mt -81.87 -50.97 8.58 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.922 0.889 . . . . 0.0 108.988 173.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . 0.545 HD21 ' CE2' ' A' ' 64' ' ' PHE . 96.1 mt -138.06 155.25 48.99 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.769 1.628 . . . . 0.0 110.512 -176.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.42 132.53 53.98 Favored 'General case' 0 CA--C 1.516 -0.328 1 N-CA-C 100.106 -4.035 . . . . 0.0 100.106 167.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . 0.407 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -147.66 122.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.01 -165.603 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -71.63 69.07 0.62 Allowed 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.409 1.083 . . . . 0.0 111.025 -179.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 56.5 mt -49.11 -42.81 40.39 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.69 0.796 . . . . 0.0 111.166 178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -50.03 -48.43 52.73 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.628 0.771 . . . . 0.0 112.131 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.48 -31.34 22.85 Favored 'General case' 0 CA--C 1.527 0.078 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.8 t -64.02 -51.76 65.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.64 -0.662 . . . . 0.0 109.945 179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.407 0.0 OUTLIER -41.11 -57.95 3.11 Favored Pre-proline 0 CA--C 1.542 0.647 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -177.303 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -59.27 -19.34 49.74 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.256 1.971 . . . . 0.0 113.227 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -98.43 11.42 38.21 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.826 0.85 . . . . 0.0 112.283 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.83 151.31 73.82 Favored Pre-proline 0 CA--C 1.532 0.284 0 CA-C-N 119.837 1.199 . . . . 0.0 110.86 178.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -72.97 -24.06 17.87 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 122.744 2.296 . . . . 0.0 110.658 177.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 14.6 t -158.75 147.91 18.89 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.389 0.614 . . . . 0.0 109.864 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.0 tp -97.54 2.25 49.89 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.862 1.665 . . . . 0.0 110.51 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 19.3 mmt -52.01 119.19 4.05 Favored 'General case' 0 C--N 1.344 0.36 0 CA-C-N 118.208 0.458 . . . . 0.0 109.794 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 32.2 m -111.37 89.48 10.45 Favored Pre-proline 0 N--CA 1.447 -0.609 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -81.08 146.56 16.06 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.331 2.021 . . . . 0.0 111.364 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.4 mt -127.37 126.47 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 175.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.41 147.83 26.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 N-CA-C 106.819 -1.549 . . . . 0.0 106.819 178.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.401 ' HB2' HD21 ' A' ' 136' ' ' LEU . 13.6 m-85 -122.55 125.71 46.27 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 101.945 -3.354 . . . . 0.0 101.945 178.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.7 p -89.15 -82.77 0.24 Allowed 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.4 0.546 . . . . 0.0 111.422 -171.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 20.6 p30 -47.37 -49.01 25.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.111 1.765 . . . . 0.0 111.884 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.401 HD21 ' HB2' ' A' ' 133' ' ' PHE . 23.0 mt 42.8 49.03 5.02 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 125.111 1.365 . . . . 0.0 110.864 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 34.82 40.96 0.05 Allowed 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.325 1.85 . . . . 0.0 111.966 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 36.88 55.18 1.2 Allowed 'General case' 0 N--CA 1.446 -0.631 0 C-N-CA 128.319 2.648 . . . . 0.0 114.349 -176.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 163.09 -3.48 0.07 OUTLIER Glycine 0 CA--C 1.524 0.625 0 CA-C-O 118.885 -0.953 . . . . 0.0 114.482 175.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.677 ' HB3' HG23 ' A' ' 160' ' ' ILE . 63.7 mm-40 -76.61 109.86 10.71 Favored 'General case' 0 C--O 1.228 -0.074 0 CA-C-N 119.219 1.51 . . . . 0.0 110.483 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.4 p -78.8 138.68 38.31 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 171.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -85.55 84.79 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.5 m -78.27 93.76 4.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 O-C-N 120.6 -1.312 . . . . 0.0 110.844 -175.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 14.2 mt -64.91 130.91 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 C-N-CA 123.939 0.896 . . . . 0.0 108.608 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -107.44 -55.36 2.36 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.711 1.204 . . . . 0.0 108.026 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.84 70.22 1.91 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.357 0.599 . . . . 0.0 110.511 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 24.7 m -79.0 63.92 3.79 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 178.35 -140.91 4.8 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.368 -1.893 . . . . 0.0 108.368 -176.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.6 t -66.43 151.84 46.34 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 117.039 0.419 . . . . 0.0 110.989 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -133.97 154.07 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.538 1.535 . . . . 0.0 107.996 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -132.95 150.92 52.12 Favored 'General case' 0 C--O 1.233 0.22 0 C-N-CA 124.965 1.306 . . . . 0.0 108.634 178.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -57.48 150.33 18.98 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.149 0.979 . . . . 0.0 112.12 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 58.51 3.52 0.29 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 127.148 2.179 . . . . 0.0 115.263 174.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 55.5 mm-40 -72.29 164.25 26.6 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 119.056 0.844 . . . . 0.0 111.075 179.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -114.04 168.23 9.99 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.715 2.406 . . . . 0.0 108.22 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 25.9 t0 51.73 40.53 27.73 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.099 1.36 . . . . 0.0 112.811 176.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.445 HD12 ' H ' ' A' ' 158' ' ' VAL . 0.9 OUTLIER -99.78 -43.64 11.24 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.414 1.086 . . . . 0.0 109.636 178.674 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.445 ' H ' HD12 ' A' ' 157' ' ' ILE . 9.1 p -142.69 143.97 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 105.782 -1.933 . . . . 0.0 105.782 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -123.65 116.11 22.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.232 0.613 . . . . 0.0 109.547 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.677 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.4 mp -79.23 104.06 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 103.54 -2.763 . . . . 0.0 103.54 173.371 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -142.83 158.11 43.95 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 123.175 0.59 . . . . 0.0 109.865 -174.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.8 mptt . . . . . 0 CA--C 1.53 0.195 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.188 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.452 -0.329 0 N-CA-C 106.583 -1.636 . . . . 0.0 106.583 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -103.61 90.92 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 C-N-CA 122.714 0.406 . . . . 0.0 111.686 -177.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 89.9 p -22.94 124.03 0.14 Allowed Pre-proline 0 CA--C 1.555 1.141 0 C-N-CA 126.037 1.735 . . . . 0.0 114.298 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -73.97 -36.74 3.25 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.023 2.482 . . . . 0.0 118.201 -171.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.44 148.33 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 119.905 1.229 . . . . 0.0 111.524 -175.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.6 m -80.48 140.6 35.83 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 173.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 163.58 -142.93 8.19 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -116.8 126.78 53.58 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 124.818 1.247 . . . . 0.0 108.457 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 tt -85.11 154.88 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -145.09 144.31 23.27 Favored Pre-proline 0 N--CA 1.451 -0.419 0 C-N-CA 124.989 1.316 . . . . 0.0 107.619 177.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -62.88 31.19 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 124.832 3.688 . . . . 0.0 116.838 177.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER 72.34 -39.69 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.071 1.349 . . . . 0.0 113.077 179.28 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -44.85 -41.38 7.03 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 125.298 1.439 . . . . 0.0 112.177 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.23 -14.1 62.73 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.646 1.579 . . . . 0.0 113.089 -175.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.6 t -71.3 127.91 90.8 Favored Pre-proline 0 CA--C 1.536 0.411 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 58.02 6.78 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.567 2.178 . . . . 0.0 112.043 -176.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -166.96 107.57 0.63 Allowed 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.686 -0.634 . . . . 0.0 110.203 177.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -28.6 -53.39 0.1 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 129.233 3.013 . . . . 0.0 115.967 -179.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 60.5 t -53.76 -45.61 61.74 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 CA-C-O 121.406 0.622 . . . . 0.0 109.703 -178.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -76.69 -54.47 6.6 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.9 m -45.37 -43.9 11.39 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 124.609 1.164 . . . . 0.0 114.119 -178.438 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -98.6 12.76 62.94 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 117.926 -1.486 . . . . 0.0 112.61 -176.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 56.8 mttp 70.97 -34.11 0.29 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 119.723 1.761 . . . . 0.0 113.994 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 26.3 ttt 28.57 -71.57 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 130.895 3.678 . . . . 0.0 117.191 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ttt -79.03 -17.08 55.91 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.971 0.908 . . . . 0.0 112.732 -175.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -168.15 -137.03 2.15 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.445 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.3 t0 -133.65 158.03 44.28 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 171.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -176.98 -162.79 28.06 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 119.361 -1.399 . . . . 0.0 113.46 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -151.4 165.14 35.02 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.991 1.316 . . . . 0.0 107.516 177.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -119.11 141.59 48.65 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -115.88 132.59 64.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 170.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.42 107.03 42.97 Favored Pre-proline 0 N--CA 1.445 -0.69 1 N-CA-C 98.298 -4.705 . . . . 0.0 98.298 169.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -82.9 167.01 14.67 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.732 2.954 . . . . 0.0 114.417 -168.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.8 p -127.73 -67.74 0.81 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.312 1.445 . . . . 0.0 108.499 176.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -53.24 124.81 15.59 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.802 0.841 . . . . 0.0 111.973 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.01 39.31 2.03 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 173.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.3 mt -140.01 117.14 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 104.181 -2.526 . . . . 0.0 104.181 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.9 t -116.71 114.01 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 123.904 0.881 . . . . 0.0 109.024 -175.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.3 m -90.64 178.03 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 172.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -97.85 145.73 30.25 Favored Pre-proline 0 C--O 1.223 -0.318 0 CA-C-O 117.147 -1.406 . . . . 0.0 110.064 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -62.43 -39.18 47.69 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 N-CA-C 106.92 -1.992 . . . . 0.0 106.92 172.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 p -157.54 139.57 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 101.495 -3.52 . . . . 0.0 101.495 169.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.441 ' HE ' ' CG1' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -91.29 -67.71 0.84 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 178.282 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 62.86 -74.4 0.03 OUTLIER Glycine 0 C--N 1.34 0.768 0 C-N-CA 126.155 1.835 . . . . 0.0 112.334 172.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.97 114.16 3.37 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 39.0 mm -61.74 128.33 23.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.138 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 8.4 tt -78.89 -52.55 8.14 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 177.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -179.19 161.81 1.15 Allowed 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 28.9 m -136.94 123.17 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 125.506 1.522 . . . . 0.0 107.503 175.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 153.84 0.6 Allowed Pre-proline 0 CA--C 1.537 0.454 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 176.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -50.42 -34.44 41.52 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 123.068 2.512 . . . . 0.0 112.671 175.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 25.0 p -79.62 4.14 16.91 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.972 0.909 . . . . 0.0 112.458 -179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 11.4 tppt? 66.36 -33.79 0.2 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 128.351 2.66 . . . . 0.0 115.803 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -54.44 -32.71 58.08 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 114.8 1.407 . . . . 0.0 114.8 -174.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.07 178.89 6.7 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 114.663 1.356 . . . . 0.0 114.663 -173.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.789 23.1 mm 117.86 -131.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.331 1 C-N-CA 132.719 4.408 . . . . 0.0 109.607 -179.312 . . . . . . . . 3 2 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.28 171.44 41.97 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 119.448 2.539 . . . . 0.0 119.448 -176.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.9 mt -118.97 179.68 4.08 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.81 2.444 . . . . 0.0 109.591 -177.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -149.63 152.3 35.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 127.016 2.126 . . . . 0.0 105.425 177.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 53.9 p . . . . . 0 CA--C 1.535 0.366 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 176.589 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 42.6 mtt85 . . . . . 0 N--CA 1.458 -0.056 0 CA-C-O 121.652 0.739 . . . . 0.0 109.988 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . 0.48 ' H ' ' ND2' ' A' ' 135' ' ' ASN . 8.4 tm-20 -76.87 134.19 39.08 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 176.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.3 mt -120.7 111.54 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.218 0.607 . . . . 0.0 110.995 -172.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.7 tt -83.04 138.28 33.79 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 68.3 mt -134.17 148.37 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 125.122 1.369 . . . . 0.0 108.887 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.42 78.92 1.64 Allowed 'General case' 0 C--N 1.34 0.192 0 C-N-CA 124.77 1.228 . . . . 0.0 109.743 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.438 ' HA ' HG23 ' A' ' 129' ' ' THR . 1.3 t80 -51.52 107.02 0.16 Allowed 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 123.102 0.561 . . . . 0.0 111.558 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.53 -173.29 2.51 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.647 0.641 . . . . 0.0 113.086 -178.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mm -121.67 146.0 27.43 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.3 t70 65.12 7.86 4.39 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.855 0.862 . . . . 0.0 113.07 -178.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -71.61 -35.21 70.39 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 125.738 1.615 . . . . 0.0 107.996 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 13.1 p -55.14 -45.79 77.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 CA-C-N 113.122 -1.854 . . . . 0.0 108.048 171.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.23 -38.66 92.05 Favored 'General case' 0 C--N 1.339 0.137 0 C-N-CA 124.354 1.061 . . . . 0.0 109.743 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.65 2.06 7.2 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 126.199 1.8 . . . . 0.0 110.615 175.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.4 mttp 45.88 30.23 0.84 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 128.016 2.526 . . . . 0.0 114.372 176.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.97 24.94 55.66 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.876 -0.402 . . . . 0.0 112.156 -178.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -56.66 -35.14 68.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 119.145 1.473 . . . . 0.0 112.79 -178.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -89.43 10.32 73.78 Favored Glycine 0 CA--C 1.533 1.192 0 CA-C-N 112.765 -2.016 . . . . 0.0 113.032 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -108.55 108.14 18.92 Favored 'General case' 0 C--N 1.343 0.325 0 CA-C-N 119.234 1.517 . . . . 0.0 111.996 -174.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.0 m -91.17 100.14 13.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.8 p -80.21 130.44 35.22 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 121.276 -0.89 . . . . 0.0 111.117 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -90.78 -46.96 7.91 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.705 1.202 . . . . 0.0 109.109 178.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.441 ' CG1' ' HE ' ' A' ' 57' ' ' ARG . 2.5 m -66.59 133.85 30.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 C-N-CA 118.105 -1.438 . . . . 0.0 108.421 174.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 59.5 m -110.88 53.29 0.71 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 170.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.292 3.4 pm0 -7.07 75.71 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.552 1 C-N-CA 131.815 4.046 . . . . 0.0 116.797 -171.603 . . . . . . . . 3 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.04 45.32 3.01 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 113.187 -1.824 . . . . 0.0 109.596 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 4.2 p30 5.23 41.57 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.226 2 C-N-CA 133.016 4.526 . . . . 0.0 122.206 -176.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.38 123.89 1.95 Allowed 'General case' 0 N--CA 1.436 -1.154 1 C-N-CA 133.163 4.585 . . . . 0.0 105.298 176.408 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -163.58 150.74 3.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 119.524 1.056 . . . . 0.0 110.482 -171.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -85.85 149.81 51.68 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 118.17 -0.919 . . . . 0.0 110.631 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_exo -46.71 150.84 2.29 Favored 'Trans proline' 0 CA--C 1.532 0.402 1 C-N-CA 126.222 4.615 . . . . 0.0 117.668 -176.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 66.44 -79.57 0.12 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.071 1.32 . . . . 0.0 112.504 176.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 1.44 76.12 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 131.581 3.953 . . . . 0.0 113.698 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? 17.49 109.94 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 129.723 3.209 . . . . 0.0 117.29 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 88.3 mt -78.75 -50.02 12.07 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 12.5 mt -144.56 156.8 44.32 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.971 0.909 . . . . 0.0 111.836 -173.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -119.06 131.39 55.95 Favored 'General case' 0 CA--C 1.516 -0.346 1 N-CA-C 98.694 -4.558 . . . . 0.0 98.694 165.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -140.91 129.89 24.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -166.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -76.24 63.2 1.86 Allowed 'General case' 0 C--O 1.234 0.25 0 CA-C-O 121.509 0.671 . . . . 0.0 110.068 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 78.6 mt -55.26 -34.56 64.15 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 123.221 0.609 . . . . 0.0 110.654 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.44 -40.23 71.29 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.047 0.539 . . . . 0.0 111.915 177.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.33 -35.3 17.27 Favored 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 122.788 0.435 . . . . 0.0 111.197 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.63 -51.19 75.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.554 -0.716 . . . . 0.0 109.518 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 20.8 pttm -40.66 -57.64 3.02 Favored Pre-proline 0 CA--C 1.541 0.616 0 N-CA-C 116.957 2.206 . . . . 0.0 116.957 -177.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -60.79 -25.64 81.52 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.696 2.264 . . . . 0.0 113.151 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -83.78 -43.03 15.85 Favored 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.62 0.646 . . . . 0.0 111.148 -178.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 35.7 m -78.91 150.57 75.37 Favored Pre-proline 0 CA--C 1.534 0.363 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -73.01 -25.19 16.52 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.515 2.143 . . . . 0.0 110.12 176.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.9 t -159.06 145.06 16.55 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 123.397 0.679 . . . . 0.0 109.539 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.9 tp -101.95 4.92 40.5 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.331 1.452 . . . . 0.0 110.287 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.8 mmt -51.97 111.4 0.6 Allowed 'General case' 0 C--N 1.342 0.263 0 C-N-CA 123.764 0.826 . . . . 0.0 110.104 179.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.438 HG23 ' HA ' ' A' ' 84' ' ' PHE . 85.7 m -107.3 114.57 60.86 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -90.55 145.75 4.0 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.976 2.45 . . . . 0.0 108.937 179.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.2 mp -124.84 116.57 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 101.787 -3.412 . . . . 0.0 101.787 172.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -124.58 117.21 49.79 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 C-N-CA 124.607 1.163 . . . . 0.0 108.719 -176.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -91.05 121.86 33.21 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.163 -2.532 . . . . 0.0 104.163 178.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -86.63 -73.17 0.47 Allowed 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.638 0.654 . . . . 0.0 110.757 -174.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . 0.48 ' ND2' ' H ' ' A' ' 79' ' ' GLU . 6.5 p30 -75.09 63.5 1.28 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 122.164 0.983 . . . . 0.0 112.507 -178.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.445 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 29.8 mt -77.02 65.12 2.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.864 1.666 . . . . 0.0 108.34 177.152 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.48 46.97 0.08 Allowed 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 127.432 2.293 . . . . 0.0 111.179 -175.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 31.9 58.61 0.34 Allowed 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.852 2.861 . . . . 0.0 115.374 -175.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 156.56 -4.82 0.19 Allowed Glycine 0 CA--C 1.525 0.664 0 CA-C-O 118.972 -0.905 . . . . 0.0 114.32 174.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.615 ' HB3' HG23 ' A' ' 160' ' ' ILE . 43.7 mt-10 -74.87 111.81 10.44 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 119.18 1.49 . . . . 0.0 110.031 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 59.9 p -78.42 133.37 37.51 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 176.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.456 HG23 HG13 ' A' ' 160' ' ' ILE 0.26 0.4 OUTLIER -84.37 82.72 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 CA-C-O 122.875 1.321 . . . . 0.0 107.964 -176.646 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 41.9 m -79.08 94.65 5.36 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 120.986 -1.071 . . . . 0.0 110.363 -176.504 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 10.5 mt -57.91 128.32 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.4 mmpt? -98.5 -52.63 3.57 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 125.188 1.395 . . . . 0.0 108.931 177.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -79.0 61.51 3.19 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 120.819 0.342 . . . . 0.0 110.133 -178.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 60.2 p -77.84 72.77 4.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.843 0.857 . . . . 0.0 110.472 -176.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.37 -143.74 5.54 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 26.5 t -72.2 146.45 47.34 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 19.2 m -137.1 156.51 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.617 0.767 . . . . 0.0 109.33 -178.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -114.05 158.38 21.29 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 174.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.21 164.8 26.17 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.12 0.486 . . . . 0.0 110.249 175.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 60.7 32.91 20.31 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.339 1.055 . . . . 0.0 112.953 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -105.79 145.79 30.71 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 175.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -115.79 161.9 18.08 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.133 0.973 . . . . 0.0 110.585 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 19.3 t70 56.99 18.46 3.97 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 126.436 1.894 . . . . 0.0 113.566 -177.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.434 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -61.64 -21.2 24.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 125.464 1.506 . . . . 0.0 112.006 177.728 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.424 HG21 HG22 ' A' ' 142' ' ' VAL . 13.4 p -138.83 150.44 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 126.554 1.941 . . . . 0.0 107.048 178.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -120.77 109.07 14.72 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.184 0.994 . . . . 0.0 109.765 177.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.615 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.2 mp -77.65 92.47 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 N-CA-C 104.345 -2.465 . . . . 0.0 104.345 178.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 58.5 mt-10 -119.25 122.7 42.52 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.233 1.013 . . . . 0.0 111.055 -174.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--N 1.332 -0.179 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 177.332 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.529 0.171 0 N-CA-C 102.831 -3.026 . . . . 0.0 102.831 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -131.27 96.99 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 122.231 2.287 . . . . 0.0 110.272 176.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 t -32.57 120.94 0.41 Allowed Pre-proline 0 CA--C 1.548 0.887 0 C-N-CA 125.574 1.55 . . . . 0.0 112.808 -178.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -74.06 -38.14 2.35 Favored 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 123.29 2.66 . . . . 0.0 117.571 -171.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.92 152.02 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 120.113 1.324 . . . . 0.0 109.84 -176.049 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.6 m -79.09 134.17 36.75 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 172.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.86 -177.09 45.54 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -92.0 122.08 34.17 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.4 tt -86.61 138.65 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 123.12 0.568 . . . . 0.0 110.141 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 78.8 m-70 -137.66 145.63 49.64 Favored Pre-proline 0 C--O 1.234 0.278 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 176.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.47 145.69 67.18 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.115 1.877 . . . . 0.0 110.218 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.4 tp -50.8 -33.84 12.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 p -56.02 -27.71 54.25 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 123.78 0.832 . . . . 0.0 112.388 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -76.22 -11.89 60.0 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.923 0.889 . . . . 0.0 112.714 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.675 HG22 ' HB2' ' A' ' 44' ' ' ALA . 42.3 t -66.85 129.45 94.05 Favored Pre-proline 0 CA--C 1.538 0.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.445 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -77.17 59.48 6.59 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.696 2.931 . . . . 0.0 111.024 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -167.58 105.19 0.52 Allowed 'General case' 0 N--CA 1.463 0.209 0 O-C-N 121.356 -0.84 . . . . 0.0 109.344 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -24.56 -58.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 128.162 2.585 . . . . 0.0 114.164 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.9 t -48.57 -50.44 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 123.954 0.902 . . . . 0.0 110.464 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -76.31 -47.81 22.29 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.2 m -49.31 -41.29 38.0 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 113.793 1.035 . . . . 0.0 113.793 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -104.6 20.27 39.81 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-O 118.081 -1.4 . . . . 0.0 110.897 -177.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.0 mttt 72.03 -46.52 0.65 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.401 1.48 . . . . 0.0 113.248 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 45.0 tpp 45.16 -72.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.731 2.812 . . . . 0.0 115.352 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.7 ttp -101.8 -14.69 17.19 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.314 1.446 . . . . 0.0 113.018 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.06 -169.21 38.0 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 119.531 1.06 . . . . 0.0 111.965 -178.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -128.79 157.54 41.17 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.99 -126.71 1.35 Allowed Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 108.533 -1.827 . . . . 0.0 108.533 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -166.44 167.1 16.01 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 118.125 0.963 . . . . 0.0 111.542 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.675 ' HB2' HG22 ' A' ' 29' ' ' VAL . . . -99.35 126.19 45.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.475 1.11 . . . . 0.0 108.5 177.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.0 mm -107.31 121.12 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 104.193 -2.521 . . . . 0.0 104.193 170.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 7.0 tt -89.03 109.5 31.12 Favored Pre-proline 0 C--O 1.233 0.233 1 N-CA-C 100.073 -4.047 . . . . 0.0 100.073 170.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -81.52 162.61 19.34 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 123.594 2.863 . . . . 0.0 115.037 -167.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.2 p -132.04 -63.52 0.81 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.639 1.576 . . . . 0.0 108.947 177.095 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.43 123.93 17.83 Favored 'General case' 0 C--N 1.338 0.096 0 C-N-CA 122.56 0.344 . . . . 0.0 110.166 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.08 45.34 2.98 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 173.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.2 mt -145.84 115.96 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 105.17 -2.159 . . . . 0.0 105.17 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.1 t -114.01 121.51 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 125.084 1.354 . . . . 0.0 108.252 -177.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.9 m -103.66 156.93 5.34 Favored 'Isoleucine or valine' 0 C--N 1.339 0.11 0 C-N-CA 123.642 0.777 . . . . 0.0 110.071 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 m -69.12 127.17 93.13 Favored Pre-proline 0 CA--C 1.537 0.471 0 CA-C-O 117.598 -1.191 . . . . 0.0 109.92 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -60.41 -33.2 94.39 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.763 2.976 . . . . 0.0 111.302 177.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.1 m -150.6 144.16 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 102.139 -3.282 . . . . 0.0 102.139 172.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 -98.72 -97.41 0.22 Allowed 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 101.754 -3.424 . . . . 0.0 101.754 169.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.95 -66.43 3.59 Favored Glycine 0 CA--C 1.535 1.303 0 N-CA-C 106.575 -2.61 . . . . 0.0 106.575 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.21 132.36 2.49 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 166.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.0 mm -65.04 131.78 30.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 103.55 -2.759 . . . . 0.0 103.55 169.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 29.3 tp -79.01 -46.36 18.33 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 175.0 156.05 0.15 Allowed 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 125.669 1.588 . . . . 0.0 107.787 176.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.3 t -131.12 121.06 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -47.44 153.01 1.05 Allowed Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 112.579 0.585 . . . . 0.0 112.579 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -59.67 -14.97 28.92 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 124.192 3.262 . . . . 0.0 113.652 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 40.5 p -76.26 -21.29 56.49 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.078 0.951 . . . . 0.0 109.697 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 70.98 9.52 6.78 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 128.14 2.576 . . . . 0.0 111.03 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -83.91 -31.21 25.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 118.611 -0.709 . . . . 0.0 112.864 -176.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.82 -175.38 5.33 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.679 1.127 . . . . 0.0 112.348 -174.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.965 16.6 mm 130.89 -141.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.334 -0.085 1 C-N-CA 132.018 4.127 . . . . 0.0 111.824 176.4 . . . . . . . . 3 2 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -152.14 176.2 30.53 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 118.511 2.164 . . . . 0.0 118.511 -171.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.2 mp -132.51 158.46 42.05 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 128.012 2.525 . . . . 0.0 109.817 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.7 mm-40 -133.03 123.85 26.57 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 177.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.3 p . . . . . 0 C--N 1.322 -0.629 0 C-N-CA 124.689 1.196 . . . . 0.0 108.778 177.82 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 . . . . . 0 N--CA 1.46 0.036 0 CA-C-O 121.821 0.82 . . . . 0.0 111.824 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -76.34 141.15 41.64 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 174.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.2 mt -126.66 144.36 37.08 Favored 'Isoleucine or valine' 0 C--N 1.338 0.08 0 N-CA-C 112.789 0.662 . . . . 0.0 112.789 -172.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -119.82 136.63 54.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 128.891 2.876 . . . . 0.0 105.732 175.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.0 mt -131.48 140.15 49.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 C-N-CA 125.075 1.35 . . . . 0.0 107.764 177.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -132.89 114.81 14.49 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -76.05 116.52 16.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 118.766 0.712 . . . . 0.0 110.402 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.63 -170.57 4.82 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.694 -0.562 . . . . 0.0 111.694 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 22.5 mm -116.59 141.36 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.7 t0 50.2 41.98 24.76 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.412 1.085 . . . . 0.0 112.892 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.423 ' O ' ' N ' ' A' ' 90' ' ' SER . 7.7 p -83.83 -89.12 0.1 Allowed 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 103.273 -2.862 . . . . 0.0 103.273 172.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.435 HG13 ' H ' ' A' ' 90' ' ' SER . 7.3 p 33.03 -67.31 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 C-N-CA 128.313 2.645 . . . . 0.0 116.946 172.354 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.435 ' H ' HG13 ' A' ' 89' ' ' VAL . 12.9 m -63.43 -40.44 97.18 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 126.27 1.828 . . . . 0.0 109.758 176.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -58.35 -43.53 88.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 126.862 2.065 . . . . 0.0 108.8 178.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? 77.02 169.59 0.24 Allowed 'General case' 0 N--CA 1.442 -0.871 0 C-N-CA 126.823 2.049 . . . . 0.0 106.837 -174.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.03 54.96 0.56 Allowed Glycine 0 CA--C 1.538 1.493 0 C-N-CA 124.898 1.237 . . . . 0.0 112.718 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -75.41 79.88 2.47 Favored 'General case' 0 CA--C 1.519 -0.236 0 O-C-N 121.158 -1.201 . . . . 0.0 108.781 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.78 11.72 2.31 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 112.919 -1.946 . . . . 0.0 111.594 -176.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -96.94 96.93 8.86 Favored 'General case' 0 C--N 1.342 0.267 0 C-N-CA 124.753 1.221 . . . . 0.0 110.731 -175.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.4 m -79.72 94.67 5.78 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 35.9 p -79.51 122.93 27.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 121.569 -0.707 . . . . 0.0 110.653 -176.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -83.57 -53.18 5.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 27.9 m -84.82 131.02 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 171.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 69.6 m -96.06 57.63 1.79 Allowed 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 170.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.378 0.0 OUTLIER 37.97 49.6 1.2 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 111.458 -2.61 . . . . 0.0 110.6 -167.265 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -72.44 59.46 1.57 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 129.639 3.495 . . . . 0.0 111.152 -178.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.401 16.4 p30 2.04 -103.22 0.0 OUTLIER 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 119.583 3.179 . . . . 0.0 119.583 -178.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.322 0.1 OUTLIER -40.6 131.29 2.33 Favored 'General case' 0 N--CA 1.432 -1.367 1 N-CA-C 125.478 5.362 . . . . 0.0 125.478 -165.667 . . . . . . . . 4 3 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.489 9.7 p 32.63 -38.27 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.247 2 N-CA-C 130.203 7.112 . . . . 0.0 130.203 168.148 . . . . . . . . 3 2 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . 0.485 ' HA ' ' HD3' ' A' ' 108' ' ' PRO 0.287 0.0 OUTLIER -70.33 115.16 31.88 Favored Pre-proline 0 C--N 1.308 -1.197 0 C-N-CA 115.422 -2.511 . . . . 0.0 114.333 -166.865 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . 0.485 ' HD3' ' HA ' ' A' ' 107' ' ' GLU . 47.7 Cg_exo -62.45 162.82 22.71 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 124.875 3.717 . . . . 0.0 113.576 -170.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 54.04 15.91 5.63 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 124.423 1.011 . . . . 0.0 115.314 174.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -59.88 136.89 58.15 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 117.987 0.893 . . . . 0.0 108.752 178.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -64.23 119.42 10.22 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 174.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.6 mt -81.07 -52.33 7.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 17.1 mt -145.56 149.31 34.35 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.29 1.036 . . . . 0.0 110.995 -173.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -114.39 128.19 56.22 Favored 'General case' 0 CA--C 1.515 -0.402 1 N-CA-C 98.762 -4.532 . . . . 0.0 98.762 165.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.65 127.0 44.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.744 -165.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -74.26 68.29 1.47 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.664 0.786 . . . . 0.0 110.108 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.0 mt -54.2 -38.36 65.56 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.929 0.491 . . . . 0.0 111.102 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -53.68 -44.75 69.97 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.99 0.516 . . . . 0.0 112.162 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.89 -32.52 20.16 Favored 'General case' 0 CA--C 1.527 0.079 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -67.13 -50.59 62.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 O-C-N 121.759 -0.588 . . . . 0.0 110.326 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.345 22.1 pttm -37.0 -54.15 1.84 Allowed Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 118.283 2.698 . . . . 0.0 118.283 -176.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -52.63 -22.15 16.33 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.66 2.24 . . . . 0.0 114.095 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 -84.19 -14.36 50.31 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 118.13 -0.938 . . . . 0.0 113.096 -177.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 29.3 m -108.77 149.05 38.99 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 119.731 1.15 . . . . 0.0 112.44 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.32 -26.29 20.85 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.586 2.19 . . . . 0.0 110.372 175.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 10.0 m -157.85 137.41 12.03 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.564 1.146 . . . . 0.0 108.287 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 13.2 tp -90.29 6.78 41.5 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.876 0.87 . . . . 0.0 111.396 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.1 mmt -50.57 114.26 1.09 Allowed 'General case' 0 C--N 1.342 0.244 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 45.6 m -107.73 88.36 4.3 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -72.49 139.92 32.27 Favored 'Trans proline' 0 N--CA 1.445 -1.352 0 C-N-CA 121.923 1.749 . . . . 0.0 111.976 -178.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 16.6 mm -115.51 128.48 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 102.404 -3.184 . . . . 0.0 102.404 173.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.5 t -137.43 122.36 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -175.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -84.72 123.05 29.95 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.035 -2.58 . . . . 0.0 104.035 174.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 40.2 p -80.74 -72.78 0.4 Allowed 'General case' 0 C--O 1.227 -0.129 0 CA-C-N 118.841 0.746 . . . . 0.0 110.796 -175.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 22.2 p30 -65.14 -30.06 70.96 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -177.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 mt 46.27 44.54 12.5 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.156 0.982 . . . . 0.0 110.347 -176.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 42.53 37.39 0.97 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 126.351 1.86 . . . . 0.0 112.662 -175.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 75.5 mm-40 48.25 75.32 0.14 Allowed 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 126.706 2.002 . . . . 0.0 113.874 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.03 -14.21 5.19 Favored Glycine 0 C--N 1.335 0.484 0 CA-C-O 118.702 -1.055 . . . . 0.0 113.339 174.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -72.65 139.21 47.19 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.206 1.503 . . . . 0.0 109.776 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 77.2 p -111.87 130.81 55.7 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 124.97 1.308 . . . . 0.0 109.128 176.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -60.42 112.6 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 123.973 0.909 . . . . 0.0 110.387 -175.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 87.28 2.61 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 126.407 1.883 . . . . 0.0 106.518 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 34.7 mt -66.77 131.82 32.35 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -96.58 -44.2 7.25 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.457 ' HB2' HG23 ' A' ' 157' ' ' ILE . . . -47.23 83.1 0.0 OUTLIER 'General case' 0 C--N 1.34 0.158 0 C-N-CA 126.348 1.859 . . . . 0.0 114.206 -178.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 37.7 m -82.71 54.59 2.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 123.996 0.918 . . . . 0.0 108.787 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 157.47 -171.65 34.73 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.211 -0.755 . . . . 0.0 111.211 -177.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 29.6 t -58.47 138.05 56.93 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 122.794 0.438 . . . . 0.0 110.101 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.7 m -92.86 -173.01 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 123.7 0.8 . . . . 0.0 109.928 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.85 166.7 29.76 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.62 155.03 24.64 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.986 0.812 . . . . 0.0 110.336 176.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 62.56 5.12 1.55 Allowed 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.762 1.625 . . . . 0.0 114.301 178.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -67.95 118.22 10.85 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 62.7 tt0 -67.51 138.03 56.23 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 29.2 t70 84.92 -113.87 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 128.327 2.651 . . . . 0.0 109.043 -179.318 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.457 HG23 ' HB2' ' A' ' 146' ' ' ALA 0.366 1.7 mp 73.31 -28.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 129.565 3.146 . . . . 0.0 111.509 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.0 p -134.9 148.09 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 127.519 2.328 . . . . 0.0 106.978 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . 0.496 ' C ' HD13 ' A' ' 160' ' ' ILE . 26.3 mtpp -134.67 144.93 48.1 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 104.009 -2.589 . . . . 0.0 104.009 173.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.496 HD13 ' C ' ' A' ' 159' ' ' LYS . 0.3 OUTLIER -112.0 112.55 40.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.156 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.1 134.02 44.74 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 123.66 0.784 . . . . 0.0 111.247 -174.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp . . . . . 0 CA--C 1.528 0.117 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 176.73 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 CA--C 1.528 0.119 0 N-CA-C 114.387 1.254 . . . . 0.0 114.387 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -142.55 103.88 1.05 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 C-N-CA 126.68 1.992 . . . . 0.0 106.267 172.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 t -29.14 118.53 0.28 Allowed Pre-proline 0 CA--C 1.552 1.033 0 C-N-CA 124.728 1.211 . . . . 0.0 113.43 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -75.31 -37.47 1.87 Allowed 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 122.693 2.262 . . . . 0.0 117.324 -173.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.27 148.06 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 120.397 1.453 . . . . 0.0 109.3 -176.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.4 m -78.64 137.04 37.64 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 175.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.19 -147.14 14.54 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -107.72 144.1 35.3 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.1 tt -105.62 95.17 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 C-N-CA 124.304 1.041 . . . . 0.0 108.398 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -85.63 151.58 55.86 Favored Pre-proline 0 C--O 1.237 0.404 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.26 145.32 88.5 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 N-CA-C 107.888 -1.62 . . . . 0.0 107.888 174.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.3 tp -50.67 -32.64 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.672 0.789 . . . . 0.0 111.134 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.9 -29.87 63.41 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.829 1.252 . . . . 0.0 113.057 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -82.24 3.65 26.64 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.403 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 58.2 t -82.06 128.04 69.56 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-O 117.508 -1.234 . . . . 0.0 111.755 -176.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_exo -58.74 40.75 0.05 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 1 C-N-CA 126.354 4.702 . . . . 0.0 117.451 175.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -164.48 109.59 0.97 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 120.98 1.718 . . . . 0.0 109.033 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 18.8 mp0 -34.13 -48.52 0.32 Allowed 'General case' 0 C--O 1.231 0.117 0 C-N-CA 128.956 2.902 . . . . 0.0 114.401 -176.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.5 p -53.44 -38.95 34.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 CA-C-N 118.158 0.435 . . . . 0.0 110.878 -178.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -84.48 -48.83 9.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 177.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -51.03 -39.23 55.38 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -178.131 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.38 17.15 57.24 Favored Glycine 0 N--CA 1.445 -0.716 0 CA-C-O 118.219 -1.323 . . . . 0.0 111.06 -177.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.7 mttp 71.18 -40.71 0.48 Allowed 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.463 1.505 . . . . 0.0 114.07 178.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 29.97 -73.96 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 130.005 3.322 . . . . 0.0 116.753 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.19 -21.3 46.56 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.476 1.11 . . . . 0.0 113.263 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 172.43 -144.21 7.83 Favored Glycine 0 C--O 1.223 -0.564 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -141.57 160.05 40.95 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.55 -126.13 1.23 Allowed Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.05 163.73 15.86 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 118.636 1.218 . . . . 0.0 112.261 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.403 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -99.94 96.88 7.84 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 124.575 1.15 . . . . 0.0 110.466 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 32.1 mm -80.44 126.11 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.4 tt -101.03 105.5 39.03 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 100.529 -3.878 . . . . 0.0 100.529 171.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -84.37 168.18 11.68 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.891 3.061 . . . . 0.0 114.255 -168.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.9 p -130.8 -71.7 0.57 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.347 1.459 . . . . 0.0 108.199 176.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -48.89 127.25 13.72 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 124.609 1.164 . . . . 0.0 112.088 178.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.21 42.26 2.34 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 173.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 35.9 mt -143.74 120.87 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 104.381 -2.452 . . . . 0.0 104.381 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . 0.408 HG21 ' CE2' ' A' ' 84' ' ' PHE . 53.1 t -119.97 131.09 73.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 124.911 1.284 . . . . 0.0 107.549 -176.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.4 m -110.72 159.39 10.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 C-N-CA 124.08 0.952 . . . . 0.0 110.947 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.84 132.7 94.83 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-O 118.41 -0.805 . . . . 0.0 110.21 -179.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -68.58 -15.95 42.02 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.638 2.892 . . . . 0.0 115.926 -177.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -143.99 162.02 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.046 0 CA-C-N 119.523 1.056 . . . . 0.0 110.409 -178.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 108' ' ' PRO . 9.0 ptp85 -76.73 117.14 18.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 168.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 172.96 -179.62 44.28 Favored Glycine 0 N--CA 1.433 -1.529 0 C-N-CA 115.277 -3.344 . . . . 0.0 114.954 -167.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.63 127.91 42.05 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 124.558 1.143 . . . . 0.0 109.815 -176.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 9.6 mm -73.94 113.32 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 N-CA-C 102.633 -3.099 . . . . 0.0 102.633 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 61.0 tp -76.44 -47.93 21.37 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -174.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -174.77 157.4 2.47 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 13.5 t -138.91 119.24 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 175.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -42.04 151.53 0.34 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.572 0.624 . . . . 0.0 112.201 177.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.19 -26.36 15.03 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 123.89 3.06 . . . . 0.0 114.303 175.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 19.2 p -75.73 -15.2 60.31 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 123.871 0.869 . . . . 0.0 110.925 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 71.87 10.11 6.2 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.545 1.538 . . . . 0.0 113.536 178.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.437 ' CG ' ' HA ' ' A' ' 89' ' ' VAL . 22.6 p-80 -90.51 -31.62 16.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 119.428 1.013 . . . . 0.0 113.403 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.97 -178.82 7.16 Favored 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -171.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.663 23.0 mm 124.01 -132.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 1 C-N-CA 135.155 5.382 . . . . 0.0 105.216 -176.709 . . . . . . . . 3 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -169.86 -179.1 41.33 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 119.165 2.426 . . . . 0.0 119.165 -177.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.6 mp -124.56 172.33 9.3 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.747 2.419 . . . . 0.0 110.279 -178.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -134.42 142.01 47.0 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 169.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 40.8 p . . . . . 0 C--N 1.324 -0.516 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.041 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.453 -0.306 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -103.53 136.35 43.43 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 173.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 22.3 mt -125.01 122.95 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -173.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 28.2 tp -89.65 136.83 32.8 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 127.193 2.197 . . . . 0.0 106.914 173.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.4 mt -120.14 155.63 23.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.652 1.181 . . . . 0.0 109.522 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.57 96.64 1.79 Allowed 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 126.223 1.809 . . . . 0.0 107.021 174.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.408 ' CE2' HG21 ' A' ' 52' ' ' VAL . 1.0 OUTLIER -73.68 76.69 1.53 Allowed 'General case' 0 N--CA 1.454 -0.238 0 O-C-N 121.519 -0.738 . . . . 0.0 110.565 -178.071 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.11 170.84 39.89 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.634 1.588 . . . . 0.0 111.775 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 2.0 tp -107.41 125.86 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.845 1.658 . . . . 0.0 106.935 178.03 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t0 58.88 38.6 24.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 125.323 1.449 . . . . 0.0 111.206 -176.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -95.88 -70.85 0.7 Allowed 'General case' 0 CA--C 1.496 -1.126 0 N-CA-C 101.366 -3.568 . . . . 0.0 101.366 171.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.437 ' HA ' ' CG ' ' A' ' 68' ' ' HIS 0.335 1.3 p 45.44 49.22 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 104.492 -2.41 . . . . 0.0 104.492 -172.758 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 21.4 m 12.97 48.38 0.0 OUTLIER 'General case' 0 C--N 1.35 0.592 1 C-N-CA 133.111 4.565 . . . . 0.0 112.83 -165.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.414 HD23 ' HA ' ' A' ' 91' ' ' LEU . 1.9 mt 33.66 50.52 0.31 Allowed 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 131.053 3.741 . . . . 0.0 109.001 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 90.5 mttt 76.66 50.26 0.05 Allowed 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 128.148 2.579 . . . . 0.0 111.595 -176.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 47.43 37.28 12.24 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 126.472 1.987 . . . . 0.0 114.059 -178.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -92.5 161.66 14.53 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 170.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 63.56 -4.14 1.11 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.137 1.351 . . . . 0.0 114.822 178.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -106.64 105.57 15.67 Favored 'General case' 0 C--N 1.342 0.262 0 CA-C-N 119.077 1.438 . . . . 0.0 111.327 -175.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 18.9 m -93.11 104.36 16.57 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 174.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.6 t -80.15 148.83 30.77 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 119.203 0.91 . . . . 0.0 110.775 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -115.9 3.85 13.77 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 126.323 1.849 . . . . 0.0 110.785 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.6 m -134.02 145.96 32.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 176.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.6 m -82.6 -16.87 46.83 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.973 1.309 . . . . 0.0 112.211 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.472 1.3 pp20? 73.29 140.86 0.06 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.203 3.001 . . . . 0.0 109.574 -172.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 97.5 -16.48 60.5 Favored Glycine 0 CA--C 1.54 1.642 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -169.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -57.87 115.66 2.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.632 1.973 . . . . 0.0 108.901 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.25 123.01 29.67 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 128.912 2.885 . . . . 0.0 114.254 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.345 27.3 m 52.23 70.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.301 0 C-N-CA 126.992 2.117 . . . . 0.0 116.032 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 138.44 26.55 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 170.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . 0.404 ' HA ' ' HA ' ' A' ' 57' ' ' ARG . 0.9 OUTLIER -93.63 -135.49 0.01 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.004 0 C-N-CA 124.978 3.785 . . . . 0.0 108.522 -179.229 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -64.21 30.09 0.09 OUTLIER Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.334 1.921 . . . . 0.0 115.678 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.8 tt0 -64.58 149.8 48.12 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 169.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -64.32 122.11 15.91 Favored 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.739 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.7 mt -80.44 -49.43 11.44 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 175.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.1 mt -144.04 152.43 41.0 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.007 0.923 . . . . 0.0 110.708 -173.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -114.49 128.83 56.54 Favored 'General case' 0 CA--C 1.517 -0.298 1 N-CA-C 98.95 -4.463 . . . . 0.0 98.95 165.802 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.44 128.47 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.469 -165.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -76.82 63.57 2.23 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.623 0.725 . . . . 0.0 109.856 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 80.0 mt -54.34 -37.68 65.16 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 123.248 0.619 . . . . 0.0 110.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -53.76 -43.37 69.13 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.761 0.824 . . . . 0.0 112.247 178.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.92 -34.54 20.9 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.059 0.391 . . . . 0.0 111.411 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 75.4 t -62.01 -55.43 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.355 18.8 pttp -38.96 -58.33 1.76 Allowed Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 117.596 2.443 . . . . 0.0 117.596 -176.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.49 -20.28 48.43 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.774 2.316 . . . . 0.0 113.717 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -100.13 9.2 43.18 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 118.551 -0.738 . . . . 0.0 112.726 -176.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 22.8 m -136.23 158.48 73.53 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 119.573 1.079 . . . . 0.0 109.36 -178.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -75.7 -30.0 6.63 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.017 1.811 . . . . 0.0 112.783 -177.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -163.88 133.96 4.2 Favored 'General case' 0 N--CA 1.454 -0.241 0 O-C-N 121.395 -0.816 . . . . 0.0 111.287 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -93.42 9.07 38.02 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.961 0.904 . . . . 0.0 111.564 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -50.89 110.04 0.38 Allowed 'General case' 0 C--N 1.342 0.242 0 C-N-CA 124.301 1.041 . . . . 0.0 108.327 177.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.8 m -95.83 102.49 10.52 Favored Pre-proline 0 N--CA 1.447 -0.607 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -92.39 99.66 0.18 Allowed 'Trans proline' 0 N--CA 1.444 -1.422 0 C-N-CA 123.414 2.743 . . . . 0.0 107.679 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.08 126.5 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 103.503 -2.777 . . . . 0.0 103.503 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.05 120.43 51.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 CA-C-O 121.928 0.871 . . . . 0.0 109.303 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.485 ' N ' ' CD1' ' A' ' 133' ' ' PHE . 0.5 OUTLIER -83.0 114.14 21.06 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 101.732 -3.432 . . . . 0.0 101.732 177.592 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -77.16 -79.69 0.11 Allowed 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 121.007 0.432 . . . . 0.0 111.216 -170.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.23 68.12 0.72 Allowed 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.988 0.899 . . . . 0.0 111.298 -178.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.1 mt -76.76 65.28 2.47 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.128 -0.982 . . . . 0.0 108.364 177.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 10.18 63.03 0.0 OUTLIER 'General case' 0 C--N 1.347 0.458 0 C-N-CA 130.582 3.553 . . . . 0.0 112.815 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 25.97 58.02 0.06 Allowed 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 128.52 2.728 . . . . 0.0 114.514 -176.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 148.71 6.2 0.23 Allowed Glycine 0 CA--C 1.524 0.617 0 CA-C-O 118.577 -1.124 . . . . 0.0 114.033 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.733 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 22.4 mt-10 -77.76 92.76 4.21 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 119.439 1.62 . . . . 0.0 107.894 177.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 70.1 p -76.69 135.06 39.08 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -177.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.2 t -87.32 90.74 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 124.0 0.92 . . . . 0.0 109.26 -176.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 42.1 m -85.68 95.6 9.42 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 33.0 mt -64.58 131.84 30.36 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -100.94 -45.9 5.28 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 124.665 1.186 . . . . 0.0 109.055 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.67 74.81 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.234 0 C-N-CA 126.113 1.765 . . . . 0.0 112.02 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.1 m -79.71 54.47 1.82 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.443 1.097 . . . . 0.0 110.025 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 160.7 179.66 35.6 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 40.5 t -57.16 144.83 33.46 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.172 0.589 . . . . 0.0 111.616 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 4.9 m -145.04 166.96 10.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -102.36 166.86 10.33 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 124.849 1.26 . . . . 0.0 111.48 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.29 163.41 23.02 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 63.96 -9.42 0.15 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.727 2.011 . . . . 0.0 114.552 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 34.2 mm-40 -64.32 148.96 49.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.456 1.025 . . . . 0.0 111.581 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -99.33 159.38 15.05 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.527 2.331 . . . . 0.0 111.099 -176.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 24.9 t70 57.55 21.83 7.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 126.137 1.775 . . . . 0.0 114.621 174.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.464 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -70.35 -28.64 36.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 C-N-CA 123.61 0.764 . . . . 0.0 111.812 178.951 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.44 145.14 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 C-N-CA 125.5 1.52 . . . . 0.0 107.866 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -120.57 111.86 18.2 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 174.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.733 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.03 110.53 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 103.84 -2.652 . . . . 0.0 103.84 172.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -109.11 125.04 51.73 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.956 1.303 . . . . 0.0 109.883 -178.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 56.2 tptt . . . . . 0 C--N 1.333 -0.14 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.109 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.461 0.117 0 CA-C-O 118.311 -0.852 . . . . 0.0 111.467 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.2 m -90.51 101.5 12.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 CA-C-N 118.882 0.765 . . . . 0.0 110.568 177.072 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.3 p -35.44 115.56 0.56 Allowed Pre-proline 0 CA--C 1.556 1.211 0 C-N-CA 125.831 1.652 . . . . 0.0 110.891 177.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -75.72 -30.45 6.16 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.832 2.354 . . . . 0.0 117.685 -171.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.49 148.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 120.513 1.506 . . . . 0.0 110.806 -176.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.8 m -79.27 138.81 37.91 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 171.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.62 -151.69 20.51 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -117.05 116.33 27.14 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.218 1.407 . . . . 0.0 108.435 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 7.5 mt -78.84 138.17 20.58 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 CA-C-N 118.666 0.666 . . . . 0.0 109.617 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -137.03 144.75 47.56 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 174.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -54.9 142.73 74.67 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 C-N-CA 121.967 1.778 . . . . 0.0 110.109 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.22 -36.44 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 124.646 1.178 . . . . 0.0 113.187 -177.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.2 p -51.38 -32.68 26.91 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.911 1.285 . . . . 0.0 112.559 178.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -75.94 -9.61 58.75 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 124.224 1.009 . . . . 0.0 112.505 -175.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.551 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 52.9 t -75.16 119.73 78.33 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-O 117.662 -1.161 . . . . 0.0 111.529 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -59.34 53.94 0.07 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 1 C-N-CA 126.067 4.511 . . . . 0.0 117.071 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -167.69 112.03 0.67 Allowed 'General case' 0 N--CA 1.463 0.186 0 O-C-N 120.464 -1.398 . . . . 0.0 108.684 177.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -30.67 -51.46 0.15 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 127.609 2.363 . . . . 0.0 114.589 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.3 t -52.97 -47.33 53.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 CA-C-O 121.508 0.67 . . . . 0.0 110.05 -178.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -78.08 -46.95 19.41 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -50.38 -43.01 54.3 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -97.62 11.94 64.69 Favored Glycine 0 C--N 1.338 0.657 0 CA-C-O 118.909 -0.94 . . . . 0.0 111.499 -178.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? 70.13 -34.8 0.3 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.809 1.644 . . . . 0.0 114.032 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.6 tmt? 32.18 -69.27 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 131.286 3.834 . . . . 0.0 116.576 178.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 7.8 tpt -78.58 -19.99 51.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.185 0.994 . . . . 0.0 111.981 -175.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.15 -133.13 1.82 Allowed Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.429 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 44.9 t0 -136.45 158.56 44.14 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 172.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 176.19 -154.45 16.93 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.383 -0.913 . . . . 0.0 111.706 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.556 ' CE2' HD11 ' A' ' 45' ' ' ILE . 38.7 p90 -158.25 164.48 36.43 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 122.533 0.333 . . . . 0.0 110.2 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.551 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -102.45 146.3 28.3 Favored 'General case' 0 CA--C 1.508 -0.665 0 C-N-CA 123.742 0.817 . . . . 0.0 109.369 178.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.556 HD11 ' CE2' ' A' ' 43' ' ' PHE . 4.4 mp -124.93 128.19 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 102.635 -3.098 . . . . 0.0 102.635 169.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.3 tt -91.33 106.78 17.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 172.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -61.32 170.34 5.35 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 124.111 3.207 . . . . 0.0 116.166 -171.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.5 p -152.29 -65.01 0.17 Allowed 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 125.089 1.356 . . . . 0.0 107.876 176.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -61.85 127.61 32.25 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.47 0.708 . . . . 0.0 110.188 176.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.83 43.95 2.9 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 172.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -145.36 124.35 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 127.381 2.273 . . . . 0.0 105.138 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 89.9 t -123.53 126.49 73.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.03 155.04 9.0 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 C-N-CA 123.716 0.807 . . . . 0.0 110.268 178.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.79 139.31 95.5 Favored Pre-proline 0 N--CA 1.449 -0.519 0 C-N-CA 123.585 0.754 . . . . 0.0 110.192 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -78.28 -21.91 10.08 Favored 'Trans proline' 0 N--CA 1.453 -0.885 0 C-N-CA 123.51 2.807 . . . . 0.0 114.221 -177.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.7 m -138.92 166.61 22.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.163 0 C-N-CA 124.325 1.05 . . . . 0.0 111.007 -177.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -78.81 115.96 18.83 Favored 'General case' 0 C--O 1.234 0.253 1 N-CA-C 99.376 -4.305 . . . . 0.0 99.376 168.338 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.32 176.6 47.89 Favored Glycine 0 N--CA 1.441 -1.015 0 C-N-CA 115.606 -3.188 . . . . 0.0 117.015 -168.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 123.72 30.54 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.769 1.628 . . . . 0.0 108.505 178.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 16.7 mm -75.45 95.77 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 172.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 49.9 tp -72.41 -51.27 21.13 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -171.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -171.19 137.06 1.1 Allowed 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 118.472 0.578 . . . . 0.0 111.423 177.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -128.15 123.9 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 103.761 -2.681 . . . . 0.0 103.761 172.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.33 156.61 0.48 Allowed Pre-proline 0 CA--C 1.54 0.578 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -178.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -50.05 -29.71 22.63 Favored 'Trans proline' 0 C--N 1.348 0.517 0 C-N-CA 123.924 3.083 . . . . 0.0 114.562 178.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.6 p -77.56 -9.04 58.7 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.511 1.124 . . . . 0.0 111.64 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.22 8.43 3.36 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 127.835 2.454 . . . . 0.0 113.202 -178.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -80.88 -27.76 36.22 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -160.68 -176.35 5.5 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 119.204 0.911 . . . . 0.0 111.677 -174.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.402 HG22 ' H ' ' A' ' 71' ' ' GLY 0.898 18.3 mm 129.0 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.184 1 C-N-CA 131.846 4.058 . . . . 0.0 111.355 176.485 . . . . . . . . 4 3 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . 0.402 ' H ' HG22 ' A' ' 70' ' ' ILE . . . -147.36 168.23 28.44 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 116.6 1.4 . . . . 0.0 116.6 -173.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -132.49 169.15 16.98 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 126.349 1.86 . . . . 0.0 108.619 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.11 144.71 38.82 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 175.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 89.2 p . . . . . 0 C--N 1.32 -0.685 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 176.446 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 . . . . . 0 C--O 1.238 0.464 0 N-CA-C 113.656 0.984 . . . . 0.0 113.656 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -111.55 148.3 33.53 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.283 2.233 . . . . 0.0 107.107 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.38 144.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 124.269 1.028 . . . . 0.0 109.66 -176.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -125.62 132.58 52.46 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 128.159 2.583 . . . . 0.0 105.439 176.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 39.0 mt -131.98 141.9 44.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 C-N-CA 124.798 1.239 . . . . 0.0 109.715 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -132.55 104.96 6.94 Favored 'General case' 0 C--O 1.226 -0.178 0 C-N-CA 124.335 1.054 . . . . 0.0 108.475 174.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.7 t80 -68.35 109.65 3.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 121.109 -0.995 . . . . 0.0 109.092 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.67 -165.82 7.79 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -176.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 31.4 mt -122.29 136.5 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.7 t0 55.48 42.61 29.69 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.555 1.142 . . . . 0.0 112.645 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.435 ' O ' ' N ' ' A' ' 90' ' ' SER . 1.8 p -80.19 -85.22 0.09 Allowed 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 103.093 -2.929 . . . . 0.0 103.093 172.215 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.418 HG13 ' H ' ' A' ' 90' ' ' SER . 12.1 p 26.43 -64.82 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 C-N-CA 128.883 2.873 . . . . 0.0 117.293 173.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 88' ' ' THR . 11.8 m -60.44 -36.83 79.13 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 126.624 1.97 . . . . 0.0 109.675 178.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -50.9 -36.71 39.65 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 128.216 2.606 . . . . 0.0 109.617 176.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp 70.49 151.75 0.1 Allowed 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 126.303 1.841 . . . . 0.0 109.673 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -65.91 25.99 0.15 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 115.153 0.821 . . . . 0.0 115.153 -178.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 20.5 mm-40 -59.21 -35.16 73.13 Favored 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.689 1.744 . . . . 0.0 112.085 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -98.02 15.26 61.81 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.764 178.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -123.31 96.57 5.04 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 118.884 1.342 . . . . 0.0 109.545 -176.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.7 m -81.52 111.77 18.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 173.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.8 p -86.11 138.53 31.85 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.563 -0.711 . . . . 0.0 111.279 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -107.51 7.16 28.68 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 125.57 1.548 . . . . 0.0 113.389 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 20.5 m -140.42 144.37 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 175.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.7 m -79.51 -15.77 57.16 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.175 0.99 . . . . 0.0 112.772 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.442 16.1 pm0 69.03 147.46 0.06 Allowed 'General case' 0 N--CA 1.446 -0.671 0 C-N-CA 130.065 3.346 . . . . 0.0 111.209 -173.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 95.22 -21.78 42.25 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 124.709 1.147 . . . . 0.0 110.466 -172.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -60.63 124.57 20.78 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.919 1.688 . . . . 0.0 108.914 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.33 123.64 31.8 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 129.162 2.985 . . . . 0.0 113.308 -174.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.373 28.5 m 52.23 69.89 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.142 0 N-CA-C 117.018 2.229 . . . . 0.0 117.018 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.35 139.85 27.36 Favored Pre-proline 0 N--CA 1.45 -0.455 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 168.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -88.19 -151.25 0.04 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 123.686 2.924 . . . . 0.0 108.544 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -69.68 54.36 0.71 Allowed Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.908 1.242 . . . . 0.0 113.924 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -54.22 -55.07 31.57 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 124.97 1.308 . . . . 0.0 110.037 177.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt 144.87 125.67 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.621 1 C-N-CA 132.615 4.366 . . . . 0.0 106.098 -175.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 69.9 mt -91.83 -45.51 8.35 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 123.652 0.781 . . . . 0.0 109.385 178.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.2 mt -147.52 151.87 37.07 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 122.798 0.439 . . . . 0.0 111.101 -174.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -116.31 127.21 54.49 Favored 'General case' 0 CA--C 1.517 -0.291 1 N-CA-C 98.557 -4.608 . . . . 0.0 98.557 165.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.23 126.34 45.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.721 -166.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -74.75 61.03 0.96 Allowed 'General case' 0 C--O 1.233 0.224 0 C-N-CA 125.259 1.423 . . . . 0.0 111.239 -176.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.5 mt -45.94 -41.82 12.08 Favored 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 124.326 1.05 . . . . 0.0 111.94 -178.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -49.15 -41.4 36.17 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.622 0.769 . . . . 0.0 112.501 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -92.57 -33.77 14.3 Favored 'General case' 0 CA--C 1.527 0.066 0 C-N-CA 123.467 0.707 . . . . 0.0 111.353 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.26 -51.95 64.77 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.617 -0.677 . . . . 0.0 109.468 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.368 46.1 pttt -41.87 -58.07 3.58 Favored Pre-proline 0 CA--C 1.541 0.599 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -177.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -57.18 -19.8 35.56 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.435 2.09 . . . . 0.0 113.327 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -95.49 7.98 44.63 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 118.097 -0.954 . . . . 0.0 112.488 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 23.9 m -132.91 150.51 75.87 Favored Pre-proline 0 N--CA 1.466 0.333 0 CA-C-N 120.086 1.312 . . . . 0.0 111.506 179.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -73.78 -27.41 12.52 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 C-N-CA 122.867 2.378 . . . . 0.0 111.635 179.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -157.42 132.01 8.56 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.598 -0.689 . . . . 0.0 109.926 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -90.35 -2.06 57.96 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.712 1.205 . . . . 0.0 111.769 -179.019 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.6 mmt -49.65 111.26 0.48 Allowed 'General case' 0 C--N 1.34 0.194 0 C-N-CA 124.399 1.08 . . . . 0.0 109.353 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 49.9 m -102.73 110.14 62.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 -178.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -91.33 137.62 2.1 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 122.843 2.362 . . . . 0.0 110.538 -179.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 15.3 mm -114.46 121.17 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 102.893 -3.003 . . . . 0.0 102.893 173.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.1 t -126.43 149.11 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -177.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -123.1 124.99 44.34 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 36.1 p -83.58 -67.76 0.76 Allowed 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.771 0.796 . . . . 0.0 110.638 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.8 p30 -72.0 51.7 0.23 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.99 1.716 . . . . 0.0 113.587 -177.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.429 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 78.2 mt -80.49 54.31 2.03 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.393 1.077 . . . . 0.0 108.961 175.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 16.33 55.67 0.01 OUTLIER 'General case' 0 C--N 1.346 0.438 0 C-N-CA 129.59 3.156 . . . . 0.0 113.403 -177.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 27.56 56.47 0.08 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 127.715 2.406 . . . . 0.0 113.829 -175.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 165.68 -10.83 0.07 OUTLIER Glycine 0 CA--C 1.526 0.758 0 CA-C-O 119.321 -0.71 . . . . 0.0 113.638 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.585 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 16.2 mt-10 -78.73 82.07 4.98 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.752 1.276 . . . . 0.0 107.932 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.7 p -74.3 138.49 43.59 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.404 -0.81 . . . . 0.0 109.93 -175.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -83.65 122.29 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 123.66 0.784 . . . . 0.0 109.234 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.6 m -112.75 97.82 6.81 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.867 1.267 . . . . 0.0 109.178 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.2 pt -71.08 108.37 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 176.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -77.08 -55.47 5.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -82.88 66.08 8.32 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 49.2 m -77.6 69.72 3.88 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.81 -150.16 7.62 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 107.105 -2.398 . . . . 0.0 107.105 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 10.4 t -75.64 146.08 40.56 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 118.297 1.048 . . . . 0.0 110.556 178.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -143.71 167.3 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 124.555 1.142 . . . . 0.0 109.777 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 35.2 m-80 -113.69 163.75 14.59 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 125.236 1.414 . . . . 0.0 107.647 174.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.94 165.35 25.4 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 170.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 56.88 48.42 15.99 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.565 1.146 . . . . 0.0 111.862 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -121.96 159.18 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 173.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -126.46 153.66 44.77 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 119.228 0.922 . . . . 0.0 111.188 -176.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.7 t70 62.95 13.65 6.83 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 126.702 2.001 . . . . 0.0 113.191 -176.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.54 -37.85 78.79 Favored 'Isoleucine or valine' 0 C--O 1.233 0.207 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.7 p -117.88 129.29 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 N-CA-C 103.486 -2.783 . . . . 0.0 103.486 168.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -122.81 123.73 41.7 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.585 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.26 130.61 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 174.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -130.97 139.25 50.0 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.221 1.408 . . . . 0.0 107.269 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.3 tptm . . . . . 0 C--N 1.331 -0.215 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 -177.795 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.226 -0.168 0 N-CA-C 105.6 -2.0 . . . . 0.0 105.6 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.32 91.3 2.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.269 0 CA-C-N 118.991 0.814 . . . . 0.0 112.352 -176.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.6 t -21.95 111.34 0.14 Allowed Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 126.373 1.869 . . . . 0.0 112.282 176.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -74.11 -28.58 10.74 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.181 2.587 . . . . 0.0 118.338 -169.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.64 153.31 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 120.339 1.427 . . . . 0.0 110.496 -176.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 92.1 m -88.32 125.38 34.65 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 172.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 179.72 -170.43 41.74 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -176.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -98.63 133.93 42.27 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 11.2 tt -81.94 146.22 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 123.111 0.564 . . . . 0.0 111.148 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -144.8 137.35 13.49 Favored Pre-proline 0 C--O 1.237 0.397 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -59.58 146.18 95.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.094 1.863 . . . . 0.0 111.452 178.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.9 tp -50.04 -36.93 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 C-N-CA 125.176 1.39 . . . . 0.0 112.062 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 p -70.27 -12.08 61.34 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.034 1.734 . . . . 0.0 114.195 -179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -112.79 29.12 8.22 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.897 0.772 . . . . 0.0 111.636 -173.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.3 t -94.08 135.11 24.95 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 124.327 1.051 . . . . 0.0 109.564 178.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -65.5 50.82 0.24 Allowed 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 124.216 3.277 . . . . 0.0 115.054 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -166.77 133.89 2.49 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 120.489 -1.382 . . . . 0.0 109.815 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -59.8 -47.51 85.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.873 1.269 . . . . 0.0 113.109 -177.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 55.0 t -55.07 -54.97 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 118.596 0.634 . . . . 0.0 109.389 -178.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -61.38 -58.68 7.25 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.973 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 59.0 m -69.47 -16.0 63.38 Favored 'General case' 0 N--CA 1.461 0.082 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -177.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -88.91 -0.1 81.62 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 108.44 -1.864 . . . . 0.0 108.44 173.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 57.5 mttp 74.16 -39.88 0.44 Allowed 'General case' 0 C--N 1.346 0.438 0 C-N-CA 126.498 1.919 . . . . 0.0 111.56 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 14.9 tpt 28.9 -76.74 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 130.436 3.494 . . . . 0.0 116.461 178.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 11.0 ttt -79.24 -17.57 54.52 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.741 0.816 . . . . 0.0 113.059 -175.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.44 -135.28 2.83 Favored Glycine 0 C--N 1.338 0.643 0 CA-C-N 119.128 0.877 . . . . 0.0 112.382 -176.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -137.23 157.84 45.75 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.53 -157.77 19.15 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.764 -175.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -158.74 158.81 34.36 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.773 1.229 . . . . 0.0 108.203 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.23 132.96 52.49 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-N 118.836 0.744 . . . . 0.0 110.418 177.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.457 HD12 HG21 ' A' ' 150' ' ' VAL . 22.6 mm -117.35 107.25 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 173.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 11.9 tp -74.79 119.06 74.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 N-CA-C 102.329 -3.212 . . . . 0.0 102.329 172.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.04 153.38 22.04 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 123.095 2.53 . . . . 0.0 113.721 -168.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 79.2 p -126.18 -45.78 1.68 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.651 0.78 . . . . 0.0 112.242 178.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -64.43 -42.27 96.11 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.58 25.34 70.32 Favored Glycine 0 CA--C 1.533 1.188 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -173.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 54.0 mt -136.5 123.59 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 102.496 -3.149 . . . . 0.0 102.496 177.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 79.1 t -124.49 124.66 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 C-N-CA 124.397 1.079 . . . . 0.0 109.945 -171.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -107.12 155.8 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.126 0 C-N-CA 123.715 0.806 . . . . 0.0 109.493 176.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -61.82 139.63 95.52 Favored Pre-proline 0 N--CA 1.448 -0.551 0 C-N-CA 123.624 0.77 . . . . 0.0 110.544 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -75.31 -13.01 20.9 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 124.307 3.338 . . . . 0.0 115.03 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -148.11 161.65 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.056 0 CA-C-N 119.443 1.02 . . . . 0.0 110.213 -176.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 116.99 19.6 Favored 'General case' 0 C--O 1.237 0.402 1 N-CA-C 100.103 -4.036 . . . . 0.0 100.103 167.653 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 173.27 -177.34 45.73 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 115.544 -3.217 . . . . 0.0 116.428 -168.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.15 122.04 28.78 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.161 0.984 . . . . 0.0 112.512 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.4 mm -66.2 125.59 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 N-CA-C 103.058 -2.942 . . . . 0.0 103.058 168.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 40.7 tp -78.39 -40.75 35.23 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 119.643 1.111 . . . . 0.0 109.213 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -175.43 -163.75 0.13 Allowed 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.683 ' HA ' HG21 ' A' ' 70' ' ' ILE . 7.3 p -160.51 125.42 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 172.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.3 m-85 -68.0 145.1 97.61 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 119.291 0.951 . . . . 0.0 110.361 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -50.6 -29.27 24.59 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 123.484 2.789 . . . . 0.0 113.532 176.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.1 p -77.3 -7.91 56.76 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.756 0.822 . . . . 0.0 111.956 -178.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.8 ttmt 64.06 -11.18 0.12 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.828 1.651 . . . . 0.0 114.914 177.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 9.3 p-80 -74.72 -29.4 61.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 121.665 -0.647 . . . . 0.0 112.688 -175.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.46 176.8 11.62 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-N 118.893 0.77 . . . . 0.0 110.368 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.683 HG21 ' HA ' ' A' ' 63' ' ' VAL . 0.1 OUTLIER 157.31 -148.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.355 0 C-N-CA 130.492 3.517 . . . . 0.0 106.056 176.318 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . 0.494 ' H ' ' CG1' ' A' ' 70' ' ' ILE . . . -152.51 174.21 31.44 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 123.477 0.561 . . . . 0.0 111.804 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -141.19 176.78 8.56 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 126.486 1.914 . . . . 0.0 108.045 -178.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 30.5 mt-30 -143.08 156.02 44.73 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 103.634 -2.728 . . . . 0.0 103.634 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 69.6 p . . . . . 0 C--N 1.326 -0.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.608 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 69.0 mtm180 . . . . . 0 CA--C 1.525 0.012 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -73.45 119.77 18.14 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.7 mp -98.38 149.97 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 125.432 1.493 . . . . 0.0 108.574 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.6 tp -128.88 136.05 49.91 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 127.745 2.418 . . . . 0.0 104.849 176.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 46.0 mt -129.93 136.2 59.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -129.74 84.71 2.23 Favored 'General case' 0 N--CA 1.466 0.335 0 C-N-CA 123.481 0.712 . . . . 0.0 110.619 176.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -56.67 98.94 0.03 OUTLIER 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.528 0.731 . . . . 0.0 111.303 -179.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.75 -177.16 5.17 Favored Glycine 0 CA--C 1.531 1.059 0 C-N-CA 124.092 0.853 . . . . 0.0 112.463 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.1 mt -121.73 140.23 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 69.82 9.4 7.13 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.384 1.474 . . . . 0.0 112.313 -177.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -75.6 -34.41 60.62 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 126.358 1.863 . . . . 0.0 108.156 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.5 p -54.32 -46.79 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 CA-C-N 113.468 -1.696 . . . . 0.0 108.028 171.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -62.05 -39.21 91.57 Favored 'General case' 0 N--CA 1.455 -0.198 0 C-N-CA 124.491 1.116 . . . . 0.0 109.425 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.99 3.17 5.67 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.934 1.694 . . . . 0.0 111.322 177.14 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 48.13 32.48 3.02 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 126.068 1.747 . . . . 0.0 112.993 178.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.74 28.29 60.07 Favored Glycine 0 CA--C 1.535 1.323 0 O-C-N 122.009 -0.432 . . . . 0.0 112.828 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 51.9 mt-10 -72.4 91.04 1.33 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.963 1.381 . . . . 0.0 108.843 178.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 6.12 4.24 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 126.745 2.117 . . . . 0.0 111.391 -176.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.529 ' CD1' HG12 ' A' ' 115' ' ' VAL . 14.6 m-30 -103.27 131.12 50.57 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.187 1.395 . . . . 0.0 108.477 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 14.3 m -119.98 122.79 41.95 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 126.245 1.818 . . . . 0.0 107.159 -179.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.1 p -99.32 124.63 44.57 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.612 0.765 . . . . 0.0 109.957 -176.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -90.59 -48.81 6.85 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.566 1.546 . . . . 0.0 111.294 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.43 130.76 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 C-N-CA 117.149 -1.82 . . . . 0.0 107.283 175.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 71.1 m -94.51 55.1 1.9 Allowed 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 102.743 -3.058 . . . . 0.0 102.743 168.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.588 0.4 OUTLIER 43.58 -77.63 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.774 0 C-N-CA 130.627 3.571 . . . . 0.0 113.465 -167.57 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.4 35.6 36.2 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 125.108 1.337 . . . . 0.0 110.45 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.373 4.1 p30 4.38 -106.6 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 130.049 3.34 . . . . 0.0 119.313 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -33.62 111.94 0.12 Allowed 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 130.993 3.717 . . . . 0.0 119.047 -169.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.363 27.4 m 48.61 68.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 129.08 2.952 . . . . 0.0 118.036 173.487 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 139.22 27.48 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 167.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -90.37 -145.04 0.03 OUTLIER 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.56 2.84 . . . . 0.0 108.302 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -70.81 52.05 0.92 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 124.875 1.226 . . . . 0.0 113.885 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.7 tp60 -61.83 -22.25 65.34 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 125.858 1.663 . . . . 0.0 113.707 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt 108.1 111.84 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 130.103 3.361 . . . . 0.0 107.971 -176.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 73.5 mt -80.25 -53.2 6.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 23.0 mt -143.04 163.94 31.44 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 123.743 0.817 . . . . 0.0 111.721 -174.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -128.19 135.33 49.58 Favored 'General case' 0 CA--C 1.515 -0.4 1 N-CA-C 99.81 -4.145 . . . . 0.0 99.81 166.707 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . 0.529 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -144.92 121.28 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -166.303 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -70.53 64.98 0.29 Allowed 'General case' 0 C--O 1.234 0.246 0 C-N-CA 125.569 1.548 . . . . 0.0 113.019 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 88.5 mt -40.81 -54.27 2.7 Favored 'General case' 0 C--O 1.226 -0.165 0 C-N-CA 124.91 1.284 . . . . 0.0 111.909 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -49.81 -41.36 44.57 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.485 1.114 . . . . 0.0 113.879 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.43 -35.01 15.4 Favored 'General case' 0 C--O 1.23 0.056 0 C-N-CA 122.454 0.302 . . . . 0.0 111.496 -177.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.9 t -67.21 -50.61 61.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 O-C-N 121.764 -0.585 . . . . 0.0 109.529 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.347 48.5 pttt -40.11 -57.78 2.61 Favored Pre-proline 0 CA--C 1.539 0.55 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.91 -21.85 43.06 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 122.509 2.139 . . . . 0.0 113.132 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -97.43 6.89 47.51 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 118.387 -0.816 . . . . 0.0 112.655 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 30.2 m -136.49 151.14 72.39 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-N 119.898 1.226 . . . . 0.0 110.262 178.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.79 -25.16 12.59 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.535 2.157 . . . . 0.0 112.206 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.9 m -158.24 128.09 5.95 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 119.038 0.835 . . . . 0.0 111.27 -177.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.32 -0.23 57.31 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.823 1.249 . . . . 0.0 110.72 176.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 82.6 mmm -50.37 103.0 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 126.221 1.808 . . . . 0.0 109.754 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 68.6 m -99.09 117.39 64.27 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 123.814 0.845 . . . . 0.0 109.091 -177.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.56 139.49 1.87 Allowed 'Trans proline' 0 N--CA 1.442 -1.556 0 C-N-CA 123.211 2.607 . . . . 0.0 108.914 178.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.51 HD12 ' N ' ' A' ' 131' ' ' ILE . 1.1 mp -113.08 117.82 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 N-CA-C 100.523 -3.88 . . . . 0.0 100.523 171.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -126.01 158.13 35.55 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.714 ' HB2' HD21 ' A' ' 136' ' ' LEU . 32.5 m-85 -134.1 137.49 44.62 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 103.751 -2.685 . . . . 0.0 103.751 -176.534 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -92.46 -73.41 0.55 Allowed 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 119.223 0.92 . . . . 0.0 109.216 -179.195 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -75.96 68.79 2.5 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.714 HD21 ' HB2' ' A' ' 133' ' ' PHE . 2.9 mm? -78.6 66.0 4.01 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 171.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 31.46 47.45 0.06 Allowed 'General case' 0 C--N 1.343 0.299 0 C-N-CA 127.831 2.452 . . . . 0.0 111.717 -173.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 29.61 61.22 0.16 Allowed 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 128.243 2.617 . . . . 0.0 114.343 -177.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.38 -14.78 0.22 Allowed Glycine 0 CA--C 1.525 0.668 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.968 177.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.563 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 44.2 mm-40 -80.4 123.66 28.22 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.201 1.001 . . . . 0.0 109.638 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.2 p -89.78 143.28 26.93 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.925 0.89 . . . . 0.0 109.257 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -89.94 113.23 25.8 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 C-N-CA 123.664 0.786 . . . . 0.0 109.874 -178.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 36.2 m -106.74 98.85 8.47 Favored 'General case' 0 C--N 1.34 0.178 0 C-N-CA 124.333 1.053 . . . . 0.0 110.576 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 3.2 pt -64.07 128.74 26.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 175.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -98.09 -34.71 10.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.064 0.946 . . . . 0.0 112.223 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.567 ' HB2' HG23 ' A' ' 157' ' ' ILE . . . -70.98 100.72 2.03 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 119.773 1.169 . . . . 0.0 109.915 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 1.2 m -79.49 51.26 1.22 Allowed 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 176.2 -145.76 7.7 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -175.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 47.1 t -73.92 132.49 42.52 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 122.203 -0.586 . . . . 0.0 111.216 -178.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.457 HG21 HD12 ' A' ' 45' ' ' ILE . 18.4 m -89.7 157.15 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 174.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.78 152.44 49.27 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.5 mtp180 -58.29 150.07 22.82 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 122.685 0.394 . . . . 0.0 111.603 177.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 63.03 1.73 0.91 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 126.412 1.885 . . . . 0.0 115.339 172.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 58.9 mm-40 -70.13 119.32 14.15 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 119.569 1.077 . . . . 0.0 108.635 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -81.99 125.86 31.28 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 121.369 0.604 . . . . 0.0 112.242 -176.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.9 t0 70.08 27.9 4.19 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 128.472 2.709 . . . . 0.0 115.459 175.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.567 HG23 ' HB2' ' A' ' 146' ' ' ALA 0.26 1.7 mp -71.27 -8.89 12.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 CA-C-O 121.306 0.575 . . . . 0.0 110.264 178.257 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.7 p -122.39 120.15 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 102.75 -3.056 . . . . 0.0 102.75 168.385 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 5.5 mtpm? -108.13 128.42 54.68 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.563 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.45 133.14 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -145.08 -174.87 4.48 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 125.078 1.351 . . . . 0.0 108.716 -177.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 49.3 mtmt . . . . . 0 C--O 1.233 0.201 0 C-N-CA 125.307 1.443 . . . . 0.0 107.31 174.981 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.529 0.163 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.9 m -125.44 84.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-N 118.61 0.641 . . . . 0.0 112.65 -176.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 21.9 t -19.86 122.01 0.09 OUTLIER Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 129.373 3.069 . . . . 0.0 112.553 177.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -71.48 -37.35 5.65 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 117.632 2.128 . . . . 0.0 117.632 -171.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.3 151.64 18.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 119.717 1.144 . . . . 0.0 111.387 -175.109 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.1 m -88.46 146.38 25.24 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.42 -128.6 2.17 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -127.57 138.64 52.94 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.007 1.323 . . . . 0.0 108.141 178.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.8 tt -106.51 139.71 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 16.6 m-70 -136.94 155.55 76.27 Favored Pre-proline 0 N--CA 1.453 -0.315 0 C-N-CA 125.628 1.571 . . . . 0.0 108.329 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 146.08 84.25 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 N-CA-C 107.916 -1.609 . . . . 0.0 107.916 172.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -56.79 -21.31 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.534 -1.666 . . . . 0.0 113.119 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.0 p -53.42 -32.51 50.03 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.562 0.745 . . . . 0.0 111.124 175.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -77.11 -6.1 51.55 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.903 0.881 . . . . 0.0 113.075 -175.083 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.3 t -77.84 132.6 67.53 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 119.228 0.922 . . . . 0.0 110.171 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -77.32 58.12 6.14 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 123.692 2.928 . . . . 0.0 111.176 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -168.83 110.25 0.51 Allowed 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 20.0 mp0 -37.42 -44.8 0.66 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 127.486 2.314 . . . . 0.0 113.553 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 95.4 t -50.26 -43.82 22.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 123.414 0.686 . . . . 0.0 110.16 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -87.3 -48.99 7.55 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.757 0.823 . . . . 0.0 109.52 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.12 -40.99 34.52 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.03 13.93 60.22 Favored Glycine 0 C--N 1.338 0.676 0 CA-C-O 118.938 -0.923 . . . . 0.0 111.853 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 37.1 mttp 70.31 -34.05 0.28 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.757 1.623 . . . . 0.0 114.584 179.106 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.5 ttm 24.38 -61.6 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 1 C-N-CA 132.029 4.131 . . . . 0.0 118.203 178.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.11 -22.72 48.47 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.944 0.898 . . . . 0.0 111.59 -177.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.02 -128.89 1.3 Allowed Glycine 0 C--N 1.336 0.535 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . 0.418 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.0 t0 -131.4 159.25 38.53 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 171.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.4 -166.18 34.25 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.016 -1.088 . . . . 0.0 113.461 -176.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 p90 -144.38 160.92 40.23 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 124.534 1.134 . . . . 0.0 109.714 178.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -105.95 118.46 36.67 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.525 1.53 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.6 mm -98.46 130.3 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 172.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 tt -101.11 108.01 52.69 Favored Pre-proline 0 N--CA 1.448 -0.541 1 N-CA-C 99.604 -4.221 . . . . 0.0 99.604 170.105 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -85.91 148.49 9.5 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 122.617 2.211 . . . . 0.0 114.958 -168.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.5 p -113.51 -51.24 2.81 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.974 1.31 . . . . 0.0 108.685 174.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -73.56 122.4 22.17 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.515 0.326 . . . . 0.0 111.328 179.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.22 41.07 2.6 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 173.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 81.0 mt -136.22 113.78 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 103.413 -2.81 . . . . 0.0 103.413 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.2 t -119.54 119.62 61.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 C-N-CA 123.769 0.828 . . . . 0.0 109.87 -172.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.3 m -99.87 164.7 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 CA-C-O 121.159 0.504 . . . . 0.0 109.935 176.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.5 m -76.46 131.93 73.66 Favored Pre-proline 0 N--CA 1.45 -0.444 0 CA-C-O 117.576 -1.202 . . . . 0.0 108.423 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -60.96 -31.79 91.79 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.002 2.468 . . . . 0.0 110.783 177.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . 0.453 HG22 HD12 ' A' ' 80' ' ' ILE . 10.8 m -151.11 150.09 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 102.925 -2.991 . . . . 0.0 102.925 173.389 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.0 tpt180 -101.25 -93.74 0.29 Allowed 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 101.176 -3.638 . . . . 0.0 101.176 169.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.75 2.5 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 107.405 -2.278 . . . . 0.0 107.405 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 125.23 1.91 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 167.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.5 mm -62.92 128.62 25.16 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 169.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.05 -49.04 11.38 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 178.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -175.88 151.15 1.08 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.434 0.294 . . . . 0.0 111.361 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.5 m -113.17 126.23 70.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 169.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.446 ' CG ' ' HB3' ' A' ' 69' ' ' ALA . 5.7 m-85 -65.73 156.63 82.51 Favored Pre-proline 0 CA--C 1.534 0.333 0 O-C-N 121.426 -0.796 . . . . 0.0 110.03 -176.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -48.44 -43.4 32.84 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.114 2.543 . . . . 0.0 112.952 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.0 p -79.57 3.87 17.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.842 1.257 . . . . 0.0 112.761 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.18 -21.9 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 128.525 2.73 . . . . 0.0 116.84 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.87 -31.54 72.75 Favored 'General case' 0 C--O 1.227 -0.103 0 CA-C-N 119.483 1.038 . . . . 0.0 111.884 -174.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . 0.446 ' HB3' ' CG ' ' A' ' 64' ' ' PHE . . . -103.6 135.67 44.74 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.091 0.956 . . . . 0.0 110.081 -179.365 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.9 mt -140.06 146.54 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -125.32 136.74 9.95 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 125.862 1.696 . . . . 0.0 109.076 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.8 mp -137.86 163.82 30.5 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 124.959 1.304 . . . . 0.0 110.409 -177.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 70.8 mt-30 -145.38 125.23 13.46 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.606 ' HG ' ' N ' ' A' ' 78' ' ' ARG . 57.2 p . . . . . 0 CA--C 1.538 0.519 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 175.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . 0.606 ' N ' ' HG ' ' A' ' 74' ' ' SER . 0.0 OUTLIER . . . . . 0 N--CA 1.454 -0.261 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 . . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -93.09 126.8 38.36 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 125.589 1.556 . . . . 0.0 106.932 177.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . 0.453 HD12 HG22 ' A' ' 56' ' ' VAL . 5.8 mt -125.03 143.45 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.1 0.96 . . . . 0.0 111.205 -172.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -122.89 130.74 53.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.219 2.208 . . . . 0.0 105.413 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.5 mt -123.49 146.73 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 C-N-CA 124.767 1.227 . . . . 0.0 108.019 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -134.33 131.8 38.77 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 105.283 -2.117 . . . . 0.0 105.283 171.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -103.05 106.21 16.68 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 124.774 1.229 . . . . 0.0 107.879 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.1 -169.82 34.94 Favored Glycine 0 CA--C 1.534 1.229 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 29.3 mm -109.78 -84.42 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.05 0 CA-C-O 123.224 1.488 . . . . 0.0 110.469 -178.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.41 4.82 0.48 Allowed 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 126.432 1.893 . . . . 0.0 113.033 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.22 -30.24 71.11 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.438 1.895 . . . . 0.0 107.573 175.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.55 -46.98 89.75 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 CA-C-N 114.374 -1.285 . . . . 0.0 108.348 174.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.68 -41.02 98.21 Favored 'General case' 0 C--O 1.227 -0.112 0 C-N-CA 125.036 1.334 . . . . 0.0 109.017 177.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -65.05 -8.41 16.19 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 125.69 1.596 . . . . 0.0 110.943 176.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? 52.54 34.14 14.91 Favored 'General case' 0 C--N 1.343 0.315 0 C-N-CA 125.301 1.441 . . . . 0.0 111.823 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.18 21.07 61.33 Favored Glycine 0 CA--C 1.536 1.37 0 CA-C-O 119.67 -0.517 . . . . 0.0 112.875 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.84 90.18 1.1 Allowed 'General case' 0 C--N 1.341 0.227 0 CA-C-N 119.388 1.594 . . . . 0.0 108.625 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 141.83 -2.41 1.9 Allowed Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.484 1.992 . . . . 0.0 111.591 -175.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -97.86 103.53 15.47 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 125.57 1.548 . . . . 0.0 111.063 -176.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 50.0 m -84.36 98.15 9.87 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.636 -2.727 . . . . 0.0 103.636 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 43.0 p -79.59 121.37 25.18 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 121.793 -0.567 . . . . 0.0 109.983 -177.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -79.94 -52.82 7.38 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.524 1.13 . . . . 0.0 109.361 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 24.3 m -82.17 129.0 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.121 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.43 175.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 67.5 m -98.21 56.69 1.2 Allowed 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 102.397 -3.186 . . . . 0.0 102.397 169.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.312 7.8 pt-20 36.16 61.08 0.8 Allowed 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 111.09 -2.777 . . . . 0.0 110.734 -167.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.42 55.08 2.41 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 111.108 -2.769 . . . . 0.0 109.834 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.35 3.3 p30 1.81 -110.63 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 130.997 3.719 . . . . 0.0 118.566 -178.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 45.0 mmm-85 -44.94 142.46 1.81 Allowed 'General case' 0 N--CA 1.425 -1.698 1 N-CA-C 122.56 4.281 . . . . 0.0 122.56 -167.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.722 4.7 m 36.95 -55.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.428 2 N-CA-C 130.351 7.167 . . . . 0.0 130.351 173.971 . . . . . . . . 3 2 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.52 121.98 86.29 Favored Pre-proline 0 C--N 1.317 -0.831 0 C-N-CA 116.472 -2.091 . . . . 0.0 113.172 -165.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -69.84 172.31 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 125.021 3.814 . . . . 0.0 113.081 -169.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 55.81 19.51 21.67 Favored Glycine 0 CA--C 1.528 0.895 0 C-N-CA 124.582 1.087 . . . . 0.0 115.21 176.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -61.6 143.22 56.4 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 118.488 1.144 . . . . 0.0 109.328 177.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -69.96 119.61 14.43 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.2 mt -80.85 -51.43 8.61 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -143.28 155.17 44.41 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 -174.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -122.39 125.76 46.57 Favored 'General case' 0 CA--C 1.514 -0.425 1 N-CA-C 98.305 -4.702 . . . . 0.0 98.305 166.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.36 129.33 56.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 114.691 -1.141 . . . . 0.0 112.165 -165.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -73.22 67.95 0.98 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.798 0.839 . . . . 0.0 110.397 -179.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.8 mt -52.59 -41.56 63.73 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-O 119.301 -0.38 . . . . 0.0 110.583 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -49.45 -44.46 45.63 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 123.507 0.723 . . . . 0.0 112.272 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.59 -35.33 19.51 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 117.933 0.333 . . . . 0.0 111.841 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 53.9 t -64.59 -49.69 79.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 121.537 -0.727 . . . . 0.0 110.567 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.357 0.0 OUTLIER -47.48 -53.84 26.7 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 116.943 2.201 . . . . 0.0 116.943 -177.557 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -60.9 -25.64 81.71 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.231 1.954 . . . . 0.0 112.323 177.151 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -79.92 -50.15 10.87 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 118.651 0.66 . . . . 0.0 110.617 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 18.7 m -79.72 142.83 57.51 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.721 -177.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.33 -15.81 22.34 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.48 2.12 . . . . 0.0 111.717 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 16.6 m -156.76 128.41 7.13 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.07 0.948 . . . . 0.0 108.907 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.2 tp -94.73 9.91 37.1 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.403 1.481 . . . . 0.0 111.54 -178.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 74.1 mmm -53.42 118.75 4.09 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 34.0 m -113.94 86.96 11.89 Favored Pre-proline 0 N--CA 1.445 -0.678 0 C-N-CA 126.168 1.787 . . . . 0.0 107.752 -177.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.477 ' C ' HD12 ' A' ' 131' ' ' ILE . 60.9 Cg_endo -83.25 149.72 13.41 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.814 1.676 . . . . 0.0 112.403 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.477 HD12 ' C ' ' A' ' 130' ' ' PRO . 1.1 mp -122.13 130.3 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 103.494 -2.78 . . . . 0.0 103.494 174.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -126.56 143.55 39.67 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 C-N-CA 125.751 1.62 . . . . 0.0 106.93 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -117.15 123.56 47.02 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 64.7 p -83.96 -72.22 0.47 Allowed 'General case' 0 C--N 1.335 -0.06 0 CA-C-O 121.504 0.669 . . . . 0.0 111.046 -171.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p30 -71.7 52.63 0.22 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 126.091 1.756 . . . . 0.0 113.113 -178.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.418 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 38.8 mt -74.35 63.68 1.06 Allowed 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.324 1.45 . . . . 0.0 109.38 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 17.4 57.69 0.01 OUTLIER 'General case' 0 C--N 1.348 0.503 0 C-N-CA 129.509 3.124 . . . . 0.0 112.209 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 23.88 57.43 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.108 2.963 . . . . 0.0 114.371 -174.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.26 -5.51 0.12 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-O 119.006 -0.886 . . . . 0.0 113.891 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.689 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 29.7 mt-10 -75.49 93.14 2.94 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 119.254 1.527 . . . . 0.0 108.796 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 34.1 p -76.65 130.46 37.83 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.836 0.827 . . . . 0.0 109.421 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -83.6 100.35 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 14.8 m -98.71 102.28 13.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.971 1.308 . . . . 0.0 110.578 -175.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 8.4 pt -66.95 146.3 13.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 O-C-N 121.909 -0.494 . . . . 0.0 110.363 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -119.13 -45.5 2.55 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.976 1.71 . . . . 0.0 110.359 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -66.87 79.94 0.11 Allowed 'General case' 0 C--O 1.224 -0.244 0 CA-C-O 121.45 0.643 . . . . 0.0 109.929 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.3 m -77.82 65.82 3.36 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.805 0.842 . . . . 0.0 109.848 -176.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 162.48 -128.69 1.92 Allowed Glycine 0 C--N 1.336 0.554 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -177.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.2 t -66.7 157.92 31.46 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.188 178.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.58 HG23 HG21 ' A' ' 157' ' ' ILE . 2.9 p -138.96 153.25 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 C-N-CA 125.604 1.561 . . . . 0.0 107.684 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -125.93 150.39 48.01 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 125.222 1.409 . . . . 0.0 108.379 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 35.8 ptt85 -74.37 162.07 29.23 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 176.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 61.69 55.0 2.81 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 126.262 1.825 . . . . 0.0 111.881 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . 0.461 ' CB ' HD13 ' A' ' 157' ' ' ILE . 33.2 mm-40 -146.64 155.78 42.7 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.91 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -103.79 -70.16 0.78 Allowed 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 119.862 1.21 . . . . 0.0 111.188 176.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -50.12 5.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 130.4 3.48 . . . . 0.0 118.047 -172.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.58 HG21 HG23 ' A' ' 150' ' ' VAL . 1.7 mp -76.86 -32.04 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 129.785 3.234 . . . . 0.0 106.262 173.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.58 145.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 127.128 2.171 . . . . 0.0 106.59 175.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 4.6 mmpt? -132.42 125.92 31.88 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 178.164 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.689 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -78.88 125.93 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 172.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -138.44 163.64 31.41 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.45 1.1 . . . . 0.0 109.502 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 65.6 mttm . . . . . 0 C--O 1.231 0.129 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 175.357 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.465 0.305 0 N-CA-C 114.32 1.23 . . . . 0.0 114.32 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.7 m -83.05 98.15 4.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 C-N-CA 123.95 0.9 . . . . 0.0 111.128 175.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 34.7 t -36.07 121.18 0.71 Allowed Pre-proline 0 CA--C 1.547 0.84 0 C-N-CA 126.686 1.994 . . . . 0.0 111.163 174.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -76.2 -38.95 0.95 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.803 2.335 . . . . 0.0 117.773 -173.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.13 146.57 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 CA-C-N 120.245 1.384 . . . . 0.0 110.395 -175.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.8 m -78.83 135.44 37.05 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 173.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.18 -167.97 41.01 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 -178.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -96.17 135.09 38.45 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.9 tt -97.19 143.07 13.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 123.01 0.524 . . . . 0.0 109.994 -179.256 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -145.29 156.25 53.97 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 178.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -62.54 155.33 58.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 N-CA-C 107.097 -1.924 . . . . 0.0 107.097 171.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 tt -62.65 -34.36 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.468 -178.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 m -71.03 74.05 0.63 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.685 1.194 . . . . 0.0 109.01 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -179.64 -34.58 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 127.994 2.518 . . . . 0.0 108.992 -174.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.423 ' HA ' ' HD3' ' A' ' 30' ' ' PRO . 91.0 t -58.47 127.66 81.84 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 117.63 -1.176 . . . . 0.0 111.025 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 29' ' ' VAL . 71.2 Cg_exo -57.57 59.68 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.191 1 C-N-CA 126.381 4.72 . . . . 0.0 115.778 176.407 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -171.43 119.65 0.47 Allowed 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 125.953 1.701 . . . . 0.0 107.707 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 6.8 pm0 -54.48 -44.8 72.94 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.429 1.092 . . . . 0.0 113.817 -177.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 40.7 t -56.49 -56.84 11.57 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -178.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -62.64 -52.85 61.72 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.3 t -50.83 -42.36 58.45 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.951 0.9 . . . . 0.0 113.394 -177.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -89.42 11.59 69.39 Favored Glycine 0 N--CA 1.446 -0.634 0 CA-C-O 118.198 -1.334 . . . . 0.0 112.022 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 58.5 mttm 72.35 -36.33 0.35 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.564 1.682 . . . . 0.0 113.242 -179.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER 28.68 -78.77 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 130.398 3.479 . . . . 0.0 116.226 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.5 ttp -83.17 -7.3 59.64 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -174.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.63 -138.19 2.75 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 38.9 t0 -140.11 158.7 43.63 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 172.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.77 -168.75 37.83 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 119.937 -1.125 . . . . 0.0 113.334 -176.213 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -141.68 156.83 45.61 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.635 1.174 . . . . 0.0 109.448 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.82 127.09 52.51 Favored 'General case' 0 CA--C 1.51 -0.587 0 C-N-CA 124.282 1.033 . . . . 0.0 109.876 179.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 28.4 mm -107.84 128.53 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 104.611 -2.366 . . . . 0.0 104.611 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.7 tt -96.97 102.97 13.31 Favored Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 172.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -63.37 157.16 51.88 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.951 3.101 . . . . 0.0 116.585 -169.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.4 p -138.84 -51.13 0.55 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.856 1.263 . . . . 0.0 109.528 173.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -80.14 130.67 35.41 Favored 'General case' 0 C--N 1.342 0.263 0 O-C-N 121.926 -0.484 . . . . 0.0 110.455 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -66.42 -24.35 72.24 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.824 -0.911 . . . . 0.0 110.824 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . 0.404 ' N ' HD12 ' A' ' 51' ' ' ILE . 2.5 mp -78.2 108.52 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 C-N-CA 124.585 1.154 . . . . 0.0 107.923 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.22 116.65 52.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 125.212 1.405 . . . . 0.0 108.14 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.5 m -93.41 155.68 3.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.147 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 47.1 m -73.17 139.94 79.6 Favored Pre-proline 0 N--CA 1.448 -0.574 0 CA-C-O 118.6 -0.714 . . . . 0.0 111.144 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -64.17 -35.9 50.01 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 N-CA-C 107.609 -1.727 . . . . 0.0 107.609 171.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.6 p -175.98 150.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 129.798 3.239 . . . . 0.0 103.68 175.346 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.446 ' CZ ' ' HB3' ' A' ' 110' ' ' GLN . 43.1 mtm180 -112.14 -75.93 0.6 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.19 -68.38 2.35 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.49 128.32 8.03 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 104.228 -2.508 . . . . 0.0 104.228 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.1 mm -61.13 130.47 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 7.3 tt -77.45 -51.96 9.91 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 104.601 -2.37 . . . . 0.0 104.601 178.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 50.9 t30 179.62 165.5 1.1 Allowed 'General case' 0 CA--C 1.527 0.081 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.462 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.7 m -152.35 129.09 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 C-N-CA 126.239 1.816 . . . . 0.0 106.168 174.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -47.49 146.47 3.46 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-O 118.744 -0.646 . . . . 0.0 111.092 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -50.0 -33.74 35.44 Favored 'Trans proline' 0 CA--C 1.534 0.525 0 C-N-CA 123.534 2.823 . . . . 0.0 113.796 176.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 37.0 p -77.67 -7.98 57.24 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 124.574 1.15 . . . . 0.0 111.993 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 68.38 13.4 9.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.205 1.802 . . . . 0.0 113.641 178.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.445 ' ND1' ' N ' ' A' ' 89' ' ' VAL . 0.0 OUTLIER -77.91 -23.62 48.61 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 119.358 0.981 . . . . 0.0 111.626 -179.333 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -167.12 -173.22 2.25 Favored 'General case' 0 C--O 1.225 -0.22 0 CA-C-N 120.12 1.327 . . . . 0.0 110.777 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 63' ' ' VAL 1.06 1.9 mt 130.97 -139.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.192 1 C-N-CA 136.95 6.1 . . . . 0.0 110.372 176.382 . . . . . . . . 4 3 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -157.04 170.13 34.28 Favored Glycine 0 CA--C 1.531 1.061 0 N-CA-C 118.229 2.052 . . . . 0.0 118.229 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 18.1 mt -124.03 174.35 7.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 128.199 2.6 . . . . 0.0 109.085 -177.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -126.28 -165.42 1.44 Allowed 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 60.3 p . . . . . 0 N--CA 1.44 -0.957 0 C-N-CA 125.611 1.564 . . . . 0.0 107.39 176.776 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 . . . . . 0 CA--C 1.533 0.301 0 CA-C-O 120.991 0.424 . . . . 0.0 110.563 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -92.85 131.58 37.76 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 127.642 2.377 . . . . 0.0 105.605 -179.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 34.1 mt -123.04 119.62 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 O-C-N 123.436 0.46 . . . . 0.0 112.056 -173.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 6.0 tp -89.09 139.63 30.27 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 171.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 72.8 mt -130.33 132.49 64.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -123.75 84.47 2.28 Favored 'General case' 0 C--O 1.223 -0.298 0 O-C-N 123.526 0.517 . . . . 0.0 111.77 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.52 104.75 0.24 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.236 0.614 . . . . 0.0 111.932 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.76 -177.93 7.64 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 122.092 0.829 . . . . 0.0 112.323 179.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.9 mm -123.92 146.54 29.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 174.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 37.2 t70 50.77 32.29 6.94 Favored 'General case' 0 CA--C 1.543 0.702 0 CA-C-O 121.91 0.862 . . . . 0.0 111.295 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.8 m -97.85 -25.07 15.16 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.803 2.041 . . . . 0.0 107.289 -177.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.445 ' N ' ' ND1' ' A' ' 68' ' ' HIS . 4.0 p -53.6 -43.71 55.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 C-N-CA 126.258 1.823 . . . . 0.0 107.634 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -58.73 -26.2 63.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.801 2.04 . . . . 0.0 111.898 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.14 -11.21 60.45 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.892 1.677 . . . . 0.0 109.608 177.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp 51.55 29.66 5.69 Favored 'General case' 0 C--N 1.342 0.244 0 C-N-CA 126.325 1.85 . . . . 0.0 112.38 178.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.22 26.71 50.82 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-O 118.702 -1.054 . . . . 0.0 112.53 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.266 0.2 OUTLIER -59.15 -18.25 34.38 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.851 1.826 . . . . 0.0 115.478 -176.776 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -122.3 21.17 7.8 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 126.11 1.814 . . . . 0.0 110.849 177.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.483 ' HA ' HG12 ' A' ' 115' ' ' VAL . 3.5 m-85 -106.05 85.2 2.17 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 118.089 0.944 . . . . 0.0 111.046 -177.378 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.66 101.11 5.61 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.326 -2.472 . . . . 0.0 104.326 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.8 t -87.01 157.82 19.37 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-O 121.183 0.516 . . . . 0.0 110.605 -179.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -115.59 5.23 14.31 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.038 1.735 . . . . 0.0 112.224 -175.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.5 m -129.42 137.06 57.9 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.147 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 68.6 m -107.03 49.31 0.81 Allowed 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 169.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.299 1.3 pm0 -2.68 70.98 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 132.184 4.194 . . . . 0.0 116.644 -172.661 . . . . . . . . 3 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -85.99 46.44 3.62 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 112.845 -1.979 . . . . 0.0 109.882 176.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 3.36 52.08 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.21 0 C-N-CA 131.356 3.863 . . . . 0.0 120.897 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -168.74 121.78 0.82 Allowed 'General case' 0 C--N 1.312 -1.022 1 C-N-CA 133.475 4.71 . . . . 0.0 107.051 176.553 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -167.52 136.72 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 118.784 0.72 . . . . 0.0 111.073 -172.332 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -78.74 149.99 75.11 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 118.146 -0.93 . . . . 0.0 109.853 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -55.67 175.55 0.2 Allowed 'Trans proline' 0 CA--C 1.542 0.896 1 C-N-CA 125.696 4.264 . . . . 0.0 117.837 -174.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 51.85 -7.65 0.01 OUTLIER Glycine 0 C--N 1.344 0.985 0 C-N-CA 129.28 3.324 . . . . 0.0 119.238 175.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 57' ' ' ARG . 25.0 tt0 -61.63 160.59 11.2 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 120.31 2.055 . . . . 0.0 110.128 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -67.04 140.64 57.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 122.94 0.496 . . . . 0.0 109.76 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 94.5 mt -108.63 -37.39 5.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 124.246 1.018 . . . . 0.0 110.088 176.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . 0.447 ' HB3' HG13 ' A' ' 115' ' ' VAL . 22.2 mt -143.23 146.99 34.14 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.61 0.764 . . . . 0.0 110.208 -176.38 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -132.94 68.49 1.5 Allowed 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . 0.483 HG12 ' HA ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -79.45 127.03 39.38 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 CA-C-N 109.053 -3.703 . . . . 0.0 110.621 -171.755 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -76.19 67.64 2.5 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.008 0.923 . . . . 0.0 109.179 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -48.61 -39.37 23.69 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.651 0.78 . . . . 0.0 111.727 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -54.04 -42.18 68.89 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.113 0.565 . . . . 0.0 112.201 178.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.07 -33.29 18.35 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.744 0.417 . . . . 0.0 111.39 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 79.5 t -63.31 -53.91 39.66 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.372 17.8 pttp -40.45 -58.23 2.56 Favored Pre-proline 0 CA--C 1.541 0.611 0 N-CA-C 116.97 2.211 . . . . 0.0 116.97 -176.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -58.53 -20.1 47.85 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.436 2.091 . . . . 0.0 113.36 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -100.03 8.26 44.11 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 118.301 -0.857 . . . . 0.0 112.674 -177.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 33.3 m -133.9 147.67 65.12 Favored Pre-proline 0 CA--C 1.535 0.382 0 CA-C-N 119.986 1.266 . . . . 0.0 109.856 178.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -71.04 -36.55 7.29 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.98 2.453 . . . . 0.0 111.622 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 62.3 p -151.45 121.85 7.33 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -177.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.0 tp -79.88 -2.95 45.88 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.136 1.374 . . . . 0.0 111.904 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -44.88 117.92 1.47 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 124.842 1.257 . . . . 0.0 110.465 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.6 m -117.7 107.47 44.46 Favored Pre-proline 0 N--CA 1.447 -0.581 0 C-N-CA 124.034 0.933 . . . . 0.0 108.692 -178.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -91.53 143.59 3.01 Favored 'Trans proline' 0 N--CA 1.441 -1.617 0 C-N-CA 123.039 2.492 . . . . 0.0 110.249 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 17.2 mm -113.9 116.82 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.5 t -121.48 123.61 69.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 C-N-CA 125.006 1.323 . . . . 0.0 108.632 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -95.9 117.66 31.04 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 178.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 52.6 p -84.1 -73.91 0.4 Allowed 'General case' 0 C--O 1.23 0.045 0 CA-C-O 121.467 0.651 . . . . 0.0 111.563 -171.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p-10 -73.08 57.61 0.47 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.824 1.65 . . . . 0.0 111.38 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 20.5 mt -72.01 66.72 0.6 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.918 1.687 . . . . 0.0 109.007 177.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.91 47.68 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 129.179 2.992 . . . . 0.0 112.488 -176.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 29.34 55.48 0.12 Allowed 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 127.81 2.444 . . . . 0.0 113.34 -174.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.43 -5.29 0.05 OUTLIER Glycine 0 CA--C 1.526 0.738 0 CA-C-O 118.896 -0.946 . . . . 0.0 114.332 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.654 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 21.0 mt-10 -83.83 139.87 32.39 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.185 1.492 . . . . 0.0 109.83 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 45.4 p -110.91 136.58 49.72 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -91.28 101.93 12.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -178.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 20.3 m -100.01 105.83 17.54 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 123.96 0.904 . . . . 0.0 110.493 -176.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 20.1 pt -67.05 139.71 20.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.799 -0.563 . . . . 0.0 110.252 177.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.6 mmpt? -101.83 -41.42 6.52 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 125.155 1.382 . . . . 0.0 108.864 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.39 86.9 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.208 1.003 . . . . 0.0 112.783 -176.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.5 m -80.73 54.68 2.18 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 177.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.49 -178.65 37.31 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -177.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 35.4 t -52.07 146.8 8.22 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.567 0.747 . . . . 0.0 112.416 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.9 m -115.47 159.55 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 125.207 1.403 . . . . 0.0 109.827 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.8 157.3 30.05 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.75 1.22 . . . . 0.0 108.321 175.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.47 158.86 28.45 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.473 0.654 . . . . 0.0 110.738 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 64.58 -10.11 0.16 Allowed 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 126.137 1.775 . . . . 0.0 114.868 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.67 149.81 38.4 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.933 1.242 . . . . 0.0 109.571 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -120.54 158.14 27.94 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 29.9 t0 63.89 26.56 14.29 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 128.074 2.549 . . . . 0.0 112.009 -174.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -82.87 -22.75 8.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 C-N-CA 123.825 0.85 . . . . 0.0 108.825 176.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.3 p -142.36 149.66 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 127.897 2.479 . . . . 0.0 106.477 175.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -131.81 127.47 36.7 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 174.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.654 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.54 122.0 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 170.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -105.52 176.11 5.27 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 106.544 -1.651 . . . . 0.0 106.544 174.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.0 tppt? . . . . . 0 CA--C 1.532 0.254 0 O-C-N 121.292 -0.88 . . . . 0.0 110.956 -179.358 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 CA--C 1.529 0.138 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 m -90.75 84.81 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 122.598 0.359 . . . . 0.0 110.894 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -19.1 115.52 0.09 OUTLIER Pre-proline 0 CA--C 1.546 0.789 0 C-N-CA 127.016 2.127 . . . . 0.0 113.667 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -75.02 -26.01 11.28 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 122.718 2.278 . . . . 0.0 117.535 -170.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -138.25 158.08 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 119.886 1.221 . . . . 0.0 109.445 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.9 m -94.61 128.6 41.36 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 174.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.67 -161.68 33.16 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.585 -0.341 . . . . 0.0 112.654 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -95.24 118.46 32.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.846 1.258 . . . . 0.0 108.551 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.94 136.04 25.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 C-N-CA 123.455 0.702 . . . . 0.0 109.427 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -135.13 142.9 43.61 Favored Pre-proline 0 C--O 1.236 0.345 0 C-N-CA 126.486 1.914 . . . . 0.0 107.048 177.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -64.61 160.06 41.88 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 121.446 1.431 . . . . 0.0 108.476 176.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 tp -61.55 -39.88 84.57 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 57.1 m -76.48 74.1 3.22 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.124 0.97 . . . . 0.0 109.344 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -178.54 -37.34 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 127.601 2.36 . . . . 0.0 108.986 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 97.0 t -52.0 115.45 6.71 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-O 117.507 -1.235 . . . . 0.0 111.905 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_exo -58.06 64.37 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.212 1 C-N-CA 125.515 4.144 . . . . 0.0 115.551 177.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -133.58 -42.63 0.84 Allowed 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 -177.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 105.73 -65.08 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 129.695 3.198 . . . . 0.0 110.606 -178.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 92.3 t -52.67 -62.13 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 C-N-CA 124.004 0.922 . . . . 0.0 108.722 179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -59.99 -42.79 94.98 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.909 0.385 . . . . 0.0 110.123 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -51.57 -45.51 63.12 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 124.012 0.925 . . . . 0.0 112.81 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -92.99 17.57 57.91 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-O 118.274 -1.292 . . . . 0.0 110.5 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 60.5 mttp 73.79 -47.77 0.66 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.079 1.752 . . . . 0.0 111.359 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 19.6 ttt 35.49 -67.17 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 130.602 3.561 . . . . 0.0 117.077 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 33.2 ttm -87.52 -23.6 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.385 1.074 . . . . 0.0 112.435 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.67 -148.1 9.53 Favored Glycine 0 C--O 1.224 -0.505 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -177.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -142.47 159.75 41.61 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-N 118.349 1.074 . . . . 0.0 108.582 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.3 -127.29 1.45 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 106.773 -2.531 . . . . 0.0 106.773 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -177.01 -179.28 0.9 Allowed 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 119.055 1.427 . . . . 0.0 110.763 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -127.67 135.86 50.79 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 123.734 0.814 . . . . 0.0 109.447 176.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -109.49 98.55 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 103.316 -2.846 . . . . 0.0 103.316 172.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.5 tt -58.81 113.6 7.11 Favored Pre-proline 0 CA--C 1.532 0.258 0 N-CA-C 103.08 -2.933 . . . . 0.0 103.08 175.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -78.07 149.01 25.12 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 122.916 2.411 . . . . 0.0 115.005 -167.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 p -115.74 -47.88 2.78 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 125.217 1.407 . . . . 0.0 107.594 173.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -76.76 122.39 24.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.11 44.21 2.79 Favored Glycine 0 CA--C 1.531 1.082 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 173.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.1 mt -144.33 126.37 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 104.446 -2.427 . . . . 0.0 104.446 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 66.3 t -126.66 126.71 69.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 C-N-CA 125.019 1.328 . . . . 0.0 109.033 -173.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.7 m -109.78 157.59 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.833 1.253 . . . . 0.0 110.792 178.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.6 m -62.87 133.02 95.07 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.873 -0.517 . . . . 0.0 111.077 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.04 -13.89 23.67 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.278 3.319 . . . . 0.0 116.531 -174.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -151.31 165.54 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 CA-C-N 119.441 1.018 . . . . 0.0 109.713 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -76.12 125.54 29.34 Favored 'General case' 0 C--O 1.236 0.394 1 N-CA-C 99.122 -4.399 . . . . 0.0 99.122 166.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 179.82 171.95 43.31 Favored Glycine 0 N--CA 1.435 -1.425 0 C-N-CA 116.658 -2.687 . . . . 0.0 113.198 -168.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.64 126.24 34.84 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.58 116.9 8.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 102.644 -3.095 . . . . 0.0 102.644 168.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 85.1 mt -78.53 -50.04 12.27 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 32.6 t30 178.16 164.1 0.7 Allowed 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 124.14 0.976 . . . . 0.0 108.372 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.4 m -137.74 116.73 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 126.732 2.013 . . . . 0.0 106.079 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.73 154.03 0.73 Allowed Pre-proline 0 N--CA 1.469 0.524 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -52.05 -33.29 52.44 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 123.483 2.788 . . . . 0.0 113.212 176.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.8 p -78.09 -2.84 39.29 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.996 0.919 . . . . 0.0 111.631 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.76 21.48 1.94 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 127.244 2.218 . . . . 0.0 114.301 179.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 25.9 p-80 -89.31 -25.02 21.86 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 118.46 -0.781 . . . . 0.0 111.18 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -162.5 -172.62 3.22 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.566 0.621 . . . . 0.0 112.531 -172.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.716 27.6 mm 125.89 -127.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.478 1 C-N-CA 134.583 5.153 . . . . 0.0 107.177 -179.815 . . . . . . . . 3 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 177.71 -172.83 45.54 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 118.354 2.101 . . . . 0.0 118.354 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.0 mp -133.7 169.58 16.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 126.856 2.062 . . . . 0.0 109.42 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.76 126.94 37.7 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 171.018 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . 0.602 ' HG ' ' N ' ' A' ' 78' ' ' ARG . 54.2 p . . . . . 0 N--CA 1.427 -1.579 0 CA-C-O 123.774 1.749 . . . . 0.0 108.136 175.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . 0.602 ' N ' ' HG ' ' A' ' 74' ' ' SER . 16.1 tpp85 . . . . . 0 C--O 1.23 0.071 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.61 101.39 8.29 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 125.457 1.503 . . . . 0.0 108.434 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.0 mt -96.81 103.85 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 126.479 1.912 . . . . 0.0 109.92 -176.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.0 tt -79.18 135.59 36.85 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 105.055 -2.202 . . . . 0.0 105.055 171.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.3 mt -113.97 153.22 15.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 125.179 1.392 . . . . 0.0 108.613 179.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.34 144.75 29.99 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 171.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.98 91.36 3.26 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.377 1.471 . . . . 0.0 110.504 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.27 154.63 5.43 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -178.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mt -98.33 135.28 33.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.267 -1.753 . . . . 0.0 106.267 178.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.0 t70 70.25 18.11 6.94 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.626 1.17 . . . . 0.0 112.818 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 p -81.9 -32.03 31.15 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 124.872 1.269 . . . . 0.0 108.501 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 8.1 p -55.06 -44.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.784 1.233 . . . . 0.0 108.143 172.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -61.34 -35.43 77.41 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.777 1.231 . . . . 0.0 109.813 176.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.99 9.43 5.44 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 126.851 2.061 . . . . 0.0 110.915 176.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.6 mttp 47.27 35.2 3.6 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 127.067 2.147 . . . . 0.0 114.787 173.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.05 19.12 63.29 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.63 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -71.26 90.47 0.92 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.064 1.432 . . . . 0.0 109.908 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.21 -1.06 6.61 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 126.068 1.794 . . . . 0.0 111.928 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.443 ' CD1' HG12 ' A' ' 115' ' ' VAL . 16.4 m-30 -100.42 111.57 23.84 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.723 1.209 . . . . 0.0 109.662 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 9.6 m -104.28 113.49 27.08 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 124.779 1.232 . . . . 0.0 108.132 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.7 p -81.43 144.94 31.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 118.92 0.782 . . . . 0.0 111.292 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -114.95 -41.98 3.28 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.186 1.394 . . . . 0.0 111.959 -178.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -70.94 130.19 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 174.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 61.0 m -92.28 53.71 2.18 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 104.934 -2.247 . . . . 0.0 104.934 172.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.365 1.2 pm0 16.35 62.89 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.466 3.507 . . . . 0.0 113.01 -169.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -79.09 48.99 3.44 Favored Glycine 0 CA--C 1.524 0.629 0 CA-C-N 111.729 -2.487 . . . . 0.0 109.818 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.403 4.3 p30 2.66 -111.25 0.0 OUTLIER 'General case' 0 N--CA 1.435 -1.22 0 C-N-CA 129.627 3.171 . . . . 0.0 117.366 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.254 0.2 OUTLIER -35.92 118.29 0.5 Allowed 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 121.599 3.926 . . . . 0.0 121.599 -169.726 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.268 27.6 m 36.89 70.39 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 128.421 2.688 . . . . 0.0 117.241 170.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.39 127.93 25.41 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 170.018 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -97.01 154.75 1.1 Allowed 'Trans proline' 0 N--CA 1.449 -1.141 0 C-N-CA 124.594 3.529 . . . . 0.0 110.401 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 49.07 2.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.303 0 N-CA-C 118.362 2.105 . . . . 0.0 118.362 172.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -60.69 136.49 58.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 119.948 1.874 . . . . 0.0 107.935 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -59.12 117.02 4.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.0 mt -79.91 -47.53 14.92 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.8 mp -149.97 166.0 30.97 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -177.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -126.33 132.1 51.68 Favored 'General case' 0 CA--C 1.518 -0.262 1 N-CA-C 98.458 -4.645 . . . . 0.0 98.458 166.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . 0.443 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -141.25 123.19 14.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.846 -166.176 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 63.1 t0 -72.55 70.54 0.92 Allowed 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 124.497 1.119 . . . . 0.0 110.772 -178.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -50.37 -45.1 54.98 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.347 0.659 . . . . 0.0 110.432 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -50.71 -50.11 55.96 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.362 1.065 . . . . 0.0 112.709 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.87 -33.34 24.83 Favored 'General case' 0 CA--C 1.527 0.087 0 N-CA-C 111.771 0.285 . . . . 0.0 111.771 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -65.28 -52.86 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.776 -0.578 . . . . 0.0 109.993 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.344 19.4 pttp -40.25 -57.31 2.94 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 117.413 2.375 . . . . 0.0 117.413 -177.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -57.09 -22.04 45.46 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.526 2.15 . . . . 0.0 113.146 179.063 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -94.11 4.97 53.14 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 118.08 -0.962 . . . . 0.0 112.683 -178.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 21.3 m -136.1 150.19 70.45 Favored Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 120.182 1.355 . . . . 0.0 111.992 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -71.17 -28.9 18.2 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 122.891 2.394 . . . . 0.0 111.974 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 3.2 m -158.79 131.59 7.05 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.54 0.609 . . . . 0.0 110.024 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -90.4 21.44 3.88 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.114 1.366 . . . . 0.0 112.055 -177.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 24.3 mmt -59.64 146.85 39.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 121.348 -0.845 . . . . 0.0 110.933 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 18.2 p -112.41 68.69 0.96 Allowed Pre-proline 0 CA--C 1.536 0.418 0 C-N-CA 124.558 1.143 . . . . 0.0 108.296 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.45 92.83 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.236 1.957 . . . . 0.0 112.825 -175.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 3.2 mt -86.15 129.97 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 105.315 -2.105 . . . . 0.0 105.315 175.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.6 t -133.59 121.67 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-O 121.798 0.809 . . . . 0.0 109.192 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -82.15 108.83 15.92 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 101.653 -3.462 . . . . 0.0 101.653 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.8 p -75.5 -63.55 1.26 Allowed 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.712 0.768 . . . . 0.0 109.75 -173.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -72.16 52.14 0.25 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.682 1.193 . . . . 0.0 113.951 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 56.9 mt -78.96 49.11 0.89 Allowed 'General case' 0 CA--C 1.539 0.547 0 O-C-N 121.083 -1.011 . . . . 0.0 109.042 173.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 23.99 40.42 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 130.0 3.32 . . . . 0.0 115.042 -179.21 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 38.85 45.31 0.93 Allowed 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.209 1.804 . . . . 0.0 112.604 -175.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -175.69 -8.86 0.02 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 119.062 -0.855 . . . . 0.0 113.997 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.687 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 9.8 mm-40 -86.87 92.33 8.96 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 118.945 1.373 . . . . 0.0 108.299 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -77.37 132.44 38.55 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 123.248 0.619 . . . . 0.0 110.164 -177.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 1.9 t -86.15 91.4 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 125.293 1.437 . . . . 0.0 109.782 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.0 m -88.54 96.26 10.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 27.1 mt -65.76 131.8 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -102.47 -42.2 6.04 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 125.774 1.629 . . . . 0.0 110.801 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -54.72 83.75 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.186 0 C-N-CA 124.907 1.283 . . . . 0.0 112.799 -176.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 22.4 m -80.93 55.9 2.59 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.778 0.831 . . . . 0.0 109.418 179.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.68 -167.47 36.47 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 41.6 t -60.16 152.72 23.78 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 123.12 0.568 . . . . 0.0 110.831 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 55.2 t -123.49 148.81 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 C-N-CA 124.944 1.298 . . . . 0.0 107.739 178.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.1 m-80 -119.48 153.43 35.32 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.789 1.636 . . . . 0.0 110.111 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -47.53 135.45 11.15 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.838 0.855 . . . . 0.0 110.628 177.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 67.23 8.57 6.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.509 1.924 . . . . 0.0 114.933 178.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -64.5 150.88 45.8 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 120.062 1.301 . . . . 0.0 108.859 174.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -122.84 161.53 23.88 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 125.215 1.406 . . . . 0.0 108.487 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 21.1 t0 66.69 14.1 9.63 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 125.735 1.614 . . . . 0.0 113.713 -178.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.474 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -65.65 -26.76 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 C-N-CA 124.371 1.068 . . . . 0.0 111.104 176.736 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.5 p -138.75 147.2 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 C-N-CA 125.626 1.57 . . . . 0.0 107.935 179.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.18 109.76 15.37 Favored 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.687 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -77.57 98.85 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 174.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -87.93 147.94 24.82 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.038 0.935 . . . . 0.0 108.87 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.1 tptm . . . . . 0 C--N 1.329 -0.297 0 CA-C-O 121.927 0.87 . . . . 0.0 109.026 -178.437 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 t80 . . . . . 0 CA--C 1.534 0.365 0 N-CA-C 112.119 0.414 . . . . 0.0 112.119 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.1 m -78.73 80.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.178 0 O-C-N 120.481 -1.387 . . . . 0.0 111.435 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -21.68 105.04 0.09 OUTLIER Pre-proline 0 CA--C 1.551 1.015 0 C-N-CA 129.229 3.012 . . . . 0.0 109.605 175.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.06 -20.56 21.63 Favored 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 123.535 2.823 . . . . 0.0 119.177 -167.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.35 147.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.34 0.164 0 CA-C-N 119.699 1.136 . . . . 0.0 110.547 -177.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.2 m -85.79 135.31 33.78 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 173.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 166.59 -140.38 6.29 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 -178.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.1 tp10 -125.81 122.68 36.87 Favored 'General case' 0 CA--C 1.528 0.122 0 C-N-CA 124.933 1.293 . . . . 0.0 110.089 -178.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.55 146.01 9.11 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -142.52 140.23 18.5 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 125.155 1.382 . . . . 0.0 107.656 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -57.13 145.55 85.79 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.116 1.877 . . . . 0.0 110.161 176.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -49.37 -37.63 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 124.304 1.041 . . . . 0.0 112.596 -178.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.6 p -55.96 -28.66 58.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.105 1.362 . . . . 0.0 112.606 178.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -77.23 -8.81 58.2 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 123.678 0.791 . . . . 0.0 112.745 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.425 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 46.7 t -74.26 131.01 81.32 Favored Pre-proline 0 CA--C 1.535 0.402 0 O-C-N 121.162 -0.961 . . . . 0.0 109.994 -178.07 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -77.17 55.93 5.24 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.515 2.81 . . . . 0.0 111.954 -177.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -167.72 108.68 0.59 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.47 -0.768 . . . . 0.0 109.19 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -35.47 -48.17 0.48 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 127.521 2.329 . . . . 0.0 115.375 -176.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.0 p -50.57 -38.1 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 122.932 0.493 . . . . 0.0 110.938 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.411 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 23.2 m-85 -89.38 -49.7 6.55 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 124.115 0.966 . . . . 0.0 108.828 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -48.07 -40.96 24.74 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.765 1.024 . . . . 0.0 113.765 -177.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.48 15.01 59.1 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.201 -1.333 . . . . 0.0 111.956 -177.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 53.1 mttp 71.87 -39.22 0.44 Allowed 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 119.285 1.542 . . . . 0.0 113.813 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 9.4 ttp 27.97 -69.18 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 131.341 3.856 . . . . 0.0 117.118 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.9 ttp -79.54 -25.53 41.65 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 126.047 1.739 . . . . 0.0 113.541 -175.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.71 -141.1 4.21 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 119.605 1.093 . . . . 0.0 110.658 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -121.96 154.4 37.24 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 174.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 179.51 -165.2 33.73 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.236 -175.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.535 ' CE2' HD11 ' A' ' 45' ' ' ILE . 37.4 p90 -159.37 168.91 25.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.425 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -112.37 151.28 29.97 Favored 'General case' 0 CA--C 1.501 -0.942 0 CA-C-O 121.346 0.593 . . . . 0.0 109.475 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.535 HD11 ' CE2' ' A' ' 43' ' ' PHE . 4.4 mp -125.08 132.31 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 102.18 -3.267 . . . . 0.0 102.18 170.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.0 tt -96.15 108.74 43.24 Favored Pre-proline 0 N--CA 1.442 -0.837 1 N-CA-C 98.589 -4.597 . . . . 0.0 98.589 169.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -82.17 156.1 17.19 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 123.664 2.909 . . . . 0.0 114.405 -168.201 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.2 p -124.98 -45.83 1.86 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.895 1.278 . . . . 0.0 108.794 174.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 120.34 14.59 Favored 'General case' 0 C--N 1.339 0.11 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 177.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.69 37.59 2.09 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 175.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.7 mt -142.33 119.39 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 127.007 2.123 . . . . 0.0 105.85 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.08 113.86 45.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.157 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.1 m -100.53 152.26 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 C-N-CA 123.094 0.558 . . . . 0.0 109.988 179.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 70.6 m -58.24 130.0 83.56 Favored Pre-proline 0 CA--C 1.537 0.463 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.106 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.2 -22.94 13.96 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 124.938 3.759 . . . . 0.0 115.774 -175.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.6 m -137.79 161.68 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 123.914 0.885 . . . . 0.0 109.769 -173.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.1 ttt180 -76.71 126.31 30.76 Favored 'General case' 0 CA--C 1.518 -0.271 1 N-CA-C 99.562 -4.236 . . . . 0.0 99.562 167.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.31 175.07 47.23 Favored Glycine 0 N--CA 1.436 -1.343 0 C-N-CA 116.709 -2.663 . . . . 0.0 114.33 -167.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 36.2 mtmt -100.62 135.16 42.49 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.231 1.812 . . . . 0.0 108.371 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 26.9 mm -76.47 107.93 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 173.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 64.3 tp -77.3 -50.6 12.48 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 123.358 0.663 . . . . 0.0 109.998 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.6 t30 179.53 107.68 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . 0.463 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 10.3 m -117.82 147.4 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 123.587 0.755 . . . . 0.0 112.392 -178.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER 42.53 123.72 0.0 OUTLIER Pre-proline 0 CA--C 1.536 0.441 1 C-N-CA 132.901 4.48 . . . . 0.0 120.801 171.706 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -80.94 -50.16 0.05 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.216 0 N-CA-C 106.676 -2.086 . . . . 0.0 106.676 168.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 8.9 p -113.99 43.08 1.91 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 127.281 2.232 . . . . 0.0 111.14 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 ttmm 56.91 25.62 10.74 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 115.762 1.764 . . . . 0.0 115.762 171.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -135.09 9.32 3.51 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 115.262 1.578 . . . . 0.0 115.262 -175.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -168.25 -159.29 0.27 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 122.053 2.206 . . . . 0.0 113.988 -173.06 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.463 ' HB ' ' HA ' ' A' ' 63' ' ' VAL 1.014 0.2 OUTLIER 93.18 -161.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 131.632 3.973 . . . . 0.0 117.697 172.683 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -115.14 154.1 17.2 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 120.06 2.784 . . . . 0.0 120.06 -167.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.8 mp -133.23 165.83 23.89 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 128.558 2.743 . . . . 0.0 108.519 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.7 mm-40 -136.86 139.58 41.78 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 175.153 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.8 m . . . . . 0 C--N 1.322 -0.618 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.356 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 41.6 mtm180 . . . . . 0 CA--C 1.533 0.299 0 N-CA-C 111.569 0.211 . . . . 0.0 111.569 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -90.0 130.12 36.23 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.0 mt -119.05 150.49 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 C-N-CA 124.89 1.276 . . . . 0.0 110.744 -176.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.75 132.84 44.17 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 128.373 2.669 . . . . 0.0 105.94 177.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.4 mt -124.87 143.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 124.841 1.256 . . . . 0.0 108.853 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -134.82 124.73 25.56 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -87.78 122.52 31.53 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 118.675 -0.679 . . . . 0.0 109.558 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.05 -157.4 5.9 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 118.358 0.526 . . . . 0.0 112.491 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 17.6 mm -132.77 142.92 41.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 106.36 -1.719 . . . . 0.0 106.36 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.6 t70 58.96 29.06 18.46 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.058 0.943 . . . . 0.0 112.555 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 p -86.41 -37.3 18.5 Favored 'General case' 0 CA--C 1.517 -0.296 0 C-N-CA 126.162 1.785 . . . . 0.0 108.067 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 3.7 p -51.46 -46.75 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.235 171.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -61.6 -31.33 71.4 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.332 1.453 . . . . 0.0 111.147 178.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.89 -2.99 29.37 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.344 2.258 . . . . 0.0 110.379 178.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm 51.61 33.44 10.72 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 125.176 1.39 . . . . 0.0 112.629 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.49 18.15 63.05 Favored Glycine 0 CA--C 1.537 1.426 0 O-C-N 121.919 -0.488 . . . . 0.0 113.357 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -73.01 85.27 1.29 Allowed 'General case' 0 C--N 1.34 0.152 0 CA-C-N 118.88 1.34 . . . . 0.0 109.745 179.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 17.48 1.7 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.714 2.102 . . . . 0.0 111.575 -177.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.454 ' CD2' HG12 ' A' ' 115' ' ' VAL . 37.1 m-85 -117.26 150.15 39.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.8 1.24 . . . . 0.0 109.907 -178.381 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 30.7 m -145.15 102.45 3.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.8 p -81.33 127.49 32.8 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.964 0.906 . . . . 0.0 108.959 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -91.13 -45.03 8.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.859 1.264 . . . . 0.0 112.612 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 6.7 m -73.36 129.19 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 118.383 -1.327 . . . . 0.0 111.67 -177.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -87.97 64.56 7.88 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 172.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.3 0.0 OUTLIER -14.11 84.47 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 130.039 3.336 . . . . 0.0 116.485 -173.213 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.14 -2.12 0.03 OUTLIER Glycine 0 CA--C 1.534 1.257 0 CA-C-N 113.528 -1.669 . . . . 0.0 113.194 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 121.57 14.71 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 127.266 2.226 . . . . 0.0 107.073 177.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.94 121.02 41.66 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 127.808 2.443 . . . . 0.0 111.061 -179.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.337 33.7 m 43.23 66.62 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 C-N-CA 126.682 1.993 . . . . 0.0 115.615 178.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -132.7 141.58 41.65 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 171.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -103.37 171.29 0.21 Allowed 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.935 3.09 . . . . 0.0 110.529 -179.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 60.04 -23.01 0.04 OUTLIER Glycine 0 CA--C 1.534 1.234 0 N-CA-C 118.856 2.303 . . . . 0.0 118.856 170.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -50.24 137.49 18.06 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 120.457 2.128 . . . . 0.0 110.529 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -60.59 123.7 18.18 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.5 mt -85.79 -48.2 9.01 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.5 mp -143.12 155.8 44.66 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.724 0.81 . . . . 0.0 110.666 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -122.11 135.36 54.79 Favored 'General case' 0 C--O 1.236 0.356 1 N-CA-C 99.023 -4.436 . . . . 0.0 99.023 167.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . 0.454 HG12 ' CD2' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -143.71 126.47 12.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.592 -165.754 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 38.7 m-20 -76.83 61.61 1.93 Allowed 'General case' 0 C--O 1.235 0.294 0 C-N-CA 124.904 1.282 . . . . 0.0 110.544 -178.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.0 mt -45.12 -45.5 11.28 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 123.886 0.875 . . . . 0.0 112.192 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -44.95 -42.01 7.78 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.488 1.115 . . . . 0.0 112.611 178.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.56 -33.67 15.81 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.113 0.565 . . . . 0.0 111.364 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 96.6 t -62.62 -52.78 55.46 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 O-C-N 121.756 -0.59 . . . . 0.0 110.004 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.391 8.8 ptmt -42.79 -57.22 5.11 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 116.895 2.183 . . . . 0.0 116.895 -177.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -61.59 -21.37 71.84 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 122.187 1.925 . . . . 0.0 113.184 178.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 -87.88 -42.29 12.62 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 119.064 0.847 . . . . 0.0 111.317 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.9 m -78.69 149.19 74.15 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.95 -0.469 . . . . 0.0 111.807 -177.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -70.53 -24.5 26.07 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.506 2.137 . . . . 0.0 110.228 175.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.2 t -158.05 145.06 17.93 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.2 tp -98.18 6.5 47.42 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.56 1.144 . . . . 0.0 110.31 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 21.3 mmt -53.36 115.16 1.77 Allowed 'General case' 0 C--N 1.344 0.343 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 47.3 m -106.33 88.6 3.34 Favored Pre-proline 0 N--CA 1.447 -0.579 0 C-N-CA 124.706 1.203 . . . . 0.0 108.241 -178.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 83.8 Cg_endo -72.93 144.0 37.64 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 122.668 2.246 . . . . 0.0 111.948 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.9 mt -125.01 126.29 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 103.788 -2.671 . . . . 0.0 103.788 173.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -123.53 153.41 29.16 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 C-N-CA 126.008 1.723 . . . . 0.0 106.651 178.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -129.92 121.58 26.9 Favored 'General case' 0 N--CA 1.428 -1.541 0 N-CA-C 102.914 -2.995 . . . . 0.0 102.914 -176.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 23.9 p -89.18 -86.17 0.19 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 -177.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -77.49 54.82 1.21 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 122.922 0.489 . . . . 0.0 111.696 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -78.26 80.07 4.69 Favored 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 174.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.12 51.51 0.21 Allowed 'General case' 0 C--N 1.343 0.289 0 C-N-CA 127.819 2.448 . . . . 0.0 111.641 -175.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 21.55 69.57 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 129.261 3.024 . . . . 0.0 113.964 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 146.42 -3.25 1.01 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-O 118.591 -1.116 . . . . 0.0 113.455 176.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.704 ' HB3' HG23 ' A' ' 160' ' ' ILE . 56.0 mt-10 -70.99 115.57 10.27 Favored 'General case' 0 C--N 1.339 0.116 0 CA-C-N 119.686 1.743 . . . . 0.0 109.933 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 81.5 p -78.78 128.99 34.13 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.12 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.266 0.4 OUTLIER -81.05 78.73 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 CA-C-O 123.498 1.618 . . . . 0.0 106.8 -177.538 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 38.5 m -78.8 91.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 120.962 -1.086 . . . . 0.0 111.249 -174.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.3 pt -63.19 104.58 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 C-N-CA 123.004 0.522 . . . . 0.0 109.597 176.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.23 -56.01 4.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . 0.731 ' HB3' HG23 ' A' ' 157' ' ' ILE . . . -84.14 69.97 10.47 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 46.4 m -77.7 68.66 3.82 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 176.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.17 -142.06 3.83 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 106.433 -2.667 . . . . 0.0 106.433 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.4 t -67.0 145.99 54.83 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 117.975 0.888 . . . . 0.0 110.645 177.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . 0.66 HG23 HG21 ' A' ' 157' ' ' ILE . 3.8 p -123.57 153.59 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 C-N-CA 125.881 1.673 . . . . 0.0 107.351 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.68 158.1 40.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 -65.46 147.99 52.48 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 43.44 48.69 6.12 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 128.109 2.564 . . . . 0.0 114.057 172.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -89.29 10.21 23.09 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 177.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 53.62 8.86 0.15 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 128.752 2.821 . . . . 0.0 115.566 177.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -156.97 -126.13 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 125.146 1.378 . . . . 0.0 107.405 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.731 HG23 ' HB3' ' A' ' 146' ' ' ALA 0.312 1.5 mp 80.63 -36.89 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 128.559 2.744 . . . . 0.0 108.615 178.552 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -119.85 129.11 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 168.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 9.2 mmmt -111.3 111.51 22.61 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 124.168 0.987 . . . . 0.0 109.077 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.704 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.3 mp -77.24 91.51 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 103.409 -2.812 . . . . 0.0 103.409 175.049 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -103.46 116.1 31.77 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.587 1.555 . . . . 0.0 110.282 -173.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 28.6 tptp . . . . . 0 CA--C 1.528 0.129 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 178.987 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 29.3 t80 . . . . . 0 N--CA 1.451 -0.406 0 N-CA-C 104.402 -2.444 . . . . 0.0 104.402 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.76 77.05 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.4 t -15.91 124.06 0.04 OUTLIER Pre-proline 0 CA--C 1.552 1.043 0 C-N-CA 129.063 2.945 . . . . 0.0 114.449 179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . 0.429 ' HG2' HD12 ' A' ' 19' ' ' ILE . 50.5 Cg_endo -74.8 -42.72 0.51 Allowed 'Trans proline' 0 CA--C 1.538 0.684 0 N-CA-C 120.825 3.356 . . . . 0.0 120.825 -170.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . 0.429 HD12 ' HG2' ' A' ' 18' ' ' PRO . 0.2 OUTLIER -138.16 145.49 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 121.014 1.734 . . . . 0.0 111.665 -172.646 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 m -79.88 131.88 35.96 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 171.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 178.41 -160.49 26.55 Favored Glycine 0 CA--C 1.518 0.249 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.7 tp10 -108.04 131.74 54.28 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.1 tt -75.85 151.71 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-N 118.679 0.672 . . . . 0.0 110.535 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.5 m-70 -140.14 129.75 13.59 Favored Pre-proline 0 N--CA 1.446 -0.628 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 172.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -57.41 143.0 95.22 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 122.512 2.141 . . . . 0.0 107.578 174.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . 0.408 HD13 ' C ' ' A' ' 42' ' ' GLY . 1.8 tp -43.46 -49.45 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 123.764 0.826 . . . . 0.0 112.269 -177.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 p -53.9 -24.58 16.59 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.14 1.376 . . . . 0.0 114.321 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -78.81 -8.06 58.43 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 118.756 0.707 . . . . 0.0 112.61 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 93.0 t -70.1 134.67 87.35 Favored Pre-proline 0 CA--C 1.543 0.696 0 O-C-N 121.106 -0.996 . . . . 0.0 110.922 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.85 64.6 5.92 Favored 'Trans proline' 0 CA--C 1.537 0.673 0 C-N-CA 124.674 3.582 . . . . 0.0 110.556 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.09 178.69 6.84 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.37 1.468 . . . . 0.0 107.177 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.46 -63.83 1.2 Allowed 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 124.383 1.073 . . . . 0.0 110.565 178.314 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.9 p -47.26 -56.6 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 C-N-CA 124.22 1.008 . . . . 0.0 112.775 -177.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -61.06 -57.32 13.05 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-O 121.703 0.763 . . . . 0.0 108.959 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.3 m -53.67 -36.97 62.71 Favored 'General case' 0 N--CA 1.446 -0.648 0 C-N-CA 126.18 1.792 . . . . 0.0 115.592 -174.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.35 7.04 82.27 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 26.1 mtmt 74.99 -39.94 0.42 Allowed 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.974 1.71 . . . . 0.0 111.44 -177.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 26.6 ttt 28.01 -70.05 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 131.305 3.842 . . . . 0.0 116.909 177.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 9.6 tpt -79.13 -16.98 55.9 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.383 1.073 . . . . 0.0 112.654 -176.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.37 -135.29 2.18 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -178.556 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -131.24 154.94 47.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 105.833 -1.914 . . . . 0.0 105.833 173.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.408 ' C ' HD13 ' A' ' 26' ' ' ILE . . . -177.94 -159.48 22.79 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.249 -0.977 . . . . 0.0 114.177 -174.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 25.5 p90 -163.63 171.15 16.13 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.01 0.924 . . . . 0.0 109.521 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.431 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -120.34 137.3 54.35 Favored 'General case' 0 CA--C 1.508 -0.669 0 C-N-CA 122.936 0.494 . . . . 0.0 109.705 174.045 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 20.3 mm -112.09 129.6 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.903 0 N-CA-C 103.38 -2.822 . . . . 0.0 103.38 171.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 15.6 tp -94.85 110.63 50.7 Favored Pre-proline 0 N--CA 1.446 -0.651 0 N-CA-C 102.019 -3.326 . . . . 0.0 102.019 172.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -64.55 155.27 67.46 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 123.639 2.893 . . . . 0.0 116.916 -169.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.3 p -127.55 -50.94 1.38 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.124 1.37 . . . . 0.0 107.725 171.132 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -79.0 122.5 26.26 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 123.276 0.63 . . . . 0.0 110.37 177.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 40.31 2.26 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 174.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 72.7 mt -136.89 117.82 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.767 -2.679 . . . . 0.0 103.767 -179.237 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.3 t -120.59 109.4 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 122.962 0.505 . . . . 0.0 110.128 -173.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.5 m -91.15 -173.2 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 172.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.6 m -116.3 147.57 39.78 Favored Pre-proline 0 N--CA 1.469 0.49 0 CA-C-O 117.199 -1.381 . . . . 0.0 112.723 -175.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -61.54 -38.92 58.98 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 121.883 1.722 . . . . 0.0 108.305 174.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.46 142.0 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 102.921 -2.992 . . . . 0.0 102.921 171.151 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 29.1 mtm180 -95.12 -79.91 0.42 Allowed 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 102.094 -3.299 . . . . 0.0 102.094 171.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.88 -73.76 0.99 Allowed Glycine 0 C--N 1.338 0.64 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 176.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.21 123.1 8.72 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 24.1 mm -70.12 128.4 33.39 Favored 'Isoleucine or valine' 0 C--N 1.344 0.369 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.7 tt -78.43 -52.54 8.41 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.049 -2.204 . . . . 0.0 105.049 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 174.18 161.17 0.18 Allowed 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 124.614 1.166 . . . . 0.0 108.56 178.539 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.7 p -135.54 121.5 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 172.04 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -38.53 146.46 0.3 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.791 0.723 . . . . 0.0 112.947 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -58.63 -43.01 48.42 Favored 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.931 2.421 . . . . 0.0 109.723 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 15.9 p -78.23 74.27 4.77 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 173.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -34.4 93.24 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 129.261 3.024 . . . . 0.0 113.471 -173.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . 0.442 ' CD2' HG23 ' A' ' 89' ' ' VAL . 0.0 OUTLIER -158.56 -19.2 0.07 Allowed 'General case' 0 C--O 1.225 -0.229 0 N-CA-C 113.409 0.892 . . . . 0.0 113.409 175.31 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -164.77 -177.84 4.96 Favored 'General case' 0 C--O 1.222 -0.363 0 CA-C-N 120.238 1.381 . . . . 0.0 110.839 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.875 14.3 mm 135.57 -128.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 1 C-N-CA 133.254 4.622 . . . . 0.0 109.141 177.274 . . . . . . . . 3 2 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.4 175.29 42.49 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 118.769 2.268 . . . . 0.0 118.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 39.0 mt -128.72 172.94 10.76 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 127.478 2.311 . . . . 0.0 109.576 -178.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 -148.61 140.91 24.14 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.828 1.651 . . . . 0.0 106.835 176.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 59.6 p . . . . . 0 CA--C 1.536 0.417 0 CA-C-O 121.049 0.452 . . . . 0.0 110.363 178.33 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.4 ttp180 . . . . . 0 CA--C 1.529 0.137 0 N-CA-C 108.84 -0.8 . . . . 0.0 108.84 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -79.28 134.32 36.64 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.3 mp -116.85 114.67 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 C-N-CA 123.268 0.627 . . . . 0.0 109.905 -177.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -81.2 125.84 30.78 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 104.196 -2.52 . . . . 0.0 104.196 170.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 62.7 mt -123.06 132.01 72.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -128.29 132.77 48.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 106.309 -1.737 . . . . 0.0 106.309 174.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -116.44 104.42 11.43 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 126.16 1.784 . . . . 0.0 109.489 -177.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.77 163.06 10.02 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 -178.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 10.7 mm -109.02 119.85 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 -179.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.4 t70 77.09 4.61 3.28 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.391 1.477 . . . . 0.0 113.779 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -61.78 -24.87 67.12 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 120.761 -1.212 . . . . 0.0 110.757 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . 0.442 HG23 ' CD2' ' A' ' 68' ' ' HIS . 0.5 OUTLIER -59.86 -47.88 89.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 C-N-CA 125.92 1.688 . . . . 0.0 108.127 173.594 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 4.5 m -63.47 -35.59 80.94 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.125 0.97 . . . . 0.0 108.766 177.43 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.58 19.75 0.78 Allowed 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 125.426 1.49 . . . . 0.0 110.873 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 4.8 mptt 37.77 37.59 0.13 Allowed 'General case' 0 C--N 1.346 0.42 0 C-N-CA 128.658 2.783 . . . . 0.0 114.595 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 52.58 34.42 43.07 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -67.41 92.64 0.3 Allowed 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 121.401 -1.058 . . . . 0.0 110.164 -178.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.47 1.67 5.12 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 126.043 1.782 . . . . 0.0 112.214 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -96.58 103.35 15.26 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.801 1.241 . . . . 0.0 111.263 -176.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.5 m -89.7 105.78 18.03 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.081 -2.192 . . . . 0.0 105.081 172.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.7 p -81.6 123.85 29.03 Favored 'General case' 0 N--CA 1.451 -0.406 0 O-C-N 121.613 -0.68 . . . . 0.0 110.402 -178.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -81.41 -52.3 7.41 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.915 1.286 . . . . 0.0 108.911 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.9 m -78.32 130.46 36.16 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 C-N-CA 117.999 -1.48 . . . . 0.0 107.224 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.5 m -94.37 57.06 2.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 169.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.341 9.8 pt-20 29.32 65.96 0.11 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 128.737 2.815 . . . . 0.0 111.681 -168.33 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -73.3 58.44 1.94 Allowed Glycine 0 CA--C 1.525 0.662 0 CA-C-N 111.574 -2.557 . . . . 0.0 111.253 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -10.59 -17.87 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.533 2 C-N-CA 136.188 5.795 . . . . 0.0 124.342 -179.317 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -142.88 110.7 5.9 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 128.062 2.545 . . . . 0.0 106.612 178.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.0 155.76 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 123.908 0.883 . . . . 0.0 112.833 -171.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -80.88 151.61 70.89 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-O 117.948 -1.025 . . . . 0.0 108.662 175.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -47.88 164.62 0.16 Allowed 'Trans proline' 0 CA--C 1.533 0.428 1 C-N-CA 127.018 5.145 . . . . 0.0 120.304 -174.158 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 68.45 -92.5 0.27 Allowed Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.84 1.686 . . . . 0.0 113.678 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 35.5 tp60 1.18 101.9 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.793 1 C-N-CA 132.258 4.223 . . . . 0.0 114.735 -176.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -4.14 112.95 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 130.168 3.387 . . . . 0.0 116.172 178.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.6 mt -83.18 -45.25 14.12 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 173.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.0 mt -140.38 151.23 44.8 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.723 1.209 . . . . 0.0 111.282 -174.285 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -119.84 128.58 53.82 Favored 'General case' 0 CA--C 1.514 -0.407 1 N-CA-C 99.12 -4.4 . . . . 0.0 99.12 167.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.93 124.41 27.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-N 115.1 -0.954 . . . . 0.0 112.756 -165.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -73.87 69.13 1.37 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.938 0.895 . . . . 0.0 110.037 178.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.1 mt -47.2 -52.49 15.62 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.793 0.837 . . . . 0.0 110.583 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -43.46 -49.65 7.16 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 125.392 1.477 . . . . 0.0 112.343 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -82.81 -31.36 28.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 123.175 0.297 . . . . 0.0 111.774 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 42.2 t -63.1 -56.48 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 118.901 -0.571 . . . . 0.0 110.839 179.007 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.324 3.8 pttm -42.78 -56.29 6.22 Favored Pre-proline 0 N--CA 1.47 0.535 0 N-CA-C 116.391 1.997 . . . . 0.0 116.391 -176.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -60.86 -14.63 33.41 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.699 1.6 . . . . 0.0 113.22 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 -98.98 5.08 47.36 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.056 -0.973 . . . . 0.0 112.303 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 20.1 m -142.07 155.11 65.44 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 120.332 1.424 . . . . 0.0 112.166 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.31 -39.78 89.16 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.086 2.524 . . . . 0.0 113.927 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -159.97 141.37 12.62 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.156 0.582 . . . . 0.0 110.012 -177.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -92.46 14.58 16.27 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.539 1.135 . . . . 0.0 112.068 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.4 mmt -53.04 134.01 38.33 Favored 'General case' 0 N--CA 1.457 -0.111 0 O-C-N 121.415 -0.803 . . . . 0.0 110.369 -178.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -110.28 78.78 1.46 Allowed Pre-proline 0 N--CA 1.451 -0.378 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 176.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.2 136.59 27.1 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 C-N-CA 122.449 2.1 . . . . 0.0 110.269 178.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -128.98 134.66 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 178.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 t -136.53 126.15 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 125.165 1.386 . . . . 0.0 108.55 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.457 ' HB2' ' CD2' ' A' ' 136' ' ' LEU . 13.9 m-85 -92.93 124.13 36.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 103.525 -2.769 . . . . 0.0 103.525 176.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 77.7 p -86.49 -82.28 0.2 Allowed 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.071 0.85 . . . . 0.0 109.319 -176.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -77.01 52.34 0.87 Allowed 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.457 ' CD2' ' HB2' ' A' ' 133' ' ' PHE . 0.2 OUTLIER -78.78 72.26 5.29 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.249 -0.907 . . . . 0.0 108.666 174.509 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 41.87 47.86 3.74 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 126.603 1.961 . . . . 0.0 111.256 -178.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 18.9 68.42 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 129.394 3.077 . . . . 0.0 113.245 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 154.75 -9.65 0.39 Allowed Glycine 0 CA--C 1.523 0.574 0 CA-C-O 118.508 -1.162 . . . . 0.0 113.021 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.666 ' HB3' HG23 ' A' ' 160' ' ' ILE . 59.1 mm-40 -69.09 116.93 10.1 Favored 'General case' 0 C--N 1.342 0.281 0 CA-C-N 119.626 1.713 . . . . 0.0 110.069 178.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.2 p -77.73 136.07 38.11 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.828 -1.915 . . . . 0.0 105.828 173.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -86.69 86.74 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 -176.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.2 m -77.42 83.31 3.85 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.82 -1.175 . . . . 0.0 110.99 -175.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . 0.471 HG22 HG22 ' A' ' 158' ' ' VAL . 2.1 pt -56.59 111.15 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 173.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -88.73 -38.57 14.62 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 123.892 0.877 . . . . 0.0 109.636 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -81.12 75.77 8.08 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.463 -175.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 50.6 p -77.39 69.44 3.65 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 169.38 -137.43 4.52 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -176.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.7 t -75.43 149.07 38.64 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.7 m -119.98 158.93 21.59 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 C-N-CA 125.374 1.469 . . . . 0.0 109.048 178.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -131.79 166.98 20.34 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 125.688 1.595 . . . . 0.0 112.22 176.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 73.5 mtm-85 -85.65 154.25 21.81 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -175.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 57.52 55.11 5.9 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 126.448 1.899 . . . . 0.0 113.591 176.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . 0.503 ' CB ' HD13 ' A' ' 157' ' ' ILE . 4.3 mm-40 -143.05 161.12 38.99 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.964 0.906 . . . . 0.0 109.76 176.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . 0.452 ' C ' ' H ' ' A' ' 157' ' ' ILE . 62.9 tt0 -105.52 -61.1 1.53 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 122.817 1.294 . . . . 0.0 112.314 -177.412 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . 0.436 ' C ' HD12 ' A' ' 157' ' ' ILE . 0.9 OUTLIER -65.68 27.34 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 127.705 2.402 . . . . 0.0 114.682 -174.326 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.503 HD13 ' CB ' ' A' ' 154' ' ' GLN . 1.7 mp -103.17 -34.7 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 130.225 3.41 . . . . 0.0 104.976 177.451 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.471 HG22 HG22 ' A' ' 144' ' ' ILE . 59.4 t -149.05 109.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 106.062 -1.829 . . . . 0.0 106.062 173.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -101.77 124.31 47.2 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 118.049 0.386 . . . . 0.0 111.78 -176.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.666 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.4 mp -78.15 108.8 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 174.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -128.9 150.62 50.28 Favored 'General case' 0 C--O 1.226 -0.157 0 C-N-CA 124.383 1.073 . . . . 0.0 109.261 -175.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 50.9 tptt . . . . . 0 C--N 1.333 -0.136 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -179.815 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.225 -0.215 0 N-CA-C 104.269 -2.493 . . . . 0.0 104.269 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.4 m -123.77 85.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 CA-C-N 118.846 0.748 . . . . 0.0 110.958 -176.375 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.4 p -19.45 110.25 0.09 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 129.569 3.147 . . . . 0.0 110.512 177.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -68.64 -25.13 34.6 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.776 2.317 . . . . 0.0 117.931 -168.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.95 146.1 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.611 1.096 . . . . 0.0 109.598 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.1 m -79.34 137.45 37.33 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 170.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 173.82 -158.25 27.09 Favored Glycine 0 C--O 1.227 -0.312 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -108.4 120.61 42.89 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 tt -85.51 134.92 26.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 118.569 0.622 . . . . 0.0 109.718 178.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -137.59 149.42 64.97 Favored Pre-proline 0 N--CA 1.451 -0.389 0 C-N-CA 125.79 1.636 . . . . 0.0 107.753 176.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.65 143.37 96.57 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 121.366 1.378 . . . . 0.0 108.566 173.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -55.05 -24.82 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -173.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.3 p -52.42 -31.02 32.28 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 124.279 1.032 . . . . 0.0 111.134 174.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -75.16 -9.72 58.8 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.5 1.12 . . . . 0.0 112.65 -176.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.9 t -76.63 131.74 73.53 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 119.13 0.877 . . . . 0.0 109.861 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -77.8 60.1 7.1 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 123.17 2.58 . . . . 0.0 110.847 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -165.55 102.6 0.71 Allowed 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.487 -0.758 . . . . 0.0 110.01 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -24.41 -59.0 0.05 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.476 2.71 . . . . 0.0 115.055 -178.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -52.03 -41.85 33.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 123.178 0.591 . . . . 0.0 111.583 -177.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -80.67 -48.56 12.43 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.7 m -48.71 -41.54 32.16 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -179.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.61 11.2 61.2 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-O 118.629 -1.095 . . . . 0.0 111.515 -178.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm 73.37 -39.5 0.44 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.573 1.549 . . . . 0.0 112.773 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 13.7 tpt 21.7 -62.24 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 1 C-N-CA 132.264 4.226 . . . . 0.0 117.996 178.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -77.71 -21.63 51.67 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.991 0.916 . . . . 0.0 111.898 -176.465 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.32 -136.29 2.78 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -130.27 157.55 42.21 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 172.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.71 -167.74 36.87 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.943 -176.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -146.81 154.72 41.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 124.283 1.033 . . . . 0.0 109.718 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.76 119.09 38.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.009 0.923 . . . . 0.0 109.917 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.3 mm -100.8 129.53 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 171.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.3 tt -98.14 105.83 30.98 Favored Pre-proline 0 N--CA 1.45 -0.426 0 N-CA-C 101.326 -3.583 . . . . 0.0 101.326 172.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -60.5 167.31 8.26 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 123.434 2.756 . . . . 0.0 117.124 -169.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.1 p -146.98 -58.92 0.28 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.72 1.608 . . . . 0.0 106.942 173.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -69.81 119.0 13.37 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 175.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.75 44.85 3.03 Favored Glycine 0 CA--C 1.53 1.005 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 22.0 mt -144.06 114.64 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 N-CA-C 105.253 -2.129 . . . . 0.0 105.253 -177.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.65 126.14 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 124.479 1.111 . . . . 0.0 109.131 -175.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.8 m -109.29 156.91 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 C-N-CA 123.387 0.675 . . . . 0.0 110.363 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 m -65.67 127.2 92.86 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-O 118.982 -0.532 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.49 -7.96 22.5 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 124.468 3.445 . . . . 0.0 116.765 -174.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.4 m -147.99 169.51 3.58 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 CA-C-N 119.754 1.161 . . . . 0.0 109.388 -177.207 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.06 116.18 17.49 Favored 'General case' 0 C--O 1.235 0.336 1 N-CA-C 97.978 -4.823 . . . . 0.0 97.978 166.893 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.69 170.26 42.11 Favored Glycine 0 N--CA 1.438 -1.215 0 C-N-CA 116.026 -2.988 . . . . 0.0 116.557 -167.08 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 10.0 mtpp -97.2 132.84 42.57 Favored 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 127.989 2.515 . . . . 0.0 109.003 -175.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.7 mm -72.8 123.96 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 104.618 -2.364 . . . . 0.0 104.618 173.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 42.0 tp -78.63 -48.88 14.2 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 179.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -177.46 171.79 1.91 Allowed 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 123.531 0.732 . . . . 0.0 109.444 173.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 51.5 t -144.16 115.08 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 176.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -45.5 147.33 1.47 Allowed Pre-proline 0 CA--C 1.542 0.65 0 CA-C-N 118.689 0.677 . . . . 0.0 111.454 177.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.45 -24.22 11.84 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 124.102 3.202 . . . . 0.0 114.881 176.247 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.8 p -76.34 -15.17 60.03 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.636 1.174 . . . . 0.0 111.165 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.6 tppt? 70.94 4.8 5.22 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 127.852 2.461 . . . . 0.0 113.344 -178.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.2 p-80 -78.97 -25.93 43.48 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 113.41 0.893 . . . . 0.0 113.41 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.96 -173.94 2.53 Favored 'General case' 0 C--O 1.222 -0.348 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -172.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.439 HG22 ' N ' ' A' ' 71' ' ' GLY 0.62 25.9 mm 132.03 -124.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.345 1 C-N-CA 136.505 5.922 . . . . 0.0 105.75 178.863 . . . . . . . . 4 3 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . 0.439 ' N ' HG22 ' A' ' 70' ' ' ILE . . . -179.96 -176.68 47.55 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 116.976 1.55 . . . . 0.0 116.976 -179.106 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.3 mp -126.29 171.92 10.54 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 127.519 2.327 . . . . 0.0 110.126 -178.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -140.36 136.37 33.09 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 62.9 p . . . . . 0 N--CA 1.448 -0.556 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.925 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 24.8 mtp180 . . . . . 0 C--O 1.235 0.338 0 N-CA-C 112.836 0.68 . . . . 0.0 112.836 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 13.2 tm-20 -93.3 150.72 20.27 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 126.866 2.066 . . . . 0.0 109.318 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.65 103.39 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 C-N-CA 124.376 1.071 . . . . 0.0 109.052 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.4 tt -85.64 136.64 33.29 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.498 -1.668 . . . . 0.0 106.498 174.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 20.0 mt -122.77 148.72 26.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 123.444 0.698 . . . . 0.0 109.938 -178.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.37 126.48 21.17 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 170.551 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -102.41 106.22 16.94 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.705 1.202 . . . . 0.0 108.773 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 64.29 176.63 4.73 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 118.184 0.447 . . . . 0.0 113.09 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.6 mm -113.29 141.17 29.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.9 t70 63.27 13.32 6.88 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.423 1.089 . . . . 0.0 112.486 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 p -74.15 -39.74 63.06 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 126.265 1.826 . . . . 0.0 107.231 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 p -47.11 -47.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 124.923 1.289 . . . . 0.0 109.287 171.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -63.98 -54.58 32.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 125.347 1.459 . . . . 0.0 111.304 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.23 -36.89 78.74 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 123.991 0.916 . . . . 0.0 112.008 -178.257 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 81.5 mttt 79.57 145.6 0.09 Allowed 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 128.854 2.862 . . . . 0.0 108.706 -176.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.45 48.71 0.29 Allowed Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.609 1.1 . . . . 0.0 115.537 -176.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 25.7 pt-20 -63.75 -17.31 62.9 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 119.168 1.484 . . . . 0.0 113.67 177.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -109.84 15.43 31.43 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 126.544 2.021 . . . . 0.0 111.13 177.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -107.95 99.42 8.88 Favored 'General case' 0 C--N 1.343 0.283 0 CA-C-N 118.156 0.978 . . . . 0.0 110.665 -176.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -79.44 93.99 5.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 174.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 p -79.11 127.4 31.96 Favored 'General case' 0 N--CA 1.453 -0.31 0 O-C-N 120.983 -1.073 . . . . 0.0 110.505 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -89.17 -49.11 6.94 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 123.836 0.854 . . . . 0.0 110.375 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -78.1 133.29 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.032 0 C-N-CA 119.019 -1.072 . . . . 0.0 110.559 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 m -87.73 61.5 6.5 Favored 'General case' 0 C--N 1.333 -0.128 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 172.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.271 1.6 pm0 3.22 79.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 130.451 3.501 . . . . 0.0 115.211 -174.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 174.65 6.54 0.02 OUTLIER Glycine 0 CA--C 1.533 1.202 0 CA-C-N 113.32 -1.763 . . . . 0.0 114.812 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.24 121.52 14.46 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 119.493 1.646 . . . . 0.0 107.396 176.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 37.8 mmt-85 -100.07 100.53 11.41 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 129.796 3.238 . . . . 0.0 111.817 -175.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.551 7.3 p 60.47 78.23 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 N-CA-C 116.813 2.153 . . . . 0.0 116.813 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -135.99 150.14 70.5 Favored Pre-proline 0 N--CA 1.446 -0.632 0 CA-C-N 111.933 -2.394 . . . . 0.0 105.141 169.15 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -105.42 142.59 0.1 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.969 3.112 . . . . 0.0 111.803 -177.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 56.93 15.26 12.46 Favored Glycine 0 CA--C 1.531 1.046 0 O-C-N 121.417 -0.802 . . . . 0.0 114.289 175.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.3 130.28 45.41 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 25.7 ttpt -59.39 117.64 5.07 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.112 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.4 mt -80.41 -54.2 5.92 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 25.0 mt -144.82 151.13 38.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.215 1.006 . . . . 0.0 110.871 -173.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 6.1 tm-20 -116.45 128.44 55.48 Favored 'General case' 0 CA--C 1.515 -0.398 1 N-CA-C 97.922 -4.844 . . . . 0.0 97.922 166.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.52 121.69 22.78 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.834 -166.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -71.91 69.96 0.73 Allowed 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.844 1.258 . . . . 0.0 111.112 -177.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.3 mt -47.95 -44.85 30.53 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.057 0.943 . . . . 0.0 110.718 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -52.83 -43.78 66.24 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.473 0.709 . . . . 0.0 112.794 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -84.71 -33.36 23.16 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.114 0.416 . . . . 0.0 111.305 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 40.3 t -63.87 -56.25 17.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 O-C-N 121.865 -0.522 . . . . 0.0 109.852 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.359 0.1 OUTLIER -40.74 -55.52 4.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 117.891 2.552 . . . . 0.0 117.891 -177.125 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -57.91 -21.65 50.38 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.515 2.143 . . . . 0.0 112.87 178.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -93.68 9.57 36.42 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.457 -0.782 . . . . 0.0 112.216 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 15.9 m -138.96 152.02 69.36 Favored Pre-proline 0 C--N 1.344 0.36 0 CA-C-N 119.923 1.238 . . . . 0.0 111.695 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.03 -26.8 12.62 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.044 2.496 . . . . 0.0 111.594 179.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 15.6 t -153.1 142.81 21.97 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.09 6.99 47.56 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.226 1.01 . . . . 0.0 110.595 178.404 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 16.5 mmt -51.01 119.61 4.12 Favored 'General case' 0 C--N 1.344 0.347 0 CA-C-N 118.5 0.591 . . . . 0.0 109.955 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 29.9 m -117.2 87.52 24.05 Favored Pre-proline 0 N--CA 1.446 -0.66 0 C-N-CA 125.588 1.555 . . . . 0.0 107.645 -177.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.403 ' C ' HD12 ' A' ' 131' ' ' ILE . 49.8 Cg_endo -84.89 151.61 11.2 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 C-N-CA 121.411 1.407 . . . . 0.0 112.011 -178.686 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . 0.47 HD12 ' N ' ' A' ' 131' ' ' ILE . 1.3 mp -118.55 130.14 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 N-CA-C 102.792 -3.04 . . . . 0.0 102.792 173.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.0 t -128.6 153.4 38.05 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.58 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -127.02 109.82 12.31 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 103.418 -2.808 . . . . 0.0 103.418 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.0 p -75.2 -78.05 0.11 Allowed 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -175.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -74.03 65.86 1.15 Allowed 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.587 0.708 . . . . 0.0 112.096 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 16.4 mt -72.81 70.41 0.98 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.144 1.378 . . . . 0.0 108.273 176.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 27.74 48.99 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 128.508 2.723 . . . . 0.0 111.921 -176.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 28.5 53.52 0.08 Allowed 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 128.74 2.816 . . . . 0.0 114.44 -175.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 167.09 -4.71 0.05 OUTLIER Glycine 0 CA--C 1.528 0.848 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.227 178.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.571 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 3.7 mm-40 -87.35 148.01 25.23 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.838 1.319 . . . . 0.0 110.178 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 51.0 p -123.89 140.42 53.0 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.943 1.297 . . . . 0.0 108.102 179.035 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -86.08 95.35 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-O 122.064 0.935 . . . . 0.0 108.952 -177.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 62.1 m -84.74 87.36 7.3 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.301 -0.875 . . . . 0.0 109.836 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.8 pt -66.07 128.78 29.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 174.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -103.2 -46.9 4.48 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.557 1.143 . . . . 0.0 109.708 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -76.14 156.69 33.53 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.433 0.635 . . . . 0.0 111.629 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 27.9 p -150.62 113.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 104.774 -2.306 . . . . 0.0 104.774 178.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 115.8 -151.57 18.33 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.9 t -59.12 139.93 56.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.347 1.074 . . . . 0.0 112.379 -177.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.5 m -143.52 146.32 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 C-N-CA 126.23 1.812 . . . . 0.0 108.64 177.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -101.59 160.18 14.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.491 1.116 . . . . 0.0 110.768 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.2 ttp180 -75.77 154.99 35.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.524 1.53 . . . . 0.0 110.887 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 57.98 52.96 7.23 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.903 1.681 . . . . 0.0 113.222 178.219 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . 0.634 ' HB2' HD13 ' A' ' 157' ' ' ILE . 17.2 mm-40 -135.93 168.01 20.14 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.635 1.574 . . . . 0.0 108.509 177.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -119.69 -77.53 0.58 Allowed 'General case' 0 C--N 1.344 0.327 0 CA-C-N 120.027 1.285 . . . . 0.0 114.238 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -37.08 -7.62 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.065 1 C-N-CA 132.073 4.149 . . . . 0.0 120.194 -174.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.672 ' H ' HD12 ' A' ' 157' ' ' ILE . 4.9 mp -68.39 -33.44 60.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 130.874 3.67 . . . . 0.0 106.889 174.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -137.29 133.62 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 C-N-CA 127.281 2.233 . . . . 0.0 106.599 173.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -127.08 133.03 50.52 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.571 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.06 116.2 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 175.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -98.26 170.83 8.6 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 175.551 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp . . . . . 0 CA--C 1.532 0.259 0 O-C-N 121.457 -0.777 . . . . 0.0 110.811 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 N--CA 1.469 0.5 0 CA-C-O 118.386 -0.816 . . . . 0.0 110.637 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.3 m -117.35 108.36 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 119.244 0.929 . . . . 0.0 109.04 172.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.3 t -38.87 115.96 0.95 Allowed Pre-proline 0 CA--C 1.553 1.066 0 C-N-CA 124.759 1.224 . . . . 0.0 111.761 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -76.82 -23.38 10.95 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 123.507 2.805 . . . . 0.0 118.293 -172.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.89 154.41 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 120.698 1.59 . . . . 0.0 109.989 -178.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.5 m -89.74 137.73 32.08 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 175.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 160.71 -130.71 2.44 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -131.32 139.01 49.47 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 124.653 1.181 . . . . 0.0 109.087 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.9 tt -101.39 131.6 48.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 CA-C-N 118.673 0.669 . . . . 0.0 110.01 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.64 145.49 49.6 Favored Pre-proline 0 N--CA 1.452 -0.358 0 C-N-CA 126.069 1.748 . . . . 0.0 108.036 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -62.82 141.97 86.93 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 121.749 1.633 . . . . 0.0 108.598 174.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.6 tt -53.61 -27.29 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 114.334 1.235 . . . . 0.0 114.334 -174.431 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.7 p -55.02 -29.0 56.41 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.879 0.871 . . . . 0.0 111.553 176.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -78.98 -1.45 35.47 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.81 0.844 . . . . 0.0 112.937 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.4 t -81.68 134.58 50.42 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.068 -1.02 . . . . 0.0 110.181 -178.292 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -77.83 54.1 4.68 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.741 2.961 . . . . 0.0 111.934 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -167.98 109.28 0.58 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.308 0.958 . . . . 0.0 110.651 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -29.43 -54.48 0.14 Allowed 'General case' 0 C--O 1.234 0.249 0 C-N-CA 128.35 2.66 . . . . 0.0 115.186 -177.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -51.56 -40.49 25.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.973 0.416 . . . . 0.0 110.565 -176.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.469 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 24.5 m-85 -83.15 -52.87 6.23 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 177.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -46.66 -39.94 12.27 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 114.349 1.241 . . . . 0.0 114.349 -177.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -109.11 22.77 24.62 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-O 118.339 -1.256 . . . . 0.0 111.39 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.8 mppt? 70.69 -45.02 0.6 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.028 1.731 . . . . 0.0 114.384 178.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.8 tpp 32.76 -68.92 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 130.2 3.4 . . . . 0.0 116.703 -178.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.32 -26.01 42.28 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.974 1.31 . . . . 0.0 112.771 -176.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.12 -154.55 16.09 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -178.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -108.39 153.34 23.43 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 174.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -174.25 -167.46 33.77 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.42 -176.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.506 ' CE2' HG11 ' A' ' 158' ' ' VAL . 9.4 p90 -150.02 165.13 33.64 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.894 1.278 . . . . 0.0 109.044 -178.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -117.85 117.19 28.61 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 123.706 0.802 . . . . 0.0 111.289 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -87.83 134.34 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 103.994 -2.595 . . . . 0.0 103.994 170.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.2 tt -100.89 106.62 45.22 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.054 -4.795 . . . . 0.0 98.054 169.287 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_endo -83.92 161.38 13.9 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 123.439 2.76 . . . . 0.0 114.191 -168.051 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.7 p -130.18 -53.39 1.11 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.867 1.267 . . . . 0.0 109.639 176.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -67.11 128.03 34.85 Favored 'General case' 0 CA--C 1.519 -0.214 0 O-C-N 122.18 -0.325 . . . . 0.0 111.493 179.432 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.45 39.55 1.93 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 174.089 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 5.0 mp -143.62 120.53 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 104.676 -2.342 . . . . 0.0 104.676 178.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 69.8 t -119.41 120.08 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 C-N-CA 125.695 1.598 . . . . 0.0 107.415 -176.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 22.0 m -106.77 157.29 7.06 Favored 'Isoleucine or valine' 0 C--N 1.338 0.099 0 N-CA-C 114.42 1.266 . . . . 0.0 114.42 -175.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 48.2 m -61.62 125.76 85.32 Favored Pre-proline 0 CA--C 1.537 0.48 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.488 179.017 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -77.52 -4.12 14.31 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 124.945 3.763 . . . . 0.0 116.012 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.5 m -155.21 172.88 0.57 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 125.297 1.439 . . . . 0.0 108.055 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . 0.421 ' NE ' ' H ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -76.26 87.89 3.09 Favored 'General case' 0 C--N 1.34 0.16 1 N-CA-C 98.374 -4.676 . . . . 0.0 98.374 168.028 . . . . . . . . 4 4 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.07 176.26 30.43 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 118.543 2.177 . . . . 0.0 118.543 -164.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.01 110.54 5.31 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 172.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.2 mm -61.82 125.14 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 37.1 mt -78.95 -48.75 13.94 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 105.779 -1.934 . . . . 0.0 105.779 173.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -173.25 159.33 3.8 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.4 t -135.4 119.81 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 102.879 -3.008 . . . . 0.0 102.879 173.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -45.55 147.39 1.49 Allowed Pre-proline 0 CA--C 1.535 0.384 0 O-C-N 123.43 0.456 . . . . 0.0 111.55 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -56.51 -25.96 61.26 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.642 2.228 . . . . 0.0 111.214 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 55.2 p -79.97 13.49 2.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 117.03 -1.462 . . . . 0.0 112.596 177.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' A' ' 96' ' ' PHE 0.275 0.1 OUTLIER 66.28 -39.6 0.33 Allowed 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 117.857 2.539 . . . . 0.0 117.857 178.477 . . . . . . . . 4 4 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.9 p-80 -57.63 -26.6 61.82 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 116.269 1.951 . . . . 0.0 116.269 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.93 -175.99 5.67 Favored 'General case' 0 C--O 1.221 -0.396 0 N-CA-C 114.292 1.219 . . . . 0.0 114.292 -172.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.847 26.9 mm 127.0 -135.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.52 -0.192 1 C-N-CA 133.25 4.62 . . . . 0.0 110.289 178.51 . . . . . . . . 3 2 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -166.89 173.47 42.2 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 118.43 2.132 . . . . 0.0 118.43 -176.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.7 mp -127.64 175.16 8.49 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 128.208 2.603 . . . . 0.0 109.854 -177.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -137.07 160.74 38.07 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 103.258 -2.867 . . . . 0.0 103.258 168.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 83.6 p . . . . . 0 CA--C 1.535 0.388 0 O-C-N 124.055 0.847 . . . . 0.0 109.448 177.861 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 74.4 mtp180 . . . . . 0 CA--C 1.524 -0.041 0 CA-C-O 121.655 0.74 . . . . 0.0 109.84 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -79.63 109.96 14.51 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 125.327 1.451 . . . . 0.0 107.389 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.4 mp -95.96 116.56 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 C-N-CA 125.381 1.472 . . . . 0.0 109.763 -176.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 9.2 tp -93.58 122.29 35.87 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 105.316 -2.105 . . . . 0.0 105.316 172.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.0 mt -113.82 134.53 56.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 124.938 1.295 . . . . 0.0 108.741 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -131.24 109.76 10.63 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 171.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.435 ' HA ' HG23 ' A' ' 129' ' ' THR . 6.4 t80 -78.51 119.6 22.02 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 118.708 -0.663 . . . . 0.0 109.443 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.1 -161.26 2.97 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-O 121.71 0.617 . . . . 0.0 113.341 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.9 mm -131.17 145.5 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.4 t70 62.67 15.34 7.96 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.5 1.12 . . . . 0.0 113.426 179.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.9 p -78.52 -37.7 42.42 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 126.251 1.821 . . . . 0.0 107.468 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 9.1 p -50.71 -45.26 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 CA-C-N 113.77 -1.559 . . . . 0.0 108.787 172.386 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -63.31 -37.86 88.92 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 125.531 1.532 . . . . 0.0 111.329 178.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.65 -39.44 94.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 127.145 2.178 . . . . 0.0 109.898 -179.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mttp 59.62 88.01 0.08 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.782 1.633 . . . . 0.0 114.223 175.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.4 -55.63 2.85 Favored Glycine 0 CA--C 1.539 1.582 0 O-C-N 121.375 -0.828 . . . . 0.0 112.856 175.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -28.17 108.3 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 128.911 2.884 . . . . 0.0 114.034 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 92.24 -2.14 74.39 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-N 113.976 -1.466 . . . . 0.0 114.764 175.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.473 ' CG ' HG12 ' A' ' 115' ' ' VAL . 2.4 m-85 -108.86 109.51 20.63 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 117.857 0.828 . . . . 0.0 109.823 -176.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.7 m -79.9 81.18 6.2 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 102.741 -3.059 . . . . 0.0 102.741 169.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.8 p -76.99 114.09 15.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 -178.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . 0.402 ' CE1' ' HG3' ' A' ' 114' ' ' GLU . 22.7 m-85 -77.64 -46.17 22.86 Favored 'General case' 0 CA--C 1.511 -0.551 0 C-N-CA 123.459 0.703 . . . . 0.0 111.297 -173.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.56 125.98 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 C-N-CA 117.122 -1.831 . . . . 0.0 109.96 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.7 m -92.48 58.39 3.16 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 102.375 -3.195 . . . . 0.0 102.375 168.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.449 0.0 OUTLIER 30.47 54.35 0.16 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 129.307 3.043 . . . . 0.0 112.907 -168.43 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.03 62.92 2.08 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 110.265 -3.152 . . . . 0.0 110.712 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 33.0 t70 3.92 -106.46 0.0 OUTLIER 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 130.098 3.359 . . . . 0.0 116.312 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -55.14 106.99 0.26 Allowed 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.084 1.754 . . . . 0.0 111.617 -173.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 2.5 m -124.14 157.1 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 126.811 2.044 . . . . 0.0 111.692 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.4 mm-40 -86.83 164.17 37.97 Favored Pre-proline 0 CA--C 1.535 0.379 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 172.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -70.25 154.21 65.98 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 N-CA-C 106.58 -2.123 . . . . 0.0 106.58 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.9 -15.15 8.62 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 119.586 -1.292 . . . . 0.0 114.072 178.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.29 125.96 25.66 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 106.606 -1.628 . . . . 0.0 106.606 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . 0.311 0.0 OUTLIER -66.74 119.95 12.68 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.102 0.865 . . . . 0.0 111.428 -177.268 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 77.4 mt -79.67 -41.5 26.74 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.3 mp -147.82 146.26 29.06 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.126 0.97 . . . . 0.0 111.059 -178.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG3' ' CE1' ' A' ' 99' ' ' PHE . 93.7 mt-10 -114.55 130.6 56.77 Favored 'General case' 0 N--CA 1.463 0.196 1 N-CA-C 99.203 -4.369 . . . . 0.0 99.203 166.539 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . 0.473 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -138.74 127.81 30.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.633 -164.307 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -75.71 65.41 1.87 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-O 121.137 0.494 . . . . 0.0 110.247 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.5 mt -50.42 -38.1 41.37 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 123.617 0.767 . . . . 0.0 111.796 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -54.21 -40.19 67.38 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 122.899 0.48 . . . . 0.0 112.162 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -91.06 -32.77 15.76 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 122.829 0.452 . . . . 0.0 111.34 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.27 -48.58 84.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 O-C-N 121.622 -0.673 . . . . 0.0 109.699 178.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.376 40.6 pttt -41.73 -58.38 3.23 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 116.498 2.036 . . . . 0.0 116.498 -177.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -59.42 -20.0 54.22 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.258 1.972 . . . . 0.0 113.137 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -95.61 9.11 41.37 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.773 0.829 . . . . 0.0 112.351 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 31.4 m -133.44 149.46 72.38 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 119.747 1.158 . . . . 0.0 109.9 177.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -72.24 -27.71 16.22 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.576 2.184 . . . . 0.0 111.187 179.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 5.4 m -160.2 138.31 10.03 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.0 tp -91.54 7.11 42.94 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.344 1.058 . . . . 0.0 111.524 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 20.3 mmt -50.3 116.13 1.74 Allowed 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.71 0.804 . . . . 0.0 109.226 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.435 HG23 ' HA ' ' A' ' 84' ' ' PHE . 50.1 m -108.59 84.38 2.42 Favored Pre-proline 0 N--CA 1.444 -0.744 0 C-N-CA 124.276 1.03 . . . . 0.0 108.317 -179.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.469 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 72.5 Cg_endo -72.41 142.29 36.72 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.44 2.094 . . . . 0.0 110.765 179.039 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 29.6 mt -131.15 128.52 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 104.459 -2.422 . . . . 0.0 104.459 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -125.59 152.55 32.56 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 C-N-CA 125.314 1.446 . . . . 0.0 107.863 -177.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -120.69 117.8 28.43 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 102.867 -3.012 . . . . 0.0 102.867 177.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.4 p -81.38 -67.89 0.74 Allowed 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.478 0.656 . . . . 0.0 110.353 -173.003 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.6 p30 -70.82 51.88 0.14 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 126.442 1.897 . . . . 0.0 113.034 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.7 mt -75.72 63.84 1.66 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.809 1.244 . . . . 0.0 108.874 177.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 24.32 49.96 0.01 OUTLIER 'General case' 0 C--N 1.346 0.445 0 C-N-CA 128.969 2.908 . . . . 0.0 112.051 -176.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 28.03 54.21 0.07 Allowed 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 128.649 2.78 . . . . 0.0 114.135 -174.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.9 0.05 OUTLIER Glycine 0 CA--C 1.528 0.873 0 CA-C-O 118.853 -0.97 . . . . 0.0 114.3 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 26.8 mt-10 -80.96 138.34 36.09 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.152 1.476 . . . . 0.0 109.701 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 7.7 p -111.08 139.39 46.48 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.223 1.409 . . . . 0.0 109.273 179.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.64 120.79 35.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.3 m -114.75 95.71 5.37 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.665 1.186 . . . . 0.0 111.308 -174.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 2.3 pt -63.32 124.75 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 176.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -96.08 -53.82 3.52 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.655 1.182 . . . . 0.0 108.376 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -86.22 74.0 10.11 Favored 'General case' 0 N--CA 1.456 -0.136 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 47.1 p -77.04 72.76 3.61 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 -179.364 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 179.87 -136.51 2.77 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -177.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.0 t -69.0 148.78 49.6 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.38 163.02 38.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 C-N-CA 125.222 1.409 . . . . 0.0 108.097 177.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -133.44 162.59 31.46 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.687 1.195 . . . . 0.0 109.039 -178.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 68.6 mtp180 -65.23 147.6 53.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.869 0.468 . . . . 0.0 110.509 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 25.8 tp10 57.65 12.97 1.76 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 126.847 2.059 . . . . 0.0 114.749 173.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -71.55 117.87 13.66 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -65.97 137.47 57.15 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . 0.462 ' C ' ' H ' ' A' ' 158' ' ' VAL . 27.9 t0 74.18 -111.81 0.04 OUTLIER 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 128.027 2.531 . . . . 0.0 108.448 -175.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.271 1.6 mp 70.86 -29.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 129.456 3.103 . . . . 0.0 110.866 -176.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.506 HG11 ' CE2' ' A' ' 43' ' ' PHE . 6.2 p -143.35 119.4 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 130.197 3.399 . . . . 0.0 105.003 173.148 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 28.0 tttm -111.9 139.3 47.5 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.767 0.427 . . . . 0.0 110.077 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.533 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.14 132.06 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 172.152 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -141.26 167.96 20.91 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 106.627 -1.619 . . . . 0.0 106.627 177.482 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 24.1 tptp . . . . . 0 C--N 1.33 -0.239 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.865 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.45 -0.462 0 CA-C-O 121.146 0.498 . . . . 0.0 109.691 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.7 m -77.9 84.16 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 O-C-N 121.857 -0.527 . . . . 0.0 111.747 -176.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.7 t -10.66 112.97 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 128.64 2.776 . . . . 0.0 113.796 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.42 -32.3 3.02 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 122.601 2.201 . . . . 0.0 115.781 -174.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.65 139.62 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 120.4 1.455 . . . . 0.0 109.933 -177.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 56.4 m -78.18 140.84 38.97 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 168.28 -159.82 33.15 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 -103.02 126.44 50.2 Favored 'General case' 0 N--CA 1.458 -0.072 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 176.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.2 tt -97.26 141.27 16.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 CA-C-N 118.57 0.623 . . . . 0.0 109.695 -179.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 25.5 m-70 -136.78 148.31 62.81 Favored Pre-proline 0 C--O 1.235 0.316 0 C-N-CA 124.701 1.2 . . . . 0.0 108.019 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.89 146.11 69.61 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.025 1.817 . . . . 0.0 110.176 176.151 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.7 tp -49.53 -34.88 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 C-N-CA 123.766 0.826 . . . . 0.0 113.117 -177.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 p -55.83 -26.78 48.25 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.863 0.865 . . . . 0.0 112.581 178.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -74.99 -13.05 60.47 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.829 0.852 . . . . 0.0 112.594 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.522 HG22 ' HB2' ' A' ' 44' ' ' ALA . 46.3 t -67.85 129.18 93.36 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.306 -0.871 . . . . 0.0 110.057 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -76.52 59.48 6.2 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 124.197 3.265 . . . . 0.0 111.849 -178.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -169.08 108.66 0.45 Allowed 'General case' 0 N--CA 1.465 0.296 0 O-C-N 121.351 -0.843 . . . . 0.0 110.104 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -24.25 -58.86 0.05 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.153 2.581 . . . . 0.0 114.98 -179.018 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 52.7 t -52.9 -50.24 44.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.613 0.765 . . . . 0.0 110.082 -178.06 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -71.49 -48.36 49.53 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.3 m -49.44 -43.11 44.59 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.968 0.907 . . . . 0.0 113.068 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.94 11.88 69.1 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-O 118.907 -0.94 . . . . 0.0 111.456 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt 71.55 -37.18 0.38 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.749 1.62 . . . . 0.0 113.358 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 30.8 -71.78 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 131.063 3.745 . . . . 0.0 116.538 178.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 37.8 tpp -78.4 -16.82 57.23 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.013 0.925 . . . . 0.0 112.145 -175.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.99 -133.93 2.11 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -146.26 163.31 35.89 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 173.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 164.87 -134.9 3.49 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -168.07 169.89 10.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 117.967 0.884 . . . . 0.0 111.546 -177.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.522 ' HB2' HG22 ' A' ' 29' ' ' VAL . . . -102.22 132.46 48.13 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 124.061 0.945 . . . . 0.0 109.25 179.12 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -109.39 135.62 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 103.102 -2.925 . . . . 0.0 103.102 168.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.1 tt -101.25 104.74 35.14 Favored Pre-proline 0 N--CA 1.447 -0.619 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 171.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.16 169.81 1.36 Allowed 'Trans proline' 0 C--N 1.348 0.543 1 C-N-CA 125.375 4.05 . . . . 0.0 116.278 -171.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 65.7 p -155.38 -54.94 0.09 Allowed 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 124.14 0.976 . . . . 0.0 111.279 176.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -57.84 -43.86 86.11 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -176.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.29 25.81 69.83 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -174.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -139.04 130.9 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 176.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.7 t -125.11 126.07 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 -175.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.1 m -105.71 162.84 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 C-N-CA 124.013 0.925 . . . . 0.0 111.075 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 15.9 m -67.46 126.39 92.49 Favored Pre-proline 0 CA--C 1.536 0.419 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -75.66 -16.72 18.63 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 124.125 3.216 . . . . 0.0 115.577 -174.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.18 163.97 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.067 0 CA-C-N 118.861 0.755 . . . . 0.0 109.183 -174.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 18.1 ttt85 -75.67 119.29 19.5 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 100.31 -3.959 . . . . 0.0 100.31 169.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.1 177.1 48.32 Favored Glycine 0 N--CA 1.436 -1.31 0 C-N-CA 116.562 -2.732 . . . . 0.0 115.089 -168.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.01 133.85 34.96 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 10.0 mm -79.22 100.03 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 172.272 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 46.7 tp -73.66 -56.5 4.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 -174.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.83 163.86 5.07 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 115.936 1.828 . . . . 0.0 115.936 174.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.5 m -144.18 118.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 176.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -40.12 153.8 0.2 Allowed Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 119.086 0.857 . . . . 0.0 111.8 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.02 -22.01 44.67 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.262 2.641 . . . . 0.0 113.545 178.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 17.8 p -77.1 -7.73 56.26 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.947 1.299 . . . . 0.0 110.939 177.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.09 25.17 10.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 127.106 2.162 . . . . 0.0 110.692 -174.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -93.94 -28.03 16.03 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.87 -178.23 4.18 Favored 'General case' 0 C--O 1.222 -0.365 0 CA-C-N 120.146 1.339 . . . . 0.0 109.768 -178.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.47 HG22 ' N ' ' A' ' 71' ' ' GLY 0.752 24.2 mm 137.73 -125.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.409 1 C-N-CA 132.95 4.5 . . . . 0.0 109.676 177.162 . . . . . . . . 4 3 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . 0.47 ' N ' HG22 ' A' ' 70' ' ' ILE . . . -177.04 174.69 47.26 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 117.172 1.629 . . . . 0.0 117.172 -177.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.3 mp -128.51 169.78 13.95 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 127.612 2.365 . . . . 0.0 110.137 -176.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 84.5 mt-30 -143.1 126.47 16.68 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 123.313 0.645 . . . . 0.0 111.049 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 m . . . . . 0 CA--C 1.533 0.296 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 174.791 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? . . . . . 0 CA--C 1.531 0.219 0 N-CA-C 110.083 -0.34 . . . . 0.0 110.083 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -95.71 132.42 40.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.247 1.419 . . . . 0.0 107.803 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.75 113.59 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 C-N-CA 124.128 0.971 . . . . 0.0 111.538 -174.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.6 tt -85.56 137.41 32.89 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 106.006 -1.85 . . . . 0.0 106.006 171.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.1 mt -133.19 137.18 53.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.188 0.995 . . . . 0.0 109.574 179.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . 0.429 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 45.4 t-80 -126.16 120.51 30.28 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 171.469 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -68.92 122.18 18.12 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 175.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.37 -147.1 0.97 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-N 119.245 0.929 . . . . 0.0 113.119 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.7 mm -128.06 143.57 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.4 t0 49.31 44.13 23.37 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.418 1.087 . . . . 0.0 113.044 178.438 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.5 p -90.79 -19.05 23.9 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.655 1.582 . . . . 0.0 108.427 177.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.4 p -52.39 -46.22 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 174.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.8 m -61.63 -23.17 65.86 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.62 1.568 . . . . 0.0 112.736 176.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.54 -18.5 59.76 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.312 1.445 . . . . 0.0 108.836 177.312 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 59.9 mttm 47.95 33.89 3.7 Favored 'General case' 0 C--N 1.344 0.336 0 C-N-CA 125.831 1.652 . . . . 0.0 112.379 178.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.1 17.03 54.71 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.321 -1.266 . . . . 0.0 114.446 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.71 1.88 1.6 Allowed 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 120.232 2.016 . . . . 0.0 115.116 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -136.43 18.03 3.71 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 126.668 2.08 . . . . 0.0 110.193 175.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.61 ' CD1' HG12 ' A' ' 115' ' ' VAL . 22.4 m-30 -118.75 155.94 30.23 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.702 1.251 . . . . 0.0 110.638 -177.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.7 m -148.95 131.0 15.34 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.0 p -101.48 146.32 27.8 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 123.658 0.783 . . . . 0.0 112.173 -176.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -127.34 20.42 6.78 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.698 1.599 . . . . 0.0 113.753 -174.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.5 m -150.62 154.21 9.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.208 0 C-N-CA 123.861 0.864 . . . . 0.0 109.27 175.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.9 m -87.71 125.32 34.34 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 170.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.84 78.72 2.11 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 123.189 1.471 . . . . 0.0 109.851 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 179.06 -18.4 0.03 OUTLIER Glycine 0 CA--C 1.532 1.15 0 C-N-CA 128.447 2.927 . . . . 0.0 110.601 -176.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -53.41 120.09 5.64 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.168 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.14 115.4 28.96 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 127.709 2.404 . . . . 0.0 113.167 -170.161 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.372 20.8 m 52.03 74.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 117.154 2.279 . . . . 0.0 117.154 175.054 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -140.71 144.72 37.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 168.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -102.82 171.74 0.22 Allowed 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 123.733 2.955 . . . . 0.0 109.68 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 52.71 -8.82 0.01 OUTLIER Glycine 0 CA--C 1.536 1.399 0 N-CA-C 120.039 2.775 . . . . 0.0 120.039 170.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.2 tp60 -59.22 142.01 52.86 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 120.957 2.378 . . . . 0.0 109.264 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 16.6 ptpt -61.07 114.26 3.01 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 175.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 78.2 mt -79.53 -52.26 8.25 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 20.5 mt -141.41 159.34 42.43 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.979 0.511 . . . . 0.0 111.625 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -122.46 134.69 54.58 Favored 'General case' 0 CA--C 1.516 -0.363 1 N-CA-C 99.965 -4.087 . . . . 0.0 99.965 166.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . 0.61 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.1 OUTLIER -147.37 117.92 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -166.826 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -71.12 72.59 0.61 Allowed 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.799 1.639 . . . . 0.0 111.978 -175.352 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.6 mt -47.71 -42.18 24.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.493 178.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -54.21 -39.89 67.11 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.72 -33.52 19.98 Favored 'General case' 0 CA--C 1.529 0.141 0 CA-C-O 120.815 0.341 . . . . 0.0 111.125 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.98 -50.36 65.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 O-C-N 121.705 -0.622 . . . . 0.0 110.237 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.388 3.2 pptp? -42.59 -54.93 7.65 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -178.485 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.16 -24.2 76.13 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.422 2.082 . . . . 0.0 112.862 177.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -84.15 -42.77 15.66 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.806 0.73 . . . . 0.0 111.108 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.2 m -78.69 147.91 71.96 Favored Pre-proline 0 CA--C 1.535 0.398 0 O-C-N 122.025 -0.422 . . . . 0.0 111.769 -177.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -70.48 -27.28 23.24 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.617 2.211 . . . . 0.0 110.462 176.154 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.8 m -158.04 137.81 12.16 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.659 1.184 . . . . 0.0 108.218 179.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -87.1 2.96 48.1 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 124.313 1.045 . . . . 0.0 111.788 -178.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.3 mmt -55.04 103.92 0.1 Allowed 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.029 0.932 . . . . 0.0 110.346 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 53.3 m -90.05 105.32 10.89 Favored Pre-proline 0 N--CA 1.445 -0.69 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD2' ' HB3' ' A' ' 83' ' ' HIS . 1.7 Cg_endo -84.26 136.8 6.86 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.723 2.282 . . . . 0.0 108.521 -177.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.1 mt -118.88 120.22 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.817 0 N-CA-C 102.721 -3.066 . . . . 0.0 102.721 175.284 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.3 t -130.05 114.73 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.598 0 CA-C-O 122.368 1.08 . . . . 0.0 108.242 -177.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.473 ' CB ' HD21 ' A' ' 136' ' ' LEU . 4.0 m-85 -81.89 116.8 21.71 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 103.914 -2.624 . . . . 0.0 103.914 176.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 82.1 p -83.03 -83.47 0.14 Allowed 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.94 0.4 . . . . 0.0 110.319 -173.658 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -75.61 64.27 1.65 Allowed 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.542 0.737 . . . . 0.0 110.806 179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . 0.473 HD21 ' CB ' ' A' ' 133' ' ' PHE . 17.0 mt -65.33 -29.76 70.54 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 124.288 1.035 . . . . 0.0 112.968 178.715 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 127.76 -132.7 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 1 C-N-CA 132.631 4.372 . . . . 0.0 105.587 -176.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -136.1 146.6 47.17 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 127.228 2.211 . . . . 0.0 108.471 177.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 59.33 37.53 92.06 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 -177.053 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.403 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 0.0 OUTLIER -97.35 82.42 3.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 C-N-CA 126.127 1.771 . . . . 0.0 107.569 -177.421 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 71.1 p -79.48 115.22 18.98 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.071 178.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -72.93 78.83 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -178.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -82.72 92.32 7.18 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.842 -176.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 39.9 mt -65.44 129.83 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.272 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 9.8 mmpt? -98.21 -51.03 4.14 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.508 1.523 . . . . 0.0 108.853 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -75.65 69.55 2.37 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.57 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 54.2 p -77.48 73.4 4.05 Favored 'General case' 0 CA--C 1.533 0.304 0 O-C-N 121.368 -0.832 . . . . 0.0 108.851 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 175.12 -124.61 1.02 Allowed Glycine 0 CA--C 1.52 0.401 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -177.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.2 t -94.15 151.0 19.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 2.6 m -131.72 148.85 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 125.031 1.332 . . . . 0.0 107.586 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -114.89 155.32 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 177.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.8 mtm105 -57.74 157.64 7.13 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 120.913 0.387 . . . . 0.0 110.483 177.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 70.25 -12.59 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.568 1.547 . . . . 0.0 115.055 175.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -63.17 131.51 48.71 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-N 119.989 1.268 . . . . 0.0 107.745 176.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -97.32 -36.37 10.42 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 115.51 1.671 . . . . 0.0 115.51 -173.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -87.62 21.4 2.58 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 127.658 2.383 . . . . 0.0 113.938 -176.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -71.29 -26.57 27.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.6 p -142.39 152.59 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 125.567 1.547 . . . . 0.0 108.643 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -128.24 116.51 19.98 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 173.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.89 87.0 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 102.554 -3.128 . . . . 0.0 102.554 172.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -85.88 148.33 25.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.461 1.104 . . . . 0.0 111.004 -173.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.8 mmtt . . . . . 0 N--CA 1.455 -0.19 0 C-N-CA 124.057 0.943 . . . . 0.0 109.604 178.07 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.41 ' CZ ' ' CE1' ' A' ' 133' ' ' PHE . 0.1 OUTLIER . . . . . 0 N--CA 1.455 -0.206 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 . . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 m -115.99 96.28 4.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.388 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 177.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 90.6 p -35.23 119.11 0.6 Allowed Pre-proline 0 CA--C 1.556 1.206 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -77.64 -28.39 5.37 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.677 2.251 . . . . 0.0 116.738 -171.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.29 146.07 28.52 Favored 'Isoleucine or valine' 0 C--N 1.341 0.239 0 CA-C-N 119.42 1.009 . . . . 0.0 110.96 -176.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.4 m -79.04 137.75 37.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 172.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 167.41 -150.35 16.76 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.193 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -118.18 129.18 55.36 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.152 0.981 . . . . 0.0 109.153 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 2.7 mt -79.95 137.27 21.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 176.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -131.16 144.58 54.09 Favored Pre-proline 0 N--CA 1.45 -0.429 0 C-N-CA 126.003 1.721 . . . . 0.0 106.732 175.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -58.22 143.55 96.84 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.407 2.071 . . . . 0.0 110.001 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.1 tp -52.38 -39.75 29.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.207 0.527 . . . . 0.0 111.24 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 p -56.0 -28.1 55.77 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.565 1.546 . . . . 0.0 112.902 177.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -79.68 -8.24 59.1 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.414 0.686 . . . . 0.0 112.826 -178.382 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.472 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 58.8 t -69.71 123.43 88.56 Favored Pre-proline 0 CA--C 1.539 0.539 0 CA-C-O 117.82 -1.086 . . . . 0.0 111.693 -177.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 29' ' ' VAL . 50.0 Cg_exo -61.43 61.55 0.11 Allowed 'Trans proline' 0 CA--C 1.549 1.233 0 C-N-CA 124.971 3.781 . . . . 0.0 115.137 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -168.59 131.72 1.44 Allowed 'General case' 0 CA--C 1.528 0.12 0 O-C-N 120.565 -1.334 . . . . 0.0 108.447 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -53.89 -51.09 64.8 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 113.884 1.068 . . . . 0.0 113.884 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.8 t -54.71 -55.96 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 123.22 0.608 . . . . 0.0 109.603 -178.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -64.06 -54.09 39.55 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.819 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 79.3 p -58.05 -34.14 69.77 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 113.517 0.932 . . . . 0.0 113.517 -178.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -89.64 10.73 72.52 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-O 118.173 -1.348 . . . . 0.0 110.854 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 72.18 -40.77 0.48 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 125.873 1.669 . . . . 0.0 112.793 -177.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 14.9 tpt 25.43 -68.87 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 130.907 3.683 . . . . 0.0 117.144 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.7 tpp -78.96 -20.95 47.95 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.505 1.122 . . . . 0.0 113.53 -175.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 171.45 -145.36 8.77 Favored Glycine 0 C--N 1.337 0.617 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 -178.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -136.18 160.77 37.67 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.219 1.01 . . . . 0.0 108.559 174.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . 0.421 ' HA2' HG21 ' A' ' 142' ' ' VAL . . . 165.28 -130.31 2.14 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -178.42 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . 0.493 ' CE2' HG21 ' A' ' 158' ' ' VAL . 8.5 p90 -166.39 173.62 9.79 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 117.822 0.811 . . . . 0.0 110.485 -175.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.472 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -113.25 140.71 47.74 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 178.193 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -111.47 136.23 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.603 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 169.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.6 105.63 34.98 Favored Pre-proline 0 N--CA 1.444 -0.759 0 N-CA-C 100.64 -3.837 . . . . 0.0 100.64 170.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -59.56 172.79 1.85 Allowed 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 124.548 3.499 . . . . 0.0 115.482 -173.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 67.3 p -154.34 -64.37 0.13 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 123.895 0.878 . . . . 0.0 110.504 177.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -51.4 -46.87 63.02 Favored 'General case' 0 C--N 1.335 -0.06 0 C-N-CA 125.859 1.664 . . . . 0.0 114.913 -176.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.31 28.93 60.96 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.811 -1.315 . . . . 0.0 109.811 -173.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.7 mt -139.58 120.65 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 102.664 -3.087 . . . . 0.0 102.664 177.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 45.0 t -126.12 123.74 64.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 C-N-CA 124.26 1.024 . . . . 0.0 109.764 -171.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.5 m -109.6 169.66 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.187 0.995 . . . . 0.0 109.036 176.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.1 p -63.7 148.66 94.04 Favored Pre-proline 0 CA--C 1.537 0.48 0 O-C-N 121.331 -0.856 . . . . 0.0 111.071 -177.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -87.64 -16.14 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 124.29 3.327 . . . . 0.0 112.707 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.1 m -145.32 166.83 10.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 123.891 0.876 . . . . 0.0 110.052 -176.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.1 mtt-85 -78.46 119.54 21.92 Favored 'General case' 0 N--CA 1.454 -0.253 1 N-CA-C 98.887 -4.486 . . . . 0.0 98.887 168.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 171.37 -177.4 44.27 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 115.078 -3.439 . . . . 0.0 115.587 -167.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.73 135.51 41.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 126.011 1.724 . . . . 0.0 110.451 -177.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.4 mm -79.07 114.9 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 103.537 -2.764 . . . . 0.0 103.537 170.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 34.3 tp -77.8 -53.41 7.53 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -176.29 155.79 1.52 Allowed 'General case' 0 C--O 1.228 -0.033 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.5 m -135.32 120.73 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.417 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -43.77 149.75 0.61 Allowed Pre-proline 0 CA--C 1.539 0.538 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -49.65 -28.16 16.46 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 124.077 3.184 . . . . 0.0 113.861 177.08 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 24.7 p -78.02 1.22 21.6 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.457 0.703 . . . . 0.0 111.969 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 46.84 62.35 2.4 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 127.323 2.249 . . . . 0.0 113.125 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 15.4 p-80 -146.93 -38.82 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 122.307 -0.246 . . . . 0.0 111.619 176.147 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -128.19 177.32 7.0 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.694 24.5 mm 116.0 -134.38 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.306 0 C-N-CA 131.654 3.982 . . . . 0.0 108.342 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -171.88 179.71 43.38 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 118.637 2.215 . . . . 0.0 118.637 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.7 mp -126.53 173.07 9.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 127.771 2.428 . . . . 0.0 109.073 -177.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -145.09 137.84 26.24 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 176.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 84.1 p . . . . . 0 CA--C 1.535 0.396 0 CA-C-O 121.154 0.502 . . . . 0.0 109.812 178.86 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.2 mtp-105 . . . . . 0 N--CA 1.457 -0.106 0 CA-C-O 121.456 0.646 . . . . 0.0 109.489 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -77.95 125.57 29.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.06 108.37 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 C-N-CA 124.722 1.209 . . . . 0.0 109.597 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -85.01 134.48 34.22 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 126.083 1.753 . . . . 0.0 106.732 174.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.0 mt -128.01 153.79 37.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 C-N-CA 125.339 1.455 . . . . 0.0 110.106 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -151.25 76.46 1.22 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 125.788 1.635 . . . . 0.0 109.191 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . 0.415 ' HA ' HG23 ' A' ' 129' ' ' THR . 1.7 t80 -50.86 104.07 0.07 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.186 0.594 . . . . 0.0 112.592 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.62 173.27 5.39 Favored Glycine 0 CA--C 1.533 1.189 0 C-N-CA 124.685 1.136 . . . . 0.0 112.745 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.1 mm -108.72 130.93 60.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 124.484 1.114 . . . . 0.0 108.932 -178.301 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 48.89 43.1 21.34 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.965 1.306 . . . . 0.0 110.917 -178.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.6 -72.6 0.61 Allowed 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 102.16 -3.274 . . . . 0.0 102.16 174.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . 0.33 3.3 p 44.89 49.64 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 104.065 -2.568 . . . . 0.0 104.065 -173.507 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . 0.441 ' HB3' ' CD1' ' A' ' 96' ' ' PHE . 19.3 m 12.1 45.83 0.0 OUTLIER 'General case' 0 C--N 1.349 0.565 1 C-N-CA 134.077 4.951 . . . . 0.0 114.178 -164.679 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 91' ' ' LEU . 2.0 mt 37.48 50.16 1.07 Allowed 'General case' 0 N--CA 1.434 -1.235 0 C-N-CA 130.492 3.517 . . . . 0.0 107.139 178.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 76.43 53.52 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 128.798 2.839 . . . . 0.0 111.36 -176.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.04 -64.12 1.61 Allowed Glycine 0 CA--C 1.535 1.296 0 C-N-CA 124.387 0.994 . . . . 0.0 111.713 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 22.62 -98.22 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 127.694 2.397 . . . . 0.0 115.873 178.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -59.89 -1.68 1.53 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 127.302 2.382 . . . . 0.0 115.859 -176.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' A' ' 90' ' ' SER . 4.6 m-85 -103.75 97.54 7.54 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 119.001 1.4 . . . . 0.0 113.145 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.9 m -80.05 99.99 7.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 105.785 -1.931 . . . . 0.0 105.785 173.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 29.0 p -83.45 135.37 34.7 Favored 'General case' 0 N--CA 1.451 -0.414 0 O-C-N 121.556 -0.715 . . . . 0.0 110.945 -178.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -103.79 -42.12 5.71 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.058 1.343 . . . . 0.0 111.927 -177.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.28 136.0 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.736 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 58.7 m -87.83 66.43 8.76 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 170.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.258 1.6 pm0 -24.72 96.69 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 129.074 2.95 . . . . 0.0 112.999 -173.162 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 154.06 -17.96 0.63 Allowed Glycine 0 CA--C 1.537 1.466 0 C-N-CA 128.157 2.789 . . . . 0.0 109.744 -175.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -42.87 107.74 0.09 Allowed 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 129.612 3.165 . . . . 0.0 107.821 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.0 119.3 30.24 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 127.496 2.318 . . . . 0.0 114.077 -172.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.336 34.4 m 48.02 66.82 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 126.653 1.981 . . . . 0.0 115.395 177.461 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.97 133.79 25.19 Favored Pre-proline 0 N--CA 1.454 -0.275 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 171.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -98.4 147.15 0.65 Allowed 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 123.346 2.697 . . . . 0.0 110.472 -177.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 58.02 18.37 33.54 Favored Glycine 0 CA--C 1.528 0.894 0 O-C-N 121.724 -0.61 . . . . 0.0 113.551 177.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -61.96 139.51 58.39 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -66.06 116.88 7.64 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 49.6 mt -81.04 -54.19 5.77 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.7 mt -149.08 157.45 43.41 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.34 0.656 . . . . 0.0 111.856 -172.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -124.75 129.42 50.44 Favored 'General case' 0 CA--C 1.519 -0.234 1 N-CA-C 98.738 -4.541 . . . . 0.0 98.738 165.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . 0.408 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -139.22 127.91 28.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -164.101 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -75.01 67.41 1.71 Allowed 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.045 0.938 . . . . 0.0 110.48 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 93.1 mt -52.05 -45.85 64.85 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.194 179.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -48.98 -45.3 41.94 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 124.231 1.012 . . . . 0.0 112.611 -178.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.84 -33.91 24.77 Favored 'General case' 0 CA--C 1.527 0.092 0 CA-C-N 118.184 0.447 . . . . 0.0 111.6 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.08 -58.49 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 O-C-N 121.937 -0.477 . . . . 0.0 109.806 178.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 2.5 pptp? -38.16 -57.0 1.87 Allowed Pre-proline 0 CA--C 1.542 0.658 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 -176.664 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -60.88 -18.25 55.74 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.427 2.085 . . . . 0.0 113.572 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -104.55 10.66 34.95 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 118.386 -0.816 . . . . 0.0 112.797 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 26.9 m -137.57 151.97 71.97 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 119.884 1.22 . . . . 0.0 110.595 -178.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -64.45 -36.22 45.21 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.086 2.524 . . . . 0.0 113.202 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.6 t -156.58 153.0 27.95 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 119.059 0.845 . . . . 0.0 110.556 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.4 tp -100.62 -1.77 34.5 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.549 1.54 . . . . 0.0 110.565 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -53.22 116.97 2.68 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 118.311 0.505 . . . . 0.0 109.643 179.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . 0.415 HG23 ' HA ' ' A' ' 84' ' ' PHE . 52.7 m -107.99 118.81 51.85 Favored Pre-proline 0 N--CA 1.446 -0.646 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.391 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -87.05 150.43 8.23 Favored 'Trans proline' 0 N--CA 1.442 -1.525 0 C-N-CA 122.056 1.838 . . . . 0.0 107.75 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.8 mt -132.59 113.93 21.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 101.586 -3.487 . . . . 0.0 101.586 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.94 122.07 51.18 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.012 -173.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . 0.41 ' CE1' ' CZ ' ' A' ' 15' ' ' PHE . 4.7 m-85 -86.29 112.3 21.27 Favored 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 177.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.0 p -74.41 -76.06 0.15 Allowed 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 121.853 0.835 . . . . 0.0 109.401 -175.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -76.78 69.4 3.13 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.707 0.803 . . . . 0.0 110.771 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.3 mt -68.86 169.21 11.94 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 171.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.72 -139.07 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.482 -0.761 . . . . 0.0 111.128 -178.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -67.06 81.12 0.12 Allowed 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.683 0.793 . . . . 0.0 112.417 -176.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 47.51 38.02 13.6 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.76 1.171 . . . . 0.0 111.068 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.572 ' HB3' HG23 ' A' ' 160' ' ' ILE . 70.0 mm-40 -55.23 119.25 5.24 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 111.517 0.192 . . . . 0.0 111.517 -176.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -78.02 132.09 37.64 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 172.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . 0.421 HG21 ' HA2' ' A' ' 42' ' ' GLY 0.266 1.0 OUTLIER -84.99 88.61 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 -176.51 . . . . . . . . 4 4 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.8 t -78.4 83.99 4.59 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -173.183 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . 0.595 HG23 HG22 ' A' ' 158' ' ' VAL . 1.8 mt -62.26 118.92 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 124.595 1.158 . . . . 0.0 108.116 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -97.77 -55.25 2.86 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.974 1.31 . . . . 0.0 108.938 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.71 66.34 1.45 Allowed 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.319 0.648 . . . . 0.0 111.587 -177.396 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 35.1 m -78.61 65.44 3.88 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.556 0.742 . . . . 0.0 109.011 178.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.38 -145.78 6.44 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -177.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 12.3 t -76.2 150.74 37.04 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 117.325 0.563 . . . . 0.0 110.646 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.68 156.02 28.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.087 1.355 . . . . 0.0 108.463 178.168 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -109.45 -171.43 1.84 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.424 1.49 . . . . 0.0 108.489 175.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 52.5 mtm-85 -85.65 157.69 20.27 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.971 0.805 . . . . 0.0 110.354 177.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 45.63 38.91 4.42 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.621 1.969 . . . . 0.0 114.432 177.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -76.09 134.07 40.13 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 104.8 -2.296 . . . . 0.0 104.8 172.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -108.99 35.86 3.09 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.733 0.813 . . . . 0.0 111.759 -177.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -172.6 94.61 0.13 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.198 1.799 . . . . 0.0 108.448 177.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.44 ' N ' HD13 ' A' ' 157' ' ' ILE . 0.2 OUTLIER -150.97 -37.73 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -175.524 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.595 HG22 HG23 ' A' ' 144' ' ' ILE . 57.8 t -151.5 104.29 0.28 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.058 0 CA-C-N 119.397 0.999 . . . . 0.0 108.594 -177.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.2 mttm -90.13 124.49 34.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -176.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.572 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.5 mp -78.86 107.77 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 104.378 -2.453 . . . . 0.0 104.378 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 24.9 pt-20 -153.73 -175.35 5.33 Favored 'General case' 0 C--O 1.227 -0.127 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -175.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 C--N 1.332 -0.185 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.261 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.451 -0.398 0 N-CA-C 107.803 -1.184 . . . . 0.0 107.803 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -78.89 85.15 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.114 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.3 t -10.59 109.39 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.814 0 C-N-CA 127.839 2.456 . . . . 0.0 113.211 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -68.81 -28.15 30.46 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.595 2.197 . . . . 0.0 116.449 -173.318 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -149.0 145.93 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.918 1.235 . . . . 0.0 110.232 -177.322 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.9 m -79.07 136.68 37.23 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.0 -150.11 14.2 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tp10 -117.13 123.21 46.19 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.785 1.634 . . . . 0.0 108.71 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 10.1 mt -85.07 125.66 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -117.92 142.8 31.44 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 173.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -55.15 152.65 29.8 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 121.814 1.676 . . . . 0.0 109.515 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.3 tp -57.06 -49.01 80.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.1 m -67.86 85.41 0.22 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.732 1.613 . . . . 0.0 108.604 176.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.5 t70 172.95 -35.66 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 127.373 2.269 . . . . 0.0 108.81 -176.046 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 96.5 t -52.86 138.29 44.15 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 124.643 1.177 . . . . 0.0 110.558 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -72.95 59.26 3.54 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 124.127 3.218 . . . . 0.0 111.542 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -171.74 130.81 0.68 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 124.923 1.289 . . . . 0.0 108.592 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -62.03 -48.42 80.37 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 124.322 1.049 . . . . 0.0 113.061 -177.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.6 t -50.24 -55.23 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' PHE . . . . . 0.416 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 8.2 m-85 -65.06 -58.79 5.15 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.397 -179.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -58.08 -27.99 64.17 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 115.244 1.572 . . . . 0.0 115.244 -177.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -95.36 10.12 69.38 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-O 117.899 -1.501 . . . . 0.0 110.646 -178.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 61.3 mttm 74.42 -46.25 0.61 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.574 1.55 . . . . 0.0 111.928 -178.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 36.9 ttm 39.29 -64.92 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 130.533 3.533 . . . . 0.0 117.272 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 29.9 ttp -109.34 -10.28 14.93 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.712 1.205 . . . . 0.0 113.452 -176.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -171.83 -165.55 29.18 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-N 119.464 1.029 . . . . 0.0 110.796 -179.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -131.72 156.58 45.67 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 176.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 168.45 -137.07 4.38 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.28 166.13 14.86 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 118.048 0.924 . . . . 0.0 111.214 -175.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' ALA . . . . . 0.416 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -103.31 113.29 26.66 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 123.043 0.537 . . . . 0.0 111.485 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -88.65 129.21 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 103.887 -2.634 . . . . 0.0 103.887 169.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.0 tt -96.03 109.2 45.6 Favored Pre-proline 0 N--CA 1.448 -0.542 1 N-CA-C 98.34 -4.689 . . . . 0.0 98.34 168.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.6 161.54 24.92 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.501 2.801 . . . . 0.0 115.336 -167.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.4 p -136.9 -41.54 0.59 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.588 1.155 . . . . 0.0 111.981 177.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.99 -44.36 91.62 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.37 23.8 77.19 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 -174.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.5 mt -139.99 111.97 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 177.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 47.0 t -100.39 122.71 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.883 1.273 . . . . 0.0 108.673 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.39 156.04 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 123.389 0.676 . . . . 0.0 110.349 177.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 17.4 m -63.88 122.11 75.06 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.81 -21.52 12.52 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 124.923 3.749 . . . . 0.0 114.662 -176.269 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -136.48 173.09 14.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 124.94 1.296 . . . . 0.0 108.842 -175.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.29 90.59 3.76 Favored 'General case' 0 CA--C 1.518 -0.275 1 N-CA-C 98.228 -4.73 . . . . 0.0 98.228 168.858 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -90.26 174.52 40.29 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 117.381 1.712 . . . . 0.0 117.381 -166.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.88 134.09 21.68 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 101.475 -3.528 . . . . 0.0 101.475 170.471 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ILE . . . . . 0.433 HG21 ' HG3' ' A' ' 102' ' ' GLU . 0.2 OUTLIER -88.79 127.3 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -169.791 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.402 ' O ' ' CB ' ' A' ' 62' ' ' ASN . 78.5 mt -79.74 -29.66 40.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 169.161 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 59.1 t30 125.79 -176.53 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 129.587 3.155 . . . . 0.0 109.514 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.98 122.24 51.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 C-N-CA 127.452 2.301 . . . . 0.0 106.353 172.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -44.77 157.92 0.3 Allowed Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 124.315 1.046 . . . . 0.0 111.316 175.361 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -51.4 -29.47 31.05 Favored 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.381 2.721 . . . . 0.0 113.414 174.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.6 p -76.94 -5.98 50.69 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.429 1.092 . . . . 0.0 111.646 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? 60.53 16.4 6.44 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.334 1.854 . . . . 0.0 115.007 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 16.1 p-80 -98.03 -33.77 11.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.562 0.345 . . . . 0.0 111.654 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -149.17 -177.58 5.9 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-N 118.186 0.448 . . . . 0.0 111.929 -173.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ILE . . . . . 0.432 HG22 ' H ' ' A' ' 71' ' ' GLY 0.541 24.4 mm 131.82 -123.39 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.453 1 C-N-CA 136.273 5.829 . . . . 0.0 102.359 -177.199 . . . . . . . . 4 3 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' GLY . . . . . 0.432 ' H ' HG22 ' A' ' 70' ' ' ILE . . . -178.4 -173.23 43.6 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 116.751 -2.643 . . . . 0.0 119.382 177.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.4 mp -137.32 170.83 15.42 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 127.208 2.203 . . . . 0.0 108.488 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -147.83 157.26 43.44 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 172.366 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 81.3 p . . . . . 0 C--O 1.225 -0.235 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 174.27 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.6 mmt85 . . . . . 0 N--CA 1.456 -0.144 0 CA-C-O 121.353 0.597 . . . . 0.0 109.779 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -80.37 110.29 15.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 177.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.94 127.28 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 124.063 0.945 . . . . 0.0 111.464 -174.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 33.5 tp -103.23 135.07 45.57 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 104.375 -2.454 . . . . 0.0 104.375 170.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.4 mt -120.43 155.37 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 C-N-CA 124.965 1.306 . . . . 0.0 107.589 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -149.37 81.95 1.41 Allowed 'General case' 0 C--O 1.224 -0.281 0 N-CA-C 104.96 -2.237 . . . . 0.0 104.96 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -63.12 97.33 0.11 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -176.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 69.27 168.33 5.79 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.226 0.917 . . . . 0.0 111.586 -175.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 15.8 mm -100.26 135.89 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 124.623 1.169 . . . . 0.0 109.094 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 57.24 23.98 9.36 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.943 1.297 . . . . 0.0 112.732 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 p -76.93 -32.97 57.74 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.657 1.583 . . . . 0.0 107.567 175.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.8 p -56.71 -46.16 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-N 113.76 -1.563 . . . . 0.0 107.546 170.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.73 -42.28 98.75 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 124.187 0.995 . . . . 0.0 108.546 176.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -73.61 12.27 0.67 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 125.525 1.53 . . . . 0.0 111.682 175.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 48.3 tttp 45.68 35.06 1.97 Allowed 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.869 2.067 . . . . 0.0 113.258 177.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 55.39 28.44 50.57 Favored Glycine 0 CA--C 1.535 1.289 0 O-C-N 121.751 -0.593 . . . . 0.0 112.751 -179.116 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -70.97 91.56 0.88 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 118.744 1.272 . . . . 0.0 109.769 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 132.61 -1.05 4.72 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 126.435 1.969 . . . . 0.0 111.707 -178.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' PHE . . . . . 0.459 ' CD1' HG12 ' A' ' 115' ' ' VAL . 16.5 m-30 -96.52 131.91 42.64 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 124.507 1.123 . . . . 0.0 109.675 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 10.9 m -120.55 113.96 21.05 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 126.597 1.959 . . . . 0.0 107.316 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 44.9 p -93.38 126.49 38.54 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 121.056 -1.028 . . . . 0.0 111.213 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -90.26 -26.73 19.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 123.932 0.893 . . . . 0.0 108.998 176.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' VAL . . . . . 0.624 ' HB ' ' CG ' ' A' ' 102' ' ' GLU . 3.1 m -52.63 126.83 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-O 121.192 0.52 . . . . 0.0 110.995 179.213 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 24.9 m -115.51 -52.34 2.65 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 127.456 2.302 . . . . 0.0 105.255 175.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' GLU . . . . . 0.624 ' CG ' ' HB ' ' A' ' 100' ' ' VAL . 0.1 OUTLIER 50.77 107.98 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 120.969 3.692 . . . . 0.0 120.969 166.26 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.23 55.35 2.12 Favored Glycine 0 CA--C 1.53 1.0 1 N-CA-C 100.996 -4.842 . . . . 0.0 100.996 164.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.253 7.4 p-10 6.77 70.36 0.0 OUTLIER 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 118.569 2.803 . . . . 0.0 118.569 -169.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -169.58 137.04 1.72 Allowed 'General case' 0 N--CA 1.43 -1.464 1 C-N-CA 132.916 4.486 . . . . 0.0 105.655 173.309 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -157.27 158.19 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 125.681 1.592 . . . . 0.0 108.692 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -89.04 163.42 34.61 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 106.425 -1.695 . . . . 0.0 106.425 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -70.71 169.54 19.87 Favored 'Trans proline' 0 N--CA 1.451 -0.978 0 N-CA-C 108.259 -1.477 . . . . 0.0 108.259 178.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 73.45 -27.77 0.86 Allowed Glycine 0 CA--C 1.534 1.227 0 O-C-N 121.02 -1.05 . . . . 0.0 115.38 175.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.4 tp-100 -58.07 139.88 53.75 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 119.527 1.664 . . . . 0.0 109.8 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -70.16 128.3 35.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.875 0.47 . . . . 0.0 111.544 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' LEU . . . . . 0.505 HD22 HG12 ' A' ' 100' ' ' VAL . 72.1 mt -105.04 -41.49 5.57 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.937 0.895 . . . . 0.0 111.807 -178.317 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 48.5 mt -143.99 146.52 32.96 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 123.588 0.755 . . . . 0.0 109.371 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -118.06 133.24 56.09 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 100.683 -3.821 . . . . 0.0 100.683 167.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' VAL . . . . . 0.459 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -143.15 117.47 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -166.731 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 62.9 t0 -67.69 74.11 0.17 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.408 1.483 . . . . 0.0 112.395 -175.273 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 75.8 mt -50.43 -47.49 56.64 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.687 178.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -49.4 -49.07 46.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.588 1.155 . . . . 0.0 112.684 -177.323 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.25 -34.36 25.85 Favored 'General case' 0 C--N 1.333 -0.121 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 49.4 t -65.16 -53.65 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 O-C-N 121.697 -0.627 . . . . 0.0 110.541 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.328 19.1 pttp -42.92 -54.64 8.54 Favored Pre-proline 0 CA--C 1.54 0.595 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -61.12 -24.07 78.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.49 2.127 . . . . 0.0 112.716 178.248 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 57.3 m-80 -90.18 -48.24 7.29 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 118.46 0.573 . . . . 0.0 111.885 -177.268 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.77 147.93 56.37 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -174.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_exo -51.61 -41.51 60.76 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 124.064 3.176 . . . . 0.0 114.804 179.169 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.2 m -158.81 142.7 15.31 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.825 -0.547 . . . . 0.0 110.235 -176.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.2 tp -88.09 -4.6 58.75 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 124.878 1.271 . . . . 0.0 112.293 -178.392 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.1 mmt -46.93 118.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.028 0.931 . . . . 0.0 109.802 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.4 m -112.1 94.23 24.88 Favored Pre-proline 0 N--CA 1.448 -0.534 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' PRO . . . . . 0.416 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 74.1 Cg_endo -76.5 111.06 3.18 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 123.594 2.863 . . . . 0.0 108.74 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mt -94.28 119.06 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 N-CA-C 102.718 -3.068 . . . . 0.0 102.718 174.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.2 t -126.56 129.06 71.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -97.39 114.61 26.46 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 104.343 -2.465 . . . . 0.0 104.343 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 44.8 p -80.28 -75.39 0.27 Allowed 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' ASN . . . . . . . . . . . . 0.259 0.4 OUTLIER -74.06 69.68 1.5 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-O 122.204 1.002 . . . . 0.0 111.207 179.156 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 13.2 mt -78.21 62.2 2.87 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 126.174 1.79 . . . . 0.0 107.537 175.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.53 -109.63 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.578 2.351 . . . . 0.0 112.545 -177.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -80.33 58.64 3.16 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 125.146 1.379 . . . . 0.0 112.446 -178.265 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 46.19 35.67 6.82 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 124.259 0.933 . . . . 0.0 110.959 -178.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' GLU . . . . . 0.671 ' HB3' HG23 ' A' ' 160' ' ' ILE . 38.9 mt-10 -49.01 126.91 13.32 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.349 0.659 . . . . 0.0 112.014 -175.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 31.8 p -86.54 133.35 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.256 0.3 OUTLIER -85.58 87.48 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 CA-C-O 122.407 1.099 . . . . 0.0 109.936 -176.009 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.5 m -79.33 84.48 5.25 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 120.646 -1.284 . . . . 0.0 110.85 -177.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' ILE . . . . . 0.521 HG23 HG22 ' A' ' 158' ' ' VAL . 6.5 mt -60.66 130.67 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 124.287 1.035 . . . . 0.0 108.656 178.418 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.33 -52.78 2.75 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.769 0.828 . . . . 0.0 108.767 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -78.95 64.64 3.94 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 122.892 0.477 . . . . 0.0 109.933 179.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 45.0 m -78.98 66.05 4.32 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -171.45 -148.79 6.23 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 107.809 -2.116 . . . . 0.0 107.809 -177.375 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 15.8 t -78.14 148.11 34.28 Favored 'General case' 0 N--CA 1.456 -0.136 0 CA-C-N 117.658 0.729 . . . . 0.0 110.735 178.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.63 160.59 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 124.864 1.266 . . . . 0.0 108.663 178.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -114.78 157.79 22.75 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.719 1.208 . . . . 0.0 108.592 176.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 2.2 ptm180 -66.43 154.11 41.05 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 53.15 59.98 4.06 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.537 1.535 . . . . 0.0 112.06 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 16.9 mm-40 -131.07 151.02 51.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 126.821 2.048 . . . . 0.0 105.751 175.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.47 166.0 14.19 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.2 1.4 . . . . 0.0 111.05 -177.338 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 16.9 t70 70.63 -7.48 1.04 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 117.051 2.241 . . . . 0.0 117.051 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 157' ' ' ILE . . . . . 0.443 ' CD1' ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -53.06 -31.87 17.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 C-N-CA 127.213 2.205 . . . . 0.0 112.501 177.116 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 158' ' ' VAL . . . . . 0.521 HG22 HG23 ' A' ' 144' ' ' ILE . 62.9 t -145.47 133.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -108.75 120.53 42.75 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.414 0.686 . . . . 0.0 109.828 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 160' ' ' ILE . . . . . 0.671 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.3 mp -79.1 97.22 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.204 -2.146 . . . . 0.0 105.204 173.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -108.7 -155.26 0.55 Allowed 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 125.369 1.467 . . . . 0.0 107.963 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 35.5 mtmm . . . . . 0 C--N 1.333 -0.131 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 176.977 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 16.3 tpt . . . . . 0 N--CA 1.453 -0.277 0 CA-C-O 121.221 0.534 . . . . 0.0 109.728 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 27.3 mm -75.4 73.7 0.41 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.333 0 N-CA-C 108.119 -1.067 . . . . 0.0 108.119 179.1 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -65.56 79.94 0.06 Allowed 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 124.523 1.129 . . . . 0.0 111.662 -178.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 14.3 mp0 -49.02 -44.8 73.31 Favored Pre-proline 0 CA--C 1.539 0.548 0 C-N-CA 124.238 1.015 . . . . 0.0 113.652 179.645 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 32.0 Cg_exo -66.4 40.4 0.15 Allowed 'Trans proline' 0 CA--C 1.542 0.886 0 C-N-CA 123.886 3.057 . . . . 0.0 116.306 -177.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.1 tt -79.22 63.55 3.89 Favored 'General case' 0 CA--C 1.535 0.397 0 O-C-N 120.44 -1.413 . . . . 0.0 107.26 176.726 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 40.6 mt-30 -78.3 -50.68 11.37 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 125.135 1.374 . . . . 0.0 112.035 -175.608 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 56.5 t30 72.18 154.12 0.14 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 125.584 1.554 . . . . 0.0 110.582 -176.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.1 tt0 -70.45 -62.84 1.24 Allowed 'General case' 0 N--CA 1.453 -0.275 0 N-CA-C 107.394 -1.336 . . . . 0.0 107.394 177.736 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 6.9 tp -79.95 52.13 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 CA-C-O 121.705 0.764 . . . . 0.0 109.392 178.089 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -78.48 50.5 3.52 Favored Glycine 0 CA--C 1.529 0.917 0 O-C-N 120.928 -1.108 . . . . 0.0 111.794 -179.278 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -118.5 82.38 1.84 Allowed 'General case' 0 N--CA 1.447 -0.618 0 N-CA-C 107.261 -1.385 . . . . 0.0 107.261 179.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 18.5 mp0 -76.53 66.81 2.6 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 107.008 -1.479 . . . . 0.0 107.008 177.445 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.8 t 46.85 44.84 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.396 0 C-N-CA 126.765 2.026 . . . . 0.0 108.86 -179.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.7 OUTLIER -132.63 83.29 2.06 Favored 'General case' 0 CA--C 1.532 0.258 0 CA-C-N 114.561 -1.199 . . . . 0.0 112.705 -175.925 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -87.0 89.92 3.14 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.204 0 N-CA-C 105.846 -1.909 . . . . 0.0 105.846 172.165 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 8.1 t -13.36 116.17 0.04 OUTLIER Pre-proline 0 CA--C 1.55 0.956 0 C-N-CA 126.965 2.106 . . . . 0.0 115.377 -179.198 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -71.38 -34.88 9.07 Favored 'Trans proline' 0 N--CA 1.455 -0.784 0 C-N-CA 122.995 2.463 . . . . 0.0 117.37 -174.371 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -143.3 162.73 16.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.819 1.191 . . . . 0.0 111.371 -175.228 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 88.2 m -101.52 135.65 42.68 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 106.899 -1.519 . . . . 0.0 106.899 174.785 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 161.96 -136.33 4.32 Favored Glycine 0 CA--C 1.526 0.741 0 N-CA-C 110.541 -1.024 . . . . 0.0 110.541 -179.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 39.0 tp10 -127.79 124.63 38.12 Favored 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 124.941 1.297 . . . . 0.0 110.34 -178.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 45.9 mt -80.19 145.43 9.17 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.207 0 N-CA-C 108.769 -0.826 . . . . 0.0 108.769 177.016 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 96.7 m-70 -143.95 141.67 18.94 Favored Pre-proline 0 N--CA 1.452 -0.347 0 C-N-CA 125.08 1.352 . . . . 0.0 107.903 176.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -54.94 145.33 63.26 Favored 'Trans proline' 0 N--CA 1.454 -0.828 0 C-N-CA 122.163 1.908 . . . . 0.0 111.183 176.695 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.67 -39.19 6.92 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.497 0 C-N-CA 124.853 1.261 . . . . 0.0 112.316 -178.923 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.1 p -53.48 -31.61 46.57 Favored 'General case' 0 N--CA 1.451 -0.407 0 C-N-CA 125.362 1.465 . . . . 0.0 112.442 179.143 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.9 m-20 -69.78 -14.32 62.71 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.898 0.879 . . . . 0.0 112.852 -178.593 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.4 t -69.87 130.26 90.26 Favored Pre-proline 0 CA--C 1.539 0.53 0 O-C-N 121.373 -0.829 . . . . 0.0 111.057 -175.151 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -76.38 62.6 6.99 Favored 'Trans proline' 0 CA--C 1.536 0.62 0 C-N-CA 123.416 2.744 . . . . 0.0 111.374 -179.171 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 0.7 OUTLIER -165.21 132.01 2.88 Favored 'General case' 0 C--O 1.226 -0.138 0 N-CA-C 107.506 -1.294 . . . . 0.0 107.506 178.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 22.0 mp0 -54.9 -53.05 60.48 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 124.521 1.128 . . . . 0.0 112.675 -176.451 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 58.0 t -51.68 -57.0 3.94 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.215 0 C-N-CA 123.299 0.639 . . . . 0.0 110.317 -177.675 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 17.1 m-85 -64.95 -53.54 44.73 Favored 'General case' 0 N--CA 1.453 -0.289 0 C-N-CA 122.264 0.226 . . . . 0.0 110.535 -179.575 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 16.9 t -51.99 -43.05 63.44 Favored 'General case' 0 CA--C 1.531 0.235 0 N-CA-C 112.841 0.682 . . . . 0.0 112.841 -178.032 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -90.91 13.36 66.25 Favored Glycine 0 N--CA 1.445 -0.73 0 CA-C-O 117.994 -1.448 . . . . 0.0 111.814 -177.841 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.2 mtpp 69.44 -34.68 0.29 Allowed 'General case' 0 CA--C 1.536 0.428 0 CA-C-N 119.421 1.611 . . . . 0.0 114.52 -179.39 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 15.7 tpt 26.16 -76.31 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 130.056 3.343 . . . . 0.0 116.426 -179.576 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.1 ttm -79.49 -15.98 56.82 Favored 'General case' 0 CA--C 1.537 0.463 0 N-CA-C 114.142 1.164 . . . . 0.0 114.142 -174.263 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 178.51 -135.75 2.73 Favored Glycine 0 C--N 1.338 0.686 0 CA-C-N 120.037 1.29 . . . . 0.0 113.076 -178.111 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.3 t0 -129.1 163.1 26.2 Favored 'General case' 0 CA--C 1.509 -0.632 0 N-CA-C 106.007 -1.849 . . . . 0.0 106.007 175.717 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 167.27 -157.5 29.96 Favored Glycine 0 N--CA 1.443 -0.853 0 C-N-CA 119.877 -1.154 . . . . 0.0 112.586 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 38.8 p90 -162.35 171.07 17.8 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 123.053 0.541 . . . . 0.0 109.839 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -111.35 149.18 31.51 Favored 'General case' 0 CA--C 1.502 -0.867 0 O-C-N 124.119 0.887 . . . . 0.0 109.429 176.729 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 5.0 mp -124.21 133.56 68.98 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 N-CA-C 102.482 -3.155 . . . . 0.0 102.482 170.314 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.2 tt -99.38 108.44 50.33 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.789 -4.523 . . . . 0.0 98.789 170.626 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -82.8 161.04 16.29 Favored 'Trans proline' 0 N--CA 1.454 -0.81 0 C-N-CA 123.347 2.698 . . . . 0.0 113.932 -168.463 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 51.3 p -124.59 -55.56 1.63 Allowed 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 124.699 1.2 . . . . 0.0 108.723 175.551 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 13.9 mt-10 -68.15 124.15 22.66 Favored 'General case' 0 N--CA 1.457 -0.11 0 C-N-CA 122.303 0.241 . . . . 0.0 110.857 178.318 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.33 37.11 2.0 Allowed Glycine 0 CA--C 1.532 1.135 0 N-CA-C 111.336 -0.706 . . . . 0.0 111.336 175.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 70.7 mt -138.43 120.63 18.11 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.327 0 N-CA-C 103.868 -2.641 . . . . 0.0 103.868 -179.432 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 46.8 t -120.24 109.35 25.53 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 108.982 -0.747 . . . . 0.0 108.982 -174.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 10.7 m -89.25 -178.26 0.4 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.361 0 N-CA-C 106.941 -1.504 . . . . 0.0 106.941 173.517 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER -109.59 146.19 33.5 Favored Pre-proline 0 N--CA 1.465 0.306 0 CA-C-O 117.561 -1.209 . . . . 0.0 111.464 -174.683 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 44.0 Cg_endo -63.3 -44.6 14.37 Favored 'Trans proline' 0 C--N 1.348 0.53 0 N-CA-C 107.453 -1.787 . . . . 0.0 107.453 174.751 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.48 HG21 ' HA ' ' A' ' 74' ' ' SER . 3.4 p -146.2 145.59 19.83 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 102.433 -3.173 . . . . 0.0 102.433 171.506 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.539 ' HB3' HG23 ' A' ' 106' ' ' VAL . 28.6 mtm180 -97.27 -75.21 0.55 Allowed 'General case' 0 N--CA 1.45 -0.447 1 N-CA-C 98.979 -4.452 . . . . 0.0 98.979 169.659 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 77.23 -78.19 1.46 Allowed Glycine 0 N--CA 1.447 -0.6 0 N-CA-C 107.141 -2.383 . . . . 0.0 107.141 171.474 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -151.75 118.73 5.84 Favored 'General case' 0 N--CA 1.438 -1.067 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.893 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.458 HG21 ' CB ' ' A' ' 102' ' ' GLU . 28.3 mm -65.98 124.85 21.9 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.591 0 N-CA-C 105.975 -1.861 . . . . 0.0 105.975 175.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -87.42 -42.47 12.81 Favored 'General case' 0 N--CA 1.451 -0.403 0 C-N-CA 124.069 0.948 . . . . 0.0 109.206 -177.44 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 56.2 t30 -156.88 152.66 27.05 Favored 'General case' 0 N--CA 1.463 0.204 0 O-C-N 121.94 -0.475 . . . . 0.0 111.722 178.784 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 9.5 p -82.89 170.55 1.37 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.845 1.658 . . . . 0.0 112.323 -178.369 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.545 ' CE2' HD21 ' A' ' 113' ' ' LEU . 0.0 OUTLIER -76.54 135.85 68.32 Favored Pre-proline 0 N--CA 1.437 -1.118 0 CA-C-N 112.681 -2.054 . . . . 0.0 109.778 173.589 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_endo -74.37 -43.28 0.53 Allowed 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 121.374 1.383 . . . . 0.0 108.61 172.901 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.4 p -131.39 46.24 2.69 Favored 'General case' 0 CA--C 1.535 0.374 0 C-N-CA 126.192 1.797 . . . . 0.0 109.917 -177.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.447 ' HA ' ' CB ' ' A' ' 64' ' ' PHE . 16.5 ttmt 57.16 -17.41 0.02 OUTLIER 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 128.225 2.61 . . . . 0.0 116.609 179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 27.8 p-80 -75.98 -5.9 48.46 Favored 'General case' 0 CA--C 1.529 0.146 0 N-CA-C 116.769 2.137 . . . . 0.0 116.769 -174.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -150.35 160.53 43.66 Favored 'General case' 0 CA--C 1.512 -0.496 0 CA-C-N 120.456 1.48 . . . . 0.0 110.348 -173.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 13.0 tt -157.23 157.15 3.86 Favored 'Isoleucine or valine' 0 C--O 1.237 0.42 0 N-CA-C 107.436 -1.32 . . . . 0.0 107.436 178.072 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -117.31 128.58 7.92 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 107.646 -2.181 . . . . 0.0 107.646 178.186 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 9.9 mt -124.74 171.75 9.85 Favored 'General case' 0 N--CA 1.464 0.241 0 C-N-CA 124.724 1.209 . . . . 0.0 110.359 -177.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -150.47 139.33 20.88 Favored 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 126.631 1.972 . . . . 0.0 105.697 174.201 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . 0.48 ' HA ' HG21 ' A' ' 56' ' ' VAL . 89.4 p -71.93 -83.05 0.04 OUTLIER 'General case' 0 N--CA 1.449 -0.487 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 176.235 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -121.84 -70.04 0.8 Allowed 'General case' 0 N--CA 1.453 -0.299 0 C-N-CA 125.206 1.402 . . . . 0.0 107.684 176.63 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -168.62 85.07 0.09 OUTLIER Glycine 0 CA--C 1.521 0.437 0 N-CA-C 106.097 -2.801 . . . . 0.0 106.097 178.276 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 169.15 -41.35 0.21 Allowed Glycine 0 C--N 1.337 0.584 0 CA-C-O 119.36 -0.689 . . . . 0.0 111.639 -176.606 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 38.2 ttp180 -122.56 109.07 13.86 Favored 'General case' 0 C--N 1.341 0.208 0 N-CA-C 109.267 -0.642 . . . . 0.0 109.267 177.742 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.7 tt0 -106.48 130.64 54.24 Favored 'General case' 0 N--CA 1.445 -0.678 0 C-N-CA 129.374 3.069 . . . . 0.0 104.386 177.712 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.4 mt -120.22 145.16 26.96 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.376 0 C-N-CA 124.339 1.056 . . . . 0.0 110.649 -172.12 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 46.7 tp -124.38 131.45 53.51 Favored 'General case' 0 N--CA 1.449 -0.49 0 N-CA-C 105.278 -2.119 . . . . 0.0 105.278 173.634 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 79.4 mt -121.93 146.8 26.48 Favored 'Isoleucine or valine' 0 C--N 1.326 -0.418 0 C-N-CA 123.789 0.836 . . . . 0.0 109.317 -179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -135.34 136.23 41.36 Favored 'General case' 0 N--CA 1.453 -0.322 0 N-CA-C 105.143 -2.169 . . . . 0.0 105.143 169.9 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 7.0 t80 -106.96 108.4 19.89 Favored 'General case' 0 N--CA 1.441 -0.913 0 C-N-CA 125.224 1.41 . . . . 0.0 109.037 -177.73 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.53 -178.0 7.17 Favored Glycine 0 CA--C 1.534 1.22 0 N-CA-C 111.072 -0.811 . . . . 0.0 111.072 -176.372 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.7 mm -118.87 143.54 29.68 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.265 0 N-CA-C 106.663 -1.606 . . . . 0.0 106.663 179.152 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 9.1 t70 65.69 11.58 7.64 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 124.38 1.072 . . . . 0.0 113.143 179.913 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.6 p -74.83 -32.51 61.96 Favored 'General case' 0 C--N 1.33 -0.265 0 C-N-CA 125.583 1.553 . . . . 0.0 108.587 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.5 p -54.57 -49.85 63.55 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.338 0 CA-C-N 113.202 -1.817 . . . . 0.0 107.143 170.512 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -62.69 -42.42 99.62 Favored 'General case' 0 C--O 1.227 -0.119 0 C-N-CA 124.668 1.187 . . . . 0.0 109.641 177.875 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 24.5 tp -66.21 -2.55 4.41 Favored 'General case' 0 CA--C 1.541 0.621 0 C-N-CA 125.463 1.505 . . . . 0.0 111.539 176.706 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 34.5 mtmm 51.94 34.1 13.0 Favored 'General case' 0 C--N 1.344 0.329 0 C-N-CA 125.18 1.392 . . . . 0.0 111.325 -179.157 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.95 30.91 60.77 Favored Glycine 0 CA--C 1.537 1.45 0 CA-C-O 120.015 -0.325 . . . . 0.0 112.802 -178.583 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 66.1 mt-10 -67.21 93.38 0.3 Allowed 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.759 1.279 . . . . 0.0 109.477 178.464 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 127.54 7.98 4.57 Favored Glycine 0 CA--C 1.533 1.217 0 C-N-CA 126.682 2.087 . . . . 0.0 112.122 -178.493 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.407 ' CG ' HG12 ' A' ' 115' ' ' VAL . 3.5 m-85 -101.35 153.04 20.01 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.696 1.198 . . . . 0.0 110.732 -177.441 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 59.3 m -145.41 121.81 10.97 Favored 'General case' 0 N--CA 1.451 -0.39 0 N-CA-C 105.3 -2.111 . . . . 0.0 105.3 176.312 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.421 ' HA ' HD23 ' A' ' 113' ' ' LEU . 35.1 p -96.04 128.22 42.75 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.539 0.736 . . . . 0.0 110.371 -173.255 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 18.4 m-85 -92.05 -49.12 6.38 Favored 'General case' 0 N--CA 1.448 -0.57 0 O-C-N 124.336 1.023 . . . . 0.0 109.431 -178.289 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 9.9 m -75.22 124.7 33.63 Favored 'Isoleucine or valine' 0 C--N 1.34 0.193 0 C-N-CA 117.21 -1.796 . . . . 0.0 107.749 173.494 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 60.7 m -100.8 55.71 0.87 Allowed 'General case' 0 C--N 1.328 -0.332 0 N-CA-C 103.578 -2.749 . . . . 0.0 103.578 170.852 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.458 ' CB ' HG21 ' A' ' 60' ' ' ILE 0.5 0.0 OUTLIER 5.39 64.15 0.0 OUTLIER 'General case' 0 N--CA 1.445 -0.693 0 C-N-CA 130.767 3.627 . . . . 0.0 117.915 -168.517 . . . . . . . . 4 4 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -81.28 61.24 4.62 Favored Glycine 0 N--CA 1.448 -0.545 0 N-CA-C 107.155 -2.378 . . . . 0.0 107.155 173.239 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . 0.6 ' O ' HG22 ' A' ' 106' ' ' VAL 0.391 3.3 p30 6.01 -94.56 0.0 OUTLIER 'General case' 0 N--CA 1.439 -0.987 0 C-N-CA 128.506 2.722 . . . . 0.0 116.939 -174.283 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.4 mmm180 -55.69 106.09 0.23 Allowed 'General case' 0 C--N 1.306 -1.297 0 C-N-CA 126.472 1.909 . . . . 0.0 112.262 -175.269 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . 0.6 HG22 ' O ' ' A' ' 104' ' ' ASP . 0.0 OUTLIER -147.6 159.19 8.53 Favored 'Isoleucine or valine' 0 C--N 1.342 0.239 0 C-N-CA 124.841 1.257 . . . . 0.0 111.704 179.051 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 19.0 mm-40 -85.88 155.34 58.5 Favored Pre-proline 0 CA--C 1.546 0.795 0 CA-C-O 118.473 -0.775 . . . . 0.0 109.636 177.218 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 85.5 Cg_exo -48.82 168.61 0.1 Allowed 'Trans proline' 0 CA--C 1.534 0.514 1 C-N-CA 126.824 5.016 . . . . 0.0 120.381 -173.081 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 69.69 -97.37 0.55 Allowed Glycine 0 C--N 1.34 0.773 0 C-N-CA 125.956 1.741 . . . . 0.0 112.754 175.635 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 26.3 tt0 1.97 92.97 0.01 OUTLIER 'General case' 0 C--N 1.32 -0.681 0 C-N-CA 131.03 3.732 . . . . 0.0 114.102 -176.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 21.1 ttmt 4.21 114.82 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 130.321 3.449 . . . . 0.0 117.193 178.189 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 91.1 mt -81.87 -50.97 8.58 Favored 'General case' 0 CA--C 1.532 0.269 0 C-N-CA 123.922 0.889 . . . . 0.0 108.988 173.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.545 HD21 ' CE2' ' A' ' 64' ' ' PHE . 96.1 mt -138.06 155.25 48.99 Favored 'General case' 0 CA--C 1.541 0.623 0 C-N-CA 125.769 1.628 . . . . 0.0 110.512 -176.494 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 35.9 tt0 -123.42 132.53 53.98 Favored 'General case' 0 CA--C 1.516 -0.328 1 N-CA-C 100.106 -4.035 . . . . 0.0 100.106 167.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.407 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -147.66 122.17 2.22 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.804 0 CA-C-N 115.153 -0.93 . . . . 0.0 111.01 -165.603 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.8 t0 -71.63 69.07 0.62 Allowed 'General case' 0 CA--C 1.532 0.268 0 C-N-CA 124.409 1.083 . . . . 0.0 111.025 -179.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 56.5 mt -49.11 -42.81 40.39 Favored 'General case' 0 N--CA 1.456 -0.143 0 C-N-CA 123.69 0.796 . . . . 0.0 111.166 178.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 27.6 t70 -50.03 -48.43 52.73 Favored 'General case' 0 CA--C 1.532 0.259 0 C-N-CA 123.628 0.771 . . . . 0.0 112.131 179.573 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.48 -31.34 22.85 Favored 'General case' 0 CA--C 1.527 0.078 0 N-CA-C 111.805 0.298 . . . . 0.0 111.805 -179.845 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 44.8 t -64.02 -51.76 65.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 O-C-N 121.64 -0.662 . . . . 0.0 109.945 179.402 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.407 0.0 OUTLIER -41.11 -57.95 3.11 Favored Pre-proline 0 CA--C 1.542 0.647 0 N-CA-C 116.963 2.209 . . . . 0.0 116.963 -177.303 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.5 Cg_endo -59.27 -19.34 49.74 Favored 'Trans proline' 0 N--CA 1.456 -0.732 0 C-N-CA 122.256 1.971 . . . . 0.0 113.227 178.546 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.7 m-80 -98.43 11.42 38.21 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 123.826 0.85 . . . . 0.0 112.283 -179.056 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 27.9 m -135.83 151.31 73.82 Favored Pre-proline 0 CA--C 1.532 0.284 0 CA-C-N 119.837 1.199 . . . . 0.0 110.86 178.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 75.5 Cg_endo -72.97 -24.06 17.87 Favored 'Trans proline' 0 N--CA 1.452 -0.923 0 C-N-CA 122.744 2.296 . . . . 0.0 110.658 177.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 14.6 t -158.75 147.91 18.89 Favored 'General case' 0 N--CA 1.452 -0.365 0 CA-C-O 121.389 0.614 . . . . 0.0 109.864 179.347 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.0 tp -97.54 2.25 49.89 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.862 1.665 . . . . 0.0 110.51 178.795 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 19.3 mmt -52.01 119.19 4.05 Favored 'General case' 0 C--N 1.344 0.36 0 CA-C-N 118.208 0.458 . . . . 0.0 109.794 -179.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 32.2 m -111.37 89.48 10.45 Favored Pre-proline 0 N--CA 1.447 -0.609 0 N-CA-C 106.549 -1.649 . . . . 0.0 106.549 -179.394 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -81.08 146.56 16.06 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.331 2.021 . . . . 0.0 111.364 -178.421 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.4 mt -127.37 126.47 67.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.665 0 N-CA-C 104.377 -2.453 . . . . 0.0 104.377 175.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -122.41 147.83 26.36 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 N-CA-C 106.819 -1.549 . . . . 0.0 106.819 178.926 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.401 ' HB2' HD21 ' A' ' 136' ' ' LEU . 13.6 m-85 -122.55 125.71 46.27 Favored 'General case' 0 N--CA 1.438 -1.056 0 N-CA-C 101.945 -3.354 . . . . 0.0 101.945 178.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.7 p -89.15 -82.77 0.24 Allowed 'General case' 0 CA--C 1.53 0.19 0 CA-C-N 118.4 0.546 . . . . 0.0 111.422 -171.838 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 20.6 p30 -47.37 -49.01 25.54 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 126.111 1.765 . . . . 0.0 111.884 179.345 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.401 HD21 ' HB2' ' A' ' 133' ' ' PHE . 23.0 mt 42.8 49.03 5.02 Favored 'General case' 0 CA--C 1.535 0.392 0 C-N-CA 125.111 1.365 . . . . 0.0 110.864 178.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 34.82 40.96 0.05 Allowed 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 126.325 1.85 . . . . 0.0 111.966 -176.029 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 4.6 mp0 36.88 55.18 1.2 Allowed 'General case' 0 N--CA 1.446 -0.631 0 C-N-CA 128.319 2.648 . . . . 0.0 114.349 -176.277 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 163.09 -3.48 0.07 OUTLIER Glycine 0 CA--C 1.524 0.625 0 CA-C-O 118.885 -0.953 . . . . 0.0 114.482 175.211 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.677 ' HB3' HG23 ' A' ' 160' ' ' ILE . 63.7 mm-40 -76.61 109.86 10.71 Favored 'General case' 0 C--O 1.228 -0.074 0 CA-C-N 119.219 1.51 . . . . 0.0 110.483 -179.943 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 5.4 p -78.8 138.68 38.31 Favored 'General case' 0 N--CA 1.447 -0.625 0 N-CA-C 105.98 -1.859 . . . . 0.0 105.98 171.817 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -85.55 84.79 2.2 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.664 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 -177.864 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 74.5 m -78.27 93.76 4.69 Favored 'General case' 0 N--CA 1.455 -0.188 0 O-C-N 120.6 -1.312 . . . . 0.0 110.844 -175.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 14.2 mt -64.91 130.91 30.59 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.131 0 C-N-CA 123.939 0.896 . . . . 0.0 108.608 177.622 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 71.8 mmtt -107.44 -55.36 2.36 Favored 'General case' 0 N--CA 1.452 -0.353 0 C-N-CA 124.711 1.204 . . . . 0.0 108.026 177.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.84 70.22 1.91 Allowed 'General case' 0 N--CA 1.453 -0.316 0 CA-C-O 121.357 0.599 . . . . 0.0 110.511 179.666 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 24.7 m -79.0 63.92 3.79 Favored 'General case' 0 C--N 1.331 -0.237 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 177.942 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 178.35 -140.91 4.8 Favored Glycine 0 CA--C 1.524 0.635 0 N-CA-C 108.368 -1.893 . . . . 0.0 108.368 -176.485 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 16.6 t -66.43 151.84 46.34 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 117.039 0.419 . . . . 0.0 110.989 178.515 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 7.3 p -133.97 154.07 37.39 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.301 0 C-N-CA 125.538 1.535 . . . . 0.0 107.996 179.021 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 14.3 m-80 -132.95 150.92 52.12 Favored 'General case' 0 C--O 1.233 0.22 0 C-N-CA 124.965 1.306 . . . . 0.0 108.634 178.009 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 50.1 mtp180 -57.48 150.33 18.98 Favored 'General case' 0 CA--C 1.531 0.23 0 C-N-CA 124.149 0.979 . . . . 0.0 112.12 178.566 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 51.6 mt-10 58.51 3.52 0.29 Allowed 'General case' 0 CA--C 1.534 0.34 0 C-N-CA 127.148 2.179 . . . . 0.0 115.263 174.379 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 55.5 mm-40 -72.29 164.25 26.6 Favored 'General case' 0 N--CA 1.45 -0.46 0 CA-C-N 119.056 0.844 . . . . 0.0 111.075 179.008 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 44.7 tt0 -114.04 168.23 9.99 Favored 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 127.715 2.406 . . . . 0.0 108.22 -178.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 25.9 t0 51.73 40.53 27.73 Favored 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.099 1.36 . . . . 0.0 112.811 176.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.445 HD12 ' H ' ' A' ' 158' ' ' VAL . 0.9 OUTLIER -99.78 -43.64 11.24 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.284 0 C-N-CA 124.414 1.086 . . . . 0.0 109.636 178.674 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.445 ' H ' HD12 ' A' ' 157' ' ' ILE . 9.1 p -142.69 143.97 24.97 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 105.782 -1.933 . . . . 0.0 105.782 173.673 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 47.2 mtpt -123.65 116.11 22.56 Favored 'General case' 0 N--CA 1.448 -0.549 0 C-N-CA 123.232 0.613 . . . . 0.0 109.547 179.579 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.677 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.4 mp -79.23 104.06 6.84 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.589 0 N-CA-C 103.54 -2.763 . . . . 0.0 103.54 173.371 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 23.6 pt-20 -142.83 158.11 43.95 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 123.175 0.59 . . . . 0.0 109.865 -174.231 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 12.8 mptt . . . . . 0 CA--C 1.53 0.195 0 N-CA-C 107.949 -1.13 . . . . 0.0 107.949 177.188 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.3 mmt . . . . . 0 N--CA 1.454 -0.239 0 CA-C-O 120.867 0.365 . . . . 0.0 110.017 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 26.3 mt -76.26 68.08 0.29 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.392 0 N-CA-C 108.635 -0.876 . . . . 0.0 108.635 179.997 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -112.39 5.62 18.25 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 124.888 1.275 . . . . 0.0 112.003 -178.513 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.5 pm0 -67.99 155.2 92.43 Favored Pre-proline 0 CA--C 1.538 0.481 0 CA-C-O 118.918 -0.563 . . . . 0.0 109.985 179.312 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 60.1 Cg_exo -53.69 125.76 19.66 Favored 'Trans proline' 0 N--CA 1.455 -0.759 0 C-N-CA 122.419 2.079 . . . . 0.0 110.283 177.231 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 71.9 mt -75.89 67.58 2.29 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 121.267 0.556 . . . . 0.0 109.868 -179.179 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 5.5 pt20 -168.86 -172.06 1.51 Allowed 'General case' 0 N--CA 1.452 -0.365 0 C-N-CA 126.846 2.058 . . . . 0.0 106.841 -178.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.4 t-20 -64.94 138.55 58.43 Favored 'General case' 0 CA--C 1.534 0.334 0 N-CA-C 107.359 -1.348 . . . . 0.0 107.359 172.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 73.8 mm-40 -67.52 -5.64 16.1 Favored 'General case' 0 CA--C 1.536 0.424 0 N-CA-C 114.785 1.402 . . . . 0.0 114.785 -176.243 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 32.0 pt 37.06 45.96 0.25 Allowed 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 126.981 2.112 . . . . 0.0 113.44 178.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 148.47 -66.51 0.39 Allowed Glycine 0 C--N 1.336 0.562 0 N-CA-C 111.248 -0.741 . . . . 0.0 111.248 -178.526 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 26.1 tt0 -79.45 55.09 1.86 Allowed 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 122.067 0.936 . . . . 0.0 110.44 -178.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 53.7 mt-10 -84.03 54.23 2.86 Favored 'General case' 0 C--N 1.328 -0.326 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 178.986 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.9 p 45.23 36.72 0.26 Allowed 'Isoleucine or valine' 0 C--N 1.34 0.174 0 C-N-CA 125.738 1.615 . . . . 0.0 110.583 -171.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -80.16 99.92 8.01 Favored 'General case' 0 N--CA 1.452 -0.329 0 CA-C-N 112.719 -2.037 . . . . 0.0 106.583 -176.916 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -103.61 90.92 1.74 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.583 0 C-N-CA 122.714 0.406 . . . . 0.0 111.686 -177.739 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 89.9 p -22.94 124.03 0.14 Allowed Pre-proline 0 CA--C 1.555 1.141 0 C-N-CA 126.037 1.735 . . . . 0.0 114.298 179.304 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -73.97 -36.74 3.25 Favored 'Trans proline' 0 N--CA 1.458 -0.611 0 C-N-CA 123.023 2.482 . . . . 0.0 118.201 -171.654 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -141.44 148.33 21.23 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.34 0 CA-C-N 119.905 1.229 . . . . 0.0 111.524 -175.422 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 45.6 m -80.48 140.6 35.83 Favored 'General case' 0 C--O 1.235 0.328 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 173.957 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 163.58 -142.93 8.19 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 111.036 -0.826 . . . . 0.0 111.036 178.629 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 32.3 tp10 -116.8 126.78 53.58 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 124.818 1.247 . . . . 0.0 108.457 179.458 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 3.9 tt -85.11 154.88 3.52 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.216 0 N-CA-C 109.329 -0.619 . . . . 0.0 109.329 178.208 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 82.3 m-70 -145.09 144.31 23.27 Favored Pre-proline 0 N--CA 1.451 -0.419 0 C-N-CA 124.989 1.316 . . . . 0.0 107.619 177.745 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.3 Cg_exo -62.88 31.19 0.07 OUTLIER 'Trans proline' 0 C--N 1.347 0.495 0 C-N-CA 124.832 3.688 . . . . 0.0 116.838 177.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER 72.34 -39.69 0.08 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.071 1.349 . . . . 0.0 113.077 179.28 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.9 p -44.85 -41.38 7.03 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 125.298 1.439 . . . . 0.0 112.177 178.498 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -68.23 -14.1 62.73 Favored 'General case' 0 CA--C 1.537 0.465 0 C-N-CA 125.646 1.579 . . . . 0.0 113.089 -175.978 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.6 t -71.3 127.91 90.8 Favored Pre-proline 0 CA--C 1.536 0.411 0 N-CA-C 107.827 -1.175 . . . . 0.0 107.827 179.858 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 36.5 Cg_endo -80.1 58.02 6.78 Favored 'Trans proline' 0 N--CA 1.456 -0.714 0 C-N-CA 122.567 2.178 . . . . 0.0 112.043 -176.953 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 9.2 t70 -166.96 107.57 0.63 Allowed 'General case' 0 CA--C 1.531 0.245 0 O-C-N 121.686 -0.634 . . . . 0.0 110.203 177.348 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 3.3 pm0 -28.6 -53.39 0.1 Allowed 'General case' 0 CA--C 1.533 0.323 0 C-N-CA 129.233 3.013 . . . . 0.0 115.967 -179.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 60.5 t -53.76 -45.61 61.74 Favored 'Isoleucine or valine' 0 C--N 1.341 0.199 0 CA-C-O 121.406 0.622 . . . . 0.0 109.703 -178.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 6.5 m-85 -76.69 -54.47 6.6 Favored 'General case' 0 N--CA 1.444 -0.75 0 N-CA-C 108.518 -0.919 . . . . 0.0 108.518 179.792 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.9 m -45.37 -43.9 11.39 Favored 'General case' 0 CA--C 1.527 0.087 0 C-N-CA 124.609 1.164 . . . . 0.0 114.119 -178.438 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -98.6 12.76 62.94 Favored Glycine 0 C--N 1.337 0.603 0 CA-C-O 117.926 -1.486 . . . . 0.0 112.61 -176.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 56.8 mttp 70.97 -34.11 0.29 Allowed 'General case' 0 CA--C 1.541 0.611 0 CA-C-N 119.723 1.761 . . . . 0.0 113.994 -179.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 26.3 ttt 28.57 -71.57 0.0 OUTLIER 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 130.895 3.678 . . . . 0.0 117.191 178.276 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 19.9 ttt -79.03 -17.08 55.91 Favored 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 123.971 0.908 . . . . 0.0 112.732 -175.599 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -168.15 -137.03 2.15 Favored Glycine 0 C--N 1.335 0.519 0 N-CA-C 110.372 -1.091 . . . . 0.0 110.372 -179.16 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.445 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.3 t0 -133.65 158.03 44.28 Favored 'General case' 0 CA--C 1.518 -0.275 0 N-CA-C 104.792 -2.299 . . . . 0.0 104.792 171.848 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -176.98 -162.79 28.06 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 119.361 -1.399 . . . . 0.0 113.46 -174.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 3.8 p90 -151.4 165.14 35.02 Favored 'General case' 0 N--CA 1.448 -0.539 0 C-N-CA 124.991 1.316 . . . . 0.0 107.516 177.406 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -119.11 141.59 48.65 Favored 'General case' 0 CA--C 1.507 -0.69 0 N-CA-C 108.861 -0.792 . . . . 0.0 108.861 176.042 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -115.88 132.59 64.91 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.842 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 170.576 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 3.0 tt -99.42 107.03 42.97 Favored Pre-proline 0 N--CA 1.445 -0.69 1 N-CA-C 98.298 -4.705 . . . . 0.0 98.298 169.249 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 78.1 Cg_endo -82.9 167.01 14.67 Favored 'Trans proline' 0 N--CA 1.454 -0.816 0 C-N-CA 123.732 2.954 . . . . 0.0 114.417 -168.214 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 29.8 p -127.73 -67.74 0.81 Allowed 'General case' 0 CA--C 1.532 0.28 0 C-N-CA 125.312 1.445 . . . . 0.0 108.499 176.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mt-10 -53.24 124.81 15.59 Favored 'General case' 0 N--CA 1.457 -0.107 0 C-N-CA 123.802 0.841 . . . . 0.0 111.973 179.78 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.01 39.31 2.03 Favored Glycine 0 CA--C 1.531 1.048 0 N-CA-C 111.224 -0.75 . . . . 0.0 111.224 173.826 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.3 mt -140.01 117.14 9.71 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.278 0 N-CA-C 104.181 -2.526 . . . . 0.0 104.181 -179.621 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 97.9 t -116.71 114.01 44.67 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 123.904 0.881 . . . . 0.0 109.024 -175.408 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 5.3 m -90.64 178.03 0.57 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.376 -1.713 . . . . 0.0 106.376 172.744 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 2.9 m -97.85 145.73 30.25 Favored Pre-proline 0 C--O 1.223 -0.318 0 CA-C-O 117.147 -1.406 . . . . 0.0 110.064 -178.175 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.8 Cg_endo -62.43 -39.18 47.69 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 N-CA-C 106.92 -1.992 . . . . 0.0 106.92 172.256 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.1 p -157.54 139.57 5.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.643 0 N-CA-C 101.495 -3.52 . . . . 0.0 101.495 169.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.441 ' HE ' ' CG1' ' A' ' 100' ' ' VAL . 0.0 OUTLIER -91.29 -67.71 0.84 Allowed 'General case' 0 C--N 1.327 -0.381 0 N-CA-C 103.131 -2.914 . . . . 0.0 103.131 178.282 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 62.86 -74.4 0.03 OUTLIER Glycine 0 C--N 1.34 0.768 0 C-N-CA 126.155 1.835 . . . . 0.0 112.334 172.569 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.97 114.16 3.37 Favored 'General case' 0 N--CA 1.446 -0.67 0 N-CA-C 106.847 -1.538 . . . . 0.0 106.847 178.217 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 39.0 mm -61.74 128.33 23.06 Favored 'Isoleucine or valine' 0 C--N 1.339 0.138 0 N-CA-C 107.219 -1.4 . . . . 0.0 107.219 178.149 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 8.4 tt -78.89 -52.55 8.14 Favored 'General case' 0 N--CA 1.454 -0.236 0 N-CA-C 105.58 -2.007 . . . . 0.0 105.58 177.236 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 37.7 t30 -179.19 161.81 1.15 Allowed 'General case' 0 CA--C 1.529 0.135 0 N-CA-C 108.332 -0.988 . . . . 0.0 108.332 178.283 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 28.9 m -136.94 123.17 28.33 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.307 0 C-N-CA 125.506 1.522 . . . . 0.0 107.503 175.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER -45.74 153.84 0.6 Allowed Pre-proline 0 CA--C 1.537 0.454 0 N-CA-C 112.705 0.631 . . . . 0.0 112.705 176.353 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 75.2 Cg_exo -50.42 -34.44 41.52 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 123.068 2.512 . . . . 0.0 112.671 175.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 25.0 p -79.62 4.14 16.91 Favored 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 123.972 0.909 . . . . 0.0 112.458 -179.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 11.4 tppt? 66.36 -33.79 0.2 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 128.351 2.66 . . . . 0.0 115.803 178.099 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 7.2 p-80 -54.44 -32.71 58.08 Favored 'General case' 0 N--CA 1.449 -0.505 0 N-CA-C 114.8 1.407 . . . . 0.0 114.8 -174.315 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -136.07 178.89 6.7 Favored 'General case' 0 C--O 1.224 -0.265 0 N-CA-C 114.663 1.356 . . . . 0.0 114.663 -173.542 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.789 23.1 mm 117.86 -131.97 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.331 1 C-N-CA 132.719 4.408 . . . . 0.0 109.607 -179.312 . . . . . . . . 3 2 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.28 171.44 41.97 Favored Glycine 0 CA--C 1.529 0.931 0 N-CA-C 119.448 2.539 . . . . 0.0 119.448 -176.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 14.9 mt -118.97 179.68 4.08 Favored 'General case' 0 CA--C 1.532 0.264 0 C-N-CA 127.81 2.444 . . . . 0.0 109.591 -177.655 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 5.8 mt-30 -149.63 152.3 35.19 Favored 'General case' 0 N--CA 1.448 -0.558 0 C-N-CA 127.016 2.126 . . . . 0.0 105.425 177.088 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 53.9 p -92.09 -123.19 0.08 Allowed 'General case' 0 CA--C 1.535 0.366 0 N-CA-C 109.382 -0.599 . . . . 0.0 109.382 176.589 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 19.5 t70 -120.95 -60.74 1.62 Allowed 'General case' 0 N--CA 1.449 -0.515 0 C-N-CA 127.357 2.263 . . . . 0.0 105.827 175.711 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -78.41 61.64 3.87 Favored Glycine 0 CA--C 1.528 0.856 0 N-CA-C 109.088 -1.605 . . . . 0.0 109.088 175.096 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 60.95 -116.48 9.39 Favored Glycine 0 CA--C 1.529 0.915 0 N-CA-C 110.704 -0.959 . . . . 0.0 110.704 -178.912 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 42.6 mtt85 48.65 72.56 0.27 Allowed 'General case' 0 C--N 1.338 0.101 0 C-N-CA 125.276 1.431 . . . . 0.0 109.988 -178.303 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . 0.48 ' H ' ' ND2' ' A' ' 135' ' ' ASN . 8.4 tm-20 -76.87 134.19 39.08 Favored 'General case' 0 N--CA 1.442 -0.831 0 N-CA-C 105.637 -1.986 . . . . 0.0 105.637 176.744 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 7.3 mt -120.7 111.54 32.35 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 C-N-CA 123.218 0.607 . . . . 0.0 110.995 -172.658 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.7 tt -83.04 138.28 33.79 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 107.187 -1.412 . . . . 0.0 107.187 173.517 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 68.3 mt -134.17 148.37 30.04 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.282 0 C-N-CA 125.122 1.369 . . . . 0.0 108.887 -179.566 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 47.3 t-80 -142.42 78.92 1.64 Allowed 'General case' 0 C--N 1.34 0.192 0 C-N-CA 124.77 1.228 . . . . 0.0 109.743 176.897 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.438 ' HA ' HG23 ' A' ' 129' ' ' THR . 1.3 t80 -51.52 107.02 0.16 Allowed 'General case' 0 C--N 1.331 -0.206 0 C-N-CA 123.102 0.561 . . . . 0.0 111.558 -178.378 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 57.53 -173.29 2.51 Favored Glycine 0 CA--C 1.53 1.003 0 C-N-CA 123.647 0.641 . . . . 0.0 113.086 -178.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mm -121.67 146.0 27.43 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.286 0 N-CA-C 105.767 -1.938 . . . . 0.0 105.767 179.586 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 11.3 t70 65.12 7.86 4.39 Favored 'General case' 0 CA--C 1.542 0.672 0 C-N-CA 123.855 0.862 . . . . 0.0 113.07 -178.963 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -71.61 -35.21 70.39 Favored 'General case' 0 CA--C 1.515 -0.372 0 C-N-CA 125.738 1.615 . . . . 0.0 107.996 177.268 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 13.1 p -55.14 -45.79 77.35 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.395 0 CA-C-N 113.122 -1.854 . . . . 0.0 108.048 171.881 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.23 -38.66 92.05 Favored 'General case' 0 C--N 1.339 0.137 0 C-N-CA 124.354 1.061 . . . . 0.0 109.743 176.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.65 2.06 7.2 Favored 'General case' 0 CA--C 1.548 0.904 0 C-N-CA 126.199 1.8 . . . . 0.0 110.615 175.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.4 mttp 45.88 30.23 0.84 Allowed 'General case' 0 C--N 1.342 0.282 0 C-N-CA 128.016 2.526 . . . . 0.0 114.372 176.522 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.97 24.94 55.66 Favored Glycine 0 CA--C 1.536 1.404 0 CA-C-O 119.876 -0.402 . . . . 0.0 112.156 -178.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 48.6 mt-10 -56.66 -35.14 68.06 Favored 'General case' 0 N--CA 1.468 0.427 0 CA-C-N 119.145 1.473 . . . . 0.0 112.79 -178.49 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -89.43 10.32 73.78 Favored Glycine 0 CA--C 1.533 1.192 0 CA-C-N 112.765 -2.016 . . . . 0.0 113.032 178.843 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.8 m-85 -108.55 108.14 18.92 Favored 'General case' 0 C--N 1.343 0.325 0 CA-C-N 119.234 1.517 . . . . 0.0 111.996 -174.514 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.0 m -91.17 100.14 13.02 Favored 'General case' 0 N--CA 1.452 -0.361 0 N-CA-C 105.259 -2.126 . . . . 0.0 105.259 172.921 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.8 p -80.21 130.44 35.22 Favored 'General case' 0 N--CA 1.451 -0.424 0 O-C-N 121.276 -0.89 . . . . 0.0 111.117 -178.112 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.9 m-85 -90.78 -46.96 7.91 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 124.705 1.202 . . . . 0.0 109.109 178.442 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.441 ' CG1' ' HE ' ' A' ' 57' ' ' ARG . 2.5 m -66.59 133.85 30.74 Favored 'Isoleucine or valine' 0 C--N 1.34 0.187 0 C-N-CA 118.105 -1.438 . . . . 0.0 108.421 174.491 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 59.5 m -110.88 53.29 0.71 Allowed 'General case' 0 C--N 1.331 -0.238 0 N-CA-C 104.26 -2.496 . . . . 0.0 104.26 170.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.292 3.4 pm0 -7.07 75.71 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.552 1 C-N-CA 131.815 4.046 . . . . 0.0 116.797 -171.603 . . . . . . . . 3 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -90.04 45.32 3.01 Favored Glycine 0 CA--C 1.527 0.796 0 CA-C-N 113.187 -1.824 . . . . 0.0 109.596 175.728 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 4.2 p30 5.23 41.57 0.0 OUTLIER 'General case' 0 N--CA 1.464 0.226 2 C-N-CA 133.016 4.526 . . . . 0.0 122.206 -176.814 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -164.38 123.89 1.95 Allowed 'General case' 0 N--CA 1.436 -1.154 1 C-N-CA 133.163 4.585 . . . . 0.0 105.298 176.408 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -163.58 150.74 3.15 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.47 0 CA-C-N 119.524 1.056 . . . . 0.0 110.482 -171.511 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 5.7 mm-40 -85.85 149.81 51.68 Favored Pre-proline 0 CA--C 1.545 0.752 0 CA-C-O 118.17 -0.919 . . . . 0.0 110.631 179.695 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 90.6 Cg_exo -46.71 150.84 2.29 Favored 'Trans proline' 0 CA--C 1.532 0.402 1 C-N-CA 126.222 4.615 . . . . 0.0 117.668 -176.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 66.44 -79.57 0.12 Allowed Glycine 0 CA--C 1.529 0.908 0 C-N-CA 125.071 1.32 . . . . 0.0 112.504 176.873 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 28.8 tt0 1.44 76.12 0.0 OUTLIER 'General case' 0 C--N 1.319 -0.723 0 C-N-CA 131.581 3.953 . . . . 0.0 113.698 -179.323 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 2.8 ttmp? 17.49 109.94 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 129.723 3.209 . . . . 0.0 117.29 177.089 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 88.3 mt -78.75 -50.02 12.07 Favored 'General case' 0 N--CA 1.455 -0.201 0 N-CA-C 109.672 -0.492 . . . . 0.0 109.672 174.68 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 12.5 mt -144.56 156.8 44.32 Favored 'General case' 0 CA--C 1.54 0.577 0 C-N-CA 123.971 0.909 . . . . 0.0 111.836 -173.061 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.5 mt-10 -119.06 131.39 55.95 Favored 'General case' 0 CA--C 1.516 -0.346 1 N-CA-C 98.694 -4.558 . . . . 0.0 98.694 165.586 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -140.91 129.89 24.81 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.83 0 N-CA-C 109.386 -0.598 . . . . 0.0 109.386 -166.497 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.3 t0 -76.24 63.2 1.86 Allowed 'General case' 0 C--O 1.234 0.25 0 CA-C-O 121.509 0.671 . . . . 0.0 110.068 -178.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 78.6 mt -55.26 -34.56 64.15 Favored 'General case' 0 N--CA 1.452 -0.354 0 C-N-CA 123.221 0.609 . . . . 0.0 110.654 -179.336 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.8 t70 -55.44 -40.23 71.29 Favored 'General case' 0 CA--C 1.532 0.287 0 C-N-CA 123.047 0.539 . . . . 0.0 111.915 177.57 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.33 -35.3 17.27 Favored 'General case' 0 CA--C 1.527 0.088 0 C-N-CA 122.788 0.435 . . . . 0.0 111.197 179.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 76.4 t -62.63 -51.19 75.18 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.554 -0.716 . . . . 0.0 109.518 178.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 20.8 pttm -40.66 -57.64 3.02 Favored Pre-proline 0 CA--C 1.541 0.616 0 N-CA-C 116.957 2.206 . . . . 0.0 116.957 -177.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 55.9 Cg_endo -60.79 -25.64 81.52 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 122.696 2.264 . . . . 0.0 113.151 177.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 48.6 m-80 -83.78 -43.03 15.85 Favored 'General case' 0 C--N 1.339 0.15 0 CA-C-N 118.62 0.646 . . . . 0.0 111.148 -178.148 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 35.7 m -78.91 150.57 75.37 Favored Pre-proline 0 CA--C 1.534 0.363 0 N-CA-C 112.114 0.413 . . . . 0.0 112.114 -177.162 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_endo -73.01 -25.19 16.52 Favored 'Trans proline' 0 N--CA 1.451 -1.006 0 C-N-CA 122.515 2.143 . . . . 0.0 110.12 176.465 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.9 t -159.06 145.06 16.55 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 123.397 0.679 . . . . 0.0 109.539 178.782 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.9 tp -101.95 4.92 40.5 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.331 1.452 . . . . 0.0 110.287 177.836 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.8 mmt -51.97 111.4 0.6 Allowed 'General case' 0 C--N 1.342 0.263 0 C-N-CA 123.764 0.826 . . . . 0.0 110.104 179.031 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.438 HG23 ' HA ' ' A' ' 84' ' ' PHE . 85.7 m -107.3 114.57 60.86 Favored Pre-proline 0 N--CA 1.448 -0.555 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 -179.672 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 31.7 Cg_endo -90.55 145.75 4.0 Favored 'Trans proline' 0 N--CA 1.444 -1.409 0 C-N-CA 122.976 2.45 . . . . 0.0 108.937 179.634 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.2 mp -124.84 116.57 47.66 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.626 0 N-CA-C 101.787 -3.412 . . . . 0.0 101.787 172.918 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -124.58 117.21 49.79 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.322 0 C-N-CA 124.607 1.163 . . . . 0.0 108.719 -176.914 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.9 m-85 -91.05 121.86 33.21 Favored 'General case' 0 N--CA 1.442 -0.839 0 N-CA-C 104.163 -2.532 . . . . 0.0 104.163 178.349 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -86.63 -73.17 0.47 Allowed 'General case' 0 N--CA 1.455 -0.191 0 CA-C-N 118.638 0.654 . . . . 0.0 110.757 -174.346 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . 0.48 ' ND2' ' H ' ' A' ' 79' ' ' GLU . 6.5 p30 -75.09 63.5 1.28 Allowed 'General case' 0 CA--C 1.533 0.293 0 CA-C-O 122.164 0.983 . . . . 0.0 112.507 -178.808 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.445 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 29.8 mt -77.02 65.12 2.61 Favored 'General case' 0 CA--C 1.535 0.368 0 C-N-CA 125.864 1.666 . . . . 0.0 108.34 177.152 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.48 46.97 0.08 Allowed 'General case' 0 N--CA 1.468 0.448 0 C-N-CA 127.432 2.293 . . . . 0.0 111.179 -175.929 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 31.9 58.61 0.34 Allowed 'General case' 0 N--CA 1.447 -0.622 0 C-N-CA 128.852 2.861 . . . . 0.0 115.374 -175.972 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 156.56 -4.82 0.19 Allowed Glycine 0 CA--C 1.525 0.664 0 CA-C-O 118.972 -0.905 . . . . 0.0 114.32 174.804 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.615 ' HB3' HG23 ' A' ' 160' ' ' ILE . 43.7 mt-10 -74.87 111.81 10.44 Favored 'General case' 0 N--CA 1.461 0.102 0 CA-C-N 119.18 1.49 . . . . 0.0 110.031 -179.008 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 59.9 p -78.42 133.37 37.51 Favored 'General case' 0 N--CA 1.453 -0.321 0 N-CA-C 107.513 -1.292 . . . . 0.0 107.513 176.885 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.456 HG23 HG13 ' A' ' 160' ' ' ILE 0.26 0.4 OUTLIER -84.37 82.72 1.86 Allowed 'Isoleucine or valine' 0 CA--C 1.54 0.588 0 CA-C-O 122.875 1.321 . . . . 0.0 107.964 -176.646 . . . . . . . . 4 4 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 41.9 m -79.08 94.65 5.36 Favored 'General case' 0 CA--C 1.53 0.194 0 O-C-N 120.986 -1.071 . . . . 0.0 110.363 -176.504 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 10.5 mt -57.91 128.32 18.32 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.349 0 C-N-CA 123.577 0.751 . . . . 0.0 109.954 -179.721 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.4 mmpt? -98.5 -52.63 3.57 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 125.188 1.395 . . . . 0.0 108.931 177.827 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -79.0 61.51 3.19 Favored 'General case' 0 CA--C 1.531 0.233 0 CA-C-O 120.819 0.342 . . . . 0.0 110.133 -178.482 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 60.2 p -77.84 72.77 4.4 Favored 'General case' 0 N--CA 1.453 -0.319 0 C-N-CA 123.843 0.857 . . . . 0.0 110.472 -176.861 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.37 -143.74 5.54 Favored Glycine 0 CA--C 1.524 0.604 0 N-CA-C 109.134 -1.586 . . . . 0.0 109.134 179.445 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 26.5 t -72.2 146.45 47.34 Favored 'General case' 0 N--CA 1.453 -0.294 0 N-CA-C 107.845 -1.169 . . . . 0.0 107.845 174.32 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 19.2 m -137.1 156.51 34.24 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.462 0 C-N-CA 123.617 0.767 . . . . 0.0 109.33 -178.543 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 1.4 m120 -114.05 158.38 21.29 Favored 'General case' 0 N--CA 1.45 -0.452 0 N-CA-C 106.599 -1.63 . . . . 0.0 106.599 174.415 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.21 164.8 26.17 Favored 'General case' 0 CA--C 1.535 0.391 0 CA-C-O 121.12 0.486 . . . . 0.0 110.249 175.091 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 45.2 mt-10 60.7 32.91 20.31 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.339 1.055 . . . . 0.0 112.953 178.716 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.8 mt-30 -105.79 145.79 30.71 Favored 'General case' 0 C--O 1.233 0.186 0 N-CA-C 107.296 -1.372 . . . . 0.0 107.296 175.044 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -115.79 161.9 18.08 Favored 'General case' 0 CA--C 1.532 0.255 0 C-N-CA 124.133 0.973 . . . . 0.0 110.585 -177.643 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 19.3 t70 56.99 18.46 3.97 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 126.436 1.894 . . . . 0.0 113.566 -177.489 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.434 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -61.64 -21.2 24.98 Favored 'Isoleucine or valine' 0 C--O 1.232 0.183 0 C-N-CA 125.464 1.506 . . . . 0.0 112.006 177.728 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.424 HG21 HG22 ' A' ' 142' ' ' VAL . 13.4 p -138.83 150.44 23.59 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.967 0 C-N-CA 126.554 1.941 . . . . 0.0 107.048 178.804 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 8.1 mtpm? -120.77 109.07 14.72 Favored 'General case' 0 N--CA 1.446 -0.637 0 C-N-CA 124.184 0.994 . . . . 0.0 109.765 177.136 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.615 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.2 mp -77.65 92.47 1.22 Allowed 'Isoleucine or valine' 0 N--CA 1.446 -0.668 0 N-CA-C 104.345 -2.465 . . . . 0.0 104.345 178.178 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 58.5 mt-10 -119.25 122.7 42.52 Favored 'General case' 0 N--CA 1.456 -0.133 0 C-N-CA 124.233 1.013 . . . . 0.0 111.055 -174.158 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 40.1 ttmt . . . . . 0 C--N 1.332 -0.179 0 N-CA-C 109.025 -0.732 . . . . 0.0 109.025 177.332 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.8 mtm . . . . . 0 C--O 1.232 0.17 0 CA-C-O 120.991 0.424 . . . . 0.0 110.268 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 49.1 mm -120.43 146.4 25.34 Favored 'Isoleucine or valine' 0 C--O 1.233 0.209 0 C-N-CA 125.409 1.483 . . . . 0.0 107.485 177.416 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -67.94 79.01 0.22 Allowed 'General case' 0 N--CA 1.452 -0.375 0 C-N-CA 123.703 0.801 . . . . 0.0 112.453 -179.299 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 3.4 mp0 58.89 71.46 0.97 Allowed Pre-proline 0 CA--C 1.536 0.416 0 C-N-CA 125.588 1.555 . . . . 0.0 112.614 176.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 84.9 Cg_endo -72.2 77.31 2.04 Favored 'Trans proline' 0 N--CA 1.456 -0.734 0 C-N-CA 123.052 2.501 . . . . 0.0 108.736 177.513 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER 45.62 36.76 2.77 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 127.428 2.291 . . . . 0.0 112.055 -175.94 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 35.5 mt-30 -150.11 166.57 29.37 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 127.165 2.186 . . . . 0.0 106.606 -178.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 t30 63.9 89.42 0.09 Allowed 'General case' 0 CA--C 1.532 0.281 0 C-N-CA 125.082 1.353 . . . . 0.0 112.842 177.235 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.8 tt0 68.88 -60.33 0.45 Allowed 'General case' 0 CA--C 1.531 0.241 0 C-N-CA 126.975 2.11 . . . . 0.0 112.969 176.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 3.8 mt 57.54 38.65 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.629 0 C-N-CA 124.356 1.063 . . . . 0.0 110.016 -178.162 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -77.12 66.23 2.9 Favored Glycine 0 CA--C 1.527 0.817 0 N-CA-C 109.244 -1.543 . . . . 0.0 109.244 178.61 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . 0.48 ' HA ' ' HB2' ' A' ' 156' ' ' ASP . 29.7 tt0 -63.53 72.16 0.02 OUTLIER 'General case' 0 CA--C 1.554 1.131 0 C-N-CA 125.927 1.691 . . . . 0.0 113.69 -174.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 20.7 tt0 -75.8 161.12 29.29 Favored 'General case' 0 CA--C 1.539 0.521 0 C-N-CA 125.262 1.425 . . . . 0.0 110.383 176.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.5 p -71.92 102.34 1.23 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.419 0 CA-C-O 122.464 1.126 . . . . 0.0 113.587 -179.913 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -163.33 151.46 13.55 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 129.998 3.319 . . . . 0.0 102.831 173.475 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -131.27 96.99 2.82 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.476 0 CA-C-N 122.231 2.287 . . . . 0.0 110.272 176.676 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 25.5 t -32.57 120.94 0.41 Allowed Pre-proline 0 CA--C 1.548 0.887 0 C-N-CA 125.574 1.55 . . . . 0.0 112.808 -178.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_endo -74.06 -38.14 2.35 Favored 'Trans proline' 0 N--CA 1.456 -0.705 0 C-N-CA 123.29 2.66 . . . . 0.0 117.571 -171.917 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.92 152.02 17.29 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.435 0 CA-C-N 120.113 1.324 . . . . 0.0 109.84 -176.049 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 57.6 m -79.09 134.17 36.75 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.979 -1.86 . . . . 0.0 105.979 172.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.86 -177.09 45.54 Favored Glycine 0 N--CA 1.441 -0.984 0 N-CA-C 111.042 -0.823 . . . . 0.0 111.042 -178.315 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 42.2 tt0 -92.0 122.08 34.17 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 106.838 -1.541 . . . . 0.0 106.838 177.407 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 15.4 tt -86.61 138.65 18.67 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.184 0 C-N-CA 123.12 0.568 . . . . 0.0 110.141 -179.975 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 78.8 m-70 -137.66 145.63 49.64 Favored Pre-proline 0 C--O 1.234 0.278 0 N-CA-C 107.778 -1.193 . . . . 0.0 107.778 176.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 51.1 Cg_exo -55.47 145.69 67.18 Favored 'Trans proline' 0 N--CA 1.456 -0.728 0 C-N-CA 122.115 1.877 . . . . 0.0 110.218 176.431 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.4 tp -50.8 -33.84 12.59 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.501 0 N-CA-C 113.268 0.84 . . . . 0.0 113.268 -176.729 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.3 p -56.02 -27.71 54.25 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 123.78 0.832 . . . . 0.0 112.388 177.949 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -76.22 -11.89 60.0 Favored 'General case' 0 CA--C 1.534 0.355 0 C-N-CA 123.923 0.889 . . . . 0.0 112.714 -179.409 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.675 HG22 ' HB2' ' A' ' 44' ' ' ALA . 42.3 t -66.85 129.45 94.05 Favored Pre-proline 0 CA--C 1.538 0.51 0 O-C-N 121.245 -0.909 . . . . 0.0 109.445 -178.292 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -77.17 59.48 6.59 Favored 'Trans proline' 0 CA--C 1.54 0.809 0 C-N-CA 123.696 2.931 . . . . 0.0 111.024 -179.206 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 51.6 t0 -167.58 105.19 0.52 Allowed 'General case' 0 N--CA 1.463 0.209 0 O-C-N 121.356 -0.84 . . . . 0.0 109.344 -179.755 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 1.4 tm0? -24.56 -58.03 0.05 Allowed 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 128.162 2.585 . . . . 0.0 114.164 179.75 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 96.9 t -48.57 -50.44 12.66 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.214 0 C-N-CA 123.954 0.902 . . . . 0.0 110.464 -178.485 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.9 m-85 -76.31 -47.81 22.29 Favored 'General case' 0 N--CA 1.448 -0.532 0 N-CA-C 109.111 -0.7 . . . . 0.0 109.111 179.894 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 2.2 m -49.31 -41.29 38.0 Favored 'General case' 0 N--CA 1.455 -0.192 0 N-CA-C 113.793 1.035 . . . . 0.0 113.793 -179.558 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -104.6 20.27 39.81 Favored Glycine 0 C--N 1.339 0.71 0 CA-C-O 118.081 -1.4 . . . . 0.0 110.897 -177.068 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.0 mttt 72.03 -46.52 0.65 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.401 1.48 . . . . 0.0 113.248 179.758 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 45.0 tpp 45.16 -72.83 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 128.731 2.812 . . . . 0.0 115.352 -178.988 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 30.7 ttp -101.8 -14.69 17.19 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 125.314 1.446 . . . . 0.0 113.018 -176.476 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.06 -169.21 38.0 Favored Glycine 0 C--N 1.338 0.674 0 CA-C-N 119.531 1.06 . . . . 0.0 111.965 -178.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 18.2 t0 -128.79 157.54 41.17 Favored 'General case' 0 CA--C 1.517 -0.306 0 N-CA-C 108.069 -1.086 . . . . 0.0 108.069 177.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.99 -126.71 1.35 Allowed Glycine 0 N--CA 1.445 -0.743 0 N-CA-C 108.533 -1.827 . . . . 0.0 108.533 179.291 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.2 p90 -166.44 167.1 16.01 Favored 'General case' 0 N--CA 1.451 -0.399 0 CA-C-N 118.125 0.963 . . . . 0.0 111.542 -176.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.675 ' HB2' HG22 ' A' ' 29' ' ' VAL . . . -99.35 126.19 45.17 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.475 1.11 . . . . 0.0 108.5 177.418 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 27.0 mm -107.31 121.12 59.77 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.644 0 N-CA-C 104.193 -2.521 . . . . 0.0 104.193 170.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 7.0 tt -89.03 109.5 31.12 Favored Pre-proline 0 C--O 1.233 0.233 1 N-CA-C 100.073 -4.047 . . . . 0.0 100.073 170.498 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -81.52 162.61 19.34 Favored 'Trans proline' 0 N--CA 1.457 -0.66 0 C-N-CA 123.594 2.863 . . . . 0.0 115.037 -167.649 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 21.2 p -132.04 -63.52 0.81 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 125.639 1.576 . . . . 0.0 108.947 177.095 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -58.43 123.93 17.83 Favored 'General case' 0 C--N 1.338 0.096 0 C-N-CA 122.56 0.344 . . . . 0.0 110.166 178.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.08 45.34 2.98 Favored Glycine 0 CA--C 1.531 1.057 0 N-CA-C 109.887 -1.285 . . . . 0.0 109.887 173.304 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 36.2 mt -145.84 115.96 1.66 Allowed 'Isoleucine or valine' 0 N--CA 1.454 -0.235 0 N-CA-C 105.17 -2.159 . . . . 0.0 105.17 -179.055 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 99.1 t -114.01 121.51 66.3 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 125.084 1.354 . . . . 0.0 108.252 -177.283 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.9 m -103.66 156.93 5.34 Favored 'Isoleucine or valine' 0 C--N 1.339 0.11 0 C-N-CA 123.642 0.777 . . . . 0.0 110.071 177.222 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 8.4 m -69.12 127.17 93.13 Favored Pre-proline 0 CA--C 1.537 0.471 0 CA-C-O 117.598 -1.191 . . . . 0.0 109.92 -178.942 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.1 Cg_endo -60.41 -33.2 94.39 Favored 'Trans proline' 0 C--N 1.347 0.475 0 C-N-CA 123.763 2.976 . . . . 0.0 111.302 177.521 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.1 m -150.6 144.16 17.08 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.342 0 N-CA-C 102.139 -3.282 . . . . 0.0 102.139 172.704 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 7.3 tpt180 -98.72 -97.41 0.22 Allowed 'General case' 0 CA--C 1.508 -0.647 0 N-CA-C 101.754 -3.424 . . . . 0.0 101.754 169.354 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 79.95 -66.43 3.59 Favored Glycine 0 CA--C 1.535 1.303 0 N-CA-C 106.575 -2.61 . . . . 0.0 106.575 179.732 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -166.21 132.36 2.49 Favored 'General case' 0 N--CA 1.444 -0.742 0 N-CA-C 106.111 -1.811 . . . . 0.0 106.111 166.617 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 21.0 mm -65.04 131.78 30.85 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.299 0 N-CA-C 103.55 -2.759 . . . . 0.0 103.55 169.069 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 29.3 tp -79.01 -46.36 18.33 Favored 'General case' 0 N--CA 1.455 -0.176 0 N-CA-C 106.375 -1.713 . . . . 0.0 106.375 -179.912 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.8 t-20 175.0 156.05 0.15 Allowed 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 125.669 1.588 . . . . 0.0 107.787 176.034 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 50.3 t -131.12 121.06 48.46 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.5 0 N-CA-C 103.443 -2.799 . . . . 0.0 103.443 172.067 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -47.44 153.01 1.05 Allowed Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 112.579 0.585 . . . . 0.0 112.579 179.604 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -59.67 -14.97 28.92 Favored 'Trans proline' 0 C--N 1.348 0.535 0 C-N-CA 124.192 3.262 . . . . 0.0 113.652 -179.598 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 40.5 p -76.26 -21.29 56.49 Favored 'General case' 0 N--CA 1.452 -0.372 0 C-N-CA 124.078 0.951 . . . . 0.0 109.697 176.86 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 70.98 9.52 6.78 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 128.14 2.576 . . . . 0.0 111.03 -173.101 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 2.3 p-80 -83.91 -31.21 25.78 Favored 'General case' 0 N--CA 1.451 -0.376 0 CA-C-O 118.611 -0.709 . . . . 0.0 112.864 -176.927 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.82 -175.38 5.33 Favored 'General case' 0 C--O 1.226 -0.154 0 CA-C-N 119.679 1.127 . . . . 0.0 112.348 -174.314 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.965 16.6 mm 130.89 -141.8 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.334 -0.085 1 C-N-CA 132.018 4.127 . . . . 0.0 111.824 176.4 . . . . . . . . 3 2 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -152.14 176.2 30.53 Favored Glycine 0 CA--C 1.527 0.782 0 N-CA-C 118.511 2.164 . . . . 0.0 118.511 -171.804 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.2 mp -132.51 158.46 42.05 Favored 'General case' 0 N--CA 1.454 -0.247 0 C-N-CA 128.012 2.525 . . . . 0.0 109.817 -176.972 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.7 mm-40 -133.03 123.85 26.57 Favored 'General case' 0 N--CA 1.441 -0.923 0 N-CA-C 107.579 -1.267 . . . . 0.0 107.579 177.379 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 9.3 p -73.79 -83.57 0.05 OUTLIER 'General case' 0 C--N 1.322 -0.629 0 C-N-CA 124.689 1.196 . . . . 0.0 108.778 177.82 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 45.6 t0 -149.28 52.04 0.95 Allowed 'General case' 0 N--CA 1.448 -0.543 0 C-N-CA 127.138 2.175 . . . . 0.0 107.608 -179.194 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 80.25 -70.45 2.95 Favored Glycine 0 CA--C 1.526 0.72 0 N-CA-C 107.916 -2.073 . . . . 0.0 107.916 -174.512 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -69.29 112.2 4.37 Favored Glycine 0 CA--C 1.528 0.845 0 C-N-CA 125.313 1.435 . . . . 0.0 111.25 179.574 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 97.5 mtt180 93.1 62.01 0.0 OUTLIER 'General case' 0 C--N 1.335 -0.058 0 C-N-CA 129.494 3.117 . . . . 0.0 111.824 179.991 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 36.2 tt0 -76.34 141.15 41.64 Favored 'General case' 0 N--CA 1.452 -0.332 0 N-CA-C 107.442 -1.318 . . . . 0.0 107.442 174.43 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.2 mt -126.66 144.36 37.08 Favored 'Isoleucine or valine' 0 C--N 1.338 0.08 0 N-CA-C 112.789 0.662 . . . . 0.0 112.789 -172.795 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -119.82 136.63 54.39 Favored 'General case' 0 N--CA 1.451 -0.393 0 C-N-CA 128.891 2.876 . . . . 0.0 105.732 175.789 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.0 mt -131.48 140.15 49.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.267 0 C-N-CA 125.075 1.35 . . . . 0.0 107.764 177.529 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 62.5 t-80 -132.89 114.81 14.49 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 107.559 -1.274 . . . . 0.0 107.559 175.263 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.5 t80 -76.05 116.52 16.83 Favored 'General case' 0 N--CA 1.449 -0.511 0 CA-C-N 118.766 0.712 . . . . 0.0 110.402 -179.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.63 -170.57 4.82 Favored Glycine 0 CA--C 1.529 0.954 0 N-CA-C 111.694 -0.562 . . . . 0.0 111.694 -179.392 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 22.5 mm -116.59 141.36 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 107.097 -1.446 . . . . 0.0 107.097 178.159 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.7 t0 50.2 41.98 24.76 Favored 'General case' 0 CA--C 1.533 0.324 0 C-N-CA 124.412 1.085 . . . . 0.0 112.892 179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.423 ' O ' ' N ' ' A' ' 90' ' ' SER . 7.7 p -83.83 -89.12 0.1 Allowed 'General case' 0 CA--C 1.505 -0.755 0 N-CA-C 103.273 -2.862 . . . . 0.0 103.273 172.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.435 HG13 ' H ' ' A' ' 90' ' ' SER . 7.3 p 33.03 -67.31 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.541 0 C-N-CA 128.313 2.645 . . . . 0.0 116.946 172.354 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.435 ' H ' HG13 ' A' ' 89' ' ' VAL . 12.9 m -63.43 -40.44 97.18 Favored 'General case' 0 C--N 1.332 -0.178 0 C-N-CA 126.27 1.828 . . . . 0.0 109.758 176.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 1.1 tm? -58.35 -43.53 88.36 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 126.862 2.065 . . . . 0.0 108.8 178.415 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 7.2 mtmp? 77.02 169.59 0.24 Allowed 'General case' 0 N--CA 1.442 -0.871 0 C-N-CA 126.823 2.049 . . . . 0.0 106.837 -174.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -69.03 54.96 0.56 Allowed Glycine 0 CA--C 1.538 1.493 0 C-N-CA 124.898 1.237 . . . . 0.0 112.718 -179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 92.0 mt-10 -75.41 79.88 2.47 Favored 'General case' 0 CA--C 1.519 -0.236 0 O-C-N 121.158 -1.201 . . . . 0.0 108.781 179.671 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.78 11.72 2.31 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 112.919 -1.946 . . . . 0.0 111.594 -176.93 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.9 m-85 -96.94 96.93 8.86 Favored 'General case' 0 C--N 1.342 0.267 0 C-N-CA 124.753 1.221 . . . . 0.0 110.731 -175.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.4 m -79.72 94.67 5.78 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 103.957 -2.609 . . . . 0.0 103.957 172.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 35.9 p -79.51 122.93 27.07 Favored 'General case' 0 N--CA 1.448 -0.558 0 O-C-N 121.569 -0.707 . . . . 0.0 110.653 -176.446 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -83.57 -53.18 5.86 Favored 'General case' 0 N--CA 1.448 -0.539 0 N-CA-C 108.289 -1.004 . . . . 0.0 108.289 178.602 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 27.9 m -84.82 131.02 35.05 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.12 0 N-CA-C 106.125 -1.805 . . . . 0.0 106.125 171.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 69.6 m -96.06 57.63 1.79 Allowed 'General case' 0 C--N 1.328 -0.354 0 N-CA-C 103.149 -2.908 . . . . 0.0 103.149 170.351 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.378 0.0 OUTLIER 37.97 49.6 1.2 Allowed 'General case' 0 C--N 1.325 -0.458 0 CA-C-N 111.458 -2.61 . . . . 0.0 110.6 -167.265 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -72.44 59.46 1.57 Allowed Glycine 0 CA--C 1.52 0.4 0 C-N-CA 129.639 3.495 . . . . 0.0 111.152 -178.066 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.401 16.4 p30 2.04 -103.22 0.0 OUTLIER 'General case' 0 N--CA 1.439 -1.007 0 N-CA-C 119.583 3.179 . . . . 0.0 119.583 -178.942 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.322 0.1 OUTLIER -40.6 131.29 2.33 Favored 'General case' 0 N--CA 1.432 -1.367 1 N-CA-C 125.478 5.362 . . . . 0.0 125.478 -165.667 . . . . . . . . 4 3 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.489 9.7 p 32.63 -38.27 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.493 -1.247 2 N-CA-C 130.203 7.112 . . . . 0.0 130.203 168.148 . . . . . . . . 3 2 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . 0.485 ' HA ' ' HD3' ' A' ' 108' ' ' PRO 0.287 0.0 OUTLIER -70.33 115.16 31.88 Favored Pre-proline 0 C--N 1.308 -1.197 0 C-N-CA 115.422 -2.511 . . . . 0.0 114.333 -166.865 . . . . . . . . 4 4 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.485 ' HD3' ' HA ' ' A' ' 107' ' ' GLU . 47.7 Cg_exo -62.45 162.82 22.71 Favored 'Trans proline' 0 C--N 1.355 0.905 0 C-N-CA 124.875 3.717 . . . . 0.0 113.576 -170.141 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 54.04 15.91 5.63 Favored Glycine 0 CA--C 1.53 0.969 0 C-N-CA 124.423 1.011 . . . . 0.0 115.314 174.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 47.3 tp60 -59.88 136.89 58.15 Favored 'General case' 0 N--CA 1.449 -0.515 0 CA-C-N 117.987 0.893 . . . . 0.0 108.752 178.929 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.8 ptpt -64.23 119.42 10.22 Favored 'General case' 0 N--CA 1.449 -0.499 0 N-CA-C 107.632 -1.248 . . . . 0.0 107.632 174.381 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.6 mt -81.07 -52.33 7.51 Favored 'General case' 0 N--CA 1.449 -0.491 0 N-CA-C 109.003 -0.74 . . . . 0.0 109.003 -178.534 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 17.1 mt -145.56 149.31 34.35 Favored 'General case' 0 CA--C 1.536 0.424 0 C-N-CA 124.29 1.036 . . . . 0.0 110.995 -173.387 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -114.39 128.19 56.22 Favored 'General case' 0 CA--C 1.515 -0.402 1 N-CA-C 98.762 -4.532 . . . . 0.0 98.762 165.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.65 127.0 44.83 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.737 0 CA-C-N 115.926 -0.579 . . . . 0.0 111.744 -165.469 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.2 t0 -74.26 68.29 1.47 Allowed 'General case' 0 CA--C 1.531 0.217 0 C-N-CA 123.664 0.786 . . . . 0.0 110.108 -179.641 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.0 mt -54.2 -38.36 65.56 Favored 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 122.929 0.491 . . . . 0.0 111.102 -179.57 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 35.6 t70 -53.68 -44.75 69.97 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 122.99 0.516 . . . . 0.0 112.162 179.531 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.89 -32.52 20.16 Favored 'General case' 0 CA--C 1.527 0.079 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -179.778 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -67.13 -50.59 62.25 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.527 0 O-C-N 121.759 -0.588 . . . . 0.0 110.326 179.87 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.345 22.1 pttm -37.0 -54.15 1.84 Allowed Pre-proline 0 CA--C 1.54 0.596 0 N-CA-C 118.283 2.698 . . . . 0.0 118.283 -176.796 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 25.9 Cg_endo -52.63 -22.15 16.33 Favored 'Trans proline' 0 N--CA 1.458 -0.596 0 C-N-CA 122.66 2.24 . . . . 0.0 114.095 179.237 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 22.4 m-80 -84.19 -14.36 50.31 Favored 'General case' 0 CA--C 1.53 0.202 0 CA-C-O 118.13 -0.938 . . . . 0.0 113.096 -177.767 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 29.3 m -108.77 149.05 38.99 Favored Pre-proline 0 N--CA 1.465 0.322 0 CA-C-N 119.731 1.15 . . . . 0.0 112.44 -176.327 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -71.32 -26.29 20.85 Favored 'Trans proline' 0 N--CA 1.452 -0.961 0 C-N-CA 122.586 2.19 . . . . 0.0 110.372 175.674 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 10.0 m -157.85 137.41 12.03 Favored 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.564 1.146 . . . . 0.0 108.287 179.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 13.2 tp -90.29 6.78 41.5 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.876 0.87 . . . . 0.0 111.396 -178.891 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.1 mmt -50.57 114.26 1.09 Allowed 'General case' 0 C--N 1.342 0.244 0 N-CA-C 108.745 -0.835 . . . . 0.0 108.745 178.451 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 45.6 m -107.73 88.36 4.3 Favored Pre-proline 0 N--CA 1.445 -0.708 0 N-CA-C 107.037 -1.468 . . . . 0.0 107.037 -179.143 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -72.49 139.92 32.27 Favored 'Trans proline' 0 N--CA 1.445 -1.352 0 C-N-CA 121.923 1.749 . . . . 0.0 111.976 -178.718 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 16.6 mm -115.51 128.48 72.72 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.519 0 N-CA-C 102.404 -3.184 . . . . 0.0 102.404 173.555 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.5 t -137.43 122.36 24.49 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.248 0 N-CA-C 109.339 -0.615 . . . . 0.0 109.339 -175.989 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 9.5 m-85 -84.72 123.05 29.95 Favored 'General case' 0 N--CA 1.442 -0.855 0 N-CA-C 104.035 -2.58 . . . . 0.0 104.035 174.673 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 40.2 p -80.74 -72.78 0.4 Allowed 'General case' 0 C--O 1.227 -0.129 0 CA-C-N 118.841 0.746 . . . . 0.0 110.796 -175.683 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 22.2 p30 -65.14 -30.06 70.96 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.756 1.021 . . . . 0.0 113.756 -177.37 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 1.5 mt 46.27 44.54 12.5 Favored 'General case' 0 CA--C 1.541 0.617 0 C-N-CA 124.156 0.982 . . . . 0.0 110.347 -176.973 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 42.53 37.39 0.97 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 126.351 1.86 . . . . 0.0 112.662 -175.645 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 75.5 mm-40 48.25 75.32 0.14 Allowed 'General case' 0 N--CA 1.45 -0.462 0 C-N-CA 126.706 2.002 . . . . 0.0 113.874 179.661 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 132.03 -14.21 5.19 Favored Glycine 0 C--N 1.335 0.484 0 CA-C-O 118.702 -1.055 . . . . 0.0 113.339 174.723 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . . . . . . . . . 49.4 mt-10 -72.65 139.21 47.19 Favored 'General case' 0 CA--C 1.539 0.53 0 CA-C-N 119.206 1.503 . . . . 0.0 109.776 179.919 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 77.2 p -111.87 130.81 55.7 Favored 'General case' 0 C--O 1.236 0.352 0 C-N-CA 124.97 1.308 . . . . 0.0 109.128 176.022 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -60.42 112.6 0.74 Allowed 'Isoleucine or valine' 0 CA--C 1.528 0.109 0 C-N-CA 123.973 0.909 . . . . 0.0 110.387 -175.363 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -114.62 87.28 2.61 Favored 'General case' 0 N--CA 1.445 -0.691 0 C-N-CA 126.407 1.883 . . . . 0.0 106.518 179.398 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 34.7 mt -66.77 131.82 32.35 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.14 0 N-CA-C 108.069 -1.085 . . . . 0.0 108.069 -179.249 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -96.58 -44.2 7.25 Favored 'General case' 0 C--N 1.333 -0.144 0 N-CA-C 108.944 -0.762 . . . . 0.0 108.944 177.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.457 ' HB2' HG23 ' A' ' 157' ' ' ILE . . . -47.23 83.1 0.0 OUTLIER 'General case' 0 C--N 1.34 0.158 0 C-N-CA 126.348 1.859 . . . . 0.0 114.206 -178.753 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 37.7 m -82.71 54.59 2.72 Favored 'General case' 0 N--CA 1.449 -0.477 0 C-N-CA 123.996 0.918 . . . . 0.0 108.787 178.685 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 157.47 -171.65 34.73 Favored Glycine 0 CA--C 1.522 0.53 0 N-CA-C 111.211 -0.755 . . . . 0.0 111.211 -177.548 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 29.6 t -58.47 138.05 56.93 Favored 'General case' 0 C--O 1.234 0.284 0 C-N-CA 122.794 0.438 . . . . 0.0 110.101 179.465 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.7 m -92.86 -173.01 0.22 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.221 0 C-N-CA 123.7 0.8 . . . . 0.0 109.928 179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -150.85 166.7 29.76 Favored 'General case' 0 C--O 1.233 0.21 0 N-CA-C 105.427 -2.064 . . . . 0.0 105.427 178.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -82.62 155.03 24.64 Favored 'General case' 0 CA--C 1.536 0.411 0 CA-C-N 118.986 0.812 . . . . 0.0 110.336 176.034 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.5 mt-10 62.56 5.12 1.55 Allowed 'General case' 0 CA--C 1.535 0.378 0 C-N-CA 125.762 1.625 . . . . 0.0 114.301 178.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 31.6 mm-40 -67.95 118.22 10.85 Favored 'General case' 0 C--O 1.235 0.293 0 N-CA-C 107.998 -1.112 . . . . 0.0 107.998 178.926 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 62.7 tt0 -67.51 138.03 56.23 Favored 'General case' 0 N--CA 1.447 -0.593 0 N-CA-C 108.533 -0.914 . . . . 0.0 108.533 178.885 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.48 ' HB2' ' HA ' ' A' ' 12' ' ' GLU . 29.2 t70 84.92 -113.87 0.01 OUTLIER 'General case' 0 N--CA 1.449 -0.507 0 C-N-CA 128.327 2.651 . . . . 0.0 109.043 -179.318 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.457 HG23 ' HB2' ' A' ' 146' ' ' ALA 0.366 1.7 mp 73.31 -28.48 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.319 -0.751 0 C-N-CA 129.565 3.146 . . . . 0.0 111.509 179.687 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.0 p -134.9 148.09 29.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.7 0 C-N-CA 127.519 2.328 . . . . 0.0 106.978 169.811 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . 0.496 ' C ' HD13 ' A' ' 160' ' ' ILE . 26.3 mtpp -134.67 144.93 48.1 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 104.009 -2.589 . . . . 0.0 104.009 173.608 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.496 HD13 ' C ' ' A' ' 159' ' ' LYS . 0.3 OUTLIER -112.0 112.55 40.99 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.457 0 N-CA-C 105.828 -1.916 . . . . 0.0 105.828 178.156 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -101.1 134.02 44.74 Favored 'General case' 0 N--CA 1.466 0.352 0 C-N-CA 123.66 0.784 . . . . 0.0 111.247 -174.908 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 26.4 mtpp . . . . . 0 CA--C 1.528 0.117 0 N-CA-C 109.599 -0.519 . . . . 0.0 109.599 176.73 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.8 ttt . . . . . 0 N--CA 1.455 -0.212 0 CA-C-O 120.995 0.426 . . . . 0.0 109.866 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 37.1 mm -74.09 79.26 0.44 Allowed 'Isoleucine or valine' 0 N--CA 1.453 -0.277 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 178.239 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -62.93 67.68 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 126.548 1.939 . . . . 0.0 113.9 -175.767 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 47.0 mt-10 -119.05 -72.67 0.02 OUTLIER Pre-proline 0 CA--C 1.537 0.47 0 C-N-CA 126.238 1.815 . . . . 0.0 108.273 176.494 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -69.41 157.49 60.86 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 CA-C-N 121.258 1.485 . . . . 0.0 109.495 176.181 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -71.25 64.62 0.38 Allowed 'General case' 0 CA--C 1.537 0.452 0 C-N-CA 124.853 1.261 . . . . 0.0 112.245 -179.7 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 1.9 pt20 -71.69 59.82 0.34 Allowed 'General case' 0 CA--C 1.535 0.402 0 C-N-CA 126.123 1.769 . . . . 0.0 112.055 -179.728 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 25.4 t30 -66.16 149.33 50.47 Favored 'General case' 0 CA--C 1.531 0.231 0 O-C-N 121.854 -0.529 . . . . 0.0 110.223 178.875 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 54.0 mt-10 -76.06 73.14 2.92 Favored 'General case' 0 N--CA 1.452 -0.358 0 N-CA-C 108.023 -1.102 . . . . 0.0 108.023 176.132 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.7 pt -66.51 69.93 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 C-N-CA 124.797 1.239 . . . . 0.0 112.486 -178.113 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -73.72 67.67 1.62 Allowed Glycine 0 CA--C 1.526 0.729 0 C-N-CA 124.332 0.968 . . . . 0.0 110.776 178.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 -74.07 79.25 1.72 Allowed 'General case' 0 N--CA 1.449 -0.506 0 N-CA-C 107.698 -1.223 . . . . 0.0 107.698 177.688 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 40.2 mm-40 -73.36 64.65 0.83 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 122.949 0.5 . . . . 0.0 110.486 -179.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER 69.14 -3.51 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.531 0.23 0 C-N-CA 128.352 2.661 . . . . 0.0 115.116 179.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -84.83 147.35 26.86 Favored 'General case' 0 C--N 1.331 -0.217 0 C-N-CA 125.443 1.497 . . . . 0.0 114.387 -176.239 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.6 OUTLIER -142.55 103.88 1.05 Allowed 'Isoleucine or valine' 0 C--O 1.223 -0.331 0 C-N-CA 126.68 1.992 . . . . 0.0 106.267 172.995 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 20.2 t -29.14 118.53 0.28 Allowed Pre-proline 0 CA--C 1.552 1.033 0 C-N-CA 124.728 1.211 . . . . 0.0 113.43 -179.26 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 39.2 Cg_endo -75.31 -37.47 1.87 Allowed 'Trans proline' 0 CA--C 1.537 0.672 0 C-N-CA 122.693 2.262 . . . . 0.0 117.324 -173.115 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -143.27 148.06 19.7 Favored 'Isoleucine or valine' 0 N--CA 1.468 0.458 0 CA-C-N 120.397 1.453 . . . . 0.0 109.3 -176.727 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 98.4 m -78.64 137.04 37.64 Favored 'General case' 0 C--O 1.236 0.373 0 N-CA-C 107.727 -1.212 . . . . 0.0 107.727 175.301 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 158.19 -147.14 14.54 Favored Glycine 0 N--CA 1.448 -0.547 0 N-CA-C 109.623 -1.391 . . . . 0.0 109.623 179.477 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -107.72 144.1 35.3 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 108.544 -0.91 . . . . 0.0 108.544 178.858 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 6.1 tt -105.62 95.17 3.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.262 0 C-N-CA 124.304 1.041 . . . . 0.0 108.398 -179.67 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 18.3 m-70 -85.63 151.58 55.86 Favored Pre-proline 0 C--O 1.237 0.404 0 N-CA-C 108.242 -1.021 . . . . 0.0 108.242 178.047 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 30.4 Cg_endo -64.26 145.32 88.5 Favored 'Trans proline' 0 N--CA 1.449 -1.136 0 N-CA-C 107.888 -1.62 . . . . 0.0 107.888 174.887 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.3 tp -50.67 -32.64 10.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.534 0 C-N-CA 123.672 0.789 . . . . 0.0 111.134 178.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -56.9 -29.87 63.41 Favored 'General case' 0 N--CA 1.45 -0.432 0 C-N-CA 124.829 1.252 . . . . 0.0 113.057 179.406 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 26.4 t0 -82.24 3.65 26.64 Favored 'General case' 0 CA--C 1.537 0.459 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.524 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.403 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 58.2 t -82.06 128.04 69.56 Favored Pre-proline 0 CA--C 1.536 0.435 0 CA-C-O 117.508 -1.234 . . . . 0.0 111.755 -176.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 82.2 Cg_exo -58.74 40.75 0.05 OUTLIER 'Trans proline' 0 CA--C 1.545 1.04 1 C-N-CA 126.354 4.702 . . . . 0.0 117.451 175.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 20.4 t0 -164.48 109.59 0.97 Allowed 'General case' 0 CA--C 1.533 0.296 0 CA-C-N 120.98 1.718 . . . . 0.0 109.033 -179.793 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 18.8 mp0 -34.13 -48.52 0.32 Allowed 'General case' 0 C--O 1.231 0.117 0 C-N-CA 128.956 2.902 . . . . 0.0 114.401 -176.805 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 9.5 p -53.44 -38.95 34.28 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 CA-C-N 118.158 0.435 . . . . 0.0 110.878 -178.606 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -84.48 -48.83 9.2 Favored 'General case' 0 N--CA 1.449 -0.493 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 177.419 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -51.03 -39.23 55.38 Favored 'General case' 0 CA--C 1.529 0.163 0 N-CA-C 113.801 1.037 . . . . 0.0 113.801 -178.131 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.38 17.15 57.24 Favored Glycine 0 N--CA 1.445 -0.716 0 CA-C-O 118.219 -1.323 . . . . 0.0 111.06 -177.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 62.7 mttp 71.18 -40.71 0.48 Allowed 'General case' 0 CA--C 1.541 0.622 0 C-N-CA 125.463 1.505 . . . . 0.0 114.07 178.88 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 29.97 -73.96 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.584 0 C-N-CA 130.005 3.322 . . . . 0.0 116.753 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.19 -21.3 46.56 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.476 1.11 . . . . 0.0 113.263 -175.667 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 172.43 -144.21 7.83 Favored Glycine 0 C--O 1.223 -0.564 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 -178.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 10.4 t0 -141.57 160.05 40.95 Favored 'General case' 0 CA--C 1.513 -0.48 0 N-CA-C 108.226 -1.027 . . . . 0.0 108.226 176.482 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 172.55 -126.13 1.23 Allowed Glycine 0 N--CA 1.442 -0.931 0 N-CA-C 106.672 -2.571 . . . . 0.0 106.672 -179.253 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.05 163.73 15.86 Favored 'General case' 0 N--CA 1.454 -0.232 0 CA-C-N 118.636 1.218 . . . . 0.0 112.261 -179.838 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.403 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -99.94 96.88 7.84 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 124.575 1.15 . . . . 0.0 110.466 -178.185 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 32.1 mm -80.44 126.11 39.4 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.727 0 N-CA-C 106.173 -1.788 . . . . 0.0 106.173 173.886 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.4 tt -101.03 105.5 39.03 Favored Pre-proline 0 N--CA 1.446 -0.665 0 N-CA-C 100.529 -3.878 . . . . 0.0 100.529 171.381 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.4 Cg_endo -84.37 168.18 11.68 Favored 'Trans proline' 0 N--CA 1.454 -0.835 0 C-N-CA 123.891 3.061 . . . . 0.0 114.255 -168.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 22.9 p -130.8 -71.7 0.57 Allowed 'General case' 0 CA--C 1.532 0.285 0 C-N-CA 125.347 1.459 . . . . 0.0 108.199 176.081 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -48.89 127.25 13.72 Favored 'General case' 0 C--O 1.23 0.07 0 C-N-CA 124.609 1.164 . . . . 0.0 112.088 178.748 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.21 42.26 2.34 Favored Glycine 0 CA--C 1.531 1.069 0 N-CA-C 110.715 -0.954 . . . . 0.0 110.715 173.899 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 35.9 mt -143.74 120.87 5.61 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 104.381 -2.452 . . . . 0.0 104.381 179.207 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.408 HG21 ' CE2' ' A' ' 84' ' ' PHE . 53.1 t -119.97 131.09 73.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 C-N-CA 124.911 1.284 . . . . 0.0 107.549 -176.528 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.4 m -110.72 159.39 10.64 Favored 'Isoleucine or valine' 0 C--O 1.231 0.129 0 C-N-CA 124.08 0.952 . . . . 0.0 110.947 179.316 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.6 OUTLIER -65.84 132.7 94.83 Favored Pre-proline 0 CA--C 1.533 0.321 0 CA-C-O 118.41 -0.805 . . . . 0.0 110.21 -179.584 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 57.6 Cg_endo -68.58 -15.95 42.02 Favored 'Trans proline' 0 N--CA 1.458 -0.572 0 C-N-CA 123.638 2.892 . . . . 0.0 115.926 -177.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 16.3 m -143.99 162.02 15.51 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.046 0 CA-C-N 119.523 1.056 . . . . 0.0 110.409 -178.66 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.404 ' HA ' ' HA ' ' A' ' 108' ' ' PRO . 9.0 ptp85 -76.73 117.14 18.06 Favored 'General case' 0 CA--C 1.514 -0.441 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 168.716 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 172.96 -179.62 44.28 Favored Glycine 0 N--CA 1.433 -1.529 0 C-N-CA 115.277 -3.344 . . . . 0.0 114.954 -167.246 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -95.63 127.91 42.05 Favored 'General case' 0 N--CA 1.445 -0.723 0 C-N-CA 124.558 1.143 . . . . 0.0 109.815 -176.233 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 9.6 mm -73.94 113.32 11.98 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.35 0 N-CA-C 102.633 -3.099 . . . . 0.0 102.633 173.108 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 61.0 tp -76.44 -47.93 21.37 Favored 'General case' 0 N--CA 1.453 -0.287 0 N-CA-C 107.45 -1.315 . . . . 0.0 107.45 -174.571 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 20.3 t-20 -174.77 157.4 2.47 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 175.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 13.5 t -138.91 119.24 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.45 0 N-CA-C 104.599 -2.371 . . . . 0.0 104.599 175.791 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 15.6 m-85 -42.04 151.53 0.34 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.572 0.624 . . . . 0.0 112.201 177.91 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.19 -26.36 15.03 Favored 'Trans proline' 0 CA--C 1.536 0.595 0 C-N-CA 123.89 3.06 . . . . 0.0 114.303 175.0 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 19.2 p -75.73 -15.2 60.31 Favored 'General case' 0 C--O 1.223 -0.321 0 C-N-CA 123.871 0.869 . . . . 0.0 110.925 -179.527 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 71.87 10.11 6.2 Favored 'General case' 0 CA--C 1.54 0.59 0 C-N-CA 125.545 1.538 . . . . 0.0 113.536 178.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.437 ' CG ' ' HA ' ' A' ' 89' ' ' VAL . 22.6 p-80 -90.51 -31.62 16.68 Favored 'General case' 0 N--CA 1.464 0.247 0 CA-C-N 119.428 1.013 . . . . 0.0 113.403 179.395 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -152.97 -178.82 7.16 Favored 'General case' 0 C--O 1.221 -0.422 0 N-CA-C 112.928 0.714 . . . . 0.0 112.928 -171.007 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.663 23.0 mm 124.01 -132.3 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.275 1 C-N-CA 135.155 5.382 . . . . 0.0 105.216 -176.709 . . . . . . . . 3 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -169.86 -179.1 41.33 Favored Glycine 0 CA--C 1.527 0.797 0 N-CA-C 119.165 2.426 . . . . 0.0 119.165 -177.829 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.6 mp -124.56 172.33 9.3 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.747 2.419 . . . . 0.0 110.279 -178.208 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 2.4 mm-40 -134.42 142.01 47.0 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 102.561 -3.126 . . . . 0.0 102.561 169.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 40.8 p -73.91 -127.37 0.01 OUTLIER 'General case' 0 C--N 1.324 -0.516 0 N-CA-C 108.573 -0.899 . . . . 0.0 108.573 178.041 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 25.6 t70 -70.53 -48.44 55.47 Favored 'General case' 0 CA--C 1.53 0.196 0 O-C-N 120.653 -1.279 . . . . 0.0 108.36 176.719 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 170.42 64.78 0.04 OUTLIER Glycine 0 CA--C 1.521 0.406 0 N-CA-C 106.545 -2.622 . . . . 0.0 106.545 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -165.58 -93.81 0.09 OUTLIER Glycine 0 C--N 1.334 0.425 0 N-CA-C 108.885 -1.686 . . . . 0.0 108.885 -177.808 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -60.38 123.27 16.79 Favored 'General case' 0 N--CA 1.453 -0.306 0 CA-C-N 117.795 0.798 . . . . 0.0 109.424 178.041 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.9 tt0 -103.53 136.35 43.43 Favored 'General case' 0 N--CA 1.45 -0.466 0 N-CA-C 103.85 -2.648 . . . . 0.0 103.85 173.676 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 22.3 mt -125.01 122.95 64.51 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.368 0 N-CA-C 112.356 0.502 . . . . 0.0 112.356 -173.782 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 28.2 tp -89.65 136.83 32.8 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 127.193 2.197 . . . . 0.0 106.914 173.367 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.4 mt -120.14 155.63 23.12 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.348 0 C-N-CA 124.652 1.181 . . . . 0.0 109.522 177.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -155.57 96.64 1.79 Allowed 'General case' 0 C--O 1.224 -0.265 0 C-N-CA 126.223 1.809 . . . . 0.0 107.021 174.977 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.408 ' CE2' HG21 ' A' ' 52' ' ' VAL . 1.0 OUTLIER -73.68 76.69 1.53 Allowed 'General case' 0 N--CA 1.454 -0.238 0 O-C-N 121.519 -0.738 . . . . 0.0 110.565 -178.071 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 93.11 170.84 39.89 Favored Glycine 0 CA--C 1.528 0.897 0 C-N-CA 125.634 1.588 . . . . 0.0 111.775 -178.395 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 2.0 tp -107.41 125.86 63.67 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 125.845 1.658 . . . . 0.0 106.935 178.03 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 25.0 t0 58.88 38.6 24.47 Favored 'General case' 0 N--CA 1.465 0.3 0 C-N-CA 125.323 1.449 . . . . 0.0 111.206 -176.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -95.88 -70.85 0.7 Allowed 'General case' 0 CA--C 1.496 -1.126 0 N-CA-C 101.366 -3.568 . . . . 0.0 101.366 171.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.437 ' HA ' ' CG ' ' A' ' 68' ' ' HIS 0.335 1.3 p 45.44 49.22 0.39 Allowed 'Isoleucine or valine' 0 N--CA 1.45 -0.461 0 N-CA-C 104.492 -2.41 . . . . 0.0 104.492 -172.758 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 21.4 m 12.97 48.38 0.0 OUTLIER 'General case' 0 C--N 1.35 0.592 1 C-N-CA 133.111 4.565 . . . . 0.0 112.83 -165.219 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.414 HD23 ' HA ' ' A' ' 91' ' ' LEU . 1.9 mt 33.66 50.52 0.31 Allowed 'General case' 0 N--CA 1.437 -1.102 0 C-N-CA 131.053 3.741 . . . . 0.0 109.001 -179.864 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 90.5 mttt 76.66 50.26 0.05 Allowed 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 128.148 2.579 . . . . 0.0 111.595 -176.966 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 47.43 37.28 12.24 Favored Glycine 0 CA--C 1.529 0.911 0 C-N-CA 126.472 1.987 . . . . 0.0 114.059 -178.35 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 2.9 pp20? -92.5 161.66 14.53 Favored 'General case' 0 N--CA 1.433 -1.314 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 170.366 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 63.56 -4.14 1.11 Allowed Glycine 0 CA--C 1.536 1.358 0 C-N-CA 125.137 1.351 . . . . 0.0 114.822 178.695 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -106.64 105.57 15.67 Favored 'General case' 0 C--N 1.342 0.262 0 CA-C-N 119.077 1.438 . . . . 0.0 111.327 -175.72 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 18.9 m -93.11 104.36 16.57 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 105.502 -2.036 . . . . 0.0 105.502 174.341 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 47.6 t -80.15 148.83 30.77 Favored 'General case' 0 N--CA 1.457 -0.089 0 CA-C-N 119.203 0.91 . . . . 0.0 110.775 179.684 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 39.3 m-85 -115.9 3.85 13.77 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 126.323 1.849 . . . . 0.0 110.785 179.371 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 28.6 m -134.02 145.96 32.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.268 0 N-CA-C 108.234 -1.024 . . . . 0.0 108.234 176.611 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 15.6 m -82.6 -16.87 46.83 Favored 'General case' 0 N--CA 1.454 -0.255 0 C-N-CA 124.973 1.309 . . . . 0.0 112.211 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.472 1.3 pp20? 73.29 140.86 0.06 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 129.203 3.001 . . . . 0.0 109.574 -172.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 97.5 -16.48 60.5 Favored Glycine 0 CA--C 1.54 1.642 0 N-CA-C 109.319 -1.513 . . . . 0.0 109.319 -169.23 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 10.8 m-20 -57.87 115.66 2.99 Favored 'General case' 0 N--CA 1.448 -0.567 0 C-N-CA 126.632 1.973 . . . . 0.0 108.901 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -84.25 123.01 29.67 Favored 'General case' 0 C--N 1.316 -0.851 0 C-N-CA 128.912 2.885 . . . . 0.0 114.254 -173.821 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.345 27.3 m 52.23 70.11 0.12 Allowed 'Isoleucine or valine' 0 C--N 1.343 0.301 0 C-N-CA 126.992 2.117 . . . . 0.0 116.032 175.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 138.44 26.55 Favored Pre-proline 0 N--CA 1.449 -0.505 0 N-CA-C 105.822 -1.918 . . . . 0.0 105.822 170.161 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . 0.404 ' HA ' ' HA ' ' A' ' 57' ' ' ARG . 0.9 OUTLIER -93.63 -135.49 0.01 OUTLIER 'Trans proline' 0 N--CA 1.451 -1.004 0 C-N-CA 124.978 3.785 . . . . 0.0 108.522 -179.229 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -64.21 30.09 0.09 OUTLIER Glycine 0 CA--C 1.535 1.332 0 C-N-CA 126.334 1.921 . . . . 0.0 115.678 179.821 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 23.8 tt0 -64.58 149.8 48.12 Favored 'General case' 0 N--CA 1.445 -0.724 0 N-CA-C 106.246 -1.761 . . . . 0.0 106.246 169.262 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -64.32 122.11 15.91 Favored 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 121.02 -0.272 . . . . 0.0 110.739 176.293 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 26.7 mt -80.44 -49.43 11.44 Favored 'General case' 0 N--CA 1.452 -0.337 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 175.468 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.1 mt -144.04 152.43 41.0 Favored 'General case' 0 CA--C 1.538 0.518 0 C-N-CA 124.007 0.923 . . . . 0.0 110.708 -173.873 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.2 mt-10 -114.49 128.83 56.54 Favored 'General case' 0 CA--C 1.517 -0.298 1 N-CA-C 98.95 -4.463 . . . . 0.0 98.95 165.802 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -139.44 128.47 28.71 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.806 0 CA-C-N 116.016 -0.538 . . . . 0.0 111.469 -165.603 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.5 t0 -76.82 63.57 2.23 Favored 'General case' 0 CA--C 1.531 0.249 0 CA-C-O 121.623 0.725 . . . . 0.0 109.856 -179.881 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 80.0 mt -54.34 -37.68 65.16 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 123.248 0.619 . . . . 0.0 110.546 -179.607 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -53.76 -43.37 69.13 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.761 0.824 . . . . 0.0 112.247 178.342 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -85.92 -34.54 20.9 Favored 'General case' 0 CA--C 1.527 0.071 0 CA-C-N 118.059 0.391 . . . . 0.0 111.411 179.931 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 75.4 t -62.01 -55.43 24.23 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 N-CA-C 109.41 -0.589 . . . . 0.0 109.41 178.722 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.355 18.8 pttp -38.96 -58.33 1.76 Allowed Pre-proline 0 CA--C 1.542 0.651 0 N-CA-C 117.596 2.443 . . . . 0.0 117.596 -176.098 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -58.49 -20.28 48.43 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.774 2.316 . . . . 0.0 113.717 179.663 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.0 m-80 -100.13 9.2 43.18 Favored 'General case' 0 CA--C 1.532 0.264 0 CA-C-O 118.551 -0.738 . . . . 0.0 112.726 -176.795 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 22.8 m -136.23 158.48 73.53 Favored Pre-proline 0 CA--C 1.536 0.419 0 CA-C-N 119.573 1.079 . . . . 0.0 109.36 -178.761 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 98.9 Cg_endo -75.7 -30.0 6.63 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.017 1.811 . . . . 0.0 112.783 -177.47 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 0.4 OUTLIER -163.88 133.96 4.2 Favored 'General case' 0 N--CA 1.454 -0.241 0 O-C-N 121.395 -0.816 . . . . 0.0 111.287 -177.931 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -93.42 9.07 38.02 Favored 'General case' 0 CA--C 1.536 0.441 0 C-N-CA 123.961 0.904 . . . . 0.0 111.564 -179.894 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -50.89 110.04 0.38 Allowed 'General case' 0 C--N 1.342 0.242 0 C-N-CA 124.301 1.041 . . . . 0.0 108.327 177.87 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 92.8 m -95.83 102.49 10.52 Favored Pre-proline 0 N--CA 1.447 -0.607 0 N-CA-C 106.745 -1.576 . . . . 0.0 106.745 -179.496 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 57.3 Cg_endo -92.39 99.66 0.18 Allowed 'Trans proline' 0 N--CA 1.444 -1.422 0 C-N-CA 123.414 2.743 . . . . 0.0 107.679 -177.556 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 4.0 mp -87.08 126.5 40.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.451 0 N-CA-C 103.503 -2.777 . . . . 0.0 103.503 174.584 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 4.1 t -129.05 120.43 51.7 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.418 0 CA-C-O 121.928 0.871 . . . . 0.0 109.303 -176.528 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.485 ' N ' ' CD1' ' A' ' 133' ' ' PHE . 0.5 OUTLIER -83.0 114.14 21.06 Favored 'General case' 0 N--CA 1.437 -1.081 0 N-CA-C 101.732 -3.432 . . . . 0.0 101.732 177.592 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 66.4 p -77.16 -79.69 0.11 Allowed 'General case' 0 N--CA 1.456 -0.168 0 CA-C-O 121.007 0.432 . . . . 0.0 111.216 -170.824 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -72.23 68.12 0.72 Allowed 'General case' 0 CA--C 1.535 0.39 0 CA-C-O 121.988 0.899 . . . . 0.0 111.298 -178.696 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.1 mt -76.76 65.28 2.47 Favored 'General case' 0 CA--C 1.537 0.48 0 O-C-N 121.128 -0.982 . . . . 0.0 108.364 177.119 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 10.18 63.03 0.0 OUTLIER 'General case' 0 C--N 1.347 0.458 0 C-N-CA 130.582 3.553 . . . . 0.0 112.815 -178.022 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 25.97 58.02 0.06 Allowed 'General case' 0 N--CA 1.449 -0.506 0 C-N-CA 128.52 2.728 . . . . 0.0 114.514 -176.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 148.71 6.2 0.23 Allowed Glycine 0 CA--C 1.524 0.617 0 CA-C-O 118.577 -1.124 . . . . 0.0 114.033 176.823 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.733 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 22.4 mt-10 -77.76 92.76 4.21 Favored 'General case' 0 CA--C 1.531 0.228 0 CA-C-N 119.439 1.62 . . . . 0.0 107.894 177.251 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 70.1 p -76.69 135.06 39.08 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 109.127 -0.694 . . . . 0.0 109.127 -177.359 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.2 t -87.32 90.74 3.34 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.356 0 C-N-CA 124.0 0.92 . . . . 0.0 109.26 -176.768 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 42.1 m -85.68 95.6 9.42 Favored 'General case' 0 N--CA 1.453 -0.295 0 N-CA-C 108.88 -0.785 . . . . 0.0 108.88 179.353 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 33.0 mt -64.58 131.84 30.36 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.269 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 178.394 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.0 mmpt? -100.94 -45.9 5.28 Favored 'General case' 0 C--O 1.232 0.164 0 C-N-CA 124.665 1.186 . . . . 0.0 109.055 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.67 74.81 0.01 OUTLIER 'General case' 0 N--CA 1.454 -0.234 0 C-N-CA 126.113 1.765 . . . . 0.0 112.02 -178.785 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 17.1 m -79.71 54.47 1.82 Allowed 'General case' 0 N--CA 1.452 -0.348 0 C-N-CA 124.443 1.097 . . . . 0.0 110.025 -179.302 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 160.7 179.66 35.6 Favored Glycine 0 CA--C 1.526 0.776 0 N-CA-C 109.386 -1.486 . . . . 0.0 109.386 -178.238 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 40.5 t -57.16 144.83 33.46 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 123.172 0.589 . . . . 0.0 111.616 -178.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 4.9 m -145.04 166.96 10.93 Favored 'Isoleucine or valine' 0 C--O 1.233 0.194 0 C-N-CA 124.19 0.996 . . . . 0.0 109.753 179.418 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.2 m-80 -102.36 166.86 10.33 Favored 'General case' 0 C--O 1.232 0.183 0 C-N-CA 124.849 1.26 . . . . 0.0 111.48 -179.89 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -68.29 163.41 23.02 Favored 'General case' 0 CA--C 1.536 0.409 0 N-CA-C 109.647 -0.501 . . . . 0.0 109.647 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 58.9 mt-10 63.96 -9.42 0.15 Allowed 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 126.727 2.011 . . . . 0.0 114.552 -179.626 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 34.2 mm-40 -64.32 148.96 49.15 Favored 'General case' 0 N--CA 1.452 -0.358 0 CA-C-N 119.456 1.025 . . . . 0.0 111.581 -178.139 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.0 tt0 -99.33 159.38 15.05 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 127.527 2.331 . . . . 0.0 111.099 -176.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 24.9 t70 57.55 21.83 7.51 Favored 'General case' 0 CA--C 1.533 0.299 0 C-N-CA 126.137 1.775 . . . . 0.0 114.621 174.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.464 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -70.35 -28.64 36.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.259 0 C-N-CA 123.61 0.764 . . . . 0.0 111.812 178.951 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.8 p -142.44 145.14 23.88 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.772 0 C-N-CA 125.5 1.52 . . . . 0.0 107.866 179.398 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 97.2 mttt -120.57 111.86 18.2 Favored 'General case' 0 N--CA 1.445 -0.686 0 N-CA-C 106.69 -1.596 . . . . 0.0 106.69 174.054 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.733 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.03 110.53 13.84 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.813 0 N-CA-C 103.84 -2.652 . . . . 0.0 103.84 172.871 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 85.1 mt-10 -109.11 125.04 51.73 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 124.956 1.303 . . . . 0.0 109.883 -178.188 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 56.2 tptt . . . . . 0 C--N 1.333 -0.14 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 179.109 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 38.7 mtt . . . . . 0 N--CA 1.449 -0.52 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 9.4 tp -49.62 -31.67 6.3 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 123.324 0.65 . . . . 0.0 112.239 179.815 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -126.59 38.28 4.15 Favored 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.802 0.841 . . . . 0.0 111.126 178.205 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 6.5 tm-20 -156.02 122.15 2.59 Favored Pre-proline 0 CA--C 1.537 0.476 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 178.091 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -72.09 63.44 3.37 Favored 'Trans proline' 0 CA--C 1.541 0.848 0 C-N-CA 123.174 2.583 . . . . 0.0 113.918 -177.02 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 17.9 tp 38.7 58.73 1.66 Allowed 'General case' 0 CA--C 1.536 0.43 0 C-N-CA 127.58 2.352 . . . . 0.0 113.604 176.775 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 10.5 pt20 -163.76 -143.92 0.08 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 125.101 1.36 . . . . 0.0 107.661 179.057 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 29.0 t30 -128.84 148.77 50.92 Favored 'General case' 0 N--CA 1.455 -0.199 0 N-CA-C 106.859 -1.534 . . . . 0.0 106.859 175.332 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 24.4 mp0 -70.62 70.58 0.46 Allowed 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 124.537 1.135 . . . . 0.0 111.478 -178.197 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 11.9 pt -137.48 119.46 18.87 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.292 0 C-N-CA 125.851 1.66 . . . . 0.0 106.863 177.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 77.11 -72.58 2.08 Favored Glycine 0 CA--C 1.524 0.645 0 N-CA-C 107.04 -2.424 . . . . 0.0 107.04 -175.143 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 4.7 tt0 -79.69 70.62 6.23 Favored 'General case' 0 CA--C 1.536 0.44 0 N-CA-C 104.697 -2.335 . . . . 0.0 104.697 171.151 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 11.7 pt-20 -122.08 -166.95 1.47 Allowed 'General case' 0 CA--C 1.54 0.582 0 C-N-CA 126.024 1.729 . . . . 0.0 111.829 -178.017 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.486 8.1 p 64.64 -114.0 0.02 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 116.687 2.106 . . . . 0.0 116.687 176.339 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -75.66 130.76 39.25 Favored 'General case' 0 C--N 1.325 -0.496 0 C-N-CA 127.552 2.341 . . . . 0.0 111.467 -168.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.2 m -90.51 101.5 12.41 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.243 0 CA-C-N 118.882 0.765 . . . . 0.0 110.568 177.072 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 57.3 p -35.44 115.56 0.56 Allowed Pre-proline 0 CA--C 1.556 1.211 0 C-N-CA 125.831 1.652 . . . . 0.0 110.891 177.317 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.8 Cg_endo -75.72 -30.45 6.16 Favored 'Trans proline' 0 CA--C 1.537 0.636 0 C-N-CA 122.832 2.354 . . . . 0.0 117.685 -171.01 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -142.49 148.67 19.79 Favored 'Isoleucine or valine' 0 N--CA 1.469 0.501 0 CA-C-N 120.513 1.506 . . . . 0.0 110.806 -176.764 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.8 m -79.27 138.81 37.91 Favored 'General case' 0 C--O 1.236 0.359 0 N-CA-C 105.594 -2.002 . . . . 0.0 105.594 171.539 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 165.62 -151.69 20.51 Favored Glycine 0 N--CA 1.449 -0.465 0 N-CA-C 110.707 -0.957 . . . . 0.0 110.707 -179.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 1.7 tm-20 -117.05 116.33 27.14 Favored 'General case' 0 N--CA 1.452 -0.339 0 C-N-CA 125.218 1.407 . . . . 0.0 108.435 -179.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 7.5 mt -78.84 138.17 20.58 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.123 0 CA-C-N 118.666 0.666 . . . . 0.0 109.617 179.535 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 73.3 m-70 -137.03 144.75 47.56 Favored Pre-proline 0 C--O 1.236 0.356 0 N-CA-C 108.293 -1.003 . . . . 0.0 108.293 174.458 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 48.5 Cg_exo -54.9 142.73 74.67 Favored 'Trans proline' 0 N--CA 1.454 -0.844 0 C-N-CA 121.967 1.778 . . . . 0.0 110.109 175.508 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.2 tp -47.22 -36.44 3.91 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.522 0 C-N-CA 124.646 1.178 . . . . 0.0 113.187 -177.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.2 p -51.38 -32.68 26.91 Favored 'General case' 0 N--CA 1.454 -0.227 0 C-N-CA 124.911 1.285 . . . . 0.0 112.559 178.185 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -75.94 -9.61 58.75 Favored 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 124.224 1.009 . . . . 0.0 112.505 -175.288 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.551 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 52.9 t -75.16 119.73 78.33 Favored Pre-proline 0 CA--C 1.538 0.484 0 CA-C-O 117.662 -1.161 . . . . 0.0 111.529 -176.374 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 77.8 Cg_exo -59.34 53.94 0.07 OUTLIER 'Trans proline' 0 CA--C 1.55 1.311 1 C-N-CA 126.067 4.511 . . . . 0.0 117.071 177.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 7.6 t70 -167.69 112.03 0.67 Allowed 'General case' 0 N--CA 1.463 0.186 0 O-C-N 120.464 -1.398 . . . . 0.0 108.684 177.083 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -30.67 -51.46 0.15 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 127.609 2.363 . . . . 0.0 114.589 -178.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 61.3 t -52.97 -47.33 53.62 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.155 0 CA-C-O 121.508 0.67 . . . . 0.0 110.05 -178.627 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 12.3 m-85 -78.08 -46.95 19.41 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 109.256 -0.646 . . . . 0.0 109.256 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -50.38 -43.01 54.3 Favored 'General case' 0 CA--C 1.532 0.275 0 N-CA-C 112.82 0.674 . . . . 0.0 112.82 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -97.62 11.94 64.69 Favored Glycine 0 C--N 1.338 0.657 0 CA-C-O 118.909 -0.94 . . . . 0.0 111.499 -178.779 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.6 mtmp? 70.13 -34.8 0.3 Allowed 'General case' 0 CA--C 1.541 0.607 0 C-N-CA 125.809 1.644 . . . . 0.0 114.032 -179.238 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.6 tmt? 32.18 -69.27 0.0 OUTLIER 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 131.286 3.834 . . . . 0.0 116.576 178.312 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 7.8 tpt -78.58 -19.99 51.55 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 124.185 0.994 . . . . 0.0 111.981 -175.918 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.15 -133.13 1.82 Allowed Glycine 0 C--N 1.338 0.668 0 N-CA-C 110.576 -1.01 . . . . 0.0 110.576 -179.04 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.429 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 44.9 t0 -136.45 158.56 44.14 Favored 'General case' 0 CA--C 1.514 -0.413 0 N-CA-C 105.054 -2.202 . . . . 0.0 105.054 172.944 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 176.19 -154.45 16.93 Favored Glycine 0 N--CA 1.445 -0.722 0 C-N-CA 120.383 -0.913 . . . . 0.0 111.706 -176.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.556 ' CE2' HD11 ' A' ' 45' ' ' ILE . 38.7 p90 -158.25 164.48 36.43 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 122.533 0.333 . . . . 0.0 110.2 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.551 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -102.45 146.3 28.3 Favored 'General case' 0 CA--C 1.508 -0.665 0 C-N-CA 123.742 0.817 . . . . 0.0 109.369 178.267 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.556 HD11 ' CE2' ' A' ' 43' ' ' PHE . 4.4 mp -124.93 128.19 72.99 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.843 0 N-CA-C 102.635 -3.098 . . . . 0.0 102.635 169.131 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.3 tt -91.33 106.78 17.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 101.384 -3.561 . . . . 0.0 101.384 172.865 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -61.32 170.34 5.35 Favored 'Trans proline' 0 C--N 1.347 0.471 0 C-N-CA 124.111 3.207 . . . . 0.0 116.166 -171.074 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 50.5 p -152.29 -65.01 0.17 Allowed 'General case' 0 CA--C 1.53 0.207 0 C-N-CA 125.089 1.356 . . . . 0.0 107.876 176.361 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 9.7 mm-40 -61.85 127.61 32.25 Favored 'General case' 0 N--CA 1.455 -0.18 0 C-N-CA 123.47 0.708 . . . . 0.0 110.188 176.812 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.83 43.95 2.9 Favored Glycine 0 CA--C 1.529 0.925 0 N-CA-C 109.55 -1.42 . . . . 0.0 109.55 172.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -145.36 124.35 5.68 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 127.381 2.273 . . . . 0.0 105.138 -177.369 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 89.9 t -123.53 126.49 73.12 Favored 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 107.166 -1.42 . . . . 0.0 107.166 -179.271 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 4.0 m -108.03 155.04 9.0 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 C-N-CA 123.716 0.807 . . . . 0.0 110.268 178.7 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -61.79 139.31 95.5 Favored Pre-proline 0 N--CA 1.449 -0.519 0 C-N-CA 123.585 0.754 . . . . 0.0 110.192 179.983 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 63.2 Cg_endo -78.28 -21.91 10.08 Favored 'Trans proline' 0 N--CA 1.453 -0.885 0 C-N-CA 123.51 2.807 . . . . 0.0 114.221 -177.299 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.7 m -138.92 166.61 22.05 Favored 'Isoleucine or valine' 0 C--N 1.34 0.163 0 C-N-CA 124.325 1.05 . . . . 0.0 111.007 -177.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -78.81 115.96 18.83 Favored 'General case' 0 C--O 1.234 0.253 1 N-CA-C 99.376 -4.305 . . . . 0.0 99.376 168.338 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.32 176.6 47.89 Favored Glycine 0 N--CA 1.441 -1.015 0 C-N-CA 115.606 -3.188 . . . . 0.0 117.015 -168.839 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -84.42 123.72 30.54 Favored 'General case' 0 N--CA 1.443 -0.798 0 C-N-CA 125.769 1.628 . . . . 0.0 108.505 178.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 16.7 mm -75.45 95.77 1.09 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.411 0 N-CA-C 103.11 -2.922 . . . . 0.0 103.11 172.862 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 49.9 tp -72.41 -51.27 21.13 Favored 'General case' 0 N--CA 1.451 -0.4 0 N-CA-C 109.186 -0.672 . . . . 0.0 109.186 -171.05 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 -171.19 137.06 1.1 Allowed 'General case' 0 C--O 1.223 -0.326 0 CA-C-N 118.472 0.578 . . . . 0.0 111.423 177.323 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 0.1 OUTLIER -128.15 123.9 61.32 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.608 0 N-CA-C 103.761 -2.681 . . . . 0.0 103.761 172.433 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.33 156.61 0.48 Allowed Pre-proline 0 CA--C 1.54 0.578 0 N-CA-C 113.381 0.882 . . . . 0.0 113.381 -178.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 77.3 Cg_exo -50.05 -29.71 22.63 Favored 'Trans proline' 0 C--N 1.348 0.517 0 C-N-CA 123.924 3.083 . . . . 0.0 114.562 178.265 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 2.6 p -77.56 -9.04 58.7 Favored 'General case' 0 CA--C 1.535 0.375 0 C-N-CA 124.511 1.124 . . . . 0.0 111.64 -179.717 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 63.22 8.43 3.36 Favored 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 127.835 2.454 . . . . 0.0 113.202 -178.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.7 p-80 -80.88 -27.76 36.22 Favored 'General case' 0 N--CA 1.452 -0.346 0 N-CA-C 112.885 0.698 . . . . 0.0 112.885 -177.475 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -160.68 -176.35 5.5 Favored 'General case' 0 N--CA 1.455 -0.209 0 CA-C-N 119.204 0.911 . . . . 0.0 111.677 -174.111 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.402 HG22 ' H ' ' A' ' 71' ' ' GLY 0.898 18.3 mm 129.0 -139.02 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.184 1 C-N-CA 131.846 4.058 . . . . 0.0 111.355 176.485 . . . . . . . . 4 3 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.402 ' H ' HG22 ' A' ' 70' ' ' ILE . . . -147.36 168.23 28.44 Favored Glycine 0 CA--C 1.526 0.745 0 N-CA-C 116.6 1.4 . . . . 0.0 116.6 -173.997 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -132.49 169.15 16.98 Favored 'General case' 0 N--CA 1.451 -0.419 0 C-N-CA 126.349 1.86 . . . . 0.0 108.619 -178.609 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -139.11 144.71 38.82 Favored 'General case' 0 N--CA 1.437 -1.083 0 N-CA-C 105.298 -2.112 . . . . 0.0 105.298 175.847 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 89.2 p -81.5 -112.67 0.02 OUTLIER 'General case' 0 C--N 1.32 -0.685 0 N-CA-C 107.84 -1.17 . . . . 0.0 107.84 176.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 16.6 t70 -148.72 -55.94 0.2 Allowed 'General case' 0 N--CA 1.446 -0.673 0 C-N-CA 128.248 2.619 . . . . 0.0 106.689 177.024 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -75.52 62.31 2.73 Favored Glycine 0 CA--C 1.529 0.919 0 C-N-CA 124.113 0.863 . . . . 0.0 111.5 177.782 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 72.34 -54.05 1.51 Allowed Glycine 0 CA--C 1.532 1.126 0 N-CA-C 115.585 0.994 . . . . 0.0 115.585 175.739 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 4.3 tpp180 -39.53 121.52 1.22 Allowed 'General case' 0 C--O 1.238 0.464 0 C-N-CA 124.696 1.199 . . . . 0.0 113.656 -174.595 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 38.8 tt0 -111.55 148.3 33.53 Favored 'General case' 0 N--CA 1.451 -0.377 0 C-N-CA 127.283 2.233 . . . . 0.0 107.107 176.851 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.5 mp -132.38 144.79 35.9 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.226 0 C-N-CA 124.269 1.028 . . . . 0.0 109.66 -176.585 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.8 tm? -125.62 132.58 52.46 Favored 'General case' 0 N--CA 1.455 -0.208 0 C-N-CA 128.159 2.583 . . . . 0.0 105.439 176.693 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 39.0 mt -131.98 141.9 44.3 Favored 'Isoleucine or valine' 0 C--O 1.235 0.312 0 C-N-CA 124.798 1.239 . . . . 0.0 109.715 -178.712 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 1.6 t60 -132.55 104.96 6.94 Favored 'General case' 0 C--O 1.226 -0.178 0 C-N-CA 124.335 1.054 . . . . 0.0 108.475 174.648 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.7 t80 -68.35 109.65 3.74 Favored 'General case' 0 N--CA 1.45 -0.461 0 O-C-N 121.109 -0.995 . . . . 0.0 109.092 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 58.67 -165.82 7.79 Favored Glycine 0 CA--C 1.527 0.84 0 N-CA-C 111.064 -0.814 . . . . 0.0 111.064 -176.785 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 31.4 mt -122.29 136.5 58.95 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.395 0 N-CA-C 106.401 -1.703 . . . . 0.0 106.401 177.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.7 t0 55.48 42.61 29.69 Favored 'General case' 0 CA--C 1.533 0.315 0 C-N-CA 124.555 1.142 . . . . 0.0 112.645 -179.824 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.435 ' O ' ' N ' ' A' ' 90' ' ' SER . 1.8 p -80.19 -85.22 0.09 Allowed 'General case' 0 CA--C 1.505 -0.788 0 N-CA-C 103.093 -2.929 . . . . 0.0 103.093 172.215 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.418 HG13 ' H ' ' A' ' 90' ' ' SER . 12.1 p 26.43 -64.82 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.541 0.601 0 C-N-CA 128.883 2.873 . . . . 0.0 117.293 173.441 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.435 ' N ' ' O ' ' A' ' 88' ' ' THR . 11.8 m -60.44 -36.83 79.13 Favored 'General case' 0 C--N 1.332 -0.192 0 C-N-CA 126.624 1.97 . . . . 0.0 109.675 178.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -50.9 -36.71 39.65 Favored 'General case' 0 N--CA 1.448 -0.55 0 C-N-CA 128.216 2.606 . . . . 0.0 109.617 176.343 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 16.3 mtpp 70.49 151.75 0.1 Allowed 'General case' 0 N--CA 1.447 -0.588 0 C-N-CA 126.303 1.841 . . . . 0.0 109.673 -178.583 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -65.91 25.99 0.15 Allowed Glycine 0 CA--C 1.539 1.544 0 N-CA-C 115.153 0.821 . . . . 0.0 115.153 -178.315 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 20.5 mm-40 -59.21 -35.16 73.13 Favored 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.689 1.744 . . . . 0.0 112.085 179.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -98.02 15.26 61.81 Favored Glycine 0 CA--C 1.529 0.918 0 CA-C-N 112.862 -1.972 . . . . 0.0 111.764 178.23 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 4.0 m-85 -123.31 96.57 5.04 Favored 'General case' 0 C--N 1.344 0.333 0 CA-C-N 118.884 1.342 . . . . 0.0 109.545 -176.716 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 32.7 m -81.52 111.77 18.14 Favored 'General case' 0 N--CA 1.452 -0.34 0 N-CA-C 104.827 -2.286 . . . . 0.0 104.827 173.251 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 24.8 p -86.11 138.53 31.85 Favored 'General case' 0 N--CA 1.452 -0.345 0 O-C-N 121.563 -0.711 . . . . 0.0 111.279 -177.081 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 35.8 m-85 -107.51 7.16 28.68 Favored 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 125.57 1.548 . . . . 0.0 113.389 -177.21 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 20.5 m -140.42 144.37 27.66 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.179 0 N-CA-C 107.5 -1.296 . . . . 0.0 107.5 175.808 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 12.7 m -79.51 -15.77 57.16 Favored 'General case' 0 CA--C 1.529 0.167 0 C-N-CA 124.175 0.99 . . . . 0.0 112.772 -179.68 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.442 16.1 pm0 69.03 147.46 0.06 Allowed 'General case' 0 N--CA 1.446 -0.671 0 C-N-CA 130.065 3.346 . . . . 0.0 111.209 -173.214 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 95.22 -21.78 42.25 Favored Glycine 0 CA--C 1.535 1.297 0 C-N-CA 124.709 1.147 . . . . 0.0 110.466 -172.84 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 12.4 t0 -60.63 124.57 20.78 Favored 'General case' 0 N--CA 1.44 -0.933 0 C-N-CA 125.919 1.688 . . . . 0.0 108.914 179.892 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -86.33 123.64 31.8 Favored 'General case' 0 C--N 1.318 -0.781 0 C-N-CA 129.162 2.985 . . . . 0.0 113.308 -174.571 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.373 28.5 m 52.23 69.89 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.521 -0.142 0 N-CA-C 117.018 2.229 . . . . 0.0 117.018 176.583 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -118.35 139.85 27.36 Favored Pre-proline 0 N--CA 1.45 -0.455 0 N-CA-C 104.669 -2.345 . . . . 0.0 104.669 168.767 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 20.2 Cg_endo -88.19 -151.25 0.04 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.211 0 C-N-CA 123.686 2.924 . . . . 0.0 108.544 178.64 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -69.68 54.36 0.71 Allowed Glycine 0 CA--C 1.529 0.954 0 C-N-CA 124.908 1.242 . . . . 0.0 113.924 -179.245 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 3.1 tt0 -54.22 -55.07 31.57 Favored 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 124.97 1.308 . . . . 0.0 110.037 177.314 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt 144.87 125.67 0.0 OUTLIER 'General case' 0 C--N 1.322 -0.621 1 C-N-CA 132.615 4.366 . . . . 0.0 106.098 -175.591 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 69.9 mt -91.83 -45.51 8.35 Favored 'General case' 0 N--CA 1.455 -0.185 0 C-N-CA 123.652 0.781 . . . . 0.0 109.385 178.182 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 15.2 mt -147.52 151.87 37.07 Favored 'General case' 0 CA--C 1.539 0.534 0 C-N-CA 122.798 0.439 . . . . 0.0 111.101 -174.881 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -116.31 127.21 54.49 Favored 'General case' 0 CA--C 1.517 -0.291 1 N-CA-C 98.557 -4.608 . . . . 0.0 98.557 165.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -135.23 126.34 45.53 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.717 0 CA-C-N 115.961 -0.563 . . . . 0.0 110.721 -166.357 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 12.4 m-20 -74.75 61.03 0.96 Allowed 'General case' 0 C--O 1.233 0.224 0 C-N-CA 125.259 1.423 . . . . 0.0 111.239 -176.765 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 95.5 mt -45.94 -41.82 12.08 Favored 'General case' 0 C--O 1.226 -0.181 0 C-N-CA 124.326 1.05 . . . . 0.0 111.94 -178.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.4 t70 -49.15 -41.4 36.17 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.622 0.769 . . . . 0.0 112.501 178.356 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -92.57 -33.77 14.3 Favored 'General case' 0 CA--C 1.527 0.066 0 C-N-CA 123.467 0.707 . . . . 0.0 111.353 -179.42 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 93.2 t -63.26 -51.95 64.77 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.564 0 O-C-N 121.617 -0.677 . . . . 0.0 109.468 178.957 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.368 46.1 pttt -41.87 -58.07 3.58 Favored Pre-proline 0 CA--C 1.541 0.599 0 N-CA-C 117.271 2.323 . . . . 0.0 117.271 -177.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -57.18 -19.8 35.56 Favored 'Trans proline' 0 N--CA 1.456 -0.729 0 C-N-CA 122.435 2.09 . . . . 0.0 113.327 178.745 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 60.9 m-80 -95.49 7.98 44.63 Favored 'General case' 0 CA--C 1.533 0.31 0 CA-C-O 118.097 -0.954 . . . . 0.0 112.488 -178.427 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 23.9 m -132.91 150.51 75.87 Favored Pre-proline 0 N--CA 1.466 0.333 0 CA-C-N 120.086 1.312 . . . . 0.0 111.506 179.643 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 86.4 Cg_endo -73.78 -27.41 12.52 Favored 'Trans proline' 0 N--CA 1.453 -0.904 0 C-N-CA 122.867 2.378 . . . . 0.0 111.635 179.243 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -157.42 132.01 8.56 Favored 'General case' 0 CA--C 1.532 0.253 0 O-C-N 121.598 -0.689 . . . . 0.0 109.926 -178.657 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -90.35 -2.06 57.96 Favored 'General case' 0 CA--C 1.537 0.474 0 C-N-CA 124.712 1.205 . . . . 0.0 111.769 -179.019 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 14.6 mmt -49.65 111.26 0.48 Allowed 'General case' 0 C--N 1.34 0.194 0 C-N-CA 124.399 1.08 . . . . 0.0 109.353 178.375 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 49.9 m -102.73 110.14 62.58 Favored Pre-proline 0 N--CA 1.449 -0.501 0 N-CA-C 107.55 -1.278 . . . . 0.0 107.55 -178.432 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -91.33 137.62 2.1 Favored 'Trans proline' 0 N--CA 1.447 -1.226 0 C-N-CA 122.843 2.362 . . . . 0.0 110.538 -179.201 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 15.3 mm -114.46 121.17 66.02 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.363 0 N-CA-C 102.893 -3.003 . . . . 0.0 102.893 173.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.1 t -126.43 149.11 31.16 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.403 0 N-CA-C 107.609 -1.256 . . . . 0.0 107.609 -177.393 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 6.6 m-85 -123.1 124.99 44.34 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.019 -2.585 . . . . 0.0 104.019 179.191 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 36.1 p -83.58 -67.76 0.76 Allowed 'General case' 0 N--CA 1.448 -0.557 0 CA-C-O 121.771 0.796 . . . . 0.0 110.638 -173.213 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.8 p30 -72.0 51.7 0.23 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 125.99 1.716 . . . . 0.0 113.587 -177.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.429 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 78.2 mt -80.49 54.31 2.03 Favored 'General case' 0 CA--C 1.537 0.47 0 C-N-CA 124.393 1.077 . . . . 0.0 108.961 175.615 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 16.33 55.67 0.01 OUTLIER 'General case' 0 C--N 1.346 0.438 0 C-N-CA 129.59 3.156 . . . . 0.0 113.403 -177.938 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 36.9 mt-10 27.56 56.47 0.08 Allowed 'General case' 0 N--CA 1.454 -0.269 0 C-N-CA 127.715 2.406 . . . . 0.0 113.829 -175.465 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 165.68 -10.83 0.07 OUTLIER Glycine 0 CA--C 1.526 0.758 0 CA-C-O 119.321 -0.71 . . . . 0.0 113.638 179.279 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.585 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 16.2 mt-10 -78.73 82.07 4.98 Favored 'General case' 0 CA--C 1.531 0.23 0 CA-C-N 118.752 1.276 . . . . 0.0 107.932 179.372 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.7 p -74.3 138.49 43.59 Favored 'General case' 0 N--CA 1.452 -0.374 0 O-C-N 121.404 -0.81 . . . . 0.0 109.93 -175.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.8 OUTLIER -83.65 122.29 37.47 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.4 0 C-N-CA 123.66 0.784 . . . . 0.0 109.234 -176.769 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.6 m -112.75 97.82 6.81 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 124.867 1.267 . . . . 0.0 109.178 -178.455 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.2 pt -71.08 108.37 2.71 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 108.234 -1.025 . . . . 0.0 108.234 176.503 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 70.7 mmtt -77.08 -55.47 5.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 -179.082 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -82.88 66.08 8.32 Favored 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 179.192 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 49.2 m -77.6 69.72 3.88 Favored 'General case' 0 CA--C 1.532 0.286 0 N-CA-C 108.174 -1.047 . . . . 0.0 108.174 178.293 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.81 -150.16 7.62 Favored Glycine 0 CA--C 1.525 0.686 0 N-CA-C 107.105 -2.398 . . . . 0.0 107.105 -178.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 10.4 t -75.64 146.08 40.56 Favored 'General case' 0 N--CA 1.457 -0.111 0 CA-C-N 118.297 1.048 . . . . 0.0 110.556 178.316 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 33.9 m -143.71 167.3 12.96 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 124.555 1.142 . . . . 0.0 109.777 -178.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 35.2 m-80 -113.69 163.75 14.59 Favored 'General case' 0 C--O 1.232 0.158 0 C-N-CA 125.236 1.414 . . . . 0.0 107.647 174.557 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.94 165.35 25.4 Favored 'General case' 0 CA--C 1.537 0.467 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 170.637 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.0 mt-10 56.88 48.42 15.99 Favored 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 124.565 1.146 . . . . 0.0 111.862 177.931 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 1.4 mm-40 -121.96 159.18 27.47 Favored 'General case' 0 C--N 1.327 -0.371 0 N-CA-C 103.96 -2.607 . . . . 0.0 103.96 173.83 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 mt-10 -126.46 153.66 44.77 Favored 'General case' 0 N--CA 1.455 -0.202 0 CA-C-N 119.228 0.922 . . . . 0.0 111.188 -176.687 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 6.7 t70 62.95 13.65 6.83 Favored 'General case' 0 N--CA 1.465 0.297 0 C-N-CA 126.702 2.001 . . . . 0.0 113.191 -176.554 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -61.54 -37.85 78.79 Favored 'Isoleucine or valine' 0 C--O 1.233 0.207 0 N-CA-C 107.736 -1.209 . . . . 0.0 107.736 177.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.7 p -117.88 129.29 74.49 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.846 0 N-CA-C 103.486 -2.783 . . . . 0.0 103.486 168.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.0 tttm -122.81 123.73 41.7 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 108.113 -1.069 . . . . 0.0 108.113 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.585 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.26 130.61 35.85 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.75 0 N-CA-C 105.403 -2.073 . . . . 0.0 105.403 174.584 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 59.2 mt-10 -130.97 139.25 50.0 Favored 'General case' 0 N--CA 1.454 -0.264 0 C-N-CA 125.221 1.408 . . . . 0.0 107.269 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 22.3 tptm . . . . . 0 C--N 1.331 -0.215 0 N-CA-C 109.67 -0.493 . . . . 0.0 109.67 -177.795 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 63.2 mtt . . . . . 0 N--CA 1.453 -0.303 0 CA-C-O 120.652 0.263 . . . . 0.0 110.675 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 23.2 mt -78.17 65.31 0.28 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 N-CA-C 108.125 -1.065 . . . . 0.0 108.125 179.225 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -87.68 -35.19 18.12 Favored 'General case' 0 C--O 1.223 -0.332 0 C-N-CA 124.974 1.31 . . . . 0.0 111.92 -177.431 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 5.6 mm-40 51.58 72.29 1.25 Allowed Pre-proline 0 CA--C 1.543 0.69 0 C-N-CA 124.507 1.123 . . . . 0.0 112.331 179.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_exo -55.19 127.37 26.02 Favored 'Trans proline' 0 N--CA 1.455 -0.771 0 C-N-CA 123.288 2.659 . . . . 0.0 111.609 179.567 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 21.9 tp -69.49 70.96 0.29 Allowed 'General case' 0 CA--C 1.535 0.376 0 C-N-CA 125.434 1.494 . . . . 0.0 111.088 -178.045 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 3.0 mp0 57.51 15.94 3.04 Favored 'General case' 0 CA--C 1.536 0.408 0 C-N-CA 126.762 2.025 . . . . 0.0 114.058 178.383 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 15.2 t-20 -165.72 156.32 13.29 Favored 'General case' 0 N--CA 1.454 -0.263 0 O-C-N 121.374 -0.829 . . . . 0.0 108.935 177.669 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 6.2 tp10 -160.84 -43.23 0.04 OUTLIER 'General case' 0 CA--C 1.535 0.387 0 C-N-CA 128.107 2.563 . . . . 0.0 107.142 178.57 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 79.0 mt -50.74 102.53 0.03 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.466 0 C-N-CA 126.918 2.087 . . . . 0.0 106.724 175.406 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 171.09 -52.43 0.19 Allowed Glycine 0 CA--C 1.524 0.631 0 N-CA-C 106.104 -2.798 . . . . 0.0 106.104 -176.342 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 19.3 tt0 41.17 46.95 2.75 Favored 'General case' 0 CA--C 1.55 0.946 0 C-N-CA 126.105 1.762 . . . . 0.0 113.408 176.153 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -68.97 153.42 43.82 Favored 'General case' 0 CA--C 1.537 0.467 0 C-N-CA 125.819 1.647 . . . . 0.0 110.673 176.924 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 15.4 m -63.99 66.91 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.436 -1.133 0 N-CA-C 117.776 2.51 . . . . 0.0 117.776 -175.058 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -135.43 105.82 6.4 Favored 'General case' 0 C--N 1.33 -0.262 0 N-CA-C 105.6 -2.0 . . . . 0.0 105.6 171.482 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.7 m -97.32 91.3 2.54 Favored 'Isoleucine or valine' 0 C--O 1.224 -0.269 0 CA-C-N 118.991 0.814 . . . . 0.0 112.352 -176.901 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.6 t -21.95 111.34 0.14 Allowed Pre-proline 0 CA--C 1.55 0.946 0 C-N-CA 126.373 1.869 . . . . 0.0 112.282 176.602 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_endo -74.11 -28.58 10.74 Favored 'Trans proline' 0 N--CA 1.458 -0.585 0 C-N-CA 123.181 2.587 . . . . 0.0 118.338 -169.716 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -140.64 153.31 21.24 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.347 0 CA-C-N 120.339 1.427 . . . . 0.0 110.496 -176.722 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 92.1 m -88.32 125.38 34.65 Favored 'General case' 0 C--O 1.239 0.52 0 N-CA-C 105.751 -1.944 . . . . 0.0 105.751 172.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 179.72 -170.43 41.74 Favored Glycine 0 CA--C 1.521 0.422 0 N-CA-C 111.47 -0.652 . . . . 0.0 111.47 -176.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.3 tp10 -98.63 133.93 42.27 Favored 'General case' 0 N--CA 1.456 -0.164 0 N-CA-C 108.722 -0.844 . . . . 0.0 108.722 179.289 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 11.2 tt -81.94 146.22 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.385 0 C-N-CA 123.111 0.564 . . . . 0.0 111.148 -178.37 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.6 m-70 -144.8 137.35 13.49 Favored Pre-proline 0 C--O 1.237 0.397 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 175.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 34.9 Cg_exo -59.58 146.18 95.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 C-N-CA 122.094 1.863 . . . . 0.0 111.452 178.509 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.9 tp -50.04 -36.93 12.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.432 0 C-N-CA 125.176 1.39 . . . . 0.0 112.062 -179.677 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.2 p -70.27 -12.08 61.34 Favored 'General case' 0 N--CA 1.452 -0.325 0 C-N-CA 126.034 1.734 . . . . 0.0 114.195 -179.436 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.1 m-20 -112.79 29.12 8.22 Favored 'General case' 0 CA--C 1.53 0.211 0 CA-C-N 118.897 0.772 . . . . 0.0 111.636 -173.537 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 43.3 t -94.08 135.11 24.95 Favored Pre-proline 0 CA--C 1.54 0.563 0 C-N-CA 124.327 1.051 . . . . 0.0 109.564 178.605 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 32.5 Cg_exo -65.5 50.82 0.24 Allowed 'Trans proline' 0 CA--C 1.55 1.276 0 C-N-CA 124.216 3.277 . . . . 0.0 115.054 177.965 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -166.77 133.89 2.49 Favored 'General case' 0 CA--C 1.534 0.336 0 O-C-N 120.489 -1.382 . . . . 0.0 109.815 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.0 mt-30 -59.8 -47.51 85.43 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.873 1.269 . . . . 0.0 113.109 -177.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 55.0 t -55.07 -54.97 18.8 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.234 0 CA-C-N 118.596 0.634 . . . . 0.0 109.389 -178.61 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.2 m-85 -61.38 -58.68 7.25 Favored 'General case' 0 N--CA 1.452 -0.36 0 CA-C-N 116.385 -0.37 . . . . 0.0 110.973 -179.316 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 59.0 m -69.47 -16.0 63.38 Favored 'General case' 0 N--CA 1.461 0.082 0 N-CA-C 115.866 1.802 . . . . 0.0 115.866 -177.292 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -88.91 -0.1 81.62 Favored Glycine 0 N--CA 1.442 -0.934 0 N-CA-C 108.44 -1.864 . . . . 0.0 108.44 173.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 57.5 mttp 74.16 -39.88 0.44 Allowed 'General case' 0 C--N 1.346 0.438 0 C-N-CA 126.498 1.919 . . . . 0.0 111.56 -177.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 14.9 tpt 28.9 -76.74 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 0 C-N-CA 130.436 3.494 . . . . 0.0 116.461 178.263 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 11.0 ttt -79.24 -17.57 54.52 Favored 'General case' 0 CA--C 1.534 0.329 0 C-N-CA 123.741 0.816 . . . . 0.0 113.059 -175.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 176.44 -135.28 2.83 Favored Glycine 0 C--N 1.338 0.643 0 CA-C-N 119.128 0.877 . . . . 0.0 112.382 -176.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 36.7 t0 -137.23 157.84 45.75 Favored 'General case' 0 CA--C 1.514 -0.439 0 N-CA-C 107.288 -1.375 . . . . 0.0 107.288 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.53 -157.77 19.15 Favored Glycine 0 N--CA 1.448 -0.516 0 C-N-CA 120.959 -0.639 . . . . 0.0 112.764 -175.62 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 31.6 p90 -158.74 158.81 34.36 Favored 'General case' 0 N--CA 1.453 -0.28 0 C-N-CA 124.773 1.229 . . . . 0.0 108.203 178.851 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -107.23 132.96 52.49 Favored 'General case' 0 CA--C 1.512 -0.514 0 CA-C-N 118.836 0.744 . . . . 0.0 110.418 177.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.457 HD12 HG21 ' A' ' 150' ' ' VAL . 22.6 mm -117.35 107.25 21.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 105.181 -2.155 . . . . 0.0 105.181 173.896 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 11.9 tp -74.79 119.06 74.92 Favored Pre-proline 0 CA--C 1.538 0.484 0 N-CA-C 102.329 -3.212 . . . . 0.0 102.329 172.067 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 91.4 Cg_endo -80.04 153.38 22.04 Favored 'Trans proline' 0 N--CA 1.455 -0.742 0 C-N-CA 123.095 2.53 . . . . 0.0 113.721 -168.98 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 79.2 p -126.18 -45.78 1.68 Allowed 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.651 0.78 . . . . 0.0 112.242 178.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.6 tt0 -64.43 -42.27 96.11 Favored 'General case' 0 N--CA 1.462 0.138 0 N-CA-C 114.445 1.276 . . . . 0.0 114.445 -175.833 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.58 25.34 70.32 Favored Glycine 0 CA--C 1.533 1.188 0 N-CA-C 109.858 -1.297 . . . . 0.0 109.858 -173.012 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 54.0 mt -136.5 123.59 32.03 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.335 0 N-CA-C 102.496 -3.149 . . . . 0.0 102.496 177.042 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 79.1 t -124.49 124.66 68.81 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.324 0 C-N-CA 124.397 1.079 . . . . 0.0 109.945 -171.752 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 28.0 m -107.12 155.8 7.7 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.126 0 C-N-CA 123.715 0.806 . . . . 0.0 109.493 176.743 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -61.82 139.63 95.52 Favored Pre-proline 0 N--CA 1.448 -0.551 0 C-N-CA 123.624 0.77 . . . . 0.0 110.544 179.7 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 96.9 Cg_endo -75.31 -13.01 20.9 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 124.307 3.338 . . . . 0.0 115.03 -177.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.3 m -148.11 161.65 6.69 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.056 0 CA-C-N 119.443 1.02 . . . . 0.0 110.213 -176.651 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.94 116.99 19.6 Favored 'General case' 0 C--O 1.237 0.402 1 N-CA-C 100.103 -4.036 . . . . 0.0 100.103 167.653 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 173.27 -177.34 45.73 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 115.544 -3.217 . . . . 0.0 116.428 -168.451 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -85.15 122.04 28.78 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 124.161 0.984 . . . . 0.0 112.512 -177.541 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.4 mm -66.2 125.59 23.73 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.259 0 N-CA-C 103.058 -2.942 . . . . 0.0 103.058 168.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 40.7 tp -78.39 -40.75 35.23 Favored 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 119.643 1.111 . . . . 0.0 109.213 -174.68 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 6.0 t-20 -175.43 -163.75 0.13 Allowed 'General case' 0 CA--C 1.531 0.232 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.683 ' HA ' HG21 ' A' ' 70' ' ' ILE . 7.3 p -160.51 125.42 0.46 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.357 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 172.446 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 19.3 m-85 -68.0 145.1 97.61 Favored Pre-proline 0 CA--C 1.534 0.339 0 CA-C-N 119.291 0.951 . . . . 0.0 110.361 -179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_exo -50.6 -29.27 24.59 Favored 'Trans proline' 0 C--N 1.347 0.497 0 C-N-CA 123.484 2.789 . . . . 0.0 113.532 176.096 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.1 p -77.3 -7.91 56.76 Favored 'General case' 0 N--CA 1.451 -0.376 0 C-N-CA 123.756 0.822 . . . . 0.0 111.956 -178.92 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 25.8 ttmt 64.06 -11.18 0.12 Allowed 'General case' 0 CA--C 1.532 0.288 0 C-N-CA 125.828 1.651 . . . . 0.0 114.914 177.618 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 9.3 p-80 -74.72 -29.4 61.17 Favored 'General case' 0 N--CA 1.449 -0.514 0 O-C-N 121.665 -0.647 . . . . 0.0 112.688 -175.853 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -153.46 176.8 11.62 Favored 'General case' 0 CA--C 1.511 -0.531 0 CA-C-N 118.893 0.77 . . . . 0.0 110.368 -175.838 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.683 HG21 ' HA ' ' A' ' 63' ' ' VAL . 0.1 OUTLIER 157.31 -148.11 0.0 OUTLIER 'Isoleucine or valine' 0 C--O 1.236 0.355 0 C-N-CA 130.492 3.517 . . . . 0.0 106.056 176.318 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.494 ' H ' ' CG1' ' A' ' 70' ' ' ILE . . . -152.51 174.21 31.44 Favored Glycine 0 N--CA 1.446 -0.67 0 C-N-CA 123.477 0.561 . . . . 0.0 111.804 -179.864 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.0 mp -141.19 176.78 8.56 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 126.486 1.914 . . . . 0.0 108.045 -178.128 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 30.5 mt-30 -143.08 156.02 44.73 Favored 'General case' 0 N--CA 1.441 -0.887 0 N-CA-C 103.634 -2.728 . . . . 0.0 103.634 173.357 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 69.6 p -78.26 -117.46 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.415 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 176.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 24.3 t70 -71.1 -51.04 27.36 Favored 'General case' 0 CA--C 1.529 0.171 0 O-C-N 121.366 -0.834 . . . . 0.0 108.79 177.107 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -171.73 46.27 0.18 Allowed Glycine 0 CA--C 1.528 0.874 0 N-CA-C 109.006 -1.637 . . . . 0.0 109.006 179.228 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 179.93 179.12 48.79 Favored Glycine 0 CA--C 1.525 0.66 0 N-CA-C 107.031 -2.428 . . . . 0.0 107.031 -178.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 69.0 mtm180 55.94 65.91 1.33 Allowed 'General case' 0 C--N 1.337 0.031 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -175.65 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.9 tt0 -73.45 119.77 18.14 Favored 'General case' 0 N--CA 1.445 -0.712 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 178.571 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.7 mp -98.38 149.97 5.07 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.53 0 C-N-CA 125.432 1.493 . . . . 0.0 108.574 -179.12 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.6 tp -128.88 136.05 49.91 Favored 'General case' 0 N--CA 1.45 -0.435 0 C-N-CA 127.745 2.418 . . . . 0.0 104.849 176.087 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 46.0 mt -129.93 136.2 59.44 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.179 0 N-CA-C 108.264 -1.013 . . . . 0.0 108.264 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 16.9 t-80 -129.74 84.71 2.23 Favored 'General case' 0 N--CA 1.466 0.335 0 C-N-CA 123.481 0.712 . . . . 0.0 110.619 176.993 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.1 t80 -56.67 98.94 0.03 OUTLIER 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 123.528 0.731 . . . . 0.0 111.303 -179.241 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 61.75 -177.16 5.17 Favored Glycine 0 CA--C 1.531 1.059 0 C-N-CA 124.092 0.853 . . . . 0.0 112.463 -177.608 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.1 mt -121.73 140.23 46.38 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.305 0 N-CA-C 106.978 -1.49 . . . . 0.0 106.978 -179.327 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 16.0 t70 69.82 9.4 7.13 Favored 'General case' 0 N--CA 1.47 0.575 0 C-N-CA 125.384 1.474 . . . . 0.0 112.313 -177.428 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.2 p -75.6 -34.41 60.62 Favored 'General case' 0 C--N 1.329 -0.315 0 C-N-CA 126.358 1.863 . . . . 0.0 108.156 178.169 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.5 p -54.32 -46.79 69.43 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.243 0 CA-C-N 113.468 -1.696 . . . . 0.0 108.028 171.653 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -62.05 -39.21 91.57 Favored 'General case' 0 N--CA 1.455 -0.198 0 C-N-CA 124.491 1.116 . . . . 0.0 109.425 177.989 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -72.99 3.17 5.67 Favored 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 125.934 1.694 . . . . 0.0 111.322 177.14 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 32.8 mmtp 48.13 32.48 3.02 Favored 'General case' 0 C--N 1.344 0.354 0 C-N-CA 126.068 1.747 . . . . 0.0 112.993 178.141 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 57.74 28.29 60.07 Favored Glycine 0 CA--C 1.535 1.323 0 O-C-N 122.009 -0.432 . . . . 0.0 112.828 -178.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 51.9 mt-10 -72.4 91.04 1.33 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 118.963 1.381 . . . . 0.0 108.843 178.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 6.12 4.24 Favored Glycine 0 CA--C 1.533 1.213 0 C-N-CA 126.745 2.117 . . . . 0.0 111.391 -176.877 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.529 ' CD1' HG12 ' A' ' 115' ' ' VAL . 14.6 m-30 -103.27 131.12 50.57 Favored 'General case' 0 N--CA 1.453 -0.32 0 C-N-CA 125.187 1.395 . . . . 0.0 108.477 179.739 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 14.3 m -119.98 122.79 41.95 Favored 'General case' 0 CA--C 1.53 0.211 0 C-N-CA 126.245 1.818 . . . . 0.0 107.159 -179.315 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 31.1 p -99.32 124.63 44.57 Favored 'General case' 0 N--CA 1.454 -0.275 0 C-N-CA 123.612 0.765 . . . . 0.0 109.957 -176.372 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 24.1 m-85 -90.59 -48.81 6.85 Favored 'General case' 0 N--CA 1.449 -0.497 0 C-N-CA 125.566 1.546 . . . . 0.0 111.294 -177.942 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -73.43 130.76 35.66 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 C-N-CA 117.149 -1.82 . . . . 0.0 107.283 175.666 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 71.1 m -94.51 55.1 1.9 Allowed 'General case' 0 C--N 1.33 -0.269 0 N-CA-C 102.743 -3.058 . . . . 0.0 102.743 168.693 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.588 0.4 OUTLIER 43.58 -77.63 0.0 OUTLIER 'General case' 0 N--CA 1.444 -0.774 0 C-N-CA 130.627 3.571 . . . . 0.0 113.465 -167.57 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 51.4 35.6 36.2 Favored Glycine 0 CA--C 1.529 0.942 0 C-N-CA 125.108 1.337 . . . . 0.0 110.45 178.494 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.373 4.1 p30 4.38 -106.6 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.297 0 C-N-CA 130.049 3.34 . . . . 0.0 119.313 -175.6 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 9.2 mmm180 -33.62 111.94 0.12 Allowed 'General case' 0 N--CA 1.43 -1.451 0 C-N-CA 130.993 3.717 . . . . 0.0 119.047 -169.234 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.363 27.4 m 48.61 68.92 0.12 Allowed 'Isoleucine or valine' 0 N--CA 1.447 -0.6 0 C-N-CA 129.08 2.952 . . . . 0.0 118.036 173.487 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -119.49 139.22 27.48 Favored Pre-proline 0 N--CA 1.449 -0.521 0 N-CA-C 104.09 -2.559 . . . . 0.0 104.09 167.797 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 11.7 Cg_endo -90.37 -145.04 0.03 OUTLIER 'Trans proline' 0 N--CA 1.448 -1.16 0 C-N-CA 123.56 2.84 . . . . 0.0 108.302 179.972 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . -70.81 52.05 0.92 Allowed Glycine 0 CA--C 1.532 1.112 0 C-N-CA 124.875 1.226 . . . . 0.0 113.885 -179.555 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 18.7 tp60 -61.83 -22.25 65.34 Favored 'General case' 0 N--CA 1.454 -0.243 0 C-N-CA 125.858 1.663 . . . . 0.0 113.707 178.366 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 39.0 ttmt 108.1 111.84 0.01 OUTLIER 'General case' 0 C--N 1.328 -0.327 0 C-N-CA 130.103 3.361 . . . . 0.0 107.971 -176.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 73.5 mt -80.25 -53.2 6.87 Favored 'General case' 0 N--CA 1.45 -0.47 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.137 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 23.0 mt -143.04 163.94 31.44 Favored 'General case' 0 CA--C 1.545 0.753 0 C-N-CA 123.743 0.817 . . . . 0.0 111.721 -174.728 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 85.8 mt-10 -128.19 135.33 49.58 Favored 'General case' 0 CA--C 1.515 -0.4 1 N-CA-C 99.81 -4.145 . . . . 0.0 99.81 166.707 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.529 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -144.92 121.28 4.1 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 109.189 -0.671 . . . . 0.0 109.189 -166.303 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 71.9 m-20 -70.53 64.98 0.29 Allowed 'General case' 0 C--O 1.234 0.246 0 C-N-CA 125.569 1.548 . . . . 0.0 113.019 -174.173 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 88.5 mt -40.81 -54.27 2.7 Favored 'General case' 0 C--O 1.226 -0.165 0 C-N-CA 124.91 1.284 . . . . 0.0 111.909 -179.887 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.0 t70 -49.81 -41.36 44.57 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.485 1.114 . . . . 0.0 113.879 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.43 -35.01 15.4 Favored 'General case' 0 C--O 1.23 0.056 0 C-N-CA 122.454 0.302 . . . . 0.0 111.496 -177.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.9 t -67.21 -50.61 61.56 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.355 0 O-C-N 121.764 -0.585 . . . . 0.0 109.529 179.425 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.347 48.5 pttt -40.11 -57.78 2.61 Favored Pre-proline 0 CA--C 1.539 0.55 0 N-CA-C 116.975 2.213 . . . . 0.0 116.975 -177.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_endo -56.91 -21.85 43.06 Favored 'Trans proline' 0 N--CA 1.457 -0.674 0 C-N-CA 122.509 2.139 . . . . 0.0 113.132 178.799 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 63.3 m-80 -97.43 6.89 47.51 Favored 'General case' 0 CA--C 1.532 0.288 0 CA-C-O 118.387 -0.816 . . . . 0.0 112.655 -178.24 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 30.2 m -136.49 151.14 72.39 Favored Pre-proline 0 CA--C 1.533 0.304 0 CA-C-N 119.898 1.226 . . . . 0.0 110.262 178.958 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.79 -25.16 12.59 Favored 'Trans proline' 0 N--CA 1.452 -0.95 0 C-N-CA 122.535 2.157 . . . . 0.0 112.206 -178.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.9 m -158.24 128.09 5.95 Favored 'General case' 0 CA--C 1.531 0.216 0 CA-C-N 119.038 0.835 . . . . 0.0 111.27 -177.764 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -89.32 -0.23 57.31 Favored 'General case' 0 CA--C 1.54 0.567 0 C-N-CA 124.823 1.249 . . . . 0.0 110.72 176.708 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 82.6 mmm -50.37 103.0 0.04 OUTLIER 'General case' 0 N--CA 1.454 -0.24 0 C-N-CA 126.221 1.808 . . . . 0.0 109.754 -179.591 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 68.6 m -99.09 117.39 64.27 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 123.814 0.845 . . . . 0.0 109.091 -177.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 27.5 Cg_endo -92.56 139.49 1.87 Allowed 'Trans proline' 0 N--CA 1.442 -1.556 0 C-N-CA 123.211 2.607 . . . . 0.0 108.914 178.749 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.51 HD12 ' N ' ' A' ' 131' ' ' ILE . 1.1 mp -113.08 117.82 56.38 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.677 0 N-CA-C 100.523 -3.88 . . . . 0.0 100.523 171.469 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.1 t -126.01 158.13 35.55 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.57 0 N-CA-C 106.629 -1.619 . . . . 0.0 106.629 -177.201 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.714 ' HB2' HD21 ' A' ' 136' ' ' LEU . 32.5 m-85 -134.1 137.49 44.62 Favored 'General case' 0 N--CA 1.432 -1.342 0 N-CA-C 103.751 -2.685 . . . . 0.0 103.751 -176.534 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 81.3 p -92.46 -73.41 0.55 Allowed 'General case' 0 CA--C 1.53 0.185 0 CA-C-N 119.223 0.92 . . . . 0.0 109.216 -179.195 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 5.2 p30 -75.96 68.79 2.5 Favored 'General case' 0 CA--C 1.532 0.271 0 N-CA-C 113.196 0.813 . . . . 0.0 113.196 -178.779 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.714 HD21 ' HB2' ' A' ' 133' ' ' PHE . 2.9 mm? -78.6 66.0 4.01 Favored 'General case' 0 CA--C 1.539 0.521 0 N-CA-C 106.162 -1.792 . . . . 0.0 106.162 171.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 31.46 47.45 0.06 Allowed 'General case' 0 C--N 1.343 0.299 0 C-N-CA 127.831 2.452 . . . . 0.0 111.717 -173.813 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 29.61 61.22 0.16 Allowed 'General case' 0 N--CA 1.452 -0.343 0 C-N-CA 128.243 2.617 . . . . 0.0 114.343 -177.464 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.38 -14.78 0.22 Allowed Glycine 0 CA--C 1.525 0.668 0 CA-C-O 119.649 -0.528 . . . . 0.0 112.968 177.773 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.563 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 44.2 mm-40 -80.4 123.66 28.22 Favored 'General case' 0 CA--C 1.532 0.286 0 CA-C-N 118.201 1.001 . . . . 0.0 109.638 -178.59 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 15.2 p -89.78 143.28 26.93 Favored 'General case' 0 CA--C 1.53 0.183 0 C-N-CA 123.925 0.89 . . . . 0.0 109.257 178.86 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -89.94 113.23 25.8 Favored 'Isoleucine or valine' 0 CA--C 1.541 0.623 0 C-N-CA 123.664 0.786 . . . . 0.0 109.874 -178.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 36.2 m -106.74 98.85 8.47 Favored 'General case' 0 C--N 1.34 0.178 0 C-N-CA 124.333 1.053 . . . . 0.0 110.576 -179.614 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 3.2 pt -64.07 128.74 26.94 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.352 0 N-CA-C 109.513 -0.551 . . . . 0.0 109.513 175.325 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.3 mmtt -98.09 -34.71 10.67 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 124.064 0.946 . . . . 0.0 112.223 -178.398 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.567 ' HB2' HG23 ' A' ' 157' ' ' ILE . . . -70.98 100.72 2.03 Favored 'General case' 0 N--CA 1.462 0.128 0 CA-C-N 119.773 1.169 . . . . 0.0 109.915 178.257 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 1.2 m -79.49 51.26 1.22 Allowed 'General case' 0 CA--C 1.538 0.49 0 N-CA-C 108.795 -0.817 . . . . 0.0 108.795 176.174 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 176.2 -145.76 7.7 Favored Glycine 0 CA--C 1.524 0.632 0 N-CA-C 110.461 -1.056 . . . . 0.0 110.461 -175.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 47.1 t -73.92 132.49 42.52 Favored 'General case' 0 N--CA 1.453 -0.318 0 O-C-N 122.203 -0.586 . . . . 0.0 111.216 -178.792 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.457 HG21 HD12 ' A' ' 45' ' ' ILE . 18.4 m -89.7 157.15 3.02 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 N-CA-C 107.24 -1.393 . . . . 0.0 107.24 174.493 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 2.6 m120 -129.78 152.44 49.27 Favored 'General case' 0 C--O 1.233 0.198 0 N-CA-C 107.373 -1.343 . . . . 0.0 107.373 179.345 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 54.5 mtp180 -58.29 150.07 22.82 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 122.685 0.394 . . . . 0.0 111.603 177.634 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 48.4 mt-10 63.03 1.73 0.91 Allowed 'General case' 0 CA--C 1.531 0.228 0 C-N-CA 126.412 1.885 . . . . 0.0 115.339 172.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 58.9 mm-40 -70.13 119.32 14.15 Favored 'General case' 0 N--CA 1.452 -0.327 0 CA-C-N 119.569 1.077 . . . . 0.0 108.635 179.802 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 41.2 tt0 -81.99 125.86 31.28 Favored 'General case' 0 N--CA 1.447 -0.602 0 CA-C-O 121.369 0.604 . . . . 0.0 112.242 -176.355 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.9 t0 70.08 27.9 4.19 Favored 'General case' 0 C--N 1.328 -0.368 0 C-N-CA 128.472 2.709 . . . . 0.0 115.459 175.188 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.567 HG23 ' HB2' ' A' ' 146' ' ' ALA 0.26 1.7 mp -71.27 -8.89 12.09 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.586 0 CA-C-O 121.306 0.575 . . . . 0.0 110.264 178.257 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 8.7 p -122.39 120.15 60.29 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.013 0 N-CA-C 102.75 -3.056 . . . . 0.0 102.75 168.385 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 5.5 mtpm? -108.13 128.42 54.68 Favored 'General case' 0 N--CA 1.451 -0.394 0 N-CA-C 108.11 -1.07 . . . . 0.0 108.11 179.299 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.563 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -79.45 133.14 30.48 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.974 0 N-CA-C 105.847 -1.909 . . . . 0.0 105.847 173.729 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -145.08 -174.87 4.48 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 125.078 1.351 . . . . 0.0 108.716 -177.912 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 49.3 mtmt . . . . . 0 C--O 1.233 0.201 0 C-N-CA 125.307 1.443 . . . . 0.0 107.31 174.981 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 42.3 ttp . . . . . 0 N--CA 1.455 -0.202 0 N-CA-C 111.366 0.136 . . . . 0.0 111.366 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 24.8 mt -76.55 66.12 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.534 0.353 0 C-N-CA 123.751 0.82 . . . . 0.0 108.901 -179.022 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -77.37 60.45 2.02 Favored 'General case' 0 CA--C 1.533 0.293 0 C-N-CA 123.691 0.797 . . . . 0.0 109.583 178.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 57.8 tt0 -151.97 130.75 6.42 Favored Pre-proline 0 CA--C 1.533 0.3 0 C-N-CA 124.126 0.97 . . . . 0.0 108.514 -178.738 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 90.8 Cg_endo -74.43 81.92 1.97 Allowed 'Trans proline' 0 N--CA 1.452 -0.965 0 C-N-CA 122.532 2.155 . . . . 0.0 109.359 179.06 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 57.1 mt -66.65 69.85 0.07 Allowed 'General case' 0 CA--C 1.535 0.367 0 C-N-CA 124.565 1.146 . . . . 0.0 112.389 -179.237 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 2.1 pt20 -76.59 62.18 1.89 Allowed 'General case' 0 CA--C 1.533 0.319 0 C-N-CA 125.613 1.565 . . . . 0.0 108.988 176.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 12.6 t30 -77.17 168.4 20.12 Favored 'General case' 0 CA--C 1.537 0.473 0 C-N-CA 125.576 1.55 . . . . 0.0 110.252 -178.375 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -76.36 -52.41 9.96 Favored 'General case' 0 N--CA 1.453 -0.317 0 C-N-CA 124.093 0.957 . . . . 0.0 110.932 -179.386 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 20.5 tt -166.4 147.76 1.67 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.562 0 N-CA-C 106.936 -1.505 . . . . 0.0 106.936 -178.658 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 119.43 -100.71 0.81 Allowed Glycine 0 CA--C 1.522 0.493 0 N-CA-C 108.071 -2.011 . . . . 0.0 108.071 -179.665 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 74.6 tt0 -88.0 133.3 33.98 Favored 'General case' 0 N--CA 1.448 -0.526 0 N-CA-C 107.204 -1.406 . . . . 0.0 107.204 175.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 67.1 mm-40 -145.54 -140.79 0.11 Allowed 'General case' 0 CA--C 1.537 0.453 0 N-CA-C 107.775 -1.194 . . . . 0.0 107.775 178.408 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.0 t -55.51 -52.77 43.4 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.105 0 C-N-CA 124.849 1.259 . . . . 0.0 113.724 -177.576 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -79.25 128.96 33.97 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 106.077 -1.823 . . . . 0.0 106.077 179.871 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 6.9 m -125.44 84.54 0.88 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.327 0 CA-C-N 118.61 0.641 . . . . 0.0 112.65 -176.159 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 21.9 t -19.86 122.01 0.09 OUTLIER Pre-proline 0 CA--C 1.547 0.83 0 C-N-CA 129.373 3.069 . . . . 0.0 112.553 177.524 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 31.0 Cg_endo -71.48 -37.35 5.65 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 N-CA-C 117.632 2.128 . . . . 0.0 117.632 -171.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.3 151.64 18.26 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.368 0 CA-C-N 119.717 1.144 . . . . 0.0 111.387 -175.109 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.1 m -88.46 146.38 25.24 Favored 'General case' 0 C--O 1.236 0.35 0 N-CA-C 107.492 -1.299 . . . . 0.0 107.492 173.548 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 157.42 -128.6 2.17 Favored Glycine 0 CA--C 1.525 0.67 0 N-CA-C 109.573 -1.411 . . . . 0.0 109.573 -179.533 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 31.9 tt0 -127.57 138.64 52.94 Favored 'General case' 0 N--CA 1.457 -0.124 0 C-N-CA 125.007 1.323 . . . . 0.0 108.141 178.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.8 tt -106.51 139.71 27.03 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.137 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -179.951 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 16.6 m-70 -136.94 155.55 76.27 Favored Pre-proline 0 N--CA 1.453 -0.315 0 C-N-CA 125.628 1.571 . . . . 0.0 108.329 -179.26 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -65.47 146.08 84.25 Favored 'Trans proline' 0 N--CA 1.446 -1.27 0 N-CA-C 107.916 -1.609 . . . . 0.0 107.916 172.534 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -56.79 -21.31 13.57 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.923 0 CA-C-N 113.534 -1.666 . . . . 0.0 113.119 -177.032 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 18.0 p -53.42 -32.51 50.03 Favored 'General case' 0 N--CA 1.454 -0.271 0 C-N-CA 123.562 0.745 . . . . 0.0 111.124 175.074 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -77.11 -6.1 51.55 Favored 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 123.903 0.881 . . . . 0.0 113.075 -175.083 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.3 t -77.84 132.6 67.53 Favored Pre-proline 0 CA--C 1.536 0.411 0 CA-C-N 119.228 0.922 . . . . 0.0 110.171 -177.085 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 42.9 Cg_endo -77.32 58.12 6.14 Favored 'Trans proline' 0 CA--C 1.54 0.782 0 C-N-CA 123.692 2.928 . . . . 0.0 111.176 -179.242 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 33.8 t0 -168.83 110.25 0.51 Allowed 'General case' 0 N--CA 1.461 0.115 0 N-CA-C 108.35 -0.981 . . . . 0.0 108.35 179.601 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 20.0 mp0 -37.42 -44.8 0.66 Allowed 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 127.486 2.314 . . . . 0.0 113.553 -179.317 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 95.4 t -50.26 -43.82 22.32 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.246 0 C-N-CA 123.414 0.686 . . . . 0.0 110.16 179.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 25.2 m-85 -87.3 -48.99 7.55 Favored 'General case' 0 N--CA 1.447 -0.606 0 C-N-CA 123.757 0.823 . . . . 0.0 109.52 179.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER -49.12 -40.99 34.52 Favored 'General case' 0 CA--C 1.532 0.26 0 N-CA-C 113.293 0.849 . . . . 0.0 113.293 -178.688 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.03 13.93 60.22 Favored Glycine 0 C--N 1.338 0.676 0 CA-C-O 118.938 -0.923 . . . . 0.0 111.853 -178.831 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 37.1 mttp 70.31 -34.05 0.28 Allowed 'General case' 0 CA--C 1.541 0.624 0 C-N-CA 125.757 1.623 . . . . 0.0 114.584 179.106 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.5 ttm 24.38 -61.6 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.437 1 C-N-CA 132.029 4.131 . . . . 0.0 118.203 178.319 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -78.11 -22.72 48.47 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.944 0.898 . . . . 0.0 111.59 -177.276 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.02 -128.89 1.3 Allowed Glycine 0 C--N 1.336 0.535 0 N-CA-C 109.048 -1.621 . . . . 0.0 109.048 -178.603 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . 0.418 ' HB3' ' CD1' ' A' ' 136' ' ' LEU . 40.0 t0 -131.4 159.25 38.53 Favored 'General case' 0 CA--C 1.517 -0.304 0 N-CA-C 105.006 -2.22 . . . . 0.0 105.006 171.321 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.4 -166.18 34.25 Favored Glycine 0 N--CA 1.447 -0.592 0 C-N-CA 120.016 -1.088 . . . . 0.0 113.461 -176.872 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 13.7 p90 -144.38 160.92 40.23 Favored 'General case' 0 N--CA 1.454 -0.256 0 C-N-CA 124.534 1.134 . . . . 0.0 109.714 178.553 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -105.95 118.46 36.67 Favored 'General case' 0 N--CA 1.451 -0.409 0 C-N-CA 125.525 1.53 . . . . 0.0 109.891 179.402 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 33.6 mm -98.46 130.3 47.48 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.524 0 N-CA-C 105.915 -1.883 . . . . 0.0 105.915 172.675 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 2.6 tt -101.11 108.01 52.69 Favored Pre-proline 0 N--CA 1.448 -0.541 1 N-CA-C 99.604 -4.221 . . . . 0.0 99.604 170.105 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 63.1 Cg_endo -85.91 148.49 9.5 Favored 'Trans proline' 0 N--CA 1.455 -0.743 0 C-N-CA 122.617 2.211 . . . . 0.0 114.958 -168.118 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.5 p -113.51 -51.24 2.81 Favored 'General case' 0 CA--C 1.531 0.233 0 C-N-CA 124.974 1.31 . . . . 0.0 108.685 174.498 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.2 mt-10 -73.56 122.4 22.17 Favored 'General case' 0 N--CA 1.456 -0.169 0 C-N-CA 122.515 0.326 . . . . 0.0 111.328 179.215 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -81.22 41.07 2.6 Favored Glycine 0 CA--C 1.53 0.993 0 N-CA-C 110.504 -1.039 . . . . 0.0 110.504 173.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 81.0 mt -136.22 113.78 14.22 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.199 0 N-CA-C 103.413 -2.81 . . . . 0.0 103.413 179.739 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 90.2 t -119.54 119.62 61.04 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.389 0 C-N-CA 123.769 0.828 . . . . 0.0 109.87 -172.657 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 23.3 m -99.87 164.7 2.58 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.085 0 CA-C-O 121.159 0.504 . . . . 0.0 109.935 176.802 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 9.5 m -76.46 131.93 73.66 Favored Pre-proline 0 N--CA 1.45 -0.444 0 CA-C-O 117.576 -1.202 . . . . 0.0 108.423 178.997 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 39.3 Cg_endo -60.96 -31.79 91.79 Favored 'Trans proline' 0 C--N 1.346 0.434 0 C-N-CA 123.002 2.468 . . . . 0.0 110.783 177.469 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . 0.453 HG22 HD12 ' A' ' 80' ' ' ILE . 10.8 m -151.11 150.09 13.61 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.407 0 N-CA-C 102.925 -2.991 . . . . 0.0 102.925 173.389 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 3.0 tpt180 -101.25 -93.74 0.29 Allowed 'General case' 0 CA--C 1.506 -0.729 0 N-CA-C 101.176 -3.638 . . . . 0.0 101.176 169.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.12 -66.75 2.5 Favored Glycine 0 CA--C 1.537 1.458 0 N-CA-C 107.405 -2.278 . . . . 0.0 107.405 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -165.03 125.23 1.91 Allowed 'General case' 0 N--CA 1.449 -0.494 0 N-CA-C 106.793 -1.558 . . . . 0.0 106.793 167.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 33.5 mm -62.92 128.62 25.16 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.172 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 169.909 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -81.05 -49.04 11.38 Favored 'General case' 0 N--CA 1.452 -0.351 0 N-CA-C 106.72 -1.585 . . . . 0.0 106.72 178.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 4.8 t-20 -175.88 151.15 1.08 Allowed 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 122.434 0.294 . . . . 0.0 111.361 -179.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 24.5 m -113.17 126.23 70.56 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 169.53 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.446 ' CG ' ' HB3' ' A' ' 69' ' ' ALA . 5.7 m-85 -65.73 156.63 82.51 Favored Pre-proline 0 CA--C 1.534 0.333 0 O-C-N 121.426 -0.796 . . . . 0.0 110.03 -176.621 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 85.8 Cg_exo -48.44 -43.4 32.84 Favored 'Trans proline' 0 N--CA 1.459 -0.533 0 C-N-CA 123.114 2.543 . . . . 0.0 112.952 177.89 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 18.0 p -79.57 3.87 17.59 Favored 'General case' 0 CA--C 1.537 0.456 0 C-N-CA 124.842 1.257 . . . . 0.0 112.761 -179.709 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 60.18 -21.9 0.03 OUTLIER 'General case' 0 CA--C 1.538 0.483 0 C-N-CA 128.525 2.73 . . . . 0.0 116.84 179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 0.0 OUTLIER -63.87 -31.54 72.75 Favored 'General case' 0 C--O 1.227 -0.103 0 CA-C-N 119.483 1.038 . . . . 0.0 111.884 -174.8 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . 0.446 ' HB3' ' CG ' ' A' ' 64' ' ' PHE . . . -103.6 135.67 44.74 Favored 'General case' 0 N--CA 1.454 -0.237 0 C-N-CA 124.091 0.956 . . . . 0.0 110.081 -179.365 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . . 53.9 mt -140.06 146.54 24.71 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.233 0 N-CA-C 108.914 -0.773 . . . . 0.0 108.914 -179.063 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -125.32 136.74 9.95 Favored Glycine 0 CA--C 1.528 0.854 0 C-N-CA 125.862 1.696 . . . . 0.0 109.076 178.148 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.8 mp -137.86 163.82 30.5 Favored 'General case' 0 N--CA 1.464 0.246 0 C-N-CA 124.959 1.304 . . . . 0.0 110.409 -177.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 70.8 mt-30 -145.38 125.23 13.46 Favored 'General case' 0 N--CA 1.449 -0.502 0 N-CA-C 107.434 -1.321 . . . . 0.0 107.434 176.055 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 57.2 p -73.01 72.76 1.15 Allowed 'General case' 0 CA--C 1.538 0.519 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 175.443 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 11.4 t0 44.42 60.26 2.92 Favored 'General case' 0 N--CA 1.449 -0.511 0 C-N-CA 127.374 2.27 . . . . 0.0 110.183 -177.597 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 81.07 -11.67 41.39 Favored Glycine 0 CA--C 1.531 1.083 0 CA-C-N 114.722 -1.127 . . . . 0.0 114.024 179.995 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -78.36 -102.84 0.2 Allowed Glycine 0 CA--C 1.53 0.998 0 CA-C-N 119.076 1.438 . . . . 0.0 112.802 -177.756 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -78.25 116.96 19.06 Favored 'General case' 0 N--CA 1.454 -0.261 0 N-CA-C 107.901 -1.148 . . . . 0.0 107.901 -178.307 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 43.7 tt0 -93.09 126.8 38.36 Favored 'General case' 0 N--CA 1.446 -0.635 0 C-N-CA 125.589 1.556 . . . . 0.0 106.932 177.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . 0.453 HD12 HG22 ' A' ' 56' ' ' VAL . 5.8 mt -125.03 143.45 38.56 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.437 0 C-N-CA 124.1 0.96 . . . . 0.0 111.205 -172.003 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.9 tm? -122.89 130.74 53.23 Favored 'General case' 0 N--CA 1.45 -0.454 0 C-N-CA 127.219 2.208 . . . . 0.0 105.413 174.641 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.5 mt -123.49 146.73 28.41 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.457 0 C-N-CA 124.767 1.227 . . . . 0.0 108.019 179.326 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -134.33 131.8 38.77 Favored 'General case' 0 N--CA 1.448 -0.552 0 N-CA-C 105.283 -2.117 . . . . 0.0 105.283 171.324 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.9 t80 -103.05 106.21 16.68 Favored 'General case' 0 N--CA 1.441 -0.898 0 C-N-CA 124.774 1.229 . . . . 0.0 107.879 179.944 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 67.1 -169.82 34.94 Favored Glycine 0 CA--C 1.534 1.229 0 N-CA-C 110.669 -0.972 . . . . 0.0 110.669 -177.053 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 29.3 mm -109.78 -84.42 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.23 0.05 0 CA-C-O 123.224 1.488 . . . . 0.0 110.469 -178.104 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -65.41 4.82 0.48 Allowed 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 126.432 1.893 . . . . 0.0 113.033 -179.925 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -65.22 -30.24 71.11 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.438 1.895 . . . . 0.0 107.573 175.195 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 2.4 p -58.55 -46.98 89.75 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.185 0 CA-C-N 114.374 -1.285 . . . . 0.0 108.348 174.362 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -63.68 -41.02 98.21 Favored 'General case' 0 C--O 1.227 -0.112 0 C-N-CA 125.036 1.334 . . . . 0.0 109.017 177.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -65.05 -8.41 16.19 Favored 'General case' 0 CA--C 1.541 0.633 0 C-N-CA 125.69 1.596 . . . . 0.0 110.943 176.727 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 5.6 mtmp? 52.54 34.14 14.91 Favored 'General case' 0 C--N 1.343 0.315 0 C-N-CA 125.301 1.441 . . . . 0.0 111.823 179.227 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.18 21.07 61.33 Favored Glycine 0 CA--C 1.536 1.37 0 CA-C-O 119.67 -0.517 . . . . 0.0 112.875 -179.225 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 52.3 mt-10 -71.84 90.18 1.1 Allowed 'General case' 0 C--N 1.341 0.227 0 CA-C-N 119.388 1.594 . . . . 0.0 108.625 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 141.83 -2.41 1.9 Allowed Glycine 0 CA--C 1.535 1.323 0 C-N-CA 126.484 1.992 . . . . 0.0 111.591 -175.144 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -97.86 103.53 15.47 Favored 'General case' 0 N--CA 1.452 -0.328 0 C-N-CA 125.57 1.548 . . . . 0.0 111.063 -176.758 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 50.0 m -84.36 98.15 9.87 Favored 'General case' 0 N--CA 1.448 -0.554 0 N-CA-C 103.636 -2.727 . . . . 0.0 103.636 171.062 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 43.0 p -79.59 121.37 25.18 Favored 'General case' 0 N--CA 1.451 -0.401 0 O-C-N 121.793 -0.567 . . . . 0.0 109.983 -177.205 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 17.6 m-85 -79.94 -52.82 7.38 Favored 'General case' 0 N--CA 1.45 -0.444 0 C-N-CA 124.524 1.13 . . . . 0.0 109.361 -179.712 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 24.3 m -82.17 129.0 38.21 Favored 'Isoleucine or valine' 0 CA--C 1.522 -0.121 0 C-N-CA 117.951 -1.5 . . . . 0.0 107.43 175.142 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 67.5 m -98.21 56.69 1.2 Allowed 'General case' 0 C--N 1.328 -0.364 0 N-CA-C 102.397 -3.186 . . . . 0.0 102.397 169.105 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.312 7.8 pt-20 36.16 61.08 0.8 Allowed 'General case' 0 N--CA 1.447 -0.603 0 CA-C-N 111.09 -2.777 . . . . 0.0 110.734 -167.498 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.42 55.08 2.41 Favored Glycine 0 CA--C 1.525 0.679 0 CA-C-N 111.108 -2.769 . . . . 0.0 109.834 178.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.35 3.3 p30 1.81 -110.63 0.0 OUTLIER 'General case' 0 N--CA 1.433 -1.305 0 C-N-CA 130.997 3.719 . . . . 0.0 118.566 -178.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 45.0 mmm-85 -44.94 142.46 1.81 Allowed 'General case' 0 N--CA 1.425 -1.698 1 N-CA-C 122.56 4.281 . . . . 0.0 122.56 -167.03 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.722 4.7 m 36.95 -55.13 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.45 -0.428 2 N-CA-C 130.351 7.167 . . . . 0.0 130.351 173.971 . . . . . . . . 3 2 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -72.52 121.98 86.29 Favored Pre-proline 0 C--N 1.317 -0.831 0 C-N-CA 116.472 -2.091 . . . . 0.0 113.172 -165.083 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -69.84 172.31 12.95 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 125.021 3.814 . . . . 0.0 113.081 -169.12 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 55.81 19.51 21.67 Favored Glycine 0 CA--C 1.528 0.895 0 C-N-CA 124.582 1.087 . . . . 0.0 115.21 176.282 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.6 tp-100 -61.6 143.22 56.4 Favored 'General case' 0 N--CA 1.45 -0.431 0 CA-C-N 118.488 1.144 . . . . 0.0 109.328 177.775 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 35.6 ttmt -69.96 119.61 14.43 Favored 'General case' 0 N--CA 1.453 -0.285 0 N-CA-C 107.798 -1.186 . . . . 0.0 107.798 176.293 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.2 mt -80.85 -51.43 8.61 Favored 'General case' 0 N--CA 1.453 -0.31 0 N-CA-C 108.656 -0.868 . . . . 0.0 108.656 177.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 13.3 mt -143.28 155.17 44.41 Favored 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 123.667 0.787 . . . . 0.0 112.024 -174.008 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 31.5 tt0 -122.39 125.76 46.57 Favored 'General case' 0 CA--C 1.514 -0.425 1 N-CA-C 98.305 -4.702 . . . . 0.0 98.305 166.296 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -133.36 129.33 56.3 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.936 0 CA-C-N 114.691 -1.141 . . . . 0.0 112.165 -165.711 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.5 t0 -73.22 67.95 0.98 Allowed 'General case' 0 CA--C 1.532 0.284 0 C-N-CA 123.798 0.839 . . . . 0.0 110.397 -179.209 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 79.8 mt -52.59 -41.56 63.73 Favored 'General case' 0 C--O 1.224 -0.266 0 CA-C-O 119.301 -0.38 . . . . 0.0 110.583 179.806 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -49.45 -44.46 45.63 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 123.507 0.723 . . . . 0.0 112.272 179.111 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.59 -35.33 19.51 Favored 'General case' 0 CA--C 1.53 0.184 0 CA-C-N 117.933 0.333 . . . . 0.0 111.841 -179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 53.9 t -64.59 -49.69 79.31 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.584 0 O-C-N 121.537 -0.727 . . . . 0.0 110.567 -179.716 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.357 0.0 OUTLIER -47.48 -53.84 26.7 Favored Pre-proline 0 CA--C 1.541 0.603 0 N-CA-C 116.943 2.201 . . . . 0.0 116.943 -177.557 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -60.9 -25.64 81.71 Favored 'Trans proline' 0 N--CA 1.455 -0.786 0 C-N-CA 122.231 1.954 . . . . 0.0 112.323 177.151 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 39.4 m-80 -79.92 -50.15 10.87 Favored 'General case' 0 C--N 1.34 0.159 0 CA-C-N 118.651 0.66 . . . . 0.0 110.617 -179.109 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 18.7 m -79.72 142.83 57.51 Favored Pre-proline 0 CA--C 1.535 0.377 0 C-N-CA 120.472 -0.491 . . . . 0.0 111.721 -177.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 99.0 Cg_endo -74.33 -15.81 22.34 Favored 'Trans proline' 0 N--CA 1.452 -0.946 0 C-N-CA 122.48 2.12 . . . . 0.0 111.717 178.499 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 16.6 m -156.76 128.41 7.13 Favored 'General case' 0 CA--C 1.533 0.302 0 C-N-CA 124.07 0.948 . . . . 0.0 108.907 -179.073 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.2 tp -94.73 9.91 37.1 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 125.403 1.481 . . . . 0.0 111.54 -178.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 74.1 mmm -53.42 118.75 4.09 Favored 'General case' 0 N--CA 1.453 -0.306 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.385 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 34.0 m -113.94 86.96 11.89 Favored Pre-proline 0 N--CA 1.445 -0.678 0 C-N-CA 126.168 1.787 . . . . 0.0 107.752 -177.247 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.477 ' C ' HD12 ' A' ' 131' ' ' ILE . 60.9 Cg_endo -83.25 149.72 13.41 Favored 'Trans proline' 0 N--CA 1.444 -1.407 0 C-N-CA 121.814 1.676 . . . . 0.0 112.403 -178.435 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.477 HD12 ' C ' ' A' ' 130' ' ' PRO . 1.1 mp -122.13 130.3 74.67 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.484 0 N-CA-C 103.494 -2.78 . . . . 0.0 103.494 174.919 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -126.56 143.55 39.67 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.387 0 C-N-CA 125.751 1.62 . . . . 0.0 106.93 179.098 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 7.3 m-85 -117.15 123.56 47.02 Favored 'General case' 0 N--CA 1.447 -0.621 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 178.618 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 64.7 p -83.96 -72.22 0.47 Allowed 'General case' 0 C--N 1.335 -0.06 0 CA-C-O 121.504 0.669 . . . . 0.0 111.046 -171.677 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p30 -71.7 52.63 0.22 Allowed 'General case' 0 CA--C 1.534 0.353 0 C-N-CA 126.091 1.756 . . . . 0.0 113.113 -178.325 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.418 ' CD1' ' HB3' ' A' ' 41' ' ' ASP . 38.8 mt -74.35 63.68 1.06 Allowed 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.324 1.45 . . . . 0.0 109.38 177.176 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 17.4 57.69 0.01 OUTLIER 'General case' 0 C--N 1.348 0.503 0 C-N-CA 129.509 3.124 . . . . 0.0 112.209 -177.392 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.7 mm-40 23.88 57.43 0.03 OUTLIER 'General case' 0 N--CA 1.451 -0.422 0 C-N-CA 129.108 2.963 . . . . 0.0 114.371 -174.801 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 159.26 -5.51 0.12 Allowed Glycine 0 CA--C 1.526 0.778 0 CA-C-O 119.006 -0.886 . . . . 0.0 113.891 178.294 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.689 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 29.7 mt-10 -75.49 93.14 2.94 Favored 'General case' 0 CA--C 1.53 0.208 0 CA-C-N 119.254 1.527 . . . . 0.0 108.796 179.816 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 34.1 p -76.65 130.46 37.83 Favored 'General case' 0 N--CA 1.451 -0.412 0 CA-C-O 121.836 0.827 . . . . 0.0 109.421 -178.971 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -83.6 100.35 7.03 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.468 0 N-CA-C 107.495 -1.298 . . . . 0.0 107.495 -178.135 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 14.8 m -98.71 102.28 13.97 Favored 'General case' 0 N--CA 1.451 -0.379 0 C-N-CA 124.971 1.308 . . . . 0.0 110.578 -175.778 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 8.4 pt -66.95 146.3 13.29 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 O-C-N 121.909 -0.494 . . . . 0.0 110.363 176.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.1 mmtt -119.13 -45.5 2.55 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.976 1.71 . . . . 0.0 110.359 -178.496 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -66.87 79.94 0.11 Allowed 'General case' 0 C--O 1.224 -0.244 0 CA-C-O 121.45 0.643 . . . . 0.0 109.929 -179.522 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.3 m -77.82 65.82 3.36 Favored 'General case' 0 C--N 1.328 -0.36 0 C-N-CA 123.805 0.842 . . . . 0.0 109.848 -176.234 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 162.48 -128.69 1.92 Allowed Glycine 0 C--N 1.336 0.554 0 N-CA-C 109.995 -1.242 . . . . 0.0 109.995 -177.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 14.2 t -66.7 157.92 31.46 Favored 'General case' 0 CA--C 1.535 0.39 0 CA-C-N 115.21 -0.495 . . . . 0.0 110.188 178.279 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.58 HG23 HG21 ' A' ' 157' ' ' ILE . 2.9 p -138.96 153.25 24.78 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.206 0 C-N-CA 125.604 1.561 . . . . 0.0 107.684 178.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 25.1 m120 -125.93 150.39 48.01 Favored 'General case' 0 C--O 1.233 0.235 0 C-N-CA 125.222 1.409 . . . . 0.0 108.379 177.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 35.8 ptt85 -74.37 162.07 29.23 Favored 'General case' 0 CA--C 1.534 0.359 0 N-CA-C 110.373 -0.232 . . . . 0.0 110.373 176.268 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 49.9 mt-10 61.69 55.0 2.81 Favored 'General case' 0 CA--C 1.531 0.215 0 C-N-CA 126.262 1.825 . . . . 0.0 111.881 178.305 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . 0.461 ' CB ' HD13 ' A' ' 157' ' ' ILE . 33.2 mm-40 -146.64 155.78 42.7 Favored 'General case' 0 CA--C 1.537 0.455 0 CA-C-O 117.935 -1.031 . . . . 0.0 109.91 179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 23.5 tt0 -103.79 -70.16 0.78 Allowed 'General case' 0 CA--C 1.512 -0.508 0 CA-C-N 119.862 1.21 . . . . 0.0 111.188 176.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 23.0 m-20 -50.12 5.52 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.582 0 C-N-CA 130.4 3.48 . . . . 0.0 118.047 -172.048 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.58 HG21 HG23 ' A' ' 150' ' ' VAL . 1.7 mp -76.86 -32.04 19.69 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.602 0 C-N-CA 129.785 3.234 . . . . 0.0 106.262 173.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 11.3 p -134.58 145.39 32.72 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.688 0 C-N-CA 127.128 2.171 . . . . 0.0 106.59 175.449 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 4.6 mmpt? -132.42 125.92 31.88 Favored 'General case' 0 N--CA 1.451 -0.402 0 N-CA-C 108.296 -1.001 . . . . 0.0 108.296 178.164 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.689 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -78.88 125.93 38.57 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 N-CA-C 104.039 -2.578 . . . . 0.0 104.039 172.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 49.6 mt-10 -138.44 163.64 31.41 Favored 'General case' 0 CA--C 1.53 0.19 0 C-N-CA 124.45 1.1 . . . . 0.0 109.502 -178.814 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 65.6 mttm . . . . . 0 C--O 1.231 0.129 0 N-CA-C 107.806 -1.183 . . . . 0.0 107.806 175.357 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 76.5 mtm . . . . . 0 N--CA 1.452 -0.333 0 CA-C-O 120.556 0.217 . . . . 0.0 110.778 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . 0.447 ' O ' HG23 ' A' ' 2' ' ' ILE . 10.6 tp -74.57 72.94 0.34 Allowed 'Isoleucine or valine' 0 CA--C 1.535 0.383 0 CA-C-O 121.474 0.654 . . . . 0.0 110.388 -178.448 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -70.68 66.72 0.35 Allowed 'General case' 0 CA--C 1.536 0.416 0 C-N-CA 124.669 1.187 . . . . 0.0 111.322 -179.334 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -146.84 171.08 6.78 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 128.047 2.539 . . . . 0.0 105.748 179.459 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 75.0 Cg_exo -52.06 117.74 3.87 Favored 'Trans proline' 0 N--CA 1.457 -0.63 0 C-N-CA 122.251 1.967 . . . . 0.0 110.239 178.33 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 82.3 mt -77.67 63.93 2.86 Favored 'General case' 0 N--CA 1.454 -0.245 0 C-N-CA 123.633 0.773 . . . . 0.0 110.634 -175.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 35.9 mt-30 66.86 -63.14 0.28 Allowed 'General case' 0 CA--C 1.535 0.388 0 C-N-CA 126.651 1.98 . . . . 0.0 110.965 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -143.87 127.39 16.96 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 125.436 1.494 . . . . 0.0 107.093 174.835 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 72.1 mm-40 -76.15 68.91 2.64 Favored 'General case' 0 CA--C 1.531 0.221 0 C-N-CA 122.905 0.482 . . . . 0.0 110.025 -179.656 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 0.0 OUTLIER -72.1 72.49 0.19 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.424 0 C-N-CA 124.795 1.238 . . . . 0.0 108.66 178.506 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 78.27 -58.01 4.04 Favored Glycine 0 CA--C 1.527 0.838 0 O-C-N 121.024 -1.047 . . . . 0.0 111.047 -178.983 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER 57.41 83.09 0.11 Allowed 'General case' 0 CA--C 1.543 0.684 0 C-N-CA 126.01 1.724 . . . . 0.0 112.241 177.427 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 40.3 mt-10 -150.78 170.19 19.85 Favored 'General case' 0 CA--C 1.537 0.455 0 C-N-CA 126.787 2.035 . . . . 0.0 109.067 179.681 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.442 14.9 p 57.2 -125.07 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.583 0 N-CA-C 116.692 2.108 . . . . 0.0 116.692 173.874 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -77.97 135.33 37.79 Favored 'General case' 0 C--N 1.329 -0.308 0 C-N-CA 125.28 1.432 . . . . 0.0 114.32 -168.275 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 5.7 m -83.05 98.15 4.88 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.585 0 C-N-CA 123.95 0.9 . . . . 0.0 111.128 175.533 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 34.7 t -36.07 121.18 0.71 Allowed Pre-proline 0 CA--C 1.547 0.84 0 C-N-CA 126.686 1.994 . . . . 0.0 111.163 174.918 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 45.5 Cg_endo -76.2 -38.95 0.95 Allowed 'Trans proline' 0 N--CA 1.455 -0.747 0 C-N-CA 122.803 2.335 . . . . 0.0 117.773 -173.021 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.13 146.57 27.88 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.541 0 CA-C-N 120.245 1.384 . . . . 0.0 110.395 -175.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 89.8 m -78.83 135.44 37.05 Favored 'General case' 0 C--O 1.238 0.46 0 N-CA-C 106.505 -1.665 . . . . 0.0 106.505 173.224 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.18 -167.97 41.01 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 110.058 -1.217 . . . . 0.0 110.058 -178.645 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 10.6 tp10 -96.17 135.09 38.45 Favored 'General case' 0 N--CA 1.456 -0.162 0 N-CA-C 107.161 -1.422 . . . . 0.0 107.161 176.57 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 14.9 tt -97.19 143.07 13.14 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.213 0 C-N-CA 123.01 0.524 . . . . 0.0 109.994 -179.256 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 44.3 m-70 -145.29 156.25 53.97 Favored Pre-proline 0 N--CA 1.452 -0.345 0 N-CA-C 107.032 -1.47 . . . . 0.0 107.032 178.875 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 33.1 Cg_endo -62.54 155.33 58.97 Favored 'Trans proline' 0 N--CA 1.45 -1.062 0 N-CA-C 107.097 -1.924 . . . . 0.0 107.097 171.311 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.4 tt -62.65 -34.36 64.86 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.091 0 CA-C-N 114.435 -1.257 . . . . 0.0 110.468 -178.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 7.9 m -71.03 74.05 0.63 Allowed 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 124.685 1.194 . . . . 0.0 109.01 178.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 19.7 t70 -179.64 -34.58 0.01 OUTLIER 'General case' 0 CA--C 1.534 0.343 0 C-N-CA 127.994 2.518 . . . . 0.0 108.992 -174.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.423 ' HA ' ' HD3' ' A' ' 30' ' ' PRO . 91.0 t -58.47 127.66 81.84 Favored Pre-proline 0 CA--C 1.539 0.542 0 CA-C-O 117.63 -1.176 . . . . 0.0 111.025 -178.962 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.423 ' HD3' ' HA ' ' A' ' 29' ' ' VAL . 71.2 Cg_exo -57.57 59.68 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.191 1 C-N-CA 126.381 4.72 . . . . 0.0 115.778 176.407 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 3.6 t70 -171.43 119.65 0.47 Allowed 'General case' 0 CA--C 1.531 0.223 0 C-N-CA 125.953 1.701 . . . . 0.0 107.707 178.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 6.8 pm0 -54.48 -44.8 72.94 Favored 'General case' 0 CA--C 1.534 0.331 0 C-N-CA 124.429 1.092 . . . . 0.0 113.817 -177.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 40.7 t -56.49 -56.84 11.57 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.114 0 N-CA-C 109.7 -0.482 . . . . 0.0 109.7 -178.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 4.4 m-30 -62.64 -52.85 61.72 Favored 'General case' 0 N--CA 1.454 -0.266 0 N-CA-C 109.212 -0.662 . . . . 0.0 109.212 -179.888 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 12.3 t -50.83 -42.36 58.45 Favored 'General case' 0 CA--C 1.531 0.246 0 C-N-CA 123.951 0.9 . . . . 0.0 113.394 -177.773 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -89.42 11.59 69.39 Favored Glycine 0 N--CA 1.446 -0.634 0 CA-C-O 118.198 -1.334 . . . . 0.0 112.022 -178.528 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 58.5 mttm 72.35 -36.33 0.35 Allowed 'General case' 0 CA--C 1.539 0.552 0 CA-C-N 119.564 1.682 . . . . 0.0 113.242 -179.047 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.0 OUTLIER 28.68 -78.77 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 130.398 3.479 . . . . 0.0 116.226 179.589 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 24.5 ttp -83.17 -7.3 59.64 Favored 'General case' 0 CA--C 1.536 0.415 0 N-CA-C 114.026 1.121 . . . . 0.0 114.026 -174.498 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -175.63 -138.19 2.75 Favored Glycine 0 C--N 1.336 0.536 0 N-CA-C 110.075 -1.21 . . . . 0.0 110.075 -179.161 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 38.9 t0 -140.11 158.7 43.63 Favored 'General case' 0 CA--C 1.516 -0.357 0 N-CA-C 105.282 -2.118 . . . . 0.0 105.282 172.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -177.77 -168.75 37.83 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 119.937 -1.125 . . . . 0.0 113.334 -176.213 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 28.7 p90 -141.68 156.83 45.61 Favored 'General case' 0 N--CA 1.453 -0.318 0 C-N-CA 124.635 1.174 . . . . 0.0 109.448 179.072 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -104.82 127.09 52.51 Favored 'General case' 0 CA--C 1.51 -0.587 0 C-N-CA 124.282 1.033 . . . . 0.0 109.876 179.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 28.4 mm -107.84 128.53 63.04 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.859 0 N-CA-C 104.611 -2.366 . . . . 0.0 104.611 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 4.7 tt -96.97 102.97 13.31 Favored Pre-proline 0 N--CA 1.449 -0.513 0 N-CA-C 100.94 -3.726 . . . . 0.0 100.94 172.751 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -63.37 157.16 51.88 Favored 'Trans proline' 0 C--N 1.347 0.466 0 C-N-CA 123.951 3.101 . . . . 0.0 116.585 -169.377 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.4 p -138.84 -51.13 0.55 Allowed 'General case' 0 CA--C 1.534 0.336 0 C-N-CA 124.856 1.263 . . . . 0.0 109.528 173.502 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 27.9 mt-10 -80.14 130.67 35.41 Favored 'General case' 0 C--N 1.342 0.263 0 O-C-N 121.926 -0.484 . . . . 0.0 110.455 176.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -66.42 -24.35 72.24 Favored Glycine 0 CA--C 1.528 0.876 0 N-CA-C 110.824 -0.911 . . . . 0.0 110.824 174.542 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.404 ' N ' HD12 ' A' ' 51' ' ' ILE . 2.5 mp -78.2 108.52 11.68 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.485 0 C-N-CA 124.585 1.154 . . . . 0.0 107.923 -179.246 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 67.5 t -108.22 116.65 52.01 Favored 'Isoleucine or valine' 0 C--O 1.234 0.261 0 C-N-CA 125.212 1.405 . . . . 0.0 108.14 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 17.5 m -93.41 155.68 3.13 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.147 0 N-CA-C 108.097 -1.075 . . . . 0.0 108.097 174.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 47.1 m -73.17 139.94 79.6 Favored Pre-proline 0 N--CA 1.448 -0.574 0 CA-C-O 118.6 -0.714 . . . . 0.0 111.144 179.531 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -64.17 -35.9 50.01 Favored 'Trans proline' 0 CA--C 1.537 0.65 0 N-CA-C 107.609 -1.727 . . . . 0.0 107.609 171.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.6 p -175.98 150.13 0.33 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.495 0 C-N-CA 129.798 3.239 . . . . 0.0 103.68 175.346 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.446 ' CZ ' ' HB3' ' A' ' 110' ' ' GLN . 43.1 mtm180 -112.14 -75.93 0.6 Allowed 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 107.737 -1.209 . . . . 0.0 107.737 178.791 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 76.19 -68.38 2.35 Favored Glycine 0 CA--C 1.523 0.584 0 N-CA-C 108.126 -1.99 . . . . 0.0 108.126 -179.438 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -155.49 128.32 8.03 Favored 'General case' 0 N--CA 1.442 -0.873 0 N-CA-C 104.228 -2.508 . . . . 0.0 104.228 175.479 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 49.1 mm -61.13 130.47 25.2 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.256 0 N-CA-C 105.656 -1.979 . . . . 0.0 105.656 175.915 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 7.3 tt -77.45 -51.96 9.91 Favored 'General case' 0 CA--C 1.519 -0.236 0 N-CA-C 104.601 -2.37 . . . . 0.0 104.601 178.361 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 50.9 t30 179.62 165.5 1.1 Allowed 'General case' 0 CA--C 1.527 0.081 0 N-CA-C 107.257 -1.386 . . . . 0.0 107.257 177.237 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.462 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 2.7 m -152.35 129.09 2.0 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.192 0 C-N-CA 126.239 1.816 . . . . 0.0 106.168 174.512 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 40.2 m-85 -47.49 146.47 3.46 Favored Pre-proline 0 CA--C 1.539 0.538 0 CA-C-O 118.744 -0.646 . . . . 0.0 111.092 178.829 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.0 Cg_exo -50.0 -33.74 35.44 Favored 'Trans proline' 0 CA--C 1.534 0.525 0 C-N-CA 123.534 2.823 . . . . 0.0 113.796 176.6 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 37.0 p -77.67 -7.98 57.24 Favored 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 124.574 1.15 . . . . 0.0 111.993 -179.306 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER 68.38 13.4 9.0 Favored 'General case' 0 N--CA 1.448 -0.531 0 C-N-CA 126.205 1.802 . . . . 0.0 113.641 178.366 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.445 ' ND1' ' N ' ' A' ' 89' ' ' VAL . 0.0 OUTLIER -77.91 -23.62 48.61 Favored 'General case' 0 C--O 1.22 -0.468 0 CA-C-N 119.358 0.981 . . . . 0.0 111.626 -179.333 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -167.12 -173.22 2.25 Favored 'General case' 0 C--O 1.225 -0.22 0 CA-C-N 120.12 1.327 . . . . 0.0 110.777 -179.758 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.462 ' HB ' ' HA ' ' A' ' 63' ' ' VAL 1.06 1.9 mt 130.97 -139.54 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.192 1 C-N-CA 136.95 6.1 . . . . 0.0 110.372 176.382 . . . . . . . . 4 3 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -157.04 170.13 34.28 Favored Glycine 0 CA--C 1.531 1.061 0 N-CA-C 118.229 2.052 . . . . 0.0 118.229 -175.73 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 18.1 mt -124.03 174.35 7.67 Favored 'General case' 0 N--CA 1.453 -0.29 0 C-N-CA 128.199 2.6 . . . . 0.0 109.085 -177.663 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 17.3 mt-30 -126.28 -165.42 1.44 Allowed 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 178.098 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 60.3 p -166.11 154.52 10.87 Favored 'General case' 0 N--CA 1.44 -0.957 0 C-N-CA 125.611 1.564 . . . . 0.0 107.39 176.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 26.0 t70 -59.35 -34.79 72.81 Favored 'General case' 0 C--N 1.327 -0.381 0 C-N-CA 124.918 1.287 . . . . 0.0 108.717 175.921 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -74.45 10.4 8.47 Favored Glycine 0 CA--C 1.532 1.113 0 C-N-CA 123.716 0.674 . . . . 0.0 112.279 176.174 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 82.43 -41.18 2.79 Favored Glycine 0 C--N 1.339 0.725 0 CA-C-N 119.538 1.669 . . . . 0.0 112.813 177.396 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 99.1 mtt180 -42.34 103.98 0.03 OUTLIER 'General case' 0 CA--C 1.533 0.301 0 C-N-CA 125.341 1.457 . . . . 0.0 110.563 179.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 3.6 tm-20 -92.85 131.58 37.76 Favored 'General case' 0 N--CA 1.44 -0.934 0 C-N-CA 127.642 2.377 . . . . 0.0 105.605 -179.477 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 34.1 mt -123.04 119.62 58.28 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.354 0 O-C-N 123.436 0.46 . . . . 0.0 112.056 -173.315 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 6.0 tp -89.09 139.63 30.27 Favored 'General case' 0 N--CA 1.447 -0.589 0 N-CA-C 106.286 -1.746 . . . . 0.0 106.286 171.529 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 72.8 mt -130.33 132.49 64.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.346 0 N-CA-C 106.65 -1.611 . . . . 0.0 106.65 178.675 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 23.2 t-80 -123.75 84.47 2.28 Favored 'General case' 0 C--O 1.223 -0.298 0 O-C-N 123.526 0.517 . . . . 0.0 111.77 179.368 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.9 OUTLIER -58.52 104.75 0.24 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.236 0.614 . . . . 0.0 111.932 179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 63.76 -177.93 7.64 Favored Glycine 0 CA--C 1.531 1.066 0 CA-C-O 122.092 0.829 . . . . 0.0 112.323 179.282 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.9 mm -123.92 146.54 29.23 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.213 0 N-CA-C 104.366 -2.457 . . . . 0.0 104.366 174.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 37.2 t70 50.77 32.29 6.94 Favored 'General case' 0 CA--C 1.543 0.702 0 CA-C-O 121.91 0.862 . . . . 0.0 111.295 -178.186 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 61.8 m -97.85 -25.07 15.16 Favored 'General case' 0 CA--C 1.537 0.445 0 C-N-CA 126.803 2.041 . . . . 0.0 107.289 -177.846 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.445 ' N ' ' ND1' ' A' ' 68' ' ' HIS . 4.0 p -53.6 -43.71 55.06 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.406 0 C-N-CA 126.258 1.823 . . . . 0.0 107.634 170.784 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -58.73 -26.2 63.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 126.801 2.04 . . . . 0.0 111.898 176.13 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -73.14 -11.21 60.45 Favored 'General case' 0 CA--C 1.541 0.616 0 C-N-CA 125.892 1.677 . . . . 0.0 109.608 177.149 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 15.4 mtpp 51.55 29.66 5.69 Favored 'General case' 0 C--N 1.342 0.244 0 C-N-CA 126.325 1.85 . . . . 0.0 112.38 178.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 56.22 26.71 50.82 Favored Glycine 0 CA--C 1.533 1.199 0 CA-C-O 118.702 -1.054 . . . . 0.0 112.53 -178.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . 0.266 0.2 OUTLIER -59.15 -18.25 34.38 Favored 'General case' 0 N--CA 1.469 0.51 0 CA-C-N 119.851 1.826 . . . . 0.0 115.478 -176.776 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -122.3 21.17 7.8 Favored Glycine 0 CA--C 1.529 0.955 0 C-N-CA 126.11 1.814 . . . . 0.0 110.849 177.482 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.483 ' HA ' HG12 ' A' ' 115' ' ' VAL . 3.5 m-85 -106.05 85.2 2.17 Favored 'General case' 0 C--N 1.342 0.271 0 CA-C-N 118.089 0.944 . . . . 0.0 111.046 -177.378 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -76.66 101.11 5.61 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 104.326 -2.472 . . . . 0.0 104.326 175.057 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.8 t -87.01 157.82 19.37 Favored 'General case' 0 N--CA 1.457 -0.112 0 CA-C-O 121.183 0.516 . . . . 0.0 110.605 -179.22 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 15.8 m-85 -115.59 5.23 14.31 Favored 'General case' 0 N--CA 1.45 -0.455 0 C-N-CA 126.038 1.735 . . . . 0.0 112.224 -175.636 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 2.5 m -129.42 137.06 57.9 Favored 'Isoleucine or valine' 0 C--O 1.226 -0.147 0 N-CA-C 108.378 -0.971 . . . . 0.0 108.378 174.265 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 68.6 m -107.03 49.31 0.81 Allowed 'General case' 0 C--N 1.332 -0.159 0 N-CA-C 105.064 -2.199 . . . . 0.0 105.064 169.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.299 1.3 pm0 -2.68 70.98 0.0 OUTLIER 'General case' 0 N--CA 1.449 -0.519 1 C-N-CA 132.184 4.194 . . . . 0.0 116.644 -172.661 . . . . . . . . 3 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -85.99 46.44 3.62 Favored Glycine 0 CA--C 1.526 0.731 0 CA-C-N 112.845 -1.979 . . . . 0.0 109.882 176.571 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 7.8 p-10 3.36 52.08 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.21 0 C-N-CA 131.356 3.863 . . . . 0.0 120.897 -177.417 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -168.74 121.78 0.82 Allowed 'General case' 0 C--N 1.312 -1.022 1 C-N-CA 133.475 4.71 . . . . 0.0 107.051 176.553 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -167.52 136.72 0.6 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.446 0 CA-C-N 118.784 0.72 . . . . 0.0 111.073 -172.332 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 18.2 mt-10 -78.74 149.99 75.11 Favored Pre-proline 0 CA--C 1.545 0.754 0 CA-C-O 118.146 -0.93 . . . . 0.0 109.853 178.819 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_exo -55.67 175.55 0.2 Allowed 'Trans proline' 0 CA--C 1.542 0.896 1 C-N-CA 125.696 4.264 . . . . 0.0 117.837 -174.396 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 51.85 -7.65 0.01 OUTLIER Glycine 0 C--N 1.344 0.985 0 C-N-CA 129.28 3.324 . . . . 0.0 119.238 175.316 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . 0.446 ' HB3' ' CZ ' ' A' ' 57' ' ' ARG . 25.0 tt0 -61.63 160.59 11.2 Favored 'General case' 0 N--CA 1.451 -0.391 0 CA-C-N 120.31 2.055 . . . . 0.0 110.128 178.981 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 26.9 ttmt -67.04 140.64 57.67 Favored 'General case' 0 N--CA 1.449 -0.485 0 C-N-CA 122.94 0.496 . . . . 0.0 109.76 177.126 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 94.5 mt -108.63 -37.39 5.93 Favored 'General case' 0 N--CA 1.464 0.249 0 C-N-CA 124.246 1.018 . . . . 0.0 110.088 176.547 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . 0.447 ' HB3' HG13 ' A' ' 115' ' ' VAL . 22.2 mt -143.23 146.99 34.14 Favored 'General case' 0 CA--C 1.537 0.461 0 C-N-CA 123.61 0.764 . . . . 0.0 110.208 -176.38 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 30.6 tt0 -132.94 68.49 1.5 Allowed 'General case' 0 N--CA 1.463 0.204 0 N-CA-C 102.813 -3.032 . . . . 0.0 102.813 171.52 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.483 HG12 ' HA ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -79.45 127.03 39.38 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.053 0 CA-C-N 109.053 -3.703 . . . . 0.0 110.621 -171.755 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.1 t0 -76.19 67.64 2.5 Favored 'General case' 0 CA--C 1.529 0.161 0 C-N-CA 124.008 0.923 . . . . 0.0 109.179 -179.62 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 90.0 mt -48.61 -39.37 23.69 Favored 'General case' 0 N--CA 1.456 -0.152 0 C-N-CA 123.651 0.78 . . . . 0.0 111.727 -178.395 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 33.3 t70 -54.04 -42.18 68.89 Favored 'General case' 0 CA--C 1.533 0.297 0 C-N-CA 123.113 0.565 . . . . 0.0 112.201 178.548 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -88.07 -33.29 18.35 Favored 'General case' 0 CA--C 1.528 0.127 0 C-N-CA 122.744 0.417 . . . . 0.0 111.39 179.955 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 79.5 t -63.31 -53.91 39.66 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.407 0 N-CA-C 109.304 -0.628 . . . . 0.0 109.304 178.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.372 17.8 pttp -40.45 -58.23 2.56 Favored Pre-proline 0 CA--C 1.541 0.611 0 N-CA-C 116.97 2.211 . . . . 0.0 116.97 -176.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_endo -58.53 -20.1 47.85 Favored 'Trans proline' 0 N--CA 1.456 -0.72 0 C-N-CA 122.436 2.091 . . . . 0.0 113.36 178.868 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 67.1 m-80 -100.03 8.26 44.11 Favored 'General case' 0 CA--C 1.532 0.269 0 CA-C-O 118.301 -0.857 . . . . 0.0 112.674 -177.67 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 33.3 m -133.9 147.67 65.12 Favored Pre-proline 0 CA--C 1.535 0.382 0 CA-C-N 119.986 1.266 . . . . 0.0 109.856 178.711 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -71.04 -36.55 7.29 Favored 'Trans proline' 0 N--CA 1.453 -0.863 0 C-N-CA 122.98 2.453 . . . . 0.0 111.622 -179.465 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 62.3 p -151.45 121.85 7.33 Favored 'General case' 0 N--CA 1.451 -0.398 0 N-CA-C 109.547 -0.538 . . . . 0.0 109.547 -177.532 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 12.0 tp -79.88 -2.95 45.88 Favored 'General case' 0 CA--C 1.539 0.55 0 C-N-CA 125.136 1.374 . . . . 0.0 111.904 179.705 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 18.6 mmt -44.88 117.92 1.47 Allowed 'General case' 0 C--N 1.342 0.258 0 C-N-CA 124.842 1.257 . . . . 0.0 110.465 179.652 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 64.6 m -117.7 107.47 44.46 Favored Pre-proline 0 N--CA 1.447 -0.581 0 C-N-CA 124.034 0.933 . . . . 0.0 108.692 -178.425 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -91.53 143.59 3.01 Favored 'Trans proline' 0 N--CA 1.441 -1.617 0 C-N-CA 123.039 2.492 . . . . 0.0 110.249 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 17.2 mm -113.9 116.82 53.72 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.046 -2.946 . . . . 0.0 103.046 174.034 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.5 t -121.48 123.61 69.99 Favored 'Isoleucine or valine' 0 CA--C 1.512 -0.489 0 C-N-CA 125.006 1.323 . . . . 0.0 108.632 -176.1 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -95.9 117.66 31.04 Favored 'General case' 0 N--CA 1.442 -0.854 0 N-CA-C 101.931 -3.359 . . . . 0.0 101.931 178.37 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 52.6 p -84.1 -73.91 0.4 Allowed 'General case' 0 C--O 1.23 0.045 0 CA-C-O 121.467 0.651 . . . . 0.0 111.563 -171.233 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.0 p-10 -73.08 57.61 0.47 Allowed 'General case' 0 CA--C 1.536 0.439 0 C-N-CA 125.824 1.65 . . . . 0.0 111.38 179.811 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 20.5 mt -72.01 66.72 0.6 Allowed 'General case' 0 CA--C 1.538 0.49 0 C-N-CA 125.918 1.687 . . . . 0.0 109.007 177.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.91 47.68 0.01 OUTLIER 'General case' 0 N--CA 1.467 0.389 0 C-N-CA 129.179 2.992 . . . . 0.0 112.488 -176.722 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 22.3 tt0 29.34 55.48 0.12 Allowed 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 127.81 2.444 . . . . 0.0 113.34 -174.809 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.43 -5.29 0.05 OUTLIER Glycine 0 CA--C 1.526 0.738 0 CA-C-O 118.896 -0.946 . . . . 0.0 114.332 179.045 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.654 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 21.0 mt-10 -83.83 139.87 32.39 Favored 'General case' 0 CA--C 1.53 0.188 0 CA-C-N 119.185 1.492 . . . . 0.0 109.83 179.781 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 45.4 p -110.91 136.58 49.72 Favored 'General case' 0 N--CA 1.455 -0.223 0 N-CA-C 107.528 -1.286 . . . . 0.0 107.528 176.898 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 7.9 t -91.28 101.93 12.98 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.463 0 N-CA-C 107.482 -1.303 . . . . 0.0 107.482 -178.402 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 20.3 m -100.01 105.83 17.54 Favored 'General case' 0 N--CA 1.455 -0.215 0 C-N-CA 123.96 0.904 . . . . 0.0 110.493 -176.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 20.1 pt -67.05 139.71 20.61 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.277 0 O-C-N 121.799 -0.563 . . . . 0.0 110.252 177.044 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 11.6 mmpt? -101.83 -41.42 6.52 Favored 'General case' 0 C--O 1.233 0.228 0 C-N-CA 125.155 1.382 . . . . 0.0 108.864 178.287 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -59.39 86.9 0.01 OUTLIER 'General case' 0 N--CA 1.451 -0.421 0 C-N-CA 124.208 1.003 . . . . 0.0 112.783 -176.863 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 19.5 m -80.73 54.68 2.18 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 108.731 -0.84 . . . . 0.0 108.731 177.779 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.49 -178.65 37.31 Favored Glycine 0 CA--C 1.529 0.932 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -177.074 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 35.4 t -52.07 146.8 8.22 Favored 'General case' 0 CA--C 1.533 0.312 0 C-N-CA 123.567 0.747 . . . . 0.0 112.416 -178.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 29.9 m -115.47 159.55 15.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 C-N-CA 125.207 1.403 . . . . 0.0 109.827 -179.862 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 18.0 m-80 -120.8 157.3 30.05 Favored 'General case' 0 C--O 1.235 0.311 0 C-N-CA 124.75 1.22 . . . . 0.0 108.321 175.635 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.47 158.86 28.45 Favored 'General case' 0 CA--C 1.537 0.458 0 CA-C-O 121.473 0.654 . . . . 0.0 110.738 177.086 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 64.58 -10.11 0.16 Allowed 'General case' 0 CA--C 1.535 0.404 0 C-N-CA 126.137 1.775 . . . . 0.0 114.868 179.927 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 0.3 OUTLIER -61.67 149.81 38.4 Favored 'General case' 0 N--CA 1.455 -0.186 0 CA-C-N 119.933 1.242 . . . . 0.0 109.571 -179.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 2.5 mt-10 -120.54 158.14 27.94 Favored 'General case' 0 N--CA 1.446 -0.657 0 N-CA-C 107.835 -1.172 . . . . 0.0 107.835 177.214 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 29.9 t0 63.89 26.56 14.29 Favored 'General case' 0 CA--C 1.536 0.421 0 C-N-CA 128.074 2.549 . . . . 0.0 112.009 -174.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 1.5 mp -82.87 -22.75 8.77 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 C-N-CA 123.825 0.85 . . . . 0.0 108.825 176.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 14.3 p -142.36 149.66 19.15 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.691 0 C-N-CA 127.897 2.479 . . . . 0.0 106.477 175.662 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 54.4 mttm -131.81 127.47 36.7 Favored 'General case' 0 N--CA 1.452 -0.349 0 N-CA-C 107.573 -1.269 . . . . 0.0 107.573 174.741 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.654 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.54 122.0 33.9 Favored 'Isoleucine or valine' 0 N--CA 1.44 -0.946 0 N-CA-C 105.085 -2.191 . . . . 0.0 105.085 170.797 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 69.0 mt-10 -105.52 176.11 5.27 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 106.544 -1.651 . . . . 0.0 106.544 174.553 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 16.0 tppt? . . . . . 0 CA--C 1.532 0.254 0 O-C-N 121.292 -0.88 . . . . 0.0 110.956 -179.358 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 88.3 mtp . . . . . 0 N--CA 1.45 -0.426 0 N-CA-C 108.349 -0.982 . . . . 0.0 108.349 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 16.3 pt -64.68 145.23 14.06 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.372 0 N-CA-C 109.498 -0.556 . . . . 0.0 109.498 179.247 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.19 67.82 1.4 Allowed 'General case' 0 CA--C 1.532 0.279 0 C-N-CA 123.339 0.655 . . . . 0.0 111.458 -178.081 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 45.5 mt-10 -52.62 113.1 4.05 Favored Pre-proline 0 CA--C 1.539 0.554 0 C-N-CA 124.255 1.022 . . . . 0.0 111.062 179.869 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 62.7 Cg_endo -79.75 169.52 18.07 Favored 'Trans proline' 0 N--CA 1.45 -1.035 0 C-N-CA 122.528 2.152 . . . . 0.0 109.547 179.158 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 3.1 mm? -75.78 67.66 2.24 Favored 'General case' 0 CA--C 1.533 0.317 0 C-N-CA 123.499 0.72 . . . . 0.0 109.306 179.097 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 24.1 mt-30 -131.61 161.09 33.51 Favored 'General case' 0 CA--C 1.532 0.256 0 C-N-CA 125.438 1.495 . . . . 0.0 107.862 177.829 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 50.1 t-20 -145.72 -158.22 0.88 Allowed 'General case' 0 CA--C 1.536 0.434 0 N-CA-C 106.336 -1.727 . . . . 0.0 106.336 -178.547 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 14.4 mm-40 -76.47 63.25 1.99 Allowed 'General case' 0 CA--C 1.534 0.344 0 CA-C-N 120.057 1.299 . . . . 0.0 109.785 177.35 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.0 pp -140.46 -143.67 0.04 OUTLIER 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 C-N-CA 126.886 2.074 . . . . 0.0 106.5 179.576 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 155.62 -131.39 3.05 Favored Glycine 0 N--CA 1.443 -0.842 0 N-CA-C 106.374 -2.691 . . . . 0.0 106.374 178.475 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 63.7 tt0 49.37 60.93 3.42 Favored 'General case' 0 CA--C 1.535 0.371 0 C-N-CA 124.313 1.045 . . . . 0.0 110.347 178.496 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 1.4 pm0 -81.89 -158.96 0.26 Allowed 'General case' 0 CA--C 1.535 0.37 0 N-CA-C 105.818 -1.919 . . . . 0.0 105.818 173.878 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.7 t -80.77 47.19 0.06 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.578 0 O-C-N 120.29 -1.506 . . . . 0.0 109.763 178.399 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -83.32 85.06 7.28 Favored 'General case' 0 C--N 1.33 -0.281 0 N-CA-C 108.31 -0.996 . . . . 0.0 108.31 -179.389 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 9.9 m -90.75 84.81 2.26 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.403 0 C-N-CA 122.598 0.359 . . . . 0.0 110.894 -179.288 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 16.4 m -19.1 115.52 0.09 OUTLIER Pre-proline 0 CA--C 1.546 0.789 0 C-N-CA 127.016 2.127 . . . . 0.0 113.667 179.537 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 62.0 Cg_endo -75.02 -26.01 11.28 Favored 'Trans proline' 0 N--CA 1.458 -0.602 0 C-N-CA 122.718 2.278 . . . . 0.0 117.535 -170.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -138.25 158.08 31.82 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.276 0 CA-C-N 119.886 1.221 . . . . 0.0 109.445 -177.834 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.9 m -94.61 128.6 41.36 Favored 'General case' 0 C--O 1.238 0.464 0 N-CA-C 106.758 -1.571 . . . . 0.0 106.758 174.439 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 172.67 -161.68 33.16 Favored Glycine 0 CA--C 1.526 0.761 0 C-N-CA 121.585 -0.341 . . . . 0.0 112.654 -178.681 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 41.3 tt0 -95.24 118.46 32.04 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.846 1.258 . . . . 0.0 108.551 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -76.94 136.04 25.37 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.448 0 C-N-CA 123.455 0.702 . . . . 0.0 109.427 -179.71 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.1 m-70 -135.13 142.9 43.61 Favored Pre-proline 0 C--O 1.236 0.345 0 C-N-CA 126.486 1.914 . . . . 0.0 107.048 177.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_endo -64.61 160.06 41.88 Favored 'Trans proline' 0 N--CA 1.448 -1.15 0 C-N-CA 121.446 1.431 . . . . 0.0 108.476 176.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.3 tp -61.55 -39.88 84.57 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.521 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.268 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 57.1 m -76.48 74.1 3.22 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.124 0.97 . . . . 0.0 109.344 177.163 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 22.6 t70 -178.54 -37.34 0.01 OUTLIER 'General case' 0 CA--C 1.53 0.188 0 C-N-CA 127.601 2.36 . . . . 0.0 108.986 -179.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 97.0 t -52.0 115.45 6.71 Favored Pre-proline 0 CA--C 1.539 0.548 0 CA-C-O 117.507 -1.235 . . . . 0.0 111.905 -178.835 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 87.9 Cg_exo -58.06 64.37 0.05 OUTLIER 'Trans proline' 0 CA--C 1.548 1.212 1 C-N-CA 125.515 4.144 . . . . 0.0 115.551 177.046 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 1.6 t70 -133.58 -42.63 0.84 Allowed 'General case' 0 CA--C 1.537 0.481 0 N-CA-C 114.535 1.309 . . . . 0.0 114.535 -177.467 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 14.5 mt-30 105.73 -65.08 0.0 OUTLIER 'General case' 0 N--CA 1.471 0.581 0 C-N-CA 129.695 3.198 . . . . 0.0 110.606 -178.48 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 92.3 t -52.67 -62.13 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.465 0.284 0 C-N-CA 124.004 0.922 . . . . 0.0 108.722 179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 9.2 m-85 -59.99 -42.79 94.98 Favored 'General case' 0 N--CA 1.455 -0.208 0 CA-C-O 120.909 0.385 . . . . 0.0 110.123 179.321 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -51.57 -45.51 63.12 Favored 'General case' 0 N--CA 1.451 -0.395 0 C-N-CA 124.012 0.925 . . . . 0.0 112.81 -179.533 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -92.99 17.57 57.91 Favored Glycine 0 N--CA 1.446 -0.66 0 CA-C-O 118.274 -1.292 . . . . 0.0 110.5 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 60.5 mttp 73.79 -47.77 0.66 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 126.079 1.752 . . . . 0.0 111.359 -178.17 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 19.6 ttt 35.49 -67.17 0.0 OUTLIER 'General case' 0 CA--C 1.541 0.598 0 C-N-CA 130.602 3.561 . . . . 0.0 117.077 178.74 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 33.2 ttm -87.52 -23.6 24.34 Favored 'General case' 0 CA--C 1.535 0.386 0 C-N-CA 124.385 1.074 . . . . 0.0 112.435 -178.272 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 174.67 -148.1 9.53 Favored Glycine 0 C--O 1.224 -0.505 0 N-CA-C 109.188 -1.565 . . . . 0.0 109.188 -177.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 16.2 t0 -142.47 159.75 41.61 Favored 'General case' 0 CA--C 1.517 -0.313 0 CA-C-N 118.349 1.074 . . . . 0.0 108.582 177.643 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 170.3 -127.29 1.45 Allowed Glycine 0 N--CA 1.444 -0.829 0 N-CA-C 106.773 -2.531 . . . . 0.0 106.773 -179.069 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 1.8 p90 -177.01 -179.28 0.9 Allowed 'General case' 0 CA--C 1.527 0.093 0 CA-C-N 119.055 1.427 . . . . 0.0 110.763 -177.212 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -127.67 135.86 50.79 Favored 'General case' 0 C--O 1.225 -0.203 0 C-N-CA 123.734 0.814 . . . . 0.0 109.447 176.201 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -109.49 98.55 7.18 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.17 0 N-CA-C 103.316 -2.846 . . . . 0.0 103.316 172.812 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 8.5 tt -58.81 113.6 7.11 Favored Pre-proline 0 CA--C 1.532 0.258 0 N-CA-C 103.08 -2.933 . . . . 0.0 103.08 175.708 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 97.1 Cg_endo -78.07 149.01 25.12 Favored 'Trans proline' 0 N--CA 1.451 -0.977 0 C-N-CA 122.916 2.411 . . . . 0.0 115.005 -167.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.0 p -115.74 -47.88 2.78 Favored 'General case' 0 CA--C 1.531 0.227 0 C-N-CA 125.217 1.407 . . . . 0.0 107.594 173.98 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 16.8 mt-10 -76.76 122.39 24.68 Favored 'General case' 0 N--CA 1.453 -0.28 0 N-CA-C 109.82 -0.437 . . . . 0.0 109.82 176.255 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.11 44.21 2.79 Favored Glycine 0 CA--C 1.531 1.082 0 N-CA-C 109.759 -1.337 . . . . 0.0 109.759 173.239 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 46.1 mt -144.33 126.37 10.34 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 N-CA-C 104.446 -2.427 . . . . 0.0 104.446 -178.999 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 66.3 t -126.66 126.71 69.26 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 C-N-CA 125.019 1.328 . . . . 0.0 109.033 -173.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 12.7 m -109.78 157.59 10.2 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.313 0 C-N-CA 124.833 1.253 . . . . 0.0 110.792 178.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 50.6 m -62.87 133.02 95.07 Favored Pre-proline 0 CA--C 1.539 0.541 0 O-C-N 121.873 -0.517 . . . . 0.0 111.077 -179.796 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 72.4 Cg_endo -74.04 -13.89 23.67 Favored 'Trans proline' 0 N--CA 1.459 -0.558 0 C-N-CA 124.278 3.319 . . . . 0.0 116.531 -174.92 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 18.2 m -151.31 165.54 2.23 Favored 'Isoleucine or valine' 0 CA--C 1.518 -0.267 0 CA-C-N 119.441 1.018 . . . . 0.0 109.713 -175.879 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 11.0 ttt180 -76.12 125.54 29.34 Favored 'General case' 0 C--O 1.236 0.394 1 N-CA-C 99.122 -4.399 . . . . 0.0 99.122 166.768 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 179.82 171.95 43.31 Favored Glycine 0 N--CA 1.435 -1.425 0 C-N-CA 116.658 -2.687 . . . . 0.0 113.198 -168.235 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -87.64 126.24 34.84 Favored 'General case' 0 N--CA 1.439 -0.985 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 179.609 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 12.5 mm -67.58 116.9 8.0 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.268 0 N-CA-C 102.644 -3.095 . . . . 0.0 102.644 168.775 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 85.1 mt -78.53 -50.04 12.27 Favored 'General case' 0 CA--C 1.517 -0.314 0 N-CA-C 106.638 -1.616 . . . . 0.0 106.638 -179.181 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 32.6 t30 178.16 164.1 0.7 Allowed 'General case' 0 CA--C 1.53 0.204 0 C-N-CA 124.14 0.976 . . . . 0.0 108.372 178.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.4 m -137.74 116.73 14.52 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.446 0 C-N-CA 126.732 2.013 . . . . 0.0 106.079 175.856 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -46.73 154.03 0.73 Allowed Pre-proline 0 N--CA 1.469 0.524 0 N-CA-C 114.119 1.155 . . . . 0.0 114.119 -179.659 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -52.05 -33.29 52.44 Favored 'Trans proline' 0 N--CA 1.46 -0.498 0 C-N-CA 123.483 2.788 . . . . 0.0 113.212 176.492 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 6.8 p -78.09 -2.84 39.29 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 123.996 0.919 . . . . 0.0 111.631 -179.8 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 52.76 21.48 1.94 Allowed 'General case' 0 N--CA 1.45 -0.464 0 C-N-CA 127.244 2.218 . . . . 0.0 114.301 179.397 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 25.9 p-80 -89.31 -25.02 21.86 Favored 'General case' 0 N--CA 1.449 -0.502 0 CA-C-O 118.46 -0.781 . . . . 0.0 111.18 179.091 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -162.5 -172.62 3.22 Favored 'General case' 0 N--CA 1.451 -0.394 0 CA-C-N 118.566 0.621 . . . . 0.0 112.531 -172.919 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.716 27.6 mm 125.89 -127.68 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.478 1 C-N-CA 134.583 5.153 . . . . 0.0 107.177 -179.815 . . . . . . . . 3 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . 177.71 -172.83 45.54 Favored Glycine 0 CA--C 1.523 0.564 0 N-CA-C 118.354 2.101 . . . . 0.0 118.354 -179.798 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 4.0 mp -133.7 169.58 16.82 Favored 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 126.856 2.062 . . . . 0.0 109.42 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.0 OUTLIER -130.76 126.94 37.7 Favored 'General case' 0 N--CA 1.446 -0.64 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 171.018 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 54.2 p -68.18 172.78 5.34 Favored 'General case' 0 N--CA 1.427 -1.579 0 CA-C-O 123.774 1.749 . . . . 0.0 108.136 175.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 30.6 t70 -55.2 -37.75 67.51 Favored 'General case' 0 C--N 1.315 -0.915 0 CA-C-N 112.143 -2.299 . . . . 0.0 108.999 175.021 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -87.49 13.01 61.36 Favored Glycine 0 CA--C 1.534 1.239 0 C-N-CA 124.334 0.968 . . . . 0.0 112.589 177.441 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 75.55 14.73 81.76 Favored Glycine 0 CA--C 1.529 0.914 0 CA-C-N 118.287 1.044 . . . . 0.0 114.503 178.037 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.1 tpp85 -70.77 107.49 4.0 Favored 'General case' 0 C--N 1.339 0.152 0 N-CA-C 106.672 -1.603 . . . . 0.0 106.672 177.73 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -79.61 101.39 8.29 Favored 'General case' 0 N--CA 1.45 -0.45 0 C-N-CA 125.457 1.503 . . . . 0.0 108.434 -176.957 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 6.0 mt -96.81 103.85 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.697 0 C-N-CA 126.479 1.912 . . . . 0.0 109.92 -176.296 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.0 tt -79.18 135.59 36.85 Favored 'General case' 0 N--CA 1.448 -0.546 0 N-CA-C 105.055 -2.202 . . . . 0.0 105.055 171.116 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 8.3 mt -113.97 153.22 15.54 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 C-N-CA 125.179 1.392 . . . . 0.0 108.613 179.065 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -146.34 144.75 29.99 Favored 'General case' 0 N--CA 1.449 -0.477 0 N-CA-C 105.699 -1.963 . . . . 0.0 105.699 171.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 0.5 OUTLIER -127.98 91.36 3.26 Favored 'General case' 0 N--CA 1.445 -0.715 0 C-N-CA 125.377 1.471 . . . . 0.0 110.504 -179.833 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 76.27 154.63 5.43 Favored Glycine 0 CA--C 1.526 0.728 0 N-CA-C 110.42 -1.072 . . . . 0.0 110.42 -178.494 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 9.5 mt -98.33 135.28 33.68 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.303 0 N-CA-C 106.267 -1.753 . . . . 0.0 106.267 178.705 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 14.0 t70 70.25 18.11 6.94 Favored 'General case' 0 CA--C 1.54 0.573 0 C-N-CA 124.626 1.17 . . . . 0.0 112.818 -179.546 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 5.6 p -81.9 -32.03 31.15 Favored 'General case' 0 CA--C 1.518 -0.286 0 C-N-CA 124.872 1.269 . . . . 0.0 108.501 177.684 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 8.1 p -55.06 -44.67 75.3 Favored 'Isoleucine or valine' 0 N--CA 1.437 -1.088 0 C-N-CA 124.784 1.233 . . . . 0.0 108.143 172.575 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.4 m -61.34 -35.43 77.41 Favored 'General case' 0 N--CA 1.455 -0.214 0 C-N-CA 124.777 1.231 . . . . 0.0 109.813 176.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -79.99 9.43 5.44 Favored 'General case' 0 CA--C 1.546 0.798 0 C-N-CA 126.851 2.061 . . . . 0.0 110.915 176.734 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 46.6 mttp 47.27 35.2 3.6 Favored 'General case' 0 C--N 1.341 0.234 0 C-N-CA 127.067 2.147 . . . . 0.0 114.787 173.809 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.05 19.12 63.29 Favored Glycine 0 CA--C 1.534 1.22 0 C-N-CA 120.808 -0.711 . . . . 0.0 112.63 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.3 mt-10 -71.26 90.47 0.92 Allowed 'General case' 0 C--N 1.339 0.134 0 CA-C-N 119.064 1.432 . . . . 0.0 109.908 -178.902 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 128.21 -1.06 6.61 Favored Glycine 0 CA--C 1.532 1.102 0 C-N-CA 126.068 1.794 . . . . 0.0 111.928 -178.05 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.443 ' CD1' HG12 ' A' ' 115' ' ' VAL . 16.4 m-30 -100.42 111.57 23.84 Favored 'General case' 0 N--CA 1.454 -0.229 0 C-N-CA 124.723 1.209 . . . . 0.0 109.662 -179.003 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 9.6 m -104.28 113.49 27.08 Favored 'General case' 0 N--CA 1.455 -0.177 0 C-N-CA 124.779 1.232 . . . . 0.0 108.132 179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 12.7 p -81.43 144.94 31.05 Favored 'General case' 0 C--N 1.33 -0.248 0 CA-C-N 118.92 0.782 . . . . 0.0 111.292 179.625 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 28.9 m-85 -114.95 -41.98 3.28 Favored 'General case' 0 N--CA 1.452 -0.373 0 C-N-CA 125.186 1.394 . . . . 0.0 111.959 -178.369 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -70.94 130.19 34.9 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.387 0 N-CA-C 105.743 -1.947 . . . . 0.0 105.743 174.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 61.0 m -92.28 53.71 2.18 Favored 'General case' 0 C--N 1.328 -0.344 0 N-CA-C 104.934 -2.247 . . . . 0.0 104.934 172.001 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.365 1.2 pm0 16.35 62.89 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.551 0 C-N-CA 130.466 3.507 . . . . 0.0 113.01 -169.509 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -79.09 48.99 3.44 Favored Glycine 0 CA--C 1.524 0.629 0 CA-C-N 111.729 -2.487 . . . . 0.0 109.818 179.428 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.403 4.3 p30 2.66 -111.25 0.0 OUTLIER 'General case' 0 N--CA 1.435 -1.22 0 C-N-CA 129.627 3.171 . . . . 0.0 117.366 -176.107 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . 0.254 0.2 OUTLIER -35.92 118.29 0.5 Allowed 'General case' 0 C--N 1.315 -0.908 0 N-CA-C 121.599 3.926 . . . . 0.0 121.599 -169.726 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.268 27.6 m 36.89 70.39 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.448 -0.528 0 C-N-CA 128.421 2.688 . . . . 0.0 117.241 170.99 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -123.39 127.93 25.41 Favored Pre-proline 0 N--CA 1.45 -0.444 0 N-CA-C 107.452 -1.314 . . . . 0.0 107.452 170.018 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 44.9 Cg_endo -97.01 154.75 1.1 Allowed 'Trans proline' 0 N--CA 1.449 -1.141 0 C-N-CA 124.594 3.529 . . . . 0.0 110.401 -179.881 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 49.07 2.63 0.01 OUTLIER Glycine 0 CA--C 1.535 1.303 0 N-CA-C 118.362 2.105 . . . . 0.0 118.362 172.449 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 13.4 tt0 -60.69 136.49 58.08 Favored 'General case' 0 N--CA 1.449 -0.507 0 CA-C-N 119.948 1.874 . . . . 0.0 107.935 -179.478 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 36.9 ttmt -59.12 117.02 4.25 Favored 'General case' 0 N--CA 1.45 -0.441 0 N-CA-C 109.645 -0.502 . . . . 0.0 109.645 -178.745 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.0 mt -79.91 -47.53 14.92 Favored 'General case' 0 N--CA 1.448 -0.527 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 178.45 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.8 mp -149.97 166.0 30.97 Favored 'General case' 0 CA--C 1.541 0.632 0 N-CA-C 112.399 0.518 . . . . 0.0 112.399 -177.623 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 99.1 mt-10 -126.33 132.1 51.68 Favored 'General case' 0 CA--C 1.518 -0.262 1 N-CA-C 98.458 -4.645 . . . . 0.0 98.458 166.243 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.443 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -141.25 123.19 14.25 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.716 0 C-N-CA 120.848 -0.341 . . . . 0.0 110.846 -166.176 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 63.1 t0 -72.55 70.54 0.92 Allowed 'General case' 0 CA--C 1.531 0.212 0 C-N-CA 124.497 1.119 . . . . 0.0 110.772 -178.279 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 91.9 mt -50.37 -45.1 54.98 Favored 'General case' 0 N--CA 1.456 -0.164 0 C-N-CA 123.347 0.659 . . . . 0.0 110.432 178.721 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.1 t70 -50.71 -50.11 55.96 Favored 'General case' 0 CA--C 1.53 0.178 0 C-N-CA 124.362 1.065 . . . . 0.0 112.709 -178.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.87 -33.34 24.83 Favored 'General case' 0 CA--C 1.527 0.087 0 N-CA-C 111.771 0.285 . . . . 0.0 111.771 -178.819 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 54.2 t -65.28 -52.86 47.17 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.376 0 O-C-N 121.776 -0.578 . . . . 0.0 109.993 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.344 19.4 pttp -40.25 -57.31 2.94 Favored Pre-proline 0 CA--C 1.541 0.627 0 N-CA-C 117.413 2.375 . . . . 0.0 117.413 -177.066 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -57.09 -22.04 45.46 Favored 'Trans proline' 0 N--CA 1.455 -0.739 0 C-N-CA 122.526 2.15 . . . . 0.0 113.146 179.063 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.9 m-80 -94.11 4.97 53.14 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-O 118.08 -0.962 . . . . 0.0 112.683 -178.132 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 21.3 m -136.1 150.19 70.45 Favored Pre-proline 0 CA--C 1.532 0.27 0 CA-C-N 120.182 1.355 . . . . 0.0 111.992 -179.312 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 71.2 Cg_endo -71.17 -28.9 18.2 Favored 'Trans proline' 0 N--CA 1.452 -0.964 0 C-N-CA 122.891 2.394 . . . . 0.0 111.974 179.928 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 3.2 m -158.79 131.59 7.05 Favored 'General case' 0 CA--C 1.532 0.275 0 CA-C-N 118.54 0.609 . . . . 0.0 110.024 -179.006 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -90.4 21.44 3.88 Favored 'General case' 0 CA--C 1.538 0.503 0 C-N-CA 125.114 1.366 . . . . 0.0 112.055 -177.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 24.3 mmt -59.64 146.85 39.52 Favored 'General case' 0 N--CA 1.456 -0.162 0 O-C-N 121.348 -0.845 . . . . 0.0 110.933 -178.32 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 18.2 p -112.41 68.69 0.96 Allowed Pre-proline 0 CA--C 1.536 0.418 0 C-N-CA 124.558 1.143 . . . . 0.0 108.296 177.939 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 18.9 Cg_endo -62.45 92.83 0.13 Allowed 'Trans proline' 0 N--CA 1.454 -0.797 0 C-N-CA 122.236 1.957 . . . . 0.0 112.825 -175.083 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 3.2 mt -86.15 129.97 37.32 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 105.315 -2.105 . . . . 0.0 105.315 175.498 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 5.6 t -133.59 121.67 41.5 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.362 0 CA-C-O 121.798 0.809 . . . . 0.0 109.192 -179.311 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 3.3 m-85 -82.15 108.83 15.92 Favored 'General case' 0 N--CA 1.438 -1.064 0 N-CA-C 101.653 -3.462 . . . . 0.0 101.653 173.019 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 34.8 p -75.5 -63.55 1.26 Allowed 'General case' 0 N--CA 1.454 -0.264 0 CA-C-O 121.712 0.768 . . . . 0.0 109.75 -173.611 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 51.5 p30 -72.16 52.14 0.25 Allowed 'General case' 0 CA--C 1.534 0.356 0 C-N-CA 124.682 1.193 . . . . 0.0 113.951 -178.015 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 56.9 mt -78.96 49.11 0.89 Allowed 'General case' 0 CA--C 1.539 0.547 0 O-C-N 121.083 -1.011 . . . . 0.0 109.042 173.697 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 23.99 40.42 0.0 OUTLIER 'General case' 0 N--CA 1.467 0.418 0 C-N-CA 130.0 3.32 . . . . 0.0 115.042 -179.21 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 39.6 mt-10 38.85 45.31 0.93 Allowed 'General case' 0 N--CA 1.453 -0.279 0 C-N-CA 126.209 1.804 . . . . 0.0 112.604 -175.232 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . -175.69 -8.86 0.02 OUTLIER Glycine 0 CA--C 1.529 0.926 0 CA-C-O 119.062 -0.855 . . . . 0.0 113.997 -179.156 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.687 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 9.8 mm-40 -86.87 92.33 8.96 Favored 'General case' 0 C--N 1.34 0.179 0 CA-C-N 118.945 1.373 . . . . 0.0 108.299 179.82 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -77.37 132.44 38.55 Favored 'General case' 0 N--CA 1.451 -0.399 0 C-N-CA 123.248 0.619 . . . . 0.0 110.164 -177.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 1.9 t -86.15 91.4 3.29 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.326 0 C-N-CA 125.293 1.437 . . . . 0.0 109.782 -177.318 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 45.0 m -88.54 96.26 10.55 Favored 'General case' 0 N--CA 1.454 -0.227 0 N-CA-C 108.249 -1.019 . . . . 0.0 108.249 178.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 27.1 mt -65.76 131.8 31.48 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.338 0 N-CA-C 108.947 -0.761 . . . . 0.0 108.947 -179.651 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 10.3 mmpt? -102.47 -42.2 6.04 Favored 'General case' 0 C--O 1.232 0.181 0 C-N-CA 125.774 1.629 . . . . 0.0 110.801 -179.285 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -54.72 83.75 0.0 OUTLIER 'General case' 0 C--O 1.225 -0.186 0 C-N-CA 124.907 1.283 . . . . 0.0 112.799 -176.71 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 22.4 m -80.93 55.9 2.59 Favored 'General case' 0 N--CA 1.451 -0.397 0 C-N-CA 123.778 0.831 . . . . 0.0 109.418 179.563 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 161.68 -167.47 36.47 Favored Glycine 0 CA--C 1.528 0.898 0 N-CA-C 110.068 -1.213 . . . . 0.0 110.068 -178.051 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 41.6 t -60.16 152.72 23.78 Favored 'General case' 0 CA--C 1.534 0.347 0 C-N-CA 123.12 0.568 . . . . 0.0 110.831 179.447 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 55.2 t -123.49 148.81 27.35 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.174 0 C-N-CA 124.944 1.298 . . . . 0.0 107.739 178.238 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 13.1 m-80 -119.48 153.43 35.32 Favored 'General case' 0 C--O 1.234 0.261 0 C-N-CA 125.789 1.636 . . . . 0.0 110.111 -179.477 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 69.6 mtp180 -47.53 135.45 11.15 Favored 'General case' 0 CA--C 1.532 0.273 0 C-N-CA 123.838 0.855 . . . . 0.0 110.628 177.696 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 31.9 mt-10 67.23 8.57 6.31 Favored 'General case' 0 N--CA 1.45 -0.471 0 C-N-CA 126.509 1.924 . . . . 0.0 114.933 178.224 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 27.6 mt-30 -64.5 150.88 45.8 Favored 'General case' 0 C--N 1.341 0.221 0 CA-C-N 120.062 1.301 . . . . 0.0 108.859 174.283 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 10.5 tp10 -122.84 161.53 23.88 Favored 'General case' 0 N--CA 1.45 -0.447 0 C-N-CA 125.215 1.406 . . . . 0.0 108.487 179.125 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 21.1 t0 66.69 14.1 9.63 Favored 'General case' 0 N--CA 1.465 0.315 0 C-N-CA 125.735 1.614 . . . . 0.0 113.713 -178.932 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.474 HD13 ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -65.65 -26.76 39.73 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.315 0 C-N-CA 124.371 1.068 . . . . 0.0 111.104 176.736 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 7.5 p -138.75 147.2 25.27 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.912 0 C-N-CA 125.626 1.57 . . . . 0.0 107.935 179.36 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.5 mttm -121.18 109.76 15.37 Favored 'General case' 0 N--CA 1.44 -0.933 0 N-CA-C 106.592 -1.633 . . . . 0.0 106.592 173.394 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.687 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -77.57 98.85 2.29 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.825 0 N-CA-C 104.522 -2.399 . . . . 0.0 104.522 174.724 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 39.4 mt-10 -87.93 147.94 24.82 Favored 'General case' 0 N--CA 1.451 -0.404 0 C-N-CA 124.038 0.935 . . . . 0.0 108.87 178.6 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 21.1 tptm . . . . . 0 C--N 1.329 -0.297 0 CA-C-O 121.927 0.87 . . . . 0.0 109.026 -178.437 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 3.0 ppp? . . . . . 0 CA--C 1.537 0.455 0 N-CA-C 112.948 0.722 . . . . 0.0 112.948 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 15.7 pt -74.21 61.12 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.429 0 C-N-CA 124.508 1.123 . . . . 0.0 111.802 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.93 79.97 1.65 Allowed 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.692 0.797 . . . . 0.0 108.987 177.707 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 72.0 mt-10 -46.89 126.9 8.62 Favored Pre-proline 0 CA--C 1.541 0.597 0 C-N-CA 123.745 0.818 . . . . 0.0 110.563 -179.139 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 91.1 Cg_endo -74.39 69.53 5.01 Favored 'Trans proline' 0 N--CA 1.456 -0.711 0 C-N-CA 123.187 2.591 . . . . 0.0 111.469 -177.072 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -160.67 170.2 21.3 Favored 'General case' 0 N--CA 1.453 -0.308 0 C-N-CA 124.665 1.186 . . . . 0.0 108.729 178.12 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 4.3 mp0 -101.72 146.73 27.35 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 108.366 -0.976 . . . . 0.0 108.366 -179.958 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.6 t30 -163.75 149.92 11.5 Favored 'General case' 0 N--CA 1.452 -0.356 0 N-CA-C 108.788 -0.819 . . . . 0.0 108.788 179.789 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -161.14 30.68 0.14 Allowed 'General case' 0 N--CA 1.449 -0.492 0 C-N-CA 125.15 1.38 . . . . 0.0 109.572 176.166 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 2.5 pp -132.83 -34.49 0.51 Allowed 'Isoleucine or valine' 0 C--N 1.342 0.255 0 C-N-CA 123.674 0.79 . . . . 0.0 111.731 -178.567 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -155.87 -125.46 0.91 Allowed Glycine 0 C--N 1.335 0.492 0 N-CA-C 107.945 -2.062 . . . . 0.0 107.945 179.02 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 51.82 -160.8 0.09 Allowed 'General case' 0 CA--C 1.552 1.023 0 C-N-CA 125.138 1.375 . . . . 0.0 110.032 179.197 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 13.5 pt-20 22.87 52.76 0.02 OUTLIER 'General case' 0 CA--C 1.54 0.586 0 C-N-CA 129.147 2.979 . . . . 0.0 118.438 174.287 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 74.4 t -145.31 -39.1 0.13 Allowed 'Isoleucine or valine' 0 N--CA 1.467 0.422 0 N-CA-C 115.735 1.754 . . . . 0.0 115.735 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 39.7 t80 -160.3 113.97 2.15 Favored 'General case' 0 C--N 1.32 -0.696 0 C-N-CA 123.411 0.684 . . . . 0.0 112.119 -173.347 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.1 m -78.73 80.81 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.463 0.178 0 O-C-N 120.481 -1.387 . . . . 0.0 111.435 179.876 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -21.68 105.04 0.09 OUTLIER Pre-proline 0 CA--C 1.551 1.015 0 C-N-CA 129.229 3.012 . . . . 0.0 109.605 175.183 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 73.8 Cg_endo -73.06 -20.56 21.63 Favored 'Trans proline' 0 N--CA 1.46 -0.454 0 C-N-CA 123.535 2.823 . . . . 0.0 119.177 -167.42 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -147.35 147.16 17.75 Favored 'Isoleucine or valine' 0 C--N 1.34 0.164 0 CA-C-N 119.699 1.136 . . . . 0.0 110.547 -177.05 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 99.2 m -85.79 135.31 33.78 Favored 'General case' 0 C--O 1.239 0.506 0 N-CA-C 107.182 -1.414 . . . . 0.0 107.182 173.947 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 166.59 -140.38 6.29 Favored Glycine 0 CA--C 1.526 0.739 0 N-CA-C 111.094 -0.803 . . . . 0.0 111.094 -178.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 46.1 tp10 -125.81 122.68 36.87 Favored 'General case' 0 CA--C 1.528 0.122 0 C-N-CA 124.933 1.293 . . . . 0.0 110.089 -178.532 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.3 mt -77.55 146.01 9.11 Favored 'Isoleucine or valine' 0 C--O 1.231 0.094 0 N-CA-C 109.187 -0.672 . . . . 0.0 109.187 177.006 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 95.3 m-70 -142.52 140.23 18.5 Favored Pre-proline 0 N--CA 1.45 -0.428 0 C-N-CA 125.155 1.382 . . . . 0.0 107.656 176.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 38.4 Cg_exo -57.13 145.55 85.79 Favored 'Trans proline' 0 N--CA 1.453 -0.911 0 C-N-CA 122.116 1.877 . . . . 0.0 110.161 176.351 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 0.7 OUTLIER -49.37 -37.63 11.12 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.544 0 C-N-CA 124.304 1.041 . . . . 0.0 112.596 -178.449 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.6 p -55.96 -28.66 58.0 Favored 'General case' 0 CA--C 1.534 0.354 0 C-N-CA 125.105 1.362 . . . . 0.0 112.606 178.353 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -77.23 -8.81 58.2 Favored 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 123.678 0.791 . . . . 0.0 112.745 -178.692 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.425 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 46.7 t -74.26 131.01 81.32 Favored Pre-proline 0 CA--C 1.535 0.402 0 O-C-N 121.162 -0.961 . . . . 0.0 109.994 -178.07 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 49.3 Cg_endo -77.17 55.93 5.24 Favored 'Trans proline' 0 CA--C 1.54 0.798 0 C-N-CA 123.515 2.81 . . . . 0.0 111.954 -177.979 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 58.0 t0 -167.72 108.68 0.59 Allowed 'General case' 0 CA--C 1.531 0.224 0 O-C-N 121.47 -0.768 . . . . 0.0 109.19 178.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 10.8 mm-40 -35.47 -48.17 0.48 Allowed 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 127.521 2.329 . . . . 0.0 115.375 -176.56 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 8.0 p -50.57 -38.1 16.1 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.435 0 C-N-CA 122.932 0.493 . . . . 0.0 110.938 179.839 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.411 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 23.2 m-85 -89.38 -49.7 6.55 Favored 'General case' 0 N--CA 1.45 -0.463 0 C-N-CA 124.115 0.966 . . . . 0.0 108.828 177.155 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.1 m -48.07 -40.96 24.74 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 113.765 1.024 . . . . 0.0 113.765 -177.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -100.48 15.01 59.1 Favored Glycine 0 C--N 1.338 0.663 0 CA-C-O 118.201 -1.333 . . . . 0.0 111.956 -177.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 53.1 mttp 71.87 -39.22 0.44 Allowed 'General case' 0 CA--C 1.54 0.588 0 CA-C-N 119.285 1.542 . . . . 0.0 113.813 -179.835 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 9.4 ttp 27.97 -69.18 0.0 OUTLIER 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 131.341 3.856 . . . . 0.0 117.118 -179.497 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 16.9 ttp -79.54 -25.53 41.65 Favored 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 126.047 1.739 . . . . 0.0 113.541 -175.33 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -178.71 -141.1 4.21 Favored Glycine 0 C--O 1.224 -0.512 0 CA-C-N 119.605 1.093 . . . . 0.0 110.658 -178.079 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 46.6 t0 -121.96 154.4 37.24 Favored 'General case' 0 CA--C 1.509 -0.616 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 174.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 179.51 -165.2 33.73 Favored Glycine 0 N--CA 1.445 -0.718 0 C-N-CA 120.267 -0.968 . . . . 0.0 112.236 -175.806 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.535 ' CE2' HD11 ' A' ' 45' ' ' ILE . 37.4 p90 -159.37 168.91 25.17 Favored 'General case' 0 N--CA 1.451 -0.418 0 N-CA-C 108.637 -0.875 . . . . 0.0 108.637 177.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.425 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -112.37 151.28 29.97 Favored 'General case' 0 CA--C 1.501 -0.942 0 CA-C-O 121.346 0.593 . . . . 0.0 109.475 175.919 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.535 HD11 ' CE2' ' A' ' 43' ' ' PHE . 4.4 mp -125.08 132.31 71.41 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.429 0 N-CA-C 102.18 -3.267 . . . . 0.0 102.18 170.868 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.0 tt -96.15 108.74 43.24 Favored Pre-proline 0 N--CA 1.442 -0.837 1 N-CA-C 98.589 -4.597 . . . . 0.0 98.589 169.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 70.2 Cg_endo -82.17 156.1 17.19 Favored 'Trans proline' 0 N--CA 1.454 -0.846 0 C-N-CA 123.664 2.909 . . . . 0.0 114.405 -168.201 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 73.2 p -124.98 -45.83 1.86 Allowed 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 124.895 1.278 . . . . 0.0 108.794 174.711 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -68.79 120.34 14.59 Favored 'General case' 0 C--N 1.339 0.11 0 N-CA-C 109.698 -0.482 . . . . 0.0 109.698 177.492 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.69 37.59 2.09 Favored Glycine 0 CA--C 1.53 0.992 0 N-CA-C 111.612 -0.595 . . . . 0.0 111.612 175.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.7 mt -142.33 119.39 6.91 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 C-N-CA 127.007 2.123 . . . . 0.0 105.85 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 58.7 t -109.08 113.86 45.3 Favored 'Isoleucine or valine' 0 C--O 1.233 0.206 0 N-CA-C 106.522 -1.659 . . . . 0.0 106.522 179.157 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 2.1 m -100.53 152.26 4.95 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.222 0 C-N-CA 123.094 0.558 . . . . 0.0 109.988 179.081 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 70.6 m -58.24 130.0 83.56 Favored Pre-proline 0 CA--C 1.537 0.463 0 CA-C-O 118.601 -0.714 . . . . 0.0 111.106 -177.697 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 73.6 Cg_endo -75.2 -22.94 13.96 Favored 'Trans proline' 0 N--CA 1.46 -0.482 0 C-N-CA 124.938 3.759 . . . . 0.0 115.774 -175.464 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.6 m -137.79 161.68 32.8 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.284 0 C-N-CA 123.914 0.885 . . . . 0.0 109.769 -173.54 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 75.1 ttt180 -76.71 126.31 30.76 Favored 'General case' 0 CA--C 1.518 -0.271 1 N-CA-C 99.562 -4.236 . . . . 0.0 99.562 167.957 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.31 175.07 47.23 Favored Glycine 0 N--CA 1.436 -1.343 0 C-N-CA 116.709 -2.663 . . . . 0.0 114.33 -167.853 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 36.2 mtmt -100.62 135.16 42.49 Favored 'General case' 0 N--CA 1.44 -0.955 0 C-N-CA 126.231 1.812 . . . . 0.0 108.371 -179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 26.9 mm -76.47 107.93 8.38 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 104.867 -2.271 . . . . 0.0 104.867 173.333 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 64.3 tp -77.3 -50.6 12.48 Favored 'General case' 0 N--CA 1.451 -0.392 0 C-N-CA 123.358 0.663 . . . . 0.0 109.998 -174.493 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.6 t30 179.53 107.68 0.03 OUTLIER 'General case' 0 CA--C 1.519 -0.238 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 -179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.463 ' HA ' ' HB ' ' A' ' 70' ' ' ILE . 10.3 m -117.82 147.4 21.28 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 C-N-CA 123.587 0.755 . . . . 0.0 112.392 -178.285 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.0 OUTLIER 42.53 123.72 0.0 OUTLIER Pre-proline 0 CA--C 1.536 0.441 1 C-N-CA 132.901 4.48 . . . . 0.0 120.801 171.706 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 98.6 Cg_endo -80.94 -50.16 0.05 OUTLIER 'Trans proline' 0 N--CA 1.447 -1.216 0 N-CA-C 106.676 -2.086 . . . . 0.0 106.676 168.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 8.9 p -113.99 43.08 1.91 Allowed 'General case' 0 CA--C 1.536 0.404 0 C-N-CA 127.281 2.232 . . . . 0.0 111.14 -178.47 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 10.4 ttmm 56.91 25.62 10.74 Favored 'General case' 0 N--CA 1.467 0.396 0 N-CA-C 115.762 1.764 . . . . 0.0 115.762 171.748 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 12.6 p-80 -135.09 9.32 3.51 Favored 'General case' 0 CA--C 1.536 0.431 0 N-CA-C 115.262 1.578 . . . . 0.0 115.262 -175.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -168.25 -159.29 0.27 Allowed 'General case' 0 N--CA 1.473 0.719 0 CA-C-N 122.053 2.206 . . . . 0.0 113.988 -173.06 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.463 ' HB ' ' HA ' ' A' ' 63' ' ' VAL 1.014 0.2 OUTLIER 93.18 -161.05 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.533 0.318 0 C-N-CA 131.632 3.973 . . . . 0.0 117.697 172.683 . . . . . . . . 4 4 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -115.14 154.1 17.2 Favored Glycine 0 C--N 1.338 0.671 0 N-CA-C 120.06 2.784 . . . . 0.0 120.06 -167.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.8 mp -133.23 165.83 23.89 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 128.558 2.743 . . . . 0.0 108.519 -179.231 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.7 mm-40 -136.86 139.58 41.78 Favored 'General case' 0 N--CA 1.44 -0.969 0 N-CA-C 105.417 -2.068 . . . . 0.0 105.417 175.153 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 6.8 m -82.33 -131.72 0.03 OUTLIER 'General case' 0 C--N 1.322 -0.618 0 N-CA-C 107.621 -1.252 . . . . 0.0 107.621 176.356 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 23.5 t0 -88.74 49.9 1.87 Allowed 'General case' 0 CA--C 1.53 0.203 0 N-CA-C 107.356 -1.349 . . . . 0.0 107.356 174.916 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 77.57 -49.25 3.03 Favored Glycine 0 CA--C 1.53 1.027 0 C-N-CA 124.323 0.963 . . . . 0.0 112.905 -179.865 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -56.81 -16.58 17.9 Favored Glycine 0 CA--C 1.534 1.264 0 N-CA-C 116.118 1.207 . . . . 0.0 116.118 -177.015 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 41.6 mtm180 -142.04 104.54 4.5 Favored 'General case' 0 CA--C 1.533 0.299 0 CA-C-N 119.226 1.513 . . . . 0.0 111.569 -178.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -90.0 130.12 36.23 Favored 'General case' 0 N--CA 1.456 -0.144 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 173.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 58.0 mt -119.05 150.49 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.21 0 C-N-CA 124.89 1.276 . . . . 0.0 110.744 -176.329 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -131.75 132.84 44.17 Favored 'General case' 0 N--CA 1.45 -0.443 0 C-N-CA 128.373 2.669 . . . . 0.0 105.94 177.15 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 63.4 mt -124.87 143.33 38.77 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.373 0 C-N-CA 124.841 1.256 . . . . 0.0 108.853 179.871 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 4.6 t60 -134.82 124.73 25.56 Favored 'General case' 0 N--CA 1.451 -0.414 0 N-CA-C 104.923 -2.251 . . . . 0.0 104.923 171.136 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 5.3 t80 -87.78 122.52 31.53 Favored 'General case' 0 N--CA 1.447 -0.618 0 CA-C-O 118.675 -0.679 . . . . 0.0 109.558 -178.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 54.05 -157.4 5.9 Favored Glycine 0 CA--C 1.53 1.03 0 CA-C-N 118.358 0.526 . . . . 0.0 112.491 179.462 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 17.6 mm -132.77 142.92 41.12 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.273 0 N-CA-C 106.36 -1.719 . . . . 0.0 106.36 178.62 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.6 t70 58.96 29.06 18.46 Favored 'General case' 0 CA--C 1.539 0.554 0 C-N-CA 124.058 0.943 . . . . 0.0 112.555 178.648 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.8 p -86.41 -37.3 18.5 Favored 'General case' 0 CA--C 1.517 -0.296 0 C-N-CA 126.162 1.785 . . . . 0.0 108.067 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 3.7 p -51.46 -46.75 36.08 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.798 0 CA-C-N 114.815 -1.084 . . . . 0.0 108.235 171.154 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -61.6 -31.33 71.4 Favored 'General case' 0 CA--C 1.529 0.153 0 C-N-CA 125.332 1.453 . . . . 0.0 111.147 178.312 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -74.89 -2.99 29.37 Favored 'General case' 0 CA--C 1.542 0.642 0 C-N-CA 127.344 2.258 . . . . 0.0 110.379 178.3 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 33.3 mtmm 51.61 33.44 10.72 Favored 'General case' 0 C--N 1.344 0.331 0 C-N-CA 125.176 1.39 . . . . 0.0 112.629 177.846 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 64.49 18.15 63.05 Favored Glycine 0 CA--C 1.537 1.426 0 O-C-N 121.919 -0.488 . . . . 0.0 113.357 -179.621 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 53.5 mt-10 -73.01 85.27 1.29 Allowed 'General case' 0 C--N 1.34 0.152 0 CA-C-N 118.88 1.34 . . . . 0.0 109.745 179.609 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 129.71 17.48 1.7 Allowed Glycine 0 CA--C 1.533 1.159 0 C-N-CA 126.714 2.102 . . . . 0.0 111.575 -177.809 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.454 ' CD2' HG12 ' A' ' 115' ' ' VAL . 37.1 m-85 -117.26 150.15 39.25 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 124.8 1.24 . . . . 0.0 109.907 -178.381 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 30.7 m -145.15 102.45 3.74 Favored 'General case' 0 N--CA 1.453 -0.304 0 N-CA-C 106.53 -1.656 . . . . 0.0 106.53 178.471 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.8 p -81.33 127.49 32.8 Favored 'General case' 0 N--CA 1.453 -0.306 0 C-N-CA 123.964 0.906 . . . . 0.0 108.959 -179.387 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 19.0 m-85 -91.13 -45.03 8.9 Favored 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 124.859 1.264 . . . . 0.0 112.612 -177.143 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 6.7 m -73.36 129.19 36.28 Favored 'Isoleucine or valine' 0 N--CA 1.465 0.308 0 C-N-CA 118.383 -1.327 . . . . 0.0 111.67 -177.992 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 53.0 m -87.97 64.56 7.88 Favored 'General case' 0 C--N 1.332 -0.171 0 N-CA-C 105.974 -1.862 . . . . 0.0 105.974 172.825 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.3 0.0 OUTLIER -14.11 84.47 0.0 OUTLIER 'General case' 0 C--N 1.323 -0.555 0 C-N-CA 130.039 3.336 . . . . 0.0 116.485 -173.213 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -173.14 -2.12 0.03 OUTLIER Glycine 0 CA--C 1.534 1.257 0 CA-C-N 113.528 -1.669 . . . . 0.0 113.194 178.879 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.3 m-20 -64.48 121.57 14.71 Favored 'General case' 0 N--CA 1.44 -0.969 0 C-N-CA 127.266 2.226 . . . . 0.0 107.073 177.045 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -102.94 121.02 41.66 Favored 'General case' 0 C--N 1.318 -0.775 0 C-N-CA 127.808 2.443 . . . . 0.0 111.061 -179.427 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.337 33.7 m 43.23 66.62 0.13 Allowed 'Isoleucine or valine' 0 C--O 1.232 0.166 0 C-N-CA 126.682 1.993 . . . . 0.0 115.615 178.781 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -132.7 141.58 41.65 Favored Pre-proline 0 CA--C 1.534 0.335 0 N-CA-C 106.499 -1.667 . . . . 0.0 106.499 171.949 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 55.1 Cg_endo -103.37 171.29 0.21 Allowed 'Trans proline' 0 N--CA 1.452 -0.936 0 C-N-CA 123.935 3.09 . . . . 0.0 110.529 -179.048 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 60.04 -23.01 0.04 OUTLIER Glycine 0 CA--C 1.534 1.234 0 N-CA-C 118.856 2.303 . . . . 0.0 118.856 170.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.7 tt0 -50.24 137.49 18.06 Favored 'General case' 0 N--CA 1.454 -0.271 0 CA-C-N 120.457 2.128 . . . . 0.0 110.529 -178.075 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 34.2 ttmt -60.59 123.7 18.18 Favored 'General case' 0 N--CA 1.45 -0.45 0 N-CA-C 109.875 -0.417 . . . . 0.0 109.875 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 83.5 mt -85.79 -48.2 9.01 Favored 'General case' 0 N--CA 1.451 -0.423 0 N-CA-C 108.461 -0.94 . . . . 0.0 108.461 177.108 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 2.5 mp -143.12 155.8 44.66 Favored 'General case' 0 CA--C 1.533 0.326 0 C-N-CA 123.724 0.81 . . . . 0.0 110.666 -179.65 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 33.7 tt0 -122.11 135.36 54.79 Favored 'General case' 0 C--O 1.236 0.356 1 N-CA-C 99.023 -4.436 . . . . 0.0 99.023 167.075 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.454 HG12 ' CD2' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -143.71 126.47 12.15 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.812 0 CA-C-N 114.951 -1.022 . . . . 0.0 110.592 -165.754 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 38.7 m-20 -76.83 61.61 1.93 Allowed 'General case' 0 C--O 1.235 0.294 0 C-N-CA 124.904 1.282 . . . . 0.0 110.544 -178.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.0 mt -45.12 -45.5 11.28 Favored 'General case' 0 CA--C 1.52 -0.195 0 C-N-CA 123.886 0.875 . . . . 0.0 112.192 -177.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 28.9 t70 -44.95 -42.01 7.78 Favored 'General case' 0 CA--C 1.534 0.339 0 C-N-CA 124.488 1.115 . . . . 0.0 112.611 178.063 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -90.56 -33.67 15.81 Favored 'General case' 0 N--CA 1.456 -0.135 0 C-N-CA 123.113 0.565 . . . . 0.0 111.364 -179.783 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 96.6 t -62.62 -52.78 55.46 Favored 'Isoleucine or valine' 0 CA--C 1.54 0.562 0 O-C-N 121.756 -0.59 . . . . 0.0 110.004 178.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.391 8.8 ptmt -42.79 -57.22 5.11 Favored Pre-proline 0 CA--C 1.538 0.492 0 N-CA-C 116.895 2.183 . . . . 0.0 116.895 -177.79 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_endo -61.59 -21.37 71.84 Favored 'Trans proline' 0 N--CA 1.455 -0.778 0 C-N-CA 122.187 1.925 . . . . 0.0 113.184 178.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 41.9 m-80 -87.88 -42.29 12.62 Favored 'General case' 0 CA--C 1.528 0.131 0 CA-C-N 119.064 0.847 . . . . 0.0 111.317 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.9 m -78.69 149.19 74.15 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.95 -0.469 . . . . 0.0 111.807 -177.183 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 74.2 Cg_endo -70.53 -24.5 26.07 Favored 'Trans proline' 0 N--CA 1.453 -0.893 0 C-N-CA 122.506 2.137 . . . . 0.0 110.228 175.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.2 t -158.05 145.06 17.93 Favored 'General case' 0 N--CA 1.45 -0.43 0 N-CA-C 108.303 -0.999 . . . . 0.0 108.303 178.725 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.2 tp -98.18 6.5 47.42 Favored 'General case' 0 CA--C 1.538 0.485 0 C-N-CA 124.56 1.144 . . . . 0.0 110.31 178.296 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 21.3 mmt -53.36 115.16 1.77 Allowed 'General case' 0 C--N 1.344 0.343 0 N-CA-C 109.343 -0.614 . . . . 0.0 109.343 179.13 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 47.3 m -106.33 88.6 3.34 Favored Pre-proline 0 N--CA 1.447 -0.579 0 C-N-CA 124.706 1.203 . . . . 0.0 108.241 -178.622 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.411 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 83.8 Cg_endo -72.93 144.0 37.64 Favored 'Trans proline' 0 N--CA 1.447 -1.212 0 C-N-CA 122.668 2.246 . . . . 0.0 111.948 179.982 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 24.9 mt -125.01 126.29 70.93 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 103.788 -2.671 . . . . 0.0 103.788 173.102 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.9 t -123.53 153.41 29.16 Favored 'Isoleucine or valine' 0 CA--C 1.511 -0.539 0 C-N-CA 126.008 1.723 . . . . 0.0 106.651 178.669 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 13.1 m-85 -129.92 121.58 26.9 Favored 'General case' 0 N--CA 1.428 -1.541 0 N-CA-C 102.914 -2.995 . . . . 0.0 102.914 -176.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 23.9 p -89.18 -86.17 0.19 Allowed 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 107.564 -1.273 . . . . 0.0 107.564 -177.041 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -77.49 54.82 1.21 Allowed 'General case' 0 CA--C 1.532 0.276 0 C-N-CA 122.922 0.489 . . . . 0.0 111.696 179.488 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -78.26 80.07 4.69 Favored 'General case' 0 CA--C 1.534 0.36 0 N-CA-C 108.417 -0.957 . . . . 0.0 108.417 174.692 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 32.12 51.51 0.21 Allowed 'General case' 0 C--N 1.343 0.289 0 C-N-CA 127.819 2.448 . . . . 0.0 111.641 -175.747 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 21.55 69.57 0.03 OUTLIER 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 129.261 3.024 . . . . 0.0 113.964 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 146.42 -3.25 1.01 Allowed Glycine 0 CA--C 1.523 0.573 0 CA-C-O 118.591 -1.116 . . . . 0.0 113.455 176.981 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.704 ' HB3' HG23 ' A' ' 160' ' ' ILE . 56.0 mt-10 -70.99 115.57 10.27 Favored 'General case' 0 C--N 1.339 0.116 0 CA-C-N 119.686 1.743 . . . . 0.0 109.933 179.886 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 81.5 p -78.78 128.99 34.13 Favored 'General case' 0 N--CA 1.448 -0.553 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.12 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.266 0.4 OUTLIER -81.05 78.73 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.6 0 CA-C-O 123.498 1.618 . . . . 0.0 106.8 -177.538 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 38.5 m -78.8 91.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 120.962 -1.086 . . . . 0.0 111.249 -174.44 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.3 pt -63.19 104.58 0.38 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.315 0 C-N-CA 123.004 0.522 . . . . 0.0 109.597 176.649 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 65.0 mmtt -77.23 -56.01 4.93 Favored 'General case' 0 N--CA 1.449 -0.496 0 N-CA-C 107.973 -1.121 . . . . 0.0 107.973 -179.616 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . 0.731 ' HB3' HG23 ' A' ' 157' ' ' ILE . . . -84.14 69.97 10.47 Favored 'General case' 0 N--CA 1.454 -0.23 0 N-CA-C 108.436 -0.95 . . . . 0.0 108.436 178.854 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 46.4 m -77.7 68.66 3.82 Favored 'General case' 0 CA--C 1.532 0.281 0 N-CA-C 106.85 -1.537 . . . . 0.0 106.85 176.666 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -174.17 -142.06 3.83 Favored Glycine 0 CA--C 1.523 0.547 0 N-CA-C 106.433 -2.667 . . . . 0.0 106.433 -176.468 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.4 t -67.0 145.99 54.83 Favored 'General case' 0 CA--C 1.533 0.3 0 CA-C-N 117.975 0.888 . . . . 0.0 110.645 177.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . 0.66 HG23 HG21 ' A' ' 157' ' ' ILE . 3.8 p -123.57 153.59 29.32 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.254 0 C-N-CA 125.881 1.673 . . . . 0.0 107.351 177.317 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.9 OUTLIER -129.68 158.1 40.29 Favored 'General case' 0 N--CA 1.455 -0.187 0 N-CA-C 106.862 -1.533 . . . . 0.0 106.862 178.268 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 55.6 mtp180 -65.46 147.99 52.48 Favored 'General case' 0 CA--C 1.534 0.342 0 N-CA-C 112.663 0.616 . . . . 0.0 112.663 179.038 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 38.5 mt-10 43.44 48.69 6.12 Favored 'General case' 0 N--CA 1.456 -0.134 0 C-N-CA 128.109 2.564 . . . . 0.0 114.057 172.816 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 60.9 mm-40 -89.29 10.21 23.09 Favored 'General case' 0 CA--C 1.537 0.456 0 N-CA-C 112.709 0.633 . . . . 0.0 112.709 177.528 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 53.62 8.86 0.15 Allowed 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 128.752 2.821 . . . . 0.0 115.566 177.801 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 14.0 t70 -156.97 -126.13 0.03 OUTLIER 'General case' 0 C--N 1.325 -0.488 0 C-N-CA 125.146 1.378 . . . . 0.0 107.405 -179.74 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.731 HG23 ' HB3' ' A' ' 146' ' ' ALA 0.312 1.5 mp 80.63 -36.89 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.262 0 C-N-CA 128.559 2.744 . . . . 0.0 108.615 178.552 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -119.85 129.11 75.81 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.73 0 N-CA-C 105.021 -2.215 . . . . 0.0 105.021 168.372 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 9.2 mmmt -111.3 111.51 22.61 Favored 'General case' 0 N--CA 1.447 -0.584 0 C-N-CA 124.168 0.987 . . . . 0.0 109.077 -178.814 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.704 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.3 mp -77.24 91.51 1.07 Allowed 'Isoleucine or valine' 0 N--CA 1.443 -0.808 0 N-CA-C 103.409 -2.812 . . . . 0.0 103.409 175.049 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 10.0 tp10 -103.46 116.1 31.77 Favored 'General case' 0 N--CA 1.451 -0.384 0 C-N-CA 125.587 1.555 . . . . 0.0 110.282 -173.009 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 28.6 tptp . . . . . 0 CA--C 1.528 0.129 0 N-CA-C 109.664 -0.495 . . . . 0.0 109.664 178.987 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 73.3 mtm . . . . . 0 CA--C 1.531 0.214 0 CA-C-O 120.77 0.319 . . . . 0.0 110.82 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 33.4 pt -74.47 -172.5 0.12 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.456 0 C-N-CA 123.809 0.844 . . . . 0.0 110.343 179.507 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -73.71 63.19 0.84 Allowed 'General case' 0 CA--C 1.536 0.427 0 C-N-CA 123.764 0.826 . . . . 0.0 111.028 179.055 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 41.7 mt-10 -66.02 -46.9 63.99 Favored Pre-proline 0 CA--C 1.538 0.504 0 C-N-CA 124.466 1.106 . . . . 0.0 113.745 -179.472 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 48.1 Cg_endo -78.13 70.39 7.14 Favored 'Trans proline' 0 N--CA 1.456 -0.698 0 C-N-CA 121.418 1.412 . . . . 0.0 111.535 -175.473 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 93.8 mt -70.47 67.96 0.36 Allowed 'General case' 0 CA--C 1.535 0.382 0 C-N-CA 125.813 1.645 . . . . 0.0 110.496 178.829 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 18.4 mt-30 -71.66 72.52 0.76 Allowed 'General case' 0 N--CA 1.452 -0.346 0 C-N-CA 125.541 1.536 . . . . 0.0 110.948 -178.614 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -60.13 97.46 0.05 OUTLIER 'General case' 0 CA--C 1.532 0.278 0 C-N-CA 123.575 0.75 . . . . 0.0 110.338 178.743 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 56.7 tt0 72.07 -62.6 0.46 Allowed 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 126.763 2.025 . . . . 0.0 111.226 179.848 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . 0.298 15.5 tt 52.73 -58.68 0.05 OUTLIER 'Isoleucine or valine' 0 CA--C 1.54 0.587 0 C-N-CA 129.562 3.145 . . . . 0.0 116.378 179.669 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -143.92 57.25 0.54 Allowed Glycine 0 CA--C 1.524 0.595 0 N-CA-C 109.266 -1.533 . . . . 0.0 109.266 -178.354 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 32.6 tt0 -134.46 -1.06 2.87 Favored 'General case' 0 CA--C 1.543 0.686 0 C-N-CA 125.72 1.608 . . . . 0.0 113.751 -178.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 1.8 pm0 -86.94 166.77 14.85 Favored 'General case' 0 CA--C 1.537 0.453 0 C-N-CA 124.847 1.259 . . . . 0.0 111.545 179.568 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.311 6.5 t 59.2 -17.76 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 N-CA-C 119.156 3.021 . . . . 0.0 119.156 176.105 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 29.3 t80 -152.11 127.94 10.25 Favored 'General case' 0 C--N 1.318 -0.785 0 C-N-CA 127.877 2.471 . . . . 0.0 104.402 175.98 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -127.76 77.05 0.55 Allowed 'Isoleucine or valine' 0 N--CA 1.449 -0.505 0 N-CA-C 109.232 -0.655 . . . . 0.0 109.232 -179.404 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 45.4 t -15.91 124.06 0.04 OUTLIER Pre-proline 0 CA--C 1.552 1.043 0 C-N-CA 129.063 2.945 . . . . 0.0 114.449 179.576 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . 0.429 ' HG2' HD12 ' A' ' 19' ' ' ILE . 50.5 Cg_endo -74.8 -42.72 0.51 Allowed 'Trans proline' 0 CA--C 1.538 0.684 0 N-CA-C 120.825 3.356 . . . . 0.0 120.825 -170.467 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . 0.429 HD12 ' HG2' ' A' ' 18' ' ' PRO . 0.2 OUTLIER -138.16 145.49 28.48 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.631 0 CA-C-N 121.014 1.734 . . . . 0.0 111.665 -172.646 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 6.7 m -79.88 131.88 35.96 Favored 'General case' 0 C--O 1.239 0.519 0 N-CA-C 105.873 -1.899 . . . . 0.0 105.873 171.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 178.41 -160.49 26.55 Favored Glycine 0 CA--C 1.518 0.249 0 N-CA-C 110.883 -0.887 . . . . 0.0 110.883 -178.905 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.7 tp10 -108.04 131.74 54.28 Favored 'General case' 0 N--CA 1.455 -0.219 0 N-CA-C 107.439 -1.319 . . . . 0.0 107.439 177.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.1 tt -75.85 151.71 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.311 0 CA-C-N 118.679 0.672 . . . . 0.0 110.535 -179.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 84.5 m-70 -140.14 129.75 13.59 Favored Pre-proline 0 N--CA 1.446 -0.628 0 N-CA-C 106.361 -1.718 . . . . 0.0 106.361 172.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 26.8 Cg_exo -57.41 143.0 95.22 Favored 'Trans proline' 0 N--CA 1.449 -1.128 0 C-N-CA 122.512 2.141 . . . . 0.0 107.578 174.751 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . 0.408 HD13 ' C ' ' A' ' 42' ' ' GLY . 1.8 tp -43.46 -49.45 1.51 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 123.764 0.826 . . . . 0.0 112.269 -177.666 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 2.7 p -53.9 -24.58 16.59 Favored 'General case' 0 CA--C 1.535 0.372 0 C-N-CA 125.14 1.376 . . . . 0.0 114.321 -179.811 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 30.0 t70 -78.81 -8.06 58.43 Favored 'General case' 0 CA--C 1.537 0.479 0 CA-C-N 118.756 0.707 . . . . 0.0 112.61 -179.357 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.431 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 93.0 t -70.1 134.67 87.35 Favored Pre-proline 0 CA--C 1.543 0.696 0 O-C-N 121.106 -0.996 . . . . 0.0 110.922 -177.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 64.2 Cg_endo -74.85 64.6 5.92 Favored 'Trans proline' 0 CA--C 1.537 0.673 0 C-N-CA 124.674 3.582 . . . . 0.0 110.556 -179.235 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -165.09 178.69 6.84 Favored 'General case' 0 CA--C 1.537 0.479 0 C-N-CA 125.37 1.468 . . . . 0.0 107.177 -179.582 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 35.3 mt-30 -105.46 -63.83 1.2 Allowed 'General case' 0 CA--C 1.534 0.364 0 C-N-CA 124.383 1.073 . . . . 0.0 110.565 178.314 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 2.9 p -47.26 -56.6 1.46 Allowed 'Isoleucine or valine' 0 N--CA 1.466 0.345 0 C-N-CA 124.22 1.008 . . . . 0.0 112.775 -177.411 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.1 m-85 -61.06 -57.32 13.05 Favored 'General case' 0 CA--C 1.529 0.169 0 CA-C-O 121.703 0.763 . . . . 0.0 108.959 179.996 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.3 m -53.67 -36.97 62.71 Favored 'General case' 0 N--CA 1.446 -0.648 0 C-N-CA 126.18 1.792 . . . . 0.0 115.592 -174.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -87.35 7.04 82.27 Favored Glycine 0 N--CA 1.446 -0.678 0 N-CA-C 110.407 -1.077 . . . . 0.0 110.407 179.498 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 26.1 mtmt 74.99 -39.94 0.42 Allowed 'General case' 0 CA--C 1.536 0.429 0 C-N-CA 125.974 1.71 . . . . 0.0 111.44 -177.368 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 26.6 ttt 28.01 -70.05 0.0 OUTLIER 'General case' 0 CA--C 1.535 0.4 0 C-N-CA 131.305 3.842 . . . . 0.0 116.909 177.687 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 9.6 tpt -79.13 -16.98 55.9 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 124.383 1.073 . . . . 0.0 112.654 -176.279 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -177.37 -135.29 2.18 Favored Glycine 0 C--N 1.337 0.604 0 N-CA-C 110.322 -1.111 . . . . 0.0 110.322 -178.556 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 40.3 t0 -131.24 154.94 47.93 Favored 'General case' 0 CA--C 1.513 -0.478 0 N-CA-C 105.833 -1.914 . . . . 0.0 105.833 173.467 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.408 ' C ' HD13 ' A' ' 26' ' ' ILE . . . -177.94 -159.48 22.79 Favored Glycine 0 N--CA 1.447 -0.608 0 C-N-CA 120.249 -0.977 . . . . 0.0 114.177 -174.953 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 25.5 p90 -163.63 171.15 16.13 Favored 'General case' 0 N--CA 1.454 -0.254 0 C-N-CA 124.01 0.924 . . . . 0.0 109.521 -178.596 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.431 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -120.34 137.3 54.35 Favored 'General case' 0 CA--C 1.508 -0.669 0 C-N-CA 122.936 0.494 . . . . 0.0 109.705 174.045 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 20.3 mm -112.09 129.6 67.28 Favored 'Isoleucine or valine' 0 N--CA 1.441 -0.903 0 N-CA-C 103.38 -2.822 . . . . 0.0 103.38 171.189 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 15.6 tp -94.85 110.63 50.7 Favored Pre-proline 0 N--CA 1.446 -0.651 0 N-CA-C 102.019 -3.326 . . . . 0.0 102.019 172.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 49.6 Cg_exo -64.55 155.27 67.46 Favored 'Trans proline' 0 N--CA 1.458 -0.559 0 C-N-CA 123.639 2.893 . . . . 0.0 116.916 -169.487 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 77.3 p -127.55 -50.94 1.38 Allowed 'General case' 0 CA--C 1.534 0.344 0 C-N-CA 125.124 1.37 . . . . 0.0 107.725 171.132 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.7 mm-40 -79.0 122.5 26.26 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 123.276 0.63 . . . . 0.0 110.37 177.553 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -79.8 40.31 2.26 Favored Glycine 0 CA--C 1.53 0.979 0 N-CA-C 110.73 -0.948 . . . . 0.0 110.73 174.491 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 72.7 mt -136.89 117.82 17.82 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.439 0 N-CA-C 103.767 -2.679 . . . . 0.0 103.767 -179.237 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 95.3 t -120.59 109.4 25.44 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.348 0 C-N-CA 122.962 0.505 . . . . 0.0 110.128 -173.891 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 7.5 m -91.15 -173.2 0.21 Allowed 'Isoleucine or valine' 0 CA--C 1.538 0.493 0 N-CA-C 106.578 -1.638 . . . . 0.0 106.578 172.705 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 3.6 m -116.3 147.57 39.78 Favored Pre-proline 0 N--CA 1.469 0.49 0 CA-C-O 117.199 -1.381 . . . . 0.0 112.723 -175.108 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 42.6 Cg_endo -61.54 -38.92 58.98 Favored 'Trans proline' 0 C--N 1.349 0.594 0 C-N-CA 121.883 1.722 . . . . 0.0 108.305 174.65 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 2.5 p -154.46 142.0 12.75 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.702 0 N-CA-C 102.921 -2.992 . . . . 0.0 102.921 171.151 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 29.1 mtm180 -95.12 -79.91 0.42 Allowed 'General case' 0 CA--C 1.511 -0.53 0 N-CA-C 102.094 -3.299 . . . . 0.0 102.094 171.902 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 72.88 -73.76 0.99 Allowed Glycine 0 C--N 1.338 0.64 0 N-CA-C 107.96 -2.056 . . . . 0.0 107.96 176.166 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -150.21 123.1 8.72 Favored 'General case' 0 N--CA 1.438 -1.04 0 N-CA-C 106.796 -1.557 . . . . 0.0 106.796 176.765 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 24.1 mm -70.12 128.4 33.39 Favored 'Isoleucine or valine' 0 C--N 1.344 0.369 0 N-CA-C 106.294 -1.743 . . . . 0.0 106.294 178.129 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.7 tt -78.43 -52.54 8.41 Favored 'General case' 0 N--CA 1.453 -0.303 0 N-CA-C 105.049 -2.204 . . . . 0.0 105.049 176.881 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 13.3 t-20 174.18 161.17 0.18 Allowed 'General case' 0 N--CA 1.463 0.2 0 C-N-CA 124.614 1.166 . . . . 0.0 108.56 178.539 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 7.7 p -135.54 121.5 31.16 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.436 0 N-CA-C 104.999 -2.223 . . . . 0.0 104.999 172.04 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 29.6 m-85 -38.53 146.46 0.3 Allowed Pre-proline 0 CA--C 1.541 0.611 0 CA-C-N 118.791 0.723 . . . . 0.0 112.947 178.286 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 35.1 Cg_endo -58.63 -43.01 48.42 Favored 'Trans proline' 0 N--CA 1.458 -0.588 0 C-N-CA 122.931 2.421 . . . . 0.0 109.723 176.453 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 15.9 p -78.23 74.27 4.77 Favored 'General case' 0 N--CA 1.452 -0.347 0 N-CA-C 104.978 -2.23 . . . . 0.0 104.978 173.591 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -34.4 93.24 0.01 OUTLIER 'General case' 0 N--CA 1.444 -0.746 0 C-N-CA 129.261 3.024 . . . . 0.0 113.471 -173.671 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . 0.442 ' CD2' HG23 ' A' ' 89' ' ' VAL . 0.0 OUTLIER -158.56 -19.2 0.07 Allowed 'General case' 0 C--O 1.225 -0.229 0 N-CA-C 113.409 0.892 . . . . 0.0 113.409 175.31 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -164.77 -177.84 4.96 Favored 'General case' 0 C--O 1.222 -0.363 0 CA-C-N 120.238 1.381 . . . . 0.0 110.839 -179.447 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.875 14.3 mm 135.57 -128.54 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.33 -0.254 1 C-N-CA 133.254 4.622 . . . . 0.0 109.141 177.274 . . . . . . . . 3 2 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -167.4 175.29 42.49 Favored Glycine 0 CA--C 1.529 0.91 0 N-CA-C 118.769 2.268 . . . . 0.0 118.769 -178.349 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 39.0 mt -128.72 172.94 10.76 Favored 'General case' 0 CA--C 1.531 0.245 0 C-N-CA 127.478 2.311 . . . . 0.0 109.576 -178.255 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 42.4 mt-30 -148.61 140.91 24.14 Favored 'General case' 0 N--CA 1.448 -0.545 0 C-N-CA 125.828 1.651 . . . . 0.0 106.835 176.339 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 59.6 p -77.45 -106.95 0.02 OUTLIER 'General case' 0 CA--C 1.536 0.417 0 CA-C-O 121.049 0.452 . . . . 0.0 110.363 178.33 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.0 t0 -90.41 53.24 2.41 Favored 'General case' 0 C--N 1.331 -0.212 0 N-CA-C 105.721 -1.955 . . . . 0.0 105.721 175.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 79.86 -56.11 4.53 Favored Glycine 0 CA--C 1.529 0.917 0 N-CA-C 109.127 -1.589 . . . . 0.0 109.127 -174.933 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -67.54 173.97 28.79 Favored Glycine 0 CA--C 1.533 1.202 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 176.766 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 35.4 ttp180 54.13 69.73 0.69 Allowed 'General case' 0 CA--C 1.529 0.137 0 C-N-CA 124.446 1.099 . . . . 0.0 108.84 -177.864 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 12.9 tm-20 -79.28 134.32 36.64 Favored 'General case' 0 N--CA 1.444 -0.743 0 N-CA-C 106.34 -1.726 . . . . 0.0 106.34 176.168 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.3 mp -116.85 114.67 46.56 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 C-N-CA 123.268 0.627 . . . . 0.0 109.905 -177.521 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 1.7 tm? -81.2 125.84 30.78 Favored 'General case' 0 N--CA 1.447 -0.609 0 N-CA-C 104.196 -2.52 . . . . 0.0 104.196 170.706 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 62.7 mt -123.06 132.01 72.2 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 N-CA-C 107.63 -1.248 . . . . 0.0 107.63 -179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -128.29 132.77 48.68 Favored 'General case' 0 N--CA 1.449 -0.517 0 N-CA-C 106.309 -1.737 . . . . 0.0 106.309 174.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 1.9 t80 -116.44 104.42 11.43 Favored 'General case' 0 N--CA 1.443 -0.801 0 C-N-CA 126.16 1.784 . . . . 0.0 109.489 -177.608 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 74.77 163.06 10.02 Favored Glycine 0 CA--C 1.525 0.708 0 N-CA-C 109.894 -1.283 . . . . 0.0 109.894 -178.261 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 10.7 mm -109.02 119.85 59.33 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.512 0 N-CA-C 105.262 -2.125 . . . . 0.0 105.262 -179.05 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 13.4 t70 77.09 4.61 3.28 Favored 'General case' 0 CA--C 1.538 0.506 0 C-N-CA 125.391 1.477 . . . . 0.0 113.779 -179.861 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.0 OUTLIER -61.78 -24.87 67.12 Favored 'General case' 0 CA--C 1.531 0.228 0 O-C-N 120.761 -1.212 . . . . 0.0 110.757 177.621 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . 0.442 HG23 ' CD2' ' A' ' 68' ' ' HIS . 0.5 OUTLIER -59.86 -47.88 89.79 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.525 0 C-N-CA 125.92 1.688 . . . . 0.0 108.127 173.594 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 4.5 m -63.47 -35.59 80.94 Favored 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 124.125 0.97 . . . . 0.0 108.766 177.43 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -80.58 19.75 0.78 Allowed 'General case' 0 CA--C 1.545 0.769 0 C-N-CA 125.426 1.49 . . . . 0.0 110.873 175.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 4.8 mptt 37.77 37.59 0.13 Allowed 'General case' 0 C--N 1.346 0.42 0 C-N-CA 128.658 2.783 . . . . 0.0 114.595 178.679 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 52.58 34.42 43.07 Favored Glycine 0 CA--C 1.538 1.503 0 N-CA-C 111.938 -0.465 . . . . 0.0 111.938 -178.486 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 37.6 mt-10 -67.41 92.64 0.3 Allowed 'General case' 0 N--CA 1.455 -0.185 0 O-C-N 121.401 -1.058 . . . . 0.0 110.164 -178.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 130.47 1.67 5.12 Favored Glycine 0 CA--C 1.531 1.07 0 C-N-CA 126.043 1.782 . . . . 0.0 112.214 -178.741 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 3.8 m-85 -96.58 103.35 15.26 Favored 'General case' 0 N--CA 1.453 -0.296 0 C-N-CA 124.801 1.241 . . . . 0.0 111.263 -176.552 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 57.5 m -89.7 105.78 18.03 Favored 'General case' 0 N--CA 1.449 -0.516 0 N-CA-C 105.081 -2.192 . . . . 0.0 105.081 172.931 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 21.7 p -81.6 123.85 29.03 Favored 'General case' 0 N--CA 1.451 -0.406 0 O-C-N 121.613 -0.68 . . . . 0.0 110.402 -178.329 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 11.3 m-85 -81.41 -52.3 7.41 Favored 'General case' 0 N--CA 1.45 -0.433 0 C-N-CA 124.915 1.286 . . . . 0.0 108.911 178.847 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 17.9 m -78.32 130.46 36.16 Favored 'Isoleucine or valine' 0 C--N 1.341 0.212 0 C-N-CA 117.999 -1.48 . . . . 0.0 107.224 174.088 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.5 m -94.37 57.06 2.24 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 103.329 -2.841 . . . . 0.0 103.329 169.37 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.341 9.8 pt-20 29.32 65.96 0.11 Allowed 'General case' 0 N--CA 1.449 -0.491 0 C-N-CA 128.737 2.815 . . . . 0.0 111.681 -168.33 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -73.3 58.44 1.94 Allowed Glycine 0 CA--C 1.525 0.662 0 CA-C-N 111.574 -2.557 . . . . 0.0 111.253 -179.123 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 1.8 p-10 -10.59 -17.87 0.0 OUTLIER 'General case' 0 CA--C 1.511 -0.533 2 C-N-CA 136.188 5.795 . . . . 0.0 124.342 -179.317 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 2.1 mmm180 -142.88 110.7 5.9 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 128.062 2.545 . . . . 0.0 106.612 178.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -153.0 155.76 6.18 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.225 0 C-N-CA 123.908 0.883 . . . . 0.0 112.833 -171.847 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.7 mt-10 -80.88 151.61 70.89 Favored Pre-proline 0 CA--C 1.544 0.725 0 CA-C-O 117.948 -1.025 . . . . 0.0 108.662 175.162 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 80.6 Cg_exo -47.88 164.62 0.16 Allowed 'Trans proline' 0 CA--C 1.533 0.428 1 C-N-CA 127.018 5.145 . . . . 0.0 120.304 -174.158 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 68.45 -92.5 0.27 Allowed Glycine 0 C--N 1.34 0.796 0 C-N-CA 125.84 1.686 . . . . 0.0 113.678 175.337 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 35.5 tp60 1.18 101.9 0.01 OUTLIER 'General case' 0 N--CA 1.443 -0.793 1 C-N-CA 132.258 4.223 . . . . 0.0 114.735 -176.548 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.2 ttmt -4.14 112.95 0.01 OUTLIER 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 130.168 3.387 . . . . 0.0 116.172 178.344 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 67.6 mt -83.18 -45.25 14.12 Favored 'General case' 0 N--CA 1.453 -0.276 0 N-CA-C 108.736 -0.839 . . . . 0.0 108.736 173.563 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.0 mt -140.38 151.23 44.8 Favored 'General case' 0 CA--C 1.539 0.524 0 C-N-CA 124.723 1.209 . . . . 0.0 111.282 -174.285 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 34.4 tt0 -119.84 128.58 53.82 Favored 'General case' 0 CA--C 1.514 -0.407 1 N-CA-C 99.12 -4.4 . . . . 0.0 99.12 167.363 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.93 124.41 27.11 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.876 0 CA-C-N 115.1 -0.954 . . . . 0.0 112.756 -165.223 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 67.5 t0 -73.87 69.13 1.37 Allowed 'General case' 0 CA--C 1.533 0.316 0 C-N-CA 123.938 0.895 . . . . 0.0 110.037 178.984 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 92.1 mt -47.2 -52.49 15.62 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 123.793 0.837 . . . . 0.0 110.583 -179.991 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 29.0 t70 -43.46 -49.65 7.16 Favored 'General case' 0 N--CA 1.456 -0.171 0 C-N-CA 125.392 1.477 . . . . 0.0 112.343 -177.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -82.81 -31.36 28.21 Favored 'General case' 0 N--CA 1.457 -0.096 0 O-C-N 123.175 0.297 . . . . 0.0 111.774 -179.73 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 42.2 t -63.1 -56.48 17.13 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.48 0 CA-C-O 118.901 -0.571 . . . . 0.0 110.839 179.007 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.324 3.8 pttm -42.78 -56.29 6.22 Favored Pre-proline 0 N--CA 1.47 0.535 0 N-CA-C 116.391 1.997 . . . . 0.0 116.391 -176.93 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 39.6 Cg_endo -60.86 -14.63 33.41 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 121.699 1.6 . . . . 0.0 113.22 -178.249 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 58.4 m-80 -98.98 5.08 47.36 Favored 'General case' 0 N--CA 1.452 -0.326 0 CA-C-O 118.056 -0.973 . . . . 0.0 112.303 179.77 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 20.1 m -142.07 155.11 65.44 Favored Pre-proline 0 CA--C 1.536 0.405 0 CA-C-N 120.332 1.424 . . . . 0.0 112.166 178.651 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 51.6 Cg_exo -55.31 -39.78 89.16 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 123.086 2.524 . . . . 0.0 113.927 178.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.1 m -159.97 141.37 12.62 Favored 'General case' 0 CA--C 1.532 0.271 0 C-N-CA 123.156 0.582 . . . . 0.0 110.012 -177.511 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -92.46 14.58 16.27 Favored 'General case' 0 CA--C 1.538 0.497 0 C-N-CA 124.539 1.135 . . . . 0.0 112.068 -178.613 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.4 mmt -53.04 134.01 38.33 Favored 'General case' 0 N--CA 1.457 -0.111 0 O-C-N 121.415 -0.803 . . . . 0.0 110.369 -178.377 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 89.7 m -110.28 78.78 1.46 Allowed Pre-proline 0 N--CA 1.451 -0.378 0 N-CA-C 108.132 -1.062 . . . . 0.0 108.132 176.759 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -72.2 136.59 27.1 Favored 'Trans proline' 0 N--CA 1.448 -1.155 0 C-N-CA 122.449 2.1 . . . . 0.0 110.269 178.381 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 30.8 mt -128.98 134.66 63.79 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.471 0 N-CA-C 106.059 -1.83 . . . . 0.0 106.059 178.395 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 6.2 t -136.53 126.15 38.77 Favored 'Isoleucine or valine' 0 CA--C 1.521 -0.17 0 C-N-CA 125.165 1.386 . . . . 0.0 108.55 -179.071 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.457 ' HB2' ' CD2' ' A' ' 136' ' ' LEU . 13.9 m-85 -92.93 124.13 36.68 Favored 'General case' 0 N--CA 1.445 -0.721 0 N-CA-C 103.525 -2.769 . . . . 0.0 103.525 176.819 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 77.7 p -86.49 -82.28 0.2 Allowed 'General case' 0 N--CA 1.453 -0.32 0 CA-C-N 119.071 0.85 . . . . 0.0 109.319 -176.117 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 6.6 p30 -77.01 52.34 0.87 Allowed 'General case' 0 CA--C 1.534 0.361 0 N-CA-C 112.446 0.535 . . . . 0.0 112.446 -179.451 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.457 ' CD2' ' HB2' ' A' ' 133' ' ' PHE . 0.2 OUTLIER -78.78 72.26 5.29 Favored 'General case' 0 CA--C 1.534 0.361 0 O-C-N 121.249 -0.907 . . . . 0.0 108.666 174.509 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 41.87 47.86 3.74 Favored 'General case' 0 CA--C 1.53 0.209 0 C-N-CA 126.603 1.961 . . . . 0.0 111.256 -178.259 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.7 mp0 18.9 68.42 0.02 OUTLIER 'General case' 0 N--CA 1.456 -0.137 0 C-N-CA 129.394 3.077 . . . . 0.0 113.245 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 154.75 -9.65 0.39 Allowed Glycine 0 CA--C 1.523 0.574 0 CA-C-O 118.508 -1.162 . . . . 0.0 113.021 179.356 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.666 ' HB3' HG23 ' A' ' 160' ' ' ILE . 59.1 mm-40 -69.09 116.93 10.1 Favored 'General case' 0 C--N 1.342 0.281 0 CA-C-N 119.626 1.713 . . . . 0.0 110.069 178.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 4.2 p -77.73 136.07 38.11 Favored 'General case' 0 N--CA 1.44 -0.959 0 N-CA-C 105.828 -1.915 . . . . 0.0 105.828 173.006 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -86.69 86.74 2.58 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.517 0 N-CA-C 107.538 -1.282 . . . . 0.0 107.538 -176.768 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.2 m -77.42 83.31 3.85 Favored 'General case' 0 N--CA 1.451 -0.402 0 O-C-N 120.82 -1.175 . . . . 0.0 110.99 -175.034 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . 0.471 HG22 HG22 ' A' ' 158' ' ' VAL . 2.1 pt -56.59 111.15 0.39 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.432 0 N-CA-C 107.75 -1.204 . . . . 0.0 107.75 173.636 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 1.2 mmmp? -88.73 -38.57 14.62 Favored 'General case' 0 C--N 1.33 -0.249 0 C-N-CA 123.892 0.877 . . . . 0.0 109.636 -179.399 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -81.12 75.77 8.08 Favored 'General case' 0 N--CA 1.448 -0.557 0 CA-C-N 116.056 -0.52 . . . . 0.0 110.463 -175.782 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 50.6 p -77.39 69.44 3.65 Favored 'General case' 0 N--CA 1.453 -0.324 0 N-CA-C 107.893 -1.151 . . . . 0.0 107.893 178.34 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 169.38 -137.43 4.52 Favored Glycine 0 CA--C 1.523 0.558 0 N-CA-C 108.313 -1.915 . . . . 0.0 108.313 -176.7 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.7 t -75.43 149.07 38.64 Favored 'General case' 0 CA--C 1.531 0.247 0 N-CA-C 109.802 -0.444 . . . . 0.0 109.802 176.646 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.7 m -119.98 158.93 21.59 Favored 'Isoleucine or valine' 0 C--O 1.233 0.191 0 C-N-CA 125.374 1.469 . . . . 0.0 109.048 178.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -131.79 166.98 20.34 Favored 'General case' 0 CA--C 1.519 -0.233 0 C-N-CA 125.688 1.595 . . . . 0.0 112.22 176.416 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 73.5 mtm-85 -85.65 154.25 21.81 Favored 'General case' 0 N--CA 1.455 -0.205 0 N-CA-C 113.977 1.103 . . . . 0.0 113.977 -175.347 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 52.1 mt-10 57.52 55.11 5.9 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 126.448 1.899 . . . . 0.0 113.591 176.324 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . 0.503 ' CB ' HD13 ' A' ' 157' ' ' ILE . 4.3 mm-40 -143.05 161.12 38.99 Favored 'General case' 0 CA--C 1.539 0.543 0 C-N-CA 123.964 0.906 . . . . 0.0 109.76 176.835 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . 0.452 ' C ' ' H ' ' A' ' 157' ' ' ILE . 62.9 tt0 -105.52 -61.1 1.53 Allowed 'General case' 0 CA--C 1.509 -0.602 0 CA-C-O 122.817 1.294 . . . . 0.0 112.314 -177.412 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.436 ' C ' HD12 ' A' ' 157' ' ' ILE . 0.9 OUTLIER -65.68 27.34 0.02 OUTLIER 'General case' 0 C--N 1.321 -0.642 0 C-N-CA 127.705 2.402 . . . . 0.0 114.682 -174.326 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.503 HD13 ' CB ' ' A' ' 154' ' ' GLN . 1.7 mp -103.17 -34.7 3.56 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.826 0 C-N-CA 130.225 3.41 . . . . 0.0 104.976 177.451 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.471 HG22 HG22 ' A' ' 144' ' ' ILE . 59.4 t -149.05 109.82 0.55 Allowed 'Isoleucine or valine' 0 C--N 1.344 0.336 0 N-CA-C 106.062 -1.829 . . . . 0.0 106.062 173.147 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 52.4 mtpt -101.77 124.31 47.2 Favored 'General case' 0 C--O 1.226 -0.158 0 CA-C-N 118.049 0.386 . . . . 0.0 111.78 -176.772 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.666 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.4 mp -78.15 108.8 12.02 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.422 0 N-CA-C 104.544 -2.391 . . . . 0.0 104.544 174.685 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 93.7 mt-10 -128.9 150.62 50.28 Favored 'General case' 0 C--O 1.226 -0.157 0 C-N-CA 124.383 1.073 . . . . 0.0 109.261 -175.783 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 50.9 tptt . . . . . 0 C--N 1.333 -0.136 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 -179.815 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 27.8 ttt . . . . . 0 N--CA 1.453 -0.279 0 N-CA-C 109.936 -0.394 . . . . 0.0 109.936 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 31.0 mm -77.07 62.77 0.17 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 124.463 1.105 . . . . 0.0 108.562 179.746 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -76.39 55.09 0.96 Allowed 'General case' 0 CA--C 1.533 0.3 0 C-N-CA 124.519 1.128 . . . . 0.0 111.93 -177.523 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 52.6 mt-10 -61.28 -42.97 88.24 Favored Pre-proline 0 CA--C 1.538 0.516 0 CA-C-O 118.005 -0.998 . . . . 0.0 112.463 177.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 24.6 Cg_exo -67.4 66.14 0.73 Allowed 'Trans proline' 0 CA--C 1.544 1.007 0 C-N-CA 123.568 2.845 . . . . 0.0 113.219 179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 94.7 mt -73.31 65.29 0.85 Allowed 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 125.295 1.438 . . . . 0.0 110.696 179.948 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 2.6 pt20 -73.53 56.64 0.52 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 125.998 1.719 . . . . 0.0 111.393 -179.609 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.0 OUTLIER -77.37 73.65 3.94 Favored 'General case' 0 C--O 1.231 0.1 0 O-C-N 121.508 -0.745 . . . . 0.0 109.288 179.631 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 7.2 mm-40 46.61 54.32 8.94 Favored 'General case' 0 C--N 1.327 -0.386 0 C-N-CA 124.892 1.277 . . . . 0.0 111.467 177.274 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 45.2 pt -92.12 18.32 0.99 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.418 0 C-N-CA 123.89 0.876 . . . . 0.0 113.232 -176.906 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 177.07 -147.06 8.12 Favored Glycine 0 N--CA 1.447 -0.609 0 N-CA-C 107.487 -2.245 . . . . 0.0 107.487 179.068 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -79.81 68.35 5.86 Favored 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 107.404 -1.332 . . . . 0.0 107.404 177.513 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 34.4 mt-10 -105.2 -139.25 0.36 Allowed 'General case' 0 CA--C 1.541 0.622 0 N-CA-C 116.464 2.024 . . . . 0.0 116.464 -172.743 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 2.1 t -71.64 52.05 0.03 OUTLIER 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 N-CA-C 116.96 2.207 . . . . 0.0 116.96 -169.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -160.53 128.45 4.53 Favored 'General case' 0 C--N 1.32 -0.688 0 N-CA-C 104.269 -2.493 . . . . 0.0 104.269 171.255 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 3.4 m -123.77 85.67 0.97 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.244 0 CA-C-N 118.846 0.748 . . . . 0.0 110.958 -176.375 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 97.4 p -19.45 110.25 0.09 OUTLIER Pre-proline 0 CA--C 1.553 1.077 0 C-N-CA 129.569 3.147 . . . . 0.0 110.512 177.806 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -68.64 -25.13 34.6 Favored 'Trans proline' 0 N--CA 1.459 -0.551 0 C-N-CA 122.776 2.317 . . . . 0.0 117.931 -168.498 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -145.95 146.1 19.57 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 CA-C-N 119.611 1.096 . . . . 0.0 109.598 -178.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 34.1 m -79.34 137.45 37.33 Favored 'General case' 0 C--O 1.238 0.454 0 N-CA-C 104.703 -2.332 . . . . 0.0 104.703 170.615 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 173.82 -158.25 27.09 Favored Glycine 0 C--O 1.227 -0.312 0 N-CA-C 109.19 -1.564 . . . . 0.0 109.19 -178.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 27.5 tt0 -108.4 120.61 42.89 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.367 -0.975 . . . . 0.0 108.367 179.17 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 17.9 tt -85.51 134.92 26.05 Favored 'Isoleucine or valine' 0 C--O 1.235 0.34 0 CA-C-N 118.569 0.622 . . . . 0.0 109.718 178.635 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 87.0 m-70 -137.59 149.42 64.97 Favored Pre-proline 0 N--CA 1.451 -0.389 0 C-N-CA 125.79 1.636 . . . . 0.0 107.753 176.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 23.7 Cg_exo -61.65 143.37 96.57 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 C-N-CA 121.366 1.378 . . . . 0.0 108.566 173.935 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.1 tt -55.05 -24.82 15.27 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.69 0 N-CA-C 114.582 1.327 . . . . 0.0 114.582 -173.774 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 12.3 p -52.42 -31.02 32.28 Favored 'General case' 0 N--CA 1.453 -0.3 0 C-N-CA 124.279 1.032 . . . . 0.0 111.134 174.696 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 2.3 m-20 -75.16 -9.72 58.8 Favored 'General case' 0 CA--C 1.535 0.384 0 C-N-CA 124.5 1.12 . . . . 0.0 112.65 -176.448 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 46.9 t -76.63 131.74 73.53 Favored Pre-proline 0 CA--C 1.533 0.305 0 CA-C-N 119.13 0.877 . . . . 0.0 109.861 -177.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 48.7 Cg_endo -77.8 60.1 7.1 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 123.17 2.58 . . . . 0.0 110.847 -179.848 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 53.0 t0 -165.55 102.6 0.71 Allowed 'General case' 0 CA--C 1.53 0.183 0 O-C-N 121.487 -0.758 . . . . 0.0 110.01 179.983 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 24.0 tt0 -24.41 -59.0 0.05 Allowed 'General case' 0 CA--C 1.534 0.35 0 C-N-CA 128.476 2.71 . . . . 0.0 115.055 -178.45 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -52.03 -41.85 33.04 Favored 'Isoleucine or valine' 0 CA--C 1.535 0.39 0 C-N-CA 123.178 0.591 . . . . 0.0 111.583 -177.723 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 22.7 m-85 -80.67 -48.56 12.43 Favored 'General case' 0 N--CA 1.45 -0.429 0 N-CA-C 108.528 -0.916 . . . . 0.0 108.528 177.125 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.7 m -48.71 -41.54 32.16 Favored 'General case' 0 CA--C 1.532 0.272 0 N-CA-C 113.665 0.987 . . . . 0.0 113.665 -179.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -99.61 11.2 61.2 Favored Glycine 0 C--N 1.337 0.62 0 CA-C-O 118.629 -1.095 . . . . 0.0 111.515 -178.411 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 27.5 mtmm 73.37 -39.5 0.44 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.573 1.549 . . . . 0.0 112.773 -179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 13.7 tpt 21.7 -62.24 0.0 OUTLIER 'General case' 0 CA--C 1.536 0.422 1 C-N-CA 132.264 4.226 . . . . 0.0 117.996 178.455 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -77.71 -21.63 51.67 Favored 'General case' 0 CA--C 1.534 0.365 0 C-N-CA 123.991 0.916 . . . . 0.0 111.898 -176.465 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 179.32 -136.29 2.78 Favored Glycine 0 C--N 1.336 0.528 0 N-CA-C 109.074 -1.611 . . . . 0.0 109.074 -179.202 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 39.0 t0 -130.27 157.55 42.21 Favored 'General case' 0 CA--C 1.515 -0.395 0 N-CA-C 104.955 -2.239 . . . . 0.0 104.955 172.915 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -178.71 -167.74 36.87 Favored Glycine 0 N--CA 1.449 -0.436 0 C-N-CA 120.53 -0.843 . . . . 0.0 112.943 -176.103 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 27.4 p90 -146.81 154.72 41.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 C-N-CA 124.283 1.033 . . . . 0.0 109.718 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -100.76 119.09 38.11 Favored 'General case' 0 N--CA 1.45 -0.436 0 C-N-CA 124.009 0.923 . . . . 0.0 109.917 -179.921 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 31.3 mm -100.8 129.53 51.56 Favored 'Isoleucine or valine' 0 N--CA 1.449 -0.504 0 N-CA-C 104.7 -2.333 . . . . 0.0 104.7 171.334 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 5.3 tt -98.14 105.83 30.98 Favored Pre-proline 0 N--CA 1.45 -0.426 0 N-CA-C 101.326 -3.583 . . . . 0.0 101.326 172.561 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 58.4 Cg_exo -60.5 167.31 8.26 Favored 'Trans proline' 0 N--CA 1.459 -0.502 0 C-N-CA 123.434 2.756 . . . . 0.0 117.124 -169.968 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 74.1 p -146.98 -58.92 0.28 Allowed 'General case' 0 CA--C 1.53 0.208 0 C-N-CA 125.72 1.608 . . . . 0.0 106.942 173.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 15.8 mt-10 -69.81 119.0 13.37 Favored 'General case' 0 N--CA 1.454 -0.233 0 N-CA-C 109.74 -0.467 . . . . 0.0 109.74 175.724 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -80.75 44.85 3.03 Favored Glycine 0 CA--C 1.53 1.005 0 N-CA-C 109.314 -1.515 . . . . 0.0 109.314 173.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 22.0 mt -144.06 114.64 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.371 0 N-CA-C 105.253 -2.129 . . . . 0.0 105.253 -177.045 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 60.3 t -114.65 126.14 72.13 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.288 0 C-N-CA 124.479 1.111 . . . . 0.0 109.131 -175.373 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 35.8 m -109.29 156.91 9.82 Favored 'Isoleucine or valine' 0 N--CA 1.463 0.214 0 C-N-CA 123.387 0.675 . . . . 0.0 110.363 177.949 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 26.2 m -65.67 127.2 92.86 Favored Pre-proline 0 CA--C 1.536 0.408 0 CA-C-O 118.982 -0.532 . . . . 0.0 109.879 179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 61.5 Cg_endo -70.49 -7.96 22.5 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 124.468 3.445 . . . . 0.0 116.765 -174.573 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 17.4 m -147.99 169.51 3.58 Favored 'Isoleucine or valine' 0 C--O 1.23 0.064 0 CA-C-N 119.754 1.161 . . . . 0.0 109.388 -177.207 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.06 116.18 17.49 Favored 'General case' 0 C--O 1.235 0.336 1 N-CA-C 97.978 -4.823 . . . . 0.0 97.978 166.893 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -178.69 170.26 42.11 Favored Glycine 0 N--CA 1.438 -1.215 0 C-N-CA 116.026 -2.988 . . . . 0.0 116.557 -167.08 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 10.0 mtpp -97.2 132.84 42.57 Favored 'General case' 0 N--CA 1.438 -1.041 0 C-N-CA 127.989 2.515 . . . . 0.0 109.003 -175.015 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 14.7 mm -72.8 123.96 28.65 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.259 0 N-CA-C 104.618 -2.364 . . . . 0.0 104.618 173.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 42.0 tp -78.63 -48.88 14.2 Favored 'General case' 0 N--CA 1.454 -0.267 0 N-CA-C 105.677 -1.971 . . . . 0.0 105.677 179.515 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER -177.46 171.79 1.91 Allowed 'General case' 0 N--CA 1.454 -0.251 0 C-N-CA 123.531 0.732 . . . . 0.0 109.444 173.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 51.5 t -144.16 115.08 2.27 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.298 0 N-CA-C 105.337 -2.097 . . . . 0.0 105.337 176.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 18.7 m-85 -45.5 147.33 1.47 Allowed Pre-proline 0 CA--C 1.542 0.65 0 CA-C-N 118.689 0.677 . . . . 0.0 111.454 177.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_exo -50.45 -24.22 11.84 Favored 'Trans proline' 0 CA--C 1.536 0.623 0 C-N-CA 124.102 3.202 . . . . 0.0 114.881 176.247 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 9.8 p -76.34 -15.17 60.03 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 124.636 1.174 . . . . 0.0 111.165 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.6 tppt? 70.94 4.8 5.22 Favored 'General case' 0 CA--C 1.534 0.342 0 C-N-CA 127.852 2.461 . . . . 0.0 113.344 -178.837 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 13.2 p-80 -78.97 -25.93 43.48 Favored 'General case' 0 N--CA 1.455 -0.207 0 N-CA-C 113.41 0.893 . . . . 0.0 113.41 -178.198 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.96 -173.94 2.53 Favored 'General case' 0 C--O 1.222 -0.348 0 N-CA-C 113.493 0.923 . . . . 0.0 113.493 -172.296 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.439 HG22 ' N ' ' A' ' 71' ' ' GLY 0.62 25.9 mm 132.03 -124.44 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.516 -0.345 1 C-N-CA 136.505 5.922 . . . . 0.0 105.75 178.863 . . . . . . . . 4 3 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.439 ' N ' HG22 ' A' ' 70' ' ' ILE . . . -179.96 -176.68 47.55 Favored Glycine 0 CA--C 1.523 0.583 0 N-CA-C 116.976 1.55 . . . . 0.0 116.976 -179.106 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.3 mp -126.29 171.92 10.54 Favored 'General case' 0 N--CA 1.447 -0.587 0 C-N-CA 127.519 2.327 . . . . 0.0 110.126 -178.613 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 31.0 mt-30 -140.36 136.37 33.09 Favored 'General case' 0 N--CA 1.441 -0.883 0 N-CA-C 105.009 -2.219 . . . . 0.0 105.009 169.477 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 62.9 p -71.66 -92.12 0.01 OUTLIER 'General case' 0 N--CA 1.448 -0.556 0 N-CA-C 108.904 -0.776 . . . . 0.0 108.904 178.925 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 14.6 t70 -150.21 -64.04 0.21 Allowed 'General case' 0 N--CA 1.448 -0.535 0 C-N-CA 125.221 1.409 . . . . 0.0 109.504 179.229 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -76.23 60.99 3.12 Favored Glycine 0 CA--C 1.527 0.787 0 C-N-CA 123.627 0.632 . . . . 0.0 111.54 -179.885 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 75.29 -60.07 2.77 Favored Glycine 0 CA--C 1.528 0.884 0 C-N-CA 124.054 0.835 . . . . 0.0 112.388 178.79 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 24.8 mtp180 -19.23 96.92 0.01 OUTLIER 'General case' 0 C--O 1.235 0.338 0 C-N-CA 128.449 2.7 . . . . 0.0 112.836 -179.403 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 13.2 tm-20 -93.3 150.72 20.27 Favored 'General case' 0 N--CA 1.446 -0.659 0 C-N-CA 126.866 2.066 . . . . 0.0 109.318 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.65 103.39 4.59 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.561 0 C-N-CA 124.376 1.071 . . . . 0.0 109.052 -179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 8.4 tt -85.64 136.64 33.29 Favored 'General case' 0 N--CA 1.451 -0.388 0 N-CA-C 106.498 -1.668 . . . . 0.0 106.498 174.467 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 20.0 mt -122.77 148.72 26.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.26 0 C-N-CA 123.444 0.698 . . . . 0.0 109.938 -178.738 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -139.37 126.48 21.17 Favored 'General case' 0 N--CA 1.454 -0.244 0 N-CA-C 106.49 -1.67 . . . . 0.0 106.49 170.551 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 4.0 t80 -102.41 106.22 16.94 Favored 'General case' 0 N--CA 1.446 -0.655 0 C-N-CA 124.705 1.202 . . . . 0.0 108.773 179.683 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 64.29 176.63 4.73 Favored Glycine 0 CA--C 1.533 1.191 0 CA-C-N 118.184 0.447 . . . . 0.0 113.09 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 14.6 mm -113.29 141.17 29.94 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.279 0 N-CA-C 107.473 -1.306 . . . . 0.0 107.473 179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 19.9 t70 63.27 13.32 6.88 Favored 'General case' 0 CA--C 1.54 0.591 0 C-N-CA 124.423 1.089 . . . . 0.0 112.486 -178.707 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 1.7 p -74.15 -39.74 63.06 Favored 'General case' 0 CA--C 1.505 -0.764 0 C-N-CA 126.265 1.826 . . . . 0.0 107.231 177.986 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 6.2 p -47.11 -47.56 8.83 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.151 0 C-N-CA 124.923 1.289 . . . . 0.0 109.287 171.916 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.2 m -63.98 -54.58 32.14 Favored 'General case' 0 N--CA 1.452 -0.347 0 C-N-CA 125.347 1.459 . . . . 0.0 111.304 179.399 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.1 OUTLIER -60.23 -36.89 78.74 Favored 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 123.991 0.916 . . . . 0.0 112.008 -178.257 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 81.5 mttt 79.57 145.6 0.09 Allowed 'General case' 0 N--CA 1.452 -0.344 0 C-N-CA 128.854 2.862 . . . . 0.0 108.706 -176.67 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -67.45 48.71 0.29 Allowed Glycine 0 CA--C 1.535 1.286 0 C-N-CA 124.609 1.1 . . . . 0.0 115.537 -176.25 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 25.7 pt-20 -63.75 -17.31 62.9 Favored 'General case' 0 N--CA 1.463 0.177 0 CA-C-N 119.168 1.484 . . . . 0.0 113.67 177.687 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -109.84 15.43 31.43 Favored Glycine 0 CA--C 1.531 1.054 0 C-N-CA 126.544 2.021 . . . . 0.0 111.13 177.033 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . . . . . . . . . 2.6 m-85 -107.95 99.42 8.88 Favored 'General case' 0 C--N 1.343 0.283 0 CA-C-N 118.156 0.978 . . . . 0.0 110.665 -176.809 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 4.7 m -79.44 93.99 5.48 Favored 'General case' 0 N--CA 1.445 -0.688 0 N-CA-C 104.989 -2.226 . . . . 0.0 104.989 174.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 60.1 p -79.11 127.4 31.96 Favored 'General case' 0 N--CA 1.453 -0.31 0 O-C-N 120.983 -1.073 . . . . 0.0 110.505 -177.366 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 26.0 m-85 -89.17 -49.11 6.94 Favored 'General case' 0 N--CA 1.451 -0.412 0 C-N-CA 123.836 0.854 . . . . 0.0 110.375 -179.614 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 15.0 m -78.1 133.29 30.69 Favored 'Isoleucine or valine' 0 N--CA 1.46 0.032 0 C-N-CA 119.019 -1.072 . . . . 0.0 110.559 179.8 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 55.1 m -87.73 61.5 6.5 Favored 'General case' 0 C--N 1.333 -0.128 0 N-CA-C 106.427 -1.694 . . . . 0.0 106.427 172.793 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.271 1.6 pm0 3.22 79.98 0.0 OUTLIER 'General case' 0 C--N 1.324 -0.506 0 C-N-CA 130.451 3.501 . . . . 0.0 115.211 -174.244 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 174.65 6.54 0.02 OUTLIER Glycine 0 CA--C 1.533 1.202 0 CA-C-N 113.32 -1.763 . . . . 0.0 114.812 179.333 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 3.1 m-20 -64.24 121.52 14.46 Favored 'General case' 0 N--CA 1.445 -0.713 0 CA-C-N 119.493 1.646 . . . . 0.0 107.396 176.115 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 37.8 mmt-85 -100.07 100.53 11.41 Favored 'General case' 0 N--CA 1.433 -1.289 0 C-N-CA 129.796 3.238 . . . . 0.0 111.817 -175.297 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.551 7.3 p 60.47 78.23 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.442 -0.845 0 N-CA-C 116.813 2.153 . . . . 0.0 116.813 174.173 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 -135.99 150.14 70.5 Favored Pre-proline 0 N--CA 1.446 -0.632 0 CA-C-N 111.933 -2.394 . . . . 0.0 105.141 169.15 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 84.0 Cg_endo -105.42 142.59 0.1 Allowed 'Trans proline' 0 N--CA 1.454 -0.842 0 C-N-CA 123.969 3.112 . . . . 0.0 111.803 -177.123 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 56.93 15.26 12.46 Favored Glycine 0 CA--C 1.531 1.046 0 O-C-N 121.417 -0.802 . . . . 0.0 114.289 175.588 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 62.0 tt0 -61.3 130.28 45.41 Favored 'General case' 0 N--CA 1.448 -0.536 0 N-CA-C 107.515 -1.291 . . . . 0.0 107.515 178.393 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 25.7 ttpt -59.39 117.64 5.07 Favored 'General case' 0 N--CA 1.453 -0.305 0 N-CA-C 108.456 -0.942 . . . . 0.0 108.456 178.112 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 79.4 mt -80.41 -54.2 5.92 Favored 'General case' 0 N--CA 1.447 -0.623 0 N-CA-C 108.835 -0.802 . . . . 0.0 108.835 -179.954 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 25.0 mt -144.82 151.13 38.32 Favored 'General case' 0 CA--C 1.533 0.321 0 C-N-CA 124.215 1.006 . . . . 0.0 110.871 -173.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 6.1 tm-20 -116.45 128.44 55.48 Favored 'General case' 0 CA--C 1.515 -0.398 1 N-CA-C 97.922 -4.844 . . . . 0.0 97.922 166.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . . . . . . . . . 0.0 OUTLIER -137.52 121.69 22.78 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.898 0 CA-C-N 115.193 -0.912 . . . . 0.0 111.834 -166.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.9 t0 -71.91 69.96 0.73 Allowed 'General case' 0 C--O 1.233 0.185 0 C-N-CA 124.844 1.258 . . . . 0.0 111.112 -177.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 76.3 mt -47.95 -44.85 30.53 Favored 'General case' 0 N--CA 1.454 -0.238 0 C-N-CA 124.057 0.943 . . . . 0.0 110.718 177.961 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -52.83 -43.78 66.24 Favored 'General case' 0 CA--C 1.532 0.275 0 C-N-CA 123.473 0.709 . . . . 0.0 112.794 -179.516 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -84.71 -33.36 23.16 Favored 'General case' 0 CA--C 1.529 0.164 0 CA-C-N 118.114 0.416 . . . . 0.0 111.305 179.849 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 40.3 t -63.87 -56.25 17.78 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.475 0 O-C-N 121.865 -0.522 . . . . 0.0 109.852 179.147 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.359 0.1 OUTLIER -40.74 -55.52 4.49 Favored Pre-proline 0 CA--C 1.542 0.656 0 N-CA-C 117.891 2.552 . . . . 0.0 117.891 -177.125 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -57.91 -21.65 50.38 Favored 'Trans proline' 0 N--CA 1.456 -0.71 0 C-N-CA 122.515 2.143 . . . . 0.0 112.87 178.893 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 65.6 m-80 -93.68 9.57 36.42 Favored 'General case' 0 CA--C 1.532 0.282 0 CA-C-O 118.457 -0.782 . . . . 0.0 112.216 -178.797 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 15.9 m -138.96 152.02 69.36 Favored Pre-proline 0 C--N 1.344 0.36 0 CA-C-N 119.923 1.238 . . . . 0.0 111.695 179.801 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 82.5 Cg_endo -74.03 -26.8 12.62 Favored 'Trans proline' 0 N--CA 1.454 -0.795 0 C-N-CA 123.044 2.496 . . . . 0.0 111.594 179.291 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 15.6 t -153.1 142.81 21.97 Favored 'General case' 0 N--CA 1.452 -0.364 0 N-CA-C 109.088 -0.708 . . . . 0.0 109.088 179.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -97.09 6.99 47.56 Favored 'General case' 0 N--CA 1.45 -0.465 0 C-N-CA 124.226 1.01 . . . . 0.0 110.595 178.404 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 16.5 mmt -51.01 119.61 4.12 Favored 'General case' 0 C--N 1.344 0.347 0 CA-C-N 118.5 0.591 . . . . 0.0 109.955 -179.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 29.9 m -117.2 87.52 24.05 Favored Pre-proline 0 N--CA 1.446 -0.66 0 C-N-CA 125.588 1.555 . . . . 0.0 107.645 -177.082 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.403 ' C ' HD12 ' A' ' 131' ' ' ILE . 49.8 Cg_endo -84.89 151.61 11.2 Favored 'Trans proline' 0 N--CA 1.44 -1.655 0 C-N-CA 121.411 1.407 . . . . 0.0 112.011 -178.686 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . 0.47 HD12 ' N ' ' A' ' 131' ' ' ILE . 1.3 mp -118.55 130.14 73.81 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.661 0 N-CA-C 102.792 -3.04 . . . . 0.0 102.792 173.853 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.0 t -128.6 153.4 38.05 Favored 'Isoleucine or valine' 0 CA--C 1.51 -0.58 0 N-CA-C 106.569 -1.641 . . . . 0.0 106.569 -179.5 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 17.7 m-85 -127.02 109.82 12.31 Favored 'General case' 0 N--CA 1.437 -1.087 0 N-CA-C 103.418 -2.808 . . . . 0.0 103.418 -178.557 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 69.0 p -75.2 -78.05 0.11 Allowed 'General case' 0 CA--C 1.528 0.123 0 N-CA-C 109.064 -0.717 . . . . 0.0 109.064 -175.864 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.6 OUTLIER -74.03 65.86 1.15 Allowed 'General case' 0 CA--C 1.536 0.415 0 CA-C-O 121.587 0.708 . . . . 0.0 112.096 -179.941 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 16.4 mt -72.81 70.41 0.98 Allowed 'General case' 0 CA--C 1.537 0.462 0 C-N-CA 125.144 1.378 . . . . 0.0 108.273 176.315 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 27.74 48.99 0.02 OUTLIER 'General case' 0 N--CA 1.468 0.434 0 C-N-CA 128.508 2.723 . . . . 0.0 111.921 -176.63 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.1 mm-40 28.5 53.52 0.08 Allowed 'General case' 0 N--CA 1.452 -0.371 0 C-N-CA 128.74 2.816 . . . . 0.0 114.44 -175.647 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 167.09 -4.71 0.05 OUTLIER Glycine 0 CA--C 1.528 0.848 0 CA-C-O 118.979 -0.901 . . . . 0.0 114.227 178.499 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.571 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 3.7 mm-40 -87.35 148.01 25.23 Favored 'General case' 0 CA--C 1.532 0.266 0 CA-C-N 118.838 1.319 . . . . 0.0 110.178 -179.147 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 51.0 p -123.89 140.42 53.0 Favored 'General case' 0 N--CA 1.456 -0.147 0 C-N-CA 124.943 1.297 . . . . 0.0 108.102 179.035 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -86.08 95.35 4.6 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.449 0 CA-C-O 122.064 0.935 . . . . 0.0 108.952 -177.563 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 62.1 m -84.74 87.36 7.3 Favored 'General case' 0 N--CA 1.452 -0.33 0 O-C-N 121.301 -0.875 . . . . 0.0 109.836 -179.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 1.8 pt -66.07 128.78 29.63 Favored 'Isoleucine or valine' 0 CA--C 1.528 0.105 0 N-CA-C 108.419 -0.956 . . . . 0.0 108.419 174.733 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 82.8 mttt -103.2 -46.9 4.48 Favored 'General case' 0 N--CA 1.45 -0.428 0 C-N-CA 124.557 1.143 . . . . 0.0 109.708 179.044 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -76.14 156.69 33.53 Favored 'General case' 0 N--CA 1.453 -0.309 0 CA-C-O 121.433 0.635 . . . . 0.0 111.629 -179.619 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 27.9 p -150.62 113.26 4.71 Favored 'General case' 0 N--CA 1.451 -0.407 0 N-CA-C 104.774 -2.306 . . . . 0.0 104.774 178.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 115.8 -151.57 18.33 Favored Glycine 0 CA--C 1.527 0.833 0 N-CA-C 109.599 -1.4 . . . . 0.0 109.599 -175.943 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 22.9 t -59.12 139.93 56.38 Favored 'General case' 0 CA--C 1.532 0.273 0 CA-C-N 118.347 1.074 . . . . 0.0 112.379 -177.701 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 28.5 m -143.52 146.32 21.36 Favored 'Isoleucine or valine' 0 N--CA 1.456 -0.168 0 C-N-CA 126.23 1.812 . . . . 0.0 108.64 177.363 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 84.2 m-20 -101.59 160.18 14.67 Favored 'General case' 0 C--O 1.231 0.109 0 C-N-CA 124.491 1.116 . . . . 0.0 110.768 -179.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 32.2 ttp180 -75.77 154.99 35.93 Favored 'General case' 0 CA--C 1.539 0.522 0 C-N-CA 125.524 1.53 . . . . 0.0 110.887 178.192 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 50.1 mt-10 57.98 52.96 7.23 Favored 'General case' 0 CA--C 1.532 0.257 0 C-N-CA 125.903 1.681 . . . . 0.0 113.222 178.219 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . 0.634 ' HB2' HD13 ' A' ' 157' ' ' ILE . 17.2 mm-40 -135.93 168.01 20.14 Favored 'General case' 0 CA--C 1.539 0.547 0 C-N-CA 125.635 1.574 . . . . 0.0 108.509 177.792 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -119.69 -77.53 0.58 Allowed 'General case' 0 C--N 1.344 0.327 0 CA-C-N 120.027 1.285 . . . . 0.0 114.238 179.403 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 2.8 p30 -37.08 -7.62 0.0 OUTLIER 'General case' 0 N--CA 1.48 1.065 1 C-N-CA 132.073 4.149 . . . . 0.0 120.194 -174.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.672 ' H ' HD12 ' A' ' 157' ' ' ILE . 4.9 mp -68.39 -33.44 60.33 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.847 0 C-N-CA 130.874 3.67 . . . . 0.0 106.889 174.565 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 10.9 p -137.29 133.62 46.84 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.628 0 C-N-CA 127.281 2.233 . . . . 0.0 106.599 173.428 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 67.0 mttm -127.08 133.03 50.52 Favored 'General case' 0 CA--C 1.52 -0.201 0 N-CA-C 109.421 -0.585 . . . . 0.0 109.421 179.423 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.571 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.06 116.2 22.58 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.783 0 N-CA-C 107.298 -1.371 . . . . 0.0 107.298 175.347 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.0 tp10 -98.26 170.83 8.6 Favored 'General case' 0 N--CA 1.45 -0.437 0 N-CA-C 106.38 -1.711 . . . . 0.0 106.38 175.551 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 34.0 mmtp . . . . . 0 CA--C 1.532 0.259 0 O-C-N 121.457 -0.777 . . . . 0.0 110.811 179.983 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 28.0 ttt . . . . . 0 N--CA 1.453 -0.296 0 N-CA-C 109.47 -0.567 . . . . 0.0 109.47 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 33.1 mm -44.02 -41.87 1.78 Allowed 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 126.349 1.86 . . . . 0.0 112.976 -177.377 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . 0.425 ' HB3' ' HA ' ' A' ' 7' ' ' GLN . . . -76.74 71.89 3.33 Favored 'General case' 0 CA--C 1.537 0.453 0 CA-C-O 121.638 0.732 . . . . 0.0 110.243 -179.79 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 47.7 mt-10 -24.8 -57.17 0.16 Allowed Pre-proline 0 CA--C 1.54 0.593 0 C-N-CA 128.062 2.545 . . . . 0.0 116.243 -179.599 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.0 Cg_endo -67.63 74.01 0.62 Allowed 'Trans proline' 0 CA--C 1.538 0.714 0 C-N-CA 122.611 2.207 . . . . 0.0 112.2 -179.174 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 71.1 mt 45.13 41.99 6.29 Favored 'General case' 0 CA--C 1.532 0.26 0 C-N-CA 126.23 1.812 . . . . 0.0 111.969 178.43 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . 0.425 ' HA ' ' HB3' ' A' ' 3' ' ' ALA . 54.3 mm-40 57.1 47.81 16.62 Favored 'General case' 0 N--CA 1.454 -0.266 0 C-N-CA 123.921 0.888 . . . . 0.0 110.282 -177.511 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.3 OUTLIER 59.6 46.0 12.52 Favored 'General case' 0 CA--C 1.528 0.117 0 C-N-CA 125.259 1.424 . . . . 0.0 108.078 -176.555 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 16.2 mp0 48.91 61.07 3.29 Favored 'General case' 0 CA--C 1.531 0.235 0 C-N-CA 124.493 1.117 . . . . 0.0 108.423 -176.428 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 48.2 mt 73.13 -40.79 0.09 OUTLIER 'Isoleucine or valine' 0 CA--C 1.536 0.421 0 C-N-CA 126.535 1.934 . . . . 0.0 110.796 -176.029 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 76.35 -71.33 2.05 Favored Glycine 0 C--N 1.335 0.524 0 N-CA-C 109.624 -1.39 . . . . 0.0 109.624 179.538 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 30.2 tt0 -68.54 68.19 0.14 Allowed 'General case' 0 CA--C 1.542 0.663 0 C-N-CA 126.058 1.743 . . . . 0.0 111.735 -178.839 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 20.2 pt-20 -150.02 -161.68 1.39 Allowed 'General case' 0 CA--C 1.542 0.666 0 C-N-CA 126.678 1.991 . . . . 0.0 110.93 179.749 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.472 12.9 p 65.23 -73.91 0.09 OUTLIER 'Isoleucine or valine' 0 C--O 1.235 0.297 0 N-CA-C 119.286 3.069 . . . . 0.0 119.286 175.392 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -115.43 153.26 31.39 Favored 'General case' 0 C--N 1.315 -0.904 0 C-N-CA 125.213 1.405 . . . . 0.0 110.637 -170.639 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 4.3 m -117.35 108.36 24.57 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.312 0 CA-C-N 119.244 0.929 . . . . 0.0 109.04 172.504 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 40.3 t -38.87 115.96 0.95 Allowed Pre-proline 0 CA--C 1.553 1.066 0 C-N-CA 124.759 1.224 . . . . 0.0 111.761 178.01 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_endo -76.82 -23.38 10.95 Favored 'Trans proline' 0 CA--C 1.537 0.646 0 C-N-CA 123.507 2.805 . . . . 0.0 118.293 -172.338 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -142.89 154.41 17.31 Favored 'Isoleucine or valine' 0 N--CA 1.467 0.38 0 CA-C-N 120.698 1.59 . . . . 0.0 109.989 -178.552 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 94.5 m -89.74 137.73 32.08 Favored 'General case' 0 C--O 1.236 0.378 0 N-CA-C 108.244 -1.021 . . . . 0.0 108.244 175.329 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 160.71 -130.71 2.44 Favored Glycine 0 CA--C 1.523 0.546 0 N-CA-C 109.46 -1.456 . . . . 0.0 109.46 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 37.6 tt0 -131.32 139.01 49.47 Favored 'General case' 0 N--CA 1.456 -0.149 0 C-N-CA 124.653 1.181 . . . . 0.0 109.087 179.648 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 13.9 tt -101.39 131.6 48.85 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.148 0 CA-C-N 118.673 0.669 . . . . 0.0 110.01 179.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 15.9 m-70 -124.64 145.49 49.6 Favored Pre-proline 0 N--CA 1.452 -0.358 0 C-N-CA 126.069 1.748 . . . . 0.0 108.036 -179.287 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 19.7 Cg_exo -62.82 141.97 86.93 Favored 'Trans proline' 0 N--CA 1.453 -0.891 0 C-N-CA 121.749 1.633 . . . . 0.0 108.598 174.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 1.6 tt -53.61 -27.29 14.71 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 114.334 1.235 . . . . 0.0 114.334 -174.431 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 6.7 p -55.02 -29.0 56.41 Favored 'General case' 0 CA--C 1.534 0.337 0 C-N-CA 123.879 0.871 . . . . 0.0 111.553 176.111 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 27.4 t0 -78.98 -1.45 35.47 Favored 'General case' 0 CA--C 1.538 0.513 0 C-N-CA 123.81 0.844 . . . . 0.0 112.937 -178.658 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 58.4 t -81.68 134.58 50.42 Favored Pre-proline 0 CA--C 1.535 0.368 0 O-C-N 121.068 -1.02 . . . . 0.0 110.181 -178.292 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 43.6 Cg_endo -77.83 54.1 4.68 Favored 'Trans proline' 0 CA--C 1.541 0.83 0 C-N-CA 123.741 2.961 . . . . 0.0 111.934 -178.62 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 41.1 t0 -167.98 109.28 0.58 Allowed 'General case' 0 CA--C 1.534 0.358 0 CA-C-N 119.308 0.958 . . . . 0.0 110.651 179.624 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.9 OUTLIER -29.43 -54.48 0.14 Allowed 'General case' 0 C--O 1.234 0.249 0 C-N-CA 128.35 2.66 . . . . 0.0 115.186 -177.716 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 11.7 p -51.56 -40.49 25.42 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.256 0 CA-C-O 120.973 0.416 . . . . 0.0 110.565 -176.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.469 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 24.5 m-85 -83.15 -52.87 6.23 Favored 'General case' 0 N--CA 1.447 -0.622 0 N-CA-C 108.407 -0.961 . . . . 0.0 108.407 177.666 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 1.4 m -46.66 -39.94 12.27 Favored 'General case' 0 CA--C 1.533 0.312 0 N-CA-C 114.349 1.241 . . . . 0.0 114.349 -177.79 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -109.11 22.77 24.62 Favored Glycine 0 C--N 1.339 0.743 0 CA-C-O 118.339 -1.256 . . . . 0.0 111.39 -177.688 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 2.8 mppt? 70.69 -45.02 0.6 Allowed 'General case' 0 CA--C 1.538 0.495 0 C-N-CA 126.028 1.731 . . . . 0.0 114.384 178.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 47.8 tpp 32.76 -68.92 0.0 OUTLIER 'General case' 0 CA--C 1.54 0.579 0 C-N-CA 130.2 3.4 . . . . 0.0 116.703 -178.096 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -79.32 -26.01 42.28 Favored 'General case' 0 CA--C 1.537 0.45 0 C-N-CA 124.974 1.31 . . . . 0.0 112.771 -176.652 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 177.12 -154.55 16.09 Favored Glycine 0 CA--C 1.523 0.582 0 N-CA-C 110.287 -1.125 . . . . 0.0 110.287 -178.957 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 42.6 t0 -108.39 153.34 23.43 Favored 'General case' 0 CA--C 1.511 -0.52 0 N-CA-C 105.555 -2.017 . . . . 0.0 105.555 174.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . -174.25 -167.46 33.77 Favored Glycine 0 N--CA 1.442 -0.951 0 C-N-CA 119.96 -1.114 . . . . 0.0 113.42 -176.325 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.506 ' CE2' HG11 ' A' ' 158' ' ' VAL . 9.4 p90 -150.02 165.13 33.64 Favored 'General case' 0 N--CA 1.45 -0.448 0 C-N-CA 124.894 1.278 . . . . 0.0 109.044 -178.461 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . . . . . . . . . . . -117.85 117.19 28.61 Favored 'General case' 0 CA--C 1.507 -0.676 0 C-N-CA 123.706 0.802 . . . . 0.0 111.289 179.346 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.8 mp -87.83 134.34 28.17 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.713 0 N-CA-C 103.994 -2.595 . . . . 0.0 103.994 170.023 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.2 tt -100.89 106.62 45.22 Favored Pre-proline 0 N--CA 1.444 -0.773 1 N-CA-C 98.054 -4.795 . . . . 0.0 98.054 169.287 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 66.7 Cg_endo -83.92 161.38 13.9 Favored 'Trans proline' 0 N--CA 1.455 -0.737 0 C-N-CA 123.439 2.76 . . . . 0.0 114.191 -168.051 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 58.7 p -130.18 -53.39 1.11 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 124.867 1.267 . . . . 0.0 109.639 176.63 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 11.7 mt-10 -67.11 128.03 34.85 Favored 'General case' 0 CA--C 1.519 -0.214 0 O-C-N 122.18 -0.325 . . . . 0.0 111.493 179.432 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . -78.45 39.55 1.93 Allowed Glycine 0 CA--C 1.529 0.927 0 N-CA-C 111.499 -0.64 . . . . 0.0 111.499 174.089 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 5.0 mp -143.62 120.53 5.53 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.258 0 N-CA-C 104.676 -2.342 . . . . 0.0 104.676 178.187 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 69.8 t -119.41 120.08 62.55 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.357 0 C-N-CA 125.695 1.598 . . . . 0.0 107.415 -176.055 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 22.0 m -106.77 157.29 7.06 Favored 'Isoleucine or valine' 0 C--N 1.338 0.099 0 N-CA-C 114.42 1.266 . . . . 0.0 114.42 -175.879 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 48.2 m -61.62 125.76 85.32 Favored Pre-proline 0 CA--C 1.537 0.48 0 CA-C-N 115.43 -0.805 . . . . 0.0 109.488 179.017 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 86.2 Cg_endo -77.52 -4.12 14.31 Favored 'Trans proline' 0 N--CA 1.456 -0.708 0 C-N-CA 124.945 3.763 . . . . 0.0 116.012 -174.312 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 31.5 m -155.21 172.88 0.57 Allowed 'Isoleucine or valine' 0 C--O 1.233 0.214 0 C-N-CA 125.297 1.439 . . . . 0.0 108.055 -176.939 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . 0.421 ' NE ' ' H ' ' A' ' 57' ' ' ARG . 0.0 OUTLIER -76.26 87.89 3.09 Favored 'General case' 0 C--N 1.34 0.16 1 N-CA-C 98.374 -4.676 . . . . 0.0 98.374 168.028 . . . . . . . . 4 4 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -98.07 176.26 30.43 Favored Glycine 0 N--CA 1.437 -1.241 0 N-CA-C 118.543 2.177 . . . . 0.0 118.543 -164.971 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.01 110.54 5.31 Favored 'General case' 0 N--CA 1.442 -0.843 0 N-CA-C 104.513 -2.403 . . . . 0.0 104.513 172.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 4.2 mm -61.82 125.14 17.58 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.269 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 -178.542 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 37.1 mt -78.95 -48.75 13.94 Favored 'General case' 0 N--CA 1.454 -0.229 0 N-CA-C 105.779 -1.934 . . . . 0.0 105.779 173.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 18.6 t-20 -173.25 159.33 3.8 Favored 'General case' 0 N--CA 1.454 -0.259 0 N-CA-C 108.725 -0.843 . . . . 0.0 108.725 177.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 55.4 t -135.4 119.81 26.75 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.563 0 N-CA-C 102.879 -3.008 . . . . 0.0 102.879 173.459 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -45.55 147.39 1.49 Allowed Pre-proline 0 CA--C 1.535 0.384 0 O-C-N 123.43 0.456 . . . . 0.0 111.55 178.208 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 30.6 Cg_endo -56.51 -25.96 61.26 Favored 'Trans proline' 0 N--CA 1.455 -0.791 0 C-N-CA 122.642 2.228 . . . . 0.0 111.214 178.753 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 55.2 p -79.97 13.49 2.21 Favored 'General case' 0 N--CA 1.447 -0.594 0 CA-C-O 117.03 -1.462 . . . . 0.0 112.596 177.294 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . 0.428 ' HD2' ' HB2' ' A' ' 96' ' ' PHE 0.275 0.1 OUTLIER 66.28 -39.6 0.33 Allowed 'General case' 0 N--CA 1.467 0.406 0 N-CA-C 117.857 2.539 . . . . 0.0 117.857 178.477 . . . . . . . . 4 4 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 6.9 p-80 -57.63 -26.6 61.82 Favored 'General case' 0 N--CA 1.446 -0.636 0 N-CA-C 116.269 1.951 . . . . 0.0 116.269 -167.278 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -157.93 -175.99 5.67 Favored 'General case' 0 C--O 1.221 -0.396 0 N-CA-C 114.292 1.219 . . . . 0.0 114.292 -172.237 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.847 26.9 mm 127.0 -135.24 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.52 -0.192 1 C-N-CA 133.25 4.62 . . . . 0.0 110.289 178.51 . . . . . . . . 3 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -166.89 173.47 42.2 Favored Glycine 0 CA--C 1.526 0.762 0 N-CA-C 118.43 2.132 . . . . 0.0 118.43 -176.044 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 3.7 mp -127.64 175.16 8.49 Favored 'General case' 0 N--CA 1.454 -0.273 0 C-N-CA 128.208 2.603 . . . . 0.0 109.854 -177.825 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 1.6 mt-30 -137.07 160.74 38.07 Favored 'General case' 0 N--CA 1.443 -0.802 0 N-CA-C 103.258 -2.867 . . . . 0.0 103.258 168.567 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 83.6 p -79.69 -99.77 0.03 OUTLIER 'General case' 0 CA--C 1.535 0.388 0 O-C-N 124.055 0.847 . . . . 0.0 109.448 177.861 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 20.6 t70 -98.57 -56.4 2.47 Favored 'General case' 0 CA--C 1.529 0.142 0 C-N-CA 124.553 1.141 . . . . 0.0 108.97 177.603 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . -158.26 49.05 0.43 Allowed Glycine 0 CA--C 1.524 0.615 0 N-CA-C 108.69 -1.764 . . . . 0.0 108.69 179.25 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . 168.02 -168.95 41.11 Favored Glycine 0 CA--C 1.523 0.577 0 N-CA-C 107.87 -2.092 . . . . 0.0 107.87 -178.079 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 74.4 mtp180 49.37 68.64 0.69 Allowed 'General case' 0 CA--C 1.524 -0.041 0 C-N-CA 124.833 1.253 . . . . 0.0 109.84 -178.72 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 39.5 tt0 -79.63 109.96 14.51 Favored 'General case' 0 N--CA 1.438 -1.07 0 C-N-CA 125.327 1.451 . . . . 0.0 107.389 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 2.4 mp -95.96 116.56 38.07 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.692 0 C-N-CA 125.381 1.472 . . . . 0.0 109.763 -176.467 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 9.2 tp -93.58 122.29 35.87 Favored 'General case' 0 N--CA 1.452 -0.366 0 N-CA-C 105.316 -2.105 . . . . 0.0 105.316 172.663 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 24.0 mt -113.82 134.53 56.34 Favored 'Isoleucine or valine' 0 C--N 1.332 -0.185 0 C-N-CA 124.938 1.295 . . . . 0.0 108.741 179.269 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 50.7 t-80 -131.24 109.76 10.63 Favored 'General case' 0 N--CA 1.454 -0.238 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 171.799 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.435 ' HA ' HG23 ' A' ' 129' ' ' THR . 6.4 t80 -78.51 119.6 22.02 Favored 'General case' 0 N--CA 1.445 -0.703 0 CA-C-O 118.708 -0.663 . . . . 0.0 109.443 179.871 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 53.1 -161.26 2.97 Favored Glycine 0 CA--C 1.534 1.235 0 CA-C-O 121.71 0.617 . . . . 0.0 113.341 178.545 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 12.9 mm -131.17 145.5 35.29 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.336 0 N-CA-C 105.741 -1.948 . . . . 0.0 105.741 178.301 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 17.4 t70 62.67 15.34 7.96 Favored 'General case' 0 CA--C 1.541 0.6 0 C-N-CA 124.5 1.12 . . . . 0.0 113.426 179.713 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.9 p -78.52 -37.7 42.42 Favored 'General case' 0 C--N 1.329 -0.287 0 C-N-CA 126.251 1.821 . . . . 0.0 107.468 178.584 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 9.1 p -50.71 -45.26 27.08 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.025 0 CA-C-N 113.77 -1.559 . . . . 0.0 108.787 172.386 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.3 m -63.31 -37.86 88.92 Favored 'General case' 0 N--CA 1.456 -0.16 0 C-N-CA 125.531 1.532 . . . . 0.0 111.329 178.455 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER -63.65 -39.44 94.36 Favored 'General case' 0 CA--C 1.538 0.493 0 C-N-CA 127.145 2.178 . . . . 0.0 109.898 -179.804 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 50.7 mttp 59.62 88.01 0.08 Allowed 'General case' 0 N--CA 1.466 0.369 0 C-N-CA 125.782 1.633 . . . . 0.0 114.223 175.853 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 75.4 -55.63 2.85 Favored Glycine 0 CA--C 1.539 1.582 0 O-C-N 121.375 -0.828 . . . . 0.0 112.856 175.244 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 76.1 mt-10 -28.17 108.3 0.04 OUTLIER 'General case' 0 N--CA 1.45 -0.43 0 C-N-CA 128.911 2.884 . . . . 0.0 114.034 179.752 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 92.24 -2.14 74.39 Favored Glycine 0 CA--C 1.53 0.994 0 CA-C-N 113.976 -1.466 . . . . 0.0 114.764 175.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.473 ' CG ' HG12 ' A' ' 115' ' ' VAL . 2.4 m-85 -108.86 109.51 20.63 Favored 'General case' 0 CA--C 1.516 -0.344 0 CA-C-N 117.857 0.828 . . . . 0.0 109.823 -176.684 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 19.7 m -79.9 81.18 6.2 Favored 'General case' 0 N--CA 1.443 -0.8 0 N-CA-C 102.741 -3.059 . . . . 0.0 102.741 169.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 56.8 p -76.99 114.09 15.41 Favored 'General case' 0 N--CA 1.449 -0.515 0 N-CA-C 105.613 -1.995 . . . . 0.0 105.613 -178.492 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . 0.402 ' CE1' ' HG3' ' A' ' 114' ' ' GLU . 22.7 m-85 -77.64 -46.17 22.86 Favored 'General case' 0 CA--C 1.511 -0.551 0 C-N-CA 123.459 0.703 . . . . 0.0 111.297 -173.265 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 16.4 m -81.56 125.98 39.75 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.297 0 C-N-CA 117.122 -1.831 . . . . 0.0 109.96 -179.27 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 70.7 m -92.48 58.39 3.16 Favored 'General case' 0 C--N 1.329 -0.299 0 N-CA-C 102.375 -3.195 . . . . 0.0 102.375 168.476 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.449 0.0 OUTLIER 30.47 54.35 0.16 Allowed 'General case' 0 N--CA 1.449 -0.519 0 C-N-CA 129.307 3.043 . . . . 0.0 112.907 -168.43 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -74.03 62.92 2.08 Favored Glycine 0 CA--C 1.522 0.515 0 CA-C-N 110.265 -3.152 . . . . 0.0 110.712 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 33.0 t70 3.92 -106.46 0.0 OUTLIER 'General case' 0 N--CA 1.441 -0.882 0 C-N-CA 130.098 3.359 . . . . 0.0 116.312 -179.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 5.2 mmm180 -55.14 106.99 0.26 Allowed 'General case' 0 N--CA 1.437 -1.105 0 C-N-CA 126.084 1.754 . . . . 0.0 111.617 -173.018 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 2.5 m -124.14 157.1 31.54 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.196 0 C-N-CA 126.811 2.044 . . . . 0.0 111.692 -179.128 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 24.4 mm-40 -86.83 164.17 37.97 Favored Pre-proline 0 CA--C 1.535 0.379 0 N-CA-C 106.923 -1.51 . . . . 0.0 106.923 172.289 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 2.7 Cg_exo -70.25 154.21 65.98 Favored 'Trans proline' 0 N--CA 1.449 -1.139 0 N-CA-C 106.58 -2.123 . . . . 0.0 106.58 178.072 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 77.9 -15.15 8.62 Favored Glycine 0 CA--C 1.534 1.223 0 C-N-CA 119.586 -1.292 . . . . 0.0 114.072 178.466 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 0.2 OUTLIER -60.29 125.96 25.66 Favored 'General case' 0 CA--C 1.539 0.524 0 N-CA-C 106.606 -1.628 . . . . 0.0 106.606 176.86 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . 0.311 0.0 OUTLIER -66.74 119.95 12.68 Favored 'General case' 0 C--N 1.343 0.3 0 CA-C-N 119.102 0.865 . . . . 0.0 111.428 -177.268 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 77.4 mt -79.67 -41.5 26.74 Favored 'General case' 0 N--CA 1.452 -0.35 0 N-CA-C 108.007 -1.109 . . . . 0.0 108.007 178.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 3.3 mp -147.82 146.26 29.06 Favored 'General case' 0 CA--C 1.534 0.359 0 C-N-CA 124.126 0.97 . . . . 0.0 111.059 -178.69 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . 0.402 ' HG3' ' CE1' ' A' ' 99' ' ' PHE . 93.7 mt-10 -114.55 130.6 56.77 Favored 'General case' 0 N--CA 1.463 0.196 1 N-CA-C 99.203 -4.369 . . . . 0.0 99.203 166.539 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.473 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -138.74 127.81 30.6 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.746 0 CA-C-N 116.444 -0.344 . . . . 0.0 110.633 -164.307 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 65.3 t0 -75.71 65.41 1.87 Allowed 'General case' 0 C--O 1.233 0.216 0 CA-C-O 121.137 0.494 . . . . 0.0 110.247 -179.009 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 84.5 mt -50.42 -38.1 41.37 Favored 'General case' 0 N--CA 1.456 -0.125 0 C-N-CA 123.617 0.767 . . . . 0.0 111.796 -178.686 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 34.4 t70 -54.21 -40.19 67.38 Favored 'General case' 0 CA--C 1.533 0.325 0 C-N-CA 122.899 0.48 . . . . 0.0 112.162 178.507 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -91.06 -32.77 15.76 Favored 'General case' 0 CA--C 1.527 0.096 0 C-N-CA 122.829 0.452 . . . . 0.0 111.34 179.734 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.27 -48.58 84.88 Favored 'Isoleucine or valine' 0 CA--C 1.534 0.354 0 O-C-N 121.622 -0.673 . . . . 0.0 109.699 178.955 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.376 40.6 pttt -41.73 -58.38 3.23 Favored Pre-proline 0 CA--C 1.544 0.714 0 N-CA-C 116.498 2.036 . . . . 0.0 116.498 -177.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 49.2 Cg_endo -59.42 -20.0 54.22 Favored 'Trans proline' 0 N--CA 1.456 -0.679 0 C-N-CA 122.258 1.972 . . . . 0.0 113.137 177.897 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 64.1 m-80 -95.61 9.11 41.37 Favored 'General case' 0 CA--C 1.532 0.286 0 C-N-CA 123.773 0.829 . . . . 0.0 112.351 -178.863 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 31.4 m -133.44 149.46 72.38 Favored Pre-proline 0 N--CA 1.464 0.274 0 CA-C-N 119.747 1.158 . . . . 0.0 109.9 177.559 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_endo -72.24 -27.71 16.22 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 C-N-CA 122.576 2.184 . . . . 0.0 111.187 179.433 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 5.4 m -160.2 138.31 10.03 Favored 'General case' 0 N--CA 1.454 -0.274 0 N-CA-C 108.28 -1.007 . . . . 0.0 108.28 -179.282 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.0 tp -91.54 7.11 42.94 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.344 1.058 . . . . 0.0 111.524 -179.16 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 20.3 mmt -50.3 116.13 1.74 Allowed 'General case' 0 N--CA 1.453 -0.309 0 C-N-CA 123.71 0.804 . . . . 0.0 109.226 179.222 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.435 HG23 ' HA ' ' A' ' 84' ' ' PHE . 50.1 m -108.59 84.38 2.42 Favored Pre-proline 0 N--CA 1.444 -0.744 0 C-N-CA 124.276 1.03 . . . . 0.0 108.317 -179.372 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.469 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 72.5 Cg_endo -72.41 142.29 36.72 Favored 'Trans proline' 0 N--CA 1.444 -1.424 0 C-N-CA 122.44 2.094 . . . . 0.0 110.765 179.039 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 29.6 mt -131.15 128.52 62.05 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.814 0 N-CA-C 104.459 -2.422 . . . . 0.0 104.459 176.479 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 1.8 t -125.59 152.55 32.56 Favored 'Isoleucine or valine' 0 CA--C 1.515 -0.396 0 C-N-CA 125.314 1.446 . . . . 0.0 107.863 -177.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 18.6 m-85 -120.69 117.8 28.43 Favored 'General case' 0 N--CA 1.443 -0.82 0 N-CA-C 102.867 -3.012 . . . . 0.0 102.867 177.935 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 45.4 p -81.38 -67.89 0.74 Allowed 'General case' 0 C--N 1.333 -0.146 0 CA-C-O 121.478 0.656 . . . . 0.0 110.353 -173.003 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 49.6 p30 -70.82 51.88 0.14 Allowed 'General case' 0 CA--C 1.536 0.432 0 C-N-CA 126.442 1.897 . . . . 0.0 113.034 -179.561 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 32.7 mt -75.72 63.84 1.66 Allowed 'General case' 0 CA--C 1.536 0.419 0 C-N-CA 124.809 1.244 . . . . 0.0 108.874 177.392 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 24.32 49.96 0.01 OUTLIER 'General case' 0 C--N 1.346 0.445 0 C-N-CA 128.969 2.908 . . . . 0.0 112.051 -176.439 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 3.6 mm-40 28.03 54.21 0.07 Allowed 'General case' 0 N--CA 1.45 -0.472 0 C-N-CA 128.649 2.78 . . . . 0.0 114.135 -174.894 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 166.72 -5.9 0.05 OUTLIER Glycine 0 CA--C 1.528 0.873 0 CA-C-O 118.853 -0.97 . . . . 0.0 114.3 178.847 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.533 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 26.8 mt-10 -80.96 138.34 36.09 Favored 'General case' 0 CA--C 1.53 0.187 0 CA-C-N 119.152 1.476 . . . . 0.0 109.701 -179.973 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 7.7 p -111.08 139.39 46.48 Favored 'General case' 0 N--CA 1.454 -0.246 0 C-N-CA 125.223 1.409 . . . . 0.0 109.273 179.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 0.4 OUTLIER -84.64 120.79 35.88 Favored 'Isoleucine or valine' 0 CA--C 1.538 0.487 0 N-CA-C 108.168 -1.049 . . . . 0.0 108.168 -179.177 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 6.3 m -114.75 95.71 5.37 Favored 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 124.665 1.186 . . . . 0.0 111.308 -174.899 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 2.3 pt -63.32 124.75 18.57 Favored 'Isoleucine or valine' 0 N--CA 1.462 0.168 0 N-CA-C 109.7 -0.481 . . . . 0.0 109.7 176.655 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 75.9 mmtt -96.08 -53.82 3.52 Favored 'General case' 0 N--CA 1.452 -0.358 0 C-N-CA 124.655 1.182 . . . . 0.0 108.376 179.328 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -86.22 74.0 10.11 Favored 'General case' 0 N--CA 1.456 -0.136 0 N-CA-C 108.785 -0.82 . . . . 0.0 108.785 179.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 47.1 p -77.04 72.76 3.61 Favored 'General case' 0 N--CA 1.454 -0.248 0 N-CA-C 108.493 -0.929 . . . . 0.0 108.493 -179.364 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 179.87 -136.51 2.77 Favored Glycine 0 N--CA 1.449 -0.487 0 N-CA-C 108.208 -1.957 . . . . 0.0 108.208 -177.391 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 19.0 t -69.0 148.78 49.6 Favored 'General case' 0 CA--C 1.533 0.291 0 N-CA-C 109.64 -0.504 . . . . 0.0 109.64 176.947 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 24.1 m -134.38 163.02 38.03 Favored 'Isoleucine or valine' 0 C--O 1.234 0.265 0 C-N-CA 125.222 1.409 . . . . 0.0 108.097 177.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -133.44 162.59 31.46 Favored 'General case' 0 CA--C 1.529 0.166 0 C-N-CA 124.687 1.195 . . . . 0.0 109.039 -178.313 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 68.6 mtp180 -65.23 147.6 53.16 Favored 'General case' 0 CA--C 1.531 0.218 0 C-N-CA 122.869 0.468 . . . . 0.0 110.509 175.676 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 25.8 tp10 57.65 12.97 1.76 Allowed 'General case' 0 N--CA 1.45 -0.425 0 C-N-CA 126.847 2.059 . . . . 0.0 114.749 173.855 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 54.1 mm-40 -71.55 117.87 13.66 Favored 'General case' 0 N--CA 1.45 -0.439 0 N-CA-C 107.58 -1.267 . . . . 0.0 107.58 176.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 14.9 tp10 -65.97 137.47 57.15 Favored 'General case' 0 N--CA 1.448 -0.54 0 N-CA-C 108.134 -1.061 . . . . 0.0 108.134 178.629 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . 0.462 ' C ' ' H ' ' A' ' 158' ' ' VAL . 27.9 t0 74.18 -111.81 0.04 OUTLIER 'General case' 0 N--CA 1.439 -1.0 0 C-N-CA 128.027 2.531 . . . . 0.0 108.448 -175.672 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . 0.271 1.6 mp 70.86 -29.06 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.322 -0.625 0 C-N-CA 129.456 3.103 . . . . 0.0 110.866 -176.703 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.506 HG11 ' CE2' ' A' ' 43' ' ' PHE . 6.2 p -143.35 119.4 4.97 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.129 0 C-N-CA 130.197 3.399 . . . . 0.0 105.003 173.148 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 28.0 tttm -111.9 139.3 47.5 Favored 'General case' 0 N--CA 1.453 -0.294 0 C-N-CA 122.767 0.427 . . . . 0.0 110.077 -176.083 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.533 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.8 mp -79.14 132.06 32.97 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.788 0 N-CA-C 105.39 -2.078 . . . . 0.0 105.39 172.152 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 94.4 mt-10 -141.26 167.96 20.91 Favored 'General case' 0 C--N 1.332 -0.192 0 N-CA-C 106.627 -1.619 . . . . 0.0 106.627 177.482 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 24.1 tptp . . . . . 0 C--N 1.33 -0.239 0 N-CA-C 109.162 -0.681 . . . . 0.0 109.162 179.865 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 26.7 ttt . . . . . 0 CA--C 1.532 0.276 0 CA-C-O 120.702 0.287 . . . . 0.0 110.406 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 23.2 mm -76.83 67.72 0.31 Allowed 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 N-CA-C 107.662 -1.236 . . . . 0.0 107.662 178.738 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -71.44 68.1 0.53 Allowed 'General case' 0 CA--C 1.532 0.254 0 C-N-CA 125.128 1.371 . . . . 0.0 112.888 -175.298 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 20.7 mm-40 -63.79 -47.33 81.61 Favored Pre-proline 0 CA--C 1.541 0.626 0 CA-C-O 118.465 -0.778 . . . . 0.0 110.617 175.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 25.0 Cg_exo -63.34 143.86 89.92 Favored 'Trans proline' 0 N--CA 1.457 -0.67 0 C-N-CA 121.695 1.597 . . . . 0.0 108.117 176.405 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 2.5 mm? -72.1 61.7 0.45 Allowed 'General case' 0 CA--C 1.541 0.611 0 N-CA-C 112.971 0.73 . . . . 0.0 112.971 -175.092 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 28.8 mm100 -81.74 63.22 5.91 Favored 'General case' 0 CA--C 1.531 0.234 0 C-N-CA 124.628 1.171 . . . . 0.0 108.079 177.033 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 0.7 OUTLIER -142.06 43.02 1.68 Allowed 'General case' 0 C--N 1.333 -0.133 0 C-N-CA 123.842 0.857 . . . . 0.0 110.967 -175.96 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 16.6 pm0 -69.08 75.23 0.33 Allowed 'General case' 0 CA--C 1.539 0.548 0 C-N-CA 125.441 1.496 . . . . 0.0 112.062 -178.634 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 10.6 tp -136.82 -35.8 0.36 Allowed 'Isoleucine or valine' 0 CA--C 1.536 0.416 0 C-N-CA 123.928 0.891 . . . . 0.0 112.577 179.513 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 172.13 140.58 3.14 Favored Glycine 0 N--CA 1.445 -0.7 0 N-CA-C 108.619 -1.792 . . . . 0.0 108.619 179.58 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 31.8 tt0 52.19 65.95 1.35 Allowed 'General case' 0 CA--C 1.537 0.472 0 C-N-CA 124.116 0.966 . . . . 0.0 110.597 178.493 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 4.1 mp0 -75.67 52.68 0.67 Allowed 'General case' 0 N--CA 1.465 0.291 0 C-N-CA 124.693 1.197 . . . . 0.0 110.495 -178.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 54.6 t 46.21 32.01 0.18 Allowed 'Isoleucine or valine' 0 CA--C 1.541 0.625 0 C-N-CA 125.589 1.556 . . . . 0.0 109.487 -177.199 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -79.43 75.1 6.04 Favored 'General case' 0 N--CA 1.45 -0.462 0 CA-C-N 114.929 -1.032 . . . . 0.0 109.691 -174.069 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 12.7 m -77.9 84.16 0.93 Allowed 'Isoleucine or valine' 0 N--CA 1.448 -0.547 0 O-C-N 121.857 -0.527 . . . . 0.0 111.747 -176.859 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 47.7 t -10.66 112.97 0.04 OUTLIER Pre-proline 0 CA--C 1.545 0.761 0 C-N-CA 128.64 2.776 . . . . 0.0 113.796 178.169 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -77.42 -32.3 3.02 Favored 'Trans proline' 0 N--CA 1.454 -0.825 0 C-N-CA 122.601 2.201 . . . . 0.0 115.781 -174.484 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -137.65 139.62 42.81 Favored 'Isoleucine or valine' 0 N--CA 1.466 0.362 0 CA-C-N 120.4 1.455 . . . . 0.0 109.933 -177.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 56.4 m -78.18 140.84 38.97 Favored 'General case' 0 C--O 1.236 0.387 0 N-CA-C 106.391 -1.707 . . . . 0.0 106.391 175.047 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 168.28 -159.82 33.15 Favored Glycine 0 CA--C 1.522 0.511 0 N-CA-C 110.962 -0.855 . . . . 0.0 110.962 -178.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 52.7 tp10 -103.02 126.44 50.2 Favored 'General case' 0 N--CA 1.458 -0.072 0 N-CA-C 106.343 -1.725 . . . . 0.0 106.343 176.262 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 8.2 tt -97.26 141.27 16.03 Favored 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 CA-C-N 118.57 0.623 . . . . 0.0 109.695 -179.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 25.5 m-70 -136.78 148.31 62.81 Favored Pre-proline 0 C--O 1.235 0.316 0 C-N-CA 124.701 1.2 . . . . 0.0 108.019 179.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 46.3 Cg_exo -55.89 146.11 69.61 Favored 'Trans proline' 0 N--CA 1.455 -0.78 0 C-N-CA 122.025 1.817 . . . . 0.0 110.176 176.151 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 3.7 tp -49.53 -34.88 8.7 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.52 0 C-N-CA 123.766 0.826 . . . . 0.0 113.117 -177.144 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 9.0 p -55.83 -26.78 48.25 Favored 'General case' 0 CA--C 1.534 0.363 0 C-N-CA 123.863 0.865 . . . . 0.0 112.581 178.301 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 38.1 t70 -74.99 -13.05 60.47 Favored 'General case' 0 CA--C 1.534 0.352 0 C-N-CA 123.829 0.852 . . . . 0.0 112.594 -179.965 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.522 HG22 ' HB2' ' A' ' 44' ' ' ALA . 46.3 t -67.85 129.18 93.36 Favored Pre-proline 0 CA--C 1.54 0.569 0 O-C-N 121.306 -0.871 . . . . 0.0 110.057 -177.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 54.9 Cg_endo -76.52 59.48 6.2 Favored 'Trans proline' 0 CA--C 1.54 0.78 0 C-N-CA 124.197 3.265 . . . . 0.0 111.849 -178.863 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -169.08 108.66 0.45 Allowed 'General case' 0 N--CA 1.465 0.296 0 O-C-N 121.351 -0.843 . . . . 0.0 110.104 178.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 0.6 OUTLIER -24.25 -58.86 0.05 Allowed 'General case' 0 CA--C 1.535 0.383 0 C-N-CA 128.153 2.581 . . . . 0.0 114.98 -179.018 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 52.7 t -52.9 -50.24 44.56 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.182 0 C-N-CA 123.613 0.765 . . . . 0.0 110.082 -178.06 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 10.1 m-85 -71.49 -48.36 49.53 Favored 'General case' 0 N--CA 1.448 -0.548 0 N-CA-C 109.144 -0.687 . . . . 0.0 109.144 179.295 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.3 m -49.44 -43.11 44.59 Favored 'General case' 0 CA--C 1.531 0.232 0 C-N-CA 123.968 0.907 . . . . 0.0 113.068 179.512 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -94.94 11.88 69.1 Favored Glycine 0 C--N 1.337 0.634 0 CA-C-O 118.907 -0.94 . . . . 0.0 111.456 -178.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 17.0 mtmt 71.55 -37.18 0.38 Allowed 'General case' 0 CA--C 1.54 0.575 0 C-N-CA 125.749 1.62 . . . . 0.0 113.358 -178.924 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 1.1 tmt? 30.8 -71.78 0.0 OUTLIER 'General case' 0 CA--C 1.533 0.304 0 C-N-CA 131.063 3.745 . . . . 0.0 116.538 178.786 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 37.8 tpp -78.4 -16.82 57.23 Favored 'General case' 0 CA--C 1.535 0.381 0 C-N-CA 124.013 0.925 . . . . 0.0 112.145 -175.615 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -179.99 -133.93 2.11 Favored Glycine 0 C--N 1.337 0.612 0 N-CA-C 110.108 -1.197 . . . . 0.0 110.108 -179.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 11.2 t0 -146.26 163.31 35.89 Favored 'General case' 0 C--N 1.332 -0.19 0 N-CA-C 106.037 -1.838 . . . . 0.0 106.037 173.832 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 164.87 -134.9 3.49 Favored Glycine 0 N--CA 1.446 -0.644 0 N-CA-C 109.7 -1.36 . . . . 0.0 109.7 -179.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 5.0 p90 -168.07 169.89 10.79 Favored 'General case' 0 N--CA 1.453 -0.282 0 CA-C-N 117.967 0.884 . . . . 0.0 111.546 -177.375 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.522 ' HB2' HG22 ' A' ' 29' ' ' VAL . . . -102.22 132.46 48.13 Favored 'General case' 0 CA--C 1.512 -0.501 0 C-N-CA 124.061 0.945 . . . . 0.0 109.25 179.12 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -109.39 135.62 47.77 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.438 0 N-CA-C 103.102 -2.925 . . . . 0.0 103.102 168.474 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.1 tt -101.25 104.74 35.14 Favored Pre-proline 0 N--CA 1.447 -0.619 0 N-CA-C 101.324 -3.584 . . . . 0.0 101.324 171.559 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 73.4 Cg_exo -56.16 169.81 1.36 Allowed 'Trans proline' 0 C--N 1.348 0.543 1 C-N-CA 125.375 4.05 . . . . 0.0 116.278 -171.952 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 65.7 p -155.38 -54.94 0.09 Allowed 'General case' 0 CA--C 1.536 0.433 0 C-N-CA 124.14 0.976 . . . . 0.0 111.279 176.542 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 2.2 tt0 -57.84 -43.86 86.11 Favored 'General case' 0 N--CA 1.464 0.26 0 N-CA-C 115.06 1.504 . . . . 0.0 115.06 -176.775 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 74.29 25.81 69.83 Favored Glycine 0 CA--C 1.531 1.077 0 N-CA-C 110.413 -1.075 . . . . 0.0 110.413 -174.17 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 59.4 mt -139.04 130.9 36.17 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.424 0 N-CA-C 101.92 -3.363 . . . . 0.0 101.92 176.12 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 91.7 t -125.11 126.07 70.43 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 N-CA-C 107.659 -1.237 . . . . 0.0 107.659 -175.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 25.1 m -105.71 162.84 4.79 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 C-N-CA 124.013 0.925 . . . . 0.0 111.075 176.789 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 15.9 m -67.46 126.39 92.49 Favored Pre-proline 0 CA--C 1.536 0.419 0 N-CA-C 109.176 -0.675 . . . . 0.0 109.176 179.094 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 85.7 Cg_endo -75.66 -16.72 18.63 Favored 'Trans proline' 0 N--CA 1.455 -0.765 0 C-N-CA 124.125 3.216 . . . . 0.0 115.577 -174.724 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 27.0 m -145.18 163.97 12.36 Favored 'Isoleucine or valine' 0 N--CA 1.458 -0.067 0 CA-C-N 118.861 0.755 . . . . 0.0 109.183 -174.842 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 18.1 ttt85 -75.67 119.29 19.5 Favored 'General case' 0 CA--C 1.516 -0.345 0 N-CA-C 100.31 -3.959 . . . . 0.0 100.31 169.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -179.1 177.1 48.32 Favored Glycine 0 N--CA 1.436 -1.31 0 C-N-CA 116.562 -2.732 . . . . 0.0 115.089 -168.066 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -91.01 133.85 34.96 Favored 'General case' 0 N--CA 1.448 -0.565 0 N-CA-C 107.1 -1.444 . . . . 0.0 107.1 178.621 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 10.0 mm -79.22 100.03 3.68 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.56 0 N-CA-C 102.756 -3.053 . . . . 0.0 102.756 172.272 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 46.7 tp -73.66 -56.5 4.92 Favored 'General case' 0 N--CA 1.449 -0.479 0 N-CA-C 106.694 -1.595 . . . . 0.0 106.694 -174.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -172.83 163.86 5.07 Favored 'General case' 0 CA--C 1.517 -0.309 0 N-CA-C 115.936 1.828 . . . . 0.0 115.936 174.912 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 4.5 m -144.18 118.19 3.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.728 0 N-CA-C 104.341 -2.466 . . . . 0.0 104.341 176.672 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 31.2 m-85 -40.12 153.8 0.2 Allowed Pre-proline 0 CA--C 1.545 0.759 0 CA-C-N 119.086 0.857 . . . . 0.0 111.8 176.964 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_endo -57.02 -22.01 44.67 Favored 'Trans proline' 0 CA--C 1.537 0.633 0 C-N-CA 123.262 2.641 . . . . 0.0 113.545 178.851 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 17.8 p -77.1 -7.73 56.26 Favored 'General case' 0 CA--C 1.536 0.435 0 C-N-CA 124.947 1.299 . . . . 0.0 110.939 177.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER 57.09 25.17 10.52 Favored 'General case' 0 N--CA 1.45 -0.449 0 C-N-CA 127.106 2.162 . . . . 0.0 110.692 -174.44 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 1.2 p-80 -93.94 -28.03 16.03 Favored 'General case' 0 N--CA 1.451 -0.413 0 N-CA-C 113.822 1.045 . . . . 0.0 113.822 -175.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -166.87 -178.23 4.18 Favored 'General case' 0 C--O 1.222 -0.365 0 CA-C-N 120.146 1.339 . . . . 0.0 109.768 -178.192 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.47 HG22 ' N ' ' A' ' 71' ' ' GLY 0.752 24.2 mm 137.73 -125.77 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.467 0.409 1 C-N-CA 132.95 4.5 . . . . 0.0 109.676 177.162 . . . . . . . . 4 3 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.47 ' N ' HG22 ' A' ' 70' ' ' ILE . . . -177.04 174.69 47.26 Favored Glycine 0 CA--C 1.532 1.135 0 N-CA-C 117.172 1.629 . . . . 0.0 117.172 -177.773 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 1.3 mp -128.51 169.78 13.95 Favored 'General case' 0 CA--C 1.53 0.196 0 C-N-CA 127.612 2.365 . . . . 0.0 110.137 -176.784 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 84.5 mt-30 -143.1 126.47 16.68 Favored 'General case' 0 N--CA 1.451 -0.41 0 C-N-CA 123.313 0.645 . . . . 0.0 111.049 177.642 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 1.6 m -73.6 77.3 1.49 Allowed 'General case' 0 CA--C 1.533 0.296 0 N-CA-C 108.372 -0.974 . . . . 0.0 108.372 174.791 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 16.6 t70 46.63 57.83 5.17 Favored 'General case' 0 N--CA 1.45 -0.466 0 C-N-CA 127.896 2.479 . . . . 0.0 110.357 -178.52 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 73.44 -8.48 9.68 Favored Glycine 0 CA--C 1.533 1.214 0 CA-C-O 119.149 -0.806 . . . . 0.0 113.655 -179.284 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -87.42 -124.72 1.97 Allowed Glycine 0 C--N 1.339 0.727 0 N-CA-C 109.302 -1.519 . . . . 0.0 109.302 178.954 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 10.4 mmp_? -48.66 110.35 0.34 Allowed 'General case' 0 CA--C 1.531 0.219 0 C-N-CA 123.988 0.915 . . . . 0.0 110.083 -177.683 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 34.6 tt0 -95.71 132.42 40.93 Favored 'General case' 0 N--CA 1.449 -0.513 0 C-N-CA 125.247 1.419 . . . . 0.0 107.803 -177.409 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 4.0 mp -120.75 113.59 40.54 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.241 0 C-N-CA 124.128 0.971 . . . . 0.0 111.538 -174.838 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 7.6 tt -85.56 137.41 32.89 Favored 'General case' 0 N--CA 1.451 -0.403 0 N-CA-C 106.006 -1.85 . . . . 0.0 106.006 171.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.1 mt -133.19 137.18 53.96 Favored 'Isoleucine or valine' 0 C--O 1.233 0.21 0 C-N-CA 124.188 0.995 . . . . 0.0 109.574 179.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . 0.429 ' HB3' ' HD2' ' A' ' 130' ' ' PRO . 45.4 t-80 -126.16 120.51 30.28 Favored 'General case' 0 C--O 1.225 -0.22 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 171.469 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 3.4 t80 -68.92 122.18 18.12 Favored 'General case' 0 N--CA 1.447 -0.603 0 N-CA-C 106.295 -1.742 . . . . 0.0 106.295 175.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 43.37 -147.1 0.97 Allowed Glycine 0 CA--C 1.532 1.155 0 CA-C-N 119.245 0.929 . . . . 0.0 113.119 -179.113 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 18.7 mm -128.06 143.57 40.44 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 N-CA-C 106.59 -1.633 . . . . 0.0 106.59 177.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 26.4 t0 49.31 44.13 23.37 Favored 'General case' 0 CA--C 1.54 0.57 0 C-N-CA 124.418 1.087 . . . . 0.0 113.044 178.438 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.5 p -90.79 -19.05 23.9 Favored 'General case' 0 C--O 1.225 -0.232 0 C-N-CA 125.655 1.582 . . . . 0.0 108.427 177.402 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 11.4 p -52.39 -46.22 46.26 Favored 'Isoleucine or valine' 0 N--CA 1.439 -1.01 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 174.84 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 18.8 m -61.63 -23.17 65.86 Favored 'General case' 0 CA--C 1.534 0.361 0 C-N-CA 125.62 1.568 . . . . 0.0 112.736 176.427 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.7 OUTLIER -75.54 -18.5 59.76 Favored 'General case' 0 CA--C 1.54 0.565 0 C-N-CA 125.312 1.445 . . . . 0.0 108.836 177.312 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 59.9 mttm 47.95 33.89 3.7 Favored 'General case' 0 C--N 1.344 0.336 0 C-N-CA 125.831 1.652 . . . . 0.0 112.379 178.112 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 62.1 17.03 54.71 Favored Glycine 0 CA--C 1.527 0.809 0 CA-C-O 118.321 -1.266 . . . . 0.0 114.446 179.684 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 11.9 pt-20 -66.71 1.88 1.6 Allowed 'General case' 0 CA--C 1.536 0.414 0 CA-C-N 120.232 2.016 . . . . 0.0 115.116 -179.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -136.43 18.03 3.71 Favored Glycine 0 CA--C 1.53 1.023 0 C-N-CA 126.668 2.08 . . . . 0.0 110.193 175.996 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.61 ' CD1' HG12 ' A' ' 115' ' ' VAL . 22.4 m-30 -118.75 155.94 30.23 Favored 'General case' 0 C--N 1.341 0.211 0 CA-C-N 118.702 1.251 . . . . 0.0 110.638 -177.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 16.7 m -148.95 131.0 15.34 Favored 'General case' 0 CA--C 1.532 0.27 0 N-CA-C 107.671 -1.233 . . . . 0.0 107.671 -179.503 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 26.0 p -101.48 146.32 27.8 Favored 'General case' 0 N--CA 1.456 -0.158 0 C-N-CA 123.658 0.783 . . . . 0.0 112.173 -176.47 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 68.5 m-85 -127.34 20.42 6.78 Favored 'General case' 0 CA--C 1.534 0.345 0 C-N-CA 125.698 1.599 . . . . 0.0 113.753 -174.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 13.5 m -150.62 154.21 9.07 Favored 'Isoleucine or valine' 0 CA--C 1.52 -0.208 0 C-N-CA 123.861 0.864 . . . . 0.0 109.27 175.354 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 3.9 m -87.71 125.32 34.34 Favored 'General case' 0 N--CA 1.447 -0.605 0 N-CA-C 103.664 -2.717 . . . . 0.0 103.664 170.39 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -74.84 78.72 2.11 Favored 'General case' 0 N--CA 1.453 -0.314 0 CA-C-O 123.189 1.471 . . . . 0.0 109.851 -179.573 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 179.06 -18.4 0.03 OUTLIER Glycine 0 CA--C 1.532 1.15 0 C-N-CA 128.447 2.927 . . . . 0.0 110.601 -176.768 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 14.3 t70 -53.41 120.09 5.64 Favored 'General case' 0 N--CA 1.445 -0.676 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 177.168 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -99.14 115.4 28.96 Favored 'General case' 0 C--N 1.314 -0.977 0 C-N-CA 127.709 2.404 . . . . 0.0 113.167 -170.161 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.372 20.8 m 52.03 74.38 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.451 -0.399 0 N-CA-C 117.154 2.279 . . . . 0.0 117.154 175.054 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 17.6 mt-10 -140.71 144.72 37.14 Favored Pre-proline 0 N--CA 1.45 -0.449 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 168.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 71.9 Cg_endo -102.82 171.74 0.22 Allowed 'Trans proline' 0 N--CA 1.45 -1.042 0 C-N-CA 123.733 2.955 . . . . 0.0 109.68 -179.532 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 52.71 -8.82 0.01 OUTLIER Glycine 0 CA--C 1.536 1.399 0 N-CA-C 120.039 2.775 . . . . 0.0 120.039 170.109 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 11.2 tp60 -59.22 142.01 52.86 Favored 'General case' 0 C--O 1.234 0.237 0 CA-C-N 120.957 2.378 . . . . 0.0 109.264 -179.976 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 16.6 ptpt -61.07 114.26 3.01 Favored 'General case' 0 N--CA 1.45 -0.451 0 N-CA-C 109.163 -0.68 . . . . 0.0 109.163 175.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 78.2 mt -79.53 -52.26 8.25 Favored 'General case' 0 N--CA 1.448 -0.561 0 N-CA-C 109.062 -0.718 . . . . 0.0 109.062 179.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 20.5 mt -141.41 159.34 42.43 Favored 'General case' 0 CA--C 1.538 0.507 0 C-N-CA 122.979 0.511 . . . . 0.0 111.625 -174.537 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -122.46 134.69 54.58 Favored 'General case' 0 CA--C 1.516 -0.363 1 N-CA-C 99.965 -4.087 . . . . 0.0 99.965 166.8 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.61 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.1 OUTLIER -147.37 117.92 1.44 Allowed 'Isoleucine or valine' 0 N--CA 1.44 -0.935 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -166.826 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 64.6 t0 -71.12 72.59 0.61 Allowed 'General case' 0 C--O 1.233 0.229 0 C-N-CA 125.799 1.639 . . . . 0.0 111.978 -175.352 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 89.6 mt -47.71 -42.18 24.47 Favored 'General case' 0 C--O 1.223 -0.308 0 CA-C-N 115.614 -0.721 . . . . 0.0 111.493 178.618 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 37.6 t70 -54.21 -39.89 67.11 Favored 'General case' 0 CA--C 1.531 0.227 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -179.598 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -86.72 -33.52 19.98 Favored 'General case' 0 CA--C 1.529 0.141 0 CA-C-O 120.815 0.341 . . . . 0.0 111.125 179.597 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 77.8 t -66.98 -50.36 65.21 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.555 0 O-C-N 121.705 -0.622 . . . . 0.0 110.237 -179.731 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.388 3.2 pptp? -42.59 -54.93 7.65 Favored Pre-proline 0 CA--C 1.542 0.64 0 N-CA-C 116.792 2.145 . . . . 0.0 116.792 -178.485 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 57.0 Cg_endo -62.16 -24.2 76.13 Favored 'Trans proline' 0 N--CA 1.454 -0.804 0 C-N-CA 122.422 2.082 . . . . 0.0 112.862 177.399 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 47.0 m-80 -84.15 -42.77 15.66 Favored 'General case' 0 C--N 1.339 0.121 0 CA-C-N 118.806 0.73 . . . . 0.0 111.108 -178.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 34.2 m -78.69 147.91 71.96 Favored Pre-proline 0 CA--C 1.535 0.398 0 O-C-N 122.025 -0.422 . . . . 0.0 111.769 -177.327 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 70.3 Cg_endo -70.48 -27.28 23.24 Favored 'Trans proline' 0 N--CA 1.453 -0.894 0 C-N-CA 122.617 2.211 . . . . 0.0 110.462 176.154 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 13.8 m -158.04 137.81 12.16 Favored 'General case' 0 CA--C 1.534 0.332 0 C-N-CA 124.659 1.184 . . . . 0.0 108.218 179.08 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 11.3 tp -87.1 2.96 48.1 Favored 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 124.313 1.045 . . . . 0.0 111.788 -178.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 22.3 mmt -55.04 103.92 0.1 Allowed 'General case' 0 N--CA 1.455 -0.212 0 C-N-CA 124.029 0.932 . . . . 0.0 110.346 -179.557 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 53.3 m -90.05 105.32 10.89 Favored Pre-proline 0 N--CA 1.445 -0.69 0 N-CA-C 105.546 -2.02 . . . . 0.0 105.546 179.034 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.429 ' HD2' ' HB3' ' A' ' 83' ' ' HIS . 1.7 Cg_endo -84.26 136.8 6.86 Favored 'Trans proline' 0 N--CA 1.445 -1.351 0 C-N-CA 122.723 2.282 . . . . 0.0 108.521 -177.824 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.1 mt -118.88 120.22 63.38 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.817 0 N-CA-C 102.721 -3.066 . . . . 0.0 102.721 175.284 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 3.3 t -130.05 114.73 30.53 Favored 'Isoleucine or valine' 0 CA--C 1.509 -0.598 0 CA-C-O 122.368 1.08 . . . . 0.0 108.242 -177.389 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.473 ' CB ' HD21 ' A' ' 136' ' ' LEU . 4.0 m-85 -81.89 116.8 21.71 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 103.914 -2.624 . . . . 0.0 103.914 176.564 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 82.1 p -83.03 -83.47 0.14 Allowed 'General case' 0 N--CA 1.455 -0.211 0 CA-C-O 120.94 0.4 . . . . 0.0 110.319 -173.658 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 0.4 OUTLIER -75.61 64.27 1.65 Allowed 'General case' 0 CA--C 1.533 0.303 0 C-N-CA 123.542 0.737 . . . . 0.0 110.806 179.331 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . 0.473 HD21 ' CB ' ' A' ' 133' ' ' PHE . 17.0 mt -65.33 -29.76 70.54 Favored 'General case' 0 CA--C 1.528 0.134 0 C-N-CA 124.288 1.035 . . . . 0.0 112.968 178.715 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 127.76 -132.7 0.0 OUTLIER 'General case' 0 C--N 1.326 -0.428 1 C-N-CA 132.631 4.372 . . . . 0.0 105.587 -176.858 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 13.8 pt-20 -136.1 146.6 47.17 Favored 'General case' 0 C--N 1.325 -0.465 0 C-N-CA 127.228 2.211 . . . . 0.0 108.471 177.569 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 59.33 37.53 92.06 Favored Glycine 0 CA--C 1.532 1.133 0 N-CA-C 111.044 -0.822 . . . . 0.0 111.044 -177.053 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.403 ' HB3' ' CG2' ' A' ' 160' ' ' ILE . 0.0 OUTLIER -97.35 82.42 3.13 Favored 'General case' 0 N--CA 1.457 -0.122 0 C-N-CA 126.127 1.771 . . . . 0.0 107.569 -177.421 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 71.1 p -79.48 115.22 18.98 Favored 'General case' 0 N--CA 1.451 -0.386 0 C-N-CA 118.605 -1.238 . . . . 0.0 109.071 178.496 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . . 2.1 t -72.93 78.83 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.327 -0.395 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 -178.799 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 15.1 m -82.72 92.32 7.18 Favored 'General case' 0 N--CA 1.448 -0.569 0 CA-C-N 114.826 -1.079 . . . . 0.0 108.842 -176.448 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . . . . . . . . . 39.9 mt -65.44 129.83 30.07 Favored 'Isoleucine or valine' 0 CA--C 1.53 0.175 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 179.272 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 9.8 mmpt? -98.21 -51.03 4.14 Favored 'General case' 0 N--CA 1.453 -0.281 0 C-N-CA 125.508 1.523 . . . . 0.0 108.853 178.678 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -75.65 69.55 2.37 Favored 'General case' 0 N--CA 1.454 -0.229 0 CA-C-N 116.589 -0.278 . . . . 0.0 110.57 -178.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 54.2 p -77.48 73.4 4.05 Favored 'General case' 0 CA--C 1.533 0.304 0 O-C-N 121.368 -0.832 . . . . 0.0 108.851 -179.868 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . 175.12 -124.61 1.02 Allowed Glycine 0 CA--C 1.52 0.401 0 N-CA-C 109.293 -1.523 . . . . 0.0 109.293 -177.449 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 25.2 t -94.15 151.0 19.81 Favored 'General case' 0 C--N 1.328 -0.369 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 175.377 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 2.6 m -131.72 148.85 32.42 Favored 'Isoleucine or valine' 0 N--CA 1.451 -0.421 0 C-N-CA 125.031 1.332 . . . . 0.0 107.586 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 12.6 m-80 -114.89 155.32 27.05 Favored 'General case' 0 N--CA 1.449 -0.513 0 N-CA-C 106.991 -1.485 . . . . 0.0 106.991 177.261 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 27.8 mtm105 -57.74 157.64 7.13 Favored 'General case' 0 N--CA 1.45 -0.434 0 CA-C-O 120.913 0.387 . . . . 0.0 110.483 177.823 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 70.25 -12.59 0.5 Allowed 'General case' 0 CA--C 1.537 0.468 0 C-N-CA 125.568 1.547 . . . . 0.0 115.055 175.485 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 37.0 mt-30 -63.17 131.51 48.71 Favored 'General case' 0 C--N 1.34 0.173 0 CA-C-N 119.989 1.268 . . . . 0.0 107.745 176.815 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 18.4 tt0 -97.32 -36.37 10.42 Favored 'General case' 0 C--N 1.34 0.157 0 N-CA-C 115.51 1.671 . . . . 0.0 115.51 -173.616 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 12.1 p-10 -87.62 21.4 2.58 Favored 'General case' 0 C--N 1.32 -0.704 0 C-N-CA 127.658 2.383 . . . . 0.0 113.938 -176.321 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -71.29 -26.57 27.1 Favored 'Isoleucine or valine' 0 C--N 1.331 -0.237 0 N-CA-C 112.32 0.489 . . . . 0.0 112.32 -179.558 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . . . . . . . . . 9.6 p -142.39 152.59 18.01 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.616 0 C-N-CA 125.567 1.547 . . . . 0.0 108.643 -179.229 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 17.8 mtpp -128.24 116.51 19.98 Favored 'General case' 0 N--CA 1.441 -0.891 0 N-CA-C 106.738 -1.579 . . . . 0.0 106.738 173.747 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.403 ' CG2' ' HB3' ' A' ' 140' ' ' GLU . 1.7 mp -78.89 87.0 1.16 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.39 0 N-CA-C 102.554 -3.128 . . . . 0.0 102.554 172.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 9.3 tp10 -85.88 148.33 25.85 Favored 'General case' 0 N--CA 1.449 -0.503 0 C-N-CA 124.461 1.104 . . . . 0.0 111.004 -173.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 59.8 mmtt . . . . . 0 N--CA 1.455 -0.19 0 C-N-CA 124.057 0.943 . . . . 0.0 109.604 178.07 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 64.1 mtt . . . . . 0 N--CA 1.453 -0.307 0 N-CA-C 109.322 -0.622 . . . . 0.0 109.322 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 25.2 mm -91.28 -50.16 12.88 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.263 0 N-CA-C 107.277 -1.379 . . . . 0.0 107.277 177.583 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . 65.6 -67.52 0.13 Allowed 'General case' 0 CA--C 1.53 0.205 0 C-N-CA 126.644 1.977 . . . . 0.0 112.578 178.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 44.0 tt0 43.91 61.34 10.75 Favored Pre-proline 0 CA--C 1.537 0.468 0 C-N-CA 126.504 1.921 . . . . 0.0 110.528 -178.375 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 72.8 Cg_endo -68.03 82.29 0.47 Allowed 'Trans proline' 0 N--CA 1.453 -0.865 0 C-N-CA 122.753 2.302 . . . . 0.0 113.321 -175.011 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 35.5 mt -78.31 59.3 2.29 Favored 'General case' 0 C--O 1.235 0.336 0 CA-C-O 121.512 0.672 . . . . 0.0 109.31 176.232 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -79.38 68.16 5.32 Favored 'General case' 0 N--CA 1.451 -0.397 0 N-CA-C 107.287 -1.375 . . . . 0.0 107.287 179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 18.1 t30 -58.68 152.46 18.66 Favored 'General case' 0 C--O 1.234 0.244 0 O-C-N 122.288 -0.257 . . . . 0.0 110.923 -179.306 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 33.5 tt0 -72.07 75.16 0.94 Allowed 'General case' 0 CA--C 1.535 0.368 0 N-CA-C 109.255 -0.646 . . . . 0.0 109.255 178.8 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 53.6 mt 78.95 142.95 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.532 0.271 0 C-N-CA 127.231 2.212 . . . . 0.0 109.032 -178.024 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . 176.25 -61.98 0.1 Allowed Glycine 0 CA--C 1.52 0.403 0 N-CA-C 107.205 -2.358 . . . . 0.0 107.205 -179.597 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 11.6 tp10 -77.59 157.39 30.3 Favored 'General case' 0 N--CA 1.441 -0.907 0 C-N-CA 124.011 0.924 . . . . 0.0 108.754 176.953 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 44.3 mm-40 -76.18 66.36 2.3 Favored 'General case' 0 N--CA 1.45 -0.443 0 N-CA-C 107.098 -1.445 . . . . 0.0 107.098 173.256 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . 0.31 7.5 p 40.24 74.34 0.05 OUTLIER 'Isoleucine or valine' 0 N--CA 1.455 -0.186 0 C-N-CA 127.608 2.363 . . . . 0.0 113.929 -177.411 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.41 ' CZ ' ' CE1' ' A' ' 133' ' ' PHE . 0.1 OUTLIER -144.97 126.46 15.0 Favored 'General case' 0 C--N 1.328 -0.35 0 N-CA-C 105.198 -2.149 . . . . 0.0 105.198 174.966 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 2.7 m -115.99 96.28 4.45 Favored 'Isoleucine or valine' 0 C--O 1.222 -0.388 0 N-CA-C 106.373 -1.714 . . . . 0.0 106.373 177.675 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 90.6 p -35.23 119.11 0.6 Allowed Pre-proline 0 CA--C 1.556 1.206 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -176.485 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 79.6 Cg_endo -77.64 -28.39 5.37 Favored 'Trans proline' 0 N--CA 1.461 -0.399 0 C-N-CA 122.677 2.251 . . . . 0.0 116.738 -171.428 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.2 OUTLIER -137.29 146.07 28.52 Favored 'Isoleucine or valine' 0 C--N 1.341 0.239 0 CA-C-N 119.42 1.009 . . . . 0.0 110.96 -176.035 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 97.4 m -79.04 137.75 37.69 Favored 'General case' 0 N--CA 1.452 -0.341 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 172.42 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 167.41 -150.35 16.76 Favored Glycine 0 CA--C 1.518 0.281 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.193 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 36.4 tt0 -118.18 129.18 55.36 Favored 'General case' 0 N--CA 1.455 -0.194 0 C-N-CA 124.152 0.981 . . . . 0.0 109.153 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 2.7 mt -79.95 137.27 21.89 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.158 0 N-CA-C 107.98 -1.119 . . . . 0.0 107.98 176.262 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 12.6 m-70 -131.16 144.58 54.09 Favored Pre-proline 0 N--CA 1.45 -0.429 0 C-N-CA 126.003 1.721 . . . . 0.0 106.732 175.992 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -58.22 143.55 96.84 Favored 'Trans proline' 0 N--CA 1.453 -0.9 0 C-N-CA 122.407 2.071 . . . . 0.0 110.001 176.721 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 5.1 tp -52.38 -39.75 29.58 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.468 0 CA-C-O 121.207 0.527 . . . . 0.0 111.24 -179.812 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 1.7 p -56.0 -28.1 55.77 Favored 'General case' 0 N--CA 1.451 -0.396 0 C-N-CA 125.565 1.546 . . . . 0.0 112.902 177.834 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 35.4 t70 -79.68 -8.24 59.1 Favored 'General case' 0 CA--C 1.534 0.348 0 C-N-CA 123.414 0.686 . . . . 0.0 112.826 -178.382 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.472 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 58.8 t -69.71 123.43 88.56 Favored Pre-proline 0 CA--C 1.539 0.539 0 CA-C-O 117.82 -1.086 . . . . 0.0 111.693 -177.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . 0.402 ' HD3' ' HA ' ' A' ' 29' ' ' VAL . 50.0 Cg_exo -61.43 61.55 0.11 Allowed 'Trans proline' 0 CA--C 1.549 1.233 0 C-N-CA 124.971 3.781 . . . . 0.0 115.137 177.359 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 4.2 t70 -168.59 131.72 1.44 Allowed 'General case' 0 CA--C 1.528 0.12 0 O-C-N 120.565 -1.334 . . . . 0.0 108.447 179.739 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 5.8 pt20 -53.89 -51.09 64.8 Favored 'General case' 0 CA--C 1.537 0.444 0 N-CA-C 113.884 1.068 . . . . 0.0 113.884 -177.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 59.8 t -54.71 -55.96 12.89 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.116 0 C-N-CA 123.22 0.608 . . . . 0.0 109.603 -178.119 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . . . . . . . . . 8.0 m-85 -64.06 -54.09 39.55 Favored 'General case' 0 N--CA 1.452 -0.359 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.819 -178.204 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 79.3 p -58.05 -34.14 69.77 Favored 'General case' 0 CA--C 1.529 0.168 0 N-CA-C 113.517 0.932 . . . . 0.0 113.517 -178.333 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -89.64 10.73 72.52 Favored Glycine 0 N--CA 1.445 -0.705 0 CA-C-O 118.173 -1.348 . . . . 0.0 110.854 -179.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 72.18 -40.77 0.48 Allowed 'General case' 0 CA--C 1.539 0.52 0 C-N-CA 125.873 1.669 . . . . 0.0 112.793 -177.401 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 14.9 tpt 25.43 -68.87 0.0 OUTLIER 'General case' 0 CA--C 1.537 0.46 0 C-N-CA 130.907 3.683 . . . . 0.0 117.144 -179.422 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 17.7 tpp -78.96 -20.95 47.95 Favored 'General case' 0 CA--C 1.536 0.425 0 C-N-CA 124.505 1.122 . . . . 0.0 113.53 -175.214 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . 171.45 -145.36 8.77 Favored Glycine 0 C--N 1.337 0.617 0 N-CA-C 110.286 -1.125 . . . . 0.0 110.286 -178.293 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 6.5 t0 -136.18 160.77 37.67 Favored 'General case' 0 CA--C 1.516 -0.354 0 CA-C-N 118.219 1.01 . . . . 0.0 108.559 174.569 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . 0.421 ' HA2' HG21 ' A' ' 142' ' ' VAL . . . 165.28 -130.31 2.14 Favored Glycine 0 N--CA 1.445 -0.76 0 N-CA-C 109.42 -1.472 . . . . 0.0 109.42 -178.42 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . 0.493 ' CE2' HG21 ' A' ' 158' ' ' VAL . 8.5 p90 -166.39 173.62 9.79 Favored 'General case' 0 CA--C 1.515 -0.375 0 CA-C-N 117.822 0.811 . . . . 0.0 110.485 -175.805 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.472 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -113.25 140.71 47.74 Favored 'General case' 0 N--CA 1.446 -0.663 0 N-CA-C 109.568 -0.531 . . . . 0.0 109.568 178.193 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -111.47 136.23 48.23 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.603 0 N-CA-C 103.429 -2.804 . . . . 0.0 103.429 169.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -99.6 105.63 34.98 Favored Pre-proline 0 N--CA 1.444 -0.759 0 N-CA-C 100.64 -3.837 . . . . 0.0 100.64 170.304 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 50.2 Cg_exo -59.56 172.79 1.85 Allowed 'Trans proline' 0 C--N 1.348 0.539 0 C-N-CA 124.548 3.499 . . . . 0.0 115.482 -173.095 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 67.3 p -154.34 -64.37 0.13 Allowed 'General case' 0 CA--C 1.534 0.357 0 C-N-CA 123.895 0.878 . . . . 0.0 110.504 177.563 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 3.9 mt-10 -51.4 -46.87 63.02 Favored 'General case' 0 C--N 1.335 -0.06 0 C-N-CA 125.859 1.664 . . . . 0.0 114.913 -176.666 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 75.31 28.93 60.96 Favored Glycine 0 CA--C 1.531 1.042 0 N-CA-C 109.811 -1.315 . . . . 0.0 109.811 -173.617 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 30.7 mt -139.58 120.65 15.17 Favored 'Isoleucine or valine' 0 N--CA 1.453 -0.322 0 N-CA-C 102.664 -3.087 . . . . 0.0 102.664 177.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 45.0 t -126.12 123.74 64.47 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.314 0 C-N-CA 124.26 1.024 . . . . 0.0 109.764 -171.637 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 33.5 m -109.6 169.66 3.4 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.469 0 C-N-CA 124.187 0.995 . . . . 0.0 109.036 176.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 1.1 p -63.7 148.66 94.04 Favored Pre-proline 0 CA--C 1.537 0.48 0 O-C-N 121.331 -0.856 . . . . 0.0 111.071 -177.755 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -87.64 -16.14 3.13 Favored 'Trans proline' 0 N--CA 1.451 -0.992 0 C-N-CA 124.29 3.327 . . . . 0.0 112.707 179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 33.1 m -145.32 166.83 10.31 Favored 'Isoleucine or valine' 0 C--O 1.234 0.243 0 C-N-CA 123.891 0.876 . . . . 0.0 110.052 -176.818 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 23.1 mtt-85 -78.46 119.54 21.92 Favored 'General case' 0 N--CA 1.454 -0.253 1 N-CA-C 98.887 -4.486 . . . . 0.0 98.887 168.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . 171.37 -177.4 44.27 Favored Glycine 0 N--CA 1.439 -1.146 0 C-N-CA 115.078 -3.439 . . . . 0.0 115.587 -167.547 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -99.73 135.51 41.04 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 126.011 1.724 . . . . 0.0 110.451 -177.888 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . . . . . . . . . 20.4 mm -79.07 114.9 20.48 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.215 0 N-CA-C 103.537 -2.764 . . . . 0.0 103.537 170.037 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 34.3 tp -77.8 -53.41 7.53 Favored 'General case' 0 N--CA 1.451 -0.383 0 N-CA-C 107.496 -1.298 . . . . 0.0 107.496 -177.761 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 46.4 t30 -176.29 155.79 1.52 Allowed 'General case' 0 C--O 1.228 -0.033 0 N-CA-C 109.808 -0.442 . . . . 0.0 109.808 179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 16.5 m -135.32 120.73 29.7 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.474 0 N-CA-C 106.072 -1.825 . . . . 0.0 106.072 174.417 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -43.77 149.75 0.61 Allowed Pre-proline 0 CA--C 1.539 0.538 0 N-CA-C 113.914 1.079 . . . . 0.0 113.914 179.524 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 73.9 Cg_exo -49.65 -28.16 16.46 Favored 'Trans proline' 0 C--N 1.348 0.523 0 C-N-CA 124.077 3.184 . . . . 0.0 113.861 177.08 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 24.7 p -78.02 1.22 21.6 Favored 'General case' 0 N--CA 1.452 -0.349 0 C-N-CA 123.457 0.703 . . . . 0.0 111.969 -179.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 0.3 OUTLIER 46.84 62.35 2.4 Favored 'General case' 0 N--CA 1.449 -0.516 0 C-N-CA 127.323 2.249 . . . . 0.0 113.125 -179.823 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 15.4 p-80 -146.93 -38.82 0.21 Allowed 'General case' 0 C--N 1.33 -0.241 0 O-C-N 122.307 -0.246 . . . . 0.0 111.619 176.147 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -128.19 177.32 7.0 Favored 'General case' 0 N--CA 1.453 -0.313 0 N-CA-C 112.4 0.519 . . . . 0.0 112.4 -174.216 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . . . . . . . . 0.694 24.5 mm 116.0 -134.38 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.517 -0.306 0 C-N-CA 131.654 3.982 . . . . 0.0 108.342 -178.433 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . . . . . . . . . . . -171.88 179.71 43.38 Favored Glycine 0 CA--C 1.526 0.724 0 N-CA-C 118.637 2.215 . . . . 0.0 118.637 -176.828 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.7 mp -126.53 173.07 9.7 Favored 'General case' 0 N--CA 1.452 -0.357 0 C-N-CA 127.771 2.428 . . . . 0.0 109.073 -177.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 43.9 mt-30 -145.09 137.84 26.24 Favored 'General case' 0 N--CA 1.445 -0.698 0 N-CA-C 106.091 -1.818 . . . . 0.0 106.091 176.961 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 84.1 p -77.68 -108.84 0.02 OUTLIER 'General case' 0 CA--C 1.535 0.396 0 CA-C-O 121.154 0.502 . . . . 0.0 109.812 178.86 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 22.7 t0 -87.42 52.68 2.56 Favored 'General case' 0 N--CA 1.455 -0.203 0 N-CA-C 106.661 -1.607 . . . . 0.0 106.661 175.636 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 78.77 -60.47 4.11 Favored Glycine 0 CA--C 1.525 0.694 0 N-CA-C 108.949 -1.661 . . . . 0.0 108.949 -175.604 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -66.31 169.99 31.42 Favored Glycine 0 CA--C 1.531 1.083 0 N-CA-C 110.51 -1.036 . . . . 0.0 110.51 176.612 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 23.2 mtp-105 58.5 71.81 0.56 Allowed 'General case' 0 N--CA 1.457 -0.106 0 C-N-CA 124.503 1.121 . . . . 0.0 109.489 -179.484 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 28.9 tt0 -77.95 125.57 29.55 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 106.655 -1.609 . . . . 0.0 106.655 176.924 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 3.6 mp -100.06 108.37 22.7 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.597 0 C-N-CA 124.722 1.209 . . . . 0.0 109.597 -177.18 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 2.0 tm? -85.01 134.48 34.22 Favored 'General case' 0 N--CA 1.452 -0.326 0 C-N-CA 126.083 1.753 . . . . 0.0 106.732 174.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 12.0 mt -128.01 153.79 37.8 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.439 0 C-N-CA 125.339 1.455 . . . . 0.0 110.106 -179.895 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 58.7 t-80 -151.25 76.46 1.22 Allowed 'General case' 0 CA--C 1.535 0.379 0 C-N-CA 125.788 1.635 . . . . 0.0 109.191 175.376 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . 0.415 ' HA ' HG23 ' A' ' 129' ' ' THR . 1.7 t80 -50.86 104.07 0.07 Allowed 'General case' 0 CA--C 1.531 0.225 0 C-N-CA 123.186 0.594 . . . . 0.0 112.592 -176.591 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 66.62 173.27 5.39 Favored Glycine 0 CA--C 1.533 1.189 0 C-N-CA 124.685 1.136 . . . . 0.0 112.745 -178.279 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 41.1 mm -108.72 130.93 60.69 Favored 'Isoleucine or valine' 0 CA--C 1.529 0.165 0 C-N-CA 124.484 1.114 . . . . 0.0 108.932 -178.301 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 68.0 m-20 48.89 43.1 21.34 Favored 'General case' 0 N--CA 1.467 0.393 0 C-N-CA 124.965 1.306 . . . . 0.0 110.917 -178.62 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 0.8 OUTLIER -94.6 -72.6 0.61 Allowed 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 102.16 -3.274 . . . . 0.0 102.16 174.638 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . 0.33 3.3 p 44.89 49.64 0.38 Allowed 'Isoleucine or valine' 0 N--CA 1.451 -0.391 0 N-CA-C 104.065 -2.568 . . . . 0.0 104.065 -173.507 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . 0.441 ' HB3' ' CD1' ' A' ' 96' ' ' PHE . 19.3 m 12.1 45.83 0.0 OUTLIER 'General case' 0 C--N 1.349 0.565 1 C-N-CA 134.077 4.951 . . . . 0.0 114.178 -164.679 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . 0.404 HD23 ' HA ' ' A' ' 91' ' ' LEU . 2.0 mt 37.48 50.16 1.07 Allowed 'General case' 0 N--CA 1.434 -1.235 0 C-N-CA 130.492 3.517 . . . . 0.0 107.139 178.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 92.1 mttt 76.43 53.52 0.05 OUTLIER 'General case' 0 CA--C 1.536 0.431 0 C-N-CA 128.798 2.839 . . . . 0.0 111.36 -176.029 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 73.04 -64.12 1.61 Allowed Glycine 0 CA--C 1.535 1.296 0 C-N-CA 124.387 0.994 . . . . 0.0 111.713 -179.211 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 47.3 mm-40 22.62 -98.22 0.01 OUTLIER 'General case' 0 CA--C 1.528 0.097 0 C-N-CA 127.694 2.397 . . . . 0.0 115.873 178.471 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . -59.89 -1.68 1.53 Allowed Glycine 0 CA--C 1.533 1.202 0 C-N-CA 127.302 2.382 . . . . 0.0 115.859 -176.59 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.441 ' CD1' ' HB3' ' A' ' 90' ' ' SER . 4.6 m-85 -103.75 97.54 7.54 Favored 'General case' 0 N--CA 1.462 0.155 0 CA-C-N 119.001 1.4 . . . . 0.0 113.145 -175.196 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 6.9 m -80.05 99.99 7.96 Favored 'General case' 0 N--CA 1.449 -0.504 0 N-CA-C 105.785 -1.931 . . . . 0.0 105.785 173.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 29.0 p -83.45 135.37 34.7 Favored 'General case' 0 N--CA 1.451 -0.414 0 O-C-N 121.556 -0.715 . . . . 0.0 110.945 -178.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 33.0 m-85 -103.79 -42.12 5.71 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 125.058 1.343 . . . . 0.0 111.927 -177.756 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . . . . . . . . . 0.2 OUTLIER -67.28 136.0 27.49 Favored 'Isoleucine or valine' 0 N--CA 1.461 0.09 0 C-N-CA 119.229 -0.989 . . . . 0.0 111.736 -179.597 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 58.7 m -87.83 66.43 8.76 Favored 'General case' 0 N--CA 1.455 -0.217 0 N-CA-C 105.373 -2.084 . . . . 0.0 105.373 170.646 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . . . . . . . . 0.258 1.6 pm0 -24.72 96.69 0.01 OUTLIER 'General case' 0 C--N 1.326 -0.454 0 C-N-CA 129.074 2.95 . . . . 0.0 112.999 -173.162 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . 154.06 -17.96 0.63 Allowed Glycine 0 CA--C 1.537 1.466 0 C-N-CA 128.157 2.789 . . . . 0.0 109.744 -175.287 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . . 0.0 OUTLIER -42.87 107.74 0.09 Allowed 'General case' 0 N--CA 1.453 -0.305 0 C-N-CA 129.612 3.165 . . . . 0.0 107.821 178.629 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -90.0 119.3 30.24 Favored 'General case' 0 C--N 1.324 -0.527 0 C-N-CA 127.496 2.318 . . . . 0.0 114.077 -172.954 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . 0.336 34.4 m 48.02 66.82 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.455 -0.185 0 C-N-CA 126.653 1.981 . . . . 0.0 115.395 177.461 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -130.97 133.79 25.19 Favored Pre-proline 0 N--CA 1.454 -0.275 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 171.731 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 28.1 Cg_endo -98.4 147.15 0.65 Allowed 'Trans proline' 0 N--CA 1.447 -1.219 0 C-N-CA 123.346 2.697 . . . . 0.0 110.472 -177.189 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 58.02 18.37 33.54 Favored Glycine 0 CA--C 1.528 0.894 0 O-C-N 121.724 -0.61 . . . . 0.0 113.551 177.02 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.2 tp-100 -61.96 139.51 58.39 Favored 'General case' 0 N--CA 1.448 -0.534 0 N-CA-C 107.574 -1.269 . . . . 0.0 107.574 176.709 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 5.5 tppp? -66.06 116.88 7.64 Favored 'General case' 0 N--CA 1.451 -0.395 0 N-CA-C 108.098 -1.075 . . . . 0.0 108.098 178.916 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . . . . . . . . . 49.6 mt -81.04 -54.19 5.77 Favored 'General case' 0 N--CA 1.446 -0.665 0 N-CA-C 108.946 -0.761 . . . . 0.0 108.946 178.523 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 14.7 mt -149.08 157.45 43.41 Favored 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 123.34 0.656 . . . . 0.0 111.856 -172.437 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.6 mt-10 -124.75 129.42 50.44 Favored 'General case' 0 CA--C 1.519 -0.234 1 N-CA-C 98.738 -4.541 . . . . 0.0 98.738 165.858 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.408 HG12 ' CG ' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -139.22 127.91 28.4 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.7 0 N-CA-C 112.706 0.632 . . . . 0.0 112.706 -164.101 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 66.2 t0 -75.01 67.41 1.71 Allowed 'General case' 0 CA--C 1.532 0.267 0 C-N-CA 124.045 0.938 . . . . 0.0 110.48 -179.39 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 93.1 mt -52.05 -45.85 64.85 Favored 'General case' 0 N--CA 1.453 -0.29 0 CA-C-N 115.898 -0.592 . . . . 0.0 110.194 179.175 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 36.0 t70 -48.98 -45.3 41.94 Favored 'General case' 0 N--CA 1.455 -0.205 0 C-N-CA 124.231 1.012 . . . . 0.0 112.611 -178.581 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.84 -33.91 24.77 Favored 'General case' 0 CA--C 1.527 0.092 0 CA-C-N 118.184 0.447 . . . . 0.0 111.6 -179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 63.6 t -63.08 -58.49 7.33 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.477 0 O-C-N 121.937 -0.477 . . . . 0.0 109.806 178.903 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.38 2.5 pptp? -38.16 -57.0 1.87 Allowed Pre-proline 0 CA--C 1.542 0.658 0 N-CA-C 117.749 2.5 . . . . 0.0 117.749 -176.664 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 50.9 Cg_endo -60.88 -18.25 55.74 Favored 'Trans proline' 0 N--CA 1.455 -0.748 0 C-N-CA 122.427 2.085 . . . . 0.0 113.572 -179.669 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 66.0 m-80 -104.55 10.66 34.95 Favored 'General case' 0 CA--C 1.531 0.223 0 CA-C-O 118.386 -0.816 . . . . 0.0 112.797 -176.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 26.9 m -137.57 151.97 71.97 Favored Pre-proline 0 CA--C 1.535 0.385 0 CA-C-N 119.884 1.22 . . . . 0.0 110.595 -178.887 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -64.45 -36.22 45.21 Favored 'Trans proline' 0 N--CA 1.455 -0.76 0 C-N-CA 123.086 2.524 . . . . 0.0 113.202 -178.605 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 30.6 t -156.58 153.0 27.95 Favored 'General case' 0 N--CA 1.456 -0.175 0 CA-C-N 119.059 0.845 . . . . 0.0 110.556 179.086 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 9.4 tp -100.62 -1.77 34.5 Favored 'General case' 0 CA--C 1.536 0.428 0 C-N-CA 125.549 1.54 . . . . 0.0 110.565 178.525 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -53.22 116.97 2.68 Favored 'General case' 0 C--N 1.345 0.402 0 CA-C-N 118.311 0.505 . . . . 0.0 109.643 179.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . 0.415 HG23 ' HA ' ' A' ' 84' ' ' PHE . 52.7 m -107.99 118.81 51.85 Favored Pre-proline 0 N--CA 1.446 -0.646 0 N-CA-C 106.623 -1.621 . . . . 0.0 106.623 179.391 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . . . . . . . . . 26.0 Cg_endo -87.05 150.43 8.23 Favored 'Trans proline' 0 N--CA 1.442 -1.525 0 C-N-CA 122.056 1.838 . . . . 0.0 107.75 179.881 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 2.8 mt -132.59 113.93 21.77 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.827 0 N-CA-C 101.586 -3.487 . . . . 0.0 101.586 174.639 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.7 t -130.94 122.07 51.18 Favored 'Isoleucine or valine' 0 CA--C 1.516 -0.343 0 CA-C-O 121.666 0.746 . . . . 0.0 110.012 -173.334 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . 0.41 ' CE1' ' CZ ' ' A' ' 15' ' ' PHE . 4.7 m-85 -86.29 112.3 21.27 Favored 'General case' 0 N--CA 1.438 -1.046 0 N-CA-C 104.423 -2.436 . . . . 0.0 104.423 177.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 39.0 p -74.41 -76.06 0.15 Allowed 'General case' 0 N--CA 1.456 -0.159 0 CA-C-O 121.853 0.835 . . . . 0.0 109.401 -175.729 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . . 3.8 p30 -76.78 69.4 3.13 Favored 'General case' 0 N--CA 1.452 -0.361 0 C-N-CA 123.707 0.803 . . . . 0.0 110.771 179.257 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 27.3 mt -68.86 169.21 11.94 Favored 'General case' 0 CA--C 1.539 0.536 0 N-CA-C 106.729 -1.582 . . . . 0.0 106.729 171.076 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . -77.72 -139.07 0.02 OUTLIER 'General case' 0 CA--C 1.532 0.275 0 O-C-N 121.482 -0.761 . . . . 0.0 111.128 -178.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 1.4 tm-20 -67.06 81.12 0.12 Allowed 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 123.683 0.793 . . . . 0.0 112.417 -176.493 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 47.51 38.02 13.6 Favored Glycine 0 CA--C 1.524 0.651 0 C-N-CA 124.76 1.171 . . . . 0.0 111.068 179.081 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.572 ' HB3' HG23 ' A' ' 160' ' ' ILE . 70.0 mm-40 -55.23 119.25 5.24 Favored 'General case' 0 N--CA 1.455 -0.194 0 N-CA-C 111.517 0.192 . . . . 0.0 111.517 -176.907 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 22.9 p -78.02 132.09 37.64 Favored 'General case' 0 N--CA 1.44 -0.943 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 172.504 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . 0.421 HG21 ' HA2' ' A' ' 42' ' ' GLY 0.266 1.0 OUTLIER -84.99 88.61 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.606 0 N-CA-C 106.103 -1.814 . . . . 0.0 106.103 -176.51 . . . . . . . . 4 4 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 5.8 t -78.4 83.99 4.59 Favored 'General case' 0 C--O 1.232 0.165 0 O-C-N 121.38 -0.825 . . . . 0.0 110.243 -173.183 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . 0.595 HG23 HG22 ' A' ' 158' ' ' VAL . 1.8 mt -62.26 118.92 5.15 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.307 0 C-N-CA 124.595 1.158 . . . . 0.0 108.116 179.362 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 72.5 mmtt -97.77 -55.25 2.86 Favored 'General case' 0 N--CA 1.455 -0.22 0 C-N-CA 124.974 1.31 . . . . 0.0 108.938 179.959 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -74.71 66.34 1.45 Allowed 'General case' 0 N--CA 1.455 -0.219 0 C-N-CA 123.319 0.648 . . . . 0.0 111.587 -177.396 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 35.1 m -78.61 65.44 3.88 Favored 'General case' 0 CA--C 1.532 0.265 0 C-N-CA 123.556 0.742 . . . . 0.0 109.011 178.814 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -179.38 -145.78 6.44 Favored Glycine 0 CA--C 1.524 0.618 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -177.99 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 12.3 t -76.2 150.74 37.04 Favored 'General case' 0 CA--C 1.529 0.167 0 CA-C-N 117.325 0.563 . . . . 0.0 110.646 178.3 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 11.2 m -138.68 156.02 28.52 Favored 'Isoleucine or valine' 0 N--CA 1.452 -0.349 0 C-N-CA 125.087 1.355 . . . . 0.0 108.463 178.168 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 0.8 OUTLIER -109.45 -171.43 1.84 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.424 1.49 . . . . 0.0 108.489 175.988 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 52.5 mtm-85 -85.65 157.69 20.27 Favored 'General case' 0 CA--C 1.531 0.224 0 CA-C-N 118.971 0.805 . . . . 0.0 110.354 177.558 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 28.3 mt-10 45.63 38.91 4.42 Favored 'General case' 0 CA--C 1.531 0.248 0 C-N-CA 126.621 1.969 . . . . 0.0 114.432 177.662 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 25.2 mm-40 -76.09 134.07 40.13 Favored 'General case' 0 N--CA 1.451 -0.391 0 N-CA-C 104.8 -2.296 . . . . 0.0 104.8 172.488 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.8 tm-20 -108.99 35.86 3.09 Favored 'General case' 0 N--CA 1.466 0.343 0 C-N-CA 123.733 0.813 . . . . 0.0 111.759 -177.809 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 17.7 t0 -172.6 94.61 0.13 Allowed 'General case' 0 C--N 1.324 -0.522 0 C-N-CA 126.198 1.799 . . . . 0.0 108.448 177.423 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.44 ' N ' HD13 ' A' ' 157' ' ' ILE . 0.2 OUTLIER -150.97 -37.73 0.07 OUTLIER 'Isoleucine or valine' 0 CA--C 1.527 0.094 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 -175.524 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.595 HG22 HG23 ' A' ' 144' ' ' ILE . 57.8 t -151.5 104.29 0.28 Allowed 'Isoleucine or valine' 0 C--O 1.228 -0.058 0 CA-C-N 119.397 0.999 . . . . 0.0 108.594 -177.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 59.2 mttm -90.13 124.49 34.86 Favored 'General case' 0 N--CA 1.452 -0.353 0 N-CA-C 112.94 0.719 . . . . 0.0 112.94 -176.574 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.572 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.5 mp -78.86 107.77 11.63 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.555 0 N-CA-C 104.378 -2.453 . . . . 0.0 104.378 174.985 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 24.9 pt-20 -153.73 -175.35 5.33 Favored 'General case' 0 C--O 1.227 -0.127 0 N-CA-C 108.75 -0.833 . . . . 0.0 108.75 -175.787 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 30.8 mmmt . . . . . 0 C--N 1.332 -0.185 0 N-CA-C 108.843 -0.799 . . . . 0.0 108.843 176.261 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 60.7 mtm . . . . . 0 N--CA 1.454 -0.255 0 N-CA-C 111.704 0.261 . . . . 0.0 111.704 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' ILE . . . . . . . . . . . . . 3.3 mp 77.03 -54.83 0.24 Allowed 'Isoleucine or valine' 0 CA--C 1.531 0.219 0 C-N-CA 126.605 1.962 . . . . 0.0 107.258 -173.804 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' ALA . . . . . . . . . . . . . . . -74.8 64.08 1.23 Allowed 'General case' 0 CA--C 1.534 0.351 0 C-N-CA 124.349 1.06 . . . . 0.0 109.811 176.189 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' GLU . . . . . . . . . . . . . 37.6 mm-40 -68.81 -42.39 24.17 Favored Pre-proline 0 CA--C 1.538 0.508 0 CA-C-O 118.259 -0.876 . . . . 0.0 112.402 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' PRO . . . . . . . . . . . . . 51.5 Cg_exo -56.26 154.72 27.61 Favored 'Trans proline' 0 N--CA 1.456 -0.681 0 C-N-CA 122.282 1.988 . . . . 0.0 112.465 -178.795 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' LEU . . . . . . . . . . . . . 71.8 mt -73.54 67.9 1.12 Allowed 'General case' 0 CA--C 1.533 0.311 0 C-N-CA 123.664 0.786 . . . . 0.0 110.749 -179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' GLN . . . . . . . . . . . . . 34.3 mt-30 -70.8 176.16 4.46 Favored 'General case' 0 CA--C 1.536 0.41 0 C-N-CA 123.692 0.797 . . . . 0.0 109.947 178.079 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ASN . . . . . . . . . . . . . 1.1 t30 -54.49 105.59 0.16 Allowed 'General case' 0 CA--C 1.533 0.322 0 C-N-CA 123.891 0.876 . . . . 0.0 110.294 178.424 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLU . . . . . . . . . . . . . 54.5 mt-10 -48.66 -61.09 2.21 Favored 'General case' 0 N--CA 1.454 -0.244 0 C-N-CA 125.723 1.609 . . . . 0.0 112.933 -178.264 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' ILE . . . . . . . . . . . . . 35.2 mt -77.78 72.8 0.53 Allowed 'Isoleucine or valine' 0 CA--C 1.53 0.179 0 N-CA-C 108.176 -1.046 . . . . 0.0 108.176 -178.007 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -81.18 -51.83 4.53 Favored Glycine 0 CA--C 1.524 0.606 0 N-CA-C 109.802 -1.319 . . . . 0.0 109.802 -179.622 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . 0.355 0.0 OUTLIER 72.69 -49.91 0.7 Allowed 'General case' 0 N--CA 1.455 -0.182 0 C-N-CA 127.092 2.157 . . . . 0.0 115.945 178.354 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 72.2 mt-10 27.84 63.88 0.1 Allowed 'General case' 0 C--N 1.321 -0.654 0 C-N-CA 130.629 3.572 . . . . 0.0 113.207 177.759 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.3 p 23.53 92.82 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.461 0.111 0 C-N-CA 128.023 2.529 . . . . 0.0 115.557 178.376 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 0.1 OUTLIER -161.3 82.15 0.62 Allowed 'General case' 0 C--N 1.326 -0.425 0 CA-C-N 113.77 -1.559 . . . . 0.0 107.803 176.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' VAL . . . . . . . . . . . . . 1.9 m -78.89 85.15 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.461 0.114 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 179.202 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' SER . . . . . . . . . . . . . 33.3 t -10.59 109.39 0.04 OUTLIER Pre-proline 0 CA--C 1.546 0.814 0 C-N-CA 127.839 2.456 . . . . 0.0 113.211 -178.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -68.81 -28.15 30.46 Favored 'Trans proline' 0 N--CA 1.456 -0.718 0 C-N-CA 122.595 2.197 . . . . 0.0 116.449 -173.318 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ILE . . . . . . . . . . . . . 0.1 OUTLIER -149.0 145.93 17.67 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.272 0 CA-C-N 119.918 1.235 . . . . 0.0 110.232 -177.322 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' THR . . . . . . . . . . . . . 95.9 m -79.07 136.68 37.23 Favored 'General case' 0 C--O 1.239 0.504 0 N-CA-C 106.742 -1.577 . . . . 0.0 106.742 173.217 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLY . . . . . . . . . . . . . . . 170.0 -150.11 14.2 Favored Glycine 0 CA--C 1.522 0.492 0 N-CA-C 111.092 -0.803 . . . . 0.0 111.092 -179.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLU . . . . . . . . . . . . . 54.4 tp10 -117.13 123.21 46.19 Favored 'General case' 0 N--CA 1.455 -0.195 0 C-N-CA 125.785 1.634 . . . . 0.0 108.71 -179.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ILE . . . . . . . . . . . . . 10.1 mt -85.07 125.66 40.36 Favored 'Isoleucine or valine' 0 N--CA 1.457 -0.112 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 176.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' HIS . . . . . . . . . . . . . 88.3 m-70 -117.92 142.8 31.44 Favored Pre-proline 0 N--CA 1.449 -0.494 0 N-CA-C 106.101 -1.814 . . . . 0.0 106.101 173.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' PRO . . . . . . . . . . . . . 52.0 Cg_exo -55.15 152.65 29.8 Favored 'Trans proline' 0 N--CA 1.454 -0.799 0 C-N-CA 121.814 1.676 . . . . 0.0 109.515 176.03 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ILE . . . . . . . . . . . . . 2.3 tp -57.06 -49.01 80.86 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.545 0 N-CA-C 109.803 -0.443 . . . . 0.0 109.803 -179.504 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' THR . . . . . . . . . . . . . 11.1 m -67.86 85.41 0.22 Allowed 'General case' 0 N--CA 1.455 -0.222 0 C-N-CA 125.732 1.613 . . . . 0.0 108.604 176.478 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' ASP . . . . . . . . . . . . . 20.5 t70 172.95 -35.66 0.0 OUTLIER 'General case' 0 CA--C 1.53 0.202 0 C-N-CA 127.373 2.269 . . . . 0.0 108.81 -176.046 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.416 ' CG2' ' HB2' ' A' ' 44' ' ' ALA . 96.5 t -52.86 138.29 44.15 Favored Pre-proline 0 CA--C 1.538 0.517 0 C-N-CA 124.643 1.177 . . . . 0.0 110.558 -179.333 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' PRO . . . . . . . . . . . . . 69.3 Cg_endo -72.95 59.26 3.54 Favored 'Trans proline' 0 CA--C 1.541 0.828 0 C-N-CA 124.127 3.218 . . . . 0.0 111.542 -179.199 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' ASP . . . . . . . . . . . . . 2.5 t70 -171.74 130.81 0.68 Allowed 'General case' 0 CA--C 1.532 0.261 0 C-N-CA 124.923 1.289 . . . . 0.0 108.592 179.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' GLN . . . . . . . . . . . . . 39.9 mt-30 -62.03 -48.42 80.37 Favored 'General case' 0 CA--C 1.531 0.236 0 C-N-CA 124.322 1.049 . . . . 0.0 113.061 -177.261 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' VAL . . . . . . . . . . . . . 57.6 t -50.24 -55.23 6.28 Favored 'Isoleucine or valine' 0 N--CA 1.464 0.228 0 N-CA-C 109.273 -0.64 . . . . 0.0 109.273 -179.181 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' PHE . . . . . 0.416 ' CD2' ' HG3' ' A' ' 130' ' ' PRO . 8.2 m-85 -65.06 -58.79 5.15 Favored 'General case' 0 N--CA 1.449 -0.492 0 CA-C-N 115.841 -0.618 . . . . 0.0 110.397 -179.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' SER . . . . . . . . . . . . . 3.6 m -58.08 -27.99 64.17 Favored 'General case' 0 CA--C 1.53 0.185 0 N-CA-C 115.244 1.572 . . . . 0.0 115.244 -177.301 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' GLY . . . . . . . . . . . . . . . -95.36 10.12 69.38 Favored Glycine 0 N--CA 1.444 -0.77 0 CA-C-O 117.899 -1.501 . . . . 0.0 110.646 -178.981 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' LYS . . . . . . . . . . . . . 61.3 mttm 74.42 -46.25 0.61 Allowed 'General case' 0 CA--C 1.54 0.56 0 C-N-CA 125.574 1.55 . . . . 0.0 111.928 -178.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' MET . . . . . . . . . . . . . 36.9 ttm 39.29 -64.92 0.0 OUTLIER 'General case' 0 CA--C 1.539 0.541 0 C-N-CA 130.533 3.533 . . . . 0.0 117.272 -179.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' MET . . . . . . . . . . . . . 29.9 ttp -109.34 -10.28 14.93 Favored 'General case' 0 CA--C 1.535 0.397 0 C-N-CA 124.712 1.205 . . . . 0.0 113.452 -176.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -171.83 -165.55 29.18 Favored Glycine 0 C--N 1.336 0.551 0 CA-C-N 119.464 1.029 . . . . 0.0 110.796 -179.023 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' ASP . . . . . . . . . . . . . 31.5 t0 -131.72 156.58 45.67 Favored 'General case' 0 CA--C 1.513 -0.477 0 N-CA-C 106.905 -1.517 . . . . 0.0 106.905 176.6 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' GLY . . . . . . . . . . . . . . . 168.45 -137.07 4.38 Favored Glycine 0 N--CA 1.447 -0.599 0 N-CA-C 109.417 -1.473 . . . . 0.0 109.417 -179.435 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' PHE . . . . . . . . . . . . . 2.0 p90 -167.28 166.13 14.86 Favored 'General case' 0 N--CA 1.454 -0.254 0 CA-C-N 118.048 0.924 . . . . 0.0 111.214 -175.94 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' ALA . . . . . 0.416 ' HB2' ' CG2' ' A' ' 29' ' ' VAL . . . -103.31 113.29 26.66 Favored 'General case' 0 CA--C 1.508 -0.673 0 C-N-CA 123.043 0.537 . . . . 0.0 111.485 -179.239 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -88.65 129.21 40.14 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.565 0 N-CA-C 103.887 -2.634 . . . . 0.0 103.887 169.765 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' LEU . . . . . . . . . . . . . 6.0 tt -96.03 109.2 45.6 Favored Pre-proline 0 N--CA 1.448 -0.542 1 N-CA-C 98.34 -4.689 . . . . 0.0 98.34 168.526 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.6 161.54 24.92 Favored 'Trans proline' 0 N--CA 1.458 -0.587 0 C-N-CA 123.501 2.801 . . . . 0.0 115.336 -167.837 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 62.4 p -136.9 -41.54 0.59 Allowed 'General case' 0 CA--C 1.538 0.491 0 C-N-CA 124.588 1.155 . . . . 0.0 111.981 177.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -58.99 -44.36 91.62 Favored 'General case' 0 N--CA 1.467 0.384 0 N-CA-C 113.75 1.019 . . . . 0.0 113.75 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' GLY . . . . . . . . . . . . . . . 70.37 23.8 77.19 Favored Glycine 0 CA--C 1.532 1.113 0 N-CA-C 110.501 -1.04 . . . . 0.0 110.501 -174.643 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . . . . . . . . . 49.5 mt -139.99 111.97 4.95 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.257 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 177.681 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . . . . . . . . . 47.0 t -100.39 122.71 52.67 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.448 0 C-N-CA 124.883 1.273 . . . . 0.0 108.673 -176.669 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' VAL . . . . . . . . . . . . . 27.1 m -104.39 156.04 5.85 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.219 0 C-N-CA 123.389 0.676 . . . . 0.0 110.349 177.912 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' SER . . . . . . . . . . . . . 17.4 m -63.88 122.11 75.06 Favored Pre-proline 0 CA--C 1.54 0.573 0 N-CA-C 109.308 -0.626 . . . . 0.0 109.308 -179.408 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' PRO . . . . . . . . . . . . . 74.0 Cg_endo -76.81 -21.52 12.52 Favored 'Trans proline' 0 N--CA 1.459 -0.53 0 C-N-CA 124.923 3.749 . . . . 0.0 114.662 -176.269 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' VAL . . . . . . . . . . . . . 34.0 m -136.48 173.09 14.27 Favored 'Isoleucine or valine' 0 CA--C 1.532 0.285 0 C-N-CA 124.94 1.296 . . . . 0.0 108.842 -175.672 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.29 90.59 3.76 Favored 'General case' 0 CA--C 1.518 -0.275 1 N-CA-C 98.228 -4.73 . . . . 0.0 98.228 168.858 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' GLY . . . . . . . . . . . . . . . -90.26 174.52 40.29 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 117.381 1.712 . . . . 0.0 117.381 -166.632 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -145.88 134.09 21.68 Favored 'General case' 0 N--CA 1.442 -0.828 0 N-CA-C 101.475 -3.528 . . . . 0.0 101.475 170.471 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ILE . . . . . 0.433 HG21 ' HG3' ' A' ' 102' ' ' GLU . 0.2 OUTLIER -88.79 127.3 41.69 Favored 'Isoleucine or valine' 0 N--CA 1.446 -0.636 0 N-CA-C 113.916 1.08 . . . . 0.0 113.916 -169.791 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.402 ' O ' ' CB ' ' A' ' 62' ' ' ASN . 78.5 mt -79.74 -29.66 40.63 Favored 'General case' 0 N--CA 1.456 -0.152 0 N-CA-C 106.872 -1.529 . . . . 0.0 106.872 169.161 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . 0.402 ' CB ' ' O ' ' A' ' 61' ' ' LEU . 59.1 t30 125.79 -176.53 0.0 OUTLIER 'General case' 0 N--CA 1.481 1.104 0 C-N-CA 129.587 3.155 . . . . 0.0 109.514 175.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . . . . . . . . . 35.0 m -130.98 122.24 51.47 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.635 0 C-N-CA 127.452 2.301 . . . . 0.0 106.353 172.849 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 10.5 m-85 -44.77 157.92 0.3 Allowed Pre-proline 0 CA--C 1.54 0.584 0 C-N-CA 124.315 1.046 . . . . 0.0 111.316 175.361 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' PRO . . . . . . . . . . . . . 72.7 Cg_exo -51.4 -29.47 31.05 Favored 'Trans proline' 0 CA--C 1.537 0.653 0 C-N-CA 123.381 2.721 . . . . 0.0 113.414 174.186 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' THR . . . . . . . . . . . . . 12.6 p -76.94 -5.98 50.69 Favored 'General case' 0 CA--C 1.534 0.349 0 C-N-CA 124.429 1.092 . . . . 0.0 111.646 179.821 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LYS . . . . . . . . . . . . . 1.2 ttmp? 60.53 16.4 6.44 Favored 'General case' 0 N--CA 1.451 -0.411 0 C-N-CA 126.334 1.854 . . . . 0.0 115.007 172.543 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' HIS . . . . . . . . . . . . . 16.1 p-80 -98.03 -33.77 11.05 Favored 'General case' 0 N--CA 1.453 -0.302 0 C-N-CA 122.562 0.345 . . . . 0.0 111.654 179.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ALA . . . . . . . . . . . . . . . -149.17 -177.58 5.9 Favored 'General case' 0 C--O 1.219 -0.527 0 CA-C-N 118.186 0.448 . . . . 0.0 111.929 -173.575 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ILE . . . . . 0.432 HG22 ' H ' ' A' ' 71' ' ' GLY 0.541 24.4 mm 131.82 -123.39 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.513 -0.453 1 C-N-CA 136.273 5.829 . . . . 0.0 102.359 -177.199 . . . . . . . . 4 3 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' GLY . . . . . 0.432 ' H ' HG22 ' A' ' 70' ' ' ILE . . . -178.4 -173.23 43.6 Favored Glycine 0 CA--C 1.524 0.622 0 C-N-CA 116.751 -2.643 . . . . 0.0 119.382 177.05 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' LEU . . . . . . . . . . . . . 2.4 mp -137.32 170.83 15.42 Favored 'General case' 0 CA--C 1.532 0.272 0 C-N-CA 127.208 2.203 . . . . 0.0 108.488 -179.976 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLN . . . . . . . . . . . . . 81.4 mt-30 -147.83 157.26 43.44 Favored 'General case' 0 N--CA 1.445 -0.711 0 N-CA-C 104.108 -2.553 . . . . 0.0 104.108 172.366 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' SER . . . . . . . . . . . . . 81.3 p -90.31 -76.41 0.43 Allowed 'General case' 0 C--O 1.225 -0.235 0 N-CA-C 106.687 -1.597 . . . . 0.0 106.687 174.27 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' ASP . . . . . . . . . . . . . 39.9 t0 -131.36 59.66 1.68 Allowed 'General case' 0 N--CA 1.451 -0.389 0 C-N-CA 127.0 2.12 . . . . 0.0 105.928 175.777 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' GLY . . . . . . . . . . . . . . . 79.86 -60.73 4.38 Favored Glycine 0 CA--C 1.529 0.927 0 N-CA-C 108.046 -2.022 . . . . 0.0 108.046 -173.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLY . . . . . . . . . . . . . . . -57.35 163.33 7.36 Favored Glycine 0 CA--C 1.53 1.028 0 N-CA-C 110.102 -1.199 . . . . 0.0 110.102 174.802 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' ARG . . . . . . . . . . . . . 16.6 mmt85 51.91 59.98 4.16 Favored 'General case' 0 N--CA 1.456 -0.144 0 C-N-CA 123.574 0.75 . . . . 0.0 109.779 -177.449 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLU . . . . . . . . . . . . . 33.3 tt0 -80.37 110.29 15.67 Favored 'General case' 0 N--CA 1.443 -0.785 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 177.728 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' ILE . . . . . . . . . . . . . 12.2 mt -96.94 127.28 49.27 Favored 'Isoleucine or valine' 0 N--CA 1.448 -0.545 0 C-N-CA 124.063 0.945 . . . . 0.0 111.464 -174.001 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' LEU . . . . . . . . . . . . . 33.5 tp -103.23 135.07 45.57 Favored 'General case' 0 N--CA 1.447 -0.592 0 N-CA-C 104.375 -2.454 . . . . 0.0 104.375 170.585 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ILE . . . . . . . . . . . . . 16.4 mt -120.43 155.37 23.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 C-N-CA 124.965 1.306 . . . . 0.0 107.589 178.486 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER -149.37 81.95 1.41 Allowed 'General case' 0 C--O 1.224 -0.281 0 N-CA-C 104.96 -2.237 . . . . 0.0 104.96 173.806 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' PHE . . . . . . . . . . . . . 2.0 t80 -63.12 97.33 0.11 Allowed 'General case' 0 N--CA 1.452 -0.363 0 N-CA-C 109.859 -0.423 . . . . 0.0 109.859 -176.638 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 69.27 168.33 5.79 Favored Glycine 0 CA--C 1.536 1.356 0 C-N-CA 124.226 0.917 . . . . 0.0 111.586 -175.816 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ILE . . . . . . . . . . . . . 15.8 mm -100.26 135.89 34.06 Favored 'Isoleucine or valine' 0 CA--C 1.533 0.302 0 C-N-CA 124.623 1.169 . . . . 0.0 109.094 -177.278 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' ASP . . . . . . . . . . . . . 2.8 m-20 57.24 23.98 9.36 Favored 'General case' 0 CA--C 1.538 0.496 0 C-N-CA 124.943 1.297 . . . . 0.0 112.732 -179.416 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.3 p -76.93 -32.97 57.74 Favored 'General case' 0 C--N 1.327 -0.402 0 C-N-CA 125.657 1.583 . . . . 0.0 107.567 175.397 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' VAL . . . . . . . . . . . . . 7.8 p -56.71 -46.16 82.99 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.271 0 CA-C-N 113.76 -1.563 . . . . 0.0 107.546 170.702 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -61.73 -42.28 98.75 Favored 'General case' 0 C--O 1.226 -0.156 0 C-N-CA 124.187 0.995 . . . . 0.0 108.546 176.934 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -73.61 12.27 0.67 Allowed 'General case' 0 CA--C 1.548 0.902 0 C-N-CA 125.525 1.53 . . . . 0.0 111.682 175.593 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' LYS . . . . . . . . . . . . . 48.3 tttp 45.68 35.06 1.97 Allowed 'General case' 0 CA--C 1.535 0.393 0 C-N-CA 126.869 2.067 . . . . 0.0 113.258 177.764 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 55.39 28.44 50.57 Favored Glycine 0 CA--C 1.535 1.289 0 O-C-N 121.751 -0.593 . . . . 0.0 112.751 -179.116 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLU . . . . . . . . . . . . . 46.5 mt-10 -70.97 91.56 0.88 Allowed 'General case' 0 N--CA 1.456 -0.135 0 CA-C-N 118.744 1.272 . . . . 0.0 109.769 -179.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' GLY . . . . . . . . . . . . . . . 132.61 -1.05 4.72 Favored Glycine 0 CA--C 1.532 1.134 0 C-N-CA 126.435 1.969 . . . . 0.0 111.707 -178.056 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' PHE . . . . . 0.459 ' CD1' HG12 ' A' ' 115' ' ' VAL . 16.5 m-30 -96.52 131.91 42.64 Favored 'General case' 0 N--CA 1.452 -0.363 0 C-N-CA 124.507 1.123 . . . . 0.0 109.675 -179.267 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' THR . . . . . . . . . . . . . 10.9 m -120.55 113.96 21.05 Favored 'General case' 0 CA--C 1.529 0.155 0 C-N-CA 126.597 1.959 . . . . 0.0 107.316 179.957 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 44.9 p -93.38 126.49 38.54 Favored 'General case' 0 N--CA 1.451 -0.392 0 O-C-N 121.056 -1.028 . . . . 0.0 111.213 -175.956 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' PHE . . . . . . . . . . . . . 13.6 m-85 -90.26 -26.73 19.89 Favored 'General case' 0 N--CA 1.451 -0.378 0 C-N-CA 123.932 0.893 . . . . 0.0 108.998 176.502 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' VAL . . . . . 0.624 ' HB ' ' CG ' ' A' ' 102' ' ' GLU . 3.1 m -52.63 126.83 9.26 Favored 'Isoleucine or valine' 0 CA--C 1.539 0.554 0 CA-C-O 121.192 0.52 . . . . 0.0 110.995 179.213 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' SER . . . . . . . . . . . . . 24.9 m -115.51 -52.34 2.65 Favored 'General case' 0 CA--C 1.534 0.36 0 C-N-CA 127.456 2.302 . . . . 0.0 105.255 175.763 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' GLU . . . . . 0.624 ' CG ' ' HB ' ' A' ' 100' ' ' VAL . 0.1 OUTLIER 50.77 107.98 0.0 OUTLIER 'General case' 0 N--CA 1.45 -0.436 0 N-CA-C 120.969 3.692 . . . . 0.0 120.969 166.26 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' GLY . . . . . . . . . . . . . . . -94.23 55.35 2.12 Favored Glycine 0 CA--C 1.53 1.0 1 N-CA-C 100.996 -4.842 . . . . 0.0 100.996 164.808 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ASP . . . . . . . . . . . . 0.253 7.4 p-10 6.77 70.36 0.0 OUTLIER 'General case' 0 N--CA 1.443 -0.779 0 N-CA-C 118.569 2.803 . . . . 0.0 118.569 -169.255 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -169.58 137.04 1.72 Allowed 'General case' 0 N--CA 1.43 -1.464 1 C-N-CA 132.916 4.486 . . . . 0.0 105.655 173.309 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' VAL . . . . . . . . . . . . . 0.5 OUTLIER -157.27 158.19 3.25 Favored 'Isoleucine or valine' 0 N--CA 1.455 -0.193 0 C-N-CA 125.681 1.592 . . . . 0.0 108.692 179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' GLU . . . . . . . . . . . . . 37.3 mt-10 -89.04 163.42 34.61 Favored Pre-proline 0 CA--C 1.536 0.436 0 N-CA-C 106.425 -1.695 . . . . 0.0 106.425 173.514 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' PRO . . . . . . . . . . . . . 6.4 Cg_exo -70.71 169.54 19.87 Favored 'Trans proline' 0 N--CA 1.451 -0.978 0 N-CA-C 108.259 -1.477 . . . . 0.0 108.259 178.329 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' GLY . . . . . . . . . . . . . . . 73.45 -27.77 0.86 Allowed Glycine 0 CA--C 1.534 1.227 0 O-C-N 121.02 -1.05 . . . . 0.0 115.38 175.438 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' GLN . . . . . . . . . . . . . 6.4 tp-100 -58.07 139.88 53.75 Favored 'General case' 0 CA--C 1.535 0.387 0 CA-C-N 119.527 1.664 . . . . 0.0 109.8 179.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' LYS . . . . . . . . . . . . . 19.0 ptpt -70.16 128.3 35.79 Favored 'General case' 0 N--CA 1.455 -0.19 0 C-N-CA 122.875 0.47 . . . . 0.0 111.544 -179.674 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' LEU . . . . . 0.505 HD22 HG12 ' A' ' 100' ' ' VAL . 72.1 mt -105.04 -41.49 5.57 Favored 'General case' 0 CA--C 1.535 0.403 0 C-N-CA 123.937 0.895 . . . . 0.0 111.807 -178.317 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' LEU . . . . . . . . . . . . . 48.5 mt -143.99 146.52 32.96 Favored 'General case' 0 CA--C 1.541 0.613 0 C-N-CA 123.588 0.755 . . . . 0.0 109.371 -179.704 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLU . . . . . . . . . . . . . 93.8 mt-10 -118.06 133.24 56.09 Favored 'General case' 0 CA--C 1.515 -0.376 0 N-CA-C 100.683 -3.821 . . . . 0.0 100.683 167.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' VAL . . . . . 0.459 HG12 ' CD1' ' A' ' 96' ' ' PHE . 0.0 OUTLIER -143.15 117.47 3.98 Favored 'Isoleucine or valine' 0 N--CA 1.443 -0.825 0 N-CA-C 109.242 -0.651 . . . . 0.0 109.242 -166.731 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' ASP . . . . . . . . . . . . . 62.9 t0 -67.69 74.11 0.17 Allowed 'General case' 0 CA--C 1.531 0.22 0 C-N-CA 125.408 1.483 . . . . 0.0 112.395 -175.273 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 75.8 mt -50.43 -47.49 56.64 Favored 'General case' 0 N--CA 1.454 -0.234 0 CA-C-N 116.027 -0.533 . . . . 0.0 110.687 178.242 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' ASP . . . . . . . . . . . . . 31.0 t70 -49.4 -49.07 46.4 Favored 'General case' 0 N--CA 1.455 -0.223 0 C-N-CA 124.588 1.155 . . . . 0.0 112.684 -177.323 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' ALA . . . . . . . . . . . . . . . -83.25 -34.36 25.85 Favored 'General case' 0 C--N 1.333 -0.121 0 N-CA-C 111.793 0.294 . . . . 0.0 111.793 -179.133 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' VAL . . . . . . . . . . . . . 49.4 t -65.16 -53.65 38.32 Favored 'Isoleucine or valine' 0 CA--C 1.537 0.476 0 O-C-N 121.697 -0.627 . . . . 0.0 110.541 -179.5 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' LYS . . . . . . . . . . . . 0.328 19.1 pttp -42.92 -54.64 8.54 Favored Pre-proline 0 CA--C 1.54 0.595 0 N-CA-C 117.593 2.442 . . . . 0.0 117.593 -177.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' PRO . . . . . . . . . . . . . 56.6 Cg_endo -61.12 -24.07 78.54 Favored 'Trans proline' 0 N--CA 1.455 -0.751 0 C-N-CA 122.49 2.127 . . . . 0.0 112.716 178.248 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ASN . . . . . . . . . . . . . 57.3 m-80 -90.18 -48.24 7.29 Favored 'General case' 0 N--CA 1.455 -0.206 0 CA-C-N 118.46 0.573 . . . . 0.0 111.885 -177.268 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' VAL . . . . . . . . . . . . . 16.5 m -82.77 147.93 56.37 Favored Pre-proline 0 CA--C 1.537 0.471 0 N-CA-C 113.538 0.94 . . . . 0.0 113.538 -174.256 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_exo -51.61 -41.51 60.76 Favored 'Trans proline' 0 N--CA 1.458 -0.574 0 C-N-CA 124.064 3.176 . . . . 0.0 114.804 179.169 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' SER . . . . . . . . . . . . . 4.2 m -158.81 142.7 15.31 Favored 'General case' 0 CA--C 1.532 0.255 0 O-C-N 121.825 -0.547 . . . . 0.0 110.235 -176.9 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' LEU . . . . . . . . . . . . . 8.2 tp -88.09 -4.6 58.75 Favored 'General case' 0 CA--C 1.536 0.411 0 C-N-CA 124.878 1.271 . . . . 0.0 112.293 -178.392 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' MET . . . . . . . . . . . . . 23.1 mmt -46.93 118.92 2.26 Favored 'General case' 0 N--CA 1.455 -0.213 0 C-N-CA 124.028 0.931 . . . . 0.0 109.802 -179.833 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' THR . . . . . . . . . . . . . 59.4 m -112.1 94.23 24.88 Favored Pre-proline 0 N--CA 1.448 -0.534 0 N-CA-C 108.022 -1.103 . . . . 0.0 108.022 179.263 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' PRO . . . . . 0.416 ' HG3' ' CD2' ' A' ' 34' ' ' PHE . 74.1 Cg_endo -76.5 111.06 3.18 Favored 'Trans proline' 0 N--CA 1.446 -1.266 0 C-N-CA 123.594 2.863 . . . . 0.0 108.74 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ILE . . . . . . . . . . . . . 1.1 mt -94.28 119.06 41.65 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.685 0 N-CA-C 102.718 -3.068 . . . . 0.0 102.718 174.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' VAL . . . . . . . . . . . . . 2.2 t -126.56 129.06 71.71 Favored 'Isoleucine or valine' 0 CA--C 1.514 -0.413 0 N-CA-C 109.37 -0.604 . . . . 0.0 109.37 -175.887 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' PHE . . . . . . . . . . . . . 2.4 m-85 -97.39 114.61 26.46 Favored 'General case' 0 N--CA 1.438 -1.045 0 N-CA-C 104.343 -2.465 . . . . 0.0 104.343 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' THR . . . . . . . . . . . . . 44.8 p -80.28 -75.39 0.27 Allowed 'General case' 0 N--CA 1.456 -0.128 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 -176.55 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' ASN . . . . . . . . . . . . 0.259 0.4 OUTLIER -74.06 69.68 1.5 Allowed 'General case' 0 CA--C 1.534 0.349 0 CA-C-O 122.204 1.002 . . . . 0.0 111.207 179.156 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LEU . . . . . . . . . . . . . 13.2 mt -78.21 62.2 2.87 Favored 'General case' 0 CA--C 1.533 0.309 0 C-N-CA 126.174 1.79 . . . . 0.0 107.537 175.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' ALA . . . . . . . . . . . . . . . 25.53 -109.63 0.02 OUTLIER 'General case' 0 N--CA 1.45 -0.451 0 C-N-CA 127.578 2.351 . . . . 0.0 112.545 -177.852 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' GLU . . . . . . . . . . . . . 57.3 tt0 -80.33 58.64 3.16 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 125.146 1.379 . . . . 0.0 112.446 -178.265 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' GLY . . . . . . . . . . . . . . . 46.19 35.67 6.82 Favored Glycine 0 CA--C 1.527 0.836 0 C-N-CA 124.259 0.933 . . . . 0.0 110.959 -178.882 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' GLU . . . . . 0.671 ' HB3' HG23 ' A' ' 160' ' ' ILE . 38.9 mt-10 -49.01 126.91 13.32 Favored 'General case' 0 CA--C 1.532 0.258 0 C-N-CA 123.349 0.659 . . . . 0.0 112.014 -175.731 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' THR . . . . . . . . . . . . . 31.8 p -86.54 133.35 33.74 Favored 'General case' 0 N--CA 1.449 -0.482 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 177.359 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' VAL . . . . . . . . . . . . 0.256 0.3 OUTLIER -85.58 87.48 2.52 Favored 'Isoleucine or valine' 0 CA--C 1.543 0.687 0 CA-C-O 122.407 1.099 . . . . 0.0 109.936 -176.009 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' SER . . . . . . . . . . . . . 19.5 m -79.33 84.48 5.25 Favored 'General case' 0 N--CA 1.454 -0.252 0 O-C-N 120.646 -1.284 . . . . 0.0 110.85 -177.657 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' ILE . . . . . 0.521 HG23 HG22 ' A' ' 158' ' ' VAL . 6.5 mt -60.66 130.67 24.85 Favored 'Isoleucine or valine' 0 CA--C 1.531 0.217 0 C-N-CA 124.287 1.035 . . . . 0.0 108.656 178.418 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' LYS . . . . . . . . . . . . . 73.0 mmtt -110.33 -52.78 2.75 Favored 'General case' 0 N--CA 1.454 -0.236 0 C-N-CA 123.769 0.828 . . . . 0.0 108.767 178.673 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' ALA . . . . . . . . . . . . . . . -78.95 64.64 3.94 Favored 'General case' 0 C--N 1.331 -0.219 0 C-N-CA 122.892 0.477 . . . . 0.0 109.933 179.324 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' SER . . . . . . . . . . . . . 45.0 m -78.98 66.05 4.32 Favored 'General case' 0 CA--C 1.529 0.17 0 N-CA-C 107.76 -1.2 . . . . 0.0 107.76 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' GLY . . . . . . . . . . . . . . . -171.45 -148.79 6.23 Favored Glycine 0 CA--C 1.526 0.742 0 N-CA-C 107.809 -2.116 . . . . 0.0 107.809 -177.375 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' SER . . . . . . . . . . . . . 15.8 t -78.14 148.11 34.28 Favored 'General case' 0 N--CA 1.456 -0.136 0 CA-C-N 117.658 0.729 . . . . 0.0 110.735 178.195 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' VAL . . . . . . . . . . . . . 27.4 m -141.63 160.59 21.52 Favored 'Isoleucine or valine' 0 N--CA 1.454 -0.238 0 C-N-CA 124.864 1.266 . . . . 0.0 108.663 178.113 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ASN . . . . . . . . . . . . . 8.0 m-80 -114.78 157.79 22.75 Favored 'General case' 0 N--CA 1.456 -0.166 0 C-N-CA 124.719 1.208 . . . . 0.0 108.592 176.66 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ARG . . . . . . . . . . . . . 2.2 ptm180 -66.43 154.11 41.05 Favored 'General case' 0 CA--C 1.535 0.369 0 N-CA-C 110.229 -0.286 . . . . 0.0 110.229 176.863 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLU . . . . . . . . . . . . . 22.1 mt-10 53.15 59.98 4.06 Favored 'General case' 0 CA--C 1.532 0.253 0 C-N-CA 125.537 1.535 . . . . 0.0 112.06 -178.758 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 154' ' ' GLN . . . . . . . . . . . . . 16.9 mm-40 -131.07 151.02 51.87 Favored 'General case' 0 N--CA 1.454 -0.263 0 C-N-CA 126.821 2.048 . . . . 0.0 105.751 175.712 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 155' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -120.47 166.0 14.19 Favored 'General case' 0 CA--C 1.53 0.175 0 C-N-CA 125.2 1.4 . . . . 0.0 111.05 -177.338 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 156' ' ' ASP . . . . . . . . . . . . . 16.9 t70 70.63 -7.48 1.04 Allowed 'General case' 0 N--CA 1.467 0.413 0 N-CA-C 117.051 2.241 . . . . 0.0 117.051 176.223 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 157' ' ' ILE . . . . . 0.443 ' CD1' ' H ' ' A' ' 157' ' ' ILE . 0.2 OUTLIER -53.06 -31.87 17.92 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.562 0 C-N-CA 127.213 2.205 . . . . 0.0 112.501 177.116 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 158' ' ' VAL . . . . . 0.521 HG22 HG23 ' A' ' 144' ' ' ILE . 62.9 t -145.47 133.63 16.48 Favored 'Isoleucine or valine' 0 N--CA 1.447 -0.585 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.208 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 159' ' ' LYS . . . . . . . . . . . . . 62.9 mttp -108.75 120.53 42.75 Favored 'General case' 0 N--CA 1.45 -0.438 0 C-N-CA 123.414 0.686 . . . . 0.0 109.828 -179.262 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 160' ' ' ILE . . . . . 0.671 HG23 ' HB3' ' A' ' 140' ' ' GLU . 1.3 mp -79.1 97.22 2.4 Favored 'Isoleucine or valine' 0 N--CA 1.445 -0.679 0 N-CA-C 105.204 -2.146 . . . . 0.0 105.204 173.404 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 161' ' ' GLU . . . . . . . . . . . . . 80.8 mm-40 -108.7 -155.26 0.55 Allowed 'General case' 0 CA--C 1.528 0.129 0 C-N-CA 125.369 1.467 . . . . 0.0 107.963 -179.626 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 162' ' ' LYS . . . . . . . . . . . . . 35.5 mtmm . . . . . 0 C--N 1.333 -0.131 0 N-CA-C 107.572 -1.27 . . . . 0.0 107.572 176.977 . . . . . . . . 0 0 . 1 stop_ save_